<SEC-DOCUMENT>0001213900-23-010349.txt : 20230210
<SEC-HEADER>0001213900-23-010349.hdr.sgml : 20230210
<ACCEPTANCE-DATETIME>20230210165657
ACCESSION NUMBER:		0001213900-23-010349
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		154
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20230210
DATE AS OF CHANGE:		20230210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Universe Pharmaceuticals INC
		CENTRAL INDEX KEY:			0001809616
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			F4
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40231
		FILM NUMBER:		23613073

	BUSINESS ADDRESS:	
		STREET 1:		265 JINGJIU AVENUE
		STREET 2:		JINGGANGSHAN ECON. AND TECH. DEV. ZONE
		CITY:			JI'AN, JIANGXI
		STATE:			F4
		ZIP:			343100
		BUSINESS PHONE:		86-0796-8403309

	MAIL ADDRESS:	
		STREET 1:		265 JINGJIU AVENUE
		STREET 2:		JINGGANGSHAN ECON. AND TECH. DEV. ZONE
		CITY:			JI'AN, JIANGXI
		STATE:			F4
		ZIP:			343100
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>f20f2022_universe.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Feb 10 15:53:49 UTC 2023 -->
<html xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:upc="http://www.UniversePharmaceuticalsINC.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WASHINGTON,
D.C. 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM&#160;<ix:nonNumeric contextRef="c0" name="dei:DocumentType">20-F</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement">&#9744;</ix:nonNumeric>&#160;
<b>REGISTRATION STATEMENT PURSUANT TO SECTION&#160;12(b)&#160;OR (g)&#160;OF THE SECURITIES<br/>
EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric>&#160;<b>ANNUAL
REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE<br/>
ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">September&#160;30</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric>&#160;<b>TRANSITION
REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE<br/>
ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric>&#160;<b>SHELL
COMPANY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES<br/>
EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of event requiring this shell company report</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from &#160; to</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-40231</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Universe
Pharmaceuticals INC</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Registrant as specified in its charter)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of Registrant&#8217;s name into English)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cayman
Islands</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Jurisdiction
of incorporation or organization)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">265
Jingjiu Avenue,</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">Jinggangshan Economic and Technological Development Zone</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Ji&#8217;an,
Jiangxi</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">China</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">343100</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>+86-0796-8403309</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName">Gang
Lai</ix:nonNumeric>, Chief Executive Officer</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telephone:
+86-0796-8403309</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Email:
<ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelEmailAddress">gang.lai@universe-pharmacy.com</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1">265
Jingjiu Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2">Jinggangshan Economic and Technological Development Zone</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ji&#8217;an,
Jiangxi Province</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>People&#8217;s
Republic of <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">China</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered or to be registered pursuant to Section&#160;12(b)&#160;of the Act.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares</b></span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UPC</b></span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Stock Market</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section&#160;12(g)&#160;of the Act.</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of Class)</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
for which there is a reporting obligation pursuant to Section&#160;15(d)&#160;of the Act.</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of Class)</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered
by the annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
aggregate of <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">21,750,000</ix:nonFraction> ordinary shares, par value $0.003125 per share, as of September 30, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes&#160;&#9744;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric>&#160;&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13
or 15(d)&#160;of the Securities Exchange Act of 1934.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes&#160;&#9744;
<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric>&#160;&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
&#8211; Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 from their obligations under those Sections.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2)&#160;has been subject to such filing requirements for the past 90 days.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>&#160;&#9746;
No&#160;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405
of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>&#160;&#9746;
No&#160;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth
company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221;
in Rule&#160;12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging&#160;growth&#160;company</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&#160;13(a)&#160;of the Exchange Act. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the
registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard">U.S. GAAP</ix:nonNumeric> &#9746;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Financial Reporting Standards as issued by the</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Accounting Standards Board &#9744;</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other &#9744;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the
registrant has elected to follow. Item 17 &#9744; Item 18 &#9744;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange
Act). Yes&#160;&#9744; <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">No</ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes&#160;&#9744;&#160;No&#160;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#k_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTRODUCTION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#k_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART&#160;I</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFER STATISTICS AND EXPECTED TIMETABLE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KEY INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION ON THE COMPANY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNRESOLVED STAFF COMMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFER AND LISTING</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDITIONAL INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#k_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART&#160;II</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS AND PROCEDURES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[RESERVED]</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUDIT COMMITTEE FINANCIAL EXPERT</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CODE OF ETHICS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16E.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16F.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16G.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CORPORATE GOVERNANCE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16H.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_028">MINE SAFETY DISCLOSURE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16I.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSEPCTIONS.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#k_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART&#160;III</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    17.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    18.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    19.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTRODUCTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this annual report on Form 20-F, unless the context otherwise requires, references to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;China&#8221;
    or the &#8220;PRC&#8221; are to the People&#8217;s Republic of China, including the special administrative regions of Hong Kong and
    Macau and excluding Taiwan for the purposes of this annual report only;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Exchange Act&#8221;
    are to the Securities Exchange Act of 1934, as amended;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;fiscal year&#8221;
    are to the period from October 1 to September 30 of the next calendar year;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Jiangxi Universe&#8221;
    are to Jiangxi Universe Pharmaceuticals Co., Ltd., a limited liability company organized under the laws of the PRC, which is wholly
    owned by Universe Technology (as defined below);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;PRC operating entities&#8221;
    are to Jiangxi Universe and its subsidiaries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;RMB&#8221; and Renminbi&#8221;
    are to the legal currency of China;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;shares&#8221; or
    &#8220;ordinary shares&#8221; are to the ordinary shares of the Company, par value $0.003125 per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SEC&#8221; are to
    the U.S. Securities Exchange Commission;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TCM&#8221; are to
    traditional Chinese medicine;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TCMD&#8221; are
    to traditional Chinese medicine derivatives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Universe Hanhe&#8221;
    are to Guangzhou Universe Hanhe Medical Research Co., Ltd., a PRC formed on May 12, 2021, a wholly-owned subsidiary of Jiangxi Universe;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Universe HK&#8221;
    are to Universe INC&#8217;s wholly owned subsidiary, Universe Pharmaceuticals Group (International) Limited, a company incorporated
    in Hong Kong;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Universe Technology&#8221;
    are to Jiangxi Universe Pharmaceuticals Technology Co., Ltd., a limited liability company organized under the laws of the PRC, and
    is wholly owned by Universe HK;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Universe Trade&#8221;
    are to Jiangxi Universe Pharmaceuticals Trade Co., Ltd., a PRC company formed in 2010, a wholly-owned subsidiary of Jiangxi Universe;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;US$,&#8221; &#8220;U.S.
    dollars,&#8221; &#8220;$&#8221; and &#8220;dollars&#8221; are to the legal currency of the United States; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;we,&#8221; &#8220;us,&#8221;
    &#8220;our Company,&#8221; or the &#8220;Company&#8221;, are to one or more of Universe Pharmaceuticals INC, an exempted company
    incorporated in the Cayman Islands and our holding company, and its subsidiaries, as the case may be.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report on Form&#160;20-F includes our audited consolidated financial statements for the fiscal years ended September&#160;30,
2022, 2021, and 2020. In this annual report, we refer to assets, obligations, commitments, and liabilities in our consolidated financial
statements in United States dollars. These dollar references are based on the exchange rate of RMB to United States dollars, determined
as of a specific date or for a specific period. Changes in the exchange rate will affect the amount of our obligations and the value
of our assets in terms of United States dollars which may result in an increase or decrease in the amount of our obligations and the
value of our assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report contains translations of certain RMB amounts into U.S. dollars at specified rates. Unless otherwise stated, the following
exchange rates are used in this annual report:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September
    30,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">US$ Exchange Rate</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">At the end of the year - RMB</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.1135
                                            to $1.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.4580
                                            to $1.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.8033
                                            to $1.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Average rate for the year - RMB</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.5532
                                            to $1.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.5095
                                            to $1.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.0077
                                            to $1.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part&#160;I</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
2. OFFER STATISTICS AND EXPECTED TIMETABLE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
3. KEY INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
<span style="text-decoration:underline">[Reserved]</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
<span style="text-decoration:underline">Capitalization and Indebtedness</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
<span style="text-decoration:underline">Reasons for the Offer and Use of Proceeds</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
<span style="text-decoration:underline">Risk Factors</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in our securities involves significant risks. You should carefully consider all of the information in this annual report before investing
in our securities. Below is a summary of the principal risks we face. These risks are discussed more fully under &#8220;Item 3. Key Information&#8212;D.
Risk Factors.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Business and Industry (for a more detailed discussion, see &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks
Related to Our Business and Industry&#8221;)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
and uncertainties related to our business include, but are not limited to, the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price increases in raw
    materials and sourced products could harm our financial results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high quality materials
    for our products may be difficult to obtain or substantially increase our production costs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are exposed to a number
    of risks related to our supply chain for the materials required to manufacture our products which could adversely affect our business
    operations and future development;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we operate in a highly
    competitive industry. Our failure to compete effectively could adversely affect our market share, revenues and growth prospects;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high quality materials
    for our products may be difficult to obtain or substantially increase our production costs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our future success depends
    in part on our ability to increase our production capacity, and we may not able to do so in a cost-effective manner. We have engaged
    a third-party sub-contractor to build manufacturing facilities and an office building for us, and we may encounter challenges relating
    to the construction, management and operation of such facilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are subject to evolving
    regulatory requirements, non-compliance with which, or changes in which, may adversely affect our business and prospects; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to maintain
    or renew requisite licenses, permits, registrations and filings applicable to our business operations, or fail to obtain additional
    licenses, permits, registrations or filings that become necessary as a result of new enactment or promulgation of government policies,
    laws or regulations or the expansion of our business, our business and results of operations may be materially and adversely affected.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Doing Business in China (for a more detailed discussion, see &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks
Related to Doing Business in China&#8221;)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face risks and uncertainties relating to doing business in the PRC in general, including, but not limited to, the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the PRC government has
    significant authority to intervene or influence the China operations of an offshore holding company, such as ours, at any time. The
    PRC government may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers. If the
    PRC government exerts more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based
    issuers and we were to be subject to such oversight and control, it may result in a material adverse change to our business operations,
    significantly limit or completely hinder our ability to offer or continue to offer securities to investors, and cause the ordinary
    shares to significantly decline in value or become worthless;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainties arising from
    the legal system in China, including uncertainties regarding the interpretation and enforcement of PRC laws and the possibility that
    regulations and rules can change quickly with little advance notice, could hinder our ability to offer or continue to offer the ordinary
    shares, result in a material adverse change to our business operations, and damage our reputation, which would materially and adversely
    affect our financial condition and results of operations and cause the ordinary shares to significantly decline in value or become
    worthless;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ordinary shares may
    be delisted or prohibited from being traded over-the-counter under the Holding Foreign Companies Accountable Act, if the U.S. Public
    Company Accounting Oversight Board, or the PCAOB, is unable to inspect our auditors. The delisting or the cessation of trading of
    our ordinary shares, or the threat of their being delisted or prohibited from being traded, may materially and adversely affect the
    value of your investment. Additionally, the inability of the PCAOB to conduct inspections would deprive our investors with the benefits
    of such inspections. Our auditor has not been inspected by the PCAOB, but according to our auditor, it will be inspected by the PCAOB
    on a regular basis;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to comply with
    cybersecurity, data privacy, data protection, or any other laws and regulations related to data may materially and adversely affect
    our business, financial condition, and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval and/or other
    requirements of the China Securities Regulatory Commission, or the CSRC, or other PRC governmental authorities may be required in
    connection with an offering under PRC rules, regulations or policies, and, if required, we cannot predict whether or how soon we
    will be able to obtain such approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC regulation of loans
    to, and direct investments in, PRC entities by offshore holding companies may delay or prevent us from using proceeds from our offerings
    and/or other financing activities to make loans or additional capital contributions to our PRC operating subsidiaries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse changes in political,
    economic and social conditions, as well as government policies in China could have a material adverse effect on our business results
    of operations, financial conditions and prospects; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to the PRC legal
    system could have an adverse effect on us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Draft Rules Regarding
    Overseas Listings released by the CSRC for public consultation, while not yet in effect, may cause the Chinese government to exert
    more oversight and control over overseas public offerings conducted by China-based issuers, which could significantly limit or completely
    hinder our ability to offer or continue to offer our securities to investors and could cause the value of our securities to significantly
    decline or become worthless. See &#8220;Risk Factors&#8212;Risks Related to Doing Business in China&#8212;The Draft Rules Regarding
    Overseas Listings were released by the CSRC for public consultation. While such rules have not yet come into effect, the Chinese
    government may exert more oversight and control over overseas public offerings conducted by China-based issuers, which could significantly
    limit or completely hinder our ability to offer or continue to offer our securities to investors and could cause the value of our
    securities to significantly decline or become worthless&#8221;;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recent greater oversight
    by the Cyberspace Administration of China over data security, particularly for companies seeking to list on a foreign exchange, could
    adversely impact our business and our offering. See &#8220;Risk Factors&#8212;Risks Related to Doing Business in China&#8212;Recent
    greater oversight by the Cyberspace Administration of China over data security, particularly for companies seeking to list on a foreign
    exchange, could adversely impact our business and our offering&#8221;;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the extent cash and
    assets of in the business is in the PRC or a PRC entity, the funds may not be available to fund operations or for other use outside
    of the PRC due to interventions in or the imposition of restrictions and limitations on the ability of our Company or our subsidiaries
    by the PRC government to transfer cash and assets. See &#8220;Risk Factors&#8212;Risks Related to Doing Business in China&#8212;To
    the extent cash and assets of in the business is in the PRC or a PRC entity, the funds may not be available to fund operations or
    for other use outside of the PRC due to interventions in or the imposition of restrictions and limitations on the ability of our
    Company or our subsidiaries by the PRC government to transfer cash and assets.&#8221;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Relating to Our Ordinary Shares and the Trading Market (for a more detailed discussion, see &#8220;Item 3. Key Information&#8212;D. Risk
Factors&#8212;Risks Relating to Our Ordinary Shares&#8221;)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the risks described above, we are subject to general risks and uncertainties relating to our ordinary shares and the trading
market, including, but not limited to, the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our share price has recently
    declined substantially, and our ordinary shares could be delisted from the Nasdaq or trading could be suspended;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may issue additional
    ordinary shares or other equity securities without your approval, which would dilute your ownership interests and may depress the
    market price of our ordinary shares; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are a &#8220;controlled
    company&#8221; within the meaning of the Nasdaq Stock Market Rules and, as a result, may rely on exemptions from certain corporate
    governance requirements that provide protection to shareholders of other companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a foreign private issuer,
    we are not subject to certain U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit the
    information publicly available to our shareholders; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a foreign private issuer,
    we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from
    the Nasdaq listing standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully
    with corporate governance listing standards.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business and Industry</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Price
increases in raw materials and sourced products could harm our financial results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal raw materials include angelica, codonopsis, poria mushroom isatis root, and other herbs and plant extracts. These raw materials
are subject to price volatility and inflationary pressures. Our success is dependent, in part, on our ability to reduce our exposure
to increases in such costs through a variety of ways, while maintaining and improving margins and market share. The manufacturers of
such raw materials are also subject to price volatility and labor cost and other inflationary pressures, which may in turn result in
an increase in the amount we pay for sourced products. Raw materials and sourced product price increases may offset our productivity
gains and price increases and may adversely impact our financial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>High
quality materials for our products may be difficult to obtain or substantially increase our production costs.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw
materials account for a portion of our manufacturing costs and we rely on third-party suppliers to provide almost all raw materials.
Suppliers may be unable or unwilling to provide the raw materials we need in the quantities requested, at prices we are willing to pay,
or that meet our quality standards. We are also subject to potential delays in the delivery of raw materials caused by events beyond
our control, including transportation interruptions, delivery delays, labor disputes, other supply chain issues, and changes in government
regulations. See &#8220;&#8212;We are exposed to a number of risks related to our supply chain for the materials required to manufacture
our products&#8221; for details. Our business could be adversely affected if we are unable to obtain reliable sources of the raw materials
used in the manufacturing of our products that meet our quality standards. Any significant delay in or disruption of the supply of raw
materials could, among other things, substantially increase the cost of such materials, require reformulation or repackaging of products,
require the qualification of new suppliers, or result in our inability to meet customer demands, which could in turn adversely affect
our financial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are exposed to a number of risks related to our supply chain for the materials required to manufacture our products which could adversely
affect our business operations and future development.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third-party suppliers to provide almost all raw materials, and manufacturing our products is highly complex and requires sourcing
specialty materials or materials with quality standards. Many of the risks associated with the complexity of manufacturing our products
are applicable to the manufacture and supply of the raw materials. Minor deviations in the manufacturing process for these raw materials
could result in supply disruption and reduced production yields for our products, which is beyond our control. In addition, we rely on
third parties for the supply of these materials exposing us to similar risks of reliance on third parties for final products. See &#8220;&#8212;We
face risks related to our sales of products obtained from third-party suppliers&#8221; for further details.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
manufacturing processes requires many equipment and raw materials such as medicinal plants. We established supplier qualification procedures
to verify the operation conditions, production capabilities, credit-worthiness and quality standard of potential suppliers, in order
to procure quality raw materials in a timely manner. Although we are not relying on a single supplier for any of our raw materials, we
may in the future rely on sole source vendors or a limited number of vendors for some of our equipment and materials. We currently depend
on a limited number of suppliers for certain materials and equipment used in the manufacture of our products. Some of these suppliers
are small companies with limited resources and experience to support commercial production and may be&#160;ill-equipped&#160;to support
our needs from time to time. Accordingly, we may experience delays in receiving key materials and equipment to support manufacturing.
An inability to continue to source product from any of these suppliers, which could be due to regulatory actions or requirements affecting
the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands,
or quality issues, could adversely affect our ability to satisfy demand for our products, which could adversely and materially affect
our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we continue to develop and scale our manufacturing process, we expect that we will need to obtain supplies of certain raw materials and
equipment to be used as part of that process. We may not be able to obtain rights to such materials on commercially reasonable terms,
or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable
substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials
or equipment, such a change may lead to a delay in our clinical development and/or commercialization plans.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
operate in a highly competitive industry. Our failure to compete effectively could adversely affect our market share, revenues and growth
prospects</i></b><i>.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chinese patent medicine industry in the PRC is subject to significant competition and pricing pressures. We will experience significant
competitive pricing pressures as well as competitive products. Several significant competitors may offer products at the same or lower
prices than our products. The market is highly sensitive to the introduction of new products, which may rapidly capture a significant
share of the market. It is possible that one or more of our competitors could develop a significant research advantage over us that allows
them to provide superior products that are more attractive to consumers, which could put us in a competitive disadvantage. Continued
pricing pressure or improvements in research and shifts in customer preference could adversely impact our customer base or pricing structure
and have a material and adverse effect on our business, financial conditions, results of operations and cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to maintain or enhance our brands or image could have a material adverse effect on our business and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe several of our brands, such as &#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221;, &#8220;Hu Zhuo Ren (&#32993;&#21331;&#20161;)&#8221;
and &#8220;Long Zhong (&#40857;&#31181;)&#8221;, are well-recognized among our clients and other Chinese patent medicine industry players.
Our brand is integral to our sales and marketing efforts. Our continued success in maintaining and enhancing our brand and image depends
to a large extent on our ability to satisfy customer needs by further developing effective and better-quality products, as well as our
ability to respond to competitive pressures. If we are unable to satisfy customer needs or if our public image or reputation were otherwise
diminished, our business transactions with our customers may decline, which could in turn adversely affect our results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to appropriately respond to changing consumer preferences and demand for new products could significantly harm our customer relationships
and product sales.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is particularly subject to changing consumer trends and preferences. Our continued success depends in part on our ability to
anticipate and respond to these changes, and we may not be able to respond in a timely or commercially appropriate manner to these changes.
If we are unable to do so, our customer relationships and product sales could be harmed significantly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the Chinese patent medicine industry is characterized by rapid and frequent changes in demand and new product introductions. Our failure
to accurately depict these trends could negatively impact consumer opinion of our stores as a source for latest products. This could
harm our customer relationships and cause losses to our market share. The success of our new product offerings depends upon a number
of factors, including our ability to: accurately anticipate customer needs; innovate and develop new products; successfully commercialize
new products in a timely manner; price our products competitively; manufacture and deliver our products in sufficient volumes and in
a timely manner; and differentiate our product offerings from those our competitors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not introduce new products or make enhancements to meet the changing needs of our customers in a timely manner, some of our products
could become obsolete, which could have a material adverse effect on our revenues and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our products do not have the effects intended or cause undesirable side effects, our business may suffer</i>.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the ingredients in our current products have a long history of human consumption, and although we believe that all of these products
and the combinations of ingredients in them are safe when taken as directed, the products could have certain undesirable side effects
if not taken as directed or if taken by a consumer who has certain medical conditions. In addition, these products may not have the effect
intended if they are not taken in accordance with instructions, which may include dietary restrictions. Furthermore, there can be no
assurance that any of these products, even when used as directed, will have the effects intended or will not have harmful side effects
in an unforeseen way or on an unforeseen cohort. If any of our products or products we develop or commercialize in the future are shown
to be harmful or generate negative publicity from perceived harmful effects, our business, financial condition, results of operations,
and prospects could be harmed significantly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have made substantial investment in advertising our products in order to improve our brand awareness and our market position, which efforts
may not be successful, and in such event, our financial position and results of operations may be materially and negatively affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have made substantial investment in advertising our products in order to improve our brand awareness and our market position. In particular,
in the fiscal year ended September 30, 2021, we started to advertise our products through television advertisement. For example, on September
6, 2021, we entered into a service agreement with an advertising agency, engaging such agency to develop and produce a television advertisement
for our signature TCMD products, Bai Nian Dan and Guben Yanling Pill, and to coordinate with a television channel to air the advertisement
to audience in certain our target markets, with a term of one year from October 1, 2021 to September 30, 2022. In connection with this
agreement, we paid $7.5 million to the advertising agency. In the fiscal year ended September 30, 2022, we entered into an advertising
service agreement with a third-party, Health Headline Technology Co., Ltd. (&#8220;Health Headline&#8221;), pursuant to which, Health
Headline provided media advertising services to promote our brand on the Health Headline website and mobile app, with a service period
of ten months from March 1, 2022 to December 31, 2022. In addition, we incurred substantial advertising expenditures to maintain and
enhance our brand and our products, which may not prove successful. Television advertising and other brand promotion activities may not
generate customer awareness or increase revenue, and even if they do, any increase in revenue may not offset the expenses we incur in
building our brand. Additionally, there could be a negative reaction to certain advertising campaigns. If we fail to promote our brand,
or if we incur excessive expenses in this effort, we may fail to attract or retain customers necessary to realize a sufficient return
on our brand-building efforts or to achieve the desired brand awareness that is critical for our success.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success depends in part on our ability to increase our production capacity, and we may not able to do so in a cost-effective manner.
We have engaged a third-party sub-contractor to build manufacturing facilities and an office building for us, and we may encounter challenges
relating to the construction, management and operation of such facilities.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent we are successful in growing our business, we may need to increase our production capacity. We entered into a construction
agreement with a sub-contractor, who will construct four manufacturing plants and an office building for us, with a total maximum budget
of approximately RMB165 million (US$23.2 million). The construction started on August 8, 2021, with an originally estimated completion
date on August 7, 2023. However, due to resurgence in the number of COVID cases, which resulted in logistic disruptions, material and
labor shortage, and domestic travel restriction, the construction work is estimated to be completed in December 2024, and the sub-contractor
will bear the increased material and labor costs. Our ability to construct such additional facilities is subject to risks and uncertainties.
The construction of any new facilities will be subject to risks inherent in the development and construction, including risks of delays
and cost overruns as a result of factors outside of our control, which may include delays in government approvals, burdensome permitting
conditions, and delays in the delivery of manufacturing equipment or raw materials required for the construction. Additionally, we also
depend on the third-party sub-contractor for the development of new facilities, and as such, we are subject to the risk that such third
parties do not fulfill their obligations to us under the contraction agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the sub-contractor is unable to deliver the new facilities to us on time, or if we are unable to expand our manufacturing facilities
in general, we may be unable to further scale our business, which would negatively affect our results of operations and financial condition.
If we are unable to transition manufacturing operations to such new facilities in a cost-efficient and timely manner, then we may experience
disruptions in operations, which could negatively impact our business and financial results. Further, if the demand for our products
decreases or if we do not produce the expected output after any such new facilities are operational, we may not be able to spread a significant
amount of our fixed costs over the production volume, thereby increasing our per product fixed cost, which would have a negative impact
on our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have internal control deficiency in our internal control system and deficiencies in our corporate governance. If we fail to improve our
internal control function and corporate governance, we may be subject to increased risk of fraud or misuse of corporate assets, which
may materially and negatively impact our financial condition and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have internal control deficiency in our internal
control system and deficiency in our corporate governance. In the fiscal year ended September 30, 2021, we entered into several material
business transactions, including a construction agreement with a third-party sub-contractor to construct manufacturing facilities and
an office building for us, a real estate property purchase agreement with a related party for the purchase of certain real properties,
and an advertising service agreement with a third-party advertising agency to air our television advertisements. These transactions were
not submitted for approval by our board of directors or any of its committees. In the fiscal year ended September 30, 2022, we have implemented
measures to improve our internal control procedures and corporate governance as a public company, and obtained board approval prior to
entering into all material business transactions, including the entry into a series of definitive agreements with Kitanihon Pharmaceutical
Co., Ltd., and a letter of intent for the acquisition of Yunnan Faxi Pharmaceuticals Co., Ltd. (&#8220;Yunnan Faxi&#8221;). We intend
to continue improving our internal control procedures and corporate governance as a public company. Nevertheless, if we fail to communicate
with our board of directors on a regular basis or otherwise implement remedial measures to improve our internal control and corporate
governance function in this regard, we may be subject to increased risk of fraud or misuse of corporate assets, which may materially and
negatively impact our financial condition and results of operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to evolving regulatory requirements, non-compliance with which, or changes in which, may adversely affect our business and
prospects.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a manufacturer of products designed for human consumption, we are subject to legal and regulatory requirements applicable to the Chinese
patent medicine industry in the PRC. We have been subject to penalties by PRC regulatory authorities in the past due to our failure to
comply with their requirements, including noncompliance with the Good Manufacturing Practice for Drugs and the National Drug Standard.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations to which we are subject in this area are evolving. As a result, the interpretation of these laws and their enforcement is
often uncertain. Predicting the application of these laws can be difficult, and unexpected outcomes in the interpretation and enforcement
of the applicable regulations may have an adverse impact on our business and operations. Additionally, any future changes in regulations
may render our business non-compliant or require changes to our business practices or licensing arrangements to ensure compliance. These
changes may involve significant costs, which in turn may adversely affect our business and financial prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
regulatory authorities of the PRC government regulate the manufacturing and trading of Chinese patent medicine. Violations of regulations
may lead to the imposition of significant penalties which may affect our business, operations, reputation and financial prospects. See
&#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Regulations&#8221; for details.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we introduce new products to our customers, we may be required to comply with additional laws and regulations that are yet to be determined.
To comply with such additional laws and regulations, we may be required to obtain necessary certificates, licenses or permits, as well
as expend additional resources to monitor regulatory and policy developments. Our failure to adequately comply with such additional laws
and regulations may delay, or possibly prevent, some of our products from being offered to customers, which may have a material adverse
effect on our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to maintain or renew requisite licenses, permits, registrations and filings applicable to our business operations, or fail to
obtain additional licenses, permits, registrations or filings that become necessary as a result of new enactment or promulgation of government
policies, laws or regulations or the expansion of our business, our business and results of operations may be materially and adversely
affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chinese patent medicine industry in China is highly regulated, and multiple licenses, permits, filings and approvals are required to
operate our business. Currently, through our PRC subsidiaries, we have obtained a valid pharmaceutical manufacturing license, a medical
device selling license, and a pharmaceutical trade license. We have made efforts to obtain all applicable approvals, licenses and permits,
but due to the complexities, uncertainties and frequent changes in laws, rules, regulations and their interpretation and implementation,
we may not always be able to do so, and we may be penalized by governmental authorities for conducting pharmaceutical manufacturing or
sales activities without proper approvals, licenses or permits. Moreover, as we continue to increase our product variety, we may also
become subject to new or existing laws and regulations that did not affect us in the past. Failure to obtain, renew or retain requisite
licenses, permits or approvals may adversely affect our ability to conduct or expand our business, and may have a material adverse impact
on our business prospects, results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is subject to inherent risks relating to product liability and personal injury claims.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a manufacturer of products designed for human consumption, we are subject to product liability claims if the use of our products is alleged
to have resulted in injury. For instance, adverse reactions resulting from human consumption of the ingredients contained in our products
could occur. We may also be obligated to recall affected products. If we are found liable for product liability claims, we could be required
to pay substantial monetary damages. Furthermore, even if we successfully defend ourselves against this type of claim, we could be required
to spend significant management, financial and other resources, which could disrupt our business, and our reputation as well as our brand
name may also suffer. We, like many other similar companies in China, do not carry product liability insurance. As a result, any imposition
of product liability could materially harm our business, financial condition and results of operations. In addition, we do not have any
business interruption insurance, due to the limited coverage of any available business interruption insurance in China, and as a result,
any business disruption or natural disaster could severely disrupt our business and operations and significantly decrease our revenue
and profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in expanding a distribution network.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we intend to expand our distribution network to include additional cities and rural areas in the PRC in an effort to increase our geographic
presence, our distribution, logistics and products may encounter competition from various similar or substitutive businesses. Therefore,
the success of expansion will depend upon many factors, including our ability to form relationships with, and manage an increasing number
of, customers base and optimize our distribution network. If we fail to expand our distribution network as planned, our business, financial
condition and results of operations may be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
global spread of COVID-19 pandemic could materially and adversely affect our business and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations have been affected and may continue to be affected by the ongoing COVID-19 pandemic.&#160;In the fiscal year ended
September 30, 2022, due to resurgence of COVID-19 pandemic in China and related restrictive measures, including travel restrictions,
the PRC operating entities experienced delays in the receipt of purchased raw materials from suppliers and in delivering products to
customers. The prices of the raw materials increased by about 5% as compared to the fiscal year ended September 30, 2021. In addition,
we granted some customers extended payment terms of 30 days to 120 days. However, based on our present relationship with these customers
and our evaluation of their financial conditions, we do not anticipate any material collectability problems. Although the Chinese government
removed its zero-COVID policy in December 2022, China is now facing a sudden surge in COVID cases after easing the lockdown restrictions
nationwide. WHO officials had expressed hope that COVID-19 might be entering an endemic phase by early 2023, but the continued uncertainties
associated with the COVID-19 pandemic worldwide may cause our revenue and cash flows to underperform in the next 12 months from the date
of this annual report. The extent of the future impact of the COVID-19 pandemic on our business and the results of operations is still
uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on certain key personnel and loss of these key personnel could have a material effect on our business, financial condition
and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success is, to a certain extent, attributable to the management, sales and marketing, and research and development expertise of key personnel.
We are dependent upon the services of Mr. Gang Lai, the chairman of our board of directors and our chief executive officer, for the continued
growth and operation of our Company, due to his industry experiences and management experiences. Although we have no reason to believe
that Mr. Gang Lai will discontinue his services with us, the interruption or loss of his services would adversely affect our ability
to effectively run our business and pursue our business strategy as well as our results of operation. We currently do not have &#8220;key
person&#8221; insurance on any of our executives or employees. There can be no assurance that we will be able to retain our key personnel
after the terms of their employment expire. The loss of the services of one or more of our key personnel could have a material adverse
effect upon our business, financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not effectively manage our growth, which could materially harm our business</i></b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our business will continue to grow, which may place a significant strain on our management, personnel, systems and resources.
We must continue to improve our operational and financial systems and managerial controls and procedures, and we will need to continue
to expand, train and manage our technology and workforce. We must also maintain close coordination among our compliance, accounting,
finance, marketing and sales organizations. We cannot assure you that we will manage our growth effectively. If we fail to do so, our
business could be materially harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
continued growth will require an increased investment by us in technology, facilities, personnel and financial and management systems
and controls. It also will require expansion of our procedures for monitoring and assuring our compliance with applicable regulations,
and we will need to integrate, train and manage a growing employee base. The expansion of our existing businesses, any expansion into
new businesses and the resulting growth of our employee base will increase our need for internal audit and monitoring processes that
are more extensive and broader in scope than those we have historically acquired. We may not be successful in identifying or implementing
all of the processes that are necessary. Further, unless our growth results in an increase in our revenues that is proportionate to the
increase in our costs associated with this growth, our operating margins and profitability will be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to hire and retain qualified personnel to support our growth and if we are unable to retain and hire these personnel
in the future, our ability to improve our products and implement our business objects could be adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
must attract, recruit and retain a sizeable workforce of technically competent employees. Competition for senior management and personnel
in the PRC is intense and the pool of qualified candidates in the PRC is very limited. We may not be able to retain the services of our
senior executives or personnel, or attract and retain high-quality senior executives or personnel in the future. This failure could materially
and adversely affect our future growth and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success depends on our ability to protect our intellectual property.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently own 46 patents and 99 trademarks in China. We believe that our success depends on our ability to obtain and maintain patent
protection for products developed utilizing our technologies, in the PRC and in other countries, and to enforce these patents. There
is no assurance that any of our existing and future patents will be deemed to be valid and enforceable against third-party infringement
or that our products will not infringe any third-party patent or intellectual property by a court or administrative body having jurisdiction
over such matters. Although we have filed additional patent applications with Patent Administration Department of PRC, there is no assurance
that they will be granted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
patents relating to our technologies may not be sufficiently broad to protect our products. In addition, our patents may be challenged,
potentially invalidated or potentially circumvented. Our patents may not afford us protection against competitors with similar technology
or permit the commercialization of our products without infringing third-party patents or other intellectual property rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely, or intend to rely, on our trademarks, trade names and brand names to distinguish our products from the products of our competitors,
and have registered or will apply to register a number of these trademarks. However, third parties may oppose our trademark applications
or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to
rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing
these new brands. Further, our competitors may infringe our trademarks, or we may not have adequate resources to enforce our trademarks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we also have trade secrets, non-patented proprietary expertise and continuing technological innovations that we expect to seek
to protect, in part, by entering into confidentiality agreements with licensees, suppliers, employees and consultants. These agreements
may be breached and there may not be adequate remedies in the event of a breach. Disputes may arise concerning the ownership of intellectual
property or the applicability of confidentiality agreements. Moreover, our trade secrets and proprietary technology may otherwise become
known or be independently developed by our competitors. If patents are not issued with respect to products arising from research, we
may not be able to maintain the confidentiality of information relating to these products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the application and interpretation of China&#8217;s intellectual property laws are still evolving and are uncertain. If we are found
to have violated the intellectual property rights of others, we may be subject to liability and penalty for our infringement activities
or may be prohibited from using such intellectual property, and we may incur licensing fees or be forced to develop alternatives of our
own. In addition, we may incur significant expenses, and may be forced to divert management&#8217;s time and other resources from our
business and operations to defend against these infringement claims, regardless of their merits. Successful infringement or licensing
claims made against us may result in significant monetary liabilities and may materially disrupt our reputation, business and operations
by restricting or prohibiting our use of the intellectual property at issue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we rely on our manufacturing operations to produce a significant amount of the products we sell, disruptions in our manufacturing system
or losses of manufacturing certifications could adversely affect our sales and customer relationships.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
manufacturing operations produced approximately 59.8%, 61.6% and 59.8% of the total value of the products we sold for the fiscal year
ended September&#160;30, 2022, 2021, and 2020, respectively. Our products are produced in our manufacturing facility located in Jinggangshan,
Jiangxi Province, China. For the fiscal year ended September 30, 2022, one supplier accounted for approximately 10.3% of our total purchases.
For the fiscal year ended September 30, 2021, no supplier accounted for more than 10% of our total purchases. For the fiscal year ended
September 30, 2020, two suppliers accounted for approximately 19.6% and 13.6% of our total purchases, respectively. In the event any
of our third-party suppliers or vendors becomes unable or unwilling to continue to provide raw materials in the required volumes or quality
levels or in a timely manner, we would be required to identify and obtain acceptable replacement supply sources. If we are unable to
identity and obtain alternative supply sources, our business could be adversely affected. Any significant disruption in our operations
at our manufacturing facility for any reason, including government-imposed regulatory requirements, the loss of certifications, power
interruptions, fires, war, or other force of nature, could disrupt our supply of products, adversely affecting our sales and customer
relationships.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face risks related to our sales of products obtained from third-party suppliers.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
sell a significant number of products that are manufactured by third-party suppliers over which we have no direct control. While we have
implemented processes and procedures to try to ensure that the suppliers we use are complying with all applicable regulations, there
can be no assurance that such suppliers in all instances will comply with such processes and procedures or otherwise with applicable
regulations. Noncompliance could result in our marketing and distribution of contaminated or dangerous products which would subject us
to liabilities and could result in the imposition by government authorities of penalties that could restrict or eliminate our ability
to purchase products. Any or all of these effects could adversely affect our business, financial condition and results of operation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
growth of our business depends on our ability to finance new product innovations and these increased costs may reduce our cash flows
and, if the products in which we have invested fail, it would reduce our profitability.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in the Chinese patent medicine industry, which is characterized by significant competition and rapid change. New products appear
with increasing frequency to supplant existing products. If we fail to adapt to those conditions in a timely and efficient manner, our
revenues and profits would likely decline. To remain competitive, we must continue to incur significant costs in product research and
development, marketing, equipment and facilities and to make capital investment. These costs may increase, resulting in greater fixed
costs and operating expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the fiscal year ended September 30, 2022, we
incurred $7.6 million of research and development expenses, a 39.9% increase compared to the expenses in the fiscal year ended September
30, 2021. In order to diversify our profit portfolio, a large portion of the research and development expenses in the fiscal year ended
September 30, 2022 was spent on developing and testing eight new products. In the fiscal year ended September 30, 2021, we incurred $5.47
million of research and development expenses, an 837.3% increase compared to the expenses in the fiscal year ended September 30, 2020.
In order to diversify our profit portfolio, a large portion of the research and development expenses in the fiscal year ended September
30, 2021 was spent on developing and testing eight new products.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future operating results will depend to a significant extent on our ability to continue to provide new products that compare favorably
based on time to market, cost and performance with the design and manufacturing capabilities and competing third-party suppliers and
technologies. Furthermore, our research and development efforts may not produce successful results, and our new products may not achieve
market acceptance, create additional revenue for us, or bring us profits. Our failure to increase our net sales sufficient to offset
these increased costs would reduce our profitability and may materially and adversely affect our business operations and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
acquisitions may have an adverse effect on our ability to manage our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may acquire businesses, technologies, services or products which are complementary to our core business of manufacturing and selling
TCMD products. Future acquisitions may expose us to potential risks, including risks associated with: (i) the integration of new products,
services and personnel; unforeseen or hidden liabilities; (ii) the diversion of resources from our existing business; (iii) our potential
inability to generate sufficient revenue to offset new costs; the expenses of acquisitions; or (iv) the potential loss of or harm to
relationships with both employees and advertising clients resulting from our integration of new businesses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the potential risks listed above could have a material and adverse effect on our ability to manage our business, our revenues and
net income. We may need to raise additional debt funding or sell additional equity securities to make such acquisitions. The raising
of additional debt funding by us, if required, would result in increased debt service obligations and could result in additional operating
and financing covenants, or liens on our assets, that could restrict our operations. The sale of additional equity securities could result
in additional dilution to our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Increase
in labor costs in the PRC may adversely affect our business and our profitability.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China&#8217;s
economy has experienced increases in labor costs in recent years, and the average wage in China are expected to continue to grow. The
average wage level for our employees has also increased in recent years. We expect that our labor costs, including wages and employee
benefits, will continue to increase as we continue to grow our business. Unless we are able to pass on these increased labor costs to
our customers by increasing prices for our products or services, our profitability and results of operations may be materially adversely
affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have been subject to stricter regulatory requirements in terms of entering into labor contracts with our employees and paying
various statutory employee benefits, including pensions, housing fund, medical insurance, work-related injury insurance, unemployment
insurance and childbearing insurance to designated government agencies for the benefit of our employees. Pursuant to the PRC Labor Contract
Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#27861;&#12299;) (the &#8220;Labor Contract Law&#8221;)
that became effective in January 2008 and its implementing rules that became effective in September 2008 and its amendments that became
effective in July 2013, employers are subject to stricter requirements in terms of signing labor contracts, minimum wages, paying remuneration,
determining the term of employees&#8217; probation and unilaterally terminating labor contracts. In the event that we decide to terminate
some of our employees or otherwise change our employment or labor practices, the Labor Contract Law and its implementation rules may
limit our ability to effect any such terminations or those changes in a desirable or cost-effective manner, which could adversely affect
our business and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, we believe that we are in substantial compliance with labor-related laws and regulations in China,
and we have not been notified of any instance of noncompliance. As the interpretation and implementation of labor-related laws and regulations
are still evolving, we cannot assure you that our employment practice will not violate labor-related laws and regulations in China, which
may subject us to labor disputes or government investigations. If we are deemed to have violated relevant labor laws and regulations,
we could be required to provide additional compensation to our employees and our business, financial condition and results of operations
could be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Natural
disasters (whether or not caused by climate change), unusually adverse weather conditions, pandemic outbreaks, terrorist acts and global
political events could cause permanent or temporary distribution center or store closures, impair our ability to purchase, receive or
replenish inventory, or cause customer traffic to decline, all of which could result in lost sales and otherwise adversely affect our
financial performance.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of one or more natural disasters, such as hurricanes, fires, floods and earthquakes (whether or not caused by climate change),
unusually adverse weather conditions, pandemic outbreaks, terrorist acts or disruptive global political events, such as civil unrest
in countries in which our suppliers are located, or similar disruptions could adversely affect our operations and financial performance.
To the extent these events result in the closure of one or more of our distribution centers, a significant number of stores, a manufacturing
facility or our corporate headquarters, or impact one or more of our key suppliers, our operations and financial performance could be
materially adversely affected through an inability to make deliveries to our stores and through lost sales. In addition, these events
could result in increases in fuel (or other energy) prices or a fuel shortage, decrease in available raw materials of sufficient quality
and in sufficient amounts, delays in opening new stores, the temporary lack of an adequate work force in a market, the temporary or long-term
disruption in the supply of products from some local and overseas suppliers, the temporary disruption in the transport of goods from
overseas, delay in the delivery of goods to our distribution centers or stores, the temporary reduction in the availability of products
in our stores and disruption to our information systems. These events also could have indirect consequences, such as increases in the
cost of insurance, if any of such events was to result in significant loss of property or other insurable damage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Doing Business in China</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
PRC government has significant authority to intervene or influence the China operations of an offshore holding company, such as ours,
at any time. The PRC government may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers.
If the PRC government exerts more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based
issuers and we were to be subject to such oversight and control, it may result in a material adverse change to our business operations,
significantly limit or completely hinder our ability to offer or continue to offer securities to investors, and cause the ordinary shares
to significantly decline in value or become worthless.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business, prospects, financial condition, and results of operations may be influenced to a significant degree by political, economic,
and social conditions in China generally. The PRC government has significant authority to intervene or influence the China operations
of an offshore holding company at any time, which could result in a material adverse change to our operations and the value of the ordinary
shares. The PRC government has recently indicated an intent to exert more oversight and control over listings conducted overseas and/or
foreign investment in China-based issuers. Any such action may hinder our ability to offer or continue to offer our securities to investors,
result in a material adverse change to our business operations, and damage our reputation, which could cause the ordinary shares to significantly
decline in value or become worthless. See also &#8220;&#8212;Failure to comply with cybersecurity, data privacy, data protection, or
any other laws and regulations related to data may materially and adversely affect our business, financial condition, and results of
operations.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Uncertainties
arising from the legal system in China, including uncertainties regarding the interpretation and enforcement of PRC laws and the possibility
that regulations and rules can change quickly with little advance notice, could hinder our ability to offer or continue to offer the
ordinary shares, result in a material adverse change to our business operations, and damage our reputation, which would materially and
adversely affect our financial condition and results of operations and cause the ordinary shares to significantly decline in value or
become worthless.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal system in China is a civil law system based on written statutes. Unlike common law systems, it is a system in which decided legal
cases may be cited for reference but have less precedential value. The laws, regulations, and legal requirements in China are quickly
evolving and their interpretation and enforcement involve uncertainties. These uncertainties could limit the legal protections available
to you and us. In addition, we cannot predict the effect of future developments in the PRC legal system, particularly with regard to
new economies, including the promulgation of new laws, changes to existing laws or the interpretation or enforcement thereof, or the
preemption of local regulations by national laws. Furthermore, the PRC legal system is based in part on government policies and internal
rules, some of which are not published on a timely basis or at all. As a result, we may not be aware of our potential violation of these
policies and rules. In addition, any administrative and court proceedings in China may be protracted and result in substantial costs
and diversion of resources and management attention.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
laws and regulations may be enacted from time to time and substantial uncertainties exist regarding the interpretation and implementation
of current and any future PRC laws and regulations applicable to our businesses. In particular, the PRC government authorities may continue
to promulgate new laws, regulations, rules and guidelines governing companies in the patent medicine industry with respect to a wide
range of issues, such as intellectual property, unfair competition and antitrust, privacy and data protection, and other matters. Compliance
with these laws, regulations, rules, guidelines, and implementations may be costly, and any incompliance or associated inquiries, investigations,
and other governmental actions may divert significant management time and attention and our financial resources, bring negative publicity,
subject us to liabilities or administrative penalties, or materially and adversely affect our business, financial condition, results
of operations, and the value of the ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ordinary shares may be delisted or prohibited from being traded over-the-counter under the Holding Foreign Companies Accountable Act,
if the U.S. Public Company Accounting Oversight Board, or the PCAOB, is unable to inspect our auditors. The delisting or the cessation
of trading of our ordinary shares, or the threat of their being delisted or prohibited from being traded, may materially and adversely
affect the value of your investment. Additionally, the inability of the PCAOB to conduct inspections would deprive our investors with
the benefits of such inspections. Our auditor has not been inspected by the PCAOB, but according to our auditor, it will be inspected
by the PCAOB on a regular basis.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Holding Foreign Companies Accountable Act, or the HFCA Act, was enacted on December 18, 2020. The HFCA Act states if the SEC determines
that we have filed audit reports issued by a registered public accounting firm that has not been subject to inspection by the PCAOB for
three consecutive years, the SEC shall prohibit our shares from being traded on a national securities exchange or in the over-the-counter
trading market in the U.S.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
auditor, the independent registered public accounting firm that issues the audit report included elsewhere in this annual report, as
an auditor of companies that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the
United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards.
Our auditor is headquartered in California and has not been inspected by the PCAOB, but according to our auditor, it will be inspected
by the PCAOB on a regular basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2021, the SEC adopted interim final rules relating to the implementation of certain disclosure and documentation requirements
of the Holding Foreign Companies Accountable Act. We will be required to comply with these rules if the SEC identifies us as having a
&#8220;non-inspection&#8221; year under a process to be subsequently established by the SEC. The SEC is assessing how to implement other
requirements of the Holding Foreign Companies Accountable Act, including the listing and trading prohibition requirements described above.
In May 2021, the PCAOB issued for public comment a proposed rule related to the PCAOB&#8217;s responsibilities under the Holding Foreign
Companies Accountable Act, which, according to the PCAOB, would establish a framework for the PCAOB to use when determining, as contemplated
under the Holding Foreign Companies Accountable Act, whether the PCAOB is unable to inspect or investigate completely registered public
accounting firms located in a foreign jurisdiction because of a position taken by one or more authorities in that jurisdiction. The proposed
rule was adopted by the PCAOB in September 2021, pending the final approval of the SEC to become effective.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act, which, if passed by the U.S. House
of Representatives and signed into law, would reduce the number of consecutive non-inspection years required for triggering the prohibitions
under the Holding Foreign Companies Accountable Act from three years to two.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 2, 2021, the SEC issued amendments to finalize rules implementing the submission and disclosure requirements in the Holding
Foreign Companies Accountable Act. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit
report issued by a registered public accounting firm that is located in a foreign jurisdiction and that PCAOB is unable to inspect or
investigate completely because of a position taken by an authority in foreign jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 16, 2021, the PCAOB issued a report on its determination that it is unable to inspect or investigate completely PCAOB-registered
public accounting firms headquartered in China and in Hong Kong because of positions taken by PRC and Hong Kong authorities in those
jurisdictions. The PCAOB has made such determination as mandated under the Holding Foreign Companies Accountable Act. Pursuant to each
annual determination by the PCAOB, the SEC will, on an annual basis, identify issuers that have used non-inspected audit firms and thus
are at risk of such suspensions in the future. Our auditor is headquartered in California and is not subject to this determination announced
by the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC may propose additional rules or guidance that could impact us if our auditor is not subject to PCAOB inspection. For example, on
August 6, 2020, the President&#8217;s Working Group on Financial Markets, or the PWG, issued the Report on Protecting United States Investors
from Significant Risks from Chinese Companies to the then President of the United States. This report recommended that the SEC implement
five measures to address companies from jurisdictions that do not provide the PCAOB with sufficient access to fulfil its statutory mandate.
Some of the concepts of these recommendations were implemented with the enactment of the Holding Foreign Companies Accountable Act. However,
some of the recommendations were more stringent than the Holding Foreign Companies Accountable Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has announced that the SEC staff is preparing a consolidated proposal for the rules regarding the implementation of the Holding Foreign
Companies Accountable Act and to address the recommendations in the PWG report. It is unclear when the SEC will complete its rulemaking
and when such rules will become effective and what, if any, of the PWG recommendations will be adopted. The SEC has also announced amendments
to various annual report forms to accommodate the certification and disclosure requirements of the Holding Foreign Companies Accountable
Act. There could be additional regulatory or legislative requirements or guidance that could impact us if our auditor is not subject
to PCAOB inspection. The implications of this possible regulation or guidance, in addition to the requirements of the Holding Foreign
Companies Accountable Act, are uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2022, the PCAOB announced that it has completed a test inspection of two selected auditing firms in mainland China and Hong
Kong and has voted to vacate its previous Determination Report, which concluded in December 2021 that it could not inspect or investigate
completely registered public accounting firms based in mainland China or Hong Kong. Moving forward, the PCAOB will continue to demand
complete access in mainland China and Hong Kong. Despite the PCAOB&#8217;s announcement, Chinese authorities will need to ensure that
the PCAOB continues to have full access for inspections and investigations in 2023 and beyond, or the threat for Chinese companies listed
on U.S. stock exchanges has not been relieved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
for whatever reason, the PCAOB is unable to conduct full inspections of our auditor, uncertainty under the HFCA Act could cause the market
price of our ordinary shares to be materially and adversely affected, and our securities could be delisted or prohibited from being traded
&#8220;over-the-counter&#8221;. The risk and uncertainty associated with a potential delisting would have a negative impact on the price
of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing recent developments would add uncertainties to our future offerings and may result in prohibitions on the trading of our ordinary
shares on the Nasdaq Stock Market, if our auditors fail to meet the PCAOB inspection requirement in time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with cybersecurity, data privacy, data protection, or any other laws and regulations related to data may materially and adversely
affect our business, financial condition, and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to a variety of cybersecurity, data privacy, data protection, and other laws and regulations related to data, including
those relating to the collection, use, sharing, retention, security, disclosure, and transfer of confidential and private information,
such as personal information and other data. These laws and regulations apply not only to third-party transactions, but also to transfers
of information within our organization. These laws and regulations may restrict our business activities and require us to incur increased
costs and efforts to comply, and any breach or noncompliance may subject us to proceedings against us, damage our reputation, or result
in penalties and other significant legal liabilities, and thus may materially and adversely affect our business, financial condition,
and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
China, the cybersecurity, data privacy, data protection, or other data-related laws and regulations are relatively new and evolving,
and their interpretation and application may be uncertain. For example, on November 14, 2021, the Administration Regulations on Cyber
Data Security (Draft for Comments) (the &#8220;Draft Regulation&#8221;) was proposed by the Cyberspace Administration of China, or the
CAC, for public comments until December 13, 2021. The Draft Regulation reiterates that data processors which process the personal information
of at least one million users must apply for a cybersecurity review if they plan on listing its securities overseas, and the Draft Regulation
further requires the data processors to apply for cybersecurity review in accordance with relevant laws and regulations under the following
circumstances: (i) such data processor engages in merger, reorganization or division of internet platform operators that have gathered
a large number of data resources related to national security, economic development and public interests affects or may affect national
security; (ii) the listing of such data processor overseas affects or may affect national security; and (iii) such data processor engages
in other data processing activities that affect or may affect national security. Any failure to comply with such requirements may subject
us to, among others, suspension of services, fines, revocation of relevant business permits or business licenses, and/or penalties. Since
the CAC is still seeking comments on the Draft Regulation from the public as of the date of this annual report, the Draft Regulation
(especially its operative provisions) and its anticipated adoption or effective date are subject to further changes with substantial
uncertainty.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, we have not engaged in the relevant businesses provided in the Draft Regulation. As such, we currently
do not expect the draft measures by the CAC or other recent regulations will have an impact on our business or results of operations,
and we believe that we are compliant with the regulations and policies that have been issued by the CAC to date. As of the date of this
annual report, we have not received any investigation, notice, warning, or sanction from applicable government authorities (including
the CAC) with regard to our business operations concerning any issues related to cybersecurity and data security. In addition, we have
not been involved in any review, investigation, enquiry, penalty, or other legal proceedings initiated by applicable governmental or
regulatory authorities or third parties in relation to in relation to cyber security or data protection. However, we still face uncertainties
regarding the interpretation and implementation of these laws and regulations in the future. Cybersecurity review could result in disruption
in our operations, negative publicity with respect to our Company, and diversion of our managerial and financial resources. Furthermore,
if we were found to be in violation of applicable laws and regulations in China during such review, we could be subject to fines or other
government sanctions and reputational damage. Therefore, potential cybersecurity review, if applicable to us, could materially and adversely
affect our business, financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the PRC Data Security Law, which was promulgated by the Standing Committee of the National People&#8217;s Congress (the &#8220;SCNPC&#8221;)
on June 10, 2021 and took effect on September 1, 2021, requires data collection to be conducted in a legitimate and proper manner, and
stipulates that, for the purpose of data protection, data processing activities must be conducted based on data classification and hierarchical
protection system for data security. Furthermore, the recently issued Opinions on Strictly Cracking Down Illegal Securities Activities
require (i) speeding up the revision of the provisions on strengthening the confidentiality and archives management relating to overseas
issuance and listing of securities and (ii) improving the laws and regulations relating to data security, cross-border data flow, and
management of confidential information. The PRC Personal Information Protection Law, which was promulgated by the SCNPC on August 20,
2021 and took effect on November 1, 2021, integrates the scattered rules with respect to personal information rights and privacy protection
and applies to the processing of personal information within China as well as certain personal information processing activities outside
China, including those for the provision of products and services to natural persons within China or for the analysis and assessment
of acts of natural persons within China. There remain uncertainties regarding the further interpretation and implementation of those
laws and regulations, if they are deemed to be applicable to us, we cannot assure you that we will be compliant with such new regulations
in all respects, and we may be ordered to rectify and terminate any actions that are deemed illegal by the government authorities and
become subject to fines and other government sanctions, which may materially and adversely affect our business, financial condition,
and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
greater oversight by the Cyberspace Administration of China over data security, particularly for companies seeking to list on a foreign
exchange, could adversely impact our business and operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, the CAC and other relevant PRC governmental authorities jointly promulgated the Cybersecurity Review Measures, which
took effect on February 15, 2022. The Cybersecurity Review Measures provide that, in addition to critical information infrastructure
operators (the &#8220;CIIOs&#8221;) that intend to purchase Internet products and services, net platform operators engaging in data processing
activities that affect or may affect national security must be subject to cybersecurity review by the Cybersecurity Review Office of
the PRC. According to the Cybersecurity Review Measures, a cybersecurity review assesses potential national security risks that may be
brought about by any procurement, data processing, or overseas listing. The Cybersecurity Review Measures require that an online platform
operator which possesses the personal information of at least one million users must apply for a cybersecurity review by the CAC if it
intends to be listed in foreign countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 14, 2021, the CAC published the Draft Regulations on the Network Data Security Administration (Draft for Comments) (the &#8220;Security
Administration Draft&#8221;), which provides that data processing operators engaging in data processing activities that affect or may
affect national security must be subject to network data security review by the relevant Cyberspace Administration of the PRC. According
to the Security Administration Draft, data processing operators who possess personal data of at least one million users or collect data
that affects or may affect national security must be subject to network data security review by the relevant Cyberspace Administration
of the PRC. The deadline for public comments on the Security Administration Draft was December 13, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, we have not received any notice from any authorities identifying our PRC subsidiaries or the PRC operating
entities as CIIOs or requiring us to go through cybersecurity review or network data security review by the CAC. As confirmed by our
PRC counsel, AllBright Law Offices (Fuzhou), neither the operations of our PRC subsidiaries, nor of the PRC operating entities are expected
to be affected, and that we will not be subject to cybersecurity review by the CAC under the Cybersecurity Review Measures, nor will
any such entity be subject to the Security Administration Draft, if it is enacted as proposed, given that our PRC subsidiaries and the
PRC operating entities possess personal data of fewer than one million individual clients and do not collect data that affects or may
affect national security in their business operations as of the date of this annual report and do not anticipate that they will be collecting
over one million users&#8217; personal information or data that affects or may affect national security in the near future. In general,
we believe we are compliant with the regulations or policies that have been issued by the CAC to date. There remains uncertainty, however,
as to how the Cybersecurity Review Measures and the Security Administration Draft will be interpreted or implemented and whether the
PRC regulatory agencies, including the CAC, may adopt new laws, regulations, rules, or detailed implementation and interpretation related
to the Cybersecurity Review Measures and the Security Administration Draft. If any such new laws, regulations, rules, or implementation
and interpretation come into effect, we will take all reasonable measures and actions to comply and to minimize the adverse effect of
such laws on us. We cannot assure you that PRC regulatory agencies, including the CAC, would take the same view as we do. In the event
that we are subject to any mandatory cybersecurity review and other specific actions required by the CAC, we face uncertainty as to whether
any clearance or other required actions can be timely completed, or at all. If we inadvertently conclude that such approval is not required,
fail to obtain and maintain such approvals, licenses, or permits required for our business or respond to changes in the regulatory environment,
we could be subject to liabilities, penalties and operational disruption, which may materially and adversely affect our business, operating
results, financial condition, and the value of our securities, significantly limit or completely hinder our ability to offer or continue
to offer securities to investors, or cause such securities to significantly decline in value or become worthless.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
approval and/or other requirements of the China Securities Regulatory Commission, or the CSRC, or other PRC governmental authorities
may be required in connection with an offering under PRC rules, regulations or policies, and, if required, we cannot predict whether
or how soon we will be able to obtain such approval.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&amp;A Rules, purport to require offshore
special purpose vehicles that are controlled by PRC companies or individuals and that have been formed for the purpose of seeking a public
listing on an overseas stock exchange through acquisitions of PRC domestic companies or assets to obtain CSRC approval prior to publicly
listing their securities on an overseas stock exchange. The interpretation and application of the regulations remain unclear. If a governmental
approval is required, it is uncertain how long it will take for us to obtain such approval, and, even if we obtain such approval, the
approval could be rescinded. Any failure or delay in obtaining the requisite governmental approval for an offering, or a rescission of
such CSRC approval, if obtained by us, may subject us to sanctions imposed by the relevant PRC regulatory authority, which could include
fines and penalties on our operations in China, restrictions or limitations on our ability to pay dividends outside of China, and other
forms of sanctions that may materially and adversely affect our business, financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
PRC counsel, AllBright Law Offices (Fuzhou), has advised us that, based on its understanding of the current PRC laws and regulations,
we will not be required to submit an application to the CSRC for the approval under the M&amp;A Rules for an offering because (i) the
CSRC currently has not issued any definitive rule or interpretation concerning whether offerings like ours are subject to this regulation;
and (ii) we did not acquire any equity interests or assets of a &#8220;PRC domestic company&#8221; as such terms are defined under the
M&amp;A Rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
our PRC counsel has further advised us that there remains some uncertainty as to how the M&amp;A Rules will be interpreted or implemented
in the context of an overseas offering, and its opinions summarized above are subject to any new laws, rules and regulations or detailed
implementations and interpretations in any form relating to the M&amp;A Rules. We cannot assure you that relevant PRC governmental authorities,
including the CSRC, would reach the same conclusion as our PRC counsel, and hence, we may face regulatory actions or other sanctions
from them. Furthermore, relevant PRC governmental authorities promulgated the Opinions on Strictly Cracking Down Illegal Securities Activities,
which provided that the administration and supervision of overseas-listed China-based companies will be strengthened, and the special
provisions of the State Council on overseas issuance and listing of shares by such companies will be revised, clarifying the responsibilities
of domestic industry competent authorities and regulatory authorities. However, the Opinions on Strictly Cracking Down Illegal Securities
Activities were only issued recently, leaving uncertainties regarding the interpretation and implementation of these opinions. It is
possible that any new rules or regulations may impose additional requirements on us. In addition, on July 10, 2021 and November 14, 2021,
the CAC issued a revised draft of the Measures for Cybersecurity Review and a draft of the Regulations on the Network Data Security,
respectively, for public comments, according to which, among others, operators of &#8220;critical information infrastructure&#8221; or
data processors holding over one million users&#8217; personal information shall apply to the Cybersecurity Review Office for a cybersecurity
review before any listing on a foreign stock exchange. It is uncertain when the final measures will be issued and take effect, how they
will be enacted, interpreted or implemented, and whether they will affect us. If it is determined in the future that CSRC approval or
other procedural requirements are required to be met for and prior to an offering, it is uncertain whether we can or how long it will
take us to obtain such approval or complete such procedures and any such approval could be rescinded. Any failure to obtain or delay
in obtaining such approval or completing such procedures for an offering, or a rescission of any such approval, could subject us to sanctions
by the relevant PRC governmental authorities. The governmental authorities may impose restrictions and penalties on our operations in
China, such as the suspension of our apps and services, revocation of our licenses, shutting down part or all of our operations, limiting
our ability to pay dividends outside of China, delaying or restricting the repatriation of the proceeds from an offering into China,
or may take other actions that could have a material adverse effect on our business, financial condition, results of operations and prospects,
as well as the trading price of the ordinary shares. The PRC governmental authorities may also take actions requiring us, or making it
advisable for us, to halt an offering before settlement and delivery of the ordinary shares offered hereby. Consequently, if you engage
in market trading or other activities in anticipation of and prior to settlement and delivery, you do so at the risk that settlement
and delivery may not occur. In addition, if the PRC governmental authorities later promulgate new rules or requirements that we obtain
their approvals for filings, registrations or other kinds of authorizations for an offering, we cannot assure you that we can obtain
the approval, authorizations, or complete required procedures or other requirements in a timely manner, or at all, or obtain a waiver
of the requisite requirements if and when procedures are established to obtain such a waiver.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Draft Rules Regarding Overseas Listings were released by the CSRC for public consultation. While such rules have not yet come into effect,
the Chinese government may exert more oversight and control over overseas public offerings conducted by China-based issuers, which could
significantly limit or completely hinder our ability to offer or continue to offer our securities to investors and could cause the value
of our securities to significantly decline or become worthless.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 24, 2021, the CSRC and relevant departments of the State Council issued the Draft Rules Regarding Overseas Listings, which aim
to regulate overseas securities offerings and listings by China-based companies, for public consultation. The Draft Rules Regarding Overseas
Listing aim to lay out the filing regulation arrangement for both direct and indirect overseas listing and clarify the determination
criteria for indirect overseas listing in overseas markers. Where an enterprise whose principal business activities are conducted in
mainland China seeks to issue and list its shares in the name of an overseas enterprise based on equity, assets, income, or other similar
rights and interests of the relevant domestic enterprise in mainland China, such activities are deemed an indirect overseas issuance
and listing. According to the Draft Rules Regarding Overseas Listings, among other things, after making initial applications with overseas
stock markets for initial public offerings or listings, or after the completion of issuance of overseas listed securities by the overseas
listed issuer, all China-based companies shall file the required filing materials with the CSRC within three working days. In addition,
overseas offerings and listings may be prohibited for such China-based companies when any of the following applies: (i) if the intended
securities offerings and listings are specifically prohibited by the PRC laws and regulations; (ii) if the intended securities offerings
and listings may constitute a threat to, or endanger national security as reviewed and determined by competent authorities under the
State Council in accordance with laws; (iii) if there are material ownership disputes over applicants&#8217; equity interests, major
assets, core technologies, or the others; (iv) if, in the past three years, applicants&#8217; domestic enterprises, controlling shareholders,
or de facto controllers have committed corruption, bribery, embezzlement, misappropriation of property, or other criminal offenses disruptive
to the order of the socialist market economy, or are currently under judicial investigation for suspicion of criminal offenses, or are
under investigation for suspicion of major violations; (v) if, in the past three years, any directors, supervisors, or senior executives
of applicants have been subject to administrative punishments for severe violations, or are currently under judicial investigation for
suspicion of criminal offenses, or are under investigation for suspicion of major violations; or (vi) other circumstances as prescribed
by the State Council. The Draft Administrative Provisions further stipulate that a fine between RMB1 million (approximately $157,255)
and RMB10 million (approximately $1,572,550) may be imposed if an applicant fails to fulfill the filing requirements with the CSRC or
conducts an overseas offering or listing in violation of the Draft Rules Regarding Overseas Listings, and in cases of severe violations,
a parallel order to suspend relevant businesses or halt operations for rectification may be issued, and relevant business permits or
operational license revoked.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, the Draft Rules Regarding Overseas Listings have not been formally promulgated, and neither we, our
subsidiaries, nor any of the PRC operating entities have been required to complete the filing procedures. However, uncertainties remain
as to its enactment or future interpretations and implementations. Our PRC counsel, AllBright Law Offices (Fuzhou), has advised us that,
even if the final rules are promulgated as proposed in the current Draft Rules Regarding Overseas Listings, none of the situations that
would clearly prohibit overseas offering and listings would apply to us. In addition, we would only need to submit the filing materials
and no CSRC approval would be required under such rules. Notwithstanding the above, our PRC counsel has further advised us that uncertainties
still exist as to whether we, our subsidiaries, or the PRC operating entities are required to obtain permissions from the Chinese government
that is required to approve of our operations and/or offering. In the event that we, our subsidiaries, or the PRC operating entities
are subject to the compliance requirements, we cannot assure you that any of these entities will be able to receive clearance of such
compliance requirements in a timely manner, or at all. Any failure of our Company, our subsidiaries, or the PRC operating entities to
fully comply with new regulatory requirements may subject us to regulatory actions, such as fines, relevant businesses or operations
suspension for rectification, revocation of relevant business permits or operational license, or other sanctions, which may significantly
limit or completely hinder our ability to offer or continue to offer our securities cause significant disruption to our business operations,
severely damage our reputation, materially and adversely affect our financial condition and results of operations and cause our securities
to significantly decline in value or become worthless.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>PRC
regulation of loans to, and direct investments in, PRC entities by offshore holding companies may delay or prevent us from using proceeds
from our offerings and/or other financing activities to make loans or additional capital contributions to our PRC operating subsidiaries.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an offshore holding company with PRC subsidiaries, we may transfer funds to our PRC subsidiaries or finance our operating entity by means
of loans or capital contributions. Any capital contributions or loans that we, as an offshore entity, make to our Company&#8217;s PRC
subsidiaries are subject to PRC regulations. Any loans to our PRC subsidiaries, which are foreign-invested enterprises, cannot exceed
statutory limits based on the difference between the amount of our investments and registered capital in such subsidiaries, and shall
be registered with China&#8217;s State Administration of Foreign Exchange (&#8220;SAFE&#8221;), or its local counterparts. Furthermore,
any capital increase contributions we make to our PRC subsidiaries, which are foreign-invested enterprises, are subject to the requirement
of making necessary filings in the Foreign Investment Comprehensive Management Information System, or FICMIS, and registration with other
government authorities in China. We may not be able to obtain these government registrations or approvals on a timely basis, if at all.
If we fail to obtain such approvals or make such registration, our ability to make equity contributions or provide loans to our Company&#8217;s
PRC subsidiaries or to fund their operations may be negatively affected, which may adversely affect their liquidity and ability to fund
their working capital and expansion projects and meet their obligations and commitments. As a result, our liquidity and our ability to
fund and expand our business may be negatively affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
must remit proceeds of any future offerings to China before they may be used to benefit our business in China, and this process may take
several months to complete.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds of our future offerings must be sent back to China, and the process for sending such proceeds back to China may take as long
as six months after the closing of an offering. As an offshore holding company of our PRC operating subsidiaries, we may make loans to
our PRC subsidiaries, or we may make additional capital contributions to our PRC subsidiaries. Any loans to our PRC subsidiaries are
subject to PRC regulations. For example, loans by us to our subsidiaries in China, which are foreign-invested enterprises, to finance
their activities cannot exceed statutory limits and must be registered with SAFE.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
remit the proceeds of our offerings, we must take the following steps:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First, we will open a special
    foreign exchange account for capital account transactions. To open this account, we must submit to SAFE certain application forms,
    identity documents, transaction documents, form of foreign exchange registration of overseas investments of the domestic residents,
    and foreign exchange registration certificate of the invested company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second, we will remit the offering proceeds into this
    special foreign exchange account.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third, we will apply for
    settlement of the foreign exchange. In order to do so, we must submit to SAFE certain application forms, identity documents, payment
    order to a designated person, and a tax certificate.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timing of the process is difficult to estimate because the efficiencies of different SAFE branches can vary significantly. Ordinarily
the process takes several months but is required by law to be accomplished within 180 days of application.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also decide to finance our subsidiaries by means of capital contributions. These capital contributions must be subject to the requirement
of making necessary filings in the FICMIS, and registration with other government authorities in China. We cannot assure you that we
will be able to obtain these government approvals on a timely basis, if at all, with respect to future capital contributions by us to
our subsidiaries. If we fail to receive such approvals, our ability to use the proceeds of any future offerings and to capitalize our
Chinese operations may be negatively affected, which could adversely affect our liquidity and our ability to fund and expand our business.
If we fail to receive such approvals, our ability to use the proceeds of our future offerings and to capitalize our Chinese operations
may be negatively affected, which could adversely affect our liquidity and our ability to fund and expand our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may rely on dividends paid by our subsidiaries for our cash needs, and any limitation on the ability of our subsidiaries to make payments
to us could have a material adverse effect on our ability to conduct business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a holding company, we conduct substantially all of our business through our consolidated subsidiaries incorporated in China. We may rely
on dividends paid by these PRC subsidiaries for our cash needs, including the funds necessary to pay any dividends and other cash distributions
to our shareholders, to service any debt we may incur and to pay our operating expenses. The payment of dividends by entities established
in China is subject to limitations. Regulations in China currently permit payment of dividends only out of accumulated profits as determined
in accordance with accounting standards and regulations in China. In accordance with the Article 166, 168 of the Company Law of the PRC
(Amended in 2018) (the &#8220;PRC Company Law&#8221;), each of our PRC subsidiaries is required to set aside at least 10% of its after-tax
profit based on PRC accounting standards each year to its general reserves or statutory capital reserve fund until the aggregate amount
of such reserves reaches 50% of its respective registered capital. A company may discontinue the contribution when the aggregate sum
of the statutory surplus reserve is more than 50% of its registered capital. The statutory common reserve fund of a company shall be
used to cover the losses of the company, expand the business and production of the company or be converted into additional capital. As
a result, our PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to us in the form of dividends.
In addition, if any of our PRC subsidiaries incurs debt on its own behalf in the future, the instruments governing the debt may restrict
its ability to pay dividends or make other distributions to us. Any limitations on the ability of our PRC subsidiaries to transfer funds
to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business,
pay dividends and otherwise fund and conduct our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adverse
changes in political, economic and social conditions, as well as government policies in China could have a material adverse effect on
our business results of operations, financial conditions and prospects.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our business operations are conducted in China. Accordingly, our financial condition, results of operations and prospects are,
to a material extent, subject to economic, political and legal developments in China. The economy in China differs from the economies
of developed countries in many respects, including, among other things, the degree of government involvement, control of investment,
level of economic development, growth rate, foreign exchange controls and resource allocation. Although the economy in China has been
transitioning from a planned economy to a more market-oriented economy for about four decades, a substantial portion of productive assets
in China is still owned by the PRC government. The PRC government also exercises significant control over the economic growth of China
through allocating resources, controlling payments of foreign currency denominated obligations, setting monetary policy and providing
preferential treatment to particular industries or companies. In recent years, the PRC government has implemented measures emphasizing
the utilization of market forces in economic reform, the reduction of state ownership of productive assets and the establishment of sound
corporate governance practices in business enterprises. Some of these measures benefit the overall economy in China, but may adversely
affect us. For example, our financial condition and results of operations may be adversely affected by government policies on the Chinese
patent medicine industry in China or changes in tax regulations applicable to us. If the business environment in China deteriorates,
our business in China may also be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
to the PRC legal system could have an adverse effect on us.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PRC legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions under the civil
law system may be cited for reference but have limited precedential value. Since these laws and regulations are relatively new and the
PRC legal system continues to rapidly evolve, the interpretations of many laws, regulations and rules are not always uniform and the
enforcement of these laws, regulations and rules involves uncertainties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
1979, the PRC government began to promulgate a comprehensive system of laws and regulations governing economic matters in general. The
overall effect of legislation over the past decades has significantly enhanced the protections afforded to various forms of foreign investments
in China. However, recently enacted laws and regulations may not sufficiently cover all aspects of economic activities in China. In particular,
the interpretation and&#160;enforcement of these laws and regulations involve uncertainties. Since PRC administrative and court authorities
have significant&#160;discretion in interpreting and implementing statutory provisions and contractual terms, it may be difficult to
evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy. These uncertainties may affect
our judgment on the relevance of legal requirements and our ability to enforce our contractual rights or tort claims.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or
at all and may have retroactive effect. As a result, we may not be aware of our violation of any of these policies and rules until sometime
after the violation. In addition, any administrative and court&#160;proceedings in China may be protracted, resulting in substantial
costs and diversion of resources and management attention.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Labor
Contract Law and other labor-related laws in the PRC may adversely affect our business and our results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2012, the PRC government released the revision of the Labor Contract Law, which became effective on July 1, 2013. Pursuant
to the Labor Contract Law, employers are subject to stricter requirements in terms of signing labor contracts, minimum wages, paying
remuneration, determining the term of employees&#8217; probation and unilaterally terminating labor contracts. In the event that we decide
to terminate some of our employees or otherwise change our employment or labor practices, the Labor Contract Law and its implementation
rules may limit our ability to effect those changes in a desirable or cost-effective manner, which could adversely affect our business
and results of operations. According to the PRC Social Insurance Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#31038;&#20250;&#20445;&#38505;&#27861;&#12299;),
employees must participate in pension insurance, work-related injury insurance, medical insurance, unemployment insurance and maternity
insurance and the employers must, together with their employees or separately, pay the social insurance premiums for such employees.
In accordance with the Regulations on the Management of Housing Fund which was promulgated by the State Council in 1999 and amended in
2002 and 2019, employers must register at the designated administrative centers and open bank accounts for depositing employees&#8217;
housing funds. As the interpretation and implementation of labor-related laws and regulations are still evolving, we cannot assure you
that our employment practices do not and will not violate labor-related laws and regulations in China, which may subject us to labor
disputes or government investigations. As of the date of this annual report, we believe that we are in substantial compliance with labor-related
laws and regulations in China, and we have not been notified of any instance of noncompliance. We cannot assure you that we will be able
to comply with all labor-related law and regulations regarding including those relating to obligations to make social insurance payments
and contribute to the housing provident fund. If we are deemed to have violated relevant labor laws and regulations, we could be required
to provide additional compensation to our employees and our business, financial condition and results of operations will be adversely
affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
are significant uncertainties under the Enterprise Income Tax Law, or the EIT Law, relating to the withholding tax liabilities of our
PRC subsidiaries, and dividends payable by our PRC subsidiaries to our offshore subsidiaries may not qualify to enjoy certain treaty
benefits.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
passed the EIT Law, and it is implementing rules, both of which became effective on January 1, 2008. Under the PRC EIT Law and its implementation
rules, the profits of an FIE generated through operations, which are distributed to its immediate holding company outside the PRC, will
be subject to a withholding tax rate of 10%. Pursuant to a special arrangement between Hong Kong and the PRC, such rate may be reduced
to 5% if a Hong Kong resident enterprise owns more than 25% of the equity interest in the PRC company. Our PRC subsidiaries, Universe
Technology, Jiangxi Universe and Universe Trade, are wholly-owned by our Hong Kong subsidiary. Moreover, under the Notice of the State
Administration of Taxation on Issues regarding the Administration of the Dividend Provision in Tax Treaties promulgated on February 20,
2009, the taxpayer needs to satisfy certain conditions to enjoy the benefits under a tax treaty. The beneficial owner of the relevant
dividends and the corporate shareholder to receive dividends from the PRC subsidiary must have continuously met the direct ownership
thresholds during the 12 consecutive months preceding the receipt of the dividends. Further, the State Administration of Taxation (the
&#8220;SAT&#8221;) promulgated the Notice on How to Comprehend and Determine the &#8220;Beneficial Owner&#8221; in Tax Treaties (&#12298;&#22269;&#23478;&#31246;&#21153;&#24635;&#23616;&#20851;&#20110;&#31246;&#25910;&#21327;&#23450;&#20013;&#8221;&#21463;&#30410;&#25152;&#26377;&#20154;&#8221;&#26377;&#20851;&#38382;&#39064;&#30340;&#20844;&#21578;&#12299;)
on February 3, 2018, which limits the &#8220;beneficial owner&#8221; to individuals, projects or other organizations normally engaged
in substantive operations, and sets forth certain detailed factors in determining the &#8220;beneficial owner&#8221; status. In current
practice, a Hong Kong enterprise must obtain a tax resident certificate from the relevant Hong Kong tax authority to apply for the 5%
lower PRC withholding tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we
cannot assure you that we will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority. As of the date
of this annual report, we have not commenced the application process for a Hong Kong tax resident certificate from the relevant Hong
Kong tax authority, and there is no assurance that we will be granted such a Hong Kong tax resident certificate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
after we obtain the Hong Kong tax resident certificate, we are required by applicable tax laws and regulations to file required forms
and materials with relevant PRC tax authorities to prove that we can enjoy 5% lower PRC withholding tax rate. Universe HK intends to
obtain the required materials and file with the relevant tax authorities when it plans to declare and pay dividends, but there is no
assurance that the PRC tax authorities will approve the 5% withholding tax rate on dividends received from Universe HK.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to qualify for or obtain any preferential tax treatments that are available in China could adversely affect our results of operations
and financial condition.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EIT Law and its implementation rules generally impose a uniform income tax rate of 25% on all enterprises, but grant preferential treatment
to &#8220;high and new technology enterprises strongly supported by the state,&#8221; or HNTEs, with a preferential enterprise tax rate
of 15%. Our subsidiaries, Jiangxi Universe and Universe Trade, are currently accredited as HNTE and will enjoy the reduced income tax
rate of 15% for three years through November 2025 and December 2023, respectively. According to the relevant administrative measures,
to qualify as an &#8220;HNTE,&#8221; Jiangxi Universe must meet certain financial and non-financial criteria and complete verification
procedures with the administrative authorities. Continued qualification as an HNTE is subject to review by the relevant government authorities
in China every three years, and in practice, certain local tax authorities may require annual evaluation of the qualification. In the
event that Jiangxi Universe fails to renew its status as&#160;HNTE&#160;with the local tax authority, it will be subject to the standard
PRC enterprise income tax rate of 25%.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Under
the EIT Law, we may be classified as a &#8220;Resident Enterprise&#8221; of China. Such classification will likely result in unfavorable
tax consequences to us and our non-PRC shareholders.&#160;</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EIT Law and its implementing rules became effective on December 9, 2019. Under the EIT Law, an enterprise established outside of China
with &#8220;de facto management bodies&#8221; within China is considered a &#8220;resident enterprise,&#8221; meaning that it can be
treated in a manner similar to a Chinese enterprise for enterprise income tax purposes. The implementing rules of the EIT Law define
de facto management as &#8220;substantial and overall management and control over the production and operations, personnel, accounting,
and properties&#8221; of the enterprise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the PRC tax authorities determine that we are a &#8220;resident enterprise&#8221; for PRC enterprise income tax purposes, a number of
unfavorable PRC tax consequences could follow. First, we may be subject to the enterprise income tax at a rate of 25% on our worldwide
taxable income as well as PRC enterprise income tax reporting obligations. In our case, this would mean that income such as non-China
source income would be subject to PRC enterprise income tax at a rate of 25%. Currently, we do not have any non-China source income,
as we conduct our sales in China. Second, under the EIT Law and its implementing rules, dividends paid to us from our PRC subsidiaries
would be deemed as &#8220;qualified investment income between resident enterprises&#8221; and therefore qualify as &#8220;tax-exempt
income&#8221; pursuant to the clause 26 of the EIT Law. Finally, it is possible that future guidance issued with respect to the new &#8220;resident
enterprise&#8221; classification could result in a situation in which the dividends we pay with respect to our ordinary shares, or the
gain our non-PRC shareholders may realize from the transfer of our ordinary shares, may be treated as PRC-sourced income and may therefore
be subject to a 10% PRC withholding tax. The EIT Law and its implementing regulations are, however, relatively new and ambiguities exist
with respect to the interpretation and identification of PRC-sourced income, and the application and assessment of withholding taxes.
If we are required under the EIT Law and its implementing regulations to withhold PRC income tax on dividends payable to our non-PRC
shareholders, or if non-PRC shareholders are required to pay PRC income tax on gains on the transfer of their ordinary shares, our business
could be negatively impacted and the value of your investment may be materially reduced. Further, if we were to be treated as a &#8220;resident
enterprise&#8221; by PRC tax authorities, we would be subject to taxation in both China and such countries in which we have taxable income,
and our PRC tax may not be creditable against such other taxes.<b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
the extent cash in and assets of the business is in the PRC or a PRC entity, the funds and assets may not be available to fund operations
or for other use outside of the PRC due to interventions in or the imposition of restrictions and limitations on the ability of our Company
or our subsidiaries by the PRC government to transfer cash and assets.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relevant
PRC laws and regulations permit the companies in mainland China to pay dividends only out of their retained earnings, if any, as determined
in accordance with PRC accounting standards and regulations. Additionally, each of the companies in mainland China are required to set
aside at least 10% of its after-tax profits each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered
capital. The companies in mainland China are also required to further set aside a portion of their after-tax profits to fund the employee
welfare fund, although the amount to be set aside, if any, is determined at their discretion. These reserves are not distributable as
cash dividends. Furthermore, if we determine to pay dividends on any of our ordinary shares in the future, as a holding company, we will
rely on payments from subsidiaries of Jiangxi Universe to Jiangxi Universe, and from Jiangxi Universe to Universe Technology, and the
distribution of such payments to Universe HK, and then to our Company. If our PRC subsidiaries and the PRC operating entities incur debt
on their own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other payments
to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cash dividends, if any, will be paid in U.S. dollars. If we are considered a tax resident enterprise of mainland China for tax purposes,
any dividends we pay to our overseas shareholders may be regarded as China-sourced income and as a result may be subject to PRC withholding
tax. See &#8220;&#8212;Under the EIT Law, we may be classified as a &#8220;Resident Enterprise&#8221; of China. Such classification will
likely result in unfavorable tax consequences to us and our non-PRC shareholders.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PRC government also imposes controls on the convertibility of Renminbi into foreign currencies and, in certain cases, the remittance
of currency out of mainland China. The majority of our and the PRC operating entities&#8217; income is received in Renminbi and shortages
in foreign currencies may restrict our ability to pay dividends or other payments, or otherwise satisfy our foreign currency denominated
obligations, if any. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions,
interest payments and expenditures from trade-related transactions, can be made in foreign currencies without prior approval from the
State Administration of Foreign Exchange as long as certain procedural requirements are met. Approval from appropriate government authorities
is required if Renminbi is converted into foreign currency and remitted out of mainland China to pay capital expenses such as the repayment
of loans denominated in foreign currencies. The PRC government may, at its discretion, impose restrictions on access to foreign currencies
for current account transactions and if this occurs in the future, we may not be able to pay dividends in foreign currencies to our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
limitation on the ability of our PRC subsidiaries and the PRC operating entities to distribute dividends or other payments to their respective
shareholders could materially and adversely limit our ability to conduct operations, make investments, engage in acquisitions, or undertake
other activities requiring working capital. However, our operations and business, including investment and/or acquisitions by our PRC
subsidiaries and the PRC operating entities within mainland China, will not be affected as long as the capital is not transferred in
or out of mainland China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be exposed to liabilities under the Foreign Corrupt Practices Act and Chinese anti-corruption law.&#160;</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), and other laws that prohibit improper payments or offers
of payments to foreign governments and their officials and political parties by U.S. persons and issuers, as defined by the statute,
for the purpose of obtaining or retaining business. We are also subject to Chinese anti-corruption laws, which strictly prohibit the
payment of bribes to government officials. We have operations, agreements with third parties, and make sales in China, which may expose
us to claims of corruption. Our activities in China create the risk of unauthorized payments or offers of payments by one of the employees
of our Company, because these parties are not always subject to our control.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that, as of the date of this annual report on Form 20-F, we have complied in all material respects with the provisions of
the FCPA and Chinese anti-corruption law, our existing safeguards and any future improvements may prove to be less than effective, and
the employees of our Company may engage in conduct for which we might be held responsible. Violations of the FCPA or Chinese anti-corruption
law may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business,
operating results and financial condition. In addition, the government may seek to hold our Company liable for successor liability FCPA
violations committed by companies in which we invest or that we acquire.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
enforcement of stricter advertisement laws and regulations in the PRC may adversely affect our business and our profitability.</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2018, the SCNPC promulgated the PRC Advertising Law, effective on October 26, 2018. According to the Advertising Law, advertisements
shall not have any false or misleading content, or defraud or mislead consumers. Furthermore, an advertisement will be deemed as a &#8220;false
advertisement&#8221; if any of the following situations exist: (i) the advertised product or service does not exist; (ii) there is any
inconsistency that has a material impact on the decision to purchase in what is included in the advertisement with the actual circumstances
with respect to the product&#8217;s performance, functions, place of production, uses, quality, specification, ingredient, price, producer,
term of validity, sales condition, and honors received, among others, or the service&#8217;s contents, provider, form, quality, price,
sales condition, and honors received, among others, or any commitments, among others, made on the product or service; (iii) fabricated,
forged or unverifiable scientific research results, statistical data, investigation results, excerpts, quotations, or other information
have been used as supporting material; (iv) effect or results of using the good or receiving the service are fabricated; or (v) other
circumstances where consumers are defrauded or misled by any false or misleading content.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current marketing relies on advertisements on media platforms. The laws and regulations of advertising are relatively new and evolving
and there is substantial uncertainty as to the interpretation of &#8220;false advertisement&#8221; by the State Administration for Industry
and Commerce (the &#8220;SAIC&#8221;). If any of the advertisements published by our customers is deemed to be a &#8220;false advertisement&#8221;
by the SAIC or its local branch, we could be subject to various penalties, such as discontinuation of publishing the target advertisement,
imposition of fines and obligations to eliminate any adverse effects incurred by such&#160;false advertisement. Any such penalties may
disrupt our business and our competition with competitors, and could affect our results of operations and financial conditions.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
were not in compliance with the PRC&#8217;s regulations relating to employee&#8217;s social insurance and housing funds prior to April
2020, and as a result, we may be subject to penalties for such non-compliance.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Social Insurance Law of the PRC (the &#8220;Social Insurance Law&#8221;), which was promulgated by the SCNPC on October 28, 2010
and amended on December 29, 2018, and the Administrative Regulations on the Housing Provident Funds, which was promulgated by the State
Council on April 3, 1999 and last amended on March 24, 2019, employers are required to make contributions, on behalf of their employees,
to a number of social security funds, including funds for basic pension insurance, unemployment insurance, basic medical insurance, occupational
injury insurance, maternity insurance and to housing provident funds. Prior to April 2020, we only contributed to the social insurance
and housing provident funds for some, but not all, of our employees. Since April 2020, we have started contributing to the social insurance
and housing funds for our eligible full-time employees in accordance with the aforementioned PRC laws and regulations. Even though we
are currently making contributions in accordance with applicable PRC laws, there is a risk that the labor security administration authority
may take enforcement action to collect from us all the outstanding contributions of the social insurance and housing provident funds
required to be made for the employees in the past, and we may be subject to a late charge at the rate of 0.05% per day on the total outstanding
contribution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
regulatory bodies may be limited in their ability to conduct investigations or inspections of our operations in China.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), the U.S. Department of Justice and other U.S. authorities may also have
difficulties in bringing and enforcing actions against us or our directors or executive officers in the PRC. The SEC has stated that
there are significant legal and other obstacles to obtaining information needed for investigations or litigation in China. Although the
authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or
region to implement cross-border supervision and administration, such cooperation with the securities regulatory authorities in Hong
Kong or other jurisdictions may not be efficient in the absence of mutual and practical cooperation mechanism. Furthermore, China has
recently adopted a revised securities law that became effective on March 1, 2020, Article 177 of which provides, among other things,
that no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the territory
of the PRC. Accordingly, without governmental approval in China, no entity or individual in China may provide documents and information
relating to securities business activities to overseas regulators when it is under direct investigation or evidence discovery conducted
by overseas regulators. While detailed interpretation of or implementation rules under Article 177 have yet to be promulgated, it could
present significant legal and other obstacles to obtaining information needed for investigations and litigation conducted outside of
China, which may further increase difficulties faced by you in protecting your interests. See also &#8220;&#8212;You may experience difficulty
in effecting service of process, enforcing foreign judgments or bringing actions against our directors and officers.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>You
may experience difficulty in effecting service of process, enforcing foreign judgments or bringing actions against our directors and
officers.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Cayman Islands exempted company with limited liability and most of our assets are located outside of the United States. In addition,
almost all of our directors and officers are nationals or residents of the PRC, including our chief executive officer and chairman of
the board of directors, Mr. Gang Lai, our chief financial officer, Ms. Lin Yang, and our directors, Mr. Jiawen Pang and Mr. Ding Zheng,
and all or a substantial portion of their assets are located outside the United States. As a result, it may be difficult or impossible
for you to effect service of process within the United States upon our directors and executive officers. It may also be difficult for
you to enforce in the United States courts judgments obtained in the United States courts based on the civil liability provisions of
the United States federal securities laws against us and our officers and directors who reside and whose assets are located outside the
United States.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there is uncertainty as to whether the courts of the Cayman Islands or the PRC would recognize or enforce judgments of the
United States courts against us or such persons predicated upon the civil liability provisions of the securities laws of the United States
or any state. The recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may
recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties
between China and the country where the judgment is made or on principles of reciprocity between jurisdictions. China does not have any
treaties or other forms of reciprocity with the United States that provide for the reciprocal recognition and enforcement of foreign
judgments. In addition, according to the PRC Civil Procedures Law, the PRC courts will not enforce a foreign judgment against us or our
directors and officers if they decide that the judgment violates the basic principles of PRC laws or national sovereignty, security or
public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the
United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
pursuant to the PRC Civil Procedures Law, any matter, including matters arising under U.S. federal securities laws, in relation to assets
or personal relationships may be brought as an original action in China, only if the institution of such action satisfies the conditions
specified in the PRC Civil Procedures Law. As a result of the conditions set forth in the PRC Civil Procedures Law and the discretion
of the PRC courts to determine whether the conditions are satisfied and whether to accept the action for adjudication, there remains
uncertainty as to whether an investor will be able to bring an original action in a PRC court based on U.S. federal securities laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
our business is conducted in the RMB and the price of our ordinary shares is quoted in United States dollars, changes in currency conversion
rates may affect the value of your investments.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is conducted in the PRC, our books and records are maintained in the RMB, the legal currency of the PRC, and the financial statements
that we file with the SEC and provide to our shareholders are presented in United States dollars. Changes in the exchange rate between
the RMB and U.S. dollars affect the value of our assets and the results of our operations in U.S. dollars. The value of the RMB against
the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in the PRC&#8217;s political and economic
conditions and perceived changes in the economy of the PRC and the United States. Any significant revaluation of the RMB may materially
and adversely affect our cash flows, revenue and financial condition. Further, our securities will be offered in United States dollars,
and we will need to convert any net proceeds we receive into RMB in order to use the funds for our business. Changes in the conversion
rate between the United States dollar and the RMB will affect that amount of proceeds we will have available for our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Government
control in currency conversion may adversely affect our financial condition, our ability to remit dividends, and the value of your investment.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PRC government imposes controls on the convertibility of the Renminbi into foreign currencies and, in certain cases, the remittance of
currency out of China. We receive substantially all of our revenues in Renminbi. Under our current corporate structure, our Cayman Islands
holding company may rely on dividend payments from our PRC subsidiaries to fund any cash and financing requirements we may have.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
existing PRC foreign exchange regulations, the Renminbi cannot be freely converted into any foreign currency, and conversion and remittance
of foreign currencies are subject to PRC foreign exchange regulations. It cannot be guaranteed that under a certain exchange rate, we
will have sufficient foreign exchange to meet our foreign exchange requirements. Under the current PRC foreign exchange control system,
foreign exchange transactions under the current account conducted by us, including the payment of dividends, do not require advance approval
from SAFE, but we are required to present documentary evidence of such transactions and conduct such transactions at designated foreign
exchange banks within China that have the licenses to carry out foreign exchange business. Foreign exchange transactions under the capital
account conducted by us, however, must be approved in advance by SAFE.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
existing foreign exchange regulations, we are able to pay dividends in foreign currencies without prior approval from SAFE by complying
with certain procedural requirements. However, we cannot assure you that these foreign exchange policies regarding payment of dividends
in foreign currencies will continue in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fact, in light of the flood of capital outflows of China in 2016 due to the weakening Renminbi, the PRC government has imposed more restrictive
foreign exchange policies and stepped up scrutiny of major outbound capital movement including overseas direct investment. More restrictions
and substantial vetting process may be put in place by SAFE to regulate cross-border transactions falling under the capital account.
If any of our shareholders regulated by such policies fails to satisfy the applicable overseas direct investment filing or approval requirement
timely or at all, it may be subject to penalties from the relevant PRC authorities. The PRC government may, at its discretion, further
restrict access in the future to foreign currencies for current account transactions. If the foreign exchange control system prevents
us from obtaining sufficient foreign currencies to satisfy our foreign currency demands, we may not be able to pay dividends in foreign
currencies to our shareholders, including holders of the ordinary shares. Our capital expenditure plans and our business, operating results
and financial condition may be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business may be materially and adversely affected if any of our PRC subsidiaries declare bankruptcy or become subject a dissolution or
liquidation proceeding.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Enterprise Bankruptcy Law of the PRC, or the Bankruptcy Law, came into effect on June 1, 2007. The Bankruptcy Law provides that an enterprise
will be liquidated if the enterprise fails to settle its debts as and when they fall due and if the enterprise&#8217;s assets are, or
are demonstrably, insufficient to clear such debts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
PRC subsidiaries hold certain assets that are important to our business operations. If any of our PRC subsidiaries undergoes a voluntary
or involuntary liquidation proceeding, unrelated third-party creditors may claim rights to some or all of these assets, thereby hindering
our ability to operate our business, which could materially and adversely affect our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our PRC subsidiaries undergoes a voluntary or involuntary liquidation proceeding, prior approval from SAFE for remittance of foreign
exchange to our shareholders abroad is no longer required, but we still need to conduct a registration process with the SAFE local branch.
It is not clear whether &#8220;registration&#8221; is a mere formality or involves the kind of substantive review process undertaken
by SAFE and its relevant branches in the past.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current corporate structure and business operations may be affected by the newly enacted PRC Foreign Investment Law.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2019, the National People&#8217;s Congress approved the Foreign Investment Law, which became effective on January 1, 2020.
The PRC Foreign Investment Law defines the &#8220;foreign investment&#8221; as the investment activities in China conducted directly
or indirectly by foreign investors in the following manners: (i) the foreign investor, by itself or together with other investors establishes
a foreign invested enterprises in China; (ii) the foreign investor acquires shares, equities, asset tranches, or similar rights and interests
of enterprises in China; (iii) the foreign investor, by itself or together with other investors, invests and establishes new projects
in China; (iv) the foreign investor invests through other approaches as stipulated by laws, administrative regulations or otherwise regulated
by the State Council. If our PRC subsidiaries are recognized as &#8220;foreign investment enterprises,&#8221; PRC governmental authorities
will regulate foreign investment by applying the principle of re-entry national treatment together with a &#8220;negative list,&#8221;
which will be promulgated by or promulgated with approval by the State Council. Foreign investors are prohibited from making any investments
in the industries which are listed as &#8220;prohibited&#8221; in such negative list; and, after satisfying certain additional requirements
and conditions as set forth in the &#8220;negative list,&#8221; are allowed to make investments in industries which are listed as &#8220;restricted&#8221;
in such negative list. For any foreign investor that fails to comply with the negative list, the competent authorities are entitled to
ban its investment activities, require such investor to take measures to correct its non-compliance and impose other penalties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
production and distribution activities that we conduct through our PRC subsidiaries are not subject to foreign investment restrictions
or prohibitions set forth in the Special Administrative Measures for the Access of Foreign Investment (Negative List) (Edition 2021)
(the &#8220;2021 Negative List&#8221;). We do not intend to conduct any types of business activities restricted or prohibited under the
2021 Negative List in the future. However, it is unclear whether any updated &#8220;negative list&#8221; to be published by the State
Council in the future will be different from the 2021 Negative List. If future laws, administrative regulations or provisions of the
State Council set forth restrictions or prohibitions on foreign investment in our current business activities, and that our PRC subsidiaries
are recognized as &#8220;foreign investment enterprises,&#8221; we may be required to take appropriate and timely measures to comply
with such regulatory requirements. If we fail to do so, our business operations could be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with PRC regulations relating to the establishment of offshore special purpose companies by PRC residents may subject our PRC
resident shareholders to personal liability, may limit our ability to acquire PRC companies or to inject capital into our PRC subsidiaries,
may limit the ability of our PRC subsidiaries to distribute profits to us or may otherwise materially and adversely affect us</i></b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Circular on relevant issues concerning Foreign Exchange Administration of Overseas Investment and Financing and Return Investments
Conducted by Domestic Residents through Overseas Special Purpose Vehicle (the &#8220;Circular 37&#8221;), which was promulgated by SAFE,
and became effective on July 4, 2014, (1) a PRC resident must register with the local SAFE branch before he or she contributes assets
or equity interests in an overseas special purpose vehicle, or an Overseas SPV, that is directly established or indirectly controlled
by the PRC resident for the purpose of conducting investment or financing; and (2) following the initial registration, the PRC resident
is also required to register with the local SAFE branch for any major change, in respect of the Overseas SPV, including, among other
things, a change in the Overseas SPV&#8217;s PRC resident shareholder, name of the Overseas SPV, term of operation, or any increase or
reduction of the contributions by the PRC resident, share transfer or swap, and merger or division. Additionally, pursuant to the Circular
of SAFE on Further Simplifying and Improving the Direct Investment-related Foreign Exchange Administration Policies (the &#8220;Circular
13&#8221;), which was promulgated on February 13, 2015 and became effective on June 1, 2015, the aforesaid registration shall be directly
reviewed and handled by qualified banks in accordance with the Circular 13, and SAFE and its branches shall perform indirect regulation
over the foreign exchange registration via qualified banks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Gang Lai completed the initial foreign exchange registration on June 3, 2019. As it remains unclear how Circular 37 and Circular 13 will
be interpreted and implemented, and how or whether SAFE will apply them to us. Therefore, we cannot predict how they will affect our
business operations or future strategies. For example, the ability of our present and prospective PRC subsidiaries to conduct foreign
exchange activities, such as the remittance of dividends and foreign currency-denominated borrowings, may be subject to compliance with
Circular 37 and Circular 13 by our PRC resident beneficial holders. In addition, as we have little control over either our present or
prospective, direct or indirect shareholders or the outcome of such registration procedures, we cannot assure you that these shareholders
who are PRC residents will amend or update their registration as required under Circular 37 and Circular 13 in a timely manner or at
all. Failure of our present or future shareholders who are PRC residents to comply with Circular 37 and Circular 13 could subject these
shareholders to fines or legal sanctions, restrict our overseas or cross-border investment activities, limit the ability of our PRC subsidiaries
to make distributions or pay dividends or affect our ownership structure, which could adversely affect our business and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to complete a business combination transaction efficiently or on favorable terms due to complicated merger and acquisition
regulations and certain other PRC regulations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2006, six PRC regulatory authorities, including the Ministry of Commerce of the People&#8217;s Republic of China, or MOFCOM,
the State Assets Supervision and Administration Commission, the SAT, the SAIC, the CSRC and the SAFE, jointly issued the M&amp;A Rules,
which became effective on September 8, 2006 and was amended in June 2009. The M&amp;A Rules, governing the approval process by which
a PRC company may participate in an acquisition of assets or equity interests by foreign investors, requires the PRC parties to make
a series of applications and supplemental applications to the government agencies, depending on the structure of the transaction. In
some instances, the application process may require presentation of economic data concerning a transaction, including appraisals of the
target business and evaluations of the acquirer, which are designed to allow the government to assess the transaction. Accordingly, due
to the M&amp;A Rules, our ability to engage in business combination transactions has become significantly more complicated, time-consuming
and expensive, and we may not be able to negotiate a transaction that is acceptable to our Shareholders or sufficiently protect their
interests in a transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
M&amp;A Rules allow PRC government agencies to assess the economic terms of a business combination transaction. Parties to a business
combination transaction may have to submit to the MOFCOM and other relevant government agencies an appraisal report, an evaluation report
and the acquisition agreement, all of which form part of the application for approval, depending on the structure of the transaction.
The M&amp;A Rules also prohibit a transaction at an acquisition price obviously lower than the appraised value of the business or assets
in China and in certain transaction structures, require that consideration must be paid within defined periods, generally not in excess
of a year. In addition, the M&amp;A Rules also limit our ability to negotiate various terms of the acquisition, including aspects of
the initial consideration, contingent consideration, holdback provisions, indemnification provisions and provisions relating to the assumption
and allocation of assets and liabilities. Transaction structures involving trusts, nominees and similar entities are prohibited. Therefore,
such regulation may impede our ability to negotiate and complete a business combination transaction on legal and/or financial terms that
satisfy our investors and protect our shareholders&#8217; economic interests.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SAT released a circular on December 15, 2009 that addresses the transfer of shares by nonresident companies, generally referred to as
Circular 698. Circular 698, which became effective retroactively to January 1, 2008, may have a significant impact on many companies
that use offshore holding companies to invest in China. Circular 698 has the effect of taxing foreign companies on gains derived from
the indirect sale of a PRC company. Where a foreign investor indirectly transfers equity interests in a PRC resident enterprise by selling
the shares in an offshore holding company, and the latter is located in a country or jurisdiction that has an effective tax rate less
than 12.5% or does not tax foreign income of its residents, the foreign investor must report this indirect transfer to the tax authority
in charge of that PRC resident enterprise. Using a &#8220;substance over form&#8221; principle, the PRC tax authority may disregard the
existence of the overseas holding company if it lacks a reasonable commercial purpose and was established for the purpose of avoiding
PRC tax. As a result, gains derived from such indirect transfer may be subject to PRC withholding tax at a rate of up to 10.0%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SAT
subsequently released public notices to clarify issues relating to Circular 698, including the Announcement on Several Issues concerning
the EIT on the Indirect Transfers of Properties by Nonresident Enterprises (the &#8220;SAT Notice 7&#8221;), which became effective on
February 3, 2015. SAT Notice 7 abolished the compulsive reporting obligations originally set out in Circular 698. Under SAT Notice 7,
if a non-resident enterprise transfers its shares in an overseas holding company, which directly or indirectly owns PRC taxable properties,
including shares in a PRC company, via an arrangement without reasonable commercial purpose, such transfer shall be deemed as indirect
transfer of the underlying PRC taxable properties. Accordingly, the transferee shall be deemed as a withholding agent with the obligation
to withhold and remit the EIT to the competent PRC tax authorities. Factors that may be taken into consideration when determining whether
there is a &#8220;reasonable commercial purpose&#8221; include, among other factors, the economic essence of the transferred shares,
the economic essence of the assets held by the overseas holding company, the taxability of the transaction in offshore jurisdictions,
and economic essence and duration of the offshore structure. SAT Notice 7 also sets out safe harbors for the &#8220;reasonable commercial
purpose&#8221; test.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 17, 2017, the SAT released the Notice on Several Issues concerning the Withholding and Collection of Income Tax of Non-resident
Enterprises from the Source (the &#8220;SAT Notice 37&#8221;). SAT Notice 37 clarifies: (1) matters concerning the withholding and collection
of corporate income tax, and property transfer of non-resident enterprises based on the EIT Law; (2) the currencies required to be used
by the withholding agents (when the payments is made in a currency rather than RMB), as well as the time, venue and business for the
performance of the withholding and collection obligations; and (3) the abolishment of Circular 698.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is little guidance and practical experience regarding the application of SAT Notice 7 and SAT Notice 37 and the related SAT notices.
Moreover, the relevant authority has not yet promulgated any formal provisions or formally declared or stated how to calculate the effective
tax rates in foreign tax jurisdictions. As a result, due to our complex offshore restructuring, we may become at risk of being taxed
under SAT Notice 7 and SAT Notice 37 and we may be required to expend valuable resources to comply with SAT Notice 7 and SAT Notice 37
or to establish that we should not be taxed under SAT Notice 7 and SAT Notice 37, which could have a material adverse effect on our financial
condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Ordinary Shares and the Trading Market</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
share price may be volatile and could decline substantially, which could result in substantial losses to our investors.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading price of our shares is likely to continue to be volatile and could fluctuate widely due to factors beyond our control. This may
happen because of broad market and industry factors, including the performance and fluctuation of the market prices of other companies
with business operations located mainly in China that have listed their securities in the United States. The securities of some of these
companies have experienced significant volatility since their initial public offerings, including, in some cases, substantial price declines
in their trading prices. The trading performances of other Chinese companies&#8217; securities after their offerings may affect the attitudes
of investors toward Chinese companies listed in the United States in general and consequently may impact the trading performance of our
shares, regardless of our actual operating performance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our ordinary shares may be volatile, both because of actual and perceived changes in the company&#8217;s financial results
and prospects, and because of general volatility in the stock market. The factors that could cause fluctuations in our share price may
include, among other factors discussed in this section, the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations
    in the financial results and prospects of the company or other companies in the pharmaceutical business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in financial estimates
    by research analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market valuations
    of other education technology companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or
    our competitors of new education services, expansions, investments, acquisitions, strategic partnerships or joint ventures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mergers or other business
    combinations involving us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions and departures
    of key personnel and senior management;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in accounting principles;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the passage of legislation
    or other developments affecting us or our industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the trading volume of our
    ordinary shares in the public market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the release of lockup,
    escrow or other transfer restrictions on our outstanding equity securities or sales of additional equity securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential litigation or
    regulatory investigations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in economic conditions,
    including fluctuations in global and Chinese economies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial market conditions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, terrorist
    acts, acts of war or periods of civil unrest; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the realization of some
    or all of the risks described in this section.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
listing of our ordinary shares on the Nasdaq Global Market is contingent on our compliance with the Nasdaq Global Market&#8217;s conditions
for continued listing. On July 15, 2022, we received written notification (the &#8220;Notification Letter&#8221;) from the Nasdaq Stock
Market LLC (&#8220;Nasdaq&#8221;) that we were not in compliance with the minimum bid price requirement of US$1.00 per share under the
Nasdaq Listing Rules. In accordance with Nasdaq Listing Rules, we must regain compliance within 180 calendar days, or until January 11,
2023. To regain compliance, our ordinary shares must have a closing bid price of at least US$1.00 for a minimum of 10 consecutive business
days. In the event we do not regain compliance by January 11, 2023, we may be eligible for an additional 180 calendar days to regain
compliance or face delisting. On September 23, 2022, we held our 2022 annual general meeting of shareholders, during which our shareholders
approved the proposal to authorize our board of directors to effect a share consolidation at a ratio of no less than 2-for-1, and no
greater than 10-for-1 (the &#8220;Share Consolidation&#8221;). As of the date of this annual report, our board of directors has not adopted
resolutions to effect the Share Consolidation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
notification letter the Company received <span style="background-color: white">from the Listing Qualifications Department of the Nasdaq
</span>on November 9, 2022 noted that the Company evidenced a closing bid price of its ordinary shares at or greater than the $1.00 per
share minimum requirement for the last 10 consecutive business days, from October 26, 2022 through November 8, 2022. Accordingly, the
Company has regained compliance with Nasdaq Listing Rule 5450(a)(1). Even though we have regained compliance, we cannot assure you that
we will not receive other deficiency notifications from Nasdaq in the future. A decline in the closing price of our ordinary shares could
result in a breach of the requirements for listing on the Nasdaq Global Market. If we do not maintain compliance, Nasdaq could commence
suspension or delisting procedures in respect of our ordinary shares. The commencement of suspension or delisting procedures by an exchange
remains at the discretion of such exchange and would be publicly announced by the exchange. If a suspension or delisting were to occur,
there would be significantly less liquidity in the suspended or delisted securities. In addition, our ability to raise additional necessary
capital through equity or debt financing would be greatly impaired. Furthermore, with respect to any suspended or delisted ordinary shares,
we would expect decreases in institutional and other investor demand, analyst coverage, market making activity and information available
concerning trading prices and volume, and fewer broker-dealers would be willing to execute trades with respect to such ordinary shares.
A suspension or delisting would likely decrease the attractiveness of our ordinary shares to investors and cause the trading volume of
our ordinary shares to decline, which could result in a further decline in the market price of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock markets have experienced significant price and trading volume fluctuations from time to time, and the market prices
of the equity securities of pharmaceutical companies are sometimes subject to sharp price and trading volume changes. These broad market
fluctuations may materially and adversely affect the market price of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may issue additional ordinary shares or other equity securities without your approval, which would dilute your ownership interests and
may depress the market price of our ordinary shares.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue additional ordinary shares or our other securities to investors. We may also issue additional ordinary shares or other equity
securities of equal or senior rank in the future for any reason or in connection with, among other things, future acquisitions or repayment
of outstanding indebtedness, without shareholder approval, in a number of circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
issuance of additional ordinary shares or other equity securities of equal or senior rank would have the following effects:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our existing shareholders&#8217;
    proportionate ownership interest in us will decrease;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount of cash available
    per share, including for payment of dividends in the future, may decrease;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relative voting strength
    of each previously outstanding share may be diminished; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market price of our
    ordinary shares may decline.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently do not expect to pay dividends on our ordinary shares in the foreseeable future.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not expect to pay dividends on our ordinary shares in the foreseeable future. Instead, for the foreseeable future, it is
expected that we will continue to retain any earnings to finance the development and expansion of its business, and not to pay any cash
dividends on its ordinary shares. Consequently, you should not rely on an investment in the Company as a source for any future dividend
income.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has complete discretion as to whether to distribute dividends, subject to applicable laws. Even if our board of directors
decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on, among other things, our
future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us
from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors.
Accordingly, the return on your investment in our ordinary shares will likely depend entirely upon any future price appreciation of our
ordinary shares. We cannot guarantee that our ordinary shares will appreciate in value or even maintain the price at which you purchased
the ordinary shares. You may not realize a return on your investment in our ordinary shares and you may even lose your entire investment
in our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about us or our business, our ordinary
share price and trading volume could decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our ordinary shares will depend in part on the research and reports that securities or industry analysts publish about
us or our business. Securities and industry analysts do not currently, and may never, publish research on us. If no securities or industry
analysts commence coverage of our Company, the trading price for its ordinary shares would likely be negatively impacted. In the event
securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade its securities or publish inaccurate
or unfavorable research about its business, its stock price would likely decline. If one or more of these analysts cease coverage of
our Company or fail to publish reports on our Company, demand for its ordinary shares could decrease, which might cause its ordinary
share price and trading volume to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a &#8220;controlled company&#8221; within the meaning of the Nasdaq Stock Market Rules and, as a result, may rely on exemptions from
certain corporate governance requirements that provide protection to shareholders of other companies.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;controlled company&#8221; as defined under Rule 5615(c)(1) of the Nasdaq Marketplace Rules because Mr. Gang Lai holds more
than 50% of our voting power, and we expect we will continue to be a controlled company. For so long as we remain a controlled company
under that definition, we are permitted to elect to rely, and may rely, on certain exemptions from the obligation to comply with certain
corporate governance requirements, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that our
    director nominees must be selected or recommended solely by independent directors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that we
    have a corporate governance and nominating committee that is composed entirely of independent directors with a written charter addressing
    the committee&#8217;s purpose and responsibilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, you will not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance
requirements of the Nasdaq Stock Market Rules, if we utilize such exemptions. We currently do not intend to utilize the controlled company
exemptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
sale or perceived sale of a substantial number of our ordinary shares may cause the price of our ordinary shares to decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our shareholders sell substantial amounts of our ordinary shares in the public market, the market price of our ordinary shares could
fall. Moreover, the perceived risk of this potential dilution could cause shareholders to attempt to sell their shares and investors
to short our ordinary shares. These sales also make it more difficult for us to sell equity-related securities in the future at a time
and price that we deem reasonable or appropriate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
incur substantial increased costs being a public company.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incur significant legal, accounting and other expenses as a public company that we did not incur as a private company. The Sarbanes-Oxley
Act of 2002, as well as rules subsequently implemented by the SEC and Nasdaq, impose various requirements on the corporate governance
practices of public companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with these rules and regulations increases our legal and financial compliance costs and makes some corporate activities more time-consuming
and costlier. We have incurred additional costs in obtaining director and officer liability insurance. In addition, we incur additional
costs associated with our public company reporting requirements. It may also be more difficult for us to find qualified persons to serve
on our board of directors or as executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act and will remain an emerging growth company until the earlier
of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering, (b) in which
we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means
the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the prior March 31, and (2) the date
on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. An emerging growth company
may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies.
These provisions include exemption from the auditor attestation requirement under Section 404 in the assessment of the emerging growth
company&#8217;s internal control over financial reporting and permission to delay adopting new or revised accounting standards until
such time as those standards apply to private companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
we are no longer an &#8220;emerging growth company,&#8221; or until five years following the completion of our initial public offering,
whichever is earlier, we expect to incur significant additional expenses and devote substantial management effort toward ensuring compliance
with the requirements of Section 404 and the other rules and regulations of the SEC. For example, as a public company, we have been required
to increase the number of independent directors and adopt policies regarding internal controls and disclosure controls and procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently evaluating and monitoring developments with respect to these rules and regulations, and we cannot predict or estimate with
any degree of certainty the amount of additional costs we may incur or the timing of such costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
can be no assurance that we will not be a passive foreign investment company (&#8220;PFIC&#8221;) for United States federal income tax
purposes for any taxable year, which could subject United States holders of our ordinary shares could be subject to adverse United States
federal income tax consequences.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-United States corporation will be a PFIC for United States federal income tax purposes for any taxable year if either (i) at least
75% of its gross income for such taxable year is passive income or (ii) at least 50% of the value of its assets (based on average of
the quarterly values of the assets) during such year is attributable to assets that that produce or are held for the production of passive
income. Based on the current and anticipated value of our assets and the composition of our income assets, we are not currently a PFIC
under the current PFIC rules for United States federal income tax purposes. However, the determination of whether or not we are a PFIC
according to the PFIC rules is made on an annual basis and depends on the composition of our income and assets and the value of our assets
from time to time. Therefore, changes in the composition of our income or assets or value of our assets may cause us to become a PFIC.
The determination of the value of our assets (including goodwill not reflected on our balance sheet) may be based, in part, on the quarterly
market value of ordinary shares, which is subject to change and may be volatile.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
classification of certain of our income as active or passive, and certain of our assets as producing active or passive income, and hence
whether we are or will become a PFIC, depends on the interpretation of certain United States Treasury Regulations as well as certain
IRS guidance relating to the classification of assets as producing active or passive income. Such regulations guidance is potentially
subject to different interpretations. If due to different interpretations of such regulations and guidance the percentage of our passive
income or the percentage of our assets treated as producing passive income increases, we may be a PFIC in one or more taxable years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for any taxable year during which a United States person holds ordinary shares, certain adverse United States federal income
tax consequences could apply to such United States person. See &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;United
States Federal Income Taxation&#8212;PFIC.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For
as long as we are an emerging growth company, we will not be required to comply with certain reporting requirements, including those
relating to accounting standards and disclosure about our executive compensation, that apply to other public companies.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are classified as an &#8220;emerging growth company&#8221; under the JOBS Act. For as long as we are an emerging growth company, unlike
other public companies, we will not be required to, among other things, (i) provide an auditor&#8217;s attestation report on management&#8217;s
assessment of the effectiveness of our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley
Act, (ii) comply with any new requirements adopted by the Public Company Accounting Oversight Board, or the PCAOB, requiring mandatory
audit firm rotation or a supplement to the auditor&#8217;s report in which the auditor would be required to provide additional information
about the audit and the financial statements of the issuer, (iii) provide certain disclosure regarding executive compensation required
of larger public companies, or (iv) hold nonbinding advisory votes on executive compensation. We will remain an emerging growth company
for up to five years, although we will lose that status sooner if we have more than $1.235 billion of revenues in a fiscal year, have
more than $700 million in market value of our ordinary shares held by non-affiliates, or issue more than $1.0 billion of non-convertible
debt over a three-year period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that we rely on any of the exemptions available to emerging growth companies, you will receive less information about our
executive compensation and internal control over financial reporting than issuers that are not emerging growth companies. If some investors
find our ordinary shares to be less attractive as a result, there may be a less active trading market for our ordinary shares and our
share price may be more volatile.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to produce accurate financial statements have been materially adversely affected by our failure to establish proper internal
financial reporting controls. If we fail to establish and maintain proper internal financial reporting controls in a reasonably timely
manner, our ability to produce accurate financial statements or comply with applicable regulations may continue to be impaired.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm has not conducted an audit of our internal control over financial reporting. In the course
of auditing our consolidated financial statements for the year ended September 30, 2022, we identified material weaknesses in our internal
control over financial reporting and other control deficiencies as of September 30, 2022. A &#8220;material weakness&#8221; is a deficiency,
or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material
misstatement of the company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material weakness identified to date relates to a lack of accounting staff and resources with appropriate knowledge of generally accepted
accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and SEC reporting and compliance requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the identification of the material weaknesses and control deficiencies, we have undertaken certain remedial steps and plan to continue
taking remedial measures, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruiting
                                            qualified accounting personnel with relevant U.S. GAAP and SEC reporting experience and qualifications
                                            to strengthen the financial reporting function and to set up a financial and system control
                                            framework. Since very few companies in Ji&#8217;an, Jiangxi Province, the area in which our
                                            main PRC operating subsidiaries are located, have sought public listing on a U.S. exchange,
                                            we have difficulty identifying qualified accounting candidates with U.S. GAAP experience
                                            and expertise. We plan to search for qualified personnel in other regions of China;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing
                                            regular and continuous U.S. GAAP accounting and financial reporting training programs for
                                            our accounting and financial reporting personnel; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">setting
                                            up an internal audit function as well as engaging an external consulting firm to assist us
                                            with assessment of Sarbanes-Oxley compliance requirements and improvement of overall internal
                                            control.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
implementation of these measures may not fully address the material weaknesses in our internal control over financial reporting, and
we cannot conclude that they have been fully remedied. Our failure to correct theses material weaknesses or our failure to discover and
address any other material weaknesses could result in inaccuracies in our financial statements and could also impair our ability to comply
with applicable financial reporting requirements and related regulatory filings on a timely basis. As a result, our business, financial
condition, results of operations and prospects, as well as the trading price of our ordinary shares, may be materially and adversely
affected. Moreover, ineffective internal control over financial reporting significantly hinders our ability to prevent fraud.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we will be subject to Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act. Since we qualify as an &#8220;emerging growth
company&#8221; pursuant to the JOBS Act with less than US$1.235&#160;billion in revenue for our last fiscal year. An emerging growth
company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies.
These provisions include exemption from the auditor attestation requirement under Section&#160;404 of the Sarbanes-Oxley&#160;Act of
2002, or Section 404, in the assessment of the emerging growth company&#8217;s internal control over financial reporting. Moreover, even
if management concludes that our internal control over financial reporting is effective, our independent registered public accounting
firm, after conducting its own independent testing, may issue a report that is qualified if it is not satisfied with our internal controls
or the level at which our controls are documented, designed, operated or reviewed, or if it interprets the relevant requirements differently
from us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the course of documenting and testing our internal control procedures, we may identify other weaknesses and deficiencies in its internal
control over financial reporting. In addition, if we fail to maintain the adequacy of our internal control over financial reporting,
as these standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we
have effective internal control over financial reporting in accordance with Section&#160;404. Generally speaking, if we fail to achieve
and maintain an effective internal control environment, we could suffer material misstatements in our financial statements and fail to
meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could
in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading price of our securities.
Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate
assets and subject us to potential delisting from the stock exchange on which we list, regulatory investigations and civil or criminal
sanctions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a foreign private issuer, we are not subject to certain U.S. securities law disclosure requirements that apply to a domestic U.S. issuer,
which may limit the information publicly available to our shareholders.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a foreign private issuer, we are not required to comply with all of the periodic disclosure and current reporting requirements of the
Exchange Act and therefore there may be less publicly available information about us than if we were a U.S. domestic issuer. We are exempt
from certain provisions of the securities rules and regulations in the United States that are applicable to U.S. domestic issuers, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rules under the Exchange
    Act requiring the filing with the SEC of quarterly reports on Form 10-Q or current reports on Form 8-K;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sections of the Exchange
    Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered under the Exchange Act;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sections of the Exchange
    Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit
    from trades made in a short period of time; and the selective disclosure rules by issuers of material non-public information under
    Regulation FD.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to file an annual report on Form 20-F within four months of the end of each fiscal year. However, the information we are
required to file with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC
by U.S. domestic issuers. As a result, you may not be afforded the same protections or information that would be made available to you
were you investing in a U.S. domestic issuer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ
significantly from the Nasdaq listing standards. These practices may afford less protection to shareholders than they would enjoy if
we complied fully with corporate governance listing standards.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a foreign private issuer, we are permitted to take advantage of certain provisions in the Nasdaq listing standards that allow us to follow
Cayman Islands law for certain governance matters. Certain corporate governance practices in the Cayman Islands may differ significantly
from corporate governance listing standards as, except for general fiduciary duties and duties of care, Cayman Islands law has no corporate
governance regime which prescribes specific corporate governance standards. Currently, we do not intend to rely on home country practice
with respect to our corporate governance. However, if we choose to follow home country practice in the future, our shareholders may be
afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic issuers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed above, we are a foreign private issuer, and therefore, we are not required to comply with all of the periodic disclosure and
current reporting requirements of the Exchange Act. The determination of foreign private issuer status is made annually on the last business
day of an issuer&#8217;s most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example,
more than 50% of our ordinary shares are directly or indirectly held by residents of the U.S. and we fail to meet additional requirements
necessary to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required
to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive
than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements, and
our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of
Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance requirements
under the Nasdaq listing standards. As a U.S. listed public company that is not a foreign private issuer, we will incur significant additional
legal, accounting and other expenses that we will not incur as a foreign private issuer, and accounting, reporting and other expenses
in order to maintain a listing on a U.S. securities exchange.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><br/>
The laws of the Cayman Islands may not provide our shareholders with benefits comparable to those provided to shareholders of corporations
incorporated in the United States.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate affairs are governed by our amended and restated memorandum and articles of association, by the Companies Act (Revised) of
the Cayman Islands and by the common law of the Cayman Islands. The rights of shareholders to take action against our directors, actions
by minority shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent governed
by the common law of the Cayman Islands. The common law in the Cayman Islands is derived in part from comparatively limited judicial
precedent in the Cayman Islands and from English common law. Decisions of the Privy Council (which is the final Court of Appeal for British
overseas territories such as the Cayman Islands) are binding on a court in the Cayman Islands. Decisions of the English courts, and particularly
the Supreme Court and the Court of Appeal are generally of persuasive authority but are not binding in the courts of the Cayman Islands.
Decisions of courts in other Commonwealth jurisdictions are similarly of persuasive but not binding authority. The rights of our shareholders
and the fiduciary responsibilities of our directors under Cayman Islands law are not as clearly established as they would be under statutes
or judicial precedents in the United States. In particular, the Cayman Islands has a less developed body of securities laws relative
to the United States. Therefore, our public shareholders may have more difficulty protecting their interests in the face of actions by
our management, directors or controlling shareholders than would shareholders of a corporation incorporated in a jurisdiction in the
United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>You
may be unable to present proposals before annual general meetings or extraordinary general meetings not called by shareholders.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman
Islands law provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any
right to put any proposal before a general meeting. These rights, however, may be provided in a company&#8217;s amended and restated
articles of association. Our amended and restated articles of association allow our shareholders holding shares representing in aggregate
not less than 10% of our voting share capital in issue, to requisition a general meeting of our shareholders, in which case our directors
are obliged to call such meeting. Advance notice of at least 21 clear days is required for the convening of our annual general shareholders&#8217;
meeting and at least 14 days&#8217; notice any other general meeting of our shareholders. A quorum required for a meeting of shareholders
consists of at least one shareholder present or by proxy, representing not less than one-third of the total issued shares carrying the
right to vote at a general meeting of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
obligation to disclose information publicly may put us at a disadvantage to competitors that are private companies.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a public company in the United States. As a public company, we will be required to file periodic reports with the SEC upon the occurrence
of matters that are material to our Company and shareholders. Although we may be able to attain confidential treatment of some of our
developments, in some cases, we will need to disclose material agreements or results of financial operations that we would not be required
to disclose if we were a private company. Our competitors may have access to this information, which would otherwise be confidential.
This may give them advantages in competing with our Company. Similarly, as a U.S. public company, we will be governed by U.S. laws that
our competitors, which are mostly private Chinese companies, are not required to follow. To the extent compliance with U.S. laws increases
our expenses or decreases our competitiveness against such companies, our public company status could affect our results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
4. INFORMATION ON THE COMPANY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
<span style="text-decoration:underline">History and Development of the Company</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report refers to (i) Universe Pharmaceuticals INC, the Cayman Islands holding company, as &#8220;we&#8221;, &#8220;our&#8221;,
&#8220;us&#8221;, or the &#8220;Company&#8221;, (ii) the Company&#8217;s subsidiaries, as &#8220;our subsidiaries,&#8221; (iii) Jiangxi
Universe Pharmaceuticals Co., Ltd., the Company&#8217;s indirect wholly owned subsidiary in China (&#8220;Jiangxi Universe&#8221;) and
its subsidiaries, which are domiciled in China and conducting business operations in China, as the &#8220;operating entities.&#8221;
The Company does not conduct any operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Cayman Islands holding company with no operations of our own and not a PRC operating company. Our operations are conducted in China
by our PRC subsidiaries.&#160;Investors in our securities are not purchasing equity interests in our subsidiaries but instead are purchasing
equity interests in the ultimate Cayman Islands holding company. Therefore, you will not directly hold any equity interests in our operating
companies. The Chinese regulatory authorities could disallow this structure, which would likely result in a material change in our operations
and/or a material change in the value of the securities we are registering for sale, including that it could cause the value of such
securities to significantly decline or become worthless. For risks facing our Company and this offering as a result of our organizational
structure, see &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Doing Business in China.&#8221; We directly
hold 100% equity interests in our subsidiaries, and we do not currently use a variable interest entity (&#8220;VIE&#8221;) structure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face legal and operational risks associated with having the majority of our operations in China, which could significantly limit or completely
hinder our ability to offer securities to investors and cause the value of our securities to significantly decline or be worthless. The
Chinese government has significant authority to exert influence on the ability of a China-based company, such as us, to conduct its business.
Therefore, investors of our company and our business face potential uncertainty from the PRC government. Changes in China&#8217;s economic,
political or social conditions or government policies could materially adversely affect our business and results of operations. These
risks could result in a material change in our operations and/or the value of our ordinary shares or could significantly limit or completely
hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline
or be worthless. In particular, recent statements and regulatory actions by China&#8217;s government, such as those related to the use
of variable interest entities and data security or anti-monopoly concerns, as well as the PCAOB&#8217;s ability to inspect our auditors,
may impact our Company&#8217;s ability to conduct our business, accept foreign investments, or be listed on a U.S. or other foreign stock
exchange. See &#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212; Risks Related to Doing Business in China &#8212; The PRC
government has significant authority to intervene or influence the China operations of an offshore holding company, such as ours, at
any time. The PRC government may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers.
If the PRC government exerts more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based
issuers and we were to be subject to such oversight and control, it may result in a material adverse change to our business operations,
significantly limit or completely hinder our ability to offer or continue to offer securities to investors, and cause the ordinary shares
to significantly decline in value or become worthless&#8221; and &#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212; Risks
Related to Doing Business in China &#8212; Uncertainties arising from the legal system in China, including uncertainties regarding the
interpretation and enforcement of PRC laws and the possibility that regulations and rules can change quickly with little advance notice,
could hinder our ability to offer or continue to offer the ordinary shares, result in a material adverse change to our business operations,
and damage our reputation, which would materially and adversely affect our financial condition and results of operations and cause the
ordinary shares to significantly decline in value or become worthless.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, we and our subsidiaries have not been involved in any investigations on cybersecurity review initiated
by any PRC regulatory authority, nor have any of them received any inquiry, notice, or sanction. As confirmed by our PRC counsel, AllBright
Law Offices (Fuzhou), we are not subject to cybersecurity review by the CAC, since we currently do not possess any personal information
of users in our business operations. It is unlikely for us to have over one million users&#8217; personal information and we do not anticipate
that we will be collecting over one million users&#8217; personal information in the foreseeable future, which we understand might otherwise
subject us to the Cybersecurity Review Measures. We are not subject to network data security review by the CAC if the Security Administration
Draft are enacted as proposed, because we currently do not have over one million users&#8217; personal information, we do not collect
data that affect or may affect national security and we do not anticipate that we will be collecting over one million users&#8217; personal
information or data that affect or may affect national security in the foreseeable future, which we understand might otherwise subject
us to the Security Administration Draft. According to our PRC counsel, AllBright Law Offices (Fuzhou), no relevant laws or regulations
in the PRC explicitly require us to seek approval from the China Securities Regulatory Commission for our overseas listing. As of the
date of this annual report, we and our subsidiaries have not received any inquiry, notice, warning, or sanction regarding our overseas
listing from the CSRC or any other PRC governmental authorities. We believe that we and our subsidiaries have obtained all material licenses
and approvals necessary to operate in China and are not required to obtain approval from any PRC government authorities, including the
CSRC or the CAC, or any other government entity, to issue our ordinary shares to foreign investors. Since the recent regulatory actions
are new, however, it is highly uncertain how soon legislative or administrative regulation making bodies will respond and what existing
or new laws or regulations or detailed implementations and interpretations will be modified or promulgated, if any, and the potential
impact such modified or new laws and regulations will have on our daily business operation, ability to accept foreign investments, and
listing on the Nasdaq Stock Market. If we do not receive or maintain the approvals, or we inadvertently conclude that such approvals
are not required, or applicable laws, regulations, or interpretations change such that we are required to obtain approval in the future,
we may be subject to an investigation by competent regulators, fines or penalties, ordered to suspend our relevant business and rectify,
prohibited from engaging in relevant business, or subject to an order prohibiting us from conducting an offering, and these risks could
result in a material adverse change in our operations, significantly limit or completely hinder our ability to continue to offer securities
to investors, or cause such securities to significantly decline in value or become worthless. See &#8220;Item 3. Key Information&#8212;Risk
Factors&#8212;Risks Relating to Doing Business in China&#8212;Failure to comply with cybersecurity, data privacy, data protection, or
any other laws and regulations related to data may materially and adversely affect our business, financial condition, and results of
operations.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, trading in our securities may be
prohibited under the HFCA Act if the PCAOB determines that it cannot inspect the workpapers prepared by our auditor, and that as a result
an exchange may determine to delist our securities. On June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies
Accountable Act, which, if passed by the U.S. House of Representatives and signed into law, would reduce the period of time for foreign
companies to comply with PCAOB audits to two consecutive years instead of three, thus reducing the time period for triggering the prohibition
on trading. On December 16, 2021, the PCAOB issued a report on its determination that it is unable to inspect or investigate completely
PCAOB-registered public accounting firms headquartered in China and in Hong Kong because of positions taken by PRC and Hong Kong authorities
in those jurisdictions. Our auditor, the independent registered public accounting firm that issues the audit report included elsewhere
in this annual report, as an auditor of companies that are traded publicly in the U.S.&#160;and a firm registered with the PCAOB, is subject
to laws in the U.S., pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional
standards. Our auditor is headquartered in California and has not been inspected by the PCAOB, but according to our auditor, it will be
inspected by the PCAOB on a regular basis. Our auditor is not subject to the determination issued by the PCAOB on December 16, 2021. On
August 26, 2022, the CSRC, the Ministry of Finance of the PRC, and the PCAOB signed a Statement of Protocol (the &#8220;Protocol&#8221;),
governing inspections and investigations of audit firms based in China and Hong Kong. The Protocol remains unpublished and is subject
to further explanation and implementation. Pursuant to the fact sheet with respect to the Protocol disclosed by the SEC, the PCAOB shall
have independent discretion to select any issuer audits for inspection or investigation and has the unfettered ability to transfer information
to the SEC. On December 15, 2022, the PCAOB Board determined that the PCAOB was able to secure complete access to inspect and investigate
registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate its previous determinations to the
contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB&#8217;s access in the future, the PCAOB Board
will consider the need to issue a new determination. See &#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212;&#160;Risks Related
to Doing Business in China &#8212; Our ordinary shares may be delisted or prohibited from being traded over-the-counter under the Holding
Foreign Companies Accountable Act, if the U.S. Public Company Accounting Oversight Board, or the PCAOB, is unable to inspect our auditors.
The delisting or the cessation of trading of our ordinary shares, or the threat of their being delisted or prohibited from being traded,
may materially and adversely affect the value of your investment. Additionally, the inability of the PCAOB to conduct inspections would
deprive our investors with the benefits of such inspections. Our auditor has not been inspected by the PCAOB, but according to our auditor,
it will be inspected by the PCAOB on a regular basis.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Cayman Islands holding company has not declared
or paid dividends or made any distributions to our shareholders in the past, nor were any dividends or distributions made by a subsidiary
to the Cayman Islands holding company. Our board of directors has complete discretion on whether to distribute dividends, subject to applicable
laws. We intend to keep any future earnings to finance the expansion of our business, and we do not have any current plan to declare or
pay any cash dividends on our ordinary shares in the foreseeable future. See &#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212;
Risks Related to Our Ordinary Shares&#8212;We currently do not expect to pay dividends on our ordinary shares in the foreseeable future.&#8221;
If we determine to pay dividends on any of our ordinary shares in the future, as a holding company, we will rely on payments from subsidiaries
of Jiangxi Universe to Jiangxi Universe, and from Jiangxi Universe to Universe Technology, and the distribution of such payments to Universe
HK, and then to our Company.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain contractual, legal and regulatory
restrictions, and our internal cash management policy, cash and capital contributions may be transferred among our Cayman Islands holding
company and our subsidiaries. If needed, our Cayman Islands holding company can transfer cash to our PRC subsidiaries through loans and/or
capital contributions, and our PRC subsidiaries can transfer cash to our Cayman Islands holding company through issuing dividends or other
distributions. Our finance department supervises cash management, following the instructions of our management. Our finance department
is responsible for establishing our cash operation plan and coordinating cash management matters among our subsidiaries and departments.
Each subsidiary and department initiate a cash request by putting forward a cash demand plan, which explains the specific amount and timing
of cash requested, and submitting it to our finance department. The finance department reviews the cash demand plan and prepares a summary
for the management of our Company. Management examines and approves the allocation of cash based on the sources of cash and the priorities
of the needs. Other than the above, we currently do not have other cash management policies or procedures that dictate how funds are transferred.
Cash flows have occurred between our Cayman Islands holding company and our subsidiaries. For the year ended September 30, 2022, the Cayman
Islands holding company received cash in the amount of $303,746 from its subsidiary in Hong Kong for the payment of directors&#8217; compensation
and professional service fees. The Cayman Islands holding company has not received cash transfer from its subsidiaries for the years ended
September 30, 2020 and 2021, and from October 1, 2022 to the date of this annual report. There was no distribution of earnings by our
PRC subsidiaries to the Cayman Islands holding company during the years ended September 30, 2020, 2021 and 2022, and from October 1, 2022
to the date of this annual report. In the fiscal year ended September 30, 2021, our Company transferred the net proceeds from its initial
public offering, through Universe HK and Universe Technology, to Jiangxi Universe and its subsidiaries, in the amount of $6,807,507, to
be used for general corporate purposes. In the year ended September 30, 2020 and 2022, there was no cash transferred from the Cayman Islands
holding company to its PRC subsidiaries. See also &#8220;Item 8. Financial Information&#8212;A. Consolidated Statements and Other Financial
Information&#8212;Dividend Policy&#8221; and our audited consolidated financial statements for the fiscal years ended September&#160;30,
2022, 2021, and 2020.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
transfers from our Cayman Islands holding company are subject to applicable PRC laws and regulations on loans and direct investment.
We may rely on dividends from our subsidiaries in China for our cash requirements, including any payment of dividends to our shareholders.
PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us, and as a holding company, we will be dependent
on receipt of funds from our Hong Kong subsidiary, Universe HK.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
PRC regulations permit our indirect PRC subsidiaries to pay dividends to Universe HK only out of their accumulated profits, if any, determined
in accordance with Chinese accounting standards and regulations. In addition, each of our subsidiaries in China is required to set aside
at least 10% of its after-tax profits each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered
capital. Each of such entity in China is also required to further set aside a portion of its after-tax profits to fund the employee welfare
fund, although the amount to be set aside, if any, is determined at the discretion of its board of directors. Although the statutory
reserves can be used, among other ways, to increase the registered capital and eliminate future losses in excess of retained earnings
of the respective companies, the reserve funds are not distributable as cash dividends except in the event of liquidation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PRC government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of the PRC.
Therefore, we may experience difficulties in complying with the administrative requirements necessary to obtain and remit foreign currency
for the payment of dividends from our profits, if any. Furthermore, if our subsidiaries and affiliates in the PRC incur debt on their
own in the future, the instruments governing the debt may restrict their ability to pay dividends or make other payments. If we or our
subsidiaries are unable to receive all of the revenue from our operations, we may be unable to pay dividends on our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
dividends, if any, on our ordinary shares will be paid in U.S. dollars. Universe HK may be considered a non-resident enterprise for tax
purposes, so that any dividends our PRC subsidiaries pay to Universe HK may be regarded as China-sourced income and as a result may be
subject to PRC withholding tax at a rate of up to 10%. See &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;People&#8217;s
Republic of China Taxation.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order for us to pay dividends to our shareholders, we will rely on payments made from Universe Technology&#8217;s subsidiary, Jiangxi
Universe, to Universe Technology and from Universe Technology to Universe HK and then to our Company. According to the EIT Law, such
payments from subsidiaries to parent companies in China are subject to the PRC enterprise income tax at a rate of 25%. In addition, if
Jiangxi Universe or its subsidiary or branches incur debt on their own behalf in the future, the instruments governing the debt may restrict
its ability to pay dividends or make other distributions to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Double Tax Avoidance Arrangement, the 10% withholding tax rate may be lowered to 5% if a Hong Kong resident enterprise owns no
less than 25% of a PRC project. The 5% withholding tax rate, however, does not automatically apply and certain requirements must be satisfied,
including without limitation that (a) the Hong Kong project must be the beneficial owner of the relevant dividends; and (b) the Hong
Kong project must directly hold no less than 25% share ownership in the PRC project during the 12 consecutive months preceding its receipt
of the dividends. In current practice, a Hong Kong project must obtain a tax resident certificate from the Hong Kong tax authority to
apply for the 5% lower PRC withholding tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case
basis, we cannot assure you that we will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority and
enjoy the preferential withholding tax rate of 5% under the Double Taxation Arrangement with respect to any dividends paid by our PRC
subsidiaries to its immediate holding company, Universe HK. As of the date of this annual report, we have not applied for the tax resident
certificate from the relevant Hong Kong tax authority. Universe HK intends to apply for the tax resident certificate if and when Universe
Technology plans to declare and pay dividends to Universe HK. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212; There are
significant uncertainties under the Enterprise Income Tax Law, or the EIT Law, relating to the withholding tax liabilities of our PRC
subsidiaries, and dividends payable by our PRC subsidiaries to our offshore subsidiaries may not qualify to enjoy certain treaty benefits.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent cash is located in the PRC or within a PRC domiciled entity and may need to be used to fund operations outside of the PRC,
the funds may not be available due to limitations placed on us and our subsidiaries by the PRC government. To the extent cash in and
assets of the business is in the PRC or a PRC entity, the funds and assets may not be available to fund operations or for other use outside
of the PRC due to interventions in or the imposition of restrictions and limitations on the ability of us or our subsidiaries by the
PRC government to transfer cash and assets. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#160;&#8212;&#160;Risks Related
to Doing Business in China&#160;&#8212; To the extent cash and assets of in the business is in the PRC or a PRC entity, the funds may
not be available to fund operations or for other use outside of the PRC due to interventions in or the imposition of restrictions and
limitations on the ability of our Company or our subsidiaries by the PRC government to transfer cash and assets.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Corporate History and Structure</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
initially conducted our business through Jiangxi Universe, a PRC company formed in 1998 and Universe Trade, a PRC company formed in 2010,
a wholly-owned subsidiary of Jiangxi Universe.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the growth of our business and in order to facilitate international capital investment in our Company, we underwent an offshore reorganization
in 2019 and 2020. On December 11, 2019, our holding company, Universe Pharmaceuticals INC, was incorporated under the laws of the Cayman
Islands as an exempted company with limited liability. Our wholly owned subsidiary Universe HK was formed in Hong Kong on May 21, 2014
as an intermediate holding company. Universe HK in turn holds all the capital stocks of Universe Technology, a wholly foreign owned enterprise
incorporated in China on Aril 8, 2019. Universe Technology holds all the capital stocks and controls Jiangxi Universe. Jiangxi Universe
holds 100% of the equity interests in Universe Trade.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
holding company has no business operation other than holding the shares in Universe HK. Universe HK is a pass-through entity with no
business operation. Universe Technology is exclusively engaged in the business of managing the operation of Jiangxi Universe. Jiangxi
Universe specializes in manufacturing our own TCMD products. Universe Trade specializes in the distribution and sales of our own TCMD
products and third-party pharmaceutical products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foshan
Shangyu Investment Holding Co., Ltd. (&#8220;Foshan Shangyu&#8221;) is our affiliated entity, 90% owned by and controlled by Mr. Gang
Lai, our controlling shareholder. Foshan Shangyu was formed in 2004 in China as a holding company of Mr. Gang Lai. Foshan Shangyu has
no business operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following diagram illustrates our corporate structure as of the date of this annual report:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="img_001.jpg"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji&#8217;an,
Jiangxi Province, People&#8217;s Republic of China, and our phone number is +86-0796-8403309. Our registered office in the Cayman Islands
is located at Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KYI &#8211; 1205
Cayman Islands, and the phone number of our registered office is +1-(345)769-9372. We maintain a corporate website at http://www.universe-pharmacy.com.
The information contained in, or accessible from, our website or any other website does not constitute a part of this annual report.
Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York,
NY 10168.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains a website at www.sec.gov that contains reports, proxies, and information statements, and other information regarding issuers
that file electronically with the SEC using its EDGAR system.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
information regarding our principal capital expenditures, see &#8220;Item 5. Operating and Financial Review and Prospects&#8212;B. Liquidity
and Capital Resources&#8212;Capital Expenditures.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
<span style="text-decoration:underline">Business Overview</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCM
is a comprehensive form of healthcare that has been widely adopted in China for more than 23 centuries. TCM rests upon the assumption
that the human body is an ecosystem, embodying the fusion of Shen (psyche), Essence (soma), Qi, Moisture (body fluids), and Blood (tissue).
Health in the context of TCM is more than just the absence of diseases, but to identify imbalance in human body and restore harmony.
TCM is not only intended to cure diseases but to enhance the capacity for fulfillment, happiness and general well-being of people.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pharmaceutical company based in Jiangxi, China, specializing in the manufacturing, marketing, sales and distribution of TCMD products
targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being.
We have registered and obtained approval for 26 varieties of TCMD products from the National Medical Products Administration (the &#8220;NMPA&#8221;),
and we currently produce 13 varieties of TCMD products, which are sold in approximately 261 cities of 30 provinces in China. In addition,
through our subsidiary Universe Trade, we sell not only our own TCMD products, but also biomedical drugs medical instruments, Traditional
Chinese Medicine Pieces (&#8220;TCMPs&#8221;), and dietary supplements manufactured by third-party pharmaceutical companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Products
manufactured by us.&#160;</i>The 13 TCMD products currently manufactured by us fall into two categories: (1) treatment and relief for
common chronic health conditions in the elderly designed to achieve physical wellness and longevity (&#8220;chronic condition treatments&#8221;),
and (2) cold and flu medications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chronic
condition treatments</b>: Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong
Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cold and
    flu medicines</b>: Paracetamol Granule for Children, Isatis Root Granule and Qiangli Pipa Syrup.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
people age, they have an increasing risk of developing chronic health conditions. According to a report published by the Chinese Center
for Disease Control and Prevention in March 2019, 75.8% of seniors have at least one chronic health condition, and 35.1% of them have
two or more. According to the &#8220;Blue Book of Elderly Health (2020-2021)&#8221; released in December 2021 by the Chinese Academy
of Medical Sciences, the School of Public Health of Peking Union Medical College and the Social Sciences Literature Publishing House,
the prevalence of hypertension, diabetes and hypercholesterolemia in Chinese residents aged 60 and above is 58.3%, 19.4% and 10.5%, respectively,
and more than 3/4 of the residents have multiple disease coexistence, and with the increase of age, the prevalence of chronic diseases
increases. Some of the most common chronic diseases in the elderly include arthritis, chronic kidney disease, fatigue, and low back pain.
<span style="background-color: white">The operating entities&#8217;&#160;products&#160;</span>under the category of chronic condition
treatments are designed to address some of the aforementioned diseases. <span style="background-color: white">The operating entities&#8217;&#160;</span>cold
and flu medicines, on the other hand, include products designed to treat and relieve symptoms of respiratory illnesses caused by bacteria
and viruses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
operating entities&#8217; third-party products.&#160;</i>Through our subsidiary, Universe Trade, we also distribute and sell products
manufactured by third-party producers, including biomedical drugs, medical instruments, TCMPs and dietary supplements. For the years
ended September 30, 2022, 2021 and 2020, we distributed around 2,785, 2766 and 3,183 types of third-party products, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
operating entities&#8217; Customers.&#160;</i>The operating entities&#8217; major customers are pharmaceutical distributors, hospitals,
clinics and drugstore chains, primarily located in Jiangxi Province, Jiangsu Province, Guangdong Province, Hubei Province, Fujian Province,
Guangxi Province and Shandong Province, and 23 other provinces in China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe <span style="background-color: white">the operating entities&#160;</span>have implemented a successful business model, and their
business has grown substantially since inception. The operating entities&#8217; business operations gradually recovered from the negative
impact of COVID-19, and the customer base increased from a total of 2,209 customers as of September 30, 2020 to 2,708 as of September
30, 2021, and decreased slightly to 2,651 as of September 30, 2022 as we were unable to timely deliver products to our customers in 2022
due to the resurgence of COVID-19 cases in China. The revenues from selling the operating entities&#8217; own products increased from
$18,374,751 for the fiscal year ended September 30, 2020 to $29,559,286 for the fiscal year ended September 30, 2021, and decreased to
$23,988,177 for the fiscal year ended September 30, 2022 due to our inability to timely fulfill the orders of our customer in 2022 due
to the resurgence of COVID-19 cases in China. The revenues from distributing and selling third-party products increased from $12,329,209
for the year ended September 30, 2020 to $18,422,745 for the fiscal year ended September 30, 2021, and decreased to $16,154,974 in the
fiscal year ended September 30, 2022 due to a decrease in the weighted average selling price caused by a change in product mix. Our net
income was $7,558,222 for the fiscal year ended September 30, 2020, $11,319,952 for the fiscal year ended September 30, 2021, and net
loss was $8,736,566 for the fiscal year ended September 30, 2022 due to a decrease in our revenue and increase in our selling expense.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Competitive Strengths</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe we have the following competitive strengths:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
recognized manufacturer of TCMD products in China&#8217;s rapidly growing health and wellness market</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a recognized manufacturer of TCMD products in China&#8217;s rapidly growing health and wellness market. We own a number of famous
brands in the industry, which are also our registered trademarks in China. For instance, our brand &#8220;Hu Zhuo Ren (&#32993;&#21331;&#20161;)&#8221;
is especially well-recognized in Jiangxi Province. Further, our brand &#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221; is famous
for specializing in products targeted at the physical wellness of older population. Our other recognized brands include &#8220;Long Zhong
(&#40857;&#31181;)&#8221;, &#8220;Yi Ke Ting (&#30410;&#20811;&#20572;)&#8221;, &#8220;Xue Li (&#34880;&#21147;)&#8221;, &#8220;Duo Lai
Mei (&#26421;&#26469;&#32654;)&#8221;, &#8220;Shu Er Kang (&#33298;&#20799;&#24247;)&#8221;, &#8220;Hu Zhuo Ren (&#32993;&#21331;&#20161;)&#8221;,
&#8220;Ai Bi Xin (&#29233;&#24517;&#27427;)&#8221;, and &#8220;Yong He Shuang Feng (&#27704;&#21644;&#21452;&#20964;)&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chinese patent medicine industry is growing rapidly and steadily in China. The primary growth drivers of China&#8217;s Chinese patent
medicine industry include the increasing disposable income and healthcare awareness in China, growing aging population and the prevalence
of chronic diseases, and favorable governmental policies and regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
attribute our success to our recognized brand names, strong relationships with our suppliers, loyal and stable customer base, and proven
capability to develop and manufacture TCMD products aligned with the preferences of end consumers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rigorous
quality control standards and manufacturing protocols</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the quality of our products is crucial to our success as a pharmaceutical company, and we have implemented an overall quality
control system, as well as strict manufacturing protocols specifically designed for each product. Our quality control system starts from
procurement. The raw materials we source from our suppliers must first be examined and certified for quality. We review the performance
of our suppliers based on the quality of their products and adjust future orders from them accordingly. Further, an average of three
inspections are made by our personnel throughout the manufacturing process to ensure that the manufacturing protocols are strictly followed,
and that the quality of semi-products are at or above standard. After completion of manufacturing, our personnel will perform an overall
quality examination. Through the implementation of a quality control system, we are able to identify the weakness in our production process
and improve our operations over time. We believe our quality control standards and manufacturing protocols have contributed to the high
quality and consistency of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Visionary
management team with substantial industry experience</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
visionary management team is the bedrock of our success. Many members of our leadership possess extensive experience in the pharmaceutical,
biomedical, chemical and related industries. For instance, our chief executive officer, Mr. Gang Lai, has about 30 years of corporate
management experiences. Mr. Xiaojun Deng, the deputy manufacturing manager of Jiangxi Universe, holds a degree in Traditional Chinese
Medicine Manufacturing from Jiangxi Medical School with over 25 years of working experience in the Chinese patent medicine industry.
Ms. Lin Yang, our chief financial officer, has over 14 years of finance and management experience working in pharmaceutical companies.
Mr. Yajun Hu, the general manager of Jiangxi Universe, has over five years of experiences in managing a pharmaceutical company. Mr. Baochang
Liu, our chief operating officer, has over 17 years of experience in pharmaceutical marketing and had previously held marketing and management
positions at a number of listed pharmaceutical companies in China. Moreover, many members of the team have worked together for an extended
period of time and helped build the Company from the ground up. The rapport that the team has built extends beyond the talent and skills
of individual team members and contributes to a collective sense of mission.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Growth Strategy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Build
a Strong Brand Image to Achieve National Recognition</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that broader recognition and favorable
perception of our brand by consumers in our target markets are crucial to our future success. Our brand has gained a solid reputation
in Southern China, especially Jiangxi Province, and we plan to increase the awareness of our brand among consumers in other parts of China.
Specifically, we plan to build a strong brand image that we are a TCMD producer specializing in the development and manufacture of products
designed to address the physical conditions of the elderly during the aging process and to promote their general well-being. To achieve
our goal, we plan to spend most of our efforts on the development and marketing of our brand &#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221;
as the brand to be associated with our ideal brand image because &#8220;Bai Nian&#8221; (&#30334;&#24180;) signifies longevity in the
Chinese language, and &#8220;Dan&#8221; (&#20025;) alludes to our signature product, Guben Yanling Pill. In the fiscal year ended September
30, 2021, we started to advertise our products through television advertisement. We also intend to advertise targeting older customers,
including transmitting our advertisements through additional traditional media platforms such as live radio stations, newspapers, as well
as in-person marketing at drug stores and clinics. In the fiscal year ended September 30, 2022, our marketing department explored direct
selling strategy and increased its efforts to market products directly to customers in Liaoning Province. If this marketing strategy proves
successful, we intend to implement it in other provinces where our products are sold.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Enhance
Our Distribution Network to Increase Market Penetration and Customer Stickiness</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
our products are sold in 30 provinces in China. We plan to enter the markets in other parts of China. To achieve this goal, we have made
efforts to further strengthen and expand our distribution network through connecting with more local distributors, chain drugstores,
malls and supermarkets in other parts of China. Currently, our strategic focus is to attract more marketing talents and build a stronger
sales and marketing team to keep us on top of the latest information of local markets, customer preferences and industry trends. We also
plan to create an online store to reach a wider consumer demographic. In the future, we plan to start our own retail chain stores and
further diversify our distribution channels to increase our market penetration and customer base.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Integrate
Our Internal Manufacturing Capability to Ensure Productivity, Supply, and Selection of Products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to further optimize our production facilities to increase the productivity, supply and selection of our products, so that we may
gain competitive edges over our competitors. Specifically, we intend to increase productivity and supply by expanding the existing production
lines and converting them into automated production lines. To increase the selection of our products, we plan to build additional production
facilities for our licensed TCMD products to be launched in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Further
Grow Our Research and Development Capacities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
size of the Chinese patent medicine market has been growing steadily. To respond to increasing market demand, we will continue to provide
financial and operational resources to focus on the research and development of TCMD products and dietary supplements designed to address
the physical conditions of the elderly during the aging process and promote their general well-being.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Manufactured Products</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
manufacture, market and sell 13 different TCMD products to customers in 30 different provinces in China. Our TCMD products fall under
two categories: chronic condition treatments and cold and flu medications. The following list outlines our current products:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: top">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage of<br/> Gross Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Product&#160;Category</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Product Name</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Posology</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intended Uses</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 17%; font-weight: bold; text-align: left">Chronic Condition Treatments</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 13%; text-align: center">Guben Yanling Pill</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 9%; text-align: center">Pills</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">42.5</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">40.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">38.2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 33%; text-align: center">To relieve fatigue, palpitation, low back pain, and generalized weakness and soreness.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Shenrong Weisheng Pill</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Pills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To relieve fatigue, dizziness, excessive sweating, and pain in the waist and the knees.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Quanlu Pill</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Pills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To improve kidney functions and spleen functions, and relieve fatigue, low back pain, and knee pain.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Wuzi Yanzong Oral Liquid</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Oral liquid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">To improve kidney functions.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Yangxue Danggui Syrup</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Syrup</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To improve blood circulation and treating dizziness, headaches and menstrual pains.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Fengshitong Medicinal Liquor</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Medicinal liquor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To treat low back pain and numbness in the feet and hands, and relieve rheumatoid arthritis pain.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Shiquan Dabu Medicinal Liquor</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Medicinal liquor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To treat dizziness, palpitation, fatigue, and weakness, and ease menstrual flow.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Fengtong Medicinal Liquor</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Medicinal liquor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To treat low back pain and numbness in the feet and hands, and relieve symptoms of arthritis.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Shenrong Medicinal Liquor</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Medicinal liquor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To improve blood circulation and relieve symptoms of fatigue, low back pain and leg pain.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Qishe Medicinal Liquor</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Medicinal liquor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To treat blood stasis, arthritis, and numbness in the feet and hands.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font-weight: bold; text-align: center">Cold and Flu Medicines Medicinal Liquor</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Qiangli Pipa Syrup</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Syrup</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">Relieve cough and reduce mucus and phlegm.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Paracetamol Granule for Children</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Granules</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To relieve children&#8217;s headaches, muscle aches, toothaches, colds and fevers.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Isatis Root Granule</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Granules</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To treat common colds and other infections of the upper respiratory tract.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the 13 TCMD products we manufacture, Guben Yanling Pill is our signature product. For the fiscal years ended September&#160;30, 2022,
2021, and 2020, the revenue derived from the sale of Guben Yanling Pill represented 42.5%, 40.3%, and 38.2% of our total revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Manufacturing Process</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following chart illustrates our main manufacturing process from raw material purchase to marketing:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_002.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
Raw Materials and Suppliers</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
select our raw materials for the manufacturing of our products strictly in accordance with the guidance in Pharmacopoeia of the People&#8217;s
Republic of China (&#12298;&#20013;&#21326;&#33647;&#20856;&#12299;) (the &#8220;PPRC&#8221;), an official compendium of drugs covering
both TCM and western medications complied by the Pharmacopoeia Commission of the Ministry of Health of People&#8217;s Republic of China.
The PPRC specifies the standards of description, dosage, purity, storage, and other material information for each drug. In the manufacturing
of our TCMD products, a total of more than 110 raw materials are regularly used, among which angelica, codonopsis, poria mushroom, isatis
root, loquat leaves, safflower, and Baijiu liquor represent our main raw materials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we have stable access to all the raw materials necessary for our production. There are many suppliers in the industry for the regularly
used raw materials, and therefore we are not relying on a single supplier for any of our raw materials. If we are unable to purchase
any of the raw materials from one supplier, we do not expect to face material difficulties in locating another supplier at substantially
the same price. While the prices of such raw materials may vary greatly from time to time due to market forces beyond our control, we
believe we can hedge such risk by adjusting our price, or absorbing higher costs if and when necessary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
source the raw materials required for our products, we regularly contract with our suppliers by placing bulk orders with them at below
market prices. Our raw material suppliers include mostly traditional Chinese medicine manufacturers and pharmaceutical trading companies.
After years of business cooperation, we believe that our relationships with our current suppliers are strong and stable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider our raw materials suppliers whose sales to us accounted for more than 10% of our overall purchases in any given period to be
our major suppliers for such period. For the fiscal year ended September 30, 2022, one supplier, Jiangxi Hongjing Pharmaceutical Co.,
Ltd., accounted for approximately 10.3% of our total purchases. For the fiscal year ended September 30, 2021, no supplier accounted for
more than 10% of our total purchases. We had two such supplier during the fiscal year ended September 30, 2020, Jiangxi Hongjing Pharmaceutical
Co., Ltd. and Jiangxi Kangxin Pharmaceutical Packaging Co., Ltd., whose sales to us accounted for approximately 19.6% and 13.6% of our
overall purchases in the fiscal year, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Manufacturing
Process</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief description of the manufacturing process of the TCMD products we currently produce by dosage forms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Pill
Products</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
make our pill products, the raw materials first go through a preparation process, during which such materials are dried, roughly ground
and sterilized. Processed raw materials are then finely ground, mixed with honey, and made into pills before they are finally packaged.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Granule
Products</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
raw materials of our granule products typically go through a purifying process, during which such materials are stewed, filtered, condensed,
and let stand. Processed raw materials are then mixed with supplemental ingredients before they are made into granules, dried, and finally
packaged.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Syrup
Products</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
raw materials of our syrup products are first stewed together and condensed. Condensed liquid is then filtered and mixed with supplemental
ingredients before it is bottled and packaged.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Oral
Liquid Products</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
raw materials of our oral liquid products are first filtered, condensed, and fixed with other supplemental ingredients. The processed
materials are then further filtered and sterilized before being bottled and packaged.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Medicinal
Liquor Products</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
raw materials of our medicinal liquor products first go through a purifying process, during which such materials are selected, cut, rinsed,
stewed, and refrigerated. Processed raw materials then go through an extraction process that involves mixing with solvents and filtering.
Then, the liquor products are bottled and packaged.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Quality
Control and Assurance</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to ensure the high quality of our products through our quality control system and by conducting product testing and review. Our
entire manufacturing process is strictly supervised pursuant to internal quality control standards that have been set up in strict adherence
to the guidelines provided in PPRC. We conduct our quality testing by examining the quality of each and every type of raw materials.
If the raw materials meet our quality standards, we start the manufacturing process, during which we continue our quality testing for
every substantial procedure, including filtering, grinding, mixing, and pill making. After our products are packaged, we will examine
various features of our final products thoroughly, including appearance, weight, taste, water content, and microorganism content.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Third-party
Product Distribution</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to manufacturing our own products, we also distribute and sell, through our subsidiary Universe Trade, biomedical drugs, medical
instruments, TCMPs and dietary supplements manufactured by third-party pharmaceutical companies. For the fiscal year ended September
30, 2022, we had distributed roughly 2,785 third-party products, of which approximately 85.0% are biochemical drugs, such as liquid glucose,
prednisolone, and citicoline, approximately 14.8% are medical instruments, such as drug-eluting stents, surgical tubes and syringes,
approximately 0.2% are TCMPs, such as red sage tables, Longdan Xiegan pills, and Chinese skullcap capsules. For the fiscal year ended
September 30, 2021, we had distributed roughly 2,766 third-party products, of which approximately 87.30% are biochemical drugs, such
as liquid glucose, prednisolone, and citicoline, approximately 12.58% are medical instruments, such as drug-eluting stents, surgical
tubes and syringes, approximately 0.11% are TCMPs, such as red sage tables, Longdan Xiegan pills, and Chinese skullcap capsules and approximately
0.01% are dietary supplements, such as vitamins, probiotic powder, and calcium tablets. For the fiscal year ended September 30, 2020,
we had distributed roughly 2,785 third-party products, of which approximately 83.75% are biochemical drugs, such as liquid glucose, prednisolone,
and citicoline, approximately 15.82% are medical instruments, such as drug-eluting stents, surgical tubes and syringes, approximately
0.38% are TCMPs, such as red sage tables, Longdan Xiegan pills, and Chinese skullcap capsules and approximately 0.05% are dietary supplements,
such as vitamins, probiotic powder, and calcium tablets. <b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Suppliers of Third-party Products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
source third-party pharmaceutical products from their manufacturers in China. Our third-party product suppliers include mostly medical
instrument manufacturers, pharmaceutical product manufacturers and dietary supplement manufacturers. For all of the products that we
source and sell, we can generally find similar replacements in the market from the competitors of our current suppliers. Accordingly,
we do not have any continuous or long-term supply agreements with any of these suppliers. We purchase third-party medical products from
our suppliers on a per purchase order basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended September 30, 2022, 2021 and 2020, we purchased products from over 658, 665, and 728 suppliers, respectively. For
the fiscal years ended September 30, 2022, 2021 and 2020, we did not have any supplier of third-party products whose sales to us accounted
for more than 10% of our overall purchases of that fiscal year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Customers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
customers are mostly pharmaceutical distributors, hospitals, clinics and drugstore chains with pharmaceutical business qualification
certificates, awarded and authorized by the NMPA and are authorized to sell and deliver our products to end consumers. As of the date
of this annual report, our customers are scattered over 261 cities of 30 provinces in China. We determine whether to establish long-term
business relationships with our customers primarily based on two factors, their ability to promote our products and their ability to
make payments on time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, we had total of 2,651 customers, of which 1,351 were pharmaceutical distributors, 430 were clinics, 389 were drug
stores, and 481 were hospitals. As of September 30, 2021, we had total of 2,708 customers, of which 1,422 were pharmaceutical distributors,
542 were clinics, 489 were drug stores, and 255 were hospitals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended September 30, 2022, our revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore
chains represented 49.3%, 10.9%, 8.6%, and 31.2% of our total revenues, respectively. For the fiscal year ended September 30, 2021, our
revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore chains represented 59.78%, 29.63%, 10.24%
and 0.35% of our total revenues, respectively. For the fiscal year ended September 30, 2020, our revenues generated from sales to pharmaceutical
distributors, hospitals, clinics and drugstore chains represented 63.8%, 22.4%, 13.3% and 0.5% of our total revenues, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our customers generated more than 10% of our revenue for the fiscal years ended September 30, 2022, 2021 and 2020. However, our top
10 customers aggregately accounted for 32.2%, 30.4%, and 33.3% of our total revenue for the fiscal years ended September 30, 2022, 2021
and 2020, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketing
and Sales</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that marketing activities are crucial to our success in the competitive Chinese patent medicine industry. As of September 30,
2022, we had a total of 57 employees in our marketing department. Employees in our marketing department are mainly responsible for performing
various marketing activities, including researching the most updated industry and market information, analyzing market trends and consumer
preferences, setting up marketing strategies, executing sales contracts, communicating with existing customers and networking with potential
customers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
marketing and sales initiatives for the next several years will focus on three objectives: developing a strong brand image, building
a successful marketing team, and expanding retail channels. To develop our brand image as a producer of TCMD products aiming at addressing
the physical conditions of the elderly during the aging process and promoting their general well-being, we seek to promote our brand
&#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221; utilizing both online marketing channels such as WeChat official account and other
social media and traditional platforms such as television, newspapers, and live radio stations. As part of the efforts to build a successful
marketing team, we intend to hire additional sales talents and provide monetary and equity incentives to sales employees. For the purpose
of expanding our retail channels, we plan to open an online retail store, and according to the preferences of online shoppers, we may
adjust the sizes, packaging, or prices of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
established a research and development department in 1998. Our research and development team has been focusing on the upgrade of current
products and the development of production techniques to increase productivity. After years of continued development, our research and
development department has become the core of our technological innovation efforts. As of September 30, 2022, we had 19 employees dedicated
to research and development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development (&#8220;R&amp;D&#8221;) Achievements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development team has invented patented technologies to enhance the quality of our products and our manufacturing efficiency.
For instance, our patented TCM mixer is able to mix powders more evenly and thoroughly compared to a traditional mixing machine, thereby
increasing the quality of the mixed medicine powder. The special design of our patented TCM concentration device is able to increase
the contact area of the liquid medicine as compared to a regular concentration device, thereby increasing the manufacturing efficiency
of our products in liquid dosage form.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of our efforts, our subsidiary, Jiangxi Universe, became certified as a National High-Tech Enterprise by the Science and Technology
Department of Jiangxi Province in December 2013, with a term of three years. We successfully renewed the certificate in December 2019
and November 2022. This certification entitles Jiangxi Universe to a favorable corporate income tax of 15%, rather than the unified tax
rate of 25% it would pay if it were not certified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>R&amp;D
Development Plan</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
further our strong brand image, we plan to develop products designed to address the physical conditions of the elderly during the aging
process and promoting their general well-being, including TCMD products and dietary supplements. In the upcoming years, we intend to
focus on the development of immunity boost products and sleep aids.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our own efforts, our research and development team also intends to collaborate with other industry professionals and TCM
experts with respect to the development of products we plan to launch in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compete with pharmaceutical companies in China that manufacture and sell products similar to ours. Furthermore, many of these companies
are more established than we are, and have significantly greater financial, technical, and other resources than we presently possess.
Some of our competitors may be able to respond more quickly to new opportunities, market changes or changes of customer preferences,
and may be able to undertake more extensive promotional activities, offer more attractive terms to distributors, and adopt more aggressive
pricing strategies than we are. Despite that, we believe we are well-positioned to compete in this market with our diversified product
portfolio, recognized brand name, established sales and marketing network and experienced management team with a proven track record.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Competitors
of our products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the competitors of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Products</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competitors</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guben
    Yanling Pill</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiyuan Daningtang Pharmaceuticals
    Co., Ltd.;<br/>
    Shenyang Dongxin Pharmaceutical Industry Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shenrong
    Weisheng Pill</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China Beijing Tong Ren
    Tang Group Co., Ltd.;<br/>
    Jiangxi Zhongyuan Pharmaceutical Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quanlu
    Pill</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renhe Pharmaceuticals
    Co.;<br/>
    Guangzhou Pharmaceutical Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fuzi
    Lizhong Pill</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China Beijing Tong Ren
    Tang Group Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yangxue
    Danggui Syrup</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sichuan Tiancheng Pharmaceuticals
    Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qiangli
    Pipa Syrup</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangzhong Pharmaceuticals
    Co., Ltd.;<br/>
    China Resources Sanjiu Medical &amp; Pharmaceuticals Co., Ltd.;<br/>
    Jiangxi Tengwangge Pharmaceuticals Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paracetamol
    and Chlorpheniramine Maleate<br/>
    Granules for Children</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China Resources Sanjiu
    Medical &amp; Pharmaceuticals Co., Ltd.; Sunflower Pharmaceutical Group Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Isatis
    Root Granules</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guangzhou Pharmaceuticals
    Co., Ltd.;<br/>
    China Resources Sanjiu Medicine &amp; Pharmaceuticals Co., Ltd.;<br/>
    China Beijing Tong Ren Tang Group Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wuzi
    Yanzong Oral Liquid</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China Beijing Tong Ren
    Tang Group Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuquan
    Dabu Medicinal Liquor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Puzheng Pharmaceuticals
    Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shenrong
    Medicinal Liquor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Puzheng Pharmaceuticals
    Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qishe
    Medicinal Liquor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Zhongyuan Pharmaceuticals
    Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fengtong
    Medicinal Liquor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Zhongyuan Pharmaceuticals
    Co., Ltd.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Competitors
of Third-party Products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well-known manufacturers
and distributors, including China Beijing Tong Ren Tang Group Co., Ltd., Yunnan Baiyao Group, China Resources Sanjiu Medicine &amp; Pharmaceuticals
Co., Ltd., and Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors in the medical instrument market include many well-known manufacturers and distributors of medical instruments, including
Shinva Medical Instrument Co., Ltd., Jiangsu Yuyue Medical Equipment &amp; Supply Co., Ltd., Lepu Medical Technology (Beijing) Co., Ltd.,
and Shanghai Runda Medical Technology Co., Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors in the dietary supplement market include internationally and nationally well-known manufacturers and distributors of dietary
supplements, such as By-health Co., Ltd., Amway (China) Co., Ltd., and Perfect (China) Co., Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to compete with these larger companies by appealing to the specific needs and preferences of our customers and offering competitive
prices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September&#160;30, 2022, 2021, and 2020, we had a total of 224, 263, and 169 employees, all of whom are located in China. The following
table sets forth the number of our employees by function as of September 30, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Function</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.95pt 0pt 13.95pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>% of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.1pt 0pt 13.1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Purchasing Department</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">9</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Warehouse Department</td><td>&#160;</td>
    <td style="text-align: center">14</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Manufacturing Department</td><td>&#160;</td>
    <td style="text-align: center">85</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Quality Control Department</td><td>&#160;</td>
    <td style="text-align: center">16</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research and Development Department</td><td>&#160;</td>
    <td style="text-align: center">19</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Marketing Department</td><td>&#160;</td>
    <td style="text-align: center">57</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance Department</td><td>&#160;</td>
    <td style="text-align: center">6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Administration Department</td><td>&#160;</td>
    <td style="text-align: center">18</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Total</td><td>&#160;</td>
    <td style="text-align: center">224</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on our ability to attract, retain and motivate qualified personnel. As part of our human resources strategy, we offer
employees competitive salaries and other bonuses and incentives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
primarily recruit our employees in China through direct hiring. We provide training to new employees that we hire. We also conduct regular
and specialized internal training to meet the needs of our employees in different departments. We believe that such training is effective
in equipping our employees with the skill set and work ethics we require.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
required under PRC regulations, we participate in various employee social security plans that are organized by applicable local municipal
and provincial governments, including housing, pension, medical, work-related injury, maternity and unemployment benefit plans.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into standard contracts and agreements regarding confidentiality, intellectual property, employment, ethic policies and non-competition
with most of our executive officers, managers and employees. These contracts typically include a non-competition provision effective
during and up to one year after termination of their employment with us and a confidentiality provision effective during and up to one
year after their employment with us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees have not formed any employee union or association. We believe that we maintain a good working relationship with our employees
and we have not experienced any difficulty in recruiting staff for our operations as of the date of this annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Properties
and Facilities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located in Jinggangshan, Jiangxi Province, China. We own properties in Jingggangshan as office spaces, storage
facilities and manufacturing facilities with an aggregate gross floor area of approximately 825,563 square feet. We believe that our
existing facilities are generally adequate to meet our current needs, but we expect to seek additional space as needed to accommodate
future growth. Following is a list of our properties all of which we own the land use rights to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Land
    Use Right Holder</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
    Address</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
    of<br/>
    Property</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Area
    in<br/>
    Square Feet</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms
    of Use</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy
    and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">173,467</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy
    and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">470,921</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy
    and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,010</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy
    and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Storage</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,426</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy
    and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,276</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy
    and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Storage</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,083</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy
    and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,380</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
manufacture all of our products at the properties listed above. Currently, we are capable of producing a maximum of approximately 12
million bottles of liquid products, 13 million boxes of pill products, and 10 million boxes of solid products annually.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
regard our patents, trademarks, domain names and other intellectual property critical to our business operations. We rely on laws and
regulations on patents, trademarks and domain names to protect our intellectual property. As of the date of this annual report, we have
registered 46 patents in China, including 26 utility model patents, 16 design patents, and four invention patents, and 99 trademarks
in China, including our well-recognized brands &#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221;, &#8220;Hu Zhuo Ren (&#32993;&#21331;&#20161;)&#8221;
and &#8220;Long Zhong (&#40857;&#31181;).&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
implement a set of comprehensive measures to protect our intellectual property, in addition to making trademark and patent registration
application. Key measures include: (i) timely registration, filing and application for ownership of our intellectual property, (ii) actively
tracking the registration and authorization status of our intellectual property and take action in a timely manner if any potential conflicts
with our intellectual property are identified, and (iii) clearly stating all rights and obligations regarding the ownership and protection
of our intellectual property in all employment contracts and commercial contracts we enter into.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, we have not been subject to any material dispute or claims for infringement upon third parties&#8217;
trademarks, licenses and other intellectual property rights in China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Seasonality</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not experience seasonality in our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Environmental
Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
comply with the Environmental Protection Law of China as well as applicable local regulations. In addition to statutory and regulatory
compliance, we actively ensure the environmental sustainability of our operations. Parties may be levied upon us if we fail to adhere
to and maintain certain standards. Such failure has not occurred in the past, and we generally do not anticipate that it will occur in
the future, but no assurance can be given in this regard.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insurance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain certain insurance policies to safeguard
us against risks and unexpected events. For example, we provide social security insurance including pension insurance, unemployment insurance,
work-related injury insurance and medical insurance for our employees in compliance with applicable PRC laws. We also maintain directors
and officers liability insurance. We do not maintain business interruption insurance or product liability insurance, which are not mandatory
under PRC laws. We do not maintain key man insurance, insurance policies covering damages to our network infrastructures or information
technology systems nor any insurance policies for our properties. During the fiscal years ended September 30, 2022, 2021 and 2020, we
did not make any material insurance claims in relation to our business.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may from time to time become a party to various legal administrative proceedings arising in our ordinary course of our business. As of
the date of this annual report, neither we nor any of our subsidiaries is a party of any material legal proceeding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section sets forth a summary of the principal PRC laws, regulations, and rules relevant to our PRC operating entities&#8217; business
and operations in China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pharmaceutical manufacturer in China. This section sets forth a summary of applicable laws, rules, regulations, government and
industry policies and requirement that have a significant impact on our operations and business in China. This summary does not purport
to be a complete description of all laws and regulations, which apply to our business and operations. Investors should note that the
following summary is based on relevant laws and regulations in force as of the date of this annual report, which may be subject to change.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Major
Regulatory Authorities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical industry in the PRC is mainly administered by four governmental agencies: (i) the NMPA, a department under the State Administration
for Market Regulation (the &#8220;SAMR&#8221;) (&#22269;&#23478;&#24066;&#22330;&#30417;&#30563;&#31649;&#29702;&#24635;&#23616;), (ii)
the National Health Commission (the &#8220;NHC&#8221;) (&#22269;&#23478;&#21355;&#29983;&#20581;&#24247;&#22996;&#21592;&#20250;), (iii)
the National Administration of Traditional Chinese Medicine (the &#8220;NATCM&#8221;) (&#22269;&#23478;&#20013;&#21307;&#33647;&#31649;&#29702;&#23616;),
and (iv) the National Healthcare Bureau (the &#8220;NHB&#8221;) (&#22269;&#23478;&#21307;&#30103;&#20445;&#38556;&#23616;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NMPA, whose predecessor is the China Food and Drug Administration, or the CFDA, is the primary regulator of almost all key stages of
the life-cycle of pharmaceutical products, including non-clinical researches, clinical trials, marketing approvals, manufacturing, advertising
and promotion, distribution and pharmacovigilance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NHC, formerly known as the National Health and Family Planning Commission, is the principal regulator of healthcare in China. It is primarily
responsible for drafting national healthcare policies and regulating public health, medical services and health contingency system, coordinating
the healthcare reform and overseeing the operation of medical institutions and professional practice of medical personnel. The NHC is
responsible for (1) the research, production, circulation and use of Chinese medicines, including traditional Chinese medicine; (2) the
preparation and publication of the Chinese Pharmacopoeia; and (3) the supervision of the selection, approval, distribution and revision
of the National OTC Drug Catalogue. In addition, the CFDA and its local administrative authorities may take a number of enforcement actions
to enforce their regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NATCM is an agency under the NHC that oversees China&#8217;s traditional Chinese medicine industry.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NHB, a new authority established in May 2018, is responsible for (1) drafting and implementing policies, plans and standards on medical
insurance, maternity insurance and medical assistance; (2) administering healthcare fund; (3) formulating a uniform medical insurance
catalogue and payment standards on drugs, medical disposables and healthcare services; and (4) formulating and administering the bidding
and tendering policies for drugs and medical disposables.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulations
Related to Pharmaceutical Manufacture</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing
License</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Pharmaceutical Administration Law of the People&#8217;s Republic of China (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#33647;&#21697;&#31649;&#29702;&#27861;&#12299;),
which was promulgated in 1984 by the SCNPC and last amended in August 2019, a pharmaceutical manufacturer is required to obtain its manufacturing
license from the NMPA before it starts to manufacture pharmaceutical products. Prior to granting such permit, the relevant government
authority will inspect the applicant&#8217;s production facilities, and assess whether the sanitary conditions, quality assurance system,
management structure and equipment at the production facilities have met the required standards. A manufacturing license is valid for
a period of five years and the manufacturer is required to apply for renewal within six months prior to its expiration date. The manufacturer
will be subject to reassessment by the authority in accordance with then prevailing legal and regulatory requirements for the purposes
of such renewal. Currently, our subsidiary Jiangxi Universe holds a valid manufacturing license from the NMPA issued on December 21,
2020 and valid until December 20, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contract
Manufacturing of Drugs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Administrative Regulations for the Contract Manufacturing of Drugs (&#12298;&#33647;&#21697;&#22996;&#25176;&#29983;&#20135;&#30417;&#30563;&#31649;&#29702;&#35268;&#23450;&#12299;)
(the &#8220;Contract Manufacturing Regulations&#8221;) issued by the NMPA in August 2014, in the event that a drug manufacturer in China
with drug marketing authorization temporarily lacks manufacturing capability as a result of technology upgrade or is unable to meet market
demand due to insufficient manufacturing capacity, it may use contract manufacturer for its drug manufacturing. Contract manufacturing
arrangements need to be approved by the provincial branch of the NMPA. The Contract Manufacturing Regulations prohibit contract manufacturing
arrangements for certain special drugs, including narcotic drugs, psychoactive drugs, biochemical drugs and active pharmaceutical ingredients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Regulations in relation to the Pharmaceutical Industry</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#8220;Two-vote
system&#8221; for drug sales</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NHC and other six ministries and commissions issued the Notice on the Opinions on the Implementation of the &#8220;Two-Invoice System&#8221;
in Drug Procurement by Public Medical Institutions (for Trial Implementation) (&#12298;&#20851;&#20110;&#22312;&#20844;&#31435;&#21307;&#30103;&#26426;&#26500;&#33647;&#21697;&#37319;&#36141;&#20013;&#25512;&#34892;&#8220;&#20004;&#31080;&#21046;&#8221;&#30340;&#23454;&#26045;&#24847;&#35265;
(&#35797;&#34892;) &#30340;&#36890;&#30693;&#12299;) (the &#8220;Notice on Two-Invoice System&#8221;) on January 11, 2017. &#8220;Two-invoice
system&#8221; means that one invoice shall be issued by a pharmaceutical manufacturer to a distributor, and another invoice shall be
issued by the distributor to a hospital. An internal transfer of drugs from a group pharmaceutical distributor to its wholly owned or
controlled subsidiary or a transfer of drugs between such wholly owned subsidiaries may not be deemed as &#8220;one invoice&#8221; however,
the invoicing for the whole group can be done only once. Pharmaceutical manufacturers and distributors shall reasonably determine the
markup level in the spirit of fairness, legality, legitimacy and integrity. Public medical institutions is encouraged to settle the payment
for drugs directly with pharmaceutical manufacturers, and pharmaceutical manufacturers and are encouraged to settle the delivery cost
with distributors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the sale of drugs, drug manufacturers and distributors shall issue value-added tax (&#8220;VAT&#8221;) special invoices or normal VAT
invoices in accordance with the regulations regarding invoice control. The sold drug shall also be delivered in a way that confirms to
the requirements of the Good Supply Practice for Pharmaceutical Products (2016 version) (&#12298;&#33647;&#21697;&#32463;&#33829;&#36136;&#37327;&#31649;&#29702;&#35268;&#33539;(2016&#20462;&#35746;)&#12299;),
and the names of the purchaser and seller on the invoices shall be consistent with the delivery form, payment flow and amount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Drug
Advertisements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Interim Administrative Measures for the Review of Advertisements for Drugs, Medical Devices, Health Food and Formula Food for
Special Medical Purposes (&#12298;&#33647;&#21697;&#12289;&#21307;&#30103;&#22120;&#26800;&#12289;&#20445;&#20581;&#39135;&#21697;&#12289;&#29305;&#27530;&#21307;&#23398;&#29992;&#36884;&#37197;&#26041;&#39135;&#21697;&#24191;&#21578;&#23457;&#26597;&#31649;&#29702;&#26242;&#34892;&#21150;&#27861;&#12299;)
promulgated on December 24, 2019 and effective on March 1, 2020, an enterprise seeking to advertise its drugs must apply for an advertising
approval code. An advertising approval code shall expire on the earlier of the expiration dates of the product&#8217;s registration certificate,
filing certificate or production license. If an expiration date is not prescribed in the product&#8217;s registration certificate, filing
certificate or production license, the advertising approval code shall be valid for two years. The contents of an approved advertisement
shall not be altered without prior approval. Where an advertisement needs to be edited, the enterprise shall submit an application for
a new advertisement approval code.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Insert
Sheet, Labels and Packaging of Pharmaceutical Products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Measures for the Administration of the Insert Sheets and Labels of Drugs (&#12298;&#33647;&#21697;&#35828;&#26126;&#20070;&#21644;&#26631;&#31614;&#31649;&#29702;&#35268;&#23450;&#12299;)
effective on June 1, 2006, the insert sheets and labels of a pharmaceutical product shall be reviewed and approved by the NMPA. A drug
insert sheet should include the scientific data, conclusions and information concerning drug safety and efficacy in order to direct the
safe and reasonable use of pharmaceutical products. The inner label of a pharmaceutical product shall indicate the product name, indication
or function, strength, dose and usage, production date, batch number, expiration date and drug manufacturer, and the outer label of a
pharmaceutical product shall indicate the product name, ingredients, description, indication or function, strength, dose and usage and
adverse reactions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Measures for the Administration of Pharmaceutical Packaging (&#12298;&#33647;&#21697;&#21253;&#35013;&#31649;&#29702;&#21150;&#27861;&#12299;)
effective on September 1, 1988, pharmaceutical packaging must comply with national and professional standards. If no national or professional
standards are available, a manufacturer can formulate and implement its own standards after it receives approval from the provincial
food and drug administration or bureau of standards. The company shall reapply for approval if it were to change its own packaging standards.
Pharmaceutical products with no approved packing standards shall not be sold or traded in the PRC, except for drugs for military use.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Drug
Technology Transfer</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 19, 2009, the NMPA promulgated the Administrative Regulations for Technology Transfer Registration of Drugs (&#12298;&#33647;&#21697;&#25216;&#26415;&#36716;&#35753;&#27880;&#20876;&#31649;&#29702;&#35268;&#23450;&#12299;)
(the &#8220;Technology Transfer Regulations&#8221;) to regulate the drug technology transfer process, including the application, evaluation,
examination, approval and monitoring of, drug technology transfer. Drug technology transfer means that the owner transfers its pharmaceutical
manufacturing technology to a pharmaceutical manufacturer and that the transferee applies for drug registration pursuant to the Technology
Transfer Regulations. Drug technology transfer includes the transfer of new drug technology and drug manufacturing technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applications
for drug technology transfer shall be submitted to the provincial drug regulatory authority where the transferee is located. The drug
regulatory authority examines application materials and conducts on-site inspections of the transferee&#8217;s manufacturing facilities.
If the transferor and the transferee are located in different provinces, the provincial drug regulatory authority where the transferor
is located shall issue examination opinions as well. The Center for Drug Evaluation (the &#8220;CDE&#8221;), a branch of the NMPA, shall
further review the application materials, provide technical evaluation opinions and form a comprehensive evaluation opinion based on
the on-site inspection reports and the testing results of the samples. The NMPA shall determine whether to approve the application according
to the comprehensive evaluation opinion of the CDE. An approval letter of supplementary application and a drug approval number will be
issued for qualified applications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Price
of drugs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Drug Administration Law (&#12298;&#33647;&#21697;&#31649;&#29702;&#27861;&#12299;), for those drugs whose prices are determined
by market, manufacturers and distributors of pharmaceutical products and medical institutions shall set the prices in accordance with
the principles of fairness, rationality, and good faith, and provide consumers with drugs at reasonable prices. Pharmaceutical product
manufacturers, distributors and medical institutions shall determine and indicate their products&#8217; retail prices in accordance with
the regulations over drug prices promulgated by the pricing department of the State Council of the People&#8217;s Republic of China (the
&#8220;State Council&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2015, the National Development and Reform Commission, the National Health and Family Planning Commission, the Ministry of Human
Resources and Social Security, the Ministry of Industry and Information Technology, the Ministry of Finance, the MOFCOM and the NMPA
jointly issued the Notice Regarding Reforms to the Price of Medical Products (&#12298;&#20851;&#20110;&#21360;&#21457;&#25512;&#36827;&#33647;&#21697;&#20215;&#26684;&#25913;&#38761;&#24847;&#35265;&#30340;&#36890;&#30693;&#12299;),
pursuant to which, since June 1, 2015, other than anesthetics and Class 1 psychotropic drugs, the actual price of pharmaceutical products
shall be decided by market instead of by the government. As of the date of this annual report, the actual price of all products we sell,
including TCMD products and third-party products, are determined by market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
in relation to medical device registration</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Regulations on Supervision and Administration of Medical Devices (&#12298;&#21307;&#30103;&#22120;&#26800;&#30417;&#30563;&#31649;&#29702;&#26465;&#20363;&#12299;)
promulgated by the State Council of China with the last amendment effective on June 1, 2021, medical devices are classified based on
the invasiveness of, and risks associated with, each medical device. Class I medical devices have relatively low risks, whose safety
and effectiveness can be guaranteed through routine administration. Class II medical devices have moderate risks and require strict control
and administration to ensure their safety and effectiveness. Class III medical devices have relatively high risks and require especially
strict control and administration measures to ensure their safety and effectiveness. Pursuant to the Administrative Measures for the
Medical Devices Registration and Record (&#12298;&#21307;&#30103;&#22120;&#26800;&#27880;&#20876;&#19982;&#22791;&#26696;&#31649;&#29702;&#21150;&#27861;&#12299;),
which became effective on October 1, 2021, manufacturers of Class I medical devices are required to file with the local food and drug
administrative authority at the city level. Manufacturers of Class II medical devices shall obtain product registration certificates
from and be subject to the inspection and approval of the drug administrative authority at the provincial level. Manufacturers of Class
III medical devices shall obtain product registration certificates from the NMPA and be subject to its inspection and approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, we are engaged in the business of selling medical devices. We sell medical devices categorized as
Class I, Class II and Class III under the Regulation on Supervision and Administration of Medical Devices in the PRC, and we obtained
our medical device selling license in April 2020 in compliance with the applicable PRC laws and regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
relating to Company Establishment and Foreign Investment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PRC Company Law applies to the establishment, operation and
management of both PRC domestic companies and foreign-invested enterprises. Foreign investment in the PRC corporate entities are also
regulated by the foreign-Owned Enterprise Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#36164;&#20225;&#19994;&#27861;&#12299;)
(the &#8220;Foreign-Owned Enterprise Law&#8221;) promulgated on April 12, 1986 and amended on October 31, 2000 and September 3, 2016,
the Implementing Rules for the Foreign-Owned Enterprise Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#36164;&#20225;&#19994;&#27861;&#23454;&#26045;&#32454;&#21017;&#12299;)
promulgated on December 12, 1990 and amended on April 12, 2001 and February 19, 2014, and the Interim Administrative Measures for the
Record-filing of the Incorporation and Change of Foreign-invested Enterprises (&#12298;&#22806;&#21830;&#25237;&#36164;&#20225;&#19994;&#35774;&#31435;&#21450;&#21464;&#26356;&#22791;&#26696;&#31649;&#29702;&#26242;&#34892;&#21150;&#27861;&#12299;)
(the &#8220;Record-filing Measures&#8221;) promulgated on October 8, 2016 and amended on July 30, 2017 and June 29, 2018. Under these
laws and regulations, the establishment of a wholly foreign-owned enterprise is subject to the approval of, or the filing with the MOFCOM
or its local counterpart, and such wholly foreign-owned enterprises must register and file with the appropriate administrative bureau
of industry and commerce.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Foreign Investment Law of the People&#8217;s Republic of China (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#21830;&#25237;&#36164;&#27861;&#12299;)
(the &#8220;Foreign Investment Law&#8221;), which was promulgated by the National People&#8217;s Congress On March 15, 2019, and came
into effect on January 1, 2020, provides that foreign investment refers to the investment activities in China carried out directly or
indirectly by foreign natural persons, enterprises or other organizations (the &#8220;Foreign Investors&#8221;), including the following:
(1) Foreign Investors establishing foreign-invested enterprises in China alone or collectively with other investors; (2) Foreign Investors
acquiring shares, equities, properties or other similar rights of Chinese domestic enterprises; (3) Foreign Investors investing in new
projects in China alone or collectively with other investors; and (4) Foreign Investors investing through other ways prescribed by laws
and regulations or the State Council. The State adopts the management system of pre-establishment national treatment and negative list
for foreign investment. The pre-entry national treatment means the treatment given to Foreign Investors and their investments at the
stage of investment access is not lower than that of domestic investors and their investments. The negative list management system means
that the state implements special administrative measures for access of foreign investment in specific fields. Foreign investors shall
not invest in any forbidden fields stipulated in the negative list and shall mean the conditions stipulated in the negative list before
investing in any restricted fields. The negative list is released upon approval of the State Council. After the Foreign Investment Law
came into effect, it replaced the Foreign-Owned Enterprise Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Implementation Regulations for the Foreign Investment Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#21830;&#25237;&#36164;&#27861;&#23454;&#26045;&#26465;&#20363;&#12299;)
(the &#8220;Implementation Regulations for the FIL&#8221;) was adopted at the 74th executive meeting of the State Council on December
12, 2019 and came into effect on January 1, 2020. The purpose of the Implementation Regulations for the FIL is to encourage and promote
foreign investment, protect the legitimate rights and interests of investors, regulate the administration of foreign investment, and
continuously optimize the foreign investment environment. For those foreign-invested enterprises established prior to the implementation
of the Foreign Investment Law and established in accordance with the Law of the People&#8217;s Republic of China on Sino-foreign Joint
Ventures (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20013;&#22806;&#21512;&#36164;&#32463;&#33829;&#20225;&#19994;&#27861;&#12299;),
the Law of the People&#8217;s Republic of China on Foreign-invested Enterprises, and the Law of the People&#8217;s Republic of China
on Sino-Foreign Cooperative Enterprises, they can modify or retain their organizational forms and organizational structures in accordance
with the PRC Company Law, Partnership Law of the People&#8217;s Republic of China and other applicable laws within 5 years since the
implementation of the Foreign Investment Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
investment in China shall comply with the Catalogue for the Guidance of Foreign Investment Industries (2017 Revision) (&#12298;&#22806;&#21830;&#25237;&#36164;&#20135;&#19994;&#25351;&#23548;&#30446;&#24405;(2017&#24180;&#20462;&#35746;)&#12299;)
(the &#8220;2017 Catalogue&#8221;), which was promulgated on June 28, 2017 and became effective on July 28, 2017, and the Special Administrative
Measures for the Access of Foreign Investment (Negative List) (Edition 2018) (&#12298;&#22806;&#21830;&#25237;&#36164;&#20934;&#20837;&#29305;&#21035;&#31649;&#29702;&#25514;&#26045;(&#36127;&#38754;&#28165;&#21333;)
(2018&#24180;&#29256;)&#12299;) (the &#8220;2018 Negative List&#8221;) which were promulgated on June 28, 2018 and became effective on
July 28, 2018. The Catalogue classifies foreign-invested industries into two categories, (1) encouraged foreign-invested industries;
and (2) foreign-invested industries that are subject to the 2018 Negative List. The 2018 Negative List set out restrictions such as shareholding
requirements and qualifications of the senior management. According to the Record-filing Measures, foreign investments that are not subject
to special access administrative measures are only required to complete an online filing with the MOFCOM or its local counterpart. The
Catalogue for Encouraged Foreign Investment (2020 Revision) (&#12298;&#40723;&#21169;&#22806;&#21830;&#25237;&#36164;&#20135;&#19994;&#30446;&#24405;(2020&#24180;&#29256;)&#12299;),
or the 2020 Catalogue, and the Special Administrative Measures for the Access of Foreign Investment (Negative List) (Edition 2021) (&#12298;&#22806;&#21830;&#25237;&#36164;&#20934;&#20837;&#29305;&#21035;&#31649;&#29702;&#25514;&#26045;(&#36127;&#38754;&#28165;&#21333;)
(2021&#24180;&#29256;)&#12299;), or the 2021 Negative List, which were issued on September 18, 2021 and came into effect on December
27, 2021, further reduced restrictions on foreign investment. The 2020 Catalogue and the 2021 Negative List replaced the 2017 Catalogue
and the 2018 Negative List. The scope of our business as approved by the licensing authority and the actual scope of our business are
not subject to the restrictions set forth in the 2021 Negative List.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
M&amp;A Rules were jointly promulgated by the MOFCOM, the State-Owned Assets Supervision and Administration Commission of the State Council,
the SAT, the SAIC, the CSRC, and the SAFE on August 8, 2006 and was amended by MOFCOM on June 22, 2009. The M&amp;A Rules provides that
a foreign investor is required to obtain necessary approvals when it: (1) acquires equity interests in a domestic enterprise or subscribes
to additional shares in a domestic enterprise; (2) purchases the assets of a domestic enterprise through establishment of a foreign-invested
enterprise; or (3) establishes a foreign-invested enterprise through which it purchases the assets of a domestic enterprise and operates
these assets. In particular, any PRC company, enterprise or individual is required to obtain approval from the MOFCOM and comply with
applicable laws and regulations if it establishes an offshore company and attempts to acquire a domestic enterprise related to such offshore
company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
in relation to Intellectual Property Rights</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
terms of international conventions, China has entered into (including but not limited to) the Agreement on Trade-Related Aspects of Intellectual
Property Rights (&#12298;&#19982;&#36152;&#26131;&#26377;&#20851;&#30340;&#30693;&#35782;&#20135;&#26435;&#21327;&#23450;&#12299;), the
Paris Convention for the Protection of Industrial Property (&#12298;&#20445;&#25252;&#24037;&#19994;&#20135;&#26435;&#24052;&#40654;&#20844;&#32422;&#12299;),
the Madrid Agreement Concerning the International Registration of Marks (&#12298;&#21830;&#26631;&#22269;&#38469;&#27880;&#20876;&#39532;&#24503;&#37324;&#21327;&#23450;&#12299;)
and the Patent Cooperation Treaty (&#12298;&#19987;&#21033;&#21512;&#20316;&#21327;&#23450;&#12299;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Patent Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#19987;&#21033;&#27861;&#12299;), or the
Patent Law, promulgated by the SCNPC on March 12, 1984 and last amended on October 17, 2020 and effective from June 1, 2021 and the Implementation
Rules of the Patent Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#19987;&#21033;&#27861;&#23454;&#26045;&#32454;&#21017;&#12299;),
promulgated by the State Council on June 15, 2001 and amended on December 28, 2002 and January 9, 2010, respectively, patents in China
fall into three categories: invention patents, utility model patents and design patents. The term of patent protection starts from the
date of application and lasts 20 years for invention patents and 10 years for utility model patents and design patents. Any individual
or entity that utilizes a patent or conducts any other activity that infringes a patent without the patent holder&#8217;s authorization
shall pay compensation to the patent holder and be subject to a fine imposed by regulatory authorities and, if such behavior constitutes
a crime, shall be held criminally liable in accordance with applicable laws. According to the Patent Law, for public health purposes,
the State Intellectual Property Office of the PRC, or SIPO, may grant a compulsory license for manufacturing patented drugs and exporting
them to countries or regions covered under relevant international treaties to which PRC has acceded. In addition, under the Patent Law,
any organization or individual that applies for a patent in a foreign country for an invention or utility model patent established in
China is required to report to the SIPO for confidentiality examination. Patent holders may apply for extending the terms of patented
drugs to compensate for commercialization delays due to regulatory review, and may seek punitive damages for willful patent infringement
under severe circumstances.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trade
Secrets</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the PRC Anti-Unfair Competition Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21453;&#19981;&#27491;&#24403;&#31454;&#20105;&#27861;&#12299;)
promulgated by the SCNPC in September 1993, as amended on November 4, 2017 and April 23, 2019 respectively, the term &#8220;trade secrets&#8221;
refers to technical and business information that is unknown to the public, has utility, may create business interests or profits for
its legal owners or holders, and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law,
business persons are prohibited from infringing others&#8217; trade secrets by: (1) obtaining trade secrets from the legal owners or
holders by any unfair methods, such as theft, bribery, fraud, coercion, electronic intrusion, or any other illicit means; (2) disclosing,
using or permitting others to use the trade secrets obtained illegally under item (1) above; or (3) disclosing, using or permitting others
to use the trade secrets, in violation of any contractual agreements or any requirements of the legal owners or holders to keep such
trade secrets in confidence. If a third party knows or should have known of the above- mentioned illegal conduct but nevertheless obtains,
uses or discloses trade secrets of others, the third party may be deemed to have committed a misappropriation of the others&#8217; trade
secrets. The parties whose trade secrets are being misappropriated may petition for administrative corrections, and regulatory authorities
may stop any illegal activities and impose fines on the infringing parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trademarks</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Trademark Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21830;&#26631;&#27861;&#12299;)
(the &#8220;Trademark Law&#8221;), which was promulgated by the SCNPC on August 23, 1982, and was last amended on April 23, 2019 and
came into effect on November 1, 2019, any trademark which is registered with the approval of the Trademark Office is a registered trademark,
including commodity trademark, service trademark, collective trademark, certification trademark, and the trademark registrant has the
exclusive right to use a registered trademark and such right is protected by law. A registered trademark is valid for a period of 10
years commencing from the date on which the registration is approved. Upon expiration of the trademark, the registrant shall apply for
renewal within twelve months prior to the expiration date if it intends to maintain exclusive use of the trademark. If the registrant
fails to apply for renewal, a grace period of six months may be granted. In the absence of a renewal upon the expiration of a trademark
registration, the registered trademark shall be canceled. Use of a trademark that is identical with or similar to a registered trademark,
for the same kind of or similar commodities, without authorization of the trademark registrant, constitutes infringement of the exclusive
right to use a registered trademark. Industrial and commercial administrative authorities have the authority to investigate any behavior
that may constitute an infringement of the exclusive right under a registered trademark.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Domain
names</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Domain
names are protected under the Administrative Measures on the Internet Domain Names (&#12298;&#20114;&#32852;&#32593;&#22495;&#21517;&#31649;&#29702;&#21150;&#27861;&#12299;),
which was promulgated by the Ministry of Industry and Information Technology, or the MIIT, on August 24, 2017 and came into effect on
November 1, 2017, and the Implementing Rules of China Internet Network Information Center on the Registration of Domain Names (&#12298;&#20013;&#22269;&#20114;&#32852;&#32593;&#32476;&#20449;&#24687;&#20013;&#24515;&#22495;&#21517;&#27880;&#20876;&#23454;&#26045;&#32454;&#21017;&#12299;)
issued by China Internet Network Information Center (the &#8220;CNNIC&#8221;) on May 28, 2012 and came into effect on May 29, 2012. Domain
name registrations are handled through domain name service agencies established under the relevant regulations, and the applicant becomes
domain name holder upon successful registration. Domain name disputes shall be submitted to an organization authorized by CNNIC for resolution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
laws</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
Liability</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Product Quality Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20135;&#21697;&#36136;&#37327;&#27861;&#12299;),
promulgated by the SCNPC on February 22, 1993 and last amended on December 29, 2018, governs the supervision and administration of product
quality and specifies the liabilities of manufacturers and sellers. A manufacture shall be liable for compensating for any bodily injuries
or property damages, other than the defective product itself, resulting from the defects in the product, unless the manufacturer is able
to prove that: (1) the product has never been distributed; (2) the defects causing injuries or damage did not exist at the time when
the product was distributed; or (3) the science and technology at the time when the product was distributed was at a level incapable
of detecting the defects. A seller shall pay compensation if it fails to indicate either the manufacturer or the supplier of the defective
product. A person who is injured or whose property is damaged by the defects in the product may claim for compensation from the manufacturer
or the seller.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Civil Code of the People&#8217;s Republic of China (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#27665;&#27861;&#20856;&#12299;),
promulgated by the SCNPC on May 28, 2020 and became effective on January 1, 2021, manufacturers shall assume tort liabilities where the
defects in products cause damage to others. Sellers shall assume tort liability where the defects in products that have caused damage
to others are attributable to the sellers. The aggrieved party may claim for compensation from the manufacturer or the seller of the
defected product that has caused damage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Environmental
Protection</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Environmental Protection Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#29615;&#22659;&#20445;&#25252;&#27861;&#12299;)
promulgated by the SCNPC on December 26, 1989 and amended on April 24, 2014, the Environmental Impact Assessment Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#29615;&#22659;&#24433;&#21709;&#35780;&#20215;&#27861;&#12299;),
promulgated by the SCNPC on October 28, 2002 and amended on July 2, 2016 and December 29, 2018 respectively, the Administrative Regulations
on the Environmental Protection of Construction Project (&#12298;&#24314;&#35774;&#39033;&#30446;&#29615;&#22659;&#20445;&#25252;&#31649;&#29702;&#26465;&#20363;&#12299;)
promulgated by the State Council on November 29, 1998 and amended on July 16, 2017, and other applicable environmental laws and regulations,
an enterprise with a project construction plan shall submit an environmental impact assessment report, stating the environmental impacts
the project is likely to have, to the administrative authority of environmental protection for approval. Enterprises shall engage qualified
institutions to issue the environmental impact assessment reports.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Law of the PRC on the Prevention and Control of Water Pollution (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#27700;&#27745;&#26579;&#38450;&#27835;&#27861;&#12299;)
promulgated by the SCNPC on May 11, 1984 and last amended on June 27, 2017, and effective on January 1, 2018, the Law of the PRC on the
Prevention and Control of Atmospheric Pollution (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22823;&#27668;&#27745;&#26579;&#38450;&#27835;&#27861;&#12299;)
promulgated by the SCNPC on September 5, 1987 and last amended on October 26, 2018, the Law of the PRC on the Prevention and Control
of Pollution from Environmental Noise (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#29615;&#22659;&#22122;&#22768;&#27745;&#26579;&#38450;&#27835;&#27861;&#12299;)
promulgated by the SCNPC on October 29, 1996 and amended on December 29, 2018, and the Law of the PRC on the Prevention and Control of
Environmental Pollution of Solid Waste (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22266;&#20307;&#24223;&#29289;&#27745;&#26579;&#29615;&#22659;&#38450;&#27835;&#27861;&#12299;),
promulgated by the SCNPC on October 30, 1995 and last amended on April 29, 2020, all the enterprises that may cause environmental pollution
in the course of their business operation shall implement preventive and curative environmental protection measures in their plants and
establish a reliable environmental protection system.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strictly complied with the applicable environmental laws and regulations in constructing our factory. On December 8, 2004, the environmental
protection bureau of local government determined that the environmental protection facilities we constructed for our factory satisfied
the relevant standards. According to the certificate issued by the ecological environment bureau of local government (the &#8220;Bureau&#8221;),
our factory has not been assessed on its environmental impacts since its establishment in 2004. Although there were certain procedural
defects in the original construction process, we constructed our environmental protection facilities for our factory in strict compliance
with the requirements of applicable PRC environmental laws and regulations. Our environmental protection facilities were approved by
the Bureau in December 2004 and have since been under normal operations. As of the date of the date of this annual report, we have not
been found in violation of applicable environmental laws or regulations, or imposed of administrative penalties by environmental protection
authorities in the past three years. No environmental pollution incident has occurred on our manufacturing facility.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Exchange Control</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Foreign Exchange Administration Regulations of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#27719;&#31649;&#29702;&#26465;&#20363;&#12299;),
as amended on August 5, 2008, and the Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment (&#12298;&#32467;&#27719;&#12289;&#21806;&#27719;&#21450;&#20184;&#27719;&#31649;&#29702;&#35268;&#23450;&#12299;),
or the Settlement Regulations, promulgated by the People&#8217;s Bank of China on June 20, 1996 and came into effect on July 1, 1996,
foreign exchanges required for profit distributions and dividend payments may be purchased from designated foreign exchange banks in
the PRC upon presentation of a board resolution authorizing distribution of profits or payment of dividends.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Notice of SAFE on Further Improving and Adjusting Foreign Exchange Administration Policies on Direct Investment (&#12298;&#22269;&#23478;&#22806;&#27719;&#31649;&#29702;&#23616;&#20851;&#20110;&#36827;&#19968;&#27493;&#25913;&#36827;&#21644;&#35843;&#25972;&#30452;&#25509;&#25237;&#36164;&#22806;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;)
(the &#8220;Circular No. 59&#8221;), promulgated on November 19, 2012 and last amended on December 30, 2019 by the State Administration
of Exchange Control, or the SAFE, (1) the opening of and payment into foreign exchange accounts under direct investment accounts are
no longer subject to approval by the SAFE; (2) reinvestment with legal income of foreign investors in China is no longer subject to approval
by SAFE; (3) the procedures for capital verification and confirmation that foreign-funded enterprises need to go through are simplified;
(4) purchase and external payment of foreign exchange under direct investment accounts are no longer subject to approval by SAFE; (5)
domestic transfer of foreign exchange under direct investment account is no longer subject to approval by SAFE; and (6) the administration
over the conversion of foreign exchange capital of foreign-invested enterprises is improved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Circular on Further Simplifying and Improving the Direct Investment-related Foreign Exchange Administration Policies (&#12298;&#20851;&#20110;&#36827;&#19968;&#27493;&#31616;&#21270;&#21644;&#25913;&#36827;&#30452;&#25509;&#25237;&#36164;&#22806;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;)
(the &#8220;SAFE Circular No. 13&#8221;), which was promulgated on February 13, 2015 and became effective on June 1, 2015, the foreign
exchange registration under domestic direct investment and the foreign exchange registration under foreign direct investment is directly
reviewed and handled by banks in accordance with the Circular No. 13, and the SAFE and its branches shall perform indirect regulation
over the foreign exchange registration via banks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises
(&#12298;&#22269;&#23478;&#22806;&#27719;&#31649;&#29702;&#23616;&#20851;&#20110;&#25913;&#38761;&#22806;&#21830;&#25237;&#36164;&#20225;&#19994;&#22806;&#27719;&#36164;&#26412;&#37329;&#32467;&#27719;&#31649;&#29702;&#26041;&#24335;&#30340;&#36890;&#30693;&#12299;)
promulgated by the SAFE on March 30, 2015 and became effective on June 1, 2015, and the Circular on the Reform and Standardization of
the Management Policy of the Settlement of Capital Projects (&#12298;&#22269;&#23478;&#22806;&#27719;&#31649;&#29702;&#23616;&#20851;&#20110;&#25913;&#38761;&#21644;&#35268;&#33539;&#36164;&#26412;&#39033;&#30446;&#32467;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;)
promulgated by the SAFE on June 9, 2016, the settlement of foreign exchange by foreign invested enterprises shall be governed by the
policy of foreign exchange settlement on a discretionary basis. However, the settlement of foreign exchange shall only be used for its
own operation purposes within the business scope of the foreign invested enterprises in accordance with the principle of authenticity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Circular 37, a PRC resident shall register with the local SAFE branch before he or she contributes assets or equity interests
in an overseas special purpose vehicle (&#8220;Overseas SPV&#8221;), that is directly established or controlled by the PRC Resident for
the purpose of conducting investment for financing. Failure to comply with the SAFE registration requirements could result in penalties
for evasion of foreign exchange controls. The Circular No. 13 provides that banks can directly handle the initial foreign exchange registration
and amendment registration under the Circular 37. Mr. Gang Lai completed the initial foreign registration on June 3, 2019.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Labor
and Social Insurance</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Labor Contract Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#21512;&#21516;&#27861;&#12299;),
which was promulgated by the SCNPC on June 29, 2007 and became effective on January 1, 2008, and amended on December 28, 2012 and became
effective on July 1, 2013, and the Implementing Regulations of the Labor Contracts Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#21512;&#21516;&#27861;&#23454;&#26045;&#26465;&#20363;&#12299;),
which was promulgated by the State Council on September 18, 2008, labor contracts shall be concluded in writing if employment relationships
are to be or have been established between employers and employees. In addition, employee wages cannot be lower than local standards
on minimum wages.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Labor Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#27861;&#12299;), which
was promulgated by the SCNPC on July 5, 1994 and last amended and came into effect on December 29, 2018, employers shall establish and
improve their system of workplace safety and sanitation, strictly abide by state rules and standards on workplace safety, educate employees
in occupational safety and sanitation in the PRC. Occupational safety and sanitation facilities shall comply with state-fixed standards.
Enterprises and institutions shall provide employees whose work involves occupational hazards with health examinations on a regular basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Social Insurance Law, the Interim Regulations on the Collection and Payment of Social Security Funds (&#12298;&#31038;&#20250;&#20445;&#38505;&#36153;&#24449;&#32564;&#26242;&#34892;&#26465;&#20363;&#12299;),
which was promulgated by the State Council on January 22, 1999 and amended on March 24, 2019, and the Administrative Regulations on the
Housing Provident Funds (&#12298;&#20303;&#25151;&#20844;&#31215;&#37329;&#31649;&#29702;&#26465;&#20363;&#12299;), which was promulgated
by the State Council on April 3, 1999 and last amended on March 24, 2019, employers are required to make contributions, on behalf of
their employees, to a number of social security funds, including funds for basic pension insurance, unemployment insurance, basic medical
insurance, occupational injury insurance, maternity insurance and to housing provident funds. Any employer who fails to make contributions
may be fined and ordered to make good the deficit within a stipulated time limit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to April 2020, we only contributed to the social insurance and housing provident funds for some, but not all, of our employees. There
is a risk that the labor security administration authority may take enforcement action to collect from us all the outstanding contributions
of the social insurance and housing provident funds required to be made for the employees in the past, and we may be subject to a late
charge at the rate of 0.2% per day on the total outstanding contribution. We started to contribute to the social insurance and housing
provident funds for all of our employees since April 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
April 2020, we have been contributing to the social insurance and housing provident funds for our employees in accordance with the minimum
contribution requirements. Pursuant to the aforementioned applicable laws and regulations, the government or an employee has the right
to demand us to contribute to the employee&#8217;s social insurance and housing provident funds calculated based on his or her actual
salary, and an employee who has not received contributions from us has the right to demand us to contribute to his or her social insurance
and housing provident funds. As confirmed in writing by the local government, our contributions of the social insurance and housing provident
funds are in compliance with the PRC laws and the local regulations and policies, and therefore the local government is very unlikely
to impose any penalty on us for our contributions since April 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Enterprise
Income Tax</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the EIT Law, promulgated by the National People&#8217;s Congress on March 16, 2007, effective on January 1, 2008 and last amended
on December 29, 2018, and the Implementation Regulations for the Enterprise Income Tax Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20225;&#19994;&#25152;&#24471;&#31246;&#27861;&#23454;&#26045;&#26465;&#20363;&#12299;)
promulgated by the State Council on December 6, 2007 and amended on April 23, 2019, other than a few exceptions, the income tax rate
for both domestic enterprises and foreign-invested enterprises is 25%. Enterprise taxpayers are classified as either resident enterprises
or non-resident enterprises. Resident enterprises are defined as enterprises that are established in China in accordance with PRC laws,
or that are established in accordance with the laws of foreign countries but whose actual or de facto management bodies are located in
China. Non-resident enterprise refers to an entity established under foreign law whose de facto management bodies are not within the
PRC but which have an establishment or place of business in the PRC, or which do not have an establishment or place of business in the
PRC but have income sourced within the PRC. An income tax rate of 10% will normally be applicable to dividends declared to non-PRC resident
enterprise investors that do not have an establishment or place of business in the PRC, or that have such establishment or place of business
but the relevant income is not effectively connected with the establishment or place of business, to the extent such dividends are derived
from sources within the PRC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Arrangement between the Mainland of China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation
and Prevention of Fiscal Evasion with respect to Taxes on Incomes (&#12298;&#20869;&#22320;&#21644;&#39321;&#28207;&#29305;&#21035;&#34892;&#25919;&#21306;&#20851;&#20110;&#23545;&#25152;&#24471;&#36991;&#20813;&#21452;&#37325;&#24449;&#31246;&#21644;&#38450;&#27490;&#20599;&#28431;&#31246;&#30340;&#23433;&#25490;&#12299;),
or the Double Tax Avoidance Arrangement, and other applicable PRC laws, 5% withholding tax rate shall apply to the dividends paid by
a PRC company to a Hong Kong resident, provided that such Hong Kong resident directly holds at least 25% of the equity interests in the
PRC company, and 10% of withholding tax rate shall apply if the Hong Kong resident holds less than 25% of the equity interests in the
PRC company. However, pursuant to the Circular on Certain Issues Relating to the Implementation of Dividend Provisions in Tax Treaties
(&#12298;&#20851;&#20110;&#25191;&#34892;&#31246;&#25910;&#21327;&#23450;&#32929;&#24687;&#26465;&#27454;&#26377;&#20851;&#38382;&#39064;&#30340;&#36890;&#30693;&#12299;)
issued on February 20, 2009 by the SAT, if a PRC tax authority determines, in its discretion, that a company benefits from such reduced
income tax rate as a result of an arrangement that is primarily tax-driven, such PRC tax authority may adjust the preferential tax treatment
of the company. Based on the Announcement on Certain Issues with Respect to the Beneficial Owner in Tax Treaties (&#12298;&#22269;&#23478;&#31246;&#21153;&#24635;&#23616;&#20851;&#20110;&#31246;&#25910;&#21327;&#23450;&#20013;&#21463;&#30410;&#25152;&#26377;&#20154;&#26377;&#20851;&#38382;&#39064;&#30340;&#20844;&#21578;&#12299;)
issued by the SAT on February 3, 2018 and effective on April 1, 2018, if an applicant&#8217;s business activities do not constitute substantive
business activities, it could result in the negative determination of the applicant&#8217;s status as a beneficial owner, and consequently,
the applicant could be precluded from enjoying the above-mentioned reduced income tax rate of 5% under the Double Tax Avoidance Arrangement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
<span style="text-decoration:underline">Organizational Structure</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;&#8212;A. History and Development of the Company.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">D.
Property, Plants and Equipment</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;&#8212;B. Business Overview&#8212;Properties and Facilities.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
4A. UNRESOLVED STAFF COMMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion of our financial condition and results of operations is based upon and should be read in conjunction with our consolidated
financial statements and their related notes included in this annual report. This report contains forward-looking statements. In evaluating
our business, you should carefully consider the information provided under the caption &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221;
in this annual report. We caution you that our businesses and financial performance are subject to substantial risks and uncertainties.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
<span style="text-decoration:underline">Operating Results</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
the PRC operating entities, we are a pharmaceutical company specializing in the development, manufacturing, marketing and sale of TCMD
products targeted to the elderly to address their physical conditions in the aging process and to promote their general well-being. We
have registered and obtained approval for 26 varieties of TCMD products from the NMPA, and we currently produce 13 varieties of TCMD
products and sell them in 261 cities in 30 provinces in China as of the date of this annual report. In addition, we also sell biomedical
drugs, medical instruments, TCMPs and dietary supplements manufactured by third-party pharmaceutical companies (collectively referred
to as &#8220;third-party products&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
major customers are pharmaceutical companies, hospitals, clinics and drugstore chains, primarily located in Jiangxi Province, Jiangsu
Province, Guangdong Province, Hubei Province, Fujian Province, Guangxi Province and Shandong Province, and 23 other provinces in China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Development</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Entry
Into a Strategic Cooperation Agreement with a Japanese Pharmaceutical Company</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2021, we entered into definitive agreements (the &#8220;Agreements&#8221;) with Kitanihon Pharmaceutical Co., Ltd. (&#8220;Kitanihon&#8221;),
a Japanese pharmaceutical company, pursuant to which (i) both parties will build a manufacturing facility in Ji&#8217;an, Jiangxi, China,
for the manufacturing and research and development of traditional Chinese medicine derivatives products, with an aggregate area of over
430,000 square feet, and we will bear the costs associated with building the facility, and (ii) we will purchase 464 shares of Kitanihon
for an aggregate of JPY176.32 million (approximately US$1.56 million). As the date of this annual report, the building of manufacturing
facility has not started, and we have not acquired the 464 shares of Kitanihon.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relation to the Agreements, Sununion Holding Group Limited (&#8220;Sununion&#8221;), the controlling shareholder of the Company wholly
owned by Mr. Gang Lai, the chief executive officer and chairman of the board of directors of the Company, entered into an agreement with
Mr. Gang Lai and Kitanihon on December 1, 2021, pursuant to which Kitanihon authorized the Company to use certain of its intangible assets,
including technologies and certain intellectual properties, in exchange for which Mr. Gang Lai transferred 1,073,280 ordinary shares
of Sununion owned by him and valued at US$2.5 million to Kitanihon.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>COVID-19
Impact</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations have been affected and may continue to be affected by the ongoing COVID-19 pandemic. In the fiscal year ended September
30, 2022, due to resurgence of COVID-19 pandemic in China and related restrictive measures, including travel restrictions, the PRC operating
entities experienced delays in the receipt of purchased raw materials from suppliers and in delivering products to customers. The prices
of the raw materials increased by about 5% as compared to the fiscal year ended September 30, 2021. In addition, we granted some customers
extended payment terms of 30 days to 120 days. However, based on our present relationship with these customers and our evaluation of
their financial conditions, we do not anticipate any material collectability problems. Although the Chinese government removed its zero-COVID
policy in December 2022, China is now facing a sudden surge in COVID cases after easing the lockdown restrictions nationwide. WHO officials
had expressed hope that COVID-19 might be entering an endemic phase by early 2023, but the continued uncertainties associated with the
COVID-19 pandemic worldwide may cause our revenue and cash flows to underperform in the next 12 months from the date of this annual report.
The extent of the future impact of the COVID-19 pandemic on our business and the results of operations is still uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Factors that Affect Our Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the following key factors may affect our financial condition and results of operations:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Ability to Attract Additional Customers and Increase the Spending Per Customer</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
major customers are pharmaceutical distributors, hospitals, clinics and drugstore chains. We currently sell our products to these customers
in 261 cities in 30 provinces in China, with significant customers located in Jiangxi Province, Jiangsu Province, Guangdong Province,
Hubei Province, Fujian Province, Guangxi Province and Shandong Province in China. For the years ended September 30, 2022, 2021 and 2020,
we had a total of 2,651, 2,708, and 2,209 customers, respectively, and no single customer accounted for more than 10% of our total revenue
of any of these fiscal years. However, our top 10 customers in the aggregate accounted for 32.2%, 30.4% and 33.3% of our total revenues
for the years ended September 30, 2022, 2021 and 2020, respectively. Our dependence on a small number of larger customers could expose
us to the risk of substantial losses if a single large customer stops purchasing our products, purchases fewer of our products or goes
out of business and we cannot find substitute customers on equivalent terms. If any of our significant customers reduces the quantity
of the products they purchase from us or stops purchasing from us, our net revenues would be materially and adversely affected. Therefore,
the success of our business in the future depends on our effective marketing efforts to expand our distribution network including additional
cities and rural areas in the PRC in an effort to increase our geographic appearance. The success of expansion will depend upon many
factors, including our ability to form relationships with, and manage an increasing number of, customers base and optimize our distribution
network. If our marketing efforts fail to convince customers to accept our products, we may find it difficult to maintain the existing
level of sales or to increase such sales. Should this happen, our net revenues would decline and our growth prospectus would be severely
impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Ability to Increase Awareness of Our Brand and Develop Customer Loyalty</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
brands, such as &#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221; and &#8220;Hu Zhuo Ren (&#32993;&#21331;&#20161;)&#8221;, are well-recognized
among our clients and other Chinese medicine industry players. Our brand is integral to our sales and marketing efforts. We believe that
maintaining and enhancing our brand name recognition in a cost-effective manner is critical to achieving widespread acceptance of our
current and future products and is an important element in our effort to increase our customer base. Successful promotion of our brand
name will depend largely on our marketing efforts and ability to provide reliable and quality products at competitive prices. Brand promotion
activities may not necessarily yield increased revenue, and even if they do, any increased revenue may not offset the expenses we will
incur in marketing activities. If we fail to successfully promote and maintain our brand, if we incur substantial expenses in an unsuccessful
attempt to promote and maintain our brand, or if we fail to generate the desired level of brand recognition and awareness through our
recent television advertising efforts, or at all, we may fail to attract new customers or retain our existing customers, in which case
our business, operating results and financial condition, would be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Ability to Control Costs and Expenses and Improve Our Operating Efficiency</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business growth is dependent on our ability to attract and retain qualified and productive employees, identify business opportunities,
secure new contracts with customers and our ability to control costs and expenses to improve our operating efficiency. Our inventory
costs (including raw materials, labor, packaging cost, depreciation and amortization, freight costs, overhead and third-party products
purchase costs) have a direct impact on our profitability. The raw materials used in manufacturing of our TCMD products are subject to
price volatility and inflationary pressures. Our success is dependent, in part, on our ability to reduce our exposure to increase in
those costs through a variety of ways, while maintaining and improving margins and market share. We also rely on third-party manufacturers
as a source for a portion of components for a portion of components for our products. These manufacturers are also subject to price volatility
and labor cost and other inflationary pressures, which may, in turn, result in an increase in the amount we pay for sourced products.
Raw materials and sourced product price increases may offset our productivity gains and price increases and may adversely impact our
financial results. In addition, our staffing costs (including payroll and employee benefit expense) and administrative expenses also
have a direct impact on our profitability. Our ability to drive the productivity of our staff and enhance our operating efficiency affects
our profitability. To the extent that the costs we are required to pay to our suppliers and our staffs exceed our estimates, our profit
may be impaired. If we fail to implement initiatives to control costs and improve our operating efficiency over time, our profitability
will be negatively impacted.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Ability to Compete Successfully</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chinese patent medicine industry we are in is highly competitive and evolving in China. The development and commercialization of new
pharmaceutical products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant
competition and a strong emphasis on intellectual property. We will face competition with respect to our current and future pharmaceutical
product candidates from major pharmaceutical companies in China. Potential competitors also include academic institutions, government
agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative
arrangements for research, development, manufacturing and commercialization of pharmaceutical products. Some of our current or potential
competitors may have significantly greater financial resources and expertise in research and development, manufacturing, product testing,
obtaining regulatory approvals and marketing approved products than we do, and in the event that any of these happens, our competitors
may be able to establish a strong market position before our new products are able to enter the market. Additionally, technologies developed
by our competitors may render our product candidates uneconomical or obsolete. If we do not compete effectively, our operating results
could be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
Severe or Prolonged Slowdown in the Global or Chinese Economy Could Materially and Adversely Affect Our Business and Our Financial Condition</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rapid growth of the Chinese economy has slowed down since 2012 and this slowdown may continue in the future. There is considerable uncertainty
over trade conflicts between the United States and China and the long-term effects of the expansionary monetary and fiscal policies adopted
by the central banks and financial authorities of some of the world&#8217;s leading economies, including the United States and China.
The withdrawal of these expansionary monetary and fiscal policies could lead to a contraction. There continue to be concerns over unrest
and terrorist threats in the Middle East, Europe, and Africa, which have resulted in volatility in oil and other markets. There are also
concerns about the relationships between China and other Asian countries, which may result in or intensify potential conflicts in relation
to territorial disputes. The eruption of armed conflict could adversely affect global or Chinese discretionary spending, either of which
could have a material and adverse effect on our business, results of operation in financial condition. Economic conditions in China are
sensitive to global economic conditions, as well as changes in domestic economic and political policies and the expected or perceived
overall economic growth rate in China. Any severe or prolonged slowdown in the global or Chinese economy would likely materially and
adversely affect our business, results of operations and financial condition. In addition, continued turbulence in the international
markets may adversely affect our ability to access capital markets to meet liquidity needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COVID-19
Impact</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations have been affected and may continue to be affected by the ongoing COVID-19 pandemic. In the fiscal year ended September
30, 2022, due to resurgence of COVID-19 pandemic in China and related restrictive measures, including travel restrictions, the PRC operating
entities experienced delays in the receipt of purchased raw materials from suppliers and in delivering products to customers. The prices
of the raw materials increased by about 5% as compared to the fiscal year ended September 30, 2021. In addition, we granted some customers
extended payment terms of 30 days to 120 days. However, based on our present relationship with these customers and our evaluation of
their financial conditions, we do not anticipate any material collectability problems. Although the Chinese government removed its zero-COVID
policy in December 2022, China is now facing a sudden surge in COVID cases after easing the lockdown restrictions nationwide. WHO officials
had expressed hope that COVID-19 might be entering an endemic phase by early 2023, but the continued uncertainties associated with the
COVID-19 pandemic worldwide may cause our revenue and cash flows to underperform in the next 12 months from the date of this annual report.
The extent of the future impact of the COVID-19 pandemic on our business and the results of operations is still uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Financial Performance Indicators </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing our financial performance, we consider a variety of financial performance measures, including principal growth in net revenue
and gross profit, our ability to control costs and operating expenses to improve our operating efficiency and net income. Our review
of these indicators facilitates timely evaluation of the performance of our business and effective communication of results and key decisions,
allowing our business to respond promptly to competitive market conditions and different demands and preferences from our customers.
The key measures that we use to evaluate the performance of our business are set forth below and are discussed in greater details under
&#8220;&#8212;Results of Operations&#8221;:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Revenue</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenue is reported net of all value added taxes (&#8220;VAT&#8221;). Our products are sold with no right of return and we do not provide
other credits or sales incentives to customers. Our revenue is driven by changes in the number of customers, sales volume, selling price,
and mix of products sold.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance<br/> comparing<br/> 2022 to 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance<br/> comparing<br/> 2021 to 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left">Revenue from sales of self-manufactured TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">59.8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">61.6</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">59.8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1.8</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.8</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Number of customers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,651</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,708</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales volume by unit- TCMD products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,799,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,206,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,652,999</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(37.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Sales volume by unit- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,226,027</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,364,391</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,763,577</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total sales volume</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">20,025,281</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25,570,541</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24,416,576</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(21.7</td><td style="padding-bottom: 4pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.7</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Average selling price per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.72</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Average selling price per unit- Third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">79.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from sales of TCMD products manufactured by us accounted for 59.8%, 61.6% and 59.8% of our total revenues for the fiscal years ended
September 30, 2022, 2021 and 2020, respectively. The 13 TCMD products manufactured by us fall into two categories: chronic condition
treatments and cold and flu medications. Our chronic condition treatments primarily include Guben Yanling Pill, Shenrong Weisheng Pill,
Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor,
Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor, and our cold and flu medications primarily include Paracetamol Granule
for Children, Isatis Root Granule and Qiangli Pipa Syrup.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales volume of our TCMD products decreased by
6,406,896 units, or 37.2%, from 17,206,150 units sold in fiscal year 2021 to 10,799,254 units sold in fiscal year 2022. The decrease in
our sales volume was due to our inability to timely fulfill the orders of our customer in 2022 due to the resurgence of COVID-19 cases
in China, and accordingly our sales volume was negatively impacted in fiscal year 2022, which was lower than that of fiscal year 2021.
<span style="background-color: white">The number of customers purchasing our products decreased by 2.1%, from 2,708 customers in the fiscal
year 2021 to 2,651 customers in the fiscal year 2022. </span>As affected by the inflation and increased costs of raw materials, we adjusted
the selling prices of TCMD products accordingly. The average selling price of our TCMD products increased by 29.1%, from $1.72 per unit
in fiscal year 2021 to $2.22 per unit in fiscal year 2022. These combined factors led to an 18.8% decrease in our revenue from sales of
our TCMD products from fiscal year 2021 to fiscal year 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Sales
volume of our TCMD products increased by 1,553,151 units, or 9.9%, from 15,652,999 units sold in the fiscal year 2020 to 17,206,150 units
sold in the fiscal year 2021. The number of customers purchasing our products increased by 22.6%, from 2,209 customers in the fiscal
year 2020 to 2,708 customers in the fiscal year 2021. The increase in the number of customers in the fiscal year 2021 led to an increased
number of customer orders for our products, resulting in increased sales volume of our TCMD products. Among the increase in total sales
volume of 1,553,151 units, most of such increase related to our cold and flu medications because of strong market demand. The average
selling price of our TCMD products increased by 46.3%, from $1.17 per unit in the fiscal year 2020 to $1.72 per unit in the fiscal year
2021, because we increased selling prices of our TCMD products in response to increased raw material costs and general inflation. These
factors led to an increase in our revenue from sales of our TCMD products from the fiscal year 2020 to the fiscal year 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to diversify our product offerings and product mix, in addition to selling self-manufactured TCMD products, we also sell products
manufactured by third-party pharmaceutical companies, including (i) biomedical drugs, such as liquid glucose, prednisolone, and citicoline,
(ii) medical instruments, such as drug-eluting stents, surgical tubes and syringes, (iii) TCMPs, such as red sage tables, Longdan Xiegan
pills, and Chinese skullcap capsules, and (iv) dietary supplements, such as vitamins, probiotic powder, and calcium tablets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from sales of third-party products accounted for 40.2%, 38.4% and 40.2% of our total revenues for the fiscal years ended September 30,
2022, 2021 and 2020, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
volume of third-party products increased by 861,636 units or 10.3%, from 8,364,391 units sold in the fiscal year 2021 to 9,226,027 units
sold in the fiscal year 2022, while the average selling price of third-party products decreased by 20.5% from $2.20 per unit in the fiscal
year 2021 to $1.75 per unit in the fiscal year 2022 as affected by changes in product mix based on customer orders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
volume of third-party products decreased by 399,186 units, or 4.6%, from 8,763,577 units sold in fiscal year 2020 to 8,364,391 units
sold in fiscal year 2021, because we put more efforts in promoting the sales of our TCMD products in fiscal year 2021. The average selling
price of third-party products increased by 79.6%, from $1.41 per unit in fiscal year 2020 to $2.20 per unit in fiscal year 2021, due
to increased purchase costs of third-party products, as affected by the COVID-19 pandemic and general inflation, and the changes in product
mix based on customer orders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
future third-party product sales, our strategy is to select and distribute certain high-quality products with higher margin. We do not
expect that the sales of third-party products will outpace the sales of our own TCMD products going forward.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gross
Profit</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit is equal to net revenue minus cost of goods sold. Cost of goods sold primarily includes inventory costs (raw materials, labor,
packaging cost, depreciation and amortization, third-party products purchase price, freight costs and overhead). Cost of goods sold generally
changes as our production costs change, which are affected by factors including the market price of raw materials, labor productivity,
or the purchase price of third-party products, and as the customer and product mix changes. Our cost of revenues accounted for 45.5%,
47.2% and 54.1% of our total revenue for the fiscal years 2022, 2021 and 2020, respectively. We expect our cost of revenues to increase
as we further expand our operations in the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
gross margin was 54.5%, 52.8% and 45.9% for the years ended September 30, 2022, 2021 and 2020, respectively. Our gross profit and gross
margin are affected by the different product mix of those products sold during each reporting period. Our gross margin increases when
more products with lower costs and higher margin are sold, while our gross margin decreases when more products with higher costs and
lower margin are sold. See detailed discussion under &#8220;&#8211;Results of Operation&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses consist of selling expenses, general and administrative expenses and research and development expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
selling expenses primarily include salary and welfare benefit expenses paid to our sales personnel, advertising expenses to increase
the awareness of our brand, shipping and delivery expenses, expenses incurred for our business travel, meals and other sales promotion
and marketing activities related expenses. Our selling expenses accounted for 47.5%, 6.2% and 5.1% of our total revenue for the years
ended September 30, 2022, 2021 and 2020, respectively. We expect our overall selling expenses, including but not limited to, advertising
expenses, brand promotion expenses and salaries, to increase in the foreseeable future and facilitate the growth of our business, especially
when we continue to expand our business and promote our products to customers located at extended geographic areas.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses primarily consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve
expenses, inspection and maintenance expenses, office supply and utility expenses, business travel and meals expenses, land and property
taxes and professional service expenses. General and administrative expenses were 6.5%, 6.9% and 5.5% of our revenue for the years ended
September 30, 2022, 2021 and 2020, respectively. We expect our general and administrative expenses, including, but not limited to, salaries
and business consulting expenses, to continue to increase in the foreseeable future, as we plan to hire additional personnel and incur
additional expenses in connection with the expansion of our business operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chinese patent medicine industry is characterized by rapid and frequent changes in customer demand and launches of new products. If we
do not launch new products or improve our existing products to meet the changing demands of our customers in a timely manner, some of
our products could become uncompetitive in the market, thereby adversely affecting on our revenues and operating results. Our research
and development expenses primarily consist of salaries, welfare and insurance expenses paid to our employees involved in the research
and development activities, materials and supplies used in the development and testing of new TCMD products, depreciation, and other
miscellaneous expenses. Research and development expenses were 19.0%, 11.4% and 1.9% of our revenue for the years ended September 30,
2022, 2021 and 2020, respectively. As we continue to develop new products and diversify our product offerings to satisfy customer demand,
we expect our research and development expenses to continue to increase in the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of our consolidated results of operations for the periods presented, both in absolute amount and
as a percentage of our total operating revenue for the years presented. This information should be read together with our consolidated
financial statements and related notes included elsewhere in this annual report. The results of operations in any period are not necessarily
indicative of our future trends.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Year
ended September 30, 2022 compared to year ended September 30, 2021</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the results of our operations during years ended September 30, 2022 and 2021, respectively, and provides information
regarding the dollar and percentage increase or (decrease) during such periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -9pt; padding-left: 9pt">REVENUE</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,143,151</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47,982,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,838,880</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(16.3</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">COST OF REVENUE</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,251,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,655,854</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,404,039</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">GROSS PROFIT</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,891,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,326,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,434,841</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,083,135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,973,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,109,604</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">541.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,602,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,296,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(694,220</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,644,375</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,465,662</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,178,713</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,330,134</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">73.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,736,037</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,594,097</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">149.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">INCOME FROM OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,438,798</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,590,140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,028,938</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(154.7</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(162,400</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(101,604</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60,796</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,940</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(80,434</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129,374</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(160.8</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) from short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(470,477</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(710,026</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(296.4</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Equity investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,588</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,827</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,761</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(545,349</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,338</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(633,687</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(717.3</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">INCOME (LOSS) BEFORE INCOME TAX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,984,147</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19.9</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,678,478</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,662,625</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(158.4</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">PROVISION FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">752,419</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,358,526</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,606,107</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(68.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">NET INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(8,736,566</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(21.8</td><td style="padding-bottom: 4pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,319,952</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">23.6</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(20,056,518</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(177.2</td><td style="padding-bottom: 4pt; text-align: left">)%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenues:
</b>Our total revenues decreased by $7,838,880, or 16.3%, to $40,143,151 for the year ended September 30, 2022 from $47,982,031 for the
year ended September 30, 2021. The decrease in our revenues was attributable to (i) a decreased number of customers by 2.1%, from 2,708
customers in the fiscal year 2021 to 2,651 customers in the fiscal year 2022; (ii) decreased sales volume of our TCMD products by 37.2%,
from 17,206,150 units sold in the fiscal year 2021 to 10,799,254 units sold in the fiscal year 2022 due to our inability to timely fulfill
the orders of our customer in 2022 due to the resurgence of COVID-19 cases in China; and (iii) decreased average selling price of our
third-party products by 20.5% as affected by changes in product mix based on customer orders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Revenue from sales of self-manufactured TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,988,177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,559,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,571,109</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(18.8</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,154,974</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,267,771</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12.3</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">40,143,151</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,838,880</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(16.3</td><td style="padding-bottom: 4pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
from sales of our TCMD products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our TCMD products decreased by $5,571,109, or 18.8%, from $29,559,286 in the fiscal year 2021 to $23,988,177 in the fiscal year 2022.
The decrease in the sales of our TCMD products was due to the following reasons:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 17.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
                                            to the resurgence in the number of COVID cases in China recently, which disrupted the norming
                                            functioning of logistics in the country, we experienced difficulties shipping and delivering
                                            our products to customers located in certain remote geographic areas. This led to lower sales
                                            volume of our TCMD products by 37.2% in the fiscal year 2022 as compared to the fiscal year
                                            2021. The sales volume of our TCMD products decreased by 6,406,896 units from 17,206,150
                                            units in the fiscal year 2021 to 10,799,254 units in the fiscal year 2022.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 17.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            COVID-19 pandemic led to disruptions of supply chain and transportation and an overall increase
                                            in the market prices of raw materials used in manufacturing of our TCMD products. Accordingly,
                                            we adjusted the selling prices of our TCMD products in response to the increase in raw material
                                            purchase costs and general inflation. The weighted average unit selling price of our TCMD
                                            products increased by $0.50 per unit, or 29.1%, from $1.72 per unit in the fiscal year 2021
                                            to $2.22 per unit in the fiscal year 2022.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
from sales of third-party products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of third-party products decreased by $2,267,771, or 12.3%, from $18,422,745 in the fiscal year 2021 to $16,154,974 in the fiscal year
2022. Sales volume of third-party products increased by 10.3%, from 8,364,391 units sold in the fiscal year 2021 to 9,226,027 units sold
in the fiscal year 2022. In addition, due to change in product mix, the weighted average selling price of third-party products decreased
by $0.45 per unit, or 20.5%, from $2.20 per unit in the fiscal year 2021 to $1.75 per unit in the fiscal year 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of Revenues. </i></b>Our cost of revenues primarily consists of inventory costs (raw materials, labor, packaging cost, depreciation and
amortization, third-party products purchase price, freight costs and overhead) and business tax. Cost of revenues generally changes as
our production costs change, which are affected by factors including the market price of raw materials, labor productivity, or the purchase
price of third-party products, and as the customer and product mix changes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cost of revenue- TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,187,182</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,162,847</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,975,665</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(26.7</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of revenue- third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,064,633</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,493,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,428,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cost of revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,251,815</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22,655,854</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,404,039</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(19.4</td><td style="padding-bottom: 4pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cost of revenues decreased by $4,404,039, or 19.4%, from $22,655,854 in the fiscal year 2021 to $18,251,815 in the fiscal year 2022.
The decrease in our cost of revenues was primarily due to decreased sales volume and increased raw material and third-party product purchase
costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of revenues of TCMD products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenues of TCMD products accounted for 44.9% and 49.3% of our total costs of revenues for fiscal year 2022 and 2021, respectively.
Cost of revenues of TCMD products decreased by $2,975,665, or 26.7%, from $11,162,847 in the fiscal year 2021 to $8,187,182 in the fiscal
year 2022. The decrease in cost of revenues of our TCMD products was due to the following reasons:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 17.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
                                            volume of TCMD products decreased by 37.2%, from 17,206,150 units sold in the fiscal year
                                            2021 to 10,799,254 units sold in the fiscal year 2022. Due to recent resurgence of the COVID-19
                                            pandemic and related transportation and travel restrictions, we experienced difficulties
                                            shipping and delivering our products to customers located in certain remote geographic areas.
                                            These factors led to lower sales volume of our TCMD products in the fiscal year 2022 as compared
                                            to the fiscal year 2021. As sales volume decreased in the fiscal year 2022, raw materials,
                                            labor, packaging, freight and overhead costs associated with our TCMD product sales also
                                            decreased.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 17.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            a result of inflation and increased market prices of raw materials, the average per unit
                                            cost of our TCMD products increased by $0.11, or 16.9%, from $0.65 per unit in the fiscal
                                            year 2021 to $0.76 per unit in the fiscal year 2022. Among the 13 varieties of TCMD products,
                                            cost of revenues of Guben Yanling Pill, one of our key products, accounted for 20.0% and
                                            23.3% of our total cost of revenues in fiscal year 2022 and 2021, respectively. Unit production
                                            costs of Guben Yanling Pill increased by $0.30 per unit or 25.7% from $1.15 per unit in the
                                            fiscal year 2021 to $1.45 per unit in the fiscal year 2022.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decrease in the cost of revenues of our TCMD products in the fiscal year 2022 as compared to the fiscal year 2021 reflected the above-mentioned
factors combined.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of revenues of third-party products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenues of third-party products accounted for 55.1% and 50.7% of our total costs of revenues for the fiscal years 2022 and 2021,
respectively. Cost of revenues of third-party products decreased by $1,428,374, or 12.4%, from $11,493,007 in the fiscal year 2021 to
$10,064,633 in the fiscal year 2022, because of a decrease in the average unit cost of third-party products by $0.29 per unit, or 21.0%,
from $1.38 per unit in the fiscal year 2021 to $1.09 per unit in the fiscal year 2022. Sales volume of third-party products increased
by 10.3%, from 8,364,391 units sold in the fiscal year 2021 to 9,226,027 units sold in the fiscal year 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors led to the decrease in cost of revenues associated with third-party product sales in the fiscal year 2022 as compared to the
fiscal year 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gross
profit</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
gross profit decreased by $3,434,841, from $25,326,177 in the fiscal year 2021 to $21,891,336 in the fiscal year 2022. Our gross margin
increased by 1.7% from 52.8% in the fiscal year 2021 to 54.5% in the fiscal year 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Gross profit- TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,800,995</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,396,439</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,595,444</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(14.1</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit- third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,090,341</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,929,738</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(839,397</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total gross profit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21,891,336</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,326,177</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(3,434,841</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(13.6</td><td style="padding-bottom: 4pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross margin- TCMD products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross margin- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total gross margin</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Average selling price per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.72</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Average cost per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Average selling price per unit- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.45</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Average cost per unit - third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.09</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.29</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21.0</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit from the sales of our TCMD products decreased by $2,595,444, or 14.1%, from $18,396,439 in the fiscal year 2021 to $15,800,995
in the fiscal year 2022, and the gross margin of our TCMD products increased by 3.7%, from 62.2% in the fiscal year 2021 to 65.9% in
the fiscal year 2022. The decrease in our gross profit from the sales of TCMD products was due to the following reasons: (i) as discussed
above, sales volume of TCMD products decreased by 37.2%, from 17,206,150 units sold in the fiscal year 2021 to 10,799,254 units sold
in the fiscal year 2022, because we experienced difficulties shipping and delivering our products to our customers in a timely manner
due to recent resurgence of the COVID-19 pandemic and related transportation and travel restrictions; and partially offset by (ii) an
increase in the weighted average unit selling price of our TCMD products by $0.50 per unit, or 29.1%, from $1.72 per unit in the fiscal
year 2021 to $2.22 per unit in the fiscal year 2022, while the average per unit cost of our TCMD products increased by $0.11, or 16.9%,
from $0.65 per unit in the fiscal year 2021 to $0.76 per unit in the fiscal year 2022. During the fiscal year 2022, as a result of the
decrease in sales volume, our gross profit associated with the sales of Guben Yanling Pill and Shengrong Weisheng Pill decreased by $633,436
and $709,133 respectively, as compared to the fiscal year 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit from third-party product sales decreased by $839,397, or 12.1%, from $6,929,738 in the fiscal year 2021 to $6,090,341 in the fiscal
year 2022, while the gross margin of third-party product sales slightly increased by 0.1%, from 37.6% in the fiscal year 2021 to 37.7%
in the fiscal year 2022. The average unit selling price of third-party products decreased by 20.5%, or $0.45 per unit, while the average
unit cost of third-party products also decreased by 21.0%, or $0.29 per unit. The decrease in the average selling price outpaced the
decrease in average unit cost of third-party products by $0.16 per unit. The decrease in our gross profit from third-party products was
affected by changes in sales of different product mix in the fiscal year 2022 as compared to the fiscal year 2021. For example, the largest
portion of decrease in gross profit of third-party products was associated with sales of biochemical drugs products, which decreased
by $779,342 when sales volume decreased by 10.3%. For future third-party product sales, our strategy is to select and distribute certain
high-quality products with higher margin. We do not expect that the sales of third party products will outpace the sales of our own TCMD
products going forward.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the breakdown of our operating expenses for the fiscal years ended September 30, 2022 and 2021:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-align: left">Total revenue</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">40,143,151</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">100.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">47,982,031</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">100.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(7,838,880</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(16.3</td><td style="width: 1%; font-weight: bold; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,083,135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,973,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,109,604</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">541.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,602,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,296,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(694,220</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,644,375</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,465,662</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,178,713</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total operating expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">29,330,134</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">73.1</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,736,037</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24.5</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,594,097</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">149.9</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Selling
expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
selling expenses primarily include salaries and welfare benefit expenses paid to our sales personnel, advertising expenses to increase
our brand awareness, shipping and delivery expenses, expenses incurred for our business travel and meals, and other sales promotion and
marketing activities related expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and employee benefit expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">778,656</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.1</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">859,436</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(80,780</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(9.4</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Advertising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,527,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,316,654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,210,664</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1231.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Shipping and delivery expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">638,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">701,997</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(63,711</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Business travel and meals expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other sales promotion related expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,322</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,879</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,557</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total selling expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,083,135</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,973,531</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,109,604</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">541.8</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
selling expenses increased by $16,109,604, or 541.8%, from $2,973,531 in the fiscal year 2021 to $19,083,135 in the fiscal year 2022,
primarily attributable to (i) an increase in advertising expenses by $16,210,664, or 1,231.2%, from $1,316,654 in the fiscal year 2021
to $17,527,318 in the fiscal year 2022. In September 2021, we entered into an advertising service agreement with a third party, Guangdong
Fengyang Legend Consulting Co., Ltd. (&#8220;Fengyang Legend&#8221;), pursuant to which, Fengyang Legend agreed to assist us in developing
and producing a TV advertisement for promoting the sales of our major TCMD products, Bai Nian Dan and Guben Yanling Pill, and coordinating
with a TV channel to broadcast the advertisement to targeted geographic market areas. In March 2022, we entered into an advertising service
agreement with a third-party, Health Headline, pursuant to which, Health Headline provided media advertising services to promote our
brand on the Health Headline website and mobile app, with a service period of ten months from March 1, 2022 to December 31, 2022. The
advertising form, release cycle and monthly payment depended on the Company&#8217;s monthly budget. We recognized $17,501,148 in advertising
expense related to these advertising service agreements during the fiscal year 2022; (ii) business travel and meals expense increased
by $46,988 or 59.8%, from $78,565 in the fiscal year 2021 to $125,553 in the fiscal year 2022, primarily due to our increased sales activities
during the fiscal year 2022; partially offset by (iii) salary and employee benefit expenses decreased by $80,780, or 9.4% due to decreased
sale commission during the fiscal year 2022; and (iv) shipping and delivery expenses decreased by $63,711, or 9.1% due to our decreased
sales volume during the fiscal year 2022. These above-mentioned factors combined led to the increase in our selling expenses in the fiscal
year 2022 as compared to the fiscal year 2021. As a percentage of revenues, our selling expenses accounted for 47.5% and 6.2% of our
total revenue for the fiscal years 2022 and 2021, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses primarily consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve
expenses, inspection and maintenance expenses, office supply and utility expenses, business travel and meals expenses, land and property
taxes and professional service expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and employee benefit expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">641,622</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">24.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">657,543</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(15,921</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2.4</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">185,169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172,453</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Bad debt reserve expenses (recovery)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">419,353</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(230,175</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">649,528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(282.2</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Land and property tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(682</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.7</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Office supply and utility expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">307,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">376,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(68,321</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18.2</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Transportation, business travel and meals expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,047</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consulting fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">720,430</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,967,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,247,428</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(63.4</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Inspection and maintenance fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,555</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,939</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,384</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Stamp tax and other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,814</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,524</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,710</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14.8</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,602,624</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,296,844</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(694,220</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(21.1</td><td style="padding-bottom: 4pt; text-align: left">)%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses decreased by $694,220, or 21.1%, from $3,296,844 in the fiscal year 2021 to $2,602,624 in the fiscal
year 2022, primarily attributable to (i) a decrease in consulting fees by $1,247,428 because we incurred higher amount of consulting
services fees such as legal and audit expenses in the fiscal year 2021 when we completed our initial public offering (the &#8220;IPO&#8221;);
partially offset by (ii) an increase in bad debt expense by $649,528 or 282.2% because we accrued more bad debt expenses based on our
assessment of the collectability of the accounts receivable and advance to suppliers. The overall decrease in our general and administrative
expenses in the fiscal year 2022 as compared to the fiscal year 2021 reflected the above-mentioned factors combined. As a percentage
of revenues, general and administrative expenses were 6.5% and 6.9% of our revenue for the fiscal years 2022 and 2021, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and development expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses primarily consist of salaries, welfare and insurance expenses paid to our employees involved in the
research and development activities, materials and supplies used in the development and testing new TCMD products, depreciation and other
miscellaneous expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and employee benefit expenses to R&amp;D staff</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">159,924</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2.1</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">155,940</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">3,984</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2.6</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Materials used in R&amp;D activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">489,692</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">836,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(347,018</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41.5</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenditure on new product development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,973,683</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,454,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,519,283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,076</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,464</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total R&amp;D expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,644,375</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,465,662</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,178,713</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">39.9</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased by $2,178,713, or 39.9%, from $5,465,662 for the fiscal year 2021 to $7,644,375 for the fiscal year
2022, primarily attributable to <span style="background-color: white">(i) an increase in research and development expense of $</span>2,519,283
<span style="background-color: white">in order to develop and test eight new Chinese medicine products in order to diversify our future
product portfolio. In the fiscal year 2021, we entered into several cooperative agreements with external academic and research institutions
to jointly conduct the new product development and accordingly incurred significant amount of R&amp;D expense in connection with such
efforts; and partially offset by (ii) a decrease in the materials used in the R&amp;D activities by $</span>347,018 as we outsourced
part of our R&amp;D activities to <span style="background-color: white">external academic and research institutions. As a percentage
of revenues, research and development expenses were 19.0% and 11.4% of our revenue in the fiscal years 2022 and 2021, respectively.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
income (expenses), net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
other expenses, net, was $545,349 in the fiscal year 2022, compared to a net other income of $88,338 in the fiscal year 2021, due to
the following reasons:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
short-term investment loss was $470,477 in the fiscal year 2022, compared to short-term investment income of $239,549 in the fiscal year
2021. We had short-term investments of $13.1 million in wealth management financial products from financial institutions to generate
investment income, which suffered temporary loss due to fluctuations of the bond market. Such short-term investment can be redeemed anytime
at our discretion and is highly liquid.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interest
expenses increased by $60,796, or 59.8%, from $101,604 in the fiscal year 2021 to $162,400 in the fiscal year 2022. The increase in our
interest expenses was due to higher weighted average amount of outstanding loans we carried during the fiscal year 2022 as compared to
the fiscal year 2021.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provision
for Income Taxes</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
provision for income taxes was $752,419 in the fiscal year 2022, a decrease of $1,606,107, or 68.1%, from $2,358,526 in the fiscal year
2021 due to our decreased taxable income. Under the EIT Law, domestic enterprises and foreign investment enterprises are usually subject
to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on a case-by-case
basis. The EIT Law grants preferential tax treatment to HNTEs. Under this preferential tax treatment, HNTEs are entitled to an income
tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one of our main
operating subsidiaries in the PRC, was approved as an HNTE and was entitled to a reduced income tax rate of 15% beginning November 2016
with an initial term of three years. Jiangxi Universe&#8217;s HNTE status was successfully renewed in December 2019 and November 2022
for a term of three additional years. Universe Trade, the wholly owned subsidiary of Jiangxi Universe, was approved as an HNTE and was
entitled to a reduced income tax rate of 15% beginning December 2020 with an initial term of three years. The EIT Law is typically enforced
by the local tax authorities in the PRC. Each local tax authority has the discretion to grant tax holidays to local enterprises as a
way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the fiscal years 2022 and 2021 were reported
at a blended reduced rate since Jiangxi Universe and Universe Trade enjoy a 15% reduced income tax rate due to their HNTE status, and
Universe Hanhe, the wholly owned subsidiary of Jiangxi Universe, is subject to a standard 25% income tax rate. <span style="background-color: white">The
impact of the tax holidays noted above decreased PRC corporate income taxes by</span> $694,955 and $1,5<span style="background-color: white">18,979
for the years ended September 30, 2022, and 2021, respectively. The benefit of the tax holidays on net income per share (basic and diluted)
$0.03 and $0.09 for the years ended September 30, 2022 and 2021, respectively.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Income</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the foregoing, we reported a net loss of $8,736,566 for the fiscal year ended September 30, 2022, representing a decrease
of $20,056,518 from a net income of $11,319,952 for the fiscal year ended September 30, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Year
ended September 30, 2021 compared to year ended September 30, 2020</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -9pt; padding-left: 9pt">REVENUE</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47,982,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,703,960</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,278,071</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">56.3</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">COST OF REVENUE</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,655,854</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,610,140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,045,714</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">GROSS PROFIT</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,326,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,093,820</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,232,357</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">79.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,973,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,555,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,417,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,296,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,703,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,593,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,465,662</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">583,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,882,538</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">837.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,736,037</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,842,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,893,942</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">205.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">INCOME FROM OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,590,140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,251,725</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,338,415</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(101,604</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(123,760</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17.9</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(80,434</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(49,352</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,594</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income from short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Equity investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,827</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,820</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,338</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(151,292</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">239,630</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(158.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">INCOME BEFORE INCOME TAX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,678,478</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,100,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,578,045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">PROVISION FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,358,526</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,542,211</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(183,685</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7.2</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">NET INCOME</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,319,952</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">23.6</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,558,222</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24.6</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,761,730</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">49.8</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue:
</b>Our total revenues increased by $17,278,071, or 56.3%, to $47,982,031 for the year ended September 30, 2021 from $30,703,960 for
the year ended September 30, 2020. The increase in our revenues was attributable to (i) an increased number of customers by 22.6%, from
2,209 customers in fiscal year 2020 to 2,708 customers in fiscal year 2021; (ii) increased sales volume of our TCMD products by 9.9%,
from 15,652,999 units sold in fiscal year 2020 to 17,206,150 units sold in fiscal year 2021; (iii) increased average selling price of
our TCMD products by 46.3% and increased average selling price of third-party products by 79.6%, in response to increased raw material
costs and third-party products purchase costs as affected by the COVID-19 pandemic and general inflation; and (vi) an appreciation of
RMB against U.S. dollars in fiscal year 2021, with the average exchange rate between RMB and US$ being US$1.00 to RMB 7.0077 in fiscal
year 2020, as compared to that of US$1.00 to RMB 6.5104 in fiscal year 2021. The appreciation of RMB against US$ had a 7.1% positive
impact on our reported total revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Revenue from sales of self-manufactured TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,559,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,374,751</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,184,535</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">60.9</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,093,536</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,278,071</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">56.3</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
from sales of our TCMD products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our TCMD products increased by $11,184,535, or 60.9%, from $18,374,751 in fiscal year 2020 to $29,559,286 in fiscal year 2021, because
the sales volume of our TCMD products increased by 9.9% from 15,652,999 units sold in fiscal year 2020 to 17,206,150 units sold in fiscal
year 2021, and the average selling price of our TCMD products increased by 46.3% from $1.17 per unit in fiscal year 2020 to $1.72 per
unit in fiscal year 2021. The increase in the sales of our TCMD product was due to the following specific reasons:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the 13 varieties of TCMD products we manufacture, the sales of Guben Yanling Pill, one of our key&#160;Chronic Condition Treatment products,
accounted for 40.3% and 38.2% of our total revenue in fiscal year 2021 and 2020, respectively. The sales of Guben Yanling Pill increased
by $6,702,397, or 494,932 units from fiscal year 2020 to fiscal year 2021.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of customers purchasing our products increased by 22.6%, from 2,209 customers in fiscal year 2020 to 2,708 customers in fiscal
year 2021. The increase in the number of customers led to an increase in the number of customer orders for our products, resulting increased
sales volume of our TCMD products.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our flu and cold medication products (including Qiangli Pipa Syrup and Paracetamol Granule For Children) increased in fiscal year
2021 due to strong market demand. Sales volume of our Qiangli Pipa Syrup and Paracetamol Granule For Children increased by 964,266 units
and 1,297,349 units, respectively, in fiscal year 2021 as compared to fiscal year 2020. On the other hand, as affected by inflation and
increased market prices of raw materials, we adjusted our selling prices and the average selling price of our Qiangli Pipa Syrup, Isatis
Root Granule and Paracetamol Granule For Children increased by $0.20 per unit, $0.22 per unit and $0.09 per unit, or 41.5%, 34.8% and
32.5%, respectively, in fiscal year 2021 compared to fiscal year 2020.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
average exchange rate between RMB and US$ was US$1.00 to RMB 7.0077 in fiscal year 2020 as compared to an average rate of US$1.00 to
RMB 6.5104 in fiscal year 2021. The appreciation of RMB against US$ had a 7.1% positive impact on our reported total revenues.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
from sales of third-party products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of third-party products increased by $6,093,536, or 49.4%, from $12,329,209 in fiscal year 2020 to $18,422,745 in fiscal year 2021. Sales
volume of third-party products slightly decreased by 4.6%, from 8,763,577 units sold in 2020 to 8,364,391 units sold in 2021. In 2021,
due to an overall increase in the market prices of raw materials used in the manufacturing of third-party products, we paid higher purchase
prices for products from third-party pharmaceutical companies and accordingly, our average selling price of third-party products in fiscal
year 2021 was higher than in fiscal year 2020. Our average selling price of third-party products increased by 79.6%, from $1.41 per unit
in fiscal year 2020 to $2.20 per unit in fiscal year 2021. Among the total sales of third-party products, sales of biochemical drugs
increased by 44.7%, or $4,968,438, from $10,325,411 in fiscal year 2020 to $16,082,546 in fiscal year 2021, because of a 51.7% increase
in average selling price, while changes in sales of traditional Chinese medicine pieces, medical instruments, and dietary supplements
from fiscal year 2020 to fiscal year 2021 were relatively immaterial. In addition, the average exchange rate between RMB and US$ was
US$1.00 to RMB 7.0077 in fiscal year 2020, as compared to an average rate of US$1.00 to RMB 6.5095 in fiscal year 2021. The appreciation
of RMB against US$ had a 7.1% positive impact on our reported revenue from sales of third-party products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of Revenues.&#160;</i></b>Our cost of revenues primarily consists of inventory costs (raw materials, labor, packaging cost, depreciation
and amortization, third-party products purchase price, freight costs and overhead) and business tax. Cost of revenues generally changes
as our production costs change, which are affected by factors including the market price of raw materials, labor productivity, or the
purchase price of third-party products, and as the customer and product mix changes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cost of revenue- TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,162,847</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,581,939</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,580,908</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30.1</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of revenue- third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,493,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,028,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,464,807</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cost of revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22,655,854</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,610,140</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,045,714</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">36.4</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cost of revenues increased by $6,045,714, or 36.4%, from $16,610,140 in fiscal year 2020 to $22,655,854 in fiscal year 2021. The increase
in our cost of revenues was primarily due to increased sales volume, increased raw material and third-party product purchase costs, and
a 7.1% exchange rate impact as discussed in more details below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of revenues of TCMD products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenues of TCMD products accounted for 49.3% and 51.7% of our total costs of revenues for the years ended September 30, 2021 and
2020, respectively. Cost of revenues of TCMD products increased by $2,580,908, or 30.1%, from $8,581,939 in fiscal year 2020 to $11,162,847
in fiscal year 2021. The increase in cost of revenues of our TCMD products was due to the following reasons:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sales volume of TCMD products increased by 9.9%, from 15,652,999 units sold in fiscal year 2020 to 17,206,150 units sold in fiscal year
2021. As sales volume increased in fiscal year 2021, raw materials, labor, packaging, freight and overhead costs associated with our
TCMD product sales also increased.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of inflation and increased market prices of raw materials, the average per unit cost of our TCMD products increased by $0.10,
or 9.9%, from $0.55 per unit in fiscal year 2020 to $0.65 per unit in fiscal year 2021. Among the 13 varieties of TCMD products, cost
of revenues of Guben Yanling Pill, one of our key products, accounted for 23.3% and 22.7% of our total cost of revenues in fiscal years
2021 and 2020, respectively. Costs of Guben Yanling Pill increased by $1,229,987 in fiscal year 2021 as compared to fiscal year 2022,
when sales volume of Guben Yanling Pill increased by 12.1%. In addition, unit production cost of Qiangli Pipa Syrup and Paracetamol Granule
for Children increased by 43.2% and 51.4%, respectively, in fiscal year 2021 as compared to fiscal year 2022, due to increased raw material
costs, which led to corresponding increases in cost of revenues associated with these TCMD products, by $610,916 and $451,504, respectively.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
average exchange rate between RMB and US$ was US$1.00 to RMB 7.0077 in fiscal year 2020 as compared to an average rate of US$1.00 to
RMB 6.5104 in fiscal year 2021.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
appreciation of RMB against US$ had a 7.1% positive impact on our cost of revenues from sales of TCMD products. &#160; The increase in
our cost of revenues of our TCMD products in fiscal year 2021 as compared to fiscal year 2020 reflected the above-mentioned factors combined.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of revenues of third-party products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues of third-party products accounted
for 50.7% and 48.2% of our total costs of revenues for the years ended September 30, 2021 and 2020, respectively. Cost of revenues of
third-party products increased by $3,464,807, or 43.2%, from $8,028,200 in fiscal year 2020 to $11,493,007 in 2021, because of an increase
in average unit cost of third-party products by $0.79 per unit, or 79.6%, from $1.41 per unit in 2020 to $2.20 per unit in fiscal year
2021, offset by a decrease in sales volume of third-party products by 4.6%. In fiscal year 2021, due to an overall increase in the market
prices of raw materials used in the manufacturing of third-party products, we sourced third-party products at higher prices from third-party
pharmaceutical companies. In addition, the average exchange rate between RMB and US$ was US$1.00 to RMB 7.0077 in fiscal year 2020 as
compared to an average rate of US$1.00 to RMB 6.5104 in fiscal year 2021. The appreciation of RMB against US$ had a 7.1% positive impact
on our cost of revenues from sales of third-party products. These factors led to the increase in cost of revenues associated with third-party
product sales in fiscal year 2021 as compared to fiscal year 2020.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gross
profit</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
gross profit increased by $11,232,356, from $14,093,821 in the fiscal year 2020 to $25,326,177 in the fiscal year 2021. Our gross margin
increased by 6.9% from 45.9% in fiscal year 2020 to 52.8% in the fiscal year 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Gross profit- TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,396,439</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,792,811</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,603,627</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">87.9</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit- third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,929,738</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,301,009</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,628,729</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total gross profit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,326,177</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,093,820</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,232,356</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">79.7</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross margin- TCMD products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross margin- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total gross margin</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Average selling price per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.72</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Average cost per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Average selling price per unit- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.80</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Average cost per unit - third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.92</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit from the sales of our TCMD products increased by $8,603,627, or 87.9%, from $9,792,811 in 2020 to $18,396,439 in 2021, and the
gross margin of our TCMD products increased by 8.9%, from 53.3% in 2020 to 62.2% in 2021. The increase in our gross profit from the sales
of TCMD products was due to the following reasons: (i) as discussed above, the sales volume of our TCMD products increased by 9.9%, from
15,652,999 units sold in fiscal year 2020 to 17,206,150 units sold in fiscal year 2021, and the average selling price of our TCMD products
increased by 46.3% from $1.17 per unit in fiscal year 2020 to $1.72 per unit in fiscal year 2021. Although inflation and increased market
prices of raw materials led to an increase in the average cost of our TCMD products by 18.6%, the increase in the average selling price
outpaced the increase in average unit costs of our TCMD products by $0.44 per unit, which increased our profitability from sales of TCMD
products; (ii) our gross profit and gross margin were affected by the different product mix of the products sold during each reporting
period. During fiscal year 2021, more higher-margin and lower-cost TCMD products were sold as compared to fiscal year 2020; and (iii)
the appreciation of RMB against US$ had a 7.1% positive impact on our gross profit from sales of TCMD products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit from third-party product sales increased by $2,628,729, or 61.1%, from $4,301,009 in fiscal year 2020 to $6,929,738 in fiscal
year 2021, while the gross margin of third-party product sales increased by 2.7%, from 34.9% in fiscal year 2020 to 37.6% in fiscal year
2021. The average unit selling price of third-party products increased by 56.6%, or $0.80 per unit, while average unit cost of third-party
products also increased by 50.6%, or $0.46 per unit. The increase in the average selling price outpaced the increase in average unit
cost of third-party products by $0.34 per unit. The increase in our gross profit from third-party products was affected by changes in
the product mix of the products sold in fiscal year 2021 as compared to fiscal year 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the breakdown of our operating expenses for fiscal years 2021 and 2020:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-align: left">Total revenue</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">47,982,031</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">100.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">30,703,960</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">100.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">17,278,071</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">56.3</td><td style="width: 1%; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,973,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,555,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,417,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,296,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,703,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,593,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,465,662</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">583,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,882,537</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">837.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total operating expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,736,037</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24.5</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,842,095</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12.5</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,893,942</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">205.5</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Selling
expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
selling expenses primarily include salaries and welfare benefit expenses paid to our sales personnel, advertising expenses to increase
our brand awareness, shipping and delivery expenses, expenses incurred for our business travel, meals and other sales promotion and marketing
activities related expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and employee benefit expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">859,436</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">586,632</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">272,804</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">46.5</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Advertising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,316,654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">343,962</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">972,692</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">282.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Shipping and delivery expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">701,997</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">576,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,201</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Business travel and meals expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other sales promotion related expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,879</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,746</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">133</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total selling expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,973,531</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,555,546</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,417,985</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">91.2</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
selling expenses increased by $1,417,985, or 91.2%, from $1,555,546 in fiscal year 2020 to $2,973,531 in fiscal year 2021, primarily
attributable to (i) an increase in advertising expenses by $972,692, or 282.8%, from $343,962 in fiscal year 2020 to $1,316,654 in fiscal
year 2021. In fiscal year 2020, we used outdoor billboards, magazines and social media such as WeChat and Weibo to advertise our brand
and products in order to increase customer awareness. In fiscal year 2021, in connection with the sales and promotion of our TCMD products
to targeted customers, we engaged a local advertising agency to develop and produce a TV advertisement for promoting the sales of our
major TCMD products, Bai Nian Dan and Guben Yanling Pill, and coordinate with a TV channel to broadcast the advertisement to targeted
geographic market areas. As a result of our advertising efforts in fiscal year 2021, we spent more on advertising than we did in fiscal
year 2020, which led to higher advertising expenses in fiscal year 2021. In addition, we expect that our capitalized advertising costs
will be expensed, and increase our future advertising expenses in subsequent period, starting from when the advertisement was first broadcasted;
(ii) an increase in salary and benefit expenses paid to our sales employees by $272,804, or 46.5%, from $586,632 in fiscal year 2020
to $859,436 in fiscal year 2021, and an increase in business travel and meals expense by $47,155 or 150.1%, from $31,410 in fiscal year
2020 to $78,565 in fiscal year 2021, primarily due to our increased sales activities in fiscal year 2021; and (iii) an increase in shipping
and delivery expenses by $125,201, or 21.7%, from $576,796 in fiscal year 2020 to $701,997 in fiscal year 2021, due to our increased
sales volume and an increase in the number of sales orders fulfilled in fiscal year 2021. These above-mentioned factors combined led
to the increase in our selling expenses in fiscal year 2021 as compared to fiscal year 2020. As a percentage of revenues, our selling
expenses accounted for 6.2% and 5.1% of our total revenue for the years ended September 30, 2021 and 2020, respectively.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses primarily consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve
expenses, inspection and maintenance expenses, office supply and utility expenses, business travel and meals expenses, land and property
taxes and professional service expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and employee benefit expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">657,543</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">464,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">193,013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41.6</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172,453</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,217</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Bad debt reserve expenses (recovery)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(230,175</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(328,276</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(334.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Land and property tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,412</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Office supply and utility expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">376,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,891</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Transportation, business travel and meals expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,047</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consulting fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,967,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">616,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,350,876</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">218.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Inspection and maintenance fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,939</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,825</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Stamp tax and other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,524</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,289</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,296,844</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,703,424</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,593,420</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">93.5</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses increased by $1,593,420 or 93.5% from $1,703,424 in fiscal year 2020 to $3,296,844 in fiscal year
2021, primarily attributable to (i) an increase in our professional service fees by $1,350,876 in fiscal year 2021 as compared to fiscal
year 2020, primarily due to increased audit fees, legal fees, business consulting fees in connection with our public offering; (ii) an
increase in our office supply and utility expenses by $260,313, or 224.6%, to support our administration activities; and (iii) an increase
in our salaries, welfare expenses and insurance expenses paid to administration employees by $193,013, or 41.6%, because higher amount
of annual bonus was distributed to administrative staffs in fiscal year 2021 as compared to fiscal year 2020, offset by a decrease in
bad debt expense by $328,276 because we accrued more bad debt expenses in fiscal year 2020 based on estimated accounts receivable collection
trend, and approximately $0.2 million bad debt accrual in prior periods was collected in fiscal year 2021, which led to a bad debt recovery
in 2021. The overall increase in our general and administrative expenses in fiscal year 2021 as compared to fiscal year 2020 reflected
the above-mentioned factors combined. As a percentage of revenues, general and administrative expenses were 6.9% and 5.5% of our revenue
in fiscal years 2021 and 2020, respectively.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and development expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses primarily consist of salaries, welfare and insurance expenses paid to our employees involved in the
research and development activities, materials and supplies used in the development and testing new TCMD products, depreciation and other
miscellaneous expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and employee benefit expenses to R&amp;D staff</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">155,940</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">97,444</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">58,496</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">60.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Materials used in R&amp;D activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">836,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">469,788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">366,922</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenditure on new product development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,454,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,454,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,719</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total R&amp;D expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,465,662</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">583,125</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,882,537</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">837.3</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased by $4,882,537, or 837.3%, from $583,125 in fiscal year 2020 to $5,465,662 in fiscal year 2021, primarily
attributable to (i) an increase in research and development expense of $4,454,400 in order to develop and test eight new Chinese medicine
products in order to diversify our future product portfolio. In fiscal year 2021, we entered into several cooperative agreements with
external academic and research institutions to jointly conduct the new product development and accordingly incurred significant amount
of R&amp;D expense in connection with such efforts; and (ii) an increase in the materials used in the research and development (&#8220;R&amp;D&#8221;)
activities by $366,922. In fiscal year 2021, in order to develop new products and improve the formulation of several existing products,
we conducted more testing on product stability and safety, and as a result, more materials were used in our R&amp;D activities in fiscal
year 2021 than in fiscal year 2020. As a percentage of revenues, research and development expenses were 11.4% and 1.9% of our revenue
in fiscal years 2021 and 2020, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
income (expenses), net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
other income (expenses) primarily includes interest expenses incurred on our short-term bank loans, gain or loss from disposal of fixed
assets, investment income from our long-term investment in exchange for a 5% ownership interest in a local bank, and income generated
from our short-term investments to purchase wealth management products from financial institutions. Total other income, net, increased
by $239,630 or 158.4%, from net other expenses of $151,292 in fiscal year 2020 to net other income of $88,338 in fiscal year 2021 due
to the following reasons:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expenses decreased by $22,156, or 17.9%, from $123,760 in fiscal year 2020 to $101,604 in fiscal year 2021. The decrease in our interest
expenses was due to lower amount of outstanding loans we carried during fiscal year 2021 as compared to fiscal year 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expense increased by $31,082, from other expense of $49,352 in fiscal year 2020 to other expense of $80,434 in fiscal year 2021, primarily
due to payment of work injury compensation to workers in fiscal year 2021 and foreign currency transaction loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
investment income was $30,827 and $21,820 in fiscal years 2021 and 2020, respectively. From March 2009 to September 2017, we invested
approximately RMB5 million ($0.7 million) in Jiangxi Jian Rural Commercial Bank (&#8220;JX RCB Bank&#8221;) in exchange for a 5% ownership
interest in the bank. The purpose of this investment was to earn investment income as JX RCB Bank continues to grow. We account for this
investment using the measurement alternative in accordance with ASC 321. As of September 30, 2021 and 2020, the value of this investment
amounted to $744,924 and $735,000, respectively, and was reported as long-term investment in equity investee on our consolidated balance
sheets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
from short-term investments increased from Nil in fiscal year 2020 to $239,549 in fiscal year 2021. Our short-term&#160;investments consist
of wealth management financial products purchased from a financial institution, which can be redeemed anytime at our discretion. The
financial institution put our investments in certain financial instruments, including money market funds and bonds, to generate investment
income. In fiscal year 2021, we used available cash to purchase such wealth management financial products from financial institution
and generated $239,549 investment income in fiscal year 2021. There was no such income in fiscal year 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provision
for Income Taxes</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
provision for income taxes was $2,358,526 in fiscal year 2021, a decrease of $183,685, from $2,542,211 in fiscal year 2020. Under the
Enterprise Income Tax Law, or the EIT Law, domestic enterprises and foreign investment enterprises are usually subject to a unified 25%
enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on a case-by-case basis.
The EIT Law grants preferential tax treatment to High and New Technology Enterprises (&#8220;HNTEs&#8221;, individually an &#8220;HNTE&#8221;).
Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for
their HNTE status every three years. Jiangxi Universe, one of our main operating subsidiaries in the PRC, was approved as an HNTE and
was entitled to a reduced income tax rate of 15% beginning November&#160;2016 with a term of three years. Jiangxi Universe&#8217;s HNTE
status was successfully renewed in December 2019 for a term of three additional years. The EIT Law is typically enforced by the local
tax authorities in the PRC. Each local tax authority has the discretion to grant tax holidays to local enterprises as a way to encourage
entrepreneurship and stimulate local economy. The corporate income taxes for the fiscal years 2021 and 2020 were reported at a blended
reduced rate since Jiangxi Universe enjoys a 15% reduced income tax rate due to its HNTE status and Universe Trade, a wholly owned subsidiary
of Jiangxi Universe, is subject to a standard 25% income tax rate. The impact of the tax holidays noted above decreased PRC corporate
income taxes by $1,518,979 and $118,986 for the years ended September 30, 2021, and 2020, respectively. The benefit of the tax holidays
on net income per share (basic and diluted) $0.09 and $0.01 for the years ended September 30, 2021 and 2020, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Income</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the foregoing, we reported a net income of $11,319,952 in fiscal year 2021, representing a $3,761,730 increase from a net
income of $7,558,222 in fiscal year 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
<span style="text-decoration:underline">Liquidity and Capital Resources</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2022, we had $5,711,458 in
cash on hand. We also had short-term investments of $13.1 million in wealth management financial products from financial institutions
to generate investment income, which we purchased with our IPO proceeds. Such short-term investment can be redeemed anytime at our discretion
and is highly liquid. As of September 30, 2022, we also had $15.2 million in accounts receivable. Our accounts receivable primarily include
balance due from customers for our pharmaceutical products sold and delivered to customers. No single customer accounts for more than
10% of our total accounts receivable balance as of September 30, 2022. Approximately 71.9%, or $10.9 million, of our net accounts receivable
balance as of September 30, 2022 has been subsequently collected. Collected accounts receivable will be used as working capital in our
operations, if necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, our inventory balance amounted to $2,206,488, primarily consisting of raw materials and work-in-progress and finished
TCMD products, which we believe are able to be sold quickly based on the analysis of the current trends in demand for our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal year 2021, we also started to construct new manufacturing facilities in order to expand our future production capacity, and
we had made a prepayment of approximately RMB69.2 million (approximately $9.7 million) to Jiangxi Chenyuan Construction Project Co.,
Ltd. (&#8220;Chenyuan&#8221;), a sub-contractor, to start the construction-in-progress project, or CIP project, including land improvement,
building foundation and the construction of the manufacturing plants. As of September 30, 2022, $401,702 (approximately RMB2.9 million)
of prepayment for the CIP project had been used for construction work, and the amount was recorded as construction in progress which
was included in property, plant and equipment in the consolidated balance sheets. As of September 30, 2022, the remaining $9.3 million
prepayment to Chenyuan was recorded as prepayment for the CIP project on the balance sheets. There was no additional significant prepayment
to the sub-contractor during the fiscal year 2022. As of September 30, 2022, future additional capital expenditure on this CIP project
is estimated to be approximately RMB95.8 million (equivalent to $13.5 million), among which approximately $3.5 million is required for
the next 12 months. We currently plan to support our ongoing CIP project through cash flows from operations, proceeds received from the
IPO, and borrowings from banks, if necessary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, we made a prepayment of approximately $2.25 million to a related party in order to purchase certain residential
and commercial property. On May 6, 2021, we entered into a real estate property purchase agreement with a related party, Jiangxi Yueshang
Investment Co., Ltd. (&#8220;Jiangxi Yueshang&#8221;), an entity in which our chief executive officer, Mr. Gang Lai, owned 5% of its
equity interests as of the date of that agreement. Pursuant to this purchase agreement, Jiangxi Yueshang will sell and we will purchase
certain residential apartments and commercial office space totaling 2,749.30 square meters, with a total purchase price of RMB32 million
(approximately $4.50 million). Pursuant to this purchase agreement, we were required to make a prepayment in the amount of 50% of the
total purchase price, with 20% of the total purchase price payable when a certificate of occupancy is available to us, and 30% of the
total purchase price payable upon delivery of the property. As of September 30, 2022, we had made a prepayment of RMB16 million ($2,249,248)
to Jiangxi Yueshang. As of the date of this annual report, we have not received the certificate of occupancy nor access to the property.
The remaining balance is expected to be paid by August 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, we made a prepayment of approximately $3.5 million to an individual for equity acquisition. On September 26, 2022,
the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to which, Mr. Xibo Liu
shall transfer his 51% ownership in Yunnan Faxi to the Company in consideration for RMB72 million (approximately $10.1 million). Based
on contract terms, the Company prepaid RMB25 million (approximately $3.5 million) within 3 business days upon signing the letter of intent.
The intended acquisition is expected to be completed and the remaining balance is expected to be paid in June 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, we also had short-term bank loans of approximately $3.9 million that we obtained from Jiangxi Luling Rural Commercial
Bank (&#8220;LRC Bank&#8221;) and Bank of Communications for working capital purposes. We expect that we will be able to renew all of
the existing bank loans upon their maturity based on our past experiences and our outstanding credit history.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, our working capital balance was $28.4 million. In assessing our liquidity, management monitors and analyzes our
cash on-hand, our ability to generate sufficient revenue in the future, and our operating and capital expenditure commitments. We believe
that our current cash and cash flows provided by operating activities, borrowings from banks and from our principal shareholders and
proceeds received from the IPO will be sufficient to meet our working capital needs in the next 12 months from the date of this annual
report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth summary of our cash flows for the periods indicated:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash provided by (used in) operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,312,346</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,055,847</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,115,157</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,908,105</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,059,958</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51,798</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash used in financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,317,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,581,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">470,136</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of exchange rate change on cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(463,942</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">553,702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">347,386</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,366,450</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,980,294</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,880,881</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,077,908</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,058,202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,177,321</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Cash, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,711,458</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,077,908</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,058,202</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $1,312,346 for the fiscal year 2022, primarily consisted of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss of $8,736,566 for the period.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in accounts receivable of $1,549,312. Our accounts receivable
primarily includes balance due from customers for our pharmaceutical products sold and delivered to customers. As of September 30, 2022,
most of our outstanding accounts receivable aged below six months. As of date of this annual report, approximately 71.9%, or $10.9 million
of our net accounts receivable balance as of September 30, 2022 has been subsequently collected. Collected accounts receivable will be
used as working capital in our operations, if necessary.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
decrease in advance to suppliers of $2,681,214 because we made significant advance payments to suppliers for raw material purchase as
of September 30, 2021 and we received purchased raw materials valued at approximately $2.7 million during the fiscal year 2022.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
decrease in prepayment for advertising of $7,385,695. In September 2021, we engaged a third-party advertising agency to develop and produce
TV advertisement for promoting the sales of our major TCMD product, Bai Nian Dan and Guben Yanling Pill, and coordinate with a TV channel
to broadcast the advertisement to targeted geographic market areas. Such prepayment was charged to expense when our TV advertisement
was broadcasted in the fiscal year 2022.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
increase in prepaid expenses and other current assets of $1,699,929 related with VAT of advertising expense deductible upon reception
of invoice, as well as prepaid income tax deductible from future taxable income.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
decrease in accounts payable of $1,896,621 because we made payment to raw material suppliers when we received the invoices from them.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $2,055,847 for the year ended September 30, 2021, primarily consisting of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
income of $11,319,952 for the fiscal year.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
increase in accounts receivable of $3,867,457. Our accounts receivable primarily include balance due from customers for our pharmaceutical
products sold and delivered to customers. As of September 30, 2021, most of our outstanding accounts receivable aged below six months.
Approximately 75.4% of our net accounts receivable balance as of September 30, 2021 have been subsequently collected as of the date of
this annual report. Collected accounts receivable will be used as working capital in our operations, if necessary.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
increase in inventory balance of $451,634 because we increased the stockpile of raw materials in order to meet the future production
need.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
increase in advance to suppliers of $2,717,085, representing prepayments made to certain suppliers to ensure continuous supply of raw
materials at favorable purchase prices. Approximately 66.1% of the advance to suppliers balance as of September 30, 2021 has been subsequently
realized when we received the purchased raw materials from the suppliers as of the date of this annual report.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
increase in prepayment to an advertising agency of $7,434,240 in order to engage this advertising agency to develop and produce TV advertisement
for promoting the sales of our major TCMD product, Bai Nian Dan and Guben Yanling Pill, and coordinate with a TV channel to broadcast
the advertisement to targeted geographic market areas. &#160;Such prepayment has been charged to expense when our TV advertisement was
first broadcasted in October 2021.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
increase in accounts payable of $2,457,337 primarily due to increased purchase of inventories and we have not received related invoices
from the suppliers and accordingly such payable had not been settled as of September 30, 2021. Most of the outstanding accounts payable
balance has been subsequently settled as of the date of this annual report.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by operating activities was $6,115,157 for the year ended September 30, 2020, primarily consisting of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
income of $7,558,222 for the fiscal year ended September 30, 2020.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
increase in accounts receivable of $4,107,520. Our accounts receivable primarily includes balance due from customers for our pharmaceutical
products sold and delivered to customers. As of September 30, 2020, most of our outstanding accounts receivable aged below six months.
Approximately 99% of our net accounts receivable balance as of September 30, 2020 have been subsequently collected as of the date of
this annual report. Collected accounts receivable will be used as working capital in our operations, if necessary.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
decrease in inventory balance of $888,607 because in fiscal year 2020, we have implemented our&#160;inventory control policy based on
sales order level in order to avoid over-stockpile of raw materials and third-party products to reduce risks associated with slow-moving
and obsolete in inventories.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
increase in accounts payable of $639,427 because we normally arrange the payment to suppliers upon receipt of the invoices from them.
As of September 30, 2020, the increase in accounts payable was largely due to pending invoices from suppliers. Approximately 80% of the
September 30, 2020 accounts payable balance has been subsequently settled as of the date of this annual report.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase
    in taxes payable of $731,518 primarily due to an increased taxable income.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investing
Activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities amounted to $3,908,105 for the fiscal year 2022, which primarily included prepayment for acquisition
of $3,814,925. On September 26, 2022, we entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant
to which Mr. Xibo Liu shall transfer his 51% ownership in Yunnan Faxi to the Company in consideration for RMB72 million (approximately
$10.1 million). We prepaid RMB25 million (approximately $3.9 million) in the fiscal year 2022. The intended acquisition is expected to
be completed and the remaining balance is expected to be paid in June 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities amounted to $27,059,958 for the year ended September 30, 2021 and primarily included (i) purchase of
fixed assets of $444,505; (ii) prepayment of $2,457,600 made to a related party to purchase residential and commercial property; (iii)
prepayment of $10,629,120 made to a sub-contractor in order to complete the CIP Project, including four manufacturing plants and an office
building, with estimated project completion in August 2023; (iv) purchase of short-term investments of $15,330,660 because we used part
of the IPO proceeds to purchase certain wealth management financial products from financial institutions in order to earn investment
income; and (v) redemption of short-term investments of $1,801,927.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities amounted to $51,798 for the year ended September 30, 2020, and primarily included the purchase of fixed
assets in the same amount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financing
Activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities amounted to $3,317,943 for the fiscal year 2022, primarily including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
                                            from short-term bank loans in the amount of $4,272,716 and repayment of bank loans in the
                                            amount of $4,272,716.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
                                            from related party borrowings of $3,317,943. The balance due to related party mainly consisted
                                            of advances from our principal shareholders for working capital purposes during our normal
                                            course of business. These advances were non-interest bearing and due on demand.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities amounted to $26,581,809 for the year ended September 30, 2021, primarily include the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
from short-term bank loans of $4,300,800 and offset by repayment of bank loans of $2,764,800 upon loan maturity.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
proceeds of $25,957,457 received upon completion of our IPO in March 2021.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
of related party borrowings of $911,648. The balance due to related party mainly consisted of advances from our principal shareholder
for working capital purposes during our normal course of business. These advances were non-interest bearing and due on demand.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities amounted to $470,136 for the year ended September 30, 2020, primarily include the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from short-term
    bank loans of $1,427,000 and repayment of bank loans of $1,427,000. During fiscal year 2020, our subsidiary Universe Trade repaid
    RMB8 million loan to LRC Bank upon maturity and at the same time, renewed the loan agreement to borrow RMB8 million for additional
    six months until March 31, 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment for deferred public
    offering costs of $441,064. Deferred offering costs consisted principally of legal, underwriting, and other professional service
    expenses in connection with the IPO of our ordinary shares. As of September 30, 2020, we capitalized $441,064 of deferred offering
    costs. Such costs were deferred until the closing of the IPO, at which time the deferred costs were offset against the offering proceeds.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from related party
    borrowings of $911,200. The balance due to related party mainly consisted of advances from our principal shareholder for working
    capital purposes during our normal course of business. These advances were non-interest bearing and due on demand. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitments
and contingencies </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we are a party to various legal actions arising in the ordinary course of business. We accrue costs associated with these
matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies
are expensed as incurred. For the years ended September 30, 2022, 2021 and 2020, we did not have any material legal claims or litigation
that, individually or in aggregate, could have a material adverse impact on our consolidated financial position, results of operations
and cash flows.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, we had the following contractual obligations:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Payment Due by Period</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><b>Contractual obligations</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Total</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Less than 1 year</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>1-2 years</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2-3 years</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Debt obligations (1), (2) and (3)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">3,936,184</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,936,184</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Payment for advertising fees (4)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">927,815</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">927,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Capital expenditure commitment on CIP project (5)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,467,372</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,479,306</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,988,066</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">18,331,371</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8,343,305</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9,988,066</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 14, 2022, the Company&#8217;s subsidiary, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent
to $1,124,624) as working capital for one year, with the maturity date on March 13, 2023. The fixed interest rate of the loan was 4.62%
per annum. There was no guarantee requirement for this loan.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2022, the Company&#8217;s subsidiary, Jiangxi Universe, entered into a loan agreement with LRC Bank to borrow RMB10 million
(equivalent to $1,405,780) as working capital for one year, with the maturity date on June 14, 2023. The fixed interest rate of the loan
was 4.62% per annum. Certain related parties of the Company, including Mr. Gang Lai, the Company&#8217;s controlling shareholder, chairman
of the board of directors, and chief executive officer, Ms. Lin Yang, the Company&#8217;s chief financial officer, Ms. Xing Wu, Mr. Gang
Lai&#8217;s spouse, and the Company&#8217;s subsidiary, Universe Technology, jointly signed guarantee agreements with LRC Bank to provide
credit guarantee for this loan.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2022, the Company&#8217;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB10
million (equivalent to $1,405,780) as working capital for eleven months, with the maturity date on May 26, 2023. The fixed interest rate
of the loan was 4.2% per annum. Jiangxi Province Financing Guarantee Group Co., Ltd., an unrelated third party, signed a guarantee agreement
with Bank of Communications to provide credit guarantee for this loan.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2021, we entered into an advertising service agreement with a third party, Fengyang Legend, pursuant to which Fengyang Legend
agreed to assist us in developing and producing a TV advertisement for promoting our representative TCMD products, Bai Nian Dan and Guben
Yanling Pill, and coordinating with a TV channel to broadcast the advertisement to targeted geographic market areas. The total advertising
service fee under this agreement was RMB55 million (approximately $8.5 million) with a service period of one year, from October 1, 2021
to September 30, 2022. Pursuant to the terms under this agreement, we made an advance payment in the amount of 30% of the total advertising
service fee to Fengyang Legend within 7 business days upon signing the service agreement, and made payment in the amount of 58% of the
total advertising service fee when the specific TV channel used for broadcast the TV film was determined. In the fiscal year 2021, we
paid RMB48.4 million (approximately $7.5 million), the amount was recorded as prepayment for advertising on the balance sheets as of
September 30, 2021, and recognized as selling expense during the fiscal year 2022. The remaining 12% of the contract price, RMB6.6 million
(approximately $0.9 million), representing the monthly advertising fees payable when the advertising film was broadcasted through the
designated TV channels during the service period, is expected to be paid by August 2023.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 25, 2021, the Company signed a construction sub-contract with sub-contractor Chenyuan, pursuant to which, Chenyuan will construct
four manufacturing plants and an office building with a total estimated maximum budget of RMB165 million (approximately $23.2 million).
The construction work started on August 8, 2021, with an estimated completion date on August 7, 2023. However, due to resurgence of the
COVID-19 pandemic, which resulted in lingering logistic disruption, material and labor shortage, and domestic travel restrictions, the
construction work is estimated to be completed in December 2024, and Chenyuan will bear the increased material and labor costs. As of
September 30, 2022, we had made prepayment of approximately RMB69.2 million (approximately $9.7 million) to Chenyuan for land improvement,
building foundation and the construction of the manufacturing plants.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, the $9.7 million prepayment to Chenyuan was recorded as prepayment for the CIP Project on the balance sheets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, future additional capital expenditure on this CIP Project is estimated to be approximately RMB95.8 million (equivalent
to $13.5 million), among which approximately $3.5 million is required for the 12 months ending September 30, 2023. The Company currently
plans to support its ongoing CIP Project through cash flows from operations, proceeds received from the IPO, and borrowings from banks,
if necessary. The CIP Project is expected to be fully completed, and the new manufacturing plants and office building are expected to
be put into use by December 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements as of September 30, 2022, 2021 and 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, inflation in China has not materially impacted our results of operations. According to Wind Information (www.wind.com.cn), the
year-over-year percent changes in the consumer price index for November 2022 was 2.02%. According to the National Bureau of Statistics
of China, the year-over-year percent changes in the consumer price index for December 2021 was 0.9%. Although we have not been materially
affected by inflation in the past, we can provide no assurance that we will not be affected by higher rates of inflation in China in
the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Seasonality
</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seasonality
does not materially affect our business or the results of our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
<span style="text-decoration:underline">Research and Development, Patents and Licenses,&#160;etc.</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Intellectual Property&#8221; and &#8220;Item 4. Information
on the Company&#8212;B. Business Overview&#8212;Research and Development.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
<span style="text-decoration:underline">Trend Information</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as disclosed below and elsewhere in this annual report on Form&#160;20-F, we are not aware of any trends, uncertainties, demands,
commitments, or events for the period from October&#160;1, 2021 to September 30, 2022 that are reasonably likely to have a material adverse
effect on our net revenue, income, profitability, liquidity, or capital resources, or that caused the disclosed financial information
to be not necessarily indicative of future operating results or financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
<span style="text-decoration:underline">Critical Accounting Estimates</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements. These
financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;), which requires us to make estimates and assumptions that affect the reported amounts of our assets and liabilities and
revenues and expenses, to disclose contingent assets and liabilities on the date of the consolidated financial statements, and to disclose
the reported amounts of revenues and expenses incurred during the financial reporting period. The most significant estimates and assumptions
include the valuation of accounts receivable and inventories, realizability of advance to suppliers and prepaid advertising costs, useful
lives of property, plant and equipment and intangible assets, the recoverability of long-lived assets, the impairment of the short-term
investments, provision necessary for contingent liabilities, and revenue recognition. We continue to evaluate these estimates and assumptions
that we believe to be reasonable under the circumstances. We rely on these evaluations as the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Since the use of estimates is an integral component
of the financial reporting process, actual results could differ from those estimates. Some of our accounting policies require higher
degrees of judgment than others in their application. We believe critical accounting policies as disclosed in this annual report reflect
the more significant judgments and estimates used in preparation of our consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
and Uncertainties </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
main operation is located in the PRC. Accordingly, our business, financial condition, and results of operations may be influenced by
political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. Our results may be adversely
affected by changes in the political, regulatory and social conditions in the PRC. Although we have not experienced losses from these
situations and believes that we are in compliance with existing laws and regulations including our organization and structure, this may
not be indicative of future results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters, extreme
weather conditions, health epidemics and other catastrophic incidents, such as the COVID-19 pandemic, which could significantly disrupt
our operations.&#160;In the fiscal year ended September 30, 2022, due to resurgence of COVID-19 pandemic in China and related restrictive
measures, including travel restrictions, the PRC operating entities experienced delays in the receipt of purchased raw materials from
suppliers and in delivering products to customers. The prices of the raw materials increased by about 5% as compared to the fiscal year
ended September 30, 2021. In addition, we granted some customers extended payment terms of 30 days to 120 days. However, based on our
present relationship with these customers and our evaluation of their financial conditions, we do not anticipate any material collectability
problems. Although the Chinese government removed its zero-COVID policy in December 2022, China is now facing a sudden surge in COVID
cases after easing the lockdown restrictions nationwide. WHO officials had expressed hope that COVID-19 might be entering an endemic
phase by early 2023, but the continued uncertainties associated with the COVID-19 pandemic worldwide may cause our revenue and cash flows
to underperform in the next 12 months from the date of this annual report. The extent of the future impact of the COVID-19 pandemic on
our business and the results of operations is still uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by
rapidly changing technologies, significant competition and a strong emphasis on intellectual property. We may face competition with respect
to our current and future pharmaceutical product candidates from major pharmaceutical companies in China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following critical accounting policies rely upon assumptions and estimates and were used in the preparation of our consolidated financial
statements:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Uses
of estimates</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information as of the date
of the consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, the
allowance for estimated uncollectible receivables, the realizability of advance to suppliers, inventory valuation, useful lives of property,
plant and equipment, intangible assets, the recoverability of long-lived assets, provision necessary for contingent liabilities, revenue
recognition and realization of deferred tax assets. Actual results could differ from those estimates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts
receivable, net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are presented net of allowance for doubtful accounts. We determine the adequacy of reserves for doubtful accounts based on
individual account analysis and historical collection trends. We establish a provision for doubtful receivables when there is objective
evidence that we may not be able to collect amounts due. The allowance is based on management&#8217;s best estimate of specific losses
on individual exposures, as well as a provision on historical trends of collections. Actual amounts received may differ from management&#8217;s
estimate of credit worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful
accounts after management has determined that the likelihood of collection is not probable. Allowance for uncollectable balances amounted
to $791,827 and $446,527 as of September 30, 2022 and 2021, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventories,
net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and
related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision
for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less
any costs to complete and sell products. We evaluate inventories on a quarterly basis for its net realizable value adjustments, and reduces
the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable value
based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future product
sales. We recorded inventory reserve of $120,286 and $116,453 as of September 30, 2022 and 2021, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
recognition</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine revenue recognition for contracts with customers, we perform the following five steps : (i) identify the contract(s) with the
customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration
to the extent that it is probable that a significant future reversal will <i>not</i> occur, (iv) allocate the transaction price to the
respective performance obligations in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize revenue when we transfer our goods and services to customers in an amount that reflects the consideration to which we expect
to be entitled in such exchange. We account for the revenue generated from sales of our TCMD and third-party products on a gross basis
as we are acting as a principal in these transactions, are subject to inventory risk, have latitude in establishing prices, and are responsible
for fulfilling the promise to provide customers the specified goods, which we have control of the goods and has the ability to direct
the use of goods to obtain substantially all the benefits. All of our contracts have one single performance obligation as the promise
is to transfer the individual goods to customers, and there is no separately identifiable other promises in the contracts. Our revenue
streams are recognized at a point in time when title and risk of loss passes and the customer accepts the goods, which generally occurs
at delivery. Our products are sold with no right of return and we do not provide other credits or sales incentives to customers. Revenue
is reported net of all VAT.&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contract
Assets and Liabilities </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
terms are established on our pre-established credit requirements based upon an evaluation of customers&#8217; credit quality. Contract
assets are recognized for in related accounts receivable. Contract liabilities are recognized for contracts where payment has been received
in advance of delivery. The contract liability balance can vary significantly depending on the timing when an order is placed and when
shipment or delivery occurs. As of September 30, 2022 and 2021, other than accounts receivable and advances from customers, we had no
other material contract assets, contract liabilities or deferred contract costs recorded on its consolidated balance sheet. Costs of
fulfilling customers&#8217; purchase orders, such as shipping, handling and delivery, which occur prior to the transfer of control, are
recognized in selling, general and administrative expense when incurred.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disaggregation
of Revenues</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
disaggregate our revenue from contracts by product types, as we believe it best depicts how the nature, amount, timing and uncertainty
of the revenue and cash flows are affected by economic factors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of our total revenues by product categories for the years ended September 30, 2022, 2021 and 2020 was as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Revenue
by product source </span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Sales of TCMD products manufactured by the Company</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,988,177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,559,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,374,751</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,154,974</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">40,143,151</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Revenue
by product categories </span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Sales of TCMD products:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Medicinal liquor products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,095,336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,951,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,616,080</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other chronic condition treatment products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,140,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,978,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,059,403</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Cold and flu medicines</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,752,422</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,629,606</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,699,268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Sub-total of TCMD products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,988,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,559,286</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,374,751</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Sales of third-party products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Biochemical drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,730,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,082,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,325,411</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Traditional Chinese medicine pieces</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,097</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,394,348</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,318,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,950,238</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Dietary supplements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,463</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Subtotal of third-party products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,154,974</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total revenue</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">40,143,151</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Tax</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when
temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial
statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
uncertain tax position is recognized only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax
examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination.
For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest
relating to income taxes have been incurred during the years ended September 30, 2022, 2021 and 2020. We do not believe there was any
uncertain tax provision as of September 30, 2022, 2021 and 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating subsidiaries in China are subject to the income tax laws of the PRC. No significant income was generated outside the PRC for
the years ended September 30, 2022, 2021 and 2020. As of September 30, 2022 and 2021, all of our tax returns of our PRC subsidiaries
remain open for statutory examination by PRC tax authorities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected
credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and
supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost. ASU 2016-13 was subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU
2020-02. For public entities, ASU 2016-13 and its amendments are effective for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2019. For all other entities, this guidance and its amendments will be effective for fiscal years
beginning after December 15, 2022, including interim periods within those fiscal years. Early application will be permitted for all entities
for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption of this guidance did
not have a material impact on the Company&#8217;s consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the FASB issued ASU 2020-10, &#8220;Codification Improvements to Subtopic 205-10, presentation of financial statements&#8221;.
The amendments in this Update improve the codification by ensuring that all guidance that requires or provides an option for an entity
to provide information in the notes to financial statements is codified in the disclosure section of the codification. That reduce the
likelihood that the disclosure requirement would be missed. ASU 2020-10 is effective for the Company for annual and interim reporting
periods beginning January 1, 2022. Early application of the amendments is permitted for any annual or interim period for which financial
statements are available to be issued. The amendments in this Update should be applied retrospectively. An entity should apply the amendments
at the beginning of the period that includes the adoption date. The Company is currently evaluating the impact of this new standard on
Company&#8217;s consolidated financial statements and related disclosures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
<span style="text-decoration:underline">Directors and Senior Management</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding our directors and executive officers as of the date of this annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 65%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position(s)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang
    Lai</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board of Directors and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lin
    Yang</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baochang
    Liu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiawen
    Pang</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.
    David Sherman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ding
    Zheng</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief biography of each of our executive officers and directors:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mr.
Gang Lai</i></b><i>&#160;</i>is our chief executive officer and chairman of the board. Mr. Lai has served as the chief executive officer
of Jiangxi Universe since 2004 and founded Universe Trade in 2010. Before joining us, Mr. Lai was a successful entrepreneur. He founded
Jiangxi Lvzhouyuan Timber Joint Stock Co., Ltd. in 2001, a company listed on PRC National Equities Exchange and Quotations (NEEQ: 838893),
and has since served as its chairman of the board. Mr. Lai graduated from Jingdezhen Ceramic Institute with a bachelor&#8217;s degree
in mechanical engineering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ms.
Lin Yang</i></b>&#160;is our chief financial officer and director. Ms. Lin Yang has served as the financial director of Jiangxi Universe
since April 2006 and the financial director of Universe Trade since its formation in 2010. Before joining us, Ms. Yang served as an accountant
at Jiangxi Automobile Engineering Plastic Co., Ltd. from 1998 to March 2006. Ms. Yang graduated from Jiangxi University of Finance and
Economics with a bachelor&#8217;s degree in accounting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mr.
Baochang Liu </i></b> has served as our chief operating officer since December 2021. Mr. Liu has over 17 years of experience in
pharmaceutical marketing. From January 2020 to December 2021, Mr. Baochang Liu worked as the vice president of marketing and general
manager of OTC department at China Shineway Pharmaceutical Group Ltd. (HKEX: 2877). From November 2015 to December 2019, Mr.
Baochang Liu served as the general manager of OTC department at Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773). Prior
to that, Mr. Liu worked as the general marketing manager at Chengdu Rongyao Industry (Group) Co., Ltd. from December 2012 to
November 2015. Mr. Baochang Liu obtained his bachelor&#8217;s degree in accounting and in marketing management from Harbin
University of Commerce in 2004 and his master of business administration from Fudan University in 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mr.
Jiawen Pang</i></b>&#160;has served as our independent director since March 2021. Since January 1, 2021, Mr. Jiawen Pang has served as
the vice president at Guangzhou Dahua Food Technology Co., Ltd., a food manufacturing company, where Mr. Pang is responsible for overseeing
the company&#8217;s general management and marketing function. From January 1, 2018 to December 2020, Mr. Jiawen Pang served the general
manager at Pangbei (Shanghai) Medical Technology Center, a medical device company, where Mr. Pang was responsible for overseeing the
general management and marketing function of the company. Mr. Jiawen Pang graduated from Tianjin University of Commerce with a bachelor&#8217;s
degree in refrigeration and food freezing engineering in 1989 and from Sun Yat-sen University with a master of business administration
in healthcare and medicine in 2004.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mr.
H David Sherman</i></b>&#160;has served as our independent director since March 2021. Mr. H David Sherman has served as a full-time professor
at Northeastern University since September 1984. Mr. Sherman has extensive experience serving as independent director of public companies
listed on Nasdaq. Currently, Mr. Sherman serves as an independent director and chair of the audit committee of Nuvve Holding Corp. (Nasdaq:
NVVE), Lakeshore Acquisition II Corp. (Nasdaq: LBBB) and Prime Number Acquisition I Corp. (Nasdaq: PNAC). From  April 2020 to August
2021, Mr. Sherman has served as an independent director and chair of the audit committee of China Liberal Education Holdings Limited
(Nasdaq: CLEU). From December 2017 to August 2019, Mr. Sherman served as an independent director and chair of audit committee of Dunxin
financial Holdings from (NYSE American: DXF). From January 2010 to August 2012, Mr. Sherman served as the chair of the audit committee
of China HGS Real Estate Inc. (Nasdaq: HGSH). Mr. Sherman received his bachelor&#8217;s degree in economics from Brandies University
in 1969, his master&#8217;s in business administration from Harvard University in 1971, and his doctorate degree in business administration
from Harvard University in 1981. Mr. Sherman is a member of the American Institute of Certified Public Accountant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mr.
Ding Zheng</i></b><i>&#160;</i>has served as our independent director since March 2021. Mr. Ding Zheng has served as the chairman of
the board at Guangzhou Roujing Sunshade Energy-saving Technology Co., Ltd. since 2018. Mr. Zheng has also served as the general manager
at Hande Manufacturing (China) Co., Ltd., since 2015. Mr. Zheng obtained a bachelor&#8217;s degree in technology economics from Shanghai
Jiao Tong University in 2000 and a master of business administration degree from Tsinghua University in 2005. Mr. Zheng is a member of
the China Institute of Certified Public Accountants (CICPA).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Diversity</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides certain information regarding the diversity of our board of directors as of the date of this annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Diversity Matrix</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Country
    of Principal Executive Offices:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    Private Issuer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
    Prohibited under Home Country Law</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Number of Directors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 53%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Female</b></span></td>
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Male</b></span></td>
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 11%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-
    </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Binary</b></span></p></td>
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Did
    Not<br/>
    Disclose<br/>
    Gender</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part
    I: Gender Identity</b></span></td>
    <td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part
    II: Demographic Background</b></span></td>
    <td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underrepresented
    Individual in Home Country Jurisdiction</span></td>
    <td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LGBTQ+</span></td>
    <td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did
    Not Disclose Demographic Background</span></td>
    <td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our directors or executive officers has a family relationship as defined in Item 401 of Regulation S-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Controlled
Company</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Gang Lai, our chief executive officer, director, and chairman of the board of directors, currently beneficially own approximately 57.38%
of the aggregate voting power of our outstanding ordinary shares. As a result, we are a &#8220;controlled company&#8221; within the meaning
of the Nasdaq listing rules. As a controlled company, we are permitted to elect to rely on certain exemptions from the obligations to
comply with certain corporate governance requirements, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that a
    majority of the board of directors consist of independent directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that our
    director nominees be selected or recommended solely by independent directors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that we
    have a nominating and corporate governance committee and a compensation committee that are composed entirely of independent directors
    with a written charter addressing the purposes and responsibilities of the committees.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not intend to rely on the controlled company exemptions under the Nasdaq listing rules even if we are a controlled company, we
could elect to rely on these exemptions in the future, and if so, you would not have the same protection afforded to shareholders of
companies that are subject to all of the corporate governance requirements of Nasdaq.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
<span style="text-decoration:underline">Compensation</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended September 30, 2022, we paid an aggregate of $121,000 as compensation to our executive officers and directors. None
of our non-employee directors have any service contracts with us that provide for benefits upon termination of employment. We have not
set aside or accrued any amount to provide pension, retirement, or other similar benefits to our directors and executive officers. Our
PRC subsidiaries are required by law to make contributions equal to certain percentages of each employee&#8217;s salary for his or her
pension insurance, medical insurance, unemployment insurance, and other statutory benefits and a housing provident fund.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
<span style="text-decoration:underline">Board Practices</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors consists of five directors, including three independent directors. A director is not required to hold any shares in
our company to qualify to serve as a director. A director may vote with respect to any contract, proposed contract or arrangement in
which he is materially interested, provided that (a) such director, if his or her interest in such contract or arrangement is material,
has declared the nature of his or her interest at the earliest meeting of the board at which it is practicable for him or her to do so,
either specifically or by way of a general notice and (b) if such contract or arrangement is a transaction with a related party, such
transaction has been approved by the audit committee. The directors may exercise all the powers of the company to borrow money, mortgage
its undertaking, property and uncalled capital, and issue debentures or other securities whenever money is borrowed or as security for
any obligation of the company or of any third party.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of the Board of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established three committees under the board of directors: an audit committee, a compensation committee, and a nominating and corporate
governance committee. We have adopted a charter for each of the three committees. Each committee&#8217;s members and functions are described
below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Committee.</i>&#160;Our audit committee consists of Jiawen Pang, H. David Sherman, and Ding Zheng. H. David Sherman serves as the chairman
of our audit committee. We have determined that Jiawen Pang, H. David Sherman, and Ding Zheng satisfy the &#8220;independence&#8221;
requirements of&#160;Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock Market&#160;and Rule 10A-3 under the Securities Exchange
Act. Our board also has determined that H. David Sherman qualifies as an audit committee financial expert within the meaning of the SEC
rules or possesses financial sophistication within the meaning of the Nasdaq corporate governance rules. The audit committee oversees
our accounting and financial reporting processes and the audits of the financial statements of our company. The audit committee is responsible
for, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing the independent
    auditors and pre-approving all auditing and non-auditing services permitted to be performed by the independent auditors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with the independent
    auditors any audit problems or difficulties and management&#8217;s response;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing the annual audited
    financial statements with management and the independent auditors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the adequacy
    and effectiveness of our accounting and internal control policies and procedures and any steps taken to monitor and control major
    financial risk exposures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving
    all proposed related party transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting separately and
    periodically with management and the independent auditors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring compliance with
    our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
Committee.</i>&#160;Our compensation committee consists of Jiawen Pang, H. David Sherman, and Ding Zheng. Jiawen Pang serves as the chairperson
of our compensation committee. We have determined that Jiawen Pang, H. David Sherman, and Ding Zheng satisfy the &#8220;independence&#8221;
requirements of&#160;Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock Market&#160;and Rule 10C-1 under the Securities Exchange
Act. The compensation committee assists the board in reviewing and approving the compensation structure, including all forms of compensation,
relating to our directors and executive officers. Our chief executive officer may not be present at any committee meeting during which
his compensation is deliberated. The compensation committee is responsible for, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving
    the total compensation package for our most senior executive officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving and overseeing
    the total compensation package for our executives other than the most senior executive officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending
    to the board with respect to the compensation of our directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing periodically
    and approving any long-term incentive compensation or equity plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting compensation
    consultants, legal counsel or other advisors after taking into consideration all factors relevant to that person&#8217;s independence
    from management; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing programs or similar
    arrangements, annual bonuses, employee pension and welfare benefit plans.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nominating
and Corporate Governance Committee.</i>&#160;Our nominating and corporate governance committee consists of Jiawen Pang, H. David Sherman
and Ding Zheng. Ding Zheng serves as the chairperson of our nominating and corporate governance committee. Jiawen Pang, H. David Sherman,
and Ding Zheng satisfy the &#8220;independence&#8221; requirements of&#160;Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock Market.
The nominating and corporate governance committee assists the board of directors in selecting individuals qualified to become our directors
and in determining the composition of the board and its committees. The nominating and corporate governance committee is responsible
for, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying and recommending
    nominees for election or re-election to our board of directors or for appointment to fill any vacancy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing annually with
    our board of directors its current composition in light of the characteristics of independence, age, skills, experience and availability
    of service to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying and recommending
    to our board the directors to serve as members of committees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advising the board periodically
    with respect to significant developments in the law and practice of corporate governance as well as our compliance with applicable
    laws and regulations, and making recommendations to our board of directors on all matters of corporate governance and on any corrective
    action to be taken; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring compliance with
    our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Duties
of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Cayman Islands law, all of our directors owe three types of duties to us: (i) statutory duties, (ii) fiduciary duties, and (iii) common
law duties. The Companies Act (Revised) of the Cayman Islands imposes a number of statutory duties on a director. A Cayman Islands director&#8217;s
fiduciary duties are not codified, however, the courts of the Cayman Islands have held that a director owes the following fiduciary duties:
(a) a duty to act in what the director <i>bona fide</i> considers to be in the best interests of the company, (b) a duty to exercise
their powers for the purposes they were conferred, (c) a duty to avoid fettering his or her discretion in the future and (d) a duty to
avoid conflicts of interest and of duty. The common law duties owed by a director are those to act with skill, care and diligence that
may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company
and, also, to act with the skill, care and diligence in keeping with a standard of care commensurate with any particular skill they have
which enables them to meet a higher standard than a director without those skills. In fulfilling their duty of care to us, our directors
must ensure compliance with our amended and restated articles of association. We have the right to seek damages if a duty owed by any
of our directors is breached.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has all powers necessary for managing, and for directing and supervising, our business affairs. The functions and
powers of our board of directors include, among others:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convening shareholders&#8217;
    annual general meetings and reporting its work to shareholders at such meetings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">declaring dividends and
    distributions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing officers and
    determining the terms of office of the officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercising the borrowing
    powers of our company and mortgaging the property of our Company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving the transfer
    of shares in our Company, including the registration of such shares in our share register.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms
of Directors and Executive Officers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors may be elected by a resolution of our board of directors or by an ordinary resolution of our shareholders. Our directors are
not subject to a term of office and hold office until such time as they are removed from office by ordinary resolution of the shareholders.
A director will cease to be a director if, among other things, the director (i) becomes bankrupt or makes any arrangement or composition
with his creditors; (ii) dies or is found by our company to be or becomes of unsound mind; (iii) resigned his or her office by notice
in writing to the company; or (iv) without special leave of absence from our board, is absent from three consecutive board meetings and
our directors resolve that his office be vacated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers are elected by and serve at the discretion of the board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Qualification</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is currently no shareholding qualification for directors, although a shareholding qualification for directors may be fixed by our shareholders
by ordinary resolution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements and Indemnification Agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into employment agreements with each of our executive officers. Pursuant to these employment agreements, we agree to employ
each of our executive officers for a specified time period, which may be renewed automatically unless either party gives the other party
a two-month prior written notice before the end of the current employment term. We may terminate the employment for cause, at any time,
without notice or remuneration, for certain acts of the executive officer, including but not limited to, the commitments of any serious
or persistent breach or non-observance of the terms and conditions of the employment, conviction of a criminal offense, willful disobedience
of a lawful and reasonable order, fraud or dishonesty, receipt of bribery, or severe neglect of his or her duties. An executive officer
may terminate his or her employment at any time with two months&#8217; prior written notice. Each executive officer agrees to hold, both
during and after the employment agreement expires, in strict confidence and not to use or disclose to any person, corporation or other
entity without written consent, any confidential information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also entered into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree
to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with
claims made by reason of their being a director or officer of our Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Participation Concerning Executive Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
director, Mr. Gang Lai, was making all determinations regarding executive officer compensation from the inception of the Company until
our Compensation Committee was set up in March 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted a code of business conduct and ethics, which is applicable to all of our directors, officers, and employees.
Our code of business conduct and ethics is publicly available on our website.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
<span style="text-decoration:underline">Employees</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Employees.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
<span style="text-decoration:underline">Share Ownership</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to the beneficial ownership, within the meaning of Rule 13d-3 under the Exchange
Act, of our ordinary shares as of the date of this annual report for:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors and
    executive officers; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person known to us
    to own beneficially more than 5% of our ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership includes voting or investment power with respect to the securities. Except as indicated below, and subject to applicable community
property laws, the persons named in the table have sole voting and investment power with respect to all ordinary shares shown as beneficially
owned by them. Percentage of beneficial ownership of each listed person is based on 21,750,000 ordinary shares outstanding as of the
date of this annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to beneficial ownership has been furnished by each director, officer, or beneficial owner of 5% or more of our ordinary
shares. Beneficial ownership is determined in accordance with the rules of the SEC and generally requires that such person have voting
or investment power with respect to securities. In computing the number of ordinary shares beneficially owned by a person listed below
and the percentage ownership of such person, ordinary shares underlying options, warrants, or convertible securities held by each such
person that are exercisable or convertible within 60 days of the date of this annual report are deemed outstanding, but are not deemed
outstanding for computing the percentage ownership of any other person.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary <br/> Shares <br/> Beneficially <br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Voting<br/>
 Power</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors and Executive Officers<sup>*</sup>:</b></span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang Lai<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12,480,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">57.38</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">57.38</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Lin Yang</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Baochang Liu</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Jiawen Pang</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">H. David Sherman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Ding Zheng</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">All directors and executive officers as a group:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,480,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57.38</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57.38</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">5% Shareholders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sununion Holding Group Limited<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,480,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57.38</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57.38</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise indicated,
    the business address of each of our directors and officers is 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development
    Zone, Ji&#8217;an, Jiangxi, People&#8217;s Republic of China.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents 12,480,000 ordinary
    shares held by Sununion Holding Group Limited, a business company incorporated in the British Virgin Islands, which is owned as to
    91.4% and controlled by Gang Lai. The registered address of Sununion Holding Group Limited is Vistra Corporate Services Centre, Wickhams
    Cay II, Road Town, Tortola, VG1110, British Virgin Islands.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, approximately 42.62% of our issued and outstanding ordinary shares are held in the United States by
one record holder (Cede and Company).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any other arrangement that may, at a subsequent date, result in a change of control of our Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
<span style="text-decoration:underline">Major Shareholders</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 6. Directors, Senior Management and Employees&#8212;E. Share Ownership.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
<span style="text-decoration:underline">Related Party Transactions</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 6. Directors, Senior Management and Employees&#8212;C. Board Practices&#8212;Employment Agreements and Indemnification Agreements.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Transactions with Related Parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature
of relationships with related parties</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship
    with the Company</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="border-top: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gang Lai</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-top: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive
    Officer and chairman of the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Lin Yang</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greatest Group (China) Financial Management Limited
    (&#8220;Greatest Group&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One of our minority shareholders</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foshan Shangyu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our affiliated entity, 90% owned by and controlled
    by our CEO, Mr. Gang Lai </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Due
from related parties</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, there was no balances due from related parties. The balance due from related parties as of September 30, 2021
consisted of due from Greatest Group in the amount of $235,438 and due from Foshan Shangyu in the amount of $1,554. The September 30,
2021 due from related parties balance has been subsequently collected back and we do not have any intention to make additional cash advance
to related parties going forward.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Due
to related parties</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022 and 2021, the balances due to related parties were $3,379,263 and $19,723, respectively, which mainly consisted
of advances from our related parties for working capital purposes in our normal course of business. These advances are non-interest bearing
and due on demand. As of September 30, 2022, the balance consisted of balance due to Mr. Gang Lai in the amount of $3,379,263. As of
September 30, 2021, the balance consisted of balance due to Ms. Lin Yang in the amount of $19,723.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prepayment
for purchase of a property </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 6, 2021, we entered into a real estate property purchase agreement with a related party, Jiangxi Yueshang, in which our CEO, Mr.
Gang Lai, owns 5% equity interest. Pursuant to this purchase agreement, Jiangxi Yueshang will sell and we will purchase certain residential
apartments and commercial office space totaling 2,749.30 square meters, with total purchase price of RMB32 million (approximately $4.95
million). Pursuant to this purchase agreement, we were required to make a prepayment in the amount of 50% of the total purchase price,
with 20% of the total purchase price payable when certificate of occupancy is available to us, and 30% of the total purchase price payable
upon delivery of the property.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, we had made a prepayment in the amount of RMB16 million (approximately $2.25 million) to Jiangxi Yueshang. The
remaining balance is expected to be paid by August 2024. Since the property is located at urban downtown of Ji&#8217;an City, we plan
to use the property as our offices by September 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2022, Mr. Gang Lai transferred the 5% equity interest he owned in Jiangxi Yueshang to a third party. As such, after this
date, Jiangxi Yueshang is no longer our related party.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan
guarantee provided by related parties</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our borrowings from LRC Bank, our controlling shareholder and chief executive officer, Mr. Gang Lai, and Foshan Shangyu
jointly signed a guarantee agreement with LRC Bank to provide credit guarantee for our borrowings from LRC Bank.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Company&#8217;s bank borrowings from Bank of Communications, certain related parties of the Company, including Mr.
Gang Lai, the Company&#8217;s controlling shareholder, Mr. Gang Lai&#8217;s spouse, Ms. Xing Wu, and the Company&#8217;s subsidiary,
Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
<span style="text-decoration:underline">Interests of Experts and Counsel</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><div><a id="k_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8. FINANCIAL INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
<span style="text-decoration:underline">Consolidated Statements and Other Financial Information</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have appended consolidated financial statements filed as part of this annual report. See &#8220;Item 18. Financial Statements.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become a party to various legal or administrative proceedings arising in the ordinary course of our business, including
actions with respect to intellectual property infringement, violation of third-party licenses or other rights, breach of contract, and
labor and employment claims. We are currently not a party to, and we are not aware of any threat of, any legal or administrative proceedings
that, in the opinion of our management, are likely to have any material and adverse effect on our business, financial condition, cash
flow, or results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, Universe Pharmaceuticals INC has transferred the net proceeds from our initial public offering, through
Universe HK and Universe Technology, to Jiangxi Universe in the amount of RMB43,976,156 (approximately $6,807,507).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, none of our subsidiaries have made any dividends or distributions to Universe Pharmaceuticals INC
and Universe Pharmaceuticals INC has not made any dividends or distributions to U.S. investors. We intend to keep any future earnings
to finance the expansion of our business, and we do not anticipate that any cash dividends will be paid in the foreseeable future. Subject
to the PFIC rules, the gross amount of distributions we make to investors with respect to our ordinary shares (including the amount of
any taxes withheld therefrom) will be taxable as a dividend, to the extent that the distribution is paid out of our current or accumulated
earnings and profits, as determined under U.S. federal income tax principles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has discretion on whether to distribute dividends. In addition, our shareholders may by ordinary resolution declare
a dividend, but no dividend may exceed the amount recommended by our board of directors. In either case, all dividends are subject to
certain restrictions under Cayman Islands law, namely that the company may only pay dividends out of profits or share premium, and provided
always that in no circumstances may a dividend be paid if this would result in the company being unable to pay its debts as they fall
due in the ordinary course of business. Even if we decide to pay dividends, the form, frequency and amount will depend upon our future
operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that
the board of directors may deem relevant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an exempted company with limited liability incorporated in the Cayman Islands. We may rely on dividends from our subsidiaries in
China for our cash requirements, including any payment of dividends to our shareholders. PRC regulations may restrict the ability of
our PRC subsidiaries to pay dividends to us, and as a holding company, we will be dependent on receipt of funds from our Hong Kong subsidiary,
Universe HK.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
PRC regulations permit our indirect PRC subsidiaries to pay dividends to Universe HK only out of their accumulated profits, if any, determined
in accordance with Chinese accounting standards and regulations. In addition, each of our subsidiaries in China is required to set aside
at least 10% of its after-tax profits each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered
capital. Each of such entity in China is also required to further set aside a portion of its after-tax profits to fund the employee welfare
fund, although the amount to be set aside, if any, is determined at the discretion of its board of directors. Although the statutory
reserves can be used, among other ways, to increase the registered capital and eliminate future losses in excess of retained earnings
of the respective companies, the reserve funds are not distributable as cash dividends except in the event of liquidation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PRC government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of the PRC.
Therefore, we may experience difficulties in complying with the administrative requirements necessary to obtain and remit foreign currency
for the payment of dividends from our profits, if any. Furthermore, if our subsidiaries and affiliates in the PRC incur debt on their
own in the future, the instruments governing the debt may restrict their ability to pay dividends or make other payments. If we or our
subsidiaries are unable to receive all of the revenue from our operations, we may be unable to pay dividends on our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
dividends, if any, on our ordinary shares will be paid in U.S. dollars. Universe HK may be considered a non-resident enterprise for tax
purposes, so that any dividends our PRC subsidiaries pay to Universe HK may be regarded as China-sourced income and as a result may be
subject to PRC withholding tax at a rate of up to 10%. See &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;People&#8217;s
Republic of China Taxation.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order for us to pay dividends to our shareholders, we will rely on payments made from Universe Technology&#8217;s subsidiary, Jiangxi
Universe, to Universe Technology and from Universe Technology to Universe HK and then to our Company. According to the EIT Law, such
payments from subsidiaries to parent companies in China are subject to the PRC enterprise income tax at a rate of 25%. In addition, if
Jiangxi Universe or its subsidiary or branches incur debt on their own behalf in the future, the instruments governing the debt may restrict
its ability to pay dividends or make other distributions to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Double Tax Avoidance Arrangement, the 10% withholding tax rate may be lowered to 5% if a Hong Kong resident enterprise owns no
less than 25% of a PRC project. The 5% withholding tax rate, however, does not automatically apply and certain requirements must be satisfied,
including without limitation that (a) the Hong Kong project must be the beneficial owner of the relevant dividends; and (b) the Hong
Kong project must directly hold no less than 25% share ownership in the PRC project during the 12 consecutive months preceding its receipt
of the dividends. In current practice, a Hong Kong project must obtain a tax resident certificate from the Hong Kong tax authority to
apply for the 5% lower PRC withholding tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case
basis, we cannot assure you that we will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority and
enjoy the preferential withholding tax rate of 5% under the Double Taxation Arrangement with respect to any dividends paid by our PRC
subsidiaries to its immediate holding company, Universe HK. As of the date of this annual report, we have not applied for the tax resident
certificate from the relevant Hong Kong tax authority. Universe HK intends to apply for the tax resident certificate if and when Universe
Technology plan to declare and pay dividends to Universe HK. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212; There are
significant uncertainties under the Enterprise Income Tax Law, or the EIT Law, relating to the withholding tax liabilities of our PRC
subsidiaries, and dividends payable by our PRC subsidiaries to our offshore subsidiaries may not qualify to enjoy certain treaty benefits.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
<span style="text-decoration:underline">Significant Changes</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as disclosed elsewhere in this annual report, we have not experienced any significant changes since the date of our audited consolidated
financial statements included in this annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9. THE OFFER AND LISTING</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
<span style="text-decoration:underline">Offer and Listing Details.</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares have been listed on the Nasdaq Global Market since March 23, 2021 under the symbol &#8220;UPC.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
<span style="text-decoration:underline">Plan of Distribution</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
<span style="text-decoration:underline">Markets</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares have been listed on the Nasdaq Global Market since March 23, 2021 under the symbol &#8220;UPC.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
<span style="text-decoration:underline">Selling Shareholders</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
<span style="text-decoration:underline">Dilution</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
<span style="text-decoration:underline">Expenses of the Issue</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
10. ADDITIONAL INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
<span style="text-decoration:underline">Share Capital</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
<span style="text-decoration:underline">Memorandum and Articles of Association</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an exempted company incorporated under the laws of the Cayman Islands and our affairs are governed by our amended and restated memorandum
and articles of association, as amended and restated from time to time, and Companies Act (As Revised) of the Cayman Islands, which we
refer to as the Companies Act below, and the common law of the Cayman Islands.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference into this annual report the description of our second amended and restated memorandum and articles of association,
which was filed as Exhibit 3.1 to our registration statement on Form F-3 (File No.&#160;333-268028), filed with the SEC on October 27,
2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registered
Office</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
registered office in the Cayman Islands is located at Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West
Bay Road, Grand Cayman, KYI &#8211; 1205 Cayman Islands, and the phone number of our registered office is +1-(345)769-9372.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 6. Directors, Senior Management and Employees.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary
Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our issued and outstanding ordinary shares are fully paid and non-assessable. Our ordinary shares are issued in registered form, and
are issued when registered in our register of members. Unless the board of directors determine otherwise, each holder of our ordinary
shares will not receive a certificate in respect of such ordinary shares. Our shareholders who are non-residents of the Cayman Islands
may freely hold and vote their ordinary shares. We may not issue shares or warrants to bearer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized share capital is $312,500 divided into 90,000,000 ordinary shares, par value $0.003125 per share and 10,000,000 preferred
shares, par value $0.003125 per share. Subject to the provisions of the Companies Act and our articles regarding redemption and purchase
of the shares, the directors have general and unconditional authority to allot (with or without confirming rights of renunciation), grant
options over or otherwise deal with any unissued shares to such persons, at such times and on such terms and conditions as they may decide.
Such authority could be exercised by the directors to allot shares which carry rights and privileges that are preferential to the rights
attaching to ordinary shares. No share may be issued at a discount except in accordance with the provisions of the Companies Act. The
directors may refuse to accept any application for shares, and may accept any application in whole or in part, for any reason or for
no reason.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividends</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of the Companies Act and any rights attaching to any class or classes of shares under and in accordance with the articles:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
directors may declare dividends or distributions out of our funds which are lawfully available for that purpose; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company&#8217;s shareholders may, by ordinary resolution, declare dividends but no such dividend shall exceed the amount recommended
by the directors.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the requirements of the Companies Act regarding the application of a company&#8217;s share premium account and with the sanction of
an ordinary resolution, dividends may also be declared and paid out of any share premium account. The directors when paying dividends
to shareholders may make such payment either in cash or in specie.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
provided by the rights attached to a share, no dividend shall bear interest.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Voting
Rights</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to any rights or restrictions as to voting attached to any shares, unless any share carries special voting rights, on a show of hands
every shareholder who is present in person and every person representing a shareholder by proxy shall have one vote per ordinary share.
On a poll, every shareholder who is present in person and every person representing a shareholder by proxy shall have one vote for each
share of which he or the person represented by proxy is the holder. In addition, all shareholders holding shares of a particular class
are entitled to vote at a meeting of the holders of that class of shares. Votes may be given either personally or by proxy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Variation
of Rights of Shares</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
our capital is divided into different classes of shares, the rights attaching to any class of share (unless otherwise provided by the
terms of issue of the shares of that class) may be varied either with the consent in writing of the holders of not less than two-thirds
of the issued shares of that class, or with the sanction of a resolution passed by a majority of not less than two-thirds of the holders
of shares of the class present in person or by proxy at a separate general meeting of the holders of shares of that class.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the terms on which a class of shares was issued state otherwise, the rights conferred on the shareholder holding shares of any class
shall not be deemed to be varied by the creation or issue of further shares ranking pari passu with the existing shares of that class.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Alteration
of Share Capital</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Companies Act, our shareholders may, by ordinary resolution:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase our share capital
    by new shares of the amount fixed by that ordinary resolution and with the attached rights, priorities and privileges set out in
    that ordinary resolution;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate and divide
    all or any of our share capital into shares of larger amount than our existing shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convert all or any of our
    paid up shares into stock, and reconvert that stock into paid up shares of any denomination;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sub-divide our shares or
    any of them into shares of an amount smaller than that fixed, so, however, that in the sub-division, the proportion between the amount
    paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced
    share is derived; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel shares which, at
    the date of the passing of that ordinary resolution, have not been taken or agreed to be taken by any person and diminish the amount
    of our share capital by the amount of the shares so cancelled or, in the case of shares without nominal par value, diminish the number
    of shares into which our capital is divided.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Companies Act and to any rights for the time being conferred on the shareholders holding a particular class of shares, our shareholders
may, by special resolution, reduce its share capital in any way.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Calls
on Shares and Forfeiture</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of allotment, the directors may make calls on the shareholders in respect of any monies unpaid on their shares including
any premium and each shareholder shall (subject to receiving at least 14 clear days&#8217; notice specifying when and where payment is
to be made), pay to us the amount called on his shares. Shareholders registered as the joint holders of a share shall be jointly and
severally liable to pay all calls in respect of the share. If a call remains unpaid after it has become due and payable the person from
whom it is due and payable shall pay interest on the amount unpaid from the day it became due and payable until it is paid at the rate
fixed by the terms of allotment of the share or in the notice of the call or if no rate is fixed, at the rate of ten percent per annum.
The directors may, at their discretion, waive payment of the interest wholly or in part.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a first and paramount lien on all shares (whether fully paid up or not) registered in the name of a shareholder (whether solely
or jointly with others). The lien is for all monies payable to us by the shareholder or the shareholder&#8217;s estate:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">either alone or jointly with any other person, whether
    or not that other person is a shareholder; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not those monies are presently payable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any time the directors may declare any share to be wholly or partly exempt from the lien on shares provisions of the articles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell, in such manner as the directors may determine, any share on which the sum in respect of which the lien exists is presently
payable, if due notice that such sum is payable has been given (as prescribed by the articles) and, within 14 days of the date on which
the notice is deemed to be given under the articles, such notice has not been complied with.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unclaimed
Dividend</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
dividend that remains unclaimed for a period of six years after it became due for payment shall be forfeited to, and shall cease to remain
owing by, the company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Forfeiture
or Surrender of Shares</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a shareholder fails to pay any capital call, the directors may give to such shareholder not less than 14 clear days&#8217; notice requiring
payment and specifying the amount unpaid including any interest which may have accrued, any expenses which have been incurred by us due
to that person&#8217;s default and the place where payment is to be made. The notice shall also contain a warning that if the notice
is not complied with, the shares in respect of which the call is made will be liable to be forfeited.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
such notice is not complied with, the directors may, before the payment required by the notice has been received, resolve that any share
the subject of that notice be forfeited (which forfeiture shall include all dividends or other monies payable in respect of the forfeited
share and not paid before such forfeiture).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
forfeited share may be sold, re-allotted or otherwise disposed of on such terms and in such manner as the directors determine and at
any time before a sale, re-allotment or disposition the forfeiture may be cancelled on such terms as the directors think fit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person whose shares have been forfeited shall cease to be a shareholder in respect of the forfeited shares, but shall, notwithstanding
such forfeiture, remain liable to pay to us all monies which at the date of forfeiture were payable by him to us in respect of the shares,
together with all expenses and interest from the date of forfeiture or surrender until payment, but his liability shall cease if and
when we receive payment in full of the unpaid amount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
declaration, whether statutory or under oath, made by a director or the secretary shall be conclusive evidence that the person making
the declaration is our director or secretary and that the particular shares have been forfeited or surrendered on a particular date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the execution of an instrument of transfer, if necessary, the declaration shall constitute good title to the shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share
Premium Account</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
directors shall establish a share premium account and shall carry the credit of such account from time to time to a sum equal to the
amount or value of the premium paid on the issue of any share or capital contributed or such other amounts required by the Companies
Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Redemption
and Purchase of Own Shares</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Companies Act and any rights for the time being conferred on the shareholders holding a particular class of shares, we may by
action of our directors:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue shares that are to
    be redeemed or liable to be redeemed, at our option or the shareholder holding those redeemable shares, on the terms and in the manner
    our directors determine before the issue of those shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with the consent by special
    resolution of the shareholders holding shares of a particular class, vary the rights attaching to that class of shares so as to provide
    that those shares are to be redeemed or are liable to be redeemed at our option on the terms and in the manner which the directors
    determine at the time of such variation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchase all or any of
    our own shares of any class including any redeemable shares on the terms and in the manner which the directors determine at the time
    of such purchase.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may make a payment in respect of the redemption or purchase of its own shares in any manner authorized by the Companies Act, including
out of any combination of capital, our profits and the proceeds of a fresh issue of shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
making a payment in respect of the redemption or purchase of shares, the directors may make the payment in cash or in specie (or partly
in one and partly in the other) if so authorized by the terms of the allotment of those shares or by the terms applying to those shares,
or otherwise by agreement with the shareholder holding those shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transfer
of Shares</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provided
that a transfer of ordinary shares complies with applicable rules of Nasdaq, a shareholder may transfer ordinary shares to another person
by completing an instrument of transfer in a common form or in a form prescribed by Nasdaq or in any other form approved by the directors,
executed:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the ordinary shares are fully paid, by or on
    behalf of that shareholder; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the ordinary shares are partly paid, by or on
    behalf of that shareholder and the transferee.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transferor shall be deemed to remain the holder of an ordinary share until the name of the transferee is entered into the register of
members of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share that has not been fully paid
up or is subject to a company lien. Our board of directors may also decline to register any transfer of such ordinary share unless:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer
    is lodged with the Company, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as
    our board of directors may reasonably require to show the right of the transferor to make the transfer;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer
    is in respect of only one class of ordinary shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer
    is properly stamped, if required;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ordinary shares transferred
    is fully paid and free of any lien in favor of us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fee related to the
    transfer has been paid to us; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the transfer is not to
    more than four joint holders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our directors refuse to register a transfer, they are required, within three months after the date on which the instrument of transfer
was lodged, to send to each of the transferor and the transferee notice of such refusal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This,
however, is unlikely to affect market transactions of the ordinary shares purchased by investors in the public offering. The legal title
to such ordinary shares and the registration details of those ordinary shares in the Company&#8217;s register of members will remain
with Depository Trust Company (&#8220;DTC&#8221;). All market transactions with respect to those ordinary shares will then be carried
out without the need for any kind of registration by the directors, as the market transactions will all be conducted through the DTC
systems.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registration of transfers may, on 14 calendar days&#8217; notice being given by advertisement in such one or more newspapers or by electronic
means, be suspended and our register of members closed at such times and for such periods as our board of directors may from time to
time determine. The registration of transfers, however, may not be suspended, and the register may not be closed, for more than 30 days
in any year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inspection
of Books and Records</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our ordinary shares will have no general right under the Companies Act to inspect or obtain copies of our register of members or our
corporate records.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
Meetings</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Cayman Islands exempted company, we are not obligated by the Companies Act to call shareholders&#8217; annual general meetings; accordingly,
we may, but shall not be obliged to, in each year hold a general meeting as an annual general meeting. Any annual general meeting held
shall be held at such time and place as may be determined by our board of directors. All general meetings other than annual general meetings
shall be called extraordinary general meetings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
directors may convene general meetings whenever they think fit. General meetings shall also be convened on the written requisition of
one or more of the shareholders entitled to attend and vote at our general meetings who (together) hold not less than ten percent of
the rights to vote at such general meeting in accordance with the notice provisions in the articles, specifying the purpose of the meeting
and signed by each of the shareholders making the requisition. If the directors do not convene such meeting for a date not later than
21 clear days&#8217; after the date of receipt of the written requisition, those shareholders who requested the meeting may convene the
general meeting themselves within three months after the end of such period of 21 clear days in which case reasonable expenses incurred
by them as a result of the directors failing to convene a meeting shall be reimbursed by us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
least 14 days&#8217; notice of an extraordinary general meeting and 21 days&#8217; notice of an annual general meeting shall be given
to shareholders entitled to attend and vote at such meeting. The notice shall specify the place, the day and the hour of the meeting
and the general nature of that business. In addition, if a resolution is proposed as a special resolution, the text of that resolution
shall be given to all shareholders. Notice of every general meeting shall also be given to the directors and our auditors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Companies Act and with the consent of the shareholders who, individually or collectively, hold at least 90 percent of the voting
rights of all those who have a right to vote at a general meeting, a general meeting may be convened on shorter notice.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
quorum shall consist of the presence (whether in person or represented by proxy) of one or more shareholders holding shares that represent
not less than one-third of the outstanding shares carrying the right to vote at such general meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
within 15 minutes from the time appointed for the general meeting, or at any time during the meeting, a quorum is not present, the meeting,
if convened upon the requisition of shareholders, shall be cancelled. In any other case it shall stand adjourned to the same time and
place seven days or to such other time or place as is determined by the directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chairman may, with the consent of a meeting at which a quorum is present, adjourn the meeting. When a meeting is adjourned for seven
days or more, notice of the adjourned meeting shall be given in accordance with the articles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any general meeting a resolution put to the vote of the meeting shall be decided on a show of hands, unless a poll is (before, or on,
the declaration of the result of the show of hands) demanded by the chairman of the meeting or by at least two shareholders having the
right to vote on the resolutions or one or more shareholders present who together hold not less than ten percent of the voting rights
of all those who are entitled to vote on the resolution. Unless a poll is so demanded, a declaration by the chairman as to the result
of a resolution and an entry to that effect in the minutes of the meeting, shall be conclusive evidence of the outcome of a show of hands,
without proof of the number or proportion of the votes recorded in favor of, or against, that resolution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a poll is duly demanded it shall be taken in such manner as the chairman directs and the result of the poll shall be deemed to be the
resolution of the meeting at which the poll was demanded.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of an equality of votes, whether on a show of hands or on a poll, the chairman of the meeting at which the show of hands takes
place or at which the poll is demanded, shall not be entitled to a second or casting vote.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Directors</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may by ordinary resolution, from time to time, fix the maximum and minimum number of directors to be appointed. Under the articles, we
are required to have a minimum of one director and the maximum number of directors shall be unlimited.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director may be appointed by ordinary resolution or by the directors. Any appointment may be to fill a vacancy or as an additional director.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the remuneration of the directors is determined by the shareholders by ordinary resolution, the directors shall be entitled to such remuneration
as the directors may determine.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shareholding qualification for directors may be fixed by our shareholders by ordinary resolution and unless and until so fixed no share
qualification shall be required.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
removed or re-appointed, each director shall be appointed for a term expiring at the next-following annual general meeting, if one is
held. At any annual general meeting held, our directors will be elected by an ordinary resolution of our shareholders. At each annual
general meeting, each director so elected shall hold office for a one-year term and until the election of their respective successors
in office or removed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director may be removed by ordinary resolution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director may at any time resign or retire from office by giving us notice in writing. Unless the notice specifies a different date, the
director shall be deemed to have resigned on the date that the notice is delivered to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of the articles, the office of a director may be terminated forthwith if:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is prohibited by the law of the Cayman Islands from
    acting as a director;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is made bankrupt or makes an arrangement or composition
    with his creditors generally;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he resigns his office by notice to us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he only held office as a director for a fixed term
    and such term expires;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the opinion of a registered
    medical practitioner by whom he is being treated he becomes physically or mentally incapable of acting as a director;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is given notice by the
    majority of the other directors (not being less than two in number) to vacate office (without prejudice to any claim for damages
    for breach of any agreement relating to the provision of the services of such director);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is made subject to any
    law relating to mental health or incompetence, whether by court order or otherwise; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">without the consent of
    the other directors, he is absent from meetings of directors for continuous period of six months.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the compensation committee and the nominating and corporate governance committee shall consist of at least three directors and the
majority of the committee members shall be independent within the meaning of Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock
Market. The audit committee shall consist of at least three directors, all of whom shall be independent within the meaning of Rule 5605(a)(2)
of the Listing Rules of the Nasdaq Stock Market and will meet the criteria for independence set forth in Rule 10A-3 or Rule 10C-1 of
the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Powers
and Duties of Directors</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of the Companies Act and our memorandum and articles of association, our business shall be managed by the directors,
who may exercise all our powers. No prior act of the directors shall be invalidated by any subsequent alteration of our memorandum or
articles of association. To the extent allowed by the Companies Act, however, shareholders may by special resolution validate any prior
or future act of the directors which would otherwise be in breach of their duties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
directors may delegate any of their powers to any committee consisting of one or more persons who need not be shareholders and may include
non-directors so long as the majority of those persons are directors; any committee so formed shall in the exercise of the powers so
delegated conform to any regulations that may be imposed on it by the directors. Our board of directors have established an audit committee,
compensation committee, and nomination and corporate governance committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors may establish any local or divisional board of directors or agency and delegate to it its powers and authorities (with
power to sub-delegate) for managing any of our affairs whether in the Cayman Islands or elsewhere and may appoint any persons to be members
of a local or divisional board of directors, or to be managers or agents, and may fix their remuneration.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
directors may from time to time and at any time by power of attorney or in any other manner they determine appoint any person, either
generally or in respect of any specific matter, to be our agent with or without authority for that person to delegate all or any of that
person&#8217;s powers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
directors may from time to time and at any time by power of attorney or in any other manner they determine appoint any person, whether
nominated directly or indirectly by the directors, to be our attorney or our authorized signatory and for such period and subject to
such conditions as they may think fit. The powers, authorities and discretions, however, must not exceed those vested in, or exercisable,
by the directors under the articles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors may remove any person so appointed and may revoke or vary the delegation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
directors may exercise all of our powers to borrow money and to mortgage or charge its undertaking, property and assets both present
and future and uncalled capital or any part thereof, to issue debentures and other securities whether outright or as collateral security
for any debt, liability or obligation of ours or our parent undertaking (if any) or any subsidiary undertaking of us or of any third
party.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director shall not, as a director, vote in respect of any contract, transaction, arrangement or proposal in which he has an interest
which (together with any interest of any person connected with him) is a material interest (otherwise than by virtue of his interests,
direct or indirect, in shares or debentures or other securities of, or otherwise in or through, us) and if he shall do so his vote shall
not be counted, nor in relation thereto shall he be counted in the quorum present at the meeting, but (in the absence of some other material
interest than is mentioned below) none of these prohibitions shall apply to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the giving of any security,
    guarantee or indemnity in respect of:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">money lent or obligations
    incurred by him or by any other person for our benefit or any of our subsidiaries; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a debt or obligation of
    ours or any of our subsidiaries for which the director himself has assumed responsibility in whole or in part and whether alone or
    jointly with others under a guarantee or indemnity or by the giving of security;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where we or any of our
    subsidiaries is offering securities in which offer the director is or may be entitled to participate as a holder of securities or
    in the underwriting or sub-underwriting of which the director is to or may participate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any contract, transaction,
    arrangement or proposal affecting any other body corporate in which he is interested, directly or indirectly and whether as an officer,
    shareholder, creditor or otherwise howsoever, provided that he (together with persons connected with him) does not to his knowledge
    hold an interest representing one percent or more of any class of the equity share capital of such body corporate (or of any third
    body corporate through which his interest is derived) or of the voting rights available to shareholders of the relevant body corporate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any act or thing done or
    to be done in respect of any arrangement for the benefit of the employees of us or any of our subsidiaries under which he is not
    accorded as a director any privilege or advantage not generally accorded to the employees to whom such arrangement relates; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any matter connected with
    the purchase or maintenance for any director of insurance against any liability or (to the extent permitted by the Companies Act)
    indemnities in favor of directors, the funding of expenditure by one or more directors in defending proceedings against him or them
    or the doing of anything to enable such director or directors to avoid incurring such expenditure.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director may, as a director, vote (and be counted in the quorum) in respect of any contract, transaction, arrangement or proposal in
which he has an interest which is not a material interest or as described above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capitalization
of Profits</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
directors may resolve to capitalize:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any part of our profits not required for paying any
    preferential dividend (whether or not those profits are available for distribution); or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any sum standing to the credit of our share premium
    account or capital redemption reserve, if any.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount resolved to be capitalized must be appropriated to the shareholders who would have been entitled to it had it been distributed
by way of dividend and in the same proportions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidation
Rights</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are wound up, the shareholders may, subject to the articles and any other sanction required by the Companies Act, pass a special resolution
allowing the liquidator to do either or both of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to divide in specie among
    the shareholders the whole or any part of our assets and, for that purpose, to value any assets and to determine how the division
    shall be carried out as between the shareholders or different classes of shareholders; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to vest the whole or any
    part of the assets in trustees for the benefit of shareholders and those liable to contribute to the winding up.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
directors have the authority to present a petition for our winding up to the Grand Court of the Cayman Islands on our behalf without
the sanction of a resolution passed at a general meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Register
of Members</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Act, we must keep a register of members and there should be entered therein:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the names and addresses
    of our shareholders, a statement of the shares held by each shareholder, and of the amount paid or agreed to be considered as paid,
    on the shares of each shareholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the name
    of any person was entered on the register as a shareholder; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which any person
    ceased to be a shareholder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Act, the register of members of our company is prima facie evidence of the matters set out therein (that is, the register
of members will raise a presumption of fact on the matters referred to above unless rebutted) and a shareholder registered in the register
of members is deemed as a matter of the Companies Act to have legal title to the shares as set against its name in the register of members.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the name of any person is incorrectly entered in or omitted from our register of members, or if there is any default or unnecessary delay
in entering on the register the fact of any person having ceased to be a shareholder of our company, the person or shareholder aggrieved
(or any shareholder of our company or our company itself) may apply to the Grand Court of the Cayman Islands for an order that the register
be rectified, and the Court may either refuse such application or it may, if satisfied of the justice of the case, make an order for
the rectification of the register.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
directors are empowered to designate and issue from time to time one or more classes or series of preference shares and to fix and determine
the relative rights, preferences, designations, qualifications, privileges, options, conversion rights, limitations and other special
or relative rights of each such class or series so authorized. Such action could adversely affect the voting power and other rights of
the holders of our ordinary shares or could have the effect of discouraging any attempt by a person or group to obtain control of us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, no preferred shares are issued and outstanding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
<span style="text-decoration:underline">Material Contracts</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not entered into any material contracts other than in the ordinary course of business and other than those described in &#8220;Item
4. Information on the Company&#8221; or elsewhere in this annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
<span style="text-decoration:underline">Exchange Controls</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Regulations&#8212;Other Laws&#8212;Foreign Exchange Control.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
<span style="text-decoration:underline">Taxation</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>People&#8217;s
Republic of China Taxation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following brief description of Chinese enterprise laws is designed to highlight the enterprise-level taxation on our earnings, which
will affect the amount of dividends, if any, we are ultimately able to pay to our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Enterprise
Income Tax</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Enterprise Income Tax Law of the People&#8217;s Republic of China, or the EIT Law, which was promulgated by the SCNPC on March
16, 2007, and became effective on January 1, 2008, and then amended on February 24, 2017, and the Implementation Rules of the EIT Law,
or the Implementation Rules, which were promulgated by the State Council on December 6, 2007, effective on January 1, 2008, and amended
on April 23, 2019, enterprises are divided into resident enterprises and non-resident enterprises. Resident enterprises pay enterprise
income tax on their incomes obtained in and outside the PRC at the rate of 25%. Non-resident enterprises setting up institutions in the
PRC pay enterprise income tax on the incomes obtained by such institutions in and outside the PRC at the rate of 25%. Non-resident enterprises
with no institutions in the PRC, and non-resident enterprises with income having no substantial connection with their institutions in
the PRC, pay enterprise income tax on their income obtained in the PRC at a reduced rate of 10%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an exempted company incorporated with limited liability in the Cayman Islands and we gain substantial income by way of dividends
paid to us from our PRC subsidiaries, Universe Technology, Jiangxi Universe, and Universe Trade. The EIT Law and its implementation rules
provide that China-sourced income of foreign enterprises, such as dividends paid by a PRC subsidiary to its equity holders that are non-resident
enterprises, will normally be subject to PRC withholding tax at a rate of 10%, unless any such foreign investor&#8217;s jurisdiction
of incorporation has a tax treaty with China that provides for a preferential tax rate or a tax exemption.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the EIT Law, an enterprise established outside of China with a &#8220;de facto management body&#8221; within China is considered a &#8220;resident
enterprise,&#8221; which means that it is treated in a manner similar to a Chinese enterprise for enterprise income tax purposes. Although
the implementation rules of the EIT Law define &#8220;de facto management body&#8221; as a managing body that actually, comprehensively
manage and control the production and operation, staff, accounting, property and other aspects of an enterprise, the only official guidance
for this definition currently available is set forth in SAT Notice 82, which provides guidance on the determination of the tax residence
status of a Chinese-controlled offshore incorporated enterprise, defined as an enterprise that is incorporated under the laws of a foreign
country or territory and that has a PRC enterprise or enterprise group as its primary controlling shareholder. Although Universe INC
does not have a PRC enterprise or enterprise group as our primary controlling shareholder and is therefore not a Chinese-controlled offshore
incorporated enterprise within the meaning of SAT Notice 82, in the absence of guidance specifically applicable to us, we have applied
the guidance set forth in SAT Notice 82 to evaluate the tax residence status of Universe INC and its subsidiaries organized outside the
PRC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to SAT Notice 82, a Chinese-controlled offshore incorporated enterprise will be regarded as a PRC tax resident by virtue of having a
&#8220;de facto management body&#8221; in China and will be subject to PRC enterprise income tax on its worldwide income only if all
of the following criteria are met: (i) the places where senior management and senior management departments that are responsible for
daily production, operation and management of the enterprise perform their duties are mainly located within the territory of China; (ii)
financial decisions (such as money borrowing, lending, financing and financial risk management) and personnel decisions (such as appointment,
dismissal and salary and wages) are decided or need to be decided by organizations or persons located within the territory of China;
(iii) main property, accounting books, corporate seal, the board of directors and files of the minutes of shareholders&#8217; meetings
of the enterprise are located or preserved within the territory of China; and (iv) one half (or more) of the directors or senior management
staff having the right to vote habitually reside within the territory of China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we do not meet some of the conditions outlined in the immediately preceding paragraph. For example, as a holding company,
the key assets and records of Universe INC, including the resolutions and meeting minutes of our board of directors and the resolutions
and meeting minutes of our shareholders, are located and maintained outside the PRC. In addition, we are not aware of any offshore holding
companies with a corporate structure similar to ours that has been deemed a PRC &#8220;resident enterprise&#8221; by the PRC tax authorities.
Accordingly, we believe that Universe INC and its offshore subsidiaries should not be treated as a &#8220;resident enterprise&#8221;
for PRC tax purposes if the criteria for &#8220;de facto management body&#8221; as set forth in SAT Notice 82 were deemed applicable
to us. However, as the tax residency status of an enterprise is subject to determination by the PRC tax authorities and uncertainties
remain with respect to the interpretation of the term &#8220;de facto management body&#8221; as applicable to our offshore entities,
we will continue to monitor our tax status.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
implementation rules of the EIT law provides that, (i) if the enterprise that distributes dividends is domiciled in the PRC or (ii) if
gains are realized from transferring equity interests of enterprises domiciled in the PRC, then such dividends or gains are treated as
China-sourced income. It is not clear how &#8220;domicile&#8221; may be interpreted under the EIT Law, and it may be interpreted as the
jurisdiction where the enterprise is a tax resident. Therefore, if we are considered as a PRC tax resident enterprise for PRC tax purposes,
any dividends we pay to our overseas shareholders which are non-resident enterprises as well as gains realized by such shareholders from
the transfer of our shares may be regarded as China-sourced income and as a result become subject to PRC withholding tax at a rate of
up to 10%. AllBright Law Offices (Fuzhou), our PRC counsel, is unable to provide a &#8220;will&#8221; opinion because it believes that
it is more likely than not that we and our offshore subsidiaries would be treated as non-resident enterprises for PRC tax purposes because
we do not meet some of the conditions outlined in SAT Notice 82. In addition, AllBright Law Offices (Fuzhou) is not aware of any offshore
holding companies with a corporate structure similar to ours that has been deemed a PRC &#8220;resident enterprise&#8221; by the PRC
tax authorities as of the date of this annual report. Therefore, AllBright Law Offices (Fuzhou) believes that it is possible but highly
unlikely that the income received by our overseas shareholders will be regarded as China-sourced income. See &#8220;Item 3. Key Information&#8212;Risk
Factors&#8212;Risks Related to Doing Business in China&#8212;Under the EIT Law, we may be classified as a &#8216;Resident Enterprise&#8217;
of China. Such classification will likely result in unfavorable tax consequences to us and our non-PRC shareholders.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
as resident enterprises in the PRC, Universe Technology as well as Jiangxi Universe and its subsidiaries in PRC are subject to the enterprise
income tax at the rate of 25%, except that once an enterprise meets certain requirements and is identified as a small-scale minimal profit
enterprise, the part of its taxable income not more than RMB1 million is subject to a reduced rate of 5% and the part between RMB1 million
and 3 million is subject to a reduced rate of 10%. The EIT is calculated based on the entity&#8217;s global income as determined under
PRC tax laws and accounting standards. If the PRC tax authorities determine that Jiangxi Universe is a PRC resident enterprise for enterprise
income tax purposes, we may be required to withhold a 10% withholding tax from dividends we pay to our shareholders that are non-resident
enterprises. In addition, non-resident enterprise shareholders may be subject to a 10% PRC withholding tax on gains realized on the sale
or other disposition of our ordinary shares, if such income is treated as sourced from within the PRC. It is unclear whether our non-PRC
individual shareholders would be subject to any PRC tax on dividends or gains obtained by such non-PRC individual shareholders in the
event we are determined to be a PRC resident enterprise. If any PRC tax were to apply to dividends or gains realized by non-PRC individuals,
it would generally apply at a rate of 20% unless a reduced rate is available under an applicable tax treaty. However, it is also unclear
whether our non-PRC shareholders would be able to claim the benefits of any tax treaties between their country of tax residence and the
PRC in the event that we are treated as a PRC resident enterprise. There is no guidance from the PRC government to indicate whether or
not any tax treaties between the PRC and other countries would apply in circumstances where a non-PRC company was deemed to be a PRC
tax resident, and thus there is no basis for expecting how tax treaty between the PRC and other countries may impact non-resident enterprises.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Value-added
Tax</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Provisional Regulations on Value-Added Tax of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22686;&#20540;&#31246;&#26242;&#34892;&#26465;&#20363;&#12299;),
or the VAT Regulations, which were promulgated by the State Council on December 13, 1993, and amended on November 10, 2008, February
6, 2016, and November 19, 2017, respectively, and the Implementation Rules of the Provisional Regulations on Value Added Tax of the PRC
(&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22686;&#20540;&#31246;&#26242;&#34892;&#26465;&#20363;&#23454;&#26045;&#32454;&#21017;&#12299;)
promulgated by the MOF on December 25, 1993 and amended on December 15, 2008 and October 28, 2011, respectively, entities and individuals
that sell goods or labor services of processing, repair or replacement, sell services, intangible assets, or immovables, or import goods
within the territory of the People&#8217;s Republic of China are taxpayers of value-added tax.&#160;The VAT rate is 17% for taxpayers
selling goods, labor services, or tangible movable property leasing services or importing goods, except otherwise specified; 11% for
taxpayers selling goods, labor services, or tangible movable property leasing services or importing goods, except otherwise specified;
6% for taxpayers selling services or intangible assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to Provisions in the Notice on Adjusting the Value added Tax Rates (Cai Shui [2018] No. 32), or the Notice, issued by the SAT and the
MOF, where taxpayers make VAT taxable sales or import goods, the applicable tax rates shall be adjusted from 17% to 16% and from 11%
to 10%, respectively. The Notice took effect on May 1, 2018, and the adjusted VAT rates took effect at the same time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2016, the MOF and the SAT jointly issued the Circular of Full Implementation of Business Tax to VAT Reform (the &#8220;Circular
36&#8221;) (&#12298;&#20851;&#20110;&#20840;&#38754;&#25512;&#24320;&#33829;&#19994;&#31246;&#25913;&#24449;&#22686;&#20540;&#31246;&#35797;&#28857;&#30340;&#36890;&#30693;&#12299;),
which confirms that business tax will be completely replaced by VAT from May 1, 2016. The Notice of the MOF and the SAT on the Adjustment
to VAT Rates (&#12298;&#20851;&#20110;&#35843;&#25972;&#22686;&#20540;&#31246;&#31246;&#29575;&#30340;&#36890;&#30693;&#12299;), promulgated
on April 4, 2018 and effective as of May 1, 2018, adjusted the applicative rate of VAT. The deduction rates of 17% and 11% applicable
to the taxpayers who have VAT taxable sales activities or imported goods are adjusted to 16% and 10%, respectively. For the export goods
to which a tax rate of 17% was originally applicable and the export rebate rate was 17%, the export rebate rate is adjusted to 16%. For
the export goods and cross-border taxable activities to which a tax rate of 11% was originally applicable and the export rebate rate
was 11%, the export rebate rate is adjusted to 10%. Pursuant to such circular, the Value Added Tax Pilot Program has been applicable
nationwide since May 1, 2016.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequently,
the Notice on Policies for Deepening Reform of Value-added Tax was issued by the SAT, the MOF and the General Administration of Customs
on March 30, 2019 and took effective on April 1, 2019, which further adjusted the applicable tax rate for taxpayers making VAT taxable
sales or importing goods. The applicable tax rates shall be adjusted from 16% to 13% and from 10% to 9%, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the VAT Regulations and the related rules, as of the date of this annual report, as taxpayers selling goods, Jiangxi Universe and
its consolidated affiliated entities are generally subject to 13% VAT rate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Withholding Tax</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Arrangement between Mainland China and Hong Kong for the Avoidance of Double Taxation and Prevention of Fiscal Evasion with respect
to Taxes on Income (&#12298;&#20869;&#22320;&#21644;&#39321;&#28207;&#29305;&#21035;&#34892;&#25919;&#21306;&#20851;&#20110;&#25152;&#24471;&#31246;&#36991;&#20813;&#21452;&#37325;&#24449;&#31246;&#21644;&#38450;&#27490;&#20599;&#31246;&#28431;&#31246;&#30340;&#23433;&#25490;&#12299;)
effective on August 21, 2006, no more than 5% withholding tax rate applies to dividends paid by a PRC company to a Hong Kong resident,
provided that the recipient is a company that holds at least 25% of the capital of the PRC company. The 10% withholding tax rate applies
to dividends paid by a PRC company to a Hong Kong resident if the recipient is a company that holds less than 25% of the capital of the
PRC company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
pursuant to the Notice of the SAT on Issues Relating to the Implementation of Dividend Clauses in Tax Treaties (Guo Shui Han [2009] No.81)
(&#12298;&#22269;&#23478;&#31246;&#21153;&#24635;&#23616;&#20851;&#20110;&#25191;&#34892;&#31246;&#25910;&#21327;&#23450;&#32929;&#24687;&#26465;&#27454;&#26377;&#20851;&#38382;&#39064;&#30340;&#36890;&#30693;&#12299;&#65288;&#22269;&#31246;&#20989;[2009]
81&#21495;&#65289;), which was promulgated and effective on February 20, 2009, all of the following requirements should be satisfied
where a fiscal resident of the other party to the tax agreement needs to be entitled to such tax agreement treatment as being taxed at
a tax rate specified in the tax agreement for the dividends paid to it by a PRC resident company: (1) such a fiscal resident who obtains
dividends should be a company as provided in the tax agreement; (2) owner&#8217;s equity interests and voting shares of the PRC resident
company directly owned by such a fiscal resident reaches a specified percentage; and (3) the equity interests of the PRC resident company
directly owned by such a fiscal resident, at any time during the 12 months prior to the acquisition of the dividends, reaches a percentage
specified in the tax agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, according to the Administrative Measures on Non-resident Taxpayers Enjoying Treaty Benefits (&#12298;&#38750;&#23621;&#27665;&#32435;&#31246;&#20154;&#20139;&#21463;&#21327;&#23450;&#24453;&#36935;&#31649;&#29702;&#21150;&#27861;&#12299;)
promulgated by the SAT on October 14, 2019 and became effective on January 1, 2020, non-resident taxpayers claiming treaty benefits shall
adhere to the principle of &#8220;self-assessment, claiming benefits, retention of the relevant materials for future inspection.&#8221;
Where a non-resident taxpayer self-assesses and concludes that it satisfies the criteria for claiming treaty benefits, it may enjoy treaty
benefits at the time of tax declaration or withholding. However such non-resident taxpayers shall retain relevant tax-reporting materials
pursuant to the provisions of these Measures for potential future inspection, and accept follow-up administration by relevant tax authorities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, when considered as a non-PRC resident investor, which is much more likely to happen than not, Universe
HK shall be subject to the dividend withholding tax at the rate of 10%. Upon identified as the Hong Kong resident enterprise stipulated
by the Double Tax Avoidance Arrangement and other applicable laws, the withholding tax may be reduced to 5%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hong
Kong Taxation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
incorporated in Hong Kong are subject to profits tax in Hong Kong at the rate of 16.5% for each of the fiscal years ended September 30,
2022, 2021 and 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>United
States Federal Income Taxation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following does not address the tax consequences to any particular investor or to persons in special tax situations such as:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial institutions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulated investment companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment
    trusts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that elect to mark
    their securities to market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. expatriates or former
    long-term residents of the U.S.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">governments or agencies
    or instrumentalities thereof;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt entities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons liable for alternative
    minimum tax;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our ordinary
    shares as part of a straddle, hedging, conversion or integrated transaction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that actually or
    constructively own 10% or more of our voting power or value (including by reason of owning our ordinary shares);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who acquired our
    ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our ordinary
    shares through partnerships or other pass-through entities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">beneficiaries of a Trust
    holding our ordinary shares; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our ordinary
    shares through a Trust.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discussion set forth below is addressed only to U.S. Holders that purchase our ordinary shares. Prospective purchasers are urged to consult
their own tax advisors about the application of the U.S. federal income tax rules to their particular circumstances as well as the state,
local, foreign, and other tax consequences to them of the purchase, ownership, and disposition of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Material
Tax Consequences Applicable to U.S. Holders of Our Ordinary Shares</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following sets forth the material U.S. federal income tax consequences related to the ownership and disposition of our ordinary shares.
It is directed to U.S. Holders (as defined below) of our ordinary shares and is based upon laws and relevant interpretations thereof
in effect as of the date of this annual report, all of which are subject to change. This description does not deal with all possible
tax consequences relating to ownership and disposition of our ordinary shares or U.S. tax laws, other than the U.S. federal income tax
laws, such as the tax consequences under non-U.S. tax laws, state, local, and other tax laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following brief description applies only to U.S. Holders (defined below) that hold ordinary shares as capital assets and that have the
U.S. dollar as their functional currency. This brief description is based on the federal income tax laws of the United States in effect
as of the date of this annual report and on U.S. Treasury regulations in effect or, in some cases, proposed, as of the date of this annual
report, as well as judicial and administrative interpretations thereof available on or before such date. All of the foregoing authorities
are subject to change, which change could apply retroactively and could affect the tax consequences described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
brief description below of the U.S. federal income tax consequences to &#8220;U.S. Holders&#8221; will apply to you if you are a beneficial
owner of ordinary shares and you are, for U.S. federal income tax purposes,</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a
    citizen or resident of the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other
    entity taxable as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof
    or the District of Columbia;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate whose income
    is subject to U.S. federal income taxation regardless of its source; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    trust that (1) is subject to the primary supervision of a court within the United States and the control of one or more U.S. persons
    for all substantial decisions or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a
    U.S. person.</span></p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    a partnership (or other entity treated as a partnership for United&#160;States federal income tax purposes) is a beneficial owner
    of our ordinary shares, the tax treatment of a partner in the partnership will depend upon the status of the partner and the activities
    of the partnership. Partnerships and partners of a partnership holding our ordinary shares are urged to consult their tax advisors
    regarding an investment in our ordinary shares.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Taxation
of Dividends and Other Distributions on Our Ordinary Shares</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the PFIC rules discussed below, the gross amount of distributions made by us to you with respect to the ordinary shares (including
the amount of any taxes withheld therefrom) will generally be includable in your gross income as dividend income on the date of receipt
by you, but only to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined under
U.S. federal income tax principles). With respect to corporate U.S. Holders, the dividends will not be eligible for the dividends-received
deduction allowed to corporations in respect of dividends received from other U.S. corporations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to non-corporate U.S. Holders, including individual U.S. Holders, dividends will be taxed at the lower capital gains rate applicable
to qualified dividend income, provided that (1) the ordinary shares are readily tradable on an established securities market in the United
States, or we are eligible for the benefits of an approved qualifying income tax treaty with the United States that includes an exchange
of information program, (2) we are not a PFIC for either our taxable year in which the dividend is paid or the preceding taxable year,
and (3) certain holding period requirements are met. Because there is no income tax treaty between the United States and the Cayman Islands,
clause (1) above can be satisfied only if the ordinary shares are readily tradable on an established securities market in the United
States. Under U.S. Internal Revenue Service authority, ordinary shares are considered for purpose of clause (1) above to be readily tradable
on an established securities market in the United States if they are listed on certain exchanges, which presently includes the NYSE and
the Nasdaq Stock Market. You are urged to consult your tax advisors regarding the availability of the lower rate for dividends paid with
respect to our ordinary shares, including the effects of any change in law after the date of this annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
will constitute foreign source income for foreign tax credit limitation purposes. If the dividends are taxed as qualified dividend income
(as discussed above), the amount of the dividend taken into account for purposes of calculating the foreign tax credit limitation will
be limited to the gross amount of the dividend, multiplied by the reduced rate divided by the highest rate of tax normally applicable
to dividends. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income.
For this purpose, dividends distributed by us with respect to our ordinary shares will constitute &#8220;passive category income&#8221;
but could, in the case of certain U.S. Holders, constitute &#8220;general category income.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that the amount of the distribution exceeds our current and accumulated earnings and profits (as determined under U.S. federal
income tax principles), it will be treated first as a tax-free return of your tax basis in your ordinary shares, and to the extent the
amount of the distribution exceeds your tax basis, the excess will be taxed as capital gain. We do not intend to calculate our earnings
and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect that a distribution will be treated as a
dividend even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described
above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Taxation
of Dispositions of Ordinary Shares</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the PFIC rules discussed below, you will recognize taxable gain or loss on any sale, exchange, or other taxable disposition of a share
equal to the difference between the amount realized (in U.S. dollars) for the share and your tax basis (in U.S. dollars) in the ordinary
shares. The gain or loss will be capital gain or loss. If you are a non-corporate U.S. Holder, including an individual U.S. Holder, who
has held the ordinary shares for more than one year, you will generally be eligible for reduced tax rates. The deductibility of capital
losses is subject to limitations. Any such gain or loss that you recognize will generally be treated as United States source income or
loss for foreign tax credit limitation purposes which will generally limit the availability of foreign tax credits.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Passive
Foreign Investment Company Consequences </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. corporation is considered a PFIC, as defined in Section 1297(a) of the U.S. Internal Revenue Code, for any taxable year if either:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 75% of its gross
    income for such taxable year is passive income; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 50% of the value
    of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce
    or are held for the production of passive income (the &#8220;asset test&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Passive
income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of
a trade or business), and gains from the disposition of passive assets. We will be treated as owning our proportionate share of the assets
and earning our proportionate share of the income of any other corporation in which we own, directly or indirectly, at least 25% (by
value) of the stock. In determining the value and composition of our assets for purposes of the PFIC asset test, the value of our assets
must be determined based on the market value of our ordinary shares from time to time, which could cause the value of our non-passive
assets to be less than 50% of the value of all of our assets on any particular quarterly testing date for purposes of the asset test.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on our operations and the composition of our assets, we
are not currently a PFIC under the current PFIC rules. We must make a separate determination each year as to whether we are a PFIC, however,
and there can be no assurance with respect to our status as a PFIC for any future taxable years. Depending on the amount of assets held
for the production of passive income, it is possible that, for any subsequent taxable year, more than 50% of our assets may be assets
held for the production of passive income. We will make this determination following the end of any particular tax year. In addition,
because the value of our assets for purposes of the asset test will generally be determined based on the market price of our ordinary
shares, our PFIC status will depend in large part on the market price of our ordinary shares. Accordingly, fluctuations in the market
price of the ordinary shares may cause us to become a PFIC. In addition, the application of the PFIC rules is subject to uncertainty in
several respects and the composition of our income and assets will be affected by how, and how quickly, we spend our liquid assets. We
are under no obligation to take steps to reduce the risk of our being classified as a PFIC, and as stated above, the determination of
the value of our assets will depend upon material facts (including the market price of our ordinary shares from time to time) that may
not be within our control. If we are a PFIC for any year during which you hold ordinary shares, we will continue to be treated as a PFIC
for all succeeding years during which you hold ordinary shares. If we cease to be a PFIC and you did not previously make a timely &#8220;mark-to-market&#8221;
election as described below, you may avoid some of the adverse effects of the PFIC regime by making a &#8220;purging election&#8221; (as
described below) with respect to the ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for your taxable year(s) during which you hold ordinary shares, you will be subject to special tax rules with respect to
any &#8220;excess distribution&#8221; that you receive and any gain you realize from a sale or other disposition (including a pledge)
of the ordinary shares, unless you make a &#8220;mark-to-market&#8221; election as discussed below. Distributions you receive in a taxable
year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable years
or your holding period for the ordinary shares will be treated as an excess distribution. Under these special tax rules:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the excess distribution
    or gain will be allocated ratably over your holding period for the ordinary shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to
    your current taxable year, and any amount allocated to any of your taxable year(s) prior to the first taxable year in which we were
    a PFIC, will be treated as ordinary income, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to
    each of your other taxable year(s) will be subject to the highest tax rate in effect for that year and the interest charge generally
    applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax liability for amounts allocated to years prior to the year of disposition or &#8220;excess distribution&#8221; cannot be offset by
any net operating losses for such years, and gains (but not losses) realized on the sale of the ordinary shares cannot be treated as
capital, even if you hold the ordinary shares as capital assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Holder of &#8220;marketable stock&#8221; (as defined below) in a PFIC may make a mark-to-market election under Section 1296 of the
US Internal Revenue Code for such stock to elect out of the tax treatment discussed above. If you make a mark-to-market election for
first taxable year which you hold (or are deemed to hold) ordinary shares and for which we are determined to be a PFIC, you will include
in your income each year an amount equal to the excess, if any, of the fair market value of the ordinary shares as of the close of such
taxable year over your adjusted basis in such ordinary shares, which excess will be treated as ordinary income and not capital gain.
You are allowed an ordinary loss for the excess, if any, of the adjusted basis of the ordinary shares over their fair market value as
of the close of the taxable year. Such ordinary loss, however, is allowable only to the extent of any net mark-to-market gains on the
ordinary shares included in your income for prior taxable years. Amounts included in your income under a mark-to-market election, as
well as gain on the actual sale or other disposition of the ordinary shares, are treated as ordinary income. Ordinary loss treatment
also applies to any loss realized on the actual sale or disposition of the ordinary shares, to the extent that the amount of such loss
does not exceed the net mark-to-market gains previously included for such ordinary shares. Your basis in the ordinary shares will be
adjusted to reflect any such income or loss amounts. If you make a valid mark-to-market election, the tax rules that apply to distributions
by corporations which are not PFICs would apply to distributions by us, except that the lower applicable capital gains rate for qualified
dividend income discussed above under &#8220;&#8212;Taxation of Dividends and Other Distributions on our Ordinary Shares&#8221; generally
would not apply.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
mark-to-market election is available only for &#8220;marketable stock,&#8221; which is stock that is traded in other than de minimis
quantities on at least 15 days during each calendar quarter (&#8220;regularly traded&#8221;) on a qualified exchange or other market
(as defined in applicable U.S. Treasury regulations), including the Nasdaq Capital Market. If the ordinary shares are regularly traded
on the Nasdaq Capital Market and if you are a holder of ordinary shares, the mark-to-market election would be available to you were we
to be or become a PFIC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alternatively,
a U.S. Holder of stock in a PFIC may make a &#8220;qualified electing fund&#8221; election under Section 1295(b) of the US Internal Revenue
Code with respect to such PFIC to elect out of the tax treatment discussed above. A U.S. Holder who makes a valid qualified electing
fund election with respect to a PFIC will generally include in gross income for a taxable year such holder&#8217;s pro rata share of
the corporation&#8217;s earnings and profits for the taxable year. The qualified electing fund election, however, is available only if
such PFIC provides such U.S. Holder with certain information regarding its earnings and profits as required under applicable U.S. Treasury
regulations. We do not currently intend to prepare or provide the information that would enable you to make a qualified electing fund
election. If you hold ordinary shares in any taxable year in which we are a PFIC, you will be required to file U.S. Internal Revenue
Service Form 8621 in each such year and provide certain annual information regarding such ordinary shares, including regarding distributions
received on the ordinary shares and any gain realized on the disposition of the ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you do not make a timely &#8220;mark-to-market&#8221; election (as described above), and if we were a PFIC at any time during the period
you hold our ordinary shares, then such ordinary shares will continue to be treated as stock of a PFIC with respect to you even if we
cease to be a PFIC in a future year, unless you make a &#8220;purging election&#8221; for the year we cease to be a PFIC. A &#8220;purging
election&#8221; creates a deemed sale of such ordinary shares at their fair market value on the last day of the last year in which we
are treated as a PFIC. The gain recognized by the purging election will be subject to the special tax and interest charge rules treating
the gain as an excess distribution, as described above. As a result of the purging election, you will have a new basis (equal to the
fair market value of the ordinary shares on the last day of the last year in which we are treated as a PFIC) and holding period (which
new holding period will begin the day after such last day) in your ordinary shares for tax purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IRC
Section 1014(a) provides for a step-up in basis to the fair market value for our ordinary shares when inherited from a decedent that
was previously a holder of our ordinary shares. However, if we are determined to be a PFIC and a decedent that was a U.S. Holder did
not make either a timely qualified electing fund election for our first taxable year as a PFIC in which the U.S. Holder held (or was
deemed to hold) our ordinary shares, or a mark-to-market election and ownership of those ordinary shares are inherited, a special provision
in IRC Section 1291(e) provides that the new U.S. Holder&#8217;s basis should be reduced by an amount equal to the Section 1014 basis
minus the decedent&#8217;s adjusted basis just before death. As such if we are determined to be a PFIC at any time prior to a decedent&#8217;s
passing, the PFIC rules will cause any new U.S. Holder that inherits our ordinary shares from a U.S. Holder to not get a step-up in basis
under Section 1014 and instead will receive a carryover basis in those ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
are urged to consult your tax advisors regarding the application of the PFIC rules to your investment in our ordinary shares and the
elections discussed above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Information
Reporting and Backup Withholding</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
payments with respect to our ordinary shares and proceeds from the sale, exchange, or redemption of our ordinary shares may be subject
to information reporting to the U.S. Internal Revenue Service and possible U.S. backup withholding under Section 3406 of the U.S. Internal
Revenue Code with at a current flat rate of 24%. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct
taxpayer identification number and makes any other required certification on U.S. Internal Revenue Service Form W-9 or who is otherwise
exempt from backup withholding. U.S. Holders who are required to establish their exempt status generally must provide such certification
on U.S. Internal Revenue Service Form W-9. U.S. Holders are urged to consult their tax advisors regarding the application of the U.S.
information reporting and backup withholding rules.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your U.S. federal income tax liability,
and you may obtain a refund of any excess amounts withheld under the backup withholding rules by filing the appropriate claim for refund
with the U.S. Internal Revenue Service and furnishing any required information. We do not intend to withhold taxes for individual shareholders.
Transactions effected through certain brokers or other intermediaries, however, may be subject to withholding taxes (including backup
withholding), and such brokers or intermediaries may be required by law to withhold such taxes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Hiring Incentives to Restore Employment Act of 2010, certain U.S. Holders are required to report information relating to our ordinary
shares, subject to certain exceptions (including an exception for ordinary shares held in accounts maintained by certain financial institutions),
by attaching a complete Internal Revenue Service Form 8938, Statement of Specified Foreign Financial Assets, with their tax return for
each year in which they hold ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
<span style="text-decoration:underline">Dividends and Paying Agents</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
<span style="text-decoration:underline">Statement by Experts</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.
<span style="text-decoration:underline">Documents on Display</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have previously filed with the SEC our registration statements on Form&#160;F-1 (File No. 333-248067), as amended, to register our ordinary
shares in connection with our initial public offering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the periodic reporting and other informational requirements of the Exchange Act. Under the Exchange Act, we are required
to file reports and other information with the SEC. Specifically, we are required to file annually a Form&#160;20-F within four months
after the end of each fiscal year. The SEC maintains a website at http://www.sec.gov that contains reports, proxy and information statements,
and other information regarding registrants that make electronic filings with the SEC using its EDGAR system. As a foreign private issuer,
we are exempt from the rules&#160;of the Exchange Act prescribing, among other things, the furnishing and content of proxy statements
to shareholders, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit
recovery provisions contained in Section&#160;16 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.
<span style="text-decoration:underline">Subsidiary Information</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Exchange Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our revenues are denominated in Renminbi. The Renminbi is not freely convertible into foreign currencies for capital account transactions.
The value of the Renminbi against the U.S. dollar and other currencies is affected by, among other things, changes in China&#8217;s political
and economic conditions and China&#8217;s foreign exchange policies. On July 21, 2005, the PRC government changed its decade-old policy
of pegging the value of the Renminbi to the U.S. dollar, and the Renminbi appreciated more than 20% against the U.S. dollar over the
following three years. Between July 2008 and June 2010, this appreciation halted and the exchange rate between the Renminbi and the U.S.
dollar remained within a narrow band. Since June 2010, the Renminbi has fluctuated against the U.S. dollar, at times significantly and
unpredictably. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the
Renminbi and the U.S. dollar in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. To the
extent that we need to convert U.S. dollars we received from our initial public offering in March 2021 into Renminbi for our operations
or capital expenditures, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount we
would receive from the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments
for dividends on our ordinary shares or for other business purposes, appreciation of the U.S. dollar against the Renminbi would have
a negative effect on the U.S. dollar amount available to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, we had U.S. dollar-denominated cash and cash equivalents of US$5.7 million. A 10% depreciation of U.S. dollar
against the Renminbi based on the foreign exchange rate on September 30, 2022 would result in a decrease of RMB4.05 million in cash and
cash equivalents. A 10% appreciation of U.S. dollar against the Renminbi based on the foreign exchange rate on September 30, 2022 would
result in an increase of RMB4.05 million in cash and cash equivalents.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Credit
Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are typically unsecured and derived from revenue earned from customers, thereby exposed to credit risk. The risk is mitigated
by our assessment of its customers&#8217; creditworthiness and its ongoing monitoring of outstanding balances.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not used derivative financial instruments to hedge interest rate risk. Interest-earning instruments carry a degree of interest rate
risk. We have not been exposed, nor do we anticipate being exposed to material risks due to changes in market interest rates. However,
our future interest income may fall short of expectations due to changes in market interest rates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, inflation has not had a material impact on our results of operations. According to the National Bureau of Statistics of
China, the consumer price index in China increased by 2.9%, 2.5% and 0.9% in 2019, 2020 and 2021, respectively. According to Wind Information
(www.wind.com.cn), the year-over-year percent changes in the consumer price index for November 2022 was 2.02%. According to the National
Bureau of Statistics of China, the year-over-year percent changes in the consumer price index for December 2021 was 0.9%. Although we
have not in the past been materially affected by inflation since our inception, we can provide no assurance that we will not be affected
in the future by higher rates of inflation in China. If inflation rises, it may materially and adversely affect our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
<span style="text-decoration:underline">Debt Securities</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
<span style="text-decoration:underline">Warrants and Rights</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
<span style="text-decoration:underline">Other Securities</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
<span style="text-decoration:underline">American Depositary Shares</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><div><a id="k_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part&#160;II</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 10. Additional Information&#8221; for a description of the rights of securities holders, which remain unchanged.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Proceeds</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following &#8220;Use of Proceeds&#8221; information relates to the registration statement on Form&#160;F-1 (File Number 333-248067),
as amended, which was declared effective by the SEC on March 22, 2021, for our initial public offering, which was closed on March 25,
2021. We issued and sold an aggregate of 5,750,000 ordinary shares, at a price of $5.00 per share with gross proceeds of $28.75 million.
Univest Securities, LLC was the underwriter of our initial public offering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incurred approximately $2,953,114 in expenses in connection with our initial public offering and $178,758 in expenses in connection with
the issuance of overallotment shares. None of the transaction expenses included payments to directors or officers of our company or their
associates, persons owning more than 10% or more of our equity securities or our affiliates. None of the net proceeds we received from
the initial public offering were paid, directly or indirectly, to any of our directors or officers or their associates, persons owning
10% or more of our equity securities or our affiliates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds raised from the initial public offering were $25,618,128 after deducting underwriting discounts and the offering expenses
payable by us. For the period from the effectiveness of the registration statement on Form F-1 to September 30, 2022, we used approximately
US$3.2 million for research and development purposes, approximately US$3.4 million for upgrading and expanding our manufacturing facilities,
and approximately US$2.9 million for brand marketing. We still intend to use the remaining proceeds from our initial public offering
in the manner disclosed in our registration statement on Form&#160;F-1, as amended (File Number 333-248067).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><div><a id="k_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
15. CONTROLS AND PROCEDURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Controls and Procedures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our chief executive officer and chief financial officer, has performed an evaluation of the effectiveness
of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by
this report, as required by Rule 13a-15(b) under the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon this evaluation, our management has concluded that, as of September 30, 2022, our existing disclosure controls and procedures were
ineffective because of a lack of accounting staff and resources with appropriate knowledge of U.S. GAAP and SEC reporting and compliance
requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules&#160;13a-15(f)&#160;and
15d-15(f)&#160;under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with U.S. GAAP
and includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately
and fairly reflect the transactions and dispositions of a company&#8217;s assets, (ii)&#160;provide reasonable assurance that transactions
are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting
principles, and that a company&#8217;s receipts and expenditures are being made only in accordance with authorizations of a company&#8217;s
management and directors, and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use, or disposition of a company&#8217;s assets that could have a material effect on the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our chief executive officer and chief financial officer, conducted an evaluation of the effectiveness
of our Company&#8217;s internal control over financial reporting as of September 30, 2022 based on criteria established in Internal Control&#8212;Integrated
Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO 2013 Framework). Based on this evaluation,
we identified one deficiency, which related to a lack of accounting staff and resources with appropriate knowledge of U.S. GAAP and SEC
reporting and compliance requirements<span style="background-color: white">, and which we believe to be a material weakness as of September
30, 2022</span>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the above material weakness, management has concluded that our internal control over financial reporting was ineffective
as of September 30, 2022. To remedy our identified material weakness as of September 30, 2022, we have undertaken the remedial steps
and also plan to adopt certain measures to improve our internal control over financial reporting as set forth below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Remediation
plan of the Material Weakness in Internal Control over Financial Reporting Reported as of September 30, 2022</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of the
date of this annual report, we have not fully addressed the above-referenced weaknesses. However, we have made progress in implementing
remedial measures, including:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruiting
                                            qualified accounting personnel with relevant U.S. GAAP and SEC reporting experience and qualifications
                                            to strengthen the financial reporting function and to set up a financial and system control
                                            framework. Since very few companies in Ji&#8217;an, Jiangxi Province, the area in which our
                                            main PRC operating subsidiaries are located, have sought public listing on a U.S. exchange,
                                            we have difficulty identifying qualified accounting candidates with U.S. GAAP experience
                                            and expertise. We plan to search for qualified personnel in other regions of China;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing
                                            regular and continuous U.S. GAAP accounting and financial reporting training programs for
                                            our accounting and financial reporting personnel; and</span></td></tr></table><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">setting
                                            up an internal audit function as well as engaging an external consulting firm to assist us
                                            with assessment of Sarbanes-Oxley compliance requirements and improvement of overall internal
                                            control.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Attestation
Report of the Registered Public Accounting Firm</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report on Form 20-F does not include an attestation report of our registered public accounting firm regarding internal control
over financial reporting. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant
to rules&#160;of the SEC where domestic and foreign registrants that are non-accelerated filers, which we are, and &#8220;emerging growth
companies,&#8221; which we also are, are not required to provide the auditor attestation report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control over Financial Reporting</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2021, we identified a material weakness in our internal control over financial reporting, which related to the fact
that our internal audit function was not set up properly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
implemented the following remedial measures during the fiscal year ended September 30, 2022 to address the material weakness identified
as of September 30, 2021:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span>
    </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">hiring
qualified personnel to set up an internal audit function;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    an annual plan of internal audit and getting approval from audit committee; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">engaging
an external consulting firm to assist us in conducting internal audit programs.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described above, there were no changes in our internal controls over financial reporting that occurred during the period covered
by this annual report on Form&#160;20-F&#160;that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16. [RESERVED]</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
H. David Sherman qualifies as an &#8220;audit committee financial expert&#8221; as defined in Item 16A of Form&#160;20-F. Mr.&#160;H.
David Sherman satisfies the &#8220;independence&#8221; requirements of Section&#160;5605(a)(2)&#160;of the Nasdaq Listing Rules&#160;as
well as the independence requirements of Rule&#160;10A-3 under the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16B. CODE OF ETHICS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted a code of business conduct and ethics, which is applicable to all of our directors, officers, and employees.
Our code of business conduct and ethics is publicly available on our website.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the aggregate fees by categories specified below in connection with certain professional services rendered
and billed by YCM CPA INC., our independent registered public accounting firm for the periods indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>YCM
CPA INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">210,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related fees <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">All other fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">200,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">210,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees include the
    aggregate fees billed for each of the fiscal years for professional services rendered by our independent registered public accounting
    firm for the audit of our annual financial statements or for the audits of our financial statements and review of the interim financial
    statements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit related fees include
    the aggregate fees billed for related services by our principal accountant that are reasonably related to the performance of the
    audit or review of our financial statements and are not reported under audit fees.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees represent the
    aggregated fees billed for professional services rendered by our independent registered public accounting firm for tax compliance,
    tax advice, and tax planning. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee of our board of directors has established its pre-approval policies and procedures, pursuant to which the audit committee
approved the foregoing audit, tax and non-audit services provided by YCM CPA INC. in fiscal years 2021 and 2022. Consistent with our
audit committee&#8217;s responsibility for engaging our independent auditors, all audit and permitted non-audit services require pre-approval
by the audit committee. The full audit committee approves proposed services and fee estimates for these services. One or more independent
directors serving on the audit committee may be delegated by the full audit committee to pre-approve any audit and non-audit services.
Any such delegation shall be presented to the full audit committee at its next scheduled meeting. Pursuant to these procedures, the audit
committee approved the foregoing audit services provided by YCM CPA INC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><div><a id="k_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 7, 2021, we appointed YCM CPA INC. (&#8220;YCM&#8221;) as our independent registered public accounting firm, effective on the
same day. YCM replaces Friedman LLP (&#8220;Friedman&#8221;), our former independent registered public accounting firm, which we dismissed
on December 1, 2021. The appointment of YCM was made after careful consideration and evaluation process by the Company and has been approved
by the audit committee of our board of directors. Our decision to make this change was not the result of any disagreement between the
Company and Friedman on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit report of Friedman on the consolidated financial statements of the Company as of September 30, 2020 and for the fiscal years ended
September 30, 2020 did not contain an adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, scope
of accounting principles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the two most recent fiscal years and any subsequent interim periods prior to the engagement of YCM, neither the Company, nor someone
on behalf of the Company, has consulted YCM regarding either (a) the application of accounting principles to a specified transaction,
either completed or proposed; or the type of audit opinion that might be rendered on the Company&#8217;s consolidated financial statements,
and neither a written report was provided to the Company or oral advice was provided that YCM concluded was an important factor considered
by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (b) any matter that was the subject
of a disagreement as defined in Item 16F(a)(1)(iv) of Form 20-F and related instructions to Item 16F of Form 20-F, or any reportable
events as described in Item 16F(a)(1)(v) of Form 20-F.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16G. CORPORATE GOVERNANCE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Cayman Islands company listed on the Nasdaq Global Market, we are subject to the Nasdaq corporate governance listing standards. Nasdaq
rules, however,&#160;permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain
corporate governance practices in the Cayman Islands, which is our home country, may differ significantly from the Nasdaq corporate governance
listing standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
Listing Rule 5635 generally provides that shareholder approval is required of U.S. domestic companies listed on Nasdaq prior to issuance
(or potential issuance) of securities (i) equaling 20% or more of the company&#8217;s common stock or voting power for less than the
greater of market or book value (ii) resulting in a change of control of the company; and (iii) which is being issued pursuant to a stock
option or purchase plan to be established or materially amended or other equity compensation arrangement made or materially amended.
Notwithstanding this general requirement, Nasdaq Listing Rule 5615(a)(3)(A) permits foreign private issuers to follow their home country
practice rather than these shareholder approval requirements. The Companies Act does not require shareholder approval prior to any of
the foregoing types of issuances. We, therefore, are not required to obtain such shareholder approval prior to entering into a transaction
with the potential to issue securities as described above. Specifically, our board of directors has elected to follow our home country
rules and be exempt from the requirements to obtain shareholder approval for the issuance of 20% or more of our outstanding ordinary
shares under Nasdaq Listing Rule 5635(d).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
Listing Rule 5605(b)(1) requires listed companies to have, among other things, a majority of its board members be independent. As a foreign
private issuer, however, we are permitted to follow home country practice in lieu of the above requirements. The corporate governance
practice in our home country, the Cayman Islands, does not require a majority of our board to consist of independent directors. Currently,
a majority of our board members are independent. However, if we change our board composition such that independent directors do not constitute
a majority of our board of directors, our shareholders may be afforded less protection than they would otherwise enjoy under Nasdaq&#8217;s
corporate governance requirements applicable to U.S. domestic issuers. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks
Related to Our Ordinary Shares&#8212; As a foreign private issuer, we are permitted to adopt certain home country practices in relation
to corporate governance matters that differ significantly from the Nasdaq listing standards. These practices may afford less protection
to shareholders than they would enjoy if we complied fully with corporate governance listing standards.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than those described above, there are no significant differences between our corporate governance practices and those followed by U.S.
domestic companies under Nasdaq corporate governance listing standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16H. MINE SAFETY DISCLOSURE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>




</div><div><a id="k_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part
III</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
17. FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have elected to provide financial statements pursuant to Item 18.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
18. FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Universe Pharmaceuticals INC and its subsidiaries are included at the end of this annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
19. EXHIBITS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390022066745/ea167278ex3-1_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 of our Registration Statement on Form F-3 (file No. 333-268028), filed with the Securities and Exchange Commission on October 27, 2022)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex4-1_universepharm.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Certificate for Ordinary Shares (incorporated by reference to Exhibit 4.1 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390020037560/ea129847ex4-2_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriter Warrants (incorporated by reference to Exhibit 4.2 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="f20f2022ex2-3_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-1_universepharm.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Employment Agreement by and between executive officers and the Registrant (incorporated by reference to Exhibit 10.1 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-2_universepharm.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement with the Registrant&#8217;s directors and officers (incorporated by reference to Exhibit 10.2 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-7_universepharm.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Sales and Distribution Agreement by and between Universe Trade and customers (incorporated by reference to Exhibit 10.7 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390021064704/ea152145ex1-1_universepharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic Cooperation Agreement by and between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd., dated December 1, 2021 (incorporated by reference to Exhibit 1.1 of our Current Report on Form 6-K (file No. 001-40231), filed with the Securities and Exchange Commission on December 10, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390021064704/ea152145ex1-2_universepharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Purchase Agreement by and among Universe Pharmaceuticals INC, Kitanihon Pharmaceutical Co., Ltd., and Nishimura Ichiro, dated December 1, 2021 (incorporated by reference to Exhibit 1.2 of our Current Report on Form 6-K (file No. 001-40231), filed with the Securities and Exchange Commission on December 10, 2021)</span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390021064704/ea152145ex1-3_universepharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cooperation Agreement on Manufacturing Facility Construction Project by and between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd., dated December 1, 2021 (incorporated by reference to Exhibit 1.3 of our Current Report on Form 6-K (file No. 001-40231), filed with the Securities and Exchange Commission on December 10, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390021064704/ea152145ex1-4_universepharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Transfer Agreement by and among Sununion Holding Group Ltd., Kitanihon Pharmaceutical Co., Ltd., and Gang Lai, dated December 1, 2021 (incorporated by reference to Exhibit 1.4 of our Current Report on Form 6-K (file No. 001-40231), filed with the Securities and Exchange Commission on December 10, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390022004359/f20f2021ex4-13_universephar.htm">English translation of the real estate property purchase agreement entered into by and between Jiangxi Universe and Jiangxi Yueshang Investment Co., Ltd., dated May 16, 2021 (incorporated by reference to Exhibit 4.13 of our annual report on Form 20-F (file No. 001-40231), filed with the Securities and Exchange Commission on January 31, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390022004359/f20f2021ex4-15_universephar.htm">English translation of the construction agreement entered into by and between Jiangxi Universe and Jiangxi Chenyuan Construction Project Co., Ltd., dated June 25, 2021 (incorporated by reference to Exhibit 4.15 of our annual report on Form 20-F (file No. 001-40231), filed with the Securities and Exchange Commission on January 31, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390022004359/f20f2021ex4-17_universephar.htm">English translation of the advertising service agreement entered into by and between Jiangxi Universe and Guangdong Fengyang Legend Consulting Co., Ltd., dated September 6, 2021 (incorporated by reference to Exhibit 4.17 of our annual report on Form 20-F (file No. 001-40231), filed with the Securities and Exchange Commission on January 31, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f20f2022ex4-11_universe.htm">English translation of the working capital loan contract entered into by and between Universe Trade and Jiangxi Liuling Rural Commercial Bank Co., Ltd., dated March 14, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f20f2022ex4-12_universe.htm">English translation of the working capital loan contract entered into by and between Jiangxi Universe and Jiangxi Liuling Rural Commercial Bank Co., Ltd., dated June 15, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f20f2022ex4-13_universe.htm">English translation of the working capital loan contract entered into by and between Jiangxi Universe and Bank of Communications, dated June 22, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f20f2022ex4-14_universe.htm">English translation of the Letter of Intent on Transfer of Equity Interests in Yunnan Faxi Pharmaceuticals Co., Ltd., entered into by and among Jiangxi Universe, Xibo Liu, and Yunnan Faxi Pharmaceuticals Co., Ltd. dated September 26, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390022004359/f20f2021ex8-1_universephar.htm">List of subsidiaries of the Registrant (incorporated by reference to Exhibit 8.1 of our annual report on Form 20-F (file No. 001-40231), filed with the Securities and Exchange Commission on January 31, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex99-1_universepharm.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business Conduct and Ethics of the Registrant (incorporated by reference to Exhibit 99.1 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="f20f2022ex12-1_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="f20f2022ex12-2_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="f20f2022ex13-1_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="f20f2022ex13-2_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f20f2022ex15-1_universe.htm">Consent of AllBright Law Offices (Fuzhou)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="f20f2022ex15-2_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of YCM CPA INC.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f20f2022ex15-3_universe.htm">Consent of Friedman LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following financial statements from the Company&#8217;s Annual Report on Form 20-F for the fiscal year ended September 30, 2022,
    formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations and Comprehensive Income, (iii)
    Consolidated Statements of Changes in Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial
    Statements, tagged as blocks of text and including detailed tags</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    with this annual report on Form&#160;20-F</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
    with this annual report on Form&#160;20-F</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant hereby certifies that it meets all of the requirements for filing on Form&#160;20-F and that it has duly caused and authorized
the undersigned to sign this annual report on its behalf.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Pharmaceuticals
    INC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Gang Lai</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang Lai</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer,
    Director, and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board
    of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: February 10, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 89%; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Financial Statements </b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 10%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><a href="#f_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reports
    of Independent Registered Public Accounting Firms</span></a></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">F-2</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of September 30, 2022 and 2021</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Income and Comprehensive Income for the years ended September 30, 2022, 2021 and 2020</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Shareholders&#8217; Equity for the years ended September 30, 2022, 2021 and 2020</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the years ended September 30, 2022, 2021 and 2020</span></a></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8
&#8211; F-33</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 122; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><img alt="" src="img_003.jpg"/>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-transform: none"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></span>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Board of Directors and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholders of Universe Pharmaceuticals INC</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Opinion
on the Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">We have
audited the accompanying consolidated balance sheets of </span>Universe Pharmaceuticals INC <span style="background-color: white">and
subsidiaries (collectively, the &#8220;Company&#8221;) as of September&#160;30, 2022 and 2021, and the related consolidated statements
of operations and comprehensive income (loss), changes in stockholders&#8217; equity, and cash flows for the years ended September&#160;30,
2022 and 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In our opinion,
the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company
as of September&#160;30, 2022 and 2021, and the results of its operations and its cash flows for the period ended September&#160;30, 2022
and 2021, in conformity with accounting principles generally accepted in the United States of America.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Basis
for Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">These consolidated
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">We conducted
our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we
are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Our audits
included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statement.
We believe that our audits provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName">YCM CPA, Inc.</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">We have served as the Company&#8217;s
auditor since 2021. </span></p><div>

</div><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">PCAOB ID <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">6781</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c0" name="dei:AuditorLocation">Irvine, California</ix:nonNumeric><br/>
February 10, 2023</span></p><div>

</div><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><b><img alt="" src="img_004.jpg"/>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and shareholders of</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Universe Pharmaceuticals Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Opinion on the Financial Statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheet of Universe Pharmaceuticals Inc. and its subsidiaries (collectively, the &#8220;Company&#8221;) as of September 30, 2020,
and the related consolidated statements of income and comprehensive income, changes in shareholders&#8217; equity, and cash flows for
each of the years in the two-year period ended September 30, 2020, and the related notes (collectively referred to as the &#8220;consolidated
financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of September 30, 2020, and the results of its operations and its cash flows for each of the years in the two-year
period ended September 30, 2020, in conformity with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basis for Opinion</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements are the
responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the consolidated financial statement. We believe that our audits provide a reasonable
basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Friedman LLP</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2019 through 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">February 24, 2021</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">CURRENT ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 10pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">5,711,458</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">8,077,908</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">13,148,594</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">13,725,204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">15,183,890</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">15,573,742</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Inventories, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,206,488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,462,542</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" unitRef="usd">236,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Advance to suppliers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Supplies" scale="0" unitRef="usd">16,701</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Supplies" scale="0" unitRef="usd">2,738,313</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Prepayment for advertising</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsCurrent" scale="0" unitRef="usd">7,492,320</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Prepayment for acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentForAcquisitionCurrent" scale="0" unitRef="usd">3,514,450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">1,724,099</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">174,053</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; text-indent: -1.15pt; padding-left: 1.15pt">TOTAL CURRENT ASSETS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">41,505,680</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">50,481,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">4,250,638</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">4,681,353</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Prepayments made to a related party for purchase of property</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" scale="0" unitRef="usd">2,249,248</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" scale="0" unitRef="usd">2,476,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Prepayments for construction in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentsForConstructionInProgress" scale="0" unitRef="usd">9,326,296</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentsForConstructionInProgress" scale="0" unitRef="usd">10,712,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="0" unitRef="usd">157,451</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="0" unitRef="usd">178,483</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Investment in equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:InvestmentInEquitySecurities" scale="0" unitRef="usd">702,890</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="upc:InvestmentInEquitySecurities" scale="0" unitRef="usd">744,924</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" unitRef="usd">1,347,672</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" unitRef="usd">869,997</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">TOTAL NONCURRENT ASSETS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd">18,034,195</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd">19,663,717</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">59,539,875</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">70,144,781</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Short-term bank loans</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" unitRef="usd">3,936,184</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" unitRef="usd">4,334,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">3,075,393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">5,310,526</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd">167,350</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd">1,101,460</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" unitRef="usd">3,379,263</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" unitRef="usd">19,723</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">2,539,362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">444,319</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; text-indent: -1.15pt; padding-left: 1.15pt">TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">13,097,552</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">11,210,428</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Ordinary shares, $<ix:nonFraction contextRef="c2" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.003125</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">21,750,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2022 and 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">67,969</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">67,969</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">29,279,159</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">29,279,159</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Statutory reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:StatutoryReserve" scale="0" unitRef="usd">2,439,535</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="upc:StatutoryReserve" scale="0" unitRef="usd">2,439,535</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Retained earnings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" unitRef="usd">16,322,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" unitRef="usd">25,058,931</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated other comprehensive (loss) income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd">1,666,705</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">2,088,759</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">TOTAL SHAREHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">46,442,323</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">58,934,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">59,539,875</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">70,144,781</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF INCOME
AND COMPREHENSIVE INCOME</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Revenue</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">40,143,151</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">47,982,031</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">30,703,960</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Cost of revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">18,251,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">22,655,854</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">16,610,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">21,891,336</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">25,326,177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">14,093,820</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd">19,083,135</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd">2,973,531</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd">1,555,546</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">2,602,624</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">3,296,844</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,703,424</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">7,644,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">5,465,662</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">583,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">29,330,134</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">11,736,037</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">3,842,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income from operations</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:IncomeFromOperation" scale="0" unitRef="usd">7,438,798</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:IncomeFromOperation" scale="0" sign="-" unitRef="usd">13,590,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="upc:IncomeFromOperation" scale="0" sign="-" unitRef="usd">10,251,725</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">162,400</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">101,604</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">123,760</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expenses), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd">48,940</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" sign="-" unitRef="usd">80,434</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" sign="-" unitRef="usd">49,352</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term investments (loss) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:ShorttermInvestmentIncome" scale="0" unitRef="usd">470,477</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:ShorttermInvestmentIncome" scale="0" sign="-" unitRef="usd">239,549</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd">38,588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd">30,827</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd">21,820</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other (expense) income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">545,349</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd">88,338</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">151,292</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">(Loss) income before income tax provision</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">7,984,147</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd">13,678,478</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd">10,100,433</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income tax provision</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">752,419</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,358,526</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,542,211</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net (loss) income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">8,736,566</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">11,319,952</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other comprehensive income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" unitRef="usd">3,755,464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd">1,193,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd">860,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Comprehensive (loss) income</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">12,492,030</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">12,513,321</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">8,418,845</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Earnings per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt"><div style="-sec-ix-hidden: hidden-fact-5; -sec-ix-hidden: hidden-fact-4; -sec-ix-hidden: hidden-fact-3">Basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.40</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">0.60</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">0.47</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt"><div style="-sec-ix-hidden: hidden-fact-8; -sec-ix-hidden: hidden-fact-7; -sec-ix-hidden: hidden-fact-6">Basic and diluted</div></td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; font-weight: normal; text-align: right; font-style: normal"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">21,750,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">18,980,822</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">16,000,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND
SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF CHANGES
IN SHAREHOLDERS&#8217; EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FOR THE YEARS ENDED SEPTEMBER 30,
2022, 2021 AND 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional<br/>
 paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Statutory</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Retained</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated<br/>
 other<br/>
 comprehensive</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total<br/>
 shareholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">reserve</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">earnings</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 30%; font-weight: bold">Balance at September 30, 2019</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">16,000,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">3,679,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,439,535</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">6,180,757</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">34,767</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">12,384,059</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd">860,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd">860,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Balance at September 30, 2020</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">16,000,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">3,679,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,439,535</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">13,738,979</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">895,390</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">20,802,904</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">5,750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">17,969</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">28,732,031</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">28,750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Capitalized initial public offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" scale="0" sign="-" unitRef="usd">3,131,872</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" scale="0" sign="-" unitRef="usd">3,131,872</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">11,319,952</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">11,319,952</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd">1,193,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd">1,193,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Balance at September 30, 2021</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">21,750,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">67,969</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">29,279,159</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,439,535</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">25,058,931</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,088,759</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">58,934,353</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">8,736,566</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">8,736,566</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd">3,755,464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd">3,755,464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Balance at September 30, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">21,750,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">67,969</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">29,279,159</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,439,535</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">16,322,365</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">1,666,705</ix:nonFraction></td><td style="padding-bottom: 2pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">46,442,323</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flows from operating activities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 10pt">Net (loss) income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">8,736,566</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" unitRef="usd">11,319,952</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.25in">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">533,949</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">446,878</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">410,079</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Loss from disposal of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetImpairmentCharges" scale="0" unitRef="usd">983</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetImpairmentCharges" scale="0" unitRef="usd">1,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Allowance for doubtful accounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd">419,353</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd">230,175</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd">98,102</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Inventory reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" unitRef="usd">15,774</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" sign="-" unitRef="usd">75,391</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Deferred income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">605,278</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">668,341</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">9,886</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Short-term investments income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:ShorttermInvestmentsIncome" scale="0" unitRef="usd">470,477</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:ShorttermInvestmentsIncome" scale="0" sign="-" unitRef="usd">239,549</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">1,549,312</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">3,867,457</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">4,107,520</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd">16,586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd">451,634</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd">888,607</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Advance to suppliers, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" sign="-" unitRef="usd">2,681,214</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" unitRef="usd">2,717,085</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Prepayment for advertising</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidAdvertising" scale="0" sign="-" unitRef="usd">7,385,695</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidAdvertising" scale="0" unitRef="usd">7,434,240</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Advances to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" sign="-" unitRef="usd">236,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" unitRef="usd">237,720</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd">1,699,929</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd">168,188</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd">12,407</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" sign="-" unitRef="usd">1,896,621</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd">2,457,337</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd">639,427</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable" scale="0" sign="-" unitRef="usd">904,127</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable" scale="0" sign="-" unitRef="usd">298,620</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable" scale="0" unitRef="usd">731,518</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd">2,318,474</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd">31,436</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" sign="-" unitRef="usd">30,408</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash (used in) provided by operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">1,312,346</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">2,055,847</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" unitRef="usd">6,115,157</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">93,703</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">444,505</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">51,798</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Proceeds from disposal of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="0" unitRef="usd">523</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Prepayments made to a related party for purchase of property</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" scale="0" unitRef="usd">2,457,600</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Prepayments for construction in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfAdvancesForConstruction" scale="0" unitRef="usd">10,629,120</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 20pt">Prepayment for acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" unitRef="usd">3,814,925</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 20pt">Payments for short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" scale="0" unitRef="usd">15,330,660</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Redemption of short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:RedemptionOfShorttermInvestments" scale="0" unitRef="usd">1,801,927</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">3,908,105</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">27,059,958</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">51,798</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Proceeds from short-term bank loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" unitRef="usd">4,272,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" unitRef="usd">4,300,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" unitRef="usd">1,427,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Repayment of bank loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd">4,272,716</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd">2,764,800</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd">1,427,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Dividend payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Gross proceeds from initial public offerings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" unitRef="usd">28,750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Payment for deferred initial public offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" scale="0" unitRef="usd">2,792,543</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" scale="0" unitRef="usd">441,064</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Proceeds from (prepayments for) related parties borrowings</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings" scale="0" sign="-" unitRef="usd">3,317,943</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings" scale="0" unitRef="usd">911,648</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings" scale="0" sign="-" unitRef="usd">911,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">3,317,943</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">26,581,809</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">470,136</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of exchange rate changes on cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd">463,942</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">553,702</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">347,386</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net (decrease) increase in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">2,366,450</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">1,980,294</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">6,880,881</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">8,077,908</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">10,058,202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">3,177,321</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">5,711,458</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">8,077,908</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">10,058,202</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 20pt">Cash paid for interest expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">199,852</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">149,303</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">157,528</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 20pt">Cash paid for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd">2,748,629</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd">3,271,219</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd">2,167,963</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 &#8212; ORGANIZATION AND BUSINESS DESCRIPTION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:nonNumeric contextRef="c43" name="upc:EntityIncorporationDateDescription"><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">Universe Pharmaceuticals Inc. (&#8220;Universe
INC&#8221; or the &#8220;Company&#8221;) was incorporated under the laws of the Cayman Islands on December 11, 2019 as an exempted company
with limited liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:nonNumeric contextRef="c44" name="upc:EntityIncorporationDateDescription"><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Universe INC. owns <ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="upc:EquityMethodInvestmentOwnershipsPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% equity interest of Universe
Pharmaceuticals (International) Group (&#8220;Universe HK&#8221;), an entity incorporated on May 21, 2014 in accordance with the laws
and regulations in Hong Kong.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jiangxi Universe Pharmaceuticals Technology Co.,
Ltd. (&#8220;Universe Technology&#8221;) was formed on April 8, 2019, as a Wholly Foreign-Owned Enterprise (&#8220;WFOE&#8221;) in the
People&#8217;s Republic of China (&#8220;PRC&#8221; or &#8220;China&#8221;). The registered capital of Universe Technology is approximately
$<ix:nonFraction contextRef="c46" decimals="-5" format="ixt:num-dot-decimal" name="upc:AmountOfRegisteredCapital" scale="6" unitRef="usd">4.3</ix:nonFraction> million (RMB<ix:nonFraction contextRef="c46" decimals="-5" format="ixt:num-dot-decimal" name="upc:AmountOfRegisteredCapital" scale="6" unitRef="cny">30.5</ix:nonFraction> million). In December 2019, the Company made a capital contribution of $<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="upc:CapitalContribution" scale="0" unitRef="usd">500,000</ix:nonFraction> to Universe Technology. Pursuant
to the article of incorporation of Universe Technology, the remaining capital contribution of approximately $<ix:nonFraction contextRef="c47" decimals="-5" format="ixt:num-dot-decimal" name="upc:RemainingCapitalContribution" scale="6" unitRef="usd">3.8</ix:nonFraction> million for Universe
Technology is required to be completed before 2038.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">Universe INC, Universe HK and Universe
Technology are currently not engaging in any active business operations and are merely acting as holding companies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jiangxi Universe Pharmaceuticals Co., Ltd. <ix:nonNumeric contextRef="c48" name="upc:EntityIncorporationDateDescription">(&#8220;Jiangxi
Universe&#8221;) was incorporated on March 2, 1998 in accordance with PRC laws and is engaged in research and development and manufacturing
of modernized traditional Chinese medicines.</ix:nonNumeric> Jiangxi Universe owns <ix:nonFraction contextRef="c49" decimals="2" format="ixt:num-dot-decimal" name="upc:EquityMethodInvestmentOwnershipsPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of the equity interests of Jiangxi Universe Pharmaceuticals Commercial
Trade Co., Ltd. (&#8220;Universe Trade&#8221;), which was incorporated on March 10, 2010 to handle the sales and distribution of the pharmaceutical
products manufactured by Jiangxi Universe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Reorganization</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reorganization of the Company&#8217;s legal
structure (&#8220;Reorganization&#8221;) was completed on December 11, 2019. The Reorganization involved the incorporation of Universe
INC and Universe Technology, and the transfer of <ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="upc:EquityMethodInvestmentOwnershipsPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of the equity interests of Jiangxi Universe to Universe Technology. Consequently,
Universe INC, through its subsidiary Universe HK, directly controls Universe Technology and Jiangxi Universe, and became the ultimate
holding company of all other entities mentioned above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Reorganization has been accounted for as a
recapitalization among entities under common control, since the same controlling shareholders controlled all these entities before and
after the Reorganization. The consolidation of the Company and its subsidiaries has been accounted for at historical cost and prepared
on the basis as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying
consolidated financial statements. Results of operations for the periods presented comprise those of the previously separate entities
combined from the beginning of the period to the end of the period, eliminating the effects of intra-entity transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2021, the Company closed its initial
public offering (the &#8220;IPO&#8221;) of <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="upc:SharesIssued01" scale="0" unitRef="shares">5,000,000</ix:nonFraction> ordinary shares, par value $<ix:nonFraction contextRef="c51" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">0.003125</ix:nonFraction> per share (the &#8220;ordinary shares&#8221;)
at a public offering price of $<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="upc:PublicOfferingPrice" scale="0" unitRef="usdPershares">5.00</ix:nonFraction> per share. On March 29, 2021, the underwriter exercised in full its over-allotment option to purchase
an additional <ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="upc:SharesIssued01" scale="0" unitRef="shares">750,000</ix:nonFraction> ordinary shares. The closing for the sale of the over-allotment shares took place on March 31, 2021. Gross proceeds
from the IPO totaled $<ix:nonFraction contextRef="c53" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">28.75</ix:nonFraction> million. Net proceeds of the IPO, including over-allotment shares, were approximately $<ix:nonFraction contextRef="c54" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">25.6</ix:nonFraction> million. In connection
with the IPO, the Company&#8217;s ordinary shares began trading on the Nasdaq Global Market under the symbol &#8220;UPC&#8221; on March
23, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 12, 2021, through the Company&#8217;s PRC
subsidiary, Jiangxi Universe, the Company established a wholly controlled subsidiary, Guangzhou Universe Hanhe Medical Research Co., Ltd.
(&#8220;Universe Hanhe&#8221;) in Guangzhou City, China, for the business purpose of conducting research and development of new pharmaceutical
products in order to diversify the Company&#8217;s product offerings in the near future. As of September 30, 2022 and as of the date of
this report, Universe Hanhe has no active business operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 &#8212; ORGANIZATION AND BUSINESS DESCRIPTION (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details of the subsidiaries of the Company as of September 30, 2022
are set out below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_13" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Date of</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Place of</td><td style="font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">% of</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; font-weight: bold; vertical-align: top">Name of Entity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Incorporation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Incorporation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ownership</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal Activities</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Universe INC</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c55" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation">December 11, 2019</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c55" name="upc:PlaceOfIncorporation">Cayman Islands</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c55" name="upc:OwnershipPercentage">Parent, 100%</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c55" name="upc:PrincipalActivities">Investment holding</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 20%; text-align: left">Universe HK</td><td style="text-align: center; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><ix:nonNumeric contextRef="c44" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation">May 21, 2014</ix:nonNumeric></td><td style="text-align: center; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><ix:nonNumeric contextRef="c44" name="upc:PlaceOfIncorporation">Hong Kong</ix:nonNumeric></td><td style="text-align: center; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><ix:nonNumeric contextRef="c44" name="upc:OwnershipPercentage">100%</ix:nonNumeric></td><td style="text-align: center; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 28%; text-align: center"><ix:nonNumeric contextRef="c44" name="upc:PrincipalActivities">Investment holding</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Universe Technology</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c56" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation">April 18, 2019</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c56" name="upc:PlaceOfIncorporation">PRC</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c56" name="upc:OwnershipPercentage">100%</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c56" name="upc:PrincipalActivities">WFOE, Investment holding</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Jiangxi Universe</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c48" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation">March 2, 1998</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c48" name="upc:PlaceOfIncorporation">PRC</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c48" name="upc:OwnershipPercentage">100%</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c48" name="upc:PrincipalActivities">Research and development and manufacturing of modernized traditional Chinese medicines</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Universe Trade</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c57" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation">March 10, 2010</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c57" name="upc:PlaceOfIncorporation">PRC</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c57" name="upc:OwnershipPercentage">100%</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c57" name="upc:PrincipalActivities">Sales of modernized traditional Chinese medicines</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Universe Hanhe</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c58" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation">May 12, 2021</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c58" name="upc:PlaceOfIncorporation">PRC</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c58" name="upc:OwnershipPercentage">100%</ix:nonNumeric></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c58" name="upc:PrincipalActivities">Research and development of new pharmaceutical products</ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, through its wholly-owned subsidiaries,
is primarily engaged in the development, manufacturing and sale of traditional Chinese medicines derivatives (&#8220;TCMD&#8221;) products
targeted to the elderly to address their physical conditions in the aging process and to promote their general well-being. In addition,
the Company also sells biochemical drugs, medical instruments, traditional Chinese medicine pieces products and dietary supplements (collectively
&#8220;third-party products&#8221;). All of these TCMD and third-party products are currently sold to customers including pharmaceutical
companies, hospitals, clinics and drugstore chains throughout China.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis of consolidation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the financial statements of Universe INC, Universe HK, Universe Technology, Jiangxi Universe, Universe Trade and Universe Hanhe.
All inter-company balances and transactions are eliminated upon consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Uses of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing the consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;), management makes
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates
are based on information as of the date of the consolidated financial statements. Significant estimates required to be made by management
include, but are not limited to, the allowance for estimated uncollectible receivables, the realizability of advance to suppliers, inventory
valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of long-lived assets, provision necessary
for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The main operation of the Company is located in
the PRC. Accordingly, the Company&#8217;s business, financial condition, and results of operations may be influenced by political, economic,
and legal environments in the PRC, as well as by the general state of the PRC economy. The Company&#8217;s results may be adversely affected
by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations
and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1,
this may not be indicative of future results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of new pharmaceutical
products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant competition
and a strong emphasis on intellectual property. The Company may face competition with respect to its current and future pharmaceutical
product candidates from major pharmaceutical companies in China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_4" id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&#8217;s operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operations may be further
affected by the ongoing COVID-19 pandemic. Due to the resurgence of COVID-19 pandemic in China in 2022, there had been delays in purchase
of raw material supplies and deliver products to the customers of the PRC operating entities on a timely basis as a consequence of the
travel restrictions. The prices of the raw materials also increased by about <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="upc:MaterialPricePercentage" scale="-2" unitRef="pure">5</ix:nonFraction>% from January 2022 to May 2022 as compared to the same
period last year. In addition, the Company has granted some of its customers extended payment terms of <ix:nonNumeric contextRef="c59" format="ixt-sec:durday" name="upc:PaymentTerm">30</ix:nonNumeric> days to <ix:nonNumeric contextRef="c60" format="ixt-sec:durday" name="upc:PaymentTerm">120</ix:nonNumeric> days since January
2022, as a result of the COVID-19 pandemic. However, based on the present relationship with these customers and the evaluation of their
financial health, the Company does not anticipate any material collectability problems. Even though the Company does not expect that the
COVID-19 pandemic will have a negative impact on the business operations of the PRC operating entities and the financial results, due
to the high uncertainty of the evolving situation, the Company has limited visibility on how the COVID-19 pandemic affects the execution
of customer contracts, the collection of customer payments, or disrupt our supply chain, and the continued uncertainties associated with
COVID-19 may cause the revenue and cash flows to underperform in the next 12 months from the date the consolidated financial statements
are released. The extent of the future impact of the COVID-19 pandemic on the business and results of operations is still uncertain. Any
resurgence of the COVID-19 pandemic could negatively affect the execution of customer contracts, the collection of customer payments,
or disrupt the Company&#8217;s supply chain, and the continued uncertainties associated with COVID-19 may negatively impact the Company&#8217;s
revenue and cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash includes currency on hand and deposits held
by banks that can be added or withdrawn without limitation. The Company maintains most of its bank accounts in the PRC. Cash balances
in bank accounts in the PRC are not insured by the Federal Deposit Insurance Corporation or other programs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Accounts receivable, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are presented net of allowance
for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts based on individual account analysis and
historical collection trends. The Company establishes a provision for doubtful receivables when there is objective evidence that the Company
may not be able to collect amounts due. The allowance is based on management&#8217;s best estimate of specific losses on individual exposures,
as well as a provision on historical trends of collections. Actual amounts received may differ from management&#8217;s estimate of credit
worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful accounts after
management has determined that collection is not probable. Allowance for uncollectable balances amounted to $ $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:AllowanceForUncollectableBalancesAmount" scale="0" unitRef="usd">791,827</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:AllowanceForUncollectableBalancesAmount" scale="0" unitRef="usd">446,527</ix:nonFraction> as
of September 30, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Inventories, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at net realizable value
using weighted average method. Costs include the cost of raw materials, freight, direct labor and related production overhead. Any excess
of the cost over the net realizable value of each item of inventories is recognized as a provision for diminution in the value of inventories.
Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. The
Company evaluates inventories on a quarterly basis for its net realizable value adjustments, and reduces the carrying value of those inventories
that are obsolete or in excess of the forecasted usage to their estimated net realizable value based on various factors including aging,
expiration dates, as applicable, taking into consideration historical and expected future product sales. The Company recorded inventory
reserve of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">120,286</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">116,453</ix:nonFraction> as of September 30, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" continuedAt="_AdvancesToSuppliersNetPolicyTextBlock-c0_cont_1" escape="true" name="upc:AdvancesToSuppliersNetPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Advances to suppliers, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation id="_AdvancesToSuppliersNetPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -0.4pt">Advances to suppliers
represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices for raw materials. These advances
are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time to make
cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company when
the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific allowances
when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September 30, 2022
and 2021, no allowance for doubtful accounts was deemed necessary, as the Company believes that all advances to suppliers are fully realizable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -0.4pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" continuedAt="_DeferredChargesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredChargesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Deferred initial public offering (&#8220;IPO&#8221;) costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation id="_DeferredChargesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company complies with the requirement of the
ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses of Offering&#8221;. Deferred offering
costs consist of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related
to the intended IPO. Deferred offering costs were charged to shareholders&#8217; equity upon the completion of the IPO on March 25, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" continuedAt="_HeldToMaturityInvestmentPolicyTextBlock-c0_cont_1" escape="true" name="upc:HeldToMaturityInvestmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Short-term investments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation id="_HeldToMaturityInvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s short-term investments consist
of wealth management financial products purchased from a financial institution, which can be redeemed anytime. The financial institution
invests the Company&#8217;s fund in certain financial instruments including money market funds and bonds to generate investment income.
The short-term investments are deemed to be trading securities and are measured subsequently at fair value in the statement of financial
position. Unrealized holding gains and losses for investment are included in the consolidated statements of operations and comprehensive
income over the investment period (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair value of financial instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize
the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Level 1&#8201;&#8212;&#8201;inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities
in active markets.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Level 2&#8201;&#8212;&#8201;inputs to the valuation methodology include quoted prices for similar assets
and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than
quoted prices that are observable and inputs derived from or corroborated by observable market data.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>Level 3&#8201;&#8212;&#8201;inputs to the valuation methodology are unobservable.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise disclosed, the fair value of
the Company&#8217;s financial instruments, including cash, accounts receivable, inventories, short-term investments, advances to suppliers,
prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current liabilities, taxes
payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September 30, 2022 and 2021
based upon the short-term nature of the assets and liabilities. The Company&#8217;s investment in equity securities is accounted for using
the measurement alternative in accordance with ASC 321, which also approximate its recorded value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Property, plant and equipment</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property, plant and equipment are stated at cost
less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is provided using the straight-line
method over their expected useful lives, as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:nonNumeric contextRef="c0" escape="true" name="upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c66" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">20</ix:nonNumeric> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c67" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c68" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Automobiles</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c70" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office and electric equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c72" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> years</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenditures for maintenance and repairs, which
do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments
which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired
or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated statements of income and other
comprehensive income in other income or expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Property, plant and equipment (continued)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews the carrying value of property,
plant, and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable
from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future
cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the
fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and
prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors.
Based on this assessment, no impairment expenses for property, plant, and equipment were recorded in operating expenses for the years
ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Intangible Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets consist primarily of land use
rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot be sold to an individual or company.
The government grants individuals and companies the right to use parcels of land for specified periods of time. Land use rights are stated
at cost less accumulated amortization. Intangible assets are amortized using the straight-line method with the following estimated useful
lives:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Land use rights</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="us-gaap:IntermediateLifePlantsUsefulLife">50</ix:nonNumeric> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Software</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c74" format="ixt-sec:duryear" name="us-gaap:IntermediateLifePlantsUsefulLife">3</ix:nonNumeric> years</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews the carrying value of land
use rights for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the
estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash
flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair
value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects,
the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this
assessment, no impairment of land use rights was deemed necessary for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:nonNumeric contextRef="c0" continuedAt="_ConstructionContractorsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConstructionContractorsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Construction-in-Progress (&#8220;CIP&#8221;)</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation id="_ConstructionContractorsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CIP represents property and buildings under construction
and consists of construction expenditures, equipment procurement, and other direct costs attributable to the construction. CIP is not
depreciated. Upon completion and ready for intended use, CIP is reclassified to the appropriate category within property, plant and equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Impairment of long-lived Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets with finite lives, primarily
property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash flows from the use of the asset and its
eventual disposition below are the asset&#8217;s carrying value, then the asset is deemed to be impaired and written down to its fair
value. There were no impairments of these assets as of September 30, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:nonNumeric contextRef="c0" continuedAt="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Investments in Equity Securities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_2" id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its equity investments
in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 321 &#8220;Investments&#8212;Equity Securities&#8221; (&#8220;ASC
321&#8221;). In accordance with ASC 321, equity investment which the Company has no significant influence (generally less than a <ix:nonFraction contextRef="c61" decimals="2" format="ixt:num-dot-decimal" name="upc:EquityMethodInvestmentOwnershipsPercentage" scale="-2" unitRef="pure">20</ix:nonFraction>% ownership
interest) with readily determinable fair values are accounted for at fair value based on quoted market prices with the changes in fair
value recognized as unrealized gains or losses in earnings. Equity investments without readily determinable fair values are accounted
for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured
at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical
or a similar investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_3" id="_InvestmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From March 2009 to September 2017, the Company
invested approximately $<ix:nonFraction contextRef="c62" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="6" unitRef="usd">0.7</ix:nonFraction> million (RMB<ix:nonFraction contextRef="c62" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="6" unitRef="cny">5</ix:nonFraction> million) in Jiangxi Jian Rural Commercial Bank (&#8220;JX RCB Bank&#8221;) in exchange for <ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="upc:EquityMethodInvestmentOwnershipsPercentage" scale="-2" unitRef="pure">5</ix:nonFraction>%
ownership interest in the bank. The purpose of entering into these equity investment agreements with JX RCB Bank was to earn investment
income as the bank continues to grow. The Company determined that this investment in equity securities does not have a readily determinable
fair value and, accordingly, elected the measurement alternative noted above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_4" id="_InvestmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company initially recorded the investments
at historical cost and subsequently records any dividends received from the net accumulated earnings of the investee as income. As of
September 30, 2022 and 2021, this investment amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="0" unitRef="usd">702,890</ix:nonFraction> (RMB <ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="6" unitRef="cny">5</ix:nonFraction> million) and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="0" unitRef="usd">744,924</ix:nonFraction> (RMB <ix:nonFraction contextRef="c4" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="6" unitRef="cny">5</ix:nonFraction> million), respectively, and was
reported as long-term investment in equity investee on the consolidated balance sheets. Investment income amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetInvestmentIncome" scale="0" unitRef="usd">38,588</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetInvestmentIncome" scale="0" unitRef="usd">30,827</ix:nonFraction>
and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetInvestmentIncome" scale="0" unitRef="usd">21,820</ix:nonFraction> for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The investments in equity securities are evaluated
for impairment when facts or circumstances indicate that the fair value of the investment is less than its carrying value. An impairment
is recognized when a decline in fair value is determined to be other-than-temporary. The Company reviews several factors to determine
whether a loss is other-than-temporary. These factors include, but are not limited to, the: (i) nature of the investment; (ii) cause and
duration of the impairment; (iii) extent to which fair value is less than cost; (iv) financial condition and near-term prospects of the
investments; and (v) ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in fair value.
There was no impairment for the Company&#8217;s investments in equity securities as of September 30, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To determine revenue recognition for contracts
with customers, the Company performs the following five steps : (i) identify the contract(s) with the customer, (ii) identify the performance
obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable
that a significant future reversal will <i>not</i> occur, (iv) allocate the transaction price to the respective performance obligations
in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue when it transfers
its goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange.
The Company accounts for the revenue generated from sales of its TCMD and third-party products on a gross basis, as the Company is acting
as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling
the promise to provide customers the specified goods, which the Company has control of the goods and has the ability to direct the use
of goods to obtain substantially all the benefits. All of the Company&#8217;s contracts have one single performance obligation, namely,
the promise is to transfer the individual goods to customers, and there is no separately identifiable other promise in the contracts.
The Company&#8217;s revenue streams are recognized at a point in time when title and risk of loss passes and the customer accepts the
goods, which generally occurs at delivery. The Company&#8217;s products are sold with no right of return and the Company does not provide
other credits or sales incentive to customers. Revenue is reported net of all value added taxes (&#8220;VAT&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:nonNumeric contextRef="c0" continuedAt="_ContractAssetsAndLiabilitiesPolicyTextBlock-c0_cont_1" escape="true" name="upc:ContractAssetsAndLiabilitiesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contract Assets and Liabilities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:continuation id="_ContractAssetsAndLiabilitiesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment terms are established on the Company&#8217;s
pre-established credit requirements based upon an evaluation of customers&#8217; credit quality. Contract assets are recognized for in
related accounts receivable. Contract liabilities are recognized for contracts where payment has been received in advance of delivery.
The contract liability balance can vary significantly depending on the timing when an order is placed and when shipment or delivery occurs.
As of September 30, 2022 and 2021, the Company did not have contract assets and contract liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:nonNumeric contextRef="c0" continuedAt="_DisaggregationOfRevenuesPolicyTextBlock-c0_cont_1" escape="true" name="upc:DisaggregationOfRevenuesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Disaggregation of Revenues</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:continuation id="_DisaggregationOfRevenuesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disaggregates its revenue from contracts
by product types, as the Company believes it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows
are affected by economic factors. The Company&#8217;s disaggregation of revenues for the years ended September 30, 2022, 2021 and 2020
are disclosed in Note 19 of these consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:nonNumeric contextRef="c0" continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of revenue</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:continuation id="_CostOfSalesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenue consists primarily of the costs
of raw materials, freight charges, direct labor, depreciation of plants and machinery, warehousing and overhead associated with the manufacturing
process.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and development expenses</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expenses all internal research and
development costs as incurred, which primarily comprise employee costs, internal and external costs related to execution of studies, including
manufacturing costs, facility costs of the research center, and amortization and depreciation to intangible assets and property, plant
and equipment used in the research and development activities. For the years ended September 30, 2022, 2021 and 2020, total research and
development expense were approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">7,644,375</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">5,465,662</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">583,125</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:nonNumeric contextRef="c0" continuedAt="_ShippingAndHandlingCostPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ShippingAndHandlingCostPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Shipping and handling costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:continuation id="_ShippingAndHandlingCostPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shipping and handling costs are expensed as incurred.
Inbound shipping and handling cost associated with bringing the purchased raw materials and third-party products from suppliers to the
Company&#8217;s warehouse are included in cost of revenue. Outbound shipping and handling costs associated with shipping and delivery
the products to customers are included in selling expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:nonNumeric contextRef="c0" continuedAt="_AdvertisingCostsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Advertising expense</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:continuation id="_AdvertisingCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising expenses primarily relate to promotion
of the Company&#8217;s brand name and products through outdoor billboards, social media such as Weibo and WeChat, and TV advertisement.
Advertising costs are expensed as incurred or deferred and then expensed the first time the advertising takes place. Advertising expenses
are included in selling expenses in the consolidated statements of income and comprehensive income. Advertising expenses amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd">17,527,318</ix:nonFraction>,
$<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd">1,316,654</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd">343,962</ix:nonFraction> for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Segment Reporting</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the management approach in determining
reportable operating segments. The management approach considers the internal reporting used by the Company&#8217;s chief operating decision
maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining
the Company&#8217;s reportable operating segments. Management has determined that the Company has one operating segment (See Note 19).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Income taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for current income taxes
in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between
the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected
to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the
period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount
expected to be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An uncertain tax position is recognized only if
it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination. The amount recognized is the largest
amount of tax benefit that is greater than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="upc:TaxBenefitPercentage" scale="-2" unitRef="pure">50</ix:nonFraction>% likely of being realized on examination. For tax positions not meeting the &#8220;more
likely than not&#8221; test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified
as income tax expense in the period incurred. No significant penalties or interest relating to income taxes have been incurred during
the years ended September 30, 2022, 2021 and 2020. The Company does not believe there was any uncertain tax provision at September 30,
2022 and September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operating subsidiary in China
is subject to the income tax laws of the PRC. No significant income was generated outside the PRC for the years ended September 30, 2022,
2021 and 2020. As of September 30, 2022, all of the tax returns of the Company&#8217;s PRC subsidiaries remain open for statutory examination
by PRC tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_68" id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:nonNumeric contextRef="c0" continuedAt="_ValueAddedTaxPolicyTextBlock-c0_cont_1" escape="true" name="upc:ValueAddedTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Value added tax (&#8220;VAT&#8221;)</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_69" id="_SignificantAccountingPoliciesTextBlock-c0_cont_68"><ix:continuation id="_ValueAddedTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales revenue represents the invoiced value of
goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfVatRate" scale="-2" unitRef="pure">17</ix:nonFraction>% (starting from May 1, 2018, VAT rate was lowered
to <ix:nonFraction contextRef="c64" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfVatRate" scale="-2" unitRef="pure">16</ix:nonFraction>%, and starting from April 1, 2019, VAT rate was further lowered to <ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfVatRate" scale="-2" unitRef="pure">13</ix:nonFraction>%), depending on the type of products sold. The VAT may be
offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products.
The Company recorded a VAT payable or receivable net of payments in the accompanying consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_70" id="_SignificantAccountingPoliciesTextBlock-c0_cont_69"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Earnings per Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_71" id="_SignificantAccountingPoliciesTextBlock-c0_cont_70"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes earnings per share (&#8220;EPS&#8221;)
in accordance with ASC 260, &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;). ASC 260 requires companies with complex capital
structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common shares outstanding
for the period. Diluted presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options
and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares
that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation
of diluted EPS. For the years ended September 30, 2022, 2021 and 2020, there were no dilutive shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_72" id="_SignificantAccountingPoliciesTextBlock-c0_cont_71"><ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Foreign currency translation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_73" id="_SignificantAccountingPoliciesTextBlock-c0_cont_72"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The functional currency for Universe INC is the
U.S Dollar (&#8220;US$&#8221;). Universe HK uses Hong Kong dollar as its functional currency. However, Universe INC and Universe HK currently
only serve as holding companies and did not have active operations as of the date of this report. The Company operates only in the PRC
and the Company&#8217;s functional currency is the Chinese Yuan (&#8220;RMB&#8221;). The Company&#8217;s consolidated financial statements
have been translated into the reporting currency US$.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_74" id="_SignificantAccountingPoliciesTextBlock-c0_cont_73"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities of the Company are translated
at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated
at the average rate of exchange during the reporting period. The resulting translation adjustments are reported under other comprehensive
income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the results of
operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_75" id="_SignificantAccountingPoliciesTextBlock-c0_cont_74"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The RMB is not freely convertible into foreign
currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB
amounts could have been, or could be, converted into US$ at the rates used in translation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_76" id="_SignificantAccountingPoliciesTextBlock-c0_cont_75"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_5" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table outlines the currency exchange
rates that were used in creating the consolidated financial statements in this report:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_77" id="_SignificantAccountingPoliciesTextBlock-c0_cont_76"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>September&#160;30, <br/>
2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>September&#160;30, <br/>
2021</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>September&#160;30, <br/>
2020</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Year-end spot rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c0" name="upc:DescriptionOfYearEndSpotRate"><span style="font-size: 10pt">US$1=RMB7.1135</span></ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c4" name="upc:DescriptionOfYearEndSpotRate"><span style="font-size: 10pt">US$1=RMB6.4580</span></ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c5" name="upc:DescriptionOfYearEndSpotRate"><span style="font-size: 10pt">US$1=RMB6.8033</span></ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c0" name="upc:DescriptionOfAverageRate"><span style="font-size: 10pt">US$1=RMB6.5532</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c4" name="upc:DescriptionOfAverageRate"><span style="font-size: 10pt">US$1=RMB6.5095</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c5" name="upc:DescriptionOfAverageRate"><span style="font-size: 10pt">US$1=RMB7.0077</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_78" id="_SignificantAccountingPoliciesTextBlock-c0_cont_77"><ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Comprehensive income</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_79" id="_SignificantAccountingPoliciesTextBlock-c0_cont_78"><ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comprehensive income consists of two components,
net income and other comprehensive income. The foreign currency translation gain resulting from translation of the financial statements
expressed in RMB to US$ is reported in other comprehensive income in the consolidated statements of income and comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_80" id="_SignificantAccountingPoliciesTextBlock-c0_cont_79"><ix:nonNumeric contextRef="c0" continuedAt="_StatementOfCashFlowsPolicyTextBlock-c0_cont_1" escape="true" name="upc:StatementOfCashFlowsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Statement of Cash Flows</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_81" id="_SignificantAccountingPoliciesTextBlock-c0_cont_80"><ix:continuation id="_StatementOfCashFlowsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 230, &#8220;Statement of
Cash Flows&#8221;, cash flows from the Company&#8217;s operations are formulated based upon the local currencies. As a result, amounts
related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding
balances on the balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_82" id="_SignificantAccountingPoliciesTextBlock-c0_cont_81"><ix:nonNumeric contextRef="c0" continuedAt="_EmployeeDefinedContributionPlanPolicyTextBlock-c0_cont_1" escape="true" name="upc:EmployeeDefinedContributionPlanPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Employee Defined Contribution Plan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_83" id="_SignificantAccountingPoliciesTextBlock-c0_cont_82"><ix:continuation id="_EmployeeDefinedContributionPlanPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiaries in the PRC participate
in a government-mandated multi-employer defined contribution plan pursuant to which pension, work-related injury benefits, maternity insurance,
medical insurance, unemployment benefit and housing fund are provided to eligible full-time employees. The relevant labor regulations
require the Company&#8217;s subsidiaries in the PRC to pay the local labor and social welfare authorities monthly contributions based
on the applicable benchmarks and rates stipulated by the local government. The contributions to the plan are expensed as incurred. Employee
social security and welfare benefits included as expenses in the accompanying statements of income and comprehensive income amounted to
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd">465,689</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd">617,145</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd">347,312</ix:nonFraction> for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_84" id="_SignificantAccountingPoliciesTextBlock-c0_cont_83"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_85" id="_SignificantAccountingPoliciesTextBlock-c0_cont_84"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU 2016-13, Financial
Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the
reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing
incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. ASU 2016-13
was subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2020-02. For public entities, ASU 2016-13 and its
amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. For all other
entities, this guidance and its amendments will be effective for fiscal years beginning after December 15, 2022, including interim periods
within those fiscal years. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2018. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_85"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2020, the FASB issued ASU 2020-10,
&#8220;Codification Improvements to Subtopic 205-10, presentation of financial statements&#8221;. The amendments in this Update improve
the codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to
financial statements is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement
would be missed. ASU 2020-10 is effective for the Company for annual and interim reporting periods beginning January 1, 2022. Early application
of the amendments is permitted for any annual or interim period for which financial statements are available to be issued. The amendments
in this Update should be applied retrospectively. An entity should apply the amendments at the beginning of the period that includes the
adoption date. The Company is currently evaluating the impact of this new standard on Company&#8217;s consolidated financial statements
and related disclosures.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8212; ACCOUNTS RECEIVABLE, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_2" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_3" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" unitRef="usd">15,975,717</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" unitRef="usd">16,020,269</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd">791,827</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd">446,527</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Accounts receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">15,183,890</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">15,573,742</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c0" name="upc:AccountsReceivableDescription"><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_4" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s accounts receivable primarily
includes the balance due from customers when the Company&#8217;s pharmaceutical products are sold and delivered to customers. All of the
Company&#8217;s accounts receivable balance at September 30, 2021 has been collected in the fiscal year 2022. As of date of this report,
approximately 71.9%, or $10.9 million, of the Company&#8217;s net account receivable balance at September 30, 2022 has been subsequently
collected and the remaining balance is expected to be substantially collected before March 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_5" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the Company&#8217;s accounts receivable
and subsequent collection by aging bucket:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_6" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Accounts Receivable by aging bucket</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance as of September 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Subsequent collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of subsequent collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Less than 3 months</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="upc:AccountsReceivableBeforeGrossValue" scale="0" unitRef="usd">6,673,685</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="upc:SubsequentCollection" scale="0" unitRef="usd">4,135,508</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c76" decimals="3" format="ixt:num-dot-decimal" name="upc:PercentageOfSubsequentCollection" scale="-2" unitRef="pure">62.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>From 4 to 6 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="upc:AccountsReceivableBeforeGrossValue" scale="0" unitRef="usd">6,970,635</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="upc:SubsequentCollection" scale="0" unitRef="usd">5,360,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c78" decimals="3" format="ixt:num-dot-decimal" name="upc:PercentageOfSubsequentCollection" scale="-2" unitRef="pure">76.9</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>From 7 to 9 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="upc:AccountsReceivableBeforeGrossValue" scale="0" unitRef="usd">1,554,318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="upc:SubsequentCollection" scale="0" unitRef="usd">1,089,957</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="3" format="ixt:num-dot-decimal" name="upc:PercentageOfSubsequentCollection" scale="-2" unitRef="pure">70.1</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>From 10 to 12 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="upc:AccountsReceivableBeforeGrossValue" scale="0" unitRef="usd">285,871</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="upc:SubsequentCollection" scale="0" unitRef="usd">180,564</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="3" format="ixt:num-dot-decimal" name="upc:PercentageOfSubsequentCollection" scale="-2" unitRef="pure">63.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Over 1 year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="upc:AccountsReceivableBeforeGrossValue" scale="0" unitRef="usd">491,208</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="upc:SubsequentCollection" scale="0" unitRef="usd">152,711</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c84" decimals="3" format="ixt:num-dot-decimal" name="upc:PercentageOfSubsequentCollection" scale="-2" unitRef="pure">31.1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total gross accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGross" scale="0" unitRef="usd">15,975,717</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:SunsequentCollectionsTotalGrossAccountsReceivable" scale="0" unitRef="usd">10,918,976</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="upc:TotalGrossAccountsReceivablePercentage" scale="-2" unitRef="pure">68.3</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss" scale="0" unitRef="usd">791,827</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Accounts Receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd">15,183,890</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:SunsequentCollectionAccountsReceivableNet" scale="0" unitRef="usd">10,918,976</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="upc:AccountsReceivableNetPercentage" scale="-2" unitRef="pure">71.9</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>



</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8212; ACCOUNTS RECEIVABLE, NET (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_7" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Allowance for doubtful accounts movement is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Beginning balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd">446,527</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd">639,991</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="0" unitRef="usd">419,353</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debt recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="0" unitRef="usd">225,660</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" scale="0" sign="-" unitRef="usd">74,053</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" scale="0" unitRef="usd">32,196</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd">791,827</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd">446,527</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_InventoryDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 4 &#8212; INVENTORY, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_InventoryDisclosureTextBlock-c0_cont_2" id="_InventoryDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_InventoryDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd">989,043</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd">607,661</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd">1,337,731</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd">1,971,334</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Inventory valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">120,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">116,453</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total inventory, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,206,488</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,462,542</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AdvancesToSuppliersTextBlock-c0_cont_1" escape="true" name="upc:AdvancesToSuppliersTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8212; ADVANCE TO SUPPLIERS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_AdvancesToSuppliersTextBlock-c0_cont_2" id="_AdvancesToSuppliersTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advances to suppliers consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AdvancesToSuppliersTextBlock-c0_cont_3" id="_AdvancesToSuppliersTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="upc:ScheduleOfAdvancesToSuppliersNet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advances to suppliers for inventory raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="0" unitRef="usd">16,701</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="0" unitRef="usd">2,738,313</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Advances to suppliers, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToSuppliersAndEmployees" scale="0" unitRef="usd">16,701</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToSuppliersAndEmployees" scale="0" unitRef="usd">2,738,313</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation id="_AdvancesToSuppliersTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advances to suppliers represent prepayments made
to suppliers to ensure continuous high-quality supplies and favorable purchase prices for raw materials.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PrepaymentForAdvertistingTextBlock-c0_cont_1" escape="true" name="upc:PrepaymentForAdvertistingTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 &#8212; PREPAYMENT FOR ADVERTISTING</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_PrepaymentForAdvertistingTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 6, 2021, the Company entered into
an advertising service agreement with a third-party, Guangdong Fengyang Legend Consulting Co., Ltd. (&#8220;Fengyang Legend&#8221;), pursuant
to which, Fengyang Legend assisted the Company in developing and producing TV advertising films for the Company in order to promote the
Company&#8217;s sales of its major TCMD product, Bainian Pill and Guben Yanling Pill, and coordinating the specific TV Channel to broadcast
the advertising films to targeted geographic market areas. The total contracted advertising service fee was RMB<ix:nonFraction contextRef="c85" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" scale="6" unitRef="cny">55</ix:nonFraction> million (approximately
$<ix:nonFraction contextRef="c85" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" scale="6" unitRef="usd">8.5</ix:nonFraction> million), with an adverting consulting service period of one year from October 1, 2021 to September 30, 2022. Based on contract terms,
the Company was required to make a <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfAdvancePayment" scale="-2" unitRef="pure">30</ix:nonFraction>% advance payment to Fengyang Legend within 7 business days upon signing the service agreement and
make an additional <ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="upc:AdditionalContractPricePercentage" scale="-2" unitRef="pure">58</ix:nonFraction>% of the contract price to Fengyang Legend when the specific TV channel used for broadcast the TV film was determined.
In fiscal year 2021, the Company paid RMB<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="6" unitRef="cny">48.4</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="6" unitRef="usd">7.5</ix:nonFraction> million), the amount was recorded as prepayment for advertising
on the balance sheets as of September 30, 2021, and recognized as selling expense during fiscal year 2022. The remaining <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="upc:ContractPricePercentage" scale="-2" unitRef="pure">12</ix:nonFraction>% of the contract
price, RMB<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" unitRef="cny">6.6</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" unitRef="usd">0.9</ix:nonFraction> million), represented the monthly advertising fees payable when the advertising film was broadcasted
through the designated TV channels during the service period.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PrepaymentForAcquisitionTextBlock-c0_cont_1" escape="true" name="upc:PrepaymentForAcquisitionTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 &#8212; PREPAYMENT FOR ACQUISITION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_PrepaymentForAcquisitionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2022, the Company entered into
a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to which, Mr. Xibo Liu transfers his <ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="upc:EquityMethodInvestmentOwnershipsPercentage" scale="-2" unitRef="pure">51</ix:nonFraction>% ownership
in Yunnan Faxi Pharmaceuticals Co., Ltd. (&#8220;Yunnan Faxi&#8221;) to the Company at the price of RMB<ix:nonFraction contextRef="c87" decimals="-6" format="ixt:num-dot-decimal" name="upc:AssetAcquisitionPriceOfAcquisitionsExpected" scale="6" unitRef="cny">72</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c88" decimals="-5" format="ixt:num-dot-decimal" name="upc:AssetAcquisitionPriceOfAcquisitionsExpected" scale="6" unitRef="usd">10.1</ix:nonFraction>
million). Based on contract terms, the Company prepaid RMB<ix:nonFraction contextRef="c88" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" unitRef="cny">25</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c88" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" unitRef="usd">3.5</ix:nonFraction> million) within 3 business days upon signing
the letter of intent. As of September 30, 2022, the prepayment was recorded as prepayment for acquisition on the balance sheets. The intended
acquisition is expected to be completed and the remaining balance is expected to be paid in June 2023.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_HeldToMaturityInvestmentDisclosureTextBlock-c0_cont_1" escape="true" name="upc:HeldToMaturityInvestmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 &#8212; SHORT-TERM INVESTMENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_HeldToMaturityInvestmentDisclosureTextBlock-c0_cont_2" id="_HeldToMaturityInvestmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s short-term investments consist
of wealth management financial products purchased from financial institution, which can be redeemed anytime at the Company&#8217;s discretion.
The financial institution invests the Company&#8217;s fund in certain financial instruments including money market funds and bonds to
generate investment income. Short-term investments consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_HeldToMaturityInvestmentDisclosureTextBlock-c0_cont_3" id="_HeldToMaturityInvestmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:HeldToMaturitySecuritiesTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Beginning balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">13,725,204</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Add: purchase wealth management financial products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:AddPurchaseWealthManagementFinancialProducts" scale="0" unitRef="usd">15,330,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: redemption</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" unitRef="usd">1,801,927</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued investment income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable" scale="0" sign="-" unitRef="usd">470,477</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable" scale="0" unitRef="usd">239,549</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="0" sign="-" unitRef="usd">106,133</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="0" sign="-" unitRef="usd">43,078</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Ending balance of short-term investments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">13,148,594</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">13,725,204</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_HeldToMaturityInvestmentDisclosureTextBlock-c0_cont_3"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment income (loss) generated from such short-term investments
amounted to ($<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="0" unitRef="usd">470,477</ix:nonFraction>), $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="0" unitRef="usd">239,549</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-73">Nil</span> for the years ended September 30, 2022, 2021 and 2020, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 &#8212; PROPERTY, PLANT AND EQUIPMENT, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property, plant and equipment, net, consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c66" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">20</ix:nonNumeric> years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">7,492,360</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">7,808,006</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c67" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric>-<ix:nonNumeric contextRef="c68" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">77,932</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">2,047,338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Automobiles</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c70" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,912,525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">116,370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Office and electric equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c72" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">477,919</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">489,886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">9,960,736</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">10,461,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">5,710,098</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">5,780,247</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">4,250,638</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">4,681,353</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">528,919</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">441,355</ix:nonFraction> and
$<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">404,948</ix:nonFraction> for the years ended September 30, 2022, 2021 and 2020, respectively. Loss from disposal of fixed assets amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="0" unitRef="usd">983</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="0" unitRef="usd">1,559</ix:nonFraction>
and <span style="-sec-ix-hidden: hidden-fact-74">Nil</span> for the years ended September 30, 2022, 2021 and 2020, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 &#8212; INTANGIBLE ASSETS, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_2" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intangible assets, net consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_3" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Land use rights</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric> years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">252,757</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">278,327</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c99" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">5</ix:nonNumeric>-<ix:nonNumeric contextRef="c100" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">21,217</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">23,364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">273,974</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">301,691</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" sign="-" unitRef="usd">116,523</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" sign="-" unitRef="usd">123,208</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">157,451</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">178,483</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_4" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amortization expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">5,030</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">5,523</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">5,131</ix:nonFraction> for the years ended
September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_5" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Estimated future amortization expense for intangible assets is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IntangibleAssetsDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Years ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization<br/>
 expense</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" scale="0" unitRef="usd">5,055</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" scale="0" unitRef="usd">5,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" scale="0" unitRef="usd">5,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" scale="0" unitRef="usd">5,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" scale="0" unitRef="usd">5,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" scale="0" unitRef="usd">132,176</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">157,451</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PrepaymentForConstructionInProgressTextBlock-c0_cont_1" escape="true" name="upc:PrepaymentForConstructionInProgressTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11 &#8212; PREPAYMENT FOR CIP PROJECT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PrepaymentForConstructionInProgressTextBlock-c0_cont_2" id="_PrepaymentForConstructionInProgressTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CIP represents direct costs of construction incurred
for the Company&#8217;s manufacturing facilities. On June 25, 2021, the Company signed a construction sub-contract with sub-contractor
Jiangxi Chenyuan Construction Project Co., Ltd. (&#8220;Chenyuan&#8221;), pursuant to which, Chenyuan will help the Company construct
four manufacturing plant buildings and an office building with a total estimated budget of RMB<ix:nonFraction contextRef="c104" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InvestmentBuildingAndBuildingImprovements" scale="6" unitRef="cny">165</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c104" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentBuildingAndBuildingImprovements" scale="6" unitRef="usd">23.2</ix:nonFraction> million).
The construction work started on August 8, 2021, with an originally estimated completion date on August 7, 2023. However, due to resurgence
of the COVID-19 pandemic, which resulted in lingering logistic disruption, material and labor shortage, and domestic travel restriction,
the construction work is estimated to be completed in December 2024, and Chenyuan will bear the increased material and labor costs. As
of September 30, 2022, the Company had made a prepayment of approximately RMB<ix:nonFraction contextRef="c105" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentBuildingAndBuildingImprovements" scale="6" unitRef="cny">69.2</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c105" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentBuildingAndBuildingImprovements" scale="6" unitRef="usd">9.7</ix:nonFraction> million) to Chenyuan for
land improvement, building foundation and the construction of the main body of the manufacturing plants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PrepaymentForConstructionInProgressTextBlock-c0_cont_3" id="_PrepaymentForConstructionInProgressTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2022, $<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionContractCostProgressPaymentOffset" scale="0" unitRef="usd">401,702</ix:nonFraction> (approximately
RMB<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConstructionContractCostProgressPaymentOffset" scale="6" unitRef="cny">2.9</ix:nonFraction> million) of the prepayment for the CIP project had been used for construction work, and the amount was recorded as property, plant
and equipment in the consolidated balance sheets. As of September 30, 2022, the remaining $<ix:nonFraction contextRef="c107" decimals="-5" format="ixt:num-dot-decimal" name="upc:Prepayment" scale="6" unitRef="usd">9.3</ix:nonFraction> million prepayment to Chenyuan was recorded
as a prepayment for CIP project on the balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PrepaymentForConstructionInProgressTextBlock-c0_cont_4" id="_PrepaymentForConstructionInProgressTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2022, future additional capital
expenditure on this CIP project is estimated to be approximately RMB<ix:nonFraction contextRef="c108" decimals="-5" format="ixt:num-dot-decimal" name="upc:CapitalExpenditure" scale="6" unitRef="cny">95.8</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c108" decimals="-5" format="ixt:num-dot-decimal" name="upc:CapitalExpenditure" scale="6" unitRef="usd">13.5</ix:nonFraction> million), among which approximately
$<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="upc:CapitalExpenditure" scale="6" unitRef="usd">3.5</ix:nonFraction> million is required for the next 12 months. The Company currently plans to support its ongoing CIP project construction through
cash flows from operations, proceeds received from the IPO, and borrowings from PRC banks in the future and use such bank borrowings to
support the CIP project, if necessary. The construction of the four manufacturing plant buildings and the office building is expected
to be fully completed and put into use by December 2024 and December 2025, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PrepaymentForConstructionInProgressTextBlock-c0_cont_5" id="_PrepaymentForConstructionInProgressTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2022, future minimum capital
expenditures on the Company&#8217;s CIP project are estimated as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PrepaymentForConstructionInProgressTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Years ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital<br/>
 Expenditure<br/>
 on CIP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd">3,479,306</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" unitRef="usd">9,988,066</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">13,467,372</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PrepaymentForPurchaseOfAPropertyTextBlock-c0_cont_1" escape="true" name="upc:PrepaymentForPurchaseOfAPropertyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 &#8212; PREPAYMENT FOR PURCHASE OF A PROPERTY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PrepaymentForPurchaseOfAPropertyTextBlock-c0_cont_2" id="_PrepaymentForPurchaseOfAPropertyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2021, the Company entered into a real
estate property purchase agreement with related party Jiangxi Yueshang Investment Co., Ltd. (&#8220;Jiangxi Yueshang&#8221;), an entity
in which the Company&#8217;s chief executive officer, Mr. Gang Lai, owned <ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="upc:EquityInterest" scale="-2" unitRef="pure">5</ix:nonFraction>% equity interest as of the date of that agreement. Pursuant
to the property purchase agreement, Jiangxi Yueshang will sell and the Company will purchase a certain residential apartment and commercial
office space totaling <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="upc:OfficeSpaceSquareMeters" scale="0" unitRef="pure">2,749</ix:nonFraction>.30 square meters, with a total purchase price of RMB<ix:nonFraction contextRef="c110" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SupplementalDeferredPurchasePrice" scale="6" unitRef="cny">32</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c110" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:SupplementalDeferredPurchasePrice" scale="6" unitRef="usd">4.50</ix:nonFraction> million). Pursuant to
this agreement, the Company was required to make a prepayment in the amount of <ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfPrepayment" scale="-2" unitRef="pure">50</ix:nonFraction>% of the total purchase price, with <ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure">20</ix:nonFraction>% of the total
purchase price payable upon the availability of a certificate of occupancy, and <ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="upc:PayableDeliveryPropertyPercentage" scale="-2" unitRef="pure">30</ix:nonFraction>% of the total purchase price payable upon delivery
of the property.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PrepaymentForPurchaseOfAPropertyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2022, the Company had made
a prepayment of RMB<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="6" unitRef="cny">16</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c0" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="6" unitRef="usd">2.25</ix:nonFraction> million) to Jiangxi Yueshang. The remaining balance is expected to be paid by August
2024. Since the property is located in the urban downtown area of Ji&#8217;an City, the Company plans to use the property for offices
in late 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 &#8212; SHORT-TERM BANK LOANS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term bank loans consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_3" id="_DebtDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c4" continuedAt="_ScheduleOfShortTermDebtTextBlock-c4_cont_1" escape="true" name="us-gaap:ScheduleOfShortTermDebtTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Short-term bank loans:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Maturity date on June 15, 2022, interest rate 4.81% per annum</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">(1)</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,548,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maturity date on March 17, 2022, interest rate 4.81% per annum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(2)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,238,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Maturity date on March 13, 2023, interest rate 4.62% per annum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(3)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,124,624</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maturity date on June 14, 2023, interest rate 4.62% per annum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(4)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,405,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bank of Communications Co., Ltd</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maturity date on June 30, 2022, interest rate 4.50% per annum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(5)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,548,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Maturity date on June 24, 2023, interest rate 4.20% per annum</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">(6)</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,405,780</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total short-term loans</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">3,936,184</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">4,334,400</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_4" id="_DebtDisclosureTextBlock-c0_cont_3"><ix:continuation continuedAt="_ScheduleOfShortTermDebtTextBlock-c4_cont_2" id="_ScheduleOfShortTermDebtTextBlock-c4_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">On June 16, 2021, the Company&#8217;s subsidiary, Jiangxi
Universe, signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB<ix:nonFraction contextRef="c112" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="6" unitRef="cny">10</ix:nonFraction> million (equivalent
to $<ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="0" unitRef="usd">1,548,000</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c113" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, with the maturity date on <ix:nonNumeric contextRef="c113" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">June 15, 2022</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c112" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.81</ix:nonFraction>%
per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_5" id="_DebtDisclosureTextBlock-c0_cont_4"><ix:continuation continuedAt="_ScheduleOfShortTermDebtTextBlock-c4_cont_3" id="_ScheduleOfShortTermDebtTextBlock-c4_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US">On March 18, 2021, the Company&#8217;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB<ix:nonFraction contextRef="c114" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="6" unitRef="cny">8</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="0" unitRef="usd">1,238,400</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c115" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, with
the maturity date on <ix:nonNumeric contextRef="c115" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">March 17, 2022</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c114" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.81</ix:nonFraction>% per annum. There was no guarantee requirement for
this loan. The loan was fully repaid upon maturity.</ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_6" id="_DebtDisclosureTextBlock-c0_cont_5"><ix:continuation continuedAt="_ScheduleOfShortTermDebtTextBlock-c4_cont_4" id="_ScheduleOfShortTermDebtTextBlock-c4_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US">On March 14, 2022, the Company&#8217;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB<ix:nonFraction contextRef="c116" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="6" unitRef="cny">8</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="0" unitRef="usd">1,124,624</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c117" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, with
the maturity date on <ix:nonNumeric contextRef="c117" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">March 13, 2023</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c116" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.62</ix:nonFraction>% per annum. There was no guarantee requirement for
this loan.</ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_7" id="_DebtDisclosureTextBlock-c0_cont_6"><ix:continuation continuedAt="_ScheduleOfShortTermDebtTextBlock-c4_cont_5" id="_ScheduleOfShortTermDebtTextBlock-c4_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US">On June 15, 2022, the Company&#8217;s subsidiary, Jiangxi
Universe, entered into a loan agreement with LRC Bank to borrow RMB<ix:nonFraction contextRef="c118" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="6" unitRef="cny">10</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="0" unitRef="usd">1,405,780</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c119" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>,
with the maturity date on <ix:nonNumeric contextRef="c119" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">June 14, 2023</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c118" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.62</ix:nonFraction>% per annum. Certain related parties of the Company,
including Mr. Gang Lai, the Company&#8217;s controlling shareholder, chairman of the board of directors, and chief executive officer,
Ms. Lin Yang, the Company&#8217;s chief financial officer, Ms. Xing Wu, Mr. Gang Lai&#8217;s spouse, and the Company&#8217;s WFOE, Universe
Technology, jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.</ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_8" id="_DebtDisclosureTextBlock-c0_cont_7"><ix:continuation continuedAt="_ScheduleOfShortTermDebtTextBlock-c4_cont_6" id="_ScheduleOfShortTermDebtTextBlock-c4_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(5)</td><td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US">On June 30, 2021, the Company&#8217;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB<ix:nonFraction contextRef="c120" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="6" unitRef="cny">10</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="0" unitRef="usd">1,548,000</ix:nonFraction>) as working capital for
<ix:nonNumeric contextRef="c121" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, with the maturity date on <ix:nonNumeric contextRef="c121" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">June 30, 2022</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c120" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.5</ix:nonFraction>% per annum. Certain related parties of
the Company, including Mr. Gang Lai, the Company&#8217;s controlling shareholder, Mr. Gang Lai&#8217;s spouse, Mrs. Xing Wu, and the
Company&#8217;s subsidiary, Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantees
for this loan. The loan was fully repaid upon maturity.</ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17pt; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_9" id="_DebtDisclosureTextBlock-c0_cont_8"><ix:continuation id="_ScheduleOfShortTermDebtTextBlock-c4_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(6)</td><td style="text-align: justify"><ix:footnote id="ix_5_footnote" xml:lang="en-US">On June 24, 2022, the Company&#8217;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB<ix:nonFraction contextRef="c122" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="6" unitRef="cny">10</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="0" unitRef="usd">1,405,780</ix:nonFraction>) as working capital for
one year, with the maturity date on <ix:nonNumeric contextRef="c123" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">June 24, 2023</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c122" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.2</ix:nonFraction>% per annum. Jiangxi Province Financing
Guarantee Group Co., Ltd., an unrelated third party, signed a guarantee agreement with Bank of Communications to provide credit guarantee
for this loan.</ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_9"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the above-mentioned loans, the Company recorded a total interest
expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">199,852</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">149,303</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">157,528</ix:nonFraction> for the years ended September 30, 2022, 2021 and 2020, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 &#8212; RELATED PARTY TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>(a)
</b></span><b>Nature of relationships with related parties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="text-align: justify; width: 2%">&#160;</td>
    <td style="text-align: justify; border-bottom: Black 1.5pt solid; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company</b></span></td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Gang Lai</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c136" name="us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s controlling shareholder, Chief Executive Officer and chairman of the Company&#8217;s Board of Directors</span></ix:nonNumeric></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Lin Yang</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c137" name="us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Director</span></ix:nonNumeric></td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greatest Group (China) Financial Management Limited (&#8220;Greatest Group&#8221;)</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c138" name="us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One of the Company&#8217;s minority shareholders owns 8.7% of the ownership interest in this entity</span></ix:nonNumeric></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foshan Shangyu Investment Holding Co., Ltd (&#8220;Foshan Shangyu&#8221;)</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c139" name="us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An affiliated entity of the Company, 90% owned by and controlled by the Company&#8217;s Chief Executive Officer</span></ix:nonNumeric></td>
    </tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(b) Due from related parties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="upc:ScheduleOfDueFromRelatedPartiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Name</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Greatest Group</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedPartiesCurrent" scale="0" unitRef="usd">235,438</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foshan Shangyu</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedPartiesCurrent" scale="0" unitRef="usd">1,544</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total due from related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedPartiesCurrent" scale="0" unitRef="usd">236,982</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_6" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s due from related parties were interest free and
due on demand. The September 30, 2021 due from related parties balance has been subsequently collected back and the Company does not have
the intention to make additional cash advance to related parties going forward.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_7" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)
Due to related parties</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_8" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="upc:ScheduleOfDueToRelatedPartiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Name</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Mr. Gang Lai</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="0" unitRef="usd">3,379,263</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mrs. Lin Yang</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="0" unitRef="usd">19,723</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total due to related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="0" unitRef="usd">3,379,263</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="0" unitRef="usd">19,723</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_9" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_8"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of September 30, 2022 and 2021, the balance due to related parties
mainly consisted of advances from the Company&#8217;s officers for working capital purposes during the Company&#8217;s normal course of
business. These advances are non-interest bearing and due on demand.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_10" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Loan guarantee provided by related parties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_11" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company&#8217;s bank borrowings
from Bank of Communications, certain related parties of the Company, including Mr. Gang Lai, the Company&#8217;s controlling shareholder,
chairman of the board of directors, and chief executive officer, Mr. Gang Lai&#8217;s spouse, Ms. Xing Wu, and the Company&#8217;s subsidiary,
Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for these loans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_12" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company&#8217;s bank borrowings
from LRC Bank, the Company&#8217;s chief executive officer, Mr. Gang Lai, signed a guarantee agreement with LRC Bank to provide a credit
guarantee for the Company&#8217;s loans from LRC Bank within the loan period (see Note 13).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 &#8212; RELATED PARTY TRANSACTIONS (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_13" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(e) Prepayment to related party for property purchase</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_14" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c110" name="us-gaap:DeconsolidationRelatedPartyDescription">As disclosed in Note 12, on May 6, 2021, the Company
entered into a real estate property purchase agreement with a related party, Jiangxi Yueshang, to purchase certain residential apartment
and commercial office space totaling 2,749.30 square meters with total purchase price of RMB32 million (approximately $4.5 million).</ix:nonNumeric> As
of September 30, 2022, the Company had made a prepayment of RMB<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="upc:PrepaymentAmount" scale="6" unitRef="cny">16</ix:nonFraction> million ($<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentAmount" scale="0" sign="-" unitRef="usd">2,249,248</ix:nonFraction>) to Jiangxi Yueshang. The remaining balance is expected
to be paid by August 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 13, 2022, Mr. Gang Lai transferred
the <ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="upc:EquityInterestOwnershipPercentage" scale="-2" unitRef="pure">5</ix:nonFraction>% equity interest he owned in Jiangxi Yueshang to a third party. As such, after this date, Jiangxi Yueshang is no longer our related
party.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 &#8212; TAXES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(a) Corporate Income Taxes (&#8220;CIT&#8221;)</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Cayman Islands</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the current tax laws of the Cayman Islands,
Universe INC is not subject to tax on its income or capital gains. In addition, no Cayman Islands withholding tax will be imposed upon
the payment of dividends by the Company to its shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Hong Kong</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Universe HK is incorporated in Hong Kong and is
subject to profit taxes in Hong Kong at a rate of <ix:nonFraction contextRef="c148" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" scale="-2" unitRef="pure">16.5</ix:nonFraction>%. However, Universe HK did not generate any assessable profits derived from Hong
Kong sources for the years ended September 30, 2022, 2021 and 2020, and accordingly no provision for Hong Kong profits tax has been made
in these periods.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">PRC</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Enterprise Income Tax (&#8220;EIT&#8221;)
Law of PRC, domestic enterprises and Foreign Investment Enterprises (&#8220;FIEs&#8221;) are usually subject to a unified <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" unitRef="pure">25</ix:nonFraction>% enterprise
income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on a case-by-case basis. EIT grants preferential
tax treatment to High and New Technology Enterprises (&#8220;HNTEs&#8221;). <ix:nonNumeric contextRef="c0" name="upc:PreferentialTaxTreatmentDescription">Under this preferential tax treatment, HNTEs are entitled
to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one
of the Company&#8217;s main operating subsidiaries in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of
15% beginning November 2016 with a term of three years. In December 2019, Jiangxi Universe successfully renewed its HNTE certification
with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2022. In
November 2022, Jiangxi Universe successfully further renewed its HNTE certification with local government and will continue to enjoy the
reduced income tax rate of 15% for another three years through November 2025. Universe Trade, another operating subsidiary of the Company
in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15% beginning December 2020 with a term of three years
through December 2023. EIT is typically governed by the local tax authority in the PRC. Each local tax authority at times may grant tax
holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the years
ended September 30, 2022, 2021 and 2020 were reported at a blended reduced rate as a result of certain of the PRC subsidiaries of the
Company&#8217;s being approved as a HNTE and enjoying a 15% reduced income tax rate.</ix:nonNumeric> The impact of the tax holidays noted above decreased
PRC corporate income taxes by $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrentAndNoncurrent" scale="0" unitRef="usd">694,955</ix:nonFraction>, $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrentAndNoncurrent" scale="0" unitRef="usd">1,518,979</ix:nonFraction> and $<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrentAndNoncurrent" scale="0" unitRef="usd">118,986</ix:nonFraction> for the years ended September 30, 2022, 2021 and 2020, respectively. The
benefit of the tax holidays on net income per share (basic and diluted) was $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" unitRef="usdPershares">0.03</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" unitRef="usdPershares">0.09</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" unitRef="usdPershares">0.01</ix:nonFraction> for the years ended September 30, 2022,
2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 15 &#8212; TAXES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of the income tax provision (benefit) are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current tax provision:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cayman</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt">PRC</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">1,357,697</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">3,026,867</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,552,097</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Sub-total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">1,357,697</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">3,026,867</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,552,097</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax provision (benefit):</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cayman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#160;</div></td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#160;</div></td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">PRC</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">605,278</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">668,341</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">9,886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in">Sub-total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">605,278</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">668,341</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">9,886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total income tax provision</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">752,419</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,358,526</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,542,211</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">The following table reconciles the China statutory rates to the Company&#8217;s
effective tax rate for the years ended September 30, 2022, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_12" id="_IncomeTaxDisclosureTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Statutory PRC income tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">25.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">25.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">25.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of income tax holiday</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays" scale="-2" unitRef="pure">8.7</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays" scale="-2" unitRef="pure">11.0</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays" scale="-2" unitRef="pure">1.1</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent difference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" sign="-" unitRef="pure">22.3</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-PRC entities not subject to PRC income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" sign="-" unitRef="pure">3.4</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure">2.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure">1.3</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact on DTA due to change in applicable income tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" unitRef="pure">0.6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure">0.5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" sign="-" unitRef="pure">9.4</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">17.1</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">25.2</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_13" id="_IncomeTaxDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company continually evaluates expiring statutes of limitations, audits,
proposed settlements, changes in tax law and new authoritative rulings. As of September 30, 2022, all of the Company&#8217;s tax returns
of its PRC subsidiaries remain open for statutory examination by PRC tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_14" id="_IncomeTaxDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred tax assets are composed of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_15" id="_IncomeTaxDisclosureTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in">Net operating loss carry-forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">1,210,855</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">785,550</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" unitRef="usd">136,817</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" unitRef="usd">84,447</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" unitRef="usd">1,347,672</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" unitRef="usd">869,997</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Valuation allowance</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">1,347,672</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">869,997</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>


</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 15 &#8212; TAXES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_16" id="_IncomeTaxDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically evaluates the likelihood
of the realization of deferred tax assets, and reduces the carrying amount of the deferred tax assets by a valuation allowance to the
extent it believes a portion will not be realized. Management considers new evidence, both positive and negative, that could affect the
Company&#8217;s future realization of deferred tax assets including its recent cumulative earnings experience, expectation of future income,
the carry forward periods available for tax reporting purposes and other relevant factors. Although Jiangxi Universe incurred a net loss
during the year ended September 30, 2022, the Company determined that it is more likely than not that its deferred tax assets could be
realized due to the estimated future earnings in Jiangxi Universe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_17" id="_IncomeTaxDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>(b) Taxes payable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_18" id="_IncomeTaxDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Taxes payable consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" escape="true" name="upc:ScheduleOfTaxPayableTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Income tax payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd">669,780</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Value added tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="0" unitRef="usd">115,087</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="0" unitRef="usd">326,468</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" unitRef="usd">52,263</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" unitRef="usd">105,212</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total taxes payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd">167,350</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd">1,101,460</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 16 &#8212; CONCENTRATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_2" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A majority of the Company&#8217;s revenue and expense
transactions are denominated in RMB and a significant portion of the Company and its subsidiaries&#8217; assets and liabilities are denominated
in RMB. RMB is not freely convertible into foreign currencies. In the PRC, certain foreign exchange transactions are required by law to
be transacted only by authorized financial institutions at exchange rates set by the People&#8217;s Bank of China (&#8220;PBOC&#8221;).
Remittances in currencies other than RMB by the Company in China must be processed through the PBOC or other China foreign exchange regulatory
bodies which require certain supporting documentation in order to affect the remittance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_3" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022 and 2021, $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignFinancialInstitutionsMandatedDeposits" scale="0" unitRef="usd">5,711,423</ix:nonFraction> and
$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignFinancialInstitutionsMandatedDeposits" scale="0" unitRef="usd">5,892,655</ix:nonFraction> of the Company&#8217;s cash, respectively, was on deposit at financial institutions in the PRC where no existing rule or regulation
requires such financial institutions to maintain insurance to cover bank deposits in the event of bank failure. For the years ended September
30, 2022, 2021 and 2020, the Company&#8217;s substantial assets were located in the PRC and the Company&#8217;s substantial revenues were
derived from its subsidiaries located in the PRC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_4" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended September 30, 2022, 2021 and 2020,
no single customer accounted for more than <ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">10</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the Company&#8217;s total revenue. The Company&#8217;s top 10 customers aggregately
accounted for <ix:nonFraction contextRef="c160" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">32.2</ix:nonFraction>%, <ix:nonFraction contextRef="c161" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">30.4</ix:nonFraction>% and <ix:nonFraction contextRef="c162" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">33.3</ix:nonFraction>% of the total revenue for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_5" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of one of the Company&#8217;s major products,
Guben Yanling Pill, accounted for <ix:nonFraction contextRef="c163" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">42.5</ix:nonFraction>%, <ix:nonFraction contextRef="c164" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">40.3</ix:nonFraction>% and <ix:nonFraction contextRef="c165" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">38.2</ix:nonFraction>% of the Company&#8217;s total revenue for the years ended September 30, 2022,
2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_6" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022 and 2021, no customer accounted
for more than <ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c174" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">10</ix:nonFraction></ix:nonFraction>% of the total accounts receivable balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_7" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, one supplier accounted for
<ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of the total advance to supplier balance. As of September 30, 2021, two suppliers accounted for <ix:nonFraction contextRef="c168" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">35.3</ix:nonFraction>% and <ix:nonFraction contextRef="c169" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">28.0</ix:nonFraction>% of the total advance
to supplier balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_ConcentrationRiskDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended September 30, 2022, one supplier
accounted for approximately <ix:nonFraction contextRef="c170" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">10.3</ix:nonFraction>% of the total purchases. For the year ended September 30, 2021, no supplier accounted for more than <ix:nonFraction contextRef="c171" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>%
of the total purchases, respectively. For the year ended September 30, 2020, two suppliers accounted for approximately <ix:nonFraction contextRef="c172" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">19.6</ix:nonFraction>% and <ix:nonFraction contextRef="c173" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">13.6</ix:nonFraction>%
of the total purchases, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 17 &#8212; SHAREHOLDERS&#8217; EQUITY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Ordinary Shares</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Universe INC was incorporated under the laws of the
Cayman Islands on December 11, 2019. The original authorized number of ordinary shares was <ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">50,000</ix:nonFraction> shares with par value of US$<ix:nonFraction contextRef="c175" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">1.00</ix:nonFraction> per
share and <ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">50,000</ix:nonFraction> shares were issued. On August 7, 2020, the Company amended its Memorandum of Association to increase the authorized number
of shares to <ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction> shares with par value of $<ix:nonFraction contextRef="c176" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.003125</ix:nonFraction> per share, and subdivide the original issued shares from <ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">50,000</ix:nonFraction> shares at
par value of $<ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="upc:OriginalSharesParValue" scale="0" unitRef="usdPershares">1.00</ix:nonFraction> per share to <ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">16,000,000</ix:nonFraction> ordinary shares with par value of $<ix:nonFraction contextRef="c177" decimals="6" format="ixt:num-dot-decimal" name="upc:OrdinarySharesParValue" scale="0" unitRef="usdPershares">0.003125</ix:nonFraction> per share. <ix:nonNumeric contextRef="c178" name="upc:OrdinarySharesOutstandingDescription">As a result of this forward split of
the outstanding ordinary shares at a ratio of 320-for-1 share, a total of 16,000,000 shares were issued and outstanding after the split.</ix:nonNumeric>
The issuance of these <ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="upc:ReorganizationShares" scale="0" unitRef="shares">16,000,000</ix:nonFraction> shares is considered as a part of the Reorganization of the Company, which was retroactively applied
as if the transaction occurred at the beginning of the period presented (see Note 1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Initial Public Offering</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2021, the Company closed its IPO of <ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">5,000,000</ix:nonFraction>
ordinary shares at a public offering price of $<ix:nonFraction contextRef="c179" decimals="2" format="ixt:num-dot-decimal" name="upc:PublicOfferingPrice" scale="0" unitRef="usdPershares">5.00</ix:nonFraction> per share. On March 29, 2021, the underwriter exercised in full its over-allotment
option to purchase an additional <ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="upc:OptionToPurchaseAdditionalShares" scale="0" unitRef="shares">750,000</ix:nonFraction> ordinary shares. The closing for the sale of the over-allotment shares took place on March 31,
2021. Gross proceeds of the IPO, including the proceeds from the sale of the over-allotment shares, totaled $<ix:nonFraction contextRef="c179" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="6" unitRef="usd">28.75</ix:nonFraction> million, before deducting
underwriting discounts and other related expenses. Net proceeds of our IPO, including over-allotment shares, were approximately $<ix:nonFraction contextRef="c181" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">25.6</ix:nonFraction>
million. In connection with the IPO, the Company&#8217;s ordinary shares began trading on the Nasdaq Global Market under the symbol &#8220;UPC&#8221;
on March 23, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022 and 2021, the Company had
a total of <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">21,750,000</ix:nonFraction></ix:nonFraction> ordinary shares issued and outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Underwriter warrants</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Company&#8217;s IPO, the Company
also agreed to issue warrants to the underwriter, for a nominal consideration of $<ix:nonFraction contextRef="c182" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per warrant, to purchase <ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">300,000</ix:nonFraction> ordinary shares
of the Company (equal to <ix:nonFraction contextRef="c183" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" scale="-2" unitRef="pure">6</ix:nonFraction>% of the total number of ordinary shares sold in the IPO, not including any ordinary shares sold in the over-allotment
option) (the &#8220;Underwriter Warrants&#8221;). The Underwriter Warrants have a term of five years, with an exercise price of $<ix:nonFraction contextRef="c183" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares">5.50</ix:nonFraction>
per share (equal to <ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="upc:EquityMethodInvestmentOwnershipsPercentage" scale="-2" unitRef="pure">110</ix:nonFraction>% of the Company&#8217;s IPO offering price of $<ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">5.00</ix:nonFraction> per share). The Underwriter Warrants may be purchased in cash
or via cashless exercise, will be exercisable for five (5) years, and will terminate on the fifth anniversary of the closing of the IPO.
Management determined that the Underwriter Warrants meet the requirements for equity classification under ASC 815-40 because they are
indexed to its own stock. As of September 30, 2022, the Underwriter Warrants were issued and outstanding, but none of them has been exercised.
For the years ended September 30, 2022 and 2021, the Underwriter Warrants were antidilutive and accordingly were not included in the diluted
EPS calculation based on treasury stock method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cash dividends</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 21, 2016, September 13, 2017, February
2, 2018, September 20, 2018 and February 21, 2019, the board of directors of Jiangxi Universe approved resolutions to pay cash dividends
of RMB<ix:nonFraction contextRef="c185" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsShareBasedCompensationCash" scale="6" unitRef="cny">40</ix:nonFraction> million, RMB<ix:nonFraction contextRef="c186" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsShareBasedCompensationCash" scale="6" unitRef="cny">30</ix:nonFraction> million, RMB<ix:nonFraction contextRef="c187" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsShareBasedCompensationCash" scale="6" unitRef="cny">20</ix:nonFraction> million, RMB<ix:nonFraction contextRef="c188" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsShareBasedCompensationCash" scale="6" unitRef="cny">10</ix:nonFraction> million and RMB<ix:nonFraction contextRef="c189" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsShareBasedCompensationCash" scale="6" unitRef="cny">30</ix:nonFraction> million, respectively, to its shareholders at the time of record
out of the retained earnings balance of Jiangxi Universe, to be paid to these shareholders when there are sufficient available earnings
and the Company has sufficient funds. <ix:nonNumeric contextRef="c190" name="upc:CashDividendDescription">A total of RMB130 million (approximately $19.1 million) cash dividend was declared from September
2016 to February 2019, among which, approximately RMB20 million ($3.1 million) was paid in cash to its shareholders in 2018 and the remaining
RMB110 million ($16 million) was paid to its shareholders in 2019.</ix:nonNumeric> There were no additional cash dividends paid during the years ended
September 30, 2022, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><div>

</div><p style="font: 9pt Sans-Serif; margin: 0; color: Red"></p><div>


</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 17 &#8212; SHAREHOLDERS&#8217; EQUITY (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except for the dividends declared mentioned above,
the Company has not declared or paid dividends to its shareholders in the past, and may not choose to make additional distributions in
the future. Any decision as to the payment of dividends will depend on the available earnings, the capital requirements of the Company,
the Company&#8217;s general financial condition and other factors deemed pertinent by the board of directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Statutory reserve and restricted net assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s PRC subsidiaries are restricted
in their ability to transfer a portion of their net assets to the Company. The payment of dividends by entities organized in China is
subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated
profits as determined in accordance with accounting standards and regulations in China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is required to make appropriations to
certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income determined
in accordance with generally accepted accounting principles of the PRC (&#8220;PRC GAAP&#8221;). Appropriations to the statutory surplus
reserve are required to be at least <ix:nonFraction contextRef="c191" decimals="2" format="ixt:num-dot-decimal" name="upc:StatutorySurplusPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% of the after-tax net income determined in accordance with PRC GAAP until the reserve is equal
to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="upc:ReserveIsEqualPercentage" scale="-2" unitRef="pure">50</ix:nonFraction>% of the entity&#8217;s registered capital. Appropriations to the discretionary surplus reserve are made at the discretion of the
board of directors. The statutory reserve may be applied against prior year losses, if any, and may be used for general business expansion
and production or increase in registered capital, but are not distributable as cash dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Relevant PRC laws and regulations restrict the Company&#8217;s
PRC subsidiaries from transferring a portion of their net assets, equivalent to their statutory reserves and their share capital, to the
Company in the form of loans, advances or cash dividends. Only PRC entities&#8217; accumulated profits may be distributed as dividends
to the Company without the consent of a third party. As of September 30, 2022 and 2021, the restricted amounts as determined pursuant
to PRC statutory laws totaled $<ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" unitRef="usd">2,439,535</ix:nonFraction>, and total restricted net assets amounted to $<ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="upc:RestrictedNetAssets" scale="0" unitRef="usd">31,786,663</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cash transfer between the Company and its subsidiaries</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended September 30, 2022, the Company
received cash in the amount of $<ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd">303,746</ix:nonFraction> from its subsidiary in Hong Kong, and the WFOE transferred cash in the amount of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd">5,211,231</ix:nonFraction> to
Jiangxi Universe. For the year ended September 30, 2021, the Company transferred cash in the amount of $<ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd">11,358,764</ix:nonFraction> to its subsidiary in
Hong Kong, and the Company&#8217;s Hong Kong subsidiary, via the WFOE, further transferred cash in the amount of $<ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd">6,807,507</ix:nonFraction> to the PRC
subsidiaries. For the year ended September 30, 2020, there was no cash transferred from the Company to its PRC subsidiaries. The assets
transfer was for business operation purpose. There was no distribution of earnings by the PRC operating subsidiaries to the Company during
the years ended September 30, 2022, 2021 and 2020, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 18 &#8212; COMMITMENTS AND CONTINGENCIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, the Company is a party to various
legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable
and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. For the
years ended September 30, 2022, 2021 and 2020, the Company did not have any material legal claims or litigation that, individually or
in aggregate, could have a material adverse impact on the Company&#8217;s consolidated financial position, results of operations and cash
flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has an ongoing CIP project associated
with the construction of a new manufacturing facility. As of September 30, 2022, future minimum capital expenditures on the Company&#8217;s
CIP project amounted to approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="6" unitRef="usd">13.5</ix:nonFraction> million, among which, approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseCapitalSecurities" scale="6" unitRef="usd">3.5</ix:nonFraction> million is required for the next 12 months from
the date of this report (see Note 11).</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 19 &#8212; SEGMENT REPORTING</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_2" id="_SegmentReportingDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An operating segment is a component of the Company
that engages in business activities from which it may earn revenues and incur expenses, and is identified on the basis of the internal
financial reports that are provided to, and regularly reviewed by, the Company&#8217;s chief operating decision maker in order to allocate
resources and assess performance of the segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_3" id="_SegmentReportingDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The management of the Company concludes that it has
only <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure">one</ix:nonFraction> reporting segment. The Company develops, manufactures and sells TCMD products targeted to the elderly to address their physical
conditions in the aging process and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical
instruments, Traditional Chinese Medicine Pieces products and dietary supplements manufactured by third-party pharmaceutical companies.
All of these products are currently sold in China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_4" id="_SegmentReportingDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s products have similar economic
characteristics with respect to raw materials, vendors, marketing and promotions, customers and methods of distribution. The Company&#8217;s
chief operating decision maker has been identified as the Chief Executive Officer, who reviews consolidated results when making decisions
about allocating resources and assessing performance of the Company, rather than by product types or geographic area; hence the Company
has only one reporting segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_5" id="_SegmentReportingDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration:underline">Revenue by product source</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_6" id="_SegmentReportingDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For Years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Sales of TCMD products manufactured by the Company</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfOtherPropertyOperatingExpense" scale="0" unitRef="usd">23,988,177</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfOtherPropertyOperatingExpense" scale="0" unitRef="usd">29,559,286</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfOtherPropertyOperatingExpense" scale="0" unitRef="usd">18,374,751</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd">16,154,974</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd">18,422,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd">12,329,209</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">40,143,151</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">47,982,031</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">30,703,960</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_7" id="_SegmentReportingDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration:underline">Revenue by product categories</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_8" id="_SegmentReportingDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The summary of our total revenues by product categories for the years ended
September 30, 2022, 2021 and 2020 was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SegmentReportingDisclosureTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For Years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Sales of TCMD products:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Medicinal liquor products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">1,095,336</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">1,951,679</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">1,616,080</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Other chronic condition treatment products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">19,140,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">22,978,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">14,059,403</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cold and flu medicines</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">3,752,422</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">4,629,606</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">2,699,268</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Sub-total of TCMD products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">23,988,177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">29,559,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">18,374,751</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-align: justify">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Sales of third-party products</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Biochemical drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">13,730,424</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">16,082,546</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">10,325,411</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Traditional Chinese medicine pieces</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">30,202</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">20,705</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">47,097</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">2,394,348</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">2,318,536</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">1,950,238</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Dietary supplements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">958</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">6,463</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Subtotal of third-party products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">16,154,974</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">18,422,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">12,329,209</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">40,143,151</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">47,982,031</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">30,703,960</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 20 &#8212; SUBSEQUENT EVENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:nonNumeric contextRef="c0" name="us-gaap:SubsequentEventDescription"><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated the subsequent event through
the date of this report, and concluded that there are no material reportable subsequent events need to be disclosed.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 21 &#8212; CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_2" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of Rule 12-04(a), 5-04(c)
and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when the restricted net assets
of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. The
Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with such requirement and concluded that
it was applicable to the Company as the restricted net assets of the Company&#8217;s subsidiaries exceeded <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="upc:MinorityInterestsOwnershipPercentageByParent" scale="-2" unitRef="pure">25</ix:nonFraction>% of the consolidated net
assets of the Company. Therefore, the condensed financial statements for the parent company are included herein.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_3" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of the above test, restricted net assets
of consolidated subsidiaries shall mean that amount of the Company&#8217;s proportionate share of net assets of consolidated subsidiaries
(after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries
in the form of loans, advances or cash dividends without the consent of a third party.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_4" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed financial information of the parent
company has been prepared using the same accounting policies as set out in the Company&#8217;s consolidated financial statements except
that the parent company used the equity method to account for investment in its subsidiaries. Such investment is presented on the condensed
balance sheets as &#8220;Investment in subsidiaries&#8221; and the respective profit or loss as &#8220;Equity in earnings of subsidiaries&#8221;
on the condensed statements of income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_5" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The footnote disclosures contain supplemental information
relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the consolidated
financial statements of the Company. Certain information and footnote disclosures normally included in financial statements prepared in
accordance with U.S GAAP have been condensed or omitted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_6" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022 and 2021, there were no material
contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those which have been separately
disclosed in the consolidated financial statements, if any.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PARENT COMPANY BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_7" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -0.125in; padding-left: 0.25in">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">28,917</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">110,393</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">13,148,594</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">13,725,204</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">13,177,511</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">13,835,597</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Non-current assets</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Investment in subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="0" unitRef="usd">33,264,812</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="0" unitRef="usd">45,098,756</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-family: SimSun">&#160;</td>
    <td style="font-family: SimSun; text-align: left">&#160;</td><td style="font-family: SimSun; text-align: right"><span style="font-family: SimSun; font-size: 10pt">&#12288;</span></td><td style="font-family: SimSun; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.375in">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">46,442,323</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">58,934,353</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">COMMITMENTS AND CONTINGENCIES</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#160;</div></td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#160;</div></td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">SHAREHOLDERS&#8217; EQUITY</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Ordinary shares, $<ix:nonFraction contextRef="c217" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c218" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.003125</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c217" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c218" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c217" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c218" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c217" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c218" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">21,750,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2021 and 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">67,969</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">67,969</ix:nonFraction></td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">29,279,159</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">29,279,159</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Retained earnings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" unitRef="usd">18,761,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" unitRef="usd">27,498,466</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd">1,666,705</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">2,088,759</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">46,442,323</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">58,934,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">46,442,323</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">58,934,353</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PARENT COMPANY STATEMENTS OF INCOME AND COMPREHENSIVE
INCOME</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_8" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="srt:CondensedStatementOfComprehensiveIncomeTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating costs and expenses:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 10pt">General and administrative expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">384,214</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,177,869</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expenses):</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income from short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOtherShortTermBorrowings" scale="0" unitRef="usd">470,477</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOtherShortTermBorrowings" scale="0" sign="-" unitRef="usd">239,549</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd">420</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd">60,751</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity in earnings of subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd">7,881,455</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd">12,319,023</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">8,736,566</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">11,319,952</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" scale="0" sign="-" unitRef="usd">3,755,464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" scale="0" unitRef="usd">1,193,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" scale="0" unitRef="usd">860,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive income attributable to the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">12,492,030</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" unitRef="usd">12,513,321</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" unitRef="usd">8,418,845</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PARENT COMPANY STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:continuation id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedCashFlowStatementTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">8,736,566</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">11,319,952</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net cash flows from operating activities:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 12.5pt; padding-left: 10pt">Equity in earnings of subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="upc:EquityInEarningsOfSubsidiary" scale="0" unitRef="usd">7,881,455</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="upc:EquityInEarningsOfSubsidiary" scale="0" sign="-" unitRef="usd">12,319,027</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="upc:EquityInEarningsOfSubsidiary" scale="0" sign="-" unitRef="usd">7,558,222</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Short-term investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNet" scale="0" unitRef="usd">470,477</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -3.3pt; padding-left: 3.3pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">384,634</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">999,075</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; text-indent: -0.9pt; padding-left: 0.9pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -3.4pt; padding-left: 3.4pt">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt">Payment for short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" scale="0" unitRef="usd">15,330,660</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt">Redemption of short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" sign="-" unitRef="usd">1,801,927</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">13,528,733</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 23.6pt">Net proceeds from issuance of ordinary shares in IPO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">25,957,457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 23.6pt">Cash lent to subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="upc:CashLentToSubsidiaries" scale="0" unitRef="usd">11,358,764</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt">Cash repayment from subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="0" unitRef="usd">303,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">303,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">14,598,693</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; padding-bottom: 1.5pt; text-indent: -1.2pt; padding-left: 1.2pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd">588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">39,508</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CHANGES IN CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">81,476</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">110,393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">CASH, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" unitRef="usd">110,393</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">CASH, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" unitRef="usd">28,917</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" unitRef="usd">110,393</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">F-33</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="text-align: center; margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c2" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-2" name="upc:ShorttermInvestmentIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-3" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.40</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-4" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">0.47</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="2" id="hidden-fact-5" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">0.60</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="0" id="hidden-fact-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">16000000</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="0" id="hidden-fact-7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">18980822</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">21750000</ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-9" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-10" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-11" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-12" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-13" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-14" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-15" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-16" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-17" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-20" name="upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-21" name="upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-22" name="upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-23" name="upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-24" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-25" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-26" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-27" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-28" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-29" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-30" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-31" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-32" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-33" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-34" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-35" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-36" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-37" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-38" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-39" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-40" name="us-gaap:OtherAssetImpairmentCharges" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-41" name="us-gaap:InventoryLIFOReservePeriodCharge" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-42" name="upc:ShorttermInvestmentsIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-43" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-44" name="us-gaap:IncreaseDecreaseInPrepaidAdvertising" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-45" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-46" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-47" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-48" name="upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-49" name="upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-50" name="us-gaap:RepaymentsOfAdvancesForConstruction" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-51" name="us-gaap:RepaymentsOfAdvancesForConstruction" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-52" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-53" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-54" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-55" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-56" name="upc:RedemptionOfShorttermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-57" name="upc:RedemptionOfShorttermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-58" name="us-gaap:PaymentsOfDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-59" name="us-gaap:PaymentsOfDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-60" name="us-gaap:PaymentsOfDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-61" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-62" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-63" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-64" name="upc:SunsequentCollectionAllowanceForDoubtfulAccounts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-65" name="upc:AllowanceForDoubtfulAccountsReceivablePercentage" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-66" name="us-gaap:PropertyPlantAndEquipmentAdditions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-67" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-68" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-69" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-70" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="upc:AddPurchaseWealthManagementFinancialProducts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-72" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-73" name="us-gaap:OtherShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-74" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c124" id="hidden-fact-75" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c126" id="hidden-fact-76" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c129" id="hidden-fact-77" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c131" id="hidden-fact-78" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c134" id="hidden-fact-79" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-80" name="us-gaap:DueFromOtherRelatedPartiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c142" id="hidden-fact-81" name="us-gaap:DueFromOtherRelatedPartiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-82" name="us-gaap:DueFromOtherRelatedPartiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c145" id="hidden-fact-83" name="us-gaap:DueToRelatedPartiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c146" id="hidden-fact-84" name="us-gaap:DueToRelatedPartiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c149" id="hidden-fact-85" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c150" id="hidden-fact-86" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c151" id="hidden-fact-87" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-88" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c152" id="hidden-fact-89" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c153" id="hidden-fact-90" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c149" id="hidden-fact-91" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c150" id="hidden-fact-92" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c151" id="hidden-fact-93" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-94" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c152" id="hidden-fact-95" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c153" id="hidden-fact-96" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-97" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-98" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-99" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-100" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-101" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-102" name="us-gaap:Liabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c218" id="hidden-fact-103" name="us-gaap:Liabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-104" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c218" id="hidden-fact-105" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-106" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-107" name="us-gaap:InterestExpenseOtherShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-108" name="us-gaap:OtherNoncashIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-109" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c219" id="hidden-fact-110" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-111" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c219" id="hidden-fact-112" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-113" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c219" id="hidden-fact-114" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-115" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c219" id="hidden-fact-116" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-117" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c219" id="hidden-fact-118" name="upc:CashLentToSubsidiaries" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-119" name="upc:CashLentToSubsidiaries" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c220" id="hidden-fact-120" name="us-gaap:ProceedsFromContributionsFromAffiliates" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-121" name="us-gaap:ProceedsFromContributionsFromAffiliates" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-122" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-123" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-124" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c222" id="hidden-fact-125" name="upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c223" id="hidden-fact-126" name="upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c222" id="hidden-fact-127" name="upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode">+86</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode">000000</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001809616</ix:nonNumeric>
<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber">0796-8403309</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="upc-20220930.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><ix:relationship fromRefs="hidden-fact-75 ix_0_fact" toRefs="ix_0_footnote"></ix:relationship>
<ix:relationship fromRefs="hidden-fact-76 ix_1_fact" toRefs="ix_1_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_2_fact hidden-fact-77" toRefs="ix_2_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_3_fact" toRefs="ix_3_footnote"></ix:relationship>
<ix:relationship fromRefs="hidden-fact-78 ix_4_fact" toRefs="ix_4_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_5_fact hidden-fact-79" toRefs="ix_5_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseHKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-12-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JiangxiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-25</xbrli:startDate>
    <xbrli:endDate>2021-03-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-25</xbrli:startDate>
    <xbrli:endDate>2021-03-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseINCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseHanheMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:OwnershipMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JxRcbBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2009-03-01</xbrli:startDate>
    <xbrli:endDate>2017-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:OwnershipMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JxRcbBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-04-25</xbrli:startDate>
    <xbrli:endDate>2018-05-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-03-25</xbrli:startDate>
    <xbrli:endDate>2019-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:LessThan3MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:LessThan3MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From4To6MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From4To6MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From7To9MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From7To9MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From10To12MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From10To12MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:Over1YearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:Over1YearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:YunnanFaxiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">upc:AmortizationExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ChenyuanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7sSbeKneEPlmNIhj3bCSU5y7O0I8dbszuTl8jF0AJbe21t+Rq4Ior0xtAOoy+ao7RLCBcMnvOYD6nWgAt+g/C9Glm4Z6aOCF7CBTCCEgAQgDS5HDB+QiyzENbKCgT97fbEVSN80+vkpIw==] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ChenyuanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">upc:CapitalExpenditureMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-05-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-01</xbrli:startDate>
    <xbrli:endDate>2022-03-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:Maturity30To90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:Maturity30To90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOver90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOver90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MsLinYangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GreatestGroupMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GreatestGroupMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:FoshanShangyuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:FoshanShangyuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrsLinYangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrsLinYangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:TotalRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:TotalRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:TotalRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomersOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-08-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-02</xbrli:startDate>
    <xbrli:endDate>2020-08-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-25</xbrli:startDate>
    <xbrli:endDate>2021-03-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-09-01</xbrli:startDate>
    <xbrli:endDate>2016-09-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-09-01</xbrli:startDate>
    <xbrli:endDate>2017-09-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-28</xbrli:startDate>
    <xbrli:endDate>2018-02-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-09-01</xbrli:startDate>
    <xbrli:endDate>2018-09-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2019-02-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:PRCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="cny">
  <xbrli:measure>iso4217:CNY</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.3
<SEQUENCE>2
<FILENAME>f20f2022ex2-3_universe.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 2.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Description of Rights of Each Class of Securities<BR>
Registered under Section 12 of the Securities Exchange Act of 1934, as Amended (the &ldquo;Exchange Act&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The share capital of Universe Pharmaceuticals
INC (&ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;our company,&rdquo; or &ldquo;us&rdquo;) is US$312,500 divided into 90,000,000 Ordinary
Shares of par value US$0.003125 each (&ldquo;Ordinary Shares&rdquo;) and 10,000,000 Preferred Shares of par value US$0.003125 each (&ldquo;Preferred
Shares&rdquo;, and together with the Ordinary Shares, the &ldquo;Shares&rdquo;). As of September 30, 2022, we had one class of securities
registered under Section 12(b) of the Exchange Act and our Ordinary Shares are listed and traded on the Nasdaq Global Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Description of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of material provisions
of our currently effective amended and restated memorandum of association and articles of association (the &ldquo;Memorandum and Articles
of Association&rdquo; and the &ldquo;Articles&rdquo;), as well as the Companies Act (Revised) of the Cayman Islands (the &ldquo;Cayman
Companies Act&rdquo;) insofar as they relate to the material terms of our Shares. Notwithstanding this, because it is a summary, it may
not contain all the information that you may otherwise deem important. For more complete information, you should read the entire Memorandum
and Articles of Association, which have been filed with the U.S. Securities and Exchange Commission as exhibits to our Registration Statement
on Form F-3 (File No. 333-268028), as amended, initially filed with the U.S. Securities and Exchange Commission on October 27, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Type and Class of Securities (Item 9.A.5 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We had one class of securities, our Ordinary Shares,
registered pursuant to Section 12 of the Exchange Act. Each Ordinary Share has a par value of $0.003125 each. The number of Ordinary Shares
that have been issued as of the last day of the financial year ended September 30, 2022 is provided on the cover of the annual report
on Form 20-F filed on February 10, 2023. Our Ordinary Shares may be held in either certificated or uncertificated form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Preferred Share has a par value of $0.003125
each. No Preferred Shares were issued as of the last day of the financial year ended September 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Preemptive Rights (Item 9.A.3 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Ordinary Shares are not subject to any pre-emptive
or similar rights under the Cayman Companies Act or pursuant to the Memorandum and Articles of Association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Limitations or Qualifications (Item 9.A.6 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Ordinary Share entitles the holder thereof
to one vote on all matters subject to the vote at general meetings of our company, voting together as one class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Rights of Other Types of Securities (Item 9.A.7 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Rights of Ordinary Shares (Item 10.B.3 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Ordinary Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized share capital is $312,500 divided
into 90,000,000 Ordinary Shares and 10,000,000 Preferred Shares, par value $0.003125 per share. All of our issued and outstanding Ordinary
Shares are fully paid and non-assessable. Shareholders who are non-residents of the Cayman Islands may freely hold and transfer their
Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of the Cayman Companies
Act and any rights attaching to any class or classes of shares under and in accordance with the Articles:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
directors may declare dividends or distributions out of our funds which are lawfully available for that purpose; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company&rsquo;s shareholders may, by ordinary resolution, declare dividends but no such dividend shall exceed the amount recommended
by the directors.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the requirements of the Cayman Companies
Act regarding the application of a company&rsquo;s share premium account and with the sanction of an ordinary resolution, dividends may
also be declared and paid out of any share premium account. The directors when paying dividends to shareholders may make such payment
either in cash or in specie.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless provided by the rights attached to a share,
no dividend shall bear interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any rights or restrictions as to voting
attached to any shares, unless any share carries special voting rights, on a show of hands every shareholder who is present in person
and every person representing a shareholder by proxy shall have one vote per Ordinary Share. On a poll, every shareholder who is present
in person and every person representing a shareholder by proxy shall have one vote for each share of which he or the person represented
by proxy is the holder. In addition, all shareholders holding shares of a particular class are entitled to vote at a meeting of the holders
of that class of shares. Votes may be given either personally or by proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Calls on shares and forfeiture</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms of allotment, the directors
may make calls on the shareholders in respect of any monies unpaid on their shares including any premium and each shareholder shall (subject
to receiving at least 14 clear days&rsquo; notice specifying when and where payment is to be made), pay to us the amount called on his
shares. Shareholders registered as the joint holders of a share shall be jointly and severally liable to pay all calls in respect of the
share. If a call remains unpaid after it has become due and payable the person from whom it is due and payable shall pay interest on the
amount unpaid from the day it became due and payable until it is paid at the rate fixed by the terms of allotment of the share or in the
notice of the call or if no rate is fixed, at the rate of ten percent per annum. The directors may, at their discretion, waive payment
of the interest wholly or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a first and paramount lien on all shares
(whether fully paid up or not) registered in the name of a shareholder (whether solely or jointly with others). The lien is for all monies
payable to us by the shareholder or the shareholder&rsquo;s estate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">either
alone or jointly with any other person, whether or not that other person is a shareholder; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
or not those monies are presently payable.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time the directors may declare any share
to be wholly or partly exempt from the lien on shares provisions of the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell, in such manner as the directors may
determine, any share on which the sum in respect of which the lien exists is presently payable, if due notice that such sum is payable
has been given (as prescribed by the Articles) and, within 14 days of the date on which the notice is deemed to be given under the Articles,
such notice has not been complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Unclaimed Dividend</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A dividend that remains unclaimed for a period
of six years after it became due for payment shall be forfeited to, and shall cease to remain owing by, the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Forfeiture or Surrender of Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a shareholder fails to pay any capital call,
the directors may give to such shareholder not less than 14 clear days&rsquo; notice requiring payment and specifying the amount unpaid
including any interest which may have accrued, any expenses which have been incurred by us due to that person&rsquo;s default and the
place where payment is to be made. The notice shall also contain a warning that if the notice is not complied with, the shares in respect
of which the call is made will be liable to be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If such notice is not complied with, the directors
may, before the payment required by the notice has been received, resolve that any share the subject of that notice be forfeited (which
forfeiture shall include all dividends or other monies payable in respect of the forfeited share and not paid before such forfeiture).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A forfeited share may be sold, re-allotted or
otherwise disposed of on such terms and in such manner as the directors determine and at any time before a sale, re-allotment or disposition
the forfeiture may be cancelled on such terms as the directors think fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A person whose shares have been forfeited shall
cease to be a shareholder in respect of the forfeited shares, but shall, notwithstanding such forfeiture, remain liable to pay to us all
monies which at the date of forfeiture were payable by him to us in respect of the shares, together with all expenses and interest from
the date of forfeiture or surrender until payment, but his liability shall cease if and when we receive payment in full of the unpaid
amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A declaration, whether statutory or under oath,
made by a director or the secretary shall be conclusive evidence that the person making the declaration is our director or secretary and
that the particular shares have been forfeited or surrendered on a particular date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the execution of an instrument of transfer, if necessary,
the declaration shall constitute good title to the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Share Premium Account</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors shall establish a share premium
account and shall carry the credit of such account from time to time to a sum equal to the amount or value of the premium paid on the
issue of any share or capital contributed or such other amounts required by the Cayman Companies Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Redemption and Purchase of Own Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Cayman Companies Act and any rights
for the time being conferred on the shareholders holding a particular class of shares, we may by action of our directors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue shares that are to be redeemed or liable to be redeemed, at our option or the shareholder holding those redeemable shares, on the terms and in the manner our directors determine before the issue of those shares;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with the consent by special resolution of the shareholders holding shares of a particular class, vary the rights attaching to that class of shares so as to provide that those shares are to be redeemed or are liable to be redeemed at our option on the terms and in the manner which the directors determine at the time of such variation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchase all or any of our own shares of any class including any redeemable shares on the terms and in the manner which the directors determine at the time of such purchase.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may make a payment in respect of the redemption
or purchase of its own shares in any manner authorized by the Cayman Companies Act, including out of any combination of capital, our profits
and the proceeds of a fresh issue of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When making a payment in respect of the redemption
or purchase of shares, the directors may make the payment in cash or in specie (or partly in one and partly in the other) if so authorized
by the terms of the allotment of those shares or by the terms applying to those shares, or otherwise by agreement with the shareholder
holding those shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Transfer of Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provided that a transfer of Ordinary Shares complies
with applicable rules of the Nasdaq Global Market, a shareholder may transfer Ordinary Shares to another person by completing an instrument
of transfer in a common form or in a form prescribed by Nasdaq or in any other form approved by the directors, executed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
the Ordinary Shares are fully paid, by or on behalf of that shareholder; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
the Ordinary Shares are partly paid, by or on behalf of that shareholder and the transferee.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transferor shall be deemed to remain the holder
of an Ordinary Share until the name of the transferee is entered into the register of members of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may, in its absolute discretion,
decline to register any transfer of any Ordinary Share that has not been fully paid up or is subject to a company lien. Our board of directors
may also decline to register any transfer of such Ordinary Share unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is lodged with the Company, accompanied by the certificate for the Ordinary Shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is in respect of only one class of Ordinary Shares;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is properly stamped, if required;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Ordinary Share transferred is fully paid and free of any lien in favor of us;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fee related to the transfer has been paid to us; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the transfer is not to more than four joint holders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our directors refuse to register a transfer,
they are required, within three months after the date on which the instrument of transfer was lodged, to send to each of the transferor
and the transferee notice of such refusal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This, however, is unlikely to affect market transactions
of the Ordinary Shares purchased by investors in the public offering. Once the Ordinary Shares have been listed, the legal title to such
Ordinary Shares and the registration details of those Ordinary Shares in our register of members will remain with Depository Trust Company
(&ldquo;DTC&rdquo;)/Cede &amp; Co. All market transactions with respect to those Ordinary Shares will then be carried out without the
need for any kind of registration by the directors, as the market transactions will all be conducted through the DTC systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration of transfers may, on 14 calendar
days&rsquo; notice being given by advertisement in such one or more newspapers or by electronic means, be suspended and our register of
members closed at such times and for such periods as our board of directors may from time to time determine. The registration of transfers,
however, may not be suspended, and the register may not be closed, for more than 30 days in any year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Capitalization of Profits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The directors may resolve to capitalize:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
part of our profits not required for paying any preferential dividend (whether or not those profits are available for distribution);
or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
sum standing to the credit of our share premium account or capital redemption reserve, if any.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount resolved to be capitalized must be
appropriated to the shareholders who would have been entitled to it had it been distributed by way of dividend and in the same proportions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are wound up, the shareholders may, subject
to the Articles and any other sanction required by the Cayman Companies Act, pass a special resolution allowing the liquidator to do either
or both of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
divide in specie among the shareholders the whole or any part of our assets and, for that purpose, to value any assets and to determine
how the division shall be carried out as between the shareholders or different classes of shareholders; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
vest the whole or any part of the assets in trustees for the benefit of shareholders and those liable to contribute to the winding up.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors have the authority to present a
petition for our winding up to the Grand Court of the Cayman Islands on our behalf without the sanction of a resolution passed at a general
meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Requirements to Change the Rights of Holders of Ordinary Shares
(Item 10.B.4 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Variations of Rights of Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whenever our capital is divided into different
classes of shares, the rights attaching to any class of share (unless otherwise provided by the terms of issue of the shares of that class)
may be varied either with the consent in writing of the holders of not less than two-thirds of the issued shares of that class, or with
the sanction of a resolution passed by a majority of not less than two-thirds of the holders of shares of the class present in person
or by proxy at a separate general meeting of the holders of shares of that class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the terms on which a class of shares was
issued state otherwise, the rights conferred on the shareholder holding shares of any class shall not be deemed to be varied by the creation
or issue of further shares ranking pari passu with the existing shares of that class.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Limitations on the Rights to Own Ordinary Shares (Item 10.B.6
of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no limitations under the laws of the
Cayman Islands or under the Memorandum and Articles of Association that limit the right of non-resident or foreign owners to hold or vote
ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Provisions Affecting Any Change of Control (Item 10.B.7 of Form
20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Anti-Takeover Provisions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some provisions of the Memorandum and Articles
of Association may discourage, delay, or prevent a change in control of our company or management that shareholders may consider favorable,
including, among other things, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions
that authorize our board of directors to issue shares with preferred, deferred, or other special rights or restrictions without any further
vote or action by our shareholders; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions
that restrict the ability of our shareholders to call meetings and to propose special matters for consideration at shareholder meetings.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Cayman Companies Act, our directors
may only exercise the rights and powers granted to them under the Articles for what they believe in good faith to be in the best interests
of our company and for a proper purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Ownership Threshold (Item 10.B.8 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no provisions under the Cayman Companies
Act or under the Memorandum and Articles of Association that govern the ownership threshold above which shareholder ownership must be
disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Differences Between the Law of Different Jurisdictions (Item
10.B.9 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Cayman Companies Act is derived, to a large
extent, from the older Companies Acts of England and Wales but does not follow recent United Kingdom statutory enactments, and accordingly
there are significant differences between the Cayman Companies Act and the current Companies Act of the UK. In addition, the Cayman Companies
Act differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of certain significant
differences between the provisions of the Cayman Companies Act applicable to us and the comparable laws applicable to companies incorporated
in the State of Delaware in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cayman Islands</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Title of Organizational Documents</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation and Bylaws</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation and Memorandum and Articles of Association</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Duties of Directors</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, the business and affairs of a corporation are managed by or under the direction of its board of directors. In exercising their powers, directors are charged with a fiduciary duty of care to protect the interests of the corporation and a fiduciary duty of loyalty to act in the best interests of its shareholders. The duty of care requires that directors act in an informed and deliberative manner and inform themselves, prior to making a business decision, of all material information reasonably available to them. The duty of care also requires that directors exercise care in overseeing and investigating the conduct of the corporation&rsquo;s employees. The duty of loyalty may be summarized as the duty to act in good faith, not out of self-interest, and in a manner which the director reasonably believes to be in the best interests of the shareholders.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a matter of Cayman Islands law, a director owes three types of duties to the company: (i) statutory duties, (ii) fiduciary duties, and (iii) common law duties. The Cayman Companies Act imposes a number of statutory duties on a director. A Cayman Islands director&rsquo;s fiduciary duties are not codified, however the courts of the Cayman Islands have held that a director owes the following fiduciary duties (a) a duty to act in what the director bona fide considers to be in the best interests of the company, (b) a duty to exercise their powers for the purposes they were conferred, (c) a duty to avoid fettering his or her discretion in the future and (d) a duty to avoid conflicts of interest and of duty. The common law duties owed by a director are those to act with skill, care and diligence that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company and, also, to act with the skill, care and diligence in keeping with a standard of care commensurate with any particular skill they have which enables them to meet a higher standard than a director without those skills. In fulfilling their duty of care to us, our directors must ensure compliance with our amended articles of association, as amended and restated from time to time. We have the right to seek damages if a duty owed by any of our directors is breached.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitations on Personal Liability of Directors</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the limitations described below, a certificate of incorporation may provide for the elimination or limitation of the personal liability of a director to the corporation or its shareholders for monetary damages for a breach of fiduciary duty as a director. Such provision cannot limit liability for breach of loyalty, bad faith, intentional misconduct, unlawful payment of dividends or unlawful share purchase or redemption. In addition, the certificate of incorporation cannot limit liability for any act or omission occurring prior to the date when such provision becomes effective.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman Islands law does not limit the extent to which a company&rsquo;s articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Indemnification of Directors, Officers, Agents, and Others</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A corporation has the power to indemnify any director, officer, employee, or agent of corporation who was, is, or is threatened to be made a party who acted in good faith and in a manner he believed to be in the best interests of the corporation, and if with respect to a criminal proceeding, had no reasonable cause to believe his conduct would be unlawful, against amounts actually and reasonably incurred.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cayman Islands law does not limit the extent to
    which a company&rsquo;s memorandum and articles of association may provide for indemnification of directors and officers, except to the
    extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification
    against the consequences of committing a crime, or against the indemnified person&rsquo;s own fraud or dishonesty.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our articles of association provide to the extent
    permitted by law, we shall indemnify each existing or former secretary, director (including alternate director), and any of our other
    officers (including an investment adviser or an administrator or liquidator) and their personal representatives against: (a) all actions,
    proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by the existing or former director (including
    alternate director), secretary or officer in or about the conduct of our business or affairs or in the execution or discharge of the existing
    or former director (including alternate director), secretary&rsquo;s or officer&rsquo;s duties, powers, authorities or discretions; and
    (b) without limitation to paragraph (a) above, all costs, expenses, losses or liabilities incurred by the existing or former director
    (including alternate director), secretary or officer in defending (whether successfully or otherwise) any civil, criminal, administrative
    or investigative proceedings (whether threatened, pending or completed) concerning us or our affairs in any court or tribunal, whether
    in the Cayman Islands or elsewhere.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No such existing or former director (including
    alternate director), secretary or officer, however, shall be indemnified in respect of any matter arising out of his own dishonesty.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent permitted by law, we may make a
    payment, or agree to make a payment, whether by way of advance, loan or otherwise, for any legal costs incurred by an existing or former
    director (including alternate director), secretary or any of our officers in respect of any matter identified in above on condition that
    the director (including alternate director), secretary or officer must repay the amount paid by us to the extent that it is ultimately
    found not liable to indemnify the director (including alternate director), the secretary or that officer for those legal costs.</P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interested Directors</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, a transaction in which a director who has an interest in such transaction would not be voidable if (i) the material facts as to such interested director&rsquo;s relationship or interests are disclosed or are known to the board of directors and the board in good faith authorizes the transaction by the affirmative vote of a majority of the disinterested directors, even though the disinterested directors are less than a quorum, (ii) such material facts are disclosed or are known to the shareholders entitled to vote on such transaction and the transaction is specifically approved in good faith by vote of the shareholders, or (iii) the transaction is fair as to the corporation as of the time it is authorized, approved or ratified. Under Delaware law, a director could be held liable for any transaction in which such director derived an improper personal benefit.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interested director transactions are governed by the terms of a company&rsquo;s memorandum and articles of association.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting Requirements</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The certificate of incorporation may include a
    provision requiring supermajority approval by the directors or shareholders for any corporate action.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, under Delaware law, certain business
    combinations involving interested shareholders require approval by a supermajority of the non-interested shareholders.</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the protection of shareholders, certain matters
    must be approved by special resolution of the shareholders as a matter of Cayman Islands law, including alteration of the memorandum or
    articles of association, appointment of inspectors to examine company affairs, reduction of share capital (subject, in relevant circumstances,
    to court approval), change of name, authorization of a plan of merger or transfer by way of continuation to another jurisdiction or consolidation
    or voluntary winding up of the company.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Cayman Companies Act requires that a special
    resolution be passed by a majority of at least two-thirds or such higher percentage as set forth in the memorandum and articles of association,
    of shareholders being entitled to vote and do vote in person or by proxy at a general meeting, or by unanimous written consent of shareholders
    entitled to vote at a general meeting.</P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting for Directors</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, unless otherwise specified in the certificate of incorporation or bylaws of the corporation, directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Act defines &ldquo;special resolutions&rdquo; only. A company&rsquo;s memorandum and articles of association can therefore tailor the definition of &ldquo;ordinary resolutions&rdquo; as a whole, or with respect to specific provisions.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cumulative Voting</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No cumulative voting for the election of directors unless so provided in the certificate of incorporation.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No cumulative voting for the election of directors unless so provided in the memorandum and articles of association.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Directors&rsquo; Powers Regarding Bylaws</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The certificate of incorporation may grant the directors the power to adopt, amend or repeal bylaws.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The memorandum and articles of association may only be amended by a special resolution of the shareholders.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nomination and Removal of Directors and Filling Vacancies on Board</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders may generally nominate directors if they comply with advance notice provisions and other procedural requirements in company bylaws. Holders of a majority of the shares may remove a director with or without cause, except in certain cases involving a classified board or if the company uses cumulative voting. Unless otherwise provided for in the certificate of incorporation, directorship vacancies are filled by a majority of the directors elected or then in office.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nomination and removal of directors and filling of board vacancies are governed by the terms of the memorandum and articles of association.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Mergers and Similar Arrangements</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Delaware law, with certain exceptions, a
    merger, consolidation, exchange or sale of all or substantially all the assets of a corporation must be approved by the board of directors
    and a majority of the outstanding shares entitled to vote thereon. Under Delaware law, a shareholder of a corporation participating in
    certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights pursuant to which such shareholder
    may receive cash in the amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration
    such shareholder would otherwise receive in the transaction.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delaware law also provides that a parent corporation,
    by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90% of each class of capital stock without
    a vote by shareholders of such subsidiary. Upon any such merger, dissenting shareholders of the subsidiary would have appraisal rights.</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: justify">The Cayman Companies Act permits mergers
    and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies. For these purposes,
    (a) &ldquo;merger&rdquo; means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities
    in one of such companies as the surviving company, and (b) a &ldquo;consolidation&rdquo; means the combination of two or more constituent
    companies into a consolidated company and the vesting of the undertaking, property and liabilities of such companies to the consolidated
    company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger
    or consolidation, which must then be authorized by (a) a special resolution of the shareholders of each constituent company, and (b) such
    other authorization, if any, as may be specified in such constituent company&rsquo;s articles of association. The plan must be filed with
    the Registrar of Companies together with a declaration as to the solvency of the consolidated or surviving company, a list of the assets
    and liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given
    to the shareholders and creditors of each constituent company and that notification of the merger or consolidation will be published in
    the Cayman Islands Gazette. Court approval is not required for a merger or consolidation which is effected in compliance with these statutory
    procedures.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A merger between a Cayman Islands parent company
    and its Cayman Islands subsidiary or subsidiaries does not require authorization by a resolution of shareholders. For this purpose a subsidiary
    is a company of which at least 90% of the issued shares entitled to vote are owned by the parent company.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consent of each holder of a fixed or floating
    security interest of a constituent company is required unless this requirement is waived by a court in the Cayman Islands.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except in certain limited circumstances, a dissenting
    shareholder of a Cayman Islands constituent company is entitled to payment of the fair value of his or her shares upon dissenting from
    a merger or consolidation. The exercise of such dissenter rights will preclude the exercise by the dissenting shareholder of any other
    rights to which he or she might otherwise be entitled by virtue of holding shares, except for the right to seek relief on the grounds
    that the merger or consolidation is void or unlawful.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, there are statutory provisions that
    facilitate the reconstruction and amalgamation of companies, provided that the arrangement is approved by a majority in number of each
    class of shareholders and creditors with whom the arrangement is to be made, and who must, in addition, represent three-fourths in value
    of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting,
    or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand
    Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the transaction ought
    not to be approved, the court can be expected to approve the arrangement if it determines that: (a) the statutory provisions as to the
    required majority vote have been met; (b) the shareholders have been fairly represented at the meeting in question and the statutory majority
    are acting bona fide without coercion of the minority to promote interests adverse to those of the class; (c) the arrangement is such
    that may be reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and (d) the arrangement
    is not one that would more properly be sanctioned under some other provision of the Cayman Companies Act.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When a takeover offer is made and accepted by
    holders of 90% of the shares affected within four months the offeror may, within a two-month period commencing on the expiration of such
    four month period, require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection can be
    made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless
    there is evidence of fraud, bad faith or collusion.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an arrangement and reconstruction is thus approved,
    or if a takeover offer is made and accepted, a dissenting shareholder would have no rights comparable to appraisal rights, which would
    otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for
    the judicially determined value of the shares.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder Suits</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class actions and derivative actions generally are available to shareholders under Delaware law for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In such actions, the court generally has discretion to permit the winning party to recover attorneys&rsquo; fees incurred in connection with such action.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In principle, we will normally be the proper plaintiff and as a general rule a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely the rule in <I>Foss v. Harbottle</I> and the exceptions thereto) so that a non-controlling shareholder may be permitted to commence a class action against or derivative actions in the name of the company to challenge: (a) an act which is illegal or ultra vires with respect to the company and is therefore incapable of ratification by the shareholders; (b) an act which, although not ultra vires, requires authorization by a qualified (or special) majority (that is, more than a simple majority) which has not been obtained; and (c) an act which constitutes a &ldquo;fraud on the minority&rdquo; where the wrongdoers are themselves in control of the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Inspection of Corporate Records</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, shareholders of a Delaware corporation have the right during normal business hours to inspect for any proper purpose, and to obtain copies of list(s) of shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%; padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders of a Cayman Islands exempted company have no general right under Cayman Islands law to inspect or obtain copies of a list of shareholders or other corporate records (other than the register of mortgages or charges) of the company. However, these rights may be provided in the company&rsquo;s memorandum and articles of association.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder Proposals</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless provided in the corporation&rsquo;s certificate of incorporation or bylaws, Delaware law does not include a provision restricting the manner in which shareholders may bring business before a meeting.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Act provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company&rsquo;s articles of association. Our articles of association provide that general meetings shall be convened on the written requisition of one or more of the shareholders entitled to attend and vote at our general meetings who (together) hold not less than 10 percent of the rights to vote at such general meeting in accordance with the notice provisions in the articles of association, specifying the purpose of the meeting and signed by each of the shareholders making the requisition. If the directors do not convene such meeting for a date not later than twenty-one clear days&rsquo; after the date of receipt of the written requisition, those shareholders who requested the meeting may convene the general meeting themselves within three months after the end of such period of twenty-one clear days in which case reasonable expenses incurred by them as a result of the directors failing to convene a meeting shall be reimbursed by us. Our articles of association provide no other right to put any proposals before annual general meetings or extraordinary general meetings. As a Cayman Islands exempted company, we are not obligated by law to call shareholders&rsquo; annual general meetings. However, our corporate governance guidelines require us to call such meetings every year.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Approval of Corporate Matters by Written Consent</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware law permits shareholders to take action by written consent signed by the holders of outstanding shares having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting of shareholders.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%; padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Act allows a special resolution to be passed in writing if signed by all the voting shareholders (if authorized by the memorandum and articles of association).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Calling of Special Shareholders Meetings</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware law permits the board of directors or any person who is authorized under a corporation&rsquo;s certificate of incorporation or bylaws to call a special meeting of shareholders.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Act does not have provisions governing the proceedings of shareholders meetings which are usually provided in the memorandum and articles of association. Please see above.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dissolution; Winding Up</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&rsquo;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board of directors.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Cayman Companies Act and our articles of association, the Company may be wound up by a special resolution of our shareholders, or if the winding up is initiated by our board of directors, by either a special resolution of our members or, if our company is unable to pay its debts as they fall due, by an ordinary resolution of our members. In addition, a company may be wound up by an order of the courts of the Cayman Islands. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do so.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Changes in Capital (Item 10.B.10 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the Cayman Companies Act, we may, by ordinary resolution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
our share capital by new shares of the amount fixed by that ordinary resolution and with the attached rights, priorities and privileges
set out in that ordinary resolution;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate
and divide all or any of our share capital into shares of larger amount than our existing shares;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">convert
all or any of our paid up shares into stock, and reconvert that stock into paid up shares of any denomination;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sub-divide
our shares or any of them into shares of an amount smaller than that fixed, so, however, that in the sub-division, the proportion between
the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the
reduced share is derived; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel
shares which, at the date of the passing of that ordinary resolution, have not been taken or agreed to be taken by any person and diminish
the amount of our share capital by the amount of the shares so cancelled or, in the case of shares without nominal par value, diminish
the number of shares into which our capital is divided.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Cayman Companies Act and to any
rights for the time being conferred on the shareholders holding a particular class of shares, our shareholders may, by special resolution,
reduce our share capital in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Debt Securities (Item 12.A of Form&nbsp;20-F)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants and Rights (Item 12.B of Form&nbsp;20-F)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other Securities (Item 12.C of Form&nbsp;20-F)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Description of American Depositary Shares (Items 12.D.1 and 12.D.2
of Form 20-F)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">13</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>3
<FILENAME>f20f2022ex4-11_universe.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT ENTERED INTO BY AND BETWEEN UNIVERSE TRADE AND JIANGXI LIULING RURAL COMMERCIAL BANK CO., LTD., DATED MARCH 14, 2022
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2022] L.L.N.S.H.L.J.Z. No.: <U>17229202203141003001</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan Contract </B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in">Borrower</TD><TD STYLE="text-align: justify"><I><U>Jiangxi Universe Pharmaceuticals Commerce and Trade Co., Ltd.</U></I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in; text-align: left">Lender</TD><TD STYLE="text-align: justify"><I><U>Jiangxi Luling Rural Commercial Bank Co., Ltd.</U></I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex4-11_001.jpg" ALT="" STYLE="height: 18.75pt; width: 23.25pt"></FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: left; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-size: 12pt"><B>Jiangxi Rural Commercial Bank</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special Notice: In order to protect the legitimate
rights and interests of the Borrower, the Lender hereby requests the Borrower to give full attention to all provisions concerning the
rights and obligations of the parties, especially those shown in bold. If the Borrower has any objection, it shall raise the objection
to the Lender. Otherwise, after this Contract is entered into by and between the Borrower and the Lender, all the terms and conditions
herein represent the true intention of both parties, are protected by law, and shall be legally binding on both parties herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan Contract </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2022] <U><IMG SRC="ex4-11_002.jpg" ALT="" STYLE="height: 26.25pt; width: 53.25pt"></U>LJZ
No.: <U>17229202203141003001 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower: <I><U>Jiangxi Universe Pharmaceuticals
Commerce and Trade Co., Ltd.</U></I><U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business License No.: <U>___________________________________________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative / Person in Charge: <U>LAI
Gang _____________________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business Address: <U>No. 265, Jingjiu Avenue,
Jinggangshan Economic and Technological Development Zone, Ji&rsquo;an County</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mailing Address: <U>_______________________________________________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Code: <U>343100 </U>________________________________________________________Tel.:<U> __________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Electronic Contact Information (Email and WeChat
Account No.):  </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lender: <U>Jiangxi Luling Rural Commercial Bank
Co., Ltd. ___________________________________________________ </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative / Person in Charge: <U>HU
Fushan  </U>____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business Address: <U>No. 205, Fuchuan Road, Ji&rsquo;an
County __________________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Code: <U>343100 _____________________________________________________________________________ </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel.:<U> </U>____________________________________________________________________Fax: __________________<U>  </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the laws and regulations of the People&rsquo;s
Republic of China and other relevant regulations, the Borrower and the Lender have reached an agreement with respect to the matter that
the Lender grants a working capital loan to the Borrower, and hereby execute this Contract by consensus, which shall be binding on both
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 1 Execution Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1 Loan Amount and Currency </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loan Amount (in words): <U>CNY Eight Million.
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(In Figures) <U>CNY 8,000,000.00. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan amount under this Contract is: <FONT STYLE="font-family: Wingdings 2">&pound;</FONT>revolving
borrowing limit <FONT STYLE="font-family: Wingdings 2">R</FONT>non-revolving loan amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2 Loan Term </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valid loan term under this Contract shall
be: <U>12</U> months from <U>March 14</U>, <U>2022</U> to <U>March 13</U>, <U>2023</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">In the event that the loan amount hereunder is a revolving borrowing limit, the term of borrowing
limit shall be the same as the valid loan term as agreed herein. The term of each loan shall be subject to the term recorded in the loan
note.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">&#9745;</TD><TD STYLE="text-align: justify">In the event that the loan amount hereunder is a non-revolving borrowing limit, the loan
term shall be the same as the valid loan term as agreed herein. The specific loan term shall be subject to the term recorded in the loan
note.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower has any default circumstance
listed in Article 19 of this Contract, and the Borrower agrees that the Lender may recover the loan in advance, then the Lender may announce
that the date of recovering the loan in advance is the due date of the loan. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3 Loan Purpose </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan borrowed hereunder shall be used for
turnover of working <U>capital</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without the written consent of the Lender, the
Borrower may neither change the loan purpose nor use the loan for any other purposes. The Lender shall have the right to supervise the
Borrower&rsquo;s use of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4 Loan Interest Rate, Interest Calculation
and Settlement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. Loan
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The method as described
in following Item <U>(1)</U> shall apply for the determination of loan interest rate and a <B>simple interest calculation</B> shall be
applied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(1) Fixed
Interest Rate. The annual interest rate shall be <U>4.62</U>%. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan prime rate (LPR) recently published
on <FONT STYLE="font-family: Wingdings 2">R</FONT> the date of signature hereof <FONT STYLE="font-family: Wingdings 2">&pound;</FONT>
withdrawal date for <U>1</U> years&rsquo; loan, which is 3.70, and <FONT STYLE="font-family: Wingdings 2">R</FONT>increased percentage points
<FONT STYLE="font-family: Wingdings 2">&pound;</FONT>decreased percentage points, which is <U>92</U> bp (1bp = 0.01%). The annual interest
rate shall be <U>4.62</U>%. The interest rate shall remain unchanged during the loan term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(2) Floating
Interest Rate. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan interest rate shall be determined
by the loan prime rate (LPR) recently published on the working day before the withdrawal date for _____ years&rsquo; loan and <FONT STYLE="font-family: Wingdings 2">&pound;</FONT>increased
percentage points &#9744; decreased percentage points, which is ____ bp. <B>The
increased or decreased percentage points shall remain unchanged during the term of this Contract. In case of any adjustment to the
LPR, its loan interest rate determination method shall be handled according to the following Item and the Lender will not give a
further notice to the Borrower: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9312; Annual Adjustment. From January 1 of
the next year, the loan interest rate shall be adjusted, on the basis of the LPR recently published, in accordance with the increased
or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9313; Annual Adjustment. From the corresponding
date of the corresponding month in the corresponding year, the loan interest rate shall be adjusted, on the basis of the LPR recently
published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9314; Quarterly Adjustment. From the corresponding
date of the first month in the corresponding quarter, the loan interest rate shall be adjusted, on the basis of the LPR recently published,
in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9315; Quarterly Adjustment. From the first
day of the first month in the corresponding quarter, the loan interest rate shall be adjusted, on the basis of the LPR recently published,
in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9316; Monthly Adjustment. From the corresponding
date of the corresponding month, the loan interest rate shall be adjusted, on the basis of the LPR recently published, in accordance with
the increased or decreased percentage points agreed herein (If there is no corresponding day in the month of adjustment, the last day
of such month shall be treated as the corresponding day);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9317; Monthly Adjustment. From the corresponding
date of the corresponding month, the loan interest rate shall be adjusted, on the basis of the LPR recently published, in accordance with
the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9318; Immediate Adjustment. From the date
immediately following the date of the LRP recently published, the loan interest rate shall be adjusted, on the basis of the new LPR, in
accordance with the increased or decreased percentage points agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
loan interest rate shall be determined by other methods: ________/________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower chooses the &ldquo;(2) floating
interest rate&rdquo; method, and when the loan prime rate (LPR) of the loan market increases, the monthly repayment amount of the Borrower
will increase. If the Borrower still makes the repayment according to the repayment amount before adjustment, the monthly repayment amount
will be insufficient, resulting in penalty interest and compound interest and affecting the credit record of the Borrower. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. Interest
Settlement Method </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower will settle the interest in a method
as described in following Item <U>(2) </U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Quarterly
Interest Settlement. The 20<SUP>th</SUP> day of the last month of each quarter shall be the interest settlement date, and the 21<SUP>st</SUP>
day shall be the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Monthly
Interest Settlement. The 20<SUP>th</SUP> day of each month shall be the interest settlement date, and the 21<SUP>st</SUP> day shall be
the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
interest shall be settled by other methods: _____/__________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the repayment date of the last
installment of loan principal is not the interestpayment date, such repayment date of the last installment of loan principal shall be
the interest payment date on which the Borrower shall pay off all the interests payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. Penalty
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) In
the event that the Borrower fails to repay the loan within the agreed time limit, interest shall be calculated and charged over the overdue
part at the penalty interest rate for overdue loan from the overdue day, until the principal and interest are paid off;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) In
the event that the Borrower uses the loan for any purposes other than those agreed herein, interest shall be calculated and charged over
the misappropriated part at the penalty interest rate for misappropriated loan from the misappropriation date, until the principal and
interest are paid off;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) In
the event that the loan is overdue and misappropriated, interest shall be calculated and charged at the penalty interest rate for misappropriated
loan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) With
respect to the interest and penalty interest that the Borrower fails to pay as scheduled, compound interest shall be calculated and charged
at the penalty interest rate agreed in this paragraph in the interest settlement method as agreed in Paragraph 2 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) In
case of any adjustment to the loan interest rate agreed herein, the penalty interest and compound interest shall be calculated at the
adjusted interest rate from the adjustment date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Penalty
Interest Rate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The penalty interest rate for overdue loan shall
be <U>50</U>% higher than the loan interest rate agreed in Paragraph 1 hereof; the penalty interest rate for misappropriated loan shall
be <U>100</U>% higher than the loan interest rate agreed in Paragraph 1 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5 Loan Disbursement and Repayment
Account </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall open an account as follows
with the Lender as the loan disbursement and repayment account, which shall be used for loan disbursement, payment and repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bank of deposit: <U>Luling Rural Commercial Bank</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Name: <U>Jiangxi Universe Pharmaceuticals
Commerce and Trade Co., Ltd. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Number: <U>172299201000027947 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6 Repayment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise agreed by the parties, the Borrower
shall repay the loan hereunder in accordance with the repayment schedule as set forth in Item <U>1</U> below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Repay
the loan hereunder in full upon the expiration of the loan term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Repay
the loan hereunder in accordance with the following repayment schedule:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0; width: 49%; text-align: center; layout-grid-mode: char; padding-left: 0"><FONT STYLE="font-size: 10pt"><B>Repayment
Time</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0; width: 50%; text-align: center; layout-grid-mode: char; padding-left: 0"><FONT STYLE="font-size: 10pt"><B>Repayment Amount</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0"><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; vertical-align: top; text-align: justify; layout-grid-mode: char; padding-left: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0"><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0"><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0"><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0"><FONT STYLE="font-size: 10pt">6. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0"><FONT STYLE="font-size: 10pt">7. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0"><FONT STYLE="font-size: 10pt">8. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; vertical-align: top; text-align: justify; layout-grid-mode: char; padding-left: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0"><FONT STYLE="font-size: 10pt">9. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0; text-align: center; layout-grid-mode: char; padding-left: 0"><FONT STYLE="font-size: 10pt">Total </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; layout-grid-mode: char; padding-left: 0">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Other
Repayment Schedule: ________/____________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Where
the Borrower makes repayment in advance, it shall obtain the consent from the Lender <U>1</U> banking days in advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7 Guarantee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The loan hereunder shall be a <U>guaranteed</U>
(credit/ guaranteed) loan. The guarantee type shall be <U>guarantee</U> (guarantee/ mortgage/ pledge), and the guarantee contract shall
be executed separately. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8 Contract Agreements on the Borrower&rsquo;s
Financial Indicators: N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 9 Dispute Resolution </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. After
this Contract takes effect, any dispute arising from the execution or performance hereof or in connection with this Contract shall be
settled by both parties through negotiation. If such negotiation fails, either party may file a lawsuit with the People&rsquo;s Court having
jurisdiction over the place of the Lender in accordance with the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. During
the dispute resolution, in the event that the dispute does not affect the performance of the remaining provisions of this Contract, such
remaining provisions shall continue to be performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. After
negotiation between the parties, the parties may conduct notarization for the compulsory enforcement of this Contract. The Borrower agrees
that this Contract shall have the compulsory enforcement effect after it is notarized. In the event that the Borrower fails to perform
its obligations under this Contract, the Lender may apply to the People&rsquo;s Court having jurisdiction for compulsory enforcement according
to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10 Effectiveness of the Contract
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract shall take effect from the date
when both parties affix their signatures and seals hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract is made out in <U>triplicate</U>,
with <U>the Borrower, the Lender and the Guarantor</U> holding <U>one</U> counterpart each. Each counterpart shall have the same legal
effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 2 Standard Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 12 Interest Calculation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interest shall be calculated from the Borrower&rsquo;s
actual withdrawal date and shall be calculated according to the actual withdrawal amount and use days of loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest Formula: Interest = Principal &times;
Actual Days &times; Daily Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The daily interest rate is calculated on a base
of 360 days a year. Conversion Formula: Daily Interest Rate = Annual Interest Rate / 360.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 13 Loan Disbursement Conditions
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. The
Borrower must meet all the following conditions for loan disbursement, otherwise the Lender shall have no obligation to disburse any loan
to the Borrower, unless the Lender agrees to disburse the loan in advance: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The
Contract and its appendixes have become effective;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The
Borrower has reserved to the Lender the Borrower&rsquo;s documents, receipts, seals, lists of persons and specimen signatures in relation to
the execution and performance of this Contract and filled in the relevant vouchers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
Borrower has, according to the Lender&rsquo;s requirements, opened an account necessary for the performance of this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) The
Borrower, within 3 banking days prior to the withdrawal, has submitted to the Lender the written withdrawal notice and the relevant supporting
documents for loan purpose which is consistent with the purpose as agreed herein, and has completed the relevant withdrawal procedures;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) The
Borrower has submitted to the Lender the resolution and letter of authorization of the board of directors or other competent authorities,
which agree to the execution and performance of this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) In
accordance with relevant regulatory provisions and management requirements of the Lender, if the loan exceeds a certain amount or meets
other conditions, the Lender shall, according to the Borrower&rsquo;s withdrawal application and payment authorization, pay the loan to the
payment object conforming to the purpose agreed herein in a manner of authorized payment by the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) In
addition to the credit loan, the Borrower has provided the corresponding guarantee as required by the Lender and has completed the relevant
guarantee procedures, and the guarantee is legal and valid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) The
Borrower has not breached this Contract or any other contracts executed by and between the Borrower and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. In
the event that the Borrower fails to make any withdrawal for 3 consecutive months from the contract execution date, the Lender shall be
entitled to cancel the borrowing limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 14 Special Arrangements on Revolving
Loan (Maximum Loan) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. During
the term of revolving borrowing limit, the sum of the loan principal balance of at any time shall not exceed the revolving borrowing limit;
the repayment date of any withdrawal shall not exceed the term of revolving borrowing limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. As
agreed by both parties, the Lender shall reasonably set the amount and term of each revolving loan according to the scale and cycle of
the Borrower&rsquo;s production and operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 15 Loan Amount Payment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
authorized payment by the Lender means that the Lender pays the loan fund to the Borrower&rsquo;s counter-party in a transaction conforming
to the purpose agreed herein according to the Borrower&rsquo;s withdrawal notice and payment authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of the Borrower&rsquo;s loan fund for which
the amount of a single payment under this Contract exceeds the specified amount shall be made in a manner of authorized payment by the
Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of the authorized payment by the
Lender, the Borrower shall make express payment authorization and provide other necessary payment information (including name of counter-party
who receives payment, account number of such counter-party, and amount of payment) in the withdrawal notice, and submit to the Lender
the supporting documents for loan purpose such as business contracts required for the examination. In this case, the Lender shall pay
the loan fund to the counter-party of the Borrower via the Borrower&rsquo;s account upon examination and approval. In the event of the Lender&rsquo;s
failure to perform its obligation to pay upon authorization resulting from untruthfulness, incorrectness, and incompleteness of the information
of payment authorization and relevant transactions furnished by the Borrower, the Lender shall not be held liable for such failure whatsoever
and the Borrower&rsquo;s obligation to repay under the Contract shall not be affected. The Lender will make payment to the account of the Borrower&rsquo;s
counter-party in accordance with the Borrower&rsquo;s withdrawal notice and the payment certificate as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Lender, upon examination,
discovers that the supporting documents for loan purpose such as business contracts furnished by the Borrower fail to comply with the
Contract or there is any other defects, the Lender shall be entitled to request the Borrower to supplement, replace, explain or re-furnish
such documents, and the Lender may suspend granting or paying of such loans until the Borrower has furnished the supporting documents
such as business contracts to the satisfaction of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the account-holding bank of
the counterparty returns such payments, resulting in the Lender&rsquo;s failure to transfer such loans to the Borrower&rsquo;s counterparty as authorized
by the Borrower in a timely manner, the Lender shall not be liable for such failure whatsoever and the Borrower&rsquo;s obligation to repay
under the Contract shall not be affected. With respect to the funds returned by the account-holding bank of the counterparty, the Borrower
shall re-furnish the payment authorization and the supporting documents for loan purpose such as business contracts required for the examination,
and the Lender shall pay the loan fund to the counterparty of the Borrower via the Borrower&rsquo;s account upon examination and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All the expenses incurred by the payment of loan
to the counterparty designated by the Borrower in a manner of authorized payment under this Contract shall be borne by the Borrower. The
Borrower shall pay the above expenses to the Lender at the time of the authorized payment of each loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall not violate the above provisions
to dodge the authorized payment by the Lender by way of breaking up a large amount into several small amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Except
for the cases where the authorized payment by the Lender must be adopted as stipulated in the preceding paragraph, unless otherwise agreed
by both parties, payment of other loans shall be made by the Borrower itself, namely, after the Lender disburses the loans to the Borrower&rsquo;s
account pursuant to the withdrawal application submitted by the Borrower, the Borrower pay by itself to the its counterparty that complies
with the purpose as agreed in the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Borrower needs to change
the aforesaid repayment schedule, it shall submit a written application to the Lender <U>10</U> banking days prior to the maturity date
of the loan, and the changed repayment schedule is subject to the written confirmation by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. In
the event that the Borrower needs to extend the loan term agreed herein, it shall submit a written application of extension to the Lender
<U>30</U> banking days prior to the maturity date of the loan, and the Lender shall decide whether to approve the extension. In applying
for the extension of a guaranteed loan, mortgage loan or pledged loan, the guarantor, mortgagor or pledgor shall also issue a written
certificate of approval. the parties shall enter into a renewal agreement after the Lender approves the extension. In the event that the
Borrower&rsquo;s application for extension is not approved by the Lender, the Borrower shall still repay the loan in full according to the repayment
term agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4. Unless
otherwise agreed by the Parties, if both the principal and the interests are overdue by the Borrower, the Lender shall be entitled to
decide on the sequences for repaying the principal or the interests; under the condition of installment repayment, if several mature installments
and overdue installments exist under this Contract, the Lender shall be entitled to decide the sequences of repayment; if several outstanding
loan contracts exist between the Parties, the Lender shall be entitled to decide the sequences for repaying any contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The
Borrower shall repay the loan principal, interests and other amounts payable in full and on time according to provisions stated herein.
The Borrower shall, before the end of counter business on the repayment date and each interest settlement date, deposit in full the current
interests, principal and other amounts payable to the repayment account opened with the Lender, and the Borrower shall authorize the Lender
to collect the funds on the repayment date or the interest settlement date or the Borrower shall be required to cooperate in handling
the relevant transfer procedures. In the event that the amount in the repayment account is insufficient to pay the full amount due from
the Borrower, the Borrower shall agree that Lender is entitled to decide the sequences for repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. The
Lender shall be entitled to collect the loan in advance on the basis of the capital withdrawal of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. Loan
Note: The loan note shall be an integral part of this Contract. In the event that there is no record in this Contract, or the loan amount,
withdrawal amount, repayment amount, borrow date and maturity date of the loan, loan term, loan interest rate and loan purpose as recorded
in this Contract is inconsistent with those recorded in the loan note, the loan note shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 16 Guarantee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that any event occurs to the Borrower
or the guarantor, and causes the Lender to believe that it may affect the performing capability of the Borrower or the guarantor; or the
guarantee contracts are deemed as invalid, canceled or resolved; or the performing capability of the Borrower or guarantor may be affected
due to the deterioration in their financial condition or that the Borrower and the guarantor are involved in substantial lawsuit or arbitration
or other reasons; or the guarantor breaches the guarantee contracts or other contracts with the Lender; or the collateral value decreases
or gets lost due to the devaluation, damage, lost or sequestration of the collateral; the Lender shall be entitled to require, and the
Borrower shall have the obligation to provide new guarantee, supplement or replace the guarantor to guarantee the liabilities under this
Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 17 Representations and Undertakings
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
Borrower is a legal entity incorporated, registered and existing under the administration for industry and commerce or other competent
authorities and has full capacity of civil rights and conduct to conclude and perform the Contract, and capacity of loan repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The
Borrower fully agrees to the contents and terms of this Contract, executes and performs this Contract out of true intention, has obtained
all legal and valid authorizations required by the Borrower&rsquo;s Articles of Association and bylaws, and will not be in violation of any
agreement, contract, or other legal documents with binding force to the Borrower. The Borrower has obtained or will obtain all the required
approval, consent, documentation or registration for executing and performing this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. The
Borrower is in good faith and all the documents, financial statements, certifications and other information provided by the Borrower to
the Lender under this Contract are true, complete, accurate and valid, and free from false records, material omissions or misleading statements.
The financial and accounting reports provided to the Lender are prepared in accordance with Chinese accounting standards, and truly, fairly
and completely present the Borrower&rsquo;s operating and liability condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The
transaction background that the Borrower represents to the Lender is real and legal, not for any illegal purposes such as money laundering.
The loan purpose and the source of repayment are clear and legal. The loan purpose and the source of repayment are clear and legal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The
Borrower has a good credit status, does not have material bad credit record, and does not conceal from the Lender any fact that may affect
the Borrower&rsquo;s and the Guarantor&rsquo;s financial condition and performance capability. The Borrower does not conceal from the Lender any litigation,
arbitration or claim in which it is involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. The
borrower has repaid other debts payable as scheduled and has not maliciously defaulted on the payment of principal and interest of the
bank loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. The
Borrower shall withdraw and use the loan in accordance with the term and purpose agreed herein. The loan borrowed hereunder shall neither
be used for the investment in fixed asset and equity and other investments, nor flow into the securities market or the futures market
in any form, or be used for other purposes prohibited or restricted by relevant laws and regulations. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. The
Borrower shall deliver its financial statements (including but not limited to annual, quarterly and monthly reports) and other relevant
documents to the Lender on a regularly and timely basis in accordance with the requirements of the Lender; the Borrower shall ensure that
the financial indicators will comply with the Contract all the time. If the production and operation qualification/license is subject
to the annual audit, such qualification/license will pass the annual examination as scheduled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9. The
Borrower shall withdraw, repay and use the loan as stipulated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10. If
the Borrower has executed or will execute with the guarantor under this Contract a counter-guarantee agreement or similar agreement regarding
its guarantee obligations, this counter-guarantee agreement or similar agreement will not prejudice any Lender&rsquo;s right under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11. The
Borrower shall accept the credit inspection and supervision conducted by the Lender, and provide sufficient assistance and cooperation;
from the effective date of this Contract and prior to discharge of the principal and interests and related expenses hereunder, the Borrower
agrees and authorizes the Lender to monitor the account opened with the Lender, examine and analyze the Borrower&rsquo;s production and operation
(including but not limited to the construction and operation of the Borrower&rsquo;s projects), and make dynamic monitoring on the income cash
flow and overall fund flow of the Borrower; <B>the Borrower shall accept and actively cooperate with the examination and supervision made
by the Lender on the usage of the loan funds including the loan purpose by account analysis, proof inspection and site investigation,
</B>and make summary report in a periodic manner as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12. The
Borrower&rsquo;s merger, division, decrease of capital, equity transfer, external investment, substantial increase of debt financing, transfer
of material assets and claims and other events which may have adverse effect on the solvency of the Borrower shall be subject to the written
consent of the Lender. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall give a notice to the Lender
within <U>7</U> days after it becomes or should have become aware of any of the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Change
of the Articles of Association, business scope, registered capital, legal representative of the Borrower or the guarantor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Change
of management mode such as joint management in any form, cooperation with foreign enterprises, cooperation, contracting management, reorganization,
reform and planned listing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Involved
in material litigation or arbitration cases, sequestration, attachment or supervision of properties or collateral, or establishment of
new material liabilities on the collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Winding
up, dissolution, liquidation, stopping business for rectification, cancellation, revocation of business license, (applied for) applying
for bankruptcy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Shareholders,
directors and current senior managers are suspected of being involved in material cases or economic disputes; or the legal representative/person
in charge and current senior executives are found to be in bad health or other material conditions that the they are unqualified for their
job;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Events
of default by the Borrower under other contracts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Difficulty
in business operation and deterioration of financial position;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) In
the event that the Borrower is closed, suspended, merged or changes the line of production due to change, restructuring and contracting
or with the approval of the competent departments, the Borrower undertakes to give a notice to the Lender in writing within one month
prior to the occurrence of the above events and to discharge all debts owed to the Lender immediately. Subject to the consent of the Lender,
the Borrower may transfer the debts to the receiving entity or the newly incorporated entity (The Borrower shall, in the process of debt
transfer, present and submit to the Lender the documents issued by its competent authority or the contract-issuing party or relevant documents);
however, the debt receiving entity must execute a new loan contract with Lender and submit a written certificate of the corresponding
guarantor&rsquo;s approval or implement new guarantee measures, and before the execution of the new contract, the Lender shall have the right
to recover the debts from the Borrower, the Guarantor or the Borrower&rsquo;s receiver at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13. Liquidation
of the debts owed by the Borrower to the Lender shall have priority to the loan extended by the shareholders of the Borrower, and precede
the debts of the same kind owed by the Borrower to other creditors. In addition, from the effectiveness of the Contract to the time when
all the principal, interests and relative fees under the Contract are paid off, the Borrower shall not return the loan from its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14. In
respect of the loan hereunder, the loan conditions such as guarantee conditions, loan rate pricing, discharge sequence provided by the
Borrower for the Lender shall be no less than the current or future conditions provided for any other financial institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15. <B>The
Borrower shall bear the expenses incurred in connection with the execution and performance of this Contract and the expenses paid and
payable by the Lender for realization of its creditor&rsquo;s right hereunder, including but not limited to litigation or arbitration fees,
property preservation costs, attorney fees, enforcement fees, evaluation fees, auction fees, and announcement fees. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>16. Account
Management </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The
repayment account opened by the Borrower with the Lender (the account stipulated in Article 5) is a special capital withdrawal account,
which is used to collect the corresponding sales revenue or the planned repayment fund. Where the corresponding sales revenue is settled
in a non-cash manner, the Borrower shall ensure that it will be promptly transferred into the capital withdrawal account upon receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The
Lender shall have the right to supervise the capital withdrawal account, including but not limited to the understanding and supervision
of the fund income and expenditure of the account, and the Borrower shall provide relevant cooperation. At the request of the Lender,
the Borrower shall execute a special account supervision agreement with the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17. The
Borrower shall dispose the assets in a manner that will not reduce its repayment capability. The Borrower undertakes that the total amount
of the Borrower&rsquo;s external guarantee is equal to or less than _____ times of its net asset, and the total amount of external guarantee
as well as the amount of a single guarantee may not exceed the limit as stipulated in its Articles of Association; without the consent
of the Lender, the Borrower shall not provide guarantee to any third party or the loans borrowed by the Borrower from any other financial
institution with the assets formed by the loans under the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 18 the Related-party Transaction
within the Borrower </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;1. The
Borrower is not identified by the Lender as the group client in accordance with the Guidelines on the Management of Risks of Credits Granted
by Commercial Banks to Group Clients (hereinafter referred to the &ldquo;Guidelines&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;2. If
the Borrower is identified by the Lender as the group client in accordance with the Guidelines, it shall report to the Lender any of the
related-party transaction in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;3. The
Borrower is subject to such events as major merger, acquisition or reorganization, which in the opinion of the Lender may affect the safety
of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 19 Breach of Contract and Settlement
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
Borrower shall constitute or be deemed to have breached the Contract and shall be liable for breach of contract under any of the following
circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The
Borrower fails to perform the obligations of payment and liquidation to the Lender according to the stipulations of the Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The
Borrower fails to use the loan in a purpose and way stipulated in this Contract or fails to use the loan borrowed hereunder for the purpose
stipulated in the Contract; or the Borrower fails to go through the withdrawal procedures as scheduled according to the withdrawal plan,
or changes the withdrawal plan without the Lender&rsquo;s consent; or the Borrower is in violation of this Contract and dodges the authorized
payment by the Lender by way of breaking up a large amount into several small amounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
Borrower provides an untrue representation or violates the undertaking it made in this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) If
any circumstance under Subparagraph 12 of Article 17 arises, and the Lender believes that may affect the financial condition and performing
capability of the Borrower or guarantor, but the Borrower refuses to provide new guarantee or change a guarantor according to this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) The
Borrower violates any stipulation under any other contract between the Borrower and the Lender; the Borrower violates any stipulation
under any Credit Extension Contract between the Borrower and any other financial institution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) The
guarantor violates the stipulations of the guarantee contract, or any default events arise under other contract between the guarantor
and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) The
Borrower closes down or is dissolved, withdraw or bankrupted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) Where
the Borrower involves in or possibly involves in material economic disputes, litigation, arbitration, or its capital is sealed up, seized
or enforced for execution, or the administrative organs such as judicial organs or taxation authorities, and industrial and commercial
administration file for investigation or adopt punishment measures on the Borrower according to law which has influenced or may influence
the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9) Where
the main individual investors and key managerial personnel of the Borrower are changed abnormally, disappear or are investigated or the
personal freedom thereof is limited by judicial organs according to law which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(10) Where
the credit circumstances of the Borrower lowers or finance indexes of the Borrower such as profitability, debt-paying ability, operating
capacity and cash flow seriously deteriorate and break through the index binding of this Contract or other financial agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(11) The
Borrower takes advantage of the false contracts between the Borrower and the affiliated party to obtain funds or credit from the Lender
through transactions without true transaction background, and the affiliated party is subject to such events as major merger, acquisition
or reorganization which in the opinion of the Lender may affect the safety of the loan; or the Borrower intends to evade the creditor&rsquo;s
right of the Lender through related-party transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12) The
Borrower causes any liability accident due to its violation of food safety, production safety, environmental protection and other relevant
laws and regulations, regulatory provisions or industrial standards which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(13) In
the event that the loan under this Contract is granted on the basis of credit rating, the Borrower&rsquo;s credit rating, profitability, asset-liability
ratio, net cash flow from operating activities and other indicators do not meet the Lender&rsquo;s credit loan conditions; or the Borrower,
without the written consent of the Lender, establishes mortgage/pledge guarantee or provide guarantee to others with its valid operating
assets, which has influenced or may influence the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(14) Other
circumstances that may have adverse effect on the realization of the creditor&rsquo;s rights of the Lender under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. When
the aforesaid breaches arise, as the case maybe, the Borrower agrees that the Lender may take following measures respectively or simultaneously:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Require
the Borrower and guarantor to rectify their breach within time limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Decrease,
suspend or terminate all or part of the credit lines of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Suspend
or terminate all or part of the business application (such as withdrawal) of the Borrower under this Contract or other contracts between
the Borrower and the Lender; partly or totally suspend or cancel to issue, pay and transact the unissued loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Declare
that all or part of the outstanding principal and interest of the loan and other amounts payable of the Borrower under this Contract and
other contracts between the Borrower and the Lender shall become due immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Negotiate
with the Borrower to supplement the terms of loan issuance and payment; or the Lender shall have the right to change the loan disbursement
and payment conditions in accordance with the credit status of the Borrower such as lowering the minimum amount of authorized payment
of the Borrower; or the Lender shall have the right to transfer back the loan fund which the Borrower has paid for default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Terminate
or dissolve this Contract, partly or totally terminate or dissolve other contracts between the Borrower and the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Require
the Borrower to compensate the Lender for the Lender&rsquo;s loss caused by the Borrower&rsquo;s default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) <B>Deduct
from the Borrower&rsquo;s account which is opened in the Rural Commercial Bank system within the jurisdiction of Jiangxi </B>with notice before
or after the deduction, <B>so as to discharge all or part of the Borrower&rsquo;s debts to the Lender hereunder. The undue deposit in the account
shall be deemed to become due in advance. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9) Exercise
security interest; and require the guarantor to take guarantee responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(10) In
the event that the Borrower fails to repay the principal, interest (including penalty interest and compound interest) or other amounts
payable as scheduled, the Lender may disclose the default information of the Borrower and the Guarantor and make an announcement for collection
through the media or other forms. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(11) Have
the right to deduct and debit the deposits and dividends within any account opened by the Borrower in the Rural Commercial Bank system
within the jurisdiction of Jiangxi, and to dispose of the Borrower&rsquo;s equities. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12) Other
measures stipulated by laws and regulations and deemed necessary and possible by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 20 Reservation of Rights </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any failure by a party to exercise all or part
of its rights hereunder or to require the other party to perform or assume all or part of obligations or responsibilities shall not constitute
a waiver of such rights or release of the obligations and responsibilities of such party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any tolerance, grace or postponement for exercising
the rights under this Contract of one Party shall not affect its rights stipulated by this Contract, laws and regulations, and shall not
be deemed as a waiver of such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 21 Confidentiality </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each party undertakes to keep confidential the
trade secrets, technical information, business information and other business secrets obtained from the other party which are not available
through public channels. Without the consent of the original provider of the trade secret, neither party shall disclose all or part of
the trade secret to any third party, unless otherwise stipulated by laws and regulations or otherwise agreed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that either party is in violation
of the aforesaid confidentiality obligation, it shall assume the corresponding liability for breach of contract and compensate for the
losses caused thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 20 Force Majeure </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term Force Majeure as specified in this Contract
refers to the objective events that cannot be foreseen, overcome, or avoided and have a significant impact on one party, including but
not limited to the natural disasters such as flood, earthquake, fire and storm, as well as the social events such as war and turmoil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Contract cannot be performed
as a result of the occurrence of force majeure events, the party affected by the force majeure shall immediately notify the other party
of the event in writing, and within 7 days, provide written documents certifying the details of accident and the reasons for non-performance
or delay in performance hereof. Upon consensus through negotiation, both Parties may terminate or temporarily delay the performance of
the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 23 Alteration, Amendment and Termination
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract can be altered and amended in written
form upon consensus through negotiation of the Parties, and any alternation and amendment agreed on by the Parties shall constitute an
integral part of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract may not be terminated until all
the rights and obligations are fully preformed, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The invalidity of any provision of this Contract
shall not affect the legal validity of other provisions, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 24 Agreements on Service </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
contact information (including mailing address, telephone number, fax number, etc.) provided by the Borrower in this Contract shall be
true and valid and shall be the address for service of any notice of the Lender for the Borrower. In case of any change to the contact
information, the Borrower shall immediately send/mail the change information in writing to the mailing address provided by the Lender
in this Contract. Such information change shall become effective upon the Lender&rsquo;s receipt of the change notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Unless
otherwise expressly provided for in this Contract, the Lender shall be entitled to give notice to the Borrower in any of the following
methods. The Lender shall be entitled to choose the notification method as it thinks fit and shall not be held liable for any error, omission
or delay in delivery by mail, fax, telephone, WeChat or any other communication system. Where the Lender simultaneously chooses several
notification methods, the one by which the notice is served to the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) By
announcement. The notice shall be deemed to be served on the date on which the Lender publishes the announcement on its website, online
banking, telephone banking or business outlets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) By
hand. The notice shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower refuses to sign
for the receipt, the date on which the server makes a record on the proof of service on the spot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) By
mail (including express mail, surface mail or registered mail). The notice, when addressed to the Borrower&rsquo;s mailing address last known
to the Lender, shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower fails to sign
for the receipt, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) By
fax, mobile phone SMS, WeChat or other electronic communication methods. The notice, when sent to the Borrower&rsquo;s fax number, the mobile
phone number, WeChat account number or email address designated by the Borrower which is last known to the Lender, shall be deemed to
be served on the date on which the notice is sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Borrower
agrees that, unless the Lender receives from the Borrower a written notice concerning the change of mailing address, the Borrower&rsquo;s domicile
stated in this Contract is the correspondence and contact address. In the future, the delivery addresses of bank statements, collection
statements, relevant legal instruments and litigation documents related to the loans under this Contract shall prevail. The Borrower promises
to notify the Lender in time when the communication and contact information change, otherwise the documents delivered by the Lender according
to the communication and contact information stated in this Contract will be effectively delivered, and the relevant economic and legal
responsibilities arising therefrom will be borne by the Borrower and the Mortgagor. During the dispute settlement, if the court serves
the judicial documents or other written documents by mail (including express mail, surface mail or registered mail) to the Borrower mailing
address last known to the Lender, such documents shall be deemed to be served on the date on which the Borrower signs for receipt of the
proof of service; or if Borrower fails to sign for receipt of the proof of service, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The court or notary organ shall be entitled to
give any notice to the Borrower by any methods of communication agreed in this Paragraph 2. The court or notary organ shall be entitled
to choose the communication method as it thinks fit and shall not be held liable for any error, omission or delay in delivery by mail,
fax, telephone, telex or any other communication system. Where the court or notary organ simultaneously chooses several communication
methods, the one by which the notice is served on the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 25 Appendix </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The appendixes confirmed by both parties shall
constitute an integral part of this Contract and shall have the same legal effect as this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 26 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
Borrower shall not transfer any rights and obligations under this Contract to the third party without written consent of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The
Lender has the right to transfer the creditor&rsquo;s rights under this Contract to the third party, and shall notify the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. This
Contract shall be legally binding upon both Parties and their successors and assignees without prejudice to other provisions of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. All
the transactions under this Contract are carried out for each Party&rsquo;s independent benefits. If, in accordance with relevant laws, regulations
and regulatory provisions, other parties to the transaction become the related parties or affiliated persons of the Lender, no Party may
seek to affect the fairness of the transaction out of this related-party relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The
headings and business names in this Contract are used only for convenient reference, which shall not be used to interpret the provisions
or the rights and obligations of both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. In
accordance with relevant laws, regulations and regulatory provisions, the Lender shall have the right to provide the information related
to this Contract and other relevant information of the Borrower to the credit reference system of the People&rsquo;s Bank of China and other
credit information database established according to law for reference and use by the institutions or individuals with proper qualification
according to law. The Lender shall also have the right to refer the relevant information of the Borrower through credit reference system
of the People&rsquo;s Bank of China and other credit information database established according to law for the purpose of the execution and
performance of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The parties acknowledge that the Borrower and
the Lender have made a full negotiation in connection with all the terms of this Contract. The Lender has requested the Borrower to give
special attention to and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the
parties, and has made explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood
all the contents and provisions of the Contract. The Borrower confirms that there is no misunderstanding or doubt about all the contents
and terms of the Contract. Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract
and have no objection to the contents and provisions of the Contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Borrower and the Lender have made a full
negotiation in connection with all the provisions of this Contract. The Lender has requested the Borrower to give special attention to
and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the parties, and has made
explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood all the contents
and terms of the Contract. The <FONT STYLE="border: Black 1pt solid">Borrower</FONT></B><B> confirms that there is <FONT STYLE="border: Black 1pt solid">no
misunderstanding or ambiguity </FONT></B><B>about all the contents and provisions of the <FONT STYLE="border: Black 1pt solid">Contract</FONT></B><B>.
Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract and have no objection to the
contents and provisions of the Contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(The Borrower shall fill in the following by
contrast) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(The remainder of this page is intentionally left
blank for signatures)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="vertical-align: bottom; text-align: left; width: 25%">Borrower (Official Seal):</TD>
<TD STYLE="padding-bottom: 2pt; border-bottom: Black 1.5pt solid; text-align: center; width: 75%"><IMG SRC="ex4-11_005.jpg" ALT="" STYLE="height: 67px; width: 80px"></TD>
</TR></TABLE>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="vertical-align: bottom; text-align: left; width: 65%">Legal Representative or Authorized Agent (Signature &amp; Seal): Lai Gang (Signature)</TD>
<TD STYLE="padding-bottom: 2pt; border-bottom: Black 1.5pt solid; text-align: center; width: 35%"><IMG SRC="ex4-11_006.jpg" ALT=""></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>March 14, 2022 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="vertical-align: bottom; text-align: left; width: 15%">Lender (Seal):</TD>
<TD STYLE="padding-bottom: 2pt; border-bottom: Black 1.5pt solid; text-align: center; width: 85%"><IMG SRC="ex4-11_007.jpg" ALT=""></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative or Authorized Agent (Signature
&amp; Seal): <IMG SRC="ex4-11_003.jpg" ALT="" STYLE="height: 25.5pt; width: 58.5pt"> <U>(Signature) ________________________ </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>March 14, 2022 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Contract Execution Place:<U><IMG SRC="ex4-11_004.jpg" ALT="" STYLE="height: 35.25pt; width: 139.5pt">
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">20</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>4
<FILENAME>f20f2022ex4-12_universe.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT ENTERED INTO BY AND BETWEEN JIANGXI UNIVERSE AND JIANGXI LIULING RURAL COMMERCIAL BANK CO., LTD., DATED JUNE 15, 2022
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
4.12</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[2022]
L.L.N.S.H.L.J.Z. No.: <U>17229202206151003001</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Working
Capital Loan Contract </B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I><U>Jiangxi
                                    Universe Pharmaceuticals Co., Ltd.</U></I></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lender</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Jiangxi Luling Rural Commercial Bank Co., Ltd.</U></I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-top: 6pt; padding-bottom: 6pt; text-align: justify; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex4-12_001.jpg" ALT=""></FONT></TD>
    <TD STYLE="width: 95%; padding-top: 6pt; padding-bottom: 6pt; text-align: justify; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Jiangxi
    Rural Commercial Bank</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Special
Notice: In order to protect the legitimate rights and interests of the Borrower, the Lender hereby requests the Borrower to give full
attention to all provisions concerning the rights and obligations of the parties, especially those shown in bold. If the Borrower has
any objection, it shall raise the objection to the Lender. Otherwise, after this Contract is entered into by and between the Borrower
and the Lender, all the terms and conditions herein represent the true intention of both parties, are protected by law, and shall be legally
binding on both parties herein.</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Working
Capital Loan Contract </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2022] LJZ No.: <U>17229202206151003001 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Borrower:
<U>Jiangxi Universe Pharmaceutical Co., Ltd. ________________________________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Business
License No.: <U>______________________________________________________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal
Representative / Person in Charge: <U>LAI Gang ________________________________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Business
Address: <U>No. 265, Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji&rsquo;an County___</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mailing
Address: <U>The same as above__________________________________________________________________ </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Postal
Code: <U>343100________________________________________</U>Tel.: <U>____________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Electronic
Contact Information (Email and WeChat Account No.): _____________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lender:
<U>Jiangxi Luling Rural Commercial Bank Co., Ltd.______________________________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal
Representative / Person in Charge: <U>HU Fushan_______________________________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Business
Address: <U>No. 205, Fuchuan Road, Ji&rsquo;an County____________________________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Postal
Code: <U>343100________________________________________________________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tel.:
__________________________________________________Fax: <U>______________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the laws and regulations of the People&rsquo;s Republic of China and other relevant regulations, the Borrower and the Lender have
reached an agreement with respect to the matter that the Lender grants a working capital loan to the Borrower, and hereby execute this
Contract by consensus, which shall be binding on both parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Chapter
1 Execution Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
1 Loan Amount and Currency</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loan Amount (in words): <U>CNY Ten Million.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(In
figures) <U>CNY 10,000,000.00. </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
loan amount under this Contract is: &#9744; revolving borrowing limit <FONT STYLE="font-family: Wingdings">&thorn;</FONT> non-revolving loan amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
2 Loan Term</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
valid loan term under this Contract shall be: <U>12</U> months from <U>June 15</U>, <U>2022</U> to <U>June 14</U>, <U>2023</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
In the event that the loan amount hereunder is a revolving borrowing limit, the term of borrowing limit shall be the same as the valid
loan term as agreed herein. The term of each loan shall be subject to the term recorded in the loan note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&thorn;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">In the event that the loan amount hereunder is a non-revolving borrowing
limit, the loan term shall be the same as the valid loan term as agreed herein. The specific loan term shall be subject to the term recorded
in the loan note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>If
the Borrower has any default circumstance listed in Article 19 of this Contract, and the Borrower agrees that the Lender may recover
the loan in advance, then the Lender may announce that the date of recovering the loan in advance is the due date of the loan. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
3 Loan Purpose </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan borrowed hereunder shall be used for turnover of working <U>capital</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Without
the written consent of the Lender, the Borrower may neither change the loan purpose nor use the loan for any other purposes. The Lender
shall have the right to supervise the Borrower&rsquo;s use of the loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
4 Loan Interest Rate, Interest Calculation and Settlement </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.
Loan Interest Rate </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The method as described in following Item <U>(1)</U> shall apply for
the determination of loan interest rate and a <B>simple interest calculation</B> shall be applied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(1)
Fixed interest rate. The annual interest rate shall be <U>4.62%. </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
loan prime rate (LPR) recently published on </FONT><FONT STYLE="font-family: Wingdings">&thorn;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">the
date of signature hereof &#9744; withdrawal date for _<U>1</U><U>_</U> years&rsquo; loan, which is <U>3.70 </U>, and </FONT><FONT STYLE="font-family: Wingdings">&thorn;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">increased percentage points &#9744; decreased percentage points, which
is <U>92</U> bp (1bp = 0.01%). The annual interest rate shall be <U>4.62</U>%. The interest rate shall remain unchanged during the loan
term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(2)
Floating Interest Rate. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
loan interest rate shall be determined by the loan prime rate (LPR) recently published on the working day before the withdrawal date
for ______ years&rsquo; loan and &#9744; increased percentage points &#9744; decreased percentage points, which is _______ bp. <B>The
increased or decreased percentage points shall remain unchanged during the term of this Contract. In case of any adjustment to the
LPR, its loan interest rate determination method shall be handled according to the following Item and the Lender will not give a
further notice to the Borrower:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="ex4-12_002.jpg" ALT="">
</B>Annual Adjustment. From January 1 of the next year, the loan interest rate shall be adjusted, on the basis of the LPR recently published,
in accordance with the increased or decreased percentage points agreed herein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="ex4-12_003.jpg" ALT="">
</B>Annual Adjustment. From the corresponding date of the corresponding month in the corresponding year, the loan interest rate shall
be adjusted, on the basis of the LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex4-12_004.jpg" ALT="">
Quarterly Adjustment. From the corresponding date of the first month in the corresponding quarter, the loan interest rate shall be adjusted,
on the basis of the LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex4-12_005.jpg" ALT="">
Quarterly Adjustment. From the first day of the first month in the corresponding quarter, the loan interest rate shall be adjusted, on
the basis of the LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex4-12_006.jpg" ALT="">
Monthly Adjustment. From the corresponding date of the corresponding month, the loan interest rate shall be adjusted, on the basis of
the LPR recently published, in accordance with the increased or decreased percentage points agreed herein (If there is no corresponding
day in the month of adjustment, the last day of such month shall be treated as the corresponding day);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex4-12_007.jpg" ALT="">
Monthly Adjustment. From the corresponding date of the corresponding month, the loan interest rate shall be adjusted, on the basis of
the LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex4-12_008.jpg" ALT="">
Immediate Adjustment. From the date immediately following the date of the LRP recently published, the loan interest rate shall be adjusted,
on the basis of the new LPR, in accordance with the increased or decreased percentage points agreed herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The loan interest rate
shall be determined by other methods: ________/________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower chooses the &ldquo;(2) floating
interest rate&rdquo; method, and when the loan prime rate (LPR) of the loan market increases, the monthly repayment amount of the Borrower
will increase. If the Borrower still makes the repayment according to the repayment amount before adjustment, the monthly repayment amount
will be insufficient, resulting in penalty interest and compound interest and affecting the credit record of the Borrower.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.
Interest Settlement Method </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Borrower will settle the interest in a method as described in following Item <U>(2) </U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
Quarterly Interest Settlement. The 20<SUP>th </SUP>day of the last month of each quarter shall be the interest settlement date, and the
21<SUP>st</SUP> day shall be the interest payment date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
Monthly Interest Settlement. The 20<SUP>th </SUP>day of each month shall be the interest settlement date, and the 21<SUP>st</SUP> day
shall be the interest payment date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
interest shall be settled by other methods: _____/__________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the event that the repayment date of the last installment of loan principal is not the interestpayment date, such repayment date of the
last installment of loan principal shall be the interest payment date on which the Borrower shall pay off all the interests payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.
Penalty Interest Rate </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
In the event that the Borrower fails to repay the loan within the agreed time limit, interest shall be calculated and charged over the
overdue part at the penalty interest rate for overdue loan from the overdue day, until the principal and interest are paid off;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
In the event that the Borrower uses the loan for any purposes other than those agreed herein, interest shall be calculated and charged
over the misappropriated part at the penalty interest rate for misappropriated loan from the misappropriation date, until the principal
and interest are paid off;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
In the event that the loan is overdue and misappropriated, interest shall be calculated and charged at the penalty interest rate for
misappropriated loan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)
With respect to the interest and penalty interest that the Borrower fails to pay as scheduled, compound interest shall be calculated
and charged at the penalty interest rate agreed in this paragraph in the interest settlement method as agreed in Paragraph 2 hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)
In case of any adjustment to the loan interest rate agreed herein, the penalty interest and compound interest shall be calculated at
the adjusted interest rate from the adjustment date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6)
Penalty Interest Rate</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
penalty interest rate for overdue loan shall be <U>50</U>% higher than the loan interest rate agreed in Paragraph 1 hereof; the penalty
interest rate for misappropriated loan shall be <U>100</U>% higher than the loan interest rate agreed in Paragraph 1 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
5 Loan Disbursement and Repayment Account </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Borrower shall open an account as follows with the Lender as the loan disbursement and repayment account, which shall be used for loan
disbursement, payment and repayment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bank of deposit: <U>Luling Rural Commercial Bank</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Name: <U>Jiangxi Universe Pharmaceuticals Co., Ltd. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Number: <U>17229920100001758 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
6 Repayment </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless
otherwise agreed by the parties, the Borrower shall repay the loan hereunder in accordance with the repayment schedule as set forth in
Item <U>1</U> below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.
Repay the loan hereunder in full upon the expiration of the loan term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.
Repay the loan hereunder in accordance with the following repayment schedule:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Repayment
    Time </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Repayment
    Amount </B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
    </B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
    </B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
    </B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
    </B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
    </B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
    </B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
    </B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
    </B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
    </B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="text-align: justify; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Other Repayment Schedule:
________/____________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Where the Borrower makes
repayment in advance, it shall obtain the consent from the Lender <U>1</U> banking days in advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
7 Guarantee </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The loan hereunder shall be a <U>guaranteed
</U>(credit/ guaranteed) loan. The guarantee type shall be <U>guarantee</U> (guarantee/ mortgage/ pledge), and the guarantee contract
shall be executed separately.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
8 Contract Agreements on the Borrower&rsquo;s Financial Indicators: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex4-12_015.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
9 Dispute Resolution </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.
After this Contract takes effect, any dispute arising from the execution or performance hereof or in connection with this Contract shall
be settled by both parties through negotiation. If such negotiation fails, either party may file a lawsuit with the People&rsquo;s Court
having jurisdiction over the place of the Lender in accordance with the law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.
During the dispute resolution, in the event that the dispute does not affect the performance of the remaining provisions of this Contract,
such remaining provisions shall continue to be performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.
After negotiation between the parties, the parties may conduct notarization for the compulsory enforcement of this Contract. The Borrower
agrees that this Contract shall have the compulsory enforcement effect after it is notarized. In the event that the Borrower fails to
perform its obligations under this Contract, the Lender may apply to the People&rsquo;s Court having jurisdiction for compulsory enforcement
according to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
10 Effectiveness of the Contract </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Contract shall take effect from the date when both parties affix their signatures and seals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract is made out in <U>triplicate</U>, with <U>the Borrower,
the Lender and the Guarantor</U> holding <U>one</U> counterpart each. Each counterpart shall have the same legal effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
11 Other Agreements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex4-12_016.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Chapter
2 Standard Provisions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 12 Interest Calculation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.
The interest shall be calculated from the Borrower&rsquo;s actual withdrawal date and shall be calculated according to the actual withdrawal
amount and use days of loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
Formula: Interest = Principal &times; Actual Days &times; Daily Interest Rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
daily interest rate is calculated on a base of 360 days a year. Conversion Formula: Daily Interest Rate = Annual Interest Rate / 360.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
13 Loan Disbursement Conditions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. The
Borrower must meet all the following conditions for loan disbursement, otherwise the Lender shall have no obligation to disburse any
loan to the Borrower, unless the Lender agrees to disburse the loan in advance:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
The Contract and its appendixes have become effective;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
The Borrower has reserved to the Lender the Borrower&rsquo;s documents, receipts, seals, lists of persons and specimen signatures in
relation to the execution and performance of this Contract and filled in the relevant vouchers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
The Borrower has, according to the Lender&rsquo;s requirements, opened an account necessary for the performance of this Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)
The Borrower, within 3 banking days prior to the withdrawal, has submitted to the Lender the written withdrawal notice and the relevant
supporting documents for loan purpose which is consistent with the purpose as agreed herein, and has completed the relevant withdrawal
procedures;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)
The Borrower has submitted to the Lender the resolution and letter of authorization of the board of directors or other competent authorities,
which agree to the execution and performance of this Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6)
In accordance with relevant regulatory provisions and management requirements of the Lender, if the loan exceeds a certain amount or
meets other conditions, the Lender shall, according to the Borrower&rsquo;s withdrawal application and payment authorization, pay the
loan to the payment object conforming to the purpose agreed herein in a manner of authorized payment by the Lender;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7)
In addition to the credit loan, the Borrower has provided the corresponding guarantee as required by the Lender and has completed the
relevant guarantee procedures, and the guarantee is legal and valid;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8)
The Borrower has not breached this Contract or any other contracts executed by and between the Borrower and the Lender;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.
In the event that the Borrower fails to make any withdrawal for 3 consecutive months from the contract execution date, the Lender shall
be entitled to cancel the borrowing limit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
14 Special Arrangements on Revolving Loan (Maximum Loan) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.
During the term of revolving borrowing limit, the sum of the loan principal balance of at any time shall not exceed the revolving borrowing
limit; the repayment date of any withdrawal shall not exceed the term of revolving borrowing limit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.
As agreed by both parties, the Lender shall reasonably set the amount and term of each revolving loan according to the scale and cycle
of the Borrower&rsquo;s production and operation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
15 Loan Amount Payment </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.
The authorized payment by the Lender means that the Lender pays the loan fund to the Borrower&rsquo;s counter-party in a transaction
conforming to the purpose agreed herein according to the Borrower&rsquo;s withdrawal notice and payment authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Payment
of the Borrower&rsquo;s loan fund for which the amount of a single payment under this Contract exceeds the specified amount shall be
made in a manner of authorized payment by the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the event of the authorized payment by the Lender, the Borrower shall make express payment authorization and provide other necessary
payment information (including name of counter-party who receives payment, account number of such counter-party, and amount of payment)
in the withdrawal notice, and submit to the Lender the supporting documents for loan purpose such as business contracts required for
the examination. In this case, the Lender shall pay the loan fund to the counter-party of the Borrower via the Borrower&rsquo;s account
upon examination and approval. In the event of the Lender&rsquo;s failure to perform its obligation to pay upon authorization resulting
from untruthfulness, incorrectness, and incompleteness of the information of payment authorization and relevant transactions furnished
by the Borrower, the Lender shall not be held liable for such failure whatsoever and the Borrower&rsquo;s obligation to repay under the
Contract shall not be affected. The Lender will make payment to the account of the Borrower&rsquo;s counter-party in accordance with
the Borrower&rsquo;s withdrawal notice and the payment certificate as required by the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the event that the Lender, upon examination, discovers that the supporting documents for loan purpose such as business contracts furnished
by the Borrower fail to comply with the Contract or there is any other defects, the Lender shall be entitled to request the Borrower
to supplement, replace, explain or re-furnish such documents, and the Lender may suspend granting or paying of such loans until the Borrower
has furnished the supporting documents such as business contracts to the satisfaction of the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the account-holding bank of the counterparty returns
such payments, resulting in the Lender&rsquo;s failure to transfer such loans to the Borrower&rsquo;s counterparty as authorized by the Borrower in
a timely manner, the Lender shall not be liable for such failure whatsoever and the Borrower&rsquo;s obligation to repay under the Contract
shall not be affected. With respect to the funds returned by the account-holding bank of the counterparty, the Borrower shall re-furnish
the payment authorization and the supporting documents for loan purpose such as business contracts required for the examination, and the
Lender shall pay the loan fund to the counterparty of the Borrower via the Borrower&rsquo;s account upon examination and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
the expenses incurred by the payment of loan to the counterparty designated by the Borrower in a manner of authorized payment under this
Contract shall be borne by the Borrower. The Borrower shall pay the above expenses to the Lender at the time of the authorized payment
of each loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Borrower shall not violate the above provisions to dodge the authorized payment by the Lender by way of breaking up a large amount into
several small amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.
Except for the cases where the authorized payment by the Lender must be adopted as stipulated in the preceding paragraph, unless otherwise
agreed by both parties, payment of other loans shall be made by the Borrower itself, namely, after the Lender disburses the loans to
the Borrower&rsquo;s account pursuant to the withdrawal application submitted by the Borrower, the Borrower pay by itself to the its
counterparty that complies with the purpose as agreed in the Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the event that the Borrower needs to change the aforesaid repayment schedule, it shall submit a written application to the Lender 10
banking days prior to the maturity date of the loan, and the changed repayment schedule is subject to the written confirmation by the
Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.
In the event that the Borrower needs to extend the loan term agreed herein, it shall submit a written application of extension to the
Lender 30 banking days prior to the maturity date of the loan, and the Lender shall decide whether to approve the extension. In applying
for the extension of a guaranteed loan, mortgage loan or pledged loan, the guarantor, mortgagor or pledgor shall also issue a written
certificate of approval. the parties shall enter into a renewal agreement after the Lender approves the extension. In the event that
the Borrower&rsquo;s application for extension is not approved by the Lender, the Borrower shall still repay the loan in full according
to the repayment term agreed herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.
Unless otherwise agreed by the Parties, if both the principal and the interests are overdue by the Borrower, the Lender shall be entitled
to decide on the sequences for repaying the principal or the interests; under the condition of installment repayment, if several mature
installments and overdue installments exist under this Contract, the Lender shall be entitled to decide the sequences of repayment; if
several outstanding loan contracts exist between the Parties, the Lender shall be entitled to decide the sequences for repaying any contract.
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.
The Borrower shall repay the loan principal, interests and other amounts payable in full and on time according to provisions stated herein.
The Borrower shall, before the end of counter business on the repayment date and each interest settlement date, deposit in full the current
interests, principal and other amounts payable to the repayment account opened with the Lender, and the Borrower shall authorize the
Lender to collect the funds on the repayment date or the interest settlement date or the Borrower shall be required to cooperate in handling
the relevant transfer procedures. In the event that the amount in the repayment account is insufficient to pay the full amount due from
the Borrower, the Borrower shall agree that Lender is entitled to decide the sequences for repayment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.
The Lender shall be entitled to collect the loan in advance on the basis of the capital withdrawal of the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.
Loan Note: The loan note shall be an integral part of this Contract. In the event that there is no record in this Contract, or the loan
amount, withdrawal amount, repayment amount, borrow date and maturity date of the loan, loan term, loan interest rate and loan purpose
as recorded in this Contract is inconsistent with those recorded in the loan note, the loan note shall prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
16 Guarantee </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the event that any event occurs to the Borrower or the guarantor, and causes the Lender to believe that it may affect the performing
capability of the Borrower or the guarantor; or the guarantee contracts are deemed as invalid, canceled or resolved; or the performing
capability of the Borrower or guarantor may be affected due to the deterioration in their financial condition or that the Borrower and
the guarantor are involved in substantial lawsuit or arbitration or other reasons; or the guarantor breaches the guarantee contracts
or other contracts with the Lender; or the collateral value decreases or gets lost due to the devaluation, damage, lost or sequestration
of the collateral; the Lender shall be entitled to require, and the Borrower shall have the obligation to provide new guarantee, supplement
or replace the guarantor to guarantee the liabilities under this Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
17 Representations and Undertakings </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.
The Borrower is a legal entity incorporated, registered and existing under the administration for industry and commerce or other competent
authorities and has full capacity of civil rights and conduct to conclude and perform the Contract, and capacity of loan repayment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.
The Borrower fully agrees to the contents and terms of this Contract, executes and performs this Contract out of true intention, has
obtained all legal and valid authorizations required by the Borrower&rsquo;s Articles of Association and bylaws, and will not be in violation
of any agreement, contract, or other legal documents with binding force to the Borrower. The Borrower has obtained or will obtain all
the required approval, consent, documentation or registration for executing and performing this Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.
The Borrower is in good faith and all the documents, financial statements, certifications and other information provided by the Borrower
to the Lender under this Contract are true, complete, accurate and valid, and free from false records, material omissions or misleading
statements. The financial and accounting reports provided to the Lender are prepared in accordance with Chinese accounting standards,
and truly, fairly and completely present the Borrower&rsquo;s operating and liability condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.
The transaction background that the Borrower represents to the Lender is real and legal, not for any illegal purposes such as money laundering.
The loan purpose and the source of repayment are clear and legal. The loan purpose and the source of repayment are clear and legal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.
The Borrower has a good credit status, does not have material bad credit record, and does not conceal from the Lender any fact that may
affect the Borrower&rsquo;s and the Guarantor&rsquo;s financial condition and performance capability. The Borrower does not conceal from
the Lender any litigation, arbitration or claim in which it is involved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.
The borrower has repaid other debts payable as scheduled and has not maliciously defaulted on the payment of principal and interest of
the bank loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7.
The Borrower shall withdraw and use the loan in accordance with the term and purpose agreed herein. The loan borrowed hereunder shall
neither be used for the investment in fixed asset and equity and other investments, nor flow into the securities market or the futures
market in any form, or be used for other purposes prohibited or restricted by relevant laws and regulations. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.
The Borrower shall deliver its financial statements (including but not limited to annual, quarterly and monthly reports) and other relevant
documents to the Lender on a regularly and timely basis in accordance with the requirements of the Lender; the Borrower shall ensure
that the financial indicators will comply with the Contract all the time. If the production and operation qualification/license is subject
to the annual audit, such qualification/license will pass the annual examination as scheduled.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.
The Borrower shall withdraw, repay and use the loan as stipulated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.
If the Borrower has executed or will execute with the guarantor under this Contract a counter-guarantee agreement or similar agreement
regarding its guarantee obligations, this counter-guarantee agreement or similar agreement will not prejudice any Lender&rsquo;s right
under this Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.
The Borrower shall accept the credit inspection and supervision conducted by the Lender, and provide sufficient assistance and cooperation;
from the effective date of this Contract and prior to discharge of the principal and interests and related expenses hereunder, the Borrower
agrees and authorizes the Lender to monitor the account opened with the Lender, examine and analyze the Borrower&rsquo;s production and
operation (including but not limited to the construction and operation of the Borrower&rsquo;s projects), and make dynamic monitoring
on the income cash flow and overall fund flow of the Borrower; <B>the Borrower shall accept and actively cooperate with the examination
and supervision made by the Lender on the usage of the loan funds including the loan purpose by account analysis, proof inspection and
site investigation, </B>and make summary report in a periodic manner as required by the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>12.
The Borrower&rsquo;s merger, division, decrease of capital, equity transfer, external investment, substantial increase of debt financing,
transfer of material assets and claims and other events which may have adverse effect on the solvency of the Borrower shall be subject
to the written consent of the Lender. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Borrower shall give a notice to the Lender within <U>7</U> days after it becomes or should have become aware of any of the following
circumstances:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
Change of the Articles of Association, business scope, registered capital, legal representative of the Borrower or the guarantor;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
Change of management mode such as joint management in any form, cooperation with foreign enterprises, cooperation, contracting management,
reorganization, reform and planned listing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
Involved in material litigation or arbitration cases, sequestration, attachment or supervision of properties or collateral, or establishment
of new material liabilities on the collateral;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)
Winding up, dissolution, liquidation, stopping business for rectification, cancellation, revocation of business license, (applied for)
applying for bankruptcy;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)
Shareholders, directors and current senior managers are suspected of being involved in material cases or economic disputes; or the legal
representative/person in charge and current senior executives are found to be in bad health or other material conditions that the they
are unqualified for their job;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6)
Events of default by the Borrower under other contracts;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7)
Difficulty in business operation and deterioration of financial position;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8)
In the event that the Borrower is closed, suspended, merged or changes the line of production due to change, restructuring and contracting
or with the approval of the competent departments, the Borrower undertakes to give a notice to the Lender in writing within one month
prior to the occurrence of the above events and to discharge all debts owed to the Lender immediately. Subject to the consent of the
Lender, the Borrower may transfer the debts to the receiving entity or the newly incorporated entity (The Borrower shall, in the process
of debt transfer, present and submit to the Lender the documents issued by its competent authority or the contract-issuing party or relevant
documents); however, the debt receiving entity must execute a new loan contract with Lender and submit a written certificate of the corresponding
guarantor&rsquo;s approval or implement new guarantee measures, and before the execution of the new contract, the Lender shall have the
right to recover the debts from the Borrower, the Guarantor or the Borrower&rsquo;s receiver at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.
Liquidation of the debts owed by the Borrower to the Lender shall have priority to the loan extended by the shareholders of the Borrower,
and precede the debts of the same kind owed by the Borrower to other creditors. In addition, from the effectiveness of the Contract to
the time when all the principal, interests and relative fees under the Contract are paid off, the Borrower shall not return the loan
from its shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.
In respect of the loan hereunder, the loan conditions such as guarantee conditions, loan rate pricing, discharge sequence provided by
the Borrower for the Lender shall be no less than the current or future conditions provided for any other financial institution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>15.
The Borrower shall bear the expenses incurred in connection with the execution and performance of this Contract and the expenses paid
and payable by the Lender for realization of its creditor&rsquo;s right hereunder, including but not limited to litigation or arbitration
fees, property preservation costs, attorney fees, enforcement fees, evaluation fees, auction fees, and announcement fees. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>16.
Account Management </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
The repayment account opened by the Borrower with the Lender (the account stipulated in Article 5) is a special capital withdrawal account,
which is used to collect the corresponding sales revenue or the planned repayment fund. Where the corresponding sales revenue is settled
in a non-cash manner, the Borrower shall ensure that it will be promptly transferred into the capital withdrawal account upon receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
The Lender shall have the right to supervise the capital withdrawal account, including but not limited to the understanding and supervision
of the fund income and expenditure of the account, and the Borrower shall provide relevant cooperation. At the request of the Lender,
the Borrower shall execute a special account supervision agreement with the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.
The Borrower shall dispose the assets in a manner that will not reduce its repayment capability. The Borrower undertakes that the total
amount of the Borrower&rsquo;s external guarantee is equal to or less than _____ times of its net asset, and the total amount of external
guarantee as well as the amount of a single guarantee may not exceed the limit as stipulated in its Articles of Association; without
the consent of the Lender, the Borrower shall not provide guarantee to any third party or the loans borrowed by the Borrower from any
other financial institution with the assets formed by the loans under the Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
18 the Related-party Transaction within the Borrower </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The Borrower is not identified by the Lender as the group client in accordance with the Guidelines on the Management of Risks of
Credits Granted by Commercial Banks to Group Clients (hereinafter referred to the &ldquo;Guidelines&rdquo;). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
2. If the Borrower is identified by the Lender as the group client in accordance with the Guidelines, it shall report to the Lender any
of the related-party transaction in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
3. The Borrower is subject to such events as major merger, acquisition or reorganization, which in the opinion of the Lender may affect
the safety of the loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
19 Breach of Contract and Settlement </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.
The Borrower shall constitute or be deemed to have breached the Contract and shall be liable for breach of contract under any of the
following circumstances:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
The Borrower fails to perform the obligations of payment and liquidation to the Lender according to the stipulations of the Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
The Borrower fails to use the loan in a purpose and way stipulated in this Contract or fails to use the loan borrowed hereunder for the
purpose stipulated in the Contract; or the Borrower fails to go through the withdrawal procedures as scheduled according to the withdrawal
plan, or changes the withdrawal plan without the Lender&rsquo;s consent; or the Borrower is in violation of this Contract and dodges
the authorized payment by the Lender by way of breaking up a large amount into several small amounts;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
The Borrower provides an untrue representation or violates the undertaking it made in this Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)
If any circumstance under Subparagraph 12 of Article 17 arises, and the Lender believes that may affect the financial condition and performing
capability of the Borrower or guarantor, but the Borrower refuses to provide new guarantee or change a guarantor according to this Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)
The Borrower violates any stipulation under any other contract between the Borrower and the Lender; the Borrower violates any stipulation
under any Credit Extension Contract between the Borrower and any other financial institution;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6)
The guarantor violates the stipulations of the guarantee contract, or any default events arise under other contract between the guarantor
and the Lender;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7)
The Borrower closes down or is dissolved, withdraw or bankrupted;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8)
Where the Borrower involves in or possibly involves in material economic disputes, litigation, arbitration, or its capital is sealed
up, seized or enforced for execution, or the administrative organs such as judicial organs or taxation authorities, and industrial and
commercial administration file for investigation or adopt punishment measures on the Borrower according to law which has influenced or
may influence the performance of the liabilities under this Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9)
Where the main individual investors and key managerial personnel of the Borrower are changed abnormally, disappear or are investigated
or the personal freedom thereof is limited by judicial organs according to law which has influenced or may influence the performance
of the liabilities under this Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10)
Where the credit circumstances of the Borrower lowers or finance indexes of the Borrower such as profitability, debt-paying ability,
operating capacity and cash flow seriously deteriorate and break through the index binding of this Contract or other financial agreements;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11)
The Borrower takes advantage of the false contracts between the Borrower and the affiliated party to obtain funds or credit from the
Lender through transactions without true transaction background, and the affiliated party is subject to such events as major merger,
acquisition or reorganization which in the opinion of the Lender may affect the safety of the loan; or the Borrower intends to evade
the creditor&rsquo;s right of the Lender through related-party transactions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12)
The Borrower causes any liability accident due to its violation of food safety, production safety, environmental protection and other
relevant laws and regulations, regulatory provisions or industrial standards which has influenced or may influence the performance of
the liabilities under this Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(13)
In the event that the loan under this Contract is granted on the basis of credit rating, the Borrower&rsquo;s credit rating, profitability,
asset-liability ratio, net cash flow from operating activities and other indicators do not meet the Lender&rsquo;s credit loan conditions;
or the Borrower, without the written consent of the Lender, establishes mortgage/pledge guarantee or provide guarantee to others with
its valid operating assets, which has influenced or may influence the performance of the liabilities under this Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(14)
Other circumstances that may have adverse effect on the realization of the creditor&rsquo;s rights of the Lender under this Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.
When the aforesaid breaches arise, as the case maybe, the Borrower agrees that the Lender may take following measures respectively or
simultaneously:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
Require the Borrower and guarantor to rectify their breach within time limit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
Decrease, suspend or terminate all or part of the credit lines of the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
Suspend or terminate all or part of the business application (such as withdrawal) of the Borrower under this Contract or other contracts
between the Borrower and the Lender; partly or totally suspend or cancel to issue, pay and transact the unissued loans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)
Declare that all or part of the outstanding principal and interest of the loan and other amounts payable of the Borrower under this Contract
and other contracts between the Borrower and the Lender shall become due immediately.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)
Negotiate with the Borrower to supplement the terms of loan issuance and payment; or the Lender shall have the right to change the loan
disbursement and payment conditions in accordance with the credit status of the Borrower such as lowering the minimum amount of authorized
payment of the Borrower; or the Lender shall have the right to transfer back the loan fund which the Borrower has paid for default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6)
Terminate or dissolve this Contract, partly or totally terminate or dissolve other contracts between the Borrower and the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7)
Require the Borrower to compensate the Lender for the Lender&rsquo;s loss caused by the Borrower&rsquo;s default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) <B>Deduct from the Borrower&rsquo;s
account which is opened in the Rural Commercial Bank system within the jurisdiction of Jiangxi </B>with notice before or after the deduction,
<B>so as to discharge all or part of the Borrower&rsquo;s debts to the Lender hereunder. The undue deposit in the account shall be deemed to
become due in advance.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9)
Exercise security interest; and require the guarantor to take guarantee responsibility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(10) In
the event that the Borrower fails to repay the principal, interest (including penalty interest and compound interest) or other amounts
payable as scheduled, the Lender may disclose the default information of the Borrower and the Guarantor and make an announcement for
collection through the media or other forms.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(11)
Have the right to deduct and debit the deposits and dividends within any account opened by the Borrower in the Rural Commercial Bank
system within the jurisdiction of Jiangxi, and to dispose of the Borrower&rsquo;s equities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12)
Other measures stipulated by laws and regulations and deemed necessary and possible by the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
20 Reservation of Rights </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
failure by a party to exercise all or part of its rights hereunder or to require the other party to perform or assume all or part of
obligations or responsibilities shall not constitute a waiver of such rights or release of the obligations and responsibilities of such
party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
tolerance, grace or postponement for exercising the rights under this Contract of one Party shall not affect its rights stipulated by
this Contract, laws and regulations, and shall not be deemed as a waiver of such rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
21 Confidentiality </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
party undertakes to keep confidential the trade secrets, technical information, business information and other business secrets obtained
from the other party which are not available through public channels. Without the consent of the original provider of the trade secret,
neither party shall disclose all or part of the trade secret to any third party, unless otherwise stipulated by laws and regulations
or otherwise agreed by both parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the event that either party is in violation of the aforesaid confidentiality obligation, it shall assume the corresponding liability
for breach of contract and compensate for the losses caused thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
20 Force Majeure </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
term Force Majeure as specified in this Contract refers to the objective events that cannot be foreseen, overcome, or avoided and have
a significant impact on one party, including but not limited to the natural disasters such as flood, earthquake, fire and storm, as well
as the social events such as war and turmoil.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Contract cannot be performed as a result of the
occurrence of force majeure events, the party affected by the force majeure shall immediately notify the other party of the event in writing,
and within 7 days, provide written documents certifying the details of accident and the reasons for non-performance or delay in performance
hereof. Upon consensus through negotiation, both Parties may terminate or temporarily delay the performance of the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
23 Alteration, Amendment and Termination </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract can be altered and amended in written form upon consensus
through negotiation of the Parties, and any alternation and amendment agreed on by the Parties shall constitute an integral part of this
Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Contract may not be terminated until all the rights and obligations are fully preformed, unless otherwise stipulated in laws and regulations
or agreed by the both Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
invalidity of any provision of this Contract shall not affect the legal validity of other provisions, unless otherwise stipulated in
laws and regulations or agreed by the both Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
24 Agreements on Service </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.
The contact information (including mailing address, telephone number, fax number, etc.) provided by the Borrower in this Contract shall
be true and valid and shall be the address for service of any notice of the Lender for the Borrower. In case of any change to the contact
information, the Borrower shall immediately send/mail the change information in writing to the mailing address provided by the Lender
in this Contract. Such information change shall become effective upon the Lender&rsquo;s receipt of the change notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.
Unless otherwise expressly provided for in this Contract, the Lender shall be entitled to give notice to the Borrower in any of the following
methods. The Lender shall be entitled to choose the notification method as it thinks fit and shall not be held liable for any error,
omission or delay in delivery by mail, fax, telephone, WeChat or any other communication system. Where the Lender simultaneously chooses
several notification methods, the one by which the notice is served to the Borrower earlier shall prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
By announcement. The notice shall be deemed to be served on the date on which the Lender publishes the announcement on its website, online
banking, telephone banking or business outlets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
By hand. The notice shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower refuses
to sign for the receipt, the date on which the server makes a record on the proof of service on the spot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
By mail (including express mail, surface mail or registered mail). The notice, when addressed to the Borrower&rsquo;s mailing address
last known to the Lender, shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower fails
to sign for the receipt, the date on which the mail is returned;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)
By fax, mobile phone SMS, WeChat or other electronic communication methods. The notice, when sent to the Borrower&rsquo;s fax number,
the mobile phone number, WeChat account number or email address designated by the Borrower which is last known to the Lender, shall be
deemed to be served on the date on which the notice is sent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.
Borrower agrees that, unless the Lender receives from the Borrower a written notice concerning the change of mailing address, the Borrower&rsquo;s
domicile stated in this Contract is the correspondence and contact address. In the future, the delivery addresses of bank statements,
collection statements, relevant legal instruments and litigation documents related to the loans under this Contract shall prevail. The
Borrower promises to notify the Lender in time when the communication and contact information change, otherwise the documents delivered
by the Lender according to the communication and contact information stated in this Contract will be effectively delivered, and the relevant
economic and legal responsibilities arising therefrom will be borne by the Borrower and the Mortgagor. During the dispute settlement,
if the court serves the judicial documents or other written documents by mail (including express mail, surface mail or registered mail)
to the Borrower mailing address last known to the Lender, such documents shall be deemed to be served on the date on which the Borrower
signs for receipt of the proof of service; or if Borrower fails to sign for receipt of the proof of service, the date on which the mail
is returned;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
court or notary organ shall be entitled to give any notice to the Borrower by any methods of communication agreed in this Paragraph 2.
The court or notary organ shall be entitled to choose the communication method as it thinks fit and shall not be held liable for any
error, omission or delay in delivery by mail, fax, telephone, telex or any other communication system. Where the court or notary organ
simultaneously chooses several communication methods, the one by which the notice is served on the Borrower earlier shall prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
25 Appendix </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
appendixes confirmed by both parties shall constitute an integral part of this Contract and shall have the same legal effect as this
Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
26 Other Agreements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.
The Borrower shall not transfer any rights and obligations under this Contract to the third party without written consent of the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.
The Lender has the right to transfer the creditor&rsquo;s rights under this Contract to the third party, and shall notify the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.
This Contract shall be legally binding upon both Parties and their successors and assignees without prejudice to other provisions of
this Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.
All the transactions under this Contract are carried out for each Party&rsquo;s independent benefits. If, in accordance with relevant
laws, regulations and regulatory provisions, other parties to the transaction become the related parties or affiliated persons of the
Lender, no Party may seek to affect the fairness of the transaction out of this related-party relationship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.
The headings and business names in this Contract are used only for convenient reference, which shall not be used to interpret the provisions
or the rights and obligations of both Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.
In accordance with relevant laws, regulations and regulatory provisions, the Lender shall have the right to provide the information related
to this Contract and other relevant information of the Borrower to the credit reference system of the People&rsquo;s Bank of China and
other credit information database established according to law for reference and use by the institutions or individuals with proper qualification
according to law. The Lender shall also have the right to refer the relevant information of the Borrower through credit reference system
of the People&rsquo;s Bank of China and other credit information database established according to law for the purpose of the execution
and performance of this Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The parties acknowledge that the Borrower and
the Lender have made a full negotiation in connection with all the terms of this Contract. The Lender has requested the Borrower to give
special attention to and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the
parties, and has made explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood
all the contents and provisions of the Contract. The Borrower confirms that there is no misunderstanding or doubt about all the contents
and terms of the Contract. Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract
and have no objection to the contents and provisions of the Contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>The Borrower and the Lender have made a full negotiation in connection
with all the provisions of this Contract. The Lender has requested the Borrower to give special attention to and make a comprehensive
and accurate understanding of all provisions concerning the rights and obligations of the parties, and has made explanations to the relevant
provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood all the contents and terms of the Contract.
The <FONT STYLE="border: Black 1pt solid">Borrower</FONT></B><B> confirms that there is <FONT STYLE="border: Black 1pt solid">no misunderstanding
or ambiguity </FONT></B><B>about all the contents and provisions of the <FONT STYLE="border: Black 1pt solid">Contract</FONT></B><B>.
Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract and have no objection to
the contents and provisions of the Contract.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(The Borrower shall fill in the following
by contrast)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(The
remainder of this page is intentionally left blank for signatures)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="text-align: justify; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Borrower (Official Seal): _____________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex4-12_009.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal
Representative or Authorized Agent (Signature &amp; Seal):</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex4-12_010.jpg" ALT=""></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lai
                                            Gang <U>(Signature)</U></FONT></TD>
    <TD STYLE="text-align: justify; width: 10%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex4-12_011.jpg" ALT=""></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex4-12_014.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>June
15, 2022 </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lender
(Seal): ____________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 50%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal Representative
or Authorized Agent (Signature &amp; Seal):</FONT></TD><TD STYLE="vertical-align: bottom; width: 20%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex4-12_012.jpg" ALT=""></FONT></TD><TD STYLE="vertical-align: bottom; text-align: justify; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>(Signature)</U></FONT></TD>
    <TD STYLE="text-align: justify; width: 20%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">______________</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>June
15, 2022 </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 60%">&nbsp;</TD>
<TD STYLE="text-align: justify; padding-bottom: 1.5pt; width: 20%">&nbsp;</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; width: 20%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Contract Execution Place:</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 0%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex4-12_013.jpg" ALT=""></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: justify; margin: 0pt auto; width: 100%"><DIV STYLE="text-align: justify; font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.13
<SEQUENCE>5
<FILENAME>f20f2022ex4-13_universe.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT ENTERED INTO BY AND BETWEEN JIANGXI UNIVERSE AND BANK OF COMMUNICATIONS, DATED JUNE 22, 2022
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.13</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>No.: 68 (2022) 176 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan <BR>
Contract</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Bank of Communications Co., Ltd.</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>No.:</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1.5pt solid; width: 100%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Important Notice</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 22.65pt"><B>The borrower is requested to read the full
    text of this contract carefully, especially the provisions marked with &#9650;&#9650;. Please ask the Lender to explain in time in case
    of any doubt.</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">In view of the Borrower&rsquo;s application for working
capital loan line of credit from the Lender, and in order to clarify the rights and obligations of both parties, the Borrower and the
Lender hereby conclude this contract through negotiation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 1 Definition</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Line of credit&rdquo; refers to the maximum
amount of loan balance (under revolving line of credit) or total loan (under lump-sum line of credit) that the Lender may issue to the
Borrower according to the contract, and the line of credit can be revolving line of credit or lump-sum line of credit (only used once
or can be used several times) according to the contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Revolving line of credit&rdquo; means that
the Borrower can apply for using the line of credit several times as agreed in this contract to obtain the loan, but the loan balance
cannot exceed the agreed line of credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Lump-sum line of credit&rdquo; means that the
Borrower can apply for using the line of credit at one time or several times as agreed in this contract to obtain the loan, but the total
amount of loans withdrawn cumulatively cannot exceed the agreed line of credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Loan balance&rdquo; refers to the sum of the
loan principal amount obtained by the Borrower under this contract and not yet paid off.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Line of credit balance&rdquo; refers to the
amount after deducting the loan balance (under the revolving line of credit) or the total loan (under the lump-sum line of credit) from
the line of credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Credit period&rdquo; refers to the period
during which the Lender grants the loan to the Borrower according to the Borrower&rsquo;s application and the agreement in this contract,
and which belongs to the loan occurrence period rather than the loan term.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Loan term&rdquo; refers to the term of each
loan determined by both parties in the corresponding Application for Use of Loan Line of Credit of Bank of Communications (hereinafter
referred to as &ldquo;Application for Use of Line of Credit&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Pricing benchmarks&rdquo; refers to the benchmark
chosen by the Borrower and the Lender to determine the lending rate, including but not limited to the following specific pricing benchmarks
and other types.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Loan prime rate (LPR)&rdquo; refers to the
loan prime rate released by the National Interbank Funding Center on the 20th day of each month (postponed in case of holidays).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Secured Overnight Financing Rate (SOFR)&rdquo;
refers to the secured overnight financing rate governed by the Federal Reserve Bank of New York(or other entities that take over its pricing
benchmark), displayed on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or other pages of information service
institutions recognized by Lender showing this pricing benchmark) that can be applied to loans of the dollar.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Term SOFR Reference Rate&rdquo; refers to
the term SOFR reference rate governed and published by CME Group Benchmark Administration Limited (or other entities that take over its
pricing benchmark), and displayed on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or other pages of information
service institutions recognized by Lender showing this pricing benchmark) that can be applied to loans of the dollar.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Euro Interbank Offered Rate (EURIBOR)&rdquo;
refers to the Euro interbank offered rate governed by the European Money Markets Institute (or other entities that take over its pricing
benchmark), displayed on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or other pages of information service
institutions recognized by Lender showing this pricing benchmark) that can be applied to loans of the euro.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Hong Kong Interbank Offered Rate (HIBOR)&rdquo;
refers to the Hong Kong interbank offered rate governed by the Hong Kong Association of Banks(or other entities that take over its pricing
benchmark), displayed on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or other pages of information service
institutions recognized by Lender showing this pricing benchmark) that can be applied to loans of the Hong Kong dollar.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Tokyo Term Risk Free Rate (TORF)&rdquo; refers
to the Tokyo term risk free rate governed by QUICK Benchmarks Co., Ltd (or other entities that take over its pricing benchmark), displayed
on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or other pages of information service institutions recognized
by Lender showing this pricing benchmark) that can be applied to loans of the Japanese yen.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Term SONIA Reference Rate (TSRR)&rdquo; refers
to the term SONIA reference rate governed and published by Intercontinental Exchange Benchmark Administration Limited (or other entities
that take over its pricing benchmark), displayed on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or other
pages of information service institutions recognized by Lender showing this pricing benchmark) that can be applied to loans of the British
pound.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;London Interbank Offered Rate (LIBOR)&rdquo;
refers to London interbank offered rate governed by Intercontinental Exchange, Inc. (or other entities that take over its pricing benchmark),
displayed on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or other pages of information service institutions
recognized by Lender showing this pricing benchmark) that can be applied to loans of the dollar.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Bank working day&rdquo; and &ldquo;working
day&rdquo; refer to the opening day of the bank&rsquo;s corporate business in the place where the Lender is located, excluding legal holidays
and rest days (except for business due to holiday adjustment). If the loan date, repayment date, interest payment date, maturity date
and other obligation fulfillment dates meet non-bank working day, it shall be postponed to the next bank working day accordingly.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Foreign currency working day&rdquo; refers
to the bond trading days of the U.S. government (excluding Saturdays and Sundays) recommended by the Securities Industry and Financial
Markets Association (or its successor) to the Fixed Income divisions of its members for SOFR or Term SOFR Reference Rate; refers to the
normal opening day (excluding Saturdays and Sundays) of the commercial banks in London for LIBOR or TSRR; refers to Euro payment cleaning
days of TARGET 2 for EURIBOR; refers to the normal opening day (excluding Saturdays and Sundays) of banks in Hong Kong for HIBOR; and
refers to the normal opening day (excluding Saturdays and Sundays) of banks in Tokyo for TORF.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Related parties&rdquo; refer to the authorized
handler, agent, legal representative, person in charge, controlling shareholder or actual controller, beneficial owner and other related
parties directly or indirectly of the Borrower.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&ldquo;Business related parties&rdquo; refer to
all parties to the transaction under the basic transaction contract, other related entities other than the parties to the transaction,
as well as the parties to the transaction, authorized handlers, agents, legal representatives, persons in charge, controlling shareholders
or actual controllers, beneficial owners and other parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Related parties, related party transactions, individual
major investors and other words have the same meanings as those in Accounting Standards for Business Enterprises No.36 - Related Party
Disclosure (CAI KUAI No.3 [2006]) and subsequent amendments to the standards.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 2 Use of Line of Credit</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">2.1 The Borrower should apply to the Lender at least
5 banking days in advance when it needs to use the line of credit. When applying, the Borrower should fill in the Application for Use
of Line of Credit, which can only be used after being examined and approved by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650; 2.2 Every use of the line of credit
is subject to all the following conditions:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1) The loan balance (under the revolving line of
credit) or the total loan (under the lump-sum line of credit) does not exceed the line of credit;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) The applied loan amount does not exceed the
balance of the line of credit;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(3) The application date and loan date are within
the credit period;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(4) The loan term and maturity date of the loan
are in line with this contract;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(5) The guarantee contract under this contract (if
any) has come into force and continues to be valid. If the guarantee contract is a mortgage contract and/or pledge contract, the real
rights granted by way of security have been established and continue to be valid;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(6) The Borrower has completed the government permission,
approval, registration and other procedures that must be handled by law when applying for the loan, and the permission, approval or registration
continues to be valid;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(7) After the contract comes into effect, the Borrower&rsquo;s
operating and financial conditions have no significant adverse changes;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(8) The application of the Borrower meets the requirements
of relevant rules and regulations of the Lender;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(9) The Borrower has not violated the contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(10) The payment method of the loan is in accordance
with this contract. If the Lender is entrusted to pay, the Lender agrees to pay;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(11) In case of drawing foreign currency loans,
the Borrower has provided proof documents that the loans comply with relevant foreign exchange management policies, including but not
limited to valid foreign exchange purpose certificates or registration documents;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(12) The Borrower has designated a special fund
withdrawal account and signed an account management agreement as required by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;2.3 If the Lender agrees to grant
the loan, the final loan information shall be subject to the contents of the bank print column of the Application for Use of Line of Credit.
The Application for Use of Line of Credit is also used as the Loan Voucher.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;2.4 If the currency of the Application
for Use of Line of Credit is inconsistent with the currency of the line of credit, only for the purpose of determining the line of credit
balance, it shall be converted according to the exchange rate published by Bank of Communications Co., Ltd. at the beginning of each day;
if there is no directly applicable exchange rate, it shall be converted by Bank of Communications Co., Ltd. according to the exchange
rate determined in a reasonable way.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;2.5 After the Borrower becomes the
shareholder of the guarantor or the &ldquo;actual controller&rdquo; as defined in the Company Law, the Lender has the right to suspend
or cancel the unused loan line of credit of the Borrower before the guarantor provides the resolution on agreeing to provide guarantee
for the Borrower by its shareholders&rsquo; meeting (General Meeting of Shareholders) accepted by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 3 Interest Rate, Interest Calculation and
Payment</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.1 Basic rules for determining the interest rate</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.1.1 The annual loan interest rate (simple interest)
under this contract shall be agreed by both parties in the Application for Use of Line of Credit after negotiation every time the Borrower
uses its line of credit, determined according to the pricing benchmark, and calculated according to the pricing benchmark agreed in the
Application for Use of Line of Credit plus (minus) points (1 basis point is 0.01 percent, 1 percentage point is 100 basis points).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.1.2 If both parties agree to apply the fixed interest
rate in the Application for Use of Line of Credit, and the specific value is recorded in the fixed interest rate value field, the specific
interest rate of each loan shall be subject to the value recorded in the fixed interest rate value field in the Application for Use of
Line of Credit (If the currency of the loan is RMB, the specific value will be determined based on the specific value of the pricing benchmark
applicable to the applicable date of the pricing benchmark agreed in the Application for Use of Line of Credit (hereinafter referred to
as &ldquo;pricing benchmark value&rdquo;) and according to the value of plus (minus) points agreed in the Application for Use of Line
of Credit.). If the specific value is not recorded in the fixed interest rate value field, the specific interest rate of each loan shall
be determined based on the pricing benchmark value applicable to the applicable date of the pricing benchmark agreed in the Application
for Use of Line of Credit and according to the value of plus (minus) points agreed in the Application for Use of Line of Credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">If both parties agree to apply the floating interest
rate in the Application for Use of Line of Credit, the specific interest rate of each loan will be determined based on the LPR value applicable
to the applicable date of the pricing benchmark agreed in the Application for Use of Line of Credit, the value of the plus (minus) points,
the interest rate fluctuation rules, the interest rate fluctuation period, the unit of interest rate fluctuation period and the floating
start date of a specific date (if necessary) agreed in the Application for Use of Line of Credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.1.3 If the currency is RMB, the daily interest
rate = interest rate/30, and the monthly interest rate = annual interest rate/12; If the currency is Hong Kong dollars, British pounds
and Australian dollars, the daily interest rate = annual interest rate/365; If the currency is USD, Euro, Japanese yen and other foreign
currencies accepted by the Lender, the daily interest rate = annual interest rate/360.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;3.2 Loan interest rate</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">If both parties agree to apply the fixed interest
rate in the Application for Use of Line of Credit, and the specific value is recorded in the fixed interest rate value field, the interest
rate of each loan shall be subject to the value recorded in the fixed interest rate value field. If both parties agree to apply the fixed
interest rate in the Application for Use of Line of Credit, and the specific value is not recorded in the fixed interest rate value field
and both parties agree to apply the floating interest rate in the Application for Use of Line of Credit, the loan interest rate for each
loan is determined based on the applicable LPR value of the &ldquo;applicable date of the pricing benchmark&rdquo; agreed in the corresponding
Application for Use of Line of Credit, and according to the plus (minus) point value agreed in the Application for Use of Line of Credit.
Take the &ldquo;applicable date of the pricing benchmark&rdquo; as the T-day, and value rules for the applicable pricing benchmark value
on T-day shall be executed according to Article 3.5.1 of this contract.<BR STYLE="clear: both">
</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.3 Adjustment of the interest rate</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.3.1 If a fixed interest rate is recorded in the
Application for Use of Line of Credit, the recorded interest rate will be implemented for the loan within the loan term.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;3.3.2 If a floating interest rate
is recorded in the Application for Use of Line of Credit, the loan interest rate adjustment date shall be determined according to the
interest rate fluctuation rules, interest rate fluctuation period, unit of interest rate fluctuation period and floating start date of
specific date (if necessary) agreed in the Application for Use of Line of Credit, and the adjusted interest rate shall apply from the
loan interest rate adjustment date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.3.2.1 During the loan period, the period of adjustment
of the loan interest rate will be calculated from the &ldquo;loan entry date&rdquo; or the &ldquo;floating start date of the specific
date&rdquo; according to the &ldquo;floating by loan entry date&rdquo; or &ldquo;floating on specific starting date&rdquo; selected in
&ldquo;interest rate fluctuation rules&rdquo;. The blank column of interest rate floating cycle shall be filled with the number of interest
rate floating cycles, and the unit of interest rate floating cycle can be selected as daily or monthly. If &ldquo;1&rdquo; is filled in
the number of interest rate floating cycles and &ldquo;daily&rdquo; is selected as the floating cycle unit, every day from the &ldquo;loan
entry date&rdquo; or the &ldquo;floating start date of the specific date&rdquo; will be taken as the adjustment date of loan interest
rate; If &ldquo;3&rdquo; is filled in the number of interest rate floating cycles and &ldquo;daily&rdquo; is selected as the floating
cycle unit, the loan interest rate adjustment date will be the date every 3 days from the &ldquo;loan entry date&rdquo; or &ldquo;floating
start date of specific date&rdquo;; If &ldquo;1&rdquo; is filled in the number of interest rate floating cycles and &ldquo;monthly&rdquo;
is selected as the floating cycle unit, the loan interest rate adjustment date will be the date of every month from the &ldquo;loan entry
date&rdquo; or &ldquo;floating start date of specific date&rdquo;; If &ldquo;3&rdquo; is filled in the number of interest rate floating
cycles and &ldquo;monthly&rdquo; is selected as the floating cycle unit, the loan interest rate adjustment date will be every 3 months
from the &ldquo;loan entry date&rdquo; or &ldquo;floating start date of specific date&rdquo;, and so on.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.3.2.2 The loan interest rate on the loan interest
rate adjustment date is determined on the basis of the applicable pricing benchmark value on the loan interest rate adjustment date, and
the value of interest rate plus (minus) points shall be executed according to the value of interest rate plus (minus) points agreed in
the Application for Use of Line of Credit, except for the value of plus (minus) points adjusted by both parties through consultation in
this contract. Take the &ldquo;loan interest rate adjustment date&rdquo; as the T-day, and the applicable pricing benchmark value on the
T-day shall be executed according to Article 3.5.1 of this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;3.3.3 If applicable pricing benchmark
of certain loan is canceled or the corresponding publishing institution stops publishing, both parties shall negotiate and adjust the
loan interest rate separately, but the adjusted interest rate shall not be lower than the applicable interest rate at that time; If the
two parties still fail to reach an agreement on the adjusted interest rate after more than one month from the date when the pricing benchmark
is canceled or stopped publishing, the Lender has the right to declare the loan to expire in advance.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;3.3.4 Both parties can adjust the
value of the plus (minus) points of the corresponding loan interest rate after consensus on each loan interest rate adjustment date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.4 The penalty interest rate of overdue loans will
be increased by 50% according to the interest rate agreed in this contract, and the penalty interest rate of misappropriated loans will
be increased by 100% according to the interest rate agreed in this contract. In case of adjustment of pricing benchmark for floating rate
loans, the Lender has the right to adjust the applicable penalty interest rate for each loan accordingly, and apply the new penalty interest
rate from the adjustment date of loan interest rate agreed in the corresponding Application for Use of Line of Credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.5 Calculation of interest</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.5.1 According to different applicable pricing
benchmarks, the value rules for applicable pricing benchmark in T-day (namely, &ldquo;applicable date of the pricing benchmark&rdquo;,
&ldquo;loan interest rate adjustment date&rdquo;, and &ldquo;re-pricing day&rdquo;) agreed in Article 3.2, Article 3.3.2.2 and Article
9. 3.3.2 are as follow:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">If the pricing benchmark is LPR, the pricing benchmark
value applicable for T-day will be the latest published value of LPR before T-day.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">If the pricing benchmark is SOFR and the T-day is
a foreign currency working day, the pricing benchmark value applicable for T-day will be the value of SOFR displayed on the corresponding
financial telecommunication terminal page on the fifth foreign currency working days before T-day; If the T-day is not a foreign currency
working day, the pricing benchmark value applicable for T-day will be the value of SOFR of the latest foreign currency working day (which
is the value of SOFR displayed on the corresponding financial telecommunication terminal page on the fifth foreign currency working days
before the latest foreign currency working day).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">If the pricing benchmark is Term SONIA Reference
Rate, LIBOR, EURIBOR, TORF, or TSRR, and the T-day is a foreign currency working day, the pricing benchmark value applicable for T-day
will be the value of the pricing benchmark displayed on the corresponding financial telecommunication terminal page on the second foreign
currency working days before T-day; if the T-day is not a foreign currency working day, the pricing benchmark value applicable for T-day
will be the value of the pricing benchmark of the latest foreign currency working day (which is the value of the pricing benchmark displayed
on the corresponding financial telecommunication terminal page on the second foreign currency working days before the latest foreign currency
working day).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">If the pricing benchmark is HIBOR, and the T-day
is a foreign currency working day, the pricing benchmark value applicable for T-day will be the value of HIBOR displayed on the corresponding
financial telecommunication terminal page on T-day; if the T-day is not a foreign currency working day, the pricing benchmark value applicable
for T-day will be the value of HIBOR of the latest foreign currency working day (which is the value of HIBOR displayed on the corresponding
financial telecommunication terminal page on the latest foreign currency working days).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">If the pricing benchmark value displayed on the
corresponding financial telecommunication terminal page is larger than or equal to 0, the value of the pricing benchmark for determining
the loan rate of this contract will be determined based on the pricing benchmark value displayed on the corresponding financial telecommunication
terminal page; If pricing benchmark value displayed on the corresponding financial telecommunication terminal page is smaller than 0,
the value of the pricing benchmark for determining the loan rate of this contract will be determined as 0.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.5.2 Normal interest = interest rate agreed in
this contract &times; loan amount &times; occupied days</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">The occupied days are calculated from the loan date
(inclusive) to the expiration date (exclusive), which will be postponed when the expiration date is not a working day. The postponed period
will be counted as occupied days, and the interest will still be calculated according to the contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.5.3 The penalty interest for overdue loans and
misappropriated loans is calculated according to the overdue or misappropriated amount and actual days (from the overdue or misappropriated
date (inclusive) to the date of repayment of principal and interest (exclusive)).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.5.4 If the calculated interest/penalty interest
has a large number of decimal places, the Lender will keep two decimal places by rounding.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;3.6 If the Borrower repays the loan
in advance or the Lender withdraws the loan in advance according to this contract, the corresponding interest rate grade will not be adjusted,
and the interest rate agreed in this contract will still be applied.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">3.7 If the loan currency is a currency rather than
RMB, US dollar, Euro, Hong Kong dollar, Japanese yen, and British pound, the determination of the pricing benchmark of the loan, the calculation
rule of daily interest rate and applicable date of pricing benchmark, the adjustment date of loan interest and the pricing benchmark value
on repricing date shall be subject to the agreement in Article 17 of this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 4 Payment of Loan</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">4.1 If the loan account designated by the Borrower
is a special loan issuance account opened at the Lender, the issuance and payment of the loan shall be handled through this account. This
account is only used for the issuance of loan funds and external payment, only for the sale of &ldquo;Application for Settlement Business&rdquo;
vouchers; It cannot be used for handling checks, bills of exchange, bank acceptance bills and other businesses, and cannot be used for
other settlements. When the Borrower pays for the loan fund allocation independently, it must be handled at the counter of the account
opening outlet. The deposit interest of this account is included in the Borrower&rsquo;s repayment account.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">4.2 When the Borrower withdraws the loan according
to this contract, it should specify the payment method (the Lender&rsquo;s entrusted payment or the Borrower&rsquo;s independent payment),
and only one payment method can be used for each withdrawal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">4.3 The Lender&rsquo;s entrusted payment means that
the Lender directly pays the loan funds to the Borrower&rsquo;s counterparty that meets the purpose agreed in this contract through the
Borrower&rsquo;s account after issuing the loan according to the Borrower&rsquo;s entrusted payment power of attorney.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">If the single payment amount exceeds the independent
payment line of credit or meets one of the conditions agreed in Article 19.3, the entrusted loan payment method shall be adopted.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">In case of the Lender&rsquo;s entrusted payment,
the Borrower shall submit to the Lender the Application for Use of Line of Credit, the corresponding entrusted payment power of attorney
and other information required by the Lender (including but not limited to business contracts, invoices, receipt documents and other transaction
information), and specify the amount of the loan to withdraw and the object and amount of payment, and the amount of the loan to withdraw
should be equal to the total amount to be paid.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;If the payment to be made by the Borrower
does not conform to this contract or the corresponding commercial contract or has other defects, the Lender has the right to refuse the
payment and return the entrusted payment power of attorney submitted by the Borrower.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;If the Lender agrees to pay, and if
it can&rsquo;t be paid or it is refunded due to the wrong information provided by the Borrower, the Borrower must resubmit the relevant
documents and materials containing the correct information within the time line of credit specified by the Lender, and the Lender will
not be responsible for the delay or unsuccessful payment.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">4.4 The Borrower&rsquo;s independent payment means
that after the Lender grants the loan funds to the Borrower&rsquo;s account according to the agreement in this contract, the Borrower
pays the loan funds to the Borrower&rsquo;s counterparty that meets the purpose agreed in this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">If the Borrower&rsquo;s independent payment is adopted,
the Borrower shall submit to the Lender the Application for Use of Line of Credit, instructions on the use of funds and other materials
required by the Lender. The Borrower shall summarize and report the payment of loan funds to the Lender on time. The Lender has the right
to check whether the payment of loan funds meets the agreed purpose by means of account analysis, voucher inspection, on-site investigation,
etc. The Borrower shall cooperate with the Lender&rsquo;s verification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 5 Repayment of Loan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">5.1 The Borrower shall repay the loan according
to the repayment date and amount recorded in the corresponding Application for Use of Line of Credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;5.2 Without the written consent of
the Lender, the Borrower cannot repay the loan in advance.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;5.3 The repayment arrangement of the
principal and interest agreed by the Borrower and the Lender in the Application for Use of Line of Credit is the real intention reached
by both parties on a voluntary basis after consultation. Under the repayment arrangement chosen by both parties, whether the principal
is repaid before the interest does not affect the Borrower&rsquo;s repayment responsibility for the interest payable, and the Borrower
shall not argue against the repayment of the interest payable. Under any repayment arrangement, the Borrower shall bear the repayment
responsibility for all the principal and interest payable.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;5.4 When the repayment of the Borrower
(including the repayment voluntarily repaid by the Borrower and deducted by the Lender according to this contract) cannot fully pay off
all the debts of the Borrower:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1) It should be used to pay off the overdue expenses
first. If the principal and interest are overdue for less than 90 days, the balance after offsetting the expenses shall be used to offset
the overdue interest or penalty interest and compound interest, and then used to offset the overdue principal; If the principal or interest
is overdue for more than 90 days, the balance after offsetting the expenses shall be used to offset the overdue principal first, and then
used to offset the overdue interest or penalty interest and compound interest;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) If the Borrower has multiple debts (including
the debts of the Borrower to the Lender under other contracts), the Lender has the right to decide the repayment and offset order of each
debt of the Borrower by itself, as long as the offset order does not violate the mandatory provisions of laws, regulations, rules and
regulations as well as relevant regulatory requirements applicable to the Lender. The Lender shall inform the Borrower of the result of
debt repayment. Unless otherwise agreed by both parties to this article.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 6 Statement and Guarantee of the Borrower</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">6.1 The Borrower is legally established and legally
exists; It has all necessary rights and capabilities, and it can perform the obligations of this contract in its own name and bear civil
liabilities.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">6.2 Signing and performing this contract is the
true intention of the Borrower after all necessary consent, approval and authorization, and there is no any legal flaw.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">6.3 The Borrower&rsquo;s production and operation
are legal and compliant, with the ability of going concern, legal sources of repayment, no major environmental and social risks and no
major bad credit record. The senior management of the Borrower has no bad record.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">6.4 All documents, statements, data and information
provided by the Borrower to the Lender during the signing and performance of this contract are true, accurate, complete and effective.
No information that may affect its financial status and repayment ability has been concealed from the Lender, and the financial status
of the Borrower has no significant adverse changes since the reporting date of the latest financial statements.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;6.5 The Borrower, its related parties
and business related parties are not listed in the sanctions list issued by the United Nations and related countries, organizations and
institutions, or the enterprises or individuals listed in the risk list related to terrorism and anti-money laundering issued by Chinese
government departments or authorities; They are not located in countries and regions that are not sanctioned by the United Nations and
related countries, organizations and institutions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;6.6 The Borrower promises to abide
by the national anti-money laundering laws, regulations and relevant policies, not to engage in illegal activities such as assisting others
in money laundering, terrorist financing, tax evasion, evasion of bank debts, cash extraction, telecom fraud, illegal fund-raising, etc.,
actively cooperate with the Lender to carry out various anti-money laundering work such as customer identification, transaction record
keeping, due diligence on customer identity and transaction background, large and suspicious transaction reports, etc., and provide relevant
certification materials as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 7 Rights and Obligations of the Lender</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">7.1 The Lender has the right to recover the loan
principal and interest (including compound interest, penalty interest for overdue loans and misappropriation of loans, etc.) according
to this contract, collect the fees payable by the Borrower, decide to recover the loan in advance according to the Borrower&rsquo;s fund
withdrawal, and exercise other rights stipulated by law or this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;7.2 During the performance of this
contract, the Lender only conducts formal review on the information provided by the Borrower. If the materials provided by the Borrower
are untrue, inaccurate or incomplete, or the Borrower violates the agreement of this contract to make payment, resulting in the Lender&rsquo;s
failure to complete the entrusted payment in time, the Lender will not be liable.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;7.3 The Lender shall issue the loan
and handle the payment according to this contract. If the Lender fails to issue the loan or make payment on time due to any of the following
reasons, the Lender will not be liable, but it will inform the Borrower in time: The loan account designated by the Borrower is frozen,
the payment object account is frozen, force majeure, communication or network failure, system failure of the Lender, etc. Unless otherwise
agreed in this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;7.4 According to the regulatory requirements
for the Lender, the Lender shall conduct a dynamic evaluation of the Borrower&rsquo;s risks of money laundering, terrorist financing,
and tax evasion and be entitled to adopt one or all of the measures agreed in Article 9.2 when it the risks of the Borrower or the Borrower&rsquo;s
trading instructions of money laundering, terrorist financing, and tax evasion are considered high.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 8 Obligations of the Borrower</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">8.1 The Borrower shall repay the loan principal
under this contract and pay the interest according to the time, amount, currency and interest rate recorded in this contract and the corresponding
Application for Use of Line of Credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">The fund withdrawal account designated by the Borrower
is used to collect the corresponding sales revenue or planned repayment funds. If the corresponding sales revenue is settled in a non-cash
manner, the Borrower shall ensure that the money is promptly transferred to the fund withdrawal account after being received. The Borrower
shall provide the capital inflow and outflow of the capital withdrawal account as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">8.2 The Borrower shall use the line of credit according
to the purpose agreed in this contract, and use the loan according to the purpose determined in the corresponding Application for Use
of Line of Credit, and shall not use the loan for other purposes, or use the loan for fixed assets investment, equity investment, fields
and purposes prohibited by the state from production and operation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">The Borrower shall use the loan funds as agreed,
and shall not avoid the Lender&rsquo;s entrusted payment by breaking up the whole into parts; If the Borrower&rsquo;s independent payment
is adopted, the Borrower shall use the loan within a reasonable time according to the requirements of the Lender&rsquo;s supervisory authority,
and the payment of loan funds shall comply with this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;8.3 The Borrower shall bear the settlement
fees (if any) for the loan fund payment (including the Lender&rsquo;s entrusted payment and the Borrower&rsquo;s independent payment),
and the specific fees shall be implemented according to laws, regulations, rules, regulatory requirements and the Service Charges List
of the Bank of Communications effective at that time published by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">For loan fund payments involving no cross-border
payment, when the loan funds are paid (including the Lender&rsquo;s entrusted payment and the Borrower&rsquo;s independent payment), if
the collection account does not belong to the account opened in the Bank of Communications, the payment of the funds may be handled through
the payment system of the People&rsquo;s Bank of China or the local exchange system. If the loan account is not a special loan issuing
account, when the loan funds are paid (including the Lender&rsquo;s entrusted payment and the Borrower&rsquo;s independent payment), if
the collection account is an account of another bank in different places, all the payment of funds will be handled through the payment
system of the People&rsquo;s Bank of China.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">For loan fund payments involving cross-border payment,
the loan fund payment may be handled through the SWIFT system or other payment systems.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;8.4 The Borrower shall cooperate with
the Lender to handle the loan payment and supervise and inspect the loan usage as well as the Borrower&rsquo;s operation; It shall timely
provide the financial statements, loan fund usage records and materials, related party and related party transaction information, environmental
and social risk reports, other materials and information required by the Lender for post-loan risk management, and ensure that the documents,
materials and information provided are true, complete and accurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;8.5 In case of any of the following
events, the Borrower shall notify the Lender in writing at least 30 days in advance, and shall not take any action before paying off all
the loan principal and interest under this contract or providing the repayment scheme and guarantee approved by the Lender:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1) The Borrower disposes of all or most assets
or important assets by selling, donating, leasing, lending, transfer, mortgage, pledge or otherwise;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) Significant changes have taken place in the
Borrower&rsquo;s management system or property right organization form, including but not limited to the implementation of contract, lease,
joint venture, company system reform, joint-stock cooperation system reform, enterprise sale, merger (acquisition), joint venture (cooperation),
division, establishment of subsidiaries, equity transfer, property right transfer, capital reduction, etc.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(3) The Borrower&rsquo;s foreign equity or increased
debt financing exceeds the agreed line of credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;8.6 The Borrower shall notify the
Lender in writing within 7 days from the date when the following events happen or may happen and submit relevant supporting documents
according to laws, regulatory provisions, and the Lender&rsquo;s requirements:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1) The Borrower or its related party modifies the
articles of association, changes the business registration items such as enterprise name, legal representative (person in charge), residence,
postal address or business scope, or makes decisions that have a significant impact on finance and personnel;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) The Borrower, its related party or guarantor
intends to apply for bankruptcy or may have been or has been applied for bankruptcy by creditors;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(3) The Borrower or its related party is involved
in major litigation, arbitration and administrative measures, or property preservation or other compulsory measures have been taken for
its main assets or collateral under this contract, or the safety and integrity of its main assets or collateral under this contract has
been or may be affected, or its value is reduced or may be reduced;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(4) The Borrower or its related party provides a
guarantee for a third party, which has a significant adverse impact on its economic status, financial status or ability to perform its
obligations under this contract;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(5) The Borrower or its related party signs a contract
that has a significant impact on its operation and financial status;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(6) The Borrower pays off the unexpired debts in
advance or gives priority to paying off other due debts, adds any form of guarantee such as pledge for other existing debts, or makes
any arrangement or signs relevant documents with similar effect;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(7) The Borrower, its related party or guarantor
suspends production, closes down, dissolves or suspends business for rectification, is revoked or its business license is revoked;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(8) The Borrower or its related party, the individual
principal investor of the Borrower or its related party, the legal representative (person in charge), director or key management personnel
of the Borrower or its related party is missing, involved in violations of laws and regulations or in violation of applicable exchange
rules or has any abnormal changes;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(9) The Borrower or its related party has serious
difficulties in operation, or its financial situation deteriorates, or other events that have a negative impact on the operation, financial
situation, solvency or economic situation of the Borrower or its related parties occur;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(10) Related party transactions occur, and the monthly
transaction amount reaches or exceeds 10% of the recently audited net assets;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(11) Before paying off all debts under this contract,
the Borrower becomes or may become the shareholder or the &ldquo;actual controller&rdquo; as defined in the Company Law of the guarantor;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(12) The Borrower or its related party is exposed
by the media because of its violation of laws, regulations, regulatory requirements, national policies or industry standards, etc.;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(13) The Borrower or its related party has any safety
or environmental accident;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(14) The controlling or controlled relationship
between the Borrower&rsquo;s related party and the Borrower changes;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(15) The Borrower or its related party has any significant
equity change;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(16) The audit opinion issued by the external auditor
of the Borrower on its financial statements is not a standard unqualified opinion;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(17) The Borrower has been or may be investigated,
punished or taken other similar measures by the competent authority for violating laws, regulations and/or regulatory requirements;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(18) The Borrower or its related party or business
related party is included in the sanctions list issued by the United Nations and related countries, organizations and institutions, and
the list of risks related to terrorism and anti-money laundering issued by Chinese government departments or authorities; Or the country
and region where the Borrower or its related person or business related party is located is included in the list of countries and regions
sanctioned by the United Nations and related countries, organizations and institutions;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(19) Other major adverse events that affect the
solvency of the Borrower or its related party occur.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(20) According to the Lender&rsquo;s environmental
and social risk assessments standards, if the Borrower belongs to one of the clients in Category A or B of social risk, any one of the
following matters happen or may happen to the Borrower:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9312; Various
permissions, reviews, and approvals concerning environmental and social risk during commencement, construction, operation and
shutdown;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9313; The environmental
and social risk assessment and examination of the Borrower by environmental and social risk regulator or other institutions it
recognized;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9314; Supporting
construction and operation of environmental facilities;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9315; Emission and
compliance of contaminants;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9316; Safety and health
condition of employees;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9317; Major complaints
or protests of the Borrower by neighboring communities;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9318; Major
environmental and social claims;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9319; Other major
situations considered relevant to environmental and social risk by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;8.7 When the guarantee under this
contract changes to the detriment of the Lender&rsquo;s creditor&rsquo;s rights, the Borrower shall provide other guarantees recognized
by the Lender in a timely manner as required by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">The &ldquo;change&rdquo; mentioned in this paragraph
includes but is not limited to: merger, division, suspension of production, suspension of business, dissolution, suspension of business
for rectification, being revoked, revocation of business license, application or being applied for bankruptcy of the guarantor; Significant
changes have taken place in the operation or financial status of the guarantor; The guarantor involves major litigation, arbitration,
administrative measures, or property preservation or other compulsory measures have been taken for its main assets; The security and integrity
of the collateral is or may be affected; The value of collateral is reduced or may be reduced, or compulsory measures such as property
preservation such as seizure are taken; The guarantor or its legal representative (person in charge) or key management personnel is involved
in violation of laws and regulations or the applicable exchange rules; If the guarantor is an individual, the guarantor is missing or
dead (declared dead); The guarantor has breached the contract under the guarantee contract; Disputes between the guarantor and the Borrower
occur; The guarantor asks to cancel the guarantee contract; The guarantee contract is ineffective, invalid or revoked; The real rights
granted by way of security are not established or invalid; Or other events affecting the security of the Lender&rsquo;s creditor&rsquo;s
rights occur, etc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;8.8 The Borrower promises that: from
the date of signing this contract until all the loan principal and interest and related expenses under this contract are paid off, the
financial indicators, external agency rating and production and operation qualifications/licenses of the Borrower always comply with the
contract, and if the production and operation qualifications/licenses need to be examined annually, they should pass the annual examination
on time.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">8.9 The Borrower guarantees that the Borrower, the
Borrower&rsquo;s employees and agents will not provide, give, ask for or accept material benefits in any form other than those stipulated
in this contract (including but not limited to cash, physical cards, travel, etc.) or other non-material benefits to the Lender or the
Lender&rsquo;s employees in any form; The Borrower, the Borrower&rsquo;s employees and agents will not directly or indirectly use the
funds or services provided by the Lender for activities related to corruption or bribery in any form; If the Borrower is aware of any
violation of this article, it should provide clues and relevant information to the Lender in a timely, truthful, complete and accurate
manner, and cooperate with relevant matters as required by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">8.10 According to the Lender&rsquo;s environmental
and social risk assessments standards, if the Borrower belongs to one of the clients in Category A or B of social risk, the Borrower shall
be borne the following obligations:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1) Set up a sound internal administrative system
for environmental and social risks and set forth detailed responsibility, obligation, and penalty measures of relevant responsible persons;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) Set up a sound environmental and social risk
emergency mechanism and a set of measures;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(3) Set up a special department and/or assign special
personnel to be responsible for environmental and social risk events;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(4) Cooperate with the Lender or a third party recognized
by the Lender to carry out environmental and social risk assessments and examinations for the Borrower;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(5) Provide appropriate responses or take necessary
actions when the public or other stakeholders express strong suspicion of the Borrower&rsquo;s environmental and social risk performance;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(6) Urge important affiliates of the Borrower to
enhance management to prevent the contagion of affiliates&rsquo; environmental and social risks to the Borrower;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(7) Perform other obligations of controlling environmental
and social risks which are considered relevant by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#9650;&#9650; Article 9 Adjustment of the Line of
Credit, Premature Expiration of Loan and Risk Repricing</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">9.1 Any of the following events shall be regarded
as the &ldquo;premature expiration event&rdquo; of this contract:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1) The Borrower fails to repay the loan principal
or pay interest as agreed in any Application for Use of Line of Credit under this contract;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) The statements and guarantees made by the Borrower
under this contract are untrue;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(3) Any of the notifiable matters listed in Article
8.6 actually happens, which affects or may affect the security of the Lender&rsquo;s creditor&rsquo;s rights;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(4) The change of laws, regulations and regulatory
policies causes that the loan issuance by the Lender as agreed in this contract constitutes or may constitute violations of laws or regulations;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(5) When the Borrower performs other contracts with
the Lender or contracts with a third party, there is a breach of contract or the debt may or has been announced to be due in advance;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(6) The Borrower violates other agreements in this
contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(7) According to the Lender&rsquo;s environmental
and social risk assessments standards, if the Borrower belongs to one of the clients in Category A or B of social risk, the following
events happen to the Borrower:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9312; The Borrower is
punished by the competent governmental department for poor management of environmental and social risk;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9313; The Borrower is
strongly questioned by the public and/or the media for poor management of environmental and social risk;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9314; he Borrower
breaches its obligations of the management of environmental and social risk agreed with the Lender in other contracts.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">9.2 When any &ldquo;premature expiration event&rdquo;
occurs, the Lender has the right to take one, several or all of the following measures:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1) Reduce, suspend or cancel the line of credit
under this contract;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) Stop issuing loans that have not been drawn
by the Borrower;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(3) Stop handle the payment that the Borrower has
withdrawn but not yet used;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(4) Require the Borrower to negotiate with the Lender
for supplementary loan issuance and payment conditions within a time limit;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(5) Require the Borrower to change the payment method
as required by the Lender;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(6) Reprice the risk of loans as agreed in Article
9.3;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(7) Unilaterally declare that all the loan principal
issued under the contract is due in advance and require the Borrower to immediately repay all the loan principal due and settle the interest.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">9.3 According to the production and operation situation
of the Borrower at the time of signing this contract, the interest rate agreed in this contract and its adjustment are determined by both
parties through negotiation. The Borrower agrees that in the event of any &ldquo;premature expiration event&rdquo;, the Lender has the
right to reprice the risk of the loan according to this article.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">9.3.1 Risk repricing includes negotiated repricing
and direct increase of the loan interest rate. The risk repricing method adopted in this contract is agreed by both parties in Article
21.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">9.3.2 &ldquo;Negotiated repricing&rdquo; means that
the Lender has the right to ask the Borrower to negotiate with the Lender to increase the loan interest rate within a time limit, and
both parties determine the &ldquo;repricing date&rdquo; and the specific agreement on relevant interest rates by means of supplementary
agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">9.3.3 &ldquo;Direct increase of the loan interest
rate&rdquo; means that the Lender has the right to directly increase the loan interest rate according to this article and Article 21.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">9.3.3.1 Since the &ldquo;repricing date&rdquo; notified
by the Lender to the Borrower in writing, the increased loan interest rate will be applied to all loans that the borrower has not repaid
as of the &ldquo;repricing date&rdquo;.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">9.3.3.2 If the loan currency is RMB, US dollar,
Euro, Hong Kong dollar, Japanese yen, or British pound, on the basis of the applicable pricing benchmark value on the &ldquo;repricing
date&rdquo;, the loan interest rate after each loan increase shall be determined according to the value of the plus (minus) points agreed
in Article 21.2.1.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Take the &ldquo;repricing date&rdquo; as the T-day,
and the applicable pricing benchmark value on T-day is subject to Article 3.5.1 in this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">9.3.3.3 If the loan currency is other currencies
rather than RMB, US dollar, Euro, Hong Kong dollar, Japanese yen, or British pound, the loan interest rate after the increase shall be
determined according to Article 21.2.2.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">9.3.4 After the Lender reprices the risk according
to the aforementioned agreement, the new interest rate will be implemented from the &ldquo;repricing date&rdquo;. On the basis of this
interest rate, it is still subject to the floating adjustment as agreed in Article 3 of this contract. If both parties agree to change
the relevant agreement through consultation, the agreement after the change shall prevail. In case of loans overdue (including the Borrower&rsquo;s
failure to repay the loan on time or the Lender&rsquo;s announcement of premature maturity) or misappropriation, the penalty interest
rate for overdue and misappropriation will be determined on the basis of the new interest rate (including the interest rate after floating
adjustment as agreed in this contract), and the interest rate for calculating compound interest will also be adjusted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">9.3.5 The implementation of &ldquo;risk repricing&rdquo;
shall not be deemed or interpreted as the Lender waiving other rights stipulated by laws and regulations and agreed in this contract.
The Lender has the right to take other creditor&rsquo;s rights protection measures according to laws and regulations and the contract,
including but not limited to the measures agreed in Article 9.2.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#9650;&#9650;Article 10 Breach of Contract</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">10.1 If the Borrower fails to repay the loan principal
in full and on time, pay interest or use the loan according to the purpose agreed in this contract, the Lender will charge interest according
to the penalty interest rate of overdue loans or the penalty interest rate of misappropriated loans, and calculate compound interest on
the unpaid interest payable. If the penalty interest rate is adjusted according to the contract, the interest rate for calculating compound
interest will also be adjusted accordingly.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">10.2 If the Borrower fails to repay the loan principal
and pay the interest in full and on time, it shall bear the urging fees, litigation fees (or arbitration fees), preservation fees, announcement
fees, execution fees, legal fees, travel expenses and other fees paid by the Lender to realize the creditor&rsquo;s rights.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#9650;&#9650;Article 11 Agreement on Deduction</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">11.1 When the Borrower authorizes and there is the
loan principal, interest, penalty interest, compound interest or other fees due and payable, the Lender has the right to deduct the funds
in any account opened by the Borrower in all branches of Bank of Communications Co., Ltd. for repayment.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">11.2 After deduction, the Lender shall notify the
Borrower of the account number, contract number, number of Application for Use of Line of Credit, deduction amount and remaining debt
amount involved in deduction.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">11.3 If the deduction proceeds are not enough to
pay off all the debts of the Borrower, the debts to be paid off and offset shall be determined according to this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">11.4 If the currency of deduction proceeds is inconsistent
with that of the debt to be offset, it shall be converted into the amount of the debt to be offset according to the exchange rate published
by Bank of Communications Co., Ltd. at the time of deduction. If any foreign exchange settlement and sales or foreign exchange conversion
procedures need to be handled, the Borrower has the obligation to assist the Lender in handling the formalities as required by the Lender,
and the exchange rate risk shall be borne by the Borrower.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#9650;&#9650;Article 12 Notice</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">12.1 The contact information (including postal address,
telephone number, fax number, etc.) filled in by the Borrower in this contract is true and valid. In case of any change of the contact
information, the Borrower shall immediately mail/send the change information in writing to the postal address filled in by the Lender
in this contract. Such information change will take effect after the Lender receives the notice of change.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">12.2 Unless otherwise expressly agreed in this contract,
the Lender has the right to notice the Borrower in any of the following ways. The Lender has the right to choose the notice method it
deems appropriate, and does not need to be responsible for transmission errors, omissions or delays in postal, fax, telephone or any other
communication system. If the Lender chooses multiple notice methods at the same time, the one that arrives at the Borrower sooner shall
prevail. For the same matter, if the Lender sends more than one notice to the Borrower with different contents, unless otherwise specified
in the notice, the later notice shall prevail.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1) For announcement, the date when the Lender issues
an announcement on its website, online banking, telephone banking or business outlets shall be regarded as the date of delivery;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) For delivery by special person, the date of
receipt by the Borrower shall be regarded as the date of delivery;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(3) For delivery by post (including express mail,
ordinary mail and registered mail) to the latest known address of the Borrower, the 3rd day (in the same place)/5th day (in different
places) after the date of mailing shall be regarded as the delivery date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(4) For fax, mobile phone short message or other
electronic communication methods to the latest known fax number of the Borrower, the mobile phone number or email address designated by
the Borrower to the Lender, the date of sending is regarded as the date of delivery. The aforementioned delivery means that the relevant
information enters the server terminal of the service provider without taking the actual display of the relevant information in the client
terminal as the standard.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">12.3 The Borrower agrees that unless the Lender
receives a written notice from the Borrower about changing its postal address, the postal address filled in by the Borrower in this contract
is the address where the court will serve judicial documents and other written documents to the Borrower. The applicable scope of the
aforementioned service address includes, but is not limited to, civil litigation first instance, jurisdiction objection and reconsideration,
second instance, retrial, remand for retrial and execution procedures, etc. If the Borrower responds to the lawsuit and directly submits
the confirmation of the service address to the court, and if the confirmed address is inconsistent with the latest known postal address
of the Lender, the court has the right to serve according to the address on the confirmation of the service address.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">During the settlement of this contract dispute,
the court may serve the judgment, ruling and conciliation statement to the Borrower in any of the following ways:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1) For delivery by post (including express mail,
ordinary mail and registered mail), the date of receipt by the Borrower shall be regarded as the date of delivery;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) For delivery by special person, the date on
which the Borrower signs on the delivery receipt shall be regarded as the date of delivery.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">If the court uses delivery by post (including express
mail, ordinary mail and registered mail), and if the Borrower fails to sign on the service receipt, or the postal address filled in by
the Borrower is inaccurate or actually changed, but the Lender does not receive the written notice from the Borrower about the change
of postal address, which leads to the rejection of the judgment, ruling and conciliation statement, the date when the statement is returned
shall be regarded as the date of delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">If the court uses delivery by special person, and
if the Borrower fails to sign on the service receipt, the date on which the server records the situation on the service receipt on the
spot shall be regarded as the date of delivery.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Except for the judgment, ruling and conciliation
statement, the court has the right to make any notice to the Borrower by any means of communication agreed in Article 12.2. The court
has the right to choose the communication method it deems appropriate, and does not need to be responsible for transmission errors, omissions
or delays in postal, fax, telephone, telex or any other communication system. If the court chooses multiple modes of communication at
the same time, the one that arrives at the Borrower sooner shall prevail.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">12.4 The agreement in this article belongs to the
independent dispute settlement clause in the contract. The invalidity, cancellation or termination of this contract will not affect the
validity of this clause.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#9650;&#9650;Article 13 Information Disclosure and
Confidentiality</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">13.1 For the undisclosed information and materials
of the Borrower obtained and known during the signing and performance of this contract, the use of relevant information and materials
by the Lender (including but not limited to collection, storage, use, processing, transmission, provision, disclosure, etc.) shall not
violate laws, regulations and regulatory requirements; The Lender shall bear the responsibility of confidentiality according to law, and
shall not disclose such information and materials to a third party, except for the following situations:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1) The disclosure is required by applicable laws
and regulations;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) The disclosure is required by judicial departments
or regulatory agencies according to law;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(3) When the Borrower fails to repay the loan principal
and/or pay interest in full and on time, the Lender needs to disclose to the Lender&rsquo;s external professional consultant and allow
the Lender&rsquo;s external professional consultant to use it on the basis of confidentiality in order to realize the claims under this
contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(4) Other acts are reasonably carried out to safeguard
public interests or legitimate rights and interests of the Borrower;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(5) The Borrower agrees or authorizes the Lender
to make disclosure.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">13.2 The Borrower confirms to have signed the Power
of Attorney for Credit Information Inquiry and Provision. The Lender inquires, uses and saves the credit information of the Borrower within
the scope specified in the Power of Attorney.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">13.3 In addition to the situations specified in
Articles 13.1 and 13.2 of this contract, the Borrower further agrees that Bank of Communications Co., Ltd. can use or disclose the Borrower&rsquo;s
information and materials in the following situations, including but not limited to the Borrower&rsquo;s basic information, credit transaction
information, bad information and other related information and materials, and is willing to bear all the consequences arising therefrom:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">To disclose and allow business outsourcing institutions,
third-party service providers, other financial institutions and other institutions or individuals deemed necessary by the Lender, including
but not limited to other branches of Bank of Communications Co., Ltd., or wholly or partially owned subsidiaries of Bank of Communications
Co., Ltd., to use such information and materials on a confidential basis for the following purposes: &#9312; To carry out or be related
to bank credit business, such as promoting the credit business of Bank of Communications Co., Ltd., collecting the Borrower&rsquo;s arrears,
transferring the creditor&rsquo;s rights of bank credit business, etc.; &#9313; To provide or may provide new products or services or
further services for the Lender to the Borrower.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Whether Article 13.3 is applicable or not shall
be subject to the agreement of both parties in Article 24.1 of this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 14 Applicable Law and Dispute Resolution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">This contract shall be governed by the laws of the
People&rsquo;s Republic of China (excluding the laws of Hongkong, Macau and Taiwan for the purpose of this contract). Any dispute under
this contract shall be brought to the court with jurisdiction where the Lender is located unless otherwise agreed in this contract. During
the dispute, all parties should continue to perform the provisions that are not involved in the dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 15 Entry into Force, Loan Attribute, and
Composition of Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">15.1 This contract shall come into force after the
legal representative (person in charge) or authorized representative of the Borrower signs (or seals) with the official seal, and the
persons in charge or authorized representative of the Lender signs (or seals) with the special contract seal. If the special contract
seal of the Lender is the special seal contract for offshore credit business (or any other special contract seal with the word &ldquo;Offshore&rdquo;),
the loan in this contract is an offshore business loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">15.2 The Application for Use of Line of Credit signed
when using the line of credit under this contract and other relevant documents and materials are integral parts of this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">15.3 The Application for Use of Line of Credit is
a supplement to this contract. Unless otherwise agreed in the Application for Use of Line of Credit, the rights and obligations and related
matters between the Borrower and the Lender shall still be implemented according to the agreement of this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 16 Specific Content of the Line of Credit</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.1
Currency of the line of credit: __<U>RMB</U>____; Amount in words: __<U>Ten Million Yuan</U>___; It can be used in </FONT>&check;<FONT STYLE="font-family: Wingdings 2"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Currency
of the line of credit </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Currency
of the line of credit and other currencies accepted by the Lender; The line of credit belongs to </FONT>&check;<FONT STYLE="font-family: Times New Roman, Times, Serif">
revolving line of credit </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
lump-sum line of credit (can be used several times) </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
lump-sum line of credit (only used once).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">16.2 Purpose of the line of credit: ___<U>Working
Capital </U>__________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">16.3 The term of credit is from <U>06/24/2022</U>
(MM/DD/YYYY) to <U>05/26/2023</U>(MM/DD/YYYY).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 17 Agreement on Interest Rate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">If the loan currency is other currencies rather
than RMB, US dollar, Euro, Hong Kong dollar, Japanese yen, and British pound, the relevant agreements on the determination of the type
of pricing benchmark of the loan, the calculation rule of daily interest rate and applicable date of pricing benchmark, the adjustment
date of loan interest are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 18 Account Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.1
The Borrower designates the following account as the loan account, and this account </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">is </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">is
not a special loan issuing account opened by the Borrower at the Lender. If both parties agree otherwise in the corresponding
Application for Use of Line of Credit, the agreement in the Application for Use of Line of Credit shall prevail.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Account Name: <U>Jiangxi Universe Pharmaceuticals Co., Ltd.</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Account Number:__________________________________________________&#9;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Bank of Deposit: <U>Business Department of Ji&rsquo;an Branch
of Bank of Communications</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">18.2 Designation of the Borrower:_____________________________________&#9;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">(1) The repayment account is</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Account Name: <U>Jiangxi Universe Pharmaceuticals Co., Ltd.</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Account Number:<U>368899991011000009036</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Bank of Deposit: <U>Business Department of Ji&rsquo;an Branch
of Bank of Communications</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">(2) The capital withdrawal account is:__________________________________&#9;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Account Name: <U>Jiangxi Universe Pharmaceuticals Co., Ltd.</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Account Number: <U>368899991011000009036</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Bank of Deposit: Business Department of Ji&rsquo;an Branch
of Bank of Communications</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 19 Specific Agreement on Loan Issuance,
Payment and Repayment</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.1
The term of each loan drawn under this contract shall not be longer than __12__ </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">months
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">days, and the maturity
date of all loans shall not be later than <U>07/26/2023</U>_ (MM/DD/YYYY).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.2
The independent payment line of credit under this contract is </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">RMB
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">___/____(foreign
currency) __/___&times;10000 Yuan or equivalent in other currencies.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">19.3 If one of the following conditions is met,
the method of the Lender&rsquo;s entrusted payment shall be adopted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">_________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">19.4 If the Borrower&rsquo;s independent payment
is adopted, the Borrower shall report the payment of loan funds to the Lender within ___ days after the loan is issued.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 20 Financial Restrictions, External Agency
Rating and Production and Operation Qualification/License</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">20.1 The Borrower&rsquo;s foreign investment line
of credit is RMB ______&times;10000 Yuan; The increase of debt financing line of credit is RMB ______&times;10000 Yuan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">20.2 Contract agreement on financial indicators
of the Borrower:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1)_____________________________________________________________</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) _____________________________________________________________</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(3) _____________________________________________________________</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">20.3 Specific agreement on external agency rating:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1)______________________________________________________________</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) _____________________________________________________________</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">20.4 Specific agreement on the Borrower&rsquo;s
production and operation qualification/license:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(1) _____________________________________________________________</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">(2) _____________________________________________________________</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&#9650;&#9650;Article 21 Specific Agreement on Risk
Repricing</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">21.1 This contract adopts the following __1__ risk
repricing method: (1) negotiated repricing; (2) raising the loan interest rate directly.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">21.2 If the method of &ldquo;raising the loan interest
rate directly&rdquo; is adopted:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.2.1
If the loan currency is RMB, US dollar, Euro, Hong Kong dollar, Japanese yen, or British pound, the value of the interest rate plus
(minus) points after the increase is: </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">no
plus or minus point </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">plus
____ percentage points </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">minus
____ percentage points. Unless otherwise agreed in a loan, the value of the interest rate plus (minus) points after the increase of
the loan shall be subject to the records in the applicable application for use of line of credit.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">21.2.2 If the loan currency is another currency
rather than RMB, US dollar, Euro, Hong Kong dollar, Japanese yen, and British pound, the value of the interest rate plus (minus) points
after the increase is: __/___</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 22 Contact Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">The contact information of the Borrower to receive the notice
agreed in Article 12 includes:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Postal Address: <U>Jingjiu Avenue, Jinggangshan Economic
and Technological Development Zone, Ji&rsquo;an County, Ji&rsquo;an City, Jiangxi Province</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Attn: <U>Yang Lin</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Postal Code: <U>34300 </U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Tel.:_____________________________________________________________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Mobile Phone:<U>_______________________</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Fax&nbsp;:____________________________________________________________&#9;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Email:___________________________________________________________&#9;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 23 Copies of Contract</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">There are _<U>2</U>_ originals of this contract,
with _<U>1</U>_ copy held by both parties and the guarantor (if any).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">Article 24 Other Agreements</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1 Both parties agree that this contract
</FONT>&check;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
&#9744; is not applicable to Article 13.3.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">_________________________________________________________________&#9;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">_________________________________________________________________&#9;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">_________________________________________________________________&#9;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">_________________________________________________________________&#9;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 35.4pt"><IMG SRC="ex4-13_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Borrower: <U>Jiangxi Universe Pharmaceutical Co., Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Legal Representative (Person in Charge): <U>Lai Gang</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Legal Address: <U>Jingjiu Avenue, Jinggangshan Economic and Technological
Development Zone, Ji&rsquo;an County</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lender: Bank of Communications Co., Ltd. <U>Ji&rsquo;an</U>__ (Sub)
Branch</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Person in Charge: <U>Tang Haiyan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Postal Address: <U>Jinggangshan Avenue, Jizhou District, Ji&rsquo;an
City</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; text-align: left; width: 100%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Borrower has read through all the terms of the contract, and the Lender has made detailed explanations at the request of the Borrower. When signing the contract, the Borrower has no doubt or objection to all the contents, and understands the meaning and legal consequences of the terms of the contract, especially those marked with &#9650;&#9650;.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(This page is for signatures of the Working Capital Loan Contract and
is intentionally left blank)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower (Official Seal)</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lender (Special Seal for Contract)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;<IMG SRC="ex4-13_001.jpg" ALT=""></TD>
    <TD STYLE="text-align: right; font-size: 10pt"><IMG SRC="ex4-13_002.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt"><IMG SRC="ex4-13_003.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Legal Representative (Person in Charge) or Authorized Representative&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature or Seal</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Person in Charge or Authorized <BR>
Representative&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Signature or Seal)</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Signing: 06/22/2022</FONT></P>
                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(MM/DD/YYYY)</FONT></P></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Signing: 06/22/2022</FONT></P>
                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(MM/DD/YYYY)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">30</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.14
<SEQUENCE>6
<FILENAME>f20f2022ex4-14_universe.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE LETTER OF INTENT ON TRANSFER OF EQUITY INTERESTS IN YUNNAN FAXI PHARMACEUTICALS CO., LTD., ENTERED INTO BY AND AMONG JIANGXI UNIVERSE, XIBO LIU, AND YUNNAN FAXI PHARMACEUTICALS CO., LTD. DATED SEPTEMBER 26, 2022
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.14</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Letter of Intent for Equity Transfer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex4-14_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Transferee: Jiangxi Universe Pharmaceuticals Co., Ltd. (hereinafter
referred to as &ldquo;Party A&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unified Social Credit Code: [Redacted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address: No.265, Jingjiu Avenue, Jinggangshan Economic and Technological
Development Zone, Ji&rsquo;an County, Ji&rsquo;an City</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Transferor: Liu Xibo (hereinafter referred to as &ldquo;Party B&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ID Card No.: [Redacted])</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address: No. 8, 1st Lane, Xianjiangzheng Street, Luogang District,
Guangzhou City</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Party C: Yunnan Faxi Pharmaceutical Co., Ltd. (hereinafter referred
to as the &ldquo;Target Company&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unified Social Credit Code: [Redacted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address: No. 495-1, Puji Road, Wuhua District, Kunming City, Yunnan
Province</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the time of signing this Letter of Intent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1)</TD><TD STYLE="text-align: justify">Party A is a company registered and validly existing in accordance
with the laws of China;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2)</TD><TD STYLE="text-align: justify">Party B has full civil capacity for conduct in accordance
with the laws of the People&rsquo;s Republic of China;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3)</TD><TD STYLE="text-align: justify">Party C is a limited liability company registered and existing
in accordance with the laws of China, whose registered capital is RMB 10.8 million and whose business scope includes sales of drugs,
medical devices, etc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4)</TD><TD STYLE="text-align: justify">Party B owns 51% of the equity of the Target Company; the
equity ratio is the officially registered equity;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5)</TD><TD STYLE="text-align: justify">Party B is willing to transfer all the equity of the Target
Company he owns (hereinafter referred to as &ldquo;Equity for Sale&rdquo;), and Party A is willing to purchase all the equity of Party
B;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To sum up, Party A and Party B reach the following finalized contents
of this Letter of Intent, and jointly confirm this Letter of Intent as the preliminary opinion of this acquisition transaction, aiming
to make a preliminary agreement on relevant transaction conditions and steps. It is hereby stated that this intent is the basis for the
subsequent assistance of all the parties and is not a legally binding document; the specific acquisition rights and responsibilities shall
be concluded in the assessment report of a professional institution and determined in the formal Equity Transfer Agreement and other transaction
annexes to be signed separately based on conclusive opinions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">1.</TD><TD STYLE="text-align: justify">Acquisition Subject Matter:</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Party A&rsquo;s acquisition subject matter is 51% equity of the Target Company
owned by Party B and 51% ownership of the project held by the Target Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">2.</TD><TD STYLE="text-align: justify">Acquisition Price and Method</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">1)</TD><TD STYLE="text-align: justify">Acquisition Price: The acquisition price initially determined
by both parties is intended to be RMB Seventy-Two Million Only, and the final acquisition price shall be determined by both parties through
negotiation based on the completion of an assessment report by a professional institution after due diligence.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">2)</TD><TD STYLE="text-align: justify">Acquisition Method: Both Party A and Party B agree that Party
A will complete the acquisition by bank transfer. Within three days after signing the Letter of Intent for Equity Transfer, Party A shall
first pay Party B an intent deposit of RMB Twenty-Five Million, which shall be paid to the Target Company&rsquo;s company account.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">3.</TD><TD STYLE="text-align: justify">Due Diligence Procedures for Acquisition:</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the signing of this Agreement, all parties agree and will cooperate
with Party B to entrust a professional due diligence institution to conduct comprehensive legal due diligence on the subject, qualification,
assets, liabilities, equity, major contracts, litigation, arbitration and other matters of the Target Company. In this regard, the Transferor
shall provide full cooperation and assistance, and cause the Target Company to provide full cooperation and assistance, and provide documents
and information required for the investigation. The Transferee has the right to entrust a professional institution to carry out due diligence.
The professional institution shall exercise all the rights of due diligence granted in this Letter of Intent on behalf of the Transferee.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">4.</TD><TD STYLE="text-align: justify">Formal Equity Transfer Agreement</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Both parties agree that the Equity Transfer Agreement or any other
substantive transaction agreement determined by both parties through negotiation shall be formally signed by both parties within 10 days
after all the following preconditions are met;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">1)</TD><TD STYLE="text-align: justify">Party A has completed the due diligence on the Target Company,
and has not found any material fact that has a material impact on this transaction (or such material fact is found but can be settled
through friendly negotiation between both parties);</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">2)</TD><TD STYLE="text-align: justify">The content and format of the signed Equity Transfer Agreement
or any other agreement (including its annexes) are satisfactory to both parties;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">3)</TD><TD STYLE="text-align: justify">The higher competent departments of both parties and the
shareholders&rsquo; meetings of both parties and the shareholders&rsquo; meeting of the Target Company approve or pass the proposal for
the acquisition of target equity.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">Confidentiality Clause</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">1)</TD><TD STYLE="text-align: justify">Both parties agree that all terms of this Letter of Intent
and all information obtained from both parties through due diligence are confidential information (except when relevant disclosure is
an obligation and responsibility required by law). Both parties warrant that they and their entrusted consultants involved in the acquisition
will not use the confidential information for any purpose other than the following circumstances: as required by law, as expressly stipulated
in this Agreement, or any litigation, arbitration, or administrative penalty incurred in connection with this Agreement; provided that
under the above circumstances, the confidential information shall also be used in strict accordance with relevant legal procedures.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">2)</TD><TD STYLE="text-align: justify">The above restrictions do not apply to the following:</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify">a.</TD><TD STYLE="text-align: justify">Materials and information that have become generally available
to the public at the time of disclosure;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify">b.</TD><TD STYLE="text-align: justify">Materials and information that have become generally available
to the public after disclosure without the fault of the receiving party;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify">c.</TD><TD STYLE="text-align: justify">Materials that the receiving party can prove that it has mastered
before disclosure and are not directly or indirectly obtained from other parties;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify">d.</TD><TD STYLE="text-align: justify">Either party has the obligation to disclose to relevant government
departments according to legal requirements, or either party discloses the above confidential information to its direct legal advisers
and financial advisers as required for its normal operation;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">3)</TD><TD STYLE="text-align: justify">If the acquisition project fails to be completed, both parties
have the obligation to return or destroy the information and materials provided by the other party.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">4)</TD><TD STYLE="text-align: justify">The confidentiality obligation stated in this clause shall
survive the termination of this Agreement.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">6.</TD><TD STYLE="text-align: justify">Exclusion Clause and Warranty Clause</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1)</TD><TD STYLE="text-align: justify">Party B undertakes that during the entire period from the
effective date of this Letter of Intent to the date when both parties separately sign the Equity Transfer Agreement or any other transaction
document (&ldquo;Exclusion Period&rdquo;), without the consent of Party A, Party B shall not consult or negotiate with a third party
in any way on the transfer of the equity or assets of the Target Company he holds. In case of termination of the Letter of Intent in
Article 7, the Exclusion Period shall be terminated accordingly;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2)</TD><TD STYLE="text-align: justify">Any documents and information (written or oral) provided
by Party B in connection with this Letter of Intent are true, complete and accurate and are in no way false, omitted or misleading;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3)</TD><TD STYLE="text-align: justify">Party B warrants that he has complete and legal rights to
the Equity for Sale he holds, and that there is no guarantee or other reason that causes the Target Company and the rights granted above
to be limited;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4)</TD><TD STYLE="text-align: justify">Both parties have fulfilled their internal approval procedures
in signing this Letter of Intent and performing their obligations under this Letter of Intent;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5)</TD><TD STYLE="text-align: justify">Both parties have the right to conclude and perform this
Agreement, and warrant that all required authorizations have been obtained for the signing and performance of this Letter of Intent.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">7.</TD><TD STYLE="text-align: justify">Effectiveness, Change and Termination of this Letter of Intent</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1)</TD><TD STYLE="text-align: justify">This Letter of Intent shall take effect as of the date of
signature and sealing by all the parties. The contents of this Letter of Intent may be changed or terminated by mutual agreement;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2)</TD><TD STYLE="text-align: justify">In the course of due diligence, if the Transferee finds that
the Target Company has any fact that has any material impact on the transaction under this Agreement (including but not limited to any
external guarantee, litigation, untrue assets, major business risks, etc. not disclosed by the Target Company), both parties shall negotiate
to determine the solution of the matter. If both parties fail to form a solution or reach an agreement on a solution in connection with
the matter within 7 days after due diligence, either party may notify the other party in writing to rescind this Letter of Intent. The
date when the notice reaches the Transferor is the termination date of the Letter of Intent. If both parties agree to extend the term,
the new term shall prevail;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3)</TD><TD STYLE="text-align: justify">If Party A and Party B fail to reach a substantive agreement
on the acquisition matters listed in this Letter of Intent within six months after the signing of this Letter of Intent, this Letter
of Intent will be automatically terminated;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4)</TD><TD STYLE="text-align: justify">Before the expiration of the above period, if Party A is
not satisfied with the results of due diligence or the materials provided by Party B are false or misleading or involved in any material
omission, Party A has the right to unilaterally terminate this Letter of Intent;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5)</TD><TD STYLE="text-align: justify">In case of termination of this Letter of Intent, Party B
shall unconditionally return the intent deposit paid by Party A.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">8.</TD><TD STYLE="text-align: justify">Miscellaneous</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1)</TD><TD STYLE="text-align: justify">In case of termination of this Letter of Intent due to both
parties&rsquo; failure to sign transaction documents, the relevant expenses caused by this transaction, including but not limited to
the expenses of engaging lawyers, industrial and commercial file consultation fees, transportation expenses, etc., shall be shared by
both parties.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2)</TD><TD STYLE="text-align: justify">The original of this Agreement is made in duplicate, with
each party holding one copy, and both copies have the same legal effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 20%">Party A (Seal):</TD>
  <TD STYLE="width: 80%">&nbsp;<IMG SRC="ex4-14_002.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature of Legal Representative (Authorized Representative): &nbsp;&nbsp;&nbsp;&nbsp;Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 20%">Party B (Seal):</TD>
  <TD STYLE="width: 80%">&nbsp;<IMG SRC="ex4-14_003.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature of Legal Representative (Authorized Representative): Date:
9/26/2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 20%">Party C (Seal)</TD>
  <TD STYLE="width: 30%">&nbsp;<IMG SRC="ex4-14_004.jpg" ALT=""></TD>
    <TD STYLE="width: 50%">&nbsp;<IMG SRC="ex4-14_005.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature of Legal Representative (Authorized Representative): Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>7
<FILENAME>f20f2022ex12-1_universe.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Gang Lai, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on Form
20-F of Universe Pharmaceuticals INC (the &ldquo;Company&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the Company as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The Company&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period
in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Evaluated the effectiveness of the Company&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Disclosed in this report any change in the
Company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially
affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The Company&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s auditors
and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
Company&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: February 10, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Gang Lai</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 31%"><FONT STYLE="font-size: 10pt">Gang Lai</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>8
<FILENAME>f20f2022ex12-2_universe.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Lin Yang, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on Form
20-F of Universe Pharmaceuticals INC (the &ldquo;Company&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the Company as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The Company&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period
in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Evaluated the effectiveness of the Company&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Disclosed in this report any change in the
Company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially
affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The Company&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s auditors
and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent function):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
Company&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: February 10, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Lin Yang</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 31%"><FONT STYLE="font-size: 10pt">Lin Yang</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>9
<FILENAME>f20f2022ex13-1_universe.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 906 OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of Universe
Pharmaceuticals INC (the &ldquo;Company&rdquo;) on Form 20-F for the year ended September 30, 2022, as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;), I, Gang Lai, Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The Report fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: February 10, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Gang Lai</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 31%"><FONT STYLE="font-size: 10pt">Gang Lai</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>10
<FILENAME>f20f2022ex13-2_universe.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of Universe
Pharmaceuticals INC (the &ldquo;Company&rdquo;) on Form 20-F for the year ended September 30, 2022, as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;), I, Lin Yang, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The Report fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: February 10, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Lin Yang</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 31%"><FONT STYLE="font-size: 10pt">Lin Yang</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>11
<FILENAME>f20f2022ex15-1_universe.htm
<DESCRIPTION>CONSENT OF ALLBRIGHT LAW OFFICES (FUZHOU)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 15.1</B></FONT></P>

<P STYLE="margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex15-1_001.jpg" ALT="" STYLE="height: 259px; width: 670px"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
February, 2023</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:
Universe Pharmaceuticals INC</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">265
Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ji&rsquo;an,
Jiangxi Province</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">People&rsquo;s
Republic of China</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Sir/Madam,</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the references to our firm&rsquo;s name under the headings &ldquo;Item 3 Key Information&mdash;D. Risk Factors&mdash;Risks Related to
Doing Business in China&rdquo; and &ldquo;Item 10. Additional Information&mdash;E. Taxation&mdash;People&rsquo;s Republic of China Taxation&rdquo; in Universe
Pharmaceuticals INC&rsquo;s annual report on Form 20-F for the year ended September 30, 2022 (the &ldquo;Annual Report&rdquo;), which will be
filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on the date hereof. We also consent to the filing of this consent
letter with the SEC as an exhibit to the Annual Report.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section 7 of
the Securities Act of 1933, or under the Securities Exchange Act of 1934, in each case, as amended, or the regulations promulgated thereunder.&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours
sincerely,</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex15-1_002.jpg" ALT=""></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>12
<FILENAME>f20f2022ex15-2_universe.htm
<DESCRIPTION>CONSENT OF YCM CPA INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: right; text-indent: -0.25in; background-color: white"><B>Exhibit
15.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><B>&nbsp;<IMG SRC="ex15-2_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the incorporation by reference
in this Registration Statement on Form F-3 (&ldquo;Registration Statement&rdquo;) of our report dated February 10, 2023, relating to the
consolidated financial statements of Universe Pharmaceuticals INC included in its annual report (Form 20-F) for the years ended September
30, 2022 and 2021. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ YCM CPA, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PCAOB ID 6781</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Irvine, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">February 10, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.3
<SEQUENCE>13
<FILENAME>f20f2022ex15-3_universe.htm
<DESCRIPTION>CONSENT OF FRIEDMAN LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 15.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><IMG SRC="ex15-3_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the incorporation by reference
to the Registration Statement on Form F-3 of our report dated February 24, 2021, with respect to the consolidated balance sheet of Universe
Pharmaceuticals Inc. as of September 30, 2020, and the related consolidated statements of income and comprehensive income, changes in
shareholders&rsquo; equity, and cash flows for each of the years in the two-year period ended September 30, 2020, as included in the Company&rsquo;s
2022 Form 20-F annual report filed February 10, 2023. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in
such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Friedman LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York<BR>
February 10, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (0 ? # 2(  A$! Q$!_\0
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MQE_4_P#/^>] 'P5_PWBO_1FO[>O_ (CI)_\ -;1_PWBO_1FO[>O_ (CI)_\
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M=I-+:P22VL;A0Z6\CQEX5<*H=8BJL%4$' H _E'\"_'*^_9R\6_$8:1^V?\
M$'PIKOC7_@NOX-\+?$7P'\6_''A;5)]=_9\^(,WAR[TVSGC\?:'#KGP_T#Q=
MX5U>QU$R:5-I-[=>%O#NEV]HECH^D7IC]BTS]L#Q_:_LZ?'?]HKQ;^W?XZ\'
M?'O1OA#^T5HGQ]_97TWX>^"_'^H?LW_$SPK\6+'PGX!\3>&/ NK7WA6_^#%I
MX,T*/_A&_P"W?B1JL_@'XBP>*+/XHZGK\%CH4U]=_P!%WC?5OA]X*\+^*/'W
MQ"N_"OASPCX2T;4O%OB_Q9XH.F6&BZ#H?AS3;B\U37];U740EM96.D:3;W,]
MS?W4R1VME%*S2+$K5@^&/B'\)_&OPST_X[>$M7T'Q%\-?&W@2P\?:?XZTG3I
M+VT\3> M1T6/6].UJ,0V+:GJ6G76B2QW=O;O:R3O ZQK;;R(Z /Y9/"O[74'
MQ"T#X->%_C+^T7X(\=:G\&?^"\OP7\,_#74/$GQN\!_$SQ3IWP5U#X$67C?1
M#>?$G3=$\#VOC[2[#Q'XV\1Z.GC;3M$F\/7,UN_A_3/$_B:STF'5[O\ 3S_@
MEW^TM\6/BY\9?V@_AY\4_B7K_P 3;OPMHVF>+]+UG1?$7A;QQ\*YK?Q#XU\5
M:<^HPFU\+>"?B9^S[XYNAIB:/=?LO_%WP]<ZCX1TCPZOBGPEXJ\2:1X@U"2S
M_7GPK+\.?&OAO0?%W@O_ (0[Q-X4U_3+'5O#?B#0(M(U/1M4TF>$2Z?>Z7J%
MDDMK<6C1N&MY;>0H@RJ[2&%=?!96=K+<S6UI:V\U[*)KR:""*&6[E50@EN9(
MT5KB4*-H>4LP7 !P,4 ?S'2>-OV*/'EK_P %;_ GQ5\>_LUZYX!\=_\ !2O]
MFG0/%^A^(_'GPYL]-U[P1J^C_L=>'/&$-S=/J]O+'IKQZ'XUTS4M3MYT^P7V
M@>)]]Q#>Z)JIMK_BSPK^V5\+-9\0?L3^'%\1_%/X@^ /V1/VWO&'_!,G]L"[
MDM]5O/&7A#6/@Y8>&_@]\+/B+X]FC81?M ?!/QOK7AO28?%!N8X/B3\/YO#?
MCZ1(]8MO%#/_ $H-X8\-.) _A[0V$S%Y0VD6!$KEI'+R VYWL7FF8ELG=+(Q
M.78G9$<:A J(!$ (@%4",!2@$8 ^0;#MPN!M^4<<4 ?A[^Q]XJ_X)N>,_P!E
M/]BOX,VL/@*]^+7PZNO@E>V?P8@T=8OVH?AM^TGX$O\ 3)O&WB3XA> 8;9?B
MGX/\4:+\0K/Q1??%WQSXLL++2-2MKSQ!J6MZ]J6F>(X+G5/W%K/BTG2H+^;5
M(=,T^'4[E#'<:C%96T=_/&?+S'->)&+B5#Y,65>1E/E1\?(N-"@ HHHH ^"O
MVA/^3W_^">G_ %U_:N_]4_I-?>M?!7[0G_)[_P#P3T_ZZ_M7?^J?TFOO6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ^#(_^4GUU_V898?^M":E7WG7P9'_ ,I/KK_L
MPRP_]:$U*OO.@ HHHH **** "BBB@#\Y/VT+O6+G]I7_ ()L>$=7@2;X/>)_
MVDO'UWXVCNXVDTJ^^(7@WX!_$;QA\#]-U4,#;RK%XNTG4?$VB6]X/(_X2OPO
MX?O+;.J6.G _#'[,'C']G#X;?%#_ (*9>"O^"B.N?#'PU\=OB7^UC\5]46V_
M:'DT&WE^*_['NN^&] TK]GO0_@U=>*XD_P"%A?"_3_!,6I^'(O O@>76=2T#
MQW+XKTO6M%M?$.LQC4/V^^*GPJ\#_&?P7J'@+X@:3)JF@WUSIFI026>H7^C:
MUH>NZ'J%OJ_A_P 3>&?$&D7-EK/ASQ-X>U>TM-5T/7=(O;34=.OK:*:"<#>K
M].OAS2)+?1XM3M(-=N=$@MH;+5-=MK/4=5$MND*_;FO);<%;^XD@CN+BXMT@
M\RY'FJB$*% /Y?\ XH?M=S?!O]L'X!?"/X1?M(>-/A-\#O!/QS_9(_9JOO@Q
M\1?$/@WX2Z=X0^!GQ:^ .OW36UI\,/%^EZS\4_'VH"X\1>$_%0_: \6:A\-?
M#7P\UZV\'?##1(_&'B#2O%&E+Z'K/Q9_:0^'?P(_;9^&'B[]K+X_>&OC;_P3
M8^'?[6?B_P 0?'WQ3<?#]=&^+%M\5O#.I>*OV+M9\3V^O^!;+P7KUVG@.^6V
ML]&T.VAL=,^(WAO4()#=ZBME8/\ T?:IX>TC5/M,\VG:6=3FM&M(M4N-*T^^
MN[<#]Y;L&NX)1*EM<+'<QV\Q: RQJ62O)O@[\%KGX=:7XIG\=^.]5^-'Q!\>
MZM;:GXY^(/BOP_X6T*?6[?1K.'2?"NA6?ACPKI>F^&]#T#PUH]M#'9Z=8V9%
MSK-WKOB.\EEU77KZ0@'\MWQ-_;A^,'@/P!\<=?TS_@I/KWB'7_AQ^P;^PS^V
M'X?CE\7? 6.'7_C[\2/$NN:%\0/#OV'3?#",OPLUWPY%X<U#5OA%8%ECN->T
M_7(=8M!J.F^=ZW\0?^"B7BRP_;E\06?AW]NN+PK\*_$GC/\ ;4^$FJOXQ\6_
M!;0_!OP_;X=_LY#Q;\&=8\$_"/6[+6Y;+3=%^(&@B3PK\;_B/XST2S_: O=?
MNHO#'P_UCP=>Z5J\']1I\+>&3G/AS03E$C.=(T\YCC6-8XS_ *-]Q%BB5$^Z
MJQQA0 J@$_A;PS<F1KCPYH-PTR6\<S3:1I\K2QVB[+6.0R6Y+I;(-ENKDK"N
M%C"CB@#^?;_@E5^UK\1?'WQH_9O\!_$?]L2?]HK5/VA?^"87P^_:3\9:'XCU
MSX7&70?C;I/CS2_"^M1>"?#O@C2M(N] %QX8U'4D\6:#,]_)=:EX8N/$-Q!8
MWBZLB\M\2/C5X9\*?M5_\%G[WX,_&7X2^#?BW::5_P $Z=)COD\=:%X;U9HK
M?5-4\%?%+PS=^,M%\/\ CO5/AAJ%]_PD1\ :S\5M3\':]I7P3\3>)]'\:>,[
M"WL-$G9?Z.K;0=#LIX[FST;2;2YB1HXKBVTZS@GCC?S-Z1RQ0HZ(QDD+*K;6
M\R3(.]LBZ!H23W5RNBZ2MQ>K.EY.NG68FNTNF62Y6ZE$(DG6X=0\ZRLZS, T
M@9@" #^5G4/VR[.;QS^RI\=?&WQAU/P]\7O#?[!O_!6:^'B;Q!IOPM^(OQ+T
M[5/ OCCP';>&M0\%>&?AUJUAX*_:'\-:%'X'UR?X:>+?!D^G^$_CGX>\'ZEX
MWM1I5M<:\NF>4^%?V^OC2VJV7P;7_@H?#X/MY?\ @H=^Q5X,TK7-4^+_ .SI
M\</B-KWP"^.OP!TC4_BEHUY\18?"6G^#;W3M)\=6UUJ>I77@.T\4:#\-_&VM
MZAX'B^(/BK3]%MMW]?HT+1%>TD&C:4LEA;"SLG&GV@>SLUCEA6UM6$(-O;K%
M/-$((MD2QS31A=LCAJ:^$O"B^3L\,>'E^S@K!MT731Y"F0RLL.+8>6#*S2$)
MM!D)<_,2: /Y:[/]MC6OB/X6USX!?%7]M34?"'P>\+7O_!3+P7H/[0">*_AM
M=>)?C5\0/@-\6&\,_ [X(_$;QT_AZ7P;=ZA)\$_$=SXRD\*II6DZW\<K'2;2
M]M$N[.SU""]3]A?]KKXAZ3K/_!+#X<^&OB9XDO/@]XL_9X_9/^&=_P"!O!M]
MHUCKFB>($^"M[-K^D>-O@%\2/!N@^.?%_@76]<:QUS4OVE/@YXRUU/AC:>%8
M_#?C3PA;>&=;MO$MW_4Z?#GAXP?93H6C&U-TE\;8Z78F WT:>7'>>28/+^U(
MGR)<;?.5/E5P.*@UKPUIVMZ?=V3>?I=S/I6H:19ZYHK1:?X@T.WU&U-I--H.
MK)"\^E7<<>Q[>:W $,L,+[6\I!0!\#?L -<V'BK]O7PIHL21?"7P=^W%\0-+
M^%4%N NEZ:FJ_#?X5>*OBKH6@QHYAM](T?XW^(/B/"UE;106VF:S)K.E00Q1
MV(C3]&:X/X:?#/P5\(/!6B_#[X>Z)%H/A?0HIUM+,3W=]=7-U>W,U]J>K:OJ
MNHSW6J:WKNLZE<76J:WKFKWE[JNL:G=75_J%W<75Q)*W>4 %%%% !1110 44
M44 ?!7[0G_)[_P#P3T_ZZ_M7?^J?TFOO6O@K]H3_ )/?_P"">G_77]J[_P!4
M_I-?>M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!\D_&G]D#PM\9/B?HWQBMOBU\>_@
M]\0-(\!S?#276O@I\0;7P>FN>#I/$)\4PZ7KUAJ?A[Q'87K6.MR3W=E>16]K
M=PBXGA::2%PB\'_PPQJ/_1[?[>7_ (>SPK_\["OO*B@#X-_X88U'_H]O]O+_
M ,/9X5_^=A1_PPQJ/_1[?[>7_A[/"O\ \["OO*B@#X-_X88U'_H]O]O+_P /
M9X5_^=A1_P ,,:C_ -'M_MY?^'L\*_\ SL*^\J* /@W_ (88U'_H]O\ ;R_\
M/9X5_P#G84?\,,:C_P!'M_MY?^'L\*__ #L*^\J* /@W_AAC4?\ H]O]O+_P
M]GA7_P"=A1_PPQJ/_1[?[>7_ (>SPK_\["OO*B@#X-_X88U'_H]O]O+_ ,/9
MX5_^=A1_PPQJ/_1[?[>7_A[/"O\ \["OO*B@#X-_X88U'_H]O]O+_P /9X5_
M^=A1_P ,,:C_ -'M_MY?^'L\*_\ SL*^\J* /QYM_P!FWQW/^U_J?P37]M[]
MN8^!]._9QTCXG2Q_\+?\&#4(_%NI_$O5_"\;C4?^%6?;'LI-%TQA]B$QMHIT
M\\Q^=*&'TI_PPQJ/_1[?[>7_ (>SPK_\["M31CYW_!1CQZR#Y;']COX=PSDG
M!\R^^,'CV: (.K+LLYO,/&T[!@[LC[>H ^#?^&&-1_Z/;_;R_P##V>%?_G84
M?\,,:C_T>W^WE_X>SPK_ /.PK[RHH ^#?^&&-1_Z/;_;R_\ #V>%?_G84?\
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M: /O*BO@W_AOKP[_ -&L?MY?^(B_%'_Y!H_X;Z\._P#1K'[>7_B(OQ1_^0:
M/O*BO@W_ (;Z\._]&L?MY?\ B(OQ1_\ D&C_ (;Z\._]&L?MY?\ B(OQ1_\
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MUWNI_!G7M0U75=.U.\\4_#RT'BC7?AS+XB^'VG^)_!-QJ@UY0#]#-:_X*/\
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M4?"?BKPEK_@/6M \2Z ;"^LM3T'5]-=M1 /05_X*"?!OX;^"[?7_ -L*_P!
M_8T\67GC3XG^#=*\!_%OQOH-SJ/BN/X4QRWNN^,/ =]I2K_PF/@K4]#BC\1Z
M%K.G:?'-/I%]IL.I6&EZ]=/HD'=/^WE^Q\GC?6_AN?C]X$?QOX?\-Z_XKO\
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M)I/Q!U/QCJ'A?P<FM^(/%^I_$S4H=)TW3=%N-*\)>#='T/2;3Q+XFDN;J_0
M_1NBBB@#XI^&O_*0']KG_LV7]B'_ -3S]MFOM:OBGX:_\I ?VN?^S9?V(?\
MU//VV:^UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#X,C_ .4GUU_V898?^M":E7WG
M7P9'_P I/KK_ +,,L/\ UH34J^\Z "BBB@ HHHH \7_:"^-OA[]GKX3^)?BE
MXBLKK6%TJ;0=#\.^&=/F@M]5\9^.O&GB#2_!W@'P3I$USF"+4_%WC+7=$\/V
MD\RM#:27_P!LG1H+>6OB^+]NGXE?#;]H[5/@-^TQ\-_@E\,?!_@/]E&+]K+X
ML_M#6OQ]U.W\'^#O"":W>>$]7TH>#O$?PJL&\S0?&-E>:7+JVH?$"SLM2\.V
MT7BN&.RU#4$\&6GL?[?/P5\6_&OX"V,'P_LSJ_CWX2?&/X%_M$^#_#/FQ0IX
MRU;X#?%7PO\ $J;P69)Y88$N/%>CZ#JFB:5+<316\&M7FFSW$BP12&OA?XZ_
ML_?M-_M1_&#XZ?'7X5?#[X-3?"+]H'_@F_XI_9#\$6_Q:^)/Q$\ ?$;3O%/B
M_5->\6KXG^(/PTN_V??$,?ABW\.>)?$%UX7U+PX-?U35T;0QK:3))>KI-H ?
M2_Q<_P""LG[$'PP^$?BSXOZ7\9_#GQ+T7PCXF^#/A._L_A\FN>)9C?\ Q\UF
M+2OAGJQET+0]7/\ PB'B"%-5U.U\96MO>^';F#0=6T^ROKO6X8M+E^AI_P!M
M7]E*S\:?\*]U+X[_  ^T;Q>O@J_^(4FE:[JS:#';^%=)T&#Q5K-U=ZIK,%CH
M]GJ>A^%KJ#Q1KWAJZOX?$VA^&Y5U[5='L])!O!^/?B/_ ()P_MJ^)M%U;1HM
M)_9P\+P6'['W_!//X.>%8-/^,GC^\L;CXG_L-?M#>&OCU?6]]:P? 72%T3P+
MX_\ LFL>%M)U^Q_M+6?#;QV^KS^%KU=3GL;#TFS_ .":?Q7LOBC\2_'/B3P%
M\'OBSJ^M?%WXW?M,_#/QSXM_:3_:3L+#P'\1_C1X&\3Z'JGPWLOV?Y])\1_!
MBS6QO/%6K>#++XX0Z==ZH?A=="UO_AA?:] DA /MVU_X*I?\$Y[]8!IO[9'P
M)U6YN],N]9T_3-(\:6>K:YJ^EV/AK3_&%W?:'H.FK<ZUK<%OX<U2RU21](L+
MTK&\L&/M=K=V\'J6K?MR?LBZ'XC^$_A/4OV@/AS#KWQRT;P;XB^%5G%K)O(?
M%VA?$:[&G_#W5K?4;*"XTS3;'QYJ._3?!=QK5YIJ>*=2AN=/T(W]Y:W,$7YB
M_"G_ ()_?M0?"W1_^"60LOAK^R_<ZU^PU\ _C=\+OB2]A\4_%.DKKWB3QU\,
M[+X:^$M0\ ZFG[/<UW/I?_$GC\1ZY<:U;:)>Z=)X@U#3;.TU:6P.I:I\N6?_
M  2N_P""A,?P;^!GPUU=/V9=3N_@UX)_8@TRQ&A_'OXH>"])U/Q'^R+\>=4^
M)6M/X_NM'_9S;7_C!9>+?#5TL'PNM_&^H'PE\&]5U?Q$+3P!K>K7<7C  'ZP
M_"S_ (*9_LY?'Z[_ +,^&?Q;\"^#=7LOVM]0_9=M]%^+&D>*]%UOXEZ_X9N-
M<CUW0?AIH^HIX2O;GQ5K4'AO7KS09537K+1].TO[?XCTU!?VUJGMDG[?7[&-
MOK/Q,T"^_:2^%>EZC\'O#7BKQE\1/[9\1PZ)I^A>%/ MR+'QOXAM]8U9+/1]
M?TCP=J+1Z9XJO?#=_K$'A[5)H-,U=[2_GAMI/S@UC]@G]K^+7O"MII>F?L\Z
MWX7\)?\ !5KQC^WMIFOZA\3_ !YH?C&+X<?$=_'^J>(O!]M;Q_!O7K.Q\8:/
M?_$6XTVP2UU--'UB#PS;ZK=ZI8/K!TW2_+M>_P""5_[4VO?L^?#K]GC6'_9U
MURQ_9)^$7[7'PP_9V^(1\5^,--U_XTC]H_P#XE^%7A&]^,&DS_"W68_A9'X0
M\*>)Y/$_Q17PWJWQ2'Q0^(6A:)J>FQ>%;:)I(@#];M(_;[_8R\0>$_'WCG0O
MVC?AGK'A/X8P^"+GQGK>F:R]]:V%O\3 ?^%<7&FK;6\D_B:'Q],LEEX+E\+P
MZS'XHU**;2]$:^U&":U3PCQ]^W?J_B3XK_L6>$?V5Y/@W\4?AC^V%IG[3%GH
MOQ<UGQ%XFN+71O''P0^'U_XET31/^$;T33;6X72Y_$6EZIH7CBYO=3AU_P /
M7&GSZ7'X<_M!99K?X3U;_@GY^WL=8TG4?"VA?LP>&K#1?V;/^"?7P:6TM/B]
MXHEUF/5?V0?B#K7CKQI=_#_5=4_9CU?2/ACKVN_\)5?67PP^)]MX<\0>(/ U
MUH0U>TT#3]4UZWO/#+?@+^PS^U3^RWJ/[(/C'XAZ+\#(?A9^Q_\ 'C]O[XZ_
M$'5M ^-WQJ^)7C?4/ '[5=UXVU[1K/PYIFO_  .OO%OCGQMX(A\:W=GK2Z]X
MGGU/QI>Z)'=6>IBZUX6^G 'ZZ?"[]I75/C#^S_XT^*'@[X>VEG\5?AYJ'Q'\
M"^-O@SXM\:KH]KX9^,GPJU&_T7Q=X!U7XA:3X8\2(NC_ -IV N]"\:6/A"_C
MUGPQJ>B>(HM!A74?L$%3]BW]IG7OVI?V5OAO^T_X[^'OA[X*:=\3/"T?C[2O
M#-O\2S\0K;1?!-U91W]EJ7B3Q7>>"/AY9Z?J<<2WKZMI\.F7>FZ5%:I,NNWJ
MRR"V\E_9>^%WQ>\*? 7]I?QQ<>";33_BG^U#\:/C=^T!X8^%/CK7)_!O_"+Z
M=\0+32_#7PW\(^/=<TS0O&=QX8\0-X*\+^&]6\;I9Z#XAF\/^(=4U72%LKN3
M3F4^._L8?!O_ (*#_ 7X#_LK_LT>-/ ?[+NE^"?@1X';PU\3/&/A;XY^/?&N
MI_%NV\/^"_$-AX<\+:!X3U_]G+PK:^"=*\1>,;S0+OQ)K^H^(?$EYI>@Z=?6
M]AI&IW%X(P >WZ/_ ,%*?V-O#W@GPCK/Q-_:_P#V<+_6/%W@?5/BMHMWX#UV
MY&F^(/A2GC>]\):;X_T+PW)JGBCQ*_A.TN5M]+UCQ.TL^B-J%CK6KQ3V>BVT
MQLNJ\5?MZ?LO7'@#XO>(? ?[4/P TJ]^%%QX/TCQ#XJ\<:W-=> /#>L_$/5Y
M-%\ RZF]AJOA^;Q+H_C34[/4=)\+7_A/6Y['7]4L[JTTO4KF:QNX4_'OX8_\
M$POVW_!7@31O#&H^!OV3)M9T+_@FU^U1^Q)9ZYI_QL\>&1?&'Q]^)MUXS\/>
M*;::7]FBWO+'PAX;T9H],U&QBE;47ENKN+3[=;0$W&E\2_\ @FC^W%XU^'WQ
M3\&6'@O]E6U;QQ^PQ^PQ^RGH"WGQR^(!TSP]XL_93\?^(?'GB7Q6MM%^S5(L
M.A:XWBB\TSPM#8PQ:G9RV(U"[2U_M!K:T /U+^'O_!3/]E#QYK/[46DR>/?^
M$9@_93^+MO\ !OQQJ6OZ!XMT]=;\1R>%/!^MRR^%;"Z\-PWFNL?$'B35_"6G
MZ1H:ZSK.JW'A/4]>L;.7P[>Z7J%US?[9?_!23X-?L]?LC^*/VA/A=\0?@[\1
M_%VM?!GQM\5O@%X9UWQGJ6G>%_BA;^#]*;4+N>?6O"^B>)-2TK1[>7;I<MU?
M6&F6<WBN;3O!=YK&@ZQJB3VGR?X^_P"">/[4/BKQA\8?$JW7PPN_#VK?MP>#
MOVXO W@_3_CQ\=/A;KOB_5=<_9O\'? 'XG?";Q+\3?A9X;\/>)_A@/!46AZE
MXA^&/Q*\)CQ;/XEOETVU\4>#M"T>]U734\W\5_\ !+?]HKP;\-?CAX&_9O\
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MXEL=$\5:7;ZMI]KKMCIVH:M8VFIPP7"1WEO::G?01S*RQW4RC<?:* "BBB@
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MXB1\*_\ YJ*/^% ?MS_])![3_P 1(^%?_P U%?>M% 'P5_PH#]N?_I(/:?\
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M)M**[]MN&Q7>BW_:%_X6K9SG5O@R/@@/#H34-+'A[QN?BJWBS^SI@T]EKO\
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M2.UU&.]U[2?&,GBU;KP997-U<:=<0Z-%I&M"WCTZ6W-]+]N:2#VZB@#YQLO
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_BKX;\-?L11Z]X?T#QQID>O:-HVMZA\=[W3K_5]/TR],EE;:G>6%O;V5Q?I
M+J2U@BMS+Y*[#[9_P[1_X)__ /1G_P  O_#=Z%_\C5FQ_P#*3ZZ_[,,L/_6A
M-2K[SH ^'O\ AVC_ ,$__P#HS_X!?^&[T+_Y&H_X=H_\$_\ _HS_ . 7_AN]
M"_\ D:ON&B@#X>_X=H_\$_\ _HS_ . 7_AN]"_\ D:OES]M']E?]B']D_P#9
MB^,/[1_AW_@GG^SW\77^#7@[5_'^M>!)+/PQ\/KG5O#'ANTFU+Q VE>(;WPK
MXFL1K%OI]O+)IFFWEC;VVIW(CM9=3T\/YZ_L)7S[^UA\#!^TY^S+\>_V>?\
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M#X5\2>)+C['X9T>YC@MY+B]N_%%V'MO#":5%?IXDN(YH=$>_D@E5(==^&_\
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MK/B;PI;VUG=6-@^H7[*]VPM+CP7X=_L!?M9?##X ? SX;>"?^">$EMKND_\
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M//-:7^DKI-QY-Q+;W+7,?EB/F?\ AD3XG?\ 20;]MO\ [[_9$_\ H2*^VZ*
M/B3_ (9$^)O_ $D&_;;_ .^_V1/_ *$BC_AD3XF_])!OVV_^^_V1/_H2*^VZ
M* /B3_AD3XF_])!OVV_^^_V1/_H2*/\ AD3XF_\ 20;]MO\ [[_9$_\ H2*^
MVZ* /B3_ (9$^)O_ $D&_;;_ .^_V1/_ *$BC_AD3XF_])!OVV_^^_V1/_H2
M*^VZ* /B3_AD3XF_])!OVV_^^_V1/_H2*/\ AD3XF_\ 20;]MO\ [[_9$_\
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MZAM[AX);BWAN6_9%,\,%Q):VLEQ#'(L4[VML\RNT$123_AD3XF_])!OVV_\
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MT$LTJ6+3NLJ?:%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?!MW_P I//#_ /V8;XO_ /6@_ ]?>5?!MW_RD\\/
M_P#9AOB__P!:#\#UXM\?M7T#0?\ @K/^P2H\?SV'B/Q=^SG^V;HC^ -0^*&H
M6FA:RNE2?!+4O#E[:_"^XUY-%EUV:[GUV-/$UGX=DUR_T^PNK/[=/9:(\-H
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M ]/\W_@I]_SX?L&?^#;]H3_Y2T>;_P %/O\ GP_8,_\ !M^T)_\ *6O(-?\
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MK1_&WA$^'OB'KUGKGAF_.IFZM(M-UH:9ZYI/_!3G]G#4M%^(_B:[L/B9X?\
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M]_:NT_Q/8_!W]H;]K+]H'_A$E_9]TK0CXFU#]KZ6_D\>^&)M>A^)NH2Z18:
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M;4/B9X\^*US=ZEXBU6U\/?#NXO/A[J1NKSQ9\0_'OBY8M4T'2=)L-2U6Q_H
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M_I(E^UG_ .$+^Q%_]")1_P ,N?';_I(E^UG_ .$+^Q%_]")0!S_[0G_)[_\
MP3T_ZZ_M7?\ JG])K[UKXN\)?L?ZSIOQC^&_QI^)7[4G[0'QSUSX26/CFU\"
M>'OB!I7[//A_POI5U\0M&M?#_B'5;F'X1_ CX::WJEZ=)M5MK&*_UR?3[5I9
M9_L4LYC>/[1H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@#XF_P"&UHO^C4/VU_\ PP<__P TM'_#:T7_ $:A^VO_ .&#G_\ FEK[9HH
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M(VOMNB@#XD_X;!\=?]&(?MK_ /A/?L\__1&T?\-@^.O^C$/VU_\ PGOV>?\
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M\,;OP_XEUNPL)_%&AV5R ?:E%%% !1110 4444 %%%% !1110 4444 %%%%
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M\:?M/^!_&>B_%?3O&7C'P?XZ\ ?#;XE+X;O?AYH7Q0;X=-XTUW1]&M/B#>>
M/ OASQ%J>A^ ]5^)OCO5M!\$:UXFBGU*RU#3+6^32]/ -W_AV+^P]_T1-_\
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M0+J>3P#XU\/WU]X.N+"2?QC;ZCK.@:#JL= #_P#AV+^P]_T1-_\ PYOQA_\
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MXSLENMY>PM<21P*[H > ?\.Q?V'O^B)O_P"'-^,/_P \"C_AV+^P]_T1-_\
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M9G_:!_:\^+'[.G[9/C7QKX^^ D7Q*^"7QP_:$^#_ ,-=6\-? SQQ8>#H[?\
M9Z\2:KH]SKWC#PIJ7Q\U75_$=QXYM=.21=/TCQ;X4B\+SS.5N=?C0(4\*_\
M!4WX/^%;]_A1\79/B+XG^+/PT7]FG2?VA?'O@/X ^-?!_P $_ &K_M3RZ9IW
MPP\0W6K^*/$6NVMIX+U3Q)K6F^&&N]&\5>-;RWO))=29)=&L=8U#2@#VC_AV
M+^P]_P!$3?\ \.;\8?\ YX%'_#L7]A[_ *(F_P#X<WXP_P#SP*X/0?\ @HW\
M&+?XBCP=;I^T9\04\>_MK^(_V-=+U:X^#NFZ#X,^%?QD\,^#/#^OWO@W4]3N
M;7P9KEKX#O-)&K>+/#_C;Q-:>([KQ).NN66B:K?VR^&-*GN?$[_@J9^SE\&=
M(GUOXG>'/C%X/L-)O/$%_P"+FU7P9I"OX(^%_ASQT_PZNOCQXC6'Q7,LGP@O
MO$D%\-'UGP\^O>)M3TG2M8UJV\)MIFDZA<VX!TL'_!+;]@ZTN;Z\M/@'9VMY
MJDL,^J7EK\0/BO;W>J3V]K#8VT^IW4/CM)]0GMK&VMK&WFO))I8+*VM[2)DM
MX(HTM_\ #L7]A[_HB;_^'-^,/_SP*\^?_@K%^S'/XN^*O@_0O#?Q^\2S_![X
MA77PC\6>(]-^#'B33/ C_%5SX"'A?X?:7XY\5R>&_"\_B#XB?\+$T-_A[)>Z
MG8:-XEMXKR\@U:&RETFYU77^(_\ P51_93^%7A?PMXR\97GQ#TOP_JVC:9XL
M\:W%[X(N='U#X*^ ]7\?7OPQLO'OQ@T#Q%>Z-XA\.^%Y?&6EZS8!]&TKQ'K#
MV&AZOXABT>3P[8RZK0!U7_#L7]A[_HB;_P#AS?C#_P#/ H_X=B_L/?\ 1$W_
M /#F_&'_ .>!7"?\%(OVH_BE^RQX<_9H\=> ?B?\"_AMX"^)W[2OP[^!WQ/\
M6?&WP-K7BWP_X:\*_$>PUZ_B\>Z?K>D_%[X7:?HQ\/#PU+ UMK$FH:?JYUJW
ME-]I8L-FH>$Z-_P4TLKS]K+]I"TT?X[_  (^,G['/P$_9H^'7QQNI_@1\._$
M/Q%^+-QXT^)7CWQW\-]+^%$?BSPK\7?$7AW5M?BU7P=HVIZ;;VWP]T^ZU8^.
M-/TZ^70K+3WU^Z /K'_AV+^P]_T1-_\ PYOQA_\ G@4?\.Q?V'O^B)O_ .'-
M^,/_ ,\"O,D_X*V?LSO!X"L/^$,_:)D^(?Q$^-?Q=_9ST3X0V'P9UC7?']E\
M:_@MX;D\6^+? 'B"7P]?ZOX$T75+K0A9ZCX?N[OQN-(U2RU&+4FU&UTJPUR_
MTGYDU/\ X*R6FD_M'Z#\1[6[^(/CG]BWQA_P3P\2_M/6'P_\#_ JYOOBQX(\
M1_#SXXP>"?BCXR^(&I3:N;FQTKP!X<MM:M?$>@2W&CQ6-YIEY;:+9>,=;:V"
M@'W1_P .Q?V'O^B)O_X<WXP__/ H_P"'8O[#W_1$W_\ #F_&'_YX%6==_P""
MC/[,?A_XV^!O@C>^(M;EO/B!XQ\)?#'1/B):Z7:2?#&#XN^/O",OCSP3\)]1
MUR75(=;A\:>)_"(L=6TXVWAN[\,QS:OI6@ZAXCL?$UQ)HL/@_P"V/^V[\9_V
M1?VPOV9-"UC3_ASK?[&?Q3L+W3/COXBN/#FOZ=\2/@1J6M^./ /PG^&?Q$D\
M7KXVF\,ZM\.=9^*?Q-\*>'?&T5]X%T^7P;IMW#K3Z[<VDETUD >W_P##L7]A
M[_HB;_\ AS?C#_\ / H_X=B_L/?]$3?_ ,.;\8?_ )X%?/WQC_;[^(7A7_@H
M1X$_9Z\.W_PJ\(_LN>#OA!\;OB3^T;\8/&?AWQ-XD\1?\)+\&- \#^.?%'@?
MP5=:3XN\-:#X;TWPCX!\;Z+K'B_Q9?:7XXDM]8U3_A'X=#M[_0M5B?U7PW_P
M5-_9@\3Z?\0(;.+XDVWQ#\!^*/ACX3MO@G>^%=./Q=\?ZE\;--U#5O@W/\._
M#EAXBOM+URP^(]CHGB2?2I[[7]'DT!/"WB5O'</A)-%O&C .L_X=B_L/?]$3
M?_PYOQA_^>!1_P .Q?V'O^B)O_X<WXP__/ KXP_9)_X*)ZGXNB\'Z+^TO\4/
M''AOQUX\_;;_ &WOAEX!MK'X':3X%\-R_#;]FG3_ !3XBN/ _P :)-1L?%EG
M\,+GP3X2T][FZF3QROC'Q/KWAZ:XT[7/$'A=-7N*^KM%_P""G7P UW0/%FO6
M?@WX_1C2-%^$?BGP#I%S\(=836?CSX/^/GC*Y\ ?!?Q=\%;:.[EMO$.A?$+Q
M9;KINFR^)+SPE>Z)!=6>K^+['PYHMRFHT =#_P .Q?V'O^B)O_X<WXP__/ H
M_P"'8O[#W_1$W_\ #F_&'_YX%?/^G?M[:Q\;_P!H7_@GE=_ ?Q1+H_P(^//C
MO]LKX6_&KX=>,_A_86GQ%MOB!^SSX'\1-_9%_P"(#K>JV_AYO"7C;PQJ=O?6
MGAI+^T\1))9WUMXHN=((M;O]=: /S:_9I^#7P[_9_P#VV_VD?AO\)-'U+PKX
M%N_V7OV3_&DWAB7Q=XS\2Z2GBO5OBI^V!HNIZ]:6OBWQ!KRZ=J6I:3X>T'3M
M0FTTV@OK71M,2[69K.!D_26OBKP;_P I$?VB?^S./V/O_5S?MLU]JT %?%/[
M3_\ R<!_P3I_[.H^)'_K#_[6]?:U?%/[3_\ R<!_P3I_[.H^)'_K#_[6] 'V
MM1110!\"^//V>/C[\2/VQOAQ\<?$_B'X.GX1_LV6GC_Q)^SOX?T>T\;:;\2-
M4\=_$_X07GPM\5:-\8+^ZEU?PO/X2MIM4U+7-!USPA:6NL6\+VNF7^@7TD#:
ME+^1?C/_ ()!_MR^-?V5_#?[-NJ?$W]EU]+L_@Q\9_AO?6=IK/QCT/0M*\:>
M/OC_ *G\;O"WQ--_H/A&P\2_$FUT:UU4^&%^&/C>[M/!'A_5M.B\<V%OKNHZ
MG=Z7!_3=10!^!4__  3_ /VYK_5_$7C#7-3_ &2=(U'Q#_P4@^ W[>6KV'AS
MQ5\;-2MK7P[\&/AWX%\#ZC\.;.YG^&UIJ.JZKK"> XM0T_4YK*.VA.K7%E+I
M\YM89+GYF_8?TWQ[<_%72]9^!WQ(_9R^)_C30/!/[5'A7]G;X*:S\3/'VE:A
M^QE8?&WX@7?Q6\96WQH^"UI\"]-^(/A?2QXT\*^%O!&NZ+\3/B/XTUWPKJ:Z
M=X3\"74FEW5U<Q_KK%^V#\9OC'\:_CK\,/V2O@UX#\?>%OV6?&.F?#?XT_$/
MXM?$O6?ASIWB/XIW'AW1_&.N?"[X.6/A[P+XYFUO6_"'AS7-'@\3>)_%\OA7
MPK9^)]:MM!M+B_.EZY=V72:9_P %"?@;X4\+_"AOVD[RX_9L^+/C_P *?#[7
M?&_PM\7:=XC\0I\$M:^(NL0^%O#WA[XO?$;PQX<O/ /P]@U/Q?))X:\->)/B
M!K7A#0_%UW;RW.@37-NLAB /S0UO_@EC^V/X/^ /[3O[(GP/\>_LY?\ #.'Q
MWF^'/Q(\)Z9\3]=^)=SXR^&7QT7QAX+\=?'2ZTR_\-_#U+*Z^%'C[Q%X=O+O
MP;X+8B;X?NT5MHD]KX;O(/"OA[]4_P!L;]G'Q]^TK\&_A[IWA'Q3X4\"_&WX
M/?&+X+_M&_#Z^UNQU;Q'\-;GXH?!OQ':>)X/"WBJWLSI/B.Y\"^)A_:WARZU
M;34M=?TFWU"U\0VVFWEWIW]C7G/7?_!3O]@ZR\7:SX&D_:.\(W'B+P[\2?%'
MP:UV/3=(\9:OI&D?%SPCX?NO%&J?"_4/$^E>&KWPQ:_$&]T:POYO"G@^;6$\
M0>.[RPOM(\$:?XAU>SN+&.#5?^"H/[!^C:=X.O[[]H30OM'C_P (_$?QUX3\
M,V?A/XBZGX_U3PQ\']?G\+_%*];X:Z9X/O/B#IUWX!UVSU&Q\4Z+JGAFRUS2
M#HVO7-WIL=GH.LW-@ > _M*?LB_MD_M3_ O]J#0_&VO_ +-WA+XJ_&7]G^[_
M &;OAYX4\/ZO\2]>^$_A7PUXF\1P:SXU\>^+_%VI>#=(\8Z_XHO+<QV^B>&M
M-\&:;HNGC0;2&ZU>\_M^_NM+\ ^+7_!/#]N'XB>)/CQKFG:O^R5IMO\ &7QC
M_P $Y?%MM9W?BKXR2?\ ".G]AGQ5IWC;6['-O\.U6['C[5-/71-)N(A:G1M(
ME;4+R*\O$6R/Z:^$/V_/V/?'R>-I_"'QT\+:Y9^ / GAKXG:[J=O8^)(M'O_
M (?^,+N;3/#/BWP5K-UH=OI7Q*T;6M<MYO"UE<_#F\\5!_&4;>#&5/%6-'KA
M?$/_  5%_8*\(Z5X8U/Q3^T3X=\.3^,-0^)&CZ'X7UOPS\0=,^(IUOX0WUGI
MOQ)T'5_A=>>$8?B/X:U[PG=:CIPU#0_$GA72=6DM]0L+VSL[FRO+:XE ,NT_
M8I\1GX^?M0>+[OQ_8:;\"?VE? EKJEY\-= L;N#Q'X1_:.U[X<77P4^)/Q7T
MC7)_^):;37_A3I_A/3]/MA81ZA'XBM=<U:]:1-3\JOS6N?\ @CS\9M&^!$_P
MU\">&OV-=*^)&F7/[-G@Y?BWJ&J_'K4]<^*_PN_9[^,?A/XP6TWC\^)K3QE=
M>"-1UO4OA]H42?#GP9=:QX,LM<\6>+?$ZZ\PTS1-#N/UBU[_ (*"_L@6&H?%
M'PN_[0G@KPYKWPQ^'WQ!^(6OZ[XBT;Q2G@FR\-_#.+3H?B#XAT+Q1=:=H_A'
MXFV_PPU/6M(L/B-H7P\\7:QK/A75[C_A&_$2Z'K?F6\":/\ MY?LP:=KOP>^
M&/B;X\^&->^)OQ4T#X0SZ)>>'/ WCW3?"NM:M\:]'N]2^%@U*[6Q\4:!\*K[
MXMPZ5JM_\./!7Q&\;67B77;: VNE'69XO.F /E;XW_\ !.GXH?&?]J77/C#;
M_$7PU\,?"'Q!\.^(_!OQ0U7P!KOC^T\8>+OAUXB^ /B#X277P_\ $OPTU!+S
MX->,M:M/$WB>X\4>$_CM<6/AKXK>"/#^C6/@FRFUK0M3OK:U[3_@GK^P1JG[
M(^JZMKWBOP9^SYI/BR+X5^"_@T/B!\))_BCK7C'XI>'O!5Y<76G^(/&]Y\4;
MZ_N/ =HLSRZAIWPM\(ZEXD\,Z/JVO:]=P>(KA?LD0]._91_:6^.?QO\ A#^U
M'XF\4^ OA[>?%;X)?M*?M/\ P-\%^"_ FL:[IWA;Q4/@UX@N-$\"VNH^)O%,
M4]]!J'B)ULX/$/B :-86%M+//=V7A^&W@2WE\!^&O[:O[;NO_'3XV_"OQW^S
MW^R]HOA_]F#Q'^S]!\?/$GAK]HOX@WEYI'@;XW>';7QEKOC;PK%XJ^!GA70K
M^W^$GA%M4UWQ19:WKVC'6X-#O(M#N#<3VD,@!2_9H_X)NWWAC]HK]HS]IC]I
MOX6_LU^/OB;XU_:-U']H_P" ?B/PYXF^*?BB7X;>))_A[H7PYTBVU'P[XU\/
MZ7X.T[7O#NF^'Y=0TGXA>'M"N/$]E<^*]:MK/[,NF:?>7?S!HO\ P3%_;QTC
MP+^SSX9TGXA?LE^%_$/P5;_@HG+-XGMX_B5XQT^:^_;?OO$6LZ#J5OX-\1^!
MK71?$(\ :GXFNHM;TCQ+*=-\306-M<_N)[B:WC_0W3_^"MO_  3PUKPFWC?P
M_P#M(Z/XI\-M%9W5I<^$/ GQ6\77^K:==>$?$'CRXUKP_H7AGP)JNO\ B/P_
MH7A#PMK^N>,/$6@Z9J.A^"+73I(_&&H:'<RV\$WG7_!03_@IIX+_ &9O@(/&
MOP,\6_#+Q_\ %?7-+^"_C;PAH?B33OB'KW@J[^&/Q9^('A;PQI?B?6/$'@'2
MI=&\,7GBW2-;O9OA9:^.?%7@JT\<ZS9O::)=:I+:7-A* ?"OA'_@E3^VWX7^
M*%CXT36/V3[G1-3_ &K?V0?VJ/%\.N_$O]H3QQXOF\2_LP^!M2\!ZS;+XH\6
M> +J?Q'K'Q&?4KCQLFNW:^'+'PGJTD7AK2_#LNEV-OJK>_?$_P#X)]?M>^+_
M (J?M!>--!UG]F*VT/XL?\%"/V3?VPO#T.K:]\5(M9M/!7[+FB_#+P];^$/$
M2V/@B>T;Q1XNL_A5I6H&ZL+JXTC0[[Q%JEM&VH0Z59W-_P#J/8_M6?L_ZE\:
M(/V?+/XBV4GQ7O7\36VE:$^B^)[?1M>U?P3:6NH>-?#'AKQW<Z)%X \3^-?!
MFGWD-_XO\#>'_%&I>,/#%B)[S7=$L+>TNY(/!_B3^UO\2=9_::\2_LA?LK_#
M3P9\0OBM\,/AOX1^+'QM\7_%OQMKOP^^%'PW\._$2^UW3OAUX4CU'PKX-\>^
M*?$WQ%\9_P#"-ZWK<.CZ?X?MM'T#PSI@U/7-:AN=8T73[P _,KXA_P#!+/\
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M7EGJDVA7UUH]W#I%U8ZO^U%-<,58(P5RI"L0756YVLR!DW!3RRAE+ %=PZ@
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M\=ZIXA^!M]\-H?B)XM\&>!8M7\6?%KP_!X2/A>S\4Z!XKO/"6FWLGUM^T_\
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M=1\2/_6'_P!K>OM:O@7]MCQ19?#SX@?L-_%'Q!I'C>_\$?#W]IOQCJ?C;5/
MWPX^(/Q0O?#6EZ]^R'^T]X-TG5=3\.?#/PQXN\3PZ7=^*_$>@:!_::Z,]A;:
MCK.GPWES;BYC9@#[ZHKX=_X>*_LN_P#/[\>O_$-_VQ__ )PE'_#Q7]EW_G]^
M/7_B&W[8_P#\X6@#[BHKX=_X>*_LN_\ /[\>O_$-OVQ__G"T?\/%?V7?^?WX
M]?\ B&W[8_\ \X6@#[BHKX=_X>*_LN_\_OQZ_P#$-OVQ_P#YPM'_  \5_9=_
MY_?CU_XAM^V/_P#.%H ^XJ*^'?\ AXK^R[_S^_'K_P 0V_;'_P#G"T?\/%?V
M7?\ G]^/7_B&W[8__P X6@#[BHKX=_X>*_LN_P#/[\>O_$-OVQ__ )PM'_#Q
M7]EW_G]^/7_B&W[8_P#\X6@#[BK\$O'/[&?BGXL?"G]M+]B.3Q/!X!^-&M?M
MK:G_ ,% ?V;/&OBW2=7U3X=>.-/N?C7X'_:&\(0Z[<VMD\.IZ'X<^(>F:O\
M!_XC^&=.EN?%'A?0;?1/%EC820:MX;EN?T+_ .'BO[+O_/[\>O\ Q#;]L?\
M^<+1_P /%/V7,@_;?CUD=#_PQM^V/D9ZX_XL)WH ^?\ ]H63]OG]IC]D[]HW
MX/R_LH>"OA9XJ\=_L]_$SX>16>I?M >%?%:>-?''Q \$ZGX.TBU\#ZSHNFV5
MKX9\+:'K&JR^)M>\4>/+:RUF30=-M=&T;P9>:SK5S=^'?S3^+O[!G[9OBGPC
M\7_"/A#]C'X>V>C>+OV;?^":GP[\":-_PNSX1:=I7A?XC?L@_$6Z\?>.=4M[
M2+0S!I+6NC:Y=^#O!GB#38VNY[C3[V18M-TC4;:0?M9_P\5_9=_Y_?CU_P"(
M;?MC_P#SA:/^'BO[+O\ S^_'K_Q#;]L?_P"<+0!^26D?L5_M@>'_ !/KOBWP
ME^QY\-O"FM>)O^"O$_[<EW=V7Q<^%FGR/\'KWX'W/PV?3?$%WHFDQ7NH:V?$
M&L:W=ZMH-G))]JT?4]:DM=7;4=5F$UW]CWX+_M-_L-?%SQ-^T+^T+\&++0/!
M+?L4?#;]G#3?#?P_^(O@OQ9IH^+WP[^)?C77/!OPO^ /P:^'_A/2[[2?AAXT
M_P"$ZTWP[\-].E35?&D-_:^(?%/Q4N_M^IZCKDGZP?\ #Q7]EW_G]^/7_B&W
M[8__ ,X6D/\ P44_9<)!-[\>L@Y!_P"&-OVQ^#@C_H@OH2/Q- '4?L$?!+Q1
M^SE^QM^SI\%/&TD3>,? 7PTT73_%,-N\4MOI_B#4&GUS5]&MYH))H9[?0K_5
M)]%@N()7@N(;!)H28I$KZ[KX=_X>*_LN_P#/[\>O_$-OVQ__ )PM'_#Q7]EW
M_G]^/7_B&W[8_P#\X6@#[BHKX=_X>*_LN_\ /[\>O_$-OVQ__G"T?\/%?V7?
M^?WX]?\ B&W[8_\ \X6@#[BHKX=_X>*_LN_\_OQZ_P#$-OVQ_P#YPM'_  \5
M_9=_Y_?CU_XAM^V/_P#.%H ^XJ*^'?\ AXK^R[_S^_'K_P 0V_;'_P#G"T?\
M/%?V7?\ G]^/7_B&W[8__P X6@#[BHKX=_X>*_LN_P#/[\>O_$-OVQ__ )PM
M'_#Q7]EW_G]^/7_B&W[8_P#\X6@#[BKXI_;X_P"2)^!/^SOOV"__ %MCX!U3
M_P"'BO[+O_/[\>O_ !#;]L?_ .<+7SU^TI^U?\(_C[X1^&?PQ^%-A\<O$7C3
M5?VJOV,-:M--O?V5OVH_"E@FC^#?VM/@QXQ\5ZMJ?B7QA\'- \+Z'I7A_P *
MZ%K.OZKJ>NZUIMA::=IEU+)<!U2-P#]9Z*** /BS]ES_ )+C_P %#O\ L[7P
M7_ZQ-^R+7VG7Y@:%\6/'7[.G[0'[9<&L?LJ_M2_$G1OBG\>/!OQ(\$^,_A'X
M$\&^+/!^L^&8OV6OV=/A[<LFH7_Q%T'4;;4[#Q=X"\4Z5?Z=>Z1:O";"&Y@D
MN;6\@F/IG_#<VL?]&.?MY_\ AG? G_SW* /O.BO@S_AN;6/^C'/V\_\ PSO@
M3_Y[E'_#<VL?]&.?MY_^&=\"?_/<H ^\Z*^#/^&YM8_Z,<_;S_\ #.^!/_GN
M4?\ #<VL?]&.?MY_^&=\"?\ SW* /O.BO@S_ (;FUC_HQS]O/_PSO@3_ .>Y
M1_PW-K'_ $8Y^WG_ .&=\"?_ #W* /O.BO@S_AN;6/\ HQS]O/\ \,[X$_\
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M,TAO<?\ AN;6/^C'/V\__#.^!/\ Y[E'_#<VL?\ 1CG[>?\ X9WP)_\ /<H
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M^)O',3>*=(T^;Q%;^&_"OA6?4=:\3'4?$FDVUW^[E?!G_#<VL?\ 1CG[>?\
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M3\1?VH_%'BA-$TO0_%WBN>?3=(TGXB>$6N-1O?[/BENM4^S6B7+6MT\7Z#T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\?[@T4 ?CY>_\$P?B%XG^"7[7/PG\5?M0G2O$WQ\_:FT#]K_ .$/Q?\ AO\
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M'XL\5:_IWA+2-&T_5_$NNWUK-J5Q]%44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $6 D\# 2(  A$! Q$!_\0
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M)"?#T"7XQ?''S '_ -&^&R?.,_*NE:^57GJHRV!T&6]37O BC'1%' ' QPO
M'7H!P!V[5P4J%6M!554Y>:^G:S:M?KM<YXIU5SJ32DW9;-)-QM>V]U?]#P?[
M=^T.W_, ^$YP._BSQ*/_ '4?\\>@H^V_M##_ )E_X3?^%9XD/?'3_A$?7C].
MU>UWD>XI''*T+,&*[0!N *^8L9/#3M$'$2G.W+2\%%(_+*P_;^^(WQ,^,/[1
M?@;]EK]FG5OCOX _9.\16_P_^+GC1OB+H_A#6?$'Q;;1++6-6^&7P:\.Z[;C
M3/&>M^$M'N;5O$U[XC\5^%=*M=0N5@L[R]O)%A?3ZBWK*HW)[VND5[.?\\OO
M?^1]P_;_ -H7_H7_ (3?^%7XE_\ F0H^W_M"_P#0O_";_P *OQ+_ /,A7C6B
M?M[_ +*>K>(H? >K_&_X>>&?B+!K.O>%/$WPYU/Q L/B/PQXQ\-^%3XT\6>$
MM7\SR);/6O"OAEAXCU65PEE!H5OJ&I022V5I]J7DI/\ @IA^Q=<:[\ M#\/?
M'GPYXQN/VD/'>N?#SX7W/ABWOM;L]8\0>&]/MM9UV2[NK.".VT_1K'2=2TQY
M=;N-EA;Q:QHNJ2/)I\[W /J"_G?WL.2I_P _#Z3^W?M#_P#0O?"?_P *KQ+_
M /,A1]N_:&_Z%_X3=,_\C5XEZ>O_ "*'2O IO^"C/[#8\(ZUX]'[5GPA'@C0
MO'&D_#/7_%@\6V,=AHOC77YKRQ\/V%U>^;/:+_PD5SIU[:>'[Q;,:5KEU:W+
M:7=7!C!KIOAY^WG^QQ\7$\0S?#+]I3X4>,_^$:\#WOQ2\1G1O&&GW$7A_P"'
M^F:G=^']:\9:L+F:R%AI&A:EI-_;ZI'+(9+2>!EEMQ-<6PD/J"_G?WL.2I_S
M\/5OMW[0W_0O_"?KC_D:_$W7GC_D4.O/^<"C[=^T+_T /A-_X5?B;W_ZE#W_
M ,X%?/-[_P %*OV#]*TCP)XDU?\ :V^"^F:%\3M,\3ZAX&U*^\76%K:>)XO
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M,\1.X.<AM UILY5D.<V!SE&9#QRK,O1B*1_VB?@[(I5_$+." "'\/ZRP(&W
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M+^#_ ,O_ !43_*P9?^)!K7RL"2&7_0.&!9B".06)[G(?VBO@\>#XA<C=NP=
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MOR:*'V>/^XG_ 'R/\]S^0_ ^SQ_W$_[Y'^>Y_(?A?P/0?D*,#T'Y"J^KT?\
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M2=X[;LF,KR<;--=;Z;VOI_P#WPZA:C@7EL.Y'G1'^4WM33J5M_S^6W_?U?\
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MJ?V??A&2-OA/';_D8/$?)!!X_P")Z>QW8SP/?!I!^SY\)>/^*3/;_F8/$?\
ML_\ 4<]C^7TPGBL6G;V5_/\ I=C-_6$VN1-7T=WKYVM8]K_M&W_Y_+7_ +_)
M_P#':#J5L/\ E\MO^_J?TE->*C]GSX18&?"63_V,'B/CCU_MT>A'H.O0$%?^
M&??A#_T*.>W_ ",'B/W_ .H]WQ^H]#FEB<6U?V22\W_P"U&NTF^6+>EF]NRV
MZGM/]HV__/Y:_P#?Y/\ X[_G\12_VC;?\_MM_P!_4]_^FWM_G(KQ;_AG[X1#
MIX2Q_P!S#XDZY]!KW''T[#L:3_AG[X1_]"F/_"A\2_\ R^I^VQKVIQ\K_P##
M!RU_Y>9='?3Y61[4-0M&'-Y;$],>=%^7S2@]/:E^WVX(5;J  ]9/.MRH/9=A
MGW9Z'(SU ]Z\5'[/_P (P?\ D4\#N1XB\2<_0?V_D=>X'<UEZS\!/A3%IFHS
M6_A.:.XM["YGMIHM;\5/)%/#;W+QL)%UJ2)<$;E4@\@,RG*5%6OC:<%-P3T;
MM';TO:W^1O#GY6Y0=XIW3:NW9O1VZ['T7;E&5BF[[W+-NPQQG*Y9QMYXVG'M
MW,]>/? )VE^#_P /Y7>21Y/#.F%Y)KB:ZG=EAV%I[BX9YYI3M^>29VD9L[F)
M&3[#7?AJDJM&G4FK2DKM=GVZ#A+FA&5FKJ]GJUY,****W*"BBB@ I"<]#@_3
MI]<]/QKP_P#:"O\ 6-,^&/BBZT:_U'3;G[+I5C'=Z+<-!J\":QXBT?2;R>S?
MR)5BEBL;RZ:&X!$D4VUD ;#KD6_P&TEXHA_PG?Q5=HXHUDG/CO4D>X;RTS-*
MHB*!B,#]UA,Y/WB37'5Q4J<G&-&4[.UU))/Y6;,74GSN$:3DE;WN9)/Y?U^)
M]"LX7L3QVR?Y TWS1_=/Y'_XFO S\ M*_A\=?%8CV\?:B>>>Y@/\\=\=*3_A
M0>F?]#S\5O\ PO=1_P#D>L_KM7?ZM+TY]?\ TG]0=2HFU[%NW7F5OR/??-_V
M3^1_^)I?,/\ =;\F_P#B:\ /P"TL_P#,\?%4GW\>ZCT_\!_?\,Y["D_X4#I?
M_0\?%7_PO=1'_M#W/Z>@J'CZJ;2PDVN_/_\ :C4ZG_/E_P#@:7Z'O_FC^Z?R
M/_Q-'F_[)_(__$UX$/@#I(Z^//BLI/.!X]U ]<\G-N<<]O3Z8I?^% :2W_,^
M?%8^_P#PGNHCV[0#M_,UK'$XF236$LGWJQ3^ZU_P%[2?_/IW[<RV[['OOF'^
MXWY-_P#$T>8?[K?DW_Q-> GX Z0.OCKXK\^GC_4.>O\ TQ/J>OJ?4TA^ 6C=
M_'GQ87C_ *'S46]><^1[G(_QJ7B\1%V>$_\ *T/U'[7^ZT^S;5OGRV/?]Y_N
M-^3?_$T;S_<;\F_^)KP(? 71!Q_PG?Q5)]6\>ZB#_P"D_(!Q[_I2'X":*2/^
M*\^*PQZ>/M0QV[FV([#\AZ5HJ^(:3^K6N[?QH/\ X >U7E_X%_P#W[>?[C?D
MW_Q-'F8ZJP_!O_B:^?C\ ]&Q_P C[\5\=O\ BO=1.,\?\^WMT]NE*OP#TCG'
MC[XKGZ^/=0/KZVU92Q>)3:C@W-KHJT%^C#VDNE-M=)<RL_PZ]-SW_P W_9/Y
M'_XFE\S_ &6_)O?_ &?8_D:\"7X!:1GYO'GQ4;KPWCW4!CIC&(!GGN1QTYI3
M\ M&_P"AZ^*@^GCW4#]<_N/R]>>>X%C,2M)X*:EU_>1:7S4;/Y#4IM7]G_Y-
M_P#:GO?F_P"R?R;_ .)I?,ST5C^#?_$UX$/@'I Y7QU\4S]?'FH#'3.!]GX_
M'DGC(S@#? 721C/CSXJ+G^[X[OV]L\VQ[\#'4X]:KZW5U;PTDU]GG6O_ )*2
MYU4[>Q;7?G2_]M/?/-']T_D?_B:/-']T_D?_ (FO A\!-*/W?'7Q58?]CY?K
MC@D#'V<'I]>U+_PH+3/^AX^*W_A?:A[_ /3O_G\11]<J?] TO_ E_D'M*G_/
ME_\ @2_R/?!(23\K'IQ@\?\ CO>GJV[L1]01_,"OGJ;X$:5$KJ?&_P 5V,T9
M4E?'VH;D$)\X&/\ T<X=W0(2,%D)7)!(-?X,VEYH7C3XM>%!X@\1:[I&C7W@
M^\TL^)=9EUB]L)-;T2ZN=1LTFFAA>*%;B%&6',BKG(*CBLUF#]I&G*A*+D[7
MYDTM+[*(U4=X1E"SFGI=.UM[Z*Y]'T5&A.2.V,_CQ4E>G_P/Q5_U-FK.P444
M4""BBB@ HHHH   .!43Y+ $C85;Y<E7+8X*D$=LC!P<\]J<Y(Q@D=?Z53E)4
M[_FV[0H*DD"0R)L+(."!@EF[ $'@U,Y<L92M>RO;N)--2?\ ):_HU<C>\AA8
MQR7,<4@P3'//"9%4DA20LBD!L'&[=DJ0#P:9_:-O_P _EK_W^3_X[7RYX1^&
M'@CQQXC^+>L>*=+?6;^+XH:G8Q3-K_B"*.VM8/#7A9TM(+6#5+6&UB666:0P
M0IY0F>60*K2,6[K_ (9^^$?_ $*8_P#"A\2__+ZO-^M8JI[]*E'V;OR\SUT=
MGLK;IG+>M4]Z,'R-NVN]FUV\CVG^T;4<?;;4?]M8Q_[6_.C^TK3_ )_K7_O]
M'_\ 'J\6/[/WPC/_ #*F/^YA\2>__4=SZ>GMWPG_  S]\)/^A4_\N'Q)_P#+
MVCV^8=,.FEU5[?ET'RU_^??YGM7]IVG_ #_6O_?V/W_Z;>W^<BC^T[3_ )_K
M7_O]'_\ 'O;_ #D5XK_PS]\)/^A4_P#+A\2?_+VGK^S]\(^?^*3S_P!S!XD/
MK_U'/Z>OL*7M\P_Y\)?UZ#Y*_P#S[7WL]F_M*V[7MJ?^VR?TE/I_G-+_ &E;
M#K>VHZ]9DSQ[&45XRW[/?PA;[WA/;CIGQ#XD7)/7@:Z,XP,Y[\ D9IA_9Z^$
M"]/"F[/_ %,7B,D8'OKIZ_GGKUJU/,7K[&G9O1.I%/IT:T1FWB(NR@VNR>GY
M?J>T_P!I6W:]M3_VVC_7$IQ1_:-O_P _EK_W^3_X[7C"_L]_"+D_\(D<]L>(
MO$8]1GC7,'\>QS2G]GKX0MU\)-W_ .9C\1_TUL^WZ^G,RJ9HFTL+"2Z-58V?
MX%J->R?*E?I?\-$>S?VC;_\ /Y:_]_D_^.T?VE:_\_MM_P!_8_?_ *;>Q_(U
MXNW[/?PB3&WPH1G.<^(O$AZ=/^8X,=?QY Z9I/\ AG[X1_\ 0J'_ ,*'Q'[_
M /4<^GY'UX/;9A:TL.HR\I<UON6H^2N_LJ7G?_@'M7]HVW_/[;?]_4]_^FWM
M_G(H_M&V_P"?VV_[^I[_ /3;V_SD5XK_ ,,_?"/_ *%/U_YF'Q)^'_,='M^N
M>U+_ ,,_?"+_ *%/_P N'Q)[_P#4>^GZ^U#KXSK22?J__D1<F(_DC^)[1_:5
MO_S^6O\ W^3W_P"FGM_G(H_M*W_Y_+7_ +_)[_\ 33V_SD5XO_PS]\(O^A3_
M /+A\2>__4>^GZ^U'_#/WPB_Z%/_ ,N'Q)[_ /4>^GZ^U+V^._Y]Q_'_ "%R
M5_Y'_7R/:4U&U+*#>6_)"C_28%R[$!%VNY9BQ#;0H]B#GC1C+')<*&..%8L-
MO.T^@)Y/'YGBOD/XJ_!'X:Z+\-_'.L:/X>N-/U+2_"FNZA97]OXD\51RVEU:
MZ?<2P3(\>ML5D1ANC;Y61QN0C%?27A&667P[HTDK.S/I&EN R2@C=8PD_O)G
M=Y2>K.[%B<EB22:<,4Y3]G4@U/3FL]->VW0UA.2M"<6IK?YO_@G)?',?\6B^
M)[?]2!XMYQZ:'>8_,G\.HKNO#PQH^EG #-ING%F  +$V4 W,1RQVX&3D[0!T
M  X/XZ?\D@^*?_9/O%7_ *9+ZN\T'/\ 9.F#KC3; #Z"SM\45(1CBU-+WY35
MV_((_P 2ITV]?ZT=S8.[.1CWSG_/U_"D^?\ V?UJ9 ".0#SW&?2GX'H/R%=\
ME5YFXRBDU9)K;S.E3LDK;?+]#P[X_3^,[7X2?$6Z^'WC!? ?CFT\&:W>>$_%
M4WAV#Q99Z/KEG8W5S:3WOAF\U#2[?Q# SQ*'TM=2L+F559K>YWC:?QWUK]OS
M]JG7?V2?A#I&B+X0\#?MIV/Q_P# _P"SW^U;Y/AN7QAI'PU-GXS\.^%?'?C/
MPIX)OM2TB34KOQQ;^(O"VH_#?3;[4X+&*R\3WVH1WNIP>&[EI?VJ^+O@/0OB
MAX \6_#SQ*^L0^'_ !?HEQH>L3^'-<N?#>MQ:;J$<\.H/9:Y9O'=:2_V(3QK
M=VSK*QD,089Y^,O&?_!-C]E'QUHTUA?^&O&EI=7\WP4U+Q%XQ\+_ ! \7Z+X
MW^(-Y^SS8R:?\'YO&'BBWO/M/B*\\'6FZXLVD"7%_JLC3:A)*;>V:.DI62?*
MWU=GKMT,9.JVW&44NBY7HNWF>5:-_P %<?V?O$7C;XI_#+P]X;^+/BKQ-\/?
M$$/@7PE>:7X7V:9\9OB1;>.)/AHW@WPKJ$D\.F^']7NO'EL+&WD\4WNF6)T8
M7?BJ5U\/:?=W"^1? O\ X*:^(4\(Z'K/[3=AXQT#QV+;]JW7[[P=X?\ ANVB
M:)=6WPF^.'ASX4^%OAK>:[<ZM=V=G\4M*U[Q)X>\,V-B+I='\2Z?J=SXVO;V
MST>YTF2?[+UG_@GO^S9K4/Q!L[WP[XU%M\2_$2>,]0T.V^(OC>TT'PKXV.NQ
M^)+WXA_#?2?[8MK7P7XNO?%$=AXAUW5-'B$]SJ,#O#"!?7[7/#Z'_P $L/V.
MM#M=-L#X%\37FDV_A[XQ>%)M/U#XD^-M;M_$$'QNUJ'7?BAXE\3QWNJR3:CX
MP\:Z[8Z/XFU7Q%Y<-UH6O>&M)O-(^SR6-K*"S[0^YB_>Z>_'3R,GQW_P41T/
MX6V%GXO^*_P?_:D^&<OA_P"$GQI^+/BOX52_"0^+-7O-&^%VOZ!H&H366M>'
M=1O[&]O%.H)XJT>'1+J[TR;PI/?ZUJUQ96MO%$N#XN_X*L_#3P!\-[3XA^*/
M@Y\;]%L]/^+R_##QKX<U*Q\/Z?XE\#072:%>Z5XS\8:?-K,HTW3];TSQ;HFJ
MV?AF"YN?$JO<M87%C;3Z7J,*=_XL_P""9O[,WQ&\-Z/X8\:M\9=?M=+\#>/_
M (<1:CJ'QR\>R>(-6\&?$*72)_%.C:OJMOJ)_M2WUZQT33-(N+IO+N=/T33]
M.TV+9++=/+RWB'_@DO\ L;>($U$:YH_Q0NKS5M3US6=2U6;XO>-CK$IU?P_H
M/AK7;33[P7K-!I.M:/X:\,1ZE!;;;N;^R-/$>99[TS0X57)M2BELDXWLC>+A
M9<R;=M7&R7W'0>#/CI\??&W@?_@H@NH^,?"GA_Q-\"_BGXUT'X)^(='\)SS0
M^'_!=I\(O"?Q'\#P>+](UF^LK?Q%X@2YUUK;Q1=&[TS2[CS9A97$-I!!(?SQ
M_9S_ &V/^"AGB?X;>$OB/XIN%UWX>>+M5_94U!_B7\5/V?\ 4_@M=:GK?Q,\
M67^G?&OX5_#+0+77]3M_$7A#1M"B\/ZMX.^+5](FF/=ZI=Z/"-2EFT^5_P!?
M/ W[%GP3\">%/CMX/\.1>/4TK]HO4+O4/BO/??$7Q5JFMZQ?ZAX4LO!4M_I>
MIWD[W/AN[E\,6%E:SQ:'+90PO;J1&&0FJ5[^Q+\#)O@)\*/V998?&\7PJ^#N
MJ^!=4\"6Q^(?B>VU^*_^&^J6>J^!TU'Q):RKK&M6]GJ.FP74MK<W6QXX(8F<
MP/Y1TC%J.MG+J[:-_F0W*_NV26UU=[>NWD?,=Y_P5I^%-IXJ^)7@B7X+_M#:
MQXM^'7Q5^'7PPL]&\)>"HO%5WXKN/BGJ^HZ)X(\2NF@:A<0^#?#FM:EI<8FE
M\72V,^CPSP_VHEHQNTBYVP_X*NC6;JX\36'[-/Q<OO@]IW[.S?&;5/&T6L^%
MH[FQUZ[^(]S\+YOAKJ6A+?\ VR'6['Q/876F?VVC+H"/INM:G'J,NB1V^H2>
MEK_P2@_9 M-5DUC3K'XLZ(__  D^E^*8+#1_B]XVL-(L-8TO7=8\1Z2UEHMM
M=I;0P67BKQ)J_B"T@>*5;K49YKV\>7J-WPS_ ,$P/V7/!6@:%X:\(P?%_P .
MP>&?#?B/POI5QHWQF\>VNJW.A>)?%-UXOO8-2U;[:7U*73O%.IZGXATN.Z:2
M#2KW6-3M(U?2Y1:KE*%5MM2@E>]N5E)QLN9-OJU9)OT]-O\ )'V[\(?B#9?%
M?X:^"_B7I5IJVGZ;XY\.Z5XEL--UVV6SU33;34K6.:&QO[1'E%KJ%LI\O4+;
MS[@0WBRJDSIM->D?/_L_K7F7P2^%'@KX'?#+PI\)OAYIG]D^"_ FF0Z%X?L&
MNYK^6.Q@S()[N\G1#<:A>2RR7>H2QJ(7NYI3$J1[47U; ]!^0IVK_P T/N8^
M9+:.BV[_ );E?/&"1EO0_7&/P_6L;Q!\FBZJV3D:=?X8$[ABQNNA!R3D\$8Q
MV[D[C@ \#'']36#XB'_$EUKVTC4"/8_9;CD>_J:RQ/.Z$O>CI>^G77]$93G)
M*=K>]?E5MM.O?]3@?@ ^?@Y\/ 221X8T_+$Y)^5N22>3S7L5>._  ?\ %FOA
MS_V*VF9]3^Z/7W[DU[%581MX:DWNX_JR:5U3CS--\J;:T04445TF@4444 >&
M_M%OM^$?BL#@[O#F".H_XJW06.._\(Z>P]!7L-HJ"U@6)40+#'@*H4?ZM>P
M'T]ORKQ[]HOGX1^*N.=WAO\ 7Q;H?%>QVPQ;P^\49_\ (:Y_7->7"I)XJM>2
MY:;NHM7?1Z?@3S2A)O1JUTK>=M_O)AD#YB.O^?2C(]1^8KA_'/CCP_X'T]=3
M\0W\5A:EU2(M^^NIYF)5(-.TZ(F\U6]EDVQ165I')(S.K$;:\P76?B_X\_Y%
MS3X/AAX?#;HM=\7:>VL>,9X"""%\*+<6=II+W$3"6&;5KLRP_*)+5@IW]+Q4
M97<87EUBM^W;J3*O44FE'2]EH[]-]#WJ^O;:QB-Q=W$-I;*,R7,US#:I& <D
MM)<%8@H'))8'TZ5Y9J7QO^&FEW,EA!XA77]4D),>E>&+._\ $>JSJK;&,5GI
M45PTBA@4,L96,-QMZ$YEI\%/#.I21WOC2[U[Q]?G;<%_%FL7%Q9B>, ?N])T
MQK31(;0L-Z6S6USM8C,C $-ZYH6AZ1HUJ]KI6DZ;I-NSAGM]+TRUTVV<[ JD
M);1QI-M0!!(P)V@+VKD<\;4J2]G%4X7NE)7:T7DD7&5245)M1;>VKV]+(\G?
MXH^);R01>&?A3X\N[8H?+NM<MK+PQ&\KD$>9;ZY=P:DJ!2"9(K:15 VL0XVT
MR/7_ (YW;/&/!'@G1HWYBFU#QC?7LBKV>2VL=*=<C.&19F&3@,1@GV2[C$;P
MK 6B<K)Y7EH'CRA5I4DC)CB5I8P(H79P5DDRJY))^>/"O[5O[.'C;XF:G\&O
M!_QP^&?B+XKZ%>:EI^L?#G3/%%C=>+M/U/1,2:MI=UI"W)G:^TCSHWU"VA,E
MW%$WF/ (L,:>!J5).<Z\XREJXQDXI/2]DGHC.4:K;:J))[*VVBW>K[[?H=%!
MI_[0=S+(;GQ%\,K*#=F,6FB:_?2)'@9#R3RVD9=<$#<0&X;@<&Q'X>^,=T)5
M/Q.T"WP^QC;^!K=BAQT0MK<^[ZR;&&.5'!/L>GQR1K*DCNVQ@BB109.!EG,N
M094E8[H]T<;(@"E>,UQOQ,^(_@CX4^&I?&?Q$\8^'? OA.RN+6UU'Q'XIU!-
M*T:SEOKB.TLA=:A-BUMA-=RQP*US)%$\DL<;2 NH+_LVF]95JSEU:G+_ #OL
M:).R3=WU:NKOY69Q1\%?%O=D_&++]0C> =-\O')."NIYY_VLG'2I?^$7^,D(
MS#\4-'E"CD7G@>%5;C&<PZJ&QCGL=W-:GB7XM?#OP5?>#K#QAX\\,^&[OXEZ
MTNA?#_3]:U>WL-2\9:W_ &=_:HT7PS9$*^JWHLE745M++[1.]A)YY94/'<VN
MH$7 AO'ABN;M@UM:F9AYLJPF;_1XI%6>,/&NZ6&;)#[F0; :UC@*227M:^G:
M;_S,94FY.2E:_J>33Z7\>X\?8/&?P\O) .5O/"VKVH;!Z>=;:E<E21Z1MU)
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M^!E:1K.FZW;BYTS4M-U6*0AXI++4([N%H!D,\3QCIG&=V<M_%TSN@C)(92I
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M:OX'H/R%=<56>JJ0:?DRE4NDW%7_ .#Z'D?QO&[X0_$D-@C_ (0?Q,<=0?\
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M;MM[=7H:QBG'F=E?=;N]V^_?T'KM(8, =W4$9W>Q]?H:?M 7:H"@#  & /;
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M4X--U-].\2^'8;S3+K^SKS:3Y.U@#\S/B=X:_:4L?$?[)-]KW[-_QH\;Z_\
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M-=ZKHE_X?N]VG7]SIU_9RZ-JL%MJ%H;&_M9X"MU I9E)0NH#$ ]=LB3&[DW
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MH?\ I)<5N9SWS^.:P_$7_(%UK_L#ZA_Z27%:8G2C57K^5_S%65E;R?Y(X+X
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M ,DA^)7_ &)'B7_TU7%=3X1_Y%CP_P#]@72O_3?;5RWQO_Y)#\2O^Q(\2_\
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M!V. ZX(!I&AM&FCG:RA:>)9$BF:"(S1I+CS4CD*ET63:OF*K /@;@<"O#?\
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M=I2:5X<TRVL++<LDACW2W%U/M!>XOKRZ,FH7UT7RSW.H32SLV=GEQA(U[4@
MX' V@G QEB6R<<<D]2>34BJ!DX4DG)(4 D@ <GN>,9/L.U/P,YP,^O>NN-&G
M"*=!*#LK2W3[Z?UV"G%P5FT_162WM8JK_%_O'^E8OB+G1=:_[ ]_^EK<&MYP
M >!CC^IK \1_\@36O^P1?_\ I+<5-?F]A4YFI2L^9K1-V[>EA5G=-]+/\O\
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MDY)V4&UT=TK_ "9] T5\_?8_VB?^@A\'?_ ;QG[?[?U_ST/L?[1/_00^#O\
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MM:[M^/8K3EKV=U9:_)GCOP<_Y"7QC_[*[K7_ *C7A.O;:\/^$!(U'XQX./\
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MQ+X5UR2QL9= 2WE2YM[G3H;*2;:.&IQBHN-WK=Z:W]5?\1NE%W;5V]6]%?\
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M>J[^IW\_W#_NO_*O _AY_P E:^.G_80\!_\ J.7E>\/]QO\ =;^1KP?X>?\
M)6OCI_V$/ ?_ *CEY4U=<32>VLG^"(Q/_+KY_P#MQ[C*S@RJA"L8=R-C+!@Z
MC(4X0@ DG<0>@/RYKYAM-?USP-\3?BG>3_#GX@:[I/B2Z\*W>CZOX5\/V&HV
M5X-/TJZM=0WR?VG;.CPW,B(/-0-("SK\H-?548!W@@$$C(/(/ [4X11J,!$
M&=H"@8R<MCZGD^_6M\5A'B'&TU"UGM=[:_>:U(<[C=\O+9Z==$OQ1X2_QDNA
MMS\)/C4<C/R^$+%?[O7&N#GGIGL1BA/C+<X.?A%\:NW7PE8_S_MWZY^G?BO>
M-JXQM7'I@8I-B?W5_P"^1_A62PF(BK0Q"45LG&_1=;E/F;NIM>B5]N[U/"_^
M%RW'_1(OC3_X25A_\O?\X/H,L;XRW/&/A%\:OP\)6/MZ:[]?RXKW?8G]U?\
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M1JX6-RH/\0*A9$7W,;-P/3GC./(?@Y_R$OC'_P!E=UK_ -1KPG7MA /4 _4
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M#1-$CAAU>.WG72A*8M,UE@-=M8HX+>WNTM[:W2/Z[\S^Z0G7/R ELX&3U'0
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MCXQ=. /!,BCKGD?VH1QCCTXQP*1?CA:8)7X;?%X%CEB?!$F6(  )8:H"Q
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MVG\[6_X?N/GE:RA)16T==%ZI=?GYGO "@EMH+8P#T('7 (' )Y(]>:>=N!M
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M8X3=U!IMQ^UT:?77;1[;_(\[^-__ "2'XE?]B1XE_P#35<5U/A'_ )%CP_\
M]@72O_3?;5R?QM;/PB^)?'_,C^)/TTNY_P :ZSPC_P BQX?_ .P+I7_IOMJ\
M^4E+&SE'9\O^1N]EZ?JSA_CP2/A'\3\''_%O/%__ *9;BNZTMY$TO3 )%CW:
M;IJP$(9F20PJ)&:)1GR]FT>8<*.^,#/%?'3_ ))#\5/^R?>*O_3)?5WF@_\
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M@\$:==_VUJD-[XOUR0AY=<\77=SKFH/(!AQ!9W:BQL;?S SQVL%JL$!($ "
M5ZO#;V\$8B@A2"% HCAC18XHU"X54B152()C[BJ ,,0#5Q>3P <@8]>-W?/3
MT_&GA>3\@Z^OMQWY[?KZ\=T*-+E3Y?:7U<DTE+SLTWY:OH.,*5DW&[W?F]=]
MAL2K@C'0^X_PY]>WZU3N_OB)$<*4 >6-S;M;Q.SB6:.;#9=%0?NE4,0=RN.:
MT5X!X _P]SW[_P#UJH7NT/$2 &WQ?,R.RL SCRP8LNKD,[*S+Y8(RQZXV5."
M5E!)=G9O[QV2T2LNB[(_*+XR?\%)Y_@3^T=??!'X@?!G15\&6GCSX5> $\;Z
M/\>?#&H?%#61\7K>:7PSXGTGX$W.@67BC4?#6ASP2OXMU2W\2M!HNG17&JGS
M4L+F%/IV;]MW]E)O!^D^.%^/GP]LO">N_$2\^%6C^(+K7Y;33]5^(%A>C3+G
MPT\EY8Q7]A+;WS6RZ[K$]C:Z)I\%U:7$^KK;7]M--R%O^R-J<W[17[07QU\3
M^(?A]KEW\5/!>B>$/AGJ"?#+P_%\1/A!_8.B:AHEEJMAX[N3=WFJ@/>IJ-I:
M1P6DL5[$&,[0RR1K\7?!G_@EG\7/@]J\?BW3/VB/AOK'BAO'.J:W?SZQ\"].
MU72/%>F^,;+2=/\ B+<>*M+UG5;]M2\<ZY)HEEJND:U97%A8V6JF[>ZL+^Q6
M&TBI*VBLEVL+W[Z.*716>_W_ -=#ZW\#_P#!0/X':S\/U\7?%_Q'HGP.U:P7
MQ+=ZMX:\0Z_<:R+'1?#/BK4/"<7B"TU;1=-CL]4TWQ/>6B7?A[3XK./5[^ @
M?V=,MI/<#T#Q=^W#^ROX,U;1_"^J?'SX?VOBG7O"I\;^&-%OM<D_XJ;PY=:)
M=:Y8S/K$.FW>E:78WEA;27XOKV4WEKIZ7%_-91P0R*?SBTS_ ().?&_PS\.?
MBM\-=%_:M\*S>'?C5\2]4^*'C:RU_P"%%SJNG7?B:_U;4GU3PU9B37C>Z)X"
M\0:#?V^EZWH&D:CID,=]9-=Z6UJ-0O('\<\)?L*_';PA\8O#OPAN;*_U;3O"
M'P43X-^'OB7XB^#<$OP";3XOAYK/@JW^*=I=Z9\08I])^(_A_P .:Y+X?\.^
M&[WPH;>WBM4T=-7FL+B>X<L^Z^[_ ()-JG>/_@+_ ,^GXG[$>$OVR_V;O$^L
MV/@=/CC\*D^($_AW4/$VO^$;;QG;:E=Z!8Z?H5MXEOKBXNWL-+L8-&A\/W,6
MK)XAU:/2;;5-+:/4-,CN( SQ^G?L_P#[0WP._:*TOQ7J_P $_B7X=^)EAX/U
M]?"OB6[T%[^5M$UJ*T2\BTS4Y=1M;6>2\DL;B&[26,2VMQ:2V]S:RR6\T3M^
M.FI?\$P?CMX*\/>(_%]Q\9O 7Q0UBTTOPX-7\+>'?V?= M/$WQ"M?AY\#[CX
M,Z/H%O-K'B&V2[FO],>'59]!N]3@T+5+^ 64;6<4BSP_:G_!*_X;_$3X9_ [
MQ+I7Q!\+>(]#OM0\717T6L_$'P.W@'XG>++Z'1+#3=7U'QII#^+/&LES%I\U
MC;Z1X:U :]+ VAV=O96EM;VME$TJY(O5Q3;W=EK_ %WN7WO9M[NUK_(_39P!
M@ >_\L?RJ,J#V'KZ<^^*LT5E*C";:G!./1)]/^'^X++>VO?^O\SD/$'A_0?$
M,;:?KFE:7JMK- Z/;:EI\5XKH[!2/-G0QQH<\JLD<V0'3D UY)-\*;SPE,;G
MX7^*KWP>P 8^&KZ2XUSP+=*HW-;'1[EVNM,CG8!3=:'=PZG$6_=L+<,E?0[*
M".@/< @8SZX/&??%12E 5R%8 X52H.)#]U@V#MP,C(P1U)KCG@Z49N<8NCKI
M).Z6RZ-;]B)0IR;<DF^KO9[66OZ;/L>3^!O'USK%]?\ A;Q3I!\,^.-,A%U-
MH\D_VFQU6P!V+K7AZ_VQMJ&E,<+*LD0NK"61;6\>68[J]9@/WL[B3M8MDE22
M#D+Z;<8/J>:\ ^(\\>H_$OX3:7HAB?Q;I>MWVM:E<V[ G1_!'V.2SU\W@(SY
M6KR26NFVP<E$NCYBIYJ!J]SM"VPHY8M'A&# ## MR,<'<NTG'3CU-3AU*=:<
M%+FA!I*K;XNNRVM>WR^0XVNH15DM/+I_G\MB[/\ </\ NO\ RKP/X>?\E:^.
MG_80\!_^HY>5[NQ.)/9>/R->$_#O_DK?QS_["/@+_P!1V[JJW^\TKN_O2_)&
M6)5G27F_QN>^1=7^H_D*EJ*+J_U'\A4M>H]_DOR1T/?Y+\D%%%%(04444 %%
M%% $4G\/N3_*H9?]4_U3^=32]4^I_D:AE_U3_5/YUA6_A5?1_P#I)*^&OZ+\
MF>-?!\ ZG\8O?XO:T/P_X1KPE_+^M>Q31K(0Q8J8RS*<D F1)(\'G_:R <].
M.<5Y!\'?^0E\8_\ LKVM#_RV?"9_I7MF!Z#GKQUK# 4X*A&35W/FOT^U)>?0
MQHQ<J$5>VL[?^!S7R/G_ ,=Z)XET#Q%9_$#P99'7;Y--71_%?A43"UGU_2+4
M23I>Z'<NR0P^)].9BMD+UEL[RTGN;5W25XV/;>!O'OA[QM9F;0M36:^A 75=
M$OH7L=8T>ZPRR6.JZ7+BZTZ\C"$/%*IAE(::TDDA?</0YMA(4IN)!8\#H",Y
M/U(QP><<5Y?XQ^%_A+QA=6NIWMO>Z9K5O.MS8Z[X>U.Z\/:]!=QLH5?[1TOR
MKF>%PJ^;%=&:V<(BRQE>*4Z$Z,G7II2BVGR7LU:_9O=WZ!"G*$I->]K?6ZNG
M>]M'_EU/3;5U<.Z%1&S#"AMQ##.\DYQR>G?@Y]!3UK0-!\26+Z9XBT72-?TU
MY(Y7T_6M.L]5L7EA;?%*]I?0SV[21/\ -&YC+(WS*0>:\47P_P#&/PWYRZ/X
MRT?QC8@[HK/Q;I9L-3+.0K)+KWA^2!)O)X!F?3C,W!E+ DF0>/\ XB:,S)XE
M^$>NW26Z#-]X-UK3O$:7&=Q9K>PO6T:[V*=N5GN&?GY2=I%)8YI7JTI4UK=M
MW2MIT7;74MU)7:4&[>>GWV/5;3P/X*L+/3=.L/!_A:RT_1K]M4TBPM/#^DVU
MGI6I/N+:AIMK#9I!8WS%V+7=JD-P=S$R')SX-\?_ -ESX>?&WPTFD2SW_P -
M=:A\1V?BZW\?_#>WT'0O&-CJ]B[-<WD^H7.E7<>IVVH6DEQ8:G;:A!=)<QW*
MRLIG@A=.HM_CSX+3 U>#QCX<N3CS+/6_!'BB.6(C(.^>PL-3TU54]6%](,D$
M<*2=#_A=_P *93F;QSHD/'*WX>SD4,,D,MS!;L@'\6]>"/FQQFOK])ZQU71O
M3U!58?:DHOJKWMZ;7_S\AWPK^"O@'X;^#M$\*:;HEEK*Z1H=QHC^)-?TS2+S
MQ#KMEJEY=ZIJ_P#:]VFFVKLFL:A?76I7^G"&*P\^]D5+95&*[Q_ 7@:070D\
M&>$Y!?65CIMZ'\.Z.PO-.TR2.33;"Z#69^T66G21126-K-O@M'BC>WCC9%(X
ME/C?\(F/R_$OP;NQRK>)]/CD)R<?NFF#,<#I@XR <]:;+\;?A<C*8_'OAZX0
MYREK>&[<XQ@*EH9))"3G&V.0\@ =B_KM/M_Y,BO:TO\ GXOZ^9WE[X)\&ZC<
MWE[?^$O#%[>:AID>BWUW>:!I5U<WNC0LKQ:3>3SVCRW.F1.JM'83.]JC*K+$
M"!C?M+.TT^UM[&PM;:QLK2&.WM;2T@BMK6VMX4$<4$%O"J10PQ1JJ1QQHJ(B
MA5   KP^X^/'@;$G]GS^(]:<?\LM#\'^*+J4D_<$<MSHUC:-YF3M(N9%.T[F
M7C,)^)?B_5/(;PW\)/%]RL\B*;OQ-<Z/X1BP<^7(A>?Q!+*A4-YADL[-XQL4
M+*')CI8VC+1.\^L4[V^?_ (=5WTBY1Z277OLFOT1[T_;L><C.?0?TKC?&7B[
M0/!FG?VOXDUJQT/35#HUU=,SSRRDILMM.L84DN]1OI&V^3;64-U<,<!+=B=Z
M>92Z;\;_ !'(?MGB'PK\/K$RL N@V<WBWQ"(RZN8Y+O6@/#<$@V@+<KHOF+E
MS"T8SNWO#GPG\)Z+J4>NWW]H^*O$L)60^(?%NH7?B&_AE((\S3HYV-AI[-R5
M2P@C$&$5 @7%<[J3Q%5PY.1:6DW=?+]0NY-/EWZ.^G3[].MMCD-"B\0?$7Q-
MI7C37='U'P]X2\.22WWA'PYJSHNN:O?7<?V"+Q1KVGQM+;Z=!;6-Q-+IEE+*
M^JPM<R2ZAL>*WBC^@[!8S'(4!"EBF V^-A'NB5XVR00\:(3@XR!T.29[8(RL
MRQ,BN2V)5"NS.29&*$94,<=>N.G%6@     !T & /H.U=%'!PI.;D^>4]Y;;
M^6NRT'&%I.=[-[JW3UT[:=CRKXVKCX1?$SG_ )D?Q+C\=+N<?RKK/"/_ "+'
MA_\ [ NE?^F^VKEOC?\ \DA^)7_8D>)?_35<5U/A'_D6/#__ &!=*_\ 3?;5
MYKA&&,G&.RM;YZFS>WDOU9Q_QQ_Y)'\4!Z_#_P 6<>O_ !)+S^F:[CP__P @
M?2?^P7I__I'!7"_',9^$?Q0/;_A7WB[C_N!7G^(_7K7=^'QC1M+]]-T[_P!(
M;<_UKJE&=3%:P<8PEI*][VZV.>+Y:E3S:-U ,9QSGK^ I'ZCZ?S/_P!84RBN
MZI#G5K=M;_H;VGNHW71W2()[2"Y1XYX8YHI5*2Q31B6.1",[9(Y 492"?E8$
M>PK(_P"$3\-#'_%/Z$/IH]@/Y6WL>O3\#G>HJ(T())."?=W7SW7ZLATFVVZ=
MV][R1@'PCX8/70-#_P#!/8'COUM?3=^7UH_X1'PQ_P! #0__  3:?^/_ "Z^
MS?E]:WZ*?L8?RK[_ /[4/9?].E]Z,#_A$?#'_0 T/_P3:?\ C_RZ^S?E]:/^
M$1\,?] #0_\ P3:?^/\ RZ^S?E]:WZ*GV*_E?WQ_R#V7_3I?>C!7PGX85E8:
M#H8=3E6&CZ>&4Y0G:1:@CYE!XQRJYY (4>%/# &T:#H@7.<#2+ #.<YQ]FQG
M))SUSSW-;M%6J5-+^&I>=U^L1^R7_/K_ ,F7^1B1>%O#T,B3P:'HL4D3;XY(
MM*L8I8Y.N^.1+=65LX.X8;WZ8V0H'3/XTZBLGA*2DYQ@HS;OS7TOZ6]/\P<*
MEK*-EVNOS)$'4XYZ9_4C^5// .![X&.:@HY['!_S]*UA3<;W2;]7;\BE&:27
M*]/-?YCF.<'U']36#XBYT76O^P/?_I:W!K<K \2#_B2:YC_H#7YZX'_'K=$Y
M_P#U'VHK*/L*GM)*FFFU>VMD_P W]YG6C4Y7RPYK)Z7UV\KHX7X ?\D;^'7_
M &*VF?\ HHU[#7CG[/W_ "1CX<>_A;3?_1;#^E>QUG@[+#4N5\RY79VM?5]Q
MPNH1YE9\JNNV@4445U%A1110!X;^T3_R2?Q7_O>'/_4KT*O8++/V:$_],HQ^
M2C_ZU>/_ +1/_))_%?\ O>'/_4KT*O8++_CUA_ZYI_Z M>0H<V,J*]KR3_!(
MQ3_??]NLF=0Q&_ 4 D%MNW><CDGH<$_@>N":\&U?X;ZUX:U&]\1?"_6;?0;S
M49&N=8\*ZE%+=^%-<N0&_P!)>*UEM]0T6_,"B%-1T2:*0*J?;;:^@7R#] H
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M)'0]_DOR04444A!1110 4444 12?P^Y/\JAE_P!4_P!4_G4TO5/J?Y&H9?\
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M<6W8.-O&:'7A_P! [=_.&WR0.RWI.SVU6WR7W'MZP)& J@*H&  "J@#V ';
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MD_X7]IG_ $(?Q4[?\R#?>W_3]]?R[XY^AL#T'Y"C ]!^0H^JXG_H*7_@M_\
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M5;Z)-H7A7]HBW;5X(YK[1;?P;8W+W7P]T_4K6233AE7?[._[7LNH>+_'VO\
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M:??:-X\\0Q:3XCUMM7^)'P9U/3-:U.3Q;HVHZOX@TKPWXBTO0-+\:/'IL;*
M?OI/]P_[K_RKP/X><?%KXZ8_Z"'@/_U'+RO7- TI-$TBUTJ"[U2\M=-L+'3+
M>;6;ZXU34Y8].L(;..ZU#5+T-J&HZC>010S:C>7T]S<7-Z9IY9GFDF=_(_AY
M_P E:^.G_80\!_\ J.7E>96_WFE_BE^2.?$_\NOG_P"W'OL75_J/Y"I:BBZO
M]1_(5+7J/?Y+\D=+W^2_)!1112$%%%% !1110!%)_#[D_P JAE_U3_5/YU-+
MU3ZG^1J&7_5/]4_G6%;^%5]'_P"DDKX:_HOR9X[\'?\ D)?&/U_X6]K7Y?\
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M79^$?^18\/\ _8%TK_TWVU<TI<V,G*UK\NAH=51117N %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X9^T7_P DC\6?[_AK
M_P!2O0J]BL_^/:#VCC(]CY:\CT/O7CW[1?\ R27Q3Z;O#?\ ZEVA5[';D>5&
M.XCC_P#1:?XUY2J*./G4:LH1=/??FUYNO?;R1FURRD]7>SM\[_+2.I;C  .
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ME/EC>UFG?T=W==_\SM_C'O\ ^%/_ !,W$9_X0?Q)N4=4=M,O)"#D==DD>.N
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MCC_A,O"_4=#U_+'3)]L?0'EI_=%'EI_=%']G3_Y_O_P$5L1_S^7_ ( _\SP
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M_P#%4?\ "ROBG_T0K6/_  LO"W_Q5?0.!Z#\A1@>@_(4?4,3_P!!C_\  /\
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M!?\ X4VD>_\ M_3_ ">-OK>&4;*LO_ 4WOTU+5:@E;F7JK)[W/4$&,\@]/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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F54!"A%  4 '& ,   =***NG1ITY-P@HNRU7S-$E%))62V71'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ &8# 2(  A$! Q$!_\0
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MZN,>19!B\WP>7N4<5CHU%1H^YS<WLWR2<](RDK7;2YE&S3?^@^"".#GWX/\
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KS;D_1P^"H86DJ-&+4%.I.TZE6I+FJSE4FW.I4E+6<I-*_+%/EBHQ22__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U 5L# 2(  A$! Q$!_\0
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MU3_KUE_]!->9B'!XB\-M/T/6PRFL-:>]G]VMCA_@Y_R!]2_Z^%_]!KO-:_Y
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M&!#+$H(/8[C7K]>5?"\Y\5>(#ZG_ -G->JDX&37-CG>N_E^1U9<K8=+S?YG
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MQO/'.G6H8(9H(X]Q&<9=AFO9J\9^*<LL'CG3I8%WS)!&R+C.6#M@8^M;Y?\
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M2GN8YKC+JL3* $[=0>O7\:VF^$&AE2%N[X-C@EE.#_WS7H*(J(J(H55&  ,
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M.ZE-5%.$;)6.I4JCI2A4E=N^MCQ;PC\1H/#6@IITFG2SLLC/O60*.?;%;O\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex4-11_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-11_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Q #T# 2(  A$! Q$!_\0
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DT?6G=C112 3UH'3\***8Q!TI/^6X_P!TT44"%CZ4TT44 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex4-11_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-11_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  C $<# 2(  A$! Q$!_\0
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MC>WMMI5]-J^N!,6Q/3:,?A1JRDKIL]CHKAK;Q]<2^,K;PW+I;)<FU-S=/O\
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3R;D<)R#ZT44C%MW.DHHHH)/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex4-11_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-11_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "R 9(# 2(  A$! Q$!_\0
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M2OV0@+)7]KUK_K9?\^E?)8FWO6VYG^2/IZL8IU$E?9W?9K32SVWO?Y=M,
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M'?Q0T$Z@/C=_:WE?VWX>AL#/L_X4Y9>;Y7V@2&,W=IYA0K]I@SYJ?D?\/?\
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M/V8D\_*<XK^Z_P"!7P1N/@/X:G\,#7IO%RWGB!O$,FJ_V0=#6U6YL=!TYXS
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M>\TR[ETUKJQC%Z;+4K"9K431P7]K/BXC^F8W75_/-V&$=M(8X_);9"<')#$
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MY/.(1_EW5-XJ\)^&-3FO;?PWJC:WJ(U6[GGTS2]4TG4+J*V6W+27=S+%'-(
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MD27)Q&R-AA_G+^/?VO/BO\8?#_B+5_B[X;\&>!M9C\-ZSX=ALK?2?$?AU/\
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MTV3;%&<0_M)_&#*C V[2B@ERV03P"!D^%FZ;I)J[M/6W9IIMZ/1:7]=]3Z[
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MPAOG?M(,/"Z:+IL8BNQ^SE^T/XH%P=971A<3[WM=[@7B%F9T#HIVK^ 'Q?\
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M^[\)>)_C!K^LS:?X;TWX4Z3I>H:_<:!INFI:W=W=V%NUW]G,U_!&QE@^-/\
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MZ>'=AL/L6P,;)E# $QL0$/\ 2)^Q?_P3E/[(?B/7K\_&5?B,?%NK>!KHQ+X
M_P"$-&FGP9J^H:@8Q#_PFWBL_P#$P_M'R_FE!&[.WBM'BZ3A)4KZ*[OUWMJ[
MZ.UNFMSS*E+VDKVVT^]M]F?YVGPX^%*ZYKWAW1=$M_#6FZUK'B/1M+TC46BG
MM5L-3O\ 4;:UT^^-U; W-L+2[FBG,UN#/"(_,B!D4 _I?\/O^"*W[<W[1MYI
M>J>#OC5\$M,T237=-\'ZEI7BGXE?&FTBNM7:^AO-0:YMM*^%?B:QEADL->(F
MCGO(X'C+++*D;,R_Z1\@S&XSC*,,^F5(S^'6LEK+S%9OM&, \],<?>Z=L?I7
MC5ZCJ23>EDU][O\ ,UH4_9J2[M/[E;LC^3[]C_\ X-^/BK\+]-LX_CQ9?L=?
M$RXA^)%OXHN9VMM:\80W?@Y[30$GTAK?Q9\&H(KSSYX-?ADMKQH;.Y298IIQ
M&\QC_;?X9_\ !-+]D/P)JWARYN_V1OV1/MFE/JZ?:]+^!/PT69FO;8G=$6^'
MMMAUW;QF:)C@J&R0#]]W-X-)NX;0Q_:=Z>9VR<$''0_J#VZ\5N/-Y]@)2AA$
MF $*[SR2,!0/GW=-N.<8J(WLUT;M?32Z>OX&YX'I_P"RK^S3HM];W6C?L[?
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M"$AN&Y(PP2&9L'Y8I#\C?YJ'_!?G_@IR/CQX0^"OA'_A2G_",?;_  _^T7H
MU4?$C_A(/./C+3_AUX?_ +=^RGP!9?91;8-U_8WVRU$Q0V_VB#<)$[8RE)IV
MLK.^M[JZ^[WD8SULO\]-=?P_(_,7_@H9^WI^S1\??BGI&N_#'X;>./">CK\+
M[+PA=:5K7@GP+HI?6E\1^.KVYNIK30?B!)9R0R:9K^C#R78^9Y<D<B*C(9/-
MO^"?/P#U']H_]L7]D>]\,0^$[3X=7O[6OP'\$^+O!WB^".WTKQ$\WQ0\)S^(
M=.U70K;2O&.D:MINI>'=?TRRO],U$S:??VT\UG>(]O+(A^)?V8_A9_PL/XK_
M  JT?_A(3I0UWXP^"M ^U_V4;[[*=6\1:5IYN?L?V[31=^1]H,OV47]AY^WR
MS>VV_P"T1_Z0W_!(#X;G]DS]G#QG:C6/^%A'2_CMXD^(PE.F_P#"*"<6'P_^
M% &GEQ?^,3;BX_X1P0&8--Y._>(Y"H4XXG9>C_-&N'<>9I=+7>NN]G9ZK3H?
MO)^RS^S9X-_98^&NO^"?"G@;X9^!=/U#Q9J'BZ:P^$WAO3O#NA/(^C:-8F:2
MUTK0_#EM_:&[1>K66&81]0N*^EK3[5>)%<1W$QB8H8Q=;=Y^88X[$XQ[G'L1
M^5]]_P %)C-\1_!?A%O@ML/B&_\ #>E?;E^(7G?8QJFNVMD+D0MX!MA,;?S_
M #"AN[5)-NWSH WF)^F'@3QJ/&&CZ3J_]F'3QJJW+K&TZW6W[(VT$RJ% R0N
M,@_-Q]XY'E1_B?=^<F>O[+GP[=E97NW;1VOUWNELNMCJ;^"9K)T5R[YQ*%#Y
M<'Y6C'EC?EE.!L!8'D<@5Q6J_#OP=XGL!#XM\)>$_%%Q=X>ZFUWP]H6J?;Y(
M,FTDD.L6EXW_ !+\1$F2UN=BQ?+#(&97TG _X39@1N!>+*\<_P#$BG&.>.1Q
MS7Q+_P %-/VBU_9L_8_^,_Q4'@\>-CX-E^'$']CGQ*F@-J(UWXE^!M >078M
MKIK,63>)4D:X%M<F%HA,T$ZQB(^A!MI15[M7T[:+OM?_ (";V\9X:\YV5_>[
M>7IUO?0_GS_X.)?B]^QY\"/V:?#)B_9YTJPUVS_:]T[PAJ>K^$/@_P##K3[_
M %"[L_ 7QHW*-2AOO#MS=Z3-+HI5A';3S/"^$5V)S_*;_P $]?\ @FW\4OV^
M_P!I7XE0_#+6OA%I7AOQ%X"\5_&?PUI'Q/O?$&G:=IWA+4_'/A!M!M#I.B>"
M_%EO9ZI'HWC/3HX@TCQK)RS87#<?^SC^SI_P]H_X**?M>^#CXU_X9T-[K/Q]
M_:*%^WA1OC$VG_:_C-X9T7_A"AH?]I^#DD73!X]$XU,&)E.A>83&H#U_J2_L
M+?LXG]G7]F_]F[P"/%W_  E+_#S]G3X2_"UM0_L9M$74T\(^#/#5DNIBV;5_
M$)TXRKI9D&F)=HB,?+,Q W'5R45J_);ZOMUM_GYFM.G[--6M=W_"W9?UN?P3
M_M/?\$!OVD/@7X"TKQ-J7B#]E>5;WQ19>&(XO">K>,WNI#<67B+5PDRK\&+=
MFWGPYM*B> MD@31D^8O\_D_QW^-WPB,1^$GQF^+'PK.L3!]=F^&WC_QGX M=
M?M]&BO+?PO=:O/X7OO"]U?&PMM4N'TN+6K5[20HBW<;0F13_ +2&IP'78FTW
M=]C^S2I<;S']H$OE'=M,)QYJGC,>1Y@)3@&OY2O^"H/_  0/_P"&D?\ A1N/
MVJ_^$-'@F+XG0J#\$D\3/?C7CX*N!;,4^*OAY2MHNDC81:3F094VY(,;9SA[
M5QNO>2:2OS:-W6MGTZ7+]K[+K:^M[V\NZ/Q9_P""5?\ P<0Q?!D_'A?VIOB+
M^W%\<7\1)\,(OAU_:'C";XGR^$8-(N?'+^+UL5^)GQQT"UL;*ZN]7\/6C7&E
M:;=7"6^AGR;6X8+ _P#H-> /BEHGQ634F\)6^M:9+I$VF7%ZNIII]O&L>I1W
M\-LMO_8^I:_!+<1&WVWZM+!&50EFB!)7_&Q_:<_9W/[%R^#XQXO7XDM\28O$
M2?:ET0^%_P"PE\'WND7Y<Q?VYX@36S<_\)7Y&X:A;MI<FC?Z]&57C_1+_@C+
M^W.?V0?VF?!>AK\+!\0C\;?CI^S=HBW+>.?^$*'A%M"^)6NVP<K_ ,(9XI.K
M"7_A)]QLQ=(;H#R1(H<$8U*?LVE:UTV]+;.W9&E.?M$WY_?I?NS_ %GK&VN(
M[=XKV47#LS9)'&TC&/QY]/7O5/6I(=-T75KI8G5+73;ZX<P+F7;!:32-Y2F.
M7?+M4^6OE2;F 'EN"%/@?[//QND_:-^'NN^+!X97P8+/Q+J7A0Z<=7.OES!H
M>CW\EW]H.D>'25QKBLB-9R%2C'YRVU>9_:_OA\-/V*/VN?$_V<:S_P (M^S/
M\>_%7V#>=,%^="^%7BO5/L1OQ9ZB+,W7V40"[_L^_%KO$XLKK9Y$BA\2U[::
MZZ_=]XJWP_?^A_#7_P '2O[:>N^ ?VGM*^!FB>//C)X<T7XG_L)Z7::CX:\-
M>))--\ ZVOB_XB?M ^$+B#Q/ID?B/2A>V5Q;V'V?4[>72+U9[%I8#97*$P-_
M+?\ \$\?@J_QN_:D^$/@.YM/"^KV'B;_ (6"DFD^)XUGT:=]*^&/C?Q$IUF*
M2.:*;4&%D%TB.2&97D$2M&ZLR/UO_!3'XRI^T)\>_!_C5O#1\'MIGPCT#PV-
M)_MI==$QL_&/CC4Q-]K.E>%MH9M:)<FT 50&4DD[/ZT/^#;?]D)-:\'?L:_'
ME/B"T"W)_:+7_A%F\&JS0F#7/CSX/>X&LC6Y!=?/IYDC3[/)P1&XEPS-[M)V
MHR;T2;=[=+1UTU?Y_KYE6K&G%*+M)OWM=;WDEV6WG?MUM_2'_P $DOV1?"OP
M4_9<_9^FC\%?"+3M7\-'XIPG4_!NA:5;^7%J7Q/^)UP(=#FAT&VDAR=:QJ+K
M/$6Q( ^<BOU^FUNQM;H:?Y-PI0^:6A7,0",&.XY&(\ ENHP"2#S61HEC_P (
MOH-I8";[<M@&42>2MGG<7<_N@6'R[SA=V6!&,8&-Q]4SHYU#R0#G&WT&[;G/
MT]^?6O*KOFG=JZ<K*SMI=V??ON;X.I[3F\I+OU3?5LDNY$$"W,)*B7&&7KM<
M8!'^T,\9R,],4EAJ$-W<&!(9XY(ERTK* '"[>"1DE6(SS@DXZ&JLFH![..3R
M<&08SD87<,9&,=.HXQC !'6MN$A5C?L8UXQSD@$>O/\ ^JL962L]6KV_KT/8
ME;V:]=/N1!%-YEQ/$<83KGIUQSGC '7.>_3I61K<$3R6+"*$LHE93M&<A0RA
M0  <D<''7..13[ZY^U#RO)(VS*,Y/&&Z]1SW)P/0XKH7(12,9X1=H_BW,1C\
M1G.?7O0W9Q?]VUK^GR//^U+U5OQN9T=^JHBF#E44'Y@.0 .A4D?0DXHIQN""
M1]F7@D?=7M]113Y5V_$9/#PI/^>IJ..Z5Y'CQRF>G4X_Q]\?A5.QNIIF?S+&
M>WBP2LY(PX[$\G (]@ ,=ZMJ(878^=S)T!.><]>,Y/\ 3VJXV=]&WTLGOUV7
M0RJ;KT_421$N\*<@(V>0.=I'?G&>#CMGD9R*6*$6X=L_*%)SUQC))[_X\>Y%
M95YK(M2Z7,*PQL&6*::01P.S A1+(R2+'&2<.YCE"+ERC!<'^%[]M[_@Z)\,
MIX>\-^'?#/[)FC^/+[QOH'C/0YFT#]J/2VU.QO[W3]!TR&X.FP? 3Q-+!<7S
MWY:'0HKI)KIA]FC<.^ZAIJUU;336_KKIU^[8@_N5\2Z[_9%G?M]C-WY&FWEZ
M5W^7O^SV\DI7S/*FV9*X\P0R[<Y$;D;#^??QT_;Z/P'M-:N!\*SXM_LKP=J/
MC??_ ,)XNB+.MH?$D2Z>\S>$+YK<2MX=,/GI:W'DK*9/LUP5"-_FR_'#_@J5
MX@_:+TW7_#VJ?LOZ_P##67Q9X&U/X:)<7_Q&U/6?[/M=8MKJ%]:EM3\,/!<,
MPL5\3&\:W>ZM8YEA"FZ@CD$R_'7P]^ <OC2T_M"#Q6UM,NOO90VJ:"NH//+(
MBQQPJ[Z_,FZ1V5 9(95RPW1.N5.M%4.;][OM'6VG7\3GK4J]1Q='9)J7JW=?
M@?VE_MG_ /!P,=6T+QKX)?\ 9,%O_P )9\'->T4:D/CX9QIXUJW\5Z;]L^R_
M\*5'VHVIG^T>2&7S0GE''6OXG_VFO'2_M$_$CQIXL_LO_A#?^$Q7PIG3/MO_
M  D)TD:-H6CVY4S?V7X4&;TZ%D'R.">V>/J#PS^QS\:KB[L(/!/@3XH?$!9]
M3LX;>;PS\+O$NJM-?RW,:V]A - CFCDDGG*01H(9=[NH$4GW3]J?#W_@ES^V
M3\21H]CJW[./[3O@31M6CN[R36-8_9I^)6HV.E-8 LT,3G0;<8O@AR6G@'S<
MS1CYU]O#8[!X-*G_ #M2W[>[O\_ZL<-;#8U3@[ZI73WU3OL]'Z/0_$/X>_!4
MZ9+I>H#Q1DQ+=Q;/[''(N@5*_+KTJ\EATMWR",12=#]@^!/AK]C32O&G]L";
M?%>WO]F_V3MR+Q6L/M&[^'!.[?VZGI7[_P#P2_X-E_B3XTU?POX[\2_'WQK\
M/M1U"3Q%;7WA37?V5]1^T:)+H*>(=!L[I1K7Q4\,W!:[?3%NQLLY7/\ ;ORQ
M.WRG]9O@W_P;:S>")/"VMW'[8,\DVE3>(;>73)OV>%TQG%^=;0S!_P#A=,WE
MR;;A9(V,$JX&XJR\5W8G-Z,X0]ELHM/U;NM.NGD_/4XYTZT:R]K9SDG+3_$[
M^2UVU]$?R&Z?X3^R7*ZI_:'F_:T&(OLNWR-V!NWX^79][=CC\FKQ/XRZ./&^
MBQ>%S+_8W]C^([>?^T<G][_9%AXDTS</W]H?^7C/_'W:\_\ +Q ,2K_HG-_P
M1IBDT73-(/[1S?\ $LM[&W^TK\(]KR#3M*N-'&&7XFPE69+@G<LT;(0"KJ1N
M'YS?MA?\$&].TCP7#X@U/]L.RL(=:^("%([SX'BV6W;5--\1ZH<WO_"ZMU_L
M^SE_+V$3@,A7/RGY[%8GV[N]XW2_[>U_X/0]7#:63WNOR_KN?Q _L\?'P_L-
M_$?Q%\2#X+_X6A_:?AO7/A2?#7]M?\(5G?XA\*:\=0_M#^QO&XN0/^$?WX\N
M[Y&?(GXC?_3!_89_X*NG]K.?XH@_ AO 7_"!3>$?F3XICQD^N'Q7+XD07*V/
M_"$>%!:BR7P\=P\@$J, Q\FO\J[]LCX?:1\*OCU\=O 5CXSLO$:>"?CU\5O!
M/]KV=N-*_M#_ (1[QEXDT9KQ=+;5_$JV&YM-\Q7:[C$.1F8;=P_4K_@@9X'\
M?^*9?VK!X.^'_B_Q@-/E^!SZO+X3T+6-8?1HY(OC((&O;G32UE9V]UDB2XOB
M;18R9),0I(M>%759N3I/5)>[9OF;D[ZIZ65WLSV:?P_UV1_K023KFW 7!F<0
M'CF#;:F]$)_W@F,]0-H^E^=!/9S6^_89H)(]W]SS$*[_ /@.<_A6*UW%;1PM
M"AN2J+;MY<\=L'FA#1WD=P!NVW5JL3-Y/+ABR H1N$XNK.Q\F.XGMK::]D7[
M+:RW>99IY6 BBC4[=S2R,JJHSEFP,D #*'UNSO;?3?HC073-+&GV<MIYOFB5
MF82$%2"<X.,<'H?09P>!4-Q8^2&F\PMY0:39QEC&-Q7O][&WWR3Z5))9K=W,
M%_(3"]M+'MBYR[(X.TGON/ STS@U<N9 ZLABV;U9-Y_A#+@MWX7.>G.,XK>G
M2JU+NJDY+16[6N][O>QE4W7I^I1L;_S"D?DD;F53Z_,0O('3KSP >O7BGZWH
MO]L6=S:?:6M_M+PL6"AL>3C!P2">G(! .T9(!S5RSC\I57SMP.TD=SR ./Y^
M@.<5IUHJ:IW25KZO2WEV5_Q(.,TGPN-+MK2T-YY_V59UW?90#^_!&00>,$@[
ML8'7CK71Q6/E @3-TX./U)]O\^\5VGVL^2#MP>#Z9[_Y/Y"LQ-)VR%O/Z?-_
MWR<CZ< ].U:PO9V=M>UP'WNFA(=_FEM\J@H<[6W-T_'@'Z\X/%1:?J'DN;<P
M_=Q]>#_/KS[?A5N>RW")?M!7+*N>.,D=/IU'0<=!3K=?LC. GGD'.\$ ^H.,
M')XY/X>];1_ASB_>;LTK6TV;O?\ X(#[2P\FXGO?M#2?:<XB(PL9)#8'/.!Q
MC'N>:YKPE"84OR, S0Z:%)!/S>1, 6 9"1DC@,IP#\RYR.EM+> 3SSQ7!EDF
MSOBR,1$]?]KJ,8&.<<<5-,@13(=V54O\BN[_ "C)V)&DCL_& J1R,YP%1FP#
MS1_B/Y+YV??7[R*GPQ]9?H?E%_P4+_;>;]EI/@]*?AA_PG2>-X?'\HMV\6#P
M])HC>&K;P1;L6A'A#Q*KI=KXD18XENH-HW$W'[P-%_D&:7XE3Q9XDT+7?L4E
MBO@G7M/ODM&O1JLFH>?JO]JI:O=F71A"EL-(\L21V5T0 )&@D 6-_P"YC_@Y
MKT[XT^.O^&)3H?P ^*&H#0[;]HZVU!]&\*:YJEK96LT_P#6WNI6B\-B1HKY-
MS,$&\KN"$L./XN_A/\//C7-K,FBV_P #_BA-JVK:QHVG:;I-OX*\9_VEJ-_?
M2S6MGI^GZ9#X=:2_O;NXEBM[6Q3$MU/)';H,R*Q].E;D27];/]3"5U=I:I*S
MO:UW9Z=;JZ\MS] /V:?B+]O\8^!M>_LG9_9GQ/\ #=UY'V[;YOV;5]/F\O?P
M%W^7MST&>V>?N?\ :^T#_A>^C^+-6\\>%L_![6O"'V<VW]J;3L\5W@N]JRP>
M9Y7]O>9M\Z'=M \U-V\>J_\ !-__ ()W_M0_&#3]!L?%OP2^/WPGM-:^.NF^
M&M0UK7O@+\06T[P[I.KV/PWTZ_\ %&HK?:;HUFUCHEI<2ZG>+=:QI5LUO;2"
M?4K"+=<Q?U$^&O\ @A(=,\$>)O#M]^U(B#5AK=F9[KX)/;F+[9I<MN)/L@^-
MRB?9YQ<P&:$2!"A>-29!CB*:J.*;:LKZ7O=NRVN^G9[>9="K[.,E?1M/?LK=
MU^I_FEK^R[_PKR)_'/\ PG@U<>"4?Q:-(_X1H6']J?\ ".*=9_LT7W]N7IL_
MMWV/[*+LV=W]G,GG&VGV>4_^@;_P;@?M*MXO_9F_8U\")X.%H;Y?VBHCJS:Z
M;KREA^)7QQ\321"W&A6WG$I:.$C%Q%O8J"X&=W\UO_!=G_@F\W['WQUTWP];
M_&27XG0Q_LP6_P 0)=5M/A^WA,*EOXN^,,+Z5YJ>-/&#VWGIX?, F#.T.\2*
MC%0KZW_!$;_@HI\-_P!DSQ/^S'KWC]/!%O;>!+CXY2:H?$WQ=\,> H_.\7VW
MQBAM3);ZQX<N&T&)&\0 ML$C:LHYC#MY8YJV E0BJK;?/'G5TE97MV3\[M7U
MML=]#$\T9P3OS25[>EN[].GX6/\ 2I^._P :&^"7PW\5^/CX;/BIO"Z:%)_9
MBZM#I#ZJ-2\4V7AJ0B=K>Y%N;:2Z\QIS;W C*;O+<)L/^;3_ ,%HOVLQ^V3^
MWU^TI^S0? (\ )\1Y/@Y(/'$OBI_$J:2?!?P7^''C'^T!X4BT.R:5=:_X1A=
M)6[6ZMRJE"TR AJ^KO\ @JW_ ,%9G_X*)Z9\=_V0?@+\"(O'&L_%Y/A;%X:\
M6_!_XJQ_&_4=7N/ $WP]^*NNPZ%X/\)_#:2?Q?I]A:^"M;&JSV:M/9HDHMX@
MY2(?4G_!O=_P1D^)_P *_C%^R/\ M\_$/Q5X]\ :MH,_Q\FU;X%>-/@-XF\*
M:MI<?B#PY\;?A'!;Z_XPUWQ;%+;O>6FKZ+X_TRS_ .$/M &U&,-&O0>?1Q5Z
MEOY6U;T\^NG0WEA6H.3Z^]^%OZW]-;'[U?\ !&;_ ()^2_LL?!C]FWXR2?%=
M_'!\9?L:?!_PJ_AH> )/#ITI=<\%_#KQ4UQ)JS_$'Q!'<R:4_AQ='1%T"Q>9
M;J1BR$.H_;NWTL65W=:AY[3?:@1Y 7=MW'( &?FQT(_"K\#-$ L*^>I(&\]L
MDC.>2 .#@>O&3PM74-/6]M@)KEK<O(H!&W@[N% )&2>HYXX;H#7HJISSBV[>
MZDW;=7=E9:Z:[?J>?*G[-37=W_!>;.&TW15T7Q%J>NBY,@U Z@4B-J08/[2U
M"'4PS'@M@0G@YRPZ#BND_P"$;3+N9U8'S&*FU0;C.#N7++( 1T/[N0+GYHVQ
MMI\.IV\3-;[1BW/EF\8[5;'!8OV ');L 2.AJ^]W8S*,WEL0>I-TC*5(YW*[
M%77U5AM;HPP373/F7*U'ETMS;\RC:SM;1+;KOL<'M?9MJ^[OOVNNZ/R%_P""
ML'[!K?MQR? %S\4_^%9Q_"\?%.9/^*)7QD?$A\91?#V-@&7Q3X?71DLE\.+(
M-0-G?O;M)).;61((XY?\BW4O!Z?"+Q+X)\3MJ,OB06.OV_B!;$Z<FC[E\/W^
M@:O%"T[:AJGD#55GC@2==/O3 K%A973%(A_N2>)]6\.:9'8KX@\3:)HS3"6.
MU76=3TO2UN8Y%\LK9L[1MYC A(VA<NK ; 7 %?XK_P"W'\2;+XF)\+Y+""PA
M.C?\)O->3Z?J?VV"[&OS>$)K:Y>;^%&%NA/M\W8"G*WU*LM=)Q6FUG%KM9_\
M#H;X7$_[3!-[Q;\[IWM>[W/[(/\ @V]_X*4C3O@[:?"+_A2YO!\1/VUK;3#X
MF_X6$JMH_P#PF/AOX+>$C<C3/^$!M/M_V/[%YXLS>V8NA'Y7VBV\S>O]BO[8
M.G_\+$_8P_:T\.BX_LC_ (27]FOX[^&?MQM?MYLO[:^%WBK3?M?V'[;IOVW[
M/]I,OV4ZC8?:-GD_;+7S//B_R8O^"-ECXB@_;/\ V+->TCPQK/B.PTC]N[]G
M2\GOM.L6N88GL_BC\+KAK9[C ,*L(RIE_@4[CD#)_P!@6SO[WQOX3\0Q7NB:
MCX7DO(M8TSR+F!;JX*W6F3VWVM;90/M#(9=ZP@#SG"IC+YKS:5KQ2V^??S.N
MM/VCJ/K&7*_FE+7TV/\ &=_X*@_!Y/@?^T3X*\*OXF;Q4+[X1>'O$3:DND?\
M(\(Q=>,?'.F+ +<:KXG*LIT9@7^U.!D?)UW?U6?\&^7[:*_#CX.?LC^ H_AM
M)KG]ER_'>X_M!O&::8\AUKQ5\>-?/[D^'9D&TZD5'S-N !PC$JO9?\'$G_!-
MO]H/XW?M.>'OB)\+?A_\9/B)I7AK]DS2]&N+SX<_!/X@>-]'_M[2?&WQ>URZ
MLYM<\.QS+;:C+I6KZ(D>G+#*[R,B)%(66-OYJ_!'[*/[4?@&QTCPQXU_9M^/
M/@VVT<7<NI:QXB^$/CSPZ=+FO2;FUADC\1^'X %OSK@#>9-"@#$O+&N67UH*
M\?7_ "1Y=6"JVCRZP=KVO>_-)=.ES_5D^%W[2[?$:ST"]'@P:.-9COW2'_A)
M1J93[%NW LFA6XD+!?E)DB 8_,Q7-?4&EZN=2M+.[-L;<70D8*;H,1Y&<@JH
M&>F2O' YXZ?Y#FN>!)?!"7U_K%Y]DUG2WBLV\/W5A_96H"'4<1M-<GRY]@ <
M[F\B7:,MY4N-A]&^%'[3FJ_##5="\3:?\+KSQ@=&&NSH+;7&A36&UJRDT];M
MI4\)7CQ"P+;_ #%L[QDV;EMIR!$9J4%4M9?=?UZ>1T8.'LW)=7*+MY6:_%G^
ML[K%J+VU4$ GS4P-N[(9@,;?XB>FWC.<>U5K[0?MUC#%]J-J+<!\BS5MNSG(
M1B"2N,@?-GI@9K^(K]E+_@Y?\%^"5T;P-XA_9L\-:#-X,^&MAX2EO-=_:FT'
M1);FY\.+H>DA'TS6/@J)[)6?3<,2'5 =Q1PH!_IE^#W_  5(_8Z^)?@7P)XT
MG_:,_9H\+:GXT\">&O&%YX*NOVE/ACJ.H>&[GQ)IND:J="GF;4M-+-I=QJ;>
M&7EE\.Z8[36+LTT*D!.:K3G3:BEOJG;ENEI:S[;-]?+8]&O_ ,N_\+M]ZN?<
MGCKQ:/AAX2TFX33_ .V]DUAH*VXO1I/^ITR[D%T9C#<>0BKI3,9$BD,2DO&K
MA0&^(OA?^VFOQ>EU[;\-/^$>&B2:9<Y'B8:I]L_MB&YF$^W^P(=_%GD()XMP
M 7S(\AQ_*U_P7A_X+4?";XN?"N?X(_![P_\ #SXNZQ\/OVJL-<_#/]H'0?'^
ML:IX=\)Z%\8?"4?C&Z\/^%_"OB*?1M'U,:AI,<QM-12ZBBULQ6]PDS1S)X#_
M ,&ZG_!,+XR^(Y?VOE^)-E\2_@Y)IJ_L_0647CKX*^)[=/%-Q+/\9'UV;29]
M?N/#\M_86]S:VEP-6.FW12/71,;6;'E/*7*KOYO8P/\ 0P3P\VQ,7\\8VKA!
M'$0G ^0$C)"] 3R0**V[:55MX%>8S.L,0>7R&@\U@BAI/)"XAWG+>4.(\[!T
MHK.\_/[O^ !QGBOQ9I?@W1K#5-2U31M)CFGL;1)=<U)--M)&EMI=JPM*3&DN
MXC 8",$%I" NXR6.M^$=>BGCT?Q%H>K)&BM=Q:5J.D:DB>>OS,SH6*@J206P
M3D C<0M?S2?\%M?^"GWQ8_9@^$%E>>'M%^#-Z-._:='@"-/&-GXCE@DM;?PS
M\8(BLXL_&WA2^;4V30@%2RB6X:5CY"B4H1_/Q\!_^#F7]OOP@GB,ZW\(_P!D
M[2I;K_A'C$VO?#_XQV5O?75N_B-A/;:@?C8!?,U@JE$)Q(Q ) 8FNO#X=U82
M:;3B[:)-.ZNKNSU6MMM7N9SJ^S:7=7^YV[H_T!_CSK_CC0Y?#3^!_#MSXD:X
M&MOJR0Z#XFU9+9(CH#6<[CP]%+(RL4?<HBF9Q$4BB9]Z-_CE:;^QY^WQX@\>
M_#<Z[^Q5^U!9Q:?XN\-N;A/V>/C%&7%UJ6D7[7EUJ;>%V,UK=Z>XFLF64CR&
MWQEUQ*W]OG[+/_!RM\7OB^WC:/XFZC^Q!X4A\.IX6M]%FT_4/$OAVXU%]?'B
M6XNI)E\2_&>Y$(T^UT32C+NADC"%S)%*IV-^Z?@/P)^QQ\1;T7>E?M%>&=2U
M7P[?:7J$.F^'/BU\-M6N%N[FXU&"#3]1TJ\AU[4[>REU6T:'2H;+4;:]<,GV
M6ZAEC$@Z84YT:4XS34>9<K2NY-Z7M9:6MKTZ]"/K/G^/_P!L?YUVA_\ !.G]
ML[Q]\4?AWI<O['W[7DG@W6?$'@[0_$GB/2_V?OBY+'I&D:GXDL;'5;@W]UX2
MO+6T%G8S3SFZN;.[@@\KS9K6>-&C?^D?]C'_ ((0>$K^+1Y?B7X:_:[\#W:?
M%338YX[_ $_3_#*6VBR)X:2XU68>(O@S T,$-LDT[2RRPQJL,A:50C,O]>?P
MZ\-?#+PK:-!H_B^TOI$UQ[NW%SX@TJ5Y+F,1O!$$BQ(^YAM"QC>V<+DCYO<X
M]2L;L>4M[8R><!&%BNP7;?\ +A <98Y&T=2<=ZXYZSE;:_\ G?\ K_@@L3JE
M?\?^"V?EO\&_^"3'[-/P5O-,?PQXX^,U]+IGC"R\:6T.O^)_ ,\,VJVTUK#;
M1W"V7@"RNIK>6308DDCM+JVN&4R"&YBE7='^DFD>"=&T/2+30H9KZ>TM#,RO
M=7F742[M[$]<*#[8QDD9&-VYM2DJ3VYE?RTWA2V49EY5<]]Q&,>AXSFKD4K2
M68>X(@;.7X4#:#DCY\H-QSR_R_WAC-<]2DJC3?16U5]W>VS_ *Z!]9Z7_'_[
M9&#;:;I%K?;(]1::^*82W-VI98<D?<#$D8Z#J>FTY-;WVB$'RA*I=1@ L5R?
M0D [1TRP&5[=L\+J6L>#]"U6\U+5/%.BZ9+;1Q1E-2UW2=-B!FZ^<C^6RQ?,
M=^_;\FXX.,G/NOB5\*K&$^)+SXD>!X+$@P?VE?>,="ATZ.0Y B%Q).L*)NX=
MS(NQ 7*XSETZ:III*UVGM;I;LCEQ%3VDHO\ E37?>5^[-36/%.A^%O/U#Q?J
M^C^&M),R01:SKFI6^@0S7#N-EO%>SRV\=T6)RH:5?,&  <XK^/\ _P""\/\
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M^UB*6^GFX,:'#- Z(Q4$C/S;0,\$X Q[U!?Z@T]I"+(6]U?CRS-9A@6AZ;V
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M@*"6)"FV<X;/;!4G/;TQG-0:C<^)X;. 6%C:FXROR,S;6;J%;YAM!(&<8/\
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MV_M6;41_8<(_X2WX,:49)-1_T-$R_BVS2,NTJJ6>\M53.6N8%!E3]-?V,?\
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6H+]]_I_[*:**TI[/U_0!:***T __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex4-11_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-11_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X -X# 2(  A$! Q$!_\0
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?BB@!\,,<$*11(J1HH5448"@= !Z4^BB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex4-11_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-11_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MO*3T7DMWM%-Z'T%X\^(6A_"_PM=:YXDUC3-!T>Q :>]U"Y2WMX@>!EW( R2
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MADJ@*RSJ1O")E&^JO"7@_2?AWX4T_1=#TVPT71=)@2VL[&R@6"VM(D&U41%
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MMA<2=-[[%&YL=SDULBHI9-K8-5-?\26'A739+W4[ZSTVQ@&9+BZF6&*/ZLQ
M'XFITBC3FG5GU;?S;-#-0WM[#I]G)<7$T<$$*&2221@J1J!DDD\  <Y-?.'B
MC_@I7X9\1:K)H/P@T+Q!\;?%2NT0A\-P[-(M&&03<ZG+MM8E!4@[7=PV!LY%
M9B?L<>/OVJ+FWO/V@O%-K<>'0RS#X<^%I)(-"=@056^N3MGO]K -L/EQ;@OR
M-C+<<L8I/EPZYWY?"O66WR5WY'T=/AN="*K9M/ZO#>S5ZDE_=IZ2UZ2GR0?\
MPGB_]IWQ9^V-KM]X+^ <ZV?AZ%VL]?\ B?+'OL--.2LD&E(?^/R\'3S,>1$2
M"6D93'7MO[.O[.7A7]E[X<Q>&?"EBT%NTSWE[>7#F:]U>[?'FW=U,WSS3O@;
MG<DX '   ZSPQX:TWP;H%II6D:?8Z5I=A&(;6SLX%@M[9!T1$4!54>@&*T*N
MCAVI>UJOFE^"\DNGYOKT.;,,XC.C]2P,/9T+WM>\IM;2J2TNUT22C'HKMME%
M%%=1X04444 %&*** &F,$UY7\</V(OA1^TB[3>,? N@ZIJ&"J:E'$UGJ4()R
M?+NX"DZ9[[7&:**FI3A47+-)KSU.K!X[$X2I[;"U)0EWBW%_>FF>=O\ L#>,
M/ #K_P *W_:"^*GABT\P.-.UR2W\46:J  (D-[&TT<8  PLN?>GW/AG]JCP;
M#-,WC?X,^)K6+'EI=>';[3YG'^T\=Q(N?HHHHKRL7AXTHWI-KTD[?=>Q]WP_
MFU?,*_L\=&%2[2;E3IN3]9<O-\[W.0U#]HK]IS3KMH?^$3^ ]QM/WSX@U://
M_ ?LA_G6UX4\=_M0_$15CAC^!?AR1A_K%DU34MO_  %DAS^8HHKPZ6.Q$ZG)
M*;L?J&8<*Y/AL*\11PT%)*^J37W.Z_ U)/V<OVBO'<42^)/V@--\-(K?O8_!
MO@ZWA:93U7S+UK@K_O* 15G0O^"6OPON=7AU3QP_BWXO:K"6*7'CO7KC6(4#
M'=M6U8K:A0>5'D_+V(HHKZ.C@Z4HJ4US>K;_ #;/QC,.)<QH594L+-4E_P!.
MXPIM^KA&+?S9[_X;\+Z;X1TB'3]*L++3;"V&V*VM8%ABC'LJ@ 5>V8%%%>@M
7-$?)RE*4G*3NWU'#BBBB@D**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex4-11_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-11_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !- & # 2(  A$! Q$!_\0
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M (F7$_\ \W'YB?\ #HS_ ()Y_P#1NND_^%S\8/\ YMZ/^'1G_!//_HW72?\
MPN?C!_\ -O7Z=-;PKUC4?Y]C2_98O^>2\G'^>?\ ]='^KN0_]"3*?_"# ?\
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M_P"">7C/2=?_ &M;WX4?'KPG\)O '[5^A6&C:E\-]&_9^MK[0?AU=R>']+\
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M(41U7.]Y%^T@HV9B2&1E#("./SK_ ."LP9?V"?V@ 3G]Q\+L].A^,GP[(S@
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M_P#OS+_\C5_'_P#\/^?VJO\ HE7P _\ !)X__P#G@T?\/^?VJO\ HE7P _\
M!)X__P#G@T?Z]9#WS#_PW_\ X1#_ (E9\7_^?/"/_B9P_P#H,/[ /M4W_/%_
M^_,O_P C4?:IO^>+_P#?F7_Y&K^/_P#X?\_M5?\ 1*O@!_X)/'__ ,\&C_A_
MS^U5_P!$J^ '_@D\?_\ SP:/]>LA[YA_X;__ ,(A_P 2L^+_ /SYX1_\3.'_
M -!A_8!]JF_YXO\ ]^9?_D:C[5+_ ,\7/_;&7_Y'K^/_ /X?\_M5?]$J^ '_
M ()/'_\ \\&C_A_S^U5_T2KX ?\ @D\?_P#SP:/]>L@[YA_X;_\ \(A_Q*SX
MO_\ /GA'_P 3.'_T&']?_P!IDY_<OZ\0R\>P_P!&Z>H[Y/<U^;'_  5FG$O[
M!7[0BJDRW!C^%:*K03)$&/QF^&?"R&WC3E)E^7>6=C)&#E) /PG_ .'_ #^U
M5_T2KX ?^"3Q_P#_ #P:\Q^,/_!6K]H3]J_P!J7P \8^!_@YX<\.?%'6O!&D
M:GK/AS0O& UG3$TCQWX8\107%C_:/CB[M'D:XT>*'9/ ZHL\SKEF*GAS/BW)
M\QRK-\%0AF%6K7RK'TX1>'CATG+#R3;J3QE:-FO=Y7#1R4F[1:E]OX9_1V\3
M>%?$CP_XHSE<)T,GX;XRX=S[-JE+B2.85UEN49A]>QGU;"PX1HSJ8B-*DYTE
+"K&<Y15.+]]V_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex4-11_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-11_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !? &0# 2(  A$! Q$!_\0
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M:U>V&HP:_P" OV:])O%USX*_"&\ADE?0]1\5I.(].^-_QAT=I?ML_CO7K/\
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M=)U#Q!XDU_5F6+3]'T/2;::\U/4;MP[2"*UM()I2D*2SS$"&WBFF>.%_D_\
M9T\">(_BKXEG_:N^->A7FD^,/$.GRZ?\"/AGKD!@N/V?_@SK<"7$%I?::\EU
M'9?&KXHPR+K_ ,8=<BG>_P!-TV3P_P#":U-KIG@[59O$63\;HI/CC\=_AC^S
M/(S77@#PGIFD_M*?'6$AV_X2'1_#WBB_TOX'_#B^B!"+HWC'XI>']3\=:[%*
M'75]$^#=SX;>WETWQ%JLMG]V::W^CEL-EF5VRLA+,Z;RS+(JLKL6^?>-Q8$M
M\P('!.A/&8R;J<LL'@*RA3I/6%;,80A.>(F];PP$*M.CAXW3CC*^*KRO+#8=
M4OJW7?#?#F&HT4Z>?\:994Q>.Q2=L1EG!&*J8C"83*<-.$D\/6XRK9=C,RSR
MI=3K<+Y;D63PY,-GF:+'?G[\?_$WQK\-?&WP]JGPRT'XH^*_!/AWP_X&T_Q[
MX9T/3M7M_"U_J_B_]I?X&V-OKNE:AI&FPZSKNM^%_A*WQGU;Q%;:5K-UH%EH
M>D1:9X\LHK36K%+[R6#]M+]KK2EN=5\:_L[0>'O"VC>'=0\1:OKVK?#SXK:!
MIHM)?#'COQ+9SZGJLUSJVF^"X?#,VF^#=%\7KJCZR%N[C7I;:ZM(WLVL_M_]
MI/Q;XU\!_!SXD^,OAEX5E\6>//#_ (=O+_P[HL&CW^O222O<VL&HZI_PCVF"
M+4?$P\/:5<WOB;_A%]+N8-4\1OHQT+3IX;[4(98OE+Q)^U#X@^'4V@Z!#I5U
M^TQX>\4>'=0\2#XBQ:3;^#--O=$MI(-%UG0M"L_#WA36_"GBN_\ "2&3QO\
M$9KG_A%[K0OAWJ\<FE:9XKU31]9A@YL9"5+$5)?VIC<,I\F*G3AA8UJ<57E5
MPU.%-\LZU2G&6%<N3#PA"A?W^1U8<_UG"M-YEE& FN!.%.(*="IB<FIU,;GF
M*RS-*JR?#T<XS+%5E2>7Y;A<35PV<OZIB\WQ,JN9U:<<+EW]ITLBQU3">6Z?
M^UO^UMXZ^&6M^);#X4P^*K'7?@S\8M1TMOAW\(OC-H'B71OBQHEEX[N/AO\
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M%+%XMXFE@:^9QS?&8FM@:U3ZI1H3>8UJ^'H4Y3>!OB9^UWX1^)/Q6U*[\/\
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M9D+S^I/$8O$9CAGE=&A[6I]2I8.I@*M*&8JKAJN:XC-9K$QQ<\!BJ%*CN/\
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M8AVE@P9F^4#!)7Z/_L;6J>+/AEXH^.&MZ(MW-^TO\6/B%\=_#RZG9QPW=O\
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MDCUV_P#%%Y\4/$EOXHTJ:"RTU+,6::)_9DT*S#S71OV*_&UZAL/!7@[3)?\
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:UZV*QV.Q.8YKC\SS3, # QZ<4445L<!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex4-12_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  9 !\# 2(  A$! Q$!_\0
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:E4?* .B+[#)^I-=?'_Q[K^'\Z#]S\: /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ex4-12_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
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=TZRMX95 BA5F+2R&2XN)7DN+J::XEDE<HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ex4-12_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
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6"\UQ,9;N[N'ENKRXGN9997*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ex4-12_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^E'XA:G\/
M_C=\'?BI^W#^V3XQ\8+^PQ\-M"\:?$7X7_ WPA?>*8_!OC?X'^!]*F%O\>?C
M/HG@)],\2_'>/XTZ1I\_Q!\!?#3Q.=4^']E\*+SP;?77AE?$FH>*9)O+/@'\
M-/V!/B;\:?%?P ^$'[%WQ>_X)4_M/>'OA#H?Q\\)ZM\./ OP8_9F\8^(OA'K
M7B75/!6C?$G3%_9D\;_$;X2^+K+2_&<\%KXC^"G[1'A^:^.L0V&B_%CX,ZGH
M27>D7?VC^R9\4+?X8_\ !/3P+;#P?XZ^*'CC]D#X/:/\$?BQ\(/A%X>3Q#\3
MKWXO?LZ>"M.\&^,/ G@CPQK%SX56^U;7]5T*WU[P%;:M=:#'XG\(^)_"&O"/
M2]#\1Z?&?C'_ ()\:5\1+S]OKXZ_%337_:R^,GP3^)W[/7A2?Q)^T5^WI^SM
MKW[-_P ?O!_QD\._$1SI/[.?PFT?QC\*OV<KG4_@=H?A77?&_C3Q+I'PY^"7
MAGX<^$?%Z6[GQ/\ $;Q1XTU9]! /T,^#?[5-EX8TSQ=\,/VJ/&_A#P]\=/@_
MXUN_A]XPUZWL[[PIX4^*5BOAWPUXN\%?%GP1HVK3W/\ 9VE>-_ 7BWPQ>>)]
M"TR^U71_!GQ/@\?^ M.UO78?"O\ ;5^5^//[<_\ P3U^('_!37]I;Q[\7/A#
MXBM_"7@OX/MIW[-Z:O!?)I]MX]\1> +-/%'C'Q!#-;ZI;2:I)X5\6>/]9^#^
MH7UY;17<.K?##4-)8SP:9!<SE 'WU^WQX<OO@5\,OB?^W5\"O&7B[X0?''PO
MX.GU3QG!X1N=%O/AY\=;3PI=V'A/P[I/QK\!>,-#\4Z-XEDT72[Y8]*\:: /
M"GQ1TV"QL](T_P >VOAS[7HMW^#/_!'#_@L1^VA_P6S^*'CKX(_M!^(?"G[/
M?@+0/#$&L:LG['.F>(OA7XI\8Z>;S2;"^\-:KX[\>>*_BUXT\)Z=J5CXAN+:
M37_A-KWPW^(&F&QTN\\.^--$U&U:\F** /[)OAS\//!'PG\$>&_AM\./"^B^
M#/ G@K3(- \*>%?#^GVVF:-H6C60*VFGV%E:1Q11Q0JQWRLKW-U,TEW?3W5]
)/<7,Q110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ex4-12_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
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C/I]M%!9V-I;6T<:[(HE&^:7S+JYD+W%W//<222N444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ex4-12_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^FCQU8Z%^
MTE\*/BS^V9^U-J/Q!U[]CWX=>$OB9\2?@U^R[\//%6I^'?#GQ6^"'P_T'4M3
MNOC)\5=/T#Q)X?;X[Z_\9=+TEO%7PK^%_C34M+^%'AGP5J_@6QU+0;SQCJ_B
M?Q9=^8?L[?LS_ +XR:AIFN?!7_@F)\4/^"86A:Y\+G\>^%_VIOACK_['OP'^
M(MWXHNKKP5J'P^TO1?AW^R/\9OC7'\2OMWA_4]8\9>)++]I/PJ_@>9O"GA[1
M/$/P[^(<&OOIOAGZ'^!6K>$G_P""5\7PN\:_#KQ=\8Y_@5^S7J_[)_[0?P&^
M#T'VKXE>(/&_P8^&@^%'Q;^''@;3-2UOP1<Q:KXP&E:CJOPDFU+7O",_CKPC
MXI^'7C'0-3TRR\7:!))X%^PAI?B2S_;'U2V_9TT#]N#PK_P3^@_9+TVP\4^$
MOVV[7]K;2%\.?M56_P 2_"7_  KS0_@5H?[;ZCXU:9HOAGX20^/K+X@6OPY4
M? C2M4B\ 6_AL67B5=8O* /N7X+_ +56G>%-%\2?"K]J7QKX,\-_'+X,^*O^
M%=>,=;L;"X\)^$OBA;)X5\+>+_"7Q:\#^'KZ[OY_#^C>._!?B[P[J6N^$(]0
MU6S^'GQ!7QK\-].\0^*]/\'VOBS7"OR#_;6_X)]?$'_@IY^T5XZ^,7PD\:S>
M O!/PBFMOV;8M5T;4-*L-(^(_BOX=QMXA^)'BBSO+>UN+77;OPE\2/'7BWX)
M^(M2MFCCM/%GPEU_PZT8FT*5G* /T(_X*,>#[K]G#X>_%/\ ;M^ /C3Q?\)_
MC=X3\+07?C>R\.3>']2^&_Q]MO#>B-I'A:U^.'@/Q=X>\2Z9X@U3POID$.EZ
M%\0?"DG@KXKVFA06WA9_'TWA2TM-#@_ C_@CG_P5]_;)_P""V/Q5\?? ;X_Z
M]X4_9X^'V@V-\^N)^QUIGB+X9>*/'6DIF;4=!UOQM\1O%?QA\6>%(-<2\NX-
M3\1?"+5_AIX\B6<W6D>+M*U&&VO8"B@#^R7X>?#WP3\+/!/AKX=_#GPSI/@O
MP-X.TFS\/^%O"OAZV73=%T+1M,B6TL=/TZQ@*Q000PQ*#@%YI3)<3O+<2RRN
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ex4-12_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>ex4-12_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
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C6DVMM&EMI]A:P(N(HER6FG>>\N9FDN;RYN;J669RBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>ex4-12_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !J ( # 2(  A$! Q$!_\0
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M#&=DC9VDD#(C_A7L3UX-?_A)I?+:^CTU@OV6UFD,UV0BQR,P9@ &'R=2< D
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4$H^F_P!^_P"044459SA1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>ex4-12_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M "\# 2(  A$! Q$!_\0
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FQ^.[\JUF&Y2,XR,9%-@ACMX$AB7:B*%4>U)12V*JUZE6W.]C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>ex4-12_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( %H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U7PWX;T*X
M\+Z1//HNG2RR64+O(]JC,S% 222.236I_P (MX>_Z .E_P#@''_A1X6_Y%#1
M?^O"#_T6M:U90A'E6BV70[\3B:ZKS2G+XGU?=^9D_P#"+>'O^@#I?_@''_A1
M_P (MX>_Z .E_P#@''_A6M15<D>R^Y&'UJO_ ,_)?^!/_,R?^$6\/?\ 0!TO
M_P  X_\ "C_A%O#W_0!TO_P#C_PK6HHY(]E]R#ZU7_Y^2_\  G_F9/\ PBWA
M[_H Z7_X!Q_X4?\ "+>'O^@#I?\ X!Q_X5K44<D>R^Y!]:K_ //R7_@3_P S
M)_X1;P]_T =+_P# ./\ PH_X1;P]_P! '2__  #C_P *UJ*.2/9?<@^M5_\
MGY+_ ,"?^9S&LZ#HUC:6US::386\Z7]GMEAMD1ES<1@X(&>A(_&NGK)\1_\
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M27*B W>KV36WF2)F<*\(;: Q/&TGD#BNMJX-M:G+B:4(1@XK?SO_ "_JVO\
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MVS7/^@/:_P#@<?\ XW111RON'MH_R+\?\P^V:Y_T![7_ ,#C_P#&Z/MFN?\
M0'M?_ X__&Z**.5]P]M'^1?C_F5KU-:U*.&WDTZV@C%U!,\@NRY"QRHYP-@R
8<+CKWK?HHIJ-M2:E7G2C9)*^WG\WV/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>ex4-12_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B $X# 2(  A$! Q$!_\0
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J13 D21][?.W7UIR2/AOG;H.]%%("5W8-]X_G[5&LC^9C>W3UHHJD!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>ex4-12_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O +H# 2(  A$! Q$!_\0
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MGU..M6Z .(_X59H@&!J.OCW_ +6F_P#BJ/\ A5NB\?\ $S\0?^#:;_&NWHH
MXG_A5^D9XU;Q$/IJ\W^-,D^&NCVZ-<-K'B)1&I8M_:TW  SZUW--=%D1D< J
MPP0>XH \B^&_@:QU?P3:ZM)JFMQ2WTLL[&#4)$!R[ $@'&< 9/>NK'PXM%<-
M'XA\2)CTU)SG\ZZVSL[;3[2.ULX(X+>(82*-=JJ/85/0.[.*_P"%> ,2/%?B
>4<\?Z=T_2G_\( W_ $-?B/\ \#?_ *U=E10%V?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>ex4-12_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "4 )X# 2(  A$! Q$!_\0
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M@CO00""",@]0:RM*)L)6T>0\1+OM6/\ '#G@?5,A?IM/>C:7J'\2E;K'\O\
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GQ0JI_0444U"*V1,L15DK.3MZLNT4451B%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>ex4-12_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& 7T# 2(  A$! Q$!_\0
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MN?\ XW3/^%@:03@6>MY_[!%Q_P#$47#E9U5%<M_PGNFXR-.UTC&?^01<<_\
MCE*GCFR==RZ3KY'_ &"9O_B:+A9G445R_P#PG-I_T!?$/_@JE_PH_P"$YMCP
MNA^(F/MI4H_F* Y6=117+KXVA/']@>(@<9YTQZ/^$WAW8_X1_P 1GW_LQZ L
MSJ**Y?\ X39,9'AWQ'_X+F_QI!XV0_\ ,N>),>O]G-_C0%CJ:*Y;_A-X\_\
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M0@MH1A(HKV1 /R-%%(5V2KX1T]<XN=5.>QU*?_XJFCP;I@ #7&J,!ZZC/_\
M%444!S/N"^#-(#;LZ@<=CJ-QC\M]-?P-X?D.9+6X<^K7LY_F]%%,7,QI\">'
M2I#6<Q!Z@WDQ_P#9Z7_A!/#FQ4-C(57D W4QQ_X]112#F8-X&\.LQ)L7R1C/
MVJ7_ .*IO_" >&.2=+!SUS-(?_9J**&%V0R?#KP@[9?0X'/^TSG^9J7_ (0#
MPARQ\.:<Q_VH ?YT44T.[(SX \';AGPQIA)_Z=UJ4?#[P<PY\,:2?K:)_A11
M0-DB^ _""'(\+:+G_KQC_P#B:LKX1\-+]WP]I([<64?_ ,31102/7PMX>4Y7
M0=+!QCBSC_PIX\.Z&.FC:>/I:I_A110%QO\ PC&@9)_L/3,GK_HD?/Z4H\-:
M"!@:)IH&,8^RI_A110%QP\.Z(.FC:>/I:I_A4JZ-I:*%73;-0#D 0*,?I110
M.[)5L;-!A;6!1[1@5(+>%>D48^BBBB@0[8G]U?RI<#T%%% "X'I1110 4AX%
6%%)@+1113 **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>ex4-12_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !2 F8# 2(  A$! Q$!_\0
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M/%SGT&E,/YFNYQ2=Z0SB!\2')Q_PA/B[_P %O_V5"_$:5L_\43XM ]]/ _\
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MDYW-G('8>M=D_P -?"<L@=],9FSGFXEY_P#'J0:'5[E'4BD,J+U=1]37*?\
M"L?!Q.3HD1/O(Y_]FIZ_#3P:IR- M3_O;C_,TPT.E-U HR9HP/=A3/[0L_\
MG[@_[^#_ !KGU^&_@Q3G_A&]/)_VHL_SJ1?A[X/5@P\-:9D=/]'6@-#:;5-/
M49:^M@/>5?\ &F'6M+49.I68'O.O^-9T?@;PI$"$\.:6 >O^BH?Z5-'X1\-P
MC$>@:8OTM$_PH#0G/B#1E)!U:Q!'7_2$_P :B;Q3H"G!UO30?^OI/\:=_P (
MQH&,?V)IO_@*G^%.'AS0Q@#1M/XZ?Z,G^% :%23QKX6BSO\ $6E#'_3VG^-1
M?\)_X0 )_P"$FTGC_I[3_&M7^Q=*QC^S+/'_ %P7_"E&D:8.FG6@_P"V*_X4
M!H8[?$+P>IP?$VEY_P"OE?\ &F'XC^#0<?\ "2Z:3[3@UO#3-/'2QMO^_2_X
M4X6%FIR+2 'U$8H#0YL_$WP4IP?$EAG_ 'Z:?BAX)'_,QV1^C$_TKJ/LMO\
M\\(O^^!2BV@'2&,?110&ARO_  M'P5V\0VI'J W^%)_PM/P5D :] 2?1'_\
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M+KSZ#82D>&K&0#5+E/\ EYD!R($/=?[Q'T^OH<4201)%$BI&BA551@*!T %
M#@   . *6BB@ HHHH **** "BBB@ HQ110 44'I10 448YHH 3''%+110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !WHHHH **** "BBB@ HHHH **** "BBJFIZG::/IT]_?2B*V
M@7<[X)QSCH.2<D# H MT5G:)KEAXATU;_39C) 69/F0HRLIP05(!!![&M&@
MHHHH **Q=:L]?NIH3I&JVUC$H/F"2U\TN?KN&!66='\:ER3XILPO]T:</Y[J
M!V.NHKD1HOC+//BJV'TT\?\ Q5(NA>,@N&\8PGG.1I:YQZ??H'9=SKZ*Y)M
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MG'_A1_PC7A\?\P+3..G^B1_X4#LB@?B-X, S_P )1I7_ (%+_C2?\+'\%_\
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EB]J0444Q W0TU:**3&A]%%%,04444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>ex4-13_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-13_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "5 *(# 2(  A$! Q$!_\0
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M^&-)N6/+F\\)_"OQ=\//!5ZC/MECM[OPW/:VDT<4MC!:O&C _P"&%/V1I/\
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MO!WQ'UJ17W,NL>(M8VL(3#'']9UY.4?O:&(QSUEF.-Q6)3Z_5J56I@,#"_\
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M\$_LI?!+X>^*;;Q9X8T;QI'<:;J6KZSX>\,:Y\8_C-XO^&'@O5=:N+V>ZO\
MX>_!WQ?X_P!=^$WPZNK1-3U.PT*7P+X+\/-X9T75-3T'PY_96B:A>:?/=3@:
M=*MEU/"RRJM@\/C,5C*BQ>58&5*A7Q&*KU?:QRZ<<51QLZ5'$OV4GB,-5J5,
M%@<'F%3%Y+/&82!EGTJ,+7RK/<-FN!XOR'&K@Q\(</XGA[C/B+&9E+*IX')L
MN654\]C#AJ?#^$PV'R##JC1E@,XX>J3SO/,RGP]#B3+^%LXP'XA:;\$_!_@K
MX2_M4_#9?V7_ (_Z+:_&K]D#Q;K/[+6J>#_V>?C,_CKX+_#GQWJWC[QC;?L7
M^.O%WP\^%FGZEI_C2V^)FL'Q_P")/"FN:UXPMM=L_&.J_"WXB:]XM\)>!O#&
MM_$/]@OVFM#\3?$O]D>:Z^'OAKQ%KOB"TA^"?Q7T7P;<Z!J'A_QEK=M\-_B%
M\/\ XK7?A=?"GB__ (1;5](\8ZGI'A>[TJU\,>)E\/ZI:^()H=&U>/2KQ;A8
M/L>BO:P/"6'P&6X_*J&+<,-BL)@<)AO98/#TJF"CEF.KYAE]64OK%7Z_5PU6
M>%I.>+5.IB,+@J-'$U*DFJU#\YXT^D5G'&6?\*<38G()0S?AGC' \95)9GQ?
MQ'Q)@\UQF"R+ \-SPM2AFN"P^*RZGF6599@I9OB<#F=6KCLYJYWQ"L)@\WXE
MSNIB/CW2OB+I_P </$>O>)M.\$?'#P]\*_"WP8^(/AOQ'KOBKX6_''X(^/\
M5/$'C.^\)ZC/H7PZ\*Z]X=\$?&J^U30/#OA.[NY/%/@GP^(Y=:U[P_IO@#Q'
MJOBK3M<LM$_$K0O@KH_AO]GOP]X'T/X$?M2^&M8\?_\ !+#X]?#SXGR:#\!?
MVL[3Q9XB^--IXN^&EI\'/!'C;Q#!X&EUG4]1TA?"GQ*T/P;X1\2W]UX>TOX7
M78\*P:5#\)/&^@Z3X@_IWHK',^#H9I5^LULPBL7++,;ET\0\JPE62>-Q^9XZ
M=>@I8R$L/&BLQAA:.'A4DG0P=/ZSB<2Z^(IO?P_^D37\.%C<'P]PE7I9+7S'
MAW,,+E/^OF?T8TY\,X2<,!+-,52X:J+/L7_:=3^UXXO%Y?A*.$Q%'!TL%E-&
M6#HYD?EW\4_V<].\6?%SP#\8/ GP1\/^)++]K7X%2?LU?M$:OXO\!-HGBCPI
MX$O=%L_&?ASQSXJT/Q9HVE^(]&EL_"6F>-?AWXJ\,^)-,M-;UGQ?>?!#PMXF
ML[&#P5;V]AX?!^S9I-C^T[XPUGQ-I?[3OAGQ#\.O$TMO\++;X3_"SPMX9^$-
MK^R7I_POM?"EAX0\$?M"?#+]G;5OC!H&B>&O"USXAT*P_9I\(_&[P]XPU/XO
M6EEXO\'^"M-N-8M_B9;?KM??$+3?M'B;3/"^EZKX]\2>#->\):#XI\+>%YO#
M]MJ^B2>+6T6[COKRY\8:[X4T VFB>&-;A\::S:P:U-K4GARVFCT+2=<\0W6D
M:#J??4\7PEE.9UJN)H5:<8/,LTS"%..%H5L)2K9HL94J0P_L:F7*K'"YQ+.,
MPA.6(QDZ6+S/B/+\0Z7U^4<&LO\ I!<?\-Y9#+:^$Q4,+7X1K<(8.=;B+-*>
M<+)EC9XS)7BO[1H\11>%P7!6>X;@C#J'#'#^%S[A&CD\J..OEBIK\%O"?[/?
M@#3_ /@G]^SN1\(?%'ACQ_;3>%=4^).E?%7]ASXL?M+-XY\=>"O#GB#PO;:/
M^TE\&-3\(G]H3Q;X6T6WU.\T+X7^,/#MS:3?#6W@\+2^"-8A^&FECP_J%_\
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M<-Y9B:L\3G]>OG6-P]*KG6+QU'ZS@,04445]B?RT%%%% '\O/A[]M?QY\&]
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M"E4H^#_'OXQ_M5?LK>&1XK\3_$/X(_%_1%ANYX=-3X%^,/A[XH>*Q,!F2_\
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G&$G0S;$YU1E*$)5*-:=.G5I>W4445Z)\8%%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>ex4-13_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-13_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !> *D# 2(  A$! Q$!_\0
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M%=4UO7]?UO5/"MUJ>LZWK.IW5UJ.JZKJ-U<WVHWUS/=W<\UQ-)(WTQ_PP/\
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MET<SX:R_"8S+JV)XLI_67;SW_A@?]A7_ *,L_9,_\1R^#W_S'4?\,#_L*_\
M1EG[)G_B.7P>_P#F.KP#XY?ML^*)/@OJ-Y\)?A3\:/#_ ,5;7]I+X3?LR?$?
MP=<0? 6'XJ?!36_B5XS^'=E_:$$'C'XFZK\'=?\ $?BOP%\0=$U+X,^(+#7?
MB1\,)/$WBOPGJ/Q"CC\*Z3XVM-,ZKXB^._CW\//#O[+?[/4'Q.NM4^-_[27Q
M&\7>$+GXU^)_ 7@+3?%/@'X>^&/!GCKXM>(-9N?!GAB?5_A)K7QB\.>#-!TG
MP)I]]9:?)\,-5\9S7'CR3P5>^';4^ ]3R=3A2;KO#<.Y9C*=*64T*->AD.1Q
MHXS&YW4IPP&"PU3$91AXRG*G4E7KXF<OJ>$I87'0Q4Z&*P57"5?9H9-](GZO
MDL\T\7^-LAQN>9SQ/EV'RK-/&#Q)JX_#Y3P5P_#BCBWBW&?V+XE9]AJ7#F39
M'6PN8TJU.K7Q7$.$Q^6XKA7^WL/F.%F_5?\ A@?]A7_HRS]DS_Q'+X/?_,=1
M_P ,#_L*_P#1EG[)G_B.7P>_^8ZM'37\>?L\:7\2O'?QR_: N_B7\$?!W@.W
M\06OB#Q;X"\,:9\4]"N]%N/$&J^+[OQ$?@_X/\,^&_':ZE8W6D:;X1TSP9\.
M/"VKV\6D6FBG1/%_B34Y]?O_ "GQ+_P4(^'?@#1O&-Q\4?@U^T=\.O&?@?7?
M@UIVM?"B[^'N@_$'XA/X=^._B>Z\(> /B)IJ?!/QM\4?!VH>![C7M(\4:3J=
MS#XP_P"$@L-=\+W?A(>'9_&GB'P)X<\7;U%PAA80>8Y1D65UI1<I8;&Y+DOM
M:?\ M"P]-2GA<DQF'E+$.4*^%C3KRJXG!S6,IX>.'AB9X+P\OG](CB/%5:7
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M9_XCE\'O_F.H_P"&!_V%?^C+/V3/_$<O@]_\QU>.?#W]LZY^(_C'P#X:\6^
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MCX=Z9XT_:"^&&I7?PNO_ -I[Q=X'\3Z#^S7XBT/Q9X*^*W[1'Q*;XSZ'\4_
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M.$O\&=_^EY8?[B?L</\ =/I"?]A?AC_ZC<;G^A;^P/\ \F*_L6?]FF?LY?\
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MOCA)JVG>'=/TS2=)@;4M073K!O$WB'4_[7UO6KVSM[5=73PQH_AC0]$XZ/\
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M$ZC_ .D<U?YFM?S;](G^)PE_@SO_ -+RP_VG_8X?[I](3_L+\,?_ %&XW/\
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CAGG$<GP_%4<TE@OJ&=YYSK RS' K$>U>&Y7BJ/(JUY.G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>ex4-13_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-13_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !< &@# 2(  A$! Q$!_\0
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M%=4UO7]?UO5/"MUJ>LZWK.IW5UJ.JZKJ-U<WVHWUS/=W<\UQ-)(WTQ_PP/\
ML*_]&6?LF?\ B.7P>_\ F.H_8'_Y,5_8L_[-,_9R_P#5/>#:^LZ^6R/(\CGD
M>23GDF2SG/)<FG.<\FRB<YSGE&4SG.<YY3.<YSG.4YSG*4YSE*4I2E*4I?O7
MBGXI^*6&\4O%##8;Q0\3<-AL-XF^).&PV&PWB3XBX?#8;#8?Q%\0,/A\/A\/
MA_$"AA\/A\/AZ%##X?#X>A0H4*%"A0H4*%"C1HT?DS_A@?\ 85_Z,L_9,_\
M$<O@]_\ ,=1_PP/^PK_T99^R9_XCE\'O_F.KZSHKT_[!R'_H19'_ .&3)O\
MYSGPO_$6?%C_ *.MXI_^+/\ $O\ ^F*?)G_# _["O_1EG[)G_B.7P>_^8ZC_
M (8'_85_Z,L_9,_\1R^#W_S'5]9T4?V#D/\ T(LC_P##)DW_ ,YP_P"(L^+'
M_1UO%/\ \6?XE_\ TQ3Y,_X8'_85_P"C+/V3/_$<O@]_\QU'_# _["O_ $99
M^R9_XCE\'O\ YCJ^LZ*/[!R'_H19'_X9,F_^<X?\19\6/^CK>*?_ (L_Q+_^
MF*?)G_# _P"PK_T99^R9_P"(Y?![_P"8ZC_A@?\ 85_Z,L_9,_\ $<O@]_\
M,=7UG11_8.0_]"+(_P#PR9-_\YP_XBSXL?\ 1UO%/_Q9_B7_ /3%/DS_ (8'
M_85_Z,L_9,_\1R^#W_S'4?\ # _["O\ T99^R9_XCE\'O_F.KZSHH_L'(?\
MH19'_P"&3)O_ )SA_P 19\6/^CK>*?\ XL_Q+_\ IBGY;_ME?L7_ +'?@?\
M9+_:3\9>"_V3_P!FGPAXO\*_!'XE^(?"_BOPO\"?A=H'B3PWK^C^$M5O])US
M0=<TGPM::IH^L:7?007NG:GI]U;WME=PQ7-M/%-&C@KZ6_;R_P"3)_VL?^S>
M?BY_Z@^M45_,'CUA<+E^=\/0R_"X; 0J9/BYU(8##8? PJ3CFBA&=2&"P^#A
M4G&'N1G4A.:C[JDH^Z?[H?LF\]SWB_PP\7\5Q=GF=\6XK!>(_#^&P6*XKSK.
M.*<3@\-5X%EB*N&P>)XGS?B3$83#U,0E7J8?"8C"X>I72KU*%2LE62?L#_\
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MH-(_9J^)_@/]G^'1='NO#%KX/T/6GU[XM?'OQM:_%?Q'X:.LWUAXLU/X5?\
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DS#<049X'!\)/*J\L17PF#P,<-66,:C"C.%24Z7[U34?=/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>ex4-14_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-14_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !C +H# 2(  A$! Q$!_\0
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MI!,;JQ5@".&7*G#=Q@X&<5?H PM3@36=<MM,F@F-K9>7J$K[\1RMEUCC(_C
M93(<\ I'USQNU@>%<SQ:MJ$B(DUWJER&V@@8A?[.G4GJL*D^Y/2M^@ HHHH
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MJ<J#D>@]*SUUJ^N-;NK6STR.>SLKA+:ZF-SLE5V1),I&5VL@65"274\/A20
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MB@ HHHH **** "BBB@ HHHH *IZEJ4>FVZNR/--(WEP6\>"\SXR%7/T)).
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>C(''L*** -.BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>ex4-14_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-14_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !C +H# 2(  A$! Q$!_\0
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M)[8;:#SM/(,5CX@O;>YL].\0:9):W<J[3>P8>RDER %5L[D+9X#@<_*"QQN
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MR#3=,TJWR,S7<[7,F"@;B*/:O#':<R=0Q&1@M93PXUQM?5]5OM0<;&\K?Y$
M8=0(X\;E)_AD+\ #UR .U+Q5I.F3R6IFDN[Z-"[65C"UQ.%]2B E1D@9.!R.
M:BDM]>UD31W$W]BV<D0\O[)(LEWN/7<S*43 XPN_).0XQSL6=E::=:):6-K#
M:VR9V0P1A$7)). .!DDG\:GH J:?IEEI5N8+&V2%&;>Y'+2-@ N['EV( RS$
MDXY-6Z** "BBB@ HHHH **** "BBB@ HHHH *H7^AZ1JI)U'2[*\)VY^T6Z2
M9V[MOW@>F]\>FYO4T44 94GP^\(2RI+_ ,(WIL;)_P \8%C!^96^8+@-R@ZY
MX+#HS Q1_#?P?%LVZ%;'9MQN+-G;Y>,Y//\ JESGKE\YWON** '6_P ._"%L
M05\/V3X39B=/-!&U%Y#Y!.(UY/.2QZNQ.A9>%?#NFW4=U8:!I=K<19\N:"SC
D1TR"#@@9'!(_&BB@#7HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>ex4-14_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-14_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- '\# 2(  A$! Q$!_\0
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M0[@Q4*@^9BWEO@ $G:<9Q66PUOQ"E["2^CZ7*%2&9"5O77YM[<\1;LKMSEU
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ME3")62\:\@$>1NAGRVX@LQSY@F!Y'*Y 4$ =#0 4444 %%%% !1110 4444
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HEZ39:-:M;V,11'D:61GD:1Y'/5G=B68\ 9)/  Z 5=HH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>ex4-14_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-14_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !C '<# 2(  A$! Q$!_\0
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/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>ex4-14_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-14_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !R +L# 2(  A$! Q$!_\0
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MEC"ED)'WAN!&1UY!'J#678^&[.T\)1^&II)[VP6T-D3.P#O"5*[24"]%^7(
M/'7/-5_$E[K%K?:);:3<V,'V^[>VD:[M7FVXADE# +(G_/(C!_O \8P<.Z\5
M:EI^IV,.HWMHD%MK#Z?>O!:L/M>ZR-Q%Y:EG93N94V#<SL%P1G80"Y=?#Z"[
MNI+R7Q!KAOI?L_F7'G1'=Y$IEC_=F/RQABIX0?=_VY-]C_A"U_M[^UO[>U7=
M_:']H?9\6_E^9Y7DX_U6[;Y7R8W9QSG=\U:$WBC28;.VN1-/,MQN\N*WM)9I
MOE.'S$BEUVMA6RHVL0IP2!5>7QQX:BO&M1J\$LR11SR" -*(XG!*RNR A8\
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MH2IX(&5)!QP3UKH:QO"K.= CCDF$TD$\]N\@W?,T<SH3\S,W5>[,?4D\ULT
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MCL8E)5@58<+T()!'<$BK\>DZ;%<"XCT^T2<.7$BPJ&#$N2<XSG,LIS_TT?\
;O')10!<HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>ex15-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %  ST# 2(  A$! Q$!_\0
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M1_PL^/?A!_%O@?Q-::GIL%\^FW<\312+!=VS;$@:2(XW2-W4E>^X#FOY0O\
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M:WN#E%_"DK;ZEV0AUV+]WT')_,9Q_GGU4R%&YC(7=NSUR?P/KW_IQ44V44S
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M3Q1:3:J0K3M*L7E&&X(M3&5&U0A8E1DUJHRC?F?;>^GWDR:=K*WR2/ZWU20
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MXK2&\NH7\N./]YOG+$JI1]WR,V:^PHT<A\*I!.,L^3GGC@Y'U.!U^E?ST_\
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MX :AXV^*WCFY_P"$YU_4[+4[G4?$GC*1;F+1[#,E],UM-<HR6^V*)U+L!T"
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M ($I/'T)/;CZ]ZCG2.5PF<-G"G/"G/?UZ]B<?AS)L12 H(;'WL\8YX]NG:F
M(&#E2S;L]>WKS[YZ4 ,W.Z)Y@)PVTXP./<^WYU*54#<6X^A_EGV]*1@#YH'
M9LJ1Q@>H]/T/-3,F!M/'IW/UXH AQY;2,WS2?WA_G]<?7BI,%HU!'();UY/O
M_6HBS.\@V\_3C\\XY^OJ*D62/&-PR ,_E^5  /,.[T7V[?ESW_"EW/C!C7/^
M_P ]?3G%'G8)10Q"=6'.?RS^1_'VB\V(W!4!]Q^^V3A/;MD_[N?Q H D82=2
M-O&< CISSP2/U]*8DI;J,#_'_#N*FE8#@<X7'X]O\_2H-^_G;M_S_3_)H G8
M+C(.U_[Q!(R<]@#^H_.F1)#G*D*W\7/7\?P_E] ,P8#!SDY_GZ]/QIJ1'9N!
M!/Y=O?'?C'<T 2Y0_+N!;H5P<_R_SZU&S9('WCZC&8^OY]NF:8,GYER)/4]/
M<C/7VZU$YD621HUVA_QP?H.>WIU- %M8<( YW9&6/3^OH3_G%2-'OQE5X&!G
M/3/Y_G40D<Q@]BVT9QR/SZ#OV'/XO:1EXW#\1G]0#0 Z3#%57E@V2.>G.3Z=
M?\XH7AW8\*W0XZT [%W. ']"<GGZ$^Y_K0TRKUP#Z9R?RZT 1(09,]N/Z4]F
M1SQ@_4?KR*)-NW<IQD9R >F?S'/&/\*;$!R6X!Z?YYH L;U]?T/^%0DH[9)&
M.?\ ZW!_J/6G;&]/U'^-,,>\8,13_@2G^1/^?SH >C+DG/'3."/3MC(H.59N
M<ANQSQ_D>GZT]$"CIS_+_P"O[_E36'S'W_P_^M0 )M48+9_/_#_/ [4KC>N!
MSS_C]*8(B>0Q_P"^C_A3XUVKUSG_ !- #E! Y]?\*1ESCGIZY_SG^?X"GT4
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M8%6))VGC! W?P[JAP@Y*;5VMNK_S*C+EOYG ^!-+O->U*YN_LK11K!9VJVX
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MJ0+/IFM6-WIMW!,8WB>"\0Q2DI'!"'.QSLW@;2G9CFM)KNV0)YCH!)((D+.
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MWY U%/\ MF_!V*"69/&%A]@'EQ'?=1?:1.O66$R*"JC_ &@![TG4C+H_Q_1
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MY- "G"_>('U(IS.Y[\^_^/6HIHB3\I"8 /[T;\#GD;-PY].>M21C,>&R')4
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M 1G(]/ZT /I&!(('^>:6B@"LS!1DG ^A/\J52%4Y_NX_E3Y$!7IT_P \^O\
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ME0S2;8MS'Y^&(D"A;^#_ /@H=:,3*- F *XNQJ*M+$4/GKLA>4>=YG^K.X9
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M8D;B3TP#'U[9Y]SVH32DMM+Z?<!^23^%?^"ARRNT2>'7>+R[?;->QRQ2*.K
M&0\]_4Y&/>6+P1_P4/EDG,M[X4C295D$27430KL;8Z!4D+8#9&1D'J"1S7Z:
M>*O'_ASP@T::SJ-C8*R;R]U/'"58\?=><,W./N@X/?'-:7ASQ=HWBA)+C2-2
MM-0B^SVMS&]LX;;#,I+(P1RRLLBE6! QU8  &B4X2E9636ZOJ_Z[=+@?E^GP
M_P#^"AHE &I>%[@231R":740#  VTGRS($R(^>#^IQ7.:G\-O^"AY$3_ -I>
M$[EO.FVM;S?*N.NZ..5H_P _T[_L!=2NUG<20([-$DKHD9(:64?ZM%^88WD\
MG.T'J0 :_F6_;$_X.!/!'[&?QVU3X(_$_P *:OHOB!',FG)?6DMV-0CED\F.
M6W0J@,32?+YFX1CJ6"_-2NENT@/N*S^'/_!1U@KSZCX3:%69;9)IU2:,<^<9
M-\ZX$W12X '?%7!\,/\ @HC'/'#'J_A:&.Y1GDG%Y%,D;KCR\LXP">F<\#KC
MC'C>L_\ !8"ST#]GK0?V@O&7PW\2:5\/=>FMDL_$$.GEK-H95W/-(@A= H7E
MBS#:,YQBOMG]AG_@HA\$/VW?#UY-\,=>M=2U71(Q+J=E:RQADA8,1(\:LS("
M%;C&XXX'2FI16]G\T:<B=K27S:_*Z/#XOA?_ ,%"HR8GU?PRX@7(\V]\TN/7
M'G$GKV'<\4EW\+_^"ATAE>#Q!X81[@Q!8K>^!AA$/9E$WR%SU5L$=Q7Z:^*?
MB=X2\)W7]G:OXATO3M0;'[NX9(Y43CYF$DH3G/ +9]N]5(_BMX,>QCO4\2:-
M+9SL41Y+R"$R3JRJ69EE <991\F>O4@<6JE-)Z1UM;7UO_7WC]C)ZK6W;7?N
ME_PY^;A^$G_!0EY(WGU_PJB2Q^61#?#Y&_O$"<D$>N,>]+)\&_\ @H#*(Y!X
MH\.*43RO+:_5V;_IIY;2%U..N5!_K^K^A:[::W8B[M9(91O <Q.)%7*;\EE<
M@?+WSMR,=>*\Q\2_&[P-HFJ7NBWFO6%K<V#,+D-?6L<BW**&:!@9Q(KJ" WR
M_*P*$[E*B=]4B'"ILFTH[]M=O(_/&V^!?[?-P%2?QOH%OL)6.Z%Z(I5)QYN8
M@^T^<?N\87N5[7O^%!?MWB%U7XB^'#'MQ"INE#YSTG!E!/7T_2OT^\*^+]'\
M7:-'K.CWUM=0LK%[A6$L"E,!\21L5(7>H)4D+P#C!KD==^+7@;0[F6UU;Q5I
M%JT3[+F.:]B@GB;MN60J57 X;&P]CG&42?F[)\!OV[)I$$WC71(1(([LF*?<
M!<JS*4.93@"-8SAB!@XZ@@7H_@!^W1"F/^%A>')I&OH+^999&9'-KTM>&("S
M_P 1)"K_ !FOT-?XN^"(@\MKXKT66'>LA:6\0IM8*542;]@!W+W')YZ''>GQ
M%8OHT6O&_MK;26A%S<:@T@-LL##B42 $;.V5!Y^4\C%7-WMJGOL!^7Q_9U_;
MCN/M"R_%3PW#'OVJJ$H84\O9MB"RYQO^?IC/:JTW[+W[;ES+;F3XUZ-9(TET
M\LJ1&29,O$D))D< [HU8C&<8PV#@'[OM/VC/A1)K-MHJ^-=&DNKR9(K;R-0M
M[B2=Y"H0"-"[JIWJ"SJJ*3\Q&#6Y\0?C1\/_ (<P&3Q)XHT_37/E2O#+<K&?
M)F.(I%,X"F-^JL"05RY(7YJSNNZ^\#\[!^RG^VW;RPO:?';2'DA^T[_/ADQ)
MN/RN"A(Y].H'7VN3_LE_MC7T,#W/QOTIYE7S9(H[=[;:^.GFJP)/3D$^V!7Z
M">&OC'X(\5>&M3\3:+XDT[4++1+:5[V8WUNT,8\MI<S20L5C 1&8EB.F#\Q
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M1/$,GA+X@G4])U:*.VMVAOHYA%>7UXYM+:"R,KH[O*XR"I*J2-[*2#7?6_\
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M97_KR946E>ZO]Q_.;_P<Z>)_B3\$/V6[#X]?"?QSJWASQ'I6JVFEW6FVCO\
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M\2O^"OOQ4\-:SJ&H^&4O]9U^2TO]*5UD>*#5[XG;*HCPK@<EB!VX.!7Z[_\
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M^.?%/QFT\W_COXY>"[^UBNKV)WF;1]/TYAH3$SY8296/9&"L9R,D8('X!_\
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M!/SY^?T]?;_]=2I&B+M48&[=CWH B=T]'Y],_P ^33R,-STSG^N,?I2LI/\
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M(!F)CU4-D=\9Y^H,C&>V,_A3=JY!V#<OW6SQ^(SSZ=/KFFG9I]@WT/XY=?\
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M6/JQ&2NW<V3S_>(9LD_K6CQ>CM#7O;]++_@$?5XW7-JMUY>O_!['"?#SX?\
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M#\<'^@ 6(PI4GD<]OH.!U]L#K0!&[E?NECQZ]_\ /3-2(W7GK@\GK_GBFO(
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MC:-?D&W?(7[' Z%>O\O?N:CD60^8264'W'/X G^E3Q.Q"[F[X[CZY]^WU^M
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MP!U!]O4Y_P#U>E2-$<9'WO3./;KG'2FC*XV <_\ UO4TXS;1\_'X$_\ H/\
MA0!7V,&QT)_UG?/K@]/Q_P#K5+(-B(W\0Z@$'\>,^GTXICN561L<XW#'<>WI
M@9ZX-+"2Z9;D]3G^6#Z5;D]-M/\ +7Y:V^0"%6)CQQA0W8\]/UYYICO(S;'B
MP@&-P+<<GTR?:K.!D=,9P?9?;Z^E095F:(E\8SGVY_7UYSTJ6V_E^KZ@+&HD
M8LP.%/[LD'"CU/MT[\>G%1W*E98Y<\AL,<Y 7Z#G\,'ITQ4FY5C\H,>N-WOZ
M'_.*:8P[;=VT8/!')'KC@_YX'6N>6[]6 \R%ERJ[@>FP;?\ T+'\ZK.)?/?<
MYCC_ (=JJ'/KR>/_ !X<U:(0Q@?/+TX! /\ XYZ8X SZ"FL_*F9<[,XQ_%Z>
MO],_4&I;::LF_3H GS*NT'>O]_MU]6QU[G)%1JS LPYR<+R!E>>Q]^Q&:>N=
M@)Z'HF?D^N.O7U]><TR26(.5WL,=,(#_ "!]>OY^^MY36CM;?5ZW_P"& 86>
M-) 3R[ @>@/0@_CT[>HJ92'1=IPWJ>OJ3GITQWJIYA-SPI8&*Y?[K#_5A=G!
M .3N7\_KBXH"?O#D+UV8)//'49'Y'GMG'"?-'KO\_P P$II(0@A>2-O5N@_'
MW]NO>G<\ @J2,X/''U.!05R#QD#KS_@?_K47GY_=_P  "G+(8H\1;RQ^Z=Q;
MCW Z>N#CKVJZD8*)Y@WDI\P//S>A(!Z_Y/HP$(#L4CTR"?Z?S_/O2&0N&#L(
M]O3;@#([#Z^WT[XIJ4^J;^0$BJJC&YMO]WG/YXX]NOT%$;><" %VIU5^KYZD
M>GH,X_G5<,(QM4,YYYZ?3DX_GGCW%3LJG/EY&>G;Z=\<^XX-: 2R!%1<$KCK
MY73GN/\ /O402,L?,?=M_P!7U!'8=1_G]*1RVU<C9NZ;1UZ=>P_$C'Z4W!9P
M6"KY. X]SZGO^OT/2@!S'"HW&&Z]^YSGOWX^E2M&'ZA?P0#^M0H"^Y3RJ_=Z
M'KGCVZ=:"T_52A'?CUZ<]_;% $X VE1D8X.>?_K=.*%,A"A7P1U!5?\ '!Y_
MF,8J%"X)&"V>G!.?RZ=O8>U/9OF..".#_C[C\^GX4 *I82$."R'@'IG\#S[]
MJ0<$YWC;_JLGIV]?K_AUJ43#=AQS^>/7.!C\^_IW-^-Q*C!^[W^F,=/T[?B
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MYB.VT'/09[\UJ.KZ5#<H+RZM5GM1&\Z27"Q/&DK;$+J[*5+-QM(# ?,P &:
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M#[X_> /B-XOU3PYX'\8:1XKGTR5X]5@T>Y6[>P\Q2R7-SL&V-'525.<'C')
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MX:OI;37-,L4U2XT[5M/ELKU[%YV@34X(+A8'%O\ (XW8RNTD@ $UY?\ $/\
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M6YT3QIX\URT\=1:-<1RVVIQ6O@<:C-9WA5@(I+;5?+>2"<+(GEGY,-S]"_M
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MI=^J^%=0A"11?>82#RXX@BED8DD* S+_ ";W7BWQM\ /V:-9AO/$?Q$U+6_
M_A2X\,^'[)[QXM*TZVN4^QLQB'EA5@L1@0/$$W?=R>*5F26(OVW_ -H>S^$7
M@7QM'\2KJ;Q?J_QYAT";27M_+LY?#L_Q;U/P[Y<$TC(T\3:7-%,KW4=LC"Y1
M02Z,J_U(?&+X\Z/\&?!O@[6O$]OJ%P/$1T[3U:QLKR[>&]N+&.YWW4=E;7$B
MH1&Y,K((<@*9 Q4'^<?Q5X!T'XN?#C]CGX&_"SX;OH-MI&I_#+4?&/BZZM!+
MJ&I-I4^AZKJ-W;W0Q)<2:EJL37LC'<ZF9Q( R2!/ZK6LM,M]'L[6_MXGM],L
M;4NUQ$K01+90_O) #G:\7DF)SPR;L,.M '\XOQG_ ."@7A6P_P""F_PC\3R:
MSXST/X,>#O@+XZM/&5BUA>16L_B74+F:/0[W4K$08*VKL +@!H$&6:55!8=)
M^QY^UQ\1/AS^U[XX^%_B_7?$WQ#^!'Q2AA^(?PW\<RZ9-)<6LWB:Y13X?>W=
M=L-M:Q2QR+)#YD!C=9%DV'=7.?M#:MH7QC^,_P#P48^*6AZ;HW_"O?@E^S%'
M\)](UF"V@:SN_'),^I:J^GNJ?9Y[ZSMI_(DD7,Y* H6X->Y?\$QK?Q+^TQXE
M\%_M+ZQIA\/?"'X7_ /X:_!?X:Z1]G6"T\9>*['0]-U7QIXYN(SM$DL5]/;Z
M1:RA -EE+'&[MFFXM6NFK[75K@?K'\>!\74\,Z7=_!?1-(US6I-0C%]9:SJ!
MTV+^R@C.983]F5UG\Q8^/OY(.T@$CY=_MC]NS<_D_#+P<93_ *E9?% $8^I:
M$ ?0D?I7Z":EK&GV4Z123PVEV(U8>>Z1.L3[MLFSS0!&,'<^-D?&\C(S2;Q5
MI2@1S:CIZJQP9/M-ME>?[NW=^..G0T@/GW]GZ[_:0N=8\0P_&WPYHF@Z,FF6
M%SHJZ'J*:EOU":?_ $A3+Y32)LA^9U08& I^; K\,OV@_'&L?\+_ /V\+#QA
M^T+XA^'NJ>"KC3$^!GA>.:6.QUZZE\/W>H1V=L=C#S6FB3]W;F5@W4 YK^E7
M3_%.DZB8X;:Z@$EQ<3Q0H)XYU66"+SW\LK(0%EB)= Q5025X;"U_,'^UKK=]
M\0/VLS ?#_A*[U;P9^V]X4\%:3)>VL$":EIKZ#J%Q)_;\SKAK<0(^5E8)L4_
M2FDWLF_1-@<7^TE\5?C'\0O$?[(/B_QMK?B3X2>!OA1X"\*7FK_$"]AO[?3O
M%/Q(OO#-M=3#4QY9*Z<2ZR9N8TD\T^4/WP*#]9?^"3GC;X_?%?X=?$KXL_&3
MQ5;^(_"GB'QO=:9\([I89()=1\-:*9!>ZS]E91Y%M//"%TU@=UPL322 HR%O
M@?QM\*_C7^TI^UIXH^ ?Q0;1?&GP?\%>!/#'CFT\(^#I(K6RO;75@;71G$YE
M$;^6UL2'12%12K[>A]F_X)=>&_CO\-_VJ?VE_@3<>*%M_@=\#X_#<:?#V\N5
MFN]-D^(::I?^&Y+#)8"TM(=$O[>58]L(,I:5DRI+<9+>,E\F7.47:TEUZH_:
MSXT^-KSX??"[QCXNL=&U7Q!J.DZ/<RV6A:/;O<ZI?W!'[BV@A560LW]\D(O.
MYQ7YJ?\ !+[]M3XI?M5^,_VL_!OQ0\$W/@37/V?_ (HVG@DZ%?-_IQBU'1K/
MQ'8_:X@[E'BT_4[& J#N!0A@K*ZK^M]Y=V=C%=3ZE)#:V:!&EENI$6WCC?[O
M[QA@!L?Q  =#BOP*_P""4>L6,'[=_P#P6,<WEMY'B/\ :V\/3Z(Z7 <:A:K\
M+_",22V@>1T>+S$="(Y 000P'=6?9_<0?T!AEC:1@-D:H99<(XVHL4N3RN&8
M;EW*N6&02H'-?A1^WOXML(/VUOA/I/CSQIXV\*_!B3X0ZYJ%Y>>"UOKIIO$:
M:CY6G1W$,$)M8_(7D)-(A;!QWQ^Z&IV U/2]1TX7$ULE]I][9&X@8"Y@2\M3
M;^?"P.%GA)WJ20,\@U^!G[?'[&7QBTS0/AE+\(?&7CWQOJNI^.K2T\67-^L=
M[/IOA'S_ #KCRE"2>3N;KM))_NG!JH+5^C7S*C\2^?Y'S=^T5KWP:O/A?>GX
M*_%KXZZK\0[7Q#X0O_"^E7EIKEJ+D7'B"R%Y!=H+,+)'':37$CDN(PJ2#.58
M5^]7QDUN^T_]COXGZS;WDMOK6B_L]>*-9%S;2LMQ:WVF_#ZZO))G?(\N:.XC
MD=E+"4,C';D&OPI^*O@'6OA?\/\ Q!X_UWPO\7K'1O#<*ZCJ.HW-O);QZ?9P
MW$6GN\<K)$(4=H4EB=I1\UW+M):OU"T/X?6NB_\ !/GXUZW;>)_$?B5?B9^S
MWX_\1QOKUW+<3V5K>_#[6_L-K"92"%2&Z9KE%P9PRB-7(P,X0:A=IJTG:Z:W
M[!+63MKMMKT/R*U#X::KX"_9I\$_%*Z\.>(-;TBY^%'A_P"(.I^(+SQ[#:S7
M[ZGI<.H3;+%W2]PLLQ*#SMTA/R!N:Z>U^$Q\;?LV?$#Q]?>'KCP_IE]\"]>^
M).D:[;_$![G4K2Z@L;:^TZ6/2[<2R0211,MM)+,D:(YS*4'->O-J/[/OCK_@
MGYX7\):_%JU[\3]'_9H\-^&;*VM(]1>&\U6T\/V<5E;QV\99995=65BL;)QD
MN 03\W^'].L_@UX"^*@LAX@U_P &_$+]B73M!LVNI+U(/!OC[3O#CP^*-*^Q
M3%H[:+5)F@N51D5%$!7?N(!TCAH3]^ZN--Q3T>NU_(^[_P!H.SU37_V ?V)_
M"H\2:QI$/CSXG?LX^&_$.H6FJR6VIWNBZOXGT>/452Y=D*SW4<AC=Y&"D9W-
M@\>"?L7^'_@A<Z7^U#\2/B5\1?$OA_P/\2?C;XK\-_#O37UV[;4K/P[\/]3N
M/#CW"K DPMY;O4-.N+@I.((7'S*2CHS?0OQS9K#]A_\ X)^7?[G_ (EWQG_9
M?F:.[ 9I(QXJT1C"%;YBP4$D $@+R!W^:O!'Q+L/AE^T+\<O WPX^'MEXUT#
MXO?&S1+[X0>$M:T1"NDV>MVUI=^.=3L;&[@58M$AU>?4;NYG"QQYE(!8TYP6
MB?+[MUKZ]"(SE=[KU6^_<^B/#/B;]@#2]5T[Q+I'Q8\5W6L^$?$5DK3QZSJ5
M]8)J5C?>:EI?)';RV_\ I4?R/EB@R%D8$@'](OCW^UC\)_@%X!M/%WB;6[;S
M]6TI[[P]H\*B^U'5W:WW0+9Z=$&OIMTAP0+<%.L@5>:_%WX._$'PQ\$_#/[0
MOQ$E^%'AWQ/\-=(_;V\9>"/B=?#2K>\NO!7AP>%_!DFFZA;1;9!!I=EK^I7:
MR@HWDGYI D;*Y_8+XY_![P%\9/ VA?%GP_H'A[6_%OA7PO)JWPUO]9MX)=*L
MK>ZM/M%L39E1!,K1'<@=0?X  _RTX05W\/3]?(;;>Y_/3K_Q.?\ :7\2>(OV
MEOBY\3]5^$_Q>L]3:/\ 98^'$\>H03QZ5X>NI9;K^W;(0-$S>(9WW):1$1!&
M023*HX_3/]D;_@J5X=\7V_A;P-\=].U'X:^.]0UR#PM#=ZMIEW%IFNZD+AH%
MGTW4#;R1%M0NH99=K,/*CN TWEJI8?G!J7B#XF?'GXG_ +&_BVTN?AM'J&E>
M-?B%IUM8QZ=!;KI>H:):0"_TO7;=\+MM#!YMLDKA<OE2Q.:_1_\ 8:AU/]I_
MXC?$GQ;\4/#7@CQ-X&^#7B^30?!FH6>C1FQN/&FFR+-=:WHUT8T%U%:H9+6=
MXO,BCN?W3.)65*N5/1JRU[?K]Y+:6[2/"O\ @ICHFE:;^TIX%TNPDU+3HO''
M@_4_%.L:WJ'B*]M-(CN;2?[/':VWED6R-_=7=R,, 5YKP?\ 9^_:*\:_#C]E
M"^\)^!/!-WKOQ"^.GQ$^/O@&!M4U"X6WL]$^&>B65I<ZW&;V0*\3QWADT_RY
M"\NT&51TI/\ @J!XT\;6G[4OQ+O[G5-4N?!WPX\(^%;>RTJU@DFATJ+7[-5E
MO.DRPP27+J3N(!<\\@UY]^S%\'?BE\5/"7Q0\1GQW'I^M?L[77BS5;"SUU4@
MMHH?BC\'/#.O:Q:6L,Q;-T;N1S(4#/G#-P03R?5:D9J:?G9?)E1E:]K/\3[K
M_P""2GQ5^+VF6'PD_9]\6:#IEEX2'PN\6?$/0]3LKS?-JDG_  EHTN^^U1J'
M=6$VJ37"N0J8MV56RI ]U\>^-?VE?BC_ ,% OB)\ ?AMXX\->%/!?PN^&O@G
MQK=R:G:W$]S+-XNBC94C2VCD<A;N5I&*AA&O$A4$5\8_\$JK[58?C9\']'\;
M^-M)OM>L?V;?%%KX?T& ""]DTB[\:6U_<,BN521H9+4JP#EPEQ/)M\OYJ_03
MQ3^R#\;]9_;@^*O[1'@[XA6W@/PUXL^%/@_P1 T%LT^H7\VB^3EI(UWL6MMK
M8=T5"!^[9N*UY977,FK]6K?G;R*YWV7]?,_/3]@'X7?M +^W9_P4SF\/?$KP
MI'KUM\6OAM!\0[ZZTW5"=0U@_"_PY-H;V82S*K;)HDUL))"=_F ^9MD.VOTU
M_88^+WQ%\83_ +4>E_%?5+#7-1^#OQ2O?"4>K:5YB6FH:?;:6NH'$<@$B;0P
M7<R@=<$[6Q^8W[$_P8^.NL_MT?\ !2G2_#WQJ.CWFC_$OX9+XQOH[8L=>U*]
M^%^@-ITFQ5,D9M=+@LX69E"IM&\J2!7VYH/[//QS_90_9&_;QU2SOQ\2OC'\
M4+?XF^,/ HTN(_:-2U_4O!MUHOAB"2*)R5F&J2QSC!3R@FZ<Q("PJ<5&UGJ[
MW75>HG)RM>V@R/\ X*/_  6^,OP,^&WC[0?#VL^-?A_^T=\7=;^ NCM+I[&V
MNWL-3DT+4)Y8)XH7ATR*6.0+<1Q2&X*E[=I5P]>^^!/AGX(_X)Q?LQ_%R]L;
M_P 4^*O ?AW4O$_Q%M=!AM'U34/#VG:J-/>^T#0H4+276F:;(TEQ:@(BVZ*Z
MOL*L!^8-Y^S?<_LE_LE?\$D/@=.KV&N>#/C?\/(_%J3R(TTGBG4K*._\3-+*
M(QFZN=9FO)I6"ORV2Q !K]C?VMOVD/A'^SY\.])UCXG&/4M!^(OBW3/A3#I2
M;;Q]0O?&4DFF_8UM5CF607+2!I@R@;6$A940LN9)W'[./QQ\&_'SX2^%/B7X
M+U&*\T;Q)IT%_ A*Q7-J7X%KJ"!3]GNEZ2*57800^T@X^@(OO/\ C_.OSS_8
M@_9&O_V4+SXL:;IGBRXU+X8>//$<?BCX=^%IW+'PEI]XLES>6#;U(2-9+E8E
MC&S&W(4J"P_0I<J7XZ].??/_ -;\:.7JUMM?3RT_K0#\C?\ @IN^K?$SQW^Q
M3^RE:J8O#_QZ^.-QKWQ(<SI']L\!?"#1)O$U]H\NZ5)I4U+5;K1(988H'BEC
M-P5#H68<-_P5^\2>*?AA\/\ ]CO3/AYJ]UX7LKW]JSX/^#M2L-'VVPU#PW<7
M\%H=*"*R1?9DC^^K$!^P-=[_ ,% <^#/VJ_^"<7QEU.';X4\*?%7XG^ ];O/
M(;;;7_Q*\"PQ^'OM4BL?*BFN?"]U%;;E =DD&0,$\U_P5H\"^)OB?HW[%\?A
M32;[5K?1_P!KOX4Z_JK:=#)<M9:?::G!</=W6T?)#'#\[L?N@@$;OEK?E5HN
MZZNR_"X'Q_\ M-_\(?\ $;_@KOXH^&7QJ^+FN^ _A3X4_9L\ :SX8TNRU^WT
M:"XU_4WOTOUD:2Y2.:=4MXI2!DOP%+,"*[;]N#Q//X6\#?L+_L-_LS^/-6FT
MW]K#XO:MHVI?$MM4BU'7;/X;^%;2\\0^+Y['4_.C:.XN6$5M8I&)5*6P^T*%
M="?5M?\ V6M'^,?_  6&^*_C/XH^"&\0> -)_9O^&5OH%QJ%HYTN;68I-4CN
MGMKHH$DN878+)'G*Y#8V_-6Y_P %%/V<?%?@_P 1_L8_M'? +PBM[:_LB>//
M$>I:MX3TBT9YI?!/C;1Y-+UE;"!%!'E!4;<@DD7S2=G#8?QJ,79*V[?Z]_S"
M&DVWM=:_)GTS\.?^"=/PB^%OBKX9>,_!WBCQS;^(_A]>V-Q>2ZCKTFJ)XKBB
M4-=IJ]JSA"+AS@!%;![8YKQ[]K.*/X6?MZ?L5_$S0&>UN/CA-XQ^#WC>&-5B
M_MB'PY#IVN>&;^XC;:9KRV%[?V6\(S&*1"/W:Y'8^%OV_P"Q^)GQ&^'GPY\)
M_#'QU=7WB[6[*TUK57TJ\M[#P]9.?WDU]=""-+=5YSYC@^V*XO\ :ZU _$3_
M (*&_L"?!S3K*6_NOAW_ ,+,^-GB2>-'>+2=*-G8>&]!DN'P&A:ZGMKAH&R6
MG:&4JI5':LE'EG9;*^O0<MWZGZW, TQ4S!652_E=V4 #)(XY/;)/'3'3$\4Z
M%!XF\.:YH=Q<W5G!K.F7>GSW-D_EW-NDMN(RUN^5VNB_O!@Y)X7)X&L0'G+L
MFUP"B,<?/&/O'V'NP //UKE/B%X@U/PSX(\4>(-'TR?6=1T?1KV_L]*MD\RY
MO[JUBVI;0Q9WO)(< (!D]QBJBGS6VO;7HM%?^NXC^2W_ (*->%?V?M&\;_LQ
M_"G]DG7/$VA_&W3_ -H;1%\<>+KZ_O(+632[+4)%UF'7=2( >74F2:93EUQ(
MD?WRJG^BOXQ_!G]FV;P)>?'/X[:99WUA\._AFVJ^(/$U_JLT>G6VB^'=$?4;
MV[C<,D$B1+'</!*=VTJ%(+.@;\=/VO[_ ,7?MO\ PI\-_!3P!^S'XD\$?&#Q
M!\0O"/B"[\;CP\=,/@N#3M:CO-<N!J(M\*MS:VZ9WM*S^>R(&8.B_;__  4^
M^!WQM^,?[%7@O]C+X3#4O[4^-VJ_#KX0?$CQ;;%XX_#O@&.33G\:ZO?7H.;8
M7FEV%[:+N&RX^UD/G)!MT81J1DI)WO>S72W8I;2^7S/F#_@@#\+Y-:^&'QN_
M;4NM(USP[I?[4WQ0\1:]\,/#.L,QFTCX5:?J$UMX9OK6 O)-:?;-/C@NECCB
M/R3#S(T;./U._P""C#HO[$'[2.X#!^'<L+DLV #JVEQD;AF5O,2<@%5."2I(
M)(KZ.^$/PO\ #7P7^&/@7X6>#["VT[PSX"\+Z1X6TFQME2*);+1["WL(6*1@
M*[310(94'EHT@9F/S U^>W_!7_Q]J>D?LC:M\*/!\+:K\1/V@O&G@/X4>#-#
M@!:YG74_%>DWVM7J(I#-#8:;:327<SLL42)B217*J\S7/)]D]'_7H9W<92TE
MK;;R1\6W/@KX?:!X(^'^D>%/AKXL\701^!/!^IWWB2R\?6VG61O[G3[>6:S@
M2=[:0['QYT C,L/S&5$VL1%\-M%\./\ $SX=ZCKWP2M](@TWQ+:ZG;:SXB^(
MNGW=OI4UHL;)J"QSW#J\PDD=<[8OF]#BO'?VR?A3\(8_'/[-W[$7@'7->\$^
M+=2N- \4_''QK'KFJ)#X6\):!I\5QK=I'LN(XHKKQ#(LNFVJ0R2NLD@8($&^
MNVN'_9NTG]K?PW\([CP5J6L?!OQ)IVB:3X.\7_:M32.+Q3;QPK?1ZE<2$H5O
M+U6D17VAE'RD@@TO9KN_O0U)RWOIW/Z2[>XCU#3;:Y@FCGBNXEEAF1UDAFBD
M3S4DBEAWQNK)\RE&.[&!SQ4T0 .T_.R(SGMC;_J\$C;D^@.1C)P.*S]&TRVT
M72].TK3D\C3=*M+>QLX<EE2VM%$5N4)R=RI][."V!UJXTOE,6;Y847?-*>B'
M^XWH/J/6INT^5;7:&?ES^RAH]IXF_;A_;N^*NKR+=>(M-\9^$/A9H"2I+_Q*
M/#?A/P7H0:QM)G3Y+2]U"6XOY4@),C7 0AGRM5?^"@OB;P9\,_"OQ*O='_9C
MUSXQ^._B1\.=>TZYU_2= CU%-.\S2-1T_3C<W<\3-;10SO'*6L6<9578A?GJ
MW\'+_4_A/^WQ^TE\-?$$=M8:;\:I]!^+/@>^8*KZSL\/:?H^M11$Y.;34]+E
M>11L<CYD#QNKMT'QX\7_ +<VB_$3QQIWPU^%OAGQK\-;FQMX?!MS))"EW#>W
M]BL,DFHAMN^!)6D8P;?)R,YP03HXQ<H>\KV=]5I>W3^MAIM;-H_(_P#9%_9Z
M\1?$G_@C#XL^ OPQO;3X@_$W4/$CZSXB\-6%S'$?#NH-K[:K=>&[F:YEC'VR
MVB1HWL7;SPHQY9SBOL7X4?M6Z#\#?C'\+_@E\5?V8Q\!_%?C?0-5T+X<^,([
M'2XE\4ZAX?T]9;K3=,DL_-F>61(8YV@E$4KA6*JQR#ZW^R7^RA\=_P!C']E[
MQM!X,L=#\5_'/XE?$/4/B9XDTF1H(--M;G6+R66\TVS,8BMRT5I</;1OY0Y0
M,@(*FN,M_P!EW]IG]JK]J?\ 9[^-G[2/AW1_A_X'_9JD\0:WX5\-VLT,NJZW
MXIUJ$:>T]V\6&%F-/1OG(A.ZX'1D8"XQBI-MJWJM?^&UN*4I<KW=[>?]?\ \
MK_X);_"KP5\6? _[;?Q2^+.BZ;XM\=_$KXR_$_0_$6NZY8I<SZ9X;TBTDT[3
M=,L?MD):RM[6U9WRLD8+0A@<%2WY>?L_7J_&6_\ ^"=7P5\4K+X@^&6E_';X
MOK+I'VLR:=KL7@76[^/0+/4,&6QN+41VT<:6[RL[KG:A"G'Z^ZM^RS^V+\#?
M$'[0O@K]G.WT*\\ _'76-7U[3]8OY(XV\):KXJAELM1:-#''OAMXKB2YP5.]
MH]J;W*J=+6?^"8OB;X6?LU_LQ>&O@1K>EO\ &']F;Q./&T.JWUJD%OXLUK6)
M&N/%JW$JE'5=0EN+L6IE=53>"Q QFFZ2<K+>UOQ[;W^1,6VM4U^%SR[]O6+1
MO@Y^W/\  ?7OA?9V7AS6?%W[+7Q^M-1TO1[5+!-4@\'VMI>:1>26-M' TKV;
MZK*%N?+*EG"HY9& Y?\ 94^"/PP_X<Z_';7/&/A^PNM8\<?#+XT^/?%_B/4K
M.*?5E\3)I>MWEI.]]) U[YFG7,,$Z/!*Z!6"HQ*D#ZQ^$?[&7QF^*'[3VK_M
M1?M8W.DVUUH/PAU'X-_#/P-H]P+BPTBP\3S7,_BO7Y)2\S0WFH V4 0%4Q;@
M_=P3\\^(/^"?W[8]A\%_B!^QQX#\5>&=(^"'Q/UG7=(U+QE<7(G\2:1\/O$M
MP4U:PL(R/W=PVGS3P#:F[(.%Y&9M3_G73JOU_I%'CGP9^#'QM_:(_9=_X)G_
M +1/@CPSH?Q(U/X8_"QI=9TOQ1>62MJLUWIUL+6[F?498HK@SEUV,&ER#GH"
M1]Y?L<?MD7_Q&_:#^)7[,7C'X8:7\*?BU\--,T[7O%/A[0XHX=.O="UQ&L[/
M68I;. Q3-]IMGB0,S2HSDLBJ03Z]XJ^#G[1OP%^'?P<^%'['X\.#X?\ PW\"
M:/X+_LO7R$N631+9+6TNC)+YBLSI&DDGELY9N#R#GG?V,?V,O&_PM^-7QL_:
MX_: \3V/B;X[_'*Q\/>'KZ#2(43P_P"$O!?A6WF?2-)LU&XO(LGG2ZC(96#W
M:^9G:58Q.7-'H_3U_P" !C:?9Q:!_P %6O%UOI\+Q6WC7]FK2]4\1_Z3&HNK
MSPYK^EQ6%P8%E+--+%<W$43;#(I<F0(O3]3>7_<R']XIV[X^ 3COCCTZX&*_
M*W]F70];^,O[</[27[5-\7B\#Z!I.B? OX8(T4D<E^-"NQ?>(-:MXY%0W-O+
M=PP0O*B&-LAT=T5G7]4%"+()@JIY@R\9?=M/U4D$^X./2L;/L_N (E,?+C<0
MVP;"!M3LYR>>O0<Y[&K!C$LF&=ACD;#]P^_;'K_.HU&^61QR3]U000?H<X'?
M&>GUJ9<[=V/FQ\X_O>N#T'3CI6K[K>UO2^WRZ>;T8 TS<QJN#_$S_,3W[$\?
M7^M1KE -O4MEOIZ]L^A&3^0I5W,6X&>O&,_S_P Y/X*N"^SO^GYXQ^M%DD_O
M?7^O(![D !\C ..< YZ]_KUZ>]-4$[%Z[<%P#DG@=,9Y],9_GF*11]UTW?+N
M&&7K^)_'G^8-,C* !ECV2'.3O+#]"?IQ^E1)64;:[V?D!8=) "8RN1TW<_\
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MAW;O0?T#9Y^@[XIS"27RB)(B%!#?O-V >"6R>3ZX_,]:%)K:VO<#^?;X3?\
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MC'4T)Q[K[P+"YD0,C%U/IG\.H_F!^-<!XJ^%?@/QSXB\$^,/%/AC3=;U_P
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M-OV?_'7A74_AE\3/"G@V/QK9^'?$MLMOJ.L>&%3>^L6[;F:0QCB95!2%P8Y
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M:-I/S_=/W@, Y)^4 D$!+#Q%I6J7LMII5U%=- 2)_LK+);JZ8+*2/E#*74$
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M."J\D'TQ_A_6G,H&'4LG=E7(S^>/7_(HCVA, H7Z;E. ']"3@#TR>/SX>6C
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MD(4KDX+' &#R>W3OTZ_TIAYY//;D_P"30 Y6WD%2#MZ_U///3]:DV+Z?J?\
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M&C>*M*CF0&4:=KEI!JFG2.X W*L-S#SC<$DRZC:X'8Q%65FR"RL%88)*L3M
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MU;PA+X0\8Z?-:CP_XQT/Q?JEM):MH]XTXCNI[.Q>2VD+/NB?Y9 C$ YWBO\
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M^'W@>VN-5B\/:KI6D&_>#Q5?VL1BLIYIK=KJ57D1EB8EP!Q6=G=KE>GD_P
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M-.UW4+WQY:WMO)INDQZ5Q#%;-!,4N9),Y55#NP.X C-?C/\ \%(/AGXCUO\
M;._X)=?L7^#_ !_XQ\-?"_XBVGQDT[QQ]BU*X_M+7_#W@W1-/U^5;FZ.V-I9
M%M;E%W2;RMU\BG!QZG^U!I[?L^?\%!?^"6GP1^&^KZOIGP]AL/BW<W6CW=Y/
M>/K,NB>'KQ[*/4+MMK2)')$LC J0>#S46?9_<!^U.M?''X:^&_$,'A76?&.@
MVOB*:2*(:5>ZE:VM[')/_JHS&[J-TG\ SSU&1T^;/%'[>_P8\/\ [6OAG]DB
M[UF"/Q[XA^'>K?$*VN5O(%L8].TZ>RA-DSR (EU>?;,6_F2HTFP&,,17XT_\
M$QO@'X$_;<\(_M-_M3_M&^,=?OOB3KO[8?Q>\/Z% GB&>R@\":+\-?&LOAGP
M_I=O;2.A>VN;73S<)',L'F+=A@",UM?$;]F#X+:[_P %R_@_X/U73]5DTZ[_
M &4/%7CB6^?5IK<OK'AK6=#72FCF)65K1XCN>U20PS#.-Q!%;0A%Q;:U2\_/
MH!_3)"T91)8W4FY/G*^X.@4KN 5AD8(R0>0W;)&!\(_\%&?VN=4_8S_9Z@^*
M.A^&F\5:_KOQ!\(_#7P[H_VD0QRZWXQGOK&QF>08+QHUN7*%EP0-^&*D_9EO
MK?AVWU*V\(PWMC'J?]FP7,&D-<JU_P#8%C(BO%AR7-O$5=/.'R.P(C9BI%?C
M%_P7SMM9NOV,_ D>@NBZW/\ M1? RVT%YT:XV:W=ZUJ4%A,\9V;+*"94N'E0
M[U#D,$PPJ(13G;;7K\_R_P @/J_]EWXF?M3^)M;FU?\ :"\#:9X%\$P>%9]9
MM]4EU87 -U)"+AH[EGRJVT4!EE+/M54&=V",_9-O\6_A[_PA$OQ(/BS1XO Z
MJY;Q,U[$-+EA#B*UGMKO_5LER[A8GY5B=PX&:_-35/AS^U3X/_9"_:EO_C)\
M1M$\3G4?V7O'?_".6?AN.]L-0TG64^'^HM#=1[?/6&6((D:"%MQD.]>A(_(#
MQ[\2]-TG_@VF_9_B/B6X_P"$M\0^ /@GH=M%%>RIK^IZX^LZ=]NM)!G[7<7:
M0M(]WMW *&,C=!14BE+1W;[?UU_,#^G3XB?M,?!_X66D%WXT\>^'M CO-/M-
M6B74-1B@W:;?))):7RG! MIHXF=93A%4!G*AT+?F?^U_^V]JG@3]I[_@GA:^
M%_'6CVWP$^-.L>-M2\>:S;212V.IZ?H.@W^IZ+):W3XS$;BWBAFPI,K%5M5@
M.*^._P#@JS8> _BMX3_8X_8Q\'>&[36_VDOVH?#WP_T?7/&+S30CX8?!;PYH
M%CJ'BGQCJUYNACMQ=K'_ &-8,[AY;F=A#%(ROC1_;&_9L^&&E?M9_P#!&7]F
M&"TN->^&F@MXP\/PQQWZW!U/3_"WA'4K^YDGOX&=IVNIK2222158%"P))-72
MBE+FG!N*Z6>OIH!^[GP@_:;^$OQRO/$&F> /%^E:W<>'2/[2MX)'^UV\9R(+
MN9#,CI%(02&P00NXD#FO+=:_;W_9FTGQAJG@V[^*7AZ.\T6^BT;4;F"Z66UL
MM5+B(P75Q&KVT4ZR$1O&TH:-R%<*3BOR/\9^&K;]G_\ X*1?MB:-\$M+G\,V
M=S^PA'XRMM%TBUF.FGQ9'I^M6EM>6L$"LJSQ+%;W!( 9F8 $LK >%^"OAG^R
MUI7_  0@^+_Q*\1G1KWXKZU\'?BCXS\2>,[VZ#>.[OXQR7>KW&C1V)DN3J9U
M(:X-*M+:TAC,CLZ!%VG=1*BY2E..D';EC;:_Y7TW _IIN_B]\/\ 2M2\#:'J
M'B+2CK7Q#43^$-/%Q"M[K5O#$)Y9M.MS)YEPB1$-N &?NC+<4R?XS>#(_BO'
M\&H=9M9/'C^&[?Q6^@K*IU"TT6[FF@M]1N[?'RVTLUM/&'+9#1G<JY4G^;WP
M/JWB&Q^(_P#P0O\ ''Q=O-2TC6Y/@QJ/_"3ZAK!ET]+?7+KP[/(EIK*W9C6"
MZ#^4%\T#YFQN!!"^]?"+Q]X>^*'_  <&_M%^)/!^OPZ[X:^&_P"Q?\+?"6KZ
MK97JWN@6^L?\)%XKU'4UM+JV>6P>>-)H8)F$C,0A&3L95RE%QT;OO_P0/Z(&
MD?*JI#,X:-649V!3M+D#D 'VY]<"OPY_:G^-7[3_ (X_X*':'^R=\"_&GACP
M?HNG?">V^(VN7WB"(RQ7HE;:EL", DGC"L6'4@#FOUX^&?Q7\#_&#3;_ ,0_
M#KQ%IGBG0-.UBY\/S:GIURMQ;'5=+NGBU6R2XA'E/=64J-'/%&S%67:,XQ7X
M5?'_ .!>N_'S_@L[<>'](\>>*?ANNB_LQZ1?WNN^&XX'GNHGERMD9)7@8;AD
MX/W<<XZ4X)-ZVTUU=E\P/U \/_%&?]F7X+^$;S]J3XDZ)=^+_&'C^+P;8>(=
M,1$L]7U;4KNYAT/1K% 96ED^Q:<\811C?G>5/%>X^+?CUX"\$^/OA5\+=?UR
M"'QE\89]0B\&Z3,)4GU:WTNS?4+^:+]^0)K6SC:63#J<@1+NE81G\?/^"JOP
MK'PT_9E_8O\ #6L^(-8\8Z=\/?VR_AAJ^O>,-6MS-=K8Q#QE?G5-3D^U^5:"
M$SP1RR,YC9MB??*K7"?M!_'#PS\9?^"P_P#P3,\&_#&>+Q=I/@?1OC!KOC;Q
M'I<3WNF:)]H^']_=:5:3W\<8M[5Y[J"*"9!(S,9"0-H8A^SNY..W=)OO_7I8
M#Z"\:?&GQ;!\(_VUM6G_ &E]+TO5_AO\9GT)?%$4 2'X>Z-;ZBEO'X4=!%LE
MU&2"5("S[D!;<S@ L/KKXB_MA?#[X ?"KX6:AJT^M>)]5\9^"](U/3+>STB\
MU#4]1T^"UL9+W5KR&P:(1K>->R^6H*S,$#+&0R$_SR_$V.WUG]E;_@M;9PPS
M7#-^V=J5L8XX_,O+DIK%B8T1(U*N"#Q(2),9XK[@_:6^,_C^7XX_LE?LM:'?
M^"OA)X-T[]EK0_B)XM^+/CFP@,&R*PT[3AX1TB:[C\M[F)+59WMX)99F+X5"
MP(H]A)M>7DU^8'Z4?#+_ (*%?!'QO\!/B)^T)_;;6_@/X8PW\WB^]NT07&@S
MV2NTEA?6K*KVDT*HS2+(H90#NQQ7AGA[_@KC\$/%7C'PGX?TQ=<@T'QOK,7A
M[PSXOU32+NR\.:_JS% (M$U&3RHC#(DL42,CR1RNKRH[J2Y_#'X7Z!JNF_\
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M:Z_:5TO/J!\?>+?VF_V@HOV.O#'[)FA>.]6TCXH^/_VU4_9)O?B>LAFUK3O
MUM>6^M:SJUF[-OCN4\.QW-JTA8$7DXVY;Y:^P-7^"Q_X)\?M:_L9:-\./'7C
M;Q#X$^-TUU\/O&FD^+=?N-7DOM?AL_/?7[%KD/NNKZ/YC&N8;?I$=_%?'5S^
MSC\<-+_96^&W[8&L^#-7?Q/9_P#!0&P_:?UCP=+:.FLZ1\(M4U&7PW=RW&GE
MOM27=M8W$.J"(0F22V@9IX5&*^Q/'7C'5?\ @H/^WK^QM=_!S1_$5I\'OV7;
MC5OBA\1O%FI:5+IVDW6NW-I]GL?#M@ER(!>7<'0P EO4 <TW1BE?F3]&OTZ@
M?-/AK0_A'XH^/?[7GB']L7XR?%7PO=:)^T#XCT#X>6MAK^MZ+I-CX/B2S;2C
M9-%&UN;"&25UW!ASGBOZ3?@CJ/AG5? /ANS\%7L>N^!;#0]/MM"UF6\&I3ZG
M!%P;Z>[F>Y-SYG7=(=V!G QQ^1G[9W[67[/'B_X8?'?X4V_[/_C'Q9\6-8MO
M%/@3P_X?L?AWJ$NO:OXHNEDMM*UBWU6"RDABL$G9;L7[WD>40'S5&,_:G_!+
M[X*?$3]G[]B3X(?#CXJF9O'FF:(^H>(;:]O'N+K2Y-2N)[J'3+@NS;;C3[&;
MR'BWM#N3 )/%86U:6MNVN^VP'Y5?%#P+\#?BU_P4._;5'[27Q5\2>%]'^&WA
MKP$W@"WMO%]UX>L-&%WX-TV^N[O3+: R17%ZU[(R/#M*[\@C.*^M?^"*NJ_$
MSQC^SUX[\2^/;K6M4\/:9\9_'_A'X0Z]KIE.H>)OAQH%[#'I6OW0F(=WO#)/
M8Q2[%9VA#A=C(S8'P]_8]\)_&?\ X*-_MJ>._C7\,+S5_"5I+X LO!-YK$-S
M#H6O_9_#>EG4L9Q%>)]J#<+N&T%1D"OT0^/OC2^_9:^!FFW?P6^$=YXH.F>(
M/#_AG0OA_P"#M*1C%9:Q<?99[JVM;8B."VLT_P!*N78JS76'R1S5RE3Y4DE=
M;O;MZ ?D?_P5!UCX83_MX?LV>'OCYXAUNS^#G_"LO&.K:IHNFWEY%97FL6TU
MI]C:5;4[V<>8^P%#Z#!-8W_!(R*_\0_M8?M8:_\ #35?$]W^R?X?O='T_P"$
M(\37D]X\.L2PD>)(-/CG8-#:B<%/,8%T8?+D<U]9?%[]G?Q%\9?^"D7[-GQ&
M\>_#BVU_X36/[/7C:W\5_P!M0"[TO2_%-Y9VM[I^GW<)S''+'/$\7F;"Q8 %
MN1G(_9[^"GQ7_93_ &L_VI?#G@OP/K]U\ _$NAM\4_AQ/81QQ:9%KMQICMJO
MA*PF#",7EQJMO*T$2Q#(G!CW(-U8^Z];7\[/7_,#T'_@L!\6O&/@C]FSPW\-
M/A[JMSX=\:?M'_%[P'\#K37K20PWNC:1XDFN+[7+VPD)39>1Z=I[PAQ(N265
M"SC;74_"3_@EQ^R+X,\$> K>+P4]_P"*O#LFCZY)XZEUG65U[5->L9X+^35+
MJ=;XV\S7%W 7>+RFAV,0<Y KRC]H7X6_&W]O/]C/P5XTN?A[J'PM^.GPZ^+.
MB_%[P+X)\0R+;ZH+KP+=WUI)87IEMU2W.MVVH7)C#2J I7=C:12>#?VR/VKM
M23P)\.]._90^(MOXQN=:T?1_%5_J,%OIOA_0K-KFWMM3U=]3FG N;*VM1-.%
M8I)+MVPK(Q53UTW'E5FDTG?;RWO_ %IZ@?GOH/B#]IE?^"D/_!0?PY^RCX;\
M/3:DOC71_$/C7Q-XE9Y]+MY]-\$:);P6,4$K3"XNYXK41E"[$2!BZ@R#/K'C
MW]L"\^*_[ GASXM?$KX8Z#XI\9:#^U'X/^%.K>&]4^W6VD:?XJL/%RZ+>>(;
M>VL[RW66X@>7_1;-BR9F# ,JL5^\/V/OV>/B/\-?VJO^"@?Q'\7Z3+8Z7\7O
MB;IFN^";_=%)_;6CKX*T.QGGMHQ*'>)=2AFD#2)$KDD*&!.?A"#]B']HF_\
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M&(8).!7T5\9OV3Y?%/[7O@K]L.&^9U^&?[/?Q#^'0\.>03+JLWB!;N_M9(V
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M(T#PG\,OC4_@GP5'\.H_ASXC\,WEC%=V]_I\=A%I[WL!E5HQ--&C.I= ZXY
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M9RP+&Y-L9'+M@D<\D"OTH1-I=RQ)9L[3V/ID>Y[<=*4KN!"DDXZ-_J_RZ_\
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M57!+P)C:<0@M\@SD[0RLBDL&(P@RV.S=QQG)^F>W-"E^@=W^4,=Q&-OKG/\
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MI[^] &$_<\=<\<_YY_IUZ#Q,3$0<[>N3_/U_#/Z\/8B, (=@_/C@<XY_SWH
MJ1NV\^=D;?NX!.?IMSCOUQ_*K;;G1QC(;IVSU'^>G6D;!()7CGTR?7IT_P Y
M]I>P/8]/P_E0 U8\KMQ[]N.W\J5AN3:>"KY['@>X]_\ />I(R,D9YX_J:<!\
MS CKR/IG_P#5[T 5I)<$+DDD@ @'JW0<#OCJ?QIQ(53(/O#@CG@_R/3M^=(X
M\M@=F0S1DGC(VCG'/;L /_KD(+E\CY"^1SU&...H[=LT 1AA.%9AR&SMZ#'
MS^1X_D>M3B0[P.2HZG!&/3/Z$9%2+$BC %.Z' 7 [GI0 N1G&>?\FFE@V54Y
M/I@]_K@=*;D>8>O'L?3Z5'$P9V(.>G8YZ$=.O7VH ?&W&#Q]>,?GZ_Y[U#,B
M@^:6//08/?KP!V_SUJ8HS=1L^A _D3_D4QI0QP1\O7/K^&"<_ACZT *G4LN2
M!U&?;MG%,=6894$MG&/;U)]QGO4L:E0X/?)'0Y'3/%49'EW,4?*H<.<8Y_$
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MGC#QGX>\"^'M3\2^*=3MM&T31HFFO]4NYA;VUK$I56>>=P44 NHQG)SP,9H
MZA"(P&^9O,. -K;@>N"" 0/KBGM(VT_*.!GL,8],G^@XSTK(T76M/\0:3IVN
M:3=)>:=K&G6^HV5U XG2:UNH1/;7$3Q[@8IXLM&W 8Y4?."HUB5*'<0V5 '7
M.XC(&",K@<G@;1UQ0 *RC"D\E.!@^GKC';N?YT(1'\J99>_;G\<>_P#G& A
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M"C_P]^/WP>^+_P 1_!6AZ[J.O_!'Q!>>#O&?@2+3G?Q)I?B6V$9&GR6OEK+
MV)(RB8(=64HQ )'S!\5?^"Q6E_!_7/AGI?Q#^$GQ#\'1?%[XA>%OAKX-N=3T
MJ2 :EXF\47-II]K8V2&%I'-NEU)=/Y2"-/*=I'38Q5\LM?=>F^CT _=&&7?N
MZG&.=K<'T.1P?4'D=P*>[ E0,Y/3@]\8R<8&?0XK\D?CW_P4P'PW^,NK_ #X
M6?##Q!\4?''@/PA9^./B<VBV;W-GX8TN]@^U".1E*K',L'[W+NQ"_P .>*]F
M_9Y_;^^%/QP_95N/VJ[6XNE\'66HZQI=_:I;L^HV^OZ/?2Z;>:*T$:>;]LM[
MV"6W,*Q-N8!H]\;*S*S;LD[]NH'Z [U8[03E<,VX%<#>Z<E@!NW(PVYW<9Q@
M@F031F/(;(YPRY*L >2K $,.W!.?QK\^/V#OVY_#7[;^E_%K7O"GA^_T"Q^%
MOQ$OO %]#JUJ]EJ-Q>6MG'?V\\D,@ 0RPR-(58 )]QRKX4^&_&+_ (*'^/+K
MX\^-O@+^R[\)-5^+VM?"P0Q_$G7;,O#HVBZE@M-I/V^,*D]W&JGS$X*L"#@X
M &FM&FGV8'Z]/L0 YQSMP1CDG' P"<GN 0>H.*A5/)9G!+G ^0*V1NZ'&.GJ
M3PO.X]:_*[]I?]OW6_V<_AM^S]I5[\/=;U[]HS]I2:WTWP?\,-->2YU&PO\
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MSU<^*/VE-&\7:Q-?627.H"V.D2A9UC%OJ3RM(+V!%?RP-T *D,?J_P#X*9_
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M>AZD\'BC4_%NF>'=*3393<LQ5M+N=5-_+>A_,N)"?NG )M_\$S[OQ%XBUO\
MX*QW7P)\8>*/$_[+=IX<_LGX$0>(KL7GB#3_ (@7/P_\2OXA_LZ9Y0_V#[6E
MK+8ML1TE"J#O!4?0?_!3*34K#]MW]E/6_C'X2UKQA^Q]I?@GQ'J'B^QT_3YM
M2TW_ (6'!J5R='_MVT2.9?(%O)&IDD@W@*%<KC%>3_L+17_@;]M3]L[XP_ G
MP3XOT3]B1/@5I^O0?#Y]#O[*RU[XRV>I[M73P]I$UM"))I]%:9<01-$R,T2R
M-(?+J0/'O^";\G[*Z_#C]G*X_:6^*WQ/T3]HZ_UX7-_H?BS5+_2_#LGBZ#57
MCTW3I&DM]KQ.ZQKY?FE"2,M7TKXG\.:Y^W!_P6,^/?P1^(.O:]8_L^?LC? ;
MX41IX-T/5+C3I==^(7Q3L[WQ'%JUY<@QA[*PTF:TC:/+,EU%\VTG%>"_MV_$
M+P)^WY\+_!'P2_9Q^"FO^'/CEJWQ+\&WNE>)8_#%SHS^"+>QUZQU'5-1O-4M
M8HIX9Q!!,)29!N!*@,[!3[KXF@\<_L&_\%3?BY^T)XD\.ZWXJ^#G[37[.?PD
M\/R:AH=G=ZE>6'Q(^$^BGPK=64UO EP)SJD,$6I(TF'Q+Y8)D#(-DU:.JV?5
M:?#_ %\@/ESP.WQ_\"_LQ_\ !:/]D#P#XXUO5O$_[/7B#2]7^#^KM>L_B&R\
M(>.K>/7+W39KJ[>)6%AIVGZM KK/M/F6ZIN92H\0_9JU?X>_$+]K+_@FKH_[
M(GB_QYHOC3P]82:]^U%=>(-3NVL-8\/Z;9.-=LFM[C%OJ=W>S"54$!E=C(&5
M6521] :M\#OVN_'G[,7_  4B_:=\'^%M6\,^/?VL_BY\+;WPOX2M[*\L=>N/
M@A\/M4L]/\2*+*3RKEKO7]'O]1@&UE3!;Y?E.&>*M!T[XI?$?]A73/V*/@YX
MK^&7Q.^&/C_P+>_%CQ1;>'9],MQ\/=/GMO\ A+](\17'D6PGEU.&.X8K.[L_
MG[55R"!E+=^H'L?[+WP6TW_@HU^T3_P4N^)WQRU/Q+=Z-\*?VA/%_P"S-\&O
M#VD:Y+I^E>$]-\">"O#OVK7$A$AVZC>:EJIO!(4 P X)4;ATG_!.^?PY\?/^
M">?Q2^'O[3?B#Q1J7@?]F3]I;QYX/U74+&ZNTU/Q#X:^&VK6.HV5GJ1A#W%Q
M9R6]QY<WD-:#:V'/!6LCX;>+OB-_P35_:(_X*(>&=4^&?BWQSX2_:!^,T_[0
MOP<N-!TZ;4K.36/'?@WP]I>K:5)+ &2VDM];TAO-5SE;8<C!#'T']E'PQ\5O
MV$_V$Y/$OQ ^%.I_$GQ=^T+\?/%WQ1^)G@K3]/FO;KP]I7Q#N-Z65UIBQ2NS
MVUK96=M?0LC(?.W8PCE=8VY?B2LEHVK];V ^7_\ @GXW@;6/^"SGQJUC]F[5
MM=\-?L[Z;\$K/3]4\#>(KK4+5]4\<7<:R1W^D:7J\SW4UG:HZL]U:R2#G&\D
M%:_JM9@(\#J4R-O'''(SCKG@<GVK^<GX1?#7QA^T=_P4Z^#G[4/PN^%'B#X)
M?"3X6?#[Q%I?Q)-[HK>'K;QWK&IJT>BP&U5;=9TLD6,@F%T7."RD&OZ+&DYC
M!/S[9'5NRF+_ %B'UQTX&&_ASUJ)VNK6\[ ?R]?MGZY\&;;_ (+G?#ZP_:+N
M-9U3X7V/[%OB#4=.\+6\^H-93^))/$^B6L=ZUG8W%NC2)%-,?,9@ H+%@K"O
MTQU;Q]I7@7]DBP\2_L(^']&\.:'K/BB>V6[\837.F:=I$<M]<IJ6I7<&H74\
MI&]"J,I8,<>6&W+GS?Q=^RSXS\8_\%H_"W[0'B#P/!KWP9TG]CGQ-X(&M:C9
MQ75C;>+;KQ+HDUO$YG22W>Y-JK( JLJL"Q<8I_\ P5<^!?Q0\5> OV?+'X*^
M%-4U+X;>"/BLGB/XI?#[P3%)9W/B?PY+%&5L8K>U;$L<EXK7!MR" &(=58D4
MHI/=V^X#S/\ 8._;R^/OQ?\ VE_VJOV1/'\?@G6O'WPL^#>B?%+P-XO\)7B7
M>B:K=>)I-6T73+:\2:7"&+6K:(%059+0J9%C3#5XGX&_X*K?'KXQ:Y\*OV3O
M#?@ZTC_:[NOC1/X6^,.FW22V>E>!/ 7A;4)+K7?&.IS6]V\IM[[3+6:+3]Y6
M-S.HC5F(%;_[!?[-OQI^%_[:O[7_ .UROP.UGX<^ _'7[,_@SPG\+O!UY:SI
MJ>I>(O">J:]J+V\T$NZ8R7LDUB0 412"&<88+YO\-?\ @G5^U%\&_B/\+/V]
M]"TK^U_VH_B)\7)-2_:!\(/($@C^&WBZZ-K'90[I%EMKC0;"19[FT?S$<QF-
M5>5@A))*UG?YW _H*\>?"?\ X2[XI?"OQY)XLU32K/X=2:WYGAJV=TL?$USJ
M$5@MHUZZ_*@L3%* I(W DID&O<(WRP<H-BC:#M.<?3&?_'1CN*\*\=^+/B9I
M?Q<^%WAOPMX7?5O!&NV^LW'CKQ01OA\.1:>(?L F8[8X[F[\R?:4#$>2-P4%
M"WNX4CY020!GKV_/%2!#<75OI]I=7<@(AMXY[R0!<DH@RV%4,W'3;C<<# .1
M7\ZO[0W_  5-@T?_ (*(_LH>#_#\GBBW^"Z^ ?C-<?$C38]"N&GUKQ98ZKH]
MKX>^P.Z;IX;>*VO?]2LR(+D^8RYY_HLF1)8FCF6*2*1#'*'Y4J_WT.#@CW'&
M>E?&'Q$_8X\)^-?VH_@7^T/%;Z)9I\(O"GC[PM<^'3I%HT6LIXQETJXM[Z5@
M#$TUC+9W7[YD\\_:,\]:N#BI>]]X'Y)?\%9?%FD^+?%G_!.O]HSP;X?;QUXI
M\.?$K6-=\)? ;6K0'6?&^G:QI/\ 9E_=_P#"-OF>YGT$>;J<$TUNL<0 4$.Z
M(WS%^Q]XEU#3=8_X*R?M0>*8H?A7\<M>^&?B";1_@CIT2Z=<>#?#OAO0+DV6
MN_856*T%_?[8Y#)]D\I6($K(P('ZL?MG_L?_ !RU_P#:Z_9S_;*^ -EX?\3:
MS\%/!OC+P0_P^U^9;?2(['Q:FGQ2ZMI2&2.W35;6"UEAAFS$4,I((7)KS3X'
M?L _&;XE_M&_M*_M-?M*6VC>"V^-OPAF^#=C\/-"D!A@TN_MI;6\U;5D1I(;
MJ=8V49>7S6S\H;%74A3E&Z<;VVNK_P##_P!>H?EU^P[^T5XU_9!_X)I? +XL
M^*?V1;#5/A1J\6A>,OBO\7==:TU?Q;XK\2_$#Q"VH7_CFX65+C4?L;:G<VEM
M!;+$;5(K4S><)70-_0C<?\%!_A!:>*_!'@J"V\07.J>,[;PI-IYT_0[R6UCM
M_$%M!+8;IP3:MY27 ;:)0WR $ BOR^U#_@G]^W/XR_9H\#_\$\]=U'P=8_L\
M^$?$.EZ/J_CX3A]2U7X7^%O%$FL:%H]K;(K>7>/;0V:,IC555"LFQLK7[_\
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M^(/Q#^,\,5K\5/'7B-3<ZEXGL8UNXSI,CRLTBZ4B7DWDVW"C*AE!! 7+#O\
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MEY5MP*MSQGOGC' Q&6.XX.,>O ]\YP/7K_A2M&&0%6P,9 YZ'O@]O7&>V>]
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M02I.X\8Y/UQG_' ^L[JJH"AVD_B?Y#'K_0\T 28R,\8/N/\ &E(;&PD#@G/
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M\1_$;3;#X7_&?4O#NE^!/$<DD366J77BDQ+HL$.T2(7F::(1A64$MM8J5;:
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MK@22PE+<$S1C!("#]X0I'%K4#]$?]'M(W<SK#'$I:1F8(J*HRS,6("JHZL<
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MX=:)^T3?ZEHWP^U>.XBN[M=8MH5N(X-2@6:1HY5A97976+:#M;!!%>X^$_\
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M1DN' ZC:#D<C(YZ]/Z?CF4HI4,ZY/8#'IGW]\4S<1L'1%&67N!^'!^G7VZ4
M*#@^6.!W.>V.O0?E]..E1*[))C86"]7Z9_ X.1]..!]'*V_ ' V[L#KC\NN>
MHZ_U>=V&!Q@YP3C\O7\?KUH BC7/SCG<^=O91[=O?BI<*I SP_4^GT&.>M)&
M % '^?\ /6D'WSC#%>@SC\#G  _$>U #&5(GV(, CG!_R/P_.D YR..-I/8
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M3VZ_CS_GGMQBG+;A3NSEOS'Z\_Y]*?Y;;L[N/IS_ /KSWZT -:'>N&;'N/\
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M_@[>W'3'7UQWZ5"9;@8QI]P^,_>>Q'_MU^GM3FGN.UC/M_N[[+/ZW6* ./\
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MU6^T_P#L_7M3T,PW5K:Z?$D9BM/LWV6X$271D1T69/\ =M;OMUW _(_X9?\
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M#Q!H^FR:G;P^-]1\;>"]5T^WOEMC-':S&&*^2>Y:-<J.!]W/$ZIH7[1O@_\
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MP1\7?%;P-^T/\5M;^,OP\\1^"]/;49$U7Q'+/=KHM^+9F\J6TN9]JRRJ0L:
M9"XK^C8Z?;&87 @B2?#JTZ0P>=)&R,HCDE\L2;$:0NJ!BH*KG/0L&GJ0OF2R
MR_,[L'6W!=F^Z\FV'!D0?=9#&,\X'2K]H[-66O\ 6O<#^3"[_P"";W[3[?\
M!-7]H#3]8\(B\^/7[7__  4#\+_M;:[\.]/G&[PGX<U?QOX5$.CWTRL8TO\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>ex15-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "B 2P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^^UQD=0-N
M6)8X  !!)/;&:2,*%RN"7P2ZME2H(*@8Z@ #!X')//=K2H'Z/L9=J@949SDY
M&.G3)/IW[2+L&W(VIR3O&XX(.W#?PC)&%P,4 )LW$@N5SG (!0Y[<_F0?O'/
M:G(I=059<8VGY0.02.@X&<Y_'IBFNJ$@@*RD@)M&=A/&YO4;A[<#'U%##(!!
M#$G8N8W+'JP.>F/<#/?C- "?/PP(5L;=Q9F 3JH(QG<3U(SS@9-1A7+,26^<
M,#TV9;T[XST_#\5Y4'*95MS$.^\*6D78JCGA1T(&![#I*S$,KR']VR@%<Y&_
M&3\O;!!YQD''(Z4 4;^SGO;&]M+2];3KVXL+FTMM02))Y+">6&1+:^BMI?W-
MQ):SNERD<I",4\L\,QK\R_\ @D'^U-\3OVJ/V,/#^J_'C4)KS]IWX)_$+XE?
MLW_M/17?AD>#[RU^,WPC\3W6E:G)>Z!#;V]A8W.M>&;OPOXGD&FJUC*FN1S0
ME%D\M/U%*Q-D)A'D0@.H 8?+M# _WEQQG^[[5^8'_!.+Q)X9OO _[1/Q(N+O
M2]%N/VC?^"AO[:.L^&WFNX[1_%P^&WQ1U;X"Z%+IRW+1->:EJ'@KX&:==P00
M>9)+:64MW;![:(, #]/,G+9  9MP\Q6 QC QCOZ_C4,S@D!EX50 %8@/DKG;
M[+W#=1UXI'D1"%.UW89/& %/0F,C<N2& ;&/E=<Y# 1NRR,IR-JEUY^ZK?,"
MJ9 R1G! QD8P<"AM)-MI)*^OY!]_R3;^26K]$2! %5LY7Y7"A?F4X#9(^Z3G
M)./F8?>Z\QEBC@$A@Y!&%V;68;Y"03R"3D'\#TI59U#[-^$5@2$D+?*#@#G)
M 'W=HP3]W/%8>M>)?#F@PR2^(?$>BZ''"DDSW&L:G9V$4,40/FRR37=Q&D4:
M!<M)(T:*.214N<5#G;48Z:U)1IQL]GSSDEZ::]+%4H5*\_9X>G4Q%1[4Z-*O
M5JV6[=.&'E)6^UOR]V;JR.D;K(L@&=@.P@;CC)_KCKUR33-TC*2"-@=4*G/W
M"0#D]L*><^F#7@.J_M6_LTZ(\$&I?'[X26MQ=/"(8Q\0/#DTD_VAVCA6-;;4
M)6D,DB%5"C))  Q7/W/[9/[,]KXAT_PY+\8_""W.K:5?:O!J']I1OH_EV5S9
M6[V=QJ23+;Q:G=-J226=@VZ>>V@N)=H:WD(Y_KV!3Y7CL$G>S7UN@VO6U0]F
MCPQQ-B(.IA^',^KTHQ<I5:>2YQ.DHQ^)JK3RJI3ER[249MQ>C2>A]1L!EE'*
M\ >A7:O0=#D=CP<\\$TB^4&*''SQ@Y)1!SR..^/4C'7TY^;H_P!K/]F6:+2Y
MX_CS\,GM=7@N+JPGB\7:1&LT%H(A*2LM\LT!8RHD*",--)N5$9PP/K>F_$OX
M>:U,+/1O''A/4+\0VLYM;#Q'I-W=B"[W"TD,4%T[A;D(?*X#,5/&,&M%B<+)
MVIXBC6?_ $YJTJEO)M559]4MVCFKY+G6$2EB\FS7#0:;YJV69G3T3LVH5LNH
M3DEUE!2BGHY)Z'=.#MC R%0Q@ ]<^8OS>W!QCMS2!B8Q\G 0$%NAP >W.2.G
M(^M4[:[M[V-)K.XCNH6R4EM[E+F%BC,,AXW9'PRX #]=IX!7*37:0P22374-
MO;QQ22RS7)-O;001());B21WB1+>)#OD<O&@17&]<9&O-;XE*'9R247?M)2:
M??3IK<\R5XM1:<'=JU55*,DUNG"K24H_]O*.NEBPX!\M2C D!]RC"*I8@X9V
M&74?.R+DA5+8;@!P2(&(Y&-WE[5/R@L=Q(!P0&YW=<GMBOY__A[\>OVF--^.
M'[$O[9?BCXP^+M1_9P_X*3?M(^./@QH?[.NMR:?#X'^%_P $?&GP1\;_ !"_
M8F\<^%]-6VNM2TKXD>+;;X+W/BSXE7L.I266O/\ &Z#P]=VMJG@W3;N7]^BT
M>W: =ZN FU5+[MN=WS<J>@SV !.>[T>JU71E-6;3LVM'RM27RDM&O-:,D=BI
M1-JRB1E1UQ_"&*LW/_/-\>9UX/ .:&!"L0%#(&"L,\!3PK=RJ 83&<84X'2H
MU8^<[*  (P=TA**OFL&;#<#]X2"P)Y/7GHYG R&4(6)!);>/F."8UY8[B?D;
MG@YS0(4N,D*B@R$2;SU5VP?_ !YAD <X]*"556<DY8,CHP+*ZA@">.<GH">P
M)8TF%880').P#Y"=RIE6?^-#@ C=@KT&,5,$?:D?0-PQ!R?,^\<\C.Y<$GU
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M@[NJI+UW]EW_ ()T_!S]J#X1Z#\:OA9^TSXI7P_K6I:GH][I%W\,=*\*^+/
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M'/Q*\&7_ (9^'/P+%C:^3J'Q7\:S>(M&N[G3/ ^NW]O^(ND_%[X?_$O]@_\
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M;.%79@')VM\N .-ISU'7C&!&2K2%2I(-QM+*V"I";2.",#/.[I[T 2,2P&
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M@O1/CQX#^$6G^'=!N[OP=X;\6_M >'=?U7XQ_$NZ\574#AHOASX^T'P]X.\
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M+)]INCJ<<&FV$L[QR01M*3^P[)&55#*Z%0!@ =N02#W(()[=B,CCB?B/\-?
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M^^TQOJ[^>\,BQ-#/9V#D@*6'Z'_MG?&;6OV=_ LOQHN_B8_A+P!X8TRYT9?
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M3?99&B)C-UI6@^%/#]QYKDR(NM[V9&+I5#_@DG\0Y? W[1VJ^";^4V=G\7?
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M'T5AJEKX,UKQ%;:M-X@\1?$7Q#HU[I7B+Q]J&@PKHOAFPU(VDD4C+L3]\O\
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M%'9:9:"TN-+L5N ]Y+^Z:IO7<756<%B&!/S$DDC=G@$G:"" /E&5  _?> .
M:_LL/GO$&-Q&,]M1]I@L!]:K3HQ<F^6IB'[;DK4W%I.A)-<UW+56/\W_ *1W
MTDL-2Q^;>'GAOD."R667XO%8+/>)YY?A?KL,1&$8ULMX?HUL%[+"4\+B%)4L
MQ@HNGS2CATJ?O&+X8\*^&_!?AW2/"O@[0]-\.>&?#NFVVDZ!H6C6L5CI6D:=
M9)Y5I86%G $AM[>",L$B10HR6P223NYS$QYW[V4@>C.0!C[HR.AQ^-*0"R]
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MVAZ5?^*_#FD7BSW/]CV6KPKIS2:GINER)\^_'/X->(OVB/C)^Q++:?LD>/\
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M<VDP6:"8F,A\;CWK-+M*HH&[!R6 P<<<8)[?H<<\C\-/A3\*/VS?@#X;U?\
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M:-V6"2 +RHR.H&3D?Q<MWR2:^+/BA^VCX9^%GQ]\"_ WQ'X!\1QR?$#Q_P"
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MQR#N'8BG*VT,0H)4$N6.U@XQN&1C&3P>I.>"/EH ;O!$AQ)O#'!)1E YP24
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>ex15-3_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-3_001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MC!L'YN^*^V?VSOV8;/\ ;)_9J\2?#?4-5NM#M/$9M3)>VT2RRP^1=PW(PK$
MY,(7GLQ->HT5MC.(LQQ56G7KU'*5-WB[+1W3Z+NEN98+AK+<)1JX?#TE&-16
MDKO56:MJ^S>Q^9/_ !#2>%)(UBD^+7C%[?A6B_L^#:5';&XC]*^O/V'_ /@G
M%\-?V!M!OH?!MG?7FL:LJI?ZWJDJS7]TBG*Q9552.,'G8BJ"0"VX@&O>J*TQ
M_$V:8VE[#$UG*+W6B3];)7^9EEW"F4X&M[?"T%&:V>K:]+MV^1X;^UI^Q%I_
M[6'Q.^$?B:]UZ^T>;X2^(XO$5M!;VZ2+J+I-;RB)RQ!52;<#(R?F/I7,_MB_
M\$P_!W[9?[07P[^(&N7]Y97G@62,7%I% DD6NV\=RMQ';S%N50-YH.WDB=^G
M!KZ8HKCP^;XRAR.E-KD4E&UM%*]U\[O]#MQ&38+$*:K4U+G<7*]]7&W*_E9;
M?,\+^//[#VG_ !W_ &J?A9\4[G7K_3KWX7/.]OI\5NCPW_FXSO8G*XQVS6?_
M ,% /V!+/_@H'X5\+^'M<\5:MH'AW0-4.J7=E8V\;G5) GEH&=CE-L;S@$ \
MRYZJ*^A**FCFN+I3I5*<[.FFHZ+1-M]N[>Y5;)\'5A5IU(755IS5W[S5EKKV
M26FCZD5E90Z=90V]O#';V\"+''%&NU(U P%4#@  8 %?/GQ5_P""?.F_$']N
M;P7\>--\2ZCX=\2>%;1;"YL[>UCDM]8@'G*RRDX(9HIY(]W) $9'*"OHBBL,
M+C*V'E*5&5G).+\T]&G?N=&*P-#$QC"M&ZBU)=+..J:MV/ OVZ/V#--_;B_X
M0/\ M'Q%J'A__A!=:&LP_9;=)OM;#;\C;B-H^7J/6O>^=M.HI5,76J4H4)RO
M&%^5=KN[^]A2P=&G6GB(1M*=N9][*R^Y=CY7_9R_X)1>"_V7/VSO$7Q<\(ZE
M>:=;Z_9W-JOAM+:-;'3_ #WADD\EARJ;XB5CQM0/M&%4"OJBBBM,9C\1BYJI
MB9.4DDKO>RV_K<G Y?AL'!TL+!1BVW9;7>_IZ+0*_/?]H3_@W]\,_M ?'7Q;
MXZN/B5XFTJZ\6:G-J<MK;Z?"T<!D;)0,6R0/4U^A%%;99G&,R^;J8.?*VK/1
M/3?JF<^:Y+@LRA&GC:?.HNZU:U^31^8S_P#!M!X5=<?\+:\7<_\ 4.@_^*K[
MK_;"_9IM?VOOV<?$WPYO]4NM%L_$JP+)>V\2RR0>5<13C"MP<F(+SV)KTZBN
MC&<19CBZM.MB*KE*F[Q=EH[I]%Y+?L<N!X9RS!TJM##4E&-56DKO56:MJ^S>
MW<_,=?\ @V@\**N!\6O%P XP--@_^*KW[_@GI_P25T;_ ()^?%#6_$^F^-M<
M\33:WI?]EO;WMK'"D2^:DN\%223\F,>AKZZHKHQG%F;8JC*A7K.49;JT=?N1
MSX+@W)L)6CB,/049QV=Y:?>SP/X@_L':;X^_X*!^"?C])XAU"WU/P3HKZ+#I
M"6Z-;W2LE^F]I"=P/^GL< 8_=CU->^445XN(Q56LH1JN_(N5>2NW;[VSW</@
MZ-!SE2C9SES2\W9*_P!R04445SG2?&?PD_X*7V?C_P#X*0ZQ\._^$T\ 7GA?
M4M1U/P9HF@6FI6TGB"TUC2(%N+JZG@60W"0SLNKV^)(U2/\ L2W=6;[<H'::
MEJWQ6_:)^-'Q=M?!WQ)M_AW9?"76;;PYI.GKH5KJ5KKE\^CZ?JKW&J-,#,;8
M_P!I0PB"T>UE4022>>WG(L/DNEHL7_!&+]EG4%4+?S:G\'[Y[D#$SW%UXC\/
M_:IB_4R3?:)_,;.7\^3<3O;/PW_P<H?$[Q)\(_\ @I=\,=$\)^(=<\,:+\3/
M#FFV_B^PTF_ELK7Q7%_;2VFS4(XV5;M?LTCPXF#CRG9/NDB@#]4/C!XY\=_$
MSXZ?#WX:^'/&%O\ #Z/7/"FH>+==US1K>VU.]E^S36%O%:Z>;R*2#RFDO7>2
M>2W<A(X55%,V^.M\5?B?\4/A/^S]X5T";Q-X.O\ XD>+/%\/@RV\51Z:W]GV
MD4MQ,RWL]IY@ O!90E?*#B%KQD "Q-Y8^4O^#GOQ)J/[/'[$OPM\4_#^_O?
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@2L(+AIXXHTD,J,9%C0-D* /WH'2@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>52
<FILENAME>upc-20220930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Feb 10 15:53:46 UTC 2023 -->
<xs:schema xmlns:upc="http://www.UniversePharmaceuticalsINC.com/20220930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.UniversePharmaceuticalsINC.com/20220930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="upc-20220930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="upc-20220930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="upc-20220930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="upc-20220930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet" id="upc_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals" id="upc_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement" id="upc_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Income and Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement_Parentheticals" id="upc_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Consolidated Statements of Income and Comprehensive Income (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3" id="upc_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow" id="upc_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription" id="upc_r_OrganizationandBusinessDescription">
        <link:definition>007 - Disclosure - Organization and Business Description</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies" id="upc_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet" id="upc_r_AccountsReceivableNet">
        <link:definition>009 - Disclosure - Accounts Receivable, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNet" id="upc_r_InventoryNet">
        <link:definition>010 - Disclosure - Inventory, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers" id="upc_r_AdvancetoSuppliers">
        <link:definition>011 - Disclosure - Advance to Suppliers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting" id="upc_r_PrepaymentforAdvertisting">
        <link:definition>012 - Disclosure - Prepayment for Advertisting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition" id="upc_r_PrepaymentforAcquisition">
        <link:definition>013 - Disclosure - Prepayment for Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestments" id="upc_r_ShortTermInvestments">
        <link:definition>014 - Disclosure - Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet" id="upc_r_PropertyPlantandEquipmentNet">
        <link:definition>015 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet" id="upc_r_IntangibleAssetsNet">
        <link:definition>016 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject" id="upc_r_PrepaymentforCIPProject">
        <link:definition>017 - Disclosure - Prepayment for CIP Project</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty" id="upc_r_PrepaymentforPurchaseofaProperty">
        <link:definition>018 - Disclosure - Prepayment for Purchase of a Property</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans" id="upc_r_ShortTermBankLoans">
        <link:definition>019 - Disclosure - Short-Term Bank Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions" id="upc_r_RelatedPartyTransactions">
        <link:definition>020 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/Taxes" id="upc_r_Taxes">
        <link:definition>021 - Disclosure - Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/Concentrations" id="upc_r_Concentrations">
        <link:definition>022 - Disclosure - Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity" id="upc_r_ShareholdersEquity">
        <link:definition>023 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies" id="upc_r_CommitmentsandContingencies">
        <link:definition>024 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting" id="upc_r_SegmentReporting">
        <link:definition>025 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents" id="upc_r_SubsequentEvents">
        <link:definition>026 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany" id="upc_r_CondensedFinancialInformationoftheParentCompany">
        <link:definition>027 - Disclosure - Condensed Financial Information of the Parent Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy" id="upc_r_AccountingPoliciesByPolicy">
        <link:definition>028 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables" id="upc_r_OrganizationandBusinessDescriptionTables">
        <link:definition>029 - Disclosure - Organization and Business Description (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables" id="upc_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>030 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables" id="upc_r_AccountsReceivableNetTables">
        <link:definition>031 - Disclosure - Accounts Receivable, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables" id="upc_r_InventoryNetTables">
        <link:definition>032 - Disclosure - Inventory, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables" id="upc_r_AdvancetoSuppliersTables">
        <link:definition>033 - Disclosure - Advance to Suppliers (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsTables" id="upc_r_ShortTermInvestmentsTables">
        <link:definition>034 - Disclosure - Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables" id="upc_r_PropertyPlantandEquipmentNetTables">
        <link:definition>035 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables" id="upc_r_IntangibleAssetsNetTables">
        <link:definition>036 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables" id="upc_r_PrepaymentforCIPProjectTables">
        <link:definition>037 - Disclosure - Prepayment for CIP Project (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables" id="upc_r_ShortTermBankLoansTables">
        <link:definition>038 - Disclosure - Short-Term Bank Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables" id="upc_r_RelatedPartyTransactionsTables">
        <link:definition>039 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables" id="upc_r_TaxesTables">
        <link:definition>040 - Disclosure - Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables" id="upc_r_SegmentReportingTables">
        <link:definition>041 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables" id="upc_r_CondensedFinancialInformationoftheParentCompanyTables">
        <link:definition>042 - Disclosure - Condensed Financial Information of the Parent Company (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails" id="upc_r_OrganizationandBusinessDescriptionDetails">
        <link:definition>043 - Disclosure - Organization and Business Description (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable" id="upc_r_ScheduleofsubsidiariesofthecompanyTable">
        <link:definition>044 - Disclosure - Organization and Business Description (Details) - Schedule of subsidiaries of the company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails" id="upc_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>045 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable" id="upc_r_ScheduleofpropertyplantandequipmentestimatedusefullivesTable">
        <link:definition>046 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable" id="upc_r_ScheduleofintangibleassetsestimatedusefullivesTable">
        <link:definition>047 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable" id="upc_r_ScheduleofcurrencyexchangerateTable">
        <link:definition>048 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of currency exchange rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails" id="upc_r_AccountsReceivableNetDetails">
        <link:definition>049 - Disclosure - Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableconsistsTable" id="upc_r_ScheduleofaccountsreceivableconsistsTable">
        <link:definition>050 - Disclosure - Accounts Receivable, Net (Details) - Schedule of accounts receivable consists</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable" id="upc_r_ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable">
        <link:definition>051 - Disclosure - Accounts Receivable, Net (Details) - Schedule of the company&#8217;s accounts receivable and subsequent collection</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable" id="upc_r_ScheduleofallowancefordoubtfulaccountsTable">
        <link:definition>052 - Disclosure - Accounts Receivable, Net (Details) - Schedule of allowance for doubtful accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable" id="upc_r_ScheduleofinventoryTable">
        <link:definition>053 - Disclosure - Inventory, Net (Details) - Schedule of inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable" id="upc_r_ScheduleofadvancestosuppliersnetTable">
        <link:definition>054 - Disclosure - Advance to Suppliers (Details) - Schedule of advances to suppliers net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails" id="upc_r_PrepaymentforAdvertistingDetails">
        <link:definition>055 - Disclosure - Prepayment for Advertisting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails" id="upc_r_PrepaymentforAcquisitionDetails">
        <link:definition>056 - Disclosure - Prepayment for Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsDetails" id="upc_r_ShortTermInvestmentsDetails">
        <link:definition>057 - Disclosure - Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvestmentsTable" id="upc_r_ScheduleofshortterminvestmentsTable">
        <link:definition>058 - Disclosure - Short-Term Investments (Details) - Schedule of short-term investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails" id="upc_r_PropertyPlantandEquipmentNetDetails">
        <link:definition>059 - Disclosure - Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable" id="upc_r_ScheduleofpropertyplantandequipmentnetconsistsTable">
        <link:definition>060 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net consists</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails" id="upc_r_IntangibleAssetsNetDetails">
        <link:definition>061 - Disclosure - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable" id="upc_r_ScheduleofintangibleassetsnetconsistTable">
        <link:definition>062 - Disclosure - Intangible Assets, Net (Details) - Schedule of intangible assets, net consist</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" id="upc_r_ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable">
        <link:definition>063 - Disclosure - Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails" id="upc_r_PrepaymentforCIPProjectDetails">
        <link:definition>064 - Disclosure - Prepayment for CIP Project (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable" id="upc_r_ScheduleoffutureminimumcapitalexpendituresTable">
        <link:definition>065 - Disclosure - Prepayment for CIP Project (Details) - Schedule of future minimum capital expenditures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails" id="upc_r_PrepaymentforPurchaseofaPropertyDetails">
        <link:definition>066 - Disclosure - Prepayment for Purchase of a Property (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails" id="upc_r_ShortTermBankLoansDetails">
        <link:definition>067 - Disclosure - Short-Term Bank Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7sSbeKneEPlmNIhj3bCSU5y7O0I8dbszuTl8jF0AJbe21t+Rq4Ior0xtAOoy+ao7RLCBcMnvOYD6nWgAt+g/C9Glm4Z6aOCF7CBTCCEgAQgDS5HDB+QiyzEScfxZRIlDPHMlgxjGAiG/w==] CSR-->
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable" id="upc_r_ScheduleofshorttermbankloansTable">
        <link:definition>068 - Disclosure - Short-Term Bank Loans (Details) - Schedule of short-term bank loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails" id="upc_r_RelatedPartyTransactionsDetails">
        <link:definition>069 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable" id="upc_r_ScheduleofnatureofrelationshipswithrelatedpartiesTable">
        <link:definition>070 - Disclosure - Related Party Transactions (Details) - Schedule of nature of relationships with related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable" id="upc_r_ScheduleofduefromrelatedpartiesTable">
        <link:definition>071 - Disclosure - Related Party Transactions (Details) - Schedule of due from related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable" id="upc_r_ScheduleofduetorelatedpartiesTable">
        <link:definition>072 - Disclosure - Related Party Transactions (Details) - Schedule of due to related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails" id="upc_r_TaxesDetails">
        <link:definition>073 - Disclosure - Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable" id="upc_r_ScheduleofcomponentsoftheincometaxprovisionbenefitTable">
        <link:definition>074 - Disclosure - Taxes (Details) - Schedule of components of the income tax provision (benefit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable" id="upc_r_ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable">
        <link:definition>075 - Disclosure - Taxes (Details) - Schedule of table reconciles the china statutory rates to the company&#8217;s effective tax rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable" id="upc_r_ScheduleofdeferredtaxassetsTable">
        <link:definition>076 - Disclosure - Taxes (Details) - Schedule of deferred tax assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable" id="upc_r_ScheduleoftaxespayableTable">
        <link:definition>077 - Disclosure - Taxes (Details) - Schedule of taxes payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails" id="upc_r_ConcentrationsDetails">
        <link:definition>078 - Disclosure - Concentrations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails" id="upc_r_ShareholdersEquityDetails">
        <link:definition>079 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails" id="upc_r_CommitmentsandContingenciesDetails">
        <link:definition>080 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails" id="upc_r_SegmentReportingDetails">
        <link:definition>081 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable" id="upc_r_ScheduleofrevenuebyproductsourceTable">
        <link:definition>082 - Disclosure - Segment Reporting (Details) - Schedule of revenue by product source</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable" id="upc_r_ScheduleoftotalrevenuesbyproductcategoriesTable">
        <link:definition>083 - Disclosure - Segment Reporting (Details) - Schedule of total revenues by product categories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails" id="upc_r_SubsequentEventsDetails">
        <link:definition>084 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails" id="upc_r_CondensedFinancialInformationoftheParentCompanyDetails">
        <link:definition>085 - Disclosure - Condensed Financial Information of the Parent Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable" id="upc_r_ScheduleofparentcompanybalancesheetsTable">
        <link:definition>086 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals" id="upc_r_ScheduleofparentcompanybalancesheetsTable_Parentheticals">
        <link:definition>087 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable" id="upc_r_ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable">
        <link:definition>088 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of income and comprehensive income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable" id="upc_r_ScheduleofparentcompanystatementsofcashflowsTable">
        <link:definition>089 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of cash flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfSubsidiariesOfTheCompanyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfSubsidiariesOfTheCompanyAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract"/>
  <xs:element name="ScheduleOfCurrencyExchangeRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfCurrencyExchangeRateAbstract"/>
  <xs:element name="ScheduleOfAccountsReceivableConsistsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfAccountsReceivableConsistsAbstract"/>
  <xs:element name="ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract"/>
  <xs:element name="ScheduleOfAllowanceForDoubtfulAccountsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract"/>
  <xs:element name="ScheduleOfInventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfInventoryAbstract"/>
  <xs:element name="AdvancesToSuppliersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdvancesToSuppliersAbstract"/>
  <xs:element name="ScheduleOfAdvancesToSuppliersNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfAdvancesToSuppliersNetAbstract"/>
  <xs:element name="PrepaymentForAdvertistingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForAdvertistingAbstract"/>
  <xs:element name="PrepaymentForAcquisitionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForAcquisitionAbstract"/>
  <xs:element name="ScheduleOfShortTermInvestmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfShortTermInvestmentsAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsNetConsistAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfIntangibleAssetsNetConsistAbstract"/>
  <xs:element name="ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract"/>
  <xs:element name="PrepaymentForConstructionInProgressAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForConstructionInProgressAbstract"/>
  <xs:element name="ScheduleOfFutureMinimumCapitalExpendituresAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract"/>
  <xs:element name="PrepaymentForPurchaseOfAPropertyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
  <xs:element name="ScheduleOfShortTermBankLoansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfShortTermBankLoansAbstract"/>
  <xs:element name="ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfDueFromRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfDueFromRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfDueToRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfDueToRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract"/>
  <xs:element name="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfDeferredTaxAssetsAbstract"/>
  <xs:element name="ScheduleOfTaxesPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfTaxesPayableAbstract"/>
  <xs:element name="ScheduleOfRevenueByProductSourceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfRevenueByProductSourceAbstract"/>
  <xs:element name="ScheduleOfTotalRevenuesByProductCategoriesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract"/>
  <xs:element name="ScheduleOfParentCompanyBalanceSheetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfParentCompanyBalanceSheetsAbstract"/>
  <xs:element name="ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract"/>
  <xs:element name="ScheduleOfParentCompanyStatementsOfCashFlowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract8"/>
  <xs:element name="OtherIncomeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OtherIncomeExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract12"/>
  <xs:element name="OtherComprehensiveIncomeLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OtherComprehensiveIncomeLossAbstract"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract27"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract30"/>
  <xs:element name="ShortTermBankLoansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ShortTermBankLoansAbstract"/>
  <xs:element name="LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract"/>
  <xs:element name="BankOfCommunicationsCoLtdAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_BankOfCommunicationsCoLtdAbstract"/>
  <xs:element name="NameAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_NameAbstract"/>
  <xs:element name="NameAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_NameAbstract0"/>
  <xs:element name="CurrentTaxProvisionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CurrentTaxProvisionAbstract"/>
  <xs:element name="DeferredTaxProvisionBenefitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DeferredTaxProvisionBenefitAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DeferredTaxAssetsAbstract"/>
  <xs:element name="SalesOfTcmdProductsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SalesOfTcmdProductsAbstract"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract31"/>
  <xs:element name="SalesOfThirdPartyProductsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SalesOfThirdPartyProductsAbstract"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract32"/>
  <xs:element name="CurrentAssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CurrentAssetsAbstract0"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract33"/>
  <xs:element name="NonCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_NonCurrentAssetsAbstract"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract34"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract36"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract37"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract38"/>
  <xs:element name="ShareholdersEquityAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ShareholdersEquityAbstract0"/>
  <xs:element name="UnlabeledAbstract39" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract39"/>
  <xs:element name="UnlabeledAbstract40" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract40"/>
  <xs:element name="OtherIncomeExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OtherIncomeExpensesAbstract0"/>
  <xs:element name="UnlabeledAbstract41" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract41"/>
  <xs:element name="UnlabeledAbstract42" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract42"/>
  <xs:element name="CashFlowsFromOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CashFlowsFromOperatingActivitiesAbstract"/>
  <xs:element name="AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract"/>
  <xs:element name="UnlabeledAbstract43" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract43"/>
  <xs:element name="CashFlowsFromInvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CashFlowsFromInvestingActivitiesAbstract"/>
  <xs:element name="UnlabeledAbstract44" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract44"/>
  <xs:element name="CashFlowsFromFinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CashFlowsFromFinancingActivitiesAbstract"/>
  <xs:element name="UnlabeledAbstract45" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract45"/>
  <xs:element name="UnlabeledAbstract46" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract46"/>
  <xs:element name="UnlabeledAbstract47" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract47"/>
  <xs:element name="UnlabeledAbstract48" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract48"/>
  <xs:element name="PrepaymentForAcquisitionCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForAcquisitionCurrent"/>
  <xs:element name="PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
  <xs:element name="PrepaymentsForConstructionInProgress" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentsForConstructionInProgress"/>
  <xs:element name="InvestmentInEquitySecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_InvestmentInEquitySecurities"/>
  <xs:element name="StatutoryReserve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_StatutoryReserve"/>
  <xs:element name="IncomeFromOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_IncomeFromOperation"/>
  <xs:element name="ShorttermInvestmentIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_ShorttermInvestmentIncome"/>
  <xs:element name="StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts"/>
  <xs:element name="ShorttermInvestmentsIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_ShorttermInvestmentsIncome"/>
  <xs:element name="PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty"/>
  <xs:element name="RedemptionOfShorttermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_RedemptionOfShorttermInvestments"/>
  <xs:element name="ProceedsFromprepaymentsForRelatedPartiesBorrowings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings"/>
  <xs:element name="AdvancesToSuppliersTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdvancesToSuppliersTextBlock"/>
  <xs:element name="PrepaymentForAdvertistingTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForAdvertistingTextBlock"/>
  <xs:element name="PrepaymentForAcquisitionTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForAcquisitionTextBlock"/>
  <xs:element name="PrepaymentforAcquisitionTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_PrepaymentforAcquisitionTable"/>
  <xs:element name="PrepaymentforAcquisitionLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentforAcquisitionLineItems"/>
  <xs:element name="HeldToMaturityInvestmentDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_HeldToMaturityInvestmentDisclosureTextBlock"/>
  <xs:element name="PrepaymentForConstructionInProgressTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForConstructionInProgressTextBlock"/>
  <xs:element name="PrepaymentForPurchaseOfAPropertyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForPurchaseOfAPropertyTextBlock"/>
  <xs:element name="AdvancesToSuppliersNetPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdvancesToSuppliersNetPolicyTextBlock"/>
  <xs:element name="HeldToMaturityInvestmentPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_HeldToMaturityInvestmentPolicyTextBlock"/>
  <xs:element name="ContractAssetsAndLiabilitiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ContractAssetsAndLiabilitiesPolicyTextBlock"/>
  <xs:element name="DisaggregationOfRevenuesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DisaggregationOfRevenuesPolicyTextBlock"/>
  <xs:element name="ValueAddedTaxPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ValueAddedTaxPolicyTextBlock"/>
  <xs:element name="StatementOfCashFlowsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_StatementOfCashFlowsPolicyTextBlock"/>
  <xs:element name="EmployeeDefinedContributionPlanPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_EmployeeDefinedContributionPlanPolicyTextBlock"/>
  <xs:element name="PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
  <xs:element name="ScheduleOfAdvancesToSuppliersNet" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfAdvancesToSuppliersNet"/>
  <xs:element name="AdvancetoSuppliersTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_AdvancetoSuppliersTablesTable"/>
  <xs:element name="AdvancetoSuppliersTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdvancetoSuppliersTablesLineItems"/>
  <xs:element name="ScheduleOfDueFromRelatedPartiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock"/>
  <xs:element name="ScheduleOfDueToRelatedPartiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfDueToRelatedPartiesTableTextBlock"/>
  <xs:element name="ScheduleOfTaxPayableTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfTaxPayableTableTextBlock"/>
  <xs:element name="PlaceOfIncorporation" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PlaceOfIncorporation"/>
  <xs:element name="OwnershipPercentage" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OwnershipPercentage"/>
  <xs:element name="PrincipalActivities" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrincipalActivities"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems"/>
  <xs:element name="DescriptionOfYearEndSpotRate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DescriptionOfYearEndSpotRate"/>
  <xs:element name="DescriptionOfAverageRate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DescriptionOfAverageRate"/>
  <xs:element name="AccountsReceivableBeforeGrossValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_AccountsReceivableBeforeGrossValue"/>
  <xs:element name="SubsequentCollection" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_SubsequentCollection"/>
  <xs:element name="PercentageOfSubsequentCollection" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PercentageOfSubsequentCollection"/>
  <xs:element name="SunsequentCollectionsTotalGrossAccountsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_SunsequentCollectionsTotalGrossAccountsReceivable"/>
  <xs:element name="TotalGrossAccountsReceivablePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_TotalGrossAccountsReceivablePercentage"/>
  <xs:element name="SunsequentCollectionAllowanceForDoubtfulAccounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_SunsequentCollectionAllowanceForDoubtfulAccounts"/>
  <xs:element name="AllowanceForDoubtfulAccountsReceivablePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AllowanceForDoubtfulAccountsReceivablePercentage"/>
  <xs:element name="SunsequentCollectionAccountsReceivableNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_SunsequentCollectionAccountsReceivableNet"/>
  <xs:element name="AccountsReceivableNetPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AccountsReceivableNetPercentage"/>
  <xs:element name="AddPurchaseWealthManagementFinancialProducts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_AddPurchaseWealthManagementFinancialProducts"/>
  <xs:element name="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"/>
  <xs:element name="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems"/>
  <xs:element name="PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable"/>
  <xs:element name="PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems"/>
  <xs:element name="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems"/>
  <xs:element name="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems"/>
  <xs:element name="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable"/>
  <xs:element name="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems"/>
  <xs:element name="SubtotalOfTCMDProductsSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_SubtotalOfTCMDProductsSales"/>
  <xs:element name="SubtotalOfThirdpartyProductsSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_SubtotalOfThirdpartyProductsSales"/>
  <xs:element name="EquityInEarningsOfSubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_EquityInEarningsOfSubsidiary"/>
  <xs:element name="CashLentToSubsidiaries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_CashLentToSubsidiaries"/>
  <xs:element name="CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
  <xs:element name="OrganizationandBusinessDescriptionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_OrganizationandBusinessDescriptionDetailsTable"/>
  <xs:element name="OrganizationandBusinessDescriptionDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OrganizationandBusinessDescriptionDetailsLineItems"/>
  <xs:element name="EntityIncorporationDateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_EntityIncorporationDateDescription"/>
  <xs:element name="EquityMethodInvestmentOwnershipsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_EquityMethodInvestmentOwnershipsPercentage"/>
  <xs:element name="AmountOfRegisteredCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_AmountOfRegisteredCapital"/>
  <xs:element name="CapitalContribution" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_CapitalContribution"/>
  <xs:element name="RemainingCapitalContribution" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_RemainingCapitalContribution"/>
  <xs:element name="SharesIssued01" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_SharesIssued01"/>
  <xs:element name="PublicOfferingPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_PublicOfferingPrice"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="MaterialPricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MaterialPricePercentage"/>
  <xs:element name="PaymentTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PaymentTerm"/>
  <xs:element name="AllowanceForUncollectableBalancesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_AllowanceForUncollectableBalancesAmount"/>
  <xs:element name="TaxBenefitPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_TaxBenefitPercentage"/>
  <xs:element name="PercentageOfVatRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PercentageOfVatRate"/>
  <xs:element name="AccountsReceivableDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AccountsReceivableDescription"/>
  <xs:element name="PercentageOfAdvancePayment" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_PercentageOfAdvancePayment"/>
  <xs:element name="AdditionalContractPricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdditionalContractPricePercentage"/>
  <xs:element name="ContractPricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ContractPricePercentage"/>
  <xs:element name="PrepaymentforAcquisitionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_PrepaymentforAcquisitionDetailsTable"/>
  <xs:element name="PrepaymentforAcquisitionDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentforAcquisitionDetailsLineItems"/>
  <xs:element name="AssetAcquisitionPriceOfAcquisitionsExpected" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_AssetAcquisitionPriceOfAcquisitionsExpected"/>
  <xs:element name="PrepaymentforCIPProjectDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_PrepaymentforCIPProjectDetailsTable"/>
  <xs:element name="PrepaymentforCIPProjectDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentforCIPProjectDetailsLineItems"/>
  <xs:element name="Prepayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_Prepayment"/>
  <xs:element name="CapitalExpenditure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_CapitalExpenditure"/>
  <xs:element name="EquityInterest" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_EquityInterest"/>
  <xs:element name="OfficeSpaceSquareMeters" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_OfficeSpaceSquareMeters"/>
  <xs:element name="PercentageOfPrepayment" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PercentageOfPrepayment"/>
  <xs:element name="PayableDeliveryPropertyPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PayableDeliveryPropertyPercentage"/>
  <xs:element name="ShortTermBankLoansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_ShortTermBankLoansDetailsTable"/>
  <xs:element name="ShortTermBankLoansDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ShortTermBankLoansDetailsLineItems"/>
  <xs:element name="PrepaymentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentAmount"/>
  <xs:element name="EquityInterestOwnershipPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_EquityInterestOwnershipPercentage"/>
  <xs:element name="TaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_TaxesDetailsTable"/>
  <xs:element name="TaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_TaxesDetailsLineItems"/>
  <xs:element name="PreferentialTaxTreatmentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PreferentialTaxTreatmentDescription"/>
  <xs:element name="ConcentrationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_ConcentrationsDetailsTable"/>
  <xs:element name="ConcentrationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ConcentrationsDetailsLineItems"/>
  <xs:element name="ConcentrationRiskThresholdPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ConcentrationRiskThresholdPercentage"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_ShareholdersEquityDetailsTable"/>
  <xs:element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ShareholdersEquityDetailsLineItems"/>
  <xs:element name="OriginalSharesParValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OriginalSharesParValue"/>
  <xs:element name="OrdinarySharesParValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OrdinarySharesParValue"/>
  <xs:element name="OrdinarySharesOutstandingDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OrdinarySharesOutstandingDescription"/>
  <xs:element name="ReorganizationShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ReorganizationShares"/>
  <xs:element name="OptionToPurchaseAdditionalShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_OptionToPurchaseAdditionalShares"/>
  <xs:element name="CashDividendDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CashDividendDescription"/>
  <xs:element name="StatutorySurplusPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_StatutorySurplusPercentage"/>
  <xs:element name="ReserveIsEqualPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ReserveIsEqualPercentage"/>
  <xs:element name="RestrictedNetAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_RestrictedNetAssets"/>
  <xs:element name="MinorityInterestsOwnershipPercentageByParent" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_MinorityInterestsOwnershipPercentageByParent"/>
  <xs:element name="AmortizationExpenseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AmortizationExpenseMember"/>
  <xs:element name="CapitalExpenditureMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CapitalExpenditureMember"/>
  <xs:element name="CashDividendsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CashDividendsMember"/>
  <xs:element name="ChenyuanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ChenyuanMember"/>
  <xs:element name="CorporateSegmentFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CorporateSegmentFiveMember"/>
  <xs:element name="CorporateSegmentFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CorporateSegmentFourMember"/>
  <xs:element name="CorporateSegmentOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CorporateSegmentOneMember"/>
  <xs:element name="CorporateSegmentSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CorporateSegmentSixMember"/>
  <xs:element name="CorporateSegmentThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CorporateSegmentThreeMember"/>
  <xs:element name="CorporateSegmentTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CorporateSegmentTwoMember"/>
  <xs:element name="CustomerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CustomerMember"/>
  <xs:element name="CustomersOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CustomersOneMember"/>
  <xs:element name="FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember"/>
  <xs:element name="FoshanShangyuMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_FoshanShangyuMember"/>
  <xs:element name="From10To12MonthsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_From10To12MonthsMember"/>
  <xs:element name="From4To6MonthsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_From4To6MonthsMember"/>
  <xs:element name="From7To9MonthsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_From7To9MonthsMember"/>
  <xs:element name="GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember"/>
  <xs:element name="GreatestGroupMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_GreatestGroupMember"/>
  <xs:element name="GubenYanlingPillMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_GubenYanlingPillMember"/>
  <xs:element name="JiangxiLulingRuralCommercialBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_JiangxiLulingRuralCommercialBankMember"/>
  <xs:element name="JiangxiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_JiangxiMember"/>
  <xs:element name="JiangxiUniverseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_JiangxiUniverseMember"/>
  <xs:element name="JxRcbBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_JxRcbBankMember"/>
  <xs:element name="LessThan3MonthsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_LessThan3MonthsMember"/>
  <xs:element name="MaturityGreaterThan90DaysFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MaturityGreaterThan90DaysFourMember"/>
  <xs:element name="MaturityGreaterThan90DaysOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MaturityGreaterThan90DaysOneMember"/>
  <xs:element name="MaturityGreaterThan90DaysThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MaturityGreaterThan90DaysThreeMember"/>
  <xs:element name="MaturityGreaterThan90DaysTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MaturityGreaterThan90DaysTwoMember"/>
  <xs:element name="MrGangLaiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MrGangLaiMember"/>
  <xs:element name="MrsLinYangMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MrsLinYangMember"/>
  <xs:element name="MsLinYangMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MsLinYangMember"/>
  <xs:element name="OfficeAndElectricEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OfficeAndElectricEquipmentMember"/>
  <xs:element name="Over1YearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_Over1YearMember"/>
  <xs:element name="OwnershipMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OwnershipMember"/>
  <xs:element name="PRCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PRCMember"/>
  <xs:element name="StatutoryReserveAndRestrictedNetAssetsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_StatutoryReserveAndRestrictedNetAssetsMember"/>
  <xs:element name="StatutoryReservesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_StatutoryReservesMember"/>
  <xs:element name="SupplierOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SupplierOneMember"/>
  <xs:element name="SupplierTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SupplierTwoMember"/>
  <xs:element name="TotalRevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_TotalRevenueMember"/>
  <xs:element name="UnderwriterWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnderwriterWarrantsMember"/>
  <xs:element name="UniverseHKMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseHKMember"/>
  <xs:element name="UniverseHanheMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseHanheMember"/>
  <xs:element name="UniverseINCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseINCMember"/>
  <xs:element name="UniverseIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseIncMember"/>
  <xs:element name="UniverseTechnologyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseTechnologyMember"/>
  <xs:element name="UniverseTradeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseTradeMember"/>
  <xs:element name="YunnanFaxiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_YunnanFaxiMember"/>
  <xs:element name="supplierMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_supplierMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>53
<FILENAME>upc-20220930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Feb 10 15:53:46 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedBalanceSheet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedIncomeStatement" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedCashFlow" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofinventoryTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofdeferredtaxassetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleoftaxespayableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Supplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Supplies" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCostsCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAcquisitionCurrent" xlink:href="upc-20220930.xsd#upc_PrepaymentForAcquisitionCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="upc_PrepaymentForAcquisitionCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:href="upc-20220930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsForConstructionInProgress" xlink:href="upc-20220930.xsd#upc_PrepaymentsForConstructionInProgress"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="upc_PrepaymentsForConstructionInProgress" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_InvestmentInEquitySecurities" xlink:href="upc-20220930.xsd#upc_InvestmentInEquitySecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="upc_InvestmentInEquitySecurities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserve" xlink:href="upc-20220930.xsd#upc_StatutoryReserve"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="upc_StatutoryReserve" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_IncomeFromOperation" xlink:href="upc-20220930.xsd#upc_IncomeFromOperation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="upc_IncomeFromOperation" xlink:to="us-gaap_OperatingExpenses" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="upc_IncomeFromOperation" xlink:to="us-gaap_GrossProfit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="upc_ShorttermInvestmentIncome" xlink:href="upc-20220930.xsd#upc_ShorttermInvestmentIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="upc_ShorttermInvestmentIncome" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="upc_IncomeFromOperation" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7sSbeKneEPlmNIhj3bCSU5y7O0I8dbszuTl8jF0AJbe21t+Rq4Ior0xtAOoy+ao7RLCBcMnvOYD6nWgAt+g/C9Glm4Z6aOCF7CBTCCEgAQgDS5HDB+QiyzENT+9ZqsIS/wISEUF0xa8qw==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_ShorttermInvestmentsIncome" xlink:href="upc-20220930.xsd#upc_ShorttermInvestmentsIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="upc_ShorttermInvestmentsIncome" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidAdvertising"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_RedemptionOfShorttermInvestments" xlink:href="upc-20220930.xsd#upc_RedemptionOfShorttermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="upc_RedemptionOfShorttermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:href="upc-20220930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfAdvancesForConstruction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfAdvancesForConstruction"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_RepaymentsOfAdvancesForConstruction" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfBankDebt" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDividends" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:href="upc-20220930.xsd#upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryValuationReserves" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable">
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>54
<FILENAME>upc-20220930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Feb 10 15:53:46 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedBalanceSheet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedIncomeStatement" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShareholdersEquityType2or3" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedCashFlow" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_OrganizationandBusinessDescription" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_AccountsReceivableNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_InventoryNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_AdvancetoSuppliers" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforAdvertisting" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforAcquisition" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShortTermInvestments" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestments"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PropertyPlantandEquipmentNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_IntangibleAssetsNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforCIPProject" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforPurchaseofaProperty" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShortTermBankLoans" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_RelatedPartyTransactions" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_Taxes" roleURI="http://www.UniversePharmaceuticalsINC.com/role/Taxes"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_Concentrations" roleURI="http://www.UniversePharmaceuticalsINC.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShareholdersEquity" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_CommitmentsandContingencies" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SegmentReporting" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SubsequentEvents" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_CondensedFinancialInformationoftheParentCompany" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_AccountingPoliciesByPolicy" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_OrganizationandBusinessDescriptionTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_AccountsReceivableNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_InventoryNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_AdvancetoSuppliersTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShortTermInvestmentsTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PropertyPlantandEquipmentNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_IntangibleAssetsNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforCIPProjectTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShortTermBankLoansTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_RelatedPartyTransactionsTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_TaxesTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SegmentReportingTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_CondensedFinancialInformationoftheParentCompanyTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofsubsidiariesofthecompanyTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofpropertyplantandequipmentestimatedusefullivesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofintangibleassetsestimatedusefullivesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofcurrencyexchangerateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofaccountsreceivableconsistsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableconsistsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofallowancefordoubtfulaccountsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofinventoryTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofadvancestosuppliersnetTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofshortterminvestmentsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofpropertyplantandequipmentnetconsistsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofintangibleassetsnetconsistTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleoffutureminimumcapitalexpendituresTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofshorttermbankloansTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofnatureofrelationshipswithrelatedpartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofduefromrelatedpartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofduetorelatedpartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofcomponentsoftheincometaxprovisionbenefitTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofdeferredtaxassetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleoftaxespayableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofrevenuebyproductsourceTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleoftotalrevenuesbyproductcategoriesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofparentcompanybalancesheetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofparentcompanybalancesheetsTable_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofparentcompanystatementsofcashflowsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_OrganizationandBusinessDescriptionDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_AccountsReceivableNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforAdvertistingDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforAcquisitionDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShortTermInvestmentsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PropertyPlantandEquipmentNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_IntangibleAssetsNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforCIPProjectDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforPurchaseofaPropertyDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShortTermBankLoansDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_RelatedPartyTransactionsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_TaxesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConcentrationsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShareholdersEquityDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_CommitmentsandContingenciesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SegmentReportingDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SubsequentEventsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_CondensedFinancialInformationoftheParentCompanyDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#DocumentAndEntityInformation" roleURI="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Supplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Supplies" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAcquisitionCurrent" xlink:href="upc-20220930.xsd#upc_PrepaymentForAcquisitionCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="upc_PrepaymentForAcquisitionCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:href="upc-20220930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsForConstructionInProgress" xlink:href="upc-20220930.xsd#upc_PrepaymentsForConstructionInProgress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="upc_PrepaymentsForConstructionInProgress" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_InvestmentInEquitySecurities" xlink:href="upc-20220930.xsd#upc_InvestmentInEquitySecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="upc_InvestmentInEquitySecurities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AdditionalPaidInCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserve" xlink:href="upc-20220930.xsd#upc_StatutoryReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="upc_StatutoryReserve" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_IncomeFromOperation" xlink:href="upc-20220930.xsd#upc_IncomeFromOperation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="upc_IncomeFromOperation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OtherIncomeExpensesAbstract" xlink:href="upc-20220930.xsd#upc_OtherIncomeExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="upc_OtherIncomeExpensesAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ShorttermInvestmentIncome" xlink:href="upc-20220930.xsd#upc_ShorttermInvestmentIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="upc_ShorttermInvestmentIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OtherComprehensiveIncomeLossAbstract" xlink:href="upc-20220930.xsd#upc_OtherComprehensiveIncomeLossAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="upc_OtherComprehensiveIncomeLossAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherComprehensiveIncomeLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReservesMember" xlink:href="upc-20220930.xsd#upc_StatutoryReservesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="upc_StatutoryReservesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" xlink:href="upc-20220930.xsd#upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ShorttermInvestmentsIncome" xlink:href="upc-20220930.xsd#upc_ShorttermInvestmentsIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="upc_ShorttermInvestmentsIncome" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidAdvertising"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:href="upc-20220930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfAdvancesForConstruction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfAdvancesForConstruction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfAdvancesForConstruction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_RedemptionOfShorttermInvestments" xlink:href="upc-20220930.xsd#upc_RedemptionOfShorttermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="upc_RedemptionOfShorttermInvestments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfBankDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:href="upc-20220930.xsd#upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoryNet">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers">
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersAbstract" xlink:href="upc-20220930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersTextBlock" xlink:href="upc-20220930.xsd#upc_AdvancesToSuppliersTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AdvancesToSuppliersAbstract" xlink:to="upc_AdvancesToSuppliersTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertistingAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForAdvertistingAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertistingTextBlock" xlink:href="upc-20220930.xsd#upc_PrepaymentForAdvertistingTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="upc_PrepaymentForAdvertistingTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforAcquisitionLineItems" xlink:href="upc-20220930.xsd#upc_PrepaymentforAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforAcquisitionTable" xlink:href="upc-20220930.xsd#upc_PrepaymentforAcquisitionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_PrepaymentforAcquisitionLineItems" xlink:to="upc_PrepaymentforAcquisitionTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAcquisitionTextBlock" xlink:href="upc-20220930.xsd#upc_PrepaymentForAcquisitionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforAcquisitionLineItems" xlink:to="upc_PrepaymentForAcquisitionTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestments">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_HeldToMaturityInvestmentDisclosureTextBlock" xlink:href="upc-20220930.xsd#upc_HeldToMaturityInvestmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="upc_HeldToMaturityInvestmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock" xlink:href="upc-20220930.xsd#upc_PrepaymentForConstructionInProgressTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForConstructionInProgressAbstract" xlink:to="upc_PrepaymentForConstructionInProgressTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyTextBlock" xlink:href="upc-20220930.xsd#upc_PrepaymentForPurchaseOfAPropertyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="upc_PrepaymentForPurchaseOfAPropertyTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/Taxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/Concentrations">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_AdvancesToSuppliersNetPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_AdvancesToSuppliersNetPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_HeldToMaturityInvestmentPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_HeldToMaturityInvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_HeldToMaturityInvestmentPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionContractorsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_ContractAssetsAndLiabilitiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_ContractAssetsAndLiabilitiesPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_DisaggregationOfRevenuesPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_DisaggregationOfRevenuesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_DisaggregationOfRevenuesPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ValueAddedTaxPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_ValueAddedTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_ValueAddedTaxPolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_StatementOfCashFlowsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_StatementOfCashFlowsPolicyTextBlock" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_EmployeeDefinedContributionPlanPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_EmployeeDefinedContributionPlanPolicyTextBlock" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="upc-20220930.xsd#upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables">
    <loc xlink:type="locator" xlink:label="upc_AdvancetoSuppliersTablesLineItems" xlink:href="upc-20220930.xsd#upc_AdvancetoSuppliersTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancetoSuppliersTablesTable" xlink:href="upc-20220930.xsd#upc_AdvancetoSuppliersTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_AdvancetoSuppliersTablesLineItems" xlink:to="upc_AdvancetoSuppliersTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet" xlink:href="upc-20220930.xsd#upc_ScheduleOfAdvancesToSuppliersNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AdvancetoSuppliersTablesLineItems" xlink:to="upc_ScheduleOfAdvancesToSuppliersNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForConstructionInProgressAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock" xlink:href="upc-20220930.xsd#upc_ScheduleOfDueFromRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:href="upc-20220930.xsd#upc_ScheduleOfDueToRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="upc_ScheduleOfDueToRelatedPartiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock" xlink:href="upc-20220930.xsd#upc_ScheduleOfTaxPayableTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="upc_ScheduleOfTaxPayableTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseINCMember" xlink:href="upc-20220930.xsd#upc_UniverseINCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseINCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHKMember" xlink:href="upc-20220930.xsd#upc_UniverseHKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseHKMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTechnologyMember" xlink:href="upc-20220930.xsd#upc_UniverseTechnologyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseTechnologyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiUniverseMember" xlink:href="upc-20220930.xsd#upc_JiangxiUniverseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_JiangxiUniverseMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTradeMember" xlink:href="upc-20220930.xsd#upc_UniverseTradeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseTradeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHanheMember" xlink:href="upc-20220930.xsd#upc_UniverseHanheMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseHanheMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PlaceOfIncorporation" xlink:href="upc-20220930.xsd#upc_PlaceOfIncorporation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="upc_PlaceOfIncorporation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OwnershipPercentage" xlink:href="upc-20220930.xsd#upc_OwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="upc_OwnershipPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrincipalActivities" xlink:href="upc-20220930.xsd#upc_PrincipalActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="upc_PrincipalActivities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable">
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AutomobilesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AutomobilesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OfficeAndElectricEquipmentMember" xlink:href="upc-20220930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="upc_OfficeAndElectricEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable">
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_UseRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntermediateLifePlantsUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntermediateLifePlantsUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:to="us-gaap_IntermediateLifePlantsUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfCurrencyExchangeRateAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfCurrencyExchangeRateAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_DescriptionOfYearEndSpotRate" xlink:href="upc-20220930.xsd#upc_DescriptionOfYearEndSpotRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfCurrencyExchangeRateAbstract" xlink:to="upc_DescriptionOfYearEndSpotRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_DescriptionOfAverageRate" xlink:href="upc-20220930.xsd#upc_DescriptionOfAverageRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfCurrencyExchangeRateAbstract" xlink:to="upc_DescriptionOfAverageRate" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableconsistsTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAccountsReceivableConsistsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfAccountsReceivableConsistsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAccountsReceivableConsistsAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAccountsReceivableConsistsAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAccountsReceivableConsistsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_LessThan3MonthsMember" xlink:href="upc-20220930.xsd#upc_LessThan3MonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="upc_LessThan3MonthsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_From4To6MonthsMember" xlink:href="upc-20220930.xsd#upc_From4To6MonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="upc_From4To6MonthsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_From7To9MonthsMember" xlink:href="upc-20220930.xsd#upc_From7To9MonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="upc_From7To9MonthsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_From10To12MonthsMember" xlink:href="upc-20220930.xsd#upc_From10To12MonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="upc_From10To12MonthsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_Over1YearMember" xlink:href="upc-20220930.xsd#upc_Over1YearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="upc_Over1YearMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AccountsReceivableBeforeGrossValue" xlink:href="upc-20220930.xsd#upc_AccountsReceivableBeforeGrossValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_AccountsReceivableBeforeGrossValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SubsequentCollection" xlink:href="upc-20220930.xsd#upc_SubsequentCollection"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_SubsequentCollection" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfSubsequentCollection" xlink:href="upc-20220930.xsd#upc_PercentageOfSubsequentCollection"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_PercentageOfSubsequentCollection" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AccountsReceivableGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SunsequentCollectionsTotalGrossAccountsReceivable" xlink:href="upc-20220930.xsd#upc_SunsequentCollectionsTotalGrossAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_SunsequentCollectionsTotalGrossAccountsReceivable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_TotalGrossAccountsReceivablePercentage" xlink:href="upc-20220930.xsd#upc_TotalGrossAccountsReceivablePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_TotalGrossAccountsReceivablePercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SunsequentCollectionAllowanceForDoubtfulAccounts" xlink:href="upc-20220930.xsd#upc_SunsequentCollectionAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_SunsequentCollectionAllowanceForDoubtfulAccounts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AllowanceForDoubtfulAccountsReceivablePercentage" xlink:href="upc-20220930.xsd#upc_AllowanceForDoubtfulAccountsReceivablePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_AllowanceForDoubtfulAccountsReceivablePercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SunsequentCollectionAccountsReceivableNet" xlink:href="upc-20220930.xsd#upc_SunsequentCollectionAccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_SunsequentCollectionAccountsReceivableNet" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AccountsReceivableNetPercentage" xlink:href="upc-20220930.xsd#upc_AccountsReceivableNetPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_AccountsReceivableNetPercentage" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfInventoryAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAdvancesToSuppliersNetAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfAdvancesToSuppliersNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToSuppliersAndEmployees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToSuppliersAndEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="us-gaap_PaymentsToSuppliersAndEmployees" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvestmentsTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfShortTermInvestmentsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfShortTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AddPurchaseWealthManagementFinancialProducts" xlink:href="upc-20220930.xsd#upc_AddPurchaseWealthManagementFinancialProducts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfShortTermInvestmentsAbstract" xlink:to="upc_AddPurchaseWealthManagementFinancialProducts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfShortTermInvestmentsAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfShortTermInvestmentsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfShortTermInvestmentsAbstract" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AutomobilesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AutomobilesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OfficeAndElectricEquipmentMember" xlink:href="upc-20220930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="upc_OfficeAndElectricEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_UseRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:href="upc-20220930.xsd#upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" xlink:href="upc-20220930.xsd#upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:to="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AmortizationExpenseMember" xlink:href="upc-20220930.xsd#upc_AmortizationExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="upc_AmortizationExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7sSbeKneEPlmNIhj3bCSU5y7O0I8dbszuTl8jF0AJbe21t+Rq4Ior0xtAOoy+ao7RLCBcMnvOYD6nWgAt+g/C9Glm4Z6aOCF7CBTCCEgAQgDS5HDB+QiyzENxDKMscO/BY9V3rvnC2jKA==] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:href="upc-20220930.xsd#upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:href="upc-20220930.xsd#upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CapitalExpenditureMember" xlink:href="upc-20220930.xsd#upc_CapitalExpenditureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="upc_CapitalExpenditureMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Maturity30To90DaysMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Maturity30To90DaysMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="us-gaap_Maturity30To90DaysMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaturityOver90DaysMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaturityOver90DaysMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="us-gaap_MaturityOver90DaysMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysOneMember" xlink:href="upc-20220930.xsd#upc_MaturityGreaterThan90DaysOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="upc_MaturityGreaterThan90DaysOneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysTwoMember" xlink:href="upc-20220930.xsd#upc_MaturityGreaterThan90DaysTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="upc_MaturityGreaterThan90DaysTwoMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysThreeMember" xlink:href="upc-20220930.xsd#upc_MaturityGreaterThan90DaysThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="upc_MaturityGreaterThan90DaysThreeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysFourMember" xlink:href="upc-20220930.xsd#upc_MaturityGreaterThan90DaysFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="upc_MaturityGreaterThan90DaysFourMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:href="upc-20220930.xsd#upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_BankOfCommunicationsCoLtdAbstract" xlink:href="upc-20220930.xsd#upc_BankOfCommunicationsCoLtdAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:to="upc_BankOfCommunicationsCoLtdAbstract" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrGangLaiMember" xlink:href="upc-20220930.xsd#upc_MrGangLaiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MrGangLaiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MsLinYangMember" xlink:href="upc-20220930.xsd#upc_MsLinYangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MsLinYangMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember" xlink:href="upc-20220930.xsd#upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember" xlink:href="upc-20220930.xsd#upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:href="upc-20220930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:href="upc-20220930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:to="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_GreatestGroupMember" xlink:href="upc-20220930.xsd#upc_GreatestGroupMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_GreatestGroupMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_FoshanShangyuMember" xlink:href="upc-20220930.xsd#upc_FoshanShangyuMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_FoshanShangyuMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_NameAbstract" xlink:href="upc-20220930.xsd#upc_NameAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:to="upc_NameAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_NameAbstract" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:href="upc-20220930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:href="upc-20220930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:to="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrGangLaiMember" xlink:href="upc-20220930.xsd#upc_MrGangLaiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MrGangLaiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrsLinYangMember" xlink:href="upc-20220930.xsd#upc_MrsLinYangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MrsLinYangMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_NameAbstract0" xlink:href="upc-20220930.xsd#upc_NameAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:to="upc_NameAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_NameAbstract0" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable">
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:href="upc-20220930.xsd#upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:href="upc-20220930.xsd#upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KY" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KY"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KY" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_DeferredTaxAssetsAbstract" xlink:href="upc-20220930.xsd#upc_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="upc_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTaxesPayableAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfTaxesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfRevenueByProductSourceAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfRevenueByProductSourceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfOtherPropertyOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfOtherPropertyOperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfRevenueByProductSourceAbstract" xlink:to="us-gaap_CostOfOtherPropertyOperatingExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfRevenueByProductSourceAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfRevenueByProductSourceAbstract" xlink:to="us-gaap_Revenues" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_CorporateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentOneMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="upc_CorporateSegmentOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentTwoMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="upc_CorporateSegmentTwoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentThreeMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="upc_CorporateSegmentThreeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentFourMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="upc_CorporateSegmentFourMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentFiveMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="upc_CorporateSegmentFiveMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentSixMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="upc_CorporateSegmentSixMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SalesOfTcmdProductsAbstract" xlink:href="upc-20220930.xsd#upc_SalesOfTcmdProductsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="upc_SalesOfTcmdProductsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SubtotalOfTCMDProductsSales" xlink:href="upc-20220930.xsd#upc_SubtotalOfTCMDProductsSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SalesOfTcmdProductsAbstract" xlink:to="upc_SubtotalOfTCMDProductsSales" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SalesOfThirdPartyProductsAbstract" xlink:href="upc-20220930.xsd#upc_SalesOfThirdPartyProductsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="upc_SalesOfThirdPartyProductsAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SubtotalOfThirdpartyProductsSales" xlink:href="upc-20220930.xsd#upc_SubtotalOfThirdpartyProductsSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SalesOfThirdPartyProductsAbstract" xlink:to="upc_SubtotalOfThirdpartyProductsSales" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CurrentAssetsAbstract0" xlink:href="upc-20220930.xsd#upc_CurrentAssetsAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="upc_CurrentAssetsAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CurrentAssetsAbstract0" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CurrentAssetsAbstract0" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_NonCurrentAssetsAbstract" xlink:href="upc-20220930.xsd#upc_NonCurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="upc_NonCurrentAssetsAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_NonCurrentAssetsAbstract" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_NonCurrentAssetsAbstract" xlink:to="us-gaap_Assets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_Liabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityAbstract0" xlink:href="upc-20220930.xsd#upc_ShareholdersEquityAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="upc_ShareholdersEquityAbstract0" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OtherIncomeExpensesAbstract0" xlink:href="upc-20220930.xsd#upc_OtherIncomeExpensesAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="upc_OtherIncomeExpensesAbstract0" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOtherShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract0" xlink:to="us-gaap_InterestExpenseOtherShortTermBorrowings" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract0" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ProfitLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedCashFlowStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashFlowsFromOperatingActivitiesAbstract" xlink:href="upc-20220930.xsd#upc_CashFlowsFromOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="upc_CashFlowsFromOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" xlink:href="upc-20220930.xsd#upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_EquityInEarningsOfSubsidiary" xlink:href="upc-20220930.xsd#upc_EquityInEarningsOfSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" xlink:to="upc_EquityInEarningsOfSubsidiary" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:href="upc-20220930.xsd#upc_CashFlowsFromInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="upc_CashFlowsFromInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:href="upc-20220930.xsd#upc_CashFlowsFromFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="upc_CashFlowsFromFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashLentToSubsidiaries" xlink:href="upc-20220930.xsd#upc_CashLentToSubsidiaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="upc_CashLentToSubsidiaries" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="upc-20220930.xsd#upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails">
    <loc xlink:type="locator" xlink:label="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:href="upc-20220930.xsd#upc_OrganizationandBusinessDescriptionDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:href="upc-20220930.xsd#upc_OrganizationandBusinessDescriptionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_OrganizationandBusinessDescriptionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseIncMember" xlink:href="upc-20220930.xsd#upc_UniverseIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHKMember" xlink:href="upc-20220930.xsd#upc_UniverseHKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseHKMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTechnologyMember" xlink:href="upc-20220930.xsd#upc_UniverseTechnologyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseTechnologyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiUniverseMember" xlink:href="upc-20220930.xsd#upc_JiangxiUniverseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_JiangxiUniverseMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTradeMember" xlink:href="upc-20220930.xsd#upc_UniverseTradeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseTradeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiMember" xlink:href="upc-20220930.xsd#upc_JiangxiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_JiangxiMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_EntityIncorporationDateDescription" xlink:href="upc-20220930.xsd#upc_EntityIncorporationDateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_EntityIncorporationDateDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_EquityMethodInvestmentOwnershipsPercentage" xlink:href="upc-20220930.xsd#upc_EquityMethodInvestmentOwnershipsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_EquityMethodInvestmentOwnershipsPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AmountOfRegisteredCapital" xlink:href="upc-20220930.xsd#upc_AmountOfRegisteredCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_AmountOfRegisteredCapital" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CapitalContribution" xlink:href="upc-20220930.xsd#upc_CapitalContribution"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_CapitalContribution" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_RemainingCapitalContribution" xlink:href="upc-20220930.xsd#upc_RemainingCapitalContribution"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_RemainingCapitalContribution" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SharesIssued01" xlink:href="upc-20220930.xsd#upc_SharesIssued01"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_SharesIssued01" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_SharePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PublicOfferingPrice" xlink:href="upc-20220930.xsd#upc_PublicOfferingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_PublicOfferingPrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OwnershipMember" xlink:href="upc-20220930.xsd#upc_OwnershipMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="upc_OwnershipMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JxRcbBankMember" xlink:href="upc-20220930.xsd#upc_JxRcbBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_JxRcbBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MaterialPricePercentage" xlink:href="upc-20220930.xsd#upc_MaterialPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_MaterialPricePercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PaymentTerm" xlink:href="upc-20220930.xsd#upc_PaymentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_PaymentTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AllowanceForUncollectableBalancesAmount" xlink:href="upc-20220930.xsd#upc_AllowanceForUncollectableBalancesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_AllowanceForUncollectableBalancesAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_EquityMethodInvestmentOwnershipsPercentage" xlink:href="upc-20220930.xsd#upc_EquityMethodInvestmentOwnershipsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_EquityMethodInvestmentOwnershipsPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NetInvestmentIncome" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_TaxBenefitPercentage" xlink:href="upc-20220930.xsd#upc_TaxBenefitPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_TaxBenefitPercentage" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfVatRate" xlink:href="upc-20220930.xsd#upc_PercentageOfVatRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_PercentageOfVatRate" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_AccountsReceivableDescription" xlink:href="upc-20220930.xsd#upc_AccountsReceivableDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="upc_AccountsReceivableDescription" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertistingAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForAdvertistingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfAdvancePayment" xlink:href="upc-20220930.xsd#upc_PercentageOfAdvancePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="upc_PercentageOfAdvancePayment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AdditionalContractPricePercentage" xlink:href="upc-20220930.xsd#upc_AdditionalContractPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="upc_AdditionalContractPricePercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ContractPricePercentage" xlink:href="upc-20220930.xsd#upc_ContractPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="upc_ContractPricePercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforAcquisitionDetailsLineItems" xlink:href="upc-20220930.xsd#upc_PrepaymentforAcquisitionDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforAcquisitionDetailsTable" xlink:href="upc-20220930.xsd#upc_PrepaymentforAcquisitionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_PrepaymentforAcquisitionDetailsLineItems" xlink:to="upc_PrepaymentforAcquisitionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforAcquisitionDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_YunnanFaxiMember" xlink:href="upc-20220930.xsd#upc_YunnanFaxiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="upc_YunnanFaxiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_EquityMethodInvestmentOwnershipsPercentage" xlink:href="upc-20220930.xsd#upc_EquityMethodInvestmentOwnershipsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforAcquisitionDetailsLineItems" xlink:to="upc_EquityMethodInvestmentOwnershipsPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AssetAcquisitionPriceOfAcquisitionsExpected" xlink:href="upc-20220930.xsd#upc_AssetAcquisitionPriceOfAcquisitionsExpected"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforAcquisitionDetailsLineItems" xlink:to="upc_AssetAcquisitionPriceOfAcquisitionsExpected" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforAcquisitionDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_OtherShortTermInvestments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:href="upc-20220930.xsd#upc_PrepaymentforCIPProjectDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforCIPProjectDetailsTable" xlink:href="upc-20220930.xsd#upc_PrepaymentforCIPProjectDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:to="upc_PrepaymentforCIPProjectDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforCIPProjectDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforCIPProjectDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ChenyuanMember" xlink:href="upc-20220930.xsd#upc_ChenyuanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_ChenyuanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentBuildingAndBuildingImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionContractCostProgressPaymentOffset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:to="us-gaap_ConstructionContractCostProgressPaymentOffset" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_Prepayment" xlink:href="upc-20220930.xsd#upc_Prepayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:to="upc_Prepayment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CapitalExpenditure" xlink:href="upc-20220930.xsd#upc_CapitalExpenditure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:to="upc_CapitalExpenditure" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_EquityInterest" xlink:href="upc-20220930.xsd#upc_EquityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="upc_EquityInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OfficeSpaceSquareMeters" xlink:href="upc-20220930.xsd#upc_OfficeSpaceSquareMeters"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="upc_OfficeSpaceSquareMeters" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="us-gaap_SupplementalDeferredPurchasePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfPrepayment" xlink:href="upc-20220930.xsd#upc_PercentageOfPrepayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="upc_PercentageOfPrepayment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PayableDeliveryPropertyPercentage" xlink:href="upc-20220930.xsd#upc_PayableDeliveryPropertyPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="upc_PayableDeliveryPropertyPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails">
    <loc xlink:type="locator" xlink:label="upc_ShortTermBankLoansDetailsLineItems" xlink:href="upc-20220930.xsd#upc_ShortTermBankLoansDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_ShortTermBankLoansDetailsTable" xlink:href="upc-20220930.xsd#upc_ShortTermBankLoansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_ShortTermBankLoansDetailsLineItems" xlink:to="upc_ShortTermBankLoansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShortTermBankLoansDetailsTable" xlink:to="dei_LegalEntityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiLulingRuralCommercialBankMember" xlink:href="upc-20220930.xsd#upc_JiangxiLulingRuralCommercialBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="upc_JiangxiLulingRuralCommercialBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableToBankCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShortTermBankLoansDetailsLineItems" xlink:to="us-gaap_LoansPayableToBankCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShortTermBankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShortTermBankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShortTermBankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShortTermBankLoansDetailsLineItems" xlink:to="us-gaap_InterestAndDebtExpense" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeconsolidationRelatedPartyDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRelatedPartyDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_DeconsolidationRelatedPartyDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentAmount" xlink:href="upc-20220930.xsd#upc_PrepaymentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="upc_PrepaymentAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_EquityInterestOwnershipPercentage" xlink:href="upc-20220930.xsd#upc_EquityInterestOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="upc_EquityInterestOwnershipPercentage" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails">
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsLineItems" xlink:href="upc-20220930.xsd#upc_TaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsTable" xlink:href="upc-20220930.xsd#upc_TaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_TaxesDetailsLineItems" xlink:to="upc_TaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_TaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PreferentialTaxTreatmentDescription" xlink:href="upc-20220930.xsd#upc_PreferentialTaxTreatmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsLineItems" xlink:to="upc_PreferentialTaxTreatmentDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsLineItems" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails">
    <loc xlink:type="locator" xlink:label="upc_ConcentrationsDetailsLineItems" xlink:href="upc-20220930.xsd#upc_ConcentrationsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_ConcentrationsDetailsTable" xlink:href="upc-20220930.xsd#upc_ConcentrationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_ConcentrationsDetailsLineItems" xlink:to="upc_ConcentrationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SupplierOneMember" xlink:href="upc-20220930.xsd#upc_SupplierOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="upc_SupplierOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SupplierTwoMember" xlink:href="upc-20220930.xsd#upc_SupplierTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="upc_SupplierTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_supplierMember" xlink:href="upc-20220930.xsd#upc_supplierMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="upc_supplierMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CustomerMember" xlink:href="upc-20220930.xsd#upc_CustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="upc_CustomerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CustomersOneMember" xlink:href="upc-20220930.xsd#upc_CustomersOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="upc_CustomersOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_TotalRevenueMember" xlink:href="upc-20220930.xsd#upc_TotalRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="upc_TotalRevenueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_AccountsReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_GubenYanlingPillMember" xlink:href="upc-20220930.xsd#upc_GubenYanlingPillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="upc_GubenYanlingPillMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignFinancialInstitutionsMandatedDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ConcentrationsDetailsLineItems" xlink:to="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ConcentrationRiskThresholdPercentage" xlink:href="upc-20220930.xsd#upc_ConcentrationRiskThresholdPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ConcentrationsDetailsLineItems" xlink:to="upc_ConcentrationRiskThresholdPercentage" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityDetailsLineItems" xlink:href="upc-20220930.xsd#upc_ShareholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityDetailsTable" xlink:href="upc-20220930.xsd#upc_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UnderwriterWarrantsMember" xlink:href="upc-20220930.xsd#upc_UnderwriterWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="upc_UnderwriterWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PRCMember" xlink:href="upc-20220930.xsd#upc_PRCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="upc_PRCMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="upc_UnderwriterWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashDividendsMember" xlink:href="upc-20220930.xsd#upc_CashDividendsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="upc_CashDividendsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserveAndRestrictedNetAssetsMember" xlink:href="upc-20220930.xsd#upc_StatutoryReserveAndRestrictedNetAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="upc_StatutoryReserveAndRestrictedNetAssetsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseINCMember" xlink:href="upc-20220930.xsd#upc_UniverseINCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_UniverseINCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OriginalSharesParValue" xlink:href="upc-20220930.xsd#upc_OriginalSharesParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_OriginalSharesParValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OrdinarySharesParValue" xlink:href="upc-20220930.xsd#upc_OrdinarySharesParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_OrdinarySharesParValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OrdinarySharesOutstandingDescription" xlink:href="upc-20220930.xsd#upc_OrdinarySharesOutstandingDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_OrdinarySharesOutstandingDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ReorganizationShares" xlink:href="upc-20220930.xsd#upc_ReorganizationShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_ReorganizationShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PublicOfferingPrice" xlink:href="upc-20220930.xsd#upc_PublicOfferingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_PublicOfferingPrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OptionToPurchaseAdditionalShares" xlink:href="upc-20220930.xsd#upc_OptionToPurchaseAdditionalShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_OptionToPurchaseAdditionalShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesOutstanding" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_EquityMethodInvestmentOwnershipsPercentage" xlink:href="upc-20220930.xsd#upc_EquityMethodInvestmentOwnershipsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_EquityMethodInvestmentOwnershipsPercentage" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsShareBasedCompensationCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsShareBasedCompensationCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_DividendsShareBasedCompensationCash" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashDividendDescription" xlink:href="upc-20220930.xsd#upc_CashDividendDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_CashDividendDescription" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutorySurplusPercentage" xlink:href="upc-20220930.xsd#upc_StatutorySurplusPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_StatutorySurplusPercentage" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ReserveIsEqualPercentage" xlink:href="upc-20220930.xsd#upc_ReserveIsEqualPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_ReserveIsEqualPercentage" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_RestrictedCash" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_RestrictedNetAssets" xlink:href="upc-20220930.xsd#upc_RestrictedNetAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_RestrictedNetAssets" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseCapitalSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_InterestExpenseCapitalSecurities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventDescription" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent" xlink:href="upc-20220930.xsd#upc_MinorityInterestsOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="upc_MinorityInterestsOwnershipPercentageByParent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="40" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>55
<FILENAME>upc-20220930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Feb 10 15:53:46 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NONCURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_IncomeFromOperation" xlink:href="upc-20220930.xsd#upc_IncomeFromOperation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="upc_IncomeFromOperation_lbl" xml:lang="en-US">Income from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_IncomeFromOperation" xlink:to="upc_IncomeFromOperation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (expense) income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">(Loss) income before income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Ordinary shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">CHANGES IN CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfCurrencyExchangeRateAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfCurrencyExchangeRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfCurrencyExchangeRateAbstract_lbl" xml:lang="en-US">Schedule of currency exchange rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfCurrencyExchangeRateAbstract" xlink:to="upc_ScheduleOfCurrencyExchangeRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAccountsReceivableConsistsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfAccountsReceivableConsistsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfAccountsReceivableConsistsAbstract_lbl" xml:lang="en-US">Schedule of Accounts Receivable Consists [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAccountsReceivableConsistsAbstract" xlink:to="upc_ScheduleOfAccountsReceivableConsistsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_lbl" xml:lang="en-US">Class of Financing Receivable [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract_lbl" xml:lang="en-US">Schedule of Allowance for Doubtful Accounts [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfInventoryAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfInventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfInventoryAbstract_lbl" xml:lang="en-US">Schedule of inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfInventoryAbstract" xlink:to="upc_ScheduleOfInventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventories, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersAbstract" xlink:href="upc-20220930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdvancesToSuppliersAbstract_lbl" xml:lang="en-US">Advances To Suppliers [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersAbstract" xlink:to="upc_AdvancesToSuppliersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAdvancesToSuppliersNetAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfAdvancesToSuppliersNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfAdvancesToSuppliersNetAbstract_lbl" xml:lang="en-US">Schedule of Advances to Suppliers Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="upc_ScheduleOfAdvancesToSuppliersNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertistingAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForAdvertistingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForAdvertistingAbstract_lbl" xml:lang="en-US">Prepayment for Advertisting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="upc_PrepaymentForAdvertistingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowingsAbstract_lbl" xml:lang="en-US">Short-Term Invstment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermBorrowingsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfShortTermInvestmentsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfShortTermInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfShortTermInvestmentsAbstract_lbl" xml:lang="en-US">Schedule of short-term investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfShortTermInvestmentsAbstract" xlink:to="upc_ScheduleOfShortTermInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Ending balance of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl1" xml:lang="en-US">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Intangible Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForConstructionInProgressAbstract_lbl" xml:lang="en-US">Prepayment for CIP Project [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForConstructionInProgressAbstract" xlink:to="upc_PrepaymentForConstructionInProgressAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForPurchaseOfAPropertyAbstract_lbl" xml:lang="en-US">Prepayment for Purchase of a Property [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="upc_PrepaymentForPurchaseOfAPropertyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_lbl" xml:lang="en-US">Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract_lbl" xml:lang="en-US">Schedule of Table Reconciles the China Statutory Rates to the Companys Effective Tax Rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTaxesPayableAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfTaxesPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfTaxesPayableAbstract_lbl" xml:lang="en-US">Schedule of Taxes Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTaxesPayableAbstract" xlink:to="upc_ScheduleOfTaxesPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Total taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl0" xml:lang="en-US">Taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Concentrations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Shareholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="upc-20220930.xsd#upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">CASH, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0" xml:lang="en-US">CASH, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US">Contact Personnel Email Address</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Supplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Supplies_lbl" xml:lang="en-US">Advance to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Prepayment for advertising</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAcquisitionCurrent" xlink:href="upc-20220930.xsd#upc_PrepaymentForAcquisitionCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForAcquisitionCurrent_lbl" xml:lang="en-US">Prepayment for acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisitionCurrent" xlink:to="upc_PrepaymentForAcquisitionCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract" xlink:to="upc_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:href="upc-20220930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl" xml:lang="en-US">Prepayments made to a related party for purchase of property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsForConstructionInProgress" xlink:href="upc-20220930.xsd#upc_PrepaymentsForConstructionInProgress"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentsForConstructionInProgress_lbl" xml:lang="en-US">Prepayments for construction in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsForConstructionInProgress" xlink:to="upc_PrepaymentsForConstructionInProgress_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_InvestmentInEquitySecurities" xlink:href="upc-20220930.xsd#upc_InvestmentInEquitySecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_InvestmentInEquitySecurities_lbl" xml:lang="en-US">Investment in equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_InvestmentInEquitySecurities" xlink:to="upc_InvestmentInEquitySecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract0" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract0" xlink:to="upc_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract1" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract1" xlink:to="upc_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract2" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract2" xlink:to="upc_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Short-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract3" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract3" xlink:to="upc_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract4" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract4" xlink:to="upc_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares issued and outstanding as of September 30, 2022 and 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares issued and outstanding as of September 30, 2021 and 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Ordinary shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Ordinary shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserve" xlink:href="upc-20220930.xsd#upc_StatutoryReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatutoryReserve_lbl" xml:lang="en-US">Statutory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserve" xlink:to="upc_StatutoryReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract5" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract5" xlink:to="upc_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract6" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract6" xlink:to="upc_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract7" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract7" xlink:to="upc_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract8" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract8" xlink:to="upc_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OtherIncomeExpensesAbstract" xlink:href="upc-20220930.xsd#upc_OtherIncomeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OtherIncomeExpensesAbstract_lbl" xml:lang="en-US">Other income (expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="upc_OtherIncomeExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Equity investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0" xml:lang="en-US">Equity in earnings of subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract9" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract9" xlink:to="upc_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract10" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract10" xlink:to="upc_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract11" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract11" xlink:to="upc_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract12" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract12" xlink:to="upc_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OtherComprehensiveIncomeLossAbstract" xlink:href="upc-20220930.xsd#upc_OtherComprehensiveIncomeLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OtherComprehensiveIncomeLossAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherComprehensiveIncomeLossAbstract" xlink:to="upc_OtherComprehensiveIncomeLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract13" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract13" xlink:to="upc_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings per share	Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings per share diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract14" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract14" xlink:to="upc_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares outstanding Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares outstanding diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract15" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract15" xlink:to="upc_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract16" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract16" xlink:to="upc_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract17" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract17" xlink:to="upc_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" xlink:href="upc-20220930.xsd#upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts_lbl" xml:lang="en-US">Capitalized initial public offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" xlink:to="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract18" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract18" xlink:to="upc_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract19" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract19" xlink:to="upc_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract20" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract20" xlink:to="upc_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract21" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract21" xlink:to="upc_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xml:lang="en-US">Loss from disposal of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl" xml:lang="en-US">Inventory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred tax provision (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ShorttermInvestmentsIncome" xlink:href="upc-20220930.xsd#upc_ShorttermInvestmentsIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ShorttermInvestmentsIncome_lbl" xml:lang="en-US">Short-term investments income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShorttermInvestmentsIncome" xlink:to="upc_ShorttermInvestmentsIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_lbl" xml:lang="en-US">Taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract22" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract22" xlink:to="upc_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US">Proceeds from disposal of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RedemptionOfShorttermInvestments" xlink:href="upc-20220930.xsd#upc_RedemptionOfShorttermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_RedemptionOfShorttermInvestments_lbl" xml:lang="en-US">Redemption of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RedemptionOfShorttermInvestments" xlink:to="upc_RedemptionOfShorttermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract23" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract23" xlink:to="upc_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Proceeds from short-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Gross proceeds from initial public offerings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract24" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract24" xlink:to="upc_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract25" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract25" xlink:to="upc_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingExpense_lbl" xml:lang="en-US">Selling expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShorttermInvestmentIncome" xlink:href="upc-20220930.xsd#upc_ShorttermInvestmentIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="upc_ShorttermInvestmentIncome_lbl" xml:lang="en-US">Short-term investments (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShorttermInvestmentIncome" xlink:to="upc_ShorttermInvestmentIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Total income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl" xml:lang="en-US">Advance to suppliers, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidAdvertising"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising_lbl" xml:lang="en-US">Prepayment for advertising</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xml:lang="en-US">Advances to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:href="upc-20220930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty_lbl" xml:lang="en-US">Prepayments made to a related party for purchase of property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfAdvancesForConstruction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfAdvancesForConstruction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfAdvancesForConstruction_lbl" xml:lang="en-US">Prepayments for construction in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfAdvancesForConstruction" xlink:to="us-gaap_RepaymentsOfAdvancesForConstruction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Prepayment for acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl" xml:lang="en-US">Payments for short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl0" xml:lang="en-US">Payment for short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US">Repayment of bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US">Dividend payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xml:lang="en-US">Payment for deferred initial public offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:href="upc-20220930.xsd#upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings_lbl" xml:lang="en-US">Proceeds from (prepayments for) related parties borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReservesMember" xlink:href="upc-20220930.xsd#upc_StatutoryReservesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatutoryReservesMember_lbl" xml:lang="en-US">Statutory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReservesMember" xlink:to="upc_StatutoryReservesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND BUSINESS DESCRIPTION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl" xml:lang="en-US">Schedule of subsidiaries of the company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Date of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PlaceOfIncorporation" xlink:href="upc-20220930.xsd#upc_PlaceOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PlaceOfIncorporation_lbl" xml:lang="en-US">Place of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PlaceOfIncorporation" xlink:to="upc_PlaceOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OwnershipPercentage" xlink:href="upc-20220930.xsd#upc_OwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OwnershipPercentage_lbl" xml:lang="en-US">% of Ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OwnershipPercentage" xlink:to="upc_OwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrincipalActivities" xlink:href="upc-20220930.xsd#upc_PrincipalActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrincipalActivities_lbl" xml:lang="en-US">Principal Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrincipalActivities" xlink:to="upc_PrincipalActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract26" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract26" xlink:to="upc_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract27" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract27" xlink:to="upc_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract28" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract28" xlink:to="upc_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract29" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract29" xlink:to="upc_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract30" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract30" xlink:to="upc_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="upc-20220930.xsd#upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntermediateLifePlantsUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntermediateLifePlantsUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntermediateLifePlantsUsefulLife_lbl" xml:lang="en-US">Useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntermediateLifePlantsUsefulLife" xlink:to="us-gaap_IntermediateLifePlantsUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl" xml:lang="en-US">Schedule of currency exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_DescriptionOfYearEndSpotRate" xlink:href="upc-20220930.xsd#upc_DescriptionOfYearEndSpotRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_DescriptionOfYearEndSpotRate_lbl" xml:lang="en-US">Year-end spot rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DescriptionOfYearEndSpotRate" xlink:to="upc_DescriptionOfYearEndSpotRate_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_DescriptionOfAverageRate" xlink:href="upc-20220930.xsd#upc_DescriptionOfAverageRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_DescriptionOfAverageRate_lbl" xml:lang="en-US">Average rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DescriptionOfAverageRate" xlink:to="upc_DescriptionOfAverageRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS RECEIVABLE, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of accounts receivable consists</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_lbl" xml:lang="en-US">Schedule of the company&#8217;s accounts receivable and subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:to="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AccountsReceivableBeforeGrossValue" xlink:href="upc-20220930.xsd#upc_AccountsReceivableBeforeGrossValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AccountsReceivableBeforeGrossValue_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableBeforeGrossValue" xlink:to="upc_AccountsReceivableBeforeGrossValue_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SubsequentCollection" xlink:href="upc-20220930.xsd#upc_SubsequentCollection"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SubsequentCollection_lbl" xml:lang="en-US">Subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubsequentCollection" xlink:to="upc_SubsequentCollection_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfSubsequentCollection" xlink:href="upc-20220930.xsd#upc_PercentageOfSubsequentCollection"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PercentageOfSubsequentCollection_lbl" xml:lang="en-US">Percentage of subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfSubsequentCollection" xlink:to="upc_PercentageOfSubsequentCollection_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SunsequentCollectionsTotalGrossAccountsReceivable" xlink:href="upc-20220930.xsd#upc_SunsequentCollectionsTotalGrossAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SunsequentCollectionsTotalGrossAccountsReceivable_lbl" xml:lang="en-US">Subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SunsequentCollectionsTotalGrossAccountsReceivable" xlink:to="upc_SunsequentCollectionsTotalGrossAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TotalGrossAccountsReceivablePercentage" xlink:href="upc-20220930.xsd#upc_TotalGrossAccountsReceivablePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_TotalGrossAccountsReceivablePercentage_lbl" xml:lang="en-US">Percentage of subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TotalGrossAccountsReceivablePercentage" xlink:to="upc_TotalGrossAccountsReceivablePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SunsequentCollectionAllowanceForDoubtfulAccounts" xlink:href="upc-20220930.xsd#upc_SunsequentCollectionAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SunsequentCollectionAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SunsequentCollectionAllowanceForDoubtfulAccounts" xlink:to="upc_SunsequentCollectionAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AllowanceForDoubtfulAccountsReceivablePercentage" xlink:href="upc-20220930.xsd#upc_AllowanceForDoubtfulAccountsReceivablePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AllowanceForDoubtfulAccountsReceivablePercentage_lbl" xml:lang="en-US">Percentage of subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AllowanceForDoubtfulAccountsReceivablePercentage" xlink:to="upc_AllowanceForDoubtfulAccountsReceivablePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SunsequentCollectionAccountsReceivableNet" xlink:href="upc-20220930.xsd#upc_SunsequentCollectionAccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SunsequentCollectionAccountsReceivableNet_lbl" xml:lang="en-US">Subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SunsequentCollectionAccountsReceivableNet" xlink:to="upc_SunsequentCollectionAccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AccountsReceivableNetPercentage" xlink:href="upc-20220930.xsd#upc_AccountsReceivableNetPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AccountsReceivableNetPercentage_lbl" xml:lang="en-US">Percentage of subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableNetPercentage" xlink:to="upc_AccountsReceivableNetPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersTextBlock" xlink:href="upc-20220930.xsd#upc_AdvancesToSuppliersTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AdvancesToSuppliersTextBlock_lbl" xml:lang="en-US">ADVANCE TO SUPPLIERS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersTextBlock" xlink:to="upc_AdvancesToSuppliersTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet" xlink:href="upc-20220930.xsd#upc_ScheduleOfAdvancesToSuppliersNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet_lbl" xml:lang="en-US">Schedule of advances to suppliers net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAdvancesToSuppliersNet" xlink:to="upc_ScheduleOfAdvancesToSuppliersNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xml:lang="en-US">Advances to suppliers for inventory raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xml:lang="en-US">Less: allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToSuppliersAndEmployees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToSuppliersAndEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToSuppliersAndEmployees_lbl" xml:lang="en-US">Advances to suppliers, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToSuppliersAndEmployees" xlink:to="us-gaap_PaymentsToSuppliersAndEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertistingTextBlock" xlink:href="upc-20220930.xsd#upc_PrepaymentForAdvertistingTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForAdvertistingTextBlock_lbl" xml:lang="en-US">PREPAYMENT FOR ADVERTISTING</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAdvertistingTextBlock" xlink:to="upc_PrepaymentForAdvertistingTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAcquisitionTextBlock" xlink:href="upc-20220930.xsd#upc_PrepaymentForAcquisitionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForAcquisitionTextBlock_lbl" xml:lang="en-US">PREPAYMENT FOR ACQUISITION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisitionTextBlock" xlink:to="upc_PrepaymentForAcquisitionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_HeldToMaturityInvestmentDisclosureTextBlock" xlink:href="upc-20220930.xsd#upc_HeldToMaturityInvestmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_HeldToMaturityInvestmentDisclosureTextBlock_lbl" xml:lang="en-US">SHORT-TERM INVESTMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_HeldToMaturityInvestmentDisclosureTextBlock" xlink:to="upc_HeldToMaturityInvestmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AddPurchaseWealthManagementFinancialProducts" xlink:href="upc-20220930.xsd#upc_AddPurchaseWealthManagementFinancialProducts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AddPurchaseWealthManagementFinancialProducts_lbl" xml:lang="en-US">Add: purchase wealth management financial products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AddPurchaseWealthManagementFinancialProducts" xlink:to="upc_AddPurchaseWealthManagementFinancialProducts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable_lbl" xml:lang="en-US">Accrued investment income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment, net consists</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Subtotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets, net consist</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated future amortization expense for intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock" xlink:href="upc-20220930.xsd#upc_PrepaymentForConstructionInProgressTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock_lbl" xml:lang="en-US">PREPAYMENT FOR CIP PROJECT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForConstructionInProgressTextBlock" xlink:to="upc_PrepaymentForConstructionInProgressTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum capital expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyTextBlock" xlink:href="upc-20220930.xsd#upc_PrepaymentForPurchaseOfAPropertyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForPurchaseOfAPropertyTextBlock_lbl" xml:lang="en-US">PREPAYMENT FOR PURCHASE OF A PROPERTY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForPurchaseOfAPropertyTextBlock" xlink:to="upc_PrepaymentForPurchaseOfAPropertyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">SHORT-TERM BANK LOANS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xml:lang="en-US">Schedule of short-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShortTermBankLoansAbstract" xlink:href="upc-20220930.xsd#upc_ShortTermBankLoansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ShortTermBankLoansAbstract_lbl" xml:lang="en-US">Short-term bank loans:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShortTermBankLoansAbstract" xlink:to="upc_ShortTermBankLoansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:href="upc-20220930.xsd#upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract_lbl" xml:lang="en-US">Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:to="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Total short-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_BankOfCommunicationsCoLtdAbstract" xlink:href="upc-20220930.xsd#upc_BankOfCommunicationsCoLtdAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_BankOfCommunicationsCoLtdAbstract_lbl" xml:lang="en-US">Bank of Communications Co., Ltd</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_BankOfCommunicationsCoLtdAbstract" xlink:to="upc_BankOfCommunicationsCoLtdAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of nature of relationships with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" xml:lang="en-US">Relationship with the group</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock" xlink:href="upc-20220930.xsd#upc_ScheduleOfDueFromRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock" xlink:to="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_NameAbstract" xlink:href="upc-20220930.xsd#upc_NameAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_NameAbstract_lbl" xml:lang="en-US">Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NameAbstract" xlink:to="upc_NameAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl" xml:lang="en-US">Total due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:href="upc-20220930.xsd#upc_ScheduleOfDueToRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:to="upc_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_NameAbstract0" xlink:href="upc-20220930.xsd#upc_NameAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_NameAbstract0_lbl" xml:lang="en-US">Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NameAbstract0" xlink:to="upc_NameAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US">Total due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of components of the income tax provision (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CurrentTaxProvisionAbstract" xlink:href="upc-20220930.xsd#upc_CurrentTaxProvisionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CurrentTaxProvisionAbstract_lbl" xml:lang="en-US">Current tax provision:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CurrentTaxProvisionAbstract" xlink:to="upc_CurrentTaxProvisionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_DeferredTaxProvisionBenefitAbstract" xlink:href="upc-20220930.xsd#upc_DeferredTaxProvisionBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_DeferredTaxProvisionBenefitAbstract_lbl" xml:lang="en-US">Deferred tax provision (benefit):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DeferredTaxProvisionBenefitAbstract" xlink:to="upc_DeferredTaxProvisionBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of table reconciles the china statutory rates to the company&#8217;s effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory PRC income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl" xml:lang="en-US">Permanent difference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Non-PRC entities not subject to PRC income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Impact on DTA due to change in applicable income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_DeferredTaxAssetsAbstract" xlink:href="upc-20220930.xsd#upc_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DeferredTaxAssetsAbstract" xlink:to="upc_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry-forwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock" xlink:href="upc-20220930.xsd#upc_ScheduleOfTaxPayableTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTaxPayableTableTextBlock" xlink:to="upc_ScheduleOfTaxPayableTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent_lbl" xml:lang="en-US">Value added tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xml:lang="en-US">Other taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CONCENTRATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT REPORTING</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl" xml:lang="en-US">Schedule of revenue by product source</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfOtherPropertyOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfOtherPropertyOperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfOtherPropertyOperatingExpense_lbl" xml:lang="en-US">Sales of TCMD products manufactured by the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfOtherPropertyOperatingExpense" xlink:to="us-gaap_CostOfOtherPropertyOperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Sales of third-party products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of total revenues by product categories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SalesOfTcmdProductsAbstract" xlink:href="upc-20220930.xsd#upc_SalesOfTcmdProductsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SalesOfTcmdProductsAbstract_lbl" xml:lang="en-US">Sales of TCMD products:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SalesOfTcmdProductsAbstract" xlink:to="upc_SalesOfTcmdProductsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SubtotalOfTCMDProductsSales" xlink:href="upc-20220930.xsd#upc_SubtotalOfTCMDProductsSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SubtotalOfTCMDProductsSales_lbl" xml:lang="en-US">Sub-total of TCMD products sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubtotalOfTCMDProductsSales" xlink:to="upc_SubtotalOfTCMDProductsSales_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract31" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract31" xlink:to="upc_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SalesOfThirdPartyProductsAbstract" xlink:href="upc-20220930.xsd#upc_SalesOfThirdPartyProductsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SalesOfThirdPartyProductsAbstract_lbl" xml:lang="en-US">Sales of third-party products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SalesOfThirdPartyProductsAbstract" xlink:to="upc_SalesOfThirdPartyProductsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SubtotalOfThirdpartyProductsSales" xlink:href="upc-20220930.xsd#upc_SubtotalOfThirdpartyProductsSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SubtotalOfThirdpartyProductsSales_lbl" xml:lang="en-US">Subtotal of third-party products sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubtotalOfThirdpartyProductsSales" xlink:to="upc_SubtotalOfThirdpartyProductsSales_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract32" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract32" xlink:to="upc_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xml:lang="en-US">CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of parent company balance sheets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CurrentAssetsAbstract0" xlink:href="upc-20220930.xsd#upc_CurrentAssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CurrentAssetsAbstract0_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CurrentAssetsAbstract0" xlink:to="upc_CurrentAssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract33" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract33" xlink:to="upc_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_NonCurrentAssetsAbstract" xlink:href="upc-20220930.xsd#upc_NonCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_NonCurrentAssetsAbstract_lbl" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NonCurrentAssetsAbstract" xlink:to="upc_NonCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xml:lang="en-US">Investment in subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract34" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract34" xlink:to="upc_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract35" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract35" xlink:to="upc_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract36" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract36" xlink:to="upc_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract37" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract37" xlink:to="upc_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract38" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract38" xlink:to="upc_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityAbstract0" xlink:href="upc-20220930.xsd#upc_ShareholdersEquityAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ShareholdersEquityAbstract0_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="upc_ShareholdersEquityAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract39" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract39"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract39_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract39" xlink:to="upc_UnlabeledAbstract39_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of parent company statements of income and comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract40" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract40"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract40_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract40" xlink:to="upc_UnlabeledAbstract40_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OtherIncomeExpensesAbstract0" xlink:href="upc-20220930.xsd#upc_OtherIncomeExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OtherIncomeExpensesAbstract0_lbl" xml:lang="en-US">Other income (expenses):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherIncomeExpensesAbstract0" xlink:to="upc_OtherIncomeExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract41" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract41"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract41_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract41" xlink:to="upc_UnlabeledAbstract41_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract42" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract42"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract42_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract42" xlink:to="upc_UnlabeledAbstract42_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive income attributable to the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of parent company statements of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashFlowsFromOperatingActivitiesAbstract" xlink:href="upc-20220930.xsd#upc_CashFlowsFromOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CashFlowsFromOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashFlowsFromOperatingActivitiesAbstract" xlink:to="upc_CashFlowsFromOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" xlink:href="upc-20220930.xsd#upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" xlink:to="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_EquityInEarningsOfSubsidiary" xlink:href="upc-20220930.xsd#upc_EquityInEarningsOfSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_EquityInEarningsOfSubsidiary_lbl" xml:lang="en-US">Equity in earnings of subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityInEarningsOfSubsidiary" xlink:to="upc_EquityInEarningsOfSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US">Short-term investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract43" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract43"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract43_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract43" xlink:to="upc_UnlabeledAbstract43_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:href="upc-20220930.xsd#upc_CashFlowsFromInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CashFlowsFromInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:to="upc_CashFlowsFromInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract44" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract44"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract44_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract44" xlink:to="upc_UnlabeledAbstract44_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:href="upc-20220930.xsd#upc_CashFlowsFromFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CashFlowsFromFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="upc_CashFlowsFromFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of ordinary shares in IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates_lbl" xml:lang="en-US">Cash repayment from subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract45" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract45"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract45_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract45" xlink:to="upc_UnlabeledAbstract45_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract46" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract46"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract46_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract46" xlink:to="upc_UnlabeledAbstract46_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract47" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract47"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract47_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract47" xlink:to="upc_UnlabeledAbstract47_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract48" xlink:href="upc-20220930.xsd#upc_UnlabeledAbstract48"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract48_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract48" xlink:to="upc_UnlabeledAbstract48_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Less: allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:to="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xml:lang="en-US">Bad debt recovery</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Inventory valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl0" xml:lang="en-US">Inventory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Less: redemption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl0" xml:lang="en-US">Redemption of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays_lbl" xml:lang="en-US">Effect of income tax holiday</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOtherShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseOtherShortTermBorrowings_lbl" xml:lang="en-US">Income from short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:to="us-gaap_InterestExpenseOtherShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashLentToSubsidiaries" xlink:href="upc-20220930.xsd#upc_CashLentToSubsidiaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="upc_CashLentToSubsidiaries_lbl" xml:lang="en-US">Cash lent to subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashLentToSubsidiaries" xlink:to="upc_CashLentToSubsidiaries_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseINCMember" xlink:href="upc-20220930.xsd#upc_UniverseINCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseINCMember_lbl" xml:lang="en-US">Universe INC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseINCMember" xlink:to="upc_UniverseINCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHKMember" xlink:href="upc-20220930.xsd#upc_UniverseHKMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseHKMember_lbl" xml:lang="en-US">Universe HK [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseHKMember" xlink:to="upc_UniverseHKMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTechnologyMember" xlink:href="upc-20220930.xsd#upc_UniverseTechnologyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseTechnologyMember_lbl" xml:lang="en-US">Universe Technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTechnologyMember" xlink:to="upc_UniverseTechnologyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiUniverseMember" xlink:href="upc-20220930.xsd#upc_JiangxiUniverseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_JiangxiUniverseMember_lbl" xml:lang="en-US">Jiangxi Universe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiUniverseMember" xlink:to="upc_JiangxiUniverseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTradeMember" xlink:href="upc-20220930.xsd#upc_UniverseTradeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseTradeMember_lbl" xml:lang="en-US">Universe Trade [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTradeMember" xlink:to="upc_UniverseTradeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="upc_UniverseTradeMember_lbl0" xml:lang="en-US">Jiangxi Universe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTradeMember" xlink:to="upc_UniverseTradeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHanheMember" xlink:href="upc-20220930.xsd#upc_UniverseHanheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseHanheMember_lbl" xml:lang="en-US">Universe Hanhe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseHanheMember" xlink:to="upc_UniverseHanheMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Buildings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AutomobilesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AutomobilesMember_lbl" xml:lang="en-US">Automobiles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AutomobilesMember" xlink:to="us-gaap_AutomobilesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OfficeAndElectricEquipmentMember" xlink:href="upc-20220930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OfficeAndElectricEquipmentMember_lbl" xml:lang="en-US">Office and electric equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OfficeAndElectricEquipmentMember" xlink:to="upc_OfficeAndElectricEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Lower [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseRightsMember_lbl" xml:lang="en-US">Land use rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseRightsMember" xlink:to="us-gaap_UseRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_LessThan3MonthsMember" xlink:href="upc-20220930.xsd#upc_LessThan3MonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_LessThan3MonthsMember_lbl" xml:lang="en-US">Less than 3 months	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LessThan3MonthsMember" xlink:to="upc_LessThan3MonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_From4To6MonthsMember" xlink:href="upc-20220930.xsd#upc_From4To6MonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_From4To6MonthsMember_lbl" xml:lang="en-US">From 4 to 6 months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_From4To6MonthsMember" xlink:to="upc_From4To6MonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_From7To9MonthsMember" xlink:href="upc-20220930.xsd#upc_From7To9MonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_From7To9MonthsMember_lbl" xml:lang="en-US">From 7 to 9 months	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_From7To9MonthsMember" xlink:to="upc_From7To9MonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_From10To12MonthsMember" xlink:href="upc-20220930.xsd#upc_From10To12MonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_From10To12MonthsMember_lbl" xml:lang="en-US">From 10 to 12 months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_From10To12MonthsMember" xlink:to="upc_From10To12MonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_Over1YearMember" xlink:href="upc-20220930.xsd#upc_Over1YearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_Over1YearMember_lbl" xml:lang="en-US">Over 1 year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_Over1YearMember" xlink:to="upc_Over1YearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AmortizationExpenseMember" xlink:href="upc-20220930.xsd#upc_AmortizationExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AmortizationExpenseMember_lbl" xml:lang="en-US">Amortization Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AmortizationExpenseMember" xlink:to="upc_AmortizationExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CapitalExpenditureMember" xlink:href="upc-20220930.xsd#upc_CapitalExpenditureMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CapitalExpenditureMember_lbl" xml:lang="en-US">Capital Expenditure [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalExpenditureMember" xlink:to="upc_CapitalExpenditureMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Maturity30To90DaysMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Maturity30To90DaysMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Maturity30To90DaysMember_lbl" xml:lang="en-US">Maturity date on June 15, 2022, interest rate 4.81% per annum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Maturity30To90DaysMember" xlink:to="us-gaap_Maturity30To90DaysMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaturityOver90DaysMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaturityOver90DaysMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaturityOver90DaysMember_lbl" xml:lang="en-US">Maturity date on March 17, 2022, interest rate 4.81% per annum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturityOver90DaysMember" xlink:to="us-gaap_MaturityOver90DaysMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysOneMember" xlink:href="upc-20220930.xsd#upc_MaturityGreaterThan90DaysOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MaturityGreaterThan90DaysOneMember_lbl" xml:lang="en-US">Maturity date on March 13, 2023, interest rate 4.62% per annum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysOneMember" xlink:to="upc_MaturityGreaterThan90DaysOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysTwoMember" xlink:href="upc-20220930.xsd#upc_MaturityGreaterThan90DaysTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MaturityGreaterThan90DaysTwoMember_lbl" xml:lang="en-US">Maturity date on June 14, 2023, interest rate 4.62% per annum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysTwoMember" xlink:to="upc_MaturityGreaterThan90DaysTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysThreeMember" xlink:href="upc-20220930.xsd#upc_MaturityGreaterThan90DaysThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MaturityGreaterThan90DaysThreeMember_lbl" xml:lang="en-US">Maturity date on June 30, 2022, interest rate 4.50% per annum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysThreeMember" xlink:to="upc_MaturityGreaterThan90DaysThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysFourMember" xlink:href="upc-20220930.xsd#upc_MaturityGreaterThan90DaysFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MaturityGreaterThan90DaysFourMember_lbl" xml:lang="en-US">Maturity date on June 24, 2023, interest rate 4.20% per annum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysFourMember" xlink:to="upc_MaturityGreaterThan90DaysFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MrGangLaiMember" xlink:href="upc-20220930.xsd#upc_MrGangLaiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MrGangLaiMember_lbl" xml:lang="en-US">Mr. Gang Lai [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrGangLaiMember" xlink:to="upc_MrGangLaiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MsLinYangMember" xlink:href="upc-20220930.xsd#upc_MsLinYangMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MsLinYangMember_lbl" xml:lang="en-US">Ms. Lin Yang [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MsLinYangMember" xlink:to="upc_MsLinYangMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember" xlink:href="upc-20220930.xsd#upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember_lbl" xml:lang="en-US">Greatest Group (China) Financial Management Limited (&#8220;Greatest Group&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember" xlink:to="upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember" xlink:href="upc-20220930.xsd#upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember_lbl" xml:lang="en-US">Foshan Shangyu Investment Holding Co., Ltd (&#8220;Foshan Shangyu&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember" xlink:to="upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_GreatestGroupMember" xlink:href="upc-20220930.xsd#upc_GreatestGroupMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_GreatestGroupMember_lbl" xml:lang="en-US">Greatest Group [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GreatestGroupMember" xlink:to="upc_GreatestGroupMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_FoshanShangyuMember" xlink:href="upc-20220930.xsd#upc_FoshanShangyuMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_FoshanShangyuMember_lbl" xml:lang="en-US">Foshan Shangyu [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_FoshanShangyuMember" xlink:to="upc_FoshanShangyuMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MrsLinYangMember" xlink:href="upc-20220930.xsd#upc_MrsLinYangMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MrsLinYangMember_lbl" xml:lang="en-US">Mrs. Lin Yang [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrsLinYangMember" xlink:to="upc_MrsLinYangMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_KY" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KY"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_KY_lbl" xml:lang="en-US">Cayman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KY" xlink:to="country_KY_lbl"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_HK_lbl" xml:lang="en-US">Hong Kong [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CN_lbl" xml:lang="en-US">PRC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateMember_lbl" xml:lang="en-US">Medicinal liquor products [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateMember" xlink:to="us-gaap_CorporateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentOneMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CorporateSegmentOneMember_lbl" xml:lang="en-US">Other chronic condition treatment products [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentOneMember" xlink:to="upc_CorporateSegmentOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentTwoMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CorporateSegmentTwoMember_lbl" xml:lang="en-US">Cold and flu medicines [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentTwoMember" xlink:to="upc_CorporateSegmentTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentThreeMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CorporateSegmentThreeMember_lbl" xml:lang="en-US">Biochemical drugs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentThreeMember" xlink:to="upc_CorporateSegmentThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentFourMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CorporateSegmentFourMember_lbl" xml:lang="en-US">Traditional Chinese medicine pieces [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentFourMember" xlink:to="upc_CorporateSegmentFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentFiveMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CorporateSegmentFiveMember_lbl" xml:lang="en-US">Medical instruments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentFiveMember" xlink:to="upc_CorporateSegmentFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentSixMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CorporateSegmentSixMember_lbl" xml:lang="en-US">Dietary supplements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentSixMember" xlink:to="upc_CorporateSegmentSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_EntityIncorporationDateDescription" xlink:href="upc-20220930.xsd#upc_EntityIncorporationDateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_EntityIncorporationDateDescription_lbl" xml:lang="en-US">Entity incorporation date description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EntityIncorporationDateDescription" xlink:to="upc_EntityIncorporationDateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_EquityMethodInvestmentOwnershipsPercentage" xlink:href="upc-20220930.xsd#upc_EquityMethodInvestmentOwnershipsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_EquityMethodInvestmentOwnershipsPercentage_lbl" xml:lang="en-US">Equity ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityMethodInvestmentOwnershipsPercentage" xlink:to="upc_EquityMethodInvestmentOwnershipsPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="upc_EquityMethodInvestmentOwnershipsPercentage_lbl0" xml:lang="en-US">Percentage of ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityMethodInvestmentOwnershipsPercentage" xlink:to="upc_EquityMethodInvestmentOwnershipsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="upc_EquityMethodInvestmentOwnershipsPercentage_lbl1" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityMethodInvestmentOwnershipsPercentage" xlink:to="upc_EquityMethodInvestmentOwnershipsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_EquityMethodInvestmentOwnershipsPercentage_lbl2" xml:lang="en-US">Offering price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityMethodInvestmentOwnershipsPercentage" xlink:to="upc_EquityMethodInvestmentOwnershipsPercentage_lbl2"/>
    <loc xlink:type="locator" xlink:label="upc_AmountOfRegisteredCapital" xlink:href="upc-20220930.xsd#upc_AmountOfRegisteredCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AmountOfRegisteredCapital_lbl" xml:lang="en-US">Registered capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AmountOfRegisteredCapital" xlink:to="upc_AmountOfRegisteredCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CapitalContribution" xlink:href="upc-20220930.xsd#upc_CapitalContribution"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CapitalContribution_lbl" xml:lang="en-US">Capital contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalContribution" xlink:to="upc_CapitalContribution_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RemainingCapitalContribution" xlink:href="upc-20220930.xsd#upc_RemainingCapitalContribution"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_RemainingCapitalContribution_lbl" xml:lang="en-US">Remaining capital contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RemainingCapitalContribution" xlink:to="upc_RemainingCapitalContribution_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SharesIssued01" xlink:href="upc-20220930.xsd#upc_SharesIssued01"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SharesIssued01_lbl" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SharesIssued01" xlink:to="upc_SharesIssued01_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PublicOfferingPrice" xlink:href="upc-20220930.xsd#upc_PublicOfferingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PublicOfferingPrice_lbl" xml:lang="en-US">Public offering price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PublicOfferingPrice" xlink:to="upc_PublicOfferingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_MaterialPricePercentage" xlink:href="upc-20220930.xsd#upc_MaterialPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MaterialPricePercentage_lbl" xml:lang="en-US">Material price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaterialPricePercentage" xlink:to="upc_MaterialPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PaymentTerm" xlink:href="upc-20220930.xsd#upc_PaymentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PaymentTerm_lbl" xml:lang="en-US">Payment term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PaymentTerm" xlink:to="upc_PaymentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AllowanceForUncollectableBalancesAmount" xlink:href="upc-20220930.xsd#upc_AllowanceForUncollectableBalancesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AllowanceForUncollectableBalancesAmount_lbl" xml:lang="en-US">Allowance for uncollectable balance amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AllowanceForUncollectableBalancesAmount" xlink:to="upc_AllowanceForUncollectableBalancesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl" xml:lang="en-US">Investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetInvestmentIncome_lbl" xml:lang="en-US">Investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetInvestmentIncome" xlink:to="us-gaap_NetInvestmentIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TaxBenefitPercentage" xlink:href="upc-20220930.xsd#upc_TaxBenefitPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_TaxBenefitPercentage_lbl" xml:lang="en-US">Tax benefit percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxBenefitPercentage" xlink:to="upc_TaxBenefitPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfVatRate" xlink:href="upc-20220930.xsd#upc_PercentageOfVatRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PercentageOfVatRate_lbl" xml:lang="en-US">Percentage of vat rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfVatRate" xlink:to="upc_PercentageOfVatRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Comprehensive income amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AccountsReceivableDescription" xlink:href="upc-20220930.xsd#upc_AccountsReceivableDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AccountsReceivableDescription_lbl" xml:lang="en-US">Accounts receivable description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableDescription" xlink:to="upc_AccountsReceivableDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Advertising expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfAdvancePayment" xlink:href="upc-20220930.xsd#upc_PercentageOfAdvancePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PercentageOfAdvancePayment_lbl" xml:lang="en-US">Percentage of advance payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfAdvancePayment" xlink:to="upc_PercentageOfAdvancePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AdditionalContractPricePercentage" xlink:href="upc-20220930.xsd#upc_AdditionalContractPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AdditionalContractPricePercentage_lbl" xml:lang="en-US">Additional contract price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdditionalContractPricePercentage" xlink:to="upc_AdditionalContractPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Total amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ContractPricePercentage" xlink:href="upc-20220930.xsd#upc_ContractPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ContractPricePercentage_lbl" xml:lang="en-US">Contract price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ContractPricePercentage" xlink:to="upc_ContractPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Remaining total amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AssetAcquisitionPriceOfAcquisitionsExpected" xlink:href="upc-20220930.xsd#upc_AssetAcquisitionPriceOfAcquisitionsExpected"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AssetAcquisitionPriceOfAcquisitionsExpected_lbl" xml:lang="en-US">Price amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AssetAcquisitionPriceOfAcquisitionsExpected" xlink:to="upc_AssetAcquisitionPriceOfAcquisitionsExpected_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherShortTermInvestments_lbl" xml:lang="en-US">Short term investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Loss from disposal of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentBuildingAndBuildingImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements_lbl" xml:lang="en-US">Total estimated budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionContractCostProgressPaymentOffset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset_lbl" xml:lang="en-US">Construction amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:to="us-gaap_ConstructionContractCostProgressPaymentOffset_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_Prepayment" xlink:href="upc-20220930.xsd#upc_Prepayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_Prepayment_lbl" xml:lang="en-US">Prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_Prepayment" xlink:to="upc_Prepayment_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CapitalExpenditure" xlink:href="upc-20220930.xsd#upc_CapitalExpenditure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CapitalExpenditure_lbl" xml:lang="en-US">Additional capital expenditure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalExpenditure" xlink:to="upc_CapitalExpenditure_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_EquityInterest" xlink:href="upc-20220930.xsd#upc_EquityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_EquityInterest_lbl" xml:lang="en-US">Equity interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityInterest" xlink:to="upc_EquityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OfficeSpaceSquareMeters" xlink:href="upc-20220930.xsd#upc_OfficeSpaceSquareMeters"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OfficeSpaceSquareMeters_lbl" xml:lang="en-US">Office space square meters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OfficeSpaceSquareMeters" xlink:to="upc_OfficeSpaceSquareMeters_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl" xml:lang="en-US">Total purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfPrepayment" xlink:href="upc-20220930.xsd#upc_PercentageOfPrepayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PercentageOfPrepayment_lbl" xml:lang="en-US">Percentage of prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfPrepayment" xlink:to="upc_PercentageOfPrepayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xml:lang="en-US">Total purchase price payable percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PayableDeliveryPropertyPercentage" xlink:href="upc-20220930.xsd#upc_PayableDeliveryPropertyPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PayableDeliveryPropertyPercentage_lbl" xml:lang="en-US">Payable delivery property percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PayableDeliveryPropertyPercentage" xlink:to="upc_PayableDeliveryPropertyPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl" xml:lang="en-US">Prepayment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableToBankCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayableToBankCurrent_lbl" xml:lang="en-US">Borrowing amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableToBankCurrent" xlink:to="us-gaap_LoansPayableToBankCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Working capital term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Fixed interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeconsolidationRelatedPartyDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRelatedPartyDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeconsolidationRelatedPartyDescription_lbl" xml:lang="en-US">Related party description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationRelatedPartyDescription" xlink:to="us-gaap_DeconsolidationRelatedPartyDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentAmount" xlink:href="upc-20220930.xsd#upc_PrepaymentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentAmount_lbl" xml:lang="en-US">Prepayment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentAmount" xlink:to="upc_PrepaymentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_EquityInterestOwnershipPercentage" xlink:href="upc-20220930.xsd#upc_EquityInterestOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_EquityInterestOwnershipPercentage_lbl" xml:lang="en-US">Equity interest ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityInterestOwnershipPercentage" xlink:to="upc_EquityInterestOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign_lbl" xml:lang="en-US">Subject to profit taxes rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_lbl" xml:lang="en-US">Foreign tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PreferentialTaxTreatmentDescription" xlink:href="upc-20220930.xsd#upc_PreferentialTaxTreatmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PreferentialTaxTreatmentDescription_lbl" xml:lang="en-US">Preferential tax treatment, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PreferentialTaxTreatmentDescription" xlink:to="upc_PreferentialTaxTreatmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">PRC corporate income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_lbl" xml:lang="en-US">Tax holidays on net income per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:to="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignFinancialInstitutionsMandatedDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits_lbl" xml:lang="en-US">Deposit at financial institutions (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:to="us-gaap_ForeignFinancialInstitutionsMandatedDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ConcentrationRiskThresholdPercentage" xlink:href="upc-20220930.xsd#upc_ConcentrationRiskThresholdPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ConcentrationRiskThresholdPercentage_lbl" xml:lang="en-US">Total revenue percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConcentrationRiskThresholdPercentage" xlink:to="upc_ConcentrationRiskThresholdPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Ordinary issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OriginalSharesParValue" xlink:href="upc-20220930.xsd#upc_OriginalSharesParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OriginalSharesParValue_lbl" xml:lang="en-US">Original shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OriginalSharesParValue" xlink:to="upc_OriginalSharesParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OrdinarySharesParValue" xlink:href="upc-20220930.xsd#upc_OrdinarySharesParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OrdinarySharesParValue_lbl" xml:lang="en-US">Ordinary shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesParValue" xlink:to="upc_OrdinarySharesParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OrdinarySharesOutstandingDescription" xlink:href="upc-20220930.xsd#upc_OrdinarySharesOutstandingDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OrdinarySharesOutstandingDescription_lbl" xml:lang="en-US">Ordinary shares outstanding description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesOutstandingDescription" xlink:to="upc_OrdinarySharesOutstandingDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ReorganizationShares" xlink:href="upc-20220930.xsd#upc_ReorganizationShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ReorganizationShares_lbl" xml:lang="en-US">Reorganization shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReorganizationShares" xlink:to="upc_ReorganizationShares_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OptionToPurchaseAdditionalShares" xlink:href="upc-20220930.xsd#upc_OptionToPurchaseAdditionalShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Option to purchase additional shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OptionToPurchaseAdditionalShares" xlink:to="upc_OptionToPurchaseAdditionalShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US">Ordinary shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price amount (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Offering price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsShareBasedCompensationCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsShareBasedCompensationCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsShareBasedCompensationCash_lbl" xml:lang="en-US">Cash dividend (in Yuan Renminbi)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsShareBasedCompensationCash" xlink:to="us-gaap_DividendsShareBasedCompensationCash_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashDividendDescription" xlink:href="upc-20220930.xsd#upc_CashDividendDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CashDividendDescription_lbl" xml:lang="en-US">Description of dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashDividendDescription" xlink:to="upc_CashDividendDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StatutorySurplusPercentage" xlink:href="upc-20220930.xsd#upc_StatutorySurplusPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatutorySurplusPercentage_lbl" xml:lang="en-US">Statutory surplus percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutorySurplusPercentage" xlink:to="upc_StatutorySurplusPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ReserveIsEqualPercentage" xlink:href="upc-20220930.xsd#upc_ReserveIsEqualPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ReserveIsEqualPercentage_lbl" xml:lang="en-US">Reserve is equal percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReserveIsEqualPercentage" xlink:to="upc_ReserveIsEqualPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted amounts (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RestrictedNetAssets" xlink:href="upc-20220930.xsd#upc_RestrictedNetAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_RestrictedNetAssets_lbl" xml:lang="en-US">Restricted net assets (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RestrictedNetAssets" xlink:to="upc_RestrictedNetAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash transferred (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" xml:lang="en-US">Future minimum capital expenditures amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseCapitalSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseCapitalSecurities_lbl" xml:lang="en-US">Total amount of capital expenditure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseCapitalSecurities" xlink:to="us-gaap_InterestExpenseCapitalSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Reporting segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent event, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent" xlink:href="upc-20220930.xsd#upc_MinorityInterestsOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent_lbl" xml:lang="en-US">Subsidiary exceeded percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MinorityInterestsOwnershipPercentageByParent" xlink:to="upc_MinorityInterestsOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Uses of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7sSbeKneEPlmNIhj3bCSU5y7O0I8dbszuTl8jF0AJbe21t+Rq4Ior0xtAOoy+ao7RLCBcMnvOYD6nWgAt+g/C9Glm4Z6aOCF7CBTCCEgAQgDS5HDB+QiyzEbJUf5ZRbs9TW2VRaSYTQvQ==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_AdvancesToSuppliersNetPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl" xml:lang="en-US">Advances to suppliers, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:to="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred initial public offering (&#8220;IPO&#8221;) costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_HeldToMaturityInvestmentPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_HeldToMaturityInvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_HeldToMaturityInvestmentPolicyTextBlock_lbl" xml:lang="en-US">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_HeldToMaturityInvestmentPolicyTextBlock" xlink:to="upc_HeldToMaturityInvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value of financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionContractorsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionContractorsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Construction-in-Progress (&#8220;CIP&#8221;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" xlink:to="us-gaap_ConstructionContractorsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investments in Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_ContractAssetsAndLiabilitiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contract Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:to="upc_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_DisaggregationOfRevenuesPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_DisaggregationOfRevenuesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_DisaggregationOfRevenuesPolicyTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DisaggregationOfRevenuesPolicyTextBlock" xlink:to="upc_DisaggregationOfRevenuesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xml:lang="en-US">Shipping and handling costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ValueAddedTaxPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_ValueAddedTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ValueAddedTaxPolicyTextBlock_lbl" xml:lang="en-US">Value added tax (&#8220;VAT&#8221;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ValueAddedTaxPolicyTextBlock" xlink:to="upc_ValueAddedTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_StatementOfCashFlowsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock_lbl" xml:lang="en-US">Statement of Cash Flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatementOfCashFlowsPolicyTextBlock" xlink:to="upc_StatementOfCashFlowsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_EmployeeDefinedContributionPlanPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl" xml:lang="en-US">Employee Defined Contribution Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:to="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseIncMember" xlink:href="upc-20220930.xsd#upc_UniverseIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseIncMember_lbl" xml:lang="en-US">Universe Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseIncMember" xlink:to="upc_UniverseIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiMember" xlink:href="upc-20220930.xsd#upc_JiangxiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_JiangxiMember_lbl" xml:lang="en-US">Jiangxi [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiMember" xlink:to="upc_JiangxiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OwnershipMember" xlink:href="upc-20220930.xsd#upc_OwnershipMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OwnershipMember_lbl" xml:lang="en-US">Ownership [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OwnershipMember" xlink:to="upc_OwnershipMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_JxRcbBankMember" xlink:href="upc-20220930.xsd#upc_JxRcbBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_JxRcbBankMember_lbl" xml:lang="en-US">JX RCB Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JxRcbBankMember" xlink:to="upc_JxRcbBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_YunnanFaxiMember" xlink:href="upc-20220930.xsd#upc_YunnanFaxiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_YunnanFaxiMember_lbl" xml:lang="en-US">Yunnan Faxi [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_YunnanFaxiMember" xlink:to="upc_YunnanFaxiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ChenyuanMember" xlink:href="upc-20220930.xsd#upc_ChenyuanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ChenyuanMember_lbl" xml:lang="en-US">Chenyuan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ChenyuanMember" xlink:to="upc_ChenyuanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiLulingRuralCommercialBankMember" xlink:href="upc-20220930.xsd#upc_JiangxiLulingRuralCommercialBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_JiangxiLulingRuralCommercialBankMember_lbl" xml:lang="en-US">LRC Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiLulingRuralCommercialBankMember" xlink:to="upc_JiangxiLulingRuralCommercialBankMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="upc_JiangxiLulingRuralCommercialBankMember_lbl0" xml:lang="en-US">Jiangxi Luling Rural Commercial Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiLulingRuralCommercialBankMember" xlink:to="upc_JiangxiLulingRuralCommercialBankMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_CustomerMember" xlink:href="upc-20220930.xsd#upc_CustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CustomerMember" xlink:to="upc_CustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TotalRevenueMember" xlink:href="upc-20220930.xsd#upc_TotalRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_TotalRevenueMember_lbl" xml:lang="en-US">Total Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TotalRevenueMember" xlink:to="upc_TotalRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_GubenYanlingPillMember" xlink:href="upc-20220930.xsd#upc_GubenYanlingPillMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_GubenYanlingPillMember_lbl" xml:lang="en-US">Guben Yanling Pill [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GubenYanlingPillMember" xlink:to="upc_GubenYanlingPillMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CustomersOneMember" xlink:href="upc-20220930.xsd#upc_CustomersOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CustomersOneMember_lbl" xml:lang="en-US">Customer One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CustomersOneMember" xlink:to="upc_CustomersOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SupplierOneMember" xlink:href="upc-20220930.xsd#upc_SupplierOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SupplierOneMember_lbl" xml:lang="en-US">Supplier One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SupplierOneMember" xlink:to="upc_SupplierOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SupplierTwoMember" xlink:href="upc-20220930.xsd#upc_SupplierTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SupplierTwoMember_lbl" xml:lang="en-US">Supplier Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SupplierTwoMember" xlink:to="upc_SupplierTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_supplierMember" xlink:href="upc-20220930.xsd#upc_supplierMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_supplierMember_lbl" xml:lang="en-US">supplier [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_supplierMember" xlink:to="upc_supplierMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnderwriterWarrantsMember" xlink:href="upc-20220930.xsd#upc_UnderwriterWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnderwriterWarrantsMember_lbl" xml:lang="en-US">Underwriter warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnderwriterWarrantsMember" xlink:to="upc_UnderwriterWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashDividendsMember" xlink:href="upc-20220930.xsd#upc_CashDividendsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CashDividendsMember_lbl" xml:lang="en-US">Cash dividends [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashDividendsMember" xlink:to="upc_CashDividendsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserveAndRestrictedNetAssetsMember" xlink:href="upc-20220930.xsd#upc_StatutoryReserveAndRestrictedNetAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatutoryReserveAndRestrictedNetAssetsMember_lbl" xml:lang="en-US">Statutory Reserve and Restricted Net Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserveAndRestrictedNetAssetsMember" xlink:to="upc_StatutoryReserveAndRestrictedNetAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PRCMember" xlink:href="upc-20220930.xsd#upc_PRCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PRCMember_lbl" xml:lang="en-US">PRC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PRCMember" xlink:to="upc_PRCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforAcquisitionTable" xlink:href="upc-20220930.xsd#upc_PrepaymentforAcquisitionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforAcquisitionTable_lbl" xml:lang="en-US">Prepayment for Acquisition [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforAcquisitionTable" xlink:to="upc_PrepaymentforAcquisitionTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforAcquisitionLineItems" xlink:href="upc-20220930.xsd#upc_PrepaymentforAcquisitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforAcquisitionLineItems_lbl" xml:lang="en-US">Prepayment for Acquisition [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforAcquisitionLineItems" xlink:to="upc_PrepaymentforAcquisitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancetoSuppliersTablesTable" xlink:href="upc-20220930.xsd#upc_AdvancetoSuppliersTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdvancetoSuppliersTablesTable_lbl" xml:lang="en-US">Advance to Suppliers (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancetoSuppliersTablesTable" xlink:to="upc_AdvancetoSuppliersTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancetoSuppliersTablesLineItems" xlink:href="upc-20220930.xsd#upc_AdvancetoSuppliersTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AdvancetoSuppliersTablesLineItems_lbl" xml:lang="en-US">Advances To Suppliers [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancetoSuppliersTablesLineItems" xlink:to="upc_AdvancetoSuppliersTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl" xml:lang="en-US">Schedule of Subsidiary of Limited Liability Company or Limited Partnership [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_lbl" xml:lang="en-US">Class of Financing Receivable [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_lbl" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:to="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_lbl" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" xlink:href="upc-20220930.xsd#upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable_lbl" xml:lang="en-US">Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" xlink:to="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:href="upc-20220930.xsd#upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems_lbl" xml:lang="en-US">Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:to="upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:href="upc-20220930.xsd#upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable_lbl" xml:lang="en-US">Prepayment for CIP Project (Details) - Schedule of future minimum capital expenditures [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:to="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:href="upc-20220930.xsd#upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems_lbl" xml:lang="en-US">Prepayment for CIP Project (Details) - Schedule of future minimum capital expenditures [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_lbl" xml:lang="en-US">Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:href="upc-20220930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable_lbl" xml:lang="en-US">Related Party Transactions (Details) - Schedule of due from related parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:to="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:href="upc-20220930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) - Schedule of due from related parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:to="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:href="upc-20220930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable_lbl" xml:lang="en-US">Related Party Transactions (Details) - Schedule of due to related parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:to="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:href="upc-20220930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) - Schedule of due to related parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:to="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:href="upc-20220930.xsd#upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable_lbl" xml:lang="en-US">Taxes (Details) - Schedule of components of the income tax provision (benefit) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:to="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:href="upc-20220930.xsd#upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems_lbl" xml:lang="en-US">Taxes (Details) - Schedule of components of the income tax provision (benefit) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Balance Sheet Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable_lbl" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl" xml:lang="en-US">Condensed Statement of Income Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedCashFlowStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedCashFlowStatementTable_lbl" xml:lang="en-US">Condensed Cash Flow Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Cash Flow Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:href="upc-20220930.xsd#upc_OrganizationandBusinessDescriptionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OrganizationandBusinessDescriptionDetailsTable_lbl" xml:lang="en-US">Organization and Business Description (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="upc_OrganizationandBusinessDescriptionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:href="upc-20220930.xsd#upc_OrganizationandBusinessDescriptionDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OrganizationandBusinessDescriptionDetailsLineItems_lbl" xml:lang="en-US">Organization and Business Description (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_OrganizationandBusinessDescriptionDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforAcquisitionDetailsTable" xlink:href="upc-20220930.xsd#upc_PrepaymentforAcquisitionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforAcquisitionDetailsTable_lbl" xml:lang="en-US">Prepayment for Acquisition (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforAcquisitionDetailsTable" xlink:to="upc_PrepaymentforAcquisitionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforAcquisitionDetailsLineItems" xlink:href="upc-20220930.xsd#upc_PrepaymentforAcquisitionDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforAcquisitionDetailsLineItems_lbl" xml:lang="en-US">Prepayment for Acquisition (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforAcquisitionDetailsLineItems" xlink:to="upc_PrepaymentforAcquisitionDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforCIPProjectDetailsTable" xlink:href="upc-20220930.xsd#upc_PrepaymentforCIPProjectDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforCIPProjectDetailsTable_lbl" xml:lang="en-US">Prepayment for CIP Project (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforCIPProjectDetailsTable" xlink:to="upc_PrepaymentforCIPProjectDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:href="upc-20220930.xsd#upc_PrepaymentforCIPProjectDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforCIPProjectDetailsLineItems_lbl" xml:lang="en-US">Prepayment for CIP Project (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:to="upc_PrepaymentforCIPProjectDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShortTermBankLoansDetailsTable" xlink:href="upc-20220930.xsd#upc_ShortTermBankLoansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShortTermBankLoansDetailsTable_lbl" xml:lang="en-US">Short-Term Bank Loans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShortTermBankLoansDetailsTable" xlink:to="upc_ShortTermBankLoansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShortTermBankLoansDetailsLineItems" xlink:href="upc-20220930.xsd#upc_ShortTermBankLoansDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShortTermBankLoansDetailsLineItems_lbl" xml:lang="en-US">Short-Term Bank Loans (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShortTermBankLoansDetailsLineItems" xlink:to="upc_ShortTermBankLoansDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsTable" xlink:href="upc-20220930.xsd#upc_TaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TaxesDetailsTable_lbl" xml:lang="en-US">Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxesDetailsTable" xlink:to="upc_TaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsLineItems" xlink:href="upc-20220930.xsd#upc_TaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TaxesDetailsLineItems_lbl" xml:lang="en-US">Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxesDetailsLineItems" xlink:to="upc_TaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US">Supplier [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ConcentrationsDetailsTable" xlink:href="upc-20220930.xsd#upc_ConcentrationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ConcentrationsDetailsTable_lbl" xml:lang="en-US">Concentrations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="upc_ConcentrationsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ConcentrationsDetailsLineItems" xlink:href="upc-20220930.xsd#upc_ConcentrationsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ConcentrationsDetailsLineItems_lbl" xml:lang="en-US">Concentrations (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConcentrationsDetailsLineItems" xlink:to="upc_ConcentrationsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityDetailsTable" xlink:href="upc-20220930.xsd#upc_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="upc_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityDetailsLineItems" xlink:href="upc-20220930.xsd#upc_ShareholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShareholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_ShareholdersEquityDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AccountsReceivableDescription_lbl0" xml:lang="en-US">Accounts receivable, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableDescription" xlink:to="upc_AccountsReceivableDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AddPurchaseWealthManagementFinancialProducts_lbl0" xml:lang="en-US">Amount of purchase wealth management financial products.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AddPurchaseWealthManagementFinancialProducts" xlink:to="upc_AddPurchaseWealthManagementFinancialProducts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AdditionalContractPricePercentage_lbl0" xml:lang="en-US">Additional contract price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdditionalContractPricePercentage" xlink:to="upc_AdditionalContractPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for advances to suppliers net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:to="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AdvancesToSuppliersTextBlock_lbl0" xml:lang="en-US">The entire disclosure for the advances to suppliers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersTextBlock" xlink:to="upc_AdvancesToSuppliersTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AllowanceForUncollectableBalancesAmount_lbl0" xml:lang="en-US">Amount for uncollectable balances amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AllowanceForUncollectableBalancesAmount" xlink:to="upc_AllowanceForUncollectableBalancesAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AmountOfRegisteredCapital_lbl0" xml:lang="en-US">Amount of registered capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AmountOfRegisteredCapital" xlink:to="upc_AmountOfRegisteredCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AssetAcquisitionPriceOfAcquisitionsExpected_lbl0" xml:lang="en-US">Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AssetAcquisitionPriceOfAcquisitionsExpected" xlink:to="upc_AssetAcquisitionPriceOfAcquisitionsExpected_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CapitalContribution_lbl0" xml:lang="en-US">Amount of capital contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalContribution" xlink:to="upc_CapitalContribution_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CapitalExpenditure_lbl0" xml:lang="en-US">The amount of capital expenditure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalExpenditure" xlink:to="upc_CapitalExpenditure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl1" xml:lang="en-US">Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CashDividendDescription_lbl0" xml:lang="en-US">Description of dividends.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashDividendDescription" xlink:to="upc_CashDividendDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CashLentToSubsidiaries_lbl0" xml:lang="en-US">The amount of Cash lent to subsidiaries.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashLentToSubsidiaries" xlink:to="upc_CashLentToSubsidiaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ContractPricePercentage_lbl0" xml:lang="en-US">Contract price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ContractPricePercentage" xlink:to="upc_ContractPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_DescriptionOfAverageRate_lbl0" xml:lang="en-US">Description of average rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DescriptionOfAverageRate" xlink:to="upc_DescriptionOfAverageRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_DescriptionOfYearEndSpotRate_lbl0" xml:lang="en-US">Description of year end spot rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DescriptionOfYearEndSpotRate" xlink:to="upc_DescriptionOfYearEndSpotRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl0" xml:lang="en-US">The entire disclosure of employee defined contribution plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:to="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_EntityIncorporationDateDescription_lbl0" xml:lang="en-US">Entity incorporation date description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EntityIncorporationDateDescription" xlink:to="upc_EntityIncorporationDateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_EquityInEarningsOfSubsidiary_lbl0" xml:lang="en-US">Equity in earnings of subsidiary.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityInEarningsOfSubsidiary" xlink:to="upc_EquityInEarningsOfSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_EquityInterest_lbl0" xml:lang="en-US">Equity interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityInterest" xlink:to="upc_EquityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_EquityInterestOwnershipPercentage_lbl0" xml:lang="en-US">Equity interest ownership percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityInterestOwnershipPercentage" xlink:to="upc_EquityInterestOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_EquityMethodInvestmentOwnershipsPercentage_lbl3" xml:lang="en-US">Equity ownership percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityMethodInvestmentOwnershipsPercentage" xlink:to="upc_EquityMethodInvestmentOwnershipsPercentage_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_IncomeFromOperation_lbl0" xml:lang="en-US">The net result for the period of deducting operating expenses from operating revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_IncomeFromOperation" xlink:to="upc_IncomeFromOperation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_InvestmentInEquitySecurities_lbl0" xml:lang="en-US">Investment In Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_InvestmentInEquitySecurities" xlink:to="upc_InvestmentInEquitySecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_MaterialPricePercentage_lbl0" xml:lang="en-US">Material price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaterialPricePercentage" xlink:to="upc_MaterialPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent_lbl0" xml:lang="en-US">Subsidiary exceeded percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MinorityInterestsOwnershipPercentageByParent" xlink:to="upc_MinorityInterestsOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OfficeSpaceSquareMeters_lbl0" xml:lang="en-US">Office space Square meters.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OfficeSpaceSquareMeters" xlink:to="upc_OfficeSpaceSquareMeters_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OptionToPurchaseAdditionalShares_lbl0" xml:lang="en-US">Option to purchase additional shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OptionToPurchaseAdditionalShares" xlink:to="upc_OptionToPurchaseAdditionalShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OrdinarySharesOutstandingDescription_lbl0" xml:lang="en-US">Ordinary shares outstanding description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesOutstandingDescription" xlink:to="upc_OrdinarySharesOutstandingDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OrdinarySharesParValue_lbl0" xml:lang="en-US">Ordinary shares par value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesParValue" xlink:to="upc_OrdinarySharesParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OriginalSharesParValue_lbl0" xml:lang="en-US">Original shares par value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OriginalSharesParValue" xlink:to="upc_OriginalSharesParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PayableDeliveryPropertyPercentage_lbl0" xml:lang="en-US">Payable delivery property percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PayableDeliveryPropertyPercentage" xlink:to="upc_PayableDeliveryPropertyPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PaymentTerm_lbl0" xml:lang="en-US">Payment term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PaymentTerm" xlink:to="upc_PaymentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PercentageOfAdvancePayment_lbl0" xml:lang="en-US">Percentage of advance payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfAdvancePayment" xlink:to="upc_PercentageOfAdvancePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PercentageOfPrepayment_lbl0" xml:lang="en-US">Percentage of prepayment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfPrepayment" xlink:to="upc_PercentageOfPrepayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PercentageOfVatRate_lbl0" xml:lang="en-US">Percentage of VATrate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfVatRate" xlink:to="upc_PercentageOfVatRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PlaceOfIncorporation_lbl0" xml:lang="en-US">Place of incorporation or establishment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PlaceOfIncorporation" xlink:to="upc_PlaceOfIncorporation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PreferentialTaxTreatmentDescription_lbl0" xml:lang="en-US">Preferential tax treatment, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PreferentialTaxTreatmentDescription" xlink:to="upc_PreferentialTaxTreatmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_Prepayment_lbl0" xml:lang="en-US">Amount of prepayment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_Prepayment" xlink:to="upc_Prepayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentAmount_lbl0" xml:lang="en-US">Prepayment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentAmount" xlink:to="upc_PrepaymentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentForAcquisitionCurrent_lbl0" xml:lang="en-US">The amount of prepayment for acquisition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisitionCurrent" xlink:to="upc_PrepaymentForAcquisitionCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock_lbl0" xml:lang="en-US">The entire disclosure for prepayment for construction in progress.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForConstructionInProgressTextBlock" xlink:to="upc_PrepaymentForConstructionInProgressTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentsForConstructionInProgress_lbl0" xml:lang="en-US">Prepayments for construction in progress.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsForConstructionInProgress" xlink:to="upc_PrepaymentsForConstructionInProgress_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty_lbl0" xml:lang="en-US">The amount of prepayments made to a related party for purchase of property.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl0" xml:lang="en-US">Amount of prepayments made to a related party for purchase of property.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrincipalActivities_lbl0" xml:lang="en-US">Principal activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrincipalActivities" xlink:to="upc_PrincipalActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings_lbl0" xml:lang="en-US">Proceeds from (prepayments for) related parties borrowings.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl0" xml:lang="en-US">The entire disclosure of property equipment estimated useful life during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PublicOfferingPrice_lbl0" xml:lang="en-US">Public offering price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PublicOfferingPrice" xlink:to="upc_PublicOfferingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_RedemptionOfShorttermInvestments_lbl0" xml:lang="en-US">Redemption of short-term investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RedemptionOfShorttermInvestments" xlink:to="upc_RedemptionOfShorttermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_RemainingCapitalContribution_lbl0" xml:lang="en-US">Remaining capital contribution amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RemainingCapitalContribution" xlink:to="upc_RemainingCapitalContribution_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ReorganizationShares_lbl0" xml:lang="en-US">Reorganization shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReorganizationShares" xlink:to="upc_ReorganizationShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ReserveIsEqualPercentage_lbl0" xml:lang="en-US">Reserve is equal percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReserveIsEqualPercentage" xlink:to="upc_ReserveIsEqualPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_RestrictedNetAssets_lbl0" xml:lang="en-US">Restricted net assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RestrictedNetAssets" xlink:to="upc_RestrictedNetAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet_lbl0" xml:lang="en-US">Tabular disclosure of advances to suppliers net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAdvancesToSuppliersNet" xlink:to="upc_ScheduleOfAdvancesToSuppliersNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock_lbl0" xml:lang="en-US">The entire disclosure of tax payable during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTaxPayableTableTextBlock" xlink:to="upc_ScheduleOfTaxPayableTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_SharesIssued01_lbl0" xml:lang="en-US">Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SharesIssued01" xlink:to="upc_SharesIssued01_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ShorttermInvestmentsIncome_lbl0" xml:lang="en-US">Short-term investments income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShorttermInvestmentsIncome" xlink:to="upc_ShorttermInvestmentsIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock_lbl0" xml:lang="en-US">The entire disclosure of statement of cash flows policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatementOfCashFlowsPolicyTextBlock" xlink:to="upc_StatementOfCashFlowsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StatutoryReserve_lbl0" xml:lang="en-US">StatutoryReserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserve" xlink:to="upc_StatutoryReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StatutorySurplusPercentage_lbl0" xml:lang="en-US">Statutory surplus percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutorySurplusPercentage" xlink:to="upc_StatutorySurplusPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts_lbl0" xml:lang="en-US">Amount of Capitalized initial public offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" xlink:to="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_SubtotalOfThirdpartyProductsSales_lbl0" xml:lang="en-US">Subtotal of third-party products sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubtotalOfThirdpartyProductsSales" xlink:to="upc_SubtotalOfThirdpartyProductsSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_TaxBenefitPercentage_lbl0" xml:lang="en-US">Tax benefit percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxBenefitPercentage" xlink:to="upc_TaxBenefitPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ValueAddedTaxPolicyTextBlock_lbl0" xml:lang="en-US">The entire disclosure of value added tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ValueAddedTaxPolicyTextBlock" xlink:to="upc_ValueAddedTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CorporateSegmentFiveMember_lbl0" xml:lang="en-US">Corporate Segment Five [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentFiveMember" xlink:to="upc_CorporateSegmentFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CorporateSegmentFourMember_lbl0" xml:lang="en-US">Corporate Segment Four [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentFourMember" xlink:to="upc_CorporateSegmentFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CorporateSegmentOneMember_lbl0" xml:lang="en-US">Corporate Segment One [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentOneMember" xlink:to="upc_CorporateSegmentOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CorporateSegmentSixMember_lbl0" xml:lang="en-US">Corporate Segment Six [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentSixMember" xlink:to="upc_CorporateSegmentSixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CorporateSegmentThreeMember_lbl0" xml:lang="en-US">Corporate Segment Three [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentThreeMember" xlink:to="upc_CorporateSegmentThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CorporateSegmentTwoMember_lbl0" xml:lang="en-US">Corporate Segment Two [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentTwoMember" xlink:to="upc_CorporateSegmentTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_UniverseINCMember_lbl0" xml:lang="en-US">Universe INC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseINCMember" xlink:to="upc_UniverseINCMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates_lbl0" xml:lang="en-US">Proceeds from Contributions from Affiliates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl0" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseCapitalSecurities_lbl0" xml:lang="en-US">Interest Expense, Capital Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseCapitalSecurities" xlink:to="us-gaap_InterestExpenseCapitalSecurities_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PaymentTerm_lbl1" xml:lang="en-US">Payment Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PaymentTerm" xlink:to="upc_PaymentTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AmountOfRegisteredCapital_lbl1" xml:lang="en-US">Amount Of Registered Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AmountOfRegisteredCapital" xlink:to="upc_AmountOfRegisteredCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseRightsMember_lbl0" xml:lang="en-US">Use Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseRightsMember" xlink:to="us-gaap_UseRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseIncMember_lbl0" xml:lang="en-US">Universe Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseIncMember" xlink:to="upc_UniverseIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CapitalContribution_lbl1" xml:lang="en-US">Capital Contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalContribution" xlink:to="upc_CapitalContribution_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_Prepayment_lbl1" xml:lang="en-US">Prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_Prepayment" xlink:to="upc_Prepayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_JiangxiLulingRuralCommercialBankMember_lbl1" xml:lang="en-US">Jiangxi Luling Rural Commercial Bank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiLulingRuralCommercialBankMember" xlink:to="upc_JiangxiLulingRuralCommercialBankMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfShortTermBankLoansAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfShortTermBankLoansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfShortTermBankLoansAbstract_lbl" xml:lang="en-US">Schedule Of Short Term Bank Loans Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfShortTermBankLoansAbstract" xlink:to="upc_ScheduleOfShortTermBankLoansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract_lbl" xml:lang="en-US">Schedule Of Future Minimum Capital Expenditures Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract" xlink:to="upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl0" xml:lang="en-US">Computer Software, Intangible Asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AutomobilesMember_lbl0" xml:lang="en-US">Automobiles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AutomobilesMember" xlink:to="us-gaap_AutomobilesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForAcquisitionTextBlock_lbl0" xml:lang="en-US">Prepayment For Acquisition Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisitionTextBlock" xlink:to="upc_PrepaymentForAcquisitionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RedemptionOfShorttermInvestments_lbl1" xml:lang="en-US">Redemption Of Shortterm Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RedemptionOfShorttermInvestments" xlink:to="upc_RedemptionOfShorttermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_NameAbstract_lbl0" xml:lang="en-US">Name Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NameAbstract" xlink:to="upc_NameAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract38" xlink:to="upc_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract39_lbl0" xml:lang="en-US">Unlabeled Abstract39</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract39" xlink:to="upc_UnlabeledAbstract39_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AddPurchaseWealthManagementFinancialProducts_lbl1" xml:lang="en-US">Add Purchase Wealth Management Financial Products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AddPurchaseWealthManagementFinancialProducts" xlink:to="upc_AddPurchaseWealthManagementFinancialProducts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfAdvancesForConstruction_lbl0" xml:lang="en-US">Repayments of Advances for Construction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfAdvancesForConstruction" xlink:to="us-gaap_RepaymentsOfAdvancesForConstruction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MaturityGreaterThan90DaysTwoMember_lbl0" xml:lang="en-US">Maturity Greater Than90 Days Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysTwoMember" xlink:to="upc_MaturityGreaterThan90DaysTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss_lbl0" xml:lang="en-US">Accounts and Financing Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:to="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl0" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract40_lbl0" xml:lang="en-US">Unlabeled Abstract40</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract40" xlink:to="upc_UnlabeledAbstract40_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Estimated Useful Lives Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" xlink:to="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract43_lbl0" xml:lang="en-US">Unlabeled Abstract43</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract43" xlink:to="upc_UnlabeledAbstract43_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract44_lbl0" xml:lang="en-US">Unlabeled Abstract44</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract44" xlink:to="upc_UnlabeledAbstract44_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract41_lbl0" xml:lang="en-US">Unlabeled Abstract41</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract41" xlink:to="upc_UnlabeledAbstract41_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract42_lbl0" xml:lang="en-US">Unlabeled Abstract42</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract42" xlink:to="upc_UnlabeledAbstract42_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract47_lbl0" xml:lang="en-US">Unlabeled Abstract47</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract47" xlink:to="upc_UnlabeledAbstract47_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract48_lbl0" xml:lang="en-US">Unlabeled Abstract48</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract48" xlink:to="upc_UnlabeledAbstract48_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl0" xml:lang="en-US">Due to Related Parties, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract45_lbl0" xml:lang="en-US">Unlabeled Abstract45</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract45" xlink:to="upc_UnlabeledAbstract45_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract46_lbl0" xml:lang="en-US">Unlabeled Abstract46</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract46" xlink:to="upc_UnlabeledAbstract46_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl0" xml:lang="en-US">Operating Costs and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOtherShortTermBorrowings_lbl0" xml:lang="en-US">Interest Expense, Other Short-Term Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:to="us-gaap_InterestExpenseOtherShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_FoshanShangyuMember_lbl0" xml:lang="en-US">Foshan Shangyu Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_FoshanShangyuMember" xlink:to="upc_FoshanShangyuMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AccountsReceivableNetPercentage_lbl0" xml:lang="en-US">Accounts Receivable Net Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableNetPercentage" xlink:to="upc_AccountsReceivableNetPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ConcentrationRiskThresholdPercentage_lbl0" xml:lang="en-US">Concentration Risk Threshold Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConcentrationRiskThresholdPercentage" xlink:to="upc_ConcentrationRiskThresholdPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CorporateSegmentOneMember_lbl1" xml:lang="en-US">Corporate Segment One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentOneMember" xlink:to="upc_CorporateSegmentOneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent_lbl0" xml:lang="en-US">Sales and Excise Tax Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ReserveIsEqualPercentage_lbl1" xml:lang="en-US">Reserve Is Equal Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReserveIsEqualPercentage" xlink:to="upc_ReserveIsEqualPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl0" xml:lang="en-US">Capital Expenditure, Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CustomersOneMember_lbl0" xml:lang="en-US">Customers One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CustomersOneMember" xlink:to="upc_CustomersOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PRCMember_lbl0" xml:lang="en-US">PRCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PRCMember" xlink:to="upc_PRCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Due From Related Parties Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock" xlink:to="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OfficeSpaceSquareMeters_lbl1" xml:lang="en-US">Office Space Square Meters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OfficeSpaceSquareMeters" xlink:to="upc_OfficeSpaceSquareMeters_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0" xml:lang="en-US">Prepayment Fees on Advances, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract18" xlink:to="upc_UnlabeledAbstract18_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfIntangibleAssetsNetConsistAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfIntangibleAssetsNetConsistAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfIntangibleAssetsNetConsistAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Net Consist Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfIntangibleAssetsNetConsistAbstract" xlink:to="upc_ScheduleOfIntangibleAssetsNetConsistAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract19" xlink:to="upc_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract16" xlink:to="upc_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract17" xlink:to="upc_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashDividendDescription_lbl1" xml:lang="en-US">Cash Dividend Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashDividendDescription" xlink:to="upc_CashDividendDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_BankOfCommunicationsCoLtdAbstract_lbl0" xml:lang="en-US">Bank Of Communications Co Ltd Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_BankOfCommunicationsCoLtdAbstract" xlink:to="upc_BankOfCommunicationsCoLtdAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl0" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PlaceOfIncorporation_lbl1" xml:lang="en-US">Place Of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PlaceOfIncorporation" xlink:to="upc_PlaceOfIncorporation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToSuppliersAndEmployees_lbl0" xml:lang="en-US">Payments to Suppliers and Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToSuppliersAndEmployees" xlink:to="us-gaap_PaymentsToSuppliersAndEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MsLinYangMember_lbl0" xml:lang="en-US">Ms Lin Yang Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MsLinYangMember" xlink:to="upc_MsLinYangMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl0" xml:lang="en-US">Deferred Costs, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock_lbl1" xml:lang="en-US">Prepayment For Construction In Progress Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForConstructionInProgressTextBlock" xlink:to="upc_PrepaymentForConstructionInProgressTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract21" xlink:to="upc_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract22" xlink:to="upc_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements_lbl0" xml:lang="en-US">Investment Building and Building Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract20" xlink:to="upc_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember_lbl0" xml:lang="en-US">Foshan Shangyu Investment Holding Co Ltd Foshan Shangyu Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember" xlink:to="upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract25" xlink:to="upc_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl0" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract26" xlink:to="upc_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract23" xlink:to="upc_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdvancesToSuppliersTextBlock_lbl1" xml:lang="en-US">Advances To Suppliers Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersTextBlock" xlink:to="upc_AdvancesToSuppliersTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract24" xlink:to="upc_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_YunnanFaxiMember_lbl0" xml:lang="en-US">Yunnan Faxi Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_YunnanFaxiMember" xlink:to="upc_YunnanFaxiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatutoryReserveAndRestrictedNetAssetsMember_lbl0" xml:lang="en-US">Statutory Reserve And Restricted Net Assets Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserveAndRestrictedNetAssetsMember" xlink:to="upc_StatutoryReserveAndRestrictedNetAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract29" xlink:to="upc_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl0" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl1" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract27" xlink:to="upc_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract28" xlink:to="upc_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MrGangLaiMember_lbl0" xml:lang="en-US">Mr Gang Lai Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrGangLaiMember" xlink:to="upc_MrGangLaiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ReorganizationShares_lbl1" xml:lang="en-US">Reorganization Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReorganizationShares" xlink:to="upc_ReorganizationShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetInvestmentIncome_lbl0" xml:lang="en-US">Net Investment Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetInvestmentIncome" xlink:to="us-gaap_NetInvestmentIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl0" xml:lang="en-US">Other Operating Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AllowanceForUncollectableBalancesAmount_lbl1" xml:lang="en-US">Allowance For Uncollectable Balances Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AllowanceForUncollectableBalancesAmount" xlink:to="upc_AllowanceForUncollectableBalancesAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract32" xlink:to="upc_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract33" xlink:to="upc_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract30" xlink:to="upc_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract31" xlink:to="upc_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract36" xlink:to="upc_UnlabeledAbstract36_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract37" xlink:to="upc_UnlabeledAbstract37_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract_lbl" xml:lang="en-US">Schedule Of The Company SAccounts Receivable And Subsequent Collection Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract" xlink:to="upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract34" xlink:to="upc_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_IncomeFromOperation_lbl1" xml:lang="en-US">Income From Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_IncomeFromOperation" xlink:to="upc_IncomeFromOperation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract35" xlink:to="upc_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl0" xml:lang="en-US">Accrued Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_InvestmentInEquitySecurities_lbl1" xml:lang="en-US">Investment In Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_InvestmentInEquitySecurities" xlink:to="upc_InvestmentInEquitySecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableToBankCurrent_lbl0" xml:lang="en-US">Loans Payable to Bank, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableToBankCurrent" xlink:to="us-gaap_LoansPayableToBankCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForPurchaseOfAPropertyTextBlock_lbl0" xml:lang="en-US">Prepayment For Purchase Of AProperty Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForPurchaseOfAPropertyTextBlock" xlink:to="upc_PrepaymentForPurchaseOfAPropertyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl1" xml:lang="en-US">Advances To Suppliers Net Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:to="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateMember_lbl0" xml:lang="en-US">Corporate Segment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateMember" xlink:to="us-gaap_CorporateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatutorySurplusPercentage_lbl1" xml:lang="en-US">Statutory Surplus Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutorySurplusPercentage" xlink:to="upc_StatutorySurplusPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl0" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OrdinarySharesOutstandingDescription_lbl1" xml:lang="en-US">Ordinary Shares Outstanding Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesOutstandingDescription" xlink:to="upc_OrdinarySharesOutstandingDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl0" xml:lang="en-US">Inventory, LIFO Reserve, Period Charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OfficeAndElectricEquipmentMember_lbl0" xml:lang="en-US">Office And Electric Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OfficeAndElectricEquipmentMember" xlink:to="upc_OfficeAndElectricEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseTechnologyMember_lbl0" xml:lang="en-US">Universe Technology Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTechnologyMember" xlink:to="upc_UniverseTechnologyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CorporateSegmentThreeMember_lbl1" xml:lang="en-US">Corporate Segment Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentThreeMember" xlink:to="upc_CorporateSegmentThreeMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfParentCompanyBalanceSheetsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfParentCompanyBalanceSheetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfParentCompanyBalanceSheetsAbstract_lbl" xml:lang="en-US">Schedule Of Parent Company Balance Sheets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfParentCompanyBalanceSheetsAbstract" xlink:to="upc_ScheduleOfParentCompanyBalanceSheetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CorporateSegmentFourMember_lbl1" xml:lang="en-US">Corporate Segment Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentFourMember" xlink:to="upc_CorporateSegmentFourMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract10" xlink:to="upc_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OwnershipMember_lbl0" xml:lang="en-US">Ownership Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OwnershipMember" xlink:to="upc_OwnershipMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract11" xlink:to="upc_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract14" xlink:to="upc_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract15" xlink:to="upc_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SubtotalOfTCMDProductsSales_lbl0" xml:lang="en-US">Subtotal Of TCMDProducts Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubtotalOfTCMDProductsSales" xlink:to="upc_SubtotalOfTCMDProductsSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract12" xlink:to="upc_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract13" xlink:to="upc_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_Over1YearMember_lbl0" xml:lang="en-US">Over1 Year Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_Over1YearMember" xlink:to="upc_Over1YearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfOtherPropertyOperatingExpense_lbl0" xml:lang="en-US">Cost of Other Property Operating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfOtherPropertyOperatingExpense" xlink:to="us-gaap_CostOfOtherPropertyOperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseINCMember_lbl1" xml:lang="en-US">Universe INCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseINCMember" xlink:to="upc_UniverseINCMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividends_lbl0" xml:lang="en-US">Payments of Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAcquisitionAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForAcquisitionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForAcquisitionAbstract_lbl" xml:lang="en-US">Prepayment For Acquisition Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisitionAbstract" xlink:to="upc_PrepaymentForAcquisitionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract_lbl" xml:lang="en-US">Schedule Of Total Revenues By Product Categories Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract" xlink:to="upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_lbl0" xml:lang="en-US">Income Tax Holiday, Income Tax Benefits Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:to="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Estimated Useful Lives Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xlink:to="upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract2" xlink:to="upc_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract1" xlink:to="upc_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract4" xlink:to="upc_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OwnershipPercentage_lbl0" xml:lang="en-US">Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OwnershipPercentage" xlink:to="upc_OwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract3" xlink:to="upc_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl0" xml:lang="en-US">Schedule of Short-Term Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract0" xlink:to="upc_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl0" xml:lang="en-US">Other Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_lbl0" xml:lang="en-US">Temporary Equity, Foreign Currency Translation Adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract9" xlink:to="upc_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl0" xml:lang="en-US">Allowance for Doubtful Accounts, Premiums and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract6" xlink:to="upc_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract5" xlink:to="upc_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract8" xlink:to="upc_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract7" xlink:to="upc_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl0" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDueFromRelatedPartiesAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfDueFromRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfDueFromRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Due From Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDueFromRelatedPartiesAbstract" xlink:to="upc_ScheduleOfDueFromRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ValueAddedTaxPolicyTextBlock_lbl1" xml:lang="en-US">Value Added Tax Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ValueAddedTaxPolicyTextBlock" xlink:to="upc_ValueAddedTaxPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl0" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_lbl0" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:to="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_GreatestGroupMember_lbl0" xml:lang="en-US">Greatest Group Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GreatestGroupMember" xlink:to="upc_GreatestGroupMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0" xml:lang="en-US">Short-Term Bank Loans and Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PercentageOfSubsequentCollection_lbl0" xml:lang="en-US">Percentage Of Subsequent Collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfSubsequentCollection" xlink:to="upc_PercentageOfSubsequentCollection_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OtherIncomeExpensesAbstract_lbl0" xml:lang="en-US">Other Income Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="upc_OtherIncomeExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl0" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeconsolidationRelatedPartyDescription_lbl0" xml:lang="en-US">Deconsolidation, Related Party, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationRelatedPartyDescription" xlink:to="us-gaap_DeconsolidationRelatedPartyDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl1" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OriginalSharesParValue_lbl1" xml:lang="en-US">Original Shares Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OriginalSharesParValue" xlink:to="upc_OriginalSharesParValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract" xlink:to="upc_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent_lbl1" xml:lang="en-US">Minority Interests Ownership Percentage By Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MinorityInterestsOwnershipPercentageByParent" xlink:to="upc_MinorityInterestsOwnershipPercentageByParent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments To Reconcile Net Cash Flows From Operating Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" xlink:to="upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl0" xml:lang="en-US">Condensed Cash Flow Statement [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset_lbl0" xml:lang="en-US">Construction Contract Cost, Progress Payment Offset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:to="us-gaap_ConstructionContractCostProgressPaymentOffset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl0" xml:lang="en-US">Contract Assets And Liabilities Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:to="upc_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SupplierTwoMember_lbl0" xml:lang="en-US">Supplier Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SupplierTwoMember" xlink:to="upc_SupplierTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_EntityIncorporationDateDescription_lbl1" xml:lang="en-US">Entity Incorporation Date Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EntityIncorporationDateDescription" xlink:to="upc_EntityIncorporationDateDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_DisaggregationOfRevenuesPolicyTextBlock_lbl0" xml:lang="en-US">Disaggregation Of Revenues Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DisaggregationOfRevenuesPolicyTextBlock" xlink:to="upc_DisaggregationOfRevenuesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock_lbl1" xml:lang="en-US">Statement Of Cash Flows Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatementOfCashFlowsPolicyTextBlock" xlink:to="upc_StatementOfCashFlowsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract_lbl" xml:lang="en-US">Schedule Of Components Of The Income Tax Provision Benefit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" xlink:to="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Investment Income Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl1" xml:lang="en-US">Payments to Acquire Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShorttermInvestmentIncome_lbl0" xml:lang="en-US">Shortterm Investment Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShorttermInvestmentIncome" xlink:to="upc_ShorttermInvestmentIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CurrentTaxProvisionAbstract_lbl0" xml:lang="en-US">Current Tax Provision Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CurrentTaxProvisionAbstract" xlink:to="upc_CurrentTaxProvisionAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SupplierOneMember_lbl0" xml:lang="en-US">Supplier One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SupplierOneMember" xlink:to="upc_SupplierOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CorporateSegmentFiveMember_lbl1" xml:lang="en-US">Corporate Segment Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentFiveMember" xlink:to="upc_CorporateSegmentFiveMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaturityOver90DaysMember_lbl0" xml:lang="en-US">Maturity Greater than 90 Days [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturityOver90DaysMember" xlink:to="us-gaap_MaturityOver90DaysMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract_lbl" xml:lang="en-US">Schedule Of Parent Company Statements Of Cash Flows Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract" xlink:to="upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl0" xml:lang="en-US">Investment Income, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Tax Payable Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTaxPayableTableTextBlock" xlink:to="upc_ScheduleOfTaxPayableTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MrsLinYangMember_lbl0" xml:lang="en-US">Mrs Lin Yang Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrsLinYangMember" xlink:to="upc_MrsLinYangMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DeferredTaxAssetsAbstract" xlink:to="upc_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AllowanceForDoubtfulAccountsReceivablePercentage_lbl0" xml:lang="en-US">Allowance For Doubtful Accounts Receivable Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AllowanceForDoubtfulAccountsReceivablePercentage" xlink:to="upc_AllowanceForDoubtfulAccountsReceivablePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TotalGrossAccountsReceivablePercentage_lbl0" xml:lang="en-US">Total Gross Accounts Receivable Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TotalGrossAccountsReceivablePercentage" xlink:to="upc_TotalGrossAccountsReceivablePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_LessThan3MonthsMember_lbl0" xml:lang="en-US">Less Than3 Months Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LessThan3MonthsMember" xlink:to="upc_LessThan3MonthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AssetAcquisitionPriceOfAcquisitionsExpected_lbl1" xml:lang="en-US">Asset Acquisition Price Of Acquisitions Expected</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AssetAcquisitionPriceOfAcquisitionsExpected" xlink:to="upc_AssetAcquisitionPriceOfAcquisitionsExpected_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnderwriterWarrantsMember_lbl0" xml:lang="en-US">Underwriter Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnderwriterWarrantsMember" xlink:to="upc_UnderwriterWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OtherComprehensiveIncomeLossAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherComprehensiveIncomeLossAbstract" xlink:to="upc_OtherComprehensiveIncomeLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl0" xml:lang="en-US">Proceeds from Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_DescriptionOfAverageRate_lbl1" xml:lang="en-US">Description Of Average Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DescriptionOfAverageRate" xlink:to="upc_DescriptionOfAverageRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShareholdersEquityAbstract0_lbl0" xml:lang="en-US">Shareholders Equity Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="upc_ShareholdersEquityAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Supplies_lbl0" xml:lang="en-US">Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl0" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AccountsReceivableDescription_lbl1" xml:lang="en-US">Accounts Receivable Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableDescription" xlink:to="upc_AccountsReceivableDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl0" xml:lang="en-US">Defined Contribution Plan, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Nature Of Relationships With Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" xlink:to="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MaturityGreaterThan90DaysFourMember_lbl0" xml:lang="en-US">Maturity Greater Than90 Days Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysFourMember" xlink:to="upc_MaturityGreaterThan90DaysFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_JxRcbBankMember_lbl0" xml:lang="en-US">Jx Rcb Bank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JxRcbBankMember" xlink:to="upc_JxRcbBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentsForConstructionInProgress_lbl1" xml:lang="en-US">Prepayments For Construction In Progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsForConstructionInProgress" xlink:to="upc_PrepaymentsForConstructionInProgress_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherShortTermInvestments_lbl0" xml:lang="en-US">Other Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_GubenYanlingPillMember_lbl0" xml:lang="en-US">Guben Yanling Pill Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GubenYanlingPillMember" xlink:to="upc_GubenYanlingPillMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl0" xml:lang="en-US">Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_DescriptionOfYearEndSpotRate_lbl1" xml:lang="en-US">Description Of Year End Spot Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DescriptionOfYearEndSpotRate" xlink:to="upc_DescriptionOfYearEndSpotRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits_lbl0" xml:lang="en-US">Foreign Financial Institutions, Mandated Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:to="us-gaap_ForeignFinancialInstitutionsMandatedDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PayableDeliveryPropertyPercentage_lbl1" xml:lang="en-US">Payable Delivery Property Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PayableDeliveryPropertyPercentage" xlink:to="upc_PayableDeliveryPropertyPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CorporateSegmentTwoMember_lbl1" xml:lang="en-US">Corporate Segment Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentTwoMember" xlink:to="upc_CorporateSegmentTwoMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_EquityInterestOwnershipPercentage_lbl1" xml:lang="en-US">Equity Interest Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityInterestOwnershipPercentage" xlink:to="upc_EquityInterestOwnershipPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_HeldToMaturityInvestmentDisclosureTextBlock_lbl0" xml:lang="en-US">Held To Maturity Investment Disclosure Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_HeldToMaturityInvestmentDisclosureTextBlock" xlink:to="upc_HeldToMaturityInvestmentDisclosureTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OptionToPurchaseAdditionalShares_lbl1" xml:lang="en-US">Option To Purchase Additional Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OptionToPurchaseAdditionalShares" xlink:to="upc_OptionToPurchaseAdditionalShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl0" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl1" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PercentageOfPrepayment_lbl1" xml:lang="en-US">Percentage Of Prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfPrepayment" xlink:to="upc_PercentageOfPrepayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl1" xml:lang="en-US">Property And Equipment Estimated Useful Life Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashFlowsFromInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Flows From Investing Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:to="upc_CashFlowsFromInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForAcquisitionCurrent_lbl1" xml:lang="en-US">Prepayment For Acquisition Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisitionCurrent" xlink:to="upc_PrepaymentForAcquisitionCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl0" xml:lang="en-US">Interest and Debt Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Future Amortization Expense For Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl0" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl2" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SubsequentCollection_lbl0" xml:lang="en-US">Subsequent Collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubsequentCollection" xlink:to="upc_SubsequentCollection_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due from Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PublicOfferingPrice_lbl1" xml:lang="en-US">Public Offering Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PublicOfferingPrice" xlink:to="upc_PublicOfferingPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl0" xml:lang="en-US">Equity Method Investment, Amount Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl0" xml:lang="en-US">Subsequent Event, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl0" xml:lang="en-US">Property, Plant and Equipment, Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AmortizationExpenseMember_lbl0" xml:lang="en-US">Amortization Expense Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AmortizationExpenseMember" xlink:to="upc_AmortizationExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl1" xml:lang="en-US">Employee Defined Contribution Plan Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:to="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_HeldToMaturityInvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Held To Maturity Investment Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_HeldToMaturityInvestmentPolicyTextBlock" xlink:to="upc_HeldToMaturityInvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionContractorsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Construction Contractor [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" xlink:to="us-gaap_ConstructionContractorsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl0" xml:lang="en-US">Other Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_From4To6MonthsMember_lbl0" xml:lang="en-US">From4 To6 Months Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_From4To6MonthsMember" xlink:to="upc_From4To6MonthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Holiday, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseHanheMember_lbl0" xml:lang="en-US">Universe Hanhe Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseHanheMember" xlink:to="upc_UniverseHanheMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SunsequentCollectionsTotalGrossAccountsReceivable_lbl0" xml:lang="en-US">Sunsequent Collections Total Gross Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SunsequentCollectionsTotalGrossAccountsReceivable" xlink:to="upc_SunsequentCollectionsTotalGrossAccountsReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfRevenueByProductSourceAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfRevenueByProductSourceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfRevenueByProductSourceAbstract_lbl" xml:lang="en-US">Schedule Of Revenue By Product Source Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfRevenueByProductSourceAbstract" xlink:to="upc_ScheduleOfRevenueByProductSourceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashFlowsFromFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Flows From Financing Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="upc_CashFlowsFromFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_From10To12MonthsMember_lbl0" xml:lang="en-US">From10 To12 Months Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_From10To12MonthsMember" xlink:to="upc_From10To12MonthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Net Consists Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract" xlink:to="upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl0" xml:lang="en-US">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ContractPricePercentage_lbl1" xml:lang="en-US">Contract Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ContractPricePercentage" xlink:to="upc_ContractPricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0" xml:lang="en-US">Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShortTermBankLoansAbstract_lbl0" xml:lang="en-US">Short Term Bank Loans Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShortTermBankLoansAbstract" xlink:to="upc_ShortTermBankLoansAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseTradeMember_lbl1" xml:lang="en-US">Universe Trade Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTradeMember" xlink:to="upc_UniverseTradeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SunsequentCollectionAccountsReceivableNet_lbl0" xml:lang="en-US">Sunsequent Collection Accounts Receivable Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SunsequentCollectionAccountsReceivableNet" xlink:to="upc_SunsequentCollectionAccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Property and Other Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MaterialPricePercentage_lbl1" xml:lang="en-US">Material Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaterialPricePercentage" xlink:to="upc_MaterialPricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl0" xml:lang="en-US">Payments for Repurchase of Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl0" xml:lang="en-US">CHINA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SalesOfTcmdProductsAbstract_lbl0" xml:lang="en-US">Sales Of Tcmd Products Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SalesOfTcmdProductsAbstract" xlink:to="upc_SalesOfTcmdProductsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CorporateSegmentSixMember_lbl1" xml:lang="en-US">Corporate Segment Six Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentSixMember" xlink:to="upc_CorporateSegmentSixMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl0" xml:lang="en-US">Related Party Transaction, Terms and Manner of Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForAdvertistingTextBlock_lbl0" xml:lang="en-US">Prepayment For Advertisting Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAdvertistingTextBlock" xlink:to="upc_PrepaymentForAdvertistingTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShorttermInvestmentsIncome_lbl1" xml:lang="en-US">Shortterm Investments Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShorttermInvestmentsIncome" xlink:to="upc_ShorttermInvestmentsIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsShareBasedCompensationCash_lbl0" xml:lang="en-US">Dividend, Share-Based Payment Arrangement, Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsShareBasedCompensationCash" xlink:to="us-gaap_DividendsShareBasedCompensationCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty_lbl1" xml:lang="en-US">Prepayments Made To ARelated Party For Purchase Of Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_JiangxiMember_lbl0" xml:lang="en-US">Jiangxi Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiMember" xlink:to="upc_JiangxiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Due To Related Parties Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:to="upc_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl1" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_DeferredTaxProvisionBenefitAbstract_lbl0" xml:lang="en-US">Deferred Tax Provision Benefit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DeferredTaxProvisionBenefitAbstract" xlink:to="upc_DeferredTaxProvisionBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember_lbl0" xml:lang="en-US">Greatest Group China Financial Management Limited Greatest Group Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember" xlink:to="upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PreferentialTaxTreatmentDescription_lbl1" xml:lang="en-US">Preferential Tax Treatment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PreferentialTaxTreatmentDescription" xlink:to="upc_PreferentialTaxTreatmentDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntermediateLifePlantsUsefulLife_lbl0" xml:lang="en-US">Intermediate-life Plants, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntermediateLifePlantsUsefulLife" xlink:to="us-gaap_IntermediateLifePlantsUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_NonCurrentAssetsAbstract_lbl0" xml:lang="en-US">Non Current Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NonCurrentAssetsAbstract" xlink:to="upc_NonCurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ChenyuanMember_lbl0" xml:lang="en-US">Chenyuan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ChenyuanMember" xlink:to="upc_ChenyuanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl1" xml:lang="en-US">Taxes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OrdinarySharesParValue_lbl1" xml:lang="en-US">Ordinary Shares Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesParValue" xlink:to="upc_OrdinarySharesParValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CapitalExpenditure_lbl1" xml:lang="en-US">Capital Expenditure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalExpenditure" xlink:to="upc_CapitalExpenditure_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl0" xml:lang="en-US">Inventory, Raw Materials and Supplies, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl0" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl1" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl2" xml:lang="en-US">Cash Cash Equivalent Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatutoryReservesMember_lbl0" xml:lang="en-US">Statutory Reserves Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReservesMember" xlink:to="upc_StatutoryReservesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SunsequentCollectionAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Sunsequent Collection Allowance For Doubtful Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SunsequentCollectionAllowanceForDoubtfulAccounts" xlink:to="upc_SunsequentCollectionAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SalesOfThirdPartyProductsAbstract_lbl0" xml:lang="en-US">Sales Of Third Party Products Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SalesOfThirdPartyProductsAbstract" xlink:to="upc_SalesOfThirdPartyProductsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl0" xml:lang="en-US">Debt Securities, Held-to-Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl0" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatutoryReserve_lbl1" xml:lang="en-US">Statutory Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserve" xlink:to="upc_StatutoryReserve_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl1" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due from Other Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TotalRevenueMember_lbl0" xml:lang="en-US">Total Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TotalRevenueMember" xlink:to="upc_TotalRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet_lbl1" xml:lang="en-US">Schedule Of Advances To Suppliers Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAdvancesToSuppliersNet" xlink:to="upc_ScheduleOfAdvancesToSuppliersNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl1" xml:lang="en-US">Prepayments Made To ARelated Party For Purchase Of Property Non Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts_lbl1" xml:lang="en-US">Stock Issued During Period Value Capitalized Initial Public Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" xlink:to="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SharesIssued01_lbl1" xml:lang="en-US">Shares Issued01</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SharesIssued01" xlink:to="upc_SharesIssued01_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings_lbl1" xml:lang="en-US">Proceeds Fromprepayments For Related Parties Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl0" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl0" xml:lang="en-US">Supplemental Deferred Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PercentageOfAdvancePayment_lbl1" xml:lang="en-US">Percentage Of Advance Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfAdvancePayment" xlink:to="upc_PercentageOfAdvancePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdvancetoSuppliersTablesLineItems_lbl0" xml:lang="en-US">Advanceto Suppliers Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancetoSuppliersTablesLineItems" xlink:to="upc_AdvancetoSuppliersTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CurrentAssetsAbstract0_lbl0" xml:lang="en-US">Current Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CurrentAssetsAbstract0" xlink:to="upc_CurrentAssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_EquityInterest_lbl1" xml:lang="en-US">Equity Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityInterest" xlink:to="upc_EquityInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashDividendsMember_lbl0" xml:lang="en-US">Cash Dividends Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashDividendsMember" xlink:to="upc_CashDividendsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MaturityGreaterThan90DaysThreeMember_lbl0" xml:lang="en-US">Maturity Greater Than90 Days Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysThreeMember" xlink:to="upc_MaturityGreaterThan90DaysThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SubtotalOfThirdpartyProductsSales_lbl1" xml:lang="en-US">Subtotal Of Thirdparty Products Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubtotalOfThirdpartyProductsSales" xlink:to="upc_SubtotalOfThirdpartyProductsSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CapitalExpenditureMember_lbl0" xml:lang="en-US">Capital Expenditure Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalExpenditureMember" xlink:to="upc_CapitalExpenditureMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due to Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDueToRelatedPartiesAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfDueToRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfDueToRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Due To Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDueToRelatedPartiesAbstract" xlink:to="upc_ScheduleOfDueToRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl0" xml:lang="en-US">Contact Personnel Email Address</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="upc_ScheduleOfDeferredTaxAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OtherIncomeExpensesAbstract0_lbl0" xml:lang="en-US">Other Income Expenses Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherIncomeExpensesAbstract0" xlink:to="upc_OtherIncomeExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_supplierMember_lbl0" xml:lang="en-US">supplier Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_supplierMember" xlink:to="upc_supplierMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl0" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl1" xml:lang="en-US">Payments for (Proceeds from) Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl2" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentAmount_lbl1" xml:lang="en-US">Prepayment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentAmount" xlink:to="upc_PrepaymentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl0" xml:lang="en-US">Repayments of Bank Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdditionalContractPricePercentage_lbl1" xml:lang="en-US">Additional Contract Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdditionalContractPricePercentage" xlink:to="upc_AdditionalContractPricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CustomerMember_lbl0" xml:lang="en-US">Customer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CustomerMember" xlink:to="upc_CustomerMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Schedule Of Parent Company Statements Of Income And Comprehensive Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract" xlink:to="upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_JiangxiUniverseMember_lbl0" xml:lang="en-US">Jiangxi Universe Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiUniverseMember" xlink:to="upc_JiangxiUniverseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl1" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGross_lbl0" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RestrictedNetAssets_lbl1" xml:lang="en-US">Restricted Net Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RestrictedNetAssets" xlink:to="upc_RestrictedNetAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract_lbl0" xml:lang="en-US">Loans Payable To Jiangxi Luling Rural Commercial Bank Lrc Bank Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:to="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_KY_lbl0" xml:lang="en-US">CAYMAN ISLANDS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KY" xlink:to="country_KY_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashFlowsFromOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Flows From Operating Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashFlowsFromOperatingActivitiesAbstract" xlink:to="upc_CashFlowsFromOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_EquityInEarningsOfSubsidiary_lbl1" xml:lang="en-US">Equity In Earnings Of Subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityInEarningsOfSubsidiary" xlink:to="upc_EquityInEarningsOfSubsidiary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Advertising</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_From7To9MonthsMember_lbl0" xml:lang="en-US">From7 To9 Months Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_From7To9MonthsMember" xlink:to="upc_From7To9MonthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_HK_lbl0" xml:lang="en-US">HONG KONG</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_lbl0" xml:lang="en-US">Selling Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrincipalActivities_lbl1" xml:lang="en-US">Principal Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrincipalActivities" xlink:to="upc_PrincipalActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl1" xml:lang="en-US">Inventory Valuation Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl0" xml:lang="en-US">Proceeds from Sale of Productive Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TaxBenefitPercentage_lbl1" xml:lang="en-US">Tax Benefit Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxBenefitPercentage" xlink:to="upc_TaxBenefitPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AccountsReceivableBeforeGrossValue_lbl0" xml:lang="en-US">Accounts Receivable Before Gross Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableBeforeGrossValue" xlink:to="upc_AccountsReceivableBeforeGrossValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseHKMember_lbl0" xml:lang="en-US">Universe HKMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseHKMember" xlink:to="upc_UniverseHKMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Maturity30To90DaysMember_lbl0" xml:lang="en-US">Maturity 30 to 90 Days [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Maturity30To90DaysMember" xlink:to="us-gaap_Maturity30To90DaysMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MaturityGreaterThan90DaysOneMember_lbl0" xml:lang="en-US">Maturity Greater Than90 Days One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysOneMember" xlink:to="upc_MaturityGreaterThan90DaysOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RemainingCapitalContribution_lbl1" xml:lang="en-US">Remaining Capital Contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RemainingCapitalContribution" xlink:to="upc_RemainingCapitalContribution_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PercentageOfVatRate_lbl1" xml:lang="en-US">Percentage Of Vat Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfVatRate" xlink:to="upc_PercentageOfVatRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashLentToSubsidiaries_lbl1" xml:lang="en-US">Cash Lent To Subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashLentToSubsidiaries" xlink:to="upc_CashLentToSubsidiaries_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_NameAbstract0_lbl0" xml:lang="en-US">Name Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NameAbstract0" xlink:to="upc_NameAbstract0_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfSubsidiariesOfTheCompanyAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfSubsidiariesOfTheCompanyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfSubsidiariesOfTheCompanyAbstract_lbl" xml:lang="en-US">Schedule Of Subsidiaries Of The Company Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfSubsidiariesOfTheCompanyAbstract" xlink:to="upc_ScheduleOfSubsidiariesOfTheCompanyAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>56
<FILENAME>upc-20220930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Feb 10 15:53:46 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedBalanceSheet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedIncomeStatement" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShareholdersEquityType2or3" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConsolidatedCashFlow" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_OrganizationandBusinessDescription" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_AccountsReceivableNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_InventoryNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_AdvancetoSuppliers" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforAdvertisting" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforAcquisition" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShortTermInvestments" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestments"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PropertyPlantandEquipmentNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_IntangibleAssetsNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforCIPProject" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforPurchaseofaProperty" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShortTermBankLoans" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_RelatedPartyTransactions" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_Taxes" roleURI="http://www.UniversePharmaceuticalsINC.com/role/Taxes"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_Concentrations" roleURI="http://www.UniversePharmaceuticalsINC.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShareholdersEquity" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_CommitmentsandContingencies" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SegmentReporting" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SubsequentEvents" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_CondensedFinancialInformationoftheParentCompany" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_AccountingPoliciesByPolicy" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_OrganizationandBusinessDescriptionTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_AccountsReceivableNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_InventoryNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_AdvancetoSuppliersTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShortTermInvestmentsTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PropertyPlantandEquipmentNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_IntangibleAssetsNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforCIPProjectTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShortTermBankLoansTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_RelatedPartyTransactionsTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_TaxesTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SegmentReportingTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_CondensedFinancialInformationoftheParentCompanyTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofsubsidiariesofthecompanyTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofpropertyplantandequipmentestimatedusefullivesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofintangibleassetsestimatedusefullivesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofcurrencyexchangerateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofaccountsreceivableconsistsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableconsistsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofallowancefordoubtfulaccountsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofinventoryTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofadvancestosuppliersnetTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofshortterminvestmentsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofpropertyplantandequipmentnetconsistsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofintangibleassetsnetconsistTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleoffutureminimumcapitalexpendituresTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofshorttermbankloansTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofnatureofrelationshipswithrelatedpartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofduefromrelatedpartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofduetorelatedpartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofcomponentsoftheincometaxprovisionbenefitTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofdeferredtaxassetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleoftaxespayableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofrevenuebyproductsourceTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleoftotalrevenuesbyproductcategoriesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofparentcompanybalancesheetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofparentcompanybalancesheetsTable_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ScheduleofparentcompanystatementsofcashflowsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_OrganizationandBusinessDescriptionDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_AccountsReceivableNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforAdvertistingDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforAcquisitionDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShortTermInvestmentsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PropertyPlantandEquipmentNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_IntangibleAssetsNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforCIPProjectDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_PrepaymentforPurchaseofaPropertyDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShortTermBankLoansDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_RelatedPartyTransactionsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_TaxesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ConcentrationsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_ShareholdersEquityDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_CommitmentsandContingenciesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SegmentReportingDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_SubsequentEventsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#upc_r_CondensedFinancialInformationoftheParentCompanyDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20220930.xsd#DocumentAndEntityInformation" roleURI="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Supplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Supplies" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForAcquisitionCurrent" xlink:href="upc-20220930.xsd#upc_PrepaymentForAcquisitionCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="PrepaymentForAcquisitionCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:href="upc-20220930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsForConstructionInProgress" xlink:href="upc-20220930.xsd#upc_PrepaymentsForConstructionInProgress"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="PrepaymentsForConstructionInProgress" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentInEquitySecurities" xlink:href="upc-20220930.xsd#upc_InvestmentInEquitySecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="InvestmentInEquitySecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AdditionalPaidInCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserve" xlink:href="upc-20220930.xsd#upc_StatutoryReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="StatutoryReserve" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeFromOperation" xlink:href="upc-20220930.xsd#upc_IncomeFromOperation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="IncomeFromOperation" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeExpensesAbstract" xlink:href="upc-20220930.xsd#upc_OtherIncomeExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherIncomeExpensesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShorttermInvestmentIncome" xlink:href="upc-20220930.xsd#upc_ShorttermInvestmentIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="ShorttermInvestmentIncome" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherComprehensiveIncomeLossAbstract" xlink:href="upc-20220930.xsd#upc_OtherComprehensiveIncomeLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherComprehensiveIncomeLossAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReservesMember" xlink:href="upc-20220930.xsd#upc_StatutoryReservesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StatutoryReservesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" xlink:href="upc-20220930.xsd#upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShorttermInvestmentsIncome" xlink:href="upc-20220930.xsd#upc_ShorttermInvestmentsIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShorttermInvestmentsIncome" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidAdvertising"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:href="upc-20220930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfAdvancesForConstruction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfAdvancesForConstruction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfAdvancesForConstruction" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="RedemptionOfShorttermInvestments" xlink:href="upc-20220930.xsd#upc_RedemptionOfShorttermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="RedemptionOfShorttermInvestments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfBankDebt" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:href="upc-20220930.xsd#upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromprepaymentsForRelatedPartiesBorrowings" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoryNet">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers">
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersAbstract" xlink:href="upc-20220930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersTextBlock" xlink:href="upc-20220930.xsd#upc_AdvancesToSuppliersTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancesToSuppliersAbstract" xlink:to="AdvancesToSuppliersTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting">
    <loc xlink:type="locator" xlink:label="PrepaymentForAdvertistingAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForAdvertistingAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForAdvertistingTextBlock" xlink:href="upc-20220930.xsd#upc_PrepaymentForAdvertistingTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="PrepaymentForAdvertistingTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition">
    <loc xlink:type="locator" xlink:label="PrepaymentForAcquisitionAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforAcquisitionTable" xlink:href="upc-20220930.xsd#upc_PrepaymentforAcquisitionTable"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforAcquisitionLineItems" xlink:href="upc-20220930.xsd#upc_PrepaymentforAcquisitionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAcquisitionAbstract" xlink:to="PrepaymentforAcquisitionTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforAcquisitionTable" xlink:to="PrepaymentforAcquisitionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForAcquisitionTextBlock" xlink:href="upc-20220930.xsd#upc_PrepaymentForAcquisitionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforAcquisitionLineItems" xlink:to="PrepaymentForAcquisitionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestments">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="HeldToMaturityInvestmentDisclosureTextBlock" xlink:href="upc-20220930.xsd#upc_HeldToMaturityInvestmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="HeldToMaturityInvestmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject">
    <loc xlink:type="locator" xlink:label="PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForConstructionInProgressTextBlock" xlink:href="upc-20220930.xsd#upc_PrepaymentForConstructionInProgressTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForConstructionInProgressAbstract" xlink:to="PrepaymentForConstructionInProgressTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty">
    <loc xlink:type="locator" xlink:label="PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForPurchaseOfAPropertyTextBlock" xlink:href="upc-20220930.xsd#upc_PrepaymentForPurchaseOfAPropertyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="PrepaymentForPurchaseOfAPropertyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/Taxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/Concentrations">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersNetPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_AdvancesToSuppliersNetPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AdvancesToSuppliersNetPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HeldToMaturityInvestmentPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_HeldToMaturityInvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="HeldToMaturityInvestmentPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionContractorsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_ContractAssetsAndLiabilitiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ContractAssetsAndLiabilitiesPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisaggregationOfRevenuesPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_DisaggregationOfRevenuesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DisaggregationOfRevenuesPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValueAddedTaxPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_ValueAddedTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ValueAddedTaxPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatementOfCashFlowsPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_StatementOfCashFlowsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="StatementOfCashFlowsPolicyTextBlock" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeDefinedContributionPlanPolicyTextBlock" xlink:href="upc-20220930.xsd#upc_EmployeeDefinedContributionPlanPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="EmployeeDefinedContributionPlanPolicyTextBlock" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="upc-20220930.xsd#upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables">
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersAbstract" xlink:href="upc-20220930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="AdvancetoSuppliersTablesTable" xlink:href="upc-20220930.xsd#upc_AdvancetoSuppliersTablesTable"/>
    <loc xlink:type="locator" xlink:label="AdvancetoSuppliersTablesLineItems" xlink:href="upc-20220930.xsd#upc_AdvancetoSuppliersTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancesToSuppliersAbstract" xlink:to="AdvancetoSuppliersTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancetoSuppliersTablesTable" xlink:to="AdvancetoSuppliersTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAdvancesToSuppliersNet" xlink:href="upc-20220930.xsd#upc_ScheduleOfAdvancesToSuppliersNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancetoSuppliersTablesLineItems" xlink:to="ScheduleOfAdvancesToSuppliersNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables">
    <loc xlink:type="locator" xlink:label="PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForConstructionInProgressAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDueFromRelatedPartiesTableTextBlock" xlink:href="upc-20220930.xsd#upc_ScheduleOfDueFromRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfDueFromRelatedPartiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:href="upc-20220930.xsd#upc_ScheduleOfDueToRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfDueToRelatedPartiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTaxPayableTableTextBlock" xlink:href="upc-20220930.xsd#upc_ScheduleOfTaxPayableTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfTaxPayableTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSubsidiariesOfTheCompanyAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfSubsidiariesOfTheCompanyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSubsidiariesOfTheCompanyAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="UniverseINCMember" xlink:href="upc-20220930.xsd#upc_UniverseINCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseINCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseHKMember" xlink:href="upc-20220930.xsd#upc_UniverseHKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseHKMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseTechnologyMember" xlink:href="upc-20220930.xsd#upc_UniverseTechnologyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseTechnologyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiangxiUniverseMember" xlink:href="upc-20220930.xsd#upc_JiangxiUniverseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="JiangxiUniverseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseTradeMember" xlink:href="upc-20220930.xsd#upc_UniverseTradeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseTradeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseHanheMember" xlink:href="upc-20220930.xsd#upc_UniverseHanheMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseHanheMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlaceOfIncorporation" xlink:href="upc-20220930.xsd#upc_PlaceOfIncorporation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="PlaceOfIncorporation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OwnershipPercentage" xlink:href="upc-20220930.xsd#upc_OwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="OwnershipPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrincipalActivities" xlink:href="upc-20220930.xsd#upc_PrincipalActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="PrincipalActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AutomobilesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_AutomobilesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeAndElectricEquipmentMember" xlink:href="upc-20220930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="OfficeAndElectricEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_UseRightsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntermediateLifePlantsUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntermediateLifePlantsUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:to="us-gaap_IntermediateLifePlantsUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCurrencyExchangeRateAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfCurrencyExchangeRateAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfYearEndSpotRate" xlink:href="upc-20220930.xsd#upc_DescriptionOfYearEndSpotRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCurrencyExchangeRateAbstract" xlink:to="DescriptionOfYearEndSpotRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAverageRate" xlink:href="upc-20220930.xsd#upc_DescriptionOfAverageRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCurrencyExchangeRateAbstract" xlink:to="DescriptionOfAverageRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableconsistsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableConsistsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfAccountsReceivableConsistsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableConsistsAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableConsistsAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableConsistsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract" xlink:to="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LessThan3MonthsMember" xlink:href="upc-20220930.xsd#upc_LessThan3MonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="LessThan3MonthsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="From4To6MonthsMember" xlink:href="upc-20220930.xsd#upc_From4To6MonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="From4To6MonthsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="From7To9MonthsMember" xlink:href="upc-20220930.xsd#upc_From7To9MonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="From7To9MonthsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="From10To12MonthsMember" xlink:href="upc-20220930.xsd#upc_From10To12MonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="From10To12MonthsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Over1YearMember" xlink:href="upc-20220930.xsd#upc_Over1YearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="Over1YearMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableBeforeGrossValue" xlink:href="upc-20220930.xsd#upc_AccountsReceivableBeforeGrossValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="AccountsReceivableBeforeGrossValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubsequentCollection" xlink:href="upc-20220930.xsd#upc_SubsequentCollection"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="SubsequentCollection" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfSubsequentCollection" xlink:href="upc-20220930.xsd#upc_PercentageOfSubsequentCollection"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="PercentageOfSubsequentCollection" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AccountsReceivableGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SunsequentCollectionsTotalGrossAccountsReceivable" xlink:href="upc-20220930.xsd#upc_SunsequentCollectionsTotalGrossAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="SunsequentCollectionsTotalGrossAccountsReceivable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalGrossAccountsReceivablePercentage" xlink:href="upc-20220930.xsd#upc_TotalGrossAccountsReceivablePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="TotalGrossAccountsReceivablePercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="SunsequentCollectionAllowanceForDoubtfulAccounts" xlink:href="upc-20220930.xsd#upc_SunsequentCollectionAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="SunsequentCollectionAllowanceForDoubtfulAccounts" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowanceForDoubtfulAccountsReceivablePercentage" xlink:href="upc-20220930.xsd#upc_AllowanceForDoubtfulAccountsReceivablePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="AllowanceForDoubtfulAccountsReceivablePercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SunsequentCollectionAccountsReceivableNet" xlink:href="upc-20220930.xsd#upc_SunsequentCollectionAccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="SunsequentCollectionAccountsReceivableNet" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableNetPercentage" xlink:href="upc-20220930.xsd#upc_AccountsReceivableNetPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="AccountsReceivableNetPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdvancesToSuppliersNetAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfAdvancesToSuppliersNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToSuppliersAndEmployees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToSuppliersAndEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="us-gaap_PaymentsToSuppliersAndEmployees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvestmentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShortTermInvestmentsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfShortTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AddPurchaseWealthManagementFinancialProducts" xlink:href="upc-20220930.xsd#upc_AddPurchaseWealthManagementFinancialProducts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermInvestmentsAbstract" xlink:to="AddPurchaseWealthManagementFinancialProducts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermInvestmentsAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermInvestmentsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermInvestmentsAbstract" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestments_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AutomobilesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_AutomobilesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeAndElectricEquipmentMember" xlink:href="upc-20220930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="OfficeAndElectricEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsNetConsistAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfIntangibleAssetsNetConsistAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsNetConsistAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_UseRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7sSbeKneEPlmNIhj3bCSU5y7O0I8dbszuTl8jF0AJbe21t+Rq4Ior0xtAOoy+ao7RLCBcMnvOYD6nWgAt+g/C9Glm4Z6aOCF7CBTCCEgAQgDS5HDB+QiyzEmRx2qG5/uHVrpvkxjN1Mvw==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" xlink:href="upc-20220930.xsd#upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:href="upc-20220930.xsd#upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AmortizationExpenseMember" xlink:href="upc-20220930.xsd#upc_AmortizationExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="AmortizationExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" xlink:to="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumCapitalExpendituresAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:href="upc-20220930.xsd#upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:href="upc-20220930.xsd#upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCapitalExpendituresAbstract" xlink:to="PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CapitalExpenditureMember" xlink:href="upc-20220930.xsd#upc_CapitalExpenditureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="CapitalExpenditureMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:to="PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShortTermBankLoansAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfShortTermBankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermBankLoansAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Maturity30To90DaysMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Maturity30To90DaysMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="us-gaap_Maturity30To90DaysMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaturityOver90DaysMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaturityOver90DaysMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="us-gaap_MaturityOver90DaysMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityGreaterThan90DaysOneMember" xlink:href="upc-20220930.xsd#upc_MaturityGreaterThan90DaysOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="MaturityGreaterThan90DaysOneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityGreaterThan90DaysTwoMember" xlink:href="upc-20220930.xsd#upc_MaturityGreaterThan90DaysTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="MaturityGreaterThan90DaysTwoMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityGreaterThan90DaysThreeMember" xlink:href="upc-20220930.xsd#upc_MaturityGreaterThan90DaysThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="MaturityGreaterThan90DaysThreeMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityGreaterThan90DaysFourMember" xlink:href="upc-20220930.xsd#upc_MaturityGreaterThan90DaysFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="MaturityGreaterThan90DaysFourMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:href="upc-20220930.xsd#upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BankOfCommunicationsCoLtdAbstract" xlink:href="upc-20220930.xsd#upc_BankOfCommunicationsCoLtdAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:to="BankOfCommunicationsCoLtdAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MrGangLaiMember" xlink:href="upc-20220930.xsd#upc_MrGangLaiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrGangLaiMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MsLinYangMember" xlink:href="upc-20220930.xsd#upc_MsLinYangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MsLinYangMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember" xlink:href="upc-20220930.xsd#upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember" xlink:href="upc-20220930.xsd#upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDueFromRelatedPartiesAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfDueFromRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:href="upc-20220930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:href="upc-20220930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDueFromRelatedPartiesAbstract" xlink:to="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GreatestGroupMember" xlink:href="upc-20220930.xsd#upc_GreatestGroupMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GreatestGroupMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FoshanShangyuMember" xlink:href="upc-20220930.xsd#upc_FoshanShangyuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="FoshanShangyuMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:to="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NameAbstract" xlink:href="upc-20220930.xsd#upc_NameAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:to="NameAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameAbstract" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDueToRelatedPartiesAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfDueToRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:href="upc-20220930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:href="upc-20220930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDueToRelatedPartiesAbstract" xlink:to="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrGangLaiMember" xlink:href="upc-20220930.xsd#upc_MrGangLaiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrGangLaiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrsLinYangMember" xlink:href="upc-20220930.xsd#upc_MrsLinYangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrsLinYangMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:to="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NameAbstract0" xlink:href="upc-20220930.xsd#upc_NameAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:to="NameAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameAbstract0" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:href="upc-20220930.xsd#upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable"/>
    <loc xlink:type="locator" xlink:label="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:href="upc-20220930.xsd#upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" xlink:to="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_KY" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KY"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KY" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:to="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="upc-20220930.xsd#upc_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTaxesPayableAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfTaxesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenueByProductSourceAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfRevenueByProductSourceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfOtherPropertyOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfOtherPropertyOperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueByProductSourceAbstract" xlink:to="us-gaap_CostOfOtherPropertyOperatingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueByProductSourceAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueByProductSourceAbstract" xlink:to="us-gaap_Revenues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTotalRevenuesByProductCategoriesAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTotalRevenuesByProductCategoriesAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_CorporateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateSegmentOneMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateSegmentOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateSegmentTwoMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateSegmentTwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateSegmentThreeMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateSegmentThreeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateSegmentFourMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateSegmentFourMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateSegmentFiveMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateSegmentFiveMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateSegmentSixMember" xlink:href="upc-20220930.xsd#upc_CorporateSegmentSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateSegmentSixMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SalesOfTcmdProductsAbstract" xlink:href="upc-20220930.xsd#upc_SalesOfTcmdProductsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="SalesOfTcmdProductsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubtotalOfTCMDProductsSales" xlink:href="upc-20220930.xsd#upc_SubtotalOfTCMDProductsSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesOfTcmdProductsAbstract" xlink:to="SubtotalOfTCMDProductsSales" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesOfThirdPartyProductsAbstract" xlink:href="upc-20220930.xsd#upc_SalesOfThirdPartyProductsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="SalesOfThirdPartyProductsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubtotalOfThirdpartyProductsSales" xlink:href="upc-20220930.xsd#upc_SubtotalOfThirdpartyProductsSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesOfThirdPartyProductsAbstract" xlink:to="SubtotalOfThirdpartyProductsSales" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfParentCompanyBalanceSheetsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfParentCompanyBalanceSheetsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfParentCompanyBalanceSheetsAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CurrentAssetsAbstract0" xlink:href="upc-20220930.xsd#upc_CurrentAssetsAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="CurrentAssetsAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract0" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract0" xlink:to="us-gaap_ShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonCurrentAssetsAbstract" xlink:href="upc-20220930.xsd#upc_NonCurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="NonCurrentAssetsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_Liabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityAbstract0" xlink:href="upc-20220930.xsd#upc_ShareholdersEquityAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ShareholdersEquityAbstract0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityAbstract0" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityAbstract0" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityAbstract0" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityAbstract0" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityAbstract0" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfParentCompanyBalanceSheetsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfParentCompanyBalanceSheetsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfParentCompanyBalanceSheetsAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeExpensesAbstract0" xlink:href="upc-20220930.xsd#upc_OtherIncomeExpensesAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="OtherIncomeExpensesAbstract0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOtherShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract0" xlink:to="us-gaap_InterestExpenseOtherShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract0" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ProfitLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfParentCompanyStatementsOfCashFlowsAbstract" xlink:href="upc-20220930.xsd#upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedCashFlowStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfParentCompanyStatementsOfCashFlowsAbstract" xlink:to="srt_CondensedCashFlowStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromOperatingActivitiesAbstract" xlink:href="upc-20220930.xsd#upc_CashFlowsFromOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="CashFlowsFromOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" xlink:href="upc-20220930.xsd#upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityInEarningsOfSubsidiary" xlink:href="upc-20220930.xsd#upc_EquityInEarningsOfSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" xlink:to="EquityInEarningsOfSubsidiary" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromInvestingActivitiesAbstract" xlink:href="upc-20220930.xsd#upc_CashFlowsFromInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="CashFlowsFromInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromFinancingActivitiesAbstract" xlink:href="upc-20220930.xsd#upc_CashFlowsFromFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="CashFlowsFromFinancingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashLentToSubsidiaries" xlink:href="upc-20220930.xsd#upc_CashLentToSubsidiaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="CashLentToSubsidiaries" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="upc-20220930.xsd#upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0" xlink:href="upc-20220930.xsd#upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandBusinessDescriptionDetailsTable" xlink:href="upc-20220930.xsd#upc_OrganizationandBusinessDescriptionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandBusinessDescriptionDetailsLineItems" xlink:href="upc-20220930.xsd#upc_OrganizationandBusinessDescriptionDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrganizationandBusinessDescriptionDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniverseIncMember" xlink:href="upc-20220930.xsd#upc_UniverseIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseHKMember" xlink:href="upc-20220930.xsd#upc_UniverseHKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseHKMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseTechnologyMember" xlink:href="upc-20220930.xsd#upc_UniverseTechnologyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseTechnologyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiangxiUniverseMember" xlink:href="upc-20220930.xsd#upc_JiangxiUniverseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="JiangxiUniverseMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseTradeMember" xlink:href="upc-20220930.xsd#upc_UniverseTradeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseTradeMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="JiangxiMember" xlink:href="upc-20220930.xsd#upc_JiangxiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="JiangxiMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="OrganizationandBusinessDescriptionDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EntityIncorporationDateDescription" xlink:href="upc-20220930.xsd#upc_EntityIncorporationDateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="EntityIncorporationDateDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentOwnershipsPercentage" xlink:href="upc-20220930.xsd#upc_EquityMethodInvestmentOwnershipsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="EquityMethodInvestmentOwnershipsPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountOfRegisteredCapital" xlink:href="upc-20220930.xsd#upc_AmountOfRegisteredCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="AmountOfRegisteredCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalContribution" xlink:href="upc-20220930.xsd#upc_CapitalContribution"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="CapitalContribution" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainingCapitalContribution" xlink:href="upc-20220930.xsd#upc_RemainingCapitalContribution"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="RemainingCapitalContribution" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssued01" xlink:href="upc-20220930.xsd#upc_SharesIssued01"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="SharesIssued01" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_SharePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicOfferingPrice" xlink:href="upc-20220930.xsd#upc_PublicOfferingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="PublicOfferingPrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="upc-20220930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JxRcbBankMember" xlink:href="upc-20220930.xsd#upc_JxRcbBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="JxRcbBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OwnershipMember" xlink:href="upc-20220930.xsd#upc_OwnershipMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="OwnershipMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MaterialPricePercentage" xlink:href="upc-20220930.xsd#upc_MaterialPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="MaterialPricePercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentTerm" xlink:href="upc-20220930.xsd#upc_PaymentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="PaymentTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowanceForUncollectableBalancesAmount" xlink:href="upc-20220930.xsd#upc_AllowanceForUncollectableBalancesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="AllowanceForUncollectableBalancesAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentOwnershipsPercentage" xlink:href="upc-20220930.xsd#upc_EquityMethodInvestmentOwnershipsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="EquityMethodInvestmentOwnershipsPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NetInvestmentIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxBenefitPercentage" xlink:href="upc-20220930.xsd#upc_TaxBenefitPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="TaxBenefitPercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfVatRate" xlink:href="upc-20220930.xsd#upc_PercentageOfVatRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="PercentageOfVatRate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableDescription" xlink:href="upc-20220930.xsd#upc_AccountsReceivableDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="AccountsReceivableDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails">
    <loc xlink:type="locator" xlink:label="PrepaymentForAdvertistingAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForAdvertistingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAdvancePayment" xlink:href="upc-20220930.xsd#upc_PercentageOfAdvancePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="PercentageOfAdvancePayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalContractPricePercentage" xlink:href="upc-20220930.xsd#upc_AdditionalContractPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="AdditionalContractPricePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractPricePercentage" xlink:href="upc-20220930.xsd#upc_ContractPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="ContractPricePercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails">
    <loc xlink:type="locator" xlink:label="PrepaymentForAcquisitionAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforAcquisitionDetailsTable" xlink:href="upc-20220930.xsd#upc_PrepaymentforAcquisitionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforAcquisitionDetailsLineItems" xlink:href="upc-20220930.xsd#upc_PrepaymentforAcquisitionDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAcquisitionAbstract" xlink:to="PrepaymentforAcquisitionDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforAcquisitionDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="YunnanFaxiMember" xlink:href="upc-20220930.xsd#upc_YunnanFaxiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="YunnanFaxiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforAcquisitionDetailsTable" xlink:to="PrepaymentforAcquisitionDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentOwnershipsPercentage" xlink:href="upc-20220930.xsd#upc_EquityMethodInvestmentOwnershipsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforAcquisitionDetailsLineItems" xlink:to="EquityMethodInvestmentOwnershipsPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="AssetAcquisitionPriceOfAcquisitionsExpected" xlink:href="upc-20220930.xsd#upc_AssetAcquisitionPriceOfAcquisitionsExpected"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforAcquisitionDetailsLineItems" xlink:to="AssetAcquisitionPriceOfAcquisitionsExpected" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforAcquisitionDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_OtherShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails">
    <loc xlink:type="locator" xlink:label="PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforCIPProjectDetailsTable" xlink:href="upc-20220930.xsd#upc_PrepaymentforCIPProjectDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforCIPProjectDetailsLineItems" xlink:href="upc-20220930.xsd#upc_PrepaymentforCIPProjectDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForConstructionInProgressAbstract" xlink:to="PrepaymentforCIPProjectDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ChenyuanMember" xlink:href="upc-20220930.xsd#upc_ChenyuanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChenyuanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsTable" xlink:to="PrepaymentforCIPProjectDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentBuildingAndBuildingImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsLineItems" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionContractCostProgressPaymentOffset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsLineItems" xlink:to="us-gaap_ConstructionContractCostProgressPaymentOffset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Prepayment" xlink:href="upc-20220930.xsd#upc_Prepayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsLineItems" xlink:to="Prepayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalExpenditure" xlink:href="upc-20220930.xsd#upc_CapitalExpenditure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsLineItems" xlink:to="CapitalExpenditure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails">
    <loc xlink:type="locator" xlink:label="PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20220930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityInterest" xlink:href="upc-20220930.xsd#upc_EquityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="EquityInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeSpaceSquareMeters" xlink:href="upc-20220930.xsd#upc_OfficeSpaceSquareMeters"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="OfficeSpaceSquareMeters" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="us-gaap_SupplementalDeferredPurchasePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPrepayment" xlink:href="upc-20220930.xsd#upc_PercentageOfPrepayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="PercentageOfPrepayment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PayableDeliveryPropertyPercentage" xlink:href="upc-20220930.xsd#upc_PayableDeliveryPropertyPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="PayableDeliveryPropertyPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ShortTermBankLoansDetailsTable" xlink:href="upc-20220930.xsd#upc_ShortTermBankLoansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShortTermBankLoansDetailsLineItems" xlink:href="upc-20220930.xsd#upc_ShortTermBankLoansDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ShortTermBankLoansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansDetailsTable" xlink:to="dei_LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JiangxiLulingRuralCommercialBankMember" xlink:href="upc-20220930.xsd#upc_JiangxiLulingRuralCommercialBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="JiangxiLulingRuralCommercialBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansDetailsTable" xlink:to="ShortTermBankLoansDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableToBankCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansDetailsLineItems" xlink:to="us-gaap_LoansPayableToBankCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansDetailsLineItems" xlink:to="us-gaap_InterestAndDebtExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeconsolidationRelatedPartyDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRelatedPartyDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_DeconsolidationRelatedPartyDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentAmount" xlink:href="upc-20220930.xsd#upc_PrepaymentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="PrepaymentAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityInterestOwnershipPercentage" xlink:href="upc-20220930.xsd#upc_EquityInterestOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="EquityInterestOwnershipPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesDetailsTable" xlink:href="upc-20220930.xsd#upc_TaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TaxesDetailsLineItems" xlink:href="upc-20220930.xsd#upc_TaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="TaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsTable" xlink:to="TaxesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferentialTaxTreatmentDescription" xlink:href="upc-20220930.xsd#upc_PreferentialTaxTreatmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsLineItems" xlink:to="PreferentialTaxTreatmentDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsLineItems" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConcentrationsDetailsTable" xlink:href="upc-20220930.xsd#upc_ConcentrationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConcentrationsDetailsLineItems" xlink:href="upc-20220930.xsd#upc_ConcentrationsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="ConcentrationsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GubenYanlingPillMember" xlink:href="upc-20220930.xsd#upc_GubenYanlingPillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GubenYanlingPillMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TotalRevenueMember" xlink:href="upc-20220930.xsd#upc_TotalRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="TotalRevenueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SupplierOneMember" xlink:href="upc-20220930.xsd#upc_SupplierOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SupplierOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SupplierTwoMember" xlink:href="upc-20220930.xsd#upc_SupplierTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SupplierTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="supplierMember" xlink:href="upc-20220930.xsd#upc_supplierMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="supplierMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_AccountsReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CustomerMember" xlink:href="upc-20220930.xsd#upc_CustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomersOneMember" xlink:href="upc-20220930.xsd#upc_CustomersOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomersOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="ConcentrationsDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignFinancialInstitutionsMandatedDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsLineItems" xlink:to="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskThresholdPercentage" xlink:href="upc-20220930.xsd#upc_ConcentrationRiskThresholdPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsLineItems" xlink:to="ConcentrationRiskThresholdPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="upc-20220930.xsd#upc_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsLineItems" xlink:href="upc-20220930.xsd#upc_ShareholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniverseINCMember" xlink:href="upc-20220930.xsd#upc_UniverseINCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UniverseINCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderwriterWarrantsMember" xlink:href="upc-20220930.xsd#upc_UnderwriterWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="UnderwriterWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashDividendsMember" xlink:href="upc-20220930.xsd#upc_CashDividendsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="CashDividendsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserveAndRestrictedNetAssetsMember" xlink:href="upc-20220930.xsd#upc_StatutoryReserveAndRestrictedNetAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="StatutoryReserveAndRestrictedNetAssetsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UnderwriterWarrantsMember_0" xlink:href="upc-20220930.xsd#upc_UnderwriterWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="UnderwriterWarrantsMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PRCMember" xlink:href="upc-20220930.xsd#upc_PRCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PRCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="ShareholdersEquityDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalSharesParValue" xlink:href="upc-20220930.xsd#upc_OriginalSharesParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OriginalSharesParValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesParValue" xlink:href="upc-20220930.xsd#upc_OrdinarySharesParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OrdinarySharesParValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesOutstandingDescription" xlink:href="upc-20220930.xsd#upc_OrdinarySharesOutstandingDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OrdinarySharesOutstandingDescription" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReorganizationShares" xlink:href="upc-20220930.xsd#upc_ReorganizationShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ReorganizationShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicOfferingPrice" xlink:href="upc-20220930.xsd#upc_PublicOfferingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="PublicOfferingPrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionToPurchaseAdditionalShares" xlink:href="upc-20220930.xsd#upc_OptionToPurchaseAdditionalShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OptionToPurchaseAdditionalShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentOwnershipsPercentage" xlink:href="upc-20220930.xsd#upc_EquityMethodInvestmentOwnershipsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="EquityMethodInvestmentOwnershipsPercentage" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsShareBasedCompensationCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsShareBasedCompensationCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_DividendsShareBasedCompensationCash" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashDividendDescription" xlink:href="upc-20220930.xsd#upc_CashDividendDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="CashDividendDescription" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutorySurplusPercentage" xlink:href="upc-20220930.xsd#upc_StatutorySurplusPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="StatutorySurplusPercentage" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReserveIsEqualPercentage" xlink:href="upc-20220930.xsd#upc_ReserveIsEqualPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ReserveIsEqualPercentage" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_RestrictedCash" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedNetAssets" xlink:href="upc-20220930.xsd#upc_RestrictedNetAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="RestrictedNetAssets" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseCapitalSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_InterestExpenseCapitalSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="MinorityInterestsOwnershipPercentageByParent" xlink:href="upc-20220930.xsd#upc_MinorityInterestsOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="MinorityInterestsOwnershipPercentageByParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="upc-20220930.xsd#upc_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>ex15-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !R ,8# 2(  A$! Q$!_\0
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MOL!]331>0,<"5/\ OH4[,5RQ135=7&58'Z&E)P*0Q:*A:YB3[S@?4TBWD#'
ME3_OH4[,5R>BFK(K_=8'Z'-.I#"BFEPO4XJ&2\BC!+. !U).*=@+%%9#^)M'
MB;;)J=HA]#,H_K5RUU.RO?\ CVNX)O:.0-_*FX26Z%S+N6Z*3/K2U(PHI&8
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M=.CE8&5_,?:<':.GZ_RKT0W>/#.F@'[UI%_Z *\%\3:B=3\074X.8U;RX_\
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M^#],_M/Q#%N7,-N/.D_#H/Q./RK*E'V<&RYOGDD0>(+86$UII_\ %!;J9/\
M?;YF_F*B\/6?]H^)-,L\9\ZZC4_3<"?T!I?$5Q]K\17\N<CS2H^@X_I70?"R
MR^U^/K-BN5MXY)C[8&!^K54Y<M)R\B8J\TO,^B!TI:0=*6OG3V HHHH *YKQ
M%* ,9Z5TAZ5Q'C*62#3;V< _NX7(QZXK6BKR1$_A/ [^<W6I74Y.?,E9OS-=
MW\&[/[1XQFN2.+:U8Y]V('\LUY\(I<#]U)_WP:]D^"=@T5CJUZ\;*TDJ1+N7
M'"C)_5J]K%2Y:+/.H)NHKGJU%%%> >H9^K0^9;'':O OB'8/;ZU'=8.R9-I/
M^TO_ -:OHJ1!(I4]ZXGQ7X4BUBRD@D! /S(XZHW8UV86JH2U.>O3YHGSZCO&
MZR(<.K!E/H1R*^C_  WXYTO7M'BG^U11780":!V 96[]>HKP;6/#.J:),RW-
MN[19^69 2I_P_&L?(!SQGZUZ=:C&NEJ<5.K*DW<]V\6^.+#3H7VW"338^2*-
MLDGWQT%>(7=S+>W<UU<-NFE8L[>]1Q1O,X2)&=ST"+DG\J[KPK\+M6UJ9)]3
MC>PL.IWC$CCT4=OJ:(QIX>-VPDYUGH:'P>\./=:Q)KLT9%O:@QPDC[TAX)'T
M'\Z]LE.V-C4&FZ=::5I\-C90K%;PKM1%_P ]:?=DBW;'I7C5JKJU.8]"G#DA
M8\H^)5WLT6=,\RR*@'XY/\J\BKT7XGO)FRM]K'<[2' )Z<?UKSPPS%3B*0GM
M\AKV<-94T>?6NYGI^DV7D?#- 1S/!-,?QSC] *\M'W1]*][U#2VM?"T%FJ']
MU8A",=]G->#B*3 _=/\ ]\FEAI\W,_,=:-K \C2,"YR0 H]@.@KT[P9IXTGP
MC+J<HQ+=YE!/:-<X_/DUY[I>DW.K:K::?%'('N)1'G:< 'J?P&:]@\;QC3/"
M]S%;(1%# ((PH[<**,1/54UU"E'1S9XF[F21I#U<EC^)KU+X(V6_4]6OB.(X
M4A!]V))_D*\N\F7_ )Y2?]\&O<_@W8FV\)W%RRE7N;ICR,'"@ ?UI8R25%I#
MPZO4N>C"BBBO"/3"BBB@ /-5Y+2*4_.H/UJQ10M *J:?;HV1$G_?(JPJ*@PJ
M@#V&*=13;;W"P445'),L0RQQ2 ?360.,$5C:CXLT;2B/MU_! 3T5FY/X4NE^
M+M!UF40V&J6\TIZ1AL,?H#UJ_9R2O8GF5[7+\FG029W("#U&*H2>%=&E;=)I
MMH[>IB7_  K5FN$B'S&L27QMX=@F>&75K5)$8JRM)R".U.//]D3Y>IIVFD6%
MAC[+9P0X_N1@5=QZ5D6/BC0]2F6"TU6TEE;HBRC)_"M8L%&34RYK^\5%KH.I
MK*'&#TK-OM?TW38Q)>WD5O&6VAI&P"?2ETSQ!I.L2O'IVH6]S(B[F6)\D#UH
MY96O8+K8L-I]NQRT:GZC-/CLX(^D2?\ ?(JQ5:>^@MU9I) JJ"6)Z #J:+R>
M@62'2VT<OWE!J'^S;7_GC'_WR*K6'B71M4E:*PU*WN9%7>5C?) ]:2]\3:1I
MKHM]?P6Q?.WS6QG'6FE/85X[FC';Q1CY(T'N%%,DLX93\Z*?J*@L]:T[4K9K
MBQO(;F%6VEXFR ?2JUSXJT.RN3;7>J6T$XQ^[=\'GIQ1:5PO$OI86\9R(8_^
M^15A5"#"@ >@ICSI&FYF&*R=1\5Z/I./MU]!!GH';D_A0E*6VH-J.IM9I:P]
M+\7Z!K,PAL=5MY9CTCW88_0'K6V*EQ<=&AII["T444AA1110 4444 -D;8A/
MI7GGCGQ/)I&ERS0D><Q\N$'^\>_X#)KOKL$V[8]*\4^*"2?9+-L'8L[!OJ5X
M_K77A8*4]3"O)J.A3\&>")/%T-SK.ISS/#YA1<-\TK=R3V S4VM_#+5K?489
M?#MO(\>W?N,H#1.#V)KK?AGK=E#X&AM_-C$\$L@E4L 1EB0?I@T'XJP/XA72
M=/TM[TR2K"DR2@!B>I QT'//M75*I6]I+E6B_(P4*7*KO5FW>7=W'I-HU^-E
MVL"FX /1POS?J*\0\/:7'XD\1R1W,C)'())W92 ?4?J:];\=79@TC49<\I"P
M'U/']:\N\'>"[SQ9]J-K=);+;;0S,"=Q;/''TJL/:--R;L36NYI+4I>)]+M=
M"U5(;&Z9\1B0G<-T;9]1WXS7OUMJ%P?"^FR71/VF2UC:3/7<5&:X_1/A!:6%
MVEYJ]]]L$;;Q J;48CIN)Y/TJ?QYXA_LW3)9(F FD_=0@=B1U_ 5G5FJTHPC
MK;J7!.FG)Z' >++^?Q-XJBTNV;?'$_E)Z%_XF_#^E7/A+<FR\>_9B<?:(983
M[E?F'_H)K!T/3O$,875=)M9"#N19L Y]<9_G3_#EQ/I/C[3I;M3',EZHF!XQ
MN.#_ .A5V3BO9RA'L<ZE[ZD?3)^[FO//'>H/;:'J3JV#Y)0?5N/ZUZ!.VV%C
M7C_Q-N]NB^5GF:X5?P&37DX6/--'?6=HLI_"2V\N/6;\ #:D<"GZY8_R%87Q
M$NGN?$44!.[RH0 /=CG_  KM/AY;_9? 1FQ\UU<N_P!0,*/Y&N$U%3J_Q%,"
M_,&O$B'T7 _H:]*F[UI2['')6IQCW-7X;:M)8:E>Z1*2HN5W*IXQ(G4?E_*L
MZ[7^V_B@D)^97OHXO^ KC/\ (T[Q0CZ%XW7485PKNMPH]\X8?Y]:L?#B!M3^
M(2W)!/EK-<GV)X'ZM5R22E575$J]U#S/1?''B=]'TR>>(YE)\N('IN/^&,UP
M7@SP7+XQ%WK&IW$KPK(4!S\TK]3SV R*T/BA')]@MFP=BW!W?BIQ70_"_6K.
M#P2+82H)X9Y/-0L 1DY!^F/Y5S*].AS0W;-G:56TMCE==^&.J07\,GAZWEDC
MV[B3* T;@\8)KVG1?MIT6R_M)0M[Y*"< Y^?'-<'-\5H%U\:3I^F-?,TJQ)*
MDH =CUQQT'/Y5VVHZ_IVCVKW.H7*6\*<%F]?3WKFKNK-1C-?YFU+DBVXLU:*
MH:3K%AKE@M[IURL]NQ*[U[$=0?0T5QO31FZ=]B_1110,**** &L PP:YW7/#
M%KK%K+;7$8>*3J.A!]1[UTE%5&3B[H32>YXX_P %Y#.?(UADB/9XLG'X'FNR
M\*?#S2O"S&YC9[J^*E?/E'W1WVCM788I:UGB:DU9LSC1A%W2.3\2>$O^$AL)
M;(W+6XD929%7<< YQBIO!GA"'P?87-M'=/<FXE\QG9 I'& .*Z:BH=63CR="
MN2/-S=2"YC,L14'FN#\1?#8^)KU)Y]4DMXXTVI&L8(![GKU->AT40J2AK$<H
MJ2LS$@\/V]CHUMIULH$5O&(UXZXZD^Y/-<=J7PGBU36Y-3&J2VSNZN$6('##
M'.<^U>F44XUIQO9DNG%[HAE0O!M)R<=:XKQ-\/AXG-NLE\]JD)9OE0-N)Q_A
M7=4M3"I*#O$J4%+1G-Z;X9CTG0;+2HI#*MLNW>PP6.222/J:Y[1OA;#I?B)-
M9?4I)Y%=Y/*,8 +-GO[9KT6BJ5:HKV>Y+IQ=KK8X+Q-\/HO$BPJUPUN\3EA(
MJY)!ZBIO!GP\M_"5]<W:WTET\\0BPR!=HSDUV])BFZ\^3DOH"I1YN;J<[K?A
MFVU>VEM[B,/%(,$?R(]Z\_?X+N9C]GUAHXCV>+)QZ<'FO8Z3%.&(G!6BQ2I1
MEJSC/"OPYTKPNYND9[J_VD">0 ; >NT=OK3/%?@=O$]E';_:VMFCE\Q7V[@>
M,8(KMZ*E5I\W-?4?LX\O+;0P?"GAJ#PKH::;#,TIWF225AC<Q]NW045O45G*
M3D[LN*459!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507601808864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Universe
Pharmaceuticals INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UPC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">21,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001809616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">265
Jingjiu Avenue,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Jinggangshan Economic and Technological Development Zone<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ji&#8217;an,
Jiangxi<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">343100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">YCM CPA, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">6781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Irvine, California<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">265
Jingjiu Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Jinggangshan Economic and Technological Development Zone<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ji&#8217;an,
Jiangxi Province<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">000000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Gang
Lai<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">gang.lai@universe-pharmacy.com<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">0796-8403309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507598583568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 5,711,458<span></span>
</td>
<td class="nump">$ 8,077,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">13,148,594<span></span>
</td>
<td class="nump">13,725,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">15,183,890<span></span>
</td>
<td class="nump">15,573,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">2,206,488<span></span>
</td>
<td class="nump">2,462,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Advance to suppliers</a></td>
<td class="nump">16,701<span></span>
</td>
<td class="nump">2,738,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Prepayment for advertising</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,492,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForAcquisitionCurrent', window );">Prepayment for acquisition</a></td>
<td class="nump">3,514,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,724,099<span></span>
</td>
<td class="nump">174,053<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">41,505,680<span></span>
</td>
<td class="nump">50,481,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">4,250,638<span></span>
</td>
<td class="nump">4,681,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent', window );">Prepayments made to a related party for purchase of property</a></td>
<td class="nump">2,249,248<span></span>
</td>
<td class="nump">2,476,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentsForConstructionInProgress', window );">Prepayments for construction in progress</a></td>
<td class="nump">9,326,296<span></span>
</td>
<td class="nump">10,712,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">157,451<span></span>
</td>
<td class="nump">178,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_InvestmentInEquitySecurities', window );">Investment in equity securities</a></td>
<td class="nump">702,890<span></span>
</td>
<td class="nump">744,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">1,347,672<span></span>
</td>
<td class="nump">869,997<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NONCURRENT ASSETS</a></td>
<td class="nump">18,034,195<span></span>
</td>
<td class="nump">19,663,717<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">59,539,875<span></span>
</td>
<td class="nump">70,144,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short-term bank loans</a></td>
<td class="nump">3,936,184<span></span>
</td>
<td class="nump">4,334,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,075,393<span></span>
</td>
<td class="nump">5,310,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">167,350<span></span>
</td>
<td class="nump">1,101,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">3,379,263<span></span>
</td>
<td class="nump">19,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,539,362<span></span>
</td>
<td class="nump">444,319<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">13,097,552<span></span>
</td>
<td class="nump">11,210,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares issued and outstanding as of September 30, 2022 and 2021</a></td>
<td class="nump">67,969<span></span>
</td>
<td class="nump">67,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">29,279,159<span></span>
</td>
<td class="nump">29,279,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_StatutoryReserve', window );">Statutory reserve</a></td>
<td class="nump">2,439,535<span></span>
</td>
<td class="nump">2,439,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">16,322,365<span></span>
</td>
<td class="nump">25,058,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(1,666,705)<span></span>
</td>
<td class="nump">2,088,759<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">46,442,323<span></span>
</td>
<td class="nump">58,934,353<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 59,539,875<span></span>
</td>
<td class="nump">$ 70,144,781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_InvestmentInEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment In Equity Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_InvestmentInEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForAcquisitionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prepayment for acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForAcquisitionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentsForConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments for construction in progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentsForConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayments made to a related party for purchase of property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>StatutoryReserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507601553600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507598666896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 40,143,151<span></span>
</td>
<td class="nump">$ 47,982,031<span></span>
</td>
<td class="nump">$ 30,703,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="num">(18,251,815)<span></span>
</td>
<td class="num">(22,655,854)<span></span>
</td>
<td class="num">(16,610,140)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">21,891,336<span></span>
</td>
<td class="nump">25,326,177<span></span>
</td>
<td class="nump">14,093,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="num">(19,083,135)<span></span>
</td>
<td class="num">(2,973,531)<span></span>
</td>
<td class="num">(1,555,546)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(2,602,624)<span></span>
</td>
<td class="num">(3,296,844)<span></span>
</td>
<td class="num">(1,703,424)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(7,644,375)<span></span>
</td>
<td class="num">(5,465,662)<span></span>
</td>
<td class="num">(583,125)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(29,330,134)<span></span>
</td>
<td class="num">(11,736,037)<span></span>
</td>
<td class="num">(3,842,095)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_IncomeFromOperation', window );">Income from operations</a></td>
<td class="num">(7,438,798)<span></span>
</td>
<td class="nump">13,590,140<span></span>
</td>
<td class="nump">10,251,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OtherIncomeExpensesAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(162,400)<span></span>
</td>
<td class="num">(101,604)<span></span>
</td>
<td class="num">(123,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (expenses), net</a></td>
<td class="nump">48,940<span></span>
</td>
<td class="num">(80,434)<span></span>
</td>
<td class="num">(49,352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShorttermInvestmentIncome', window );">Short-term investments (loss) income</a></td>
<td class="num">(470,477)<span></span>
</td>
<td class="nump">239,549<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income</a></td>
<td class="nump">38,588<span></span>
</td>
<td class="nump">30,827<span></span>
</td>
<td class="nump">21,820<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(545,349)<span></span>
</td>
<td class="nump">88,338<span></span>
</td>
<td class="num">(151,292)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income tax provision</a></td>
<td class="num">(7,984,147)<span></span>
</td>
<td class="nump">13,678,478<span></span>
</td>
<td class="nump">10,100,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(752,419)<span></span>
</td>
<td class="num">(2,358,526)<span></span>
</td>
<td class="num">(2,542,211)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(8,736,566)<span></span>
</td>
<td class="nump">11,319,952<span></span>
</td>
<td class="nump">7,558,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OtherComprehensiveIncomeLossAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(3,755,464)<span></span>
</td>
<td class="nump">1,193,369<span></span>
</td>
<td class="nump">860,623<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (12,492,030)<span></span>
</td>
<td class="nump">$ 12,513,321<span></span>
</td>
<td class="nump">$ 8,418,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share Basic (in Dollars per share)</a></td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding Basic (in Shares)</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">18,980,822<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_IncomeFromOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_IncomeFromOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OtherComprehensiveIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OtherComprehensiveIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OtherIncomeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OtherIncomeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShorttermInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShorttermInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599319872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share diluted</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding diluted</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">18,980,822<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507600806352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Statutory reserve</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 3,679,000<span></span>
</td>
<td class="nump">$ 2,439,535<span></span>
</td>
<td class="nump">$ 6,180,757<span></span>
</td>
<td class="nump">$ 34,767<span></span>
</td>
<td class="nump">$ 12,384,059<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2019</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,558,222<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,558,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">860,623<span></span>
</td>
<td class="nump">860,623<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">3,679,000<span></span>
</td>
<td class="nump">2,439,535<span></span>
</td>
<td class="nump">13,738,979<span></span>
</td>
<td class="nump">895,390<span></span>
</td>
<td class="nump">20,802,904<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2020</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross</a></td>
<td class="nump">$ 17,969<span></span>
</td>
<td class="nump">28,732,031<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross (in Shares)</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts', window );">Capitalized initial public offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,131,872)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,131,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,319,952<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,319,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,193,369<span></span>
</td>
<td class="nump">1,193,369<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 67,969<span></span>
</td>
<td class="nump">29,279,159<span></span>
</td>
<td class="nump">2,439,535<span></span>
</td>
<td class="nump">25,058,931<span></span>
</td>
<td class="nump">2,088,759<span></span>
</td>
<td class="nump">$ 58,934,353<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2021</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,736,566)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (8,736,566)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,755,464)<span></span>
</td>
<td class="num">(3,755,464)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 67,969<span></span>
</td>
<td class="nump">$ 29,279,159<span></span>
</td>
<td class="nump">$ 2,439,535<span></span>
</td>
<td class="nump">$ 16,322,365<span></span>
</td>
<td class="num">$ (1,666,705)<span></span>
</td>
<td class="nump">$ 46,442,323<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2022</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Capitalized initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507600690384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (8,736,566)<span></span>
</td>
<td class="nump">$ 11,319,952<span></span>
</td>
<td class="nump">$ 7,558,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">533,949<span></span>
</td>
<td class="nump">446,878<span></span>
</td>
<td class="nump">410,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Loss from disposal of fixed assets</a></td>
<td class="nump">983<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">419,353<span></span>
</td>
<td class="num">(230,175)<span></span>
</td>
<td class="nump">98,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Inventory reserve</a></td>
<td class="nump">15,774<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(75,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="num">(605,278)<span></span>
</td>
<td class="num">(668,341)<span></span>
</td>
<td class="num">(9,886)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShorttermInvestmentsIncome', window );">Short-term investments income</a></td>
<td class="nump">470,477<span></span>
</td>
<td class="num">(239,549)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,549,312)<span></span>
</td>
<td class="num">(3,867,457)<span></span>
</td>
<td class="num">(4,107,520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="nump">16,586<span></span>
</td>
<td class="num">(451,634)<span></span>
</td>
<td class="nump">888,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidSupplies', window );">Advance to suppliers, net</a></td>
<td class="nump">2,681,214<span></span>
</td>
<td class="num">(2,717,085)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidAdvertising', window );">Prepayment for advertising</a></td>
<td class="nump">7,385,695<span></span>
</td>
<td class="num">(7,434,240)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Advances to related parties</a></td>
<td class="nump">236,982<span></span>
</td>
<td class="num">(237,720)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,699,929)<span></span>
</td>
<td class="num">(168,188)<span></span>
</td>
<td class="nump">12,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,896,621)<span></span>
</td>
<td class="nump">2,457,337<span></span>
</td>
<td class="nump">639,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable', window );">Taxes payable</a></td>
<td class="num">(904,127)<span></span>
</td>
<td class="num">(298,620)<span></span>
</td>
<td class="nump">731,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,318,474<span></span>
</td>
<td class="nump">31,436<span></span>
</td>
<td class="num">(30,408)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(1,312,346)<span></span>
</td>
<td class="num">(2,055,847)<span></span>
</td>
<td class="nump">6,115,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(93,703)<span></span>
</td>
<td class="num">(444,505)<span></span>
</td>
<td class="num">(51,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposal of fixed assets</a></td>
<td class="nump">523<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty', window );">Prepayments made to a related party for purchase of property</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,457,600)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfAdvancesForConstruction', window );">Prepayments for construction in progress</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(10,629,120)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Prepayment for acquisition</a></td>
<td class="num">(3,814,925)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromShortTermInvestments', window );">Payments for short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(15,330,660)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_RedemptionOfShorttermInvestments', window );">Redemption of short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,801,927<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(3,908,105)<span></span>
</td>
<td class="num">(27,059,958)<span></span>
</td>
<td class="num">(51,798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term bank loans</a></td>
<td class="nump">4,272,716<span></span>
</td>
<td class="nump">4,300,800<span></span>
</td>
<td class="nump">1,427,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Repayment of bank loans</a></td>
<td class="num">(4,272,716)<span></span>
</td>
<td class="num">(2,764,800)<span></span>
</td>
<td class="num">(1,427,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividend payment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from initial public offerings</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">28,750,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payment for deferred initial public offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,792,543)<span></span>
</td>
<td class="num">(441,064)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings', window );">Proceeds from (prepayments for) related parties borrowings</a></td>
<td class="nump">3,317,943<span></span>
</td>
<td class="num">(911,648)<span></span>
</td>
<td class="nump">911,200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,317,943<span></span>
</td>
<td class="nump">26,581,809<span></span>
</td>
<td class="nump">470,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(463,942)<span></span>
</td>
<td class="nump">553,702<span></span>
</td>
<td class="nump">347,386<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash</a></td>
<td class="num">(2,366,450)<span></span>
</td>
<td class="num">(1,980,294)<span></span>
</td>
<td class="nump">6,880,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of year</a></td>
<td class="nump">8,077,908<span></span>
</td>
<td class="nump">10,058,202<span></span>
</td>
<td class="nump">3,177,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of year</a></td>
<td class="nump">5,711,458<span></span>
</td>
<td class="nump">8,077,908<span></span>
</td>
<td class="nump">10,058,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">199,852<span></span>
</td>
<td class="nump">149,303<span></span>
</td>
<td class="nump">157,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income tax</a></td>
<td class="nump">$ 2,748,629<span></span>
</td>
<td class="nump">$ 3,271,219<span></span>
</td>
<td class="nump">$ 2,167,963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prepayments made to a related party for purchase of property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from (prepayments for) related parties borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_RedemptionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption of short-term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_RedemptionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShorttermInvestmentsIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investments income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShorttermInvestmentsIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidAdvertising">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for advertising that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidAdvertising</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e99989-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfAdvancesForConstruction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payments made by the entity, generally on a straight-line basis over periods ranging from five to forty years to developers, builders, government agencies and municipalities for borrowings received in construction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfAdvancesForConstruction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507607972080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BUSINESS DESCRIPTION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 &#8212; ORGANIZATION AND BUSINESS DESCRIPTION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">Universe Pharmaceuticals Inc. (&#8220;Universe
INC&#8221; or the &#8220;Company&#8221;) was incorporated under the laws of the Cayman Islands on December 11, 2019 as an exempted company
with limited liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Universe INC. owns 100% equity interest of Universe
Pharmaceuticals (International) Group (&#8220;Universe HK&#8221;), an entity incorporated on May 21, 2014 in accordance with the laws
and regulations in Hong Kong.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jiangxi Universe Pharmaceuticals Technology Co.,
Ltd. (&#8220;Universe Technology&#8221;) was formed on April 8, 2019, as a Wholly Foreign-Owned Enterprise (&#8220;WFOE&#8221;) in the
People&#8217;s Republic of China (&#8220;PRC&#8221; or &#8220;China&#8221;). The registered capital of Universe Technology is approximately
$4.3 million (RMB30.5 million). In December 2019, the Company made a capital contribution of $500,000 to Universe Technology. Pursuant
to the article of incorporation of Universe Technology, the remaining capital contribution of approximately $3.8 million for Universe
Technology is required to be completed before 2038.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">Universe INC, Universe HK and Universe
Technology are currently not engaging in any active business operations and are merely acting as holding companies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jiangxi Universe Pharmaceuticals Co., Ltd. (&#8220;Jiangxi
Universe&#8221;) was incorporated on March 2, 1998 in accordance with PRC laws and is engaged in research and development and manufacturing
of modernized traditional Chinese medicines. Jiangxi Universe owns 100% of the equity interests of Jiangxi Universe Pharmaceuticals Commercial
Trade Co., Ltd. (&#8220;Universe Trade&#8221;), which was incorporated on March 10, 2010 to handle the sales and distribution of the pharmaceutical
products manufactured by Jiangxi Universe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Reorganization</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reorganization of the Company&#8217;s legal
structure (&#8220;Reorganization&#8221;) was completed on December 11, 2019. The Reorganization involved the incorporation of Universe
INC and Universe Technology, and the transfer of 100% of the equity interests of Jiangxi Universe to Universe Technology. Consequently,
Universe INC, through its subsidiary Universe HK, directly controls Universe Technology and Jiangxi Universe, and became the ultimate
holding company of all other entities mentioned above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Reorganization has been accounted for as a
recapitalization among entities under common control, since the same controlling shareholders controlled all these entities before and
after the Reorganization. The consolidation of the Company and its subsidiaries has been accounted for at historical cost and prepared
on the basis as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying
consolidated financial statements. Results of operations for the periods presented comprise those of the previously separate entities
combined from the beginning of the period to the end of the period, eliminating the effects of intra-entity transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2021, the Company closed its initial
public offering (the &#8220;IPO&#8221;) of 5,000,000 ordinary shares, par value $0.003125 per share (the &#8220;ordinary shares&#8221;)
at a public offering price of $5.00 per share. On March 29, 2021, the underwriter exercised in full its over-allotment option to purchase
an additional 750,000 ordinary shares. The closing for the sale of the over-allotment shares took place on March 31, 2021. Gross proceeds
from the IPO totaled $28.75 million. Net proceeds of the IPO, including over-allotment shares, were approximately $25.6 million. In connection
with the IPO, the Company&#8217;s ordinary shares began trading on the Nasdaq Global Market under the symbol &#8220;UPC&#8221; on March
23, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 12, 2021, through the Company&#8217;s PRC
subsidiary, Jiangxi Universe, the Company established a wholly controlled subsidiary, Guangzhou Universe Hanhe Medical Research Co., Ltd.
(&#8220;Universe Hanhe&#8221;) in Guangzhou City, China, for the business purpose of conducting research and development of new pharmaceutical
products in order to diversify the Company&#8217;s product offerings in the near future. As of September 30, 2022 and as of the date of
this report, Universe Hanhe has no active business operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details of the subsidiaries of the Company as of September 30, 2022
are set out below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Date of</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Place of</td><td style="font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">% of</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; font-weight: bold; vertical-align: top">Name of Entity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Incorporation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Incorporation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ownership</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal Activities</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Universe INC</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">December 11, 2019</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">Cayman Islands</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">Parent, 100%</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">Investment holding</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 20%; text-align: left">Universe HK</td><td style="text-align: center; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">May 21, 2014</td><td style="text-align: center; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">Hong Kong</td><td style="text-align: center; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">100%</td><td style="text-align: center; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 28%; text-align: center">Investment holding</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Universe Technology</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">April 18, 2019</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PRC</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">100%</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">WFOE, Investment holding</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Jiangxi Universe</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">March 2, 1998</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PRC</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">100%</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">Research and development and manufacturing of modernized traditional Chinese medicines</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Universe Trade</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">March 10, 2010</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PRC</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">100%</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">Sales of modernized traditional Chinese medicines</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Universe Hanhe</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">May 12, 2021</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PRC</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">100%</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">Research and development of new pharmaceutical products</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, through its wholly-owned subsidiaries,
is primarily engaged in the development, manufacturing and sale of traditional Chinese medicines derivatives (&#8220;TCMD&#8221;) products
targeted to the elderly to address their physical conditions in the aging process and to promote their general well-being. In addition,
the Company also sells biochemical drugs, medical instruments, traditional Chinese medicine pieces products and dietary supplements (collectively
&#8220;third-party products&#8221;). All of these TCMD and third-party products are currently sold to customers including pharmaceutical
companies, hospitals, clinics and drugstore chains throughout China.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599924096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis of consolidation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the financial statements of Universe INC, Universe HK, Universe Technology, Jiangxi Universe, Universe Trade and Universe Hanhe.
All inter-company balances and transactions are eliminated upon consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Uses of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing the consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;), management makes
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates
are based on information as of the date of the consolidated financial statements. Significant estimates required to be made by management
include, but are not limited to, the allowance for estimated uncollectible receivables, the realizability of advance to suppliers, inventory
valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of long-lived assets, provision necessary
for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The main operation of the Company is located in
the PRC. Accordingly, the Company&#8217;s business, financial condition, and results of operations may be influenced by political, economic,
and legal environments in the PRC, as well as by the general state of the PRC economy. The Company&#8217;s results may be adversely affected
by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations
and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1,
this may not be indicative of future results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of new pharmaceutical
products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant competition
and a strong emphasis on intellectual property. The Company may face competition with respect to its current and future pharmaceutical
product candidates from major pharmaceutical companies in China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&#8217;s operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operations may be further
affected by the ongoing COVID-19 pandemic. Due to the resurgence of COVID-19 pandemic in China in 2022, there had been delays in purchase
of raw material supplies and deliver products to the customers of the PRC operating entities on a timely basis as a consequence of the
travel restrictions. The prices of the raw materials also increased by about 5% from January 2022 to May 2022 as compared to the same
period last year. In addition, the Company has granted some of its customers extended payment terms of 30 days to 120 days since January
2022, as a result of the COVID-19 pandemic. However, based on the present relationship with these customers and the evaluation of their
financial health, the Company does not anticipate any material collectability problems. Even though the Company does not expect that the
COVID-19 pandemic will have a negative impact on the business operations of the PRC operating entities and the financial results, due
to the high uncertainty of the evolving situation, the Company has limited visibility on how the COVID-19 pandemic affects the execution
of customer contracts, the collection of customer payments, or disrupt our supply chain, and the continued uncertainties associated with
COVID-19 may cause the revenue and cash flows to underperform in the next 12 months from the date the consolidated financial statements
are released. The extent of the future impact of the COVID-19 pandemic on the business and results of operations is still uncertain. Any
resurgence of the COVID-19 pandemic could negatively affect the execution of customer contracts, the collection of customer payments,
or disrupt the Company&#8217;s supply chain, and the continued uncertainties associated with COVID-19 may negatively impact the Company&#8217;s
revenue and cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash includes currency on hand and deposits held
by banks that can be added or withdrawn without limitation. The Company maintains most of its bank accounts in the PRC. Cash balances
in bank accounts in the PRC are not insured by the Federal Deposit Insurance Corporation or other programs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Accounts receivable, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are presented net of allowance
for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts based on individual account analysis and
historical collection trends. The Company establishes a provision for doubtful receivables when there is objective evidence that the Company
may not be able to collect amounts due. The allowance is based on management&#8217;s best estimate of specific losses on individual exposures,
as well as a provision on historical trends of collections. Actual amounts received may differ from management&#8217;s estimate of credit
worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful accounts after
management has determined that collection is not probable. Allowance for uncollectable balances amounted to $ $791,827 and $446,527 as
of September 30, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Inventories, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at net realizable value
using weighted average method. Costs include the cost of raw materials, freight, direct labor and related production overhead. Any excess
of the cost over the net realizable value of each item of inventories is recognized as a provision for diminution in the value of inventories.
Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. The
Company evaluates inventories on a quarterly basis for its net realizable value adjustments, and reduces the carrying value of those inventories
that are obsolete or in excess of the forecasted usage to their estimated net realizable value based on various factors including aging,
expiration dates, as applicable, taking into consideration historical and expected future product sales. The Company recorded inventory
reserve of $120,286 and $116,453 as of September 30, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Advances to suppliers, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -0.4pt">Advances to suppliers
represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices for raw materials. These advances
are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time to make
cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company when
the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific allowances
when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September 30, 2022
and 2021, no allowance for doubtful accounts was deemed necessary, as the Company believes that all advances to suppliers are fully realizable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -0.4pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Deferred initial public offering (&#8220;IPO&#8221;) costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company complies with the requirement of the
ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses of Offering&#8221;. Deferred offering
costs consist of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related
to the intended IPO. Deferred offering costs were charged to shareholders&#8217; equity upon the completion of the IPO on March 25, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Short-term investments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s short-term investments consist
of wealth management financial products purchased from a financial institution, which can be redeemed anytime. The financial institution
invests the Company&#8217;s fund in certain financial instruments including money market funds and bonds to generate investment income.
The short-term investments are deemed to be trading securities and are measured subsequently at fair value in the statement of financial
position. Unrealized holding gains and losses for investment are included in the consolidated statements of operations and comprehensive
income over the investment period (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair value of financial instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize
the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Level 1&#8201;&#8212;&#8201;inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities
in active markets.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Level 2&#8201;&#8212;&#8201;inputs to the valuation methodology include quoted prices for similar assets
and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than
quoted prices that are observable and inputs derived from or corroborated by observable market data.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Level 3&#8201;&#8212;&#8201;inputs to the valuation methodology are unobservable.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise disclosed, the fair value of
the Company&#8217;s financial instruments, including cash, accounts receivable, inventories, short-term investments, advances to suppliers,
prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current liabilities, taxes
payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September 30, 2022 and 2021
based upon the short-term nature of the assets and liabilities. The Company&#8217;s investment in equity securities is accounted for using
the measurement alternative in accordance with ASC 321, which also approximate its recorded value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Property, plant and equipment</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property, plant and equipment are stated at cost
less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is provided using the straight-line
method over their expected useful lives, as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">20 years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5&#8211;10 years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Automobiles</td><td>&#160;</td>
    <td style="text-align: center">3&#8211;5 years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office and electric equipment</td><td>&#160;</td>
    <td style="text-align: center">3&#8211;5 years</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenditures for maintenance and repairs, which
do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments
which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired
or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated statements of income and other
comprehensive income in other income or expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews the carrying value of property,
plant, and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable
from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future
cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the
fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and
prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors.
Based on this assessment, no impairment expenses for property, plant, and equipment were recorded in operating expenses for the years
ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Intangible Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets consist primarily of land use
rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot be sold to an individual or company.
The government grants individuals and companies the right to use parcels of land for specified periods of time. Land use rights are stated
at cost less accumulated amortization. Intangible assets are amortized using the straight-line method with the following estimated useful
lives:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Land use rights</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">50 years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Software</td><td>&#160;</td>
    <td style="text-align: center">3 years</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews the carrying value of land
use rights for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the
estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash
flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair
value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects,
the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this
assessment, no impairment of land use rights was deemed necessary for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Construction-in-Progress (&#8220;CIP&#8221;)</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CIP represents property and buildings under construction
and consists of construction expenditures, equipment procurement, and other direct costs attributable to the construction. CIP is not
depreciated. Upon completion and ready for intended use, CIP is reclassified to the appropriate category within property, plant and equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Impairment of long-lived Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets with finite lives, primarily
property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash flows from the use of the asset and its
eventual disposition below are the asset&#8217;s carrying value, then the asset is deemed to be impaired and written down to its fair
value. There were no impairments of these assets as of September 30, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Investments in Equity Securities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its equity investments
in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 321 &#8220;Investments&#8212;Equity Securities&#8221; (&#8220;ASC
321&#8221;). In accordance with ASC 321, equity investment which the Company has no significant influence (generally less than a 20% ownership
interest) with readily determinable fair values are accounted for at fair value based on quoted market prices with the changes in fair
value recognized as unrealized gains or losses in earnings. Equity investments without readily determinable fair values are accounted
for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured
at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical
or a similar investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From March 2009 to September 2017, the Company
invested approximately $0.7 million (RMB5 million) in Jiangxi Jian Rural Commercial Bank (&#8220;JX RCB Bank&#8221;) in exchange for 5%
ownership interest in the bank. The purpose of entering into these equity investment agreements with JX RCB Bank was to earn investment
income as the bank continues to grow. The Company determined that this investment in equity securities does not have a readily determinable
fair value and, accordingly, elected the measurement alternative noted above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company initially recorded the investments
at historical cost and subsequently records any dividends received from the net accumulated earnings of the investee as income. As of
September 30, 2022 and 2021, this investment amounted to $702,890 (RMB 5 million) and $744,924 (RMB 5 million), respectively, and was
reported as long-term investment in equity investee on the consolidated balance sheets. Investment income amounted to $38,588, $30,827
and $21,820 for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The investments in equity securities are evaluated
for impairment when facts or circumstances indicate that the fair value of the investment is less than its carrying value. An impairment
is recognized when a decline in fair value is determined to be other-than-temporary. The Company reviews several factors to determine
whether a loss is other-than-temporary. These factors include, but are not limited to, the: (i) nature of the investment; (ii) cause and
duration of the impairment; (iii) extent to which fair value is less than cost; (iv) financial condition and near-term prospects of the
investments; and (v) ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in fair value.
There was no impairment for the Company&#8217;s investments in equity securities as of September 30, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To determine revenue recognition for contracts
with customers, the Company performs the following five steps : (i) identify the contract(s) with the customer, (ii) identify the performance
obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable
that a significant future reversal will <i>not</i> occur, (iv) allocate the transaction price to the respective performance obligations
in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue when it transfers
its goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange.
The Company accounts for the revenue generated from sales of its TCMD and third-party products on a gross basis, as the Company is acting
as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling
the promise to provide customers the specified goods, which the Company has control of the goods and has the ability to direct the use
of goods to obtain substantially all the benefits. All of the Company&#8217;s contracts have one single performance obligation, namely,
the promise is to transfer the individual goods to customers, and there is no separately identifiable other promise in the contracts.
The Company&#8217;s revenue streams are recognized at a point in time when title and risk of loss passes and the customer accepts the
goods, which generally occurs at delivery. The Company&#8217;s products are sold with no right of return and the Company does not provide
other credits or sales incentive to customers. Revenue is reported net of all value added taxes (&#8220;VAT&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contract Assets and Liabilities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment terms are established on the Company&#8217;s
pre-established credit requirements based upon an evaluation of customers&#8217; credit quality. Contract assets are recognized for in
related accounts receivable. Contract liabilities are recognized for contracts where payment has been received in advance of delivery.
The contract liability balance can vary significantly depending on the timing when an order is placed and when shipment or delivery occurs.
As of September 30, 2022 and 2021, the Company did not have contract assets and contract liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Disaggregation of Revenues</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disaggregates its revenue from contracts
by product types, as the Company believes it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows
are affected by economic factors. The Company&#8217;s disaggregation of revenues for the years ended September 30, 2022, 2021 and 2020
are disclosed in Note 19 of these consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of revenue</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenue consists primarily of the costs
of raw materials, freight charges, direct labor, depreciation of plants and machinery, warehousing and overhead associated with the manufacturing
process.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and development expenses</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expenses all internal research and
development costs as incurred, which primarily comprise employee costs, internal and external costs related to execution of studies, including
manufacturing costs, facility costs of the research center, and amortization and depreciation to intangible assets and property, plant
and equipment used in the research and development activities. For the years ended September 30, 2022, 2021 and 2020, total research and
development expense were approximately $7,644,375, $5,465,662 and $583,125, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Shipping and handling costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shipping and handling costs are expensed as incurred.
Inbound shipping and handling cost associated with bringing the purchased raw materials and third-party products from suppliers to the
Company&#8217;s warehouse are included in cost of revenue. Outbound shipping and handling costs associated with shipping and delivery
the products to customers are included in selling expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Advertising expense</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising expenses primarily relate to promotion
of the Company&#8217;s brand name and products through outdoor billboards, social media such as Weibo and WeChat, and TV advertisement.
Advertising costs are expensed as incurred or deferred and then expensed the first time the advertising takes place. Advertising expenses
are included in selling expenses in the consolidated statements of income and comprehensive income. Advertising expenses amounted to $17,527,318,
$1,316,654 and $343,962 for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Segment Reporting</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the management approach in determining
reportable operating segments. The management approach considers the internal reporting used by the Company&#8217;s chief operating decision
maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining
the Company&#8217;s reportable operating segments. Management has determined that the Company has one operating segment (See Note 19).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Income taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for current income taxes
in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between
the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected
to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the
period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount
expected to be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An uncertain tax position is recognized only if
it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination. The amount recognized is the largest
amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more
likely than not&#8221; test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified
as income tax expense in the period incurred. No significant penalties or interest relating to income taxes have been incurred during
the years ended September 30, 2022, 2021 and 2020. The Company does not believe there was any uncertain tax provision at September 30,
2022 and September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operating subsidiary in China
is subject to the income tax laws of the PRC. No significant income was generated outside the PRC for the years ended September 30, 2022,
2021 and 2020. As of September 30, 2022, all of the tax returns of the Company&#8217;s PRC subsidiaries remain open for statutory examination
by PRC tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Value added tax (&#8220;VAT&#8221;)</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales revenue represents the invoiced value of
goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to 17% (starting from May 1, 2018, VAT rate was lowered
to 16%, and starting from April 1, 2019, VAT rate was further lowered to 13%), depending on the type of products sold. The VAT may be
offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products.
The Company recorded a VAT payable or receivable net of payments in the accompanying consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Earnings per Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes earnings per share (&#8220;EPS&#8221;)
in accordance with ASC 260, &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;). ASC 260 requires companies with complex capital
structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common shares outstanding
for the period. Diluted presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options
and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares
that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation
of diluted EPS. For the years ended September 30, 2022, 2021 and 2020, there were no dilutive shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Foreign currency translation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The functional currency for Universe INC is the
U.S Dollar (&#8220;US$&#8221;). Universe HK uses Hong Kong dollar as its functional currency. However, Universe INC and Universe HK currently
only serve as holding companies and did not have active operations as of the date of this report. The Company operates only in the PRC
and the Company&#8217;s functional currency is the Chinese Yuan (&#8220;RMB&#8221;). The Company&#8217;s consolidated financial statements
have been translated into the reporting currency US$.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities of the Company are translated
at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated
at the average rate of exchange during the reporting period. The resulting translation adjustments are reported under other comprehensive
income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the results of
operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The RMB is not freely convertible into foreign
currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB
amounts could have been, or could be, converted into US$ at the rates used in translation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table outlines the currency exchange
rates that were used in creating the consolidated financial statements in this report:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>September&#160;30, <br/>
2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>September&#160;30, <br/>
2021</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>September&#160;30, <br/>
2020</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Year-end spot rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">US$1=RMB7.1135</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">US$1=RMB6.4580</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">US$1=RMB6.8033</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">US$1=RMB6.5532</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">US$1=RMB6.5095</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">US$1=RMB7.0077</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Comprehensive income</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comprehensive income consists of two components,
net income and other comprehensive income. The foreign currency translation gain resulting from translation of the financial statements
expressed in RMB to US$ is reported in other comprehensive income in the consolidated statements of income and comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Statement of Cash Flows</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 230, &#8220;Statement of
Cash Flows&#8221;, cash flows from the Company&#8217;s operations are formulated based upon the local currencies. As a result, amounts
related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding
balances on the balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Employee Defined Contribution Plan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiaries in the PRC participate
in a government-mandated multi-employer defined contribution plan pursuant to which pension, work-related injury benefits, maternity insurance,
medical insurance, unemployment benefit and housing fund are provided to eligible full-time employees. The relevant labor regulations
require the Company&#8217;s subsidiaries in the PRC to pay the local labor and social welfare authorities monthly contributions based
on the applicable benchmarks and rates stipulated by the local government. The contributions to the plan are expensed as incurred. Employee
social security and welfare benefits included as expenses in the accompanying statements of income and comprehensive income amounted to
$465,689, $617,145 and $347,312 for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU 2016-13, Financial
Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the
reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing
incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. ASU 2016-13
was subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2020-02. For public entities, ASU 2016-13 and its
amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. For all other
entities, this guidance and its amendments will be effective for fiscal years beginning after December 15, 2022, including interim periods
within those fiscal years. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2018. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2020, the FASB issued ASU 2020-10,
&#8220;Codification Improvements to Subtopic 205-10, presentation of financial statements&#8221;. The amendments in this Update improve
the codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to
financial statements is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement
would be missed. ASU 2020-10 is effective for the Company for annual and interim reporting periods beginning January 1, 2022. Early application
of the amendments is permitted for any annual or interim period for which financial statements are available to be issued. The amendments
in this Update should be applied retrospectively. An entity should apply the amendments at the beginning of the period that includes the
adoption date. The Company is currently evaluating the impact of this new standard on Company&#8217;s consolidated financial statements
and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599924096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">ACCOUNTS RECEIVABLE, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8212; ACCOUNTS RECEIVABLE, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,975,717</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,020,269</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(791,827</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(446,527</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Accounts receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,183,890</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,573,742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s accounts receivable primarily
includes the balance due from customers when the Company&#8217;s pharmaceutical products are sold and delivered to customers. All of the
Company&#8217;s accounts receivable balance at September 30, 2021 has been collected in the fiscal year 2022. As of date of this report,
approximately 71.9%, or $10.9 million, of the Company&#8217;s net account receivable balance at September 30, 2022 has been subsequently
collected and the remaining balance is expected to be substantially collected before March 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the Company&#8217;s accounts receivable
and subsequent collection by aging bucket:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Accounts Receivable by aging bucket</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance as of September 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Subsequent collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of subsequent collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Less than 3 months</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,673,685</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,135,508</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">62.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>From 4 to 6 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,970,635</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,360,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>From 7 to 9 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,554,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,089,957</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>From 10 to 12 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">285,871</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">180,564</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Over 1 year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">491,208</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">152,711</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total gross accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,975,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,918,976</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(791,827</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Accounts Receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,183,890</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,918,976</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">71.9</td><td style="padding-bottom: 2pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Allowance for doubtful accounts movement is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Beginning balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">446,527</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">639,991</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">419,353</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debt recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(225,660</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(74,053</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,196</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">791,827</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">446,527</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599958384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 4 &#8212; INVENTORY, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">989,043</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">607,661</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,337,731</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,971,334</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Inventory valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(120,286</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(116,453</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total inventory, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,206,488</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,462,542</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507607974560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advance to Suppliers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AdvancesToSuppliersAbstract', window );"><strong>Advances To Suppliers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AdvancesToSuppliersTextBlock', window );">ADVANCE TO SUPPLIERS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8212; ADVANCE TO SUPPLIERS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advances to suppliers consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advances to suppliers for inventory raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,701</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,738,313</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Advances to suppliers, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,701</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,738,313</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advances to suppliers represent prepayments made
to suppliers to ensure continuous high-quality supplies and favorable purchase prices for raw materials.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancesToSuppliersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancesToSuppliersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancesToSuppliersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the advances to suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancesToSuppliersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507607992448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Advertisting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForAdvertistingAbstract', window );"><strong>Prepayment for Advertisting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForAdvertistingTextBlock', window );">PREPAYMENT FOR ADVERTISTING</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 &#8212; PREPAYMENT FOR ADVERTISTING</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 6, 2021, the Company entered into
an advertising service agreement with a third-party, Guangdong Fengyang Legend Consulting Co., Ltd. (&#8220;Fengyang Legend&#8221;), pursuant
to which, Fengyang Legend assisted the Company in developing and producing TV advertising films for the Company in order to promote the
Company&#8217;s sales of its major TCMD product, Bainian Pill and Guben Yanling Pill, and coordinating the specific TV Channel to broadcast
the advertising films to targeted geographic market areas. The total contracted advertising service fee was RMB55 million (approximately
$8.5 million), with an adverting consulting service period of one year from October 1, 2021 to September 30, 2022. Based on contract terms,
the Company was required to make a 30% advance payment to Fengyang Legend within 7 business days upon signing the service agreement and
make an additional 58% of the contract price to Fengyang Legend when the specific TV channel used for broadcast the TV film was determined.
In fiscal year 2021, the Company paid RMB48.4 million (approximately $7.5 million), the amount was recorded as prepayment for advertising
on the balance sheets as of September 30, 2021, and recognized as selling expense during fiscal year 2022. The remaining 12% of the contract
price, RMB6.6 million (approximately $0.9 million), represented the monthly advertising fees payable when the advertising film was broadcasted
through the designated TV channels during the service period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForAdvertistingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForAdvertistingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForAdvertistingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForAdvertistingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507608102448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforAcquisitionLineItems', window );"><strong>Prepayment for Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForAcquisitionTextBlock', window );">PREPAYMENT FOR ACQUISITION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 &#8212; PREPAYMENT FOR ACQUISITION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2022, the Company entered into
a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to which, Mr. Xibo Liu transfers his 51% ownership
in Yunnan Faxi Pharmaceuticals Co., Ltd. (&#8220;Yunnan Faxi&#8221;) to the Company at the price of RMB72 million (approximately $10.1
million). Based on contract terms, the Company prepaid RMB25 million (approximately $3.5 million) within 3 business days upon signing
the letter of intent. As of September 30, 2022, the prepayment was recorded as prepayment for acquisition on the balance sheets. The intended
acquisition is expected to be completed and the remaining balance is expected to be paid in June 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentforAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentforAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599964560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-Term Invstment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_HeldToMaturityInvestmentDisclosureTextBlock', window );">SHORT-TERM INVESTMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 &#8212; SHORT-TERM INVESTMENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s short-term investments consist
of wealth management financial products purchased from financial institution, which can be redeemed anytime at the Company&#8217;s discretion.
The financial institution invests the Company&#8217;s fund in certain financial instruments including money market funds and bonds to
generate investment income. Short-term investments consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Beginning balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,725,204</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Add: purchase wealth management financial products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,330,660</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: redemption</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,801,927</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued investment income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(470,477</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(106,133</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,078</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Ending balance of short-term investments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,148,594</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,725,204</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment income (loss) generated from such short-term investments
amounted to ($470,477), $239,549 and <span style="-sec-ix-hidden: hidden-fact-73">Nil</span> for the years ended September 30, 2022, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_HeldToMaturityInvestmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_HeldToMaturityInvestmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507608039648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 &#8212; PROPERTY, PLANT AND EQUIPMENT, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property, plant and equipment, net, consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">20 years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,492,360</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,808,006</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5-10 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,932</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,047,338</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Automobiles</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,912,525</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,370</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Office and electric equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">3-5 years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">477,919</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">489,886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,960,736</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,461,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,710,098</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,780,247</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,250,638</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,681,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $528,919, $441,355 and
$404,948 for the years ended September 30, 2022, 2021 and 2020, respectively. Loss from disposal of fixed assets amounted to $983, $1,559
and <span style="-sec-ix-hidden: hidden-fact-74">Nil</span> for the years ended September 30, 2022, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507608198656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 &#8212; INTANGIBLE ASSETS, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intangible assets, net consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Land use rights</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">20 years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">252,757</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">278,327</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">5-10 years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,217</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273,974</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,691</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(116,523</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(123,208</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">157,451</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">178,483</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amortization expense was $5,030, $5,523 and $5,131 for the years ended
September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Estimated future amortization expense for intangible assets is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Years ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization<br/>
 expense</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,055</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">132,176</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">157,451</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599964560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for CIP Project<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForConstructionInProgressAbstract', window );"><strong>Prepayment for CIP Project [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForConstructionInProgressTextBlock', window );">PREPAYMENT FOR CIP PROJECT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11 &#8212; PREPAYMENT FOR CIP PROJECT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CIP represents direct costs of construction incurred
for the Company&#8217;s manufacturing facilities. On June 25, 2021, the Company signed a construction sub-contract with sub-contractor
Jiangxi Chenyuan Construction Project Co., Ltd. (&#8220;Chenyuan&#8221;), pursuant to which, Chenyuan will help the Company construct
four manufacturing plant buildings and an office building with a total estimated budget of RMB165 million (approximately $23.2 million).
The construction work started on August 8, 2021, with an originally estimated completion date on August 7, 2023. However, due to resurgence
of the COVID-19 pandemic, which resulted in lingering logistic disruption, material and labor shortage, and domestic travel restriction,
the construction work is estimated to be completed in December 2024, and Chenyuan will bear the increased material and labor costs. As
of September 30, 2022, the Company had made a prepayment of approximately RMB69.2 million (approximately $9.7 million) to Chenyuan for
land improvement, building foundation and the construction of the main body of the manufacturing plants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2022, $401,702 (approximately
RMB2.9 million) of the prepayment for the CIP project had been used for construction work, and the amount was recorded as property, plant
and equipment in the consolidated balance sheets. As of September 30, 2022, the remaining $9.3 million prepayment to Chenyuan was recorded
as a prepayment for CIP project on the balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2022, future additional capital
expenditure on this CIP project is estimated to be approximately RMB95.8 million (equivalent to $13.5 million), among which approximately
$3.5 million is required for the next 12 months. The Company currently plans to support its ongoing CIP project construction through
cash flows from operations, proceeds received from the IPO, and borrowings from PRC banks in the future and use such bank borrowings to
support the CIP project, if necessary. The construction of the four manufacturing plant buildings and the office building is expected
to be fully completed and put into use by December 2024 and December 2025, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2022, future minimum capital
expenditures on the Company&#8217;s CIP project are estimated as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Years ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital<br/>
 Expenditure<br/>
 on CIP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,479,306</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,988,066</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,467,372</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForConstructionInProgressAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForConstructionInProgressAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForConstructionInProgressTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepayment for construction in progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForConstructionInProgressTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599974752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Purchase of a Property<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForPurchaseOfAPropertyAbstract', window );"><strong>Prepayment for Purchase of a Property [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForPurchaseOfAPropertyTextBlock', window );">PREPAYMENT FOR PURCHASE OF A PROPERTY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 &#8212; PREPAYMENT FOR PURCHASE OF A PROPERTY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2021, the Company entered into a real
estate property purchase agreement with related party Jiangxi Yueshang Investment Co., Ltd. (&#8220;Jiangxi Yueshang&#8221;), an entity
in which the Company&#8217;s chief executive officer, Mr. Gang Lai, owned 5% equity interest as of the date of that agreement. Pursuant
to the property purchase agreement, Jiangxi Yueshang will sell and the Company will purchase a certain residential apartment and commercial
office space totaling 2,749.30 square meters, with a total purchase price of RMB32 million (approximately $4.50 million). Pursuant to
this agreement, the Company was required to make a prepayment in the amount of 50% of the total purchase price, with 20% of the total
purchase price payable upon the availability of a certificate of occupancy, and 30% of the total purchase price payable upon delivery
of the property.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2022, the Company had made
a prepayment of RMB16 million (approximately $2.25 million) to Jiangxi Yueshang. The remaining balance is expected to be paid by August
2024. Since the property is located in the urban downtown area of Ji&#8217;an City, the Company plans to use the property for offices
in late 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForPurchaseOfAPropertyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForPurchaseOfAPropertyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForPurchaseOfAPropertyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForPurchaseOfAPropertyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599982112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Bank Loans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">SHORT-TERM BANK LOANS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 &#8212; SHORT-TERM BANK LOANS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term bank loans consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Short-term bank loans:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Maturity date on June 15, 2022, interest rate 4.81% per annum</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">(1)</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,548,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maturity date on March 17, 2022, interest rate 4.81% per annum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(2)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,238,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Maturity date on March 13, 2023, interest rate 4.62% per annum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(3)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,124,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maturity date on June 14, 2023, interest rate 4.62% per annum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(4)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,405,780</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bank of Communications Co., Ltd</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maturity date on June 30, 2022, interest rate 4.50% per annum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(5)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,548,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Maturity date on June 24, 2023, interest rate 4.20% per annum</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">(6)</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,405,780</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total short-term loans</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,936,184</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,334,400</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">On June 16, 2021, the Company&#8217;s subsidiary, Jiangxi
Universe, signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB10 million (equivalent
to $1,548,000) as working capital for one year, with the maturity date on June 15, 2022. The fixed interest rate of the loan was 4.81%
per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">On March 18, 2021, the Company&#8217;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,238,400) as working capital for one year, with
the maturity date on March 17, 2022. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for
this loan. The loan was fully repaid upon maturity.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">On March 14, 2022, the Company&#8217;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,124,624) as working capital for one year, with
the maturity date on March 13, 2023. The fixed interest rate of the loan was 4.62% per annum. There was no guarantee requirement for
this loan.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">On June 15, 2022, the Company&#8217;s subsidiary, Jiangxi
Universe, entered into a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,405,780) as working capital for one year,
with the maturity date on June 14, 2023. The fixed interest rate of the loan was 4.62% per annum. Certain related parties of the Company,
including Mr. Gang Lai, the Company&#8217;s controlling shareholder, chairman of the board of directors, and chief executive officer,
Ms. Lin Yang, the Company&#8217;s chief financial officer, Ms. Xing Wu, Mr. Gang Lai&#8217;s spouse, and the Company&#8217;s WFOE, Universe
Technology, jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(5)</td><td style="text-align: justify">On June 30, 2021, the Company&#8217;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,548,000) as working capital for
one year, with the maturity date on June 30, 2022. The fixed interest rate of the loan was 4.5% per annum. Certain related parties of
the Company, including Mr. Gang Lai, the Company&#8217;s controlling shareholder, Mr. Gang Lai&#8217;s spouse, Mrs. Xing Wu, and the
Company&#8217;s subsidiary, Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantees
for this loan. The loan was fully repaid upon maturity.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(6)</td><td style="text-align: justify">On June 24, 2022, the Company&#8217;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,405,780) as working capital for
one year, with the maturity date on June 24, 2023. The fixed interest rate of the loan was 4.2% per annum. Jiangxi Province Financing
Guarantee Group Co., Ltd., an unrelated third party, signed a guarantee agreement with Bank of Communications to provide credit guarantee
for this loan.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the above-mentioned loans, the Company recorded a total interest
expense of $199,852, $149,303 and $157,528 for the years ended September 30, 2022, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599964560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 &#8212; RELATED PARTY TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>(a)
</b></span><b>Nature of relationships with related parties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="text-align: justify; width: 2%">&#160;</td>
    <td style="text-align: justify; border-bottom: Black 1.5pt solid; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company</b></span></td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Gang Lai</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s controlling shareholder, Chief Executive Officer and chairman of the Company&#8217;s Board of Directors</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Lin Yang</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Director</span></td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greatest Group (China) Financial Management Limited (&#8220;Greatest Group&#8221;)</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One of the Company&#8217;s minority shareholders owns 8.7% of the ownership interest in this entity</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foshan Shangyu Investment Holding Co., Ltd (&#8220;Foshan Shangyu&#8221;)</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An affiliated entity of the Company, 90% owned by and controlled by the Company&#8217;s Chief Executive Officer</span></td>
    </tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(b) Due from related parties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Name</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Greatest Group</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">235,438</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foshan Shangyu</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,544</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total due from related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">236,982</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s due from related parties were interest free and
due on demand. The September 30, 2021 due from related parties balance has been subsequently collected back and the Company does not have
the intention to make additional cash advance to related parties going forward.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)
Due to related parties</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Name</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Mr. Gang Lai</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,379,263</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mrs. Lin Yang</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,723</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total due to related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,379,263</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,723</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of September 30, 2022 and 2021, the balance due to related parties
mainly consisted of advances from the Company&#8217;s officers for working capital purposes during the Company&#8217;s normal course of
business. These advances are non-interest bearing and due on demand.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Loan guarantee provided by related parties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company&#8217;s bank borrowings
from Bank of Communications, certain related parties of the Company, including Mr. Gang Lai, the Company&#8217;s controlling shareholder,
chairman of the board of directors, and chief executive officer, Mr. Gang Lai&#8217;s spouse, Ms. Xing Wu, and the Company&#8217;s subsidiary,
Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for these loans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company&#8217;s bank borrowings
from LRC Bank, the Company&#8217;s chief executive officer, Mr. Gang Lai, signed a guarantee agreement with LRC Bank to provide a credit
guarantee for the Company&#8217;s loans from LRC Bank within the loan period (see Note 13).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(e) Prepayment to related party for property purchase</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As disclosed in Note 12, on May 6, 2021, the Company
entered into a real estate property purchase agreement with a related party, Jiangxi Yueshang, to purchase certain residential apartment
and commercial office space totaling 2,749.30 square meters with total purchase price of RMB32 million (approximately $4.5 million). As
of September 30, 2022, the Company had made a prepayment of RMB16 million ($2,249,248) to Jiangxi Yueshang. The remaining balance is expected
to be paid by August 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 13, 2022, Mr. Gang Lai transferred
the 5% equity interest he owned in Jiangxi Yueshang to a third party. As such, after this date, Jiangxi Yueshang is no longer our related
party.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507598648544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 &#8212; TAXES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(a) Corporate Income Taxes (&#8220;CIT&#8221;)</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Cayman Islands</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the current tax laws of the Cayman Islands,
Universe INC is not subject to tax on its income or capital gains. In addition, no Cayman Islands withholding tax will be imposed upon
the payment of dividends by the Company to its shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Hong Kong</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Universe HK is incorporated in Hong Kong and is
subject to profit taxes in Hong Kong at a rate of 16.5%. However, Universe HK did not generate any assessable profits derived from Hong
Kong sources for the years ended September 30, 2022, 2021 and 2020, and accordingly no provision for Hong Kong profits tax has been made
in these periods.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">PRC</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Enterprise Income Tax (&#8220;EIT&#8221;)
Law of PRC, domestic enterprises and Foreign Investment Enterprises (&#8220;FIEs&#8221;) are usually subject to a unified 25% enterprise
income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on a case-by-case basis. EIT grants preferential
tax treatment to High and New Technology Enterprises (&#8220;HNTEs&#8221;). Under this preferential tax treatment, HNTEs are entitled
to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one
of the Company&#8217;s main operating subsidiaries in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of
15% beginning November 2016 with a term of three years. In December 2019, Jiangxi Universe successfully renewed its HNTE certification
with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2022. In
November 2022, Jiangxi Universe successfully further renewed its HNTE certification with local government and will continue to enjoy the
reduced income tax rate of 15% for another three years through November 2025. Universe Trade, another operating subsidiary of the Company
in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15% beginning December 2020 with a term of three years
through December 2023. EIT is typically governed by the local tax authority in the PRC. Each local tax authority at times may grant tax
holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the years
ended September 30, 2022, 2021 and 2020 were reported at a blended reduced rate as a result of certain of the PRC subsidiaries of the
Company&#8217;s being approved as a HNTE and enjoying a 15% reduced income tax rate. The impact of the tax holidays noted above decreased
PRC corporate income taxes by $694,955, $1,518,979 and $118,986 for the years ended September 30, 2022, 2021 and 2020, respectively. The
benefit of the tax holidays on net income per share (basic and diluted) was $0.03, $0.09 and $0.01 for the years ended September 30, 2022,
2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of the income tax provision (benefit) are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current tax provision:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cayman</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt">PRC</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,357,697</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,026,867</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,552,097</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Sub-total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,357,697</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,026,867</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,552,097</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax provision (benefit):</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cayman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#160;</div></td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#160;</div></td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">PRC</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(605,278</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(668,341</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,886</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in">Sub-total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(605,278</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(668,341</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,886</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total income tax provision</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">752,419</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,358,526</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,542,211</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">The following table reconciles the China statutory rates to the Company&#8217;s
effective tax rate for the years ended September 30, 2022, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Statutory PRC income tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of income tax holiday</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent difference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-PRC entities not subject to PRC income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact on DTA due to change in applicable income tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(9.4</td><td style="padding-bottom: 4pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17.1</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25.2</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company continually evaluates expiring statutes of limitations, audits,
proposed settlements, changes in tax law and new authoritative rulings. As of September 30, 2022, all of the Company&#8217;s tax returns
of its PRC subsidiaries remain open for statutory examination by PRC tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred tax assets are composed of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in">Net operating loss carry-forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,210,855</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">785,550</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">136,817</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,447</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347,672</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">869,997</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Valuation allowance</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,347,672</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">869,997</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically evaluates the likelihood
of the realization of deferred tax assets, and reduces the carrying amount of the deferred tax assets by a valuation allowance to the
extent it believes a portion will not be realized. Management considers new evidence, both positive and negative, that could affect the
Company&#8217;s future realization of deferred tax assets including its recent cumulative earnings experience, expectation of future income,
the carry forward periods available for tax reporting purposes and other relevant factors. Although Jiangxi Universe incurred a net loss
during the year ended September 30, 2022, the Company determined that it is more likely than not that its deferred tax assets could be
realized due to the estimated future earnings in Jiangxi Universe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>(b) Taxes payable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Taxes payable consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Income tax payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">669,780</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Value added tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,087</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326,468</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,263</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,212</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total taxes payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">167,350</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,101,460</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599915136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Concentrations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 16 &#8212; CONCENTRATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A majority of the Company&#8217;s revenue and expense
transactions are denominated in RMB and a significant portion of the Company and its subsidiaries&#8217; assets and liabilities are denominated
in RMB. RMB is not freely convertible into foreign currencies. In the PRC, certain foreign exchange transactions are required by law to
be transacted only by authorized financial institutions at exchange rates set by the People&#8217;s Bank of China (&#8220;PBOC&#8221;).
Remittances in currencies other than RMB by the Company in China must be processed through the PBOC or other China foreign exchange regulatory
bodies which require certain supporting documentation in order to affect the remittance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022 and 2021, $5,711,423 and
$5,892,655 of the Company&#8217;s cash, respectively, was on deposit at financial institutions in the PRC where no existing rule or regulation
requires such financial institutions to maintain insurance to cover bank deposits in the event of bank failure. For the years ended September
30, 2022, 2021 and 2020, the Company&#8217;s substantial assets were located in the PRC and the Company&#8217;s substantial revenues were
derived from its subsidiaries located in the PRC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended September 30, 2022, 2021 and 2020,
no single customer accounted for more than 10% of the Company&#8217;s total revenue. The Company&#8217;s top 10 customers aggregately
accounted for 32.2%, 30.4% and 33.3% of the total revenue for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of one of the Company&#8217;s major products,
Guben Yanling Pill, accounted for 42.5%, 40.3% and 38.2% of the Company&#8217;s total revenue for the years ended September 30, 2022,
2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022 and 2021, no customer accounted
for more than 10% of the total accounts receivable balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, one supplier accounted for
100% of the total advance to supplier balance. As of September 30, 2021, two suppliers accounted for 35.3% and 28.0% of the total advance
to supplier balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended September 30, 2022, one supplier
accounted for approximately 10.3% of the total purchases. For the year ended September 30, 2021, no supplier accounted for more than 10%
of the total purchases, respectively. For the year ended September 30, 2020, two suppliers accounted for approximately 19.6% and 13.6%
of the total purchases, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599314608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 17 &#8212; SHAREHOLDERS&#8217; EQUITY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Ordinary Shares</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Universe INC was incorporated under the laws of the
Cayman Islands on December 11, 2019. The original authorized number of ordinary shares was 50,000 shares with par value of US$1.00 per
share and 50,000 shares were issued. On August 7, 2020, the Company amended its Memorandum of Association to increase the authorized number
of shares to 100,000,000 shares with par value of $0.003125 per share, and subdivide the original issued shares from 50,000 shares at
par value of $1.00 per share to 16,000,000 ordinary shares with par value of $0.003125 per share. As a result of this forward split of
the outstanding ordinary shares at a ratio of 320-for-1 share, a total of 16,000,000 shares were issued and outstanding after the split.
The issuance of these 16,000,000 shares is considered as a part of the Reorganization of the Company, which was retroactively applied
as if the transaction occurred at the beginning of the period presented (see Note 1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Initial Public Offering</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2021, the Company closed its IPO of 5,000,000
ordinary shares at a public offering price of $5.00 per share. On March 29, 2021, the underwriter exercised in full its over-allotment
option to purchase an additional 750,000 ordinary shares. The closing for the sale of the over-allotment shares took place on March 31,
2021. Gross proceeds of the IPO, including the proceeds from the sale of the over-allotment shares, totaled $28.75 million, before deducting
underwriting discounts and other related expenses. Net proceeds of our IPO, including over-allotment shares, were approximately $25.6
million. In connection with the IPO, the Company&#8217;s ordinary shares began trading on the Nasdaq Global Market under the symbol &#8220;UPC&#8221;
on March 23, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022 and 2021, the Company had
a total of 21,750,000 ordinary shares issued and outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Underwriter warrants</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Company&#8217;s IPO, the Company
also agreed to issue warrants to the underwriter, for a nominal consideration of $0.001 per warrant, to purchase 300,000 ordinary shares
of the Company (equal to 6% of the total number of ordinary shares sold in the IPO, not including any ordinary shares sold in the over-allotment
option) (the &#8220;Underwriter Warrants&#8221;). The Underwriter Warrants have a term of five years, with an exercise price of $5.50
per share (equal to 110% of the Company&#8217;s IPO offering price of $5.00 per share). The Underwriter Warrants may be purchased in cash
or via cashless exercise, will be exercisable for five (5) years, and will terminate on the fifth anniversary of the closing of the IPO.
Management determined that the Underwriter Warrants meet the requirements for equity classification under ASC 815-40 because they are
indexed to its own stock. As of September 30, 2022, the Underwriter Warrants were issued and outstanding, but none of them has been exercised.
For the years ended September 30, 2022 and 2021, the Underwriter Warrants were antidilutive and accordingly were not included in the diluted
EPS calculation based on treasury stock method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cash dividends</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 21, 2016, September 13, 2017, February
2, 2018, September 20, 2018 and February 21, 2019, the board of directors of Jiangxi Universe approved resolutions to pay cash dividends
of RMB40 million, RMB30 million, RMB20 million, RMB10 million and RMB30 million, respectively, to its shareholders at the time of record
out of the retained earnings balance of Jiangxi Universe, to be paid to these shareholders when there are sufficient available earnings
and the Company has sufficient funds. A total of RMB130 million (approximately $19.1 million) cash dividend was declared from September
2016 to February 2019, among which, approximately RMB20 million ($3.1 million) was paid in cash to its shareholders in 2018 and the remaining
RMB110 million ($16 million) was paid to its shareholders in 2019. There were no additional cash dividends paid during the years ended
September 30, 2022, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except for the dividends declared mentioned above,
the Company has not declared or paid dividends to its shareholders in the past, and may not choose to make additional distributions in
the future. Any decision as to the payment of dividends will depend on the available earnings, the capital requirements of the Company,
the Company&#8217;s general financial condition and other factors deemed pertinent by the board of directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Statutory reserve and restricted net assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s PRC subsidiaries are restricted
in their ability to transfer a portion of their net assets to the Company. The payment of dividends by entities organized in China is
subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated
profits as determined in accordance with accounting standards and regulations in China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is required to make appropriations to
certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income determined
in accordance with generally accepted accounting principles of the PRC (&#8220;PRC GAAP&#8221;). Appropriations to the statutory surplus
reserve are required to be at least 10% of the after-tax net income determined in accordance with PRC GAAP until the reserve is equal
to 50% of the entity&#8217;s registered capital. Appropriations to the discretionary surplus reserve are made at the discretion of the
board of directors. The statutory reserve may be applied against prior year losses, if any, and may be used for general business expansion
and production or increase in registered capital, but are not distributable as cash dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Relevant PRC laws and regulations restrict the Company&#8217;s
PRC subsidiaries from transferring a portion of their net assets, equivalent to their statutory reserves and their share capital, to the
Company in the form of loans, advances or cash dividends. Only PRC entities&#8217; accumulated profits may be distributed as dividends
to the Company without the consent of a third party. As of September 30, 2022 and 2021, the restricted amounts as determined pursuant
to PRC statutory laws totaled $2,439,535, and total restricted net assets amounted to $31,786,663.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cash transfer between the Company and its subsidiaries</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended September 30, 2022, the Company
received cash in the amount of $303,746 from its subsidiary in Hong Kong, and the WFOE transferred cash in the amount of $5,211,231 to
Jiangxi Universe. For the year ended September 30, 2021, the Company transferred cash in the amount of $11,358,764 to its subsidiary in
Hong Kong, and the Company&#8217;s Hong Kong subsidiary, via the WFOE, further transferred cash in the amount of $6,807,507 to the PRC
subsidiaries. For the year ended September 30, 2020, there was no cash transferred from the Company to its PRC subsidiaries. The assets
transfer was for business operation purpose. There was no distribution of earnings by the PRC operating subsidiaries to the Company during
the years ended September 30, 2022, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507607979040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 18 &#8212; COMMITMENTS AND CONTINGENCIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, the Company is a party to various
legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable
and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. For the
years ended September 30, 2022, 2021 and 2020, the Company did not have any material legal claims or litigation that, individually or
in aggregate, could have a material adverse impact on the Company&#8217;s consolidated financial position, results of operations and cash
flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has an ongoing CIP project associated
with the construction of a new manufacturing facility. As of September 30, 2022, future minimum capital expenditures on the Company&#8217;s
CIP project amounted to approximately $13.5 million, among which, approximately $3.5 million is required for the next 12 months from
the date of this report (see Note 11).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594594304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 19 &#8212; SEGMENT REPORTING</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An operating segment is a component of the Company
that engages in business activities from which it may earn revenues and incur expenses, and is identified on the basis of the internal
financial reports that are provided to, and regularly reviewed by, the Company&#8217;s chief operating decision maker in order to allocate
resources and assess performance of the segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The management of the Company concludes that it has
only one reporting segment. The Company develops, manufactures and sells TCMD products targeted to the elderly to address their physical
conditions in the aging process and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical
instruments, Traditional Chinese Medicine Pieces products and dietary supplements manufactured by third-party pharmaceutical companies.
All of these products are currently sold in China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s products have similar economic
characteristics with respect to raw materials, vendors, marketing and promotions, customers and methods of distribution. The Company&#8217;s
chief operating decision maker has been identified as the Chief Executive Officer, who reviews consolidated results when making decisions
about allocating resources and assessing performance of the Company, rather than by product types or geographic area; hence the Company
has only one reporting segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration:underline">Revenue by product source</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For Years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Sales of TCMD products manufactured by the Company</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,988,177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,559,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,374,751</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,154,974</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">40,143,151</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration:underline">Revenue by product categories</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The summary of our total revenues by product categories for the years ended
September 30, 2022, 2021 and 2020 was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For Years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Sales of TCMD products:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Medicinal liquor products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,095,336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,951,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,616,080</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Other chronic condition treatment products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,140,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,978,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,059,403</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cold and flu medicines</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,752,422</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,629,606</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,699,268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Sub-total of TCMD products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,988,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,559,286</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,374,751</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-align: justify">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Sales of third-party products</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Biochemical drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,730,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,082,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,325,411</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Traditional Chinese medicine pieces</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,097</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,394,348</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,318,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,950,238</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Dietary supplements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,463</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Subtotal of third-party products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,154,974</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">40,143,151</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507608039648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 20 &#8212; SUBSEQUENT EVENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated the subsequent event through
the date of this report, and concluded that there are no material reportable subsequent events need to be disclosed.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599956384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 21 &#8212; CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of Rule 12-04(a), 5-04(c)
and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when the restricted net assets
of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. The
Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with such requirement and concluded that
it was applicable to the Company as the restricted net assets of the Company&#8217;s subsidiaries exceeded 25% of the consolidated net
assets of the Company. Therefore, the condensed financial statements for the parent company are included herein.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of the above test, restricted net assets
of consolidated subsidiaries shall mean that amount of the Company&#8217;s proportionate share of net assets of consolidated subsidiaries
(after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries
in the form of loans, advances or cash dividends without the consent of a third party.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed financial information of the parent
company has been prepared using the same accounting policies as set out in the Company&#8217;s consolidated financial statements except
that the parent company used the equity method to account for investment in its subsidiaries. Such investment is presented on the condensed
balance sheets as &#8220;Investment in subsidiaries&#8221; and the respective profit or loss as &#8220;Equity in earnings of subsidiaries&#8221;
on the condensed statements of income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The footnote disclosures contain supplemental information
relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the consolidated
financial statements of the Company. Certain information and footnote disclosures normally included in financial statements prepared in
accordance with U.S GAAP have been condensed or omitted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022 and 2021, there were no material
contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those which have been separately
disclosed in the consolidated financial statements, if any.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -0.125in; padding-left: 0.25in">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">110,393</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,148,594</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,725,204</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,177,511</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,835,597</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Non-current assets</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Investment in subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,264,812</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,098,756</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-family: SimSun">&#160;</td>
    <td style="font-family: SimSun; text-align: left">&#160;</td><td style="font-family: SimSun; text-align: right"><span style="font-family: SimSun; font-size: 10pt">&#12288;</span></td><td style="font-family: SimSun; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.375in">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">46,442,323</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">58,934,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">COMMITMENTS AND CONTINGENCIES</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#160;</div></td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#160;</div></td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">SHAREHOLDERS&#8217; EQUITY</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares issued and outstanding as of September 30, 2021 and 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,969</td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">67,969</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,279,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,279,159</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Retained earnings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,761,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,498,466</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,666,705</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,088,759</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,442,323</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,934,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">46,442,323</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">58,934,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating costs and expenses:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 10pt">General and administrative expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(384,214</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,177,869</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expenses):</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income from short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(470,477</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60,751</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity in earnings of subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,881,455</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,319,023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,558,222</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,736,566</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,319,952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,558,222</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,755,464</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,193,369</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">860,623</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive income attributable to the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(12,492,030</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,513,321</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,418,845</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(8,736,566</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,319,952</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,558,222</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net cash flows from operating activities:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 12.5pt; padding-left: 10pt">Equity in earnings of subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,881,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,319,027</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,558,222</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Short-term investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">470,477</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -3.3pt; padding-left: 3.3pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(384,634</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(999,075</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; text-indent: -0.9pt; padding-left: 0.9pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -3.4pt; padding-left: 3.4pt">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt">Payment for short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,330,660</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt">Redemption of short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,801,927</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,528,733</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 23.6pt">Net proceeds from issuance of ordinary shares in IPO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,957,457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 23.6pt">Cash lent to subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,358,764</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt">Cash repayment from subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">303,746</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">303,746</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,598,693</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; padding-bottom: 1.5pt; text-indent: -1.2pt; padding-left: 1.2pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(588</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CHANGES IN CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81,476</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">CASH, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,393</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">CASH, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">28,917</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">110,393</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04(Schedule I))<br> -URI https://asc.fasb.org/extlink&amp;oid=126898705&amp;loc=d3e5864-122674<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=d3e5283-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507600833760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis of consolidation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the financial statements of Universe INC, Universe HK, Universe Technology, Jiangxi Universe, Universe Trade and Universe Hanhe.
All inter-company balances and transactions are eliminated upon consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Uses of estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Uses of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing the consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;), management makes
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates
are based on information as of the date of the consolidated financial statements. Significant estimates required to be made by management
include, but are not limited to, the allowance for estimated uncollectible receivables, the realizability of advance to suppliers, inventory
valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of long-lived assets, provision necessary
for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The main operation of the Company is located in
the PRC. Accordingly, the Company&#8217;s business, financial condition, and results of operations may be influenced by political, economic,
and legal environments in the PRC, as well as by the general state of the PRC economy. The Company&#8217;s results may be adversely affected
by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations
and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1,
this may not be indicative of future results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of new pharmaceutical
products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant competition
and a strong emphasis on intellectual property. The Company may face competition with respect to its current and future pharmaceutical
product candidates from major pharmaceutical companies in China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&#8217;s operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operations may be further
affected by the ongoing COVID-19 pandemic. Due to the resurgence of COVID-19 pandemic in China in 2022, there had been delays in purchase
of raw material supplies and deliver products to the customers of the PRC operating entities on a timely basis as a consequence of the
travel restrictions. The prices of the raw materials also increased by about 5% from January 2022 to May 2022 as compared to the same
period last year. In addition, the Company has granted some of its customers extended payment terms of 30 days to 120 days since January
2022, as a result of the COVID-19 pandemic. However, based on the present relationship with these customers and the evaluation of their
financial health, the Company does not anticipate any material collectability problems. Even though the Company does not expect that the
COVID-19 pandemic will have a negative impact on the business operations of the PRC operating entities and the financial results, due
to the high uncertainty of the evolving situation, the Company has limited visibility on how the COVID-19 pandemic affects the execution
of customer contracts, the collection of customer payments, or disrupt our supply chain, and the continued uncertainties associated with
COVID-19 may cause the revenue and cash flows to underperform in the next 12 months from the date the consolidated financial statements
are released. The extent of the future impact of the COVID-19 pandemic on the business and results of operations is still uncertain. Any
resurgence of the COVID-19 pandemic could negatively affect the execution of customer contracts, the collection of customer payments,
or disrupt the Company&#8217;s supply chain, and the continued uncertainties associated with COVID-19 may negatively impact the Company&#8217;s
revenue and cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash includes currency on hand and deposits held
by banks that can be added or withdrawn without limitation. The Company maintains most of its bank accounts in the PRC. Cash balances
in bank accounts in the PRC are not insured by the Federal Deposit Insurance Corporation or other programs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Accounts receivable, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are presented net of allowance
for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts based on individual account analysis and
historical collection trends. The Company establishes a provision for doubtful receivables when there is objective evidence that the Company
may not be able to collect amounts due. The allowance is based on management&#8217;s best estimate of specific losses on individual exposures,
as well as a provision on historical trends of collections. Actual amounts received may differ from management&#8217;s estimate of credit
worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful accounts after
management has determined that collection is not probable. Allowance for uncollectable balances amounted to $ $791,827 and $446,527 as
of September 30, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Inventories, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at net realizable value
using weighted average method. Costs include the cost of raw materials, freight, direct labor and related production overhead. Any excess
of the cost over the net realizable value of each item of inventories is recognized as a provision for diminution in the value of inventories.
Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. The
Company evaluates inventories on a quarterly basis for its net realizable value adjustments, and reduces the carrying value of those inventories
that are obsolete or in excess of the forecasted usage to their estimated net realizable value based on various factors including aging,
expiration dates, as applicable, taking into consideration historical and expected future product sales. The Company recorded inventory
reserve of $120,286 and $116,453 as of September 30, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AdvancesToSuppliersNetPolicyTextBlock', window );">Advances to suppliers, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Advances to suppliers, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -0.4pt">Advances to suppliers
represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices for raw materials. These advances
are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time to make
cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company when
the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific allowances
when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September 30, 2022
and 2021, no allowance for doubtful accounts was deemed necessary, as the Company believes that all advances to suppliers are fully realizable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -0.4pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred initial public offering (&#8220;IPO&#8221;) costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Deferred initial public offering (&#8220;IPO&#8221;) costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company complies with the requirement of the
ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses of Offering&#8221;. Deferred offering
costs consist of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related
to the intended IPO. Deferred offering costs were charged to shareholders&#8217; equity upon the completion of the IPO on March 25, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_HeldToMaturityInvestmentPolicyTextBlock', window );">Short-term investments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Short-term investments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s short-term investments consist
of wealth management financial products purchased from a financial institution, which can be redeemed anytime. The financial institution
invests the Company&#8217;s fund in certain financial instruments including money market funds and bonds to generate investment income.
The short-term investments are deemed to be trading securities and are measured subsequently at fair value in the statement of financial
position. Unrealized holding gains and losses for investment are included in the consolidated statements of operations and comprehensive
income over the investment period (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair value of financial instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize
the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Level 1&#8201;&#8212;&#8201;inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities
in active markets.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Level 2&#8201;&#8212;&#8201;inputs to the valuation methodology include quoted prices for similar assets
and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than
quoted prices that are observable and inputs derived from or corroborated by observable market data.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Level 3&#8201;&#8212;&#8201;inputs to the valuation methodology are unobservable.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise disclosed, the fair value of
the Company&#8217;s financial instruments, including cash, accounts receivable, inventories, short-term investments, advances to suppliers,
prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current liabilities, taxes
payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September 30, 2022 and 2021
based upon the short-term nature of the assets and liabilities. The Company&#8217;s investment in equity securities is accounted for using
the measurement alternative in accordance with ASC 321, which also approximate its recorded value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Property, plant and equipment</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property, plant and equipment are stated at cost
less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is provided using the straight-line
method over their expected useful lives, as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">20 years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5&#8211;10 years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Automobiles</td><td>&#160;</td>
    <td style="text-align: center">3&#8211;5 years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office and electric equipment</td><td>&#160;</td>
    <td style="text-align: center">3&#8211;5 years</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenditures for maintenance and repairs, which
do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments
which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired
or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated statements of income and other
comprehensive income in other income or expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews the carrying value of property,
plant, and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable
from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future
cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the
fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and
prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors.
Based on this assessment, no impairment expenses for property, plant, and equipment were recorded in operating expenses for the years
ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Intangible Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets consist primarily of land use
rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot be sold to an individual or company.
The government grants individuals and companies the right to use parcels of land for specified periods of time. Land use rights are stated
at cost less accumulated amortization. Intangible assets are amortized using the straight-line method with the following estimated useful
lives:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Land use rights</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">50 years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Software</td><td>&#160;</td>
    <td style="text-align: center">3 years</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews the carrying value of land
use rights for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the
estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash
flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair
value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects,
the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this
assessment, no impairment of land use rights was deemed necessary for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionContractorsPolicyPolicyTextBlock', window );">Construction-in-Progress (&#8220;CIP&#8221;)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Construction-in-Progress (&#8220;CIP&#8221;)</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CIP represents property and buildings under construction
and consists of construction expenditures, equipment procurement, and other direct costs attributable to the construction. CIP is not
depreciated. Upon completion and ready for intended use, CIP is reclassified to the appropriate category within property, plant and equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Impairment of long-lived Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets with finite lives, primarily
property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash flows from the use of the asset and its
eventual disposition below are the asset&#8217;s carrying value, then the asset is deemed to be impaired and written down to its fair
value. There were no impairments of these assets as of September 30, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments in Equity Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Investments in Equity Securities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its equity investments
in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 321 &#8220;Investments&#8212;Equity Securities&#8221; (&#8220;ASC
321&#8221;). In accordance with ASC 321, equity investment which the Company has no significant influence (generally less than a 20% ownership
interest) with readily determinable fair values are accounted for at fair value based on quoted market prices with the changes in fair
value recognized as unrealized gains or losses in earnings. Equity investments without readily determinable fair values are accounted
for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured
at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical
or a similar investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From March 2009 to September 2017, the Company
invested approximately $0.7 million (RMB5 million) in Jiangxi Jian Rural Commercial Bank (&#8220;JX RCB Bank&#8221;) in exchange for 5%
ownership interest in the bank. The purpose of entering into these equity investment agreements with JX RCB Bank was to earn investment
income as the bank continues to grow. The Company determined that this investment in equity securities does not have a readily determinable
fair value and, accordingly, elected the measurement alternative noted above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company initially recorded the investments
at historical cost and subsequently records any dividends received from the net accumulated earnings of the investee as income. As of
September 30, 2022 and 2021, this investment amounted to $702,890 (RMB 5 million) and $744,924 (RMB 5 million), respectively, and was
reported as long-term investment in equity investee on the consolidated balance sheets. Investment income amounted to $38,588, $30,827
and $21,820 for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The investments in equity securities are evaluated
for impairment when facts or circumstances indicate that the fair value of the investment is less than its carrying value. An impairment
is recognized when a decline in fair value is determined to be other-than-temporary. The Company reviews several factors to determine
whether a loss is other-than-temporary. These factors include, but are not limited to, the: (i) nature of the investment; (ii) cause and
duration of the impairment; (iii) extent to which fair value is less than cost; (iv) financial condition and near-term prospects of the
investments; and (v) ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in fair value.
There was no impairment for the Company&#8217;s investments in equity securities as of September 30, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To determine revenue recognition for contracts
with customers, the Company performs the following five steps : (i) identify the contract(s) with the customer, (ii) identify the performance
obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable
that a significant future reversal will <i>not</i> occur, (iv) allocate the transaction price to the respective performance obligations
in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue when it transfers
its goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange.
The Company accounts for the revenue generated from sales of its TCMD and third-party products on a gross basis, as the Company is acting
as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling
the promise to provide customers the specified goods, which the Company has control of the goods and has the ability to direct the use
of goods to obtain substantially all the benefits. All of the Company&#8217;s contracts have one single performance obligation, namely,
the promise is to transfer the individual goods to customers, and there is no separately identifiable other promise in the contracts.
The Company&#8217;s revenue streams are recognized at a point in time when title and risk of loss passes and the customer accepts the
goods, which generally occurs at delivery. The Company&#8217;s products are sold with no right of return and the Company does not provide
other credits or sales incentive to customers. Revenue is reported net of all value added taxes (&#8220;VAT&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ContractAssetsAndLiabilitiesPolicyTextBlock', window );">Contract Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contract Assets and Liabilities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment terms are established on the Company&#8217;s
pre-established credit requirements based upon an evaluation of customers&#8217; credit quality. Contract assets are recognized for in
related accounts receivable. Contract liabilities are recognized for contracts where payment has been received in advance of delivery.
The contract liability balance can vary significantly depending on the timing when an order is placed and when shipment or delivery occurs.
As of September 30, 2022 and 2021, the Company did not have contract assets and contract liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_DisaggregationOfRevenuesPolicyTextBlock', window );">Disaggregation of Revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Disaggregation of Revenues</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disaggregates its revenue from contracts
by product types, as the Company believes it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows
are affected by economic factors. The Company&#8217;s disaggregation of revenues for the years ended September 30, 2022, 2021 and 2020
are disclosed in Note 19 of these consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of revenue</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenue consists primarily of the costs
of raw materials, freight charges, direct labor, depreciation of plants and machinery, warehousing and overhead associated with the manufacturing
process.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and development expenses</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expenses all internal research and
development costs as incurred, which primarily comprise employee costs, internal and external costs related to execution of studies, including
manufacturing costs, facility costs of the research center, and amortization and depreciation to intangible assets and property, plant
and equipment used in the research and development activities. For the years ended September 30, 2022, 2021 and 2020, total research and
development expense were approximately $7,644,375, $5,465,662 and $583,125, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and handling costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Shipping and handling costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shipping and handling costs are expensed as incurred.
Inbound shipping and handling cost associated with bringing the purchased raw materials and third-party products from suppliers to the
Company&#8217;s warehouse are included in cost of revenue. Outbound shipping and handling costs associated with shipping and delivery
the products to customers are included in selling expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Advertising expense</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising expenses primarily relate to promotion
of the Company&#8217;s brand name and products through outdoor billboards, social media such as Weibo and WeChat, and TV advertisement.
Advertising costs are expensed as incurred or deferred and then expensed the first time the advertising takes place. Advertising expenses
are included in selling expenses in the consolidated statements of income and comprehensive income. Advertising expenses amounted to $17,527,318,
$1,316,654 and $343,962 for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Segment Reporting</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the management approach in determining
reportable operating segments. The management approach considers the internal reporting used by the Company&#8217;s chief operating decision
maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining
the Company&#8217;s reportable operating segments. Management has determined that the Company has one operating segment (See Note 19).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Income taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for current income taxes
in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between
the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected
to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the
period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount
expected to be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An uncertain tax position is recognized only if
it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination. The amount recognized is the largest
amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more
likely than not&#8221; test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified
as income tax expense in the period incurred. No significant penalties or interest relating to income taxes have been incurred during
the years ended September 30, 2022, 2021 and 2020. The Company does not believe there was any uncertain tax provision at September 30,
2022 and September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operating subsidiary in China
is subject to the income tax laws of the PRC. No significant income was generated outside the PRC for the years ended September 30, 2022,
2021 and 2020. As of September 30, 2022, all of the tax returns of the Company&#8217;s PRC subsidiaries remain open for statutory examination
by PRC tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ValueAddedTaxPolicyTextBlock', window );">Value added tax (&#8220;VAT&#8221;)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Value added tax (&#8220;VAT&#8221;)</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales revenue represents the invoiced value of
goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to 17% (starting from May 1, 2018, VAT rate was lowered
to 16%, and starting from April 1, 2019, VAT rate was further lowered to 13%), depending on the type of products sold. The VAT may be
offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products.
The Company recorded a VAT payable or receivable net of payments in the accompanying consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Earnings per Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes earnings per share (&#8220;EPS&#8221;)
in accordance with ASC 260, &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;). ASC 260 requires companies with complex capital
structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common shares outstanding
for the period. Diluted presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options
and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares
that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation
of diluted EPS. For the years ended September 30, 2022, 2021 and 2020, there were no dilutive shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Foreign currency translation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The functional currency for Universe INC is the
U.S Dollar (&#8220;US$&#8221;). Universe HK uses Hong Kong dollar as its functional currency. However, Universe INC and Universe HK currently
only serve as holding companies and did not have active operations as of the date of this report. The Company operates only in the PRC
and the Company&#8217;s functional currency is the Chinese Yuan (&#8220;RMB&#8221;). The Company&#8217;s consolidated financial statements
have been translated into the reporting currency US$.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities of the Company are translated
at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated
at the average rate of exchange during the reporting period. The resulting translation adjustments are reported under other comprehensive
income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the results of
operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The RMB is not freely convertible into foreign
currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB
amounts could have been, or could be, converted into US$ at the rates used in translation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table outlines the currency exchange
rates that were used in creating the consolidated financial statements in this report:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>September&#160;30, <br/>
2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>September&#160;30, <br/>
2021</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>September&#160;30, <br/>
2020</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Year-end spot rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">US$1=RMB7.1135</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">US$1=RMB6.4580</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">US$1=RMB6.8033</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">US$1=RMB6.5532</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">US$1=RMB6.5095</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">US$1=RMB7.0077</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive income</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Comprehensive income</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comprehensive income consists of two components,
net income and other comprehensive income. The foreign currency translation gain resulting from translation of the financial statements
expressed in RMB to US$ is reported in other comprehensive income in the consolidated statements of income and comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_StatementOfCashFlowsPolicyTextBlock', window );">Statement of Cash Flows</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Statement of Cash Flows</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 230, &#8220;Statement of
Cash Flows&#8221;, cash flows from the Company&#8217;s operations are formulated based upon the local currencies. As a result, amounts
related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding
balances on the balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EmployeeDefinedContributionPlanPolicyTextBlock', window );">Employee Defined Contribution Plan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Employee Defined Contribution Plan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiaries in the PRC participate
in a government-mandated multi-employer defined contribution plan pursuant to which pension, work-related injury benefits, maternity insurance,
medical insurance, unemployment benefit and housing fund are provided to eligible full-time employees. The relevant labor regulations
require the Company&#8217;s subsidiaries in the PRC to pay the local labor and social welfare authorities monthly contributions based
on the applicable benchmarks and rates stipulated by the local government. The contributions to the plan are expensed as incurred. Employee
social security and welfare benefits included as expenses in the accompanying statements of income and comprehensive income amounted to
$465,689, $617,145 and $347,312 for the years ended September 30, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU 2016-13, Financial
Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the
reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing
incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. ASU 2016-13
was subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2020-02. For public entities, ASU 2016-13 and its
amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. For all other
entities, this guidance and its amendments will be effective for fiscal years beginning after December 15, 2022, including interim periods
within those fiscal years. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2018. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2020, the FASB issued ASU 2020-10,
&#8220;Codification Improvements to Subtopic 205-10, presentation of financial statements&#8221;. The amendments in this Update improve
the codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to
financial statements is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement
would be missed. ASU 2020-10 is effective for the Company for annual and interim reporting periods beginning January 1, 2022. Early application
of the amendments is permitted for any annual or interim period for which financial statements are available to be issued. The amendments
in this Update should be applied retrospectively. An entity should apply the amendments at the beginning of the period that includes the
adoption date. The Company is currently evaluating the impact of this new standard on Company&#8217;s consolidated financial statements
and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancesToSuppliersNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advances to suppliers net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancesToSuppliersNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ContractAssetsAndLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ContractAssetsAndLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_DisaggregationOfRevenuesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_DisaggregationOfRevenuesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EmployeeDefinedContributionPlanPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of employee defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EmployeeDefinedContributionPlanPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_HeldToMaturityInvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_HeldToMaturityInvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StatementOfCashFlowsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of statement of cash flows policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StatementOfCashFlowsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ValueAddedTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of value added tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ValueAddedTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionContractorsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for construction contractors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126937589&amp;loc=SL119991576-234733<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6471471&amp;loc=d3e48698-109348<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionContractorsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507608198656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock', window );">Schedule of subsidiaries of the company</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Date of</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Place of</td><td style="font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">% of</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; font-weight: bold; vertical-align: top">Name of Entity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Incorporation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Incorporation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ownership</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal Activities</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Universe INC</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">December 11, 2019</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">Cayman Islands</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">Parent, 100%</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">Investment holding</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 20%; text-align: left">Universe HK</td><td style="text-align: center; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">May 21, 2014</td><td style="text-align: center; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">Hong Kong</td><td style="text-align: center; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">100%</td><td style="text-align: center; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 28%; text-align: center">Investment holding</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Universe Technology</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">April 18, 2019</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PRC</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">100%</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">WFOE, Investment holding</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Jiangxi Universe</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">March 2, 1998</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PRC</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">100%</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">Research and development and manufacturing of modernized traditional Chinese medicines</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Universe Trade</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">March 10, 2010</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PRC</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">100%</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">Sales of modernized traditional Chinese medicines</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Universe Hanhe</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">May 12, 2021</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PRC</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">100%</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">Research and development of new pharmaceutical products</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507598645568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of property, plant and equipment estimated useful lives</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">20 years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5&#8211;10 years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Automobiles</td><td>&#160;</td>
    <td style="text-align: center">3&#8211;5 years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office and electric equipment</td><td>&#160;</td>
    <td style="text-align: center">3&#8211;5 years</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets estimated useful lives</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Land use rights</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">50 years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Software</td><td>&#160;</td>
    <td style="text-align: center">3 years</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock', window );">Schedule of currency exchange rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>September&#160;30, <br/>
2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>September&#160;30, <br/>
2021</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>September&#160;30, <br/>
2020</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Year-end spot rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">US$1=RMB7.1135</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">US$1=RMB6.4580</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">US$1=RMB6.8033</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">US$1=RMB6.5532</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">US$1=RMB6.5095</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">US$1=RMB7.0077</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of property equipment estimated useful life during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594340672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of accounts receivable consists</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,975,717</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,020,269</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(791,827</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(446,527</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Accounts receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,183,890</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,573,742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock', window );">Schedule of the company&#8217;s accounts receivable and subsequent collection</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Accounts Receivable by aging bucket</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance as of September 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Subsequent collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of subsequent collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Less than 3 months</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,673,685</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,135,508</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">62.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>From 4 to 6 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,970,635</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,360,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>From 7 to 9 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,554,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,089,957</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>From 10 to 12 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">285,871</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">180,564</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Over 1 year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">491,208</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">152,711</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total gross accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,975,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,918,976</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(791,827</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Accounts Receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,183,890</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,918,976</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">71.9</td><td style="padding-bottom: 2pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of allowance for doubtful accounts</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Beginning balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">446,527</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">639,991</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">419,353</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debt recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(225,660</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(74,053</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,196</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">791,827</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">446,527</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507607974560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">989,043</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">607,661</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,337,731</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,971,334</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Inventory valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(120,286</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(116,453</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total inventory, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,206,488</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,462,542</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599959968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advance to Suppliers (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AdvancetoSuppliersTablesLineItems', window );"><strong>Advances To Suppliers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfAdvancesToSuppliersNet', window );">Schedule of advances to suppliers net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advances to suppliers for inventory raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,701</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,738,313</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Advances to suppliers, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,701</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,738,313</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancetoSuppliersTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancetoSuppliersTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfAdvancesToSuppliersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of advances to suppliers net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfAdvancesToSuppliersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599302608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-Term Invstment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Schedule of short-term investments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Beginning balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,725,204</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Add: purchase wealth management financial products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,330,660</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: redemption</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,801,927</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued investment income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(470,477</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(106,133</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,078</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Ending balance of short-term investments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,148,594</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,725,204</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599959968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment, net consists</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">20 years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,492,360</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,808,006</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5-10 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,932</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,047,338</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Automobiles</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,912,525</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,370</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Office and electric equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">3-5 years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">477,919</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">489,886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,960,736</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,461,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,710,098</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,780,247</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,250,638</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,681,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599917520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets, net consist</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Land use rights</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">20 years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">252,757</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">278,327</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">5-10 years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,217</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273,974</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,691</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(116,523</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(123,208</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">157,451</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">178,483</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated future amortization expense for intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Years ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization<br/>
 expense</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,055</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">132,176</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">157,451</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507608039648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for CIP Project (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForConstructionInProgressAbstract', window );"><strong>Prepayment for CIP Project [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Schedule of future minimum capital expenditures</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Years ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital<br/>
 Expenditure<br/>
 on CIP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,479,306</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,988,066</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,467,372</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForConstructionInProgressAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForConstructionInProgressAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599915136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Bank Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of short-term bank loans</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Short-term bank loans:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Maturity date on June 15, 2022, interest rate 4.81% per annum</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">(1)</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,548,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maturity date on March 17, 2022, interest rate 4.81% per annum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(2)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,238,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Maturity date on March 13, 2023, interest rate 4.62% per annum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(3)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,124,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maturity date on June 14, 2023, interest rate 4.62% per annum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(4)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,405,780</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bank of Communications Co., Ltd</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maturity date on June 30, 2022, interest rate 4.50% per annum</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(5)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,548,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Maturity date on June 24, 2023, interest rate 4.20% per annum</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">(6)</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,405,780</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total short-term loans</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,936,184</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,334,400</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">On June 16, 2021, the Company&#8217;s subsidiary, Jiangxi
Universe, signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB10 million (equivalent
to $1,548,000) as working capital for one year, with the maturity date on June 15, 2022. The fixed interest rate of the loan was 4.81%
per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">On March 18, 2021, the Company&#8217;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,238,400) as working capital for one year, with
the maturity date on March 17, 2022. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for
this loan. The loan was fully repaid upon maturity.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">On March 14, 2022, the Company&#8217;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,124,624) as working capital for one year, with
the maturity date on March 13, 2023. The fixed interest rate of the loan was 4.62% per annum. There was no guarantee requirement for
this loan.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">On June 15, 2022, the Company&#8217;s subsidiary, Jiangxi
Universe, entered into a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,405,780) as working capital for one year,
with the maturity date on June 14, 2023. The fixed interest rate of the loan was 4.62% per annum. Certain related parties of the Company,
including Mr. Gang Lai, the Company&#8217;s controlling shareholder, chairman of the board of directors, and chief executive officer,
Ms. Lin Yang, the Company&#8217;s chief financial officer, Ms. Xing Wu, Mr. Gang Lai&#8217;s spouse, and the Company&#8217;s WFOE, Universe
Technology, jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(5)</td><td style="text-align: justify">On June 30, 2021, the Company&#8217;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,548,000) as working capital for
one year, with the maturity date on June 30, 2022. The fixed interest rate of the loan was 4.5% per annum. Certain related parties of
the Company, including Mr. Gang Lai, the Company&#8217;s controlling shareholder, Mr. Gang Lai&#8217;s spouse, Mrs. Xing Wu, and the
Company&#8217;s subsidiary, Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantees
for this loan. The loan was fully repaid upon maturity.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(6)</td><td style="text-align: justify">On June 24, 2022, the Company&#8217;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,405,780) as working capital for
one year, with the maturity date on June 24, 2023. The fixed interest rate of the loan was 4.2% per annum. Jiangxi Province Financing
Guarantee Group Co., Ltd., an unrelated third party, signed a guarantee agreement with Bank of Communications to provide credit guarantee
for this loan.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507608389216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of nature of relationships with related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="text-align: justify; width: 2%">&#160;</td>
    <td style="text-align: justify; border-bottom: Black 1.5pt solid; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company</b></span></td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Gang Lai</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s controlling shareholder, Chief Executive Officer and chairman of the Company&#8217;s Board of Directors</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Lin Yang</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Director</span></td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greatest Group (China) Financial Management Limited (&#8220;Greatest Group&#8221;)</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One of the Company&#8217;s minority shareholders owns 8.7% of the ownership interest in this entity</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foshan Shangyu Investment Holding Co., Ltd (&#8220;Foshan Shangyu&#8221;)</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An affiliated entity of the Company, 90% owned by and controlled by the Company&#8217;s Chief Executive Officer</span></td>
    </tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfDueFromRelatedPartiesTableTextBlock', window );">Schedule of due from related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Name</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Greatest Group</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">235,438</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foshan Shangyu</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,544</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total due from related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">236,982</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfDueToRelatedPartiesTableTextBlock', window );">Schedule of due to related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Name</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Mr. Gang Lai</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,379,263</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mrs. Lin Yang</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,723</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total due to related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,379,263</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,723</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfDueFromRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfDueFromRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfDueToRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfDueToRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599151696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of the income tax provision (benefit)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current tax provision:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cayman</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt">PRC</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,357,697</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,026,867</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,552,097</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Sub-total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,357,697</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,026,867</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,552,097</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax provision (benefit):</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cayman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#160;</div></td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#160;</div></td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">PRC</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(605,278</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(668,341</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,886</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in">Sub-total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(605,278</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(668,341</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,886</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total income tax provision</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">752,419</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,358,526</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,542,211</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of table reconciles the china statutory rates to the company&#8217;s effective tax rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Statutory PRC income tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of income tax holiday</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent difference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-PRC entities not subject to PRC income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact on DTA due to change in applicable income tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(9.4</td><td style="padding-bottom: 4pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17.1</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25.2</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in">Net operating loss carry-forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,210,855</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">785,550</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">136,817</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,447</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347,672</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">869,997</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Valuation allowance</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,347,672</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">869,997</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfTaxPayableTableTextBlock', window );">Schedule of taxes payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Income tax payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">669,780</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Value added tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,087</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326,468</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,263</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,212</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total taxes payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">167,350</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,101,460</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfTaxPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of tax payable during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfTaxPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507600884016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of revenue by product source</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For Years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Sales of TCMD products manufactured by the Company</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,988,177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,559,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,374,751</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,154,974</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">40,143,151</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of total revenues by product categories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For Years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Sales of TCMD products:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Medicinal liquor products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,095,336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,951,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,616,080</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Other chronic condition treatment products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,140,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,978,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,059,403</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cold and flu medicines</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,752,422</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,629,606</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,699,268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Sub-total of TCMD products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,988,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,559,286</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,374,751</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-align: justify">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Sales of third-party products</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Biochemical drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,730,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,082,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,325,411</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Traditional Chinese medicine pieces</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,097</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,394,348</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,318,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,950,238</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Dietary supplements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,463</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Subtotal of third-party products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,154,974</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">40,143,151</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599858080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of parent company balance sheets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -0.125in; padding-left: 0.25in">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">110,393</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,148,594</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,725,204</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,177,511</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,835,597</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Non-current assets</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Investment in subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,264,812</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,098,756</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-family: SimSun">&#160;</td>
    <td style="font-family: SimSun; text-align: left">&#160;</td><td style="font-family: SimSun; text-align: right"><span style="font-family: SimSun; font-size: 10pt">&#12288;</span></td><td style="font-family: SimSun; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.375in">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">46,442,323</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">58,934,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">COMMITMENTS AND CONTINGENCIES</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#160;</div></td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#160;</div></td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">SHAREHOLDERS&#8217; EQUITY</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares issued and outstanding as of September 30, 2021 and 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,969</td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">67,969</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,279,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,279,159</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Retained earnings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,761,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,498,466</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,666,705</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,088,759</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,442,323</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,934,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">46,442,323</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">58,934,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock', window );">Schedule of parent company statements of income and comprehensive income</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating costs and expenses:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 10pt">General and administrative expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(384,214</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,177,869</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expenses):</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income from short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(470,477</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60,751</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity in earnings of subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,881,455</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,319,023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,558,222</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,736,566</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,319,952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,558,222</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,755,464</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,193,369</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">860,623</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive income attributable to the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(12,492,030</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,513,321</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,418,845</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock', window );">Schedule of parent company statements of cash flows</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(8,736,566</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,319,952</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,558,222</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net cash flows from operating activities:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 12.5pt; padding-left: 10pt">Equity in earnings of subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,881,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,319,027</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,558,222</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Short-term investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">470,477</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -3.3pt; padding-left: 3.3pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(384,634</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(999,075</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; text-indent: -0.9pt; padding-left: 0.9pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -3.4pt; padding-left: 3.4pt">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt">Payment for short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,330,660</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt">Redemption of short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,801,927</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,528,733</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 23.6pt">Net proceeds from issuance of ordinary shares in IPO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,957,457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 23.6pt">Cash lent to subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,358,764</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt">Cash repayment from subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">303,746</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">303,746</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,598,693</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; padding-bottom: 1.5pt; text-indent: -1.2pt; padding-left: 1.2pt">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(588</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CHANGES IN CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81,476</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">CASH, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,393</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">CASH, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">28,917</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">110,393</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedStatementOfComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedCashFlowStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594927904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description (Details)<br> $ / shares in Units, &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 29, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SharesIssued01', window );">Shares issued (in Shares) | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PublicOfferingPrice', window );">Public offering price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net Proceeds</a></td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SharesIssued01', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net Proceeds</a></td>
<td class="nump">$ 25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseIncMember', window );">Universe Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EntityIncorporationDateDescription', window );">Entity incorporation date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Universe Pharmaceuticals Inc. (&#8220;Universe
INC&#8221; or the &#8220;Company&#8221;) was incorporated under the laws of the Cayman Islands on December 11, 2019 as an exempted company
with limited liability.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EquityMethodInvestmentOwnershipsPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseHKMember', window );">Universe HK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EntityIncorporationDateDescription', window );">Entity incorporation date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Universe INC. owns 100% equity interest of Universe
Pharmaceuticals (International) Group (&#8220;Universe HK&#8221;), an entity incorporated on May 21, 2014 in accordance with the laws
and regulations in Hong Kong.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseTechnologyMember', window );">Universe Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AmountOfRegisteredCapital', window );">Registered capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">&#165; 30.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_CapitalContribution', window );">Capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_RemainingCapitalContribution', window );">Remaining capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_JiangxiUniverseMember', window );">Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EntityIncorporationDateDescription', window );">Entity incorporation date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(&#8220;Jiangxi
Universe&#8221;) was incorporated on March 2, 1998 in accordance with PRC laws and is engaged in research and development and manufacturing
of modernized traditional Chinese medicines.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseTradeMember', window );">Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EquityMethodInvestmentOwnershipsPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_JiangxiMember', window );">Jiangxi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EquityMethodInvestmentOwnershipsPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AmountOfRegisteredCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of registered capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AmountOfRegisteredCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital contribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EntityIncorporationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity incorporation date description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EntityIncorporationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EquityMethodInvestmentOwnershipsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EquityMethodInvestmentOwnershipsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OrganizationandBusinessDescriptionDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OrganizationandBusinessDescriptionDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_RemainingCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining capital contribution amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_RemainingCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SharesIssued01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SharesIssued01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseHKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseHKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_JiangxiUniverseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_JiangxiUniverseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseTradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseTradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_JiangxiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_JiangxiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599126832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description (Details) - Schedule of subsidiaries of the company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseINCMember', window );">Universe INC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Dec. 11,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PlaceOfIncorporation', window );">Place of Incorporation</a></td>
<td class="text">Cayman Islands<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OwnershipPercentage', window );">% of Ownership</a></td>
<td class="text">Parent, 100%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Investment holding<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseHKMember', window );">Universe HK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">May 21,  2014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PlaceOfIncorporation', window );">Place of Incorporation</a></td>
<td class="text">Hong Kong<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OwnershipPercentage', window );">% of Ownership</a></td>
<td class="text">100%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Investment holding<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseTechnologyMember', window );">Universe Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Apr. 18,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PlaceOfIncorporation', window );">Place of Incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OwnershipPercentage', window );">% of Ownership</a></td>
<td class="text">100%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrincipalActivities', window );">Principal Activities</a></td>
<td class="text">WFOE, Investment holding<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_JiangxiUniverseMember', window );">Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Mar.  02,  1998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PlaceOfIncorporation', window );">Place of Incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OwnershipPercentage', window );">% of Ownership</a></td>
<td class="text">100%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Research and development and manufacturing of modernized traditional Chinese medicines<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseTradeMember', window );">Universe Trade [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Mar. 10,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PlaceOfIncorporation', window );">Place of Incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OwnershipPercentage', window );">% of Ownership</a></td>
<td class="text">100%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Sales of modernized traditional Chinese medicines<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseHanheMember', window );">Universe Hanhe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">May 12,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PlaceOfIncorporation', window );">Place of Incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OwnershipPercentage', window );">% of Ownership</a></td>
<td class="text">100%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Research and development of new pharmaceutical products<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PlaceOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Place of incorporation or establishment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PlaceOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseHKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseHKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_JiangxiUniverseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_JiangxiUniverseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseTradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseTradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseHanheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseHanheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507595803824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="2">103 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2019</div></th>
<th class="th"><div>May 01, 2018</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_MaterialPricePercentage', window );">Material price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AllowanceForUncollectableBalancesAmount', window );">Allowance for uncollectable balance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 791,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 446,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702,890<span></span>
</td>
<td class="nump">&#165; 5<span></span>
</td>
<td class="nump">744,924<span></span>
</td>
<td class="nump">&#165; 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Investment income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,644,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,465,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,527,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,316,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_TaxBenefitPercentage', window );">Tax benefit percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PercentageOfVatRate', window );">Percentage of vat rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Comprehensive income amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 617,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_OwnershipMember', window );">Ownership [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EquityMethodInvestmentOwnershipsPercentage', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PaymentTerm', window );">Payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PercentageOfVatRate', window );">Percentage of vat rate</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PaymentTerm', window );">Payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_JxRcbBankMember', window );">JX RCB Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">&#165; 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_JxRcbBankMember', window );">JX RCB Bank [Member] | Ownership [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EquityMethodInvestmentOwnershipsPercentage', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AllowanceForUncollectableBalancesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for uncollectable balances amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AllowanceForUncollectableBalancesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EquityMethodInvestmentOwnershipsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EquityMethodInvestmentOwnershipsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_MaterialPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Material price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_MaterialPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PercentageOfVatRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of VATrate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PercentageOfVatRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_TaxBenefitPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax benefit percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_TaxBenefitPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_OwnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_OwnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_JxRcbBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_JxRcbBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599100112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember', window );">Automobiles [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember', window );">Automobiles [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember', window );">Office and electric equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember', window );">Office and electric equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594680192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember', window );">Land use rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntermediateLifePlantsUsefulLife', window );">Useful life</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntermediateLifePlantsUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntermediateLifePlantsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of intermediate-life plants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 905<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471048&amp;loc=d3e5272-110052<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntermediateLifePlantsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507601679472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of currency exchange rate<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfCurrencyExchangeRateAbstract', window );"><strong>Schedule of currency exchange rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_DescriptionOfYearEndSpotRate', window );">Year-end spot rate</a></td>
<td class="text">US$1=RMB7.1135<span></span>
</td>
<td class="text">US$1=RMB6.4580<span></span>
</td>
<td class="text">US$1=RMB6.8033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_DescriptionOfAverageRate', window );">Average rate</a></td>
<td class="text">US$1=RMB6.5532<span></span>
</td>
<td class="text">US$1=RMB6.5095<span></span>
</td>
<td class="text">US$1=RMB7.0077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_DescriptionOfAverageRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of average rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_DescriptionOfAverageRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_DescriptionOfYearEndSpotRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of year end spot rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_DescriptionOfYearEndSpotRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfCurrencyExchangeRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfCurrencyExchangeRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507685724800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AccountsReceivableDescription', window );">Accounts receivable description</a></td>
<td class="text">The Company&#8217;s accounts receivable primarily
includes the balance due from customers when the Company&#8217;s pharmaceutical products are sold and delivered to customers. All of the
Company&#8217;s accounts receivable balance at September 30, 2021 has been collected in the fiscal year 2022. As of date of this report,
approximately 71.9%, or $10.9 million, of the Company&#8217;s net account receivable balance at September 30, 2022 has been subsequently
collected and the remaining balance is expected to be substantially collected before March 31, 2023.&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AccountsReceivableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AccountsReceivableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507607330576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details) - Schedule of accounts receivable consists - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfAccountsReceivableConsistsAbstract', window );"><strong>Schedule of Accounts Receivable Consists [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 15,975,717<span></span>
</td>
<td class="nump">$ 16,020,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowance for doubtful accounts</a></td>
<td class="num">(791,827)<span></span>
</td>
<td class="num">(446,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 15,183,890<span></span>
</td>
<td class="nump">$ 15,573,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfAccountsReceivableConsistsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfAccountsReceivableConsistsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507600706256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details) - Schedule of the company&#8217;s accounts receivable and subsequent collection<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Balance</a></td>
<td class="nump">$ 15,975,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SunsequentCollectionsTotalGrossAccountsReceivable', window );">Subsequent collection</a></td>
<td class="nump">$ 10,918,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_TotalGrossAccountsReceivablePercentage', window );">Percentage of subsequent collection</a></td>
<td class="nump">68.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss', window );">Balance</a></td>
<td class="num">$ (791,827)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SunsequentCollectionAllowanceForDoubtfulAccounts', window );">Subsequent collection</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AllowanceForDoubtfulAccountsReceivablePercentage', window );">Percentage of subsequent collection</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Balance</a></td>
<td class="nump">$ 15,183,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SunsequentCollectionAccountsReceivableNet', window );">Subsequent collection</a></td>
<td class="nump">$ 10,918,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AccountsReceivableNetPercentage', window );">Percentage of subsequent collection</a></td>
<td class="nump">71.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_LessThan3MonthsMember', window );">Less than 3 months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AccountsReceivableBeforeGrossValue', window );">Balance</a></td>
<td class="nump">$ 6,673,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubsequentCollection', window );">Subsequent collection</a></td>
<td class="nump">$ 4,135,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PercentageOfSubsequentCollection', window );">Percentage of subsequent collection</a></td>
<td class="nump">62.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From4To6MonthsMember', window );">From 4 to 6 months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AccountsReceivableBeforeGrossValue', window );">Balance</a></td>
<td class="nump">$ 6,970,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubsequentCollection', window );">Subsequent collection</a></td>
<td class="nump">$ 5,360,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PercentageOfSubsequentCollection', window );">Percentage of subsequent collection</a></td>
<td class="nump">76.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From7To9MonthsMember', window );">From 7 to 9 months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AccountsReceivableBeforeGrossValue', window );">Balance</a></td>
<td class="nump">$ 1,554,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubsequentCollection', window );">Subsequent collection</a></td>
<td class="nump">$ 1,089,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PercentageOfSubsequentCollection', window );">Percentage of subsequent collection</a></td>
<td class="nump">70.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From10To12MonthsMember', window );">From 10 to 12 months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AccountsReceivableBeforeGrossValue', window );">Balance</a></td>
<td class="nump">$ 285,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubsequentCollection', window );">Subsequent collection</a></td>
<td class="nump">$ 180,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PercentageOfSubsequentCollection', window );">Percentage of subsequent collection</a></td>
<td class="nump">63.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_Over1YearMember', window );">Over 1 year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AccountsReceivableBeforeGrossValue', window );">Balance</a></td>
<td class="nump">$ 491,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubsequentCollection', window );">Subsequent collection</a></td>
<td class="nump">$ 152,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PercentageOfSubsequentCollection', window );">Percentage of subsequent collection</a></td>
<td class="nump">31.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AccountsReceivableBeforeGrossValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AccountsReceivableBeforeGrossValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AccountsReceivableNetPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AccountsReceivableNetPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AllowanceForDoubtfulAccountsReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AllowanceForDoubtfulAccountsReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PercentageOfSubsequentCollection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PercentageOfSubsequentCollection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SubsequentCollection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SubsequentCollection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SunsequentCollectionAccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SunsequentCollectionAccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SunsequentCollectionAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SunsequentCollectionAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SunsequentCollectionsTotalGrossAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SunsequentCollectionsTotalGrossAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_TotalGrossAccountsReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_TotalGrossAccountsReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss of accounts and financing receivables. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_LessThan3MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_LessThan3MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From4To6MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From4To6MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From7To9MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From7To9MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From10To12MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From10To12MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_Over1YearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_Over1YearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507601536640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details) - Schedule of allowance for doubtful accounts - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract', window );"><strong>Schedule of Allowance for Doubtful Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 446,527<span></span>
</td>
<td class="nump">$ 639,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">419,353<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Bad debt recovery</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(225,660)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments', window );">Foreign currency translation adjustments</a></td>
<td class="num">(74,053)<span></span>
</td>
<td class="nump">32,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 791,827<span></span>
</td>
<td class="nump">$ 446,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to temporary equity resulting from foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594538544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory, Net (Details) - Schedule of inventory - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfInventoryAbstract', window );"><strong>Schedule of inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 989,043<span></span>
</td>
<td class="nump">$ 607,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,337,731<span></span>
</td>
<td class="nump">1,971,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation allowance</a></td>
<td class="num">(120,286)<span></span>
</td>
<td class="num">(116,453)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory, net</a></td>
<td class="nump">$ 2,206,488<span></span>
</td>
<td class="nump">$ 2,462,542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfInventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfInventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507600639856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advance to Suppliers (Details) - Schedule of advances to suppliers net - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfAdvancesToSuppliersNetAbstract', window );"><strong>Schedule of Advances to Suppliers Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Advances to suppliers for inventory raw materials</a></td>
<td class="nump">$ 16,701<span></span>
</td>
<td class="nump">$ 2,738,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Less: allowance for doubtful accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToSuppliersAndEmployees', window );">Advances to suppliers, net</a></td>
<td class="nump">$ 16,701<span></span>
</td>
<td class="nump">$ 2,738,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfAdvancesToSuppliersNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfAdvancesToSuppliersNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToSuppliersAndEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to suppliers for goods and services provided and to employees for services provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToSuppliersAndEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594520816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Advertisting (Details)<br> &#165; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 06, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForAdvertistingAbstract', window );"><strong>Prepayment for Advertisting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">Advertising expense</a></td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">&#165; 55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PercentageOfAdvancePayment', window );">Percentage of advance payment</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AdditionalContractPricePercentage', window );">Additional contract price percentage</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">&#165; 48.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ContractPricePercentage', window );">Contract price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">&#165; 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdditionalContractPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional contract price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdditionalContractPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ContractPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ContractPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PercentageOfAdvancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of advance payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PercentageOfAdvancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForAdvertistingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForAdvertistingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594798288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepayment for Acquisition (Details)<br> &#165; in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 26, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2022 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforAcquisitionDetailsLineItems', window );"><strong>Prepayment for Acquisition (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AssetAcquisitionPriceOfAcquisitionsExpected', window );">Price amount | $</a></td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid amount</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">&#165; 25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_YunnanFaxiMember', window );">Yunnan Faxi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforAcquisitionDetailsLineItems', window );"><strong>Prepayment for Acquisition (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EquityMethodInvestmentOwnershipsPercentage', window );">Ownership percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AssetAcquisitionPriceOfAcquisitionsExpected', window );">Price amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AssetAcquisitionPriceOfAcquisitionsExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AssetAcquisitionPriceOfAcquisitionsExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EquityMethodInvestmentOwnershipsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EquityMethodInvestmentOwnershipsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentforAcquisitionDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentforAcquisitionDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_YunnanFaxiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_YunnanFaxiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507608070144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-Term Invstment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short term investment amount</a></td>
<td class="nump">$ 470,477<span></span>
</td>
<td class="nump">$ 239,549<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507600850816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments (Details) - Schedule of short-term investments - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfShortTermInvestmentsAbstract', window );"><strong>Schedule of short-term investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Beginning balance</a></td>
<td class="nump">$ 13,725,204<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AddPurchaseWealthManagementFinancialProducts', window );">Add: purchase wealth management financial products</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,330,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Less: redemption</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,801,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable', window );">Accrued investment income (loss)</a></td>
<td class="num">(470,477)<span></span>
</td>
<td class="nump">239,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="num">(106,133)<span></span>
</td>
<td class="num">(43,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Ending balance of short-term investments</a></td>
<td class="nump">$ 13,148,594<span></span>
</td>
<td class="nump">$ 13,725,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AddPurchaseWealthManagementFinancialProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase wealth management financial products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AddPurchaseWealthManagementFinancialProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in investment income that has been earned but not yet received in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507600892032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 528,919<span></span>
</td>
<td class="nump">$ 441,355<span></span>
</td>
<td class="nump">$ 404,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss from disposal of fixed assets</a></td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">$ 1,559<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594770352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net consists - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 9,960,736<span></span>
</td>
<td class="nump">$ 10,461,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(5,710,098)<span></span>
</td>
<td class="num">(5,780,247)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 4,250,638<span></span>
</td>
<td class="nump">4,681,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 7,492,360<span></span>
</td>
<td class="nump">7,808,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 77,932<span></span>
</td>
<td class="nump">2,047,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember', window );">Automobiles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 1,912,525<span></span>
</td>
<td class="nump">116,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember', window );">Automobiles [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember', window );">Automobiles [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember', window );">Office and electric equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 477,919<span></span>
</td>
<td class="nump">$ 489,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember', window );">Office and electric equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember', window );">Office and electric equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507607955488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 5,030<span></span>
</td>
<td class="nump">$ 5,523<span></span>
</td>
<td class="nump">$ 5,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594729808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - Schedule of intangible assets, net consist - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 273,974<span></span>
</td>
<td class="nump">$ 301,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(116,523)<span></span>
</td>
<td class="num">(123,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 157,451<span></span>
</td>
<td class="nump">178,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember', window );">Land use rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 252,757<span></span>
</td>
<td class="nump">278,327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 21,217<span></span>
</td>
<td class="nump">$ 23,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599989120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets - Amortization Expense [Member]<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems', window );"><strong>Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2023</a></td>
<td class="nump">$ 5,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2024</a></td>
<td class="nump">5,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2025</a></td>
<td class="nump">5,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2026</a></td>
<td class="nump">5,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">2027</a></td>
<td class="nump">5,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">132,176<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 157,451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=upc_AmortizationExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=upc_AmortizationExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594669328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for CIP Project (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 25, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 25, 2021 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforCIPProjectDetailsLineItems', window );"><strong>Prepayment for CIP Project (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionContractCostProgressPaymentOffset', window );">Construction amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_CapitalExpenditure', window );">Additional capital expenditure</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_ChenyuanMember', window );">Chenyuan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforCIPProjectDetailsLineItems', window );"><strong>Prepayment for CIP Project (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentBuildingAndBuildingImprovements', window );">Total estimated budget</a></td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 69.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforCIPProjectDetailsLineItems', window );"><strong>Prepayment for CIP Project (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentBuildingAndBuildingImprovements', window );">Total estimated budget</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,200,000<span></span>
</td>
<td class="nump">&#165; 165.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionContractCostProgressPaymentOffset', window );">Construction amount</a></td>
<td class="nump">401,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_CapitalExpenditure', window );">Additional capital expenditure</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="nump">&#165; 95.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member] | Chenyuan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforCIPProjectDetailsLineItems', window );"><strong>Prepayment for CIP Project (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_Prepayment', window );">Prepayment</a></td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CapitalExpenditure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of capital expenditure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CapitalExpenditure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_Prepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_Prepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentforCIPProjectDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentforCIPProjectDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionContractCostProgressPaymentOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of progress payment netted against construction contract cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6471471&amp;loc=d3e48698-109348<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionContractCostProgressPaymentOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentBuildingAndBuildingImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentBuildingAndBuildingImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_ChenyuanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_ChenyuanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599318320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepayment for CIP Project (Details) - Schedule of future minimum capital expenditures - Capital Expenditure [Member]<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems', window );"><strong>Prepayment for CIP Project (Details) - Schedule of future minimum capital expenditures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">$ 3,479,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">9,988,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 13,467,372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=upc_CapitalExpenditureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=upc_CapitalExpenditureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599035008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Purchase of a Property (Details)<br> $ in Thousands, &#165; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 06, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 06, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForPurchaseOfAPropertyAbstract', window );"><strong>Prepayment for Purchase of a Property [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EquityInterest', window );">Equity interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OfficeSpaceSquareMeters', window );">Office space square meters</a></td>
<td class="nump">2,749<span></span>
</td>
<td class="nump">2,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalDeferredPurchasePrice', window );">Total purchase price</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">&#165; 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PercentageOfPrepayment', window );">Percentage of prepayment</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Total purchase price payable percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PayableDeliveryPropertyPercentage', window );">Payable delivery property percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Prepayment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="nump">&#165; 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OfficeSpaceSquareMeters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Office space Square meters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OfficeSpaceSquareMeters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PayableDeliveryPropertyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payable delivery property percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PayableDeliveryPropertyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PercentageOfPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PercentageOfPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForPurchaseOfAPropertyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForPurchaseOfAPropertyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaymentFeesOnAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaymentFeesOnAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalDeferredPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalDeferredPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507596056928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Bank Loans (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 24, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 24, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 14, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShortTermBankLoansDetailsLineItems', window );"><strong>Short-Term Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableToBankCurrent', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,405,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Working capital term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 24,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Fixed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,852<span></span>
</td>
<td class="nump">$ 149,303<span></span>
</td>
<td class="nump">$ 157,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=upc_JiangxiLulingRuralCommercialBankMember', window );">LRC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShortTermBankLoansDetailsLineItems', window );"><strong>Short-Term Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableToBankCurrent', window );">Borrowing amount</a></td>
<td class="nump">$ 1,124,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,405,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,548,000<span></span>
</td>
<td class="nump">$ 1,238,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10<span></span>
</td>
<td class="nump">&#165; 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10<span></span>
</td>
<td class="nump">&#165; 8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Working capital term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Mar. 13,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 14,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 15,  2022<span></span>
</td>
<td class="text">Mar. 17,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Fixed interest rate</a></td>
<td class="nump">4.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.62%<span></span>
</td>
<td class="nump">4.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShortTermBankLoansDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShortTermBankLoansDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=upc_JiangxiLulingRuralCommercialBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=upc_JiangxiLulingRuralCommercialBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599142656">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Short-Term Bank Loans (Details) - Schedule of short-term bank loans - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,936,184<span></span>
</td>
<td class="nump">$ 4,334,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_Maturity30To90DaysMember', window );">Maturity date on June 15, 2022, interest rate 4.81% per annum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,548,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_MaturityOver90DaysMember', window );">Maturity date on March 17, 2022, interest rate 4.81% per annum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,238,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysOneMember', window );">Maturity date on March 13, 2023, interest rate 4.62% per annum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,124,624<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysTwoMember', window );">Maturity date on June 14, 2023, interest rate 4.62% per annum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,405,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysThreeMember', window );">Maturity date on June 30, 2022, interest rate 4.50% per annum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,548,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysFourMember', window );">Maturity date on June 24, 2023, interest rate 4.20% per annum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 1,405,780<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On June 16, 2021, the Company&#8217;s subsidiary, Jiangxi
Universe, signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB10 million (equivalent
to $1,548,000) as working capital for one year, with the maturity date on June 15, 2022. The fixed interest rate of the loan was 4.81%
per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On March 18, 2021, the Company&#8217;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,238,400) as working capital for one year, with
the maturity date on March 17, 2022. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for
this loan. The loan was fully repaid upon maturity.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">On March 14, 2022, the Company&#8217;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,124,624) as working capital for one year, with
the maturity date on March 13, 2023. The fixed interest rate of the loan was 4.62% per annum. There was no guarantee requirement for
this loan.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">On June 15, 2022, the Company&#8217;s subsidiary, Jiangxi
Universe, entered into a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,405,780) as working capital for one year,
with the maturity date on June 14, 2023. The fixed interest rate of the loan was 4.62% per annum. Certain related parties of the Company,
including Mr. Gang Lai, the Company&#8217;s controlling shareholder, chairman of the board of directors, and chief executive officer,
Ms. Lin Yang, the Company&#8217;s chief financial officer, Ms. Xing Wu, Mr. Gang Lai&#8217;s spouse, and the Company&#8217;s WFOE, Universe
Technology, jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">On June 30, 2021, the Company&#8217;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,548,000) as working capital for
one year, with the maturity date on June 30, 2022. The fixed interest rate of the loan was 4.5% per annum. Certain related parties of
the Company, including Mr. Gang Lai, the Company&#8217;s controlling shareholder, Mr. Gang Lai&#8217;s spouse, Mrs. Xing Wu, and the
Company&#8217;s subsidiary, Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantees
for this loan. The loan was fully repaid upon maturity.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">On June 24, 2022, the Company&#8217;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,405,780) as working capital for
one year, with the maturity date on June 24, 2023. The fixed interest rate of the loan was 4.2% per annum. Jiangxi Province Financing
Guarantee Group Co., Ltd., an unrelated third party, signed a guarantee agreement with Bank of Communications to provide credit guarantee
for this loan.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_Maturity30To90DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_Maturity30To90DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_MaturityOver90DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_MaturityOver90DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507601889344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 06, 2021</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th"><div>Jan. 13, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationRelatedPartyDescription', window );">Related party description</a></td>
<td class="text">As disclosed in Note 12, on May 6, 2021, the Company
entered into a real estate property purchase agreement with a related party, Jiangxi Yueshang, to purchase certain residential apartment
and commercial office space totaling 2,749.30 square meters with total purchase price of RMB32 million (approximately $4.5 million).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentAmount', window );">Prepayment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,249,248)<span></span>
</td>
<td class="nump">&#165; 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EquityInterestOwnershipPercentage', window );">Equity interest ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EquityInterestOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity interest ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EquityInterestOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRelatedPartyDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of related party involvement in transaction resulting in deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer; and whether former subsidiary or acquirer of group of assets would be related party after deconsolidation and derecognition transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRelatedPartyDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594895856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Schedule of nature of relationships with related parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember', window );">Mr. Gang Lai [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Relationship with the group</a></td>
<td class="text">The Company&#8217;s controlling shareholder, Chief Executive Officer and chairman of the Company&#8217;s Board of Directors<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MsLinYangMember', window );">Ms. Lin Yang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Relationship with the group</a></td>
<td class="text">Chief Financial Officer and Director<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember', window );">Greatest Group (China) Financial Management Limited (&#8220;Greatest Group&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Relationship with the group</a></td>
<td class="text">One of the Company&#8217;s minority shareholders owns 8.7% of the ownership interest in this entity<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember', window );">Foshan Shangyu Investment Holding Co., Ltd (&#8220;Foshan Shangyu&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Relationship with the group</a></td>
<td class="text">An affiliated entity of the Company, 90% owned by and controlled by the Company&#8217;s Chief Executive Officer<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the terms and manner of settlement of the related party transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MsLinYangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MsLinYangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507607202960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Schedule of due from related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_NameAbstract', window );"><strong>Name</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 236,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GreatestGroupMember', window );">Greatest Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_NameAbstract', window );"><strong>Name</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">235,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_FoshanShangyuMember', window );">Foshan Shangyu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_NameAbstract', window );"><strong>Name</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_NameAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_NameAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOtherRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount receivable from related parties classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromOtherRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GreatestGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GreatestGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_FoshanShangyuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_FoshanShangyuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507607196832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Schedule of due to related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_NameAbstract0', window );"><strong>Name</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total due to related parties</a></td>
<td class="nump">$ 3,379,263<span></span>
</td>
<td class="nump">$ 19,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember', window );">Mr. Gang Lai [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_NameAbstract0', window );"><strong>Name</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total due to related parties</a></td>
<td class="nump">3,379,263<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrsLinYangMember', window );">Mrs. Lin Yang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_NameAbstract0', window );"><strong>Name</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total due to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 19,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_NameAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_NameAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrsLinYangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrsLinYangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507601586512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_TaxesDetailsLineItems', window );"><strong>Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings', window );">Foreign tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PreferentialTaxTreatmentDescription', window );">Preferential tax treatment, description</a></td>
<td class="text">Under this preferential tax treatment, HNTEs are entitled
to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one
of the Company&#8217;s main operating subsidiaries in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of
15% beginning November 2016 with a term of three years. In December 2019, Jiangxi Universe successfully renewed its HNTE certification
with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2022. In
November 2022, Jiangxi Universe successfully further renewed its HNTE certification with local government and will continue to enjoy the
reduced income tax rate of 15% for another three years through November 2025. Universe Trade, another operating subsidiary of the Company
in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15% beginning December 2020 with a term of three years
through December 2023. EIT is typically governed by the local tax authority in the PRC. Each local tax authority at times may grant tax
holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the years
ended September 30, 2022, 2021 and 2020 were reported at a blended reduced rate as a result of certain of the PRC subsidiaries of the
Company&#8217;s being approved as a HNTE and enjoying a 15% reduced income tax rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAndNoncurrent', window );">PRC corporate income taxes</a></td>
<td class="nump">$ 694,955<span></span>
</td>
<td class="nump">$ 1,518,979<span></span>
</td>
<td class="nump">$ 118,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare', window );">Tax holidays on net income per share</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">Hong Kong [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_TaxesDetailsLineItems', window );"><strong>Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign', window );">Subject to profit taxes rate</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PreferentialTaxTreatmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferential tax treatment, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PreferentialTaxTreatmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_TaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_TaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in foreign income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599049920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details) - Schedule of components of the income tax provision (benefit) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems', window );"><strong>Taxes (Details) - Schedule of components of the income tax provision (benefit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax provision</a></td>
<td class="nump">$ 1,357,697<span></span>
</td>
<td class="nump">$ 3,026,867<span></span>
</td>
<td class="nump">$ 2,552,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision (benefit)</a></td>
<td class="num">(605,278)<span></span>
</td>
<td class="num">(668,341)<span></span>
</td>
<td class="num">(9,886)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="nump">752,419<span></span>
</td>
<td class="nump">2,358,526<span></span>
</td>
<td class="nump">2,542,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KY', window );">Cayman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems', window );"><strong>Taxes (Details) - Schedule of components of the income tax provision (benefit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">Hong Kong [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems', window );"><strong>Taxes (Details) - Schedule of components of the income tax provision (benefit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">PRC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems', window );"><strong>Taxes (Details) - Schedule of components of the income tax provision (benefit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax provision</a></td>
<td class="nump">1,357,697<span></span>
</td>
<td class="nump">3,026,867<span></span>
</td>
<td class="nump">2,552,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision (benefit)</a></td>
<td class="num">$ (605,278)<span></span>
</td>
<td class="num">$ (668,341)<span></span>
</td>
<td class="num">$ (9,886)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594575904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details) - Schedule of table reconciles the china statutory rates to the company&#8217;s effective tax rate<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract', window );"><strong>Schedule of Table Reconciles the China Statutory Rates to the Companys Effective Tax Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory PRC income tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays', window );">Effect of income tax holiday</a></td>
<td class="num">(8.70%)<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Permanent difference</a></td>
<td class="num">(22.30%)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Non-PRC entities not subject to PRC income tax</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Impact on DTA due to change in applicable income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(9.40%)<span></span>
</td>
<td class="nump">17.10%<span></span>
</td>
<td class="nump">25.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a tax holiday.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507598639456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes (Details) - Schedule of deferred tax assets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 1,210,855<span></span>
</td>
<td class="nump">$ 785,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">136,817<span></span>
</td>
<td class="nump">84,447<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total</a></td>
<td class="nump">1,347,672<span></span>
</td>
<td class="nump">869,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">$ 1,347,672<span></span>
</td>
<td class="nump">$ 869,997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507601789456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes (Details) - Schedule of taxes payable - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfTaxesPayableAbstract', window );"><strong>Schedule of Taxes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 669,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Value added tax payable</a></td>
<td class="nump">115,087<span></span>
</td>
<td class="nump">326,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Other taxes payable</a></td>
<td class="nump">52,263<span></span>
</td>
<td class="nump">105,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Total taxes payable</a></td>
<td class="nump">$ 167,350<span></span>
</td>
<td class="nump">$ 1,101,460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfTaxesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfTaxesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6419918&amp;loc=d3e35281-107843<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594477360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignFinancialInstitutionsMandatedDeposits', window );">Deposit at financial institutions (in Dollars)</a></td>
<td class="nump">$ 5,711,423<span></span>
</td>
<td class="nump">$ 5,892,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=upc_CustomerMember', window );">Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_SupplierOneMember', window );">Supplier One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.30%<span></span>
</td>
<td class="nump">19.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_SupplierTwoMember', window );">Supplier Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_supplierMember', window );">supplier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=upc_TotalRevenueMember', window );">Total Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">32.20%<span></span>
</td>
<td class="nump">30.40%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=upc_GubenYanlingPillMember', window );">Guben Yanling Pill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">42.50%<span></span>
</td>
<td class="nump">40.30%<span></span>
</td>
<td class="nump">38.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ConcentrationRiskThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ConcentrationRiskThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ConcentrationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ConcentrationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignFinancialInstitutionsMandatedDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of mandated deposits required of branches of foreign institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=d3e65207-112826<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignFinancialInstitutionsMandatedDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=upc_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=upc_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=upc_CustomersOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=upc_CustomersOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_SupplierOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_SupplierOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_SupplierTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_SupplierTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_supplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_supplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=upc_TotalRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=upc_TotalRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=upc_GubenYanlingPillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=upc_GubenYanlingPillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507591926592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br> $ / shares in Units, &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 07, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 02, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 13, 2017 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Feb. 21, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 20, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 21, 2016 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 29, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PublicOfferingPrice', window );">Public offering price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">&#165; 48.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds (in Dollars) | $</a></td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ordinary shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ReserveIsEqualPercentage', window );">Reserve is equal percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash transferred (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,211,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ordinary shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=upc_PRCMember', window );">PRC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash transferred (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,807,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_UnderwriterWarrantsMember', window );">Underwriter warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EquityMethodInvestmentOwnershipsPercentage', window );">Offering price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary issued shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PublicOfferingPrice', window );">Public offering price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OptionToPurchaseAdditionalShares', window );">Option to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds (in Dollars) | $</a></td>
<td class="nump">$ 25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=upc_UnderwriterWarrantsMember', window );">Underwriter warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Ordinary shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise price amount (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=upc_CashDividendsMember', window );">Cash dividends [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsShareBasedCompensationCash', window );">Cash dividend (in Yuan Renminbi) | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 20.0<span></span>
</td>
<td class="nump">&#165; 30.0<span></span>
</td>
<td class="nump">&#165; 30.0<span></span>
</td>
<td class="nump">&#165; 10.0<span></span>
</td>
<td class="nump">&#165; 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_CashDividendDescription', window );">Description of dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A total of RMB130 million (approximately $19.1 million) cash dividend was declared from September
2016 to February 2019, among which, approximately RMB20 million ($3.1 million) was paid in cash to its shareholders in 2018 and the remaining
RMB110 million ($16 million) was paid to its shareholders in 2019.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=upc_StatutoryReserveAndRestrictedNetAssetsMember', window );">Statutory Reserve and Restricted Net Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_StatutorySurplusPercentage', window );">Statutory surplus percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted amounts (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,439,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_RestrictedNetAssets', window );">Restricted net assets (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,786,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">Hong Kong [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash transferred (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,746<span></span>
</td>
<td class="nump">$ 11,358,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_UniverseINCMember', window );">Universe INC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OriginalSharesParValue', window );">Original shares par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrdinarySharesParValue', window );">Ordinary shares par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ReorganizationShares', window );">Reorganization shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_UniverseINCMember', window );">Universe INC [Member] | Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrdinarySharesOutstandingDescription', window );">Ordinary shares outstanding description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As a result of this forward split of
the outstanding ordinary shares at a ratio of 320-for-1 share, a total of 16,000,000 shares were issued and outstanding after the split.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CashDividendDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CashDividendDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EquityMethodInvestmentOwnershipsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EquityMethodInvestmentOwnershipsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OrdinarySharesOutstandingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares outstanding description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OrdinarySharesOutstandingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OrdinarySharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares par value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OrdinarySharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OriginalSharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Original shares par value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OriginalSharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ReorganizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reorganization shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ReorganizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ReserveIsEqualPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserve is equal percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ReserveIsEqualPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_RestrictedNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_RestrictedNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StatutorySurplusPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory surplus percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StatutorySurplusPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsShareBasedCompensationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsShareBasedCompensationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=upc_PRCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=upc_PRCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_UnderwriterWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_UnderwriterWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=upc_UnderwriterWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=upc_UnderwriterWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=upc_CashDividendsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=upc_CashDividendsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=upc_StatutoryReserveAndRestrictedNetAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=upc_StatutoryReserveAndRestrictedNetAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_UniverseINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_UniverseINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507607262320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpenditureDiscontinuedOperations', window );">Future minimum capital expenditures amount</a></td>
<td class="nump">$ 13.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseCapitalSecurities', window );">Total amount of capital expenditure</a></td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpenditureDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital expenditure attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpenditureDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense incurred during the reporting period on capital securities issued by the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507599086176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Reporting segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507600898800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details) - Schedule of revenue by product source - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfRevenueByProductSourceAbstract', window );"><strong>Schedule Of Revenue By Product Source Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfOtherPropertyOperatingExpense', window );">Sales of TCMD products manufactured by the Company</a></td>
<td class="nump">$ 23,988,177<span></span>
</td>
<td class="nump">$ 29,559,286<span></span>
</td>
<td class="nump">$ 18,374,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Sales of third-party products</a></td>
<td class="nump">16,154,974<span></span>
</td>
<td class="nump">18,422,745<span></span>
</td>
<td class="nump">12,329,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 40,143,151<span></span>
</td>
<td class="nump">$ 47,982,031<span></span>
</td>
<td class="nump">$ 30,703,960<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfRevenueByProductSourceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfRevenueByProductSourceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfOtherPropertyOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other operating costs incurred during the reporting period and may include amounts paid to maintain the property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfOtherPropertyOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507595712512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details) - Schedule of total revenues by product categories - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SalesOfTcmdProductsAbstract', window );"><strong>Sales of TCMD products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubtotalOfTCMDProductsSales', window );">Sub-total of TCMD products sales</a></td>
<td class="nump">$ 23,988,177<span></span>
</td>
<td class="nump">$ 29,559,286<span></span>
</td>
<td class="nump">$ 18,374,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SalesOfThirdPartyProductsAbstract', window );"><strong>Sales of third-party products</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubtotalOfThirdpartyProductsSales', window );">Subtotal of third-party products sales</a></td>
<td class="nump">16,154,974<span></span>
</td>
<td class="nump">18,422,745<span></span>
</td>
<td class="nump">12,329,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">40,143,151<span></span>
</td>
<td class="nump">47,982,031<span></span>
</td>
<td class="nump">30,703,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Medicinal liquor products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SalesOfTcmdProductsAbstract', window );"><strong>Sales of TCMD products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubtotalOfTCMDProductsSales', window );">Sub-total of TCMD products sales</a></td>
<td class="nump">1,095,336<span></span>
</td>
<td class="nump">1,951,679<span></span>
</td>
<td class="nump">1,616,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentOneMember', window );">Other chronic condition treatment products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SalesOfTcmdProductsAbstract', window );"><strong>Sales of TCMD products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubtotalOfTCMDProductsSales', window );">Sub-total of TCMD products sales</a></td>
<td class="nump">19,140,419<span></span>
</td>
<td class="nump">22,978,001<span></span>
</td>
<td class="nump">14,059,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentTwoMember', window );">Cold and flu medicines [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SalesOfTcmdProductsAbstract', window );"><strong>Sales of TCMD products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubtotalOfTCMDProductsSales', window );">Sub-total of TCMD products sales</a></td>
<td class="nump">3,752,422<span></span>
</td>
<td class="nump">4,629,606<span></span>
</td>
<td class="nump">2,699,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentThreeMember', window );">Biochemical drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SalesOfThirdPartyProductsAbstract', window );"><strong>Sales of third-party products</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubtotalOfThirdpartyProductsSales', window );">Subtotal of third-party products sales</a></td>
<td class="nump">13,730,424<span></span>
</td>
<td class="nump">16,082,546<span></span>
</td>
<td class="nump">10,325,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentFourMember', window );">Traditional Chinese medicine pieces [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SalesOfThirdPartyProductsAbstract', window );"><strong>Sales of third-party products</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubtotalOfThirdpartyProductsSales', window );">Subtotal of third-party products sales</a></td>
<td class="nump">30,202<span></span>
</td>
<td class="nump">20,705<span></span>
</td>
<td class="nump">47,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentFiveMember', window );">Medical instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SalesOfThirdPartyProductsAbstract', window );"><strong>Sales of third-party products</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubtotalOfThirdpartyProductsSales', window );">Subtotal of third-party products sales</a></td>
<td class="nump">$ 2,394,348<span></span>
</td>
<td class="nump">2,318,536<span></span>
</td>
<td class="nump">1,950,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentSixMember', window );">Dietary supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SalesOfThirdPartyProductsAbstract', window );"><strong>Sales of third-party products</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_SubtotalOfThirdpartyProductsSales', window );">Subtotal of third-party products sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
<td class="nump">$ 6,463<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SalesOfTcmdProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SalesOfTcmdProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SalesOfThirdPartyProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SalesOfThirdPartyProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SubtotalOfTCMDProductsSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SubtotalOfTCMDProductsSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SubtotalOfThirdpartyProductsSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subtotal of third-party products sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SubtotalOfThirdpartyProductsSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507608075280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, description</a></td>
<td class="text">The Company evaluated the subsequent event through
the date of this report, and concluded that there are no material reportable subsequent events need to be disclosed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507608100352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_MinorityInterestsOwnershipPercentageByParent', window );">Subsidiary exceeded percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_MinorityInterestsOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidiary exceeded percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_MinorityInterestsOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507595769824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets - Parent [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_CurrentAssetsAbstract0', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 28,917<span></span>
</td>
<td class="nump">$ 110,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">13,148,594<span></span>
</td>
<td class="nump">13,725,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,177,511<span></span>
</td>
<td class="nump">13,835,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_NonCurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investment in subsidiaries</a></td>
<td class="nump">33,264,812<span></span>
</td>
<td class="nump">45,098,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">46,442,323<span></span>
</td>
<td class="nump">58,934,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">LIABILITIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareholdersEquityAbstract0', window );"><strong>SHAREHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares issued and outstanding as of September 30, 2021 and 2020</a></td>
<td class="nump">67,969<span></span>
</td>
<td class="nump">67,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">29,279,159<span></span>
</td>
<td class="nump">29,279,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">18,761,900<span></span>
</td>
<td class="nump">27,498,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(1,666,705)<span></span>
</td>
<td class="nump">2,088,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">46,442,323<span></span>
</td>
<td class="nump">58,934,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 46,442,323<span></span>
</td>
<td class="nump">$ 58,934,353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CurrentAssetsAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CurrentAssetsAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_NonCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_NonCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShareholdersEquityAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShareholdersEquityAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507598653568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets (Parentheticals) - Parent [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507594771520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of income and comprehensive income - Parent [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">$ (384,214)<span></span>
</td>
<td class="num">$ (1,177,869)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OtherIncomeExpensesAbstract0', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOtherShortTermBorrowings', window );">Income from short-term investments</a></td>
<td class="num">(470,477)<span></span>
</td>
<td class="nump">239,549<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other expenses</a></td>
<td class="num">(420)<span></span>
</td>
<td class="num">(60,751)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of subsidiaries</a></td>
<td class="num">(7,881,455)<span></span>
</td>
<td class="nump">12,319,023<span></span>
</td>
<td class="nump">7,558,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="num">(8,736,566)<span></span>
</td>
<td class="nump">11,319,952<span></span>
</td>
<td class="nump">7,558,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments', window );">Foreign currency translation adjustments</a></td>
<td class="num">(3,755,464)<span></span>
</td>
<td class="nump">1,193,369<span></span>
</td>
<td class="nump">860,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to the Company</a></td>
<td class="num">$ (12,492,030)<span></span>
</td>
<td class="nump">$ 12,513,321<span></span>
</td>
<td class="nump">$ 8,418,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OtherIncomeExpensesAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OtherIncomeExpensesAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense incurred during the reporting period on other short-term borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to temporary equity resulting from foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140507590807712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of cash flows - Parent [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_CashFlowsFromOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="num">$ (8,736,566)<span></span>
</td>
<td class="nump">$ 11,319,952<span></span>
</td>
<td class="nump">$ 7,558,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EquityInEarningsOfSubsidiary', window );">Equity in earnings of subsidiary</a></td>
<td class="nump">7,881,455<span></span>
</td>
<td class="num">(12,319,027)<span></span>
</td>
<td class="num">(7,558,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Short-term investment income</a></td>
<td class="nump">470,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(384,634)<span></span>
</td>
<td class="num">(999,075)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_CashFlowsFromInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromShortTermInvestments', window );">Payment for short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(15,330,660)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Redemption of short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,801,927<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(13,528,733)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_CashFlowsFromFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of ordinary shares in IPO</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25,957,457<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_CashLentToSubsidiaries', window );">Cash lent to subsidiaries</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11,358,764)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Cash repayment from subsidiaries</a></td>
<td class="nump">303,746<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">303,746<span></span>
</td>
<td class="nump">14,598,693<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</a></td>
<td class="num">(588)<span></span>
</td>
<td class="nump">39,508<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">CHANGES IN CASH</a></td>
<td class="num">(81,476)<span></span>
</td>
<td class="nump">110,393<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, beginning of year</a></td>
<td class="nump">110,393<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, end of year</a></td>
<td class="nump">$ 28,917<span></span>
</td>
<td class="nump">$ 110,393<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CashFlowsFromFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CashFlowsFromFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CashFlowsFromInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CashFlowsFromInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CashFlowsFromOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CashFlowsFromOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CashLentToSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Cash lent to subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CashLentToSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EquityInEarningsOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity in earnings of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EquityInEarningsOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>f20f2022_universe_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:upc="http://www.UniversePharmaceuticalsINC.com/20220930"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="upc-20220930.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseHKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JiangxiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-29</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseHanheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:OwnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JxRcbBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:OwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JxRcbBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-25</startDate>
            <endDate>2018-05-01</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-25</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:LessThan3MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:LessThan3MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From4To6MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From4To6MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From7To9MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From7To9MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From10To12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From10To12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:Over1YearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:Over1YearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-06</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-09-06</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:YunnanFaxiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">upc:AmortizationExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-25</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ChenyuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ChenyuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">upc:CapitalExpenditureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-06</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-05-06</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-14</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-14</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2022-06-24</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-24</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:Maturity30To90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:Maturity30To90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOver90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOver90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2022-01-13</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MsLinYangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GreatestGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GreatestGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:FoshanShangyuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:FoshanShangyuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrsLinYangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrsLinYangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:TotalRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:TotalRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:TotalRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomersOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-02</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-29</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-21</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-13</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-28</startDate>
            <endDate>2018-02-02</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-21</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:PRCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <dei:DocumentType contextRef="c0">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0">001-40231</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">Universe Pharmaceuticals INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0">265 Jingjiu Avenue,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">Jinggangshan Economic and Technological Development Zone</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0">Ji&#x2019;an, Jiangxi</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c0">CN</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c0">343100</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName contextRef="c1">Gang Lai</dei:ContactPersonnelName>
    <dei:ContactPersonnelEmailAddress contextRef="c1">gang.lai@universe-pharmacy.com</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1 contextRef="c1">265 Jingjiu Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1">Jinggangshan Economic and Technological Development Zone</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1">Ji&#x2019;an, Jiangxi Province</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c1">CN</dei:EntityAddressCountry>
    <dei:Security12bTitle contextRef="c0">Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">UPC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">21750000</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard contextRef="c0">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:AuditorName contextRef="c0">YCM CPA, Inc.</dei:AuditorName>
    <dei:AuditorFirmId contextRef="c0">6781</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="c0">Irvine, California</dei:AuditorLocation>
    <us-gaap:Cash contextRef="c2" decimals="0" unitRef="usd">5711458</us-gaap:Cash>
    <us-gaap:Cash contextRef="c3" decimals="0" unitRef="usd">8077908</us-gaap:Cash>
    <us-gaap:ShortTermInvestments contextRef="c2" decimals="0" unitRef="usd">13148594</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c3" decimals="0" unitRef="usd">13725204</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" unitRef="usd">15183890</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" unitRef="usd">15573742</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" unitRef="usd">2206488</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" unitRef="usd">2462542</us-gaap:InventoryNet>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="c3" decimals="0" unitRef="usd">236982</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:Supplies contextRef="c2" decimals="0" unitRef="usd">16701</us-gaap:Supplies>
    <us-gaap:Supplies contextRef="c3" decimals="0" unitRef="usd">2738313</us-gaap:Supplies>
    <us-gaap:DeferredCostsCurrent contextRef="c3" decimals="0" unitRef="usd">7492320</us-gaap:DeferredCostsCurrent>
    <upc:PrepaymentForAcquisitionCurrent contextRef="c2" decimals="0" unitRef="usd">3514450</upc:PrepaymentForAcquisitionCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c2" decimals="0" unitRef="usd">1724099</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c3" decimals="0" unitRef="usd">174053</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" unitRef="usd">41505680</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" unitRef="usd">50481064</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" unitRef="usd">4250638</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">4681353</us-gaap:PropertyPlantAndEquipmentNet>
    <upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent contextRef="c2" decimals="0" unitRef="usd">2249248</upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent>
    <upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent contextRef="c3" decimals="0" unitRef="usd">2476800</upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent>
    <upc:PrepaymentsForConstructionInProgress contextRef="c2" decimals="0" unitRef="usd">9326296</upc:PrepaymentsForConstructionInProgress>
    <upc:PrepaymentsForConstructionInProgress contextRef="c3" decimals="0" unitRef="usd">10712160</upc:PrepaymentsForConstructionInProgress>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c2" decimals="0" unitRef="usd">157451</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c3" decimals="0" unitRef="usd">178483</us-gaap:OtherIntangibleAssetsNet>
    <upc:InvestmentInEquitySecurities contextRef="c2" decimals="0" unitRef="usd">702890</upc:InvestmentInEquitySecurities>
    <upc:InvestmentInEquitySecurities contextRef="c3" decimals="0" unitRef="usd">744924</upc:InvestmentInEquitySecurities>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c2" decimals="0" unitRef="usd">1347672</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c3" decimals="0" unitRef="usd">869997</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="0" unitRef="usd">18034195</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="0" unitRef="usd">19663717</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="0" unitRef="usd">59539875</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" unitRef="usd">70144781</us-gaap:Assets>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="c2" decimals="0" unitRef="usd">3936184</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="c3" decimals="0" unitRef="usd">4334400</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="0" unitRef="usd">3075393</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" unitRef="usd">5310526</us-gaap:AccountsPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="0" unitRef="usd">167350</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c3" decimals="0" unitRef="usd">1101460</us-gaap:TaxesPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">3379263</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="c3" decimals="0" unitRef="usd">19723</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">2539362</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">444319</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">13097552</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">11210428</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="6" unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="6" unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="INF" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="INF" unitRef="shares">21750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="INF" unitRef="shares">21750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">21750000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">21750000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" unitRef="usd">67969</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" unitRef="usd">67969</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" unitRef="usd">29279159</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" unitRef="usd">29279159</us-gaap:AdditionalPaidInCapital>
    <upc:StatutoryReserve contextRef="c2" decimals="0" unitRef="usd">2439535</upc:StatutoryReserve>
    <upc:StatutoryReserve contextRef="c3" decimals="0" unitRef="usd">2439535</upc:StatutoryReserve>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" unitRef="usd">16322365</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">25058931</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="0" unitRef="usd">-1666705</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" unitRef="usd">2088759</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">46442323</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">58934353</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" unitRef="usd">59539875</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" unitRef="usd">70144781</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">40143151</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="0" unitRef="usd">47982031</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" unitRef="usd">30703960</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" unitRef="usd">18251815</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c4" decimals="0" unitRef="usd">22655854</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c5" decimals="0" unitRef="usd">16610140</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" unitRef="usd">21891336</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c4" decimals="0" unitRef="usd">25326177</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c5" decimals="0" unitRef="usd">14093820</us-gaap:GrossProfit>
    <us-gaap:SellingExpense contextRef="c0" decimals="0" unitRef="usd">19083135</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c4" decimals="0" unitRef="usd">2973531</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c5" decimals="0" unitRef="usd">1555546</us-gaap:SellingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">2602624</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" unitRef="usd">3296844</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" unitRef="usd">1703424</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">7644375</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" unitRef="usd">5465662</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" unitRef="usd">583125</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" unitRef="usd">29330134</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="0" unitRef="usd">11736037</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" unitRef="usd">3842095</us-gaap:OperatingExpenses>
    <upc:IncomeFromOperation contextRef="c0" decimals="0" unitRef="usd">7438798</upc:IncomeFromOperation>
    <upc:IncomeFromOperation contextRef="c4" decimals="0" unitRef="usd">-13590140</upc:IncomeFromOperation>
    <upc:IncomeFromOperation contextRef="c5" decimals="0" unitRef="usd">-10251725</upc:IncomeFromOperation>
    <us-gaap:InterestExpense contextRef="c0" decimals="0" unitRef="usd">162400</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c4" decimals="0" unitRef="usd">101604</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c5" decimals="0" unitRef="usd">123760</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c0" decimals="0" unitRef="usd">48940</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c4" decimals="0" unitRef="usd">-80434</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c5" decimals="0" unitRef="usd">-49352</us-gaap:OtherOperatingIncomeExpenseNet>
    <upc:ShorttermInvestmentIncome contextRef="c0" decimals="0" unitRef="usd">470477</upc:ShorttermInvestmentIncome>
    <upc:ShorttermInvestmentIncome contextRef="c4" decimals="0" unitRef="usd">-239549</upc:ShorttermInvestmentIncome>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c0" decimals="0" unitRef="usd">38588</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c4" decimals="0" unitRef="usd">30827</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c5" decimals="0" unitRef="usd">21820</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" unitRef="usd">-545349</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c4" decimals="0" unitRef="usd">88338</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c5" decimals="0" unitRef="usd">-151292</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-7984147</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c4" decimals="0" unitRef="usd">13678478</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="0" unitRef="usd">10100433</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">752419</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c4" decimals="0" unitRef="usd">2358526</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">2542211</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" unitRef="usd">-8736566</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c4" decimals="0" unitRef="usd">11319952</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="0" unitRef="usd">7558222</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c0" decimals="0" unitRef="usd">3755464</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c4" decimals="0" unitRef="usd">-1193369</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c5" decimals="0" unitRef="usd">-860623</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-12492030</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c4" decimals="0" unitRef="usd">12513321</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="0" unitRef="usd">8418845</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-0.4</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="2" unitRef="usdPershares">0.6</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="shares">21750000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c4" decimals="0" unitRef="shares">18980822</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="0" unitRef="shares">16000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c6" decimals="0" unitRef="shares">16000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="0" unitRef="usd">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" unitRef="usd">3679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" unitRef="usd">2439535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" unitRef="usd">6180757</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" unitRef="usd">34767</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="0" unitRef="usd">12384059</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c15" decimals="0" unitRef="usd">7558222</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="0" unitRef="usd">7558222</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c16" decimals="0" unitRef="usd">860623</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c5" decimals="0" unitRef="usd">860623</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding contextRef="c17" decimals="0" unitRef="shares">16000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" unitRef="usd">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" unitRef="usd">3679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" unitRef="usd">2439535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" unitRef="usd">13738979</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" unitRef="usd">895390</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="0" unitRef="usd">20802904</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c23" decimals="0" unitRef="shares">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c23" decimals="0" unitRef="usd">17969</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c24" decimals="0" unitRef="usd">28732031</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c4" decimals="0" unitRef="usd">28750000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts contextRef="c24" decimals="0" unitRef="usd">-3131872</upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts>
    <upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts contextRef="c4" decimals="0" unitRef="usd">-3131872</upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts>
    <us-gaap:ProfitLoss contextRef="c26" decimals="0" unitRef="usd">11319952</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c4" decimals="0" unitRef="usd">11319952</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c27" decimals="0" unitRef="usd">1193369</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c4" decimals="0" unitRef="usd">1193369</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding contextRef="c28" decimals="0" unitRef="shares">21750000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="0" unitRef="usd">67969</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="0" unitRef="usd">29279159</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="0" unitRef="usd">2439535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="0" unitRef="usd">25058931</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="0" unitRef="usd">2088759</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">58934353</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c36" decimals="0" unitRef="usd">-8736566</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" unitRef="usd">-8736566</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c37" decimals="0" unitRef="usd">-3755464</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" unitRef="usd">-3755464</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding contextRef="c38" decimals="0" unitRef="shares">21750000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c38" decimals="0" unitRef="usd">67969</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c39" decimals="0" unitRef="usd">29279159</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="0" unitRef="usd">2439535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="0" unitRef="usd">16322365</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="0" unitRef="usd">-1666705</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">46442323</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-8736566</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" unitRef="usd">11319952</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">7558222</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" unitRef="usd">533949</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c4" decimals="0" unitRef="usd">446878</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c5" decimals="0" unitRef="usd">410079</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OtherAssetImpairmentCharges contextRef="c0" decimals="0" unitRef="usd">983</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges contextRef="c4" decimals="0" unitRef="usd">1559</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="0" unitRef="usd">419353</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c4" decimals="0" unitRef="usd">-230175</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c5" decimals="0" unitRef="usd">98102</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c0" decimals="0" unitRef="usd">15774</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c5" decimals="0" unitRef="usd">-75391</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">-605278</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c4" decimals="0" unitRef="usd">-668341</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">-9886</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <upc:ShorttermInvestmentsIncome contextRef="c0" decimals="0" unitRef="usd">470477</upc:ShorttermInvestmentsIncome>
    <upc:ShorttermInvestmentsIncome contextRef="c4" decimals="0" unitRef="usd">-239549</upc:ShorttermInvestmentsIncome>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" unitRef="usd">1549312</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c4" decimals="0" unitRef="usd">3867457</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c5" decimals="0" unitRef="usd">4107520</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" unitRef="usd">-16586</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c4" decimals="0" unitRef="usd">451634</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c5" decimals="0" unitRef="usd">-888607</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c0" decimals="0" unitRef="usd">-2681214</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c4" decimals="0" unitRef="usd">2717085</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:IncreaseDecreaseInPrepaidAdvertising contextRef="c0" decimals="0" unitRef="usd">-7385695</us-gaap:IncreaseDecreaseInPrepaidAdvertising>
    <us-gaap:IncreaseDecreaseInPrepaidAdvertising contextRef="c4" decimals="0" unitRef="usd">7434240</us-gaap:IncreaseDecreaseInPrepaidAdvertising>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c0" decimals="0" unitRef="usd">-236982</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c4" decimals="0" unitRef="usd">237720</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" unitRef="usd">1699929</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c4" decimals="0" unitRef="usd">168188</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="0" unitRef="usd">-12407</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="0" unitRef="usd">-1896621</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c4" decimals="0" unitRef="usd">2457337</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c5" decimals="0" unitRef="usd">639427</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable contextRef="c0" decimals="0" unitRef="usd">-904127</us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable>
    <us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable contextRef="c4" decimals="0" unitRef="usd">-298620</us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable>
    <us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable contextRef="c5" decimals="0" unitRef="usd">731518</us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="0" unitRef="usd">2318474</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c4" decimals="0" unitRef="usd">31436</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c5" decimals="0" unitRef="usd">-30408</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-1312346</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="0" unitRef="usd">-2055847</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="0" unitRef="usd">6115157</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" unitRef="usd">93703</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c4" decimals="0" unitRef="usd">444505</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="0" unitRef="usd">51798</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c0" decimals="0" unitRef="usd">523</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty contextRef="c4" decimals="0" unitRef="usd">2457600</upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty>
    <us-gaap:RepaymentsOfAdvancesForConstruction contextRef="c4" decimals="0" unitRef="usd">10629120</us-gaap:RepaymentsOfAdvancesForConstruction>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c0" decimals="0" unitRef="usd">3814925</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments contextRef="c4" decimals="0" unitRef="usd">15330660</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <upc:RedemptionOfShorttermInvestments contextRef="c4" decimals="0" unitRef="usd">1801927</upc:RedemptionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="usd">-3908105</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="0" unitRef="usd">-27059958</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="0" unitRef="usd">-51798</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c0" decimals="0" unitRef="usd">4272716</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c4" decimals="0" unitRef="usd">4300800</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c5" decimals="0" unitRef="usd">1427000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c0" decimals="0" unitRef="usd">4272716</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c4" decimals="0" unitRef="usd">2764800</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c5" decimals="0" unitRef="usd">1427000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c4" decimals="0" unitRef="usd">28750000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="c4" decimals="0" unitRef="usd">2792543</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="c5" decimals="0" unitRef="usd">441064</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings contextRef="c0" decimals="0" unitRef="usd">-3317943</upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings>
    <upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings contextRef="c4" decimals="0" unitRef="usd">911648</upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings>
    <upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings contextRef="c5" decimals="0" unitRef="usd">-911200</upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" unitRef="usd">3317943</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="0" unitRef="usd">26581809</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="0" unitRef="usd">470136</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="0" unitRef="usd">-463942</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" unitRef="usd">553702</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="0" unitRef="usd">347386</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">-2366450</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c4" decimals="0" unitRef="usd">-1980294</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="0" unitRef="usd">6880881</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">8077908</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c22" decimals="0" unitRef="usd">10058202</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c11" decimals="0" unitRef="usd">3177321</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" unitRef="usd">5711458</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">8077908</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c22" decimals="0" unitRef="usd">10058202</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" unitRef="usd">199852</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c4" decimals="0" unitRef="usd">149303</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c5" decimals="0" unitRef="usd">157528</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c0" decimals="0" unitRef="usd">2748629</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c4" decimals="0" unitRef="usd">3271219</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c5" decimals="0" unitRef="usd">2167963</us-gaap:IncomeTaxesPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 1 &#x2014; ORGANIZATION AND BUSINESS DESCRIPTION&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"&gt;Universe Pharmaceuticals Inc. (&#x201c;Universe
INC&#x201d; or the &#x201c;Company&#x201d;) was incorporated under the laws of the Cayman Islands on December 11, 2019 as an exempted company
with limited liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Universe INC. owns 100% equity interest of Universe
Pharmaceuticals (International) Group (&#x201c;Universe HK&#x201d;), an entity incorporated on May 21, 2014 in accordance with the laws
and regulations in Hong Kong.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Jiangxi Universe Pharmaceuticals Technology Co.,
Ltd. (&#x201c;Universe Technology&#x201d;) was formed on April 8, 2019, as a Wholly Foreign-Owned Enterprise (&#x201c;WFOE&#x201d;) in the
People&#x2019;s Republic of China (&#x201c;PRC&#x201d; or &#x201c;China&#x201d;). The registered capital of Universe Technology is approximately
$4.3 million (RMB30.5 million). In December 2019, the Company made a capital contribution of $500,000 to Universe Technology. Pursuant
to the article of incorporation of Universe Technology, the remaining capital contribution of approximately $3.8 million for Universe
Technology is required to be completed before 2038.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"&gt;Universe INC, Universe HK and Universe
Technology are currently not engaging in any active business operations and are merely acting as holding companies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Jiangxi Universe Pharmaceuticals Co., Ltd. (&#x201c;Jiangxi
Universe&#x201d;) was incorporated on March 2, 1998 in accordance with PRC laws and is engaged in research and development and manufacturing
of modernized traditional Chinese medicines. Jiangxi Universe owns 100% of the equity interests of Jiangxi Universe Pharmaceuticals Commercial
Trade Co., Ltd. (&#x201c;Universe Trade&#x201d;), which was incorporated on March 10, 2010 to handle the sales and distribution of the pharmaceutical
products manufactured by Jiangxi Universe.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Reorganization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A reorganization of the Company&#x2019;s legal
structure (&#x201c;Reorganization&#x201d;) was completed on December 11, 2019. The Reorganization involved the incorporation of Universe
INC and Universe Technology, and the transfer of 100% of the equity interests of Jiangxi Universe to Universe Technology. Consequently,
Universe INC, through its subsidiary Universe HK, directly controls Universe Technology and Jiangxi Universe, and became the ultimate
holding company of all other entities mentioned above.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Reorganization has been accounted for as a
recapitalization among entities under common control, since the same controlling shareholders controlled all these entities before and
after the Reorganization. The consolidation of the Company and its subsidiaries has been accounted for at historical cost and prepared
on the basis as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying
consolidated financial statements. Results of operations for the periods presented comprise those of the previously separate entities
combined from the beginning of the period to the end of the period, eliminating the effects of intra-entity transactions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 25, 2021, the Company closed its initial
public offering (the &#x201c;IPO&#x201d;) of 5,000,000 ordinary shares, par value $0.003125 per share (the &#x201c;ordinary shares&#x201d;)
at a public offering price of $5.00 per share. On March 29, 2021, the underwriter exercised in full its over-allotment option to purchase
an additional 750,000 ordinary shares. The closing for the sale of the over-allotment shares took place on March 31, 2021. Gross proceeds
from the IPO totaled $28.75 million. Net proceeds of the IPO, including over-allotment shares, were approximately $25.6 million. In connection
with the IPO, the Company&#x2019;s ordinary shares began trading on the Nasdaq Global Market under the symbol &#x201c;UPC&#x201d; on March
23, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 12, 2021, through the Company&#x2019;s PRC
subsidiary, Jiangxi Universe, the Company established a wholly controlled subsidiary, Guangzhou Universe Hanhe Medical Research Co., Ltd.
(&#x201c;Universe Hanhe&#x201d;) in Guangzhou City, China, for the business purpose of conducting research and development of new pharmaceutical
products in order to diversify the Company&#x2019;s product offerings in the near future. As of September 30, 2022 and as of the date of
this report, Universe Hanhe has no active business operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Details of the subsidiaries of the Company as of September 30, 2022
are set out below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Date of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Place of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;% of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid; font-weight: bold; vertical-align: top"&gt;Name of Entity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Incorporation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Incorporation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Ownership&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Principal Activities&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Universe INC&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;December 11, 2019&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Cayman Islands&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Parent, 100%&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Investment holding&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 20%; text-align: left"&gt;Universe HK&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;May 21, 2014&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;Hong Kong&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 28%; text-align: center"&gt;Investment holding&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Universe Technology&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;April 18, 2019&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;PRC&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;WFOE, Investment holding&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Jiangxi Universe&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;March 2, 1998&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;PRC&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Research and development and manufacturing of modernized traditional Chinese medicines&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Universe Trade&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;March 10, 2010&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;PRC&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Sales of modernized traditional Chinese medicines&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Universe Hanhe&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;May 12, 2021&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;PRC&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Research and development of new pharmaceutical products&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company, through its wholly-owned subsidiaries,
is primarily engaged in the development, manufacturing and sale of traditional Chinese medicines derivatives (&#x201c;TCMD&#x201d;) products
targeted to the elderly to address their physical conditions in the aging process and to promote their general well-being. In addition,
the Company also sells biochemical drugs, medical instruments, traditional Chinese medicine pieces products and dietary supplements (collectively
&#x201c;third-party products&#x201d;). All of these TCMD and third-party products are currently sold to customers including pharmaceutical
companies, hospitals, clinics and drugstore chains throughout China.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <upc:EntityIncorporationDateDescription contextRef="c43">Universe Pharmaceuticals Inc. (&#x201c;Universe
INC&#x201d; or the &#x201c;Company&#x201d;) was incorporated under the laws of the Cayman Islands on December 11, 2019 as an exempted company
with limited liability.&#160;</upc:EntityIncorporationDateDescription>
    <upc:EntityIncorporationDateDescription contextRef="c44">Universe INC. owns 100% equity interest of Universe
Pharmaceuticals (International) Group (&#x201c;Universe HK&#x201d;), an entity incorporated on May 21, 2014 in accordance with the laws
and regulations in Hong Kong.&#160;</upc:EntityIncorporationDateDescription>
    <upc:EquityMethodInvestmentOwnershipsPercentage contextRef="c45" decimals="2" unitRef="pure">1</upc:EquityMethodInvestmentOwnershipsPercentage>
    <upc:AmountOfRegisteredCapital contextRef="c46" decimals="-5" unitRef="usd">4300000</upc:AmountOfRegisteredCapital>
    <upc:AmountOfRegisteredCapital contextRef="c46" decimals="-5" unitRef="cny">30500000</upc:AmountOfRegisteredCapital>
    <upc:CapitalContribution contextRef="c47" decimals="0" unitRef="usd">500000</upc:CapitalContribution>
    <upc:RemainingCapitalContribution contextRef="c47" decimals="-5" unitRef="usd">3800000</upc:RemainingCapitalContribution>
    <upc:EntityIncorporationDateDescription contextRef="c48">(&#x201c;Jiangxi
Universe&#x201d;) was incorporated on March 2, 1998 in accordance with PRC laws and is engaged in research and development and manufacturing
of modernized traditional Chinese medicines.</upc:EntityIncorporationDateDescription>
    <upc:EquityMethodInvestmentOwnershipsPercentage contextRef="c49" decimals="2" unitRef="pure">1</upc:EquityMethodInvestmentOwnershipsPercentage>
    <upc:EquityMethodInvestmentOwnershipsPercentage contextRef="c50" decimals="2" unitRef="pure">1</upc:EquityMethodInvestmentOwnershipsPercentage>
    <upc:SharesIssued01 contextRef="c51" decimals="0" unitRef="shares">5000000</upc:SharesIssued01>
    <us-gaap:SharePrice contextRef="c51" decimals="6" unitRef="usdPershares">0.003125</us-gaap:SharePrice>
    <upc:PublicOfferingPrice contextRef="c51" decimals="2" unitRef="usdPershares">5</upc:PublicOfferingPrice>
    <upc:SharesIssued01 contextRef="c52" decimals="0" unitRef="shares">750000</upc:SharesIssued01>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c53" decimals="-4" unitRef="usd">28750000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c54" decimals="-5" unitRef="usd">25600000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Date of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Place of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;% of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid; font-weight: bold; vertical-align: top"&gt;Name of Entity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Incorporation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Incorporation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Ownership&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Principal Activities&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Universe INC&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;December 11, 2019&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Cayman Islands&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Parent, 100%&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Investment holding&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 20%; text-align: left"&gt;Universe HK&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;May 21, 2014&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;Hong Kong&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="text-align: center; width: 1%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 28%; text-align: center"&gt;Investment holding&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Universe Technology&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;April 18, 2019&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;PRC&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;WFOE, Investment holding&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Jiangxi Universe&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;March 2, 1998&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;PRC&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Research and development and manufacturing of modernized traditional Chinese medicines&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Universe Trade&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;March 10, 2010&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;PRC&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Sales of modernized traditional Chinese medicines&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Universe Hanhe&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;May 12, 2021&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;PRC&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Research and development of new pharmaceutical products&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c55">2019-12-11</dei:EntityIncorporationDateOfIncorporation>
    <upc:PlaceOfIncorporation contextRef="c55">Cayman Islands</upc:PlaceOfIncorporation>
    <upc:OwnershipPercentage contextRef="c55">Parent, 100%</upc:OwnershipPercentage>
    <upc:PrincipalActivities contextRef="c55">Investment holding</upc:PrincipalActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c44">2014-05-21</dei:EntityIncorporationDateOfIncorporation>
    <upc:PlaceOfIncorporation contextRef="c44">Hong Kong</upc:PlaceOfIncorporation>
    <upc:OwnershipPercentage contextRef="c44">100%</upc:OwnershipPercentage>
    <upc:PrincipalActivities contextRef="c44">Investment holding</upc:PrincipalActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c56">2019-04-18</dei:EntityIncorporationDateOfIncorporation>
    <upc:PlaceOfIncorporation contextRef="c56">PRC</upc:PlaceOfIncorporation>
    <upc:OwnershipPercentage contextRef="c56">100%</upc:OwnershipPercentage>
    <upc:PrincipalActivities contextRef="c56">WFOE, Investment holding</upc:PrincipalActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c48">1998-03-02</dei:EntityIncorporationDateOfIncorporation>
    <upc:PlaceOfIncorporation contextRef="c48">PRC</upc:PlaceOfIncorporation>
    <upc:OwnershipPercentage contextRef="c48">100%</upc:OwnershipPercentage>
    <upc:PrincipalActivities contextRef="c48">Research and development and manufacturing of modernized traditional Chinese medicines</upc:PrincipalActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c57">2010-03-10</dei:EntityIncorporationDateOfIncorporation>
    <upc:PlaceOfIncorporation contextRef="c57">PRC</upc:PlaceOfIncorporation>
    <upc:OwnershipPercentage contextRef="c57">100%</upc:OwnershipPercentage>
    <upc:PrincipalActivities contextRef="c57">Sales of modernized traditional Chinese medicines</upc:PrincipalActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c58">2021-05-12</dei:EntityIncorporationDateOfIncorporation>
    <upc:PlaceOfIncorporation contextRef="c58">PRC</upc:PlaceOfIncorporation>
    <upc:OwnershipPercentage contextRef="c58">100%</upc:OwnershipPercentage>
    <upc:PrincipalActivities contextRef="c58">Research and development of new pharmaceutical products</upc:PrincipalActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 2 &#x2014; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Basis of consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the financial statements of Universe INC, Universe HK, Universe Technology, Jiangxi Universe, Universe Trade and Universe Hanhe.
All inter-company balances and transactions are eliminated upon consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Uses of estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In preparing the consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;), management makes
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates
are based on information as of the date of the consolidated financial statements. Significant estimates required to be made by management
include, but are not limited to, the allowance for estimated uncollectible receivables, the realizability of advance to suppliers, inventory
valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of long-lived assets, provision necessary
for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The main operation of the Company is located in
the PRC. Accordingly, the Company&#x2019;s business, financial condition, and results of operations may be influenced by political, economic,
and legal environments in the PRC, as well as by the general state of the PRC economy. The Company&#x2019;s results may be adversely affected
by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations
and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1,
this may not be indicative of future results.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The development and commercialization of new pharmaceutical
products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant competition
and a strong emphasis on intellectual property. The Company may face competition with respect to its current and future pharmaceutical
product candidates from major pharmaceutical companies in China.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s operations may be further
affected by the ongoing COVID-19 pandemic. Due to the resurgence of COVID-19 pandemic in China in 2022, there had been delays in purchase
of raw material supplies and deliver products to the customers of the PRC operating entities on a timely basis as a consequence of the
travel restrictions. The prices of the raw materials also increased by about 5% from January 2022 to May 2022 as compared to the same
period last year. In addition, the Company has granted some of its customers extended payment terms of 30 days to 120 days since January
2022, as a result of the COVID-19 pandemic. However, based on the present relationship with these customers and the evaluation of their
financial health, the Company does not anticipate any material collectability problems. Even though the Company does not expect that the
COVID-19 pandemic will have a negative impact on the business operations of the PRC operating entities and the financial results, due
to the high uncertainty of the evolving situation, the Company has limited visibility on how the COVID-19 pandemic affects the execution
of customer contracts, the collection of customer payments, or disrupt our supply chain, and the continued uncertainties associated with
COVID-19 may cause the revenue and cash flows to underperform in the next 12 months from the date the consolidated financial statements
are released. The extent of the future impact of the COVID-19 pandemic on the business and results of operations is still uncertain. Any
resurgence of the COVID-19 pandemic could negatively affect the execution of customer contracts, the collection of customer payments,
or disrupt the Company&#x2019;s supply chain, and the continued uncertainties associated with COVID-19 may negatively impact the Company&#x2019;s
revenue and cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash includes currency on hand and deposits held
by banks that can be added or withdrawn without limitation. The Company maintains most of its bank accounts in the PRC. Cash balances
in bank accounts in the PRC are not insured by the Federal Deposit Insurance Corporation or other programs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Accounts receivable, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable are presented net of allowance
for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts based on individual account analysis and
historical collection trends. The Company establishes a provision for doubtful receivables when there is objective evidence that the Company
may not be able to collect amounts due. The allowance is based on management&#x2019;s best estimate of specific losses on individual exposures,
as well as a provision on historical trends of collections. Actual amounts received may differ from management&#x2019;s estimate of credit
worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful accounts after
management has determined that collection is not probable. Allowance for uncollectable balances amounted to $ $791,827 and $446,527 as
of September 30, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Inventories, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are stated at net realizable value
using weighted average method. Costs include the cost of raw materials, freight, direct labor and related production overhead. Any excess
of the cost over the net realizable value of each item of inventories is recognized as a provision for diminution in the value of inventories.
Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. The
Company evaluates inventories on a quarterly basis for its net realizable value adjustments, and reduces the carrying value of those inventories
that are obsolete or in excess of the forecasted usage to their estimated net realizable value based on various factors including aging,
expiration dates, as applicable, taking into consideration historical and expected future product sales. The Company recorded inventory
reserve of $120,286 and $116,453 as of September 30, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Advances to suppliers, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -0.4pt"&gt;Advances to suppliers
represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices for raw materials. These advances
are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time to make
cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company when
the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific allowances
when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September 30, 2022
and 2021, no allowance for doubtful accounts was deemed necessary, as the Company believes that all advances to suppliers are fully realizable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -0.4pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Deferred initial public offering (&#x201c;IPO&#x201d;) costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company complies with the requirement of the
ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses of Offering&#x201d;. Deferred offering
costs consist of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related
to the intended IPO. Deferred offering costs were charged to shareholders&#x2019; equity upon the completion of the IPO on March 25, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Short-term investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s short-term investments consist
of wealth management financial products purchased from a financial institution, which can be redeemed anytime. The financial institution
invests the Company&#x2019;s fund in certain financial instruments including money market funds and bonds to generate investment income.
The short-term investments are deemed to be trading securities and are measured subsequently at fair value in the statement of financial
position. Unrealized holding gains and losses for investment are included in the consolidated statements of operations and comprehensive
income over the investment period (see Note 8).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Fair value of financial instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize
the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 1&#x2009;&#x2014;&#x2009;inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities
in active markets.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 2&#x2009;&#x2014;&#x2009;inputs to the valuation methodology include quoted prices for similar assets
and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than
quoted prices that are observable and inputs derived from or corroborated by observable market data.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Level 3&#x2009;&#x2014;&#x2009;inputs to the valuation methodology are unobservable.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Unless otherwise disclosed, the fair value of
the Company&#x2019;s financial instruments, including cash, accounts receivable, inventories, short-term investments, advances to suppliers,
prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current liabilities, taxes
payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September 30, 2022 and 2021
based upon the short-term nature of the assets and liabilities. The Company&#x2019;s investment in equity securities is accounted for using
the measurement alternative in accordance with ASC 321, which also approximate its recorded value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Property, plant and equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property, plant and equipment are stated at cost
less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is provided using the straight-line
method over their expected useful lives, as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Buildings&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;20 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5&#x2013;10 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Automobiles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3&#x2013;5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office and electric equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3&#x2013;5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Expenditures for maintenance and repairs, which
do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments
which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired
or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated statements of income and other
comprehensive income in other income or expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company reviews the carrying value of property,
plant, and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable
from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future
cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the
fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and
prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors.
Based on this assessment, no impairment expenses for property, plant, and equipment were recorded in operating expenses for the years
ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets consist primarily of land use
rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot be sold to an individual or company.
The government grants individuals and companies the right to use parcels of land for specified periods of time. Land use rights are stated
at cost less accumulated amortization. Intangible assets are amortized using the straight-line method with the following estimated useful
lives:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Land use rights&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;50 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company reviews the carrying value of land
use rights for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the
estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash
flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair
value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects,
the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this
assessment, no impairment of land use rights was deemed necessary for the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Construction-in-Progress (&#x201c;CIP&#x201d;)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;CIP represents property and buildings under construction
and consists of construction expenditures, equipment procurement, and other direct costs attributable to the construction. CIP is not
depreciated. Upon completion and ready for intended use, CIP is reclassified to the appropriate category within property, plant and equipment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Impairment of long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Long-lived assets with finite lives, primarily
property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash flows from the use of the asset and its
eventual disposition below are the asset&#x2019;s carrying value, then the asset is deemed to be impaired and written down to its fair
value. There were no impairments of these assets as of September 30, 2022 and 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Investments in Equity Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for its equity investments
in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 321 &#x201c;Investments&#x2014;Equity Securities&#x201d; (&#x201c;ASC
321&#x201d;). In accordance with ASC 321, equity investment which the Company has no significant influence (generally less than a 20% ownership
interest) with readily determinable fair values are accounted for at fair value based on quoted market prices with the changes in fair
value recognized as unrealized gains or losses in earnings. Equity investments without readily determinable fair values are accounted
for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured
at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical
or a similar investment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From March 2009 to September 2017, the Company
invested approximately $0.7 million (RMB5 million) in Jiangxi Jian Rural Commercial Bank (&#x201c;JX RCB Bank&#x201d;) in exchange for 5%
ownership interest in the bank. The purpose of entering into these equity investment agreements with JX RCB Bank was to earn investment
income as the bank continues to grow. The Company determined that this investment in equity securities does not have a readily determinable
fair value and, accordingly, elected the measurement alternative noted above.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company initially recorded the investments
at historical cost and subsequently records any dividends received from the net accumulated earnings of the investee as income. As of
September 30, 2022 and 2021, this investment amounted to $702,890 (RMB 5 million) and $744,924 (RMB 5 million), respectively, and was
reported as long-term investment in equity investee on the consolidated balance sheets. Investment income amounted to $38,588, $30,827
and $21,820 for the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The investments in equity securities are evaluated
for impairment when facts or circumstances indicate that the fair value of the investment is less than its carrying value. An impairment
is recognized when a decline in fair value is determined to be other-than-temporary. The Company reviews several factors to determine
whether a loss is other-than-temporary. These factors include, but are not limited to, the: (i) nature of the investment; (ii) cause and
duration of the impairment; (iii) extent to which fair value is less than cost; (iv) financial condition and near-term prospects of the
investments; and (v) ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in fair value.
There was no impairment for the Company&#x2019;s investments in equity securities as of September 30, 2022 and 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Revenue recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To determine revenue recognition for contracts
with customers, the Company performs the following five steps : (i) identify the contract(s) with the customer, (ii) identify the performance
obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable
that a significant future reversal will &lt;i&gt;not&lt;/i&gt; occur, (iv) allocate the transaction price to the respective performance obligations
in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes revenue when it transfers
its goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange.
The Company accounts for the revenue generated from sales of its TCMD and third-party products on a gross basis, as the Company is acting
as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling
the promise to provide customers the specified goods, which the Company has control of the goods and has the ability to direct the use
of goods to obtain substantially all the benefits. All of the Company&#x2019;s contracts have one single performance obligation, namely,
the promise is to transfer the individual goods to customers, and there is no separately identifiable other promise in the contracts.
The Company&#x2019;s revenue streams are recognized at a point in time when title and risk of loss passes and the customer accepts the
goods, which generally occurs at delivery. The Company&#x2019;s products are sold with no right of return and the Company does not provide
other credits or sales incentive to customers. Revenue is reported net of all value added taxes (&#x201c;VAT&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Contract Assets and Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Payment terms are established on the Company&#x2019;s
pre-established credit requirements based upon an evaluation of customers&#x2019; credit quality. Contract assets are recognized for in
related accounts receivable. Contract liabilities are recognized for contracts where payment has been received in advance of delivery.
The contract liability balance can vary significantly depending on the timing when an order is placed and when shipment or delivery occurs.
As of September 30, 2022 and 2021, the Company did not have contract assets and contract liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Disaggregation of Revenues&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company disaggregates its revenue from contracts
by product types, as the Company believes it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows
are affected by economic factors. The Company&#x2019;s disaggregation of revenues for the years ended September 30, 2022, 2021 and 2020
are disclosed in Note 19 of these consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Cost of revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost of revenue consists primarily of the costs
of raw materials, freight charges, direct labor, depreciation of plants and machinery, warehousing and overhead associated with the manufacturing
process.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Research and development expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company expenses all internal research and
development costs as incurred, which primarily comprise employee costs, internal and external costs related to execution of studies, including
manufacturing costs, facility costs of the research center, and amortization and depreciation to intangible assets and property, plant
and equipment used in the research and development activities. For the years ended September 30, 2022, 2021 and 2020, total research and
development expense were approximately $7,644,375, $5,465,662 and $583,125, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Shipping and handling costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Shipping and handling costs are expensed as incurred.
Inbound shipping and handling cost associated with bringing the purchased raw materials and third-party products from suppliers to the
Company&#x2019;s warehouse are included in cost of revenue. Outbound shipping and handling costs associated with shipping and delivery
the products to customers are included in selling expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Advertising expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advertising expenses primarily relate to promotion
of the Company&#x2019;s brand name and products through outdoor billboards, social media such as Weibo and WeChat, and TV advertisement.
Advertising costs are expensed as incurred or deferred and then expensed the first time the advertising takes place. Advertising expenses
are included in selling expenses in the consolidated statements of income and comprehensive income. Advertising expenses amounted to $17,527,318,
$1,316,654 and $343,962 for the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the management approach in determining
reportable operating segments. The management approach considers the internal reporting used by the Company&#x2019;s chief operating decision
maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining
the Company&#x2019;s reportable operating segments. Management has determined that the Company has one operating segment (See Note 19).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Income taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for current income taxes
in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between
the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected
to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the
period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount
expected to be realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;An uncertain tax position is recognized only if
it is &#x201c;more likely than not&#x201d; that the tax position would be sustained in a tax examination. The amount recognized is the largest
amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the &#x201c;more
likely than not&#x201d; test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified
as income tax expense in the period incurred. No significant penalties or interest relating to income taxes have been incurred during
the years ended September 30, 2022, 2021 and 2020. The Company does not believe there was any uncertain tax provision at September 30,
2022 and September 30, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s operating subsidiary in China
is subject to the income tax laws of the PRC. No significant income was generated outside the PRC for the years ended September 30, 2022,
2021 and 2020. As of September 30, 2022, all of the tax returns of the Company&#x2019;s PRC subsidiaries remain open for statutory examination
by PRC tax authorities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Value added tax (&#x201c;VAT&#x201d;)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sales revenue represents the invoiced value of
goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to 17% (starting from May 1, 2018, VAT rate was lowered
to 16%, and starting from April 1, 2019, VAT rate was further lowered to 13%), depending on the type of products sold. The VAT may be
offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products.
The Company recorded a VAT payable or receivable net of payments in the accompanying consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Earnings per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company computes earnings per share (&#x201c;EPS&#x201d;)
in accordance with ASC 260, &#x201c;Earnings per Share&#x201d; (&#x201c;ASC 260&#x201d;). ASC 260 requires companies with complex capital
structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common shares outstanding
for the period. Diluted presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options
and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares
that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation
of diluted EPS. For the years ended September 30, 2022, 2021 and 2020, there were no dilutive shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Foreign currency translation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The functional currency for Universe INC is the
U.S Dollar (&#x201c;US$&#x201d;). Universe HK uses Hong Kong dollar as its functional currency. However, Universe INC and Universe HK currently
only serve as holding companies and did not have active operations as of the date of this report. The Company operates only in the PRC
and the Company&#x2019;s functional currency is the Chinese Yuan (&#x201c;RMB&#x201d;). The Company&#x2019;s consolidated financial statements
have been translated into the reporting currency US$.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Assets and liabilities of the Company are translated
at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated
at the average rate of exchange during the reporting period. The resulting translation adjustments are reported under other comprehensive
income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the results of
operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The RMB is not freely convertible into foreign
currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB
amounts could have been, or could be, converted into US$ at the rates used in translation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table outlines the currency exchange
rates that were used in creating the consolidated financial statements in this report:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;September&#160;30, &lt;br/&gt;
2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;September&#160;30, &lt;br/&gt;
2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;September&#160;30, &lt;br/&gt;
2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Year-end spot rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB7.1135&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB6.4580&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB6.8033&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB6.5532&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB6.5095&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB7.0077&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Comprehensive income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Comprehensive income consists of two components,
net income and other comprehensive income. The foreign currency translation gain resulting from translation of the financial statements
expressed in RMB to US$ is reported in other comprehensive income in the consolidated statements of income and comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Statement of Cash Flows&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 230, &#x201c;Statement of
Cash Flows&#x201d;, cash flows from the Company&#x2019;s operations are formulated based upon the local currencies. As a result, amounts
related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding
balances on the balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Employee Defined Contribution Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s subsidiaries in the PRC participate
in a government-mandated multi-employer defined contribution plan pursuant to which pension, work-related injury benefits, maternity insurance,
medical insurance, unemployment benefit and housing fund are provided to eligible full-time employees. The relevant labor regulations
require the Company&#x2019;s subsidiaries in the PRC to pay the local labor and social welfare authorities monthly contributions based
on the applicable benchmarks and rates stipulated by the local government. The contributions to the plan are expensed as incurred. Employee
social security and welfare benefits included as expenses in the accompanying statements of income and comprehensive income amounted to
$465,689, $617,145 and $347,312 for the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2016, the FASB issued ASU 2016-13, Financial
Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the
reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing
incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. ASU 2016-13
was subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2020-02. For public entities, ASU 2016-13 and its
amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. For all other
entities, this guidance and its amendments will be effective for fiscal years beginning after December 15, 2022, including interim periods
within those fiscal years. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2018. The adoption of this guidance did not have a material impact on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2020, the FASB issued ASU 2020-10,
&#x201c;Codification Improvements to Subtopic 205-10, presentation of financial statements&#x201d;. The amendments in this Update improve
the codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to
financial statements is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement
would be missed. ASU 2020-10 is effective for the Company for annual and interim reporting periods beginning January 1, 2022. Early application
of the amendments is permitted for any annual or interim period for which financial statements are available to be issued. The amendments
in this Update should be applied retrospectively. An entity should apply the amendments at the beginning of the period that includes the
adoption date. The Company is currently evaluating the impact of this new standard on Company&#x2019;s consolidated financial statements
and related disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Basis of consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the financial statements of Universe INC, Universe HK, Universe Technology, Jiangxi Universe, Universe Trade and Universe Hanhe.
All inter-company balances and transactions are eliminated upon consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Uses of estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In preparing the consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;), management makes
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates
are based on information as of the date of the consolidated financial statements. Significant estimates required to be made by management
include, but are not limited to, the allowance for estimated uncollectible receivables, the realizability of advance to suppliers, inventory
valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of long-lived assets, provision necessary
for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The main operation of the Company is located in
the PRC. Accordingly, the Company&#x2019;s business, financial condition, and results of operations may be influenced by political, economic,
and legal environments in the PRC, as well as by the general state of the PRC economy. The Company&#x2019;s results may be adversely affected
by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations
and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1,
this may not be indicative of future results.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The development and commercialization of new pharmaceutical
products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant competition
and a strong emphasis on intellectual property. The Company may face competition with respect to its current and future pharmaceutical
product candidates from major pharmaceutical companies in China.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s operations may be further
affected by the ongoing COVID-19 pandemic. Due to the resurgence of COVID-19 pandemic in China in 2022, there had been delays in purchase
of raw material supplies and deliver products to the customers of the PRC operating entities on a timely basis as a consequence of the
travel restrictions. The prices of the raw materials also increased by about 5% from January 2022 to May 2022 as compared to the same
period last year. In addition, the Company has granted some of its customers extended payment terms of 30 days to 120 days since January
2022, as a result of the COVID-19 pandemic. However, based on the present relationship with these customers and the evaluation of their
financial health, the Company does not anticipate any material collectability problems. Even though the Company does not expect that the
COVID-19 pandemic will have a negative impact on the business operations of the PRC operating entities and the financial results, due
to the high uncertainty of the evolving situation, the Company has limited visibility on how the COVID-19 pandemic affects the execution
of customer contracts, the collection of customer payments, or disrupt our supply chain, and the continued uncertainties associated with
COVID-19 may cause the revenue and cash flows to underperform in the next 12 months from the date the consolidated financial statements
are released. The extent of the future impact of the COVID-19 pandemic on the business and results of operations is still uncertain. Any
resurgence of the COVID-19 pandemic could negatively affect the execution of customer contracts, the collection of customer payments,
or disrupt the Company&#x2019;s supply chain, and the continued uncertainties associated with COVID-19 may negatively impact the Company&#x2019;s
revenue and cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <upc:MaterialPricePercentage contextRef="c0" decimals="2" unitRef="pure">0.05</upc:MaterialPricePercentage>
    <upc:PaymentTerm contextRef="c59">P30D</upc:PaymentTerm>
    <upc:PaymentTerm contextRef="c60">P120D</upc:PaymentTerm>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash includes currency on hand and deposits held
by banks that can be added or withdrawn without limitation. The Company maintains most of its bank accounts in the PRC. Cash balances
in bank accounts in the PRC are not insured by the Federal Deposit Insurance Corporation or other programs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Accounts receivable, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable are presented net of allowance
for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts based on individual account analysis and
historical collection trends. The Company establishes a provision for doubtful receivables when there is objective evidence that the Company
may not be able to collect amounts due. The allowance is based on management&#x2019;s best estimate of specific losses on individual exposures,
as well as a provision on historical trends of collections. Actual amounts received may differ from management&#x2019;s estimate of credit
worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful accounts after
management has determined that collection is not probable. Allowance for uncollectable balances amounted to $ $791,827 and $446,527 as
of September 30, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <upc:AllowanceForUncollectableBalancesAmount contextRef="c0" decimals="0" unitRef="usd">791827</upc:AllowanceForUncollectableBalancesAmount>
    <upc:AllowanceForUncollectableBalancesAmount contextRef="c4" decimals="0" unitRef="usd">446527</upc:AllowanceForUncollectableBalancesAmount>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Inventories, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are stated at net realizable value
using weighted average method. Costs include the cost of raw materials, freight, direct labor and related production overhead. Any excess
of the cost over the net realizable value of each item of inventories is recognized as a provision for diminution in the value of inventories.
Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. The
Company evaluates inventories on a quarterly basis for its net realizable value adjustments, and reduces the carrying value of those inventories
that are obsolete or in excess of the forecasted usage to their estimated net realizable value based on various factors including aging,
expiration dates, as applicable, taking into consideration historical and expected future product sales. The Company recorded inventory
reserve of $120,286 and $116,453 as of September 30, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves contextRef="c2" decimals="0" unitRef="usd">120286</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="0" unitRef="usd">116453</us-gaap:InventoryValuationReserves>
    <upc:AdvancesToSuppliersNetPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Advances to suppliers, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -0.4pt"&gt;Advances to suppliers
represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices for raw materials. These advances
are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time to make
cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company when
the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific allowances
when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September 30, 2022
and 2021, no allowance for doubtful accounts was deemed necessary, as the Company believes that all advances to suppliers are fully realizable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -0.4pt"&gt;&#160;&lt;/p&gt;</upc:AdvancesToSuppliersNetPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Deferred initial public offering (&#x201c;IPO&#x201d;) costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company complies with the requirement of the
ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses of Offering&#x201d;. Deferred offering
costs consist of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related
to the intended IPO. Deferred offering costs were charged to shareholders&#x2019; equity upon the completion of the IPO on March 25, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <upc:HeldToMaturityInvestmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Short-term investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s short-term investments consist
of wealth management financial products purchased from a financial institution, which can be redeemed anytime. The financial institution
invests the Company&#x2019;s fund in certain financial instruments including money market funds and bonds to generate investment income.
The short-term investments are deemed to be trading securities and are measured subsequently at fair value in the statement of financial
position. Unrealized holding gains and losses for investment are included in the consolidated statements of operations and comprehensive
income over the investment period (see Note 8).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</upc:HeldToMaturityInvestmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Fair value of financial instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize
the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 1&#x2009;&#x2014;&#x2009;inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities
in active markets.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 2&#x2009;&#x2014;&#x2009;inputs to the valuation methodology include quoted prices for similar assets
and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than
quoted prices that are observable and inputs derived from or corroborated by observable market data.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Level 3&#x2009;&#x2014;&#x2009;inputs to the valuation methodology are unobservable.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Unless otherwise disclosed, the fair value of
the Company&#x2019;s financial instruments, including cash, accounts receivable, inventories, short-term investments, advances to suppliers,
prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current liabilities, taxes
payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September 30, 2022 and 2021
based upon the short-term nature of the assets and liabilities. The Company&#x2019;s investment in equity securities is accounted for using
the measurement alternative in accordance with ASC 321, which also approximate its recorded value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Property, plant and equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property, plant and equipment are stated at cost
less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is provided using the straight-line
method over their expected useful lives, as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Buildings&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;20 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5&#x2013;10 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Automobiles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3&#x2013;5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office and electric equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3&#x2013;5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Expenditures for maintenance and repairs, which
do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments
which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired
or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated statements of income and other
comprehensive income in other income or expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company reviews the carrying value of property,
plant, and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable
from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future
cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the
fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and
prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors.
Based on this assessment, no impairment expenses for property, plant, and equipment were recorded in operating expenses for the years
ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Buildings&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;20 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5&#x2013;10 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Automobiles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3&#x2013;5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office and electric equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3&#x2013;5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c66">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c67">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c68">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c69">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c70">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c71">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c72">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets consist primarily of land use
rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot be sold to an individual or company.
The government grants individuals and companies the right to use parcels of land for specified periods of time. Land use rights are stated
at cost less accumulated amortization. Intangible assets are amortized using the straight-line method with the following estimated useful
lives:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Land use rights&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;50 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company reviews the carrying value of land
use rights for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the
estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash
flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair
value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects,
the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this
assessment, no impairment of land use rights was deemed necessary for the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Land use rights&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;50 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IntermediateLifePlantsUsefulLife contextRef="c73">P50Y</us-gaap:IntermediateLifePlantsUsefulLife>
    <us-gaap:IntermediateLifePlantsUsefulLife contextRef="c74">P3Y</us-gaap:IntermediateLifePlantsUsefulLife>
    <us-gaap:ConstructionContractorsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Construction-in-Progress (&#x201c;CIP&#x201d;)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;CIP represents property and buildings under construction
and consists of construction expenditures, equipment procurement, and other direct costs attributable to the construction. CIP is not
depreciated. Upon completion and ready for intended use, CIP is reclassified to the appropriate category within property, plant and equipment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ConstructionContractorsPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Impairment of long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Long-lived assets with finite lives, primarily
property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash flows from the use of the asset and its
eventual disposition below are the asset&#x2019;s carrying value, then the asset is deemed to be impaired and written down to its fair
value. There were no impairments of these assets as of September 30, 2022 and 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Investments in Equity Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for its equity investments
in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 321 &#x201c;Investments&#x2014;Equity Securities&#x201d; (&#x201c;ASC
321&#x201d;). In accordance with ASC 321, equity investment which the Company has no significant influence (generally less than a 20% ownership
interest) with readily determinable fair values are accounted for at fair value based on quoted market prices with the changes in fair
value recognized as unrealized gains or losses in earnings. Equity investments without readily determinable fair values are accounted
for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured
at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical
or a similar investment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From March 2009 to September 2017, the Company
invested approximately $0.7 million (RMB5 million) in Jiangxi Jian Rural Commercial Bank (&#x201c;JX RCB Bank&#x201d;) in exchange for 5%
ownership interest in the bank. The purpose of entering into these equity investment agreements with JX RCB Bank was to earn investment
income as the bank continues to grow. The Company determined that this investment in equity securities does not have a readily determinable
fair value and, accordingly, elected the measurement alternative noted above.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company initially recorded the investments
at historical cost and subsequently records any dividends received from the net accumulated earnings of the investee as income. As of
September 30, 2022 and 2021, this investment amounted to $702,890 (RMB 5 million) and $744,924 (RMB 5 million), respectively, and was
reported as long-term investment in equity investee on the consolidated balance sheets. Investment income amounted to $38,588, $30,827
and $21,820 for the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The investments in equity securities are evaluated
for impairment when facts or circumstances indicate that the fair value of the investment is less than its carrying value. An impairment
is recognized when a decline in fair value is determined to be other-than-temporary. The Company reviews several factors to determine
whether a loss is other-than-temporary. These factors include, but are not limited to, the: (i) nature of the investment; (ii) cause and
duration of the impairment; (iii) extent to which fair value is less than cost; (iv) financial condition and near-term prospects of the
investments; and (v) ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in fair value.
There was no impairment for the Company&#x2019;s investments in equity securities as of September 30, 2022 and 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <upc:EquityMethodInvestmentOwnershipsPercentage contextRef="c61" decimals="2" unitRef="pure">0.20</upc:EquityMethodInvestmentOwnershipsPercentage>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c62" decimals="-5" unitRef="usd">700000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c62" decimals="-6" unitRef="cny">5000000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <upc:EquityMethodInvestmentOwnershipsPercentage contextRef="c63" decimals="2" unitRef="pure">0.05</upc:EquityMethodInvestmentOwnershipsPercentage>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c0" decimals="0" unitRef="usd">702890</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c0" decimals="-6" unitRef="cny">5000000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c4" decimals="0" unitRef="usd">744924</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c4" decimals="-6" unitRef="cny">5000000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:NetInvestmentIncome contextRef="c0" decimals="0" unitRef="usd">38588</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c4" decimals="0" unitRef="usd">30827</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c5" decimals="0" unitRef="usd">21820</us-gaap:NetInvestmentIncome>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Revenue recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To determine revenue recognition for contracts
with customers, the Company performs the following five steps : (i) identify the contract(s) with the customer, (ii) identify the performance
obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable
that a significant future reversal will &lt;i&gt;not&lt;/i&gt; occur, (iv) allocate the transaction price to the respective performance obligations
in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes revenue when it transfers
its goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange.
The Company accounts for the revenue generated from sales of its TCMD and third-party products on a gross basis, as the Company is acting
as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling
the promise to provide customers the specified goods, which the Company has control of the goods and has the ability to direct the use
of goods to obtain substantially all the benefits. All of the Company&#x2019;s contracts have one single performance obligation, namely,
the promise is to transfer the individual goods to customers, and there is no separately identifiable other promise in the contracts.
The Company&#x2019;s revenue streams are recognized at a point in time when title and risk of loss passes and the customer accepts the
goods, which generally occurs at delivery. The Company&#x2019;s products are sold with no right of return and the Company does not provide
other credits or sales incentive to customers. Revenue is reported net of all value added taxes (&#x201c;VAT&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <upc:ContractAssetsAndLiabilitiesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Contract Assets and Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Payment terms are established on the Company&#x2019;s
pre-established credit requirements based upon an evaluation of customers&#x2019; credit quality. Contract assets are recognized for in
related accounts receivable. Contract liabilities are recognized for contracts where payment has been received in advance of delivery.
The contract liability balance can vary significantly depending on the timing when an order is placed and when shipment or delivery occurs.
As of September 30, 2022 and 2021, the Company did not have contract assets and contract liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</upc:ContractAssetsAndLiabilitiesPolicyTextBlock>
    <upc:DisaggregationOfRevenuesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Disaggregation of Revenues&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company disaggregates its revenue from contracts
by product types, as the Company believes it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows
are affected by economic factors. The Company&#x2019;s disaggregation of revenues for the years ended September 30, 2022, 2021 and 2020
are disclosed in Note 19 of these consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</upc:DisaggregationOfRevenuesPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Cost of revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost of revenue consists primarily of the costs
of raw materials, freight charges, direct labor, depreciation of plants and machinery, warehousing and overhead associated with the manufacturing
process.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Research and development expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company expenses all internal research and
development costs as incurred, which primarily comprise employee costs, internal and external costs related to execution of studies, including
manufacturing costs, facility costs of the research center, and amortization and depreciation to intangible assets and property, plant
and equipment used in the research and development activities. For the years ended September 30, 2022, 2021 and 2020, total research and
development expense were approximately $7,644,375, $5,465,662 and $583,125, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">7644375</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" unitRef="usd">5465662</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" unitRef="usd">583125</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Shipping and handling costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Shipping and handling costs are expensed as incurred.
Inbound shipping and handling cost associated with bringing the purchased raw materials and third-party products from suppliers to the
Company&#x2019;s warehouse are included in cost of revenue. Outbound shipping and handling costs associated with shipping and delivery
the products to customers are included in selling expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Advertising expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advertising expenses primarily relate to promotion
of the Company&#x2019;s brand name and products through outdoor billboards, social media such as Weibo and WeChat, and TV advertisement.
Advertising costs are expensed as incurred or deferred and then expensed the first time the advertising takes place. Advertising expenses
are included in selling expenses in the consolidated statements of income and comprehensive income. Advertising expenses amounted to $17,527,318,
$1,316,654 and $343,962 for the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c0" decimals="0" unitRef="usd">17527318</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c4" decimals="0" unitRef="usd">1316654</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c5" decimals="0" unitRef="usd">343962</us-gaap:AdvertisingExpense>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the management approach in determining
reportable operating segments. The management approach considers the internal reporting used by the Company&#x2019;s chief operating decision
maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining
the Company&#x2019;s reportable operating segments. Management has determined that the Company has one operating segment (See Note 19).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Income taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for current income taxes
in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between
the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected
to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the
period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount
expected to be realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;An uncertain tax position is recognized only if
it is &#x201c;more likely than not&#x201d; that the tax position would be sustained in a tax examination. The amount recognized is the largest
amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the &#x201c;more
likely than not&#x201d; test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified
as income tax expense in the period incurred. No significant penalties or interest relating to income taxes have been incurred during
the years ended September 30, 2022, 2021 and 2020. The Company does not believe there was any uncertain tax provision at September 30,
2022 and September 30, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s operating subsidiary in China
is subject to the income tax laws of the PRC. No significant income was generated outside the PRC for the years ended September 30, 2022,
2021 and 2020. As of September 30, 2022, all of the tax returns of the Company&#x2019;s PRC subsidiaries remain open for statutory examination
by PRC tax authorities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <upc:TaxBenefitPercentage contextRef="c0" decimals="2" unitRef="pure">0.50</upc:TaxBenefitPercentage>
    <upc:ValueAddedTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Value added tax (&#x201c;VAT&#x201d;)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sales revenue represents the invoiced value of
goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to 17% (starting from May 1, 2018, VAT rate was lowered
to 16%, and starting from April 1, 2019, VAT rate was further lowered to 13%), depending on the type of products sold. The VAT may be
offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products.
The Company recorded a VAT payable or receivable net of payments in the accompanying consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</upc:ValueAddedTaxPolicyTextBlock>
    <upc:PercentageOfVatRate contextRef="c0" decimals="2" unitRef="pure">0.17</upc:PercentageOfVatRate>
    <upc:PercentageOfVatRate contextRef="c64" decimals="2" unitRef="pure">0.16</upc:PercentageOfVatRate>
    <upc:PercentageOfVatRate contextRef="c65" decimals="2" unitRef="pure">0.13</upc:PercentageOfVatRate>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Earnings per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company computes earnings per share (&#x201c;EPS&#x201d;)
in accordance with ASC 260, &#x201c;Earnings per Share&#x201d; (&#x201c;ASC 260&#x201d;). ASC 260 requires companies with complex capital
structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common shares outstanding
for the period. Diluted presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options
and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares
that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation
of diluted EPS. For the years ended September 30, 2022, 2021 and 2020, there were no dilutive shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Foreign currency translation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The functional currency for Universe INC is the
U.S Dollar (&#x201c;US$&#x201d;). Universe HK uses Hong Kong dollar as its functional currency. However, Universe INC and Universe HK currently
only serve as holding companies and did not have active operations as of the date of this report. The Company operates only in the PRC
and the Company&#x2019;s functional currency is the Chinese Yuan (&#x201c;RMB&#x201d;). The Company&#x2019;s consolidated financial statements
have been translated into the reporting currency US$.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Assets and liabilities of the Company are translated
at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated
at the average rate of exchange during the reporting period. The resulting translation adjustments are reported under other comprehensive
income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the results of
operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The RMB is not freely convertible into foreign
currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB
amounts could have been, or could be, converted into US$ at the rates used in translation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table outlines the currency exchange
rates that were used in creating the consolidated financial statements in this report:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;September&#160;30, &lt;br/&gt;
2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;September&#160;30, &lt;br/&gt;
2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;September&#160;30, &lt;br/&gt;
2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Year-end spot rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB7.1135&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB6.4580&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB6.8033&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB6.5532&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB6.5095&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB7.0077&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;September&#160;30, &lt;br/&gt;
2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;September&#160;30, &lt;br/&gt;
2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;September&#160;30, &lt;br/&gt;
2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Year-end spot rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB7.1135&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB6.4580&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB6.8033&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB6.5532&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB6.5095&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;US$1=RMB7.0077&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock>
    <upc:DescriptionOfYearEndSpotRate contextRef="c0">US$1=RMB7.1135</upc:DescriptionOfYearEndSpotRate>
    <upc:DescriptionOfYearEndSpotRate contextRef="c4">US$1=RMB6.4580</upc:DescriptionOfYearEndSpotRate>
    <upc:DescriptionOfYearEndSpotRate contextRef="c5">US$1=RMB6.8033</upc:DescriptionOfYearEndSpotRate>
    <upc:DescriptionOfAverageRate contextRef="c0">US$1=RMB6.5532</upc:DescriptionOfAverageRate>
    <upc:DescriptionOfAverageRate contextRef="c4">US$1=RMB6.5095</upc:DescriptionOfAverageRate>
    <upc:DescriptionOfAverageRate contextRef="c5">US$1=RMB7.0077</upc:DescriptionOfAverageRate>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Comprehensive income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Comprehensive income consists of two components,
net income and other comprehensive income. The foreign currency translation gain resulting from translation of the financial statements
expressed in RMB to US$ is reported in other comprehensive income in the consolidated statements of income and comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <upc:StatementOfCashFlowsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Statement of Cash Flows&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 230, &#x201c;Statement of
Cash Flows&#x201d;, cash flows from the Company&#x2019;s operations are formulated based upon the local currencies. As a result, amounts
related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding
balances on the balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</upc:StatementOfCashFlowsPolicyTextBlock>
    <upc:EmployeeDefinedContributionPlanPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Employee Defined Contribution Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s subsidiaries in the PRC participate
in a government-mandated multi-employer defined contribution plan pursuant to which pension, work-related injury benefits, maternity insurance,
medical insurance, unemployment benefit and housing fund are provided to eligible full-time employees. The relevant labor regulations
require the Company&#x2019;s subsidiaries in the PRC to pay the local labor and social welfare authorities monthly contributions based
on the applicable benchmarks and rates stipulated by the local government. The contributions to the plan are expensed as incurred. Employee
social security and welfare benefits included as expenses in the accompanying statements of income and comprehensive income amounted to
$465,689, $617,145 and $347,312 for the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</upc:EmployeeDefinedContributionPlanPolicyTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c0" decimals="0" unitRef="usd">465689</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c4" decimals="0" unitRef="usd">617145</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c5" decimals="0" unitRef="usd">347312</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2016, the FASB issued ASU 2016-13, Financial
Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the
reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing
incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. ASU 2016-13
was subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2020-02. For public entities, ASU 2016-13 and its
amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. For all other
entities, this guidance and its amendments will be effective for fiscal years beginning after December 15, 2022, including interim periods
within those fiscal years. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2018. The adoption of this guidance did not have a material impact on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2020, the FASB issued ASU 2020-10,
&#x201c;Codification Improvements to Subtopic 205-10, presentation of financial statements&#x201d;. The amendments in this Update improve
the codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to
financial statements is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement
would be missed. ASU 2020-10 is effective for the Company for annual and interim reporting periods beginning January 1, 2022. Early application
of the amendments is permitted for any annual or interim period for which financial statements are available to be issued. The amendments
in this Update should be applied retrospectively. An entity should apply the amendments at the beginning of the period that includes the
adoption date. The Company is currently evaluating the impact of this new standard on Company&#x2019;s consolidated financial statements
and related disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 3 &#x2014; ACCOUNTS RECEIVABLE, NET&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable consists of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,975,717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,020,269&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(791,827&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(446,527&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,183,890&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,573,742&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s accounts receivable primarily
includes the balance due from customers when the Company&#x2019;s pharmaceutical products are sold and delivered to customers. All of the
Company&#x2019;s accounts receivable balance at September 30, 2021 has been collected in the fiscal year 2022. As of date of this report,
approximately 71.9%, or $10.9 million, of the Company&#x2019;s net account receivable balance at September 30, 2022 has been subsequently
collected and the remaining balance is expected to be substantially collected before March 31, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table summarizes the Company&#x2019;s accounts receivable
and subsequent collection by aging bucket:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Accounts Receivable by aging bucket&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Balance as of September 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Subsequent collection&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;% of subsequent collection&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Less than 3 months&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,673,685&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,135,508&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;From 4 to 6 months&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,970,635&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,360,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;From 7 to 9 months&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,554,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,089,957&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;From 10 to 12 months&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;285,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;180,564&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Over 1 year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;491,208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;152,711&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31.1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total gross accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,975,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,918,976&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(791,827&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Accounts Receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,183,890&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,918,976&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;71.9&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Allowance for doubtful accounts movement is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;446,527&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;639,991&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;419,353&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Bad debt recovery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(225,660&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(74,053&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;791,827&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;446,527&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,975,717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,020,269&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(791,827&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(446,527&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,183,890&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,573,742&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c2" decimals="0" unitRef="usd">15975717</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c3" decimals="0" unitRef="usd">16020269</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c2" decimals="0" unitRef="usd">791827</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c3" decimals="0" unitRef="usd">446527</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" unitRef="usd">15183890</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" unitRef="usd">15573742</us-gaap:AccountsReceivableNetCurrent>
    <upc:AccountsReceivableDescription contextRef="c0">The Company&#x2019;s accounts receivable primarily
includes the balance due from customers when the Company&#x2019;s pharmaceutical products are sold and delivered to customers. All of the
Company&#x2019;s accounts receivable balance at September 30, 2021 has been collected in the fiscal year 2022. As of date of this report,
approximately 71.9%, or $10.9 million, of the Company&#x2019;s net account receivable balance at September 30, 2022 has been subsequently
collected and the remaining balance is expected to be substantially collected before March 31, 2023.&#160;</upc:AccountsReceivableDescription>
    <us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Accounts Receivable by aging bucket&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Balance as of September 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Subsequent collection&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;% of subsequent collection&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Less than 3 months&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,673,685&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,135,508&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;From 4 to 6 months&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,970,635&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,360,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;From 7 to 9 months&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,554,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,089,957&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;From 10 to 12 months&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;285,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;180,564&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Over 1 year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;491,208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;152,711&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31.1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total gross accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,975,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,918,976&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(791,827&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Accounts Receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,183,890&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,918,976&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;71.9&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock>
    <upc:AccountsReceivableBeforeGrossValue contextRef="c75" decimals="0" unitRef="usd">6673685</upc:AccountsReceivableBeforeGrossValue>
    <upc:SubsequentCollection contextRef="c75" decimals="0" unitRef="usd">4135508</upc:SubsequentCollection>
    <upc:PercentageOfSubsequentCollection contextRef="c76" decimals="3" unitRef="pure">0.62</upc:PercentageOfSubsequentCollection>
    <upc:AccountsReceivableBeforeGrossValue contextRef="c77" decimals="0" unitRef="usd">6970635</upc:AccountsReceivableBeforeGrossValue>
    <upc:SubsequentCollection contextRef="c77" decimals="0" unitRef="usd">5360236</upc:SubsequentCollection>
    <upc:PercentageOfSubsequentCollection contextRef="c78" decimals="3" unitRef="pure">0.769</upc:PercentageOfSubsequentCollection>
    <upc:AccountsReceivableBeforeGrossValue contextRef="c79" decimals="0" unitRef="usd">1554318</upc:AccountsReceivableBeforeGrossValue>
    <upc:SubsequentCollection contextRef="c79" decimals="0" unitRef="usd">1089957</upc:SubsequentCollection>
    <upc:PercentageOfSubsequentCollection contextRef="c80" decimals="3" unitRef="pure">0.701</upc:PercentageOfSubsequentCollection>
    <upc:AccountsReceivableBeforeGrossValue contextRef="c81" decimals="0" unitRef="usd">285871</upc:AccountsReceivableBeforeGrossValue>
    <upc:SubsequentCollection contextRef="c81" decimals="0" unitRef="usd">180564</upc:SubsequentCollection>
    <upc:PercentageOfSubsequentCollection contextRef="c82" decimals="3" unitRef="pure">0.632</upc:PercentageOfSubsequentCollection>
    <upc:AccountsReceivableBeforeGrossValue contextRef="c83" decimals="0" unitRef="usd">491208</upc:AccountsReceivableBeforeGrossValue>
    <upc:SubsequentCollection contextRef="c83" decimals="0" unitRef="usd">152711</upc:SubsequentCollection>
    <upc:PercentageOfSubsequentCollection contextRef="c84" decimals="3" unitRef="pure">0.311</upc:PercentageOfSubsequentCollection>
    <us-gaap:AccountsReceivableGross contextRef="c2" decimals="0" unitRef="usd">15975717</us-gaap:AccountsReceivableGross>
    <upc:SunsequentCollectionsTotalGrossAccountsReceivable contextRef="c2" decimals="0" unitRef="usd">10918976</upc:SunsequentCollectionsTotalGrossAccountsReceivable>
    <upc:TotalGrossAccountsReceivablePercentage contextRef="c0" decimals="3" unitRef="pure">0.683</upc:TotalGrossAccountsReceivablePercentage>
    <us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss contextRef="c2" decimals="0" unitRef="usd">791827</us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss>
    <us-gaap:AccountsReceivableNet contextRef="c2" decimals="0" unitRef="usd">15183890</us-gaap:AccountsReceivableNet>
    <upc:SunsequentCollectionAccountsReceivableNet contextRef="c2" decimals="0" unitRef="usd">10918976</upc:SunsequentCollectionAccountsReceivableNet>
    <upc:AccountsReceivableNetPercentage contextRef="c0" decimals="3" unitRef="pure">0.719</upc:AccountsReceivableNetPercentage>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;446,527&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;639,991&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;419,353&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Bad debt recovery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(225,660&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(74,053&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;791,827&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;446,527&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c3" decimals="0" unitRef="usd">446527</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c22" decimals="0" unitRef="usd">639991</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c0" decimals="0" unitRef="usd">419353</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c4" decimals="0" unitRef="usd">225660</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c0" decimals="0" unitRef="usd">-74053</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c4" decimals="0" unitRef="usd">32196</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c2" decimals="0" unitRef="usd">791827</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c3" decimals="0" unitRef="usd">446527</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 4 &#x2014; INVENTORY, NET&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Inventory consists of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;989,043&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;607,661&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,337,731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,971,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Inventory valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(120,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(116,453&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total inventory, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,206,488&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,462,542&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;989,043&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;607,661&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,337,731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,971,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Inventory valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(120,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(116,453&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total inventory, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,206,488&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,462,542&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c2" decimals="0" unitRef="usd">989043</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c3" decimals="0" unitRef="usd">607661</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods contextRef="c2" decimals="0" unitRef="usd">1337731</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="0" unitRef="usd">1971334</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryValuationReserves contextRef="c2" decimals="0" unitRef="usd">120286</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="0" unitRef="usd">116453</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" unitRef="usd">2206488</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" unitRef="usd">2462542</us-gaap:InventoryNet>
    <upc:AdvancesToSuppliersTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 &#x2014; ADVANCE TO SUPPLIERS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advances to suppliers consist of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Advances to suppliers for inventory raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,738,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Advances to suppliers, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,701&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,738,313&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advances to suppliers represent prepayments made
to suppliers to ensure continuous high-quality supplies and favorable purchase prices for raw materials.&lt;/p&gt;</upc:AdvancesToSuppliersTextBlock>
    <upc:ScheduleOfAdvancesToSuppliersNet contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Advances to suppliers for inventory raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,738,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Advances to suppliers, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,701&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,738,313&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</upc:ScheduleOfAdvancesToSuppliersNet>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="c2" decimals="0" unitRef="usd">16701</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="c3" decimals="0" unitRef="usd">2738313</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:PaymentsToSuppliersAndEmployees contextRef="c0" decimals="0" unitRef="usd">16701</us-gaap:PaymentsToSuppliersAndEmployees>
    <us-gaap:PaymentsToSuppliersAndEmployees contextRef="c4" decimals="0" unitRef="usd">2738313</us-gaap:PaymentsToSuppliersAndEmployees>
    <upc:PrepaymentForAdvertistingTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 6 &#x2014; PREPAYMENT FOR ADVERTISTING&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 6, 2021, the Company entered into
an advertising service agreement with a third-party, Guangdong Fengyang Legend Consulting Co., Ltd. (&#x201c;Fengyang Legend&#x201d;), pursuant
to which, Fengyang Legend assisted the Company in developing and producing TV advertising films for the Company in order to promote the
Company&#x2019;s sales of its major TCMD product, Bainian Pill and Guben Yanling Pill, and coordinating the specific TV Channel to broadcast
the advertising films to targeted geographic market areas. The total contracted advertising service fee was RMB55 million (approximately
$8.5 million), with an adverting consulting service period of one year from October 1, 2021 to September 30, 2022. Based on contract terms,
the Company was required to make a 30% advance payment to Fengyang Legend within 7 business days upon signing the service agreement and
make an additional 58% of the contract price to Fengyang Legend when the specific TV channel used for broadcast the TV film was determined.
In fiscal year 2021, the Company paid RMB48.4 million (approximately $7.5 million), the amount was recorded as prepayment for advertising
on the balance sheets as of September 30, 2021, and recognized as selling expense during fiscal year 2022. The remaining 12% of the contract
price, RMB6.6 million (approximately $0.9 million), represented the monthly advertising fees payable when the advertising film was broadcasted
through the designated TV channels during the service period.&lt;/p&gt;</upc:PrepaymentForAdvertistingTextBlock>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="c85" decimals="-6" unitRef="cny">55000000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="c85" decimals="-5" unitRef="usd">8500000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <upc:PercentageOfAdvancePayment contextRef="c86" decimals="2" unitRef="pure">0.30</upc:PercentageOfAdvancePayment>
    <upc:AdditionalContractPricePercentage contextRef="c85" decimals="2" unitRef="pure">0.58</upc:AdditionalContractPricePercentage>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c3" decimals="-5" unitRef="cny">48400000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c3" decimals="-5" unitRef="usd">7500000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <upc:ContractPricePercentage contextRef="c0" decimals="2" unitRef="pure">0.12</upc:ContractPricePercentage>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c2" decimals="-5" unitRef="cny">6600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c2" decimals="-5" unitRef="usd">900000</us-gaap:RevenueRemainingPerformanceObligation>
    <upc:PrepaymentForAcquisitionTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 7 &#x2014; PREPAYMENT FOR ACQUISITION&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 26, 2022, the Company entered into
a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to which, Mr. Xibo Liu transfers his 51% ownership
in Yunnan Faxi Pharmaceuticals Co., Ltd. (&#x201c;Yunnan Faxi&#x201d;) to the Company at the price of RMB72 million (approximately $10.1
million). Based on contract terms, the Company prepaid RMB25 million (approximately $3.5 million) within 3 business days upon signing
the letter of intent. As of September 30, 2022, the prepayment was recorded as prepayment for acquisition on the balance sheets. The intended
acquisition is expected to be completed and the remaining balance is expected to be paid in June 2023.&lt;/p&gt;</upc:PrepaymentForAcquisitionTextBlock>
    <upc:EquityMethodInvestmentOwnershipsPercentage contextRef="c87" decimals="2" unitRef="pure">0.51</upc:EquityMethodInvestmentOwnershipsPercentage>
    <upc:AssetAcquisitionPriceOfAcquisitionsExpected contextRef="c87" decimals="-6" unitRef="cny">72000000</upc:AssetAcquisitionPriceOfAcquisitionsExpected>
    <upc:AssetAcquisitionPriceOfAcquisitionsExpected contextRef="c88" decimals="-5" unitRef="usd">10100000</upc:AssetAcquisitionPriceOfAcquisitionsExpected>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c88" decimals="-6" unitRef="cny">25000000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c88" decimals="-5" unitRef="usd">3500000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <upc:HeldToMaturityInvestmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 8 &#x2014; SHORT-TERM INVESTMENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s short-term investments consist
of wealth management financial products purchased from financial institution, which can be redeemed anytime at the Company&#x2019;s discretion.
The financial institution invests the Company&#x2019;s fund in certain financial instruments including money market funds and bonds to
generate investment income. Short-term investments consisted of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,725,204&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Add: purchase wealth management financial products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,330,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: redemption&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,801,927&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued investment income (loss)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(470,477&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239,549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(106,133&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(43,078&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Ending balance of short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,148,594&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,725,204&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Investment income (loss) generated from such short-term investments
amounted to ($470,477), $239,549 and &lt;span style="-sec-ix-hidden: hidden-fact-73"&gt;Nil&lt;/span&gt; for the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;</upc:HeldToMaturityInvestmentDisclosureTextBlock>
    <us-gaap:HeldToMaturitySecuritiesTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,725,204&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Add: purchase wealth management financial products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,330,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: redemption&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,801,927&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued investment income (loss)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(470,477&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239,549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(106,133&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(43,078&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Ending balance of short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,148,594&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,725,204&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:ShortTermInvestments contextRef="c3" decimals="0" unitRef="usd">13725204</us-gaap:ShortTermInvestments>
    <upc:AddPurchaseWealthManagementFinancialProducts contextRef="c4" decimals="0" unitRef="usd">15330660</upc:AddPurchaseWealthManagementFinancialProducts>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c4" decimals="0" unitRef="usd">1801927</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable contextRef="c0" decimals="0" unitRef="usd">-470477</us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable>
    <us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable contextRef="c4" decimals="0" unitRef="usd">239549</us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c0" decimals="0" unitRef="usd">-106133</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c4" decimals="0" unitRef="usd">-43078</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:ShortTermInvestments contextRef="c2" decimals="0" unitRef="usd">13148594</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c3" decimals="0" unitRef="usd">13725204</us-gaap:ShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c2" decimals="0" unitRef="usd">470477</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c3" decimals="0" unitRef="usd">239549</us-gaap:OtherShortTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 9 &#x2014; PROPERTY, PLANT AND EQUIPMENT, NET&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Property, plant and equipment, net, consists of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Buildings&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;20 years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,492,360&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,808,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5-10 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,932&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,047,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Automobiles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,912,525&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Office and electric equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;3-5 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;477,919&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;489,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,960,736&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,461,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,710,098&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,780,247&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,250,638&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,681,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expense was $528,919, $441,355 and
$404,948 for the years ended September 30, 2022, 2021 and 2020, respectively. Loss from disposal of fixed assets amounted to $983, $1,559
and &lt;span style="-sec-ix-hidden: hidden-fact-74"&gt;Nil&lt;/span&gt; for the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Buildings&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;20 years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,492,360&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,808,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5-10 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,932&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,047,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Automobiles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,912,525&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Office and electric equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;3-5 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;477,919&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;489,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,960,736&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,461,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,710,098&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,780,247&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,250,638&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,681,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c66">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c89" decimals="0" unitRef="usd">7492360</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c90" decimals="0" unitRef="usd">7808006</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c67">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c68">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c91" decimals="0" unitRef="usd">77932</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c92" decimals="0" unitRef="usd">2047338</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c69">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c70">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c93" decimals="0" unitRef="usd">1912525</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c94" decimals="0" unitRef="usd">116370</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c71">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c72">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c95" decimals="0" unitRef="usd">477919</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c96" decimals="0" unitRef="usd">489886</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="0" unitRef="usd">9960736</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" unitRef="usd">10461600</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="0" unitRef="usd">5710098</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" unitRef="usd">5780247</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" unitRef="usd">4250638</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">4681353</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="0" unitRef="usd">528919</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c4" decimals="0" unitRef="usd">441355</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="0" unitRef="usd">404948</us-gaap:Depreciation>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c0" decimals="0" unitRef="usd">983</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c4" decimals="0" unitRef="usd">1559</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 10 &#x2014; INTANGIBLE ASSETS, NET&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Intangible assets, net consist of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Land use rights&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;20 years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;252,757&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;278,327&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;5-10 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,217&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,364&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;273,974&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301,691&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(116,523&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(123,208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;157,451&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;178,483&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Amortization expense was $5,030, $5,523 and $5,131 for the years ended
September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Estimated future amortization expense for intangible assets is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Years ending September 30,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amortization&lt;br/&gt;
 expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,055&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;132,176&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;157,451&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Land use rights&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;20 years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;252,757&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;278,327&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;5-10 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,217&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,364&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;273,974&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301,691&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(116,523&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(123,208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;157,451&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;178,483&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c73">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c97" decimals="0" unitRef="usd">252757</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c98" decimals="0" unitRef="usd">278327</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c99">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c100">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c101" decimals="0" unitRef="usd">21217</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c102" decimals="0" unitRef="usd">23364</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c2" decimals="0" unitRef="usd">273974</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c3" decimals="0" unitRef="usd">301691</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c2" decimals="0" unitRef="usd">-116523</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="0" unitRef="usd">-123208</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c2" decimals="0" unitRef="usd">157451</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="0" unitRef="usd">178483</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" unitRef="usd">5030</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c4" decimals="0" unitRef="usd">5523</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c5" decimals="0" unitRef="usd">5131</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Years ending September 30,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amortization&lt;br/&gt;
 expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,055&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;132,176&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;157,451&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths contextRef="c103" decimals="0" unitRef="usd">5055</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo contextRef="c103" decimals="0" unitRef="usd">5055</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree contextRef="c103" decimals="0" unitRef="usd">5055</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour contextRef="c103" decimals="0" unitRef="usd">5055</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive contextRef="c103" decimals="0" unitRef="usd">5055</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive contextRef="c103" decimals="0" unitRef="usd">132176</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c103" decimals="0" unitRef="usd">157451</us-gaap:FiniteLivedIntangibleAssetsNet>
    <upc:PrepaymentForConstructionInProgressTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 11 &#x2014; PREPAYMENT FOR CIP PROJECT&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;CIP represents direct costs of construction incurred
for the Company&#x2019;s manufacturing facilities. On June 25, 2021, the Company signed a construction sub-contract with sub-contractor
Jiangxi Chenyuan Construction Project Co., Ltd. (&#x201c;Chenyuan&#x201d;), pursuant to which, Chenyuan will help the Company construct
four manufacturing plant buildings and an office building with a total estimated budget of RMB165 million (approximately $23.2 million).
The construction work started on August 8, 2021, with an originally estimated completion date on August 7, 2023. However, due to resurgence
of the COVID-19 pandemic, which resulted in lingering logistic disruption, material and labor shortage, and domestic travel restriction,
the construction work is estimated to be completed in December 2024, and Chenyuan will bear the increased material and labor costs. As
of September 30, 2022, the Company had made a prepayment of approximately RMB69.2 million (approximately $9.7 million) to Chenyuan for
land improvement, building foundation and the construction of the main body of the manufacturing plants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2022, $401,702 (approximately
RMB2.9 million) of the prepayment for the CIP project had been used for construction work, and the amount was recorded as property, plant
and equipment in the consolidated balance sheets. As of September 30, 2022, the remaining $9.3 million prepayment to Chenyuan was recorded
as a prepayment for CIP project on the balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2022, future additional capital
expenditure on this CIP project is estimated to be approximately RMB95.8 million (equivalent to $13.5 million), among which approximately
$3.5 million is required for the next 12 months. The Company currently plans to support its ongoing CIP project construction through
cash flows from operations, proceeds received from the IPO, and borrowings from PRC banks in the future and use such bank borrowings to
support the CIP project, if necessary. The construction of the four manufacturing plant buildings and the office building is expected
to be fully completed and put into use by December 2024 and December 2025, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2022, future minimum capital
expenditures on the Company&#x2019;s CIP project are estimated as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Years ending September 30,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Capital&lt;br/&gt;
 Expenditure&lt;br/&gt;
 on CIP&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,479,306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,988,066&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,467,372&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</upc:PrepaymentForConstructionInProgressTextBlock>
    <us-gaap:InvestmentBuildingAndBuildingImprovements contextRef="c104" decimals="-6" unitRef="cny">165000000</us-gaap:InvestmentBuildingAndBuildingImprovements>
    <us-gaap:InvestmentBuildingAndBuildingImprovements contextRef="c104" decimals="-5" unitRef="usd">23200000</us-gaap:InvestmentBuildingAndBuildingImprovements>
    <us-gaap:InvestmentBuildingAndBuildingImprovements contextRef="c105" decimals="-5" unitRef="cny">69200000</us-gaap:InvestmentBuildingAndBuildingImprovements>
    <us-gaap:InvestmentBuildingAndBuildingImprovements contextRef="c105" decimals="-5" unitRef="usd">9700000</us-gaap:InvestmentBuildingAndBuildingImprovements>
    <us-gaap:ConstructionContractCostProgressPaymentOffset contextRef="c106" decimals="0" unitRef="usd">401702</us-gaap:ConstructionContractCostProgressPaymentOffset>
    <us-gaap:ConstructionContractCostProgressPaymentOffset contextRef="c2" decimals="-5" unitRef="cny">2900000</us-gaap:ConstructionContractCostProgressPaymentOffset>
    <upc:Prepayment contextRef="c107" decimals="-5" unitRef="usd">9300000</upc:Prepayment>
    <upc:CapitalExpenditure contextRef="c108" decimals="-5" unitRef="cny">95800000</upc:CapitalExpenditure>
    <upc:CapitalExpenditure contextRef="c108" decimals="-5" unitRef="usd">13500000</upc:CapitalExpenditure>
    <upc:CapitalExpenditure contextRef="c0" decimals="-5" unitRef="usd">3500000</upc:CapitalExpenditure>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Years ending September 30,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Capital&lt;br/&gt;
 Expenditure&lt;br/&gt;
 on CIP&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,479,306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,988,066&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,467,372&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c109" decimals="0" unitRef="usd">3479306</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c109" decimals="0" unitRef="usd">9988066</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c109" decimals="0" unitRef="usd">13467372</us-gaap:FiniteLivedIntangibleAssetsNet>
    <upc:PrepaymentForPurchaseOfAPropertyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 12 &#x2014; PREPAYMENT FOR PURCHASE OF A PROPERTY&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 6, 2021, the Company entered into a real
estate property purchase agreement with related party Jiangxi Yueshang Investment Co., Ltd. (&#x201c;Jiangxi Yueshang&#x201d;), an entity
in which the Company&#x2019;s chief executive officer, Mr. Gang Lai, owned 5% equity interest as of the date of that agreement. Pursuant
to the property purchase agreement, Jiangxi Yueshang will sell and the Company will purchase a certain residential apartment and commercial
office space totaling 2,749.30 square meters, with a total purchase price of RMB32 million (approximately $4.50 million). Pursuant to
this agreement, the Company was required to make a prepayment in the amount of 50% of the total purchase price, with 20% of the total
purchase price payable upon the availability of a certificate of occupancy, and 30% of the total purchase price payable upon delivery
of the property.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2022, the Company had made
a prepayment of RMB16 million (approximately $2.25 million) to Jiangxi Yueshang. The remaining balance is expected to be paid by August
2024. Since the property is located in the urban downtown area of Ji&#x2019;an City, the Company plans to use the property for offices
in late 2024.&lt;/p&gt;</upc:PrepaymentForPurchaseOfAPropertyTextBlock>
    <upc:EquityInterest contextRef="c110" decimals="2" unitRef="pure">0.05</upc:EquityInterest>
    <upc:OfficeSpaceSquareMeters contextRef="c111" decimals="0" unitRef="pure">2749</upc:OfficeSpaceSquareMeters>
    <us-gaap:SupplementalDeferredPurchasePrice contextRef="c110" decimals="-6" unitRef="cny">32000000</us-gaap:SupplementalDeferredPurchasePrice>
    <us-gaap:SupplementalDeferredPurchasePrice contextRef="c110" decimals="-4" unitRef="usd">4500000</us-gaap:SupplementalDeferredPurchasePrice>
    <upc:PercentageOfPrepayment contextRef="c110" decimals="2" unitRef="pure">0.50</upc:PercentageOfPrepayment>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c111" decimals="2" unitRef="pure">0.20</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <upc:PayableDeliveryPropertyPercentage contextRef="c110" decimals="2" unitRef="pure">0.30</upc:PayableDeliveryPropertyPercentage>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c0" decimals="-6" unitRef="cny">16000000</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c0" decimals="-4" unitRef="usd">2250000</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 13 &#x2014; SHORT-TERM BANK LOANS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Short-term bank loans consist of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Note&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Short-term bank loans:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Loans payable to Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Maturity date on June 15, 2022, interest rate 4.81% per annum&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;(1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,548,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Maturity date on March 17, 2022, interest rate 4.81% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;(2)&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,238,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Maturity date on March 13, 2023, interest rate 4.62% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;(3)&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,124,624&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Maturity date on June 14, 2023, interest rate 4.62% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;(4)&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,405,780&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Bank of Communications Co., Ltd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Maturity date on June 30, 2022, interest rate 4.50% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;(5)&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,548,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Maturity date on June 24, 2023, interest rate 4.20% per annum&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;(6)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,405,780&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total short-term loans&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,936,184&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,334,400&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 16, 2021, the Company&#x2019;s subsidiary, Jiangxi
Universe, signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;) to borrow RMB10 million (equivalent
to $1,548,000) as working capital for one year, with the maturity date on June 15, 2022. The fixed interest rate of the loan was 4.81%
per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On March 18, 2021, the Company&#x2019;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,238,400) as working capital for one year, with
the maturity date on March 17, 2022. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for
this loan. The loan was fully repaid upon maturity.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(3)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On March 14, 2022, the Company&#x2019;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,124,624) as working capital for one year, with
the maturity date on March 13, 2023. The fixed interest rate of the loan was 4.62% per annum. There was no guarantee requirement for
this loan.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(4)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 15, 2022, the Company&#x2019;s subsidiary, Jiangxi
Universe, entered into a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,405,780) as working capital for one year,
with the maturity date on June 14, 2023. The fixed interest rate of the loan was 4.62% per annum. Certain related parties of the Company,
including Mr. Gang Lai, the Company&#x2019;s controlling shareholder, chairman of the board of directors, and chief executive officer,
Ms. Lin Yang, the Company&#x2019;s chief financial officer, Ms. Xing Wu, Mr. Gang Lai&#x2019;s spouse, and the Company&#x2019;s WFOE, Universe
Technology, jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(5)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 30, 2021, the Company&#x2019;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,548,000) as working capital for
one year, with the maturity date on June 30, 2022. The fixed interest rate of the loan was 4.5% per annum. Certain related parties of
the Company, including Mr. Gang Lai, the Company&#x2019;s controlling shareholder, Mr. Gang Lai&#x2019;s spouse, Mrs. Xing Wu, and the
Company&#x2019;s subsidiary, Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantees
for this loan. The loan was fully repaid upon maturity.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(6)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 24, 2022, the Company&#x2019;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,405,780) as working capital for
one year, with the maturity date on June 24, 2023. The fixed interest rate of the loan was 4.2% per annum. Jiangxi Province Financing
Guarantee Group Co., Ltd., an unrelated third party, signed a guarantee agreement with Bank of Communications to provide credit guarantee
for this loan.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;For the above-mentioned loans, the Company recorded a total interest
expense of $199,852, $149,303 and $157,528 for the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Note&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Short-term bank loans:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Loans payable to Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Maturity date on June 15, 2022, interest rate 4.81% per annum&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;(1)&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,548,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Maturity date on March 17, 2022, interest rate 4.81% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;(2)&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,238,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Maturity date on March 13, 2023, interest rate 4.62% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;(3)&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,124,624&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Maturity date on June 14, 2023, interest rate 4.62% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;(4)&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,405,780&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Bank of Communications Co., Ltd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Maturity date on June 30, 2022, interest rate 4.50% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;(5)&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,548,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Maturity date on June 24, 2023, interest rate 4.20% per annum&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;(6)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,405,780&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total short-term loans&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,936,184&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,334,400&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 16, 2021, the Company&#x2019;s subsidiary, Jiangxi
Universe, signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;) to borrow RMB10 million (equivalent
to $1,548,000) as working capital for one year, with the maturity date on June 15, 2022. The fixed interest rate of the loan was 4.81%
per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On March 18, 2021, the Company&#x2019;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,238,400) as working capital for one year, with
the maturity date on March 17, 2022. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for
this loan. The loan was fully repaid upon maturity.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(3)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On March 14, 2022, the Company&#x2019;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,124,624) as working capital for one year, with
the maturity date on March 13, 2023. The fixed interest rate of the loan was 4.62% per annum. There was no guarantee requirement for
this loan.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(4)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 15, 2022, the Company&#x2019;s subsidiary, Jiangxi
Universe, entered into a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,405,780) as working capital for one year,
with the maturity date on June 14, 2023. The fixed interest rate of the loan was 4.62% per annum. Certain related parties of the Company,
including Mr. Gang Lai, the Company&#x2019;s controlling shareholder, chairman of the board of directors, and chief executive officer,
Ms. Lin Yang, the Company&#x2019;s chief financial officer, Ms. Xing Wu, Mr. Gang Lai&#x2019;s spouse, and the Company&#x2019;s WFOE, Universe
Technology, jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(5)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 30, 2021, the Company&#x2019;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,548,000) as working capital for
one year, with the maturity date on June 30, 2022. The fixed interest rate of the loan was 4.5% per annum. Certain related parties of
the Company, including Mr. Gang Lai, the Company&#x2019;s controlling shareholder, Mr. Gang Lai&#x2019;s spouse, Mrs. Xing Wu, and the
Company&#x2019;s subsidiary, Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantees
for this loan. The loan was fully repaid upon maturity.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(6)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 24, 2022, the Company&#x2019;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,405,780) as working capital for
one year, with the maturity date on June 24, 2023. The fixed interest rate of the loan was 4.2% per annum. Jiangxi Province Financing
Guarantee Group Co., Ltd., an unrelated third party, signed a guarantee agreement with Bank of Communications to provide credit guarantee
for this loan.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermBorrowings contextRef="c125" decimals="0" id="ix_0_fact" unitRef="usd">1548000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c127" decimals="0" id="ix_1_fact" unitRef="usd">1238400</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c128" decimals="0" id="ix_2_fact" unitRef="usd">1124624</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c130" decimals="0" id="ix_3_fact" unitRef="usd">1405780</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c132" decimals="0" id="ix_4_fact" unitRef="usd">1548000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c133" decimals="0" id="ix_5_fact" unitRef="usd">1405780</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c2" decimals="0" unitRef="usd">3936184</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c3" decimals="0" unitRef="usd">4334400</us-gaap:ShortTermBorrowings>
    <us-gaap:LoansPayableToBankCurrent contextRef="c112" decimals="-6" unitRef="cny">10000000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent contextRef="c112" decimals="0" unitRef="usd">1548000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c113">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c113">2022-06-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c112" decimals="4" unitRef="pure">0.0481</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LoansPayableToBankCurrent contextRef="c114" decimals="-6" unitRef="cny">8000000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent contextRef="c114" decimals="0" unitRef="usd">1238400</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c115">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c115">2022-03-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c114" decimals="4" unitRef="pure">0.0481</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LoansPayableToBankCurrent contextRef="c116" decimals="-6" unitRef="cny">8000000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent contextRef="c116" decimals="0" unitRef="usd">1124624</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c117">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c117">2023-03-13</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c116" decimals="4" unitRef="pure">0.0462</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LoansPayableToBankCurrent contextRef="c118" decimals="-6" unitRef="cny">10000000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent contextRef="c118" decimals="0" unitRef="usd">1405780</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c119">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c119">2023-06-14</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c118" decimals="4" unitRef="pure">0.0462</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LoansPayableToBankCurrent contextRef="c120" decimals="-6" unitRef="cny">10000000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent contextRef="c120" decimals="0" unitRef="usd">1548000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c121">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c121">2022-06-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c120" decimals="3" unitRef="pure">0.045</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LoansPayableToBankCurrent contextRef="c122" decimals="-6" unitRef="cny">10000000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent contextRef="c122" decimals="0" unitRef="usd">1405780</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c123">2023-06-24</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c122" decimals="3" unitRef="pure">0.042</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestAndDebtExpense contextRef="c0" decimals="0" unitRef="usd">199852</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c4" decimals="0" unitRef="usd">149303</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c5" decimals="0" unitRef="usd">157528</us-gaap:InterestAndDebtExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 14 &#x2014; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(a)
&lt;/b&gt;&lt;/span&gt;&lt;b&gt;Nature of relationships with related parties&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; width: 49%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; border-bottom: Black 1.5pt solid; width: 49%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship with the Company&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Gang Lai&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s controlling shareholder, Chief Executive Officer and chairman of the Company&#x2019;s Board of Directors&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ms. Lin Yang&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief Financial Officer and Director&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Greatest Group (China) Financial Management Limited (&#x201c;Greatest Group&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;One of the Company&#x2019;s minority shareholders owns 8.7% of the ownership interest in this entity&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foshan Shangyu Investment Holding Co., Ltd (&#x201c;Foshan Shangyu&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An affiliated entity of the Company, 90% owned by and controlled by the Company&#x2019;s Chief Executive Officer&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(b) Due from related parties&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Name&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Greatest Group&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;235,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foshan Shangyu&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total due from related parties&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;236,982&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company&#x2019;s due from related parties were interest free and
due on demand. The September 30, 2021 due from related parties balance has been subsequently collected back and the Company does not have
the intention to make additional cash advance to related parties going forward.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(c)
Due to related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Name&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Mr. Gang Lai&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,379,263&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Mrs. Lin Yang&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,723&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total due to related parties&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,379,263&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,723&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of September 30, 2022 and 2021, the balance due to related parties
mainly consisted of advances from the Company&#x2019;s officers for working capital purposes during the Company&#x2019;s normal course of
business. These advances are non-interest bearing and due on demand.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(d) Loan guarantee provided by related parties&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the Company&#x2019;s bank borrowings
from Bank of Communications, certain related parties of the Company, including Mr. Gang Lai, the Company&#x2019;s controlling shareholder,
chairman of the board of directors, and chief executive officer, Mr. Gang Lai&#x2019;s spouse, Ms. Xing Wu, and the Company&#x2019;s subsidiary,
Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for these loans.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the Company&#x2019;s bank borrowings
from LRC Bank, the Company&#x2019;s chief executive officer, Mr. Gang Lai, signed a guarantee agreement with LRC Bank to provide a credit
guarantee for the Company&#x2019;s loans from LRC Bank within the loan period (see Note 13).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(e) Prepayment to related party for property purchase&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As disclosed in Note 12, on May 6, 2021, the Company
entered into a real estate property purchase agreement with a related party, Jiangxi Yueshang, to purchase certain residential apartment
and commercial office space totaling 2,749.30 square meters with total purchase price of RMB32 million (approximately $4.5 million). As
of September 30, 2022, the Company had made a prepayment of RMB16 million ($2,249,248) to Jiangxi Yueshang. The remaining balance is expected
to be paid by August 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 13, 2022, Mr. Gang Lai transferred
the 5% equity interest he owned in Jiangxi Yueshang to a third party. As such, after this date, Jiangxi Yueshang is no longer our related
party.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; width: 49%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; border-bottom: Black 1.5pt solid; width: 49%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship with the Company&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Gang Lai&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s controlling shareholder, Chief Executive Officer and chairman of the Company&#x2019;s Board of Directors&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ms. Lin Yang&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief Financial Officer and Director&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Greatest Group (China) Financial Management Limited (&#x201c;Greatest Group&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;One of the Company&#x2019;s minority shareholders owns 8.7% of the ownership interest in this entity&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foshan Shangyu Investment Holding Co., Ltd (&#x201c;Foshan Shangyu&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An affiliated entity of the Company, 90% owned by and controlled by the Company&#x2019;s Chief Executive Officer&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="c136">The Company&#x2019;s controlling shareholder, Chief Executive Officer and chairman of the Company&#x2019;s Board of Directors</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="c137">Chief Financial Officer and Director</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="c138">One of the Company&#x2019;s minority shareholders owns 8.7% of the ownership interest in this entity</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="c139">An affiliated entity of the Company, 90% owned by and controlled by the Company&#x2019;s Chief Executive Officer</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <upc:ScheduleOfDueFromRelatedPartiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Name&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Greatest Group&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;235,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foshan Shangyu&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total due from related parties&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;236,982&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</upc:ScheduleOfDueFromRelatedPartiesTableTextBlock>
    <us-gaap:DueFromOtherRelatedPartiesCurrent contextRef="c141" decimals="0" unitRef="usd">235438</us-gaap:DueFromOtherRelatedPartiesCurrent>
    <us-gaap:DueFromOtherRelatedPartiesCurrent contextRef="c143" decimals="0" unitRef="usd">1544</us-gaap:DueFromOtherRelatedPartiesCurrent>
    <us-gaap:DueFromOtherRelatedPartiesCurrent contextRef="c3" decimals="0" unitRef="usd">236982</us-gaap:DueFromOtherRelatedPartiesCurrent>
    <upc:ScheduleOfDueToRelatedPartiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Name&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Mr. Gang Lai&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,379,263&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Mrs. Lin Yang&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,723&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total due to related parties&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,379,263&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,723&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</upc:ScheduleOfDueToRelatedPartiesTableTextBlock>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="c144" decimals="0" unitRef="usd">3379263</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="c147" decimals="0" unitRef="usd">19723</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="c2" decimals="0" unitRef="usd">3379263</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="c3" decimals="0" unitRef="usd">19723</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DeconsolidationRelatedPartyDescription contextRef="c110">As disclosed in Note 12, on May 6, 2021, the Company
entered into a real estate property purchase agreement with a related party, Jiangxi Yueshang, to purchase certain residential apartment
and commercial office space totaling 2,749.30 square meters with total purchase price of RMB32 million (approximately $4.5 million).</us-gaap:DeconsolidationRelatedPartyDescription>
    <upc:PrepaymentAmount contextRef="c0" decimals="-6" unitRef="cny">16000000</upc:PrepaymentAmount>
    <upc:PrepaymentAmount contextRef="c0" decimals="0" unitRef="usd">-2249248</upc:PrepaymentAmount>
    <upc:EquityInterestOwnershipPercentage contextRef="c135" decimals="2" unitRef="pure">0.05</upc:EquityInterestOwnershipPercentage>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 15 &#x2014; TAXES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(a) Corporate Income Taxes (&#x201c;CIT&#x201d;)&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Cayman Islands&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the current tax laws of the Cayman Islands,
Universe INC is not subject to tax on its income or capital gains. In addition, no Cayman Islands withholding tax will be imposed upon
the payment of dividends by the Company to its shareholders.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Hong Kong&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Universe HK is incorporated in Hong Kong and is
subject to profit taxes in Hong Kong at a rate of 16.5%. However, Universe HK did not generate any assessable profits derived from Hong
Kong sources for the years ended September 30, 2022, 2021 and 2020, and accordingly no provision for Hong Kong profits tax has been made
in these periods.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;PRC&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the Enterprise Income Tax (&#x201c;EIT&#x201d;)
Law of PRC, domestic enterprises and Foreign Investment Enterprises (&#x201c;FIEs&#x201d;) are usually subject to a unified 25% enterprise
income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on a case-by-case basis. EIT grants preferential
tax treatment to High and New Technology Enterprises (&#x201c;HNTEs&#x201d;). Under this preferential tax treatment, HNTEs are entitled
to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one
of the Company&#x2019;s main operating subsidiaries in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of
15% beginning November 2016 with a term of three years. In December 2019, Jiangxi Universe successfully renewed its HNTE certification
with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2022. In
November 2022, Jiangxi Universe successfully further renewed its HNTE certification with local government and will continue to enjoy the
reduced income tax rate of 15% for another three years through November 2025. Universe Trade, another operating subsidiary of the Company
in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15% beginning December 2020 with a term of three years
through December 2023. EIT is typically governed by the local tax authority in the PRC. Each local tax authority at times may grant tax
holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the years
ended September 30, 2022, 2021 and 2020 were reported at a blended reduced rate as a result of certain of the PRC subsidiaries of the
Company&#x2019;s being approved as a HNTE and enjoying a 15% reduced income tax rate. The impact of the tax holidays noted above decreased
PRC corporate income taxes by $694,955, $1,518,979 and $118,986 for the years ended September 30, 2022, 2021 and 2020, respectively. The
benefit of the tax holidays on net income per share (basic and diluted) was $0.03, $0.09 and $0.01 for the years ended September 30, 2022,
2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The components of the income tax provision (benefit) are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current tax provision:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cayman&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt"&gt;PRC&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,357,697&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;3,026,867&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,552,097&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;Sub-total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,357,697&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,026,867&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,552,097&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax provision (benefit):&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cayman&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;PRC&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(605,278&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(668,341&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Sub-total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(605,278&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(668,341&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total income tax provision&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;752,419&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,358,526&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,542,211&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table reconciles the China statutory rates to the Company&#x2019;s
effective tax rate for the years ended September 30, 2022, 2021 and 2020:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Statutory PRC income tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Effect of income tax holiday&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent difference&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-PRC entities not subject to PRC income tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Impact on DTA due to change in applicable income tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(9.4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17.1&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25.2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company continually evaluates expiring statutes of limitations, audits,
proposed settlements, changes in tax law and new authoritative rulings. As of September 30, 2022, all of the Company&#x2019;s tax returns
of its PRC subsidiaries remain open for statutory examination by PRC tax authorities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Deferred tax assets are composed of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in"&gt;Net operating loss carry-forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,210,855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;785,550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;136,817&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;84,447&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;869,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,347,672&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;869,997&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company periodically evaluates the likelihood
of the realization of deferred tax assets, and reduces the carrying amount of the deferred tax assets by a valuation allowance to the
extent it believes a portion will not be realized. Management considers new evidence, both positive and negative, that could affect the
Company&#x2019;s future realization of deferred tax assets including its recent cumulative earnings experience, expectation of future income,
the carry forward periods available for tax reporting purposes and other relevant factors. Although Jiangxi Universe incurred a net loss
during the year ended September 30, 2022, the Company determined that it is more likely than not that its deferred tax assets could be
realized due to the estimated future earnings in Jiangxi Universe.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;(b) Taxes payable&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Taxes payable consist of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Income tax payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;669,780&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Value added tax payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;326,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other taxes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,263&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;105,212&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total taxes payable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;167,350&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,101,460&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign contextRef="c148" decimals="3" unitRef="pure">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings contextRef="c0" decimals="2" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <upc:PreferentialTaxTreatmentDescription contextRef="c0">Under this preferential tax treatment, HNTEs are entitled
to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one
of the Company&#x2019;s main operating subsidiaries in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of
15% beginning November 2016 with a term of three years. In December 2019, Jiangxi Universe successfully renewed its HNTE certification
with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2022. In
November 2022, Jiangxi Universe successfully further renewed its HNTE certification with local government and will continue to enjoy the
reduced income tax rate of 15% for another three years through November 2025. Universe Trade, another operating subsidiary of the Company
in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15% beginning December 2020 with a term of three years
through December 2023. EIT is typically governed by the local tax authority in the PRC. Each local tax authority at times may grant tax
holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the years
ended September 30, 2022, 2021 and 2020 were reported at a blended reduced rate as a result of certain of the PRC subsidiaries of the
Company&#x2019;s being approved as a HNTE and enjoying a 15% reduced income tax rate.</upc:PreferentialTaxTreatmentDescription>
    <us-gaap:TaxesPayableCurrentAndNoncurrent contextRef="c2" decimals="0" unitRef="usd">694955</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">1518979</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent contextRef="c22" decimals="0" unitRef="usd">118986</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare contextRef="c0" decimals="2" unitRef="usdPershares">0.03</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare contextRef="c4" decimals="2" unitRef="usdPershares">0.09</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare contextRef="c5" decimals="2" unitRef="usdPershares">0.01</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current tax provision:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cayman&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt"&gt;PRC&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,357,697&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;3,026,867&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,552,097&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;Sub-total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,357,697&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,026,867&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,552,097&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax provision (benefit):&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cayman&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;PRC&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(605,278&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(668,341&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Sub-total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(605,278&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(668,341&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total income tax provision&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;752,419&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,358,526&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,542,211&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c154" decimals="0" unitRef="usd">1357697</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c155" decimals="0" unitRef="usd">3026867</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c156" decimals="0" unitRef="usd">2552097</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">1357697</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c4" decimals="0" unitRef="usd">3026867</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">2552097</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c154" decimals="0" unitRef="usd">-605278</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c155" decimals="0" unitRef="usd">-668341</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c156" decimals="0" unitRef="usd">-9886</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c154" decimals="0" unitRef="usd">-605278</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c155" decimals="0" unitRef="usd">-668341</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c156" decimals="0" unitRef="usd">-9886</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">752419</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c4" decimals="0" unitRef="usd">2358526</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">2542211</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Statutory PRC income tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Effect of income tax holiday&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent difference&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-PRC entities not subject to PRC income tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Impact on DTA due to change in applicable income tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(9.4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17.1&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25.2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="3" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c4" decimals="3" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="3" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays contextRef="c0" decimals="3" unitRef="pure">0.087</us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays contextRef="c4" decimals="3" unitRef="pure">0.11</us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays contextRef="c5" decimals="3" unitRef="pure">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness contextRef="c0" decimals="3" unitRef="pure">-0.223</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c0" decimals="3" unitRef="pure">-0.034</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c4" decimals="3" unitRef="pure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c5" decimals="3" unitRef="pure">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c4" decimals="3" unitRef="pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c4" decimals="3" unitRef="pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="3" unitRef="pure">-0.094</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c4" decimals="3" unitRef="pure">0.171</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c5" decimals="3" unitRef="pure">0.252</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in"&gt;Net operating loss carry-forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,210,855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;785,550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;136,817&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;84,447&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;869,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,347,672&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;869,997&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="0" unitRef="usd">1210855</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="0" unitRef="usd">785550</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c2" decimals="0" unitRef="usd">136817</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c3" decimals="0" unitRef="usd">84447</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c2" decimals="0" unitRef="usd">1347672</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c3" decimals="0" unitRef="usd">869997</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="0" unitRef="usd">1347672</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="0" unitRef="usd">869997</us-gaap:DeferredTaxAssetsGross>
    <upc:ScheduleOfTaxPayableTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Income tax payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;669,780&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Value added tax payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;326,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other taxes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,263&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;105,212&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total taxes payable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;167,350&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,101,460&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</upc:ScheduleOfTaxPayableTableTextBlock>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c3" decimals="0" unitRef="usd">669780</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c2" decimals="0" unitRef="usd">115087</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c3" decimals="0" unitRef="usd">326468</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c2" decimals="0" unitRef="usd">52263</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c3" decimals="0" unitRef="usd">105212</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="0" unitRef="usd">167350</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c3" decimals="0" unitRef="usd">1101460</us-gaap:TaxesPayableCurrent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 16 &#x2014; CONCENTRATIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A majority of the Company&#x2019;s revenue and expense
transactions are denominated in RMB and a significant portion of the Company and its subsidiaries&#x2019; assets and liabilities are denominated
in RMB. RMB is not freely convertible into foreign currencies. In the PRC, certain foreign exchange transactions are required by law to
be transacted only by authorized financial institutions at exchange rates set by the People&#x2019;s Bank of China (&#x201c;PBOC&#x201d;).
Remittances in currencies other than RMB by the Company in China must be processed through the PBOC or other China foreign exchange regulatory
bodies which require certain supporting documentation in order to affect the remittance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2022 and 2021, $5,711,423 and
$5,892,655 of the Company&#x2019;s cash, respectively, was on deposit at financial institutions in the PRC where no existing rule or regulation
requires such financial institutions to maintain insurance to cover bank deposits in the event of bank failure. For the years ended September
30, 2022, 2021 and 2020, the Company&#x2019;s substantial assets were located in the PRC and the Company&#x2019;s substantial revenues were
derived from its subsidiaries located in the PRC.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended September 30, 2022, 2021 and 2020,
no single customer accounted for more than 10% of the Company&#x2019;s total revenue. The Company&#x2019;s top 10 customers aggregately
accounted for 32.2%, 30.4% and 33.3% of the total revenue for the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Sales of one of the Company&#x2019;s major products,
Guben Yanling Pill, accounted for 42.5%, 40.3% and 38.2% of the Company&#x2019;s total revenue for the years ended September 30, 2022,
2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2022 and 2021, no customer accounted
for more than 10% of the total accounts receivable balance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2022, one supplier accounted for
100% of the total advance to supplier balance. As of September 30, 2021, two suppliers accounted for 35.3% and 28.0% of the total advance
to supplier balance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the year ended September 30, 2022, one supplier
accounted for approximately 10.3% of the total purchases. For the year ended September 30, 2021, no supplier accounted for more than 10%
of the total purchases, respectively. For the year ended September 30, 2020, two suppliers accounted for approximately 19.6% and 13.6%
of the total purchases, respectively.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ForeignFinancialInstitutionsMandatedDeposits contextRef="c2" decimals="0" unitRef="usd">5711423</us-gaap:ForeignFinancialInstitutionsMandatedDeposits>
    <us-gaap:ForeignFinancialInstitutionsMandatedDeposits contextRef="c3" decimals="0" unitRef="usd">5892655</us-gaap:ForeignFinancialInstitutionsMandatedDeposits>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c157" decimals="2" unitRef="pure">0.10</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c158" decimals="2" unitRef="pure">0.10</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c159" decimals="2" unitRef="pure">0.10</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c160" decimals="3" unitRef="pure">0.322</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c161" decimals="3" unitRef="pure">0.304</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c162" decimals="3" unitRef="pure">0.333</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c163" decimals="3" unitRef="pure">0.425</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c164" decimals="3" unitRef="pure">0.403</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c165" decimals="3" unitRef="pure">0.382</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c166" decimals="2" unitRef="pure">0.10</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c174" decimals="2" unitRef="pure">0.10</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c167" decimals="2" unitRef="pure">1</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c168" decimals="3" unitRef="pure">0.353</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c169" decimals="3" unitRef="pure">0.28</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c170" decimals="3" unitRef="pure">0.103</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c171" decimals="2" unitRef="pure">0.10</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c172" decimals="3" unitRef="pure">0.196</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c173" decimals="3" unitRef="pure">0.136</upc:ConcentrationRiskThresholdPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 17 &#x2014; SHAREHOLDERS&#x2019; EQUITY&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Ordinary Shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Universe INC was incorporated under the laws of the
Cayman Islands on December 11, 2019. The original authorized number of ordinary shares was 50,000 shares with par value of US$1.00 per
share and 50,000 shares were issued. On August 7, 2020, the Company amended its Memorandum of Association to increase the authorized number
of shares to 100,000,000 shares with par value of $0.003125 per share, and subdivide the original issued shares from 50,000 shares at
par value of $1.00 per share to 16,000,000 ordinary shares with par value of $0.003125 per share. As a result of this forward split of
the outstanding ordinary shares at a ratio of 320-for-1 share, a total of 16,000,000 shares were issued and outstanding after the split.
The issuance of these 16,000,000 shares is considered as a part of the Reorganization of the Company, which was retroactively applied
as if the transaction occurred at the beginning of the period presented (see Note 1).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Initial Public Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 25, 2021, the Company closed its IPO of 5,000,000
ordinary shares at a public offering price of $5.00 per share. On March 29, 2021, the underwriter exercised in full its over-allotment
option to purchase an additional 750,000 ordinary shares. The closing for the sale of the over-allotment shares took place on March 31,
2021. Gross proceeds of the IPO, including the proceeds from the sale of the over-allotment shares, totaled $28.75 million, before deducting
underwriting discounts and other related expenses. Net proceeds of our IPO, including over-allotment shares, were approximately $25.6
million. In connection with the IPO, the Company&#x2019;s ordinary shares began trading on the Nasdaq Global Market under the symbol &#x201c;UPC&#x201d;
on March 23, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2022 and 2021, the Company had
a total of 21,750,000 ordinary shares issued and outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Underwriter warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the Company&#x2019;s IPO, the Company
also agreed to issue warrants to the underwriter, for a nominal consideration of $0.001 per warrant, to purchase 300,000 ordinary shares
of the Company (equal to 6% of the total number of ordinary shares sold in the IPO, not including any ordinary shares sold in the over-allotment
option) (the &#x201c;Underwriter Warrants&#x201d;). The Underwriter Warrants have a term of five years, with an exercise price of $5.50
per share (equal to 110% of the Company&#x2019;s IPO offering price of $5.00 per share). The Underwriter Warrants may be purchased in cash
or via cashless exercise, will be exercisable for five (5) years, and will terminate on the fifth anniversary of the closing of the IPO.
Management determined that the Underwriter Warrants meet the requirements for equity classification under ASC 815-40 because they are
indexed to its own stock. As of September 30, 2022, the Underwriter Warrants were issued and outstanding, but none of them has been exercised.
For the years ended September 30, 2022 and 2021, the Underwriter Warrants were antidilutive and accordingly were not included in the diluted
EPS calculation based on treasury stock method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Cash dividends&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 21, 2016, September 13, 2017, February
2, 2018, September 20, 2018 and February 21, 2019, the board of directors of Jiangxi Universe approved resolutions to pay cash dividends
of RMB40 million, RMB30 million, RMB20 million, RMB10 million and RMB30 million, respectively, to its shareholders at the time of record
out of the retained earnings balance of Jiangxi Universe, to be paid to these shareholders when there are sufficient available earnings
and the Company has sufficient funds. A total of RMB130 million (approximately $19.1 million) cash dividend was declared from September
2016 to February 2019, among which, approximately RMB20 million ($3.1 million) was paid in cash to its shareholders in 2018 and the remaining
RMB110 million ($16 million) was paid to its shareholders in 2019. There were no additional cash dividends paid during the years ended
September 30, 2022, 2021 and 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Except for the dividends declared mentioned above,
the Company has not declared or paid dividends to its shareholders in the past, and may not choose to make additional distributions in
the future. Any decision as to the payment of dividends will depend on the available earnings, the capital requirements of the Company,
the Company&#x2019;s general financial condition and other factors deemed pertinent by the board of directors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Statutory reserve and restricted net assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s PRC subsidiaries are restricted
in their ability to transfer a portion of their net assets to the Company. The payment of dividends by entities organized in China is
subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated
profits as determined in accordance with accounting standards and regulations in China.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is required to make appropriations to
certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income determined
in accordance with generally accepted accounting principles of the PRC (&#x201c;PRC GAAP&#x201d;). Appropriations to the statutory surplus
reserve are required to be at least 10% of the after-tax net income determined in accordance with PRC GAAP until the reserve is equal
to 50% of the entity&#x2019;s registered capital. Appropriations to the discretionary surplus reserve are made at the discretion of the
board of directors. The statutory reserve may be applied against prior year losses, if any, and may be used for general business expansion
and production or increase in registered capital, but are not distributable as cash dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Relevant PRC laws and regulations restrict the Company&#x2019;s
PRC subsidiaries from transferring a portion of their net assets, equivalent to their statutory reserves and their share capital, to the
Company in the form of loans, advances or cash dividends. Only PRC entities&#x2019; accumulated profits may be distributed as dividends
to the Company without the consent of a third party. As of September 30, 2022 and 2021, the restricted amounts as determined pursuant
to PRC statutory laws totaled $2,439,535, and total restricted net assets amounted to $31,786,663.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Cash transfer between the Company and its subsidiaries&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the year ended September 30, 2022, the Company
received cash in the amount of $303,746 from its subsidiary in Hong Kong, and the WFOE transferred cash in the amount of $5,211,231 to
Jiangxi Universe. For the year ended September 30, 2021, the Company transferred cash in the amount of $11,358,764 to its subsidiary in
Hong Kong, and the Company&#x2019;s Hong Kong subsidiary, via the WFOE, further transferred cash in the amount of $6,807,507 to the PRC
subsidiaries. For the year ended September 30, 2020, there was no cash transferred from the Company to its PRC subsidiaries. The assets
transfer was for business operation purpose. There was no distribution of earnings by the PRC operating subsidiaries to the Company during
the years ended September 30, 2022, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c175" decimals="0" unitRef="shares">50000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c175" decimals="2" unitRef="usdPershares">1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c175" decimals="0" unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized contextRef="c176" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c176" decimals="6" unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssued contextRef="c176" decimals="0" unitRef="shares">50000</us-gaap:SharesIssued>
    <upc:OriginalSharesParValue contextRef="c177" decimals="2" unitRef="usdPershares">1</upc:OriginalSharesParValue>
    <us-gaap:CommonStockSharesIssued contextRef="c176" decimals="0" unitRef="shares">16000000</us-gaap:CommonStockSharesIssued>
    <upc:OrdinarySharesParValue contextRef="c177" decimals="6" unitRef="usdPershares">0.003125</upc:OrdinarySharesParValue>
    <upc:OrdinarySharesOutstandingDescription contextRef="c178">As a result of this forward split of
the outstanding ordinary shares at a ratio of 320-for-1 share, a total of 16,000,000 shares were issued and outstanding after the split.</upc:OrdinarySharesOutstandingDescription>
    <upc:ReorganizationShares contextRef="c177" decimals="0" unitRef="shares">16000000</upc:ReorganizationShares>
    <us-gaap:SharesIssued contextRef="c179" decimals="0" unitRef="shares">5000000</us-gaap:SharesIssued>
    <upc:PublicOfferingPrice contextRef="c179" decimals="2" unitRef="usdPershares">5</upc:PublicOfferingPrice>
    <upc:OptionToPurchaseAdditionalShares contextRef="c180" decimals="0" unitRef="shares">750000</upc:OptionToPurchaseAdditionalShares>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c179" decimals="-4" unitRef="usd">28750000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c181" decimals="-5" unitRef="usd">25600000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:SharesOutstanding contextRef="c3" decimals="0" unitRef="shares">21750000</us-gaap:SharesOutstanding>
    <us-gaap:SharesIssued contextRef="c2" decimals="0" unitRef="shares">21750000</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c182" decimals="3" unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssued contextRef="c182" decimals="0" unitRef="shares">300000</us-gaap:SharesIssued>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="c183" decimals="2" unitRef="pure">0.06</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:WarrantExercisePriceIncrease contextRef="c183" decimals="2" unitRef="usdPershares">5.5</us-gaap:WarrantExercisePriceIncrease>
    <upc:EquityMethodInvestmentOwnershipsPercentage contextRef="c184" decimals="2" unitRef="pure">1.10</upc:EquityMethodInvestmentOwnershipsPercentage>
    <us-gaap:SaleOfStockPricePerShare contextRef="c182" decimals="2" unitRef="usdPershares">5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DividendsShareBasedCompensationCash contextRef="c185" decimals="-6" unitRef="cny">40000000</us-gaap:DividendsShareBasedCompensationCash>
    <us-gaap:DividendsShareBasedCompensationCash contextRef="c186" decimals="-6" unitRef="cny">30000000</us-gaap:DividendsShareBasedCompensationCash>
    <us-gaap:DividendsShareBasedCompensationCash contextRef="c187" decimals="-6" unitRef="cny">20000000</us-gaap:DividendsShareBasedCompensationCash>
    <us-gaap:DividendsShareBasedCompensationCash contextRef="c188" decimals="-6" unitRef="cny">10000000</us-gaap:DividendsShareBasedCompensationCash>
    <us-gaap:DividendsShareBasedCompensationCash contextRef="c189" decimals="-6" unitRef="cny">30000000</us-gaap:DividendsShareBasedCompensationCash>
    <upc:CashDividendDescription contextRef="c190">A total of RMB130 million (approximately $19.1 million) cash dividend was declared from September
2016 to February 2019, among which, approximately RMB20 million ($3.1 million) was paid in cash to its shareholders in 2018 and the remaining
RMB110 million ($16 million) was paid to its shareholders in 2019.</upc:CashDividendDescription>
    <upc:StatutorySurplusPercentage contextRef="c191" decimals="2" unitRef="pure">0.10</upc:StatutorySurplusPercentage>
    <upc:ReserveIsEqualPercentage contextRef="c0" decimals="2" unitRef="pure">0.50</upc:ReserveIsEqualPercentage>
    <us-gaap:RestrictedCash contextRef="c192" decimals="0" unitRef="usd">2439535</us-gaap:RestrictedCash>
    <upc:RestrictedNetAssets contextRef="c193" decimals="0" unitRef="usd">31786663</upc:RestrictedNetAssets>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c194" decimals="0" unitRef="usd">303746</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">5211231</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c195" decimals="0" unitRef="usd">11358764</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c196" decimals="0" unitRef="usd">6807507</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 18 &#x2014; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From time to time, the Company is a party to various
legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable
and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. For the
years ended September 30, 2022, 2021 and 2020, the Company did not have any material legal claims or litigation that, individually or
in aggregate, could have a material adverse impact on the Company&#x2019;s consolidated financial position, results of operations and cash
flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has an ongoing CIP project associated
with the construction of a new manufacturing facility. As of September 30, 2022, future minimum capital expenditures on the Company&#x2019;s
CIP project amounted to approximately $13.5 million, among which, approximately $3.5 million is required for the next 12 months from
the date of this report (see Note 11).&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CapitalExpenditureDiscontinuedOperations contextRef="c0" decimals="-5" unitRef="usd">13500000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <us-gaap:InterestExpenseCapitalSecurities contextRef="c0" decimals="-5" unitRef="usd">3500000</us-gaap:InterestExpenseCapitalSecurities>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 19 &#x2014; SEGMENT REPORTING&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An operating segment is a component of the Company
that engages in business activities from which it may earn revenues and incur expenses, and is identified on the basis of the internal
financial reports that are provided to, and regularly reviewed by, the Company&#x2019;s chief operating decision maker in order to allocate
resources and assess performance of the segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The management of the Company concludes that it has
only one reporting segment. The Company develops, manufactures and sells TCMD products targeted to the elderly to address their physical
conditions in the aging process and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical
instruments, Traditional Chinese Medicine Pieces products and dietary supplements manufactured by third-party pharmaceutical companies.
All of these products are currently sold in China.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s products have similar economic
characteristics with respect to raw materials, vendors, marketing and promotions, customers and methods of distribution. The Company&#x2019;s
chief operating decision maker has been identified as the Chief Executive Officer, who reviews consolidated results when making decisions
about allocating resources and assessing performance of the Company, rather than by product types or geographic area; hence the Company
has only one reporting segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Revenue by product source&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For Years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Sales of TCMD products manufactured by the Company&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23,988,177&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,559,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,374,751&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Sales of third-party products&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,154,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,422,745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,329,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;40,143,151&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,982,031&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,703,960&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Revenue by product categories&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The summary of our total revenues by product categories for the years ended
September 30, 2022, 2021 and 2020 was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For Years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Sales of TCMD products:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Medicinal liquor products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,095,336&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,951,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,616,080&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Other chronic condition treatment products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,140,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,978,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,059,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Cold and flu medicines&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,752,422&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,629,606&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,699,268&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Sub-total of TCMD products sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,988,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29,559,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,374,751&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Sales of third-party products&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Biochemical drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,730,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,082,546&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,325,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Traditional Chinese medicine pieces&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Medical instruments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,394,348&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,318,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,950,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Dietary supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;958&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,463&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Subtotal of third-party products sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,154,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,422,745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,329,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Total revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;40,143,151&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,982,031&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,703,960&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c0" decimals="0" unitRef="pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For Years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Sales of TCMD products manufactured by the Company&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23,988,177&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,559,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,374,751&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Sales of third-party products&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,154,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,422,745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,329,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;40,143,151&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,982,031&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,703,960&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CostOfOtherPropertyOperatingExpense contextRef="c0" decimals="0" unitRef="usd">23988177</us-gaap:CostOfOtherPropertyOperatingExpense>
    <us-gaap:CostOfOtherPropertyOperatingExpense contextRef="c4" decimals="0" unitRef="usd">29559286</us-gaap:CostOfOtherPropertyOperatingExpense>
    <us-gaap:CostOfOtherPropertyOperatingExpense contextRef="c5" decimals="0" unitRef="usd">18374751</us-gaap:CostOfOtherPropertyOperatingExpense>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="0" unitRef="usd">16154974</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c4" decimals="0" unitRef="usd">18422745</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c5" decimals="0" unitRef="usd">12329209</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">40143151</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="0" unitRef="usd">47982031</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" unitRef="usd">30703960</us-gaap:Revenues>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For Years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Sales of TCMD products:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Medicinal liquor products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,095,336&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,951,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,616,080&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Other chronic condition treatment products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,140,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,978,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,059,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Cold and flu medicines&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,752,422&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,629,606&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,699,268&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Sub-total of TCMD products sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,988,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29,559,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,374,751&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Sales of third-party products&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Biochemical drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,730,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,082,546&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,325,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Traditional Chinese medicine pieces&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Medical instruments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,394,348&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,318,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,950,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Dietary supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;958&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,463&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Subtotal of third-party products sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,154,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,422,745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,329,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Total revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;40,143,151&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,982,031&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,703,960&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <upc:SubtotalOfTCMDProductsSales contextRef="c197" decimals="0" unitRef="usd">1095336</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c198" decimals="0" unitRef="usd">1951679</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c199" decimals="0" unitRef="usd">1616080</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c200" decimals="0" unitRef="usd">19140419</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c201" decimals="0" unitRef="usd">22978001</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c202" decimals="0" unitRef="usd">14059403</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c203" decimals="0" unitRef="usd">3752422</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c204" decimals="0" unitRef="usd">4629606</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c205" decimals="0" unitRef="usd">2699268</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c0" decimals="0" unitRef="usd">23988177</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c4" decimals="0" unitRef="usd">29559286</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c5" decimals="0" unitRef="usd">18374751</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c206" decimals="0" unitRef="usd">13730424</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c207" decimals="0" unitRef="usd">16082546</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c208" decimals="0" unitRef="usd">10325411</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c209" decimals="0" unitRef="usd">30202</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c210" decimals="0" unitRef="usd">20705</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c211" decimals="0" unitRef="usd">47097</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c212" decimals="0" unitRef="usd">2394348</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c213" decimals="0" unitRef="usd">2318536</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c214" decimals="0" unitRef="usd">1950238</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c215" decimals="0" unitRef="usd">958</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c216" decimals="0" unitRef="usd">6463</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c0" decimals="0" unitRef="usd">16154974</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c4" decimals="0" unitRef="usd">18422745</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c5" decimals="0" unitRef="usd">12329209</upc:SubtotalOfThirdpartyProductsSales>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">40143151</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="0" unitRef="usd">47982031</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" unitRef="usd">30703960</us-gaap:Revenues>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 20 &#x2014; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluated the subsequent event through
the date of this report, and concluded that there are no material reportable subsequent events need to be disclosed.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventDescription contextRef="c0">The Company evaluated the subsequent event through
the date of this report, and concluded that there are no material reportable subsequent events need to be disclosed.</us-gaap:SubsequentEventDescription>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 21 &#x2014; CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the requirements of Rule 12-04(a), 5-04(c)
and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when the restricted net assets
of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. The
Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with such requirement and concluded that
it was applicable to the Company as the restricted net assets of the Company&#x2019;s subsidiaries exceeded 25% of the consolidated net
assets of the Company. Therefore, the condensed financial statements for the parent company are included herein.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For purposes of the above test, restricted net assets
of consolidated subsidiaries shall mean that amount of the Company&#x2019;s proportionate share of net assets of consolidated subsidiaries
(after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries
in the form of loans, advances or cash dividends without the consent of a third party.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The condensed financial information of the parent
company has been prepared using the same accounting policies as set out in the Company&#x2019;s consolidated financial statements except
that the parent company used the equity method to account for investment in its subsidiaries. Such investment is presented on the condensed
balance sheets as &#x201c;Investment in subsidiaries&#x201d; and the respective profit or loss as &#x201c;Equity in earnings of subsidiaries&#x201d;
on the condensed statements of income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The footnote disclosures contain supplemental information
relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the consolidated
financial statements of the Company. Certain information and footnote disclosures normally included in financial statements prepared in
accordance with U.S GAAP have been condensed or omitted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2022 and 2021, there were no material
contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those which have been separately
disclosed in the consolidated financial statements, if any.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current assets&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-indent: -0.125in; padding-left: 0.25in"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"&gt;Short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,148,594&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,725,204&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Total current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,177,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,835,597&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Non-current assets&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"&gt;Investment in subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,264,812&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,098,756&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: SimSun"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: SimSun; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: SimSun; text-align: right"&gt;&lt;span style="font-family: SimSun; font-size: 10pt"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: SimSun; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.375in"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,442,323&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,934,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;LIABILITIES AND SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;COMMITMENTS AND CONTINGENCIES&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in"&gt;Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares issued and outstanding as of September 30, 2021 and 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,969&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;67,969&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Additional paid-in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,279,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,279,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Retained earnings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,761,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,498,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"&gt;Accumulated other comprehensive income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,666,705&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,088,759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in"&gt;Total shareholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46,442,323&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,934,353&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Total liabilities and shareholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,442,323&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,934,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating costs and expenses:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: 10pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(384,214&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,177,869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income (expenses):&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Income from short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(470,477&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239,549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(60,751&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity in earnings of subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,881,455&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,319,023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,558,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,736,566&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,319,952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,558,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,755,464&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,193,369&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;860,623&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Comprehensive income attributable to the Company&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(12,492,030&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,513,321&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,418,845&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(8,736,566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,319,952&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,558,222&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Adjustments to reconcile net cash flows from operating activities:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 12.5pt; padding-left: 10pt"&gt;Equity in earnings of subsidiary&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,881,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,319,027&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,558,222&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"&gt;Short-term investment income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;470,477&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -3.3pt; padding-left: 3.3pt"&gt;Net cash used in operating activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(384,634&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(999,075&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.9pt; padding-left: 0.9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -3.4pt; padding-left: 3.4pt"&gt;CASH FLOWS FROM INVESTING ACTIVITIES:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt"&gt;Payment for short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15,330,660&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt"&gt;Redemption of short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,801,927&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net cash used in investing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,528,733&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;CASH FLOWS FROM FINANCING ACTIVITIES:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 23.6pt"&gt;Net proceeds from issuance of ordinary shares in IPO&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,957,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 23.6pt"&gt;Cash lent to subsidiaries&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,358,764&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt"&gt;Cash repayment from subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;303,746&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net cash provided by financing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;303,746&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,598,693&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; padding-bottom: 1.5pt; text-indent: -1.2pt; padding-left: 1.2pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;CHANGES IN CASH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(81,476&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;CASH, beginning of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;CASH, end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28,917&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <upc:MinorityInterestsOwnershipPercentageByParent contextRef="c2" decimals="2" unitRef="pure">0.25</upc:MinorityInterestsOwnershipPercentageByParent>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current assets&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-indent: -0.125in; padding-left: 0.25in"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"&gt;Short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,148,594&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,725,204&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Total current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,177,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,835,597&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Non-current assets&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"&gt;Investment in subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,264,812&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,098,756&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: SimSun"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: SimSun; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: SimSun; text-align: right"&gt;&lt;span style="font-family: SimSun; font-size: 10pt"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: SimSun; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.375in"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,442,323&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,934,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;LIABILITIES AND SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;COMMITMENTS AND CONTINGENCIES&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in"&gt;Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares issued and outstanding as of September 30, 2021 and 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,969&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;67,969&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Additional paid-in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,279,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,279,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Retained earnings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,761,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,498,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"&gt;Accumulated other comprehensive income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,666,705&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,088,759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in"&gt;Total shareholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46,442,323&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,934,353&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Total liabilities and shareholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,442,323&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,934,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:Cash contextRef="c217" decimals="0" unitRef="usd">28917</us-gaap:Cash>
    <us-gaap:Cash contextRef="c218" decimals="0" unitRef="usd">110393</us-gaap:Cash>
    <us-gaap:ShortTermInvestments contextRef="c217" decimals="0" unitRef="usd">13148594</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c218" decimals="0" unitRef="usd">13725204</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsCurrent contextRef="c217" decimals="0" unitRef="usd">13177511</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c218" decimals="0" unitRef="usd">13835597</us-gaap:AssetsCurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c217" decimals="0" unitRef="usd">33264812</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c218" decimals="0" unitRef="usd">45098756</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets contextRef="c217" decimals="0" unitRef="usd">46442323</us-gaap:Assets>
    <us-gaap:Assets contextRef="c218" decimals="0" unitRef="usd">58934353</us-gaap:Assets>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c217" decimals="6" unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c218" decimals="6" unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c217" decimals="INF" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c218" decimals="INF" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c217" decimals="INF" unitRef="shares">21750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c218" decimals="INF" unitRef="shares">21750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c217" decimals="INF" unitRef="shares">21750000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c218" decimals="INF" unitRef="shares">21750000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c217" decimals="0" unitRef="usd">67969</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c218" decimals="0" unitRef="usd">67969</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c217" decimals="0" unitRef="usd">29279159</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c218" decimals="0" unitRef="usd">29279159</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c217" decimals="0" unitRef="usd">18761900</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c218" decimals="0" unitRef="usd">27498466</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c217" decimals="0" unitRef="usd">-1666705</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c218" decimals="0" unitRef="usd">2088759</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c217" decimals="0" unitRef="usd">46442323</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c218" decimals="0" unitRef="usd">58934353</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c217" decimals="0" unitRef="usd">46442323</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c218" decimals="0" unitRef="usd">58934353</us-gaap:LiabilitiesAndStockholdersEquity>
    <srt:CondensedStatementOfComprehensiveIncomeTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating costs and expenses:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: 10pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(384,214&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,177,869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income (expenses):&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Income from short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(470,477&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239,549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(60,751&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity in earnings of subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,881,455&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,319,023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,558,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,736,566&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,319,952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,558,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,755,464&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,193,369&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;860,623&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Comprehensive income attributable to the Company&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(12,492,030&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,513,321&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,418,845&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</srt:CondensedStatementOfComprehensiveIncomeTableTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c219" decimals="0" unitRef="usd">384214</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c220" decimals="0" unitRef="usd">1177869</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:InterestExpenseOtherShortTermBorrowings contextRef="c219" decimals="0" unitRef="usd">470477</us-gaap:InterestExpenseOtherShortTermBorrowings>
    <us-gaap:InterestExpenseOtherShortTermBorrowings contextRef="c220" decimals="0" unitRef="usd">-239549</us-gaap:InterestExpenseOtherShortTermBorrowings>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c219" decimals="0" unitRef="usd">-420</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c220" decimals="0" unitRef="usd">-60751</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c219" decimals="0" unitRef="usd">-7881455</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c220" decimals="0" unitRef="usd">12319023</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c221" decimals="0" unitRef="usd">7558222</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss contextRef="c219" decimals="0" unitRef="usd">-8736566</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c220" decimals="0" unitRef="usd">11319952</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c221" decimals="0" unitRef="usd">7558222</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c219" decimals="0" unitRef="usd">-3755464</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c220" decimals="0" unitRef="usd">1193369</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c221" decimals="0" unitRef="usd">860623</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c219" decimals="0" unitRef="usd">-12492030</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c220" decimals="0" unitRef="usd">12513321</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c221" decimals="0" unitRef="usd">8418845</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <srt:ScheduleOfCondensedCashFlowStatementTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(8,736,566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,319,952&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,558,222&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Adjustments to reconcile net cash flows from operating activities:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 12.5pt; padding-left: 10pt"&gt;Equity in earnings of subsidiary&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,881,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,319,027&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,558,222&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"&gt;Short-term investment income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;470,477&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -3.3pt; padding-left: 3.3pt"&gt;Net cash used in operating activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(384,634&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(999,075&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt; text-indent: -0.9pt; padding-left: 0.9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -3.4pt; padding-left: 3.4pt"&gt;CASH FLOWS FROM INVESTING ACTIVITIES:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt"&gt;Payment for short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15,330,660&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt"&gt;Redemption of short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,801,927&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net cash used in investing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,528,733&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;CASH FLOWS FROM FINANCING ACTIVITIES:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 23.6pt"&gt;Net proceeds from issuance of ordinary shares in IPO&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,957,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 23.6pt"&gt;Cash lent to subsidiaries&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,358,764&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 23.6pt"&gt;Cash repayment from subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;303,746&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net cash provided by financing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;303,746&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,598,693&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; padding-bottom: 1.5pt; text-indent: -1.2pt; padding-left: 1.2pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;CHANGES IN CASH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(81,476&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;CASH, beginning of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;CASH, end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28,917&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedCashFlowStatementTableTextBlock>
    <us-gaap:ProfitLoss contextRef="c219" decimals="0" unitRef="usd">-8736566</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c220" decimals="0" unitRef="usd">11319952</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c221" decimals="0" unitRef="usd">7558222</us-gaap:ProfitLoss>
    <upc:EquityInEarningsOfSubsidiary contextRef="c219" decimals="0" unitRef="usd">7881455</upc:EquityInEarningsOfSubsidiary>
    <upc:EquityInEarningsOfSubsidiary contextRef="c220" decimals="0" unitRef="usd">-12319027</upc:EquityInEarningsOfSubsidiary>
    <upc:EquityInEarningsOfSubsidiary contextRef="c221" decimals="0" unitRef="usd">-7558222</upc:EquityInEarningsOfSubsidiary>
    <us-gaap:InvestmentIncomeNet contextRef="c219" decimals="0" unitRef="usd">470477</us-gaap:InvestmentIncomeNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c219" decimals="0" unitRef="usd">-384634</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c220" decimals="0" unitRef="usd">-999075</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments contextRef="c220" decimals="0" unitRef="usd">15330660</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c220" decimals="0" unitRef="usd">-1801927</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c220" decimals="0" unitRef="usd">-13528733</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c220" decimals="0" unitRef="usd">25957457</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <upc:CashLentToSubsidiaries contextRef="c220" decimals="0" unitRef="usd">11358764</upc:CashLentToSubsidiaries>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c219" decimals="0" unitRef="usd">303746</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c219" decimals="0" unitRef="usd">303746</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c220" decimals="0" unitRef="usd">14598693</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c219" decimals="0" unitRef="usd">-588</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c220" decimals="0" unitRef="usd">39508</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c219" decimals="0" unitRef="usd">-81476</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c220" decimals="0" unitRef="usd">110393</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c218" decimals="0" unitRef="usd">110393</upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c217" decimals="0" unitRef="usd">28917</upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c218" decimals="0" unitRef="usd">110393</upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:ShorttermInvestmentIncome
      contextRef="c5"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-3"
      unitRef="usdPershares">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-4"
      unitRef="usdPershares">0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="hidden-fact-5"
      unitRef="usdPershares">0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="hidden-fact-6"
      unitRef="shares">16000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="hidden-fact-7"
      unitRef="shares">18980822</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-8"
      unitRef="shares">21750000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="c12"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c13"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c14"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c16"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c12"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c13"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c14"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c15"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c25"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c26"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c27"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts
      contextRef="c23"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts
      contextRef="c25"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts
      contextRef="c26"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts
      contextRef="c27"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c23"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c24"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c25"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c27"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c23"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c24"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c25"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c26"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c33"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c34"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c35"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c37"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c33"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c34"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c35"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c36"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="c5"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryLIFOReservePeriodCharge
      contextRef="c4"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:ShorttermInvestmentsIncome
      contextRef="c5"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies
      contextRef="c5"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidAdvertising
      contextRef="c5"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="c5"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="c4"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="c5"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty
      contextRef="c0"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty
      contextRef="c5"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfAdvancesForConstruction
      contextRef="c0"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfAdvancesForConstruction
      contextRef="c5"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="c4"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="c5"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="c0"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="c5"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:RedemptionOfShorttermInvestments
      contextRef="c0"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:RedemptionOfShorttermInvestments
      contextRef="c5"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDividends
      contextRef="c0"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDividends
      contextRef="c4"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDividends
      contextRef="c5"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c0"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c5"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="c0"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:SunsequentCollectionAllowanceForDoubtfulAccounts
      contextRef="c2"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:AllowanceForDoubtfulAccountsReceivablePercentage
      contextRef="c0"
      id="hidden-fact-65"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="c4"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="c0"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="c2"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="c3"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c22"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:AddPurchaseWealthManagementFinancialProducts
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="c0"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherShortTermInvestments
      contextRef="c22"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c5"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c124"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c126"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c129"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c131"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c134"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DueFromOtherRelatedPartiesCurrent
      contextRef="c140"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DueFromOtherRelatedPartiesCurrent
      contextRef="c142"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DueFromOtherRelatedPartiesCurrent
      contextRef="c2"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="c145"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="c146"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c149"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c150"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c151"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c148"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c152"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c153"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c149"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c150"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c151"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c148"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c152"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c153"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="c4"
      id="hidden-fact-97"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="c5"
      id="hidden-fact-98"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c5"
      id="hidden-fact-99"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c3"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="c2"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="c217"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="c218"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c217"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c218"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c221"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseOtherShortTermBorrowings
      contextRef="c221"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c221"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c221"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="c219"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="c221"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="c219"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="c221"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c219"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c221"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c219"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c221"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:CashLentToSubsidiaries
      contextRef="c219"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:CashLentToSubsidiaries
      contextRef="c221"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="c220"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="c221"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c221"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c221"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c221"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="c222"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="c223"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="c222"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:CityAreaCode contextRef="c1">+86</dei:CityAreaCode>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityAddressPostalZipCode contextRef="c1">000000</dei:EntityAddressPostalZipCode>
    <dei:EntityCentralIndexKey contextRef="c0">0001809616</dei:EntityCentralIndexKey>
    <dei:LocalPhoneNumber contextRef="c1">0796-8403309</dei:LocalPhoneNumber>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-75"
          xlink:label="hidden-fact-75"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On June 16, 2021, the Company&#x2019;s subsidiary, Jiangxi
Universe, signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;) to borrow RMB10 million (equivalent
to $1,548,000) as working capital for one year, with the maturity date on June 15, 2022. The fixed interest rate of the loan was 4.81%
per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-75"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-76"
          xlink:label="hidden-fact-76"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On March 18, 2021, the Company&#x2019;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,238,400) as working capital for one year, with
the maturity date on March 17, 2022. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for
this loan. The loan was fully repaid upon maturity.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-76"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-77"
          xlink:label="hidden-fact-77"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On March 14, 2022, the Company&#x2019;s subsidiary, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,124,624) as working capital for one year, with
the maturity date on March 13, 2023. The fixed interest rate of the loan was 4.62% per annum. There was no guarantee requirement for
this loan.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-77"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On June 15, 2022, the Company&#x2019;s subsidiary, Jiangxi
Universe, entered into a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,405,780) as working capital for one year,
with the maturity date on June 14, 2023. The fixed interest rate of the loan was 4.62% per annum. Certain related parties of the Company,
including Mr. Gang Lai, the Company&#x2019;s controlling shareholder, chairman of the board of directors, and chief executive officer,
Ms. Lin Yang, the Company&#x2019;s chief financial officer, Ms. Xing Wu, Mr. Gang Lai&#x2019;s spouse, and the Company&#x2019;s WFOE, Universe
Technology, jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-78"
          xlink:label="hidden-fact-78"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On June 30, 2021, the Company&#x2019;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,548,000) as working capital for
one year, with the maturity date on June 30, 2022. The fixed interest rate of the loan was 4.5% per annum. Certain related parties of
the Company, including Mr. Gang Lai, the Company&#x2019;s controlling shareholder, Mr. Gang Lai&#x2019;s spouse, Mrs. Xing Wu, and the
Company&#x2019;s subsidiary, Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantees
for this loan. The loan was fully repaid upon maturity.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-78"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-79"
          xlink:label="hidden-fact-79"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On June 24, 2022, the Company&#x2019;s subsidiary, Jiangxi
Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,405,780) as working capital for
one year, with the maturity date on June 24, 2023. The fixed interest rate of the loan was 4.2% per annum. Jiangxi Province Financing
Guarantee Group Co., Ltd., an unrelated third party, signed a guarantee agreement with Bank of Communications to provide credit guarantee
for this loan.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-79"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>149
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MNY6K%0Y7Q!>JO@DJ?L/%PR@,]:#?KIYY1*4US:N1N^W,.^3M:#3#X$QX\?$
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M@*34<]W =30Y)D[/(Y"D$3U>J\>SZOE-BJ) .RG6B3*)\08/IB0("6.>IL4
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M+"^,^L>_1"=IA>*DI)A478SDN8YWYK8*CZTD.-Q+&G'+TMM7[8O84'OZ&9[
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MAVD#J'(WJ'[5B=[NVG$%!>C\*+G=OB-*W,96&A :FB"\G.")IS$: )B[ ?A
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M=-D8P+^OBZ)^_=(\X/!_)=S\'U!+ P04    "  :ATI6#VS31F$*  #_&@
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M1Z)D=HD=(?F7SW\?8%VA!J' E6X8]&N_2- 35PF3T&G+A96QQ!S0A8009VG
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M!&J>5W.=Y(Z@Q8 @_F@H;5#;ZX\C!^95B6KJ,-.3<X15^&*6!2EF_ )<N6=
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M_)T;/C]7<@O*6B.:7;BKNM-(KJAM4FZ,PK<%GC/S19;)MC8:KD4FBCN>EH+
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M_.K" UT+5FU8550BL5"6)*<:9J3QJ)T#K:=*V:WA-FC^-4;_ %!+ P04
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MUW &[]Z<)[WD$EZ'AGL!Q+[%<H$:DM/F"+I@<X0K62HF-D THL8,N+"RPZ!
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M[]63HEEP0,EXB4)S*4#A>NQ-H^&L8^V=P3>.6WTT!JMD)>6+G=QG8R^TA+#
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MX<6;-HW^AWGS7#XP1?>OH< UN8;M?M<#U3Q!S<3(RK7]E33TB+AA3J\V*FM
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M[( <MOH@:-'93;H6FGK''K?T(T1I%.A[*81^$HR#PZ]U]B]02P,$%     @
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M&5>'K53K8J_347%*<Z+:HJ <OXR%S(G&IIQT5"$I2:Q1GG4"S^MU<L)XZ^C
MOKN21P>BU!GC]$J"*O.<R.D)S<3]8<MO-2^NV235YD7GZ* @$WI#]>?B2F*K
M,T-)6$ZY8H*#I./#UK&_=Q*9_K;#;XS>J[EG,#,9"?'5-'Y)#EN><8AF--8&
M@>#/'3VE66: T(UO-69K-J0QG']NT,_MW'$N(Z+HJ<B^L$2GAZU^"Q(Z)F6F
MK\7]1UK/IVOP8I$I^Q_NJ[[!;@OB4FF1U\;H0<YX]4L>:A[F#/K>"H.@-@BL
MW]5 ULOW1).C RGN09K>B&8>[%2M-3K'N G*C9;XE:&=/KI)A=0[MU3F<$+X
M5[@0A*N#CD9HTZ$3US G%4RP L8/8""X3A6<\80FBP =]&GF6- X=A*L1;RA
M11M"SX7 "X(U>.%LHJ'%"U?@O:<C#>^9BC.A2DGAS^.1TA)%\=>RV598T7(L
MDRA[JB Q/6QA)B@J[VCKZ.<W?L_;7^-I-/,T6H=^=/-Q>'V[<WMV/8"3X\M?
MX6)X?'FSS,GU,)?#VS/P0_CY33_P@WU8"@M5_+6)_\C$/S/QAUA@UBD-8@PZ
MI3 6&28OXY,]YU)H"A@;3?,1E39 "RUG*>">8W4%!9F2449!"_C$")\\,+@H
MT?$)7)>29' J\IS*F.&C5>-;XWS@[5]<G]H7MNGO;^\Y Z)+R?04$H(.87I_
M*CD%OUOIQ07&T06*4Y#F>]3N^S]!@2X2SLL<WOK;L 4[^.>[W:CO>I[W%'%
M9)R"O[LA9+"-@+X;A'TW6@,76KCP*5PO6( +MQ',#R*W%T2PLVJ^T89HD4&+
MO*Z[V_<<2RV&UK!=<A834Q\5-MLN7.ADQ5A-+CX=J^LMC-6MB%C)JT4+5GH>
M+*+UYCV_%1JEH1XE5LEU"T+W7=AS_7Z$SY$;AI&-@0GSL*&J9P?T7:MHG'I!
M^-3FQNZ^PC5II%C"<%ER&V4ZGSFN%U)1%Q2;<)H L<,!F4A*<5W26*IU^GU"
M-IDP$M)4B.O!B>]AB<\RLUJ]I=]*=D<R',;!/ELS/K>!*+O2F<%B4C##""[.
MR"R%*272K=PRL\S7)DD;;DUNLP><VF(0ZK2WL[W'X:S6G5E0K"&64/.)"YB4
M1!*TI[A(H].RXL:XI%.F+$HUU QO7&;9%'L7A"50%NA8XVG;,7DTG&5+?].@
M-<%R;B5)G@M9$X5%]OO+R(>*_#JK-R3?64K^8CUY(?OP8O:=5[$?SK,?-1G_
M/[-?E\$?P7Y=?E_"_D(I?07[CJF^PR<KU,O+$+6.6H?%B[A=7E=J<NO:^CRY
MSG-U)?IN;D^IU'B00#(S[)_@?D%J1E5C6-/E.HS'69D83P>R#1^0*+@@;#FG
MN)?1$C<PIK=*B:2IR!**6HE3PG!?SQOTD2 R,8T$XQAK(96+?B78C]$QT <:
ME^8$@3W&+$8 9Z#:<('>_H'CKQC;FHX9)]RN!8TI&-/?C4=?2G=A#H]2*$1I
M@FX\6 ;]Y7QX-I]X-$ZYR,0$E?.W0-HQQ>LL?-3H3"SJJ5H**>Y80B%&A3$]
M9[18R!VSO \7MP0_?DU=L4/97-3/+);.QHMEL^MYB:B[&VK:F=<T_!!-KY72
M0,ZKKA:6LTE=A[JN;ZRLU0%<I3/EO'K'T'M49+#QDO5?*_*9,KNY(H-7E-G%
M*MOL6*],*'A,X;PJ4'SB?)A%](,493$[$[2-7J#DC8@Q3K*2\G2.N"5Z>*T<
M_JV&<]M$X)&XHSL&&1%P4'L 6(@VJB06,K$.:7M>:-AQZ$-!N;($;?GOWKG]
M+@IERX_>N:$7VH38\KN[;C?HUU6O"HG"E=?@+1Y[*YF9\F<M\0%?XC %M1=-
MV;2]["Z@,W=5@R>$B;V0,@E=<EW=VLS>SNZ\CJNKGL?NU849[F@F#%G,Z!A-
MO?9NMP6RNH2J&EH4]N)G)+06N7U,*>:Q-!WP^UC@8;YNF %F-X%'_P!02P,$
M%     @ &H=*5@]UF1_=!@  R!   !D   !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&ULI5AK4^.X$OWN7Z'*SFR1*D\>3H P/*H"P\S.%C!48!]36_>#8BNQ
M+K;DD61"_OV>EITG"7MO[0? EM6GNT^_),YFVCS95 C'7O),V?-&ZESQL=VV
M<2IR;ENZ$ I?)MKDW.'53-NV,((G7BC/VE&G<]3.N52-BS._=F\NSG3I,JG$
MO6&VS'-NYI<BT[/S1K>Q6!C):>IHH7UQ5O"I>!#NM^+>X*V]1$ED+I256C$C
M)N>-8??C99_V^PV_2S&S:\^,/!EK_40O7Y/S1H<,$IF('2%P_'D65R++" AF
M_*@Q&TN5)+C^O$#_['V'+V-NQ97._I")2\\;@P9+Q(27F1OIV2^B]N>0\&*=
M6?^;S:J]/6R.2^MT7@O#@ERJZB]_J7E8$QAT]@A$M4#D[:X4>2L_<<<OSHR>
M,4.[@48/WE4O#>.DHJ \.(.O$G+N8B0R[D3"[KEQ<_9HN++<\V7/V@[XM*L=
MUUB7%5:T!ZL;L5NM7&K9M4I$L@G0AF%+ZZ*%=9?1FX@/HFBQ7B=D42>*WL#K
M+;WM>;S>_^TM^VLXML[@[3^['*]@^[MAJ7 ^VH+'XKR!RK#"/(O&Q<\_=8\Z
MIV\8W5\:W7\+_6)T?3-\O/[$[H>CQ^_L<32\>QA>/7[]=O>PR]*WL>Z^/5ZS
M;I_]_-,@ZD:G;#\V.^#-X(Z[T@BF)Z@_,$=$I;*PR%&75DL@LP"94EALS@4;
MK>VKMKE4L"N=%US-@UO38E^XFK(;+MGCZH,WY_C4LACY8W0&LZ?,IMR(5&>)
M,"&[2J68L.L7$9=4QNS;9")C81A7"8M3+E&@BNQT.T O-3<)??PD#9J!-C:X
MM2UV(Q7[3L94V)^EXBJ6/-O 7H@$7]#RG+".?3&Z+-@!A!1OKDG=<H4NAG[E
M@)Q+8N: 3(@ZIYNR?K%[VF3?E-AG,BI=&XD<72/!,CU#H@Y:Q^\78EC .E$M
ME1.&5, IETK+8 ?D@\\:"(H]X-=T7K*OZAF;O)&_ )1HOM*MD-VXE;6;(DMK
MAVBA(":3/N@5_);Y(3OIO/=&)6P\KV)3![1:V>7JOL@>C)OL4RG8Q.C\5:ZA
M,3B1C[&-NL/&F\_#[7"]8Q_P$_4.PWYOL$W*!]8-#_O]X%$[Q#'9HW.)<12>
M#**=V;M7=(;8K$(T,4(0.0'MQV1*,&=5TO*0FXZA[77WHXYYAMP3+.5X%D)A
MLHZM^%$B-MD<S&<T^HAX'C_Y8*S1SQ(-!*4=I)]%0%_(/N5'I=,8,4^P,4DD
M+8"5F-L4[\]>(;YOVS+5E$LX),Q0:RUV$#<#"M[KG?\<NHTF\8[UPM[Q21@=
M]2@ ^+A>N1_09*-H,#AEW9/P..JMA7"'C9M8E00;6DKB5[1'GC#B/_2T+;C>
M#1W0\<=SCM.*I0_ K-FR5?!VI;ZN4MT2;_[T0AS&O)#D1%&:0EM!665H?1>
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M3D?:"6!_KI1=OS@#[2UQ_!]02P,$%     @ &H=*5AV?ZSTO#   S"   !D
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MJ>I&+V[@YGJS9]/6>5TP1F (0A4!0TW:H%F4G"0 !_5]@(_,FTYUTU@^@QA
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MP8+" ?F$8(-V)'U+.@2!G)8D6SB\&3' EY),$C39JM^ :;8?CEE)RQASKS=
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MH+9I0(!:7QKZC0X]ZMP$,'93>:7C>YV2]?.&EP.R#GXF2^"ZK':E-0$KT9V
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MT$6S"FDM!W.G$AV%C64QU C[8190VE-22X!:T%$:.?\TCH^6':M??9@ICJ'
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M3ZW-L6^?.?E)44UG32S 6$LXAZ/GA^C@SVGSOE9J.EXL];[?%6E0@7]$P=3
MT/&' )T'.S+9#DY4YQR1''5-"MIU].)',QUO[0I%$?#$G8D9J5F+6>TM@Z2A
MGYGG@1XJ$R2,YJT79!:J 2T7>;9V/7!:XR6"]GYQM4WWEX0W4KW"_!<LNR&E
MK%TQ(XX,2S^^38^MSI.ZH):^[[KF8!,BE7-;!"3S-HL1!F;<SA,C@^%M\AX8
M28"0Z[(4%R.>9"8Y-KY7!&?UB7%.T%1ZE;L&!;WU]$T6=NT:X8Z4:9=SO,@T
MRXU3USC^,&CC<?"85V%38$4'D'H1KIS^</WVC3@]LRH]PL2;O<\$IAH*4+*,
MX0**7CD!9;&@*AU)@1MUWJ.D)M$#0\TYH88 #=7.DC%O2Y>HFTW"K1\4I@FG
M)#5<D:XK;)/H-XD;L\.-)&,%%BS5,#:'!I:PQ;RLH";#'Q!%-UR0A8XS.6 X
M$@*7N67D_N@WLA,!-Q57GSA/,-V:'X>?R@4E,[=S#3 V17HMG,\JHSYJN9NI
MRQ$=T;.26A;8NPJ4SQ8)QIX$$Y!6V%(F:6U'9EJYJ,SZ763+@1NP%'&(<QT,
MFM'8J9'-$F$$3*6N_)WG:9._:6%JT".,$=34H'%OC;C,O'F+9+PK,U;I2 YQ
M60Y2 WM  6W8PV<P2\W8W+.0:TGG1PYPM\[:F_Y<88032LG2@:9FCC H[H;"
MDY@D; L']:B4'5A-X:#H]6P1;(PD/8XJHDE=8[+$!C<%F0OA,1S'5E@0YHO^
MZXOP74DEV0Z87><LOE^O/GA7REA?6U_/-QNOY[N60[7.5%SJ3SX=;D@\CH]X
MT-4_-DW\KM4PB/1B5]/O&OQT6VS \$?A8[S_8=V.+;^G;$!@X^V&/^Y$;.6)
M#""U@5BF+% 'P=4 I=E9'P5I0MWLSF"(5A)C?QS/$3@X:#LH(6>B1E;.],M<
MK1EW<!04CSX$)!IDI5O#""L[[C#FU&GVI2D  BQ9-KG.*%K'6K_X3$@BYVII
MW;CX&SH4V"=?.2!L<5]TJ :N96$&])2EWF)?=C>=XS>]71PG %_ -GN@@"TS
M:KVN]-JAA5#G,.X_ID#MX QM9X=_3!O)]60V08+>ZXD+)]/C>K_3?3GNR@*S
MFEM,P"%G)&RDYQ*;/HEH-8D]<XI8]GL\#7>RH8+7L*E;/UHZQ'33WF:X7K6/
MLKNE[K;7>O'2APR^H#7M&";YRK'9>.78M6UAP L:1)]'E(QUAHV[GUULLY5;
M4TLBH^FVN_--%20%T[2;*R2]%$<*D]ER6TE*!:E+A7OL(Z8 J31?Z/5.DG!]
M@VA!#8@Q H<!\/%M]P5'L_&"H_>P4>23Y3Y%OGNFS<$:/(A'E!L].%&[)XU+
MG[?=P ONK>;&B,(Q)*3L,V"M7N-/E7(Z41_3VUU>[K4<<.)'YZX#\H%'#"K1
M6WVV#*CEE)3O;+2H=4AV;/B"Y0@/Y_/T>1E+\A8G_81J:1KE$8DLA%ZV$F=V
MA/'8J!V/;8Q/@*T.'0!5IHA0^/YQWKNZK,>.QZ8H4VRRX\\_3\Y.3I+Y^6D2
M/SU-3LY.D[,SEG1/3R_FR10+5+\X8V/FD_9GXTG[MR" =Y;ZL%%7[HYM$.,?
MD;(_,D4\]AOI;[QC:2NK.[HI%B76A)J#;_?XQP+1T4:B?#5KIR_F(:.7C617
M"<\.AZ@KE2PST[WZRV6;VQ['OS3U0TOH]X]K/6NU)6O+N3ZC08/*#A2V'XQ/
MUQY#(9\2.AM/";W"/LYU9H*A!U'G$4FA T/' ]^%4HM9E1CYV])V?1RRGQ<5
M^4J5Y+S[390B]K*ITQ(8 >B*^:+$0'=BNTYO0<57['D!S/R'SA8EC?$/?;U1
MDNSSX5=N<0VPDH8 "FT ^CB.LSXLU>]B.!;^2?+?917VMJ*V'1OMIB(<IWX6
MI&L?#^Y7]!!J_+%J@:$Z@>&)V_&3Z3EVO$KFTXLD>CJ%_\^2L],39GKSDWER
M"1SPWYW<-O/);;/QY+9;O28N_M[>>C"(Y8_(8.L-W%(!&B-)PD%.),D.ZC)5
M./\I"E_V [#SQ25"&AY>5.FA4:S[T=;_.C7#PM,8GQK=\T)M,KT*IDM!6&-#
MJPB[JE12=$/-COK/&&D\3 B<4XM\I\^;$KBTK_J153@O2I #*G[+T.G5V9<A
MN!_8J[?CK>"Z3D%TOO6&B9_=VLKXZ>4#OA:?+S=[(%^.Z8Y<.H,8^)CDN&#,
MPTE"-L<V"YX>2A'"O:$N^$[/R_4=^MSI?HBFWI25J%E!UY4 @(YC@QU\-E0G
MS04U13"IZ;XMC.=V03#%PC9)&KE/I:8"N]ZM)T-L;]C8>]._]*([4=3J!,%&
MCBZX73N^59&-'F:"*VHOB^J%^BRE[[;FRO/ (%T9DRV&=\8*EJ4T5_')?RQ<
MI#V3M/SE-KK8K.SA57&'(TD.0<#<2GKU9BWH;9-P'\ZAH WN!]$*]ROXU;G6
M?.>EKB<O890(.AI1$CVVBAM<@$UTI3..POU>V+M;-+7[\WX+>MUE,K875A;H
MZ%Y%'&,2GRI8+9@E^@EU>8K2%F5MT]@<PV@-2KTBJ*0$%#9%G"6CMN_PD/ZL
MZ"XGU^M6(D?A]AJA,S2^P=YQ>9]$ 1P^D%@8-ES7J.0R9*>3KRRDV/Y/<[*\
M9(Q1-G,P.1E" =CLL=YJ7=L3##8@.K0!VG!R>PA;YLN0C^-W@ >Y(\X@PTC4
MH<  Y4;8XMCT>@B=-Y8\N 3GR"6KR)ZR_F@O%G'8**6B/[?S 7<.(DFF)H"X
M*SRNO&SS+'(ZDHO5P<P7)45_6'GI9"_9*('XXR3R@G%ST@[:&.NZ2<*YMR:*
MG..T-_]T]!(&E&;- M2#3'$,GVY*B-I1.U8;W%:'S)]:+O_<S;6D1W$-/A )
M>@ J(?:E+U7\HL[>'7(:<]V7 $4\BZ(R#L[N\A$$M_", L#VCA\.N:,P:"A2
M&1 ,NE7QS9ZD&Q/]/H]X-IY'_&L[I#,4T!G4"!Z12OP%4\6W%)[R*0FNK$+2
M1\IL:5L,8*J8!-HD1 4#,=[!'ZT.QQQ;YM 7)U_BX>)3+&4J$CS-CFZ!./\J
M?@8'4?G43;RK8HI'#D:%>XM0#<0)2C^4AM.SK]A&:[][!?/E\O9EYVVY@<2.
M0K//OWJ>#,0^]CM;X<SV)$8%_5KY1A.P25>8Z0[X@E]2_XVV@HW#]=T3'"/T
MW_6[/+&G@2<GJ##<B;$LV[T12QHHTN6:N;9R!ES"H1+(N"4'5<V[UM]RB*Y/
MILS^Q^Y:'*<*GX\S&\_'^<XF*P+#BF^Q%=P@$3PB':<_<J_97T,J7/@<-:-S
M]/+=NUM++X/9]+?7\>P,6)1]O#?C0"X\ON$#N/*%[\+D2TLY%X@JA#[;#@61
MNVO*L).$FYYB+L>2'4M9WN") >14J@9?PY](HDZ55=R_5]@X)Y8Z].VU:\:[
MI[ '**[&$)O'N@$4C9;%V]L#W\C4+49"\%!;=:>EJF"C%_;FSUV)Z3^<"Q=.
M^$P?KX^Q.*\@=P1BKT\:2X"?^ZN^[E5%U;K/R15#<F'O+P&2$3@+@9,TUEE1
M$(VM@G48WQ2?+@W)C&GHQ)$2*!$==9D*E)YAB#E;B?.."TJE.^KNP;/L6!\G
MU@ @)4]N\[&'XC>(/$GR(R=%V)^>BY4@',1E R]5OI2;R]!UUD*(QSK&6S4Y
M;CF\X%$^,/=)"//Q) 0 #5"O\%=/4$Y+?O":V?'A#C2+&YF#RUE!(<,/>*CV
M&43S\,I8T=VCC\>W\9LRQP(!?\/H4T_9P<6R[ 7Z >]#^SO^D_)KBD.\ Y,&
MUQNUIL8C"<=U][=%9-9PMVAE7*=!STR8-P0A=FD3%C8/'+C4TV6GM-5:?HNZ
MA.?[H!(_ZF3)A$T@>QLK-M UW1R@X_\&,G,[^?[M:[^30_KMPW?C>)W>GC+)
M67>IF/6..7C@]([#W)2.U1P*=RJ+<Z/:ZUI=T06I'? EM9+O7K.*9"?FLJWA
M,2&([<J BF_7O/'N6M<IQUU^, B,Y=^5G*4#[J$;8(-JFI \@N[NXN(1YPN7
MVTKVTT#OR>/X;]U^EYUZ'9<Y:N];Q$Z.@Z3J;DPNTO;%$9*/V8H3RO5%4?>^
M.BQ*D L@5I76%%7UTH4P1&:/W.P4VP0+Q(+E=K,%UK9!G[[ZI-E[[T(18DNP
M7\5U335D63G%6UEG!7<MMUX'@#:R_BV^0<DA=L*=*]@1D002CM8 Z&Q%'=.J
M"Z/ZK98B?I=++ [5IL[=K2YN"^R2(QZ-.V92#P,9%Z64\RL\2)]\4(Z_?-VI
M11GY%/TWYL<C%1G0&AC!8;'3;V&KSH^GT_FI^WAV?')Z,0D^7DSF\^@J) W_
MV^GI?!9^G%R>!N-.)N?GHY+.9QO-Q[.-K@?B+8,2[A%Y1D-CQX-?AN7P]3W?
M%E$6FN[1"M1#;[4,AXD8?T;$*O6TZA)\\+N]U6&(A0.KPUX C%Y(MH+68<ZD
M:VAUJ-W5GPV$C9VYSPN:/]!1.FP33%=8?8\)5(/'_IB6TL/#'ZJTG<V]S1*^
M&OE71?HF@Y7D(S=^4IOYLK*E:)U&C!@C<AH >5:N_&6/-A?-1(&_\( 7VQV_
M[?#8.M, 9E<88/W-&&6FPD6QK]H7%F,C4LI#)PO'B1A[05ZGP&P,-7SNTGP\
M=^D[F\GS1AH34[HH-I5 \G@',PYBR2.2EQZ>:;@)>>A'"[HNN1;&M2;C..B;
M=(0M5>@(MTCW1Y*M5+GFR\MP9LSYP:P.-+2""BI4<[@M>5E].K(XD16_-=7>
MI=@G[$TIN#A0;G)+(HSP+[D5JWP%>@I#0;ANW=B4MR$9;'R+ U_2PC8Q)DSE
M&6<KX=T)1Q2OMZE7QJI+$A_C>XF">Z,C,>H':>;0KJ)5K_8!M?CKCB1[X5[G
M*TJ\]!Y*OD.2-1FWK^*5BP1Y_?TUN/KE!FO4Y:I'$NB@E^PLU8;S^U.UK1'#
M*>SM)GB$!U-^8HMYD2Q!3'C6J^QZ[)%ZKY@RO92&EH_J#W'R,'DA>DHI6A>7
M2?ST;'J>3$].;=X")C3\^_,6YC[%:SZ>XO5>8WY=V+CA7546)48.#C92_Y-#
MHMCX$<@%':EGG*7]_=7M:W*%P#Y<W7ZD7XZF\R3^WK6\O_%=CX^N.8G^)U;W
MG_%=%_/9V7.;T3C<=%S:?Z.B[>)\DH\?=,KWJH((![R/4E3=R)LT9,0ZOW1@
M4OG[XQ,7% \OTI9./*8L7#=C3!ZSZ0;V_BDB?]9$4-FW=]7R/?*1BR.1TV9;
MICJWA4X!(0KUA 7F[E:]X/Z_WHJ]+Z\..KVA]_@X/)X(7=_M.PRVC,M X?+<
MQ1$ZR^7#Y='D)/QP&GR83F@!_'DV.9K,V)\D5ZW8@TQ" %R+&9K7&X_L"$/:
MY ,U>"Y$:XD/(69;YY*3AD;L,6L_[MUX= D@R+8E$^GTE",!#"6%CU!/C#R@
M9'ZLFRQUS6WI\B$/*BD/BS%P'YH>>80/F7>6%1U<%G!,A5TJ!%4XXBS [#"3
MI79]2)!6+ T]>C.C+]S,"XEGI^QW=3XBMXEM%Y._$KM]0_68,R<:CC4 2_IE
M69?<94-\D@-<:8;W\B21[1T6-K:YV:)<%PZ';3N:14U\:38YQ9?BEAW>NDS"
M ^)NXN&POL,4:\Q^W!';R7BNB%7*  BLD4"5A,UDN;#)[9Z4E@IKY.:CJ(D8
MJL+9N7IAK&+",]^'U9!90?E3X?6#V* "USJXI\B*&#;O-9$BBH9N %N&]EFX
M"EP] 4HY&Z0I8.9 MBG+(+\J&"NHQHI<XL0V,W1K=7!P"%*;UD*G&Z^\:"3)
MW:)UUXD5TJ1<+,]!P=EL@*QL=FEXEJ9+8U037TBKT#8YT0-2\3^TR:2HW:DL
MM_P>^V$1QG9Q*.K@D-G8G2)P*8VBEGX HF!<.3R0AR4#J;V>\7B'"T#PS<\H
M0QUYLY<R=/QFQON<726=N'S"6\;1OZ;O8R,]II#P_[@'EP6Q]-QVV&2.A_2J
M%V23O5&U>O7-5E=K?:WSG#QF!>A Z)MQWZ*S$/L$?'TU>_("WO2/O_IFI];Z
MK:K6Z+#,]0I>G1R?GS[A:E#[ =@&#ADORKHNM_0G5KWH"A^ WU<ET)U\P G0
M?B'P7OT?4$L#!!0    ( !J'2E:;/+SQ20,  #H'   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,P+GAM;)55WV\;-PQ^[U]!7-%A X+<C[AMDMD&;#=%LB*-
M$:?KP[ '6:+OA.JDJZ2+X_WUHW3VQ04<=WNY$R7RXT>*I(9K8[^Y"M'#4ZVT
M&R65]\UEFCI>8<W<J6E0T\G*V)IY$FV9NL8B$]&H5FF19>_2FDF=C(=Q;V['
M0]-Z)37.+;BVKIG=3%&9]2C)D]W&O2PK'S;2\;!A)2[0?VGFEJ2T1Q&R1NVD
MT6!Q-4HF^>5T$/2CPI\2UVYO#2&2I3'?@G C1DD6"*%"[@,"H]\CSE"I $0T
MOF\QD]YE,-Q?[] _QM@IEB5S.#/JJQ2^&B7G"0A<L5;Y>[.^QFT\;P,>-\K%
M+ZP[W<'[!'CKO*FWQL2@EKK[LZ=M'O8,SK,7#(JM01%Y=XXBRP_,L_'0FC78
MH$UH81%#C=9$3NIP*0MOZ522G1_?V9)I^0_K4J0%3%M'*L[!!W3<RB8>_/K
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MZ"T?/0BGP8L1MJ<]V],Q].6&1C.K!;I3JS0-J+9W3Z$2[N28S !_U+RBR;&
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MPQ]XU),YOE(*[9]P&'RS/("RUT8V1[#-H.'M\&8_CN=P!BCH3P#Q$1#[O(=
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MGQ5 )EJ#T3[YC%?AS2W#)7T\# P>8DV#>0-X5@/2%P C2JZD,$M-/H@,LN<
M ;)K*=(-Q3-Z$'$*JQ,2ASZA(:4'\.(VY-CAQ?\7\O?)3!N%M^3'OJ!KR.Y^
M2-LY [UB<QAYV!H:U -XX]>OHE[X[@#A;DNX>PA]/,5.S"JD*W/"M^190UX@
M^;G$-M%F'_.#V/N9WVG(JX(4/ >"V3=0SD"Y$CS3.I=,9*320)2]^QH+1)Z
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MUBBTIA3\*37%T5VP@BU3=31^)T\[;@OFNSGL3T9%$UC L"B6+YC0L;%T;'2
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M=AAG.Y13X0G;\(0_T2CT%%#2K4ZW8X$Y"?7S@;G;:X_UH<T'(D#[PL@Q7F)
MDV37SQLIU_5M)\(/ +9_+XBLW["'B$/Z@#V6!$-P=9MV2>/:0Q%T:A!B!W:,
M>UW'13#GJ%,'>Z-5SL3*#)"8,3KF]935OFUGU*MZ-/M/O!YP/U&Q2@L)&5NB
MJM,/L6V*>FBL'Q0OS:"VX K'/K-<XYS-A!; _27G:O>@#V@G]^F_4$L#!!0
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MURF>'3TVWW%B53<TO*VRV#Z'887_*Z#= GR_4\J^3MP&TQ_0\F]02P,$%
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M)11O4F54X5?6V,4-=FN20504:<Z(4XZ?57W:<0!!TGQ-N4;BZ,D855P[0(0
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M,\W7[GX([;:"<&R<[%>#@_M53OF3OD4*:$)5(>NK5ONVO:@.Z_O9=_'ZEOM
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MIJ=2K)&TI0W-?BCD*J)-!S-N1]:UEN8L,W%Z^E8N"&>?22DS3]#Y2IDB2J&
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M+EH8U&$$I06@M!"4%D'1VL.@\2&QVX=\1Q=,V?G8[)Y(SC1).\6%]/%FH+0
M?^F4'HP[C-*P*NC[6R7'WG#G-^4(JG5M01J7$;M=QEFI@MG+<BW9S>J^I,&-
MZ2T)_O*W]HX^#$!K#4%I$12M+5QC'V*G+V7N)/NXKGWH(7ZHA* &847;EG!\
MW*DAJ/<'2HN@:&T-&^\/N[V_7QGABT^L3DN=B8^;U5L^4+\/E!:"TB(H6EOC
MQA[#D\=-?$#],U!: $H+06D1%*T]#!I/#KL]N6_>K;NYO?4&->F^<LV;[7,U
MS>UMIKG[K?EB\RSC)<+/D']R<MRU>[YZ-RN->WLS,64VX0NR,+',OF"B:!%N
M3R7TEJ8B+QY-LM\SPE=S$NN5?5)P3\Q1)A*SY6>?3:R6)&'EWA_-EO;VI"BC
M"8OMQV'GX 1U%*%H[<'9.(K8_=!=OW4(U"X$I06@M!"4%D'1VAHW=B$^?MQU
M"-1%!*4%H+00E!9!T=K#H+';L-MNZ_EKG9O66V50MZVB.7^M>T"9"*I5[3>*
M&F=L['[";C/YNN9<-Z+WBT*@;A<H+02E15"TMK2-VS7V'W7.'8/Z8J"T )06
M@M(B*%I[&#0>V]CML?6<<]VTWBJ#/L]7T9QS[@/*1%"M*A49;;UVG%&Y*%X0
M5R@6*Z[+-Y#KH_5+Z"^+5Z]'3?'R#7:S_5@PKE!*YR;4&QZ9;:,L7PHOOVB1
M%R\QWPBM159\7%)B=A*V@#D_%T)OOM@*ZE?SI_\!4$L#!!0    ( !J'2E:_
M5@EO]P0  %\;   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;,59T6[;
M-A3]%4)#APW(8I%R$B>S#21.BWAMEB!9UX=B#[1$6T0E4B7I..[7CY0<,0.<
M2]5SD1=;E,3#<T6>>Z3+X4JJ+SIGS*#'LA!Z%.7&5&>]GDYS5E)]*"LF[)6Y
M5"4UMJD6/5TI1K.Z4UGT2!P?]TK*130>UN=NU7@HEZ;@@MTJI)=E2=7Z@A5R
M-8IP]'3BCB]RXT[TQL.*+M@],Q^K6V5;O18EXR43FDN!%)N/HG-\=I$,7(?Z
MCK\Y6^EGQ\B%,I/RBVM,LU$4.T:L8*EQ$-3^/; )*PJ'9'E\W8!&[9BNX_/C
M)_1W=? VF!G5;"*+3SPS^2@:1"AC<[HLS)U<7;%-0$<.+Y6%KG_1:G-O'*%T
MJ8TL-YTM@Y*+YI\^;AY$EPYDTX'4O)N!:I:7U-#Q4,D54NYNB^8.ZE#KWI8<
M%VY6[HVR5[GM9\8W:D$%_T:;1R0R=+'4]A:MT273J>)5?>&72V8H+_2OZ#=T
M;Q=&MBP8DG,[ES/-,TX59]JU3<Y0*LN*BO6P9RP]-T@OW5"Y:*B0%ZA@@JZE
M,+E&;T7&LO\"]&Q<;7#D*;@+ B+>L^H0)?$!(C$A %[2/JRDQNN_@/=1V!6D
M-$/3/R?H\S4K9TS]LRU0$,8)[4Q7-&6CR"I),_7 HO'//^'C^'> 9+\EV:_1
MDY>"?IJ3M9N1#[SDAF7VG\YXP<T:39KY05*U%V^I,L(&EO,*??Y@\=#4L%)O
M#:W_ T([:D,[ I^_7>'ULIN*5*I*JGK5;B,9@&'I(<+X -EU@4\!7L<MKV,0
M\+:P$7<B!N-,Z+JD DUU896H 6(G+;$3$/"-(W6SVLSM-D)P?[LPF# '",?Q
M&X#.H*4S@.$4%RFO:('.73+FQJ:-;:1@E*EX8-I89S HET7&Q0*@=MI2.^TF
M[:OWH+)!E!V7/XY]LHY?4]N;T?<<W3,KPON1=P#GFJX1V<B[#S$CGAG9D\ #
M0%=2+-!["2Y9[.T(PWX4EG< (*!K[#T'@WF_L[(#,-\E;>QM \,)OQ7W7RS-
MA2SD8@V*'(;;50?>3?#QJZH<-*%=H_.6A&%/Z:YR&.>\4M;%!V$7Q]Z><,"?
MNLL\ '0W@0AY4\*P*W40. P0$#CQSD/ W-]9X &83^]NWAZ@[Y(Y\?Y!X+S_
M!Z=B\<A1*W=(XS#6CBH@WE$(>4V-$]"&=HW.&Q.!?:6SQ@,XU]1J',7$BAR?
MG@X@;MZJ2,"J.HL\! 2*G'AW(K [A44>  B)W!L/"7S'=!4Y#'-G5Q15:5[7
M$S+VP I9U6)W;?N!LYS3U"SM6 L7>2DSI@3_9E>X433C;C8L@TGNRA ,E2SC
MJ3N$(O3F0V#3\&\"=JA @@"1=I60]R(R>-4$ 1K8KM%Y8R.P+W5/$#!.G2!P
MW+P$Q%")QSM=$G"ZSODA! 3FA\3;6@+;6C@_!  "^2'QII4$/H,ZYH< S#TM
MFG+A'J2?/*O==2S>75&1P]*'D7841^(=*GG5"E[R(TIXB;>[9$]%O ".^\K'
MI%8^P1 S;W_)OLIX(2!8^=ZMDO];O@L A)3OW2C93^4N //BFX&-4[ 5JG*J
M2CL)2\-3.U:E9+9,S5;]]Y[M>91,+>J='8U2N12FV?YHS[:[1^?-GHF_O=EZ
MLB:RX$*C@LUMU_CPQ"X\U>SF- TCJWH'92:-D65]F#/[_J#<#?;Z7$KSU' #
MM'MJXW\!4$L#!!0    ( !J'2E:27V!W# @  .I6   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0V+GAM;,6<:V_B1A2&_\J(5M6N5 7/V!C()DA)C&]JVFC3
M[46K?G!@$JSUA=H.2:3^^(XOP=@X UZ]VMT/&S!SGN.!]]AG_(+/GN+D2[KB
M/"//81"EYX-5EJU/A\-TL>*AEY[$:QZ)5^[C)/0R\31Y&*;KA'O+(B@,ADQ1
M]&'H^=%@=E9LNTEF9_%C%O@1OTE(^AB&7O)RR8/XZ7Q !Z\;/OH/JRS?,)R=
MK;T'?LNS3^N;1#P;;BE+/^11ZL<12?C]^>""GKILF@<4(_[P^5.Z\YCD4[F+
MXR_Y$V=Y/E#R/>(!7V0YPA-_-OR*!T%.$OOQ;P4=;'/F@;N/7^EF,7DQF3LO
MY5=Q\*>_S%;G@\F +/F]]QAD'^,GFU<3&N6\11RDQ?_DJ1RKCP=D\9AF<5@%
MBST(_:C\ZSU7;\1. -7>"&!5 &L'J&\$J%6 V@I@[(T K0K0C@T850&C8P/T
M*D _-F!<!8R/#9A4 9-C Z95P/38 *J\?G)*H:#R(R_T8GB9-SM+XB>2Y.,%
M+W]0B*Z(%S+QH[P^;K-$O.J+N&QV6]8%B>_)K?\0^??^PHLR<K%8Q(]1YD</
MY"8._(7/4_+.X)GG!^E[\M,/5!]]('Y$KOT@$#)/SX:9V)D<.5Q4B8TR,7LC
M,67D.HZR54KFT9(O.P#. 8"B2@A#\3YLWPSV^F9<,BGR8IV<$(7^3)A"IQU[
M="4/O_9>7J,G76^(//J6KT^(JN3AC)%/MP9Y]^/[#LR\#^;JU[_)N_+CZF*9
MQ[.H9)>L/I@#NV0?SU(DN^0<C:%C"<;M@WE[9@TUJMO25 NXBBS-S[\("G$R
M'J;_=,SGLDRI=:?,3\:GZ=I;\/.!.-NF/-GPP2R?D?*AJQR0, ,)FR-A)A)F
M(6$V$N8@82X(UB@<;5LXFHPNCL,93WPO(.O$7W"RYLF"1YGH]KH*0HKJ6Q!(
MF%'"\A.^H.5][F:FG"BCL^%F5^E'C3*1.V8A8382YB!A+@C6D/!H*^&15,(7
M@5BX>)%0KU@"D<=(M'GYBL*["[A8#@3%*UZ8GP>Z-"UE]]4T$F:4,'U'K.,I
MG;!Q2]3(G.9^3DW31^V<%C*GC80Y2)@+@C54K6]5K4M5[40;<2".14]3L;O$
M*T7T%2\29I2PT8Z0J.A")WI+O,B<9D=.JFLCM25>9$X;"7.0,!<$:XAWO!7O
M^*!XTRP4 I8<>:6(ON)%PHSQGI#&0KM3I27><AAE.^/:O40'2=.F3&M)\C#)
M1D[00<)<$*PAM,E6:)-CA>:+$W_8>924(OH*#0DS)GOR4">CR:2E,V1*LR.E
MLM=46,B4]F2OJ6"BCVE5DX-,Z8)@#4U.MYJ<2C7Y41"]9+$B7K0D2[[A0;PN
M%,J?USQ*>=<%P$LILJ]&D3!CNG\(TS5-';<75\BDYG[2D>A#=9VU=(I,:G<D
MG:B4M2;J('.Z(%A#J%2I+V@K\J73<L.3S$_S"V0R=<HQ?>4)I1D5;??P0L=B
MR:+2]G$4FM>L:(UV4Z6Z/FJ?W*%I[8ZTJJ9.VY7A0+.Z*%I3ISO&"Y7J]'?O
MF=SQB-_[V8%+5')0;Z4B:49%:UU_:A]'CQIE0O?,@M)L*,V!TEP4K2ED5@N9
M285\LQ5O;E5LO(PD7M8M9"FHMY"1-*.BM21*VU>FCAMF0O?-@M)L*,V!TEP4
MK2GEVG&C4E]B=A6'@KO*O_ZQX=7J2[+:E]-ZZQEJIU6TQF5/T6U.IFU!0ZVR
MCJPZ'5-MU.X?H#981U95$\W27O\ M;A0M*96:Y.+REVNWYXBGJ0K?TT^7_/P
MCB>=?J\<TENB4(,+2IM#:2:49D%I-I3F0&DNBM8LBMHVHZ-O_YT)"O73H#0#
M2IM#:2:49D%I-I3F0&DNBM:LH=JDHW*7KMG/Q]O3C!]E7.3K[H2@KAV49E2T
M5LO.VGT0U+:#TBPHS8;2'"C-1=&:TJ\M/BKW^*[]R \?0WE'!?7XH#0#2IM#
M:2:49D%I-I3F0&DNBM8LB=J,I)/OT%%![4LHS8#2YE":":594)H-I3E0FHNB
M-6NH-D^IW#V]\5X*LU3T3V%G.4"=4BC-.# U52%+[Z7+8)M_=:0)G8$%I=E0
MF@.EN2A:\\<SM?/*Y,[K\49 !6I?16]]J^WJC6&M+]P9\MWJ>\2&TDPHS8+2
M;"C-@=)<%*TIY=J<97)S]MI[/K@0D"/Z'K6A- -*FT-I)I1F06DVE.9 :2Z*
MUBR)VN9E[-LO!!C4$8;2#"AM#J694)H%I=E0F@.EN2A:LX9J?YG)_>5#"P%Y
M>.]R@!K*!Z9&V=LK@:\/-:%SL* T&TISH#0716L*O3:GF=R<=O\B'Z\NR:47
M?9'W4%![&DHSH+0YE&9":1:49D-I#I3FHFC-LJCM:?8=[&D&M:>A- -*FT-I
M)I1F06DVE.9 :2Z*UJRAVIYFAW]$>O!W>')&[YJ ^M%0VAQ*,Z$T"TJSH32G
MHC5^BJ[D_YH7%]UJW!N_8VQJN/:9F=QG[FJ/R'_DN*_TR=F]M0TUH*&T.91F
M0FD6E&9#:0Z4YJ)HS5JI#6CV'0QH!C6@H30#2IM#:2:49D%I-I3F0&DNBM:L
MH=J 9@<,Z*_X2I\<V;M$H*8TE#:'TDPHS8+2;"C-J6@'[CWE'AQ6BGJX<Q/+
MD"</Q4U34U(<Y<N;YFVW;F_,>E'<CK2UW:"G-NW8[M!3M[SM:HTO[P)[[24/
M?I22@-^+5,K)6*QPDO+&JN63+%X7M]"\B[,L#HN'*^XM>9(/$*_?QW'V^B1/
ML+V][>Q_4$L#!!0    ( !J'2E9U[? )? ,  %,4   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0W+GAM;-58;6_:,!#^*U8F39NT-;$I]&6 5-I-JS2TJJC;
MAVH?3'(!JXZ=VDYII?WXV0DD5&J=C@YI?('8\9V?>_S@.ZZ_D.I&SP$,NL^X
MT(-@;DQ^'(8ZGD-&]9[,0=@WJ509-7:H9J'.%="D-,IX2**H%V:4B6#8+^<N
MU+ O"\.9@ N%=)%E5#V,@,O%(,#!:N*2S>;&383#?DYG, %SE5\H.PIK+PG+
M0&@F!5*0#H(3?#PB'6=0KOC!8*'7GI$+92KEC1N<)X,@<HB 0VR<"VJ_[N 4
M.'>>+([;I=.@WM,9KC^OO'\I@[?!3*F&4\E_LL3,!\%A@!)(:<'-I5Q\A65
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M-\29$885/TIHO0'O+XVA[<03#,_<_#=02P,$%     @ &H=*5CX6MS"' @
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M.9V!VN>\;.>E(5EF.N*,2=5?S3!2-R#@VD'-+QB3+X9NLO6=*O@%4$L#!!0
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M=G;'DI$2*D%8A3CD$^O*O4Q";6\,?A+8B+TUTDH6C#WHS;=L8CDZ(*"02LV
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M;((')D3%]C#MP4UN&PO'SNS;ENW7SW;2K*" F,1+XFO?<WSO27P\V2E]9RH
M)/>UD&9**\3F+ A,44'-S*EJ0-J5E=(U0QOJ=6 :#:STH%H$<1B.@YIQ2;.)
MG[O6V41M4' )UYJ835TS_7L.0NVF-*+[B1N^KM!-!-FD86M8 -XVU]I&0<]2
M\AJDX4H2#:LIG45G>>KR?<(W#CMS,":NDZ52=RZX+*<T= 6!@ (= [.O+9R#
M$([(EO&KXZ3]E@YX.-ZS?_&]VUZ6S,"Y$M]YB=64?J2DA!7;"+Q1NPOH^ADY
MOD()XY]DU^:F"27%QJ"J.["MH.:R?;/[3H<#0#1^ A!W@/@Q('T"D'2 Y*6
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M'#KD(&$>),R'A 5 L);(MG7:Y5K?/M)6/H!T!Z5YH#0?E!9 T=K:-TXX;*"
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MRG4&]?V>,?G\HAW4]]KK?P!02P,$%     @ &H=*5H'?/Q]1 @  ? 4  !D
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MJ))N>[T-K*I]?RV5I6[UTS4]CZC=!EHOE;*/@6O9_L'-?@)02P,$%     @
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M#LZEDCH+SHZ$*VM44S<Y_=P;>86)VBB/DN._(?I)9\LAI2=<>4EPUY%MQKT
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M5\D.26.RU486-9C6!1?5/WNJXW  N K> $0U('H%B*(W (,:,/B_@+@&Q*\
M8?P&8%@#G.M^Y;L+W)P9-ATKN0-EI8G-?KCH.S3%BPM;)_=&T2DGG)G>8<X,
MIK!BRNSA3\6$9BZ%&B[F:!C/]27\^DLX&GX"+F#)\]P>CGU#RBV%G]2*9I6B
MZ U%801+*4RF82%23(\)?+*Z,3UZ-OTVZF1<LCT$HQY$012VV=.-OL>R#X/
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M1A,Z*BM YVM)#;A>6 7-S#_]#U!+ P04    "  :ATI6+,379+D#  !9#0
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M2QV%JOOX>F)D4?7.,VFH$Z^&*7W[H+(+Z/E<2K.9V V:KZGAOU!+ P04
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M6LV$:G#Z!4[_F0H5+71+$O13EVE=B=;ZO'0'&S(K(0\*Y,&K2G30)&!#9B5
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MOJHZ^1J8L(91M7<[Q7XP#$?#L;L]5.;4SO=(&(5'=O&I'0D"XAW@]?@$'9_
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M!J$!^#_E7.TZNMKWEWOT&U!+ P04    "  :ATI60@;NQH0"   7!P  &0
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MGN3H5XCZG#8\Q/*8LK))"/DR''FQN^GQ$'8>PI,>'BA; Z)9!ME;1AJBZ$"
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M]=:UAI T"D4S-6P;?QQ<R+2@TP%0&H6BF9JV,P)L[9"'F19T&E#3L&\\BOW
M[SZ,>^/P=-S?\N*V>\?V]KVQY/N#L%O2RAE<-R2-0M%,#=MY YY<R)*@4PA0
M&H6BF9JVLPAL[:J'61)TZE#3.MTQF70=.>UUI/^"(TG;[Q-[OZ^.CK2YT<X8
M6C(HC4+13/W:B0/!EW$C 9TI@-(H%,W4M)TI$&O7/,B--:IK#*_[,^LQSCX+
MM0_LM86W[3PYIYU_J@NW.A+T9WM0&H6BF2*V;3\97<B1H-, 4!J%HIF:MM,
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M6E-EY&'37]O?=)5'3>76X)J"1DU1S40U"]5L5'-0S=4ZHJ;J\6%F#.W31[4
MU4)4BRBM72N:J*DFCYJZ7WZ5#VS05"FJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6
MHEI$:>TRTD1/M?&;#FS(S-P5JAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):1&GM
M*M.D4;6>TWN^.,]7#>WG7R9=09DK>8^#:P6:*44U"]5L5'-0S44U#]5\5 M0
M+42UB-+:M:+)E&KR3"DZZU?=EVS:+_GJ#"XD:'84U2Q4LU'-0347U3Q4\U$M
M0+40U2)*:Q>2)N^JO3"YZ'I[2[0B5=:;[&8>YT*)9[.D>C!>R&H&FH-%-0/5
M3%2S4,U&-0?57%3S4,U'M4![.KEJ5UP^1'N-**U=.)J$JR:?=U0R>^!SR3/M
MZ?2BSTPA)N][<#U $ZNH9J&:C6H.JKFHYJ&:CVH!JH6H%E%:NVHTB55-GE@=
M/.V@]C0]J$VFG=<ZT"0JJIFH9J&:C6H.JKFHYJ&:CVH!JH6H%E%:^T:)35Q5
MA^.J<F_HV 35#%0S4<U"-1O5'%1S4<U#-1_5 E0+42VBM'9=:>*J^IO&574T
MKHIJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%J!916KO*:$V5>2&NVOM373DTN*"@
M6554,U'-0C4;U1Q4<VMM_T*CWG5+5K17']4"5 M1+:*T=JG8NR6\/*WZY2'0
M_C#,>>T'NO)^!E<2]O[P[ WBV3O$L[>(9^\1S]XD?J>IX[U24MVW]3#WCO;J
MHUJ :B&J1936KB1-8%671M6>WBE:^B49.3:X7)":@6HFJEFH9J.:@VINK1W,
MQSZ:'E8+LE,?U0)4"U$MHK1VM6B"I[H\>&K^49:')!=UBBQ>IIO_X-P#G105
MU0Q4,U'-0C4;U1Q4<VOM;*^63)[<VP'MTD>U -5"5(LHK5U*FERJ_L)<IT^^
MG+LK%:^N)N@,J*AFH)J):A:JV:CFH)JKOQA>]M .?50+4"U$M8C2VK6DB:;J
M\FCJ=G:S6?(CF8G5[(5/?-$T*JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6D1I
M[8K29%;U-YV554=G944U ]5,5+-0S48U!]5<5/-0S4>U -5"5(LHK5UEFHRK
MWF-6UH?SENW YY^;>*5\%:MELOJ>5(.>JK=)U[I_EMN#:PR:B:VUZO:!C^?:
MVL%GCV;70OK!0E:?A>RNA=2#A9RNA<8'"[GHR^"AFH]J :J%J!916NNP'#<Q
MTK$\1FJ(_"9+=E]W2V^;@47742BGAAZ%J&:@FHEJ%JK9J.:@FOO"SO9)*=(B
M7E0[VM?PLZJ/E&6R6%2[WKMXO<[2/Y)E7(C%G\K/ZOFQ^O#'7Y2;UGO'?9PK
M,W&SB*NYO6^S=*E<BW6Q'0;_I(W4:?6U34M\SS;51WWE ^?OJXOWJSOE?I[<
MS,M?6EV5*Z+MK<?/^G['55?K.)DIY=O5=B5*.BGRW:6Y^I2Y^EO9R]GVUD7%
M7"B96,;)*EG=_50]274?+U?NJ?V\>7[<56G13>:C6H!J(:I%E-:NM$VP=BR-
MU%U>%W&Q*=)RG_RZT[<[3/ESD24W1;DK5]\"^I3GXH4<O[R;P5483=BBFHEJ
M%JK9J.:@FHMJ'JKYJ!:@6HAJ$:6URXW6E!OM+:_JC-'8+:H9J&:BFH5J-JHY
MJ.:BFH=J/JH%J!:B6D1I[2K3A'/'\G!N<U*3;[+U8O-2J$[.#2XK: 87U4Q4
MLU#-1C4'U=Q:.PC5'29PT3Y]5 M0+42UB-+:Y:))X(ZEF;W+O='.+D_7;[H#
MN3JX:I":@6HFJEFH9J.:@VINK;4FQ!CKYQ/],/6"=NNC6H!J(:I%E-8N'$T8
M=RP/X^X5CI4HE'AWF:17[4"3MZAFH)J):A:JV:CFH)J+:M[XZ2S$NGIZ-IU.
M]8,[^Z']!J@6HEI$:>WBT<1OQ_+XK5-=_/>K_TBOJZ*A6E0S4,U$-0O5;%1S
M4,U%-0_5?%0+4"U$M8C2VL6DR=^.3]_TNBJ:R44U ]5,5+-0S48U!]5<5/-0
MS4>U -5"5(LHK5UEFDSN6#Z/[*ON82XW!]<6-(F+:B:J6:AFHYJ#:N[XZ5S#
M^D@_'1]^9;EC.575)V>GT_'A( ;-SZ):B&H1I;4K0I.?'<OSL]]6R8_RE*,\
MMXBNY.,8-"N+:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@645JKGDR:X.]D]);C
MF F:!48U ]5,5+-0S48U!]5<5/-0S4>U -5"5(LHK5UEFM#K1!YZ/9QR*=X4
M\S1+_A*SSJ*"1EMK;?]*O#H:==T1T$ [-E'-0C4;U1Q4<SLV6,=M4#RT4Q_5
M E0+42VBM'8IT)I2T'/*UX?9U^),^1$O-J^>!47>W^!JL=-.6[&CT4A7M<EA
ML4#CIZAFH9J-:@ZJN;76ND1Q6"C03"FJ!:@6HEI$:>U"T61*)_),Z6&AV$T1
MW5D!T#1IK;7.%Z;=IPMH4A35+%2S4<U!-;=C>W6>+J!1450+4"U$M8C2VE6@
MB8I.I(FR 3/$RZ'!56#<9Z\RT$Y-5+-0S48U!]5<5/-0S4>U -5"5(LHK5TI
MFFSH1)X-_35+[I+FOKS P *-C-::Y$350#LT4<U"-1O5'%1S4<U#-1_5 E0+
M42VBM'8Q:;*BDQ>F:L6O4J"QTEKK<Y4"C8RBFH5J-JHYJ.:BFH=J/JH%J!:B
M6D1I[9K21$8G\BE;OXHTNXM7R5_Q=IHE2:U PZ&3IS=@?^YZ!AK\1#4+U6Q4
M<U#-134/U7Q4"U M1+6(TMJUH@E^3N3!S\Z85WF2\7A><KT[+Y$EP.1=#"XC
M: X4U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BRBM76J:1.GD_$T38&C.%-4,5#-1
MS4(U&]4<5'-1S4,U']4"5 M1+:*T5I69-CG3J7S.S\,+*NFFR(MX-:MNAS-K
M)I_MJC!R>6B%034#U4Q4LU#-1C4'U=P7]KU/N1(K);-9%-6<L\4\R97;-+N/
MLYF2KQ=)]>A/U92M^SME>AA9+"JD&KI7AJZ-_E82?U-W?WY?_NUQ3EMU^KX<
M6U?_?VA[+S+Q\ %F-=OG?C_Q;2&R[82QVU7IG.H5?;5\5 M0+42UB-)V->\D
MGPM1&'$17UXL178GKL1BD2LWU01&U>G5WJ/EWG9;UD3UPR?MZ.3)XY;ZP5$[
M'G?5#][V\9.&O[Q8QW<BC+.[9)4K"W%;=C4Z/IT<*5ER-W_\I4C7'X_4(^5[
M6A3I<OOC7,3E*5VU0/GWVS0M'GZI.KA/L]^V3^?R_P%02P,$%     @ &H=*
M5IU^PP5: @  9@4  !D   !X;"]W;W)K<VAE971S+W-H965T.#$N>&ULG53+
M;MLP$/R5A1H4"5!8LFRG02H+\*-!<PA@Q$U[*'J@I;5%A ^5I.ST[[ND;-5%
M'!]ZL;CD[LSLFL-LI\VSK1 =O$BA[#BJG*MOX]@6%4IF>[I&12=K;21S%)I-
M;&N#K Q%4L1IDES'DG$5Y5G86Y@\TXT37.'"@&VD9.;W%(7>C:-^=-AXY)O*
M^8TXSVJVP26ZIWIA*(H[E))+5)9K!0;7XVC2OYV.?'Y(^,9Q9X_6X#M9:?WL
M@_MR'"5>$ HLG$=@]-GB#(7P0"3CUQXSZBA]X?'Z@'X7>J=>5LSB3(OOO'35
M.+J)H,0U:X1[U+LON.\G""RTL.$7=FWN:!A!T5BGY;Z8%$BNVB][V<_AJ"!-
MWRA(]P5IT-T2!95SYEB>&;T#X[,)S2]"JZ&:Q''E_Y2E,W3*J<[E,RTE=S1E
M9X&I$F9:.:XVJ J.%B[GZ!@7]@HN@"MXX$+0*&T6.Z+V '&QIYFV-.D;-/T4
M'@BYLO!9E5C^"Q"3YDYX>A ^3<\B+K'NP2#Y &F2IO"TG,/EQ=49W$$WD$'
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MU@Q-1N]/(V&[R>T,ATV8EAP=SU[85GS9@?4!?+Y&=#O#)QBNS^P74$L#!!0
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MX0(P?0L0#X XZ.X+!94;[GB6&-T1X[.1S2^"U8!&<4+YC[)S!D\%XERVUJK
M*X:"W G%52ZX)/>J_]C^UG1)7 5DRPTH1]:Z;KAZ(9\VX+B0]G/"'(KP5"P?
M"J[Z@O$;!7?03,@L^D+B*([_A3/4/AJ(1P-QX)O]IX&-L+G4MC5 ?M_NK3/8
M!W^NR>[+W%POXV=C:1N>0TJQ^2V8(]#LXX?I(OK^CHG9:&+V'GNV:_=6% *G
M@L I!RC03@,FQSO'R;BFMN>;1H'03]XQBR;Q/&''2QGLHC'\C/WDYB"4)1)*
MA$63KW-*3-^W?>!T$WIEKQUV7EA6..I@? *>EUJ[<^#;;_QY9*]02P,$%
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M4Z$-X/V<<_4ZT??*\G>$[G]02P,$%     @ &H=*5@H>HF;% @  R <  !D
M  !X;"]W;W)K<VAE971S+W-H965T.#@N>&ULK55=;],P%/TK5D!HDT;ST:9#
MHXW$.DU,8J):!3Q,>W"3V\::8P?;:3=^/==V%K6009GH0Q/;YQR?<^./R5:J
M>UT"&/)0<:&G06E,?1:&.B^AHGH@:Q XLI*JH@:;:AWJ6@$M'*GB81)%X["B
M3 39Q/7-53:1C>%,P%P1W50558_GP.5V&L3!4\<-6Y?&=H39I*9K6(#Y4L\5
MML).I6 5",VD( I6T^!#?#8;6[P#?&6PU3OOQ"992GEO&U?%-(BL(>"0&ZM
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M* O \964YJEA3_/N\LY^ E!+ P04    "  :ATI6*PU]1A $  #3#0  &0
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MK NN\0 C !@-!LC.9MR#G +(Z3-"SAV$^X!AS<(^\:+Q(&, &0\(^2WR(!,
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MN^7V^.OR^R*^+U97G.O[BN'I+U!+ P04    "  :ATI6PH ,:SH"  !H,P
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MR<^6/]C<_@102P$"% ,4    "  :ATI6!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !J'2E:U&:B.
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( !J'2E:97)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ &H=*5H\Y@X_Y!@  SB
M !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( !J'2E9*U;&@+ <  &D=   8              " @3P/  !X
M;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  :ATI6Q<@&*XX"
M  !7!P  &               @(&>%@  >&PO=V]R:W-H965T<R]S:&5E=#,N
M>&UL4$L! A0#%     @ &H=*5AD)&H".!@  A1T  !@              ("!
M8AD  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !J'2E:7
M\'[=QP(  )T'   8              " @28@  !X;"]W;W)K<VAE971S+W-H
M965T-2YX;6Q02P$"% ,4    "  :ATI6.E,+_ML%   .)   &
M    @($C(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M&H=*5@/(EW*C"0  H3   !@              ("!-"D  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !J'2E8/;--&80H  /\:   8
M          " @0TS  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    "  :ATI6 O%ELEHI  #)?P  &               @(&D/0  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ &H=*5DD+ZQ7O!   7PL
M !D              ("!-&<  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    "  :ATI654.J&J "  ">!0  &0              @(%:;
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !J'2E9C:Y6$
MT@(  $$&   9              " @3%O  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ &H=*5@EZP.+)!   LPH  !D
M ("!.G(  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  :
MATI623JDG8 #  "+!P  &0              @($Z=P  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !J'2E8L*O8GH@,  !,(   9
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M970Q.2YX;6Q02P$"% ,4    "  :ATI6@7@19Q0&   5%   &0
M    @('=D   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M !J'2E8/=9D?W08  ,@0   9              " @2B7  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ &H=*5IT>IIQN"@  <QH  !D
M             ("!/)X  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    "  :ATI6OI+/P%D%   Q#@  &0              @('AJ   >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( !J'2E8=G^L]+PP
M ,P@   9              " @7&N  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ &H=*5L0?Z)P>!   M @  !D              ("!
MU[H  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  :ATI6
MO:FU;%(&  !V#@  &0              @($LOP  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( !J'2E8=@+_+;0(  %8%   9
M      " @;7%  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ &H=*5O"-7M^S"0  ?!<  !D              ("!6<@  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  :ATI6\[9(>(TK  #QD@
M&0              @(%#T@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( !J'2E:;/+SQ20,  #H'   9              " @0?^  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ &H=*5C&)O@P3
M P  RP<  !D              ("!AP$! 'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    "  :ATI6;*/?U/L#  #1"0  &0
M@('1! $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !J'
M2E9TP?U=@0(  &L%   9              " @0,) 0!X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ &H=*5KYBH4]I @  @P4  !D
M         ("!NPL! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    "  :ATI6^F$D_=,"   4!@  &0              @(%;#@$ >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( !J'2E;XC)!4  ,  &<&
M   9              " @641 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ &H=*5CZO!U,% P  $ <  !D              ("!G!0!
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  :ATI6".Q_
MN&$"   Q!0  &0              @('8%P$ >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    ( !J'2E:ZV,8?F 4  #43   9
M  " @7 : 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
M&H=*5IA44:&\ P  G@D  !D              ("!/R ! 'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    "  :ATI6&4;_PZ,$  #%"P  &0
M            @($R) $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( !J'2E;<X5KQTP,   T)   9              " @0PI 0!X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ &H=*5ENS-)&M!@
MR@\  !D              ("!%BT! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    "  :ATI6OXN1>,X'  "F/P  &0              @('Z
M,P$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( !J'2E:_
M5@EO]P0  %\;   9              " @?\[ 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ &H=*5I)?8'<,"   ZE8  !D
M     ("!+4$! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
M"  :ATI6=>WP"7P#  !3%   &0              @(%P20$ >&PO=V]R:W-H
M965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( !J'2E;NAW>4@P(  !T(   9
M              " @2-- 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L!
M A0#%     @ &H=*5I>0J9VC @  %@@  !D              ("!W4\! 'AL
M+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  :ATI6P8)29@X#
M  #R!@  &0              @(&W4@$ >&PO=V]R:W-H965T<R]S:&5E=#4P
M+GAM;%!+ 0(4 Q0    ( !J'2E8^%K<PAP(  *$&   9              "
M@?Q5 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ &H=*
M5NH9+Q2=!   >!@  !D              ("!NE@! 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    "  :ATI6N=63] T#  "W"   &0
M        @(&.70$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( !J'2E9#+O9PE0(  /H&   9              " @=)@ 0!X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ &H=*5CXW&EBU @  E <
M !D              ("!GF,! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    "  :ATI6B;(1A+<#  "D$P  &0              @(&*9@$
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( !J'2E8UPO:L
MO@(  %\)   9              " @7AJ 0!X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ &H=*5N6FGX4Q @  !08  !D
M ("!;6T! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  :
MATI6<P$UF$8#  ##"0  &0              @('5;P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( !J'2E:A*JU$J0(  (P'   9
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M970V-"YX;6Q02P$"% ,4    "  :ATI6B:H*T6<$  #C'@  &0
M    @($SA0$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    (
M !J'2E:!WS\?40(  'P%   9              " @=&) 0!X;"]W;W)K<VAE
M971S+W-H965T-C8N>&UL4$L! A0#%     @ &H=*5DUK.2BN P  N0\  !D
M             ("!68P! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"
M% ,4    "  :ATI63YR!6%4&  "00   &0              @($^D $ >&PO
M=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( !J'2E9\9(GH]@8
M #(F   9              " @<J6 0!X;"]W;W)K<VAE971S+W-H965T-CDN
M>&UL4$L! A0#%     @ &H=*5C*./G*Z P  _PL  !D              ("!
M]YT! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    "  :ATI6
M+,379+D#  !9#0  &0              @('HH0$ >&PO=V]R:W-H965T<R]S
M:&5E=#<Q+GAM;%!+ 0(4 Q0    ( !J'2E;;572+K0(  'L*   9
M      " @=BE 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%
M  @ &H=*5NP8_6&G @  40H  !D              ("!O*@! 'AL+W=O<FMS
M:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    "  :ATI6>B'35W,%   ;$P
M&0              @(&:JP$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+
M 0(4 Q0    ( !J'2E;DQ(DE^0,  (,7   9              " @42Q 0!X
M;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ &H=*5J%PSV&Y
M P  <@T  !D              ("!=+4! 'AL+W=O<FMS:&5E=',O<VAE970W
M-BYX;6Q02P$"% ,4    "  :ATI6<"H"FZ@"  #H!P  &0
M@(%DN0$ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( !J'
M2E9"!N[&A (  !<'   9              " @4.\ 0!X;"]W;W)K<VAE971S
M+W-H965T-S@N>&UL4$L! A0#%     @ &H=*5O[/OES&!   "2,  !D
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M=#@S+GAM;%!+ 0(4 Q0    ( !J'2E9T_MQ4A@4  #DB   9
M  " @2O= 0!X;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @
M&H=*5IO (?1= @  2@4  !D              ("!Z.(! 'AL+W=O<FMS:&5E
M=',O<VAE970X-2YX;6Q02P$"% ,4    "  :ATI6[:0,W!$"  !(!   &0
M            @(%\Y0$ >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4
M Q0    ( !J'2E;CP-5UH 0  %,0   9              " @<3G 0!X;"]W
M;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ &H=*5@H>HF;% @
MR <  !D              ("!F^P! 'AL+W=O<FMS:&5E=',O<VAE970X."YX
M;6Q02P$"% ,4    "  :ATI6*PU]1A $  #3#0  &0              @(&7
M[P$ >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    ( !J'2E;Z
MRKWBFP4  -T9   9              " @=[S 0!X;"]W;W)K<VAE971S+W-H
M965T.3 N>&UL4$L! A0#%     @ &H=*5JF<9(AE P  3!8   T
M     ( !L/D! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  :ATI6EXJ[',
M   3 @  "P              @ % _0$ 7W)E;',O+G)E;'-02P$"% ,4
M"  :ATI6QG$,%B<&  !0.P  #P              @ $I_@$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ &H=*5N;BI-"@ @  !34  !H
M ( !?00" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M&H=*5L* #&LZ @  :#,  !,              ( !50<" %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     &( 8@#E&@  P D"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>224</ContextCount>
  <ElementCount>385</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>75</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Income and Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Income and Comprehensive Income (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Business Description</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription</Role>
      <ShortName>Organization and Business Description</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Accounts Receivable, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet</Role>
      <ShortName>Accounts Receivable, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Inventory, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/InventoryNet</Role>
      <ShortName>Inventory, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Advance to Suppliers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers</Role>
      <ShortName>Advance to Suppliers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Prepayment for Advertisting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting</Role>
      <ShortName>Prepayment for Advertisting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Prepayment for Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition</Role>
      <ShortName>Prepayment for Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestments</Role>
      <ShortName>Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Prepayment for CIP Project</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject</Role>
      <ShortName>Prepayment for CIP Project</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Prepayment for Purchase of a Property</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty</Role>
      <ShortName>Prepayment for Purchase of a Property</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Short-Term Bank Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans</Role>
      <ShortName>Short-Term Bank Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/Taxes</Role>
      <ShortName>Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/Concentrations</Role>
      <ShortName>Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Condensed Financial Information of the Parent Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany</Role>
      <ShortName>Condensed Financial Information of the Parent Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Organization and Business Description (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables</Role>
      <ShortName>Organization and Business Description (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Accounts Receivable, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables</Role>
      <ShortName>Accounts Receivable, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Inventory, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables</Role>
      <ShortName>Inventory, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/InventoryNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Advance to Suppliers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables</Role>
      <ShortName>Advance to Suppliers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsTables</Role>
      <ShortName>Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Prepayment for CIP Project (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables</Role>
      <ShortName>Prepayment for CIP Project (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Short-Term Bank Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables</Role>
      <ShortName>Short-Term Bank Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</Role>
      <ShortName>Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/Taxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Condensed Financial Information of the Parent Company (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Organization and Business Description (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails</Role>
      <ShortName>Organization and Business Description (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Organization and Business Description (Details) - Schedule of subsidiaries of the company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable</Role>
      <ShortName>Organization and Business Description (Details) - Schedule of subsidiaries of the company</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of currency exchange rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of currency exchange rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails</Role>
      <ShortName>Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Accounts Receivable, Net (Details) - Schedule of accounts receivable consists</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableconsistsTable</Role>
      <ShortName>Accounts Receivable, Net (Details) - Schedule of accounts receivable consists</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Accounts Receivable, Net (Details) - Schedule of the company???s accounts receivable and subsequent collection</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable</Role>
      <ShortName>Accounts Receivable, Net (Details) - Schedule of the company???s accounts receivable and subsequent collection</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Accounts Receivable, Net (Details) - Schedule of allowance for doubtful accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable</Role>
      <ShortName>Accounts Receivable, Net (Details) - Schedule of allowance for doubtful accounts</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Inventory, Net (Details) - Schedule of inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable</Role>
      <ShortName>Inventory, Net (Details) - Schedule of inventory</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Advance to Suppliers (Details) - Schedule of advances to suppliers net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable</Role>
      <ShortName>Advance to Suppliers (Details) - Schedule of advances to suppliers net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Prepayment for Advertisting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails</Role>
      <ShortName>Prepayment for Advertisting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Prepayment for Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails</Role>
      <ShortName>Prepayment for Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsDetails</Role>
      <ShortName>Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Short-Term Investments (Details) - Schedule of short-term investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvestmentsTable</Role>
      <ShortName>Short-Term Investments (Details) - Schedule of short-term investments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net consists</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable</Role>
      <ShortName>Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net consists</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Intangible Assets, Net (Details) - Schedule of intangible assets, net consist</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable</Role>
      <ShortName>Intangible Assets, Net (Details) - Schedule of intangible assets, net consist</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable</Role>
      <ShortName>Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Prepayment for CIP Project (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails</Role>
      <ShortName>Prepayment for CIP Project (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Prepayment for CIP Project (Details) - Schedule of future minimum capital expenditures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable</Role>
      <ShortName>Prepayment for CIP Project (Details) - Schedule of future minimum capital expenditures</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Prepayment for Purchase of a Property (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails</Role>
      <ShortName>Prepayment for Purchase of a Property (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Short-Term Bank Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails</Role>
      <ShortName>Short-Term Bank Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Short-Term Bank Loans (Details) - Schedule of short-term bank loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable</Role>
      <ShortName>Short-Term Bank Loans (Details) - Schedule of short-term bank loans</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Related Party Transactions (Details) - Schedule of nature of relationships with related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable</Role>
      <ShortName>Related Party Transactions (Details) - Schedule of nature of relationships with related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Related Party Transactions (Details) - Schedule of due from related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable</Role>
      <ShortName>Related Party Transactions (Details) - Schedule of due from related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Related Party Transactions (Details) - Schedule of due to related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable</Role>
      <ShortName>Related Party Transactions (Details) - Schedule of due to related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails</Role>
      <ShortName>Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Taxes (Details) - Schedule of components of the income tax provision (benefit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable</Role>
      <ShortName>Taxes (Details) - Schedule of components of the income tax provision (benefit)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Taxes (Details) - Schedule of table reconciles the china statutory rates to the company???s effective tax rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable</Role>
      <ShortName>Taxes (Details) - Schedule of table reconciles the china statutory rates to the company???s effective tax rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>076 - Disclosure - Taxes (Details) - Schedule of deferred tax assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable</Role>
      <ShortName>Taxes (Details) - Schedule of deferred tax assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>077 - Disclosure - Taxes (Details) - Schedule of taxes payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable</Role>
      <ShortName>Taxes (Details) - Schedule of taxes payable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>078 - Disclosure - Concentrations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails</Role>
      <ShortName>Concentrations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/Concentrations</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>079 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>080 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>081 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>082 - Disclosure - Segment Reporting (Details) - Schedule of revenue by product source</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable</Role>
      <ShortName>Segment Reporting (Details) - Schedule of revenue by product source</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>083 - Disclosure - Segment Reporting (Details) - Schedule of total revenues by product categories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable</Role>
      <ShortName>Segment Reporting (Details) - Schedule of total revenues by product categories</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>084 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>085 - Disclosure - Condensed Financial Information of the Parent Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>086 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>087 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>088 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of income and comprehensive income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of income and comprehensive income</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="f20f2022_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>089 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of cash flows</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: dei:CityAreaCode, dei:EntityAddressPostalZipCode, dei:LocalPhoneNumber, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  f20f2022_universe.htm 18482, 18483, 18484, 18485, 18486, 18487, 18608, 18610, 18612</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" original="f20f2022_universe.htm">f20f2022_universe.htm</File>
    <File>f20f2022ex12-1_universe.htm</File>
    <File>f20f2022ex12-2_universe.htm</File>
    <File>f20f2022ex13-1_universe.htm</File>
    <File>f20f2022ex13-2_universe.htm</File>
    <File>f20f2022ex15-1_universe.htm</File>
    <File>f20f2022ex15-2_universe.htm</File>
    <File>f20f2022ex15-3_universe.htm</File>
    <File>f20f2022ex2-3_universe.htm</File>
    <File>f20f2022ex4-11_universe.htm</File>
    <File>f20f2022ex4-12_universe.htm</File>
    <File>f20f2022ex4-13_universe.htm</File>
    <File>f20f2022ex4-14_universe.htm</File>
    <File>upc-20220930.xsd</File>
    <File>upc-20220930_cal.xml</File>
    <File>upc-20220930_def.xml</File>
    <File>upc-20220930_lab.xml</File>
    <File>upc-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img_001.jpg</File>
    <File>img_002.jpg</File>
    <File>img_003.jpg</File>
    <File>img_004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="764">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="51">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>155
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f20f2022_universe.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 3,
    "http://fasb.org/us-gaap/2022": 764,
    "http://xbrl.sec.gov/dei/2022": 51
   },
   "contextCount": 224,
   "dts": {
    "calculationLink": {
     "local": [
      "upc-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "upc-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f20f2022_universe.htm"
     ]
    },
    "labelLink": {
     "local": [
      "upc-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "upc-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "upc-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 637,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 110,
    "http://www.UniversePharmaceuticalsINC.com/20220930": 18,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 134
   },
   "keyCustom": 87,
   "keyStandard": 298,
   "memberCustom": 50,
   "memberStandard": 23,
   "nsprefix": "upc",
   "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Accounts Receivable, Net",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet",
     "shortName": "Accounts Receivable, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Inventory, Net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/InventoryNet",
     "shortName": "Inventory, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:AdvancesToSuppliersTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Advance to Suppliers",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers",
     "shortName": "Advance to Suppliers",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:AdvancesToSuppliersTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForAdvertistingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Prepayment for Advertisting",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting",
     "shortName": "Prepayment for Advertisting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForAdvertistingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Prepayment for Acquisition",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition",
     "shortName": "Prepayment for Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:HeldToMaturityInvestmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Short-Term Investments",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestments",
     "shortName": "Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:HeldToMaturityInvestmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Property, Plant and Equipment, Net",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet",
     "shortName": "Property, Plant and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Intangible Assets, Net",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForConstructionInProgressTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Prepayment for CIP Project",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject",
     "shortName": "Prepayment for CIP Project",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForConstructionInProgressTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForPurchaseOfAPropertyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Prepayment for Purchase of a Property",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty",
     "shortName": "Prepayment for Purchase of a Property",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForPurchaseOfAPropertyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Short-Term Bank Loans",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans",
     "shortName": "Short-Term Bank Loans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Taxes",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/Taxes",
     "shortName": "Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Concentrations",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/Concentrations",
     "shortName": "Concentrations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Segment Reporting",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Condensed Financial Information of the Parent Company",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany",
     "shortName": "Condensed Financial Information of the Parent Company",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "29",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "us-gaap:CommonStockSharesIssued",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Organization and Business Description (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables",
     "shortName": "Organization and Business Description (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Accounts Receivable, Net (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables",
     "shortName": "Accounts Receivable, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Inventory, Net (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables",
     "shortName": "Inventory, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:ScheduleOfAdvancesToSuppliersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Advance to Suppliers (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables",
     "shortName": "Advance to Suppliers (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:ScheduleOfAdvancesToSuppliersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Short-Term Investments (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsTables",
     "shortName": "Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Intangible Assets, Net (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Prepayment for CIP Project (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables",
     "shortName": "Prepayment for CIP Project (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Short-Term Bank Loans (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables",
     "shortName": "Short-Term Bank Loans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Income and Comprehensive Income",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
     "shortName": "Consolidated Statements of Income and Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Related Party Transactions (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Taxes (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables",
     "shortName": "Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Segment Reporting (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Condensed Financial Information of the Parent Company (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables",
     "shortName": "Condensed Financial Information of the Parent Company (Tables)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c51",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "upc:SharesIssued01",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Organization and Business Description (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
     "shortName": "Organization and Business Description (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c51",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "upc:SharesIssued01",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c55",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Organization and Business Description (Details) - Schedule of subsidiaries of the company",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable",
     "shortName": "Organization and Business Description (Details) - Schedule of subsidiaries of the company",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c55",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "upc:MaterialPricePercentage",
      "reportCount": 1,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "upc:AllowanceForUncollectableBalancesAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c66",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c73",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntermediateLifePlantsUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c73",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntermediateLifePlantsUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:DescriptionOfYearEndSpotRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of currency exchange rate",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of currency exchange rate",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:DescriptionOfYearEndSpotRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Income and Comprehensive Income (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Consolidated Statements of Income and Comprehensive Income (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:AccountsReceivableDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Accounts Receivable, Net (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails",
     "shortName": "Accounts Receivable, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:AccountsReceivableDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Accounts Receivable, Net (Details) - Schedule of accounts receivable consists",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableconsistsTable",
     "shortName": "Accounts Receivable, Net (Details) - Schedule of accounts receivable consists",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Accounts Receivable, Net (Details) - Schedule of the company\u2019s accounts receivable and subsequent collection",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable",
     "shortName": "Accounts Receivable, Net (Details) - Schedule of the company\u2019s accounts receivable and subsequent collection",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Accounts Receivable, Net (Details) - Schedule of allowance for doubtful accounts",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable",
     "shortName": "Accounts Receivable, Net (Details) - Schedule of allowance for doubtful accounts",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c22",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Inventory, Net (Details) - Schedule of inventory",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable",
     "shortName": "Inventory, Net (Details) - Schedule of inventory",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfAdvancesToSuppliersNet",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Advance to Suppliers (Details) - Schedule of advances to suppliers net",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable",
     "shortName": "Advance to Suppliers (Details) - Schedule of advances to suppliers net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfAdvancesToSuppliersNet",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c85",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherSellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Prepayment for Advertisting (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails",
     "shortName": "Prepayment for Advertisting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c85",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherSellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c88",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "upc:AssetAcquisitionPriceOfAcquisitionsExpected",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Prepayment for Acquisition (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
     "shortName": "Prepayment for Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c88",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "upc:AssetAcquisitionPriceOfAcquisitionsExpected",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Short-Term Investments (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsDetails",
     "shortName": "Short-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Short-Term Investments (Details) - Schedule of short-term investments",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvestmentsTable",
     "shortName": "Short-Term Investments (Details) - Schedule of short-term investments",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c4",
      "decimals": "0",
      "lang": null,
      "name": "upc:AddPurchaseWealthManagementFinancialProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Changes in Shareholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Property, Plant and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails",
     "shortName": "Property, Plant and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net consists",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable",
     "shortName": "Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net consists",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Intangible Assets, Net (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails",
     "shortName": "Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Intangible Assets, Net (Details) - Schedule of intangible assets, net consist",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable",
     "shortName": "Intangible Assets, Net (Details) - Schedule of intangible assets, net consist",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c103",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable",
     "shortName": "Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c103",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConstructionContractCostProgressPaymentOffset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cny",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Prepayment for CIP Project (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails",
     "shortName": "Prepayment for CIP Project (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConstructionContractCostProgressPaymentOffset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cny",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c109",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Prepayment for CIP Project (Details) - Schedule of future minimum capital expenditures",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable",
     "shortName": "Prepayment for CIP Project (Details) - Schedule of future minimum capital expenditures",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c109",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c110",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "upc:EquityInterest",
      "reportCount": 1,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "066 - Disclosure - Prepayment for Purchase of a Property (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
     "shortName": "Prepayment for Purchase of a Property (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c110",
      "decimals": "-4",
      "lang": null,
      "name": "us-gaap:SupplementalDeferredPurchasePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c122",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LoansPayableToBankCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "067 - Disclosure - Short-Term Bank Loans (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails",
     "shortName": "Short-Term Bank Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c122",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LoansPayableToBankCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "068 - Disclosure - Short-Term Bank Loans (Details) - Schedule of short-term bank loans",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable",
     "shortName": "Short-Term Bank Loans (Details) - Schedule of short-term bank loans",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c110",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationRelatedPartyDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "069 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c110",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationRelatedPartyDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c136",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070 - Disclosure - Related Party Transactions (Details) - Schedule of nature of relationships with related parties",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable",
     "shortName": "Related Party Transactions (Details) - Schedule of nature of relationships with related parties",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c136",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfDueFromRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromOtherRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "071 - Disclosure - Related Party Transactions (Details) - Schedule of due from related parties",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable",
     "shortName": "Related Party Transactions (Details) - Schedule of due from related parties",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfDueFromRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromOtherRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfDueToRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "072 - Disclosure - Related Party Transactions (Details) - Schedule of due to related parties",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable",
     "shortName": "Related Party Transactions (Details) - Schedule of due to related parties",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfDueToRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "073 - Disclosure - Taxes (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails",
     "shortName": "Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "074 - Disclosure - Taxes (Details) - Schedule of components of the income tax provision (benefit)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable",
     "shortName": "Taxes (Details) - Schedule of components of the income tax provision (benefit)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "075 - Disclosure - Taxes (Details) - Schedule of table reconciles the china statutory rates to the company\u2019s effective tax rate",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable",
     "shortName": "Taxes (Details) - Schedule of table reconciles the china statutory rates to the company\u2019s effective tax rate",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "076 - Disclosure - Taxes (Details) - Schedule of deferred tax assets",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable",
     "shortName": "Taxes (Details) - Schedule of deferred tax assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfTaxPayableTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedIncomeTaxesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "077 - Disclosure - Taxes (Details) - Schedule of taxes payable",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable",
     "shortName": "Taxes (Details) - Schedule of taxes payable",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfTaxPayableTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedIncomeTaxesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignFinancialInstitutionsMandatedDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "078 - Disclosure - Concentrations (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails",
     "shortName": "Concentrations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignFinancialInstitutionsMandatedDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Organization and Business Description",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription",
     "shortName": "Organization and Business Description",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "079 - Disclosure - Shareholders' Equity (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SharesOutstanding",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalExpenditureDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalExpenditureDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081 - Disclosure - Segment Reporting (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails",
     "shortName": "Segment Reporting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfOtherPropertyOperatingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "082 - Disclosure - Segment Reporting (Details) - Schedule of revenue by product source",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable",
     "shortName": "Segment Reporting (Details) - Schedule of revenue by product source",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfOtherPropertyOperatingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "upc:SubtotalOfTCMDProductsSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "083 - Disclosure - Segment Reporting (Details) - Schedule of total revenues by product categories",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable",
     "shortName": "Segment Reporting (Details) - Schedule of total revenues by product categories",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "upc:SubtotalOfTCMDProductsSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "084 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "upc:MinorityInterestsOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "085 - Disclosure - Condensed Financial Information of the Parent Company (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails",
     "shortName": "Condensed Financial Information of the Parent Company (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c2",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "upc:MinorityInterestsOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c217",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "086 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
     "shortName": "Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c217",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c217",
      "decimals": "6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "087 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets (Parentheticals)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals",
     "shortName": "Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c217",
      "decimals": "6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c219",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "088 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of income and comprehensive income",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable",
     "shortName": "Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of income and comprehensive income",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c219",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c219",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "089 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of cash flows",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable",
     "shortName": "Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of cash flows",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_universe.htm",
      "contextRef": "c219",
      "decimals": "0",
      "lang": null,
      "name": "upc:EquityInEarningsOfSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 75,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "PRC [Member]"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "domainItemType"
    },
    "country_HK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HONG KONG",
        "terseLabel": "Hong Kong [Member]"
       }
      }
     },
     "localname": "HK",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAYMAN ISLANDS",
        "terseLabel": "Cayman [Member]"
       }
      }
     },
     "localname": "KY",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact",
        "verboseLabel": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address",
        "terseLabel": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Date of Incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CondensedBalanceSheetStatementTable": {
     "auth_ref": [
      "r229",
      "r529",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet Statement [Table]"
       }
      }
     },
     "localname": "CondensedBalanceSheetStatementTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedBalanceSheetStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Balance Sheet Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedBalanceSheetStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedCashFlowStatementTable": {
     "auth_ref": [
      "r229",
      "r538",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.",
        "label": "Condensed Cash Flow Statement [Table]"
       }
      }
     },
     "localname": "CondensedCashFlowStatementTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedCashFlowStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Cash Flow Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedCashFlowStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_CondensedStatementOfComprehensiveIncomeTable": {
     "auth_ref": [
      "r229",
      "r529",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.",
        "label": "Condensed Statement of Comprehensive Income [Table]"
       }
      }
     },
     "localname": "CondensedStatementOfComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedStatementOfComprehensiveIncomeTableTextBlock": {
     "auth_ref": [
      "r601",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.",
        "label": "Condensed Statement of Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of parent company statements of income and comprehensive income"
       }
      }
     },
     "localname": "CondensedStatementOfComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CondensedStatementOfIncomeCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Statement of Income Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedStatementOfIncomeCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r296",
      "r561",
      "r625",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r383",
      "r461",
      "r495",
      "r521",
      "r522",
      "r559",
      "r562",
      "r568",
      "r623",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r383",
      "r461",
      "r495",
      "r521",
      "r522",
      "r559",
      "r562",
      "r568",
      "r623",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Lower [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r296",
      "r561",
      "r625",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r457",
      "r461",
      "r495",
      "r521",
      "r522",
      "r559",
      "r562",
      "r568",
      "r619",
      "r623",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r457",
      "r461",
      "r495",
      "r521",
      "r522",
      "r559",
      "r562",
      "r568",
      "r619",
      "r623",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r601",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of parent company balance sheets"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": {
     "auth_ref": [
      "r601",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.",
        "label": "Condensed Cash Flow Statement [Table Text Block]",
        "terseLabel": "Schedule of parent company statements of cash flows"
       }
      }
     },
     "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r293",
      "r294",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r527",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r560",
      "r567",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r293",
      "r294",
      "r505",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r527",
      "r528",
      "r560",
      "r567",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r607",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_AccountsReceivableBeforeGrossValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable Before Gross Value",
        "terseLabel": "Balance"
       }
      }
     },
     "localname": "AccountsReceivableBeforeGrossValue",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_AccountsReceivableDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable, description.",
        "label": "Accounts Receivable Description",
        "terseLabel": "Accounts receivable description"
       }
      }
     },
     "localname": "AccountsReceivableDescription",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_AccountsReceivableNetPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable Net Percentage",
        "terseLabel": "Percentage of subsequent collection"
       }
      }
     },
     "localname": "AccountsReceivableNetPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_AddPurchaseWealthManagementFinancialProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase wealth management financial products.",
        "label": "Add Purchase Wealth Management Financial Products",
        "terseLabel": "Add: purchase wealth management financial products"
       }
      }
     },
     "localname": "AddPurchaseWealthManagementFinancialProducts",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvestmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_AdditionalContractPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional contract price percentage.",
        "label": "Additional Contract Price Percentage",
        "terseLabel": "Additional contract price percentage"
       }
      }
     },
     "localname": "AdditionalContractPricePercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Cash Flows From Operating Activities Abstract",
        "terseLabel": "Adjustments to reconcile net cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetCashFlowsFromOperatingActivitiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_AdvancesToSuppliersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances To Suppliers [Abstract]"
       }
      }
     },
     "localname": "AdvancesToSuppliersAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_AdvancesToSuppliersNetPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advances to suppliers net",
        "label": "Advances To Suppliers Net Policy Text Block",
        "terseLabel": "Advances to suppliers, net"
       }
      }
     },
     "localname": "AdvancesToSuppliersNetPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_AdvancesToSuppliersTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the advances to suppliers.",
        "label": "Advances To Suppliers Text Block",
        "terseLabel": "ADVANCE TO SUPPLIERS"
       }
      }
     },
     "localname": "AdvancesToSuppliersTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_AdvancetoSuppliersTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanceto Suppliers Tables Line Items",
        "terseLabel": "Advances To Suppliers [Abstract]"
       }
      }
     },
     "localname": "AdvancetoSuppliersTablesLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_AdvancetoSuppliersTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance to Suppliers (Tables) [Table]"
       }
      }
     },
     "localname": "AdvancetoSuppliersTablesTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_AllowanceForDoubtfulAccountsReceivablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance For Doubtful Accounts Receivable Percentage",
        "terseLabel": "Percentage of subsequent collection"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivablePercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_AllowanceForUncollectableBalancesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for uncollectable balances amount.",
        "label": "Allowance For Uncollectable Balances Amount",
        "terseLabel": "Allowance for uncollectable balance amount"
       }
      }
     },
     "localname": "AllowanceForUncollectableBalancesAmount",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_AmortizationExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Expense Member",
        "terseLabel": "Amortization Expense [Member]"
       }
      }
     },
     "localname": "AmortizationExpenseMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_AmountOfRegisteredCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of registered capital.",
        "label": "Amount Of Registered Capital",
        "terseLabel": "Registered capital"
       }
      }
     },
     "localname": "AmountOfRegisteredCapital",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_AssetAcquisitionPriceOfAcquisitionsExpected": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.",
        "label": "Asset Acquisition Price Of Acquisitions Expected",
        "terseLabel": "Price amount"
       }
      }
     },
     "localname": "AssetAcquisitionPriceOfAcquisitionsExpected",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_BankOfCommunicationsCoLtdAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Of Communications Co Ltd Abstract",
        "terseLabel": "Bank of Communications Co., Ltd"
       }
      }
     },
     "localname": "BankOfCommunicationsCoLtdAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_CapitalContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital contribution.",
        "label": "Capital Contribution",
        "terseLabel": "Capital contribution"
       }
      }
     },
     "localname": "CapitalContribution",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_CapitalExpenditure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of capital expenditure.",
        "label": "Capital Expenditure",
        "terseLabel": "Additional capital expenditure"
       }
      }
     },
     "localname": "CapitalExpenditure",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_CapitalExpenditureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditure Member",
        "terseLabel": "Capital Expenditure [Member]"
       }
      }
     },
     "localname": "CapitalExpenditureMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalent Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "CASH, end of year",
        "periodStartLabel": "CASH, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_CashDividendDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of dividends.",
        "label": "Cash Dividend Description",
        "terseLabel": "Description of dividends"
       }
      }
     },
     "localname": "CashDividendDescription",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_CashDividendsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Dividends Member",
        "terseLabel": "Cash dividends [Member]"
       }
      }
     },
     "localname": "CashDividendsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CashFlowsFromFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities Abstract",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowsFromFinancingActivitiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_CashFlowsFromInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities Abstract",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowsFromInvestingActivitiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_CashFlowsFromOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities Abstract",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowsFromOperatingActivitiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_CashLentToSubsidiaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Cash lent to subsidiaries.",
        "label": "Cash Lent To Subsidiaries",
        "negatedLabel": "Cash lent to subsidiaries"
       }
      }
     },
     "localname": "CashLentToSubsidiaries",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_ChenyuanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chenyuan Member",
        "terseLabel": "Chenyuan [Member]"
       }
      }
     },
     "localname": "ChenyuanMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_ConcentrationRiskThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Threshold Percentage",
        "terseLabel": "Total revenue percentage"
       }
      }
     },
     "localname": "ConcentrationRiskThresholdPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_ConcentrationsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations (Details) [Line Items]"
       }
      }
     },
     "localname": "ConcentrationsDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ConcentrationsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations (Details) [Table]"
       }
      }
     },
     "localname": "ConcentrationsDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ContractAssetsAndLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Assets And Liabilities Policy Text Block",
        "terseLabel": "Contract Assets and Liabilities"
       }
      }
     },
     "localname": "ContractAssetsAndLiabilitiesPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_ContractPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract price percentage.",
        "label": "Contract Price Percentage",
        "terseLabel": "Contract price percentage"
       }
      }
     },
     "localname": "ContractPricePercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_CorporateSegmentFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Segment Five [Member].",
        "label": "Corporate Segment Five Member",
        "terseLabel": "Medical instruments [Member]"
       }
      }
     },
     "localname": "CorporateSegmentFiveMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CorporateSegmentFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Segment Four [Member].",
        "label": "Corporate Segment Four Member",
        "terseLabel": "Traditional Chinese medicine pieces [Member]"
       }
      }
     },
     "localname": "CorporateSegmentFourMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CorporateSegmentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Segment One [Member].",
        "label": "Corporate Segment One Member",
        "terseLabel": "Other chronic condition treatment products [Member]"
       }
      }
     },
     "localname": "CorporateSegmentOneMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CorporateSegmentSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Segment Six [Member].",
        "label": "Corporate Segment Six Member",
        "terseLabel": "Dietary supplements [Member]"
       }
      }
     },
     "localname": "CorporateSegmentSixMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CorporateSegmentThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Segment Three [Member].",
        "label": "Corporate Segment Three Member",
        "terseLabel": "Biochemical drugs [Member]"
       }
      }
     },
     "localname": "CorporateSegmentThreeMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CorporateSegmentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Segment Two [Member].",
        "label": "Corporate Segment Two Member",
        "terseLabel": "Cold and flu medicines [Member]"
       }
      }
     },
     "localname": "CorporateSegmentTwoMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CurrentAssetsAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets Abstract0",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract0",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_CustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Member",
        "terseLabel": "Customer [Member]"
       }
      }
     },
     "localname": "CustomerMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CustomersOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customers One Member",
        "terseLabel": "Customer One [Member]"
       }
      }
     },
     "localname": "CustomersOneMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_DeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Abstract",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_DescriptionOfAverageRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of average rate.",
        "label": "Description Of Average Rate",
        "terseLabel": "Average rate"
       }
      }
     },
     "localname": "DescriptionOfAverageRate",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_DescriptionOfYearEndSpotRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of year end spot rate.",
        "label": "Description Of Year End Spot Rate",
        "terseLabel": "Year-end spot rate"
       }
      }
     },
     "localname": "DescriptionOfYearEndSpotRate",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_DisaggregationOfRevenuesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation Of Revenues Policy Text Block",
        "terseLabel": "Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenuesPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_EmployeeDefinedContributionPlanPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of employee defined contribution plan.",
        "label": "Employee Defined Contribution Plan Policy Text Block",
        "terseLabel": "Employee Defined Contribution Plan"
       }
      }
     },
     "localname": "EmployeeDefinedContributionPlanPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_EntityIncorporationDateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity incorporation date description.",
        "label": "Entity Incorporation Date Description",
        "terseLabel": "Entity incorporation date description"
       }
      }
     },
     "localname": "EntityIncorporationDateDescription",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_EquityInEarningsOfSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity in earnings of subsidiary.",
        "label": "Equity In Earnings Of Subsidiary",
        "terseLabel": "Equity in earnings of subsidiary"
       }
      }
     },
     "localname": "EquityInEarningsOfSubsidiary",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_EquityInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity interest.",
        "label": "Equity Interest",
        "terseLabel": "Equity interest rate"
       }
      }
     },
     "localname": "EquityInterest",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_EquityInterestOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity interest ownership percentage.",
        "label": "Equity Interest Ownership Percentage",
        "terseLabel": "Equity interest ownership percentage"
       }
      }
     },
     "localname": "EquityInterestOwnershipPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_EquityMethodInvestmentOwnershipsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity ownership percentage.",
        "label": "Offering price percentage",
        "netLabel": "Ownership percentage",
        "terseLabel": "Equity ownership percentage",
        "verboseLabel": "Percentage of ownership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipsPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foshan Shangyu Investment Holding Co Ltd Foshan Shangyu Member",
        "terseLabel": "Foshan Shangyu Investment Holding Co., Ltd (\u201cFoshan Shangyu\u201d) [Member]"
       }
      }
     },
     "localname": "FoshanShangyuInvestmentHoldingCoLtdFoshanShangyuMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_FoshanShangyuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foshan Shangyu Member",
        "terseLabel": "Foshan Shangyu [Member]"
       }
      }
     },
     "localname": "FoshanShangyuMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_From10To12MonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "From10 To12 Months Member",
        "terseLabel": "From 10 to 12 months [Member]"
       }
      }
     },
     "localname": "From10To12MonthsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_From4To6MonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "From4 To6 Months Member",
        "terseLabel": "From 4 to 6 months [Member]"
       }
      }
     },
     "localname": "From4To6MonthsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_From7To9MonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "From7 To9 Months Member",
        "terseLabel": "From 7 to 9 months\t[Member]"
       }
      }
     },
     "localname": "From7To9MonthsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Greatest Group China Financial Management Limited Greatest Group Member",
        "terseLabel": "Greatest Group (China) Financial Management Limited (\u201cGreatest Group\u201d) [Member]"
       }
      }
     },
     "localname": "GreatestGroupChinaFinancialManagementLimitedGreatestGroupMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_GreatestGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Greatest Group Member",
        "terseLabel": "Greatest Group [Member]"
       }
      }
     },
     "localname": "GreatestGroupMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_GubenYanlingPillMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guben Yanling Pill Member",
        "terseLabel": "Guben Yanling Pill [Member]"
       }
      }
     },
     "localname": "GubenYanlingPillMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_HeldToMaturityInvestmentDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Held To Maturity Investment Disclosure Text Block",
        "terseLabel": "SHORT-TERM INVESTMENTS"
       }
      }
     },
     "localname": "HeldToMaturityInvestmentDisclosureTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_HeldToMaturityInvestmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Held To Maturity Investment Policy Text Block",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "HeldToMaturityInvestmentPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_IncomeFromOperation": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Income From Operation",
        "negatedTotalLabel": "Income from operations"
       }
      }
     },
     "localname": "IncomeFromOperation",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets [Line Items]"
       }
      }
     },
     "localname": "IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets [Table]"
       }
      }
     },
     "localname": "IntangibleAssetsNetDetailsScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_InvestmentInEquitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment In Equity Securities",
        "label": "Investment In Equity Securities",
        "terseLabel": "Investment in equity securities"
       }
      }
     },
     "localname": "InvestmentInEquitySecurities",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_JiangxiLulingRuralCommercialBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jiangxi Luling Rural Commercial Bank Member",
        "terseLabel": "LRC Bank [Member]",
        "verboseLabel": "Jiangxi Luling Rural Commercial Bank [Member]"
       }
      }
     },
     "localname": "JiangxiLulingRuralCommercialBankMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_JiangxiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jiangxi Member",
        "terseLabel": "Jiangxi [Member]"
       }
      }
     },
     "localname": "JiangxiMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_JiangxiUniverseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jiangxi Universe Member",
        "terseLabel": "Jiangxi Universe [Member]"
       }
      }
     },
     "localname": "JiangxiUniverseMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_JxRcbBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jx Rcb Bank Member",
        "terseLabel": "JX RCB Bank [Member]"
       }
      }
     },
     "localname": "JxRcbBankMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_LessThan3MonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less Than3 Months Member",
        "terseLabel": "Less than 3 months\t[Member]"
       }
      }
     },
     "localname": "LessThan3MonthsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable To Jiangxi Luling Rural Commercial Bank Lrc Bank Abstract",
        "terseLabel": "Loans payable to Jiangxi Luling Rural Commercial Bank (\u201cLRC Bank\u201d):"
       }
      }
     },
     "localname": "LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_MaterialPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Material price percentage.",
        "label": "Material Price Percentage",
        "terseLabel": "Material price percentage"
       }
      }
     },
     "localname": "MaterialPricePercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_MaturityGreaterThan90DaysFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity Greater Than90 Days Four Member",
        "terseLabel": "Maturity date on June 24, 2023, interest rate 4.20% per annum [Member]"
       }
      }
     },
     "localname": "MaturityGreaterThan90DaysFourMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_MaturityGreaterThan90DaysOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity Greater Than90 Days One Member",
        "terseLabel": "Maturity date on March 13, 2023, interest rate 4.62% per annum [Member]"
       }
      }
     },
     "localname": "MaturityGreaterThan90DaysOneMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_MaturityGreaterThan90DaysThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity Greater Than90 Days Three Member",
        "terseLabel": "Maturity date on June 30, 2022, interest rate 4.50% per annum [Member]"
       }
      }
     },
     "localname": "MaturityGreaterThan90DaysThreeMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_MaturityGreaterThan90DaysTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity Greater Than90 Days Two Member",
        "terseLabel": "Maturity date on June 14, 2023, interest rate 4.62% per annum [Member]"
       }
      }
     },
     "localname": "MaturityGreaterThan90DaysTwoMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_MinorityInterestsOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary exceeded percentage.",
        "label": "Minority Interests Ownership Percentage By Parent",
        "terseLabel": "Subsidiary exceeded percentage"
       }
      }
     },
     "localname": "MinorityInterestsOwnershipPercentageByParent",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_MrGangLaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Gang Lai Member",
        "terseLabel": "Mr. Gang Lai [Member]"
       }
      }
     },
     "localname": "MrGangLaiMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_MrsLinYangMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mrs Lin Yang Member",
        "terseLabel": "Mrs. Lin Yang [Member]"
       }
      }
     },
     "localname": "MrsLinYangMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_MsLinYangMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ms Lin Yang Member",
        "terseLabel": "Ms. Lin Yang [Member]"
       }
      }
     },
     "localname": "MsLinYangMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_NameAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Abstract",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "NameAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_NameAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Abstract0",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "NameAbstract0",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_NonCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Current Assets Abstract",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NonCurrentAssetsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_OfficeAndElectricEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office And Electric Equipment Member",
        "terseLabel": "Office and electric equipment [Member]"
       }
      }
     },
     "localname": "OfficeAndElectricEquipmentMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_OfficeSpaceSquareMeters": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space Square meters.",
        "label": "Office Space Square Meters",
        "terseLabel": "Office space square meters"
       }
      }
     },
     "localname": "OfficeSpaceSquareMeters",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "upc_OptionToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to purchase additional shares.",
        "label": "Option To Purchase Additional Shares",
        "terseLabel": "Option to purchase additional shares"
       }
      }
     },
     "localname": "OptionToPurchaseAdditionalShares",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "upc_OrdinarySharesOutstandingDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares outstanding description.",
        "label": "Ordinary Shares Outstanding Description",
        "terseLabel": "Ordinary shares outstanding description"
       }
      }
     },
     "localname": "OrdinarySharesOutstandingDescription",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_OrdinarySharesParValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares par value.",
        "label": "Ordinary Shares Par Value",
        "terseLabel": "Ordinary shares par value (in Dollars per share)"
       }
      }
     },
     "localname": "OrdinarySharesParValue",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "upc_OrganizationandBusinessDescriptionDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business Description (Details) [Line Items]"
       }
      }
     },
     "localname": "OrganizationandBusinessDescriptionDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_OrganizationandBusinessDescriptionDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business Description (Details) [Table]"
       }
      }
     },
     "localname": "OrganizationandBusinessDescriptionDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_OriginalSharesParValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original shares par value.",
        "label": "Original Shares Par Value",
        "terseLabel": "Original shares par value (in Dollars per share)"
       }
      }
     },
     "localname": "OriginalSharesParValue",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "upc_OtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Abstract",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_OtherIncomeExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income Expenses Abstract",
        "terseLabel": "Other income (expenses)"
       }
      }
     },
     "localname": "OtherIncomeExpensesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_OtherIncomeExpensesAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income Expenses Abstract0",
        "terseLabel": "Other income (expenses):"
       }
      }
     },
     "localname": "OtherIncomeExpensesAbstract0",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_Over1YearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over1 Year Member",
        "terseLabel": "Over 1 year [Member]"
       }
      }
     },
     "localname": "Over1YearMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_OwnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership Member",
        "terseLabel": "Ownership [Member]"
       }
      }
     },
     "localname": "OwnershipMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_OwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership Percentage",
        "terseLabel": "% of Ownership"
       }
      }
     },
     "localname": "OwnershipPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PRCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PRCMember",
        "terseLabel": "PRC [Member]"
       }
      }
     },
     "localname": "PRCMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_PayableDeliveryPropertyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payable delivery property percentage.",
        "label": "Payable Delivery Property Percentage",
        "terseLabel": "Payable delivery property percentage"
       }
      }
     },
     "localname": "PayableDeliveryPropertyPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_PaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment term.",
        "label": "Payment Term",
        "terseLabel": "Payment term"
       }
      }
     },
     "localname": "PaymentTerm",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "upc_PercentageOfAdvancePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of advance payment.",
        "label": "Percentage Of Advance Payment",
        "terseLabel": "Percentage of advance payment"
       }
      }
     },
     "localname": "PercentageOfAdvancePayment",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_PercentageOfPrepayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayment.",
        "label": "Percentage Of Prepayment",
        "terseLabel": "Percentage of prepayment"
       }
      }
     },
     "localname": "PercentageOfPrepayment",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_PercentageOfSubsequentCollection": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Subsequent Collection",
        "terseLabel": "Percentage of subsequent collection"
       }
      }
     },
     "localname": "PercentageOfSubsequentCollection",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_PercentageOfVatRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of VATrate.",
        "label": "Percentage Of Vat Rate",
        "terseLabel": "Percentage of vat rate"
       }
      }
     },
     "localname": "PercentageOfVatRate",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_PlaceOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Place of incorporation or establishment.",
        "label": "Place Of Incorporation",
        "terseLabel": "Place of Incorporation"
       }
      }
     },
     "localname": "PlaceOfIncorporation",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PreferentialTaxTreatmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferential tax treatment, description.",
        "label": "Preferential Tax Treatment Description",
        "terseLabel": "Preferential tax treatment, description"
       }
      }
     },
     "localname": "PreferentialTaxTreatmentDescription",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_Prepayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepayment.",
        "label": "Prepayment",
        "terseLabel": "Prepayment"
       }
      }
     },
     "localname": "Prepayment",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PrepaymentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment amount.",
        "label": "Prepayment Amount",
        "terseLabel": "Prepayment amount"
       }
      }
     },
     "localname": "PrepaymentAmount",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PrepaymentForAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment For Acquisition Abstract"
       }
      }
     },
     "localname": "PrepaymentForAcquisitionAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentForAcquisitionCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of prepayment for acquisition.",
        "label": "Prepayment For Acquisition Current",
        "terseLabel": "Prepayment for acquisition"
       }
      }
     },
     "localname": "PrepaymentForAcquisitionCurrent",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PrepaymentForAcquisitionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment For Acquisition Text Block",
        "terseLabel": "PREPAYMENT FOR ACQUISITION"
       }
      }
     },
     "localname": "PrepaymentForAcquisitionTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_PrepaymentForAdvertistingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Advertisting [Abstract]"
       }
      }
     },
     "localname": "PrepaymentForAdvertistingAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentForAdvertistingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment For Advertisting Text Block",
        "terseLabel": "PREPAYMENT FOR ADVERTISTING"
       }
      }
     },
     "localname": "PrepaymentForAdvertistingTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_PrepaymentForConstructionInProgressAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for CIP Project [Abstract]"
       }
      }
     },
     "localname": "PrepaymentForConstructionInProgressAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentForConstructionInProgressTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for prepayment for construction in progress.",
        "label": "Prepayment For Construction In Progress Text Block",
        "terseLabel": "PREPAYMENT FOR CIP PROJECT"
       }
      }
     },
     "localname": "PrepaymentForConstructionInProgressTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_PrepaymentForPurchaseOfAPropertyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Purchase of a Property [Abstract]"
       }
      }
     },
     "localname": "PrepaymentForPurchaseOfAPropertyAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentForPurchaseOfAPropertyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment For Purchase Of AProperty Text Block",
        "terseLabel": "PREPAYMENT FOR PURCHASE OF A PROPERTY"
       }
      }
     },
     "localname": "PrepaymentForPurchaseOfAPropertyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_PrepaymentforAcquisitionDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Acquisition (Details) [Line Items]"
       }
      }
     },
     "localname": "PrepaymentforAcquisitionDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentforAcquisitionDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Acquisition (Details) [Table]"
       }
      }
     },
     "localname": "PrepaymentforAcquisitionDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentforAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Acquisition [Abstract]"
       }
      }
     },
     "localname": "PrepaymentforAcquisitionLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentforAcquisitionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Acquisition [Table]"
       }
      }
     },
     "localname": "PrepaymentforAcquisitionTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentforCIPProjectDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for CIP Project (Details) [Line Items]"
       }
      }
     },
     "localname": "PrepaymentforCIPProjectDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for CIP Project (Details) - Schedule of future minimum capital expenditures [Line Items]"
       }
      }
     },
     "localname": "PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for CIP Project (Details) - Schedule of future minimum capital expenditures [Table]"
       }
      }
     },
     "localname": "PrepaymentforCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentforCIPProjectDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for CIP Project (Details) [Table]"
       }
      }
     },
     "localname": "PrepaymentforCIPProjectDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentsForConstructionInProgress": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments for construction in progress.",
        "label": "Prepayments For Construction In Progress",
        "terseLabel": "Prepayments for construction in progress"
       }
      }
     },
     "localname": "PrepaymentsForConstructionInProgress",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of prepayments made to a related party for purchase of property.",
        "label": "Prepayments Made To ARelated Party For Purchase Of Property",
        "negatedLabel": "Prepayments made to a related party for purchase of property"
       }
      }
     },
     "localname": "PrepaymentsMadeToARelatedPartyForPurchaseOfProperty",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepayments made to a related party for purchase of property.",
        "label": "Prepayments Made To ARelated Party For Purchase Of Property Non Current",
        "terseLabel": "Prepayments made to a related party for purchase of property"
       }
      }
     },
     "localname": "PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PrincipalActivities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal activities.",
        "label": "Principal Activities",
        "terseLabel": "Principal Activities"
       }
      }
     },
     "localname": "PrincipalActivities",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from (prepayments for) related parties borrowings.",
        "label": "Proceeds Fromprepayments For Related Parties Borrowings",
        "negatedLabel": "Proceeds from (prepayments for) related parties borrowings"
       }
      }
     },
     "localname": "ProceedsFromprepaymentsForRelatedPartiesBorrowings",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of property equipment estimated useful life during the period.",
        "label": "Property And Equipment Estimated Useful Life Table Text Block",
        "terseLabel": "Schedule of property, plant and equipment estimated useful lives"
       }
      }
     },
     "localname": "PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_PublicOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering price.",
        "label": "Public Offering Price",
        "terseLabel": "Public offering price (in Dollars per share)"
       }
      }
     },
     "localname": "PublicOfferingPrice",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "upc_RedemptionOfShorttermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption of short-term investments.",
        "label": "Redemption Of Shortterm Investments",
        "terseLabel": "Redemption of short-term investments"
       }
      }
     },
     "localname": "RedemptionOfShorttermInvestments",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) - Schedule of due from related parties [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) - Schedule of due from related parties [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) - Schedule of due to related parties [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) - Schedule of due to related parties [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_RemainingCapitalContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining capital contribution amount.",
        "label": "Remaining Capital Contribution",
        "terseLabel": "Remaining capital contribution"
       }
      }
     },
     "localname": "RemainingCapitalContribution",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_ReorganizationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reorganization shares.",
        "label": "Reorganization Shares",
        "terseLabel": "Reorganization shares"
       }
      }
     },
     "localname": "ReorganizationShares",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "upc_ReserveIsEqualPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve is equal percentage.",
        "label": "Reserve Is Equal Percentage",
        "terseLabel": "Reserve is equal percentage"
       }
      }
     },
     "localname": "ReserveIsEqualPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_RestrictedNetAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted net assets.",
        "label": "Restricted Net Assets",
        "terseLabel": "Restricted net assets (in Dollars)"
       }
      }
     },
     "localname": "RestrictedNetAssets",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SalesOfTcmdProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Of Tcmd Products Abstract",
        "terseLabel": "Sales of TCMD products:"
       }
      }
     },
     "localname": "SalesOfTcmdProductsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SalesOfThirdPartyProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Of Third Party Products Abstract",
        "terseLabel": "Sales of third-party products"
       }
      }
     },
     "localname": "SalesOfThirdPartyProductsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfAccountsReceivableConsistsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Receivable Consists [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAccountsReceivableConsistsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfAdvancesToSuppliersNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of advances to suppliers net.",
        "label": "Schedule Of Advances To Suppliers Net",
        "terseLabel": "Schedule of advances to suppliers net"
       }
      }
     },
     "localname": "ScheduleOfAdvancesToSuppliersNet",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_ScheduleOfAdvancesToSuppliersNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Advances to Suppliers Net [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAdvancesToSuppliersNetAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Allowance for Doubtful Accounts [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAllowanceForDoubtfulAccountsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of The Income Tax Provision Benefit Abstract"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfCurrencyExchangeRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of currency exchange rate [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfCurrencyExchangeRateAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Deferred Tax Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfDueFromRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Due From Related Parties Abstract"
       }
      }
     },
     "localname": "ScheduleOfDueFromRelatedPartiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfDueFromRelatedPartiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Due From Related Parties Table Text Block",
        "terseLabel": "Schedule of due from related parties"
       }
      }
     },
     "localname": "ScheduleOfDueFromRelatedPartiesTableTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_ScheduleOfDueToRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Due To Related Parties Abstract"
       }
      }
     },
     "localname": "ScheduleOfDueToRelatedPartiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfDueToRelatedPartiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Due To Related Parties Table Text Block",
        "terseLabel": "Schedule of due to related parties"
       }
      }
     },
     "localname": "ScheduleOfDueToRelatedPartiesTableTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Future Amortization Expense For Intangible Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Future Minimum Capital Expenditures Abstract"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumCapitalExpendituresAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Estimated Useful Lives Abstract"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfIntangibleAssetsNetConsistAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Net Consist Abstract"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsNetConsistAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfInventoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inventory [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInventoryAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Nature Of Relationships With Related Parties Abstract"
       }
      }
     },
     "localname": "ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfParentCompanyBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Parent Company Balance Sheets Abstract"
       }
      }
     },
     "localname": "ScheduleOfParentCompanyBalanceSheetsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Parent Company Statements Of Cash Flows Abstract"
       }
      }
     },
     "localname": "ScheduleOfParentCompanyStatementsOfCashFlowsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Parent Company Statements Of Income And Comprehensive Income Abstract"
       }
      }
     },
     "localname": "ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Lives Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Net Consists Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfRevenueByProductSourceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenue By Product Source Abstract"
       }
      }
     },
     "localname": "ScheduleOfRevenueByProductSourceAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfShortTermBankLoansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Short Term Bank Loans Abstract"
       }
      }
     },
     "localname": "ScheduleOfShortTermBankLoansAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of short-term investments [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfShortTermInvestmentsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfSubsidiariesOfTheCompanyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Subsidiaries Of The Company Abstract"
       }
      }
     },
     "localname": "ScheduleOfSubsidiariesOfTheCompanyAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Table Reconciles the China Statutory Rates to the Companys Effective Tax Rate [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfTaxPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of tax payable during the period.",
        "label": "Schedule Of Tax Payable Table Text Block",
        "terseLabel": "Schedule of taxes payable"
       }
      }
     },
     "localname": "ScheduleOfTaxPayableTableTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_ScheduleOfTaxesPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Taxes Payable [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTaxesPayableAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of The Company SAccounts Receivable And Subsequent Collection Abstract"
       }
      }
     },
     "localname": "ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Total Revenues By Product Categories Abstract"
       }
      }
     },
     "localname": "ScheduleOfTotalRevenuesByProductCategoriesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "xbrltype": "stringItemType"
    },
    "upc_ShareholdersEquityAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders Equity Abstract0",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "ShareholdersEquityAbstract0",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ShareholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ShareholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SharesIssued01": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares Issued01",
        "terseLabel": "Shares issued (in Shares)"
       }
      }
     },
     "localname": "SharesIssued01",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "upc_ShortTermBankLoansDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Bank Loans (Details) [Line Items]"
       }
      }
     },
     "localname": "ShortTermBankLoansDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ShortTermBankLoansDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Bank Loans (Details) [Table]"
       }
      }
     },
     "localname": "ShortTermBankLoansDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ShorttermInvestmentIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shortterm Investment Income",
        "negatedLabel": "Short-term investments (loss) income"
       }
      }
     },
     "localname": "ShorttermInvestmentIncome",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_ShorttermInvestmentsIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term investments income.",
        "label": "Shortterm Investments Income",
        "terseLabel": "Short-term investments income"
       }
      }
     },
     "localname": "ShorttermInvestmentsIncome",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_StatementOfCashFlowsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of statement of cash flows policy text block.",
        "label": "Statement Of Cash Flows Policy Text Block",
        "terseLabel": "Statement of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_StatutoryReserve": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "StatutoryReserve",
        "label": "Statutory Reserve",
        "terseLabel": "Statutory reserve"
       }
      }
     },
     "localname": "StatutoryReserve",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_StatutoryReserveAndRestrictedNetAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory Reserve And Restricted Net Assets Member",
        "terseLabel": "Statutory Reserve and Restricted Net Assets [Member]"
       }
      }
     },
     "localname": "StatutoryReserveAndRestrictedNetAssetsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_StatutoryReservesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory Reserves Member",
        "terseLabel": "Statutory reserve"
       }
      }
     },
     "localname": "StatutoryReservesMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_StatutorySurplusPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statutory surplus percentage.",
        "label": "Statutory Surplus Percentage",
        "terseLabel": "Statutory surplus percentage"
       }
      }
     },
     "localname": "StatutorySurplusPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Capitalized initial public offering costs.",
        "label": "Stock Issued During Period Value Capitalized Initial Public Offering Costs",
        "terseLabel": "Capitalized initial public offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SubsequentCollection": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Collection",
        "terseLabel": "Subsequent collection"
       }
      }
     },
     "localname": "SubsequentCollection",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SubtotalOfTCMDProductsSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subtotal Of TCMDProducts Sales",
        "terseLabel": "Sub-total of TCMD products sales"
       }
      }
     },
     "localname": "SubtotalOfTCMDProductsSales",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SubtotalOfThirdpartyProductsSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subtotal of third-party products sales.",
        "label": "Subtotal Of Thirdparty Products Sales",
        "terseLabel": "Subtotal of third-party products sales"
       }
      }
     },
     "localname": "SubtotalOfThirdpartyProductsSales",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of property, plant and equipment estimated useful lives [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentestimatedusefullivesTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SunsequentCollectionAccountsReceivableNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sunsequent Collection Accounts Receivable Net",
        "terseLabel": "Subsequent collection"
       }
      }
     },
     "localname": "SunsequentCollectionAccountsReceivableNet",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SunsequentCollectionAllowanceForDoubtfulAccounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sunsequent Collection Allowance For Doubtful Accounts",
        "terseLabel": "Subsequent collection"
       }
      }
     },
     "localname": "SunsequentCollectionAllowanceForDoubtfulAccounts",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SunsequentCollectionsTotalGrossAccountsReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sunsequent Collections Total Gross Accounts Receivable",
        "terseLabel": "Subsequent collection"
       }
      }
     },
     "localname": "SunsequentCollectionsTotalGrossAccountsReceivable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SupplierOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier One Member",
        "terseLabel": "Supplier One [Member]"
       }
      }
     },
     "localname": "SupplierOneMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_SupplierTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Two Member",
        "terseLabel": "Supplier Two [Member]"
       }
      }
     },
     "localname": "SupplierTwoMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_TaxBenefitPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax benefit percentage.",
        "label": "Tax Benefit Percentage",
        "terseLabel": "Tax benefit percentage"
       }
      }
     },
     "localname": "TaxBenefitPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_TaxesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes (Details) [Line Items]"
       }
      }
     },
     "localname": "TaxesDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes (Details) - Schedule of components of the income tax provision (benefit) [Line Items]"
       }
      }
     },
     "localname": "TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes (Details) - Schedule of components of the income tax provision (benefit) [Table]"
       }
      }
     },
     "localname": "TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_TaxesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes (Details) [Table]"
       }
      }
     },
     "localname": "TaxesDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_TotalGrossAccountsReceivablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Gross Accounts Receivable Percentage",
        "terseLabel": "Percentage of subsequent collection"
       }
      }
     },
     "localname": "TotalGrossAccountsReceivablePercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_TotalRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Revenue Member",
        "terseLabel": "Total Revenue [Member]"
       }
      }
     },
     "localname": "TotalRevenueMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UnderwriterWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter Warrants Member",
        "terseLabel": "Underwriter warrants [Member]"
       }
      }
     },
     "localname": "UnderwriterWarrantsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UniverseHKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universe HKMember",
        "terseLabel": "Universe HK [Member]"
       }
      }
     },
     "localname": "UniverseHKMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UniverseHanheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universe Hanhe Member",
        "terseLabel": "Universe Hanhe [Member]"
       }
      }
     },
     "localname": "UniverseHanheMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UniverseINCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Universe INC.",
        "label": "Universe INCMember",
        "terseLabel": "Universe INC [Member]"
       }
      }
     },
     "localname": "UniverseINCMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UniverseIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universe Inc Member",
        "terseLabel": "Universe Inc [Member]"
       }
      }
     },
     "localname": "UniverseIncMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UniverseTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universe Technology Member",
        "terseLabel": "Universe Technology [Member]"
       }
      }
     },
     "localname": "UniverseTechnologyMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UniverseTradeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universe Trade Member",
        "terseLabel": "Universe Trade [Member]",
        "verboseLabel": "Jiangxi Universe [Member]"
       }
      }
     },
     "localname": "UniverseTradeMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_ValueAddedTaxPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of value added tax.",
        "label": "Value Added Tax Policy Text Block",
        "terseLabel": "Value added tax (\u201cVAT\u201d)"
       }
      }
     },
     "localname": "ValueAddedTaxPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_YunnanFaxiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Yunnan Faxi Member",
        "terseLabel": "Yunnan Faxi [Member]"
       }
      }
     },
     "localname": "YunnanFaxiMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_supplierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "supplier Member",
        "terseLabel": "supplier [Member]"
       }
      }
     },
     "localname": "supplierMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20220930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss of accounts and financing receivables. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, Allowance for Credit Loss",
        "negatedLabel": "Balance"
       }
      }
     },
     "localname": "AccountsAndFinancingReceivableAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r18",
      "r566"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of allowance for doubtful accounts"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableGross": {
     "auth_ref": [
      "r190",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "terseLabel": "Balance"
       }
      }
     },
     "localname": "AccountsReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r190",
      "r298",
      "r299",
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableconsistsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r488",
      "r506"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Balance"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableconsistsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "auth_ref": [
      "r22",
      "r108",
      "r543"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable": {
       "order": 3.0,
       "parentTag": "us-gaap_TaxesPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrual for Taxes Other than Income Taxes, Current",
        "terseLabel": "Other taxes payable"
       }
      }
     },
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r5",
      "r141",
      "r158"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable": {
       "order": 1.0,
       "parentTag": "us-gaap_TaxesPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r98",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r33",
      "r34",
      "r192",
      "r489",
      "r500",
      "r501"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "verboseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r30",
      "r34",
      "r119",
      "r448",
      "r496",
      "r497",
      "r587",
      "r588",
      "r589",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r566"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid in capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r602",
      "r603",
      "r604",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expenses"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": {
     "auth_ref": [
      "r79",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.",
        "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of the company\u2019s accounts receivable and subsequent collection"
       }
      }
     },
     "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "auth_ref": [
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.",
        "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables",
        "terseLabel": "Less: allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r193",
      "r303",
      "r309",
      "r310",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r193",
      "r303",
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedLabel": "Less: allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableconsistsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r58",
      "r88",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r139",
      "r157",
      "r189",
      "r223",
      "r270",
      "r282",
      "r288",
      "r307",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r423",
      "r429",
      "r435",
      "r566",
      "r621",
      "r622",
      "r636"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r182",
      "r197",
      "r223",
      "r307",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r423",
      "r429",
      "r435",
      "r566",
      "r621",
      "r622",
      "r636"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Total current assets",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r223",
      "r307",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r423",
      "r429",
      "r435",
      "r621",
      "r622",
      "r636"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "TOTAL NONCURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain": {
     "auth_ref": [
      "r228",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats.",
        "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]"
       }
      }
     },
     "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis": {
     "auth_ref": [
      "r228",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats.",
        "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]"
       }
      }
     },
     "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AutomobilesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vehicles that are used primarily for transporting people.",
        "label": "Automobiles [Member]",
        "terseLabel": "Automobiles [Member]"
       }
      }
     },
     "localname": "AutomobilesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpenditureDiscontinuedOperations": {
     "auth_ref": [
      "r0"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital expenditure attributable to discontinued operations.",
        "label": "Capital Expenditure, Discontinued Operations",
        "terseLabel": "Future minimum capital expenditures amount"
       }
      }
     },
     "localname": "CapitalExpenditureDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r503",
      "r504",
      "r566",
      "r581"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r54",
      "r60",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, end of year",
        "periodStartLabel": "Cash, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r54",
      "r130"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "terseLabel": "CHANGES IN CASH",
        "totalLabel": "Net (decrease) increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash transferred (in Dollars)"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Price per warrant (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r26",
      "r146",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r102",
      "r336",
      "r337",
      "r508",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r602",
      "r603",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common shares",
        "verboseLabel": "Ordinary Shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "verboseLabel": "Ordinary shares par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, shares authorized",
        "verboseLabel": "Ordinary shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, shares issued",
        "verboseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r566"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares issued and outstanding as of September 30, 2022 and 2021",
        "verboseLabel": "Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares issued and outstanding as of September 30, 2021 and 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r116",
      "r117",
      "r125",
      "r200",
      "r202",
      "r210",
      "r484",
      "r492"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to the Company"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r115",
      "r125",
      "r200",
      "r202",
      "r209",
      "r483",
      "r491"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r563",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r70",
      "r71",
      "r128",
      "r129",
      "r296",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r70",
      "r71",
      "r128",
      "r129",
      "r296",
      "r502",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r70",
      "r71",
      "r128",
      "r129",
      "r296",
      "r507",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r155",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "CONCENTRATIONS"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/Concentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r70",
      "r71",
      "r128",
      "r129",
      "r296",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r229",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "terseLabel": "CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionContractCostProgressPaymentOffset": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of progress payment netted against construction contract cost.",
        "label": "Construction Contract Cost, Progress Payment Offset",
        "terseLabel": "Construction amount"
       }
      }
     },
     "localname": "ConstructionContractCostProgressPaymentOffset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionContractorsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r460",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for construction contractors.",
        "label": "Construction Contractor [Policy Text Block]",
        "terseLabel": "Construction-in-Progress (\u201cCIP\u201d)"
       }
      }
     },
     "localname": "ConstructionContractorsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate Segment [Member]",
        "terseLabel": "Medicinal liquor products [Member]"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r39",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Sales of third-party products"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfOtherPropertyOperatingExpense": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other operating costs incurred during the reporting period and may include amounts paid to maintain the property.",
        "label": "Cost of Other Property Operating Expense",
        "terseLabel": "Sales of TCMD products manufactured by the Company"
       }
      }
     },
     "localname": "CostOfOtherPropertyOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r40",
      "r223",
      "r307",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r435",
      "r621"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r406",
      "r414",
      "r599"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current tax provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r221",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "SHORT-TERM BANK LOANS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "Debt Instrument, Annual Principal Payment",
        "terseLabel": "Total amount",
        "verboseLabel": "Gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r24",
      "r132",
      "r364",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Fixed interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r198",
      "r558",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Working capital term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeconsolidationRelatedPartyDescription": {
     "auth_ref": [
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of related party involvement in transaction resulting in deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer; and whether former subsidiary or acquirer of group of assets would be related party after deconsolidation and derecognition transaction.",
        "label": "Deconsolidation, Related Party, Description",
        "terseLabel": "Related party description"
       }
      }
     },
     "localname": "DeconsolidationRelatedPartyDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred initial public offering (\u201cIPO\u201d) costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r586"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred Costs, Current",
        "terseLabel": "Prepayment for advertising"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r58",
      "r113",
      "r407",
      "r413",
      "r414",
      "r599"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax benefit",
        "verboseLabel": "Deferred tax provision (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r628"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r112",
      "r629"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry-forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r112",
      "r629"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Comprehensive income amount"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r58",
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r58",
      "r265"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsShareBasedCompensationCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash dividends declared for award under share-based payment arrangement.",
        "label": "Dividend, Share-Based Payment Arrangement, Cash",
        "terseLabel": "Cash dividend (in Yuan Renminbi)"
       }
      }
     },
     "localname": "DividendsShareBasedCompensationCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromOtherRelatedPartiesCurrent": {
     "auth_ref": [
      "r134",
      "r600"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount receivable from related parties classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Due from Other Related Parties, Current",
        "terseLabel": "Total due from related parties"
       }
      }
     },
     "localname": "DueFromOtherRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r191",
      "r344",
      "r345",
      "r346",
      "r350",
      "r351",
      "r352",
      "r452",
      "r541",
      "r600"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r18",
      "r344",
      "r345",
      "r346",
      "r350",
      "r351",
      "r352",
      "r452",
      "r600"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r25",
      "r344",
      "r345",
      "r346",
      "r350",
      "r351",
      "r352",
      "r452",
      "r600"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.",
        "label": "Due to Related Parties, Noncurrent",
        "terseLabel": "Total due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r211",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r243",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r433",
      "r434",
      "r485",
      "r493",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings per share\tBasic (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r211",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r433",
      "r434",
      "r485",
      "r493",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings per share diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash",
        "verboseLabel": "EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r224",
      "r397",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory PRC income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r627",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r415",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Impact on DTA due to change in applicable income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r627",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "terseLabel": "Permanent difference"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r627",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Non-PRC entities not subject to PRC income tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r627",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent",
        "terseLabel": "Foreign tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign": {
     "auth_ref": [
      "r627",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in foreign income tax contingency.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Percent",
        "terseLabel": "Subject to profit taxes rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays": {
     "auth_ref": [
      "r627",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a tax holiday.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Holiday, Percent",
        "negatedLabel": "Effect of income tax holiday"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxHolidays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r104",
      "r178",
      "r204",
      "r205",
      "r206",
      "r230",
      "r231",
      "r232",
      "r234",
      "r240",
      "r242",
      "r252",
      "r308",
      "r378",
      "r387",
      "r388",
      "r389",
      "r409",
      "r410",
      "r432",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r448",
      "r496",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the entity's equity method investment which has been sold.",
        "label": "Equity Method Investment, Amount Sold",
        "terseLabel": "Investment amount"
       }
      }
     },
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Financing Receivable, Allowance for Credit Loss [Line Items]"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis": {
     "auth_ref": [
      "r80",
      "r81",
      "r302",
      "r313",
      "r314",
      "r315",
      "r523",
      "r524",
      "r525",
      "r526",
      "r552",
      "r553",
      "r554",
      "r555",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of financing receivable determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk.",
        "label": "Class of Financing Receivable [Axis]"
       }
      }
     },
     "localname": "FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain": {
     "auth_ref": [
      "r523",
      "r524",
      "r525",
      "r526",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing receivables determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk.",
        "label": "Class of Financing Receivable [Domain]"
       }
      }
     },
     "localname": "FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r187",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Less: accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r331",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r92",
      "r470"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r89",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r92",
      "r469"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignFinancialInstitutionsMandatedDeposits": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of mandated deposits required of branches of foreign institutions.",
        "label": "Foreign Financial Institutions, Mandated Deposits",
        "terseLabel": "Deposit at financial institutions (in Dollars)"
       }
      }
     },
     "localname": "ForeignFinancialInstitutionsMandatedDeposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r595"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Loss from disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvestmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r38",
      "r223",
      "r270",
      "r281",
      "r287",
      "r290",
      "r307",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r435",
      "r551",
      "r621"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "upc_IncomeFromOperation",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesTextBlock": {
     "auth_ref": [
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity [Table Text Block]",
        "terseLabel": "Schedule of short-term investments"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r35",
      "r138",
      "r149",
      "r171",
      "r270",
      "r281",
      "r287",
      "r290",
      "r486",
      "r551"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "(Loss) income before income tax provision"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r36",
      "r58",
      "r83",
      "r148",
      "r169",
      "r267"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Equity investment income",
        "verboseLabel": "Equity in earnings of subsidiaries"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r224",
      "r398",
      "r400",
      "r405",
      "r411",
      "r416",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/Taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r225",
      "r241",
      "r242",
      "r268",
      "r396",
      "r412",
      "r417",
      "r494"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax provision",
        "terseLabel": "Total income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.",
        "label": "Income Tax Holiday, Income Tax Benefits Per Share",
        "terseLabel": "Tax holidays on net income per share"
       }
      }
     },
     "localname": "IncomeTaxHolidayIncomeTaxBenefitsPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r203",
      "r392",
      "r393",
      "r400",
      "r401",
      "r404",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r55",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income tax"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in investment income that has been earned but not yet received in cash.",
        "label": "Increase (Decrease) in Accrued Investment Income Receivable",
        "terseLabel": "Accrued investment income (loss)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInvestmentIncomeReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvestmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r594"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Advances to related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidAdvertising": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for advertising that provides economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Advertising",
        "negatedLabel": "Prepayment for advertising"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidAdvertising",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidSupplies": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Supplies",
        "negatedLabel": "Advance to suppliers, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidSupplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes.",
        "label": "Increase (Decrease) in Property and Other Taxes Payable",
        "terseLabel": "Taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInPropertyAndOtherTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r91",
      "r465",
      "r466",
      "r467",
      "r469",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r87",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDebtExpense": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.",
        "label": "Interest and Debt Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestAndDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r133",
      "r153",
      "r207",
      "r264",
      "r446"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseCapitalSecurities": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense incurred during the reporting period on capital securities issued by the reporting entity.",
        "label": "Interest Expense, Capital Securities",
        "terseLabel": "Total amount of capital expenditure"
       }
      }
     },
     "localname": "InterestExpenseCapitalSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseOtherShortTermBorrowings": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense incurred during the reporting period on other short-term borrowings.",
        "label": "Interest Expense, Other Short-Term Borrowings",
        "negatedLabel": "Income from short-term investments"
       }
      }
     },
     "localname": "InterestExpenseOtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r214",
      "r218",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest expense"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntermediateLifePlantsUsefulLife": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of intermediate-life plants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Intermediate-life Plants, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "IntermediateLifePlantsUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY, NET"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/InventoryNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r583"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReservePeriodCharge": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.",
        "label": "Inventory, LIFO Reserve, Period Charge",
        "terseLabel": "Inventory reserve"
       }
      }
     },
     "localname": "InventoryLIFOReservePeriodCharge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r195",
      "r539",
      "r566"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net",
        "totalLabel": "Total inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r184",
      "r194",
      "r251",
      "r316",
      "r317",
      "r318",
      "r464",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r584"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Inventory, Raw Materials and Supplies, Gross",
        "terseLabel": "Advances to suppliers for inventory raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r85",
      "r585"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Inventory valuation allowance",
        "terseLabel": "Inventory reserve"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentBuildingAndBuildingImprovements": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.",
        "label": "Investment Building and Building Improvements",
        "terseLabel": "Total estimated budget"
       }
      }
     },
     "localname": "InvestmentBuildingAndBuildingImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r42",
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Short-term investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r306",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments in Equity Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r582"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investment in subsidiaries"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r21",
      "r223",
      "r307",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r424",
      "r429",
      "r430",
      "r435",
      "r550",
      "r621",
      "r636",
      "r637"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r142",
      "r162",
      "r566",
      "r598",
      "r613",
      "r633"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "terseLabel": "Total liabilities and shareholders\u2019 equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r183",
      "r223",
      "r307",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r424",
      "r429",
      "r430",
      "r435",
      "r566",
      "r621",
      "r636",
      "r637"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "ACCOUNTS RECEIVABLE, NET"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LoansPayableToBankCurrent": {
     "auth_ref": [
      "r4"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer.",
        "label": "Loans Payable to Bank, Current",
        "terseLabel": "Borrowing amount"
       }
      }
     },
     "localname": "LoansPayableToBankCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Maturity30To90DaysMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period that is more than 29 days but fewer than 91 days from the reporting date for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements.",
        "label": "Maturity 30 to 90 Days [Member]",
        "terseLabel": "Maturity date on June 15, 2022, interest rate 4.81% per annum [Member]"
       }
      }
     },
     "localname": "Maturity30To90DaysMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaturityOver90DaysMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period of over 90 days from the reporting date for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements.",
        "label": "Maturity Greater than 90 Days [Member]",
        "terseLabel": "Maturity date on March 17, 2022, interest rate 4.81% per annum [Member]"
       }
      }
     },
     "localname": "MaturityOver90DaysMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "terseLabel": "Net cash provided by financing activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "terseLabel": "Net cash used in investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r54",
      "r56",
      "r59"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r37",
      "r59",
      "r150",
      "r170",
      "r181",
      "r199",
      "r201",
      "r206",
      "r223",
      "r233",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r246",
      "r270",
      "r281",
      "r287",
      "r290",
      "r307",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r434",
      "r435",
      "r551",
      "r621"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentIncome": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.",
        "label": "Net Investment Income",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "NetInvestmentIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Reporting segment"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "upc_IncomeFromOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BUSINESS DESCRIPTION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "auth_ref": [
      "r595",
      "r618"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.",
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Loss from disposal of fixed assets"
       }
      }
     },
     "localname": "OtherAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r29",
      "r32",
      "r436",
      "r443"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other income (expenses), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense classified as other.",
        "label": "Other Selling, General and Administrative Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "OtherSellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r147",
      "r166",
      "r586"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Other Short-Term Investments",
        "terseLabel": "Short term investment amount"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromShortTermInvestments": {
     "auth_ref": [
      "r590",
      "r591",
      "r596"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments for (Proceeds from) Short-Term Investments",
        "negatedLabel": "Payments for short-term investments",
        "negatedTerseLabel": "Payment for short-term investments"
       }
      }
     },
     "localname": "PaymentsForProceedsFromShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.",
        "label": "Payments for Repurchase of Initial Public Offering",
        "negatedLabel": "Payment for deferred initial public offering costs"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividend payment"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r46",
      "r421"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedLabel": "Prepayment for acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Less: redemption",
        "negatedTerseLabel": "Redemption of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvestmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToSuppliersAndEmployees": {
     "auth_ref": [
      "r217",
      "r592",
      "r593"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.",
        "label": "Payments to Suppliers and Employees",
        "terseLabel": "Advances to suppliers, net"
       }
      }
     },
     "localname": "PaymentsToSuppliersAndEmployees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r145",
      "r167",
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid amount"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaymentFeesOnAdvancesNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.",
        "label": "Prepayment Fees on Advances, Net",
        "terseLabel": "Prepayment amount"
       }
      }
     },
     "localname": "PrepaymentFeesOnAdvancesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.",
        "label": "Proceeds from Contributions from Affiliates",
        "terseLabel": "Cash repayment from subsidiaries"
       }
      }
     },
     "localname": "ProceedsFromContributionsFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net Proceeds",
        "verboseLabel": "Net proceeds (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Gross proceeds from initial public offerings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of ordinary shares in IPO"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from disposal of fixed assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "terseLabel": "Proceeds from short-term bank loans"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r181",
      "r199",
      "r201",
      "r215",
      "r223",
      "r233",
      "r241",
      "r242",
      "r270",
      "r281",
      "r287",
      "r290",
      "r307",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r422",
      "r425",
      "r426",
      "r434",
      "r435",
      "r486",
      "r551",
      "r564",
      "r565",
      "r589",
      "r621"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net Income (loss)",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r97",
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Subtotal"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r99",
      "r163",
      "r487",
      "r566"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment, net consists"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r212",
      "r311"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r381",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r176",
      "r451",
      "r452",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the terms and manner of settlement of the related party transaction.",
        "label": "Related Party Transaction, Terms and Manner of Settlement",
        "terseLabel": "Relationship with the group"
       }
      }
     },
     "localname": "RelatedPartyTransactionTermsAndMannerOfSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r381",
      "r451",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r449",
      "r450",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfAdvancesForConstruction": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payments made by the entity, generally on a straight-line basis over periods ranging from five to forty years to developers, builders, government agencies and municipalities for borrowings received in construction.",
        "label": "Repayments of Advances for Construction",
        "negatedLabel": "Prepayments for construction in progress"
       }
      }
     },
     "localname": "RepaymentsOfAdvancesForConstruction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to settle a bank borrowing during the year.",
        "label": "Repayments of Bank Debt",
        "negatedLabel": "Repayment of bank loans"
       }
      }
     },
     "localname": "RepaymentsOfBankDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r109",
      "r172",
      "r644"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development expenses",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r581",
      "r597",
      "r645",
      "r646"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted amounts (in Dollars)"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r105",
      "r161",
      "r499",
      "r501",
      "r566"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r178",
      "r230",
      "r231",
      "r232",
      "r234",
      "r240",
      "r242",
      "r308",
      "r387",
      "r388",
      "r389",
      "r409",
      "r410",
      "r432",
      "r496",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining total amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Total purchase price payable percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r208",
      "r223",
      "r261",
      "r262",
      "r280",
      "r285",
      "r286",
      "r292",
      "r293",
      "r296",
      "r307",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r435",
      "r486",
      "r621"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price per share (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable": {
       "order": 2.0,
       "parentTag": "us-gaap_TaxesPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Sales and Excise Tax Payable, Current",
        "terseLabel": "Value added tax payable"
       }
      }
     },
     "localname": "SalesAndExciseTaxPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of accounts receivable consists"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of table reconciles the china statutory rates to the company\u2019s effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable": {
     "auth_ref": [
      "r526",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about allowance for credit loss on financing receivable.",
        "label": "Financing Receivable, Allowance for Credit Loss [Table]"
       }
      }
     },
     "localname": "ScheduleOfFinancingReceivableAllowanceForCreditLossesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r89",
      "r91",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r89",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets, net consist"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.",
        "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]",
        "terseLabel": "Schedule of currency exchange rate"
       }
      }
     },
     "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.",
        "label": "Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]",
        "terseLabel": "Schedule of future minimum capital expenditures"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of components of the income tax provision (benefit)"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of intangible assets estimated useful lives"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r2",
      "r14",
      "r15",
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of nature of relationships with related parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of total revenues by product categories"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of short-term bank loans"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.",
        "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]",
        "terseLabel": "Schedule of subsidiaries of the company"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table describes the key aspects of a subsidiary (partnership, corporation, or other entity) of the Limited Liability Company (LLC) or Limited Partnership (LP).",
        "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of revenue by product source"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated future amortization expense for intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r296",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r334",
      "r335",
      "r557",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r270",
      "r273",
      "r284",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT REPORTING"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services.",
        "label": "Selling Expense",
        "negatedLabel": "Selling expenses"
       }
      }
     },
     "localname": "SellingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
        "label": "Supplier [Domain]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate",
        "terseLabel": "Ordinary shares percentage"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Ordinary issued shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)",
        "terseLabel": "Ordinary shares issued and outstanding"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShippingAndHandlingCostPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.",
        "label": "Shipping and Handling Cost, Policy [Policy Text Block]",
        "terseLabel": "Shipping and handling costs"
       }
      }
     },
     "localname": "ShippingAndHandlingCostPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r17",
      "r168"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Short-Term Bank Loans and Notes Payable",
        "terseLabel": "Short-term bank loans"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r3",
      "r140",
      "r160",
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Total short-term bank loans"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Invstment [Abstract]"
       }
      }
     },
     "localname": "ShortTermBorrowingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r143",
      "r144",
      "r156",
      "r586"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "periodEndLabel": "Ending balance of short-term investments",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvestmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r67",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r180",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r296",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r333",
      "r334",
      "r335",
      "r557",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r27",
      "r104",
      "r178",
      "r204",
      "r205",
      "r206",
      "r230",
      "r231",
      "r232",
      "r234",
      "r240",
      "r242",
      "r252",
      "r308",
      "r378",
      "r387",
      "r388",
      "r389",
      "r409",
      "r410",
      "r432",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r448",
      "r496",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r252",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r104",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r82",
      "r566",
      "r598",
      "r613",
      "r633"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Total shareholders\u2019 equity",
        "totalLabel": "TOTAL SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r222",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventDescription": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.",
        "label": "Subsequent Event, Description",
        "terseLabel": "Subsequent event, description"
       }
      }
     },
     "localname": "SubsequentEventDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership [Line Items]"
       }
      }
     },
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalDeferredPurchasePrice": {
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.",
        "label": "Supplemental Deferred Purchase Price",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "SupplementalDeferredPurchasePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Supplies": {
     "auth_ref": [
      "r542",
      "r556",
      "r615"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Supplies",
        "terseLabel": "Advance to suppliers"
       }
      }
     },
     "localname": "Supplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Taxes payable",
        "totalLabel": "Total taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r5",
      "r141",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.",
        "label": "Taxes Payable",
        "terseLabel": "PRC corporate income taxes"
       }
      }
     },
     "localname": "TaxesPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments.",
        "label": "Temporary Equity, Foreign Currency Translation Adjustments",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r300",
      "r301",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Bad debt recovery"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r253",
      "r254",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Uses of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseRightsMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal right to use or benefit from the use of natural resources or access. Examples include, but are not limited to, drilling rights, water rights, air rights, timber cutting rights and route authorities.",
        "label": "Use Rights [Member]",
        "terseLabel": "Land use rights [Member]"
       }
      }
     },
     "localname": "UseRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Increase",
        "terseLabel": "Exercise price amount (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r244",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of shares outstanding diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r243",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares outstanding Basic (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.8)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=d3e65207-112826",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-04(Schedule I))",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=126898705&loc=d3e5864-122674",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A)(3))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A)(4))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5066-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "905",
   "URI": "https://asc.fasb.org/extlink&oid=6471048&loc=d3e5272-110052",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991576-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=6471471&loc=d3e48698-109348",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=6471471&loc=d3e48698-109348",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1404",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1404",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(4)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1405",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(7)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921833-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r571": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r572": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r573": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r574": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r575": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r576": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r577": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r578": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r579": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3098-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269825-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5111-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.L)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e99989-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>156
<FILENAME>0001213900-23-010349-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-010349-xbrl.zip
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MJVIN7]4\OE%5\W2U,6BC9GSX_]-W>_[.T8>/_<,_UMUBVMYJ3:8U&E6KQ^Z
M'NO?J")[MLJ7^'1XO'=R]/XW</K &=S'W.T'C&RM?33KR;-6CZW1J%H]=OMZ
M[,F-JK'G*PUG?=P[!FOL\"W%L?8/#ON'.P?]]_[QWF\'>[_3'S\>'YU@>*O5
M;*UF:S7;CZ79GMZH9GNQRG?X:OIQ[\/']T=_[.VMO5Y[WGJ>ZS2J5J_=OEY[
M=I-ZK;=2L.V'_C]!EYV\ZQ_OO3MZO[MWS"G(X[WW?<Q (K;L#__TN']XTB>D
MY_JKM^>M>ENC4;7J[?;5V_,;56\K!:E;%_36,Y(K5&$O6A6V1J-J5=CMJ[ 7
M-ZK"5@KOQZ0FP\30,'N/.+'#M^NNPEZTB+!U&E6KPFY?A?4V;U2'K13(W]_=
M/4#+ZW[982_:2-DZC:I58G= B=UH-5)OI5C]__K4QVHD4%V_[9$M!G]XKW_?
M/3C9>7]T\NEX[\3OOSGZ=.I_Z!__:^_4/SXX^=>Z*[K>9NMQKM.H6DUW!S3=
MC58E]5:*X-_=.]DY/OC(L-I]_V1OY],QV&^@VH[ &SWV3]_U#_V]__J$I9GV
MP[77<KW-E@7BSJ[._6.!Z*T4"N^P0*P_#42O#0^MTZA^()UP=^V-&ZT8[*T4
M_;Z[M]__]/[TI -NU&](^K#K]X^/]_K'_;=[C$?8W7M_</A?G_8.=^Z%H=&J
MMW4:5:O>[H!ZN]$JQ=Y*4?$?^J=[QXA!^'"T>[!_L$/![Q/_](@*%H\/WKX[
M/7'\K#]\%XGUZ033?PB;A[7:;75?J_M:W?>CZ;X;K0CJK10WCQRTQT?O3W3M
MS\[>+L;(6S7V_6KLV@7P^K7(>HVVU7DWJ/-NM%9H:Z68^O\#"F[O^+>]W?^[
M_FJNA3BLTZA:S747-->-\E!LK10OW_^T>W!*Y!,'IZ=[>TX)-Y(2'I^V"JU5
M:*U"^]$4VIL;56@K1<_O'.U2_&SO]-W!SCUP.UOUM4ZC:M7775!?.S>JOE8*
MG/]X? #FUT>PO_H[.T>?#D_[AZ?^_IYD1='+/-BY#]&T[5:MK=&H6K5V%]3:
M[HVJM95"Z??^O??A(V=!]X^//E >5"H;D?_P<+=_O L?'1W[-8>T576MJFM5
MW0^GZO9N5-6M%$O_\=/QSKO^R1XA/!8P\_Z;/TCY'9R<?)(*[_[^_L'[ V;?
MD>_>@Z9&K=I;JU&U:N\NJ+W]&U5[*RU' +UU^!;TVJ%_O/<6++MC<%S_\;?G
M6[UGKT[\G;WCTX/]/X@GUKBUK8IK55RKXGXT%??V1E7<2JL6=HZ./QX=@Z'F
MOSWZ;>\8$Z7KWZBM][A58FLTJE:)W04E]NZZE=C*!EU5A\\?O/YP<+CGG_3W
M]\ MM1P6K+_65SSO@AIKX;FMSKO'.N_@1@VW%7/Y:SV'SFG_>!<=T?VCX[V#
MMX?^/S\='YSL'NQ(C=:[_JG_\7CO-Z3Y/S@\V?O('W1;0Z]!0[9D%^NK:JZ9
M[&)[I0A[E^SB'K!=/+EU8^5N;K^[.:H?2"G<7?OC1EMN;%\3)_W):?]T[UZT
M>6QUV'J-JM5A=T"'W6A?C>V5PNI;'=;JL-L>5:O#[H .N]'&&MLKQ=;O_?O=
MP9N#^ZNW'A7!(%:O?PFCL]?>+X_PGU]F5W^I:9"-(Q@X7KI2)Y[W46TWS62\
M*QSPPCW_Q\:&OQ^I.'SI?PS&ZA5\\<]2)4,8V?8K_VA61&F2O\0'G*@A_O+*
M_RV(2QRXO[$A-R,AX?O!?_0H^=D;L-W@XJU9H4>SP:+PTG^*?QND6:@R\[<W
M,:@ O]=] @/.TS@*'SCOO2@[YI[TE,V&AW"JQWE-_8*O_-/Y#-[C?7JN,IJ\
M5_YA,%4\$8<IOE[D?O&1_B:].,ZD>>5E4S#(5/!Y8Z!&:0;WG=$$NP-^VC!@
MG"KWI9TEM/IVZ</=\>)[V$6ZNV*_5.#I/X$?A;\^P":VZ'F28EK)>URW*OIE
M\/H ^7YV/^UP@X_!Z^O<V>NEBJJ3_Y\R+Z+1?*6G<N(5DRCW@R0I@]C/U"S-
M"C]-_/TTF_I;FQO[';],8I7G?C%1_A"^#P/R4_@E.X]R!=_XLXPR? 0<N2K#
M?0^7IB^O;4KXO]TG4=(X.?+'* D5WGYCL[L%E][@9J03%/9)',^",(R2\:\/
M-A_0[_"%H?[]RG-P'H7%!"_=_.G!-]N-C2;>M]LN,B:>XFL7U55Z 3<]\A=/
MG[U8T="O?:S/M[8V7^U,HB2@GWNO:*QI1@I /OYXO",?^D&F0([HPX\JG<5*
M(+NY?ZQFY2".AGXZ\NE^'3]*AG&)FX*NSV=J&('6"<)IE$1YD05%=(8J98S6
M%'[M70J7_@O_$R0AC>-#, Q*_,U77_2]3H/H'%Y_)&.<E=DLS17=H%&YQ?/5
MN6(KWE)KM(?:H5Z3=]^*5*N'M1[>^S*<! GX)_UAX:IC1^N"PUEF41'![=VK
M4?OU7FP_[O@!:,"I H,H;&5T#=9]C8?:BM3='.K:J;U1E(,D^',59$NTW@QN
MD(;^*$NG_M&P2 <J\WOXX8F:%6J*OVYOL@6H_ 1]5K@A*,$@H[NV8KL&HK#&
M0VU%ZFX.=>TTX3\C,.B^1/ZG!%SC+%<-ZK!^B?]Q$F338*A*DJ+<WTF['?]]
M$<)_ S^.IE&A0O@W&$1Q5,S]83J%0<_!Q1\'"8P@]$LP%MF7CH/S7&M1</H[
M_ODD&DY\<*K/)VD<SSDV<)[ EP9S.X)3-9PD:9R.Y_Y#,#]#-8KH$A6GYS^W
M&V4-A&^-A]J*U-T<ZMKI7E!X?@J&9E!@E%$E!7G9E]' &)^,BMS/RT$>A5&0
MP?=:&5V#=5_CH;8B=3>'NG9J[_C#&Y/< 3UVK))IE RB)8YXK,;@J0_+#'._
M<Y/K:1;-]< 7M;E=,Z:MQ[,O:[6=;W;<:[>W<W -C0D#'A^-5SY+,Q#I()O[
MU8N<O5Z[0CN&.^Q =OQ9D/EG"'OS_[[9W=S<[FT]P4 =7]X>5FL@)&L\U%:D
M[N90UTY'GNS5P"TT8%1TG[HGW<9\*VC :93GB/MM1?+N+_,:#[45J;LYU+73
M<J<['YJT7!:$$=8O@$^'?IS*E3]5803.36O K</:KO%06Y&ZFT-=1]6VZ^@V
M5FSIA;K-#^&69P'BCY<$ZMO051NZ:D-7M[BK37+M79!,FG 0;TOPQ?Z:I*5?
MO=3_@)L<-OTQ[/@@&TZJ@ C,\HW2##0!UCU]".9^;ZOC;VUN]?!3ACEL,,3!
MI/,HSEW/^K6'V1J(TAH/M16INSG4-=:D_VI0H^;3@\,=4\O%:M"OJ\'.<M#9
MVRPM9_[# ZP73@(VNW[VWS/Z##6KAIU%R3#-9FD6P-]I'%%BZ[[:#; &0K7&
M0VU%ZFX.=7UUJH6^?@M4UP'.KA*UJZMGHYHF=S&[[_[5[HPUD+8U'FHK4G=S
MJ*1LUVK$-96;!>$W%4;0%Q>C 5JU2E0 [-&MS=YF&PVX?Y*_QD-M1>IN#G7]
M+->3OW=TMD3_J7O2I6&'H.Z"+*]__G<7'RQ_DTL;4(.+"&'"TB1DT)X4X/?G
M=*=6NN^^Q*SQ4%N1NIM#73N%>:[J^K T&K*"IRXS XVVB&N71DL^E0\[6FFF
M"4*M_6D*OX*V7&J^'AR2:^^K+VHZ0V4JAJM$46U8%4U8 FH'<WA/_R"/0=WF
MI+UQD&#4$H_64..XF\K7B$>&.  #S)L'<W^@NHW[:\TSY7>>L_%T$N5>(V$C
MOQFR-@K3&F+T88&#,HQ8/A(BBR69&$5)D!#_6HYG\%0EL.*:0\TAX,A]X@[R
M#;$&/V5[L^-M;6[95"G(#/RTV?4/D@;:M8Y_KI@B$B4\R'-5P"NF Y@E2@[
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MRT7Q%OS!@4?J7I[XXQCLF"R(.X*:A"L9-]EB)N^G:[(&7LB/ZG#H7>G8V).
MH[!N(4=0%I,T,T'8 JN6N<E/E(QB-CNH00^=$HX5C=U$* *:3_#,6.C40U'*
M@+J\8$04XYCP#!@SU630.&K#HW#I%Y!5/H4H()O&/EZ SU$9>1[P9XP-8T\4
M,M@#4EB/N).)@C>3$A*ZI3Y5-KB+2I3GI<*&*P=4-=(T"!I +AV.\ '(4$8J
M<<EXR!,*>+S?.C#I@$R#T\'C<\7)[D$EZ$2SVC@NT+E%O56*\7&T=R,!IXO\
MQ+J$@$-$FIO"51C(4@4Z23!XK)FI1?%I6OA*.#F24MD_.A5%)&DX%6DFP?)A
M4.8L9V"1P[1DC :@E#U=7QU0J(98MH?O*-U<,NV,GJ=9,<$.(#<7%K\)4TXK
MQPL,HO8$NJ,G4!L'<\9:-2P#L#@I<9:E4TZ&F:Z<^3Q'-T,K2L>D7#!.QT%&
M?^="0]!XLPP\&$/PH-!%&7(R#4O;0>%3?$GWIIJEX.)H'0;:W WHFV!;5H)2
M 3V5:!7Z9QD-/X,NHH@^?+> S0=:EJ+\8.Y&0]71E0=7595+]&#G>U4[O4@8
M3-$]QVLR-2MYGCH"I#RG 2^+C''FU*8D;"4%GGV1F?#FL%NSGO\&'4_#N 4]
MWWH3;:*C5?!?&RNUW:MM;C!+:;P(Y%)QE).13.F "2A>:I@(!P!\3%H\"T(Q
MHC= 4VQH_ 07::/N>">^QK[8U=RL%,^"_I"NIMW3'Q9P:$A+9^P:][$<Q-&0
M!B+M3?7U>+,C8U2_2>$\Z>A\P\>=_M&;#A:=EXG.L40)95]M!\M4NCC*Z^']
MY.N4&M'Y#GPU^FS$B9_%J3*/+2:9"@HI;X\RF9O+SA[GD;^2X3 ND.F(.,<1
M62^EZ_=-ABB>=^1\U6>85-[3_# JE_P?/3FD\_D\"=4L0T".O7N*S1WQX,0[
M#,#A'$5%KHL%R,=Q[L+X7YEG=&(IG#10*M%7P10,YNYJ4:TNK*W8!:F[4N0H
M40?+@5IR QY)0LDL- ,R[,(9M4?-_3EJVE-EO4Z5&OI?[&XN&9@/4*U1= &4
M5!@4 =*!G 5#^UM:* '6898#%#^U![5N@&OM.U5*].U+:%*CS6TNNL$V[BPW
MCEO-TFJ6-B1^$R'Q8 ;:X S=9H[-DB(0C]_B]K1QPU'O$QNZ/+8XOQUL"B[)
M43':=DZ.=^@75B_5T#(^4X+MD3(H%%/E*& @T!8)ZRHVD#C&3K%FL8#QKA2-
MZ-3A,09#@R]'MJ^^._4X!\<:#:<9_!Z!G78^431*M*G2<S]/\9'B7(MU9#!%
MC!?BD+Y,X#V*K[9ZK-5CZZ3'2 .8K8^Z*DZ#))=J @GSP;8G9TP[<YBJ[Y#R
M@%]8!0WFR_)W6D&!OPG_)6<3RR8+O\S9V2PI;#L3EE#^&[FS.B_&L4)'QVJ+
M"+X68'V&205-@\^*7X",,^-Q8ND'<O5R@BL"EX[TG#AS^")B/\$=L0XL"J,@
MN]%ZB%8QM8JI54S.6*NI" ('H4U"@L")906;.9U&0V%JJCI(:+@@=2,8'_!O
M SC8PM4TI].9:DJ%*,E1)-54B+A>.L[D9D8:W+6VTJ)5+:UJN2NJ1:L4J9:D
M)"[FB3D_RKEB5RDD#<J@S.\7I+\%A;3[>-WV,6[>W2P8%?XQ(2J.-7J#1GRD
MD7/O.8M&T5A%V#W)SV"(A>JL9Y3-H[)I.-0#@V*(F:%UK@@GP9N?TV$6?( V
M!-)".R8&%G0B](\));^&_M/#E$$TH1-AO W0PTZ%L>JK,#L:S97Q(S4";Q=N
M)^_"A-UZ.DS^;_&+E1'2:#0NHP%RUX55-T4"RVH _,O5 ,#EIU<4%4),7D5>
MNMB-.U8<UV* #QT>6G[H[:($14/$R!$>&L1R].I-2X]4\*T J/D]TL.G\7()
MNDAZI/*C386TQW![#%_W,9PIK&'TQP@RT2H)M17#=$1U4F)UAH5!_7 :):82
M&#>[U .@/J,LJ4W (J4*4C4%&>SWD2@C#BGF2GT60 ;B6!ABH='QZ@O;^ *;
MY "B2;1&<(\F)@0WZ+CB\^>8YHCU?'V>;F>..(12G:<KSE&K95LMVVK9FW)V
M4J$L*%#9#H,<\[FBV?)<<9Y9*BAM166EJ)*J<DW61D!XHS()<\.$A8G:LR"*
M=;86/ZU4:F5,JT=9F)(HM@ILT*/CH/I18:G<(C#^,O/L$?)O.DOS2.NV#"S"
M+!K:0"G9GOJ)/'X'*8@J2(,NA>+/S=FXQTZM( OG, N2'$U3/8,R>ZOV-U)3
M@E!;L9M=+4N$6%^Q&URM"DRV8<6^8;7JK9)^D!#<7:#3>/K#,&=LM<P9/]I&
MN#[*#+'#$7Y^I''Z)US2H(O'3@72_X%)IE=.H^$M/=*6#^[&.#1N.TMYY\=_
MD'@:T*(S5\RQ$:I\F$4#$(Y@ *<GX?-J_(+"I7$I4HZFHALMH5)TXC$-^EVA
MYKAMT?DQ?<6VPNX>>)6H\6F/^]P3#2NB.)Y73=&$57KTCHT%U30%QY'<XCS"
M\Z$F. SR,/B3G HYZ,S%>9DCL;,*FRWZ.R#X:R3K[5"7#[45J;LYU/71F,+%
M3EG4.NMI71F:N N63B WO,UF8D%&"B83E<GJ.H@J=4(8Q66A^(KT' RX?!+-
M.$BC\H*-,@96SS(,'^D27.E1PPI=XF6UD;4 Q-8^NU,*IK7/EFH;-,X"[><+
M^",6GB]A2!,GG92*1)"G*DB8'L"UO4Z*=/A9QQ<8"4/E70[9<D>(O^(Y!G/5
M%S5E[ERVX\1IA =GLQ2[;CG0%:*KJ52^$9\9JC:,-]O*68)RH!["0A&D*4,E
M17K2I"[O462W54YMHG&=5 [I @VDH.)W[*U'H#&NNQ"=A,$>)\2D-0/1HSB&
M3AR<4] R3O,R:](/ 77NI$:?80HC XGCF\@SQ29"K<28-&WG1#;.*? W+*)W
M\V&I]FY%T=RLV=,JD5:)M$KD8B7"W2$DI1Z$*0Q<*Y()(CJ)4@G<EAFVTP)_
MAM+2'*UF.\(8(JX1 DJA0+N"] NV^T/.T IVM$(2*,:19EO",%<89"'3,.7*
M>3AUU!G!>X4^PDPOLFG@V62)S<6;4\E_TKG/K3NXB0_&QLI8XFQ4H-_X,HO#
MNC^VT?U)]BUPTF-D]8V+G#N0%K3K_:KKGD7CO.Q'C(UXND\@*Q6P4VS#<"XI
M+;.A"FW_4%T3EDUKE)52#-IMDZ2W/7[8=1X<-[ L,UR7RIIRLA+K^<8*FQPA
MZ#5,DW261W!'4+Q1X$_+?)*EX.A&R+27^_!S(<D.<E#A?P,IYHT#HOBF1H_F
MJ*@\T:ME83DB=Y;BZ47P*+P/4J/3:1;0,0?: LQDX:G3;2\CW?D2K.:.;GS9
M:>A\F2F05";'4U]F9'%[3D-,$G2J4*$VMD@,F);C"1S59PC$8L#6>3#/=?63
M[BU%3 LXV"EY\_ ;+ZL.0MJFV$Q=.#7-+MF]][@LIKK%,*X1Y^E79PC,>4(U
MYX6S$,W3YCH+& @IL\02W7I!8EN#2I@DF**!@6?R+&#T='W7=_WCKVD&&;:=
M97P\LF&HHM*"] S>R!L'D2D'KWY+QW,;0=A-RF9=-^E];([S+AI/O(4^U-?8
M@[H];&Y]_* 8/$<Q,/^KSZ@M.$XT8!97;UKI_LO:5YHSZ%!KM8DP]N$C-R(U
M =0@GI(.C&L'6]<[,9>+> F]++803I" 2Z ]^DZ$':IHM7-LO4?,8?0A"+(F
M]L& C<)$/C7>()V5:^_-O74P[WB$%X:KIDHTG]X0CDOUNVK6_"FBI%&_$4^0
M04(CC #4(9U,U2%3U2!5-Q*=4 [O/4^3T,/GVCX6ANB=H,2X*NPZ4AHM*V?"
MV6$>PT_OR*$31OFL+% &^-2A=9DC)PD,C]S97)I.6)82BV#V'$ZU"KY< '@R
M%712BP?L)^5T0#U!!*OE,$@R;-H9P$CPV79.# ,<<2&9,]AS59!.%N"W&58H
MUH;!H1M8QF(?0W%@<=B6PECT%PPUHC_Q\6B([ZHV$2V:3E)4=H5L%:,JORI*
M_61>Z3_##%.L26'E9'7U,&3J6(Z<?4MOVT%+ ,= RXQ9E''>6::.N<5V7AB"
M87.SCEX!^!>#DX96BPCR@^'G8"QOJM^RX^EOR+Z+Z6WTP!-01D89=/@^FK>?
M*9 =ZX_F:@AZ+IUBF9B"Z0UK=;[:*%I@'6UMC+O_-K\K[V;T174?NO)C^S<T
MM9.N=6@8E72S$/1SG,Z(!7S]EV+=C180HN^V.#KBJU2TMRLRX+!.P"!&R2/V
M@"]"5TS2EO,!@3ABI,."&U9,YC1S[1(,BS:H_@]42C1R4-!!3A1@*/N&#5X>
M+I5(R\=+VZK:^KAZ/"EV^\P)LG"LP8BBA [4LR@P]5.+9QRQ'.:YWHH+$0/>
M95;'RR.=TXPG$MW\T/4)YECUL>AO:.T?:?/(=\RCKG]@&S=W'%O4(\G@RF)E
M!EM]_]S5(Z22B%96>!I -H-,5H9JQJ1GO9:ZRKWQW(D=A[O)4G*;2M9U7!"S
ML6'$CPT2BSUM$'/7"AJ5&1W[VAI:W\V][LH)PW>-&T;E5GM,<>_C+W2D\(:H
M> :Z7> 4R8E9MC!8Q\X'^#*PQZ-\HD(C#36[BYX98CP)@V=G.%8N4#3G6X5G
MT/7,@QG;8\2</$1VY&*#6$EL'J"NS4ARC??C&'MDR(8J\U@C#U$-Z2_7(YM@
M"10PM3$JTB11&1C',0(,QQ,W78_;FW0?7H_[-59V#D::SI[-\)K"/U>>#JI1
M&6K!R7P^2/+46/TP74F(]"[D!>MB$&NEZ(\YU#8U ,7J>CIZ%98,WCQ30OF"
M45"/QK]X;WN&$0V"Y!&KH3O[G&9'1-7=$%!',DQ6>N8A'-V=XN%H&1>D@Q>/
M# 1(/"%Z\A>0GHB;8*9T&Y +_"H8ZV1T.W*D0X$#Q3L:_.P-&OE,A?P7>PLR
MW1-+G8MR0"=8A/TQ^[IS"8+V!;OJC,0ZVXCZCRBT^UG-ETZ:,_+*/NUZ_:3J
MC+AD0"(:.EQ*P[0'N#NI56\% V5\A\QRI0=#4XI> 9.P08I6A3FK(H2/:.X^
MZ]T86"X1;*AQ-'1MU-R9'PHO!,[-JF$!"ME-,*8PQOU>)OA-<I.U\X4A$;UG
M=;R@3K7A6-+._%'^8327.RT]V!=NEE1[KEGO3L\^'Y>!K12')3>-)!;(G70G
M'JP"012'7XA"4!$SOH\N8"$SJ3+M(;1'ZW569C_[82JSM]O*[!]F!ZQL_/W<
M.U>5<TFT/CMWH-Q40ZQ>#% Z/%F]<V#RG,/?'#9W^UK044'^B+9 %J %7N5
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M*$353BW"5I@B\:=I(X:*'X\UJ5M@OS)30SK1Q9AUN$XM.GR4EEB4P]V^1I9
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MD!ZF,#PFW*"LDJI#4OQT&-&^,T#KQ7T*)G8<XHA9D5"7#">^(3V2=(=?HME
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MQELU 2ENC&5Z'6T\)%(&2W^2'M;&#NP(.0;6:N82X*1F(?0[YC+83"JC?-+
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MB\&=Y.91A<)5%1(YDDN4DO>="I1=4W+>%OA+W?5<JO?\NM[S+J7W8 ,*>;G
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M&2K:]96X==\Q>.X:K<>:VS3XO*Q4LE7.*$9'PB5* E]6<:[.J8TJK?EBG5:
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M $98<F8WP<DA.5XNLY.>;+L<RQ;$E_YV? 5Z8R>4P_/._]'SYYG_/R^#?IU
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MR,V+/>3FJ]D#7ZXUU3(O3095I=)1E2H!6T\&_4%Y)E U9WY'L"&/9 9TG$*
M!9#M$:*5>-,9T,KL!-XVXX3RAT_;Y)R%8;=BP(QSF=(?7>:1R#9AFD_X=9.Q
MLUO+Q68:-PW+15J+<)4!D3-=<-<YQ8O#'E9)XH'%5G \$*R3'T7H\4TNTBV:
M3@Z:90DQ->6LE5R?3%6@F2*WK-YCWN]!PN(ON3\NW&OQ 0#HB B<BO[X!$&A
M.J!2:Z8].,E$E22QU/.83-KM$QUW/OY$/>XEJ<<='4]&9T&ED?U-]J$5A8$E
M-+-+2 '@U)%SKN:0[([_T9\W?K$<X5Y/#V;O-RTI5O6:,)NZ5N%]^69+8=R
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M;:B_Z_CPR9M(DL"$@()X!HI8I!Q5,S%VYQCABH9QIV3'KCNJV,\*,7:7KWQ
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M0*0(-^WB+$=O@K?-.9-$(B?"OD(R/ID5[>)E':=%V2XVY\P^W$UBJN6AI+
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M4]TY@)"%"0"?P"-_38S()<N6:%FD$ [+(&32,!U%-!Y,97.UU?F=!%$/=_Q
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MINZE<LX-K?LC>+]?]_OU'NU7[HGINIP[V"MBH1:>?AS"ZF OBXNB:M8<E3-
MA7UJ? 40-\8I[3?X?H/O-_C]VN *Y_*1\.8\(+EX?Z<@("UG,X*.$^O3._H>
M+-4'M#KW0]T]U/V2NI]#?5@V3AJPX<0TBT^;=8;A%MVB9248]F-"%W(J/,H@
MP6;3$Q@8ME((DBQ:N07U$E-R1KWJT1?W'M#> ]I[0/?'.JP;(D]!4X[?G]QM
MKR5%H]? 9<+0C;_?Q/M-O-_$]V83F[QBX.8)O>U=)J!>;8P:=@"<5LU<6A>T
M9T:NLC^N]SM]O]/OTTZ/P%S!]<5MOM^J^ZVZWZKW9ZO6>;^A;KUEV>6D=]U!
M*+IMVK+K,>B<>_RDE>8RAS"EB!) G;N\**O9AK@W>_!?[3?X?H/O-_B]V>"<
M6//7_WNNA +4/*^EP;RJM$6."+F(X[E;M.5\W#A[\( W]N^A 9QX < H/-W[
M+82+/^;=,O_?V7]RM,34-,2'8518)%,ZD'_>^>O0"!Z=.$=,B<JKL9S)R YF
M/Y$.9+4588'C8["^M87TF5^V9=\7-?CO@KR+I;K\T?[A+P5Q6"KA9:3(E"%^
MH%YR)\_WE[^\GCW2B^#OX7=*W79)W+@BG#/UY,2E>[XYG\W+I;28"[&<TC?^
M]<._'!T<'M+1)YWHS/Q&A)$RIK_(&X+:#JOQ@',XWFGJBTR-Q]SU1+,^')[_
MY.CE(?'V%?72'[_+?-M!092 .5641SC*G)_SIP>SC\WX2MDT7P#=5>CH%E4#
M<OLX 90C[V>4DN_#TT.Z*4R6_\;1(;-0+#;@S X@7AHEI@ L@Q=@3RYFRP;O
M8/R@\ZU]$%H\3PUEX*SP.ZND(QCWKVWN?C0WQ-S"-W#F!@VH 8@:Q*[6*&U*
M]PM+%@S%-&'TB;]?3=W(RFMP7A2Z#ZU6#I$AMDS'3,1"0RD=QX)7PBY+C*H-
M"6Z13 ;3/?Z=Y8#F#;&"0.:=B*Z9*42I 7-9>33CQ+"6!XVK&>A>F)<5\@K,
M?WK\Q$_8DR/F:*@;=^I/@E[)48\.^:\IW2QN\-K>()+.GH1VZJ50]^. D E2
M\; =CZ%DEOFR\9.^=$3.6&V"=FH1&5,FQK G'[GM^&_%#?CJZ^$&?+;G!KSI
M&C(C$RJ_!\3F1RY3XFE4<"A8(%O((()KDMR6).E.V\8?[T\63=6T_TXFO2_^
M\'^##Z+G]__KS5ZX03?['NAW=1BBL^)D\_M!_.B/ )PWK_BX(8N(,R'ODY$5
M%T2LO6#MIJF3N83F=7J<^VOX8RZQ\73-X+<(89Z>WM;!42[[B@[['6>Z>!Z8
M!651/WXNS]&?^1D[/8L/^)+_,-9=</J,="#P05TL1S[9A*<T>_;ML\-'^>-'
M1_XH^N$";."X)YW8^44Q=3$<YPMJ2.RA#^@??]ML6 ^/O,+2AS_LD6 E!*0D
MJRXOMHFS*D3M,C3E']FP:L!)(!I4'B5Y;5<R-H'SR$7^P7Q&]H7\!XG)XCMB
M?O(0!>QV][W;M3+.%A&_]4-O4'XGE$LD5^ _=MVF@ZPUBJO156*Q\:4((P9]
MN>E'8F(GO:1NAAM<V;N .40M42;R<W(.S2'9&,3GU!8A@B6A$/TJ$T+C2>:*
M>ZOH8MR%&K0F]/N8GWSGD! I$.GC8K%I,U'5")=/M<+A:56E?T=+RW.%*R^9
M?9LO3.QW 5TR$.H<J$!"?M1ZN'5!.I]^AMTB7Y>D.Z^;37 KN,N\5SX,>@8=
M+HQ!Q<1PQ))],'NS:>F12.4\&^D%TK:<'OW@+6?8/;@+,?SY7_O53PH8O$1(
MN+[L-_( 48DV:'4M_=NMEYG2<_CU0B(+IT6F%8/S_!.X]HF<G)Z1>13!1<=.
M[T5>5I1Z<%;D(&'YPV\8+\D.\*H@J==YVWSRKLFR\$&#=TO#5)$M$ VCXC/9
M/@9=%F-51:R^X;)W)[M7%&XAC)0Z3\H-V++676U8^(9&(HC3J5XG<Z1-PD+=
MC@N(<=K%>YI[.]:*[4NLV UHY_:^^9V-_VWM4L%?2[%W#0,GOU*0&:>+**F\
ML\]3GL,DTO]&3<"$D]3)@36!N5L-J;4B]1:Y(Y2-[/'<1C..5M9Z]Q %2H"S
MAK0-#>.J2X9/^0,EVJ_8B@C=?I60=.Z7^7T>?Y"\!<<IZ?#8\W&4"56@Z'@M
MJ@[9%F=ND"!GF\AF>EE69/KQC>92^"2,R*9?0AC&LEBWJO=^L]6S9XV^V_'?
M9OUL= V9Q6./X8/9+YR<A#[8;9>D2\VC_Y#9#J4UNLWK3VEX(7G/K0CHL6 ?
M!6FUB!#1PDZ)4"EQ3+S)<@%+FD(_;PN147)8KQ$T3?KK<^_QD4.2A0UC4IEF
MW\!QJ#>(]U *;A>;<U9$W9O+NQL_<>/3DE3.YU]G*W<MS,LH8I,PZ4H&M]LS
MZNY1 'L4P#U# ="!!GWIH-PJ=2FI[F+@J$JUL!14W1DY/V3O-QTGS32,W>/Y
M]AM]O]'OST9'5NF<2#O@D>7=F4F589,K?L&JD)![*?X@%VU1?EAVJ1>:L6C]
M?N?O=_Y^Y]_+G0^94:IC731\TO=M49_V9\K&A=+2NBTNRF;3D=2["?RD.,B
MFV5)54*2MM]C>O=;?;_5[]]6G\@Y3M*!R)%--9U_'H+WKB/U>S_^D-%FV7(J
MT4JY7LJI?4,.F?'$E-]@FNV%T$A=4<"D"2+A;A+.\B%E$>FBAP?/RGK_XI,D
M]&_WRF=OZZXO\F46\#SC+WFWGP#ACF^JV"/%PEBQQ+8 ; 1PI!P%=N3 &67
MR3]#*8;:6N#L5HB28H<4@1J>DJY*T8E+'G<"U70 (*BJW&6 [Q@=[I8*>9#&
M-B3A.D6*-,I)LYREP$,F7?+B>GM2$VO._]DB=_O=<GTF>P>4F/7F^P09E&.!
M7IX57 %IZ&]]6\XW?7S176;KS/EZ77E'B[9'E5]V@BLK5SM S,Z?I.4R(BK(
M8X;<E-VW7(GOR8,^S308!_ZD:8&9'RP]_P-_0[\F,TVM0<6>2OI3!1TZZ.4*
MDUKP@A#Q@?^J:BX97J3 H01.!C+>3;NN-C+DF#<(\R;T^S*\@)<$I[\#-@!
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M FU+Z1P2&=CKUJ8N0*PN-UY=!W[D4:'9RF\/EW=PQ-D[A7GT1JW-)A8^5;X
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M("A>[A$47\T>^,+Q,I&):S\!NX@H904:VTGG+V+2K(ST0$*:'6;P7OO3AGQ
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M#R+O\P1=&]0&EC&,.&*KG=C 0'^,6T!5;Q+4)7'?^?RO2E7;BOW1J:_QSZG
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MA$_*)0M;#%W'['L*\SR=1"%K--*TY=0@?6$\\]$;!1J2FC[6?6%KM(HCRH-
MATN0P.BZ:J5K-G4R[/K"[?<J?F7M4!24BSE(]IQK5XP^&,BW.<9LP%I**66B
M,HSMQ*)];NBF@D<8DU9<;I51\=6ESOEJ<<.%F=)XI-G<M(_0.^]=:_'.K]K]
MD&@U !5<\&7$-J.B-_(=QP!M+#G7\),_2C 7L-A^A=;<E-L<M@U+14HXSO-D
M3FC@=B(]_YF:5!-<SV "&Z"#$A3OV']DFI9J7+H8O\LH=>5DM5+HX@2#[2GJ
M6_G"2ZGX'@O45)919WGT2R)LL)3V5^?VF#98MZ<A#6Y"H[>NI&6V=DGPE-0K
MK8C($6PIWA#5GI<K5*QEXII*ZLN@*V6*SC"91V&U-D<:.8,'"&Y<VF8;>MZ1
M!:,NMK#UGE>9NOS48+2=THFL%;;-@8/-HAS.5HJ)X&4Y'#DMIS8MG(P[$3/-
M^FVK"Q'O4Z[*I9>$K P01[&B>1KH>>[KY<2,QMH%2_8R-D@'\M&T[!M:;D^D
M)C/,GF_01NX+LCC(*SS%*N)TA2PRG=+F5>L@<@FYH36<MKWMK?414?]/MK :
M[FC;OLC!"M0N:4X5BZ3"4^5V:;.0R^:$L0$K)6/8%H2[YG!J*J IZ[09E^/M
MK<O[L-+)O"[PPPJQR;R\N@JPJZ)SUT4_:XV_IZ4GY0]EHA4]C/H@QT?@ZS0/
M8R >+I>0) X=?D*'&".YH"%=9*'QO#5^04 ZP/M8H>@J=>[5_)G'>2[7%2T_
M;[$.TL31$T0*D&?JSS*21NQAG0!8=DY3E5?,C^;@V/2-QF1\CX)PCS0=&C*L
M#Z_S#G@V@;_0L4$A;6.S1*P$U!H#M*BVWA9=EA&>6I7A+4](#+IA:>&?AM=2
M(T&^=3H]9S['=GV%\G##+'K+P/JY+]+"#&"*KR/QR0<?/9,VT1U88-U)*-Y'
M(R4HMXNJSB6"@6$+4K_,,9Q@T'Y" ENJMD.</ 8/A@.6W_XTW) V:H(ANET&
M=;I+G)G5V(T[43D\3Z^%S _]JL$>O41^HR=C$;2NL!'8$>//,LW LJG,,W0?
MJB@]F)0=Y:P1F9E@AVWG5X:SPDCC#3NM@^K15T\;GG]2+*)LJA6_(J5#QA.>
M:M*9A%FV$4W 7A[LPNA3EXR6Y5IK;+/#(IA%F.:^NRY%>#4(@&>1'30<'(4"
M6JM@D<.MN"21#AM^;3-G),P(Q\[FJ"X4U)[RKF7Q_9F_Y,[6T<6V6"H4G[D$
MAZR1 -L( 58"A!11PG^D$PXT3ZCO424ED$)^.D5;4G-T_UV"OZBR3Z='JV[D
MJ.-_A02J&(>$,#**3(6%1L6B3I+,E#VQLDR#;_X2A5/N]%!6TNE%7Q4SSQ"D
MJ&T,YN"06#00!SC01)G(VJEU9O8J=]&M_*U>IPWK".[%,V:<!4NA,*YSHZL0
M+C:Y:*PJ&X409Q$/.*=VF NUM*ER9/S)BW7QH'-,"# GMG[ H3.*:%U"1JX7
MD*.!:-?B-GEI=8W5P'".P76]+0@,KW*'VP2M"1&<MP6J'!O+X@USD&!MU)=F
MH8%:<H\;MDNDD#HUR3>^.TG=X%H[ $ES<?L:EUG][DG470 R"5]F.Y[-[0G2
M'6*3UXWM[7\[L;U!%]N[2\JF_X1^-/WG@_?_U^\?(*6&/]W#=8 >^*I02V^O
MY[_Z]<5O;UZ?O'WUVZ\^_._MR^?^Z6^OSTY^_?U6=;7=XC<WN?$G/:\R'G$(
M$"?BXOR>G,N(4O;@IY=13O!<J/H\LTI*S;HR"^^.ZPOAAT<8?W!KS3(UDS#@
MH^@QZM$41?+/$)TNG*B2RFUSN&NG[1Y_\=,8]0@4)P'D72O!W@WT)Z <Z(\\
M^:C,S8_$SR%?G%;@>P,?&Y2XI&/\4VY_(O?UY+-PO]-(P-2_0'=/\K:N^#3M
M!?XOQ;07M+Y6ITEB#2@%K=:H")H7DF5"/7],+T/=KTF_T6UIZ&$^074E5F&<
MILMH0EF$9DSI9*+18G7JJ:NMZ]\&.ORG]\5T=D*=F< "92:4'J%M%N.-E->P
M@^@+J'.=*7Q54_CRJ\@&09*Z-*%3@-?<RHS3$ZOMOBI6FHL:GRFG?; F+D_R
M'W ,EWQ[O,FO#+RF9/LZ,4!MY*S*;+((<R)(,'>PTY<;K*M?8PJ\HH6"R)CD
MK3'/>VW/(^5C6XXEV5J7[E@EYH@5H2:=TF9$IVCJP.9NFZK92,]ZCR@@K,T\
M![I2AXQQ56Q$H7N*_.%D_^9%!KOMU$I4 $QMR83M].M+UFQU,IBX >O]CAVT
MS9_B%EV@F=$"M"7I^1H>@V Z81R8IG+ LB3AM9!E,+9J95@T)SUG7$R/JE1/
M:GQ3]/UR=O$:Q-,"G;T]K(8FO-$<X[8:;MCUKM!^I5A&1NYN6S]LL][G<!@,
M X* H'9K<V58(RJ6_JCG_TMM_%?6^4 \?_C#LY[_!C%/7X3D[Y=/W]"TWD@?
M!UC6,X+K?:HYLKXIFLEB%K<F)X_("1$QKD3Z@4ZYEZJQB2XE\W&[0]AL.%B&
M9.-1F,-OC 3ZGU?/C= Q.] 9YE^(:5/* :5S<X:UOIRHBQ$1Z;"8+I1?A!<:
M[&89_L$Y,)J<V^2\6U!5O5R"1YR9FA.D/6JE4<^@3[D4LW)1+4@RJ1W-RUWC
M[)??;?=>HSM?,T9VII&1@&DDE71XDP($0ZL/BI*49C%[",0UJ]= >1>T(4_&
MA%-L-%.="E7F@>!LDUZ#FI?6GZA%@I8 =MFRQ(G#<-SN*YQ,8A&-RT2J#0JG
M*!PEI%UB#Z:([-<>GU$LL18(%;[ 6Z68#C3AKNQ$&H39S*4!Y,IS]FQ%<$A&
MDKB=6717%M='9^8N0=H6AQU'C3VFS7J9WA5DCB\RIT$J]0HDHLO/)UK)TL%F
MSY],R40C5R!EKT'*M>0HKO+R:WCEKO WB4>U\[=G&CC9>VFNF[1/=;D-3!ZC
M$%NXOJEW#@L'Y@I5 /CVR1)H#"AF0VCS\+J\T0?H[/3DMZ<V"<!N-NA>*TU%
MTB0D#RA+!MLCR1=U:ZG2+HGO7;5_$3>)-\4J?%!+ ^,U5KK2QI::8!\6"ECK
MAPC/QS-E)\"+/R;9?1'B?DVVF\^O*MW- V_YJGM7Y69T:.AZ%^@286J%:(QA
M37O'H/=LAH56JFEZ:VK!9@VPHX5'I4@@EWIZ6B[#P!-C7DK9<Q4P>*U)Y8[*
M;])+Y5HWC\KLAG!>7:7MO9JUL$!^><YOI\$I-N_V?Z_-Q<39/F-2GD94$E6*
M8E0,4>-4L]%.MLXI0"T7MZZ5%0JKU2Q1PH MUGG@?937^3?%ZX(:LZNQ7V^K
MN(:U"6-LZN1:F\6A;^*.>=>X8_\Q\I7MR"BO= ]@%4N:<5OMR!HK9>5YS"/*
MICI!Q/2I"4W#;X5KF9B.BDC%%&'3>;RK-)?4W8V&/K*0Q,3U"<T+-E?3!>CZ
MD_>Z4!.>*V(!]#"Y08''$O':--!RP,%GTRK+D26AC7!#C+)H"<MNZP;GZATV
ML&PTF>TJ2)5PO;K>\$F$J^VPW34E=J$H\>#;"5P.N\#E-W,';A(Y0WQMB%7
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M!!82HPO,1 QP_[EW\U2-"]GI*/,0L;$EDX8]A+PNFX3&>77CHJ$S195B@EI
M WV+[[571SO^=7$+ZW=>=069VQ5+U[U@J9?A'G#!2V5WR2V!L*4D3F>M*P1O
M.@9QMW:*$][40G!+E$WKTA0&!N*E7*5I&L<ABC]7FQ)"T&E@E(>9I,D3&(4Z
M._B*2YDH]PSO8_C!T_Z#P,]3R?ZMQH;;; (DL)HF)^_F>DDN'F:X(':?XLRI
M%,:8#5+R(]4&C@&&;T,.I.T*U#NHZ4PF/J%RA3\#=:L9,AWTW?RD%A?#\Y[_
M-OS@?G*FTE6L=+J=]T89OX\H3?KW7=G)7<__5>)QP9E%"&A8%\U>8UOCPY3E
M0$RUQ8/7Q,6&&UH'NPZVA(.M>[/MR]K-V18#KM9SHR!X_NHM%F\S0IFW/<[-
M&Y/IQB:<^FC3HZO^#BTN'=X@5[5Q\8;[#VMV4S3S&EY.S#>N.NNQ$"X#=65!
MTVA(9<)1'JM%&,\^4S@3_/<517,C=:;L9.+M)O4=?3M)?7M=4M\W<P=N;/ZZ
MFD3'P)ZE)2KTH'_X)Q=IQ)ZNDRS#0DC.<\!?H=NIKBX1PQ:-+$[7NC!\_R'I
MFHZ[M4TS!&Z,,2'/]H<$OL]XP"@GP$1#T<%1TOWV=SO8"Z;_05@"E8:$PXN9
MYJN59)_KO)V*<;G$BB1T%<$#.4(6!)YU@.,;T=*E>F^G9O!1^%C2__7R9*YF
M.)M9SCW9U@D!8XJ5)>7N1F!PX.C1V([J-4>M0MHGJ5_=-FZ;2B_*%]'*M4_U
M,$X0=3"LU&LN@4(6N304Y]R*7'O1#>Z5GBU)9I.FB!E0A&H2;ML.;;+SH6DZ
MP-.@DO9"V1B@'8%4 @=WU>-SU,8]+)C(K56'1\(@*)?+AB1-C4M6&+QA^_0H
M)Q];]#T9;Y[@GQXEYG.F!9<?ASDB)U$/@CH<D+:591NHM.*C&V%H9-OT$>I"
M)7^D&\D0P:8P@F;=>D?A$&'/;.6*O?),U\YM;U245>TTL@XM)IA7UP<ILKU<
M AUQYD@M9N/&6BS<SL=0U0RR#@7-G":[[E9ZG[255<N64WQS'9_;M+ZH<F9D
M5",D"RC6)N724<(QLRAW,WDI)^226,4UH!O:.QQ(1@9ZR%T8XRJ*JB6%YY8C
MOV)]' 4!J?^R=F,.9 XB!'Y1)[4X8ITX4KD3YO/R1D\$EYPV=$.V]"71MHH!
M4:Y\B9('J>+/$NMG&6V>+H7F]=2'<V.*?#K+^J[G_S;U."^>NV%2/E;N4UX<
MET]JH84%!$!=)#CPW[:GDL2:",D,SU_*#W7VBHX8N3C<94'Q)J>:V&/C#RE0
M$Q'RZHLPBHD<IXS98B5_CA=YPLEZ9=Z.H:4KN6J= ]Y6.X!*#AIR<"PL+PP/
M-,@Y45[;B5 ;S@QG9:;./BX:HW45;7O!3@TV30EU@#?'LYNC%Z^ASDW;"F$'
M%%^(=+C,37*F";E[UNSU4.;BFV[;NGHXPZT0-BF1O.#/X9)XA3ZIKK3R:-NY
M.@>2&A_#]<\5#M/[G,/T;^HPO<L/T\UYVWZJ=6BWRTZU8]!?M$'D;V7FG9H4
M/[<'Y+EN-]3U>OQR'8<D(Y3AY73'!!?,5F>&MA02"0@G7T9D@2Q/!\?'1[7D
M42S0WO[ L#_H!UXH;1*?--HDMI0V=>[,NR,:T)%(EYEGZ;HPJ445$+Y(P^=5
M$2"D#DDB6#H'I=J(PV'P@4&175.F@=/8)%-NMS:/B>C89JA643PH 7MPS!G3
MV^W#UH:FF$6,00/A6"YB&,-?SMKJ 1B&2'U0RU5A&TSI;@Y+2M75IHL4EFYK
M$NK:BC@9>V^L>0ER\C5H8T->Z)['KZ?MWF(6UVU0'QAO0C_**3[/U2I\0-0T
MAU;:7AZHIZX3(W@)UNWF5?;/!&O(!Q#%_A&?3J\UH'3IC)RF*WF3130^\7@P
M:J8GQ];64Z_*MCI.<V?S1U6AO3BE!;)55%+R3AH' :;-F7+;BL.C0OT8LT>8
MNR=:V(G!)^U1O>;;VHDUHO2U&'Y]@0%90ARU-J8=9<;54'J*SAI:)%VS#3'5
ML,&V_\7K@K%*1&=B7ZMNWOKV]/4S](H2S%BO1M3U(1K5O53X%L;6J:*']/20
M$MN-LND3+'7;^*L*][2OWEWZV_7[\R(%XD^\<X27W)3^*RMG-1"D:6!M^G_R
M,[X\8UJ!1IPM8[+1IL:$/$9F2@Q_O'$9<LR?O,YZ_L\PEO=+& 72(I&_IQQF
MF\V U7?NJVNR;MCO[SEQ_I;D?*14_38?WM88$%B'U\HZ.AJ]W>#X\;<3'-_O
M@N/?S!VXT:QJ6]8/ZOH\"Y=^%(,B@>G)*A>^J9TFIB\S=7+\6#3K^]W=F-LZ
MV$MO?G55S#)NU <6+>=80?+/!P_\/)O\\P'\^__Z_4'OC]7\P7<[3\P_CLT2
M;M&+]R668;R4;C7N;J]JUXD++<(5F#G8!RE&]XIDDZ32\B>DZB6.[(6(^[L/
MUE,R_R,J_1,J- CHWW-0"$DU?"Z-M$EQ-88<V2_/%-APZ8K4Y?^F"3TIB;,P
M49,:>I:E%]BX)?"KR=9^(]G: LZL%MB@*2G).07L^O\[.GC2/SP^>'*TUQ^-
M^L?L#W*JM7AYVE"KE:T[P4Q8\O]028O_B'_TV/^%G4TPO=YO/?]I^L$?#0:#
M8__G#&=S%EY$,66[OHS&43XI<_]="$K]47_HOT.@E:?A!HXFA.?Y 1XV\/_U
M^RL&YAK\ /I'?]^K3LKIUN*N56S)EI7!)@R>/!KM[3\^/#A^<CPZ'!+\F6F/
M$CKB;ZW&>828,(6_*(K5]]]]MUZO>Z48N$_$#MWTP"Y@<%*WV15:'US(%B7<
M(X4P:!D&)TN7;*/H5U3:_.@/3=H7YC.!$502/@T:P5M0'3S"])PC)6'L3 -R
M(/@Z(C18!%PPT@TV ,7N3M,Y5ACY/\?IF'+^)V"O.:<]& []YUB@N3?D (I2
M1> /CHJ%_R).$90;[];O:?8^\'[]'2[1X."H,W;N5-$[?WYJR!JM6(>:D8QS
M->G-TPO.Z1)BS8608&0@F \FI<6E:POP('R&2-;]A6WW)?VMN6,@&/3*)[CM
M+$TD@]$4R>%DRURGYSU_]O/)&^F:?'M4U!&,Z\')O/8SY(I"+0FU7QQ+(+')
M3$FPRGDM76$?!,M*]P)!(K& )=*/D61"EE(>GL[M>MH#(8+%MU&Q\5@&\,O>
M*(&/DA_JSY\[D[CUZ/H.4<LUW29[_6_';7+0N4UVF;*_A#7VM.=5QJ,W3M4D
M91_N]Q26Q29E#WXR252(;8]\S2Q\M_)*M"7]!>SIFT[R,1N_(W/>]0OR]O2U
M1V%,#(9D:J$2C$%2_ 3MC(5"R)()02FBTH=15&HJL(ZFU!QAFJXJL7FT4Q"8
M0*H]1B0#2H8_@W?Y'"PO5SI!#S3*Y8I;J>AN*(L2#<)Q.J6X*&9#3%+6'0-?
M+?%S'?^<E1HAXAQ3VA^M\LUDH1X'_O,\)SGP*(=-@'__.PK\URG8CNC[?$1#
MSV+03/+'K/0^!9MGZC\J2,%]W/->TK*U=87:-)P"O@>7 ).R*\0CD51#?B5A
M.& _7-QU;+& "8V8B8])W]$2K#$J6<)6JW:=TM:OP&'1"DV3#5B@_"XT& D2
MB//].6V8NL/H]^C7J&1AT+Q!L0LG&(JF)FEE#-IZS/51BW"UL@DW&CQOK>+X
M"7?%0/.27!*=P7>7"794?U$/CNN0I>GN).ZD0+N*3'Q>^A@6# 9KX_P!KN2]
M*NBO'*GG*H<J&&8E"\ K8/&JT-=.8=C5M?;F:4C '.%TFJ%/A'\7H<-JD\N\
MI86E<5EP%H/V8X2,58_]>U/N^!-E+;1)*')48..X@LAJ-=V@3;-FH/OA@7^!
MV;VZR*.R*%MV\ZM.+'NMIC3;,_V36D]QMU/7KZ_/3FR7+D'(MV"V_!;E#T:7
M3$$##5/U.9;*Z?:X'R)L1P/## \&_L04J8SZ^"BY#6VB=[7ZW-.9*)4$YTTC
MI7*-D%-Q;+E+:_J'-(E!I)YQE"YE>Z99.0<>*/]R2M$#&EV )CP-/4:[BD#W
M9Y&B]NJR@_"FL]QLH5"A*@CEHUQ)4['<H5[=@&9KZH@I[.\XU]UIW-%/^OIX
M]:,K\YY>7H0^+;P=U3MI+U#S67^&V7R$ T5-/.&&S%/4++[W'PT><_T4(TN1
M-(TC-4,N@(#R2W3@+LA/)2I-"T?2;&VJI&$?M?!>4#]ZP\B0%QGA&:?)7%V@
ME-4TK5]B1K?3RJO<XM'P,?PJ9O8%RHC<IZ\\K83!VR:PB2MD6<G\GP_Z#^C?
M.>HK\N_;B<Z"REHLOJ<L3EAQD>G78*-T/%N]*S#*EFWR?BRF^BD9K=\;[D<)
M>FB*Z4_;OJX.%ZM9<;-;?GQP>&SWO#J1+Q#N9)KWVF@>[;CO_9_+,:CGOX<)
MY6Z=@2H:D,:>80KR.X4=)\WG_R[A9Z7\XW=4;DKE/X,_YV7DGV^R<A7X[\J_
M(OSN+WS^-U01V-$8^"]@H *+TD7HR%<8T# O;'[U;YQ!R^<X6KZ(BO:GJ/1D
M ?^ K7P6CLO&3WKND< -*#+\*]Z KPL$^=Y<:L_WG7M]]3>U<( 'XK2S%^GJ
MP]59PVV= U+5?9QD@QU]^BR_1+(&RV":HY'#J+DR[SH+,U PBW"9QA3*+J7M
M"6BW,5@[\(Y7!,@!;P156O\"><._T32+(V!EJY Y5X4A$#] BOT:6<*]G_])
M[K&3 ^/K5,^ZT8W--/8MRJH,BW'1I<-)'90UO$V/K(&3F8;NMJFRU)AJP^B4
MPB.$ OJ,73D(]8\YSA)/4U($BQKJZS #2Y&KD0[W>T=4B9*K).)&<A<4"&;0
M94R<V#9+%ENC_=Y E[(LZ6D/56KQW;6@K(EZ^Q3[GSY-4]J3YZ(OB[/L$=9/
M/4' _\>ZQP#B66A'A2FJHJ87M9TXF8!1NMQ@8;>VP<\GA,B:<ZWQ^621IN1C
MD(:T\E+\0+W'B8*!B\5,\O0IYI'/E<DF.4\I6JD'!0%=8#P3O6AGI>E>]#(M
M<\7U]MCE.(RU1V^Q68&(4-0>+\!$R[$JQ'%"7\'L8NS\ T>GEE&H;7-<F@;B
MR'TJZ3C@=A/4_P:]>_M'O='#P!\<]_8>TC>#?F__8>"@(\<;-ABLSW'TW9X%
MZ-&C$PDL$;D6B5I<@W#NZ@/Z22C1B)P4VF=C )[1;R-7H+9J34/:S^CI9["B
M'<$W9!++-"=0/=?*,K[)FG'%B$6(^%$LL%$0G*]^Y'TT3=1&/QF N5=$\U+F
M':=K?XQAQU48);6(#GX^S](RF3X!BRK-OD>W2J$H;4(GZ\/I4N%!I'3W&^9@
MVO*L\#-;J2=&YL;=#G.7/*OGD@NG8CBR*\S/G7T*,<JXY"NMIF:+>OZ-K4;F
MCW:E5[$KD18#717/*1Y 2=/ G(>QP-U%T/JL.0T$EF^6*U"^!-D[7T49M8_#
MG&.TBA6B<I?2PQT60BV5:28745;FG6/F;ATSF$:TE8*JCC5=A.7Z:]H<BT&;
M9Y$<AD[;4BH*0V_C:IMGJ/EN@BFU^&9U]V.PQ?^(/L5MKL1JGZ[<V]ZHRVW,
MU*<EV=4 \Z;;Z0^#PZ-]^.WAP0$+U6!P-/(+D >27-_<SBI?[R[#_;T,I_!.
MH+BL[K'<_L0R_ .H:Z*?(XE0\T\;(DJ1N!=I3GE/>>!-X@@DBQ NDC=% B<+
MS.'#W+T(=@?6Z8(/-?.(Z9.\=#[YN81/INB]L)^]+,?*?>I%^0<\9S_PZ"%G
M8/%SP'^K ]'U&&E,]V98H@O??YDXX5A$\]64B&(+#3O;0)IDM!2N28#I>4G)
MSK,RME60RW2J8I.O'66VV!F3!!#C(2$Y482) (7D$4>^L4\'E4)??J%:ZBUA
MV'!:TF"9FB!,C]N6+5'S$#FK!Y,'V4()]+_]SZMG3]!FTI: OJ 40C5:L(P2
M@M93<"QS& S[Q^YU)J;>TCT.]"20!/VC^B\\VV^/FY/J-^5 #0L,<="3!_N#
M;6,/\0N$9U25;@@%D 2%*6(4O%9S$_@Y.V6J?AT./8%5$GNAS.9:P=>[0XB1
M;D3QK>VPH*&T%1?>;J,?/C(\<S.?ZMYZ?Q\<!:/#O> 0%MS22FY[>SZ8^M^'
MQ\'^_G$P/#JXSK.-K2]2[^_#47!\=!0,#@^O,]10@U-Q;R<'3UN.0W(L>(,R
M:C,O50N&XN0\<"3O<\_#QNLE)=<>4%/MJ)/YWP?#8 1;"A1N>I!\_ S@_/9
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MS=W74>]P_[H7MDH-WD>H8;]W-+R-&]LXG='1%Z0&H+[^_G9J\#Z9&A@7P(U
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M],D;$/CCDJ0^2NM)@3_,E7KO8^8"5P;PVG$O\ %%Z>#A!+3798I2V9N56":
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MCL;D@(*R3S00[&&S0JUA-D[!Q-#?+/*;\2SE#%;]V664CF=JSOXPXR&3W]3
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M1V6;>DU5IU2&!2V9K @WB1041%IF#DF2J%T5&[\\RJ/D>S+]U]R VG7FG#$
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M6DNQTKKBD#D+S]628>K6N2I+*&Z-A%3QFYB&SKL:9.KRQN$BQO+15)$^BTA
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MC/YW6:&B]PV4[H?/Z!X@-6O/&];K0;^XC=!09?D%;823KM<%Q;'=J15YWKW
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M1Z,WF;GW-B%M?S>$X0-,R Z8R_N?D'[;&XQJ>54//Q^]T<%C+<^)@3E*J,+
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MX0B3I0E@(D)-HYW?=UGOTL6+%U<LETIO6ZIF?(Q=83$J7=E5]1B*G:]1\)7
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M 5ZP(](96\PPMT)ZG_TNN&AOM,W&8Q/,CL>'9LYD&XRMT?<WJ3BI.*MH45
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M'SRJ]/9?&3;CJ'4)7)_MZ3E/AVQL7GPF5(/Z<D&1!-/H@2<N?0],V'!X\6+
M-HZ;Y'N8&A:9V5ONDETQ5D]V^41K[DO?Q VFYP7)L2O#,9@Y>3P+7IP^"QKL
MM-VG?_I; (TBU[IX?09.PO@[$F0.Z&GMDR1Z8GIBCD),EYRM(B?BY[>_?/CT
M5F5(?'GUO_MV6EG,'8V9/:HICD=:1G/<!3<KHBP/,;I4,XB.Q!;+[ +FA,4<
M!+FWNX*N8CD'BJST5WE/3$],EXGION/IXZ</?[S[_.[#>QVN^-(-__;TRW,0
ML7?,'//QB>AG8G7:%XV783+'-IEI/#Z2<";;X+)KM*Z,,5@5=0B^2W)"?D^C
MFM[W=&K*1T],3\Q)**SV[NKJ^[=?I)*Z39#9CY'%\)(^C[)IP)M$8*W[WH/&
M**".+&/")O64V':V/$(;V</T'W 3;>&!:6VO#FV9_59%I*OK/F(.6".F><G+
M;E_>LF-Y"X*;;0U]GN^RVY/M;:0V+[NZE?XK]> C/_UM[G_]2=/^]E_XW[^M
MU)C8%QD4V"%0\\5?\D1_S^_T3]'2"YGX =,_\]A?O-277GSCPT?PT>$//_T-
M6SJ71[E>>$L_N/]QVSCT;.+_FXO/%DS# 8'LU1.36F61Z"S]0\-W_M_UM?Z+
MSX/YC_I'[P96Y3/_5\;#&= Y,E[J?WA!AB3KU]?R1=HNXEWXEZ)2?/LZC5;P
ML(DK)'^B5LW%GVUO;%W,NTY^/B9]9=CP$6)L>4IJ,B_U+_<KF,>KV)OZLY?Z
M>V_)Q83?1S@U=U1^Z[_4:S1K9%D^W[;Y3V/N_74]Y8LHAH%7Q,DRM6X#M<BG
M\HQ+ZU=LC]:/E^G%B10KM.<M=)HGX,\L2?W%_5/2_[?I3Y_X5Q[" 0&:IS]]
MR&(]I>2\6/PXP2QSV!@)G^O3>_U9T6.9Z5&L8[OBYPQ>T9\5_<;A,S#*+=?O
MN1?K')3<.1"P2OERRF/=&C+=')J&J&EY5G3+QM>T;:\-!_H7>$01!7_0(Z Y
MI_;.2W0O36-_FI'T1-*N_!<Z\*N82)C1D-%"GP%+HR6/$YR<:0Y<F S2I9G,
M'$Y*OX;O+/P$# -!'5*"0YM _'CC8R" KGP@H/AZX@5 Z-<HR)8<:4#ZO[S^
M_8V^BJ-Y-DN)ELE@\IQIQ"+#8:YCLLEDHF>A#[\&.3-O(PC79^@RPQEN?EB0
M5:'+ ]L'#V$B^XJL8G^&!&J-!-JX\H1!OGT$V Q^/+]>>7%Z7QED-"&. WDQ
M3U91F-!Z%0/&WAT<"#BSOA=HLRB!M_"+C<.MLGAVBUM"/@?_7RSX+!4;%_?5
MZP]_O'MS;4Q ML'F6OHS&NQ&ME;PPT7@I7X4OJ0?7WT5N\9;K6(^\^DWR(Q/
MO_^L>S>>'R:I_H_!YP&H D'@-2\]T^_\]):^K5C#OP&1(?PAAFGI4Y[><1[J
M-"A\]!^?G\'/D'7P)V,PI"7%7X[@SZ-1\0TM7W2&,YU%2^ &S!0>3V^]%'F^
M-H([<(RAW42E.%%K\]0K\P2R;CU87Z##>*ZOHL3'UA.:#U^=P<?4&5Q%<4I$
ME 7(8&_2\8""7,B2&>QKJ<K]]P_#'^CO\,),_;VJ-<YP8ZP2^(3ZTTM=M7(?
M#I\+(G:9]@\[^2@*5T2+,DMSON.HI>([P;PEEM:L6L,<D#?__8-A_[!AQ":5
M9[O*](N\,/Z/XTEZ6Q?]._IQ:P0]SMUS*%::3\])/-!/PZP3F>VN2;:'GJW[
M]+-]33='?Q1V9->K992%NY64G,5AZ.=[WO/=+2C]9"?_<1%-J> XYO,F!Y>T
M-26< =E!H&J"N;"X!JTG6X VF:$:6[$VUJ>M=*CG&WV ^5,[^3KETY/GS9[<
M"7.<"3/'-7_NQJ\T;[##DV^,F36RV<BI:0:G0;[!C+'-'*N6S' <\C<.W#('
M=UA/2MKXD:.7<K8=UB;;^^131>"$V*;)1O6DZDO+FC),9H&X,X>/SZ$[$TZX
M;#C!?K=]/F4#=-*I]9VRBZISZ9<ZU0AKX68_M1#KTP28\W#!14Z_"+^<VO2?
M+L".,:<+";#_;?K3W_R<=?Y/&*(["7>Z(%QJD%I5@ZR%D_8^L[V'4<4*G7HP
M^#.ND-88D5P+ N<6&06!T;B1<5/X76YLMH4HGQ7F='/0;,IG7I9PB@5O#Y96
M2,.PJ?[D45.M1)R(/_+V6.<6"D7<5/)J8(ST%8_IHZWL,@8C$Y_26IXRZB'Q
M@G,-!%&,?)YQ$2P$^RX*@N@.YY"L^,Q?^#,=!XK"Y,?3W<M/&<][Z!QE<D\]
MM:<2_X/9MFO#,$(+B[2Z!V$X,!T_Q,RH1@>#^'73=?AT[/9>Y*QNS[_>PS*_
M6D;A#0D*P]*_>K'/4U_L^NH1O.-ZR<'(J@?DUVS*0_W_O) .\D<_"$"LA?EA
M_HO?B]WT^C:.0C@=KZ-P[E.<_ L<%('%J+[$-&\V0[\TG'9,@[&'*DW"&@_,
MYVK,2HB\Z4S3*R*^CZD1?(8!]^!>'/4-E!?"1D-)[8*V#!;]9$2"VI[8;&*9
M4L:1#&J2.#7Y4EY;C;2GJNKT1$)!_'M0VZR]>#AU\3 ]DGB PZ(U)7O)7"$\
M-'@:FV_J4CJ8_KWI8-J6R[J)R$#D\Y0RU]J?ULF.2DCDE&=$TB,+J'UV(1FV
M*E6'.O'].3^O<SX[TCFO6"Z+(*/;<X8Z_)+/@:%T6>>G_ I.0I#A<NO_G^^%
M-X$/5^?*TS_?Q]F*7OWHQ=Z,I]XR"O1?8U <8)=@CM+K6S^8QSPLITU618%&
ME[?4KI,4%(8;7/^_>*K/.4QE/M _-YR^1]*Q9ORX-C-=5USO&KZ/.(0C9MG2
M!JKJ$JQ9[ZAF$ZY+N8'^0<@@ =YY"U]AZ[F6>28ESD$K2)1\($N)U)=R>B<0
M!TJ:-\?= <\B4RJF5;*;Y55G)-/?)4!-HGV*HC3GXL.Y^PP.T#"WUAC]W2RL
M-QP0?@2W1/$(JES&P(%+Q+('8U(#-<ND'VQ?B(VKT,OG7CX_@MWS(^IANV=
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MM6S>$@;5YEEM0,C:B8I-D%];!E!YQR,V&9ML:&T",=N)EN9]>3!6;/S\[OP
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M53?VC\02T]SI5N_>I?XE]L)D!2:ZRK+9E@&S[[TU9D.[,V O73!7;9,9G=&
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M1>E^% 1B&VEIS$,)J>2MX"A\H]=@?SP;#DP=1$* _,Z_3C3!)^'CL+4138L
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M?3>AX^-%?%"^0.U5R1CND2,.5ON.@!T5]T23=U;$[',':1-RCPS\U^HR^;S
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MZ.5J+U<?=8Z:D?\;HKQ;Q5^O)/2;N3O:>5L(S&)C=\1L9_0 @/>'1\"T[XZ
MP57T_1$P;0W,W1G8.4;\(Z-9AH#"VA#.JD/ :?70V]/@NS\^YM4+JUY8=4=8
MU<'O4539CL%<JQ+N*EI;DU\QC69_K7PAV:K1J#*>):%[%% G)1AR#?$]3O>L
M]"?F8D_,ABCQR!BQ(;9'K72J*GS:B? +X"TL04.+$:C;82) ?O"]+,H2\>M[
M><:T4HN)5%]X7Z-8* T5E,MDO8^*ZPZ,''>SD?@=[MV&+!(-066!3?-F+T9;
ML#K'[BF^WP3<6KNU3U94]$+B H5$M6.!%S9%]42,T+9L9MK#:O\."@S*4[!K
M.+ >$#M6.% OAP.U1X8#Q>%9#PKFDN@AD4'TQVD+/P:;9BT^^&&61BHD>R@)
M<VP?:R]VSE?L- 8H3/0Y,,L:E=P+JOUPKM3G2H2(\)%-X,O(8B,(M8HEJFB%
MUG2QA\+$1DEQ0WW9\31+TA"B%$<4B@5/J>%VFPHRT'^7+@G\0J-+0HZ;]W]K
M3GVM?J@;.L>Q)4+GZ<^C+ML@+$7D)0?XV2GR,NPC+_V-<3DWQONVULA-Y75M
M1Z:WQOI-WN5-OF-$QF;&$ X [.?=(S*/*$KZ_I#,< \AF<GD>P,RPSX@T\NJ
M7E8]:8I9<SQF/!XS=SC*XS$$Z%=):QX6O8)\;.^!?@].L/)B+Q7C4LN2*-!7
M4>#/BDX(FO0-D0\J0/=2Q27E@94'C\%*7V^(_8B&(D4N>R[XJ%<#>:EB/T%,
M^22)9GZ1C)J K+I>@G(?WE"?LV@*HI*G%9: ?G^Z9[D_T1=THG=PRKC6A-GF
MJ!QA#2/0&0*X/KTX)IA%"J,47N3"KY(G9?NKW"?2D#6JM6L3XHT--*(A':"+
MM7 641L*N'>K7\JI6H\[C8MN; V:0^V#O=NF(UI 1214 <1V'Z1!?M0QQ!Y,
MD_5\C^QM )PZ.H$DQ/0G)7&RCIZ^7TP(HA<KL;QOO"H!1Y;!'&-<=TI[83G9
MI+U>I!E*ZTP.=R=Z0T\NITK:Z:ND+^8,/!G] DWNG<+E[]'D.D1_K5*GJ7V"
M;&$LW'#/\F8'&Z#F1-OJFE=P7BL&+UIP:C+YV[#9Q'3:.JLV=.U^^H:JFFJH
M6OF]?NA^JMIZ/]5_\IV[I4Z*;JEM!=[ZCLU0M;X9ZF4>]**3R&ZU>3+-JG;F
MK_P7Y<0);>%_(QLU+[VV;9LY0^<E/(F/5IHTR[P,=SC,LT*]/*M"N,_0Z%;#
M5]K+5WO*JP;?]!G_A;;V'6/(7'/"#+/\(;"NKU7S8F!!V=6GCH0XX^\^ZA_C
MZ$^.V6%BXLC9A4@@"[,%O"^0A59P6%+5)5/VN=>FF1_@"[(#/*[+4DQ0C*D^
M1H<S+#4<MW R7ROL+3>T%6LL<FIIC@ZS8+5<=UCVJ-".0%9JTFF ?2CS-I5E
M[JI\W#ON!4#GLFC_*1NGE*'E1#U[_G,_A%FEF>AH6TGC\^*P1*D,N[XD%EW!
MW$#4\R75U6^;'1L/#;@\1KV8.24Q(WH$[9J$TB)CRKG4N!E(QFA2QL@;, %K
M1GZZWR%'M@9^48V6>FN@0_0W9I U]<1:MPAD"ZN=P*>+Z_% B6/'7O;]>Z!W
M=?D\G8_Z>WRK;8&OQP]TH(#8[@3N><-]E,H9.;IV_9^(0Q7J$[8MUX/("_,+
M4AQJF?-CCK!2RZ4+MZ(IU]Y[$!5-WZC[JY\8MV7;N3B+*'8O#WIY\&!Y4+6D
MIU$<TV6<2"@&>:\+7U$YHX\R5<JOHC>HW%GB0:0(@#4<7)J-E!T(]O+,7R$2
MU*T7\]LHF*ODP?7<-M#\5Q$BO$GX7LK6HSR!!Y$Q@_>$^3#-$C_D24(33WA!
MW1V/,04AO/;)"8FU4J#CD'*$^8H9=7T$>Q7^=FY2[73ULT>JM44GU(=C4RE@
MDE[%[1.S3BTQ*[]--FB,0G^SAD,X'D,!K+E8)#S%D]6F+<KJ?]>F=R@["W^!
MB9$@MM,^!;D_%YT^%WB-Y&YQVLP.FSB$5544?-*V+KGK9>T NM3!6OK=BV>W
M!ZVC[C=[O]D?\_%/2HAC4&BCE3 Q#.;:XT?8" _0^[6'J?W[5.7/(%>67/#J
M-)^ZT_V1VKT]&C+#<G>-._6J_<7D3YOVZEO',ZB?GL3:5?-X&@]DGJP[M(G@
M-7/#P.H1-I0FRB;#)']RH+\1MTF]= SO%ZRW\.>^%]_K_PBQ.!6NE"\Q)HR(
MS"RBXM/O/X_SY"RR<4#B_/;IM?XS?I141&7TB$R0M A0IS![A$8+^9V,:],
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M5L*<<=[CLD:87B9,5<N ]LQG/NC:Y?U"'05PLU9W#3RQ\(,EK>F<(R^!_OE
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MBD.5@T\#_0T/_!!#WVF^M+)66MSK=V#YI#R\CA:PV6X\/U1XH8T;3\OWCO#
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M#A+6,H8IA1JKF;!*UR)334:"BSB"_L>K+X-S<I%4YW+J.J68TVNYQ;5714;
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M8?!L_SAXMKMT@3VUA=@/GAT?!_O/7JS=H_Z @;-RN,-9;DMQ92HNZ_ZFK@Q
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M:&3B1HFO3QD['5IOA\S8.C 4&3LPX7]3,XZ\&+C;0XH/JA@DQ;%?"4A[TF]
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MU#WT?R^S* \CRM'OVKX_Y=/\]I>77_[[__8[ULE#ZEAUUIA;*8^[M<-[CS'
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M\K#0J#:/"#/YXFBH404,KURP>NZ9_^"Y9WU8H \+]&&!/^.[HN1Y[!!=/^+
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MAI<ESY"F\7@OPEMYQ>0B&Z5QK&8Y?,+\J^8&8R)N5KQ>-R";9B%?&<N689N
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M&'RUDEA7TXQ?^R?UH_%/#9VX8)<@RW+_%!8G ^GS6S3Z.E%3KN<Z50O__#R
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M@'3M/I_MN^08G4,\U@PD7Y-C+2=LCC+O+P?!P?/C8/_9 ;W]E[WCX/G^06!
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ML/X3>)X!<O",@)F&QX8AZ8[:OQWX$_CJ)5;GA:GF' !5PBVD*#D 9!!6\0A
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M<TO+K-X&LV^ULXY0T/G8JQ?^9WI<YHU0O0./!YN[H+0DXT>RO4V*"6KC4_C
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M. I,MM3?=#8"39JE"PPR(Y9!_$R@,<*(V:@%Q]:1/Y>P9J&RM04+U/QS"G;
M+.+"*<9JS"?-O!73 5')JP1;PL/$0%4[3+O3'*6!?DPUJ,O0HKXAF(BE.7H8
M'"P)RK1UMEP!/D]+C"P:VX-G[[@YN&0AI'/6IR&OM;BK67*'/;IDP^U&,:-;
M/Y:]D>4NEMO318EAC$?&IJ9V5J83C\MW5+RLR,\>EZ'VDC39<<Y-ZL<I>]RY
MU-C53Q FQGP#:Y?M:S\W2,0JLC2;VC(;N?3M6;8(&33#//7,"J"*E>"K9MJ9
MOBACQ9@XE%PO"=C1E.%Y$:VW:"F9_=#>YX@R]W6."G:43ZBQ4E/C";QVG9"[
M&!F%4.KGKE8(^T.VUD.VHL^5W7[NF9YB_(H**OF^@Y]:7B0P'XTUUKCM]L!B
MTYP"_B\WO$QW8 E'!2M/@&)R3'OT1Z[!'>Z8E[>YY17>@&Q?+,P=I,9C%9%8
MM_"M+3G-\+*.<PT/9=J>:BGNXZM#CBK#$8A!P7!+-YMU()!^]J*N%J+( _M-
M@4>@<KBJNKC7F-=SF2SA5S!/.I54"/I+#$G6'+R8Z 5[-QU R"E#'A78,,.6
MA+>P5^#K"%_P;)JN#&6Z,DI\1>JM1C PB,8L$+XB=K\PQB&^:MPQYA0M!% 3
M9B 8QD7JW)@QL;&].%7A\5.V&Z7HB]W=XIY%_S2+BB#UY/:&>Y\),LQJ?UIN
M\>FPJ4,'8^X3@_Y;<[,31;U,6_HN2@:?B39X]">$7HI8K6%5:T$KX[2F^6(5
MI*!VH]#]$^4CK(),L5%DU7L1VZBBRJ>_C30U)4&%[9([E$0)27-1P=#!&'C-
MV3J]X7K,S+73?X4*P_7+#HNCQEW5]9N+.=.7Z5<R#RZQPIFQ+TEP]E7.Z][9
MADY:\W*,'4<'": TR](YQ@RTM#])T> K+C %$J,,8-]=:%)#Z007U%@I(+Q*
M^(G?47FNX8$AR$Z#($I^-^-7(*0#Z7DV4K.H4/9FG8$T0.[)-.):HLZ;YR7R
MTA &*4W_:!;*N1Z5(JDL$EY9,-XIPQ-A-POLT@3CR\,+S_1=AB&+P(\C-8P8
M5B\S3? J%XWI.8EDH>+@3-G?BDC;V#:4HZLG"B/D?O<Q&*CD85@YH88%'DYS
MT:NM=Y5)O?]T,JE?])G4FY9)O?&7P$D38@(TMZ">Z1HP /.R,85A9<RX#=R>
M\T&SMI)[6*FX:A*'7;,8( X5!1BT\/@/MM,@FV'X#?.$^:8H&O#IA!%TI%1S
MNDWA<+3K,.865R]N5:YH2N(#=?,RRHJ2_']8=&:>S -9"U<;I\:CTC &'175
M96,2;-R[1@"7JR]&!!523+*TO)@$(.ZWZ9*"^V%B@IIABFH3$D++3+_T3%?R
MM&00I<18L^R%Y&N0>YW%,:<SFX>-GT80\0U,MR""6$@B;+:Z93HK#G.#39T3
M*+48-KR4GEU*6C_,7$) MY3 X72<SK>!O,2X4W-M2^+)KI &8K-9C##:#PQ-
MT:<=]343]Y]A=#?0%/=.)YYT@2<RWC!1? .B^:)4(+@Q<"+Y"M,$E=^:W/^I
M3R-\M.?Y\$5_GND\1]TXSVR(QZ)F508JUQ:8AKNH[X!Z9-J"6+>E*%)CL6)!
MK='CJ'"\V(1R: Q74&[Z).+^]#^)T]^1XZ_(3;7DFR)ZC7]JQ5&F4U_U:[ 6
M(,B)7,=CML[RO,34";S[,=5#7&%DQ*6QZ CLDZ/41_&RJ9A308B,W]$3#'H_
M!]7P[\:YKU9I&Q7R>*6J&#6EKVMZO.*G-R9$_-P-EM;]ERM0OL=<UZ4,D5N3
M- SJHPG4V7&46%\0_;$NA2)NO<<95BYT_(S"@=&,(N[H[.%D,D=$D \F$_V'
M1B5Q(P"L/D5$ASOUWXW;)&%$$0\AP_EN+X)Z$?3H1=#=P(3=OP*TT@7-B$4K
MW-"*>OC97#>NG4S#A9-%Z7JJ'0<Q.F)79&S45"!R;7-)>,:T.*FO@<44K'N*
M)^D\3SF#@I+>0TJ=4 72T/"+FXRZ-B=XF&KNV5NP3_EKDLY!?%YPU3L!S3M^
M]ZI_.HG"1%>=&B69U[CZ8] '3<(L]EP 58TF505II0J]L91;S? FDM%X1MSC
M9LV=%6?DZBRZU.&V!$J+9O](7UVJ*"9I531:7=JVFK&^!%VS\=U>EO>R_-'+
M\KL!H'L06:XX\H;)9Q<@QRHSDI/?Z#?+04A7S)N>Y]:9)?)J.HO3A>;ZF?)*
MPYBM4U?X@RP5R&;IKEH'RY/BF,LHUIP%HT(4-1C+1BE<I:/:]Z6RJ2(*?L'%
MBB@^W>E0M*]WO/6BZFF(JH[@D>&)Y^SQA@)F:_5G93::J)PKHA3J,ER18]/+
MC/  "10E>9G17Z5+,Y>#N*EG6T6MRF^&&<9%L:+.;UN,7_:GB:EMND'7,HKA
MS3&(.[&!]3>L3HXH"0_[T3CU7$YCN 2TL;'FET!+Q?Q>0APPM$N@ <9FU%"1
MQV%:!1U9O,.48%'PJ->@B_Q:2S$LOKI,HU!B&>1"P*<=6A\.NF#=@G'CZ:\W
MS6G/(=I".VE5JLKV7:08>:M2C.12YQN]-5&(\T)#G8^R:(@7_3"]O,?BN0[Q
MSMU7W)^RU1C]F\(66 WV,4M!9>N+[>^)U.5D;RKUOB2C>61V0]][?E;?):A7
M+.^/Q WL$F0K%TP]!<LYNH5LUVW4#&=J(4Y)(GN6:>X&%U'W9'0(PMVY9:L9
M,O;R<36\C(G^N,H;QOU9\P)N,T)TV'Y00[(_VOW1WL# Z%T?[;R<PEB*32(Q
MU-C!7^L4B\=Y&I53ZTHJI?&0>,_A#3V=40H'^N.S2TU=;>$+O86S,?2C#J6F
MM'6B/(7BFZP4J)#K7[G!,9@E8&(4E=.O%IU ?!0&RR$\D*'622W<#2PT42$!
MB^"?K"C7(9;,SM6"+7JY&:BL@,VI7$TUVT09Y0/V-LQ=%9,=/)UBLN.^F*PO
M)OLNV_YM!%IMR(;])PK1WKM1WU]=U]!_/O;FFNP#N'&PQGH6+%](Y+9S *E=
M! 8NWK8)$[E*1J*MB G3#CHWP[0!U0(OYRD$JR.E"5NF"LLPT$^8"IH+98-B
MI;@$\L:IO-27D?6V3)=MF:Y4C*6B7U(1+)YA$ C3-+FPH:Z:_,!?V.3PIM]#
M@!] C 0.E%*9(8!>P*TT0+'BD+Y]E$&6#*;.))U+EB:CA9G4JCAF'3S+(L3B
M0]0F;/A3S%%M7J*2O")C]JUP7A,G!K@/(9)@V+M*>O'RB,+K'4DL1TG M>9U
M8<).41$HI)FPE$";-P,RM)2U-/)_ED!'V6.* 79.&*0((YG51N691^S-*6>/
MSO?2=36V'L4BMPFQ@@7IPRH! WC@SS0W@[-%CM7.FKW^!4&606DM*[YJXELF
M4A\)]\S8P )Z[&81'5A:TEGD9%1Z-2/)F00P@[O0PUVMV3C]))T#,>3\CK%(
M>^MTW?3_BEF77HOY"#8KN5._:CUSVC[BB3.=*:2'189:'CE3N6@(>T/R[V$:
MW5V97IU;AZ[451WO__N/XV?/C^^(\ = (TG4U'B6PA NT%SZ(KJ1,]'= O0B
M%:J0G*]Q9=?EW,I\N/"IPT"MU(8  45=Y,#-3$4AHT=GN@K?8(%S2"(#+$=\
MA,MVTL3]#&9)-K[07D*R :>E0P>D)W4UJ3U+;2:IW1*SU,4E39PZ9Q2\1M(Z
MJ'ISD'Y&=Q+99U4N2N=U1=]*%UG/JSVIO?A[S/O49?%7B3LB>J15;O7 FH![
M=,Z_[EK!*_T#M1O*<0J( 3&BIQ=8]#'+HJGRQPI#6)I2ID:V 117<^74EE%:
ML*+;P-^B&%64U[_C.=^AAH^9(LAT<CR6DL0'SXRIGC6I?8%R>C/F-RHO\<N$
MVLMG>EAB31?#P];XT'ZXJI=I(X4JY?74%*A*A5IKTSR$!D#7*6+PQSXEG-42
MU*@9!"Z&*>NB?&5,*FM\WUGRWK&YSMP.H],U]#E"4ABEF8!4&-6.08E3J2*D
M-BAX6EIVE=",H[$XV!!@F=#QQZJ,*7VUQ/I'X%]$M@]UK!9>E/!G&$^BSBW_
M/WMOWMPVDN0-_X]/@?".GY#>H-@\=;1G.H+6T>:,+7DE>7HZ-IYX B1!$6,0
MX."0K/WT;UY5*("@1,FB1$K8B)VV2+!01V96GK^D% YG6,1R!EK$IQ=+X@([
M,SO*C\.<FP H]BKRW&MW9&TI[/V%XR@ ?RTE$@0_VU8-K BO>,D@ 5=V2N=U
MDAHY-AW@OX=P[AY"B*BNOCP@]5W@;!>0#FDL%9$X =!>6)A$F 1*V3EP%M@1
M+AY3I)OG0B252;.A@P'UJ?/=S:8$\[-X1C0+->XX-\V*A9^I_NVKN@:L"Q*W
M5?!A?6**F"+G3JGIB2OI)]Q6B7N3<,N1^<Y19KVTSBE!:/A(N@FK<IYA=L=R
M>@NVK>-F?I+F(HR*0.]P1S/&3<WX/?RAYL2=E_Z3PN8HIJ9'!8X"Q?=,/AR&
M 1A$,:7LR9"^!S> (]V?LLXIG*J'O5X+D\@<H-0ZBA&!]!JQ]8]N156W+TB(
M#:5Y)<9EG!%.P$4H#$)@,I%\N,M6-@G]0MH, \X'Y36(-"_ &R>#Y1]F:?14
M*<\OH/3X&+Z+LMZ&J!:!CD98N,8=<A6%'!0.!PGH/)P5$/H,&%()QA>;?R]6
MC=C9BL-_DQH2I)1.BB4.V!U!^"/B7J_$7J2P +>.I$ETHLITJG*(9PJW']:M
MW'CTQI$[#+DUYZ\$MN.#R'OWVQ=5C7\8<L%_K%=>U8(_RWG]X5HD/ZESGS84
MI/^Q!DM0> RQ"&KN",)ZOI;+*'&YO;)NM9Z)=OH%)V%E4 LP G;*;#4^]$$\
M6YVZW:?^RZ*G!H81>TL/-C_D&\_2%(J"H6+T9V+TH^49_?C'<(+0'<SHH5_Q
M^3,?UX7K6@:OV??R6K/UX6/=_J@X^0RTN&O/O9&OSK/.Z/+)&;'Y9^=&?7 "
M2C&LQBX>?5TXN3KVY^'2X^6Y]-+Y09]5S/GLI_35#6>^J_I&6^?N+!WXWA!O
MT\,)W*]V=C:5U^!EO0:Z',T>@ D\%GU&!P#PN+ =&FE38)1CVCE(1?;4HP'/
M#H8)V+H^-28ETU4_O..[UZYO)W+<*A'9=:( ,==J',^R* 1A6-22YV24AL<*
M2H#R*=$N2OW$0Y4.;7%)@Y\YY.XLIEU5IN]R\W]D/7GGS=23-QN-JJ!\62+:
M3!Y8Q7WH_7:L!:+5#X;8G1(N0$[9W^!5J8/9Y&7T"-$8[B)+XF394=G94:$E
MH")->=W&GM-M:@HP]+A_B;^3.X[RTF91.$W]*\< /KTX//UZB/?B%R>"F["Y
M6[-;C<8>1]@&[A #HNP*1B<V//=W)TC10=&D!_=U*"Z 6Q,N2LYZ.W$'$3W5
MZN!CS;TL8M>?PO0Q 9EOY//4=S7(O)JR)4LH>U:OQR5$H/D%88(SQ@6#H>?C
M7([<(05B;;VT^]<C2['@^QX<AF^WVK2.@YJA7+!_E#4$\?-$+N9 !TG^*1@P
M"(.=LB_K<( E/T%-(OO;\I@20(T1V]*+;/XL%F<[^W^4DQ:KC8E6S@]5S]I(
M7+^M[ONZ?;I@-IBPD$AQ%R8M>$G*H0WV3EDX7GYJ]MS4YB<VN.5H1W'$GYVM
M11T;@K!LJCA8[<Z=YWX/,GT)G\-8B&2>.(P8)]#$2'KTL-KXW-LL_;;[=D8?
M6N[,C)5C<<XH'6+#,%E_L_&^TAY?TIU+:("![?[ @!<<C,YS"'0+#.D<0I%
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M3_J?<'$<=FO$@AQ4/20:HAHM<B&9$<TL>TF-X_+2'53-""NU]!NSZ]8J"^>
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MXPU6B!<+I57V>F:M"?ZMTANQ_!8)-E>#BX&VV8SRT+D:-RL@LS[](W-,%ZK
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M40C&BC,-4Q9,H]PA3YV1BU@(::Q"<)2$!0<],Z[SHHC(<!0LDDUZ</0;@9"
M1W"8B>N/V($TCL+I-HN]*Q"M('S]6[Q*>1RZ=4%DW*+,X/F*:,9,-R%4]9%(
M2Y4Q$KE#UYLE%JP!?EZS86$Z7X<+G!,42*2KT.^,Y:.LGSD>5DLG2KISHDU"
M(*_#83J5'F^N$R%$A,C5*!RCZ<>)> AK38E I$A8"WUQ$?SAS>"<MNOV'X5-
M5@X]-Y=C5),9*TZE_<-L.=@Y%^C+4]AGN<=V:$NNW9$U<D<I:SL.)CDIB:Y]
MAY2HHV9!I*'>I(:P\>#DLJ69F;^N<E1>;/Y(/Y9!/YAWN(B&,LP3(Y"6?Z1
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M*YO.:*O3AO:S;(##<#I#$9'#2*GN@I>>?\_2<!5F00%Z;#*G-@<GJ I? 1X
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M#\!03U1O[LZ,S6=X.4/5+D&MQ+W4^%\9K(OL0.%B$%*7&P__TVQ]4) ']K)
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M!UDTF*,5\>220#)>FW^A>HW>$S@!;+QI+EY!0%=VS O.GS 7R(WZR2/G>S_
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M7$]%>3V]"6]Q5NM#$UK,[#;6'4^Q\Z03_'C[ZW-U6);YMW>?= &_Q+_0I!6
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MT$)CXVFA^W!:>!G^;S\3F1@9^M1&9Q+ZF!<A-0L*.^YM$LON6@F.SG-1A"[
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M%,6.4I ?3'[X+2P\]46.*6S$^Y',U;BTP$JRB-HW9.!Z8!M->?&B8P-Z#49
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M;*X=/W7H*E76\;R*BY7?I!IC;3=!!&,/8#CE*6FV4^P3.K@UU O"_[UQP2:
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M/6,DIJC'D]ZDW?'I+#V4%! ;*0\E72SE*$^F<8B325&&G>%D2L"T5[V8G+R
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MVZZ^O=HB<X@A2TP4?\I6>DA*T<S\7H]N?LA>+20D[->8>)+=;F1EDO*W589
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ME_?W^L7E_?G=U2W^(3KSG4J #S/'F" 1TIQWO:;VZEW"R8?/:"OY$\\G^EX
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MXCZJJ&E61GY$\,A2/H.5)'8XY4UMHHN<%WF"L<IC$+ @##/QL$WB-S6^N)D
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M\WJK5:D:[<ZBK4\Z:[6HKA169^&IK*9Y_: TK]>-3K6>A>;UHM)\MNJ*%SF
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M:63-XA%(= 2U)PA[;Q8>H[^[9TSFZ8O>:I&J!:)9MD#DVP+1*%L@BE'O7G9
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M'X%GEC'*ON8Q.U3Q\DWH&NKTKE>@T5L9ZU9;2^M6TY_[7N+H* ZF%.U5CS?
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M63$TD2 []P9$$-K:U1@#G")N!N+P?MH+25M4*PW\DC[3Q8<]KPGL(7)K<I)
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M*9;9J)BN8/,Y[HBUTF6L-6"S.&9OX!"8*V5C9C31PODQ4!_N0SI@H/YA:QK
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M261XX:CB1CRHN#G9VJ!D]AP<GCW[:-,(Z;6![VX8?B*BAD= U'C"CZO<6WD
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MM$_ZTGJ3C)#&.EIYRR1[-5TV29&OHA;LF(K?GU93>[)YFD1&%+HERG9+<*+
MBT*%V9<S29&FH*I$QJ$$JGI\;YA_L,DQRUR>WVV-2QG=V.,GHW0\GUF-2W&
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M[;GV6P.*JJEK##D?4TW^H4AS<%*0D,^RI/'T:JT\\<9>C#+NO^;&7[]P[ZO
M+@D,%57>%1BM'2&]#C-8.T-5:#O .JHP:32,*+:);=*])Y9O>2=(9)-;2(:Q
MO0"KX$TR9+.&(JE0&TN)^J@2N_]"VF'FPN$'@.$*H> "(6D0GRAT^7'$HL5<
MI5")=6--@76)U9"5P'HT'O"#0<FBLYK'E60,N\?RHQ<5I68Y>KK6TE8Y:;&
MEULA;CR]".:AF!EM3.=W3D/:(S&)\4K0")PN%@9X=Z8'[1O=^.; >NJ .H'G
M>T-^+.0?&9AS#.]YX;9*X5$C;L=]OM^O";4U[:]X]L_8.$8"N4JV];EG8)HD
M#L#MC_CA*#V>EG;K8T"L2F;("K'Q<,)/,@PZ/3F5^<_TM'7(GJ]#MA8>Z%;R
MT8G^2)*C6.2LIZ>4,J9,A6[\RHT&2?N<B5,V[$,.._%'R/+4/[V@2D7TW=#-
M1+\OJ_YIATI4J>U2T))5R1UYHD2V 'W^]%NFQ>.C=O%XO8O'A^WB\88NW&YW
MCK<[QT]WY[@PS)5%'91,7<<H*7^=Q :^HLMHTP8*)3"=K2I_$E59Z;K<<1+<
M(,Y4Y7_9[>%7$48I3^LAX'?VPGD*S45@9D):8^#&S95'?!>+%:2H$F9GXE '
M[H*M>XK%S>%@Y!7>('$;W:"??E-4E38RS=US$OF2NY,TD()8O8'H,A70<B8M
MUR"O\#,\FT<;?L6Q+KE7XI1SO- J#A[>*N$7;57F)-9^C.?8+]=8VA;@+P-T
ML&U!M=%LH34=!EG0@]EK6V5E(T0R-*P;P4(50 P[(/Z\L+SG.F]C'1!\QX,Q
MYX3?'90";%XE1:7Y<#J'B=:44&C!ZS>V@:4+)KTO ( 8\$<5\ _G06=*-[!V
M1;56NOVRXOZF2-K+3X7[78-#&B9]N4WO)@&P+)ITZL@VK:QQYSTEC'ORE;P
ME$""K!4-X83 !N0J)K<&A<GH;XN_UBABG;^;D9!E2)J3CHM[MWT$7X9[W<%>
MA5\ZP//@K&BARY4OCFE>\<8HE]@9EJZ8 =']<?Z)@Q?!%S;2%JG0$]4G6W<T
MS@7%4?EZ-C_XF/PRK1J*C2H#:@[HC(L5"&T6ON(@>,<# TY;!]30 IBV#"@
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MO=C]]>'K[(K^*/SZZ;+S2-:*96&&C29"=G=U,D(T\X+ <E[AH@(^RQZ[!OK
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MEG2)E"/ I"@9Z:X#I^*>1=79K'W%[, )_TTGXNN<JJP5-C(?+DZK],#Q<A9
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MO9.80(HVI#<O, <' 54FZP;E,QQIR68MR0[=LTIE=TTU(SDV^L-D%6^[E$N
M?;W@3(H>\N:A^-2E9#(NHM^\_DD6;)3)#/N,<>;9VTIW]-]>Q-"-#M+(+3S?
M_SZS(\VQUL=1=OBG*'5'!4!8XWECT^$6- ^(JS:!LQQ,<!8XC318^D+T%T/:
M@,6 G"/]RJVH>^BW._#*K$);(Q%"\&R9:E" J<J6U;$R%'_,@,)&QK9Z>I_/
M=%J0"M(5B^VH5>?'*R,0S[.OP&AO*G:&!; S^)#FR"7Z8J 091OG9/U3 E$$
MEH07<G1*_?P^&:M)78 RW:"RU5ZHG8'_!MPLW'^[T146M%KHJBIM3/*9<W_Z
M%82A;*T09]U?6% H"_X^8"3EORS#??XKMFB!^G31R"(T'YQXBR4' E1.T$G
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MUI$-73SY%-C'&K76#H(S!."5'WZW%'P_=-.\)]9L^2S]]!,?3FW[/Q\NPNO
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MZF6N 0K/.T& ]G:_S \$Z"QK+@$*SU)!8#W?9V;0BEP#=.M6*A?0Y@+4^$B
M+K#F$J#P! <$UO,!RKH]7'^YT>&9"0C0%@-T_2[N FL> 6I $!B+(SJ^#L>
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M;K:8D+V4?<WCE[_[Q)T<L\>&<> ?_Q]02P,$%     @ &X=*5NI-'8<'!P
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MDFXRO4AD="V]$J<*H$A#3Z;S9B.$=J$R +BD(LM-(<GF(I<I$I^1$]"*"E
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M^U9YM"C- AEC76^*(FUBML!E4[TVDSEZ3HK,P2.YX)1D&>QS?'(@==4"I'.
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MLX=O<YM['K ,VM)O-OM7'?U&] =02P,$%     @ &X=*5APCF-ZP P  %@T
M !L   !F,C!F,C R,F5X,3,M,E]U;FEV97)S92YH=&W=5UUOXD84?4?B/UQ9
M2I1(!@QL5ET@2,:8C25J$':DYG&PQS!=>\8['F]"?WWO&,PFJ[24;=.NBA#8
MGOMQSID[=SRCN_#G^;C9&-VY]A3_07]&H1?.W?&HL__'T<YA>#193!\@"!_F
M[JV1"*X&T+5R!2'+: $^?825R @W]P],"*ADB8&.Z+H\UV\(&9$;Q@>@3:TA
M*/JD6B1E&WPDV6:KC/%H,G:?MFS-%'3[[=ZH,T'8R[=(&%&NJ#3&EWQ=Y,,W
M3H*T''<5>C//L4-OX<-B!N&="\Z=Y\Y@YOFV[WCV'!^CA;MJ-I;WJ^#>]D,(
M%Q"X3N7SP7J/!O^")(A6@POLU<3VW:"U^&7N/H#MA!IVS[+^V6EYXRGXM2P4
M2W;&V.,0"<YII)C@\,C4%M26@LUY25)8T5Q(!2*!>\Z^4%E0G(0MD1F):*E8
M1-("/-^!*^USF<:?2S%T1)83OKN4U=TU8-B9D!E*U)I!(F05?T>)!,IC&B/8
M7-%L327T+1.M>CT32 $)2W'P""B@42F98LB7\!C<IVA+^ ;A8+J,%85&CU]M
M&A-%84LE1=C/@>W)U+A,\$R8,PX/&,<$9\MH C/&"8\8,E\D"8L0$\;0(0ZD
M3*P&J84S(2]E41*N0 GH_M1LW+>#MM/6."LEN_T;J^)!8H'\XA?VM9&NW4."
M@,@UX;1H+9Y2N@,[JE37967B.*G<LAU\XN(1==G0P=\IC%<JX3\JOZON-81(
M_U!H29FF.RS(+$_U3!]G7]+/)9,TPZ58-!LHS%>9KPB6F(3NS55\?13S:['4
MA5(KVOW0?S?4)?0_T:^WUX]Q7%D9J33!]:P(XUAS;+\@:G$)D^FNV<@E+;20
MIAXG:8J)L,'IHL>!'(4MS,HM.2X&C!BS*K9>>VA5IJK0:HJ<RBII\<U":?^X
MC= 83Y'O &9T+4LB=QBA:CO]MX,<VI,Y;FON?!XL;<?S/]X:EE'=+^WIM+X_
M.^DCB]56FUH70U@+&5/9BD2:DKQ ?O654;WPC,+5X<5G%$[K5%]T,\,F7I>5
M$CGN<[,%[K#/P+0*]AO=(S+&DQUV'FVA7YRFST(Z"TW.OS5Z1R8'2&NAE,@&
M,$E)] FZ[1MD5HB4Q4/X%L#>]!2&3M$Y=NY7P1SUQTO\69VEP%'7=Q?&\T G
M???@C^XW%Z=X^"3#Z]?E_&LY^MV32?Y4J-KK$.Z]]9+RV=I]CV"G"(1,I=\G
MTZG(?[#GGU%2G6IECW_,-O<RH#[?Z'/-_J"CST._ U!+ P04    "  ;ATI6
M2[;,,1\$  "9$P  &P   &8R,&8R,#(R97@Q-2TQ7W5N:79E<G-E+FAT;=U8
MVV[;1A!])\!_F JHT0*Z4'*=()(L0-8E46([@J0V<%^*%3DBUR%WF=VE+>7K
M.TM2MAP%C0OXH:P>1' O,W-FSLP.M_]N=74Y<)W^N\EP3$^PO_YJMKJ<#/JM
MXDFSK7*Z?_%Q? /+U<WEY+RVD<)TH>VE!E8\00W7> \+F3!1+P;JL$3%-S7:
M2%OG^WT)4R$77?!Z8'!K&BSF(;TJ'D:F-NA//UZO#E4T-BSA\:[[STIZD*_5
M_"L6-I&DB\%D&_$U-] ^:[;[K0N"9*738_X\FVXS;?AF]Y)6G8BU3GL_,*1A
M9)H;4[ZNI3$R.3+/1V%0O:C/9E=O8;D8G==PVSYKM/_RO';S-@UK,+Q<G==J
M>R41VFAUH7/V)MWVX)X')NK"J]=>NJT=>?FG1@.F'..@"XLLQL:<A0B-QJ _
MGOWQ;-REBK;G_5Q[LO,00VIZL)8J0%5(NHB9_QG:S3/BJ)8Q#Q[]3Q(&Y?^!
M?:TG!OZG0O,#XGR'MH60YZ3H'@W!H*7>2YK=]EQGBFN5,;6K0\?KG%8.0D4]
MOY)=U_E=\#M4&F$>,94P'S/#?19KF%V/*H>H\^K,==YS$=[R#(9W*#*L@WT/
MF0AUQ 1,?"EDPGU@(H 5^I&0L0PM8ACC'<8R32@QX4\IL'+HW_,3I;]DLD=K
MK1L(\Y;#7,D[+OSJP9FC3&,L(6G766":K6,*G=S *.*"50Y11>O$&)ERG257
MK2L6L*1>.0 5]?LG=)T(%:YW0%5+V[ID))@(0>&&QBFIM1V1F8(-5\D^54"P
M!"$3U.7DJR-D =5 #2=Q8!?,#"9P"A]P!S.QD53U#9?B) F8CGKC)BRX_@Q3
MYANI=#EJAS0L,&8& ]+I.F-)(N$BTUR@UL!%D9,G*E>1E]=#=6VO"<,@X%83
MU=ICO9,FK-CV<.1I_L-1^C^N+W62#?O3S'6^<YP]B&)"9&2$PE0J U+ E(RA
MUJ,QI2 4/ML1YP')A0&%)R4$:W+FJ9<W*!WXQ2XIX0T+88M<6&G*KW6XC[@?
M45,:Q[ F<S8\)E'WW$2Y^"7ZF2)GH,X]-=GZ=#A13SF22<*U)E!/="PGH[UD
M:ZZ="2@28-DA-TWXA$ 8Y;<T(:4V2.0P$W&]GW6=& WUG@?63$; K"6 Y?=0
M*> )MF;E$JBB>3\3KA/R.QLZG1&)RK@1IRCL$H0T-CAY76!!8J,5,6,G?4EY
M;Z/*"X[XQ)%0JIUE0$II07*(EU+C U&(%0J_9%P1.8N"0<RT.06O:9/K?,/5
MH6^LK/:;T],Z4*8\UIB#10]D?ES]6]TF)S(+AFGJR2S;DCR]<CE%30NS.,]G
M#:F221:'1;&Q4'-%S8K&LZ)FW]"Y0FV7MLVCPGCWOSOW_]7W>HR;E[U\.KY(
MZ1Q>I!Q=DK3LU5IQUV:OY/X&4$L#!!0    ( !N'2E:&>:$&@P(  " *   ;
M    9C(P9C(P,C)E>#$U+3)?=6YI=F5R<V4N:'1MW59;:]LP%'X/Y#\<\E!:
MR+UT&XT;2!RG->1&[#+Z-&3[V%;G2)DDM\F_WW'BEFWM!F4)E/I!LL[M^\XG
M"63=^--)OUJQ;IS!B&8H/LMW_8G3MUK[F;RMTFT-YZ,[\/R[B7-5BZ4PE]!I
MKPWX?(4:9O@(2[EBHKXWU,%#Q>,:)5+JXJUY/5@QE7!Q"45H>S\VNQ=<],#@
MQC18QA/R*IZDIC1Q$6%1O?$4&+#P>Z)D+J)&*#.I+N$QY09K?6O8=S8I#[BI
M5CH7S:[5&E+'BR-SO<^UX?'VS6Q/1*#7O?_GUS!RO>/X; BD,7)5VGZEFF%L
M_JU?2<J=7H.WM*]JN.E<-+K?VNU.\WZ=U& P\:]J%/FNE;6&[YS@H;:^Y/<[
MJ9!(H-JI8,]GGC/S83X&=S9R%@X-M%PZUZ[G.TMG!(O;X<2U86#;\]N9[\ZN
MJY6QNYP>5+Y7-3NR",\H7Q%25!AL(91"DS1@))@4@8M0JK54S' I@/P*8PH4
M(58K7% (U[#$A&M3AGB&&5P5%6@QEFH%X\8YG)YDT8]<]EX//5$[YQG(&&2N
M"(,0#43DCF",@<J9VE*O=>BVN^=U\F=4020ER6JE("TSOD^(N6 BY"P#_02@
MB\JW@C^@T@B+E*D5"S$W/&29IDVWBSZS/*)L:HI3/!,BIPHED]-=(]UV8WP&
ML50[9;;(E 8419*':P(*4%4KYWN67:H0%3^=)I"X!"/_E/99R<*0:Z +@/O2
M*;*H:*\4S=FL41E=JE0PU'F8_D7VYL<XD"W=@CM["O9B4 =7A!^DK84]F _!
M'<&GSU\ZQP9SU0,76 >;''1J!6?'1GQQ5P\&>/ ->E&P5;SP]D^^XF7X$U!+
M P04    "  ;ATI6^00SLI,"   *"   &P   &8R,&8R,#(R97@Q-2TS7W5N
M:79E<G-E+FAT;<U636_:0!"](_$?1C[DQ#?-)3A( 4QBB0"RC:J<JL4>\*9F
MU]E=%_CWG;4A3=,<JHI(Y6![=V;>>_.A7=R'Z'$VK-?<!^]N0F^P/S?RHYDW
M=-O5FZSMD]D=+29/$$9/,^_6V4AA;J#;R0U$?(<:YKB'0.Z8:%0;#0A1\8U#
M@12Z/,<9/)@FR_A6W(#BV]0,X&^A!K!C:LLIT+IVG*$[&GJ'E*^Y@>YUJ^^V
M1R1[^8[PW]$O!W4EUCH?7%(;9>H_WD,8C&\=/'2OF_UOG4ZW]9QO';B;1;?.
M+]*+%N7"F0S@[3S$* RJ,KOQ8AYZ\P@64_#G$V_IT8.6@7?OAY$7>!-8KD8S
M?PQWX_%B-8_\^7V]-O6#QXOF^[&\3ZW!<Z$-WQR=X5>$%!6NCQ!+H8D:C 23
M(G 12Y5+Q0R7 LBN<$..(L9Z[>02X)9K<_((#3.XLP"TF$JU@VFS#W(#LE 4
M2T@&$G))8(IK53!UA-Z7!O0ZO6X#]MRDY*1SC%\%6#TRXU7,FF6,J$&GB,:B
MK@3_@4J3F&7*U([%6!@>LTR#+^(6,&V=0LQ)TQH5]#LE%3V92$IXA5F)_!N-
M/B=1AML2[+",H(]<88I"$^W)T( X96)+'>"B7M,D U.9):3J2NF70@X 7PIN
MCA5GS'0*FTSN-9U$"I#%J>6P4H[(E 4I%V8OFW8#<FJB3 !%0L(^S,3&Q%EA
M[:?@,<EDXGCBU_4:>?:J;O0ZS2D)$07+SNW8\.QM.[H5<K\%-!142?E^)%XG
MP&X4&@J2IDI+BBSA8@M766*)O0.)-U2&<E65IZ!\/QZ8UF?/^,7/Q;9NPU1Q
M3,@59K/E_WOR.4/K]R35]P:<O]Q10.!_M/TS[K2VO<NKR]W^!_@)4$L#!!0
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MN:N=;'&@(7G->0YWE=Y]&)UDF7(E58K(3U4[X[KG%<0Y3QJT_>8FY>?S(C\
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M/[R3L$$2![=1P4[Y[@M$*O&0:>BV/8S.8&9)DC)_Q)>U.!;^B=.K7"X2!9-
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M'Z9D=X]+*_E.!N/33F^4";B=@GT5]HA2![CT^G6D6TRHP51 V,:RJN5$2Z&
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M!6B$F#2A;ZK67JAQ@]8-5P*^E>CZ":?%/1R?3#LD*WF?<%E'65I-79Q=D@N
M5049B7+2IBQ9%82[E*1$+"01]%%V[)*7N'!_$AQ'!+HD8GH4H153!!7<7'W
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M)^NEF3]T>\,[M<A&H%WEHKQZR37BW"[+[.[,;4T@<K3'R(S\+NF^_5KB_KZ
M+]T9=7I1%QQZD#SIP)'?[L@7"FT4Y^S9-=$%'&MI$/V,>T6M%5[F>==]N-;V
M[=)+/NQY"+OV8FKR"]YWWV;^G[Y'3R<FLKL3M)S_=B-;SO^AQ?RT/K_H#:X?
MP]);]/L3:0>=YZ7A/*>E.XFYN]-KW1RO1' (6C[+P]&>M,?S5:W=3HFNAC8
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M-YM7#25)\D.2J*_M?S\(DLN2:9K9H\7-8&*@EM08=X/AI^F%M#KFMU!B9W
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M1%_IXR@)XL Z4/M"K0/HOG(E_!(MN)X"'6L4L7V1N)5ESZ:C[#KYNT,,CGJ
MP1V<X%B>:'+8HEG15(2D7-O<@2MW7B\Q]M[;!\;>>J[NF>=*U"Y4'#;/<]4#
M%A?/A'6=OZY4QHC, [S<=A*1U[)<A(/ZO>KUGV<-$':@""#1M^O@!O"Z.;59
M/N:AW$UD-L!8W7AUAWPTG&+N!;0O+KUW)[:2WR9V@II9)/V8^\I")?V9"<,-
MJ]B^,(EH;&C#2K(K(VPR+4H.S2#5/91Y.(3B@8F0ID)]/1P ?)A9IAZQ $QE
MA:MCR^SND-F]:&9-QJY;YGOWDM.]!GW13_32,^B5=U\9857XU@K78(#WCV6L
M=>E_RR6YO:=WB2:AIZL=V]]R7>X[>V$(ZLL!G-S#ZWLM'Q !CW:<.:W4;),4
M<RS4QV)-T1DLN2%PW??OXIY?^[Y%#IL5?092B\K>E6LY#>ZRH.;'K9M?W/P_
M;KB;?UM0LS9F_;IP]:YX[=\!%T"':5A70U^\E%KW/PRHY6,!JWB.,?@-+*QY
MWVW0('X.8&LY[T?(V=,)@PE0GNE2( <X90NS)=)Q"X61JAG(BT<YK F:F>JC
MXCYLU$N"794B$,(6;/UL!#%&&=5AABE6'7P"M6DP*X^*7UP5!;Y*O+YC4]G0
M=R[-E=C>ECR+4M;JYM?@;WHZ'0;E5_4$F_@\[:O$:&"@8UK(I:,J] X@KL*0
MFZXM<-6<9_V2 OR<=K66^IPKJ?'Q6JFQ<P5+?P7;62\*-P%?\'FU=VUEN/]O
M:]/;W.;[PZ]_HW@"$\3[%(8Q)8CY$N,1-Q)U?73CH:LAUR!Q->5<S,NH[$6C
MKAQ5B=N!$>)Z$IG!+MX,#8G./_+ECS"N4Z><]L0 ,=K2M0<5-Q05&\Y'D\ 5
MH;-U>17P8\*5"=J\]9R"Y.!"E(3A/*<6.'QWEHQYD\Y-S<%0B96Z,-]?%#K2
M6'(K/XCZH7/\U0F(5O"+'*;!9'$G3%KY!B_SIJP:$V(,4+@DF+ <%8FML47Q
M 3+(14PD?5>VBO+&N)MT6^II:5]W\&C/5+[-M @+"M3MXQNRU#;>+QRTW^!)
M]4;CW$<OSW3&,ME@[QY02"TD-L;,$S'N8FE 8=1T.Q#</*71LF/H#6,FQIPB
MC[?50S7A54R3E&KRX&$F'FR>O$#U24-Q/QW] [^ENC[7!E+#MU5=@-$E.H]<
M0;Y/HV6G>?A$#MN]%*[:O,A]-:GRDB2MT*OO+FLP M&C&T"(A>"5NM=B?3D#
M:RPQH?\>'_[P'1IHGQ=<Y;*'2C8IX'8MSNLAR7O5MSH8_N9:#V%"QJH'#B/)
M<Z@\NIL0)-;-222 YZJ^_YF%JRLZ$.X)-U)=%-2XK6!,.-B%NF%"#Z="82%;
M!=U74\$,K0G',I8F,#67B@<%>:Z2K,BM(\%@\$I(JKQ,21EW^':$*4<8=[*8
MUC[WUQ0DQERQ+I=$X\#<N9[>C6V35H>;_L*OM^R!I;I$8/^J<#9+@@<B!8U2
M.0B51XJQ@]R)CISOI%$IE^@=Y)(%N4AQC %)*+R=G>$R*CJO8<Y$0Y"%,;)!
MOC)R&@8]O&:ZS!73].>.*Y?ID W9RBR)";.-'J\<I&@8,Y6][XW_*= ?!B2D
M35'-!XP-P:_UY3OO[ 75;7*Z3W#$%US1)(A]B05^[9.^-7\=[$Z;CY>A5';$
M1PI:_S( ;55.16!=S7.@#MVM) &NY@X)6*7;N)C[Z;2-U16D!TOD6/(%* >Y
M2Q#JIT8AARQMDGZ20/FZP730DQ#B(RC'NFH6A&%03>GP_3%UN.>OYM\(:WD(
M)Q:F,6'V/=9ZB&M"VUJM?"5+:07.8GKK@A@R9W:PIBY#DMP@KA'$0U"=3G2C
M5*:9[K8[U8G.V9,M2M/.HX%J(98*_0L)VR%UN)3&5JH9:;UMOM,&>69YF58J
M+BD-4M\F4JKR!0%>'^OJ801>T6JLWL\8*KG9E;.6VEOP@$[_7,$_V("ARQT:
M:9/T(S.U2588#T90V7%#]J$KPQ*3KL\6TLI?S$8;I/L/*1$RQ7[HZ67+^!FN
M7G] 6_]+S[%)2 JHP+3M5Q,H]++]75NZIV8.GD-(YP$28M]J#3"#Y8HT:&@$
M=@7BM*JULH+1LBAVP,:J4,D@\ ,QOTD$S$$%HF3T.OR-RS,?LF>T@#< -2E=
M(W:^^E/VGZ#\X7;ASBH.?0)8(I:6M2P=QO9>#N=^UMA_&X"V1%BFB:9#L6NM
M4O'E$JF&Q1!L,6$L!^B3MXS&<#LE23]M8Y42J_QIPV.56T_Y':& ;!C@1Q<E
M5QOAN1X!08S1HRI,S!AM(%,+TK<E(58VO@+8S$QV86;.KG"F>>R#=H[M&A])
M(+TP<'\'[FT0NKZ) 2H_8M&KE^X*4XC,A,546@UV7N?Q!MD@QL)UM$>I2,-O
MCDO )4 @>S!!Q6=*<562Q2[)GO0RMHD'IX;216<6JU,&XZ1B7,=B*"*VL;P1
MIR6);38EH_>*S'S-R'?^!>WU3(&+2\)8G"ADA#82EMX ^'7@?FFUFT8-GOA@
MG2U[^Z@&?&48Q]^KX[^6#HF*3<%BJ _$(>;"9;:E/[44",6A=$+=?L3="5P]
M.#:YD%*X$(ZVPF)L+* 7"D;CA@]>J2T.AL$<X+!_@40B"D&V;Q$0.J%]2(!O
M"2.GD7T^=)&<>T*K143E=J1.A@UY>D=HY<TLB WTT_0L?O\,*H79LI4FWLD.
M!Y*!TZM:1?I^>OIN+8GB*D#XF>^=X8+]!:I\@;\@S7G:C&(XX\H1![>04*,;
M7G%1N4@+78ZGU!!CX%)ZCY3K+3&RK88\(9-@B(F,VCGP;6%@(,0%Y??!&'P;
M955M;!G4H77&3UV'C<ZTG-U*+7)RZ7K!7GER?;)_DI/4@GO \:ZJF%F?H2'%
MF^VKT/*!/R#CZ<\I>2IJ\\%BL@#F2U@"?66,5V['"HH['29/)?!>!IX L6^,
M^H*0(.$@D1,CJCUR8PJ XOC(]S#:*,\8*K*BAY!QID4B'3W&Q.X4XF^>^FI!
M3X+^!?+;V#E&\&>=D W8R6 @!M%7I'RMPO,AP$K?VLJ8H+D?1B<P ZH4U(J$
MD=6XID>K),YZ%5.E5KEDP*>4\YQ^L-E2T%,0Y\ZES!B^EG19)JZU$[)<XBU5
MX:\;NP6<VP][68&Q2O#\8QJ$P$0#I'^VIK*LJ1Y6&/.,]BMD6YQ&TU*%"-FX
M\2J-%\K4!^4:5R)>+1*#@"!"$;,]'736'8B?:W2!?AIX_,G.EEJ65-)LPXYG
M5T0I73@W[$*L6A[^P!OZ&MY6?P;GATU1&_%^Y+^:)!USOD00:!\(TO<L\-O*
MZ'UTM#63Q4Q^=+3A=O(VIW=M.6)!>FOTODG7EQ1VBRFZ+YR.J$FUA-3$::CZ
ML4_;)34YY),MYM@'FD!.A_49!>H<-8/+LF6VJOM.'*12+4Q5JW#@F9 5 S*$
MTE"YI[T/BP4]U>'5%/'F"+> .0?VCE\1ROR@]1QJ])2+00\OTIST&@;E9X9.
MXLO %2USNW2U-Q,;P@-3S"[/19WA7G)^)FM)G)VCH9Y?'&1V A?QBJR3FTJG
M/4,P<5AQ.L=RSX5E5WF.O40S%JCU5$T$C'FGB& YX=.L@IKWLF$KN$MV9 ()
M2MZH)$M6_"-J?06TAZG=@K0Z,@3MED>_Y!<8M0TQHUO: )%0AAVF0$M,IXC*
M-B*)BWZ&QE0T%?GM<CC@$P_IH *%/V!2<U]'WH+Y7)P*07]"MY]5M(>(%_($
M[1"\'UC.RP)NZR6LUI0H)C*++,<9MSZ#DS75NMA'55;"\)CQ0\C\!><WAYJ5
MF)L>?97@.,A<L)K"KN>B./N*ZM;F%;)/./T.2 :-B47B%O1'@5K/N6&A!KTQ
M(1WQ.S'LD($)@:$/6_4*B<-!*=9;!07,L(5F3DP 7L_X=F,7Q>WZ$]C+$$X#
M\< %>1")+YB&LX&JH>CPOQJX=I0@LH=1'<Y5V?<>CCW&2<54/2JS9L#"*D5,
M;??4?F"(,.E;M(L8*E[L]'%GVS2<AF7U+IU)&ASD+7>%IC41N#;SMQ(8<U)8
M@5*L72]AX6!(*WVHDVWN^OW62\X8MD>L^A=.G+ZS*"\WL1OA4-)VURPS@X99
MMSMGTA!T&(LIWP !+CR#' GDD<,(4_G%7F/VE\-C?"<QLTG2HC"#:J_:'W3+
ML^(S*HH/E3.9"?IFN/TX]3 ,DE-\.EH7>-D.#]I.Q-6ZE6Y#[^B3->Y?',-Y
M&EU;.[FQ<K.AS /[$9LE!DF8ZDIPN@C1"*NQ _U\ OI O.PN#?@\NF[X@RG
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M.RE9'C0'->Q7K(3:%O4FUPOR#[S:MT#O*9&'40<^2+2=P6 G!:C8X0U< ^7
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MZ$:%<82R*:A$L;5:2TMEZ9WRTIT][ [F($E3X6D"1W,%U%M(.IO13[)ILL1
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MYY,"-@'IJPKWY9WHB]_0C]5M!6'P"% LH00E!K=K78Y<^Q#2X.TNGRA[)XL
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M,EV%O66:=.YHC@4,2)W 4K;1J"E<V!+.Y^]N#,.%KN9Y7'*:RU5OG\YSDQ-
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M:]-TIW5 -50P6N@Y]LH[YYVBL.(&7;^D]UK04$S33%/?#FC$H]8+;O92^V4
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M>EN'$6J(C@:5_+=O4 6#O*FE)\"H/U[\BXZ8?YR^/H%__']02P,$%     @
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M'-C6[1C\^YK_W'[P^:["P__T*-]419RJ M2L#Z!RIK!9^L!<=V_Z';O=47Y
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M6-V;9$G"-N?[4I%OZ_[N W)E,4<*%XOD'#D8\\I(H1X?IZ$N*1553'8AQUU
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MC[K_]2-\XL;O9Z<8K6<;[;= 7QUAQ\?RCA2#CBX^EM &/GC5O,*>.4J5ILV
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M7IO[I=YT\K_KKE@8P)Y7<[<FWN34#K:<1N+NHRX[-P/1B:Y0>Y((RH*-3F^
M:($2/AW&T"4W9^-)_ 81ZB=]A%I'J)_T$>IO-$)-&7M&E<.#+:E;OH <MNA2
M9>MMUQ"B&\]$.B(GGRVS:0E]:XZ0?[A;CF3P<22-LRG)BH)C% W,$G/-MR
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M*0R6JJ38#OYT\B-K>9$9G-HX#0V2>:Y_<&<V'&RE*G9&8."PV<9L\3:YM[>
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MAL:YVMUI/U?KGM.J_=TCLKSV/H8Q"\?+_O-+"$;.J\^O[;:"IO?9F[I(6[L
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MBHH<%^-"E6#X)*!\Y_/UN/ -S/%F.'7\]9%3_M0L+Y8PI5=U8XS?M 4Z<R\
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MD^Q''L<^%3F*]]M\$WV$H=7G3.VZ&6:_L\V0VGJDE!8AZ)^C6&@*(^8"?)%
M1I?)(])FKEW=-3,4W<1B;L+E;G E/!BV2X[7-EH6A(2PCR]2M-L*XV6*YMW[
MXX;P6<Z*FU0EHU#8Z+E-@9/87?B!\[1"@(V>3\[_J.GM!Q=Q0O-( #.&QBZ[
MVAYE9KV& UW"JMJ9B-W\TX]VDCEXMDBC$1<7N_U.V<(J.6S$%?PC<Q8GL&5J
MN^1OX<(].-QW1@?UG/!NB>0.P4#"&P_&S]O>7N?^A4\2 K&(^,.$]^<(*59@
M>C"3WES7'//& 1P^?M0Z@M\^O!X17\DH8'OUDF,E:CP<R&VD:%IQT\\8U'ZG
MI# , QR"G?RN@91U:3[^DEY";2PWYQSL;>U%U1V6ZYJ?SS!<66%=V2KYG'$[
MSR<\7.$.KSM8HM=:(Y[!X0P3L0Y,;&U+F\2&W()S..@[MB6V.VJWDYO6BC&D
M/N/D'PY.D KQ2[Z30W@G]XG2#4<L(FZC([4)7N.$$'TZ/<7M'?5)3:L&>F[C
M5'N/]@YX?'XVVXN7QT9M(>%6\3W)X#W0:%U2J(=@Y!Q9VC^SBIT]7V Z0%;>
MHO7<IK::)\#6>Y3CU_9>_ZG&!Z)X%RZ#F@6U0E(#Z?[=O4Z/-3/HD '#>,VQ
M0"7C]6/HR\X(1XW)ZL[JG@WAOOHAV^(77NX37LD?M-,1N(+@&5ZS)^A, )Z7
MADCS]/#QC>UI>3HNG]=.237),:B;U]R(UDJ>#P?(XJ(_;V>*4,0U<FITB1=2
M-O-O3FZZ"S.WN6[8'-!ABE"[)-5 ;__VAOU1?]"$TYW;WUR_&),PC<S2")C^
MP]VCD4Z9Y6XXD+LOV6URZQ[E'4Q23%9S69OU>V4<TPNT(.QF1Y(0>*?-#\PJ
MY!GU[Q<;/WR =OMEW78.WB=LS/8;,2V+?&28*0$1R-27[SXPDP):3T9H*N:;
M VQ[H?;IC.E-WA/]4026.(\5/V@D:1)HE+5)VW!P#>(6W&W$' FZ,S.RNHZ&
M!P0[A-?FN3=SAVTSMV9EKVWBA@-_YK8\;^P'+\3>YAD_9$Z<[;=X;;[KH&';
M9#^_3-0^=\)$E"VS^[;"]KE3AHXWS1HW?UT_::%F:U%/5YNTSY<R$94-L[;U
M#KWBI!GQHK?IX>"S)6R+N6+MJ'/0^K<HE^A)GTL4YA(]Z7.)^ERB/I>HSR6Z
M:B[1-W"JQHXMJ19\SIHGH=CL]:,PQ('E1LY\%=/T<K2R]7VM)^^(,^6#H'-X
M0UN^PR40Z!6?9I$ 'L>64(#76.3R_ P#%]33M,M%D5>G"X1G=966_%(>2%""
M7(>A+Y_8]0#TE99P.+@6T+E#\$83M*-X^J89)V3#-%$RP1BN)L(M:*A_O!B)
M*89C#- V0P*K,U]I[Y>C4-QX%4VB/]-ZL=RL1:JT@IOA+RE(#U9,7XI^82QL
M@EO_W&?B]SZ_)K;X2/P#IMD$WD'\SW,WZ!*-\SFXF2AI!041X\RK"391JO91
M<5+<DFNLB+-4U3TA=@&0M&I-.E]M.7"65VH6S+.+[C>+Q&9JFL92X\5(=@[[
M:)4P69W0NG9\DSR,7OJ2BEB0+YF7922Y3C3^+FE3DR0.J&\5J%R-PN/"TCU(
MZ^R)ATR>H;(X+>MI*C#92"&'?;28D ']9\JM3+(IEJ_R4?=H_[^;!W-MCCT4
MWCLQ?)ZX-0-8)IIXXV"[$MZ[:2!HUG[F2/9\1HLX"!DV3TXT!BP"P"$9YKK8
MJ!Z<G >G1.N'FZ"]T*ZZ?E\C0[4LF0,9K'W]$0:E-7KO,N2P.3'U#=8GT#4W
MSJ.@$-2S0#LV#6 ('OE;;I90GTHD\6C80KAE3=MY/P75I4ELM%@3DQNQD\5+
M,E4^+UUC9(,J6QO8(Q^D+-1]\VC7<LX/-3H[>3SR_L&^&V4P\L^&@V=[_'-B
M XZU\'YWBNG[[;J\9E#/[]X?C]99:XVL?>JY1O+A@^,8)L0NCI96PMH8F.0D
M9?ET6Z<4V*99ISZ"YF3F&4TP];9)\11TLFQ_WI;+9%>%7A[TG6U)'=NF\RS!
ML>;^>3)'5V##^'4@"S8YV'P^.3S-&1@.;FH*3!2<Q7?3R*,=:M5 _LM5IW*K
M'KY7G4E4\Y;M8HL/:"NR[N;..VEI>CX<, $%M=<<F0:9(VHO.3+M-D>-_=HB
MK%^V79'3JT58VQ]SW5*G%3(9-Y+O-^[@9*L=_!4GY<I;.JKOZ$LFF])'KWVV
M-ZO+#5\4*,=^DYM-_A/OWV##DO+^.@<LO?YZ3]@;WW!<1WGI1WWY!KN!R=ER
M1*U4(QW<(+P4]17 '@&?I]*PG3R,QJ#4"*S\&TNOP%7=;RN#;$5[/&XCQ[)H
M,:J0L^>RHL]M/WE[)0Y#\C^9;-?K?TMS7O4R1GXUGMC]42V^M]5L1E>?S!B9
M?&Y/)LW3/I,FS*1YVNE,FNUH1_I,FCZ3IL^D^;:9-(_VQM$OK$,M ORW=4&1
M6JI&]!T&LO7SH"V>^5D^G58K[)F'5EV7;#J,) 8?3ZAV6[&&[8(W'.P05;M.
MSM2N(\Y=)89MG4IZU"=SB6E+:NR"5:Y+L%VP;,$$]NMW6T?$,[:Y3,+=S(4H
MSIDG:G*V-8(/<EZ;E1.ZA9,7PLJ41B"RDWDRN,\.VV/,: J&\65*$FN/^%)N
MQOJY-<_!&I+:_;([N8R8J(%)-'>L,*Z_EU/EHQ81-6&F0IF^$QPI!MMYA93W
MF9>?XHEOMWP\7'O'7NY6S\S,@V;D&J/F,3ML7OW 3$T3U-/@N4Q5&&:G[?=1
MJ56$R43AA9@34"!O" A*IR:^GG?SV"R"I8LFN=56%V,QIVT\+9EH=H*YD8.[
MV,MFJF_$(+>CZ5V&A^MI$<^D)D.RR4QNUXAI$[;.WJ@I8>E9VZDE/]Q[8A:9
MUL@GM8G=OV 6%^*Q#P=$]O/;!R'1,;PW=1*>D F'3\" E4=X;L1#M_D0FS%P
MVZ5BZK(HA@-,!* -WT*:8Q)?:H'^%M;AK9)>;.;1!B8&V"4VSN^71=?H3%R.
MHA?[/WC2[019,P\/H_?NA$0GM$N3\)#Y%NRN-$UOO,8Y0AGEN+=IPYIF.I(F
MK"NK;?'V' Y.M&Q*3U$+&X^]%,3;,TWL"*P,FV:N)C>=)%5>@.8Q1?SE?5@4
M@,U J-N!286WKS);"QO_<#$?3(0J&"FD$=1ZB>B8=[FDT]2SRSZHLF2JB.@E
MF$V@>;2MHCSCAC#@9;TM,7M4#@X[,/HJJ@Y<J"DF&4W@3*"T4=.-8\2-;9BR
MB\;/ESB&KXF\U%0V-U\#RH&NU':D>B_ZW3@@]I"E(S;@NL IBF !\JFI 9@I
M;"P!3\!TIJ39:U?6F!T2V_M"%H;ZOG+;DPH&4K); X_,-39^,:K.Z"%O.;D_
MELOWJW>4]0Q;(Q/=VK?CEO5L,86L_2.TC8$!1+UD\BJ=26$H[_1:H[H=MX7M
MY"O;><YNX:)]F3P!,M?NBO5$6P[3X&LOE/I[NV4HS]2UZ_JJT/K-O*,-[:O#
M]L]ZV#Z$[9_UL'T/V_>P?0_;WVK8_J& B9<>F$N%J"'6G'%86M ,VP$N@#_$
M=!5WKG'(BO&%14L7]$BO+[SIB[<.F7#F-;B4C2?;UIA4KH06=1 3;\"<C0<T
M/WQ%I@I6L8"4%)GJ9%JSQF(99_D(!(RUO&JF!5>RAM-P8*ZK]W K9*'SS&8T
M8&)<PJW_FOG^!\_V#MD/<^O"I%>A">;:.LURY WNUA*Y0JMM3-]Z V&>.UU-
MEHD%8&1SXU^O0(078I-;["2QJ\GU\SNJMK>JE;"!WX0X\GH0&R_3J@HBS#O+
M$T*X04NI!*;0]49VKX:K,PTW$&+FC6-7J&8\7T,$WP< X-7&V+<86,YP%B%L
M]@[KN]MJ\HT/PQZ-Y.M@];C)L,(+RQSM&+D9/QSW9=(MF0\!>9/[)G+&<[)$
M,+P!!LURQ>%+D!)<Z ;,WEXWCHE;JB $R;\0HRLL0S,U5R1RGKPV*A8+-0<O
MD8\NJTI!& I55D56TW-K=XWLU1:LJQ>!MF;RO.&2.>QM@KA$-99FX^!"<EM?
M7)\,01R,7LIN.R]R"K0X[62[K==F?Q2"&P0\@0B)8D4YD);K*(6^%H+GPD?'
M*0MA[/+X2 :G9?!VC]T5TR/J1ZPP9C6I\XW2\<)\PX' <"SH.C')SAQ^2&.B
M$*PR74V1_G->6?RQ4X+V4&JZM\&*V$S&$S8V1J@WZ=15?&LKV=JR=:,U"(^T
MQ B=MOM*1GFGQ*$6^=TH#8@1LT5Z,U87<I@4U93-9\D_KOA2%SS@ \HJF>&@
MW;S:"X3<#G ),P)NNIQ3J[PH@[,VC%6$'X(#@LG=\QS,\$PDC)<""YAM)('4
M=<]VTBA2:(02OH*=4SPCS9[)XO1")["N$N# J0+5B#.%P9/[.J%^ &<*).24
MYAE62)73UEF8YOE*"6&N<+G6K.PSE!Y9L%N42WVPWZ.R(2I[L-_#LCTLV\.R
M/2S[);#L3>1U/(J._=S']LR..V%!/9)N[K53EB+DZR/!R@NASVS^$J,@]>X-
M/=O.57QG3-S_'0R;7'CJS@M$%S)A^RJI)T0]+\:NG21SU!:OYV>C>>78BI?Z
M4128,N,E$8&/UI[D+$9N#6.HN_%7:G<KM;E@RG"%1B9@:PP&\FPXJ)-LPN]B
M,)]3V&!Q<2%<IHX'SO!N[D6_6;>E_4NG"S#3LSJ)YRBT^<TL2#<6 F:\BG@[
M+Q; B^=S2AG<G&QCH8TD34J7,64?!]=A]J/#1YSS['@98=VI$U:,_E;M0^L]
MD.2!9E;B[*)]5FK;R$0PXMI$HK?6^ *\-)BT4'3,$+J\\QZZ=*/&6KDE]B(*
MX95&[#%KU@ACRTZ$(Z>:-OI4;DCBWC7Z<EZE'#2%08%Z-2LZ4Q-'RFA>U2GV
MJIV#74Q%=+$/RJMB)!?GBN,K4F&B/JT4G%'8<2 I=&E[9*_3J86[%?=1BN$B
M*K9^MB_E2'CW)$XYY7/.&8)S3$LT,F)>Z6*.9H!\(1^5YBTN9;!HUNM0+F2^
MI)QO^U.KB;+:@X,/MQ_XO/G)"&?;^@_,-/6^V/&Y7M\7MP\LHA5Q7S,<;+CK
MZM/T373,-]L3X]U&P0D":4LX@Y-5:M2&TV8LA*W*I(;158S4T3EL Z>[E_+R
M)C-5/_ 1:>25)1?3-"X=#G 8C5& PDQ*K=+Y"&L"4XRQR&N"A]C3_BS)L=:)
MKH Y! <@!YN$0C&:T<]YE,;G%.D]E?('_$<E_5#P'+4_QU>=*Y#E6-N@C+D/
M'RL J41H&FWL?;Q4YHBW1B(A1?]#Y<,Q$)2R*4WS82<.#0720[0&YXE#V1ND
MYW*6Q.PPWB:8\:"'&6LPXT$/,_8P8P\S]C#C;8,9'T<?P&]7]LS^>Q5C5%JI
M^A%]1\''QW7P$?FLU&F,[AC8E;%AM<6YD9\/!^I3HDNND:*":L0%3$M47D8M
ME4VKF/STQ-0Z<<H)\B%8TR"'5YR*(=+@9THRM(NB_#R+D).9GD&HP#0Y2]+A
M($WL"SKEWS_>&T<?X/&HS*D4CR>4?91@ C7#:F4A?D7FU\\Z[YT\G7 A!>\<
M1419<";>8UR5B[Q(_L-!8N//%,*#00 /R4DT!_NS8VMRV)X8 [,WXZP$=@LH
M>$[9E>B!\VP9KPX$&J?<!M9CP;E@P4YS3KT#PZF X?%].J\*I"+PN2)&N!#+
M^$\LOLK.DB+/\*?R$IU3VEZ1Z(^\2;-\.."+)_',Y$UQ!(%M>A""!'WE.(L#
MK#9TON"5>+_<V*UU?Q@=P<ZQ66PC;-O(9PK\'7RS6' 7F[:&,'=[UES-'YVY
M[L:ZN=U->6RXY:E'#&SW$0)O54'DOB1:2J)$BJ#BY$SM#0=@G_OI=)SH%%\8
M.!F5K^/LP\^JM,E],9ZN2"@*P41QG&2JXM3GXZEGW=4?:9LRUT6*/AHS2?!%
MLS-5@#_(=;8:D_"GUNW.79?C.DUG\"ZIINV2?(98\..]1X&6&M$:@]L?<Y8M
M.=><B6Y3R&N_)0GC='/IE,0""M/,QSC^G*I-G'S_EE%B^B\&<2 1XJ=2BE)!
M)D)>G,:9G"V"4WA]J>@"DQ:LBA7H,-1\B._-P!R859@S&HX)U1P/Q[P-]Y>"
M3X??+/E @Q/Q_C+'3.(T)OR'J$3LZ%\M<!+@"#U%>"[C@"NVLRH9$,$ !)^)
M.#?/<7(OW QA)38/QWZF?/PI?2-G1LK59@8W31LB-Y?/F]_.J]O2_C@T;T'O
M+DELL&/.!#0P!?IPJIE9A$[)-H%HH&E&AADN6X$G-Z6UP(7$SES9*=&8@@&;
MRA&/.C?A9F05=A]#X$V#;%*!/1I1FGARZJ\>68&URHQ^&'^*X-V:S##Y"ZH^
MHA\@K'.$A3 +9$LH8DGU$]95T,QQ-1O9H6%*X?TB3C0]&?/^L,B;SHCT8GV^
M'W[G-"[ 5L18^5E<)#D=#VWSA^QH]KNGL/+Y$KT-7#J;*CCR:T_$E!@.D'V)
MQC4C?EF0'<*.\JS^&#B$Z(#QGC$!7_NT8!899GTB&ZC2*U@M'&SX0CQ&M$P
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M"6)#L2#C2..[F/'#[QQB6"HMW2$!R^Y"@L-<+Q"3-CD<<(\1@3I(1TS$GQ+
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MD>*#6L[?F4(.'TF49"?2KRSW@+;@4$4GA4@']*4&%/N2M3(<>^;6JI1-@4J
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MU-BZ#.T@\]<$E6]*2MJS=LS3'[S\]?6_4+H?_'3R\[L?_C]02P,$%     @
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M%JB)4JYAJC.9HE((W?,(EL!(B]<(*^#_P>_P%&PQ) ]US#_ DE6ZX4/PX(D
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M7S:"*X/\W)/Q\NSGBU]IS_[4>WO]YC]02P,$%     @ &X=*5K;8*M1*]@
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M#X&O2Y6<-R^.0/Y\@3P".V=<0I9O?5]7TUV[->Y48F?VL$O?DE_>C7F<^,F
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M.!:JV:;[QT>X7WX&*A%UD\_&1<W-"[FIG-S'/@J^OJN*M MB':BO+_P^CS3
M<RF5T>H#P7>O*]'9/L0%+4536;?.E!X=BNRXI>@<HFI^A"C38M>M0H&;WBT^
MF3W7NU["6+'3K2HZTFQ;<)11^\B&-#61 ;/=EG=%B%).3&<I!WB>J[@/@I6[
MK2Y9#HW;[CQN0+$DQG79BQG*BX2O@UO%4H10HR*3+/A>^M<RF_=/P8]MQ!PW
MA^I:L-/(<(/;@)-&%@\/@$F!NF)U[60.R7%YW_HJ;N<\.AF^43Z6<A7$LQ0
M4^J6#DI[6C]_^M*WRKAGS^B[\6MTU^D$[7=PE5!#Z4("0%,AQO+;*2%564:2
M+#L<N(+?#(?)V:V=\Y!P$)/.<#]*H[88!<HE<'D+8RV1J7<#LNN !?K5M,^?
M"(OC[6"!T/?0YY'P-"YH-FK&!$Y/#MJ):^!-G4*V*V[IHS&,]2F\^Y@;NJ>R
M9*"UYC'[<E=P$A01%.P<N=9_?Z>(;UI[.:+3AA844EL#[;Q1E%=3PN7E>-#'
M"/)*=G55(^1^!"8K"%?XMNE$KNY&%1"?1\P?7EX+N98U1V#G'HV,ORD-_E"J
MC,CW#>PY70M3O/,#C@ZX86S)G0L<JT=L_BQ>VA@4 9@921.QTZH"A1A;^CSX
M'1BJ2&YBS49VPJG:0(0!]ZLX&8RENA(^GKZSAQY):&,-?MP+VU309)%&8YLJ
M)]@AWT-L45ZJP"H.[][("H'3[I+#BEV'%!Z4[9T'>UW$*9V=1HP&Y(6D.IF0
M=+F08/6)VSE(4CH*E&QX5;V(^"99;*:WQ>9&68/\WY7^ 4J2F+ (QHC]=OBQ
M+N&24A\?#BI#B*:BE'S$^43KK4>TI-;KBJ$1G\1GO1<)QTX)3@D&.P,E>'.Z
M#\1IXV1V0"15(!.QN2#7^>Y\)GC:@XLIAX<"*&%"XMV\ETD'P*]N^(C@79.*
M :;R]GE_JD@S\/G("*LJ2OK6&<+D"\ 03KHTN6E2.BXF/9UDX>WI9^$A[7ID
M$7P)"I]4U)4HTV)W='$JZ?.2VEVTHUR=[_:^^P/TC>0JVKGPKD\^K'F!%:-/
MX?2]@%7[8W+8.9]W9>GZ3D(U5>T#QHHH3MET5^UZF@'5PG;PQKR9/ IGIBE9
M-C!;E")I$N0)GG):.*;TU9&IBBS6(V1%I*_RP>_)9% B9&R&SY2/S;!;7%,5
MDZRI8.I!CT>!#M7/X(_!Q@R.8<@<O9#XYWV51GWMGRPB.!!^DDG1&N_4(2#?
M@+*E>\F'+*G*>E&-BF )RYH!BZ_403%N$<A2#-QX,#PL/ /6-VM\4XK&NH,>
M)D3Y0E4EY7S.21,M!>S5/(<WJER,I&I H:<XV<66/7A?FJPIRA0Z8/23]P3/
M@M[W\T[($TBN]<ROS(8KPH?Q T6S.Y5K:N=QUN,"RFA[*;ZBALK\NOSRT9E,
MF2D4J'D!'>2H7=PG;FG]Z)A>_2;D)/A12,$J)\4),D=D#V8^PX&^' S,X0:'
M[@ ].;GTV!@Y*V=XN0"2B"R# @;>@X)TA"!WW;T^\]X88PED57WGC5$#K.=\
M-FL!WA U16"].@ ,4MW0E()M3<Z^3&^ .1^ZO@=,%A,P\*20L94TA]'A;-:<
MU^&G4F#R&<ZC>BL@5R@.=_N'?I&NC.?Z&,%"MPN;*YV%"B 'MTB9>J%(*1O2
M+V>T QB^"T.*]]35&'O\W8C![_!^B#M(:L%*@^385L"&QE)H"I6KX".^V1_@
M$Q!!(1-CS&%WY<&/3&1/Z1M:80C(SN6MY,#H\"Y<T!T7BW%/XK;^KQ+*#M.N
M,+WY?)"J$%Q63QE00^8&U/>Z?-R1"RIBCMZRAV<&45MG+%^7*)_I[=L\/[U0
MH4UDY!\$X&^P1VB7DB5*<:PI(T,=^*MI#X3EA\DI4[TCOR03M1<8;2]5:53%
M<U@G#X0$3,27 U<9\1<Z&K_Q[5LRPQ&\(6#1@REW.ZW8*PMS>(&*R;E'Q4I*
M0O.PR_-^7F3IR+C_^T_,V8?J5V':"9D &$3(8UOH/?2O";:U0);@:4=^<;KV
M/*,+X$K$G9;D8G=HC@#QD,VCD^#D*KHGF-S"R6RX!*\/56(0CTJ,2,K,]J1.
MI6(R&@A2"O DL=*Q9:NJ*GR&G4&0_X.]6,UES4*60(79>L=(AA$]Y@"4R1P#
MJHXM1%])<2M3;N83QF.5*P!;GR%2IMLZ\+C>GB5,\=&P5.@\_;I>'UFNL[LH
M[XL*S2RR8I8(+GV-##S2_^ I2ENDTIN[:JT'XY[ UT-U#_1V(\.+G\$N98R>
M.OY2"6]'D55Z,NAQJ%_-(Y0A>VH&DGX[E3C4./?CT<;J[GY*56F?W7[!DZ<W
M7Z['5L;<&F"8,WHQ)H2X?N@Z'0V7*8@Y:' ZO+H+%TM5:%^Z30JG9ZH*Y];?
M"TH]D3RG4M%#WWGOK;B"%B.RWK8I74GQ;OR47CZVJ3IX'? J69V@==3W$FJH
M$SM51G.*)$'HB?)[])6Z6X#\IF"Q("8U-0_C1%.)^$OA/"76EJ9M8JR% 56[
M"]4)#FN*6@P>E=XOMNXYQ<&Y;RI1^9_L#;4[,B(=KL&715\H8?RE;V.;\I>P
M\PPH&P/J%#:' U[?V<_PHEOHV'PK&K:%, L)*Z=];*I!ML [^+[0JNN062A4
M<%<!F*VJ5Z*=Q@ [G]6)MWV#NT][<^;3? .[OMXBVL)%0;<JOJ)T+M\.URC9
M68+/OV"D'_4=A9JE!E3?%\T@AUOQ'U<__'8>YU\IIO(_#*CW[A*2)OHF9J:K
MZ$;:1]+<_^@!K/]Z&@<"I!8J*E,0R\G0KX1+E1X>E=&)Y;6N:"%_4>^'R[*#
M$+N 1U9:8IN'3<"]5WU>_Y07"B5?X;ZS$VJNOZJTO%]HG+C;SA87$I2PX#0[
MAV0IB%.'RGW57J!,7BC$F,%H34B>YBE<HPT(1]+ZU A&/CEO5?T%A3_I!S<K
M"--2,?>+-V;A8!3Y[)B4*;+8ZADDK.NF52V<X%INPRTB3P#UG<TD1R0!MH@Q
M$VHW5L#3"O=6PB6@EIB.;/P@-J>U'X(MH3"CK;9] !ZY=B'ZTGI<6,F(WX.<
MTJ SWH? A+"B4].VZVQV&_U2@:!F6NVK#3&:D5%(H@@33J:'TI?I[@#R6_HU
MNE\0&RJ4H"2*B"CZKEY>J%(7&@7%PVPE6A@D&)P6><''9,+BE= <2>84ULH2
M.-#?7>M5>?_ERK'131<Q0<A1(^,\98@P"_ V<(U27PBQA6S;KZ1Y\"UY9\;D
MA!ZSZKGRB)%VVCI.>GHHBA^?Z*KU-_Y.RU+EO-"#?6KZB01JJF+H-V_7".)3
M_HL!15Y0X0C9@**0!G_H;&6#G"1L@9%K:JE.G,L<_=(]I0D--7%>0W#8GJZ?
MH$,U2<F/$KX[/*))*68J$A[B0CBT^#$]QBZ.X7(C21T66-.SC8=A,98;Q_BS
M7LI?U9U$<?9TU_P,\APQU=.(7:?\8^9/O?H--/WG5I42F/#1!M 25/U3C5./
M,2:)F=TX"^,.?)K@YMB3I,6H/6.%5%<^AY#)"0LM;A7VG#*@Y$6 PP1_-1($
M=>;@YH"IRM=&-1 )O]/^B&R$.O, ,D&ZMT78!-CHO6DNHAFW<G"X70.P]Q@M
M5IY/-0\Z5"EOQQ98CTI2[L*1B9Y4_4)20M>*#%/U$ E>6XC8%>M^<J:JKX+N
M!Y^_Z%T_=9OP8P^.'%N14,0OC%%4$EJ=DHWR]4'E:VYE,U71L;_]P-6O>18]
MU;PG,>KS]>?!E)N5VK.,/QHPV7H[F+A?=P>_6,BAG^WFN2BQF8?.)*SZC'&*
M(]E4&2=Z^E!]WZD[SWJ]AS!N\5N_RN:\->90/*UL?]9'8E>^[GWE*QO&,62-
M<28!1A_&(A& 5_[R%$[08M^.DYY(F@CY,@O^BD:FF& _ZL&A76\C+9C@.\-!
M^T"K!^R:MY)SHP#D;F2E]ZU<RKVHT1Y:^K[>4VH?\BFKTD?TY[%&JV)DH<L9
M;2!5'BN,C"2<C-P[*9=<!HY9;A#% 6Y&*8W=TX<$:I<A%_KQ*Q.(*FTE1G..
M JCF%.;1?1*?T-?70_P[])4@]6 _LL,39U(Y)CE#:T(QGB#KOIUYT[\F88P]
MU. 7(1$@-CTI%2N5[=,54KZ2\IP#<[]&4I51 L6M_+/^R=M@<LG8&H7'$-LA
M81^-&L7K.G% \K@V;6N0%LC^VN>D&2A77V/(2-7Y_!IHX_=\W7V^PV@*JWG2
MDE;12K(AU-$#K7+*1J+L0<\_JB%!-F4J_\BZKVG ;O#\O>[1XK6-X#M]M1F3
MN^=.KT]RK:#8A4S8[,-ZXZX1Y$6!E0\*'S Z_629R$HCUX5#++7Z0<(,T^B&
MW>(87GF*-E$RI"]78LV&(HQ3%553#66Q ,A1%?PD*#+8.^T8>L'06'U*:?JX
M67 /\L)HK"Z'Z?NDTQ-_@^,:V@!&DR19!QQG9Y"X;4+TX)#2!B)=\7X'J';K
M2A!3)2DSRJ81;K[?"=8?82F.,ZS!LIR_((+8 1RNA';3]\&9=^.*BF\Y95+N
MD9>A=*=["%3!FW:1FQTT79"(E?HJBJL5A*SOX&4?6U.&?W_<.%69*1 U 8JC
M1\D5%.H*_2IF6^^ZFU$6A2W@N!=<LC^7@MV1H-XUOS*T!9>F31[3KX Y6D=:
MH";LNMRHD[((=8Z_:W\\,B)P\F';T(J4DEU06S.:*=&O[/8FPKN^!F\:4"0^
M1W:6CA4Y%:RG)FU.,B+%4?*7T3/P.>VV$T4RA7^$?O[?VE37F#U]=,^[C%=N
MSD^Z@9.=L+NDN;2V%FY4YB3]-D4:-%-:<54<YTB$T)]$'&2%]> 7CDLGD95A
M Z0%>/<AVCF1VQ+09R##)S78E-CO,Y[:N:!>CIW8J#V@;T]A3:2K,-DIV*8_
M&(Z,-N-"$:B3!0+K)(JI*KF5DQ/EVX<ST1Y\1QN*ZGZ,;'F08$"9<G@1*K8+
M;1G&^=W@>!"'5IQ&;"UL6)%\*.6W!DDF_Q\F,Z/@"\V-?OQW^DZ]-WQ7/LFL
MNPDX,-SB,3:(D;G2\9[0HQ$-?Q'\$JP($733(^6N84K'ZPJ6[;(1 TIZ?M;D
M=JB4E8%5#="]RD>*E^5MRTS"/-D6JO'4/4B:E!9J#L%4+1&>5$PR^>9DF1W.
M$\.JY2P80H((UI6UI-GOC@0")\IIU\7)Q?/@"[%E8V=$]9P*,CA:F'+ZAL.C
M'QO48^U+ZCZ3!E,5R>))<_H<72ERYHS\5C!!R58'0"6J9+6)@I6)]Y.X@U1D
MV4RRR"(8*R19(LM5[\[]V,6+/:-@6?M>YF$5C1&MH[%WX"PJ&F8>Z$_,?/KB
M^MX3^*W:A72CR[B<CLR!T5H/?8>;-XB9>%$*N\L#+PT)27:X& 6U@.$/595!
MIX>$>@O(DLG$>=ZA$4FZ?_ \$N2W/4117KRN]<@>SAA^*;3R0^&=4<F QGE7
MV1G:<I2;K,2 :OX!B*&B:>XM?ITBF=2 TOPL&,!%RM-"E75YR7+_\W^1^4O@
M_<6^C>#-6RJ=A?!L?/%JR />V_.>\K4Q1J1>-[,\WM%O@&.O2?&L;6U_!(6I
M1[78HS13Y70VW4R[#T'U<!CV1VF$W1 ZEW>FLB-)CK8<)UA/7? FH=K+&[,J
M%'_S@DK@WM":OD2V!0DF1A2WD?K7?:KT;OSA0X++LU!H4L%"["PT,C#LDC=U
M03Q^KN[ZJH%$++Q*H@[1VAX9+P):.]T6.;5B,(Q5[VB=PN$U=46DP7O#G]M:
MW%RZB_PWAE3G'NJ+BJAX5JM-JIW]EDP/,DYJG/YME ^<!A&;;[I9Z&Y0(MHP
M3]HFO+1K1BPN0.U*DUZ<O[)SD-BF7PI]S*$?JNMF=.Q?Y^?X;'@UKQ?G:7G%
M*_[\V3?YV]6>0*VSM,MT"JN81.P[-?N@#S7:$/(&VK3>YC?""4)>G0$U%SE3
MGC!CEI<X-8 $NF?B,)7MV,Q3ZWF^EA\:VD1N*_J1E66CSL[C?J\KSBC\B5'5
M-87"^H:HNTD=^D$ W$],)]5()EA*EM1.D2S"I MLD,A*^B*H7DR]&+5(0H\M
M)P\[P7>I<MT:KL7SCP,\[#W:]?T]M:D7SH^>?4<Z3+YYCE9%V=J<7-2:_C@^
MQ[_LI1YOG ":O@^_%F*V8FPK)4(+ 3I>5F^6+CB--:41B# $]2I.OU#JPH[J
M;B&NH)DRN85JBP3#1Q0"-(VMN @>"'<K51K!R9:W"A=!R*$6!G.AP/1:3[?I
M@[VA'4B8D<KJ=?=X+J!$Q;PD.&F\U+^*<@:GU02M,Q*H^QT) #^V @Y\K[$B
MTL2T$G!$OH?K(70P1,U@+$N(F@7)\A@;1J6MI= MTG4EH'G/%.9_._0)ZB\I
M\WVU>)34\Z'9)" 4V$;2VA7?#@>2TBAS;DSF\EP5;-O(P:%%SM*>\:/=I[A;
M\Q+._UI;.=OV'2YDT>$_8G:N#SHNB8F*!4E"O.<WDYKEAH;>?\R:0CO30IOP
M=J L9Y+G2GDT"!^:#._ZNM5S@UXEU#2\[_]4;75]G>:Q)JC\77#J7S=\%ZQ8
M5]*[>E9662DYI;]D=*;U5MG8@"V/ZGFS+)8*D)>WC*_;JY&$M%O@]J]]Z;+!
MMN#1GP<O+A-SN=P;/,>;Y\'P\*$=-S4#=5VEC8T\F]6[[UQ>>",F:V'W0=O-
M_2$.VQ]=1)6/_)=# ^A<AK,!]>?W0 );NXGTAFE A78.G>0/</Y/ZO_E4PKH
M?WXJF+X(@]R?&=>_VB TH,+M]G-X(_\' _+P_<W5RZY=>%^P,#K_?1$Y,B9W
M=<G^SWM6%!BCZ3[R[DWFP3F_79Q?[G$1YLBULFR2!6,ES6QOW]"./MP9.7HA
MC!<>"5U"638MXKOV)49$!H=CA[.>%&NVEGHQP(5GV9M6FRH\0_7FVZ+)%8A)
MFH7F9UBLXA@CYI+$E:$*WPDMY-02/MGB02&(OXS,F&730['Y/FJS-I(U8L.A
MQ32'?\SBN2H-*#N8L#]+$LF3\+;<&QJ.),]L*N7$A?L;]2WLH1'U(!':("1-
M=XN+S2#9XN89I1([ [=1)7"C1T$%7#!+HCC*=X1:QB5N%OV)%?E8Y?E*E4]Z
M9"_/75FY-WF YUK2IA@*-@?@/>S=15_VYDY^]MT/?_O_"O5- GAE8'.:AQQM
ME#$+7VH=D!_ K$M:TJC>%.Y44"_CU\.A%?3-.C8O!CSYN;4]LE I:6'G^-:'
M#]0H.]!M1?A*\/-,L+M(AFZ]Z_^@'O"<JLHO#X,SM7/T/;'*0,3>3@C,T<^!
M9X2*>G$$\4V%2&#)-: *"+7%;(BP#?XD>QHK=B6U&LV2WA(NC(0*6TFY)&?Z
M2B.'#+OV*<'Z3%9.XD,Z-F;1P%*H^)9"MWXF(7B?Z72#4%78[!_:XAPK<MVH
M0K=T!#:%]P^71)?0AH5*= 8'M[R"1+:.]PWGWOQ=&9$6%>RLGPSB=D^EYN^2
M#FB./+[3,[6H:O_JB=-%6S[QO9'%U=UT&V60+(^P8 +9"FTPH(@]#)?QZ2@<
M6.N,%5F&'MH_<^B6_/9^RL%U]+"'\7$6HYH42[&N8^SR0/<?)CX( LLT)G"]
M"B,-4,C4]H1C%EL)LV&FY@OLH]TVQC8Y38_4;NT\ P:T$,R!DZS%=%=(5L"U
M6*A?!K0TL,6 ,SU-29A+*]P'?FS1Q8C&RT<PEHEL:]J?8V@G6= ][)\S'R>,
M&![/L =9$VK,Q+M[0_0?>_GS@.;M=#L5.\MM+428$$#+L%FD&J(Z4KLW2(7-
M(MCKW> -@-1#T9;%\U"1T*,G)P- 3IXG+P1(*!W#&W%ZS6,XRM75.S@%-ITY
MK.,84/&6OAH\C"U'SDCX3LA.N$QQV^+;\;FJ4<R"6' 6+>]'MXV0V^\*2[O0
M!%)VU&;0[7;:"6S.U#N['Y[E[>W[-.4"J%<*$NS*I%%OAQ3(!MWC#W I-"X6
MF'[%7F0O]/PZR1S&]&!QJ=#3"%E&0V$S8 &K0GKW?]D/^_IFTPD0X;"$R\KE
M6_.Q)7#G]^!T5A*%("P\*55J#T=8C >5,U;K.'J+<0/*&9!?T[OI;AM0)X!+
M45YP7AD\U$PRH;O?H2V@%2HX+;=C=X'8RTB,G&1+N_Q1E,)_H>+,'7%.ZW^=
MKG E!FN)EY)TVR,:DP\^[<,1SLYXMT76?T8S 92 2KCX!2'IF'@;9!/,?*AO
M(2S"SX:+V^7NW\[;'X']ST )&CN8#?D*&4O3#\"QC\08484,@U#@4#DE]4A]
M_U? :?L,1T2R&O-X..I\NA["[(K$1#Q%Z4JZ&9OI#M!*5BZ7:(60X$C.:/&<
M_GM=..K#$8$USOW1&WAK9/$7+=[221QVWJ]6HW?K?R PH+;E!??_5<.[]D6W
M:.E&^J\<2""O92R0\)>_A%(5= !-]Z@X.H)?#:E@HX'/D7=:CM>%::0'/^1Q
MX+O<Z'MQ,]P'Y1=B'[P=E>9/-;[GWTVBQ*Y;<PX74O_%]=OSULT^!A29E&]
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MQV0](2,^PH]N6^?G#,FD(WEA?N$CZ$V-4:ZM6SH]FGFMY-C[QS]MO8^T;AW
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MNPRR-4@1]+K]<P?5=)B[BUBR!2J2H RZ9&P$Y10T)VEU#(1.Z@KPAM&6K]E
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M@0JU(\,US!L+;OG$R.$!QP@K/YB'FT)AH+GR$/2.6$T6RSUFQ4!\%W<YU/2
MXBR$O:0H0^K $F*=,]:6'"K#/I99H:S)<UK8I>E%6Y8PW5ZWL"A>PYR(E+*W
M.6%HP6-ISUY6*.XF9AG@(]/4?=7EL2!!&IE:"2>#GS5ZAR[):&E,%.^"#8G0
MSW'4DC8C7"9WI;_VUP831J!YYL,ZH(<N\"=&S3.U"&Q(^J+V.P@D"M#Z,T%*
MW8YF7^YS6Q:RA?IVPD)=AKN(S-#2<U@K@0QVRTLE8;K*Y^I?,0DRI@Z9WT5
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M2-@>4]%Q4_YDNVI1.$43<E'D[0+@0=]V1F,)+.;@Y! T<F&RY2941UR"1(/
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M:]]"TO2B$=6%]1;5>-C^"4OH?X[ID&<XW11CC1> -&5+_OMQRSN<D)T F0.
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M12I@E^]4P_,8#KO14_O+&+I5-[YUG5/"]%T5[TGT@X$7MT<NK+TAM0NZ)BW
M%B5!\[A$4&2GXOCI;I3K*+;H+N07J!);&O$#],[/3,B]X)B-1]3]#Q^DWA7/
MP4RQF3 6%+\9?%<P[]Z#AR.'>>M[/"?=@]ERF,,VLO?WG7KT/6'X$U[YA&)[
M1G<!&K^5SD:"FH!%V!J$#?+'?6 62&^IY:T85B^6KN=N03SODZT0F0*P1P\]
MY 0VDFPZO !2'#87QNJU\=]\W),7DL?H0)<_:#T.^A50' 9?R\'A@OV"%B"2
MB:Q_,_A$RW!!5YKNBX5+U)P1NNJCX6?D<Y"8<XZ^,*^!//=V-V]VW* K?/@'
MZ/>I<*?JHGFB[ 1!6IW]NUKOUS6%JRIEP>2#.0?@2%8G[9\7R0?^6@2>)V<"
M&I$,)]UTJKM6MHS#;R)7S;]V=TBV4&.ZS27EJ2UI;2FPT, EK>WB;G[$C4?\
M63Z9KK2-4&!Z"4Q.%\OL5$P:7Q?L+B=MA-29SDW?#$^+J\H-@3@5J((:F<MX
MZWD=POE4RCU.ZW;X_=C;AXA[(%S J9>?Z8^I&85=Y7:(J#%B-73];47YWPK7
M0(;2N]NF/,8WY25;%E7555?=?$J@,OX"W;703P(J"X,$>6+TY?73O&&10#I[
M)^RNR6LEJNQPHI"'A\F9<ZAGCFN&QO$X$=G&U?F_?*XC+HICDKW#F8HDTE9Q
M]X\[NR<$#L@W%,OVS==KE;IMN%UP31>,T,&P*>0 ?(Z1*75#*J%.X.0M-T,Z
MK+^(X<5 XTQ+_:PRK.?WX?PD.7')FSAL/>Q0SXK5/#^HR.\K #/J.R6'=&$O
MDG]9VW-S;>>CQ-R O03#IRCN4Y5W!7&FM2P775:#9%-=3@NKHA5+8?VX2$M_
MI0SJK:!9#]<14VGVZ/=0>RJ5+AI$? [V?(CG+J\(1:P_[G&JR:'2=6R[4,[5
M4<6UBMJH.W$UAA=@[L9DH9U,\T!8F==X:W4*6YO$IWW.H<GW2& <#7,*#D$G
M_R'2"-*Q%7 WZEN'P%IO?O-9#^$"BF3//*AS4DBD/=?&,_9TB7/C!IKB[\7Z
MIK<]LPBR0&T'#-95M5))%6(1S3K_,&CQ=,E;D8*8;9BZ<-=@>/QJ@/'@38"N
M2KB_4-6B4K4,LGY9=\/2G96\^Z:G)MNKYL^>;1=BBYJ-G[=K]=E28H?$!S8J
M*E$2DIX("9H+7;MYBSG7]D&NZ*&SFE4@P%<QKW)#W#)0"CV3MAIH4G2HP;&\
MNEL9N=HPCHBRLK?H:=Z>VMY$S!4'J6^!*'IZA"-4<T42=1XF!D%8>7%LH0=<
MWJR_O"DA)4 CNC@)D"/0SY_"^A:K.8J0.I],KA]XGAM5,KIEUD2\N^*"_%7,
M!5GFB<[?H/$K=>6$Q$_43)]R\S$W=&F.H1@I,7IPSAIB8.5%GAMJB<1K*%GJ
M*I%<=DEMAQZ%:QI4RAPN'10M0@,?*T5:^(.P?)CN*'6,G?X<@J">Q][53]85
ME8Z\#ZWY21U[0GZR"/3U09=V_?K1\-1TU],+N&HFS*9]P6NESZ*?%/"9*TZ7
M(C:07D&WX7F\YG1K0P3<)$@=A!P@YU#=X21%A$NO&!$S+6)4A07L>&B*4=<K
MN.IE\OTCP=W3?])XF_CHK[U1D?Q"UY0+*_T:->Y$)( ><Y.V"OT*4<))AK.=
MM"6ON,O[O-7D?BX+\01KJ6%:-8%SF4EDCF!S.Q.#RA<<':&1Z^OA9UW>09Z[
M//>(G<,WRH_)NGC?S[Q2>70CGS%.OHT&BNN15)WP54T+&6(0;;'N/C(1)4(;
MWQFUK9>I@=!'W1720J181\ET^DE56_ND2S(+?!$?IU1<F%OC1#WLDQ_UMCHG
M2N<27W[Y8DKG7^*UZ' \"Z]@_^:1D0$-^[*/='7?6PER24=>R/V\D[8Z=/C<
MC]S/4[5Z@<25(J#:0<(#RK6]J_I N#0+7>V1&/_E .>T7OYY6]EPJ'61UH]L
M=VS/'3D.3-7T\7H<8G>:'LM.!EL>Z<96C )/A,U^EF\VZV29%=2MHF&U+6UN
M7*CZ*G4.) 2%BCW4".F6 KEOC?Q6M%:H4"_B)+5T,CF.C+S&NOC7OMVC-5M^
M#/?^AT7-7RSHN"988# BZ2#.1(&7Z-$B:S6Z$1*,U6KT:61GZ1JL4[:,&@VJ
M[3C7%$SH1W19!Y6H$R[ED!M#0ADY$N_;"#L8$ESDLN^,DBAPE"%/E^4YF7L0
M+VH3_))-EH>R3"%R /I6W9^JF 84"TYID6OQ,+&!MQZ)!/W8EY.D]MV"9C5Y
MA.GL]2;@,.)#E\NLCW"RC4%*#YKKJZ'"-<*]A49FYV\==DV#:]DN<G!-)]OI
M,^O*OT +.F*_&[;([0%21[$8DE7)FHDK..S6".K, 4KQ^HR(6=5/$)>[B*/\
M[^@64WZ"F; 4R=8UF E.:WI.<8]&0TWO&VFVW8/O1KZ'?T5:%=-3_'O/NL7M
M2SCAWLG9T_4[\9"XQ24H$X@.K#Z>%6):UN7%3.-M@*Q_. OQCP1'Z]I3,1KG
MU_<-Y'EH.'18Y5<;+PDHXNZ H^J&ZTY)UTB@ZQ^RYO46BK1&LG5,S8;['18!
M?RD:/V*WC,DLLK.9$,-$W*ZK&X"E0<7H N2C3C;@#K);1/R(S0AP/!9V&-!:
MC'W4 #8^!GRVF=8U#P>0\Y*U.O;BN'-3?85.04:&S9H;27V#ZVN[%HCK38FW
MB6VB_E*-4B[K-Q,, Z:[/&=T3><D91'BH#=$F*ZAL3X9:^&D*VC0W=+L27:V
ML'I^SH/1OAM23WB^I.Y<R8-8&JDC87Q'O)?*<C3<>5^0^.8CS?>FM:)L"3[;
M#3:F.\#82WJDWG1,7=V64K9M'O>@D6$F_-( -/H"8R.T-< H$>N;-(@_^7QB
MED$\\U/?;.2C@8,885=#"W(&;E5@JQ!?G@W6=J.0#KN-Z4$3J;M%Q5;D'FP%
M[+ E$5Q/^' N?!D;"6<V?43VJN(/?J/T<CG;Y'"CKEE"8=UC#CEV;5/])/N!
MMQEWZ7;LM=3;=!WU,6X9$=H!4<JN,6PQ-QIAIT3'/D(C.R8\W5L*:8B9\  ]
M#=4HNH';R"ZY0F8;G\ *_Q8YSEN&#'[H;B21>ZN&)&>/LRM&?&\-YEE,O-E)
MX,W#ES373##5BB8!&X[\& YJW]]R/3#SQC95XS/^MNP5YVPST]G;G<6T1I<A
M21KFG!&Z]:D/T4A\[/V1NHK'A7-R]G=/;GU47)TVHG3X9OACP9'O:_\H,)"[
MN<EGX9"@/IX%=[?I7[A,Z=X&,<8/@,S^ <V]2GASJ^IPD7'Y$5S#74J"PUH.
MJYUHEJ%<RV[>2H091/*"1.D2FXHAF1W-%>D.ARKNU26EH0L3U^4E)IXECSYB
M5A-;V%< )\P7_<STH]2*0VP==##=X$;>X_H@W3!1JU0\CP9?WM+2LY-(+IUH
M9 5W$[(U$M3/1M[%L\,@/M^[C42TXPB;?T="FJIY;GWE5<Y!.1]+1O/.A:^[
MB8NLA8@SR+!$U[-57_^N,YQ"*G5XZ<*E*;ELJ*99E92)[A#.%8LRZQ0T!VB*
M+Z5P=T&M? H.B08K1O/O>T"1%>>:=KX8M"(V*\_]_GK([MC HXR5Q#8K-K8P
MTAB)X*75N)]Q-9<(Z\?>F@F+07B0S:?;4MWN<1E*WMK7R LPKW4GS+^,)L)=
MH_MDD%K>\[0..:#3VW#._:YOE%J>6(?PQNVKL_Q%&?J5D(@O^]9,.,7N;VW%
M.;M1QL<-QCT(,F:CN$J&<S2R<6=HVACVI%<2"/6]U_(;938J3B'1DO-P\-_#
M--=:B)+%-]3P-XGCO3T33>O4^\6P577!^:12(#+BK!* #LI>^;YH5K5?NFLJ
MEKB>T5*LT3UP8&/Y.7^?W? -T=U8LB/5%32*EL8)+2>)=L,13L^A9I'"^8U3
M$\9>Q*'%'Z=NU]6_L!QW;70",A.3_7*6:7H!S7WZ8UYN*<<7,QK2.J2=N)$7
MH(&P,@W=' W2,^N$@DG&8BY9^1Z2-;OW(:Q['-I'K?6M)(W+N?8#3^"O<QYR
M3KXXUF6=*SKV9OA)_Y!O6]M%BXM8E_ I9?R:\2!J:;KO17=FF0F526G2C6B4
M2?C!3#BIYQ<NA3 13(E &"#3BE.@^!L+U^CZ'#3\ 0=?SE69-N?%61=I%ECN
MTYA_.J<T=WZ7<WG$1R,/&PV"B#E,G.0'^%JW+!J5E7].9%P;B^/W<FXDGDMO
MX7CQ+76V] N\.ETP;,K@'BKE#(0]:9/)Q6%/=.,'&>%V>YYEAMYRWGU=;/FS
MB&)S2C L2J.SVU]-M?ZBBT57P=U-JK?"B]2%H"A+]:&4':G=796,(R[V67W!
M/J@]AVO_Z$W,N>D01;ESJ-+S'22^WBXO:+>W@'^*U[1\"Q_VN@!R<<R>M]-T
M6>):PHD\"#/&[4"U-4-G%:#=)2A"F&%0N\)ELW9#'[9$?7189IO@P@03WZ<=
M1P1@>7)34NC5?WE;$16%]EV)L9Z3EI8#?GX%[B]86=N^&*>?$-H(!4*Q1<X'
M%#A^#UUH*N$N9#V,X'IW>)S6P.0T(&8\&6Q6-C*RZ/83N7\'D!L%P0#XM1#T
MIS.J'6Q&;)!LY;%>4>A7/>A#M*\6QS8J>K)3.I<!*1L*G4RY":(LIZCVL7[-
M6Z3F?IR,)/8_JY4UZ?OU.G(:]EE8L.ZCEL58'LYQ/= W2>&KENZ!WC?FA;:F
M>HC;'3@UBE'19]U>P=:ZR9P(?.C+V,\.3OQFLJ5L?*%&9,U2+^:1N=N1=-&H
M='6GY)O"A4_QG/JR:@A''/X.>&??K6(D4!LODULQ0KMPIH]A$JGACU@T^]X/
M=- 9MAVZH+[)GAUC)M3DC366LF06TF5(@:X]PUN?);/W(J9M'LHK7 'Y"!+4
MBT9#:UJ>D_3?($>\W<5/X%V7H(=&[6O?PV4 I&MDVDCBH[3AYU1S6"4N)SF2
MX8NTPPC.I'.'D2)<>)4H:9\-H#LAI9R\@+L=TF>BSG# (6A^O<[(6,:I!Y69
M4@*2"JY5RF>N/_;JL?VH45X1ES'L.(6Z9I(=,GXF$A1E#RZ L-Q(3<$&<;GE
M06FU>)RN*90]WO7 Z#I25_U<*YO/:\]GY*Q&0C2RU "M1=,>;/UHQ.=(":B?
M%W$L/!9;"3]_W^P\:A3,4GFT;RHJY7I"5TNTC,5#T]7/1>&-6O=TXYJ ;ED4
M616F$[:8"6ET,3E+<E!#X=<([:4+>5W"*C.A03T/H33DM]27<L*: S3*S$U>
MC-FJ$=HZ>-]!]?;[G*R^E\0ER,68/@>'KG;_-WE\L.:2YUN(G"&K%HW7B] $
M9  2M0*5ZK'G=Q# \!U,'C-9M+;;<EB&'"3U_/F['&==$C^>&U6!##0]X91I
MHM,3W(U 6J%-_,%P>.>-&E%,:UAJ@"0GX)F/G2I@Y3Q*?S&VL#X%%*C<#5=,
M]^BQLG19)5,@78<H#;D] .[;BSQ7Z'V6= -RAYDQN$8(?DB'WN^N[N'ZZ9C$
M89YUMUAO/2PEY^WOXJWB).]X!OM?;\^>+&/1*S?=+!T,1QOOS+1P VP7UX:9
M*Y03A)G,I\QT-  Z)-/<^7N;-IF#K>6T,O*-!K44=JB\/7(8LX+)E\H3F$L$
MA#C>NKJ<L"YJT(9N;O"\7''[![=G^8/TCC=T;-$ 'A]0GV3=H ]D)HR[%B.E
M\GC[6[TE[6G4A7!8LW*Z^E8B2%["^5T7"F'IH'#VS*FQF2B]B!/0I,)J=42;
M&-^3Q47(:N77/]*7Q3FY_+L:"G[/A/8SD VEEW%(9%],;9'-H89!+UK-!/O)
M-HI&EBM9581<^QKABS@;]:"@69A)<H!:\K0ID0K2K*Z23LGGY[5O7,.>%X!1
MHJO<0YHRQHK1+>S8.^%Q/ZJ.O=H["Q*E 9KK]&IU.K;^"-+I+>BGO?\*%QAQ
MZGX+PWV8ZZM7R%1VK21*@4)62;PDILP:W?)"*W#@S!X!;$;)-L)OGL%/634L
M\ 5YX4C73K"<(G\Z?&[+=%GRE&*F"44YGJPU$[*%58ZY7B[1AA/5'9@'T+B#
M_KUZP%+>,:*::MXM+F#,X[W(I\@IQ# D0!$4J<D:=VXF;:I$#I7$S1]I&M'M
M[M!+_J_JWCVHJ>OM%X]%146( H*"D'I%BQ M(@HA6^L%*<54J49!2"U5"!33
M*DB$3;:($! QM59YA4)$0%2$%"%0)":$ /E:B\A=H)!;*W*)V;M*V"4[.V?[
M/6?F-W/>OC/O;\Z</\X?>_@C,RMKK^=Y/A>RUK/V/HC8-W3)_W!1AX4T$2C0
M'S,!$RR7#\W"3?CJP6 D:AH+32B/9=Q!BU7[!L30W*'P"7=?6)DE23Y[9Z^:
M[( .R O2_O##J; ?'SMXGZM0.*U.[4C>\W-#7=,/9&OTNBD""^Z'V")[_%^L
M1S(%8S[X"5H%*S2R2[Q-8 ("M<E<XV5DJ2/H1]CA$'WR 31)LW^:L@CU4THW
M(GZMK!464HM?U>2WKV<AOKXNS4KA_V7O=$><:U'TWAX#"?A8NHK(NTWO/42V
M=!GA!T>82EGM2@(-!A&F\14R6JN)(-N#L=VKKO#Z^Z7.[G;]21RGV"C[;LDQ
M41!\<V9W4V,?SW%W\ATN69LT^=I%E#T=<I[F<^*$1Y^L5C %F Y@]GW>=6[Q
M1\R%M(.P2EN*=Q*"OI9F'/VX5_(=W*,5R!D9[B1T7=4$91[K&/SC8V;VNTYG
M;JHF*&.:8Q-/WRB42U>A$=43^-K'W==9%WOVU5/V5>CU:BC+_8-<EKF&%G"/
M]UO4#GP4+4\X"\,1:(5NV1_T>6B$**2<!9Y,V*T19B2QIZ3DB93=;/H&*#O%
M>.T.EZ6H=S$6W45S#_=,)Q4,\O[H\NUP;AWROJ8%;"==6-FT0-'X3?_^#%%L
M069U56E\.+TB8=F;6Y5L_Z)+/8-QX:=*8FC.Y_SZSW;$)R=L#1M^MO;0FN_)
M8\H]!']X<C,8J <"J2>"3+18WD>/4;*.DRZT =BV ;A39S:^$7VVIY_&UJB6
M<Q,(]YC<QFSPIR@BMXYP/5O>8KNZ\&7Q0\]OZ+P2CT\ZI23SJ[Y)-"][$G",
M&/H\;RAJ*UJ+4(R7D)A6X> /"N7H>G.5+%HXE-$"V(% .1;6"$?E^$UI8-E!
M-%@KLD/YVOFWO;!=U6U:+RMF8S^-_@UMX9T%OKDAJ?%_WZYIO%$EU9I_MI#8
MC*NL.?35O%_=;=$P>%+C<76K:BA,%P#:/^F5KL;V(!47Q>0%D]THI9VU1)]4
M&4!>#&Y#VJH;R]RLF_WUF:U,ERQ!2D$?GEVSMB USN]<FI_>U_0-N-V<__ZD
MM6HA=K*$.WET (J#+H</* 1VH]R(YB@Z<JI0\S*1RI=Z(U5O&BM'N$!+\=KL
M_0-22G?B_L3S[J-H>+P?_E'C-GP%W)#MZ[F9W*F:!\D!V3<R$GA89K[]3NC
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MI+2J]SVUVX2/QK!\"KHAV5PD(BAG.D?V=?CL&AVUA4H">6@(XJGFMT4N AS
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M^&6_$1^![4H>5-\&=]Q_7<KJGZYR/M#8S_PD:^ZUU21S[AW99F=\D85DL@_
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MIVM=EEA&Q[YGFDY=4AP 0=U$K,&4D5O@?=+_W T.=*S'L42$XE&@XA 'V I
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MQ'AR;A)9FT:]VA@>:J98$Z>E*_K]9GIZ3W4XO[_!#-[E0%X!G6)^D?J<Z)S
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M#VC%$*32/@F<"X[\F5,QI:1I#E0.$D1=KH4DRGC;].A'+_.\/!))*PP<<4L
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M^Z0>4T9'47T^N-$1TZAVU%[P7O #%'CF-=-V0!DI[H6H&$M:\3Y,1T4S-?/
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MBWFF<A#KCHPC5B Z+&1:OZ#18X8VKT!4!VP/7-^"KD*1KR[LI115+VY![J_
MH_[$!"8_U"_$[\UWQV[QRM"*X3](Y;!W/$OE]$T&ANZV'%'*/$>#M':5C% \
M7,$BE+S]C6DZ@M'P&JMG5H#AB_;U(]7%WNOF#AP ^.ZE7Y399H\I(9>I=DY8
MIZN_)CL&<@#[RD&M1NO%=3FB>_^3_;MJ8V;NRNRS_A)0<3I!3E @"F[*-;13
MRKW_@( .$D*_GOMGDX+'0;D6ER_:A5P5,GI>>UN^<?7??/0P86#CD]'8U#_
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MSBKU4KK_S01/%*)77DZ]U$V;I>Z."_R!(B/COU\9%<R+>G=H^9;4?;U;^UJ
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MNY12NKZ>ZE;"7S-;\6#YX-?;)H?8F^Q=_3]FH?E/\]58YJ7@HII$:+N)!SG
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M3!WR&HEHWZR/CG%)LVF*OYC4=;EZ!\;09B46L%(,3>E4:QPEL3^QBI P=6+
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MTV3!_:EJY,.3Z,0/7HV9C@TX#_9 M6Q8S3!VTK:+/<J<8P]606IS$;7#@G$
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MW*401#S9AZH>4U)]JJ5^-C:$/$PD[>< +2<1=_OWN$M+1#4H\G1P ,$6,EX
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M;37KAL7/H>Z5JE; 04ZD.&2C#3J03Y>O-SOQ'D]78 M!]W^E7-IJ#)"Y"$M
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MF-V1&\!NJ.KS)M #ZEZB+D'/9+JK1J4003],/[DGS%/YY 9R^]D=P]SF@O5
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M=ZPE8@1H!(7N^7%W,&LNN_J>Y<+#HH%N>1\W+.=7X+9@A%,P>ZK5*)N:<GW
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M4, '[8XM0\RN99K--<--@AOUF6ZI2F^:4A:?Z!L#W5JA:Y-$@.2"Z-IAKD6
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M2<%3<D5/+YL0"0W51_TS>P\&EJO8<D>&,UZK"JBT!9N9*)A+NZ766QWI@X@
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M]H(T>#UP]JY(PBQ/T;./KIDN"^Q+-FU%5,J#/Z&3BI.:.8;]96^^7ABG>@,
M &@0W(>+8_G_T8".KK"2X'#EGO^IZCBW30Z2U:'[*2GI-%_62AKF)=[_WS)0
MX*$UO KZUPZ?N4=.WU)TN1V_HEO%I2C!3+B8]T+GZ$[]*W7E1:5=P4C8+ANQ
MCP)X&61' 4R .@.VWU%-4!T #K@U/RVN;]L\Q4+D=T@FWMFA8Z>_;I,/N(%M
M<ZCMXX*5Y&TE) =QI]O5/E8:0D.@L6^8\FS3XGQ9.TJR?NWJ7N01HE#3Y5OO
M:.:_25]A?WSXI[/&E",A:0VT9J1,71/+.=I=7E>6^.[#QP^<!<_D2 B^-)KA
M!^9:%YZ\D2AN+5QO@:</99?][H"6 &<&?4*?^5);*V1^>/38Z-IA4NL+%[.(
M6R]?+%5<E%-[+AM-EL8K[.$+>F[Y%%*+"5X@]MXZT*2?88?)2"N:PU,VI^58
M7G0_'O9]V21LS/O-C>G>,I!1)>7UDV),2T;2K8UQXW;YP#IC3VN)A.SVN?'&
MJ1D\J7'BA$Z# H@Y*)-<Q1),>YP$M:\FA7,38289+/&^I>#'R=QK2=\6?[4(
MNJ:.G7"S,"02C.Y)]#@I/HO[,ZYQCW1O\E<C 3RNU_")!>4R^5=\K,KJ@8'%
M3/7]PN(MIL?>T[,T3W5\&!X]X[S*=V]NW..DD0*HR-AX8C*6:EI._A:(5,/'
M1*N%8A.!'<A[>'(B+IF6F&G:,@K?INKFA:@4?ZAP1XQ^\I;R\731LWV>PUV\
M3$>HM=;3LWRV2T+5)&]%:$9"Y!>4PR^"#:'T8(T=IPF(9)[)R:9!\4:XQ'C1
M"/RT8<+>/LS*-D#Z!L[Q5B$2V:(0\OJ>5;P7P!]:L;_M8X)*M$,_KD$=/_XL
M]7<A)[!)]/;4MF@K%SUL[J[_<FW<*%,$S$-1C31CZW??W)K/-T7?YW$8H]<U
M2['JP?ZIC8W-O\Z''RF G+#A_6:\A2#^T?!ON=\S]B5;S?C19^-P/E#%!39B
MC.=K]W#.[(YI(UVFAGG'GI(HG^HV>6^'3]='19OJ=9*FEKKGIL,[,76W/V23
M.13?+-!\5['NNL]F#V(1R:4;X69D?YC$'0#>7G6\:?A\7#Z#RA$>IR2]_7=L
M?GI.^&3G%WF=%JTI)%H?D3;A#_!?3S8TWC",D>HO>06XJ:7WZ&W)A]XK'51*
M*\F59F3HY@ZSNPD%P(L(U?RQC.0CLG? &-2$\R&:Q%!LI60'F1Z/S+D4$T.2
MS_LN[9\C,[K<U)PN[85_8=W4EKNR\3<T5JREM277/KM,(%CDPVG_2H QU'@\
M+U@&[J5HK+/ZJZ6]%L$7HNS2GL5M+2BSV*JIV,B< X2X$T'%L]DO"(E)!8$?
MZJ638@^WO8-YY9 >WWAUX ?U/V@??W40XGE.2_4^0R;+2U)^=$\4:AQP["'K
M;GJ<>3#3O+4;2((6N0*'+\';TASZ4[39VNH<C&[T4+-V)^Q(C=]AG<G/;W3Y
M^"[YRX<44/=P-XH'G' 3+]ME[(V;#WC&!5^DC\ :W^+&.J<+I9=,>#^3XO[)
M\*I+62(N1OH#D,R9^9[D1!@FN'8+.S8DG.7+7EKS=7!#,B2MV[Q'F\U)@EI.
M(M[&EQE*?90JOYXN]LRFY6 FK83)S3BTZK .7HGP=U7Y\K.TYZ>[:UW0*6;6
M;/1 B2P)/C4BF'QF_[D@&%.W*6XP=06,[@X7FY0J&I$5KTO2JN-7U1GWWD%O
M$_XBD*%K67/#*<9A[)['3 ]*/?/\2BU4[YG=27%-+7H5V?3[?@<-9T.V)(B;
M:VIZF@\4"LZ/GJ</!0O!$5':EQH;;0#W.=1*=>@X6.ZD@H!4(_Y]V/7]RE<?
MKPG?FC"8*)W).(3OV^T41YDG2WF?-&Z#[':\5S^2/%>QS-V=*M!.5ISI+W=K
MY3/0-WPF*?Y?WW:-3#H%4'SJL1RN>(UT@YBAKG9^#=JPJ:JB$[@K!8:2O[=8
MD[.W*][ZFO4.ZMB&MD 2L]O;TI&+R<1%"D D#0<]2Z, N*#KJ;NM,&8*X >?
MX?FD+CD40.$K- UAG&S W'-W%J)!L"9_ED6=01]+MHU ESB+*8#?*N<96G][
MTW#,M[=C^@A:.02NF( 1TTZKW/L5TQW8K*731>W4^RWT^:)4M30EF4(..XX-
M%[NF45W,O" G%;24+%)D726J.Y,>YP_W>M(+9/;\<@G$KZE[G+'7)=CJ[F1\
MR7E*>B7W^.!22]VIE,%!YX7(/DCX-5]+5YNNOJ@_8M" &T*O^=[X&3+%62\'
MKKYZ6A*'N1IA4_ZQ_-:NW[VERG 0:'0-)/JK,A0*1).H8/C,V'M =G<SC^G+
M12\KW-%,O<I;+DDV>6G/5>T'X.8V,I8.:E/HVQVO6=,\/UQHR/W,DFIZ/W<V
MD)_F_B X"85OA\)EU$SQ1T],+X%[(<.^TCGUQMAD%L/6(SU<V(4LI6KJ7Q>S
M9^YSY7G>S^!Y],958ACW%Y7_T'^'AZ1 ^(T6"DN;):H^@K*#O4D2I5>SG,K1
M@9G2U$G\QO#MMB"%;\57W3^*#*?VFG>9%'&5:UBE-O"G9X:C@GY]FJ<;=ZA-
M&O?1;9T)()+%L\C3@O6N<2AW&,UOL.P#8I'S@CK=JBE!,$;-"XMB)RGA,3V"
MU,3%KOF[B+JQI31S/#KV!KB29(0-EE8[IXJ@0[891[<]CY/X>U'>SN!P#H(X
MB4VE=[A'0YT@VU4=WVC'U+RH&=TB^/9>,B])B^A82-(GYF&]7+7QR>](/&'?
M^@@T=I-6&U F8DM?A[,9NJ$BGLMJ$GZE*,EM^]$'P7$"H?]'"A3K0'HJ=0%
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MD9F^DW;61=ZD "3PFC&P72ND"O2W]G?H29*35<!^M[GC%]3^1]?_*M.>, N
MEI(?%%5;[NP"4U6<* #18Z'\N%M7;N;' 1(7$Y-6+&<YJG!7 V>C)9O>!BY=
MU%H4NO;BXC5.:Q& G)^I7Q\@;<,$<(#+T3$N&6Q9WG:%(A>TQ><%2- UW?S_
M\71*R_0RRV.RQ-*_PRG_20_^F_RW8@;4C62"_C!:%#Q+GP-1 &;5M-:-4V#9
M(P_@X1$Y4UA*_BS!IWV5 B@1TQ/WZ3NQL+=X0U=%<S\B8I^_W%8U7'.LH*(T
M->UU7 )P.K#^3S#D0#[5U*B"K'D](>(--[>3UG>UP[X\@;8P$+WU>0H[^"4&
MSUOG16(1*KEI+TMO/M985S33MYZA27C!XFMWQ*;'S2QY9=$RT-VAM_8K]_+<
MCVDFE=W+RCW!0PB"*W8H>DB>F==-P/_ZQYD_3C*5H7RKEQ7JQFY,R(P.:2Q.
MURJI^D;_ C)6;LW,K?LTDU_(WX?X!6T&O6S,TAAHS@S%W\4:S^*>+%3*T:8%
M[7C:F]?H#R2L7*IM>ZN4=%F?]3S8K^X/^[PATV7Z]03@3I70[XQD>39'RM\J
ML7YM4M5:R\O>74DA@?%S?1DM&A$$FFXZ[-NY=0'ZB:AOWYBIC<KZBE4JH!<4
M"(EYL>NFP#@GT5>[=J0;Q)@ /C]>_%JC5](K\UL!%[\KFM,N H*JZ";P8Z6S
M+S)B1:I0U A41J^)C5MCL_<T)F ]7X<53]/9TT>R@+$[/X9.P@0\R/9)(64?
M&R=7\VA6?AXV:E"!A?WH8TF6X9'11A0 ]^:X[O</.1O>UF!A93H]'AH>ON>:
M'&VO[&GQIKWO .$N$_M7?$<8GF,1OKF%K#-3):9Q C*Z!C)(9O!?[E[<RORJ
M]H0(8"'UAE&ZG]9::;\-I.#KMSD)?A&D.SG0V:^K%4&S&P\LD+&#,!.MG?WJ
M9"/\#4J>\XBWO]UYXE#]1/$P<6EM:4GPX,4U-CV =8E[ED!BH>[U,?\Y66.;
M"=G,8AM[F]X+- #1MCM1-"-LJKY.NA0 [WZ%[8LPTPX8Y[V:MF $F:FYJ3'A
M2\9+>]69GR(6?$$-OA?>M@?Y(HI)SXB^Y2W?G&3'MO].6@3S?D_K0O M_=R=
MYG>A%^8K,R\4-DC5>D[K.'=O-:J$NZ?'H A4G#:),98-RV@Y3K\:/3HG.KUN
MCS>A ":'K:Y\O?;&[_4/:M?:=31FM^3-A1_89.HC(7^>DY52V_FN,(X@KB.6
M6:VU;ZDS PSXV][KOK2W;@LQI.BJ[&6-/K_RF%GH]8G5AF_JV<1$Z ,T*!Q1
M[V/E\5$:7#0P[DT!K$@]95BX@(E(,O&#\F84)*.P9QZ&FR6#/YHGB]#[I,N5
M8QCA_['O&O7_M>\Z[C_[KOD) V0#\>Z=4Q8U^_-K):?_JV!3L4_V6 3&CMK2
M(OB0/U6#VD8TE^C_62;</8_(&%](>=DP9^CNJ3)I;I+LF/!TK.S)8/6O62VZ
ME!!7TJWNUTT,7YS'$U8%I\I:/[[<:5W6X1DB&XCL]]Y!%]-6JQ)@W</TQ <V
MWZH/:&4#!HHMQDEWBW2/3@Z+9.Q9[=RG-D4^5-1((((>3/U*?Z&87? 4^:[V
MWC-^ER^IUHD'IO5[][XT6XZM['A)GPF/B;I-1ONV4E-%?$C[0;U8IA8QD5PI
MWC\?<[QXC!Y:-2;6$E@3ATK"7N,K.G?E$(<NB?(-2(VV9 ENS$82HC&$6DXG
MRL8_3R:/H7R/;RQ5Q&PN9B'GRW-M\>[AA";]@9]2, Z2_JG0I>Q?<[=HH_AB
MY>3JWEA@.75\VRQ=Q=:Q.-S,\L?\G,6Y.2!0(T93W1:3]>6+[-^J%PV;+2VG
MWT)_/U9AN[NSO8/.VPJ!??_./WQV0 [3?$($7RKIW+Y\8AN=0P#AD@H/[T@%
ML4Q#;":]NQ\9-<H\;<C2LT^L3!F[Y)=WOS]ALH\H^R)N0^,&R=5\D+L?\@@]
MAPY2LG 5O3'@9QODYW<G;A AMJPF[!?RLZ='[+ST5(+L0:0_!I-VNFEF!K;*
MXCZR,4!'1;UFK"F!396$,4%E;NYW1"05)E$ B@+'9-23[61:S2O^?1DK8YJQ
M4*Y<MS&%5#Y@'.]^9EQS7];H,4Q,?_JWZ'VS7GW.IQ"^!EUE8B0AI7C$2+%[
M$!++(B2F>[8V[0R)GK9X>EF9F@Y./0:UR#B9-PO"-(3)+H<Z*-?RN]N3YYT"
M3U6A'>JM;N?LD@)(;B:M!Y9M6(39G)>)2=BF$R<(#S5MB1E&$#\3_'#BKQO!
M2+'-Y&NMNK-ELS0_- -? :1:F[T]ADFW0H$G-S'<FOAE4,X>&8TFQ<7JWIK9
M\$,1"TYT/I;8]>\#JU40<SX3AS$  078JZ#P\-SYF*Q<N:)76DL77[]ENH-6
M>R&XUP-6'^Y O)/*@G:CXFOFQ>RF@]L"H!7VT[\NW%(?RBRE]9)7LGQ+4]=J
M(#UWOS]#7+F6F(R#OE&L3FSXHQ:,1=VN)4 CI7(90\:FE;1.39JQ[$H1K'0-
M:49?*QY8?RCY'/3C;ZY8H=BBA$SZS;5L]S]A \,G(_']<G[^<\LM[5LGGLBC
M$YB^F8/B.[5GV&$^=]]-@6M37@'9/()BH&!^%T2.!4TCLO[#\^;:9A.>;>_M
MA4\7KW5;I@\[T\=2U3#1"RY2^P->OAZ:!Q\-0]"%%0_,S./-6UKJ[<@RO2-9
ML!>GZA3 ]9W_\="XMBYJAM4D5.PWP?\RD.X:PAX('P_<+EDQ=D2:DY+H%VA(
M'ZIC@(>2[K"3F^@:=/)_WX< FQZ% +%GMJ_^WTT'T?,?+0&^?\U</\4)P-/Y
M:Q3 1/6#ZJ=UY\MN ]W,@J[1.VG^WX=5$5,;VTADHQ6)(9, ) +)'^/+?R_R
M_#PXL7A'E?#FE=_=WR=Q;^/VRX=NO[-(/RXHR7QP#/<8-L(LJ1.5KEU4[@LO
M@#FI>Z@Q.%,)?%K<K0(YH!M03#V'9R#;,7]'I0>=1HE.)WS<!@SZMT1_X6<R
MJ=Y<":858GA[*3@2\AH_MU3)''6O^BIQ?60K&"+[U6G61NKW=6?[.0/_1 VW
M648*P*V^I0FAH^Q.#X'_VAQ-_KMA9Y;4/UV]L6)>:2(S9A7FW_Q7[#;X&M7,
M5Y(2!7#@*ES,J)HC_ B).^GLW0&47K5*<8 4+B48<7RBWK7PS6U6@W%IW"0.
MEC=N,V.+X_/O7Z<:))C&XK*>L?:*-M6,>8W,J)2I5B+_^*^6?O*#*XUJJ#H-
M(H&\1$'=QNM0WT*BJ]F$B-9OD<+I=A)!V2S=O+;PQ4*ZB$O=84,:I$$,K9N;
ML5,-P\F #3!_E,717FU9Y,\8)X@Z7GKF^6*G!L_'&N$<YD<,?]12-WVN?58?
M^GL\]-KAUSD=17*9_'J!%XR1,[%%=DD]_#!,JDO74@^F(@B]_D0!,)%%YA5/
M@+U0%@F6F8)QB.3"F7*P4(UM:D=5Q!IGVZ^(B;\K61H<(-%&4X(VSF$&[Z0S
MN=A(U6A6.<IU?8WS"G_H\_J/1[Z=AG8[PU<#T&#D._D*$..OW.'<6ZW;!:8[
M0#EKXB6\[V\#V:X=9GVMWFU$'Y6RD NV%>;SU)13"GB1S/(0ZHL_ZEJC>I'&
M./"L::-J55UY@^E.5IQFY+=E!.01L:'[&I>I %#BK9Y6KN[5M ]O=<-.4B%"
M38EO.PB*N,[Z%]%IO4&*=,Q/S;","8$T-#1YR@6YF#T:31.W\XI;2"X(7 9N
MU>T=Y4$'?#1_S#40M?'(T7<U8/&N"Q\3[J[?ONT02 'H,WR['';EKY^Q?V,X
M"SZ]66R\*_P:8EKK,D9G#"?Y78W;Z^BB"F-W3;5\&A8:+SU1F=S+S#^M+!33
MFCI@0T65N%ENWW3^804J6#Z7^YXB(8\/ZFFU^3&.E*;_W*'D%=JA<B66T#<@
MEG4XKJ)H_;QC+[&$04?>_,XHMA@&#-&4@96&EK6:^3I:3J'\W'=F#XF53Q&/
M4W0_")&Y/SB;$25*RQY(I&H!OGA[,@XF[R@^B=@<$9#L=-307/^0MD*2)TCR
M-P<+$\1CDD:CZ,;B9XAM:$VYN@?" ,Z7'8-"Q ^+VP)/!&/#68DI$E^#JTBW
M2M=SKT?-A9M[>7ZO;<T06X[-]?_(NIO'(_]-/,HHU]]1L7)I&JIJ3Q9L.EX&
MW330\>+W=RH+.#[.Q5]\:^\FG4 U$H$&1'P73U4/+LEIXM/B_G'$T^N[Y3N\
MH6*=L [C10IX!+'^=@!U:4^)^FL7@!OIJ^F=9ASN3$N;P95P;^U+:/PJ<WJ6
M@KGW.%)BIIY^O"W#%U*7]Z2I-5TRQ>Y^>HJ @MS!D[1<":Q3=OKZ\QLSTUF&
M)S)'XZ:R1%Y=_V/S-(,#JW98S@'Z9!<E".TZF4CG>'A;)!1JE]&29VD:)EB6
M[U[19SF>Q_!_X7%^"==7E:V52313;>S_9:S+_FPEDUAT+,SPGT(?9,]_<0Q(
M_N<8,/;_RS$ 10,]IV3QY/[#!B@S41=R4_,SYW:!>J]Z"SJ&)*@T0;Z=?%(Q
M/:I)-":>@\%JIY\R"Q;5.J_;_ P>)*F^1E,==%RL_6[QKO1FLPAV.'3SL.AW
MY[MF-YWIDV$*P"CM-L0:)WVWBQ<RC:PMLUL/Y+IM'!3@&WHS>M:^,P_&U+\P
M9".A?<UW\/6MYRE:6]W)5TVODDP(<\UI'2&/G.CQDR-!D;T:,O49.PYM=<_M
MZ-N%.Z*M%0YW']AN'_"[!%=6=?5='_M*Y9YZTD=FQ\3SYN360 ;9L46Y40$%
M;FC6S)IF@@F"?W*PY/TJS7)3\YBG9]56I9<(4Q)ZY7GK(G7H7)XNPX^X<H7C
MEQ:W+(0UGC#DU.G.(*HO!-VD2F!PU+-KR!L,@?3?,0AQQ.R0JT3%S8U+^JM!
MH,#)]'V0=E<EF<'MI-D(<VU3X!;A8,3RKD)S>1OOBZ0']2(:@N,"XT9)%_O.
M+%B[/[P#E"AIP+Z"5;MXZ=XWJ%/ICG73Y5K_]A\(#78^-F6\_6Z@M?:&N[+X
MRL$6J_4'N.\^OX%(6I](KL&&J1A*G@)8^%9'4H\YE"<\0K'!-X%,8%^U('SE
M$_-60F#1PON,0Z#@VBL1ULT0X^7$T2R0@0^G_[&,<#WR0G[+C1N@<B4[,ZO&
M]GW4XFO@2WHGP]VIW=8S[\,]3?U']_69>N)=>422E(;TA5R%<!'77N2J]_$G
MZ6DG^VE$;@)_Y23W\4,77+?5<<-1*+QI=3R0J5KSI4^\)KO&)=*MMT>X1M2B
MX'O4%1+SJ1[XD)G="'=&?Q@\A9N<:S.6KHYLP# 0*WHUF.O0\H*7Q6JE,M!7
M,WB1)0&,*-\R:(<U\A[8QY1P&%$)KC\,RNS3N$+T"BHG]O?IC;290BO!1GWS
M?&=Y)41+G%X3'GX4YS\Q,52PD#$>T"[^'1TN-'Y@']H:.C S:.RO6\>^5FJ^
MR8794ZQ>^@/YN/U-YG0.<0(;S4NZ,[-/ 3 <:7X]*/!@>I/\51,[([Q_H$P&
M(6]2 !WGR,$SU#0Z#1PRC//9FL0.OS_IVUH)O[GNI(P72 ]8;-)LE*X,P+"#
M7E, S_YLH&^#O:4UNU)L>X++,(.5;E8(%1=4<56>3[74[>%1R",*X&T!>83,
M@L<D!FC2$>,/GQ.D<@4:"5R1THW?D'+P235&'/2R(SCL'BP6J:@?$'&!R$](
M,YY(REL(/;LM4^ >%I9?5%R)XT-,>-X\Y$"EGU$ >)J?!F%1FU"B\XG,[\(E
MWZ2[F%Q3IU=^-*A-FY;JF 9'>_<)_QR5L\86KM9QJ6I8?^9%FW-B]3S09HGN
MK:XY<[]J5'6'+.?YP^IK>C+3@W<.(_'24Q&G2O;3D&OXC^'\XQ!G'$Q !PL:
M#,+=$Q# HV*WPD7<R1=:$4U3>43+12_-[I O=@'D6JC75W=%E6LJ8(+:=/HZ
M7+ .4W?4HSJ<B &0.2 V$]F&87I]R,OX?_+\F?NU$Y[^=\-*[6AE3=*X:GV#
MR\.BJA[F:CLY.MSM%,Y07HVSR-79.E\"\24*X+Z*/^9W^)?I\(?U)!9\0$,^
MD,X!Y'1A@B9;O1T3*6\_J,(JJ;$"JE 6:1KWR9>R#ON"_W;)J'BNJON%DQ/$
M$4\7G(DOZ?%A*F]JR]8:V]X'\MG9Y[&IC:Y)WG,2(#!TWZ5Z68+\7&KX?JSH
M#SCCED9\P+_6S2]/G=5>QU7>O&"@?ML73J\4]KWB)G_@%\2CI8O,#HM/F$VR
M7T<NI35F(.>M[6?\&^1>>9C<AM3:%55F9(:93Y(#]Y23J8BMVH2JU):5B%*^
M39ZWW6P/" ZV!O3Z F,GG2^2-DTFA)X[MS:V1:M^]/_=L:B_G :O_M(64#P-
MENW38";DIA2/D]E-66V(LKU6&<X_&]&7*Z@)ZRV)6\_>^<ZM[W7WU^=7=G<N
MQ?(WQAUM*J2YNR,N!S"^Q2X^=G)Y7 AE,<_[OAC5>[,+Q_$Q3[E$"6(.3S.U
M?#DV8()T?C<WP>O5M^WO?H#V$I@A):L2,>=<*09G?18K($H!C%OV!&BP4@ ?
MG+LH@,-+8ZA]C)<#K'=JN%,V%@+]E8PS'3=JI@!X-]7^*^\_-C#B4]9S'2#K
M[KQ</ZF/(>+UB7H$31I!@H\:\)S_V\?];4!\N-=^FY9+?=H[JX8EVL6 04+$
M)587TIZM]^E5 ?+VW1Z(__]V+WA"_GD4A]K_&>:X$DD!"%7>.R(/UO#L)-?.
M$'*;E@AC+1)ZF>RH/FG_M?V)U62"^*;@$ 50U&Z[9]TCR$,\Z>MA<YNNQY 4
MB$\OZLEVY["AR6S2)H39EF&02&T71$W4D_!&>&+F42JXT.4.<'WEKF0(JLOG
M$OCJ@W'G*34>4/$&C4V"@R.X]50'/FCD(!-7YS0'RI2;<YR?->1\F#!>>LE0
M[F*)1H%4X*YPX?JU#_J)?-T;=5(_;WP$+[VKH!5^J22TQ"EUI?<UMF6X\\K^
M0$6[,]:E7O--P&;)WE_/R@_5I*OERO._IM&1?PUJ6H,;OVFZC0N:3G@YTXI6
M=LM&0P1XS+HM*Q4VRHP^:UODIQKV;Q>C%C*^3BS-5F6CI.%VMM+^.V-GLLZS
M7RTL)-YL/["T;992\HP<LI;R_;$^K/PMQT$WKM?U#WW'C;+KCWQ_Q-Y+5HUE
M3N/M\Q9W;?H0^/#B<?S-EX8$/I^X+,2[0F-%W'R4;%3-O"4B8?\/G!_TW:YM
M8#>CK<T-9C/2-T_/U8)R?E/7<[C^RT5W$[UHW:EKS48RPHMD[[4*B(Y@_.H
MYEHRAJ\TC"LZ$FX^:PT(E'IY+_WKUXPX16LG>R9+9Z[%;0[S\?3*S(<GL%]'
MWW>B<^\1@?G$S<.]LUPU=SP,>YX:PUE(X<3%A9S77>$TQ"""U:(],0^/[A.$
M>T=<K@\B##%S SU4O$NPL&@H8_$$!(C//\+N1/K/ 1^,_O7"-3:C%*TW!6O
M?&0ZQ5-3DC:!N2?1J),"X&Z3Q?G0D>X2@;@=@:K8HO!!#8GX;M[Y'%?"3#>&
M@:\W8]>#5R$SB"E[H3K&"+L3!_T=*%F^B11N:DWBEG8=J\JB.3N)P6$Z;DHO
MPV/Z8$PX^)?:W&EIUZ[:F<'F!VE2MVXF/;"XI#I9EV?]M4-?0XK$VOA:%)%$
MYK?O?W[[L] 41)G^D_ZC;B=ESH2'NF]Z3<98+]"X55I)I!GL54)0"VG;SA2
MYC,*X$W!\0+RK!+BBB\Y3!]'RKI#!<,%((]14QI\I,OXDFY3%C<H%5)\_9 "
MX+^GR0EY1>B+EJ8 :N^Y-:#Q1Y$'@M1$72]%&X)349Z.5VCYG&W#5&-&B/J
M#A.B"TJ4$-^^BW-\$'H+XH.U;S62G;[[_>3Y/0K@$ND)3;*: 3X;QQCS+J\.
M/Y'+UHB?;/Q<2(R_3Q"HJ%I7Z?T@^+X8K:9X^?/=#:3P1 &>7,1XM'\%Q8&\
M=*,[=A$879[B>5MB(Y?',L;E0;"A(.L6 U;!V<TYJ40F&5?]_7<VQ$F1Z,47
M.SA$//!A%*9/W1%V\+:F-GF192VW^@LC6>LUU--@TW]+U']Z$T3.^S_"\1N_
M0^+(7G2-47-U?O85\I1H?_6<GA$1716+0+KI\"&DRL@!E!,D('-6UV9Z'J',
M+(T\7^QQ=$H=Y'9K(S$-YY4/>L]GU(ANL%]K<'QP0G5"?\XT\6?%X:KA(U".
M<$UM@C7.)SI@AX%H O94$UP  2_:@&7MQN1!/FR;!N4@WO"\2RT>+4==MOL8
MHIY7@[IUMV)?MZ(U!3#]82,#Z4FO1@'DV55W:T:H)#RYKY@0SFUTJ9N1<R27
M NC<:SO<Q4VM7!$>F'7@^^1JS]<0]>CGI0D-[0(VTZCS.N:SU8,7VF CBN/@
MO=4*U:ZN/CZO%W<2V8F]J]KXY80=J#LVC&G1)LME'*)<K*UREJV=Y.(><Z*:
MT1IGK6S$8_KY3^]TD*/Z!2OC\TPLZ =,'&[>^KX;,_1"C<O%^)-?P:N'$E'L
M(HM+QA@H3:#A4']ABE;*S1=B"B\?]'RLETM82.)^\4HUTNF^>"\LRNI_,??>
M44UU7;]H%!44 2G2(2HH*LU"DQ81 9$'(J)TB(J%(D1Z@$ 0I)<(*#R"$*5W
M1 @(!"(U M*;AA*2H'1(J!L(R8WO]YZOGW.^,>[]XV:,-4;V2/;:<]7Y^\T]
MUYRO^Q10@MJG1@=0N:+/-[MY;N]0WJ4;1 X.]IIT-Q1)B=VV_4DT#>!Z'+U\
MT?*353N&GWE:6)ICT*ZY22R)PX *%_EAWU/DV-(0@[E!R_ULUR>6Q+7FJ^,N
MXWENKC?UKFJJV>TOZ?<K#@W_"M(X6[Q63V(>O6W\<UZ^T79R"T7;1\:2A!BJ
MM+'66D6J1!\_I!4B=/O..*+DQGL]5.$4N,Z5"?X9X$9Y_+;)Y;F22D.S_"7>
MQ^"+RPQ)NG(;6M"E/@Y8U#-5ZSKZ2E>:?B%BH]&J7?Q9FJ!1,0QP-7ZF"ZY+
MMSBS'_>=OU.@[+O:J.?WF@$WP()L%5DMOPK<\CV+HT-C9[1RZ<JQ2H]'56]J
M4/<TC\K828F/A\P+$UM&#R4:)JW9=.HV<[5DO3IXZ>=A-,?93T?X:O.>1;[*
MN7O7ZHX[47R^)F%Y-J_^7;'75F*!YFW;M<(=Q4E&_=DZ45&Y MK,,R5=\^T.
M,PE1C3[]K,TXBO+.P478%N<P9".94ON>Y^?73LFM/O.^"C'P[>;_D&'!,5$&
M$!PDZNC^5=R Q,R\@/V70'ZXH/]D.1OX7PD6TOY]@@4#H0-D?#64D8QB([U&
M<M_^[8V+6]S*P&84LZZ &8JELD#_IU\;@CTJRO_-1O8[=GN;?SQLL$?(30I7
MQ5Q[4LLE<SASYEVS0<W%!H^S\-01SZL)N>(T-Y00,$[Q2>,@,Y(03LU;M6G"
MIM0RUZ-*2K[&R[EJVW%D,(_V"SN'G\1/SN[8'B^31KF[GELE6A<,?V9\ ?J>
M%+.U-_UM>>Q0PFWW@ROG!T<XIOJ>#]X@9B:$?6JN'_;Y>W7I#0?>I_+MH5 C
M@VD'Z(T1I!QY#\^#;9CCR9VGS3^:?#O*;>)F_2&VUS0W(JNM8W3L:+-QSI/3
M-K<*XDJ.WBLP[?OYY:=#_LKJVE")XLIR8SEC='1CI?Z]1P0MO%G<E[0U6L2S
M&K?9R17@VR?B,+&8'O[MB*3>,[_LC@[2]^-T8K/KI^NW3H!"K4I:X?!#C\Z?
MOG7Z>K:&DT'B^6&EDW=E[]\*<UJY&'JIC<-*).4KYRFGL83)]:$A>D'$#".\
MHJ)6:F=Y=Y<^>4RESN+75MI(I\H;W-)0B&U3>/P%&W6)1E+&6'!D6TG8Y?X]
M-&UVK';QW@H3B.%O>7/@5T)/@UW;$L4F)X,GS4!O+^].FU07-7W \< T'VU;
M9X\%VBR.6.FG"X#<Z<COB5U?KZ(51#\OS%S]7*6<RM4M_>6G19CE'6,_/_BJ
M5/* O%+<9\CYIBNH9N-90'#/"(;D!U[2GAG CM@BULE6H8(=NQ "YK@K6$@U
MB1XXY8*\2@F6FS;M??F$DF#4:BM)N\U4'%%DW.YWKO>Q$B]:O]OR6VC7#S[N
MOW47SCFOJP%#8_B>X^3*&3=QP/T<(&P1ECH$'0DY9>V8<&6V%7KV5[S5EL X
M2?7S8GW;EEK].<SAD;RVW?IQV+BI^FGXGHRK=\@ K%J$ !,$HLA;=?YTB^9
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M:S7>B>/Q\?S#Z=0LWC=/9T7K->=E5U*[<^RVSMPI.#>1#"]IS!JU96;H$E(
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M^5.LO'_CH=BSL_T=\?:%!H[$7A(@.?9MAP4B!,K%^/#QVS"NTYXDC<%33!W
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M\4;.1?@#^IT>5;)X]C67.1EZ_$"UL^8I^UF.6Y\XKO5Z;CU_)OM^LT^GQV/
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MT+NC[WOH(-\P?Q_5\013%6B6[L<<7L[EE/V[27;^[T-.JP%38/V4Q*^S8RH
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M4L9^CEMO!)(<RAL<]SF[[]K6>:GC_&N?A.#]IP+\6RM \[H\L4P]5/'B+K-
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MU*=(&_N;C 8JYN,GMI#G_^SX.0M?,+O'8( B>W#TNF',,# 3A-^1F<7\]\)
M_MO'S,X]_R/>GY:?WRV78X:E,;E1C-=>8VQIV3,@5)EYZ_^K1DMB6:"YTRS0
M-#<+E*P;\-^W+^6_?U9(Y#]:_*=F=#'E7\>'\S_UX_P_&@C>/D7:^W,C8Q/V
M+S)B3D)H+_%L&%= *EA<)/1_D0Y?$WH0R/?-?-/>:O^P,D.$!1KG//OO*H,2
MEJ_6AC(O^K-).9L?H"MV_<D$SZSWDCTP:FI24 &L8XH#*.PPX6YX&H^0WE4P
M". @R"9#QL->&8A-!.@G'_#@'-+XYU.ZLO,Y^"W-M_XN:='4N.A7O_F;!;K<
MHIH][EN7,JG![N$UU,M OX(\Y#F:=$;I>*=+\0\$W+0*C\T2/-S>^/U$!*(@
MON>:C8B,3$C K%SZ9OIU4*_6>TR98J#*?,<;&;.+ [&?51L"&UMBSY> LF//
M<[2BG#$[LDSVT@QJQ>R^G;L_Y4I\V_0NG[ON=^K)JJK@VQ9"5E<O555%/&UT
M_EA3-7PNZY?B"+/'_7!N6BWT;Q_:MISS--X9OR,;HL "H5IA?ZJ8VT[[;&T3
M5UV-P^])IRG2JRKC>AL:@C1LR8K/!UT^8M/NU*U]5S._98+KP69-J:U'91YF
M8S_)C ).K2WL;L"XM^BB)?1S+<EI=I)OZ\M^.LZ$)F>W7Z -H1=\90\E"*G^
MA*)CU 8Y^13OQD:3'J26M'67+$78"8EFMT(7_RSPB"+I]EAUXVUBGVWE\"'+
M=6)IHM!>;2M*#/"GR(5I:U$K.!>\W!P%Z4_?N5<@W*R3>6[_Q.H(WDWPJ-XC
M'ZD04N^4ZL'%J)RS3G(42>A_?@:? 3X1\HU-+W'XJNUE/=IL*ZI*.0%/-F4.
M._(!:#JJ'7)H!D\[DD&5 F]E.W@$7]-6AY/CX& 'P 9YEIYX:%#WE-OV(C5Z
MV6?YZ>!6T+(2]YB)BW_(!803\YB1+]W&EQ2)XF&!GN.C0G@RMA[#([<TK5[B
M_&F_[1 X(W]:5&L2 F6#[5=%QZ1)'P!05-0!Q/:MX>K[S&Y:\-K4V?G1WW2_
M!MZ/9W'2KYY\KW!S'6,>7 :(OPD;K9><OK@KE;Z\L4KD%EXEB$FM><<?2(%!
MD$;[V4P^I Z0-,T7SE2@K[QDZ\@8C%#"2%HKGL=1]2=^S/?D%/YQ;3VS&S?@
MLS-C(M_Q"6W74"V.G4SY86L@VS8V/8(.Q4]_)*H$EBWI<NW7,8S)*&Z@V^K3
M4'6"&V4[W(IBE+!1$0.IDBJ/H4C,UJ50[C?%J$608<0SDUB$3/J>02W-/:%[
M$JDSM"EO(SL4>9^TM+KGV%V(P!.(+-!796*M.;!8$=()J8*&J\)$G5D@\$8&
MGJ>=+MA:GZ/<+B%UA$FB2*-+3"DHOGF!LXLD%UNCB&=C'BCLT@9:V*76BD>V
M_7=6LK'?+WQY[I?\U:)]%5OMR N'1P>+ESH,Y0]8)WF-F4H<OMS56SK4)B1[
M]XG3.6U!;[/ZVD:L28;;J_K(&^1GAE,5E;&2TIHG3T=>3>J[S0S0/<)0WJ]#
M.N2$]$V)[>=O0,85526@KSXAI EM32>!$K+RX7EQ>,*R+T1T/NLJ9BMN2$59
M>L%[05J:;A2IQ- *(//Q'P;"J?+\\,=93S,H$FX]ICB.KRP0>V+MT>RFHUI@
M(,9YP&+/N:?,F+8^O9+D#P_>NS'WZ2="BU+0BB':V8TTR2$R+!OI(FV--M6D
M8\#0=-[,9>?1+<OZ1GP"U6<0:4&>/'<K?BEH<F@'U0R^N-1$W0V@R\6H]'";
MTYB88(2[!\,HZ!PFMWV+>[P=UQ0FX_7 1L&\ISKRU'?9!GF72NN&(Y(K1.UD
ML4-).+-#9OWU=0CBS8FOG>AS?R5A-KS,^;X!+PQ0FN*H5OSX>&L('^!"V5>#
MC,_>H1-B0N29HYX,Q\\C2!1MUJ9A$ GQ)9NZF0(G*<*TK4KJA0T)'AF31G=%
M;9X"0*W%3B+!)G>8840&*/R3XXP=ZCN41T44_NAF7Y2T_ A[0:!Y7%F@$PS3
M/97.Z4Q_"JEC];!S_78B#L[9LNS5O14^E$.?BJ%GZ TCSV:[2)\UO=H^ 'BW
M!-:&^3@$,B?TX+PY#\_EN(HH.-+"UW^9F6Y[-#_Y&?R-B6:!G,%$;C+?TB1Y
M688 ED!Z%C @M,2<4EO "3J*Y58,I'LPC$OJ3-5OOIH3-ZL,.+R2Z^1<*J"E
MGG&GCMOIR+SL?2W\(:8J4AY8)_^)321#;TJB)ASDL5V]T?1EZ-2PSUZ/A-7@
M>'?] ':?SP'[B2X<7C;.:=DPY-NCVT77)YSY*N,CMP:EBKP*.8_88QY-HW$V
MP[A]4$0[*C11;JR)ET1"%'>A0 L8\>IYI BEM02H)1"W\JBKT?[2(L.;)G[5
MF:6)& H+)/;3=9K8G-?N[['V%_[<(HD#!7?7VO+>S\>3;1B7]W.T(11,' 9K
MF$?EXT1T#74X"M'2EHW+Y_@9"BFFT!BPB+8.;9W@*$XSS,GKIDN33(88<F1W
M[G8_M1II$:PIK(VH5J0B,']%Z18+=!8"\46E;6:OB^U??[ K_841K%L]H]=K
M):7EI!/RKF*6N_V/:W%8 :+$!,A$39M B) 61WDZ>ND7K=48#Q='5'VUW&J2
MH*=%*3"N%B#&H8#-PWR =*_?%QPC?2ELO&W('I&U.][<[_)H/A=MTX#'A;F!
M2S\  7L.+F :U$&D65P)3Q^GB+0'H43FQ[+DT1VV49&ZTLR!)@7@(M(Z3?<<
M+3^!PJ/>IIGUEHR/7B77\: C58L8\'-%ZEN/V?JZX[+]1-G7:S)X!?A,,LRO
MY3-[=6PIOE'6>SF1B(*NI\_@C,N<=Q4;)WN+BO2>OIXCIGYPSW.9,E;8^&:[
M=Z<IMH.H%9?1M[1XRS'@<-[[[8LG9?Y2J90/ 0%[T]O+VX5(-L8*H,UV0&HP
MKUB@9RS0<>2YS[J'!LLW5P\@QBEEM0FEJGP"QA1WN:T/(ZKL'<U :CM:-4,^
M01?,@PC[S1?G5_-T<&QIN]X74"^:82N[SVG++W.!H.FHCD)MR%XP@*8R,)_]
MEU6G,?QN:2@I;=52Q)_XX>(X$Y6K"!F+>AJSEGZ6*33?37%67'Y8DV:*I?.&
MYQ2D4_6'?&^-;MPOPR8OPX$'R/$+-BY/'B]/[(_1_9=1>]< SO:IPT PE2_.
M5CB)BHZQM'4LF(8>,W8O[Z/P^'7#$G^JV/!F""<%!V0OB*?W_?XY7T^9%TDS
MCRMZ6./[N2$9G'<ZU= X+XMRTB3@;)B?C:/UHT12RIFBYZV^'GI[)ET'0P_E
M"OFJ,H80^&G4LAMG.U\,1 )W@6:WU3G(5 8JV),K+,B0>;Z?X41;V8..Y0$P
MQ;=H0AFOSM4VV,ES@].#*L/I3*I5$Y,PX&O7(+9IC!,+*+1W%;P>Q"-"5F8(
M51B,09R#GQ&(L\M&U&6Y=HR(HAT%W,H"'4%$D5<C5& "#/;4C(@*#G8+VCN'
M*#"CUV[UOJ0:,SAU$W* V&\VR'-L+/EYQ HZ<J1^8$$]/G#3/[AOW'OO+P9[
MVD2XY3-@M0!^V@J %@$9S!,-?-+*,668UNTI>0P,=?0GPJ]K__%E1S<1W?/&
M/C8*2;B^&HX38HZZ45CEF ,\GVZUZ+0^';E[IZ/R-=?-B[?K%'_+'[E[+Y89
MS)#8DV8@1U#3R>*$I=DBQCFZW$M=&6N&%=TH7EMNVL&NS?$8>Z=WUC[YA)[&
M%"SCNS_DV_I"6RU$KH?L<D[3><3W;TDW+UQZ;_V8Z5GJD@L;2+'W-A1O;8MY
M /TJ=;FFA&Y!@;=#(M.MFF'1D&IX-)B""4,]!<=<<=DFJJ.U]853*#KN6%0,
M^(BOSE7;X1FZ1T+A O/4($Z=HJA\?9#A3)^O_!P:L@O]E[R17YG2GG0W:CYD
M[I^Y(<=4>"ZHF)X9NQVV>@^''7JNX-,=@,U83+"P2-71;)'06,'RW-U0^UBX
MH/[:X#@QX=?&MKJ(>K[+KW>_DY^A9/Y+B.N M_@I%U0L+/D:';*V.,L"U4KO
MB5CMHF<NVL8J56R"O]W#+ORQ)1F9_#$K"9D;G/YS4/A/X3=FZ+*IT,5(V"9T
M$SIK83*B6[ C_L\K:TOF29@1"Y2;W"3.C%M[ELB08H%>IW5 8( =<>P7"\0U
MQEZPY?(_\QZ$QR<7.EA\_R$:=N2HSA6S*XC9=#KTE7+M7:!#)T1IT8:!5"4K
MTR"9]D 1E<?N1OC-?IR<5",I$0D+\,P%8-#Z-P;/RVOZ= O*%Q")-XC0B(U?
M&7:X6D-CK @VZJ]J ?O)-C3!1%!<U-42K96FFNPWEF7[_/N+=<?.@&LLT+S7
M^*J*MC==^18MKR?_[>%&%B@:!PN67M9JGI(*T]&W;>+M2I!7J+(ESM=<>K8O
M=Q^/JZG&'E<_^C.5DVS1@A+ H9K@4D ZM3GP9@:,R<\'(O7 _9+@29;C]^G)
M>L]*)^UOY;@OV3[6?/IZFG(^E_!W,#>9]-*'=)2X(*CXG4B(]LV(KF"84-P-
M]$8VRVZ;.-],GE ;5'!WNI[T8XX631E2M)2_KR_IF;[Q)O["HP %D-PU#3&J
M!J?D"$Y]%%;]/CT>_XL(G1SLFQK<QNZYN@YG#F=.,WNP)F-E^RI-41D(-W)?
MF/:YY*8X<J:\F;>X=MI3H7I<UN.)X]M65_>SR>77%-95VRI.>_7J]?@O"GBI
MQ9_\"[_=IX.:7+BB10^]#$L%TZSEH1R3S!X,7QG2SIWVQ]#8L)\/>=8 X9K'
MG,QHBYLVA5K5 ^A<NP4U71GXT4[>1N$83_*.[[VQF4^IY]SY]F[()V]!O069
M=X$@:SH+Q!"4VTKXT@]GJC#41ROD:)B61A.*7.CJ!AZ\&(B<$@:P]*HV2TW_
M5G@XABB2EJ;)]RI$>$Y$<&K.J4V\J8ARX7"QG4/?PVP'HHJ.$.UO5W/[3]4I
MM:JCM?MP_(2J6;+EO9$:%BARR'NW,N9>^$N"= Y#H^/RW278GYA^":A+X./X
MZ4)8-:D#'JT):^GAW H%I*:#36R!//I!GJMMZ07-C8;!L+O ?3A-KIT%$E*1
M,F8HJ4[JWZ+5U)$KQ!&68RV!O2DE;O4U>0&<T<_=-R^XJP[Q?,BA^3./=>_=
M=-VM:+%I.L]XN)^EJJ,.@[]$4_!\ (0\ECCF,.(>HHI 47QKBCZ.%[NNGLLL
M8EP;1O)_ .I_K[0,3]C#$(1;M/Q*G;?5GZKKBSUKBM1'WCZNOMWYO $\[-&^
ML0\%!BJ#(19,5<8(4HR]B6<Q H"J#R[BCD5TS'1::Z:K<O34&<\_V0QX54VA
MS5E*G]"W:.5ETZCP>E+$$ARY>@0Q3K DXJ.Y-*'Q."/41WO$W6!>B4:KNXD4
M3#ZJV03EUNI/P8@AUA;9U<$C;*V6#V9QT56\6\L0*03,89S$"Z1OMIT-\AYM
MT3G0\!U9T<%W4J:Y/A)= C.M6$B?;ZK_C!TZ-[3R$?=R37_':?L4))<08_QM
M>GWHA__F(H8P;RZ:LT#@'#[P/O!9&*KO)*/FCU$K+)39+[X:3R*@A)BJ"$Z*
M< (%#0[I%">UKKZLKVUQMVI-N *0R/D%A6ZI&#[L45MWM];=6,:-2BW?X& E
M<C_2X"E3>F2Y%'X_:VQ4]RRJ^393%ZD!P&CHCAJ(5!,GX^8HTH'.C].KF*^'
MM6"$ '^3?B1_?FN./:)B&IJ@K5^ZN+N2F<\PI&E-NATT7E*I!>)*]\--JAH&
M?(ZDSUHTIMT6J'\#!_^R1<%>:K\9;T@@E>$Y=H_2H2]Q<I0W=NZHUGJ/"L'2
MB/25#K&:*A74-<26HT+F<:^V6:<G,9+":WOHJ! EFI>)7"M<?)(X?O%J13CR
MF<Y6+?G=@.B.&O%IT?.MW:GP"V='>#&^FBO./3T)&YX[1K,0X%Q!-/(T!1P)
MDWA"$\:[4_BX?H8,DZ1/]>=7U]755V.KF^B94U@%M;N.*W5J*8X+:5;%Y/;2
M6BMU+[N6C-QD^$!VL>=;SD/\KWFYYHP^2D7/6,FN[?+4#=DG#]TO'NHV:_Y6
MX;/4H-RUB[*35IQ>C7WA6A_O*$ZW3 N81HEW1=ZJ=GAZ2TEQ,_I^AN]L%-;.
M>CK\?N6=@139U'2/CUQ9IX/SQJ\:KN_)/N>N#[V1\!$QC<GP!.=[+]M;H9$2
MV<#07W&FH\L"S@)/LP;G]<].O2M2>&RSD%K5T47O?G;Z2OO[;/L\;'>88GO
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MYHQ0)()A2M1?I>4YMMW9OQKQ@K.K@ U>D!Y.D[.1Z0?Z6@!&%3-@JP75\AW
ML'NN\F4BA'R%AC?OWV14#LF-@Z\'N.P/&*5B)H50SZ!,%)YQR+(-U?>++2)D
M71N$O UDAZQ^S7S MR>)4^Q<83.(*)7_IIL.GC0"\77]LXW1MD;"@W-URO#,
MUI\]BQ?3@H.'R_]_UMVHC1M8-$,!I\@"M9O_%\GN;_#^$4'TCP]'L+X@"Z2'
M9H% ;$T@W05CXY?DG-D"((9N^.A^T^'%#Z+??C1=H:'2Y(]8<OV:$0A_24CE
MFL_RA (F!4 33!!I3'\6IWU5+@)%5AS&:9U+RS<IM5T4**M)RNUSNHI+#=4_
M<.73CM##'<^7,+U_N*7\Z0);!:&*H[<K5#Z6(&M^!Y9@AXS6)/)GLM]C$U:6
MZ;#9#^&KZ@S.'8O"[,9#I<E+KFS2?^G8^>S0/^5,"A#<R;Q_'+^ 6<#TYJ<5
M!T/75/]Y]:F,<;&)W1;CLTC5?9&9/C'@^O5AYF7)Q^BX^@$6J-NMQ4'+VQ'O
M4Z)D/N#@(/:B^W?HXRXI^@G]MGN?OYE=M^C54)W!_"/&'/I/C#G(&I'VCOEV
M&1LI+#W$S=4SI9Y^>_):GGL(ZF-?5*Q/RLIO%FC-11X^V(G1@ '*[1A>I7)?
M6$12*^K#Q*3.5"UM\2[^2]BDT^LJ!U?'H_61\@UN/)9W"1[H8J)IKF/7'=SH
M.=4Z]">:?SN*&RA>WGBGI(33H7S(6<X2H&L+S#G*5G.$]"L^3J5"FQZ;[\U7
MFRR;=4+3,CX,EAHO7CG\7)+7N_?:,JG"E<QPFL;P(+I&GC/T/[JDXRYW=)S#
MU]@\J7G3*?Q3T4.HV==-H]DYOZ8Q[&;2O>+*^3>TS7GC>KX)V"$ME_*^I[UQ
MV+P*=X]Q8R:/O%1>G?UE7MD9Y;]#]DY^.ST>.AYX$/25FE[U5J>Y>5,23*\X
M@";C8S>./)Q&Q4B?'EH^Y#K@'*)4$]Z^^Z2^_6VBJ+(JGUS;Y1NM(3_*L1W\
MA>8>!^5_M[B11#=\X<LHCKDF^4B=#PX(DS;(@^&G!G+>^1%EI6H'?KR^T4EQ
MWJ+&AR>57CZ9 YX:_&QB0T(EO2\VUO+27>C=AK$I$\=D]*$3UT\E&FK.EH=4
MNW-\X'B_L1K_K/8Y7\')Z5JP**K* 08#_.GJ>G%.1X_2!A<'!8[]>N5XO(&N
M'5\<E->2+,HH"[M90N\C+\IA/(-+?AK>0WV#MHHS,5<>>/^V=72Y/'5#C\B5
MI?*(\++V7$;'((S&1E"0NR&5)W-33#UJ]_E7XALJA]!W^&YP+<Y=A]S1N3 R
M[;*GQSBC^*L@86ED;/7&<U7G7%D6:$AMT#A%<A8^.2.X#E*L($ BR[EM%^H3
M%F<>*C#4*=SO9"63/NGG? K1L'_;.9_R6B51*<[*"[OK85MAG+NS_,O=JIMY
M=$54\H7&_%?J_/RM2SD?S.>_<NQ:12IWN-G5J3DW<0+H\B^+4A6O5C<*GIYZ
MLY9/Y]L2SKCX^JA_VIUH@^93D:I"3?) 7?FU\)N MQL9D6G,'*:3HLNR@D(,
M^]-%PCN*/6H+G<ZP]R5C9_-7KDW._I>[.\SQ"D]Z%'4F:P5+1B][H8UM2G:=
M6:#<H#>]T<6])O'+7*#3_T]OUQK5U)6%KRVT"D)@>"IV@A4$Q?)04!!"$(>G
M\BZ$\)2%]4'M*A88D!#OC'&BQ5(4#$$I*0(2":^*/ 0"5Q(D4FN1$)Y1" (+
M ]6$0B )-_?.M=,?X]!97?W3'^?/>7SKG._L?<[>ZYRU]XW+.OZ_/!,WC',G
M!7C#'#O)3)Y+9XK[9^&AO,>!0LE]D6)M^OH[>D2_1OH*HBF=<%P4)'GX/[$X
M.KSP)?,:\P%DR TT5K)?1,[FE16Y50UZ&+%;Z<96Q^AT0N3KU[#7%;=CE5TU
M[R8%C(Y94!PVY;C)05IE>]O3'*)V2W7J8A^E9EY;UES"Z_7>*7(I*6*MJ'WT
M[(>+YD]\Y18:ZA116!?3D<XP"TKXOB*SG<IHCX=Y"FN9]7&U>T?FP"DU&'NN
M\"7BJKSW(?M*DHBK*]GY4*@,W,+PB'^13HZL2/S+\[$G&:?+I7OIUEPW$\VK
MYSU??-=Q_U*?@8_LH"<SN4+,3ZHBBZ.C8\;&8V/(XV*5P?CAC8SPB3U)IN;=
MUML!<_*SEIR!6(.?M(?V&^R_:R?J,+7Q8&4;3GY[.[KNN]&3WN$9-J_B:H4I
MPVNRZKCZ@/T_J:5SFIQ\&Z4(4!Y>=+1]@ (7=_04XU=UV^H[>,3_3I!7]&M<
MM,1?XZ+%]RM'UGU6[8Z:3"AE,#O8CYIJ"Y#6DV]LGT;'\EQ;X$\H[[B]27)0
MQM1$4"-4HD9\,2X4= 0U&0F1X1^S-A[?[:6Z\G[<SM34^O-1:IK :I:<P#B2
M(A3/C*JH?=#<@(KLLN1!D\C@BUU.*#"6, PY*'VY-H(YFI(RTC+R&-*'TR3]
M^@N36YPU:0\G+ 8:! ^?G" UBIH7CL06#R=NS@JXSB4=B.IY=V1&O\)U#\Y$
MBBEP,V(!XGIPVM!(CSI,D!A;K=9$L ]W;XL^&J23OEVG</;ZN<&HSDY5+$>:
MK!/\S?9'<[5Q]743P?%P?TAAZ[1F%X=B^N"#NX4+4H1J]P,T=2;'%05NK7:#
MRHC3F,7VBDI,3, I8_'ZQ)=4>2)B/.X'K8$A/V=)L[B$)@ZS%)+<I,38G4..
MP/W!7^@[R5@'E^%YC\W)V[))-S']&U6>18'#L@O83*N$!!00J\'";NR>3IX2
M:'!=F!_#*_%?18'/I4C(%FJRGG4*0S0-<ZN)_0J;\;!.U=#:&'A#NKE&M+B,
M CCYG9NV^*)_61$>?UAP4&$=0*"PG!8N>"PAI@)^OAJ?8X89$?L+9<C(X*!"
M0C3UW 8^79/<0X$TK'*>+U8HICAMV7'<@9;.6L\<0OWXY[5-<+-?F:[= :L2
M?V-U<7+?CR&K>PD'L]4;PG6CC30QOM#K7@Y%;3O-_J =%S8'REO^@PG!NYKR
MP17DVQDY^/82J2@PCBV1MW+_/=F/S,\,[:.C9.F=>_+]-Q+Z%<O28$#_ G<$
M,87XYR<\Y*0W=$[!"?S!,H4JY#=(9I <PL/#\XF43U5BML0S>Q,YQ&=@#&'?
M%M*N^J;J[[MZ3F/W PJ\M6F8'_)*0^R38%S<E4\CER:UL0Y!E104:,4XM,GK
M:J6'-=9"<N,)C<M'466,-B:GD?),H67>;XFU+Z" D^9L2,.>_S.<]A;7UV3(
MY"#,TOZ*GU%;(CL.A5/K\"IEURR2]/MI"_9-F_5,7FJ%=) =9+%RCF?T+#[+
MIJ?H*?_]R\MMGQ21F_J&787.;B?2KCKN8]%8!#[/74!O,DDU$-QZ*9W=P;<Z
MIFONE<4R7+(J_K[ W_(3W[TAI6[>5;O3*AQ./6\*%-O/5E76EX[X5;6C0#PR
M75>>:R?^,TZ)-V4#6^8 ZZHB,R-VBK0/:;47>4E,+)>MMJ6-SG7YVI;?HS?>
M8;6+X[.UNO!K&<B9%PH'[2SW,&Y)Z%".0]EDXG/' V:DK4&EHH*F3YO)-Z?,
MZ>)_^%NUF)UU)QE#4PDPII>W]O$3E99"S.<<,B99\,.N5\X&?]0J'?B[8YYM
M0%K@KI;9S*53Q'5]\?*&\WCPZ8VI!MC@- BGY-JJZ_$(5;!H-RI$_O:_K?E*
M$H2#7AZ5CR ;G2'$Q<>82L*A@.>T\M+=V_#E/P"/2SZB,@!YG4I,/[Q/TB'Y
MH=LHL,A9CV <IH@CPFOY+_[:R_S9$I,QBGP-N=BO!TIHF"!-?[P>P[9B_CZH
M6L7W$/(<9@ZA@,[JU*IF$VLK"G2_QT2!WCOK0<+\AE)18.DU\3)E:^(C&F(B
MX\O41AXNF(N@YX ">6&_@5*>SYE"@;EGH,&*,W3-2 R[RK6^KN_2EPN;SA34
MV'^99%13[:[#/4OKUOIFQO"?7P=EMLSG=B3'YW*N<39K17IY7PP%0C?T @^
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MA 8(@$+,/QQS5.S>8W/U%3\S"A.=#+V%EOW>I<.D=/L>[3&VIZ::VI],I?9
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M 19:0)'"EI)""+C 0D')0D'J ,  0$%-\0\#_F44%RBIJ&E M'3T#&2'NDO
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M$ESKJ,1U,5]VXD %G.W+SP"KI,8O/@_5B,"&LE)N-,:5GN]CWI0DH!XN&<>
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M7NEK"_81; A8ME%-DZ?+'F4;IX\<VT3_:KC5R3:;5S,+"%9"5&^YX]*6EB+
MMFUOY#A%S!/5LF=[HT:HE>*[,3&\=3/3#*]>6M>&9/%VTZU J]9#=(7.[I_:
M2Z@0I&03%P 7IBE_T3QJ.@L3S\_ON)HTH9+E^7L(R22>^O-KHL;(9S#15J/?
MCX@F4))UWP]=?PZ"9:C2\U/0!$K\%D0RFP&TB,9#?Q+Z8]^ECV*E#RC24RQJ
M )'ZV</VN<Q&XWEF.,SI(UH@]&!N/<#<>DB8]1#0%UAM6R"?CF;)8>@38+!G
MZ7Y::H7KPFHH_.(),,!V\/_&(JY/JM3B^'Z=__ B;4:D[!8\=I&?G:I^A@"=
MA-YP'L7TM9;G7X*DZ&2B4ZEX> \12)^WMHRD,C*QZYE[H/D(CB,$22<8,R^2
MM8%G&M#E"H!_A=I:6AO!BBV^PBJ\&LO(I#N+>5KVB:T_%4")*1ARI3%[=8:Q
MG9<)B^,*C4D1V0RR2ORVY=FXK@E3YB!I&#+9Z^H_%O.EE,A\?I)Z5@J",6!3
MD>#:*CEV?Q!9:"1!MIXUUK")Z0I\4MH\+S]9_P1!$$\O0$CJL$/W]"(6"/($
M,_;&&!I1(=+U#:]C<_9[8:^/V9O!H/1H-$PO9!,[J6[DV[8[_,Z$/OGXVK,K
M? (2M6[XD!8&9]=$XK\0G<<A2#N>I>]=NVEX.BR]=VV;O&Z6+HDW=S/=V"..
MFZ=(MI24@]MO$0@Q2 UOKCLO@6,4S5!:?EXZW+%(Z#9!C5#4UFO<'@';%!V;
M$JLX^O<1JF9:Q"[!==K^,25*3(5P.T\?1^::<HNWQ*-Q/(4^NZ<4@\=YGIUT
ME&8GM4V:-D&-4$6MU[@] K4I.A0.SYAZ8*[&MX.+XWRCP1)U6GPC289:=G)9
MU*(92.?E#*0_$,4"[-+P1G8%^RP\ 2BD][-2!ZOO^80\BXF6PI;12V- S\D_
M:8A<5F$SM^6_%Z4"P)) <E*!_H\.T3WA?QC?0*JB7+*FT.^'H5?]L"Q(;[,&
MB4<&]-C'\P@S]VLR)S7H'92(G@(FT"LN?]N;9. IQT"8<P]-0)CM@4'H'268
MJ%V,2V=NF0*W;04V!"Z;;=I-V;.TK@!9/!=/B+A0-54*'CLFMEVIL><_!-;
M*+2G4C5\ >-IY"TOO13A9GAS_N1"3ZRU8&@A%483SZA#FM[^F/@XAHAJ#N95
ML%8-BA$+.9H5*-\:L-=#W@16G&M@!GQJ*_Q0%$I12]-K  1QFKRC4T^+FO[V
ME+.O!D=X>[620^2:+,]UO<$:>E+H39@V$HQGV[*_ O@-A8+:L_BO"%LD#Q=D
M'47LE(Y(C45GJR)<LF.8U.5.G_NJ<BD'\\01024XDJR]I<"!.V+@L--R%OF5
M:F><+I 6[_YT*9!YO+)GB"R2OT90DILAI?"OWT E'-2*D+0<D]!PY$(9K-H
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MFN4^(!V0GK6QEM>V!)=?X:;#UV#H3@4?.)YC9-FTL(GGNUWA8U)PIIE,'SR
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M,O:@@D#\BS#$Z)KU-0/$2U'%YJ!69LN>1K"#N @7'4N"S\B/Y8+U*;+ELA'
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MNHE%3&"WU<X;:+9@"F=-DYM*VGX\*!GC@F/]+AZ5$,F(5[J&18\/-<9M)!'
MOO-?4$L#!!0    ( !N'2E;UE8*%$EH  *J+!0 4    =7!C+3(P,C(P.3,P
M7V1E9BYX;6SMO6F3VT;2+OK]_ H=W2_WQH1&B\?V>&)\3K WN>V6V&^S9;^>
M$R<<:*!(P@8!N@!T-_7K;Q46$FMMR&0!,C\X++4:F55/UI);9?[[?S]O@A>/
MA,9^%'[_\NW?W[Q\04(W\OQP]?W+3XM7L\7Y]?7+__V_7KSX'__^GZ]>O7A/
M0D*=A'@O'G8OSJ/-=N'Z+^ZI$\;+B&Y>_+_)YO][\>K%.DFV_WK]^NGIZ>\N
M^YW8]2F)HY2Z).8_>/'J%2-8DCRGA!/\UXLKZK^X(@\OWKYY\?;K?WW]U;_^
M\<V+3_?G+]Z]>?=5_LG_^'?@AW\\.#%YP<8=QM^_K'!Z?J#!WR.Z>OWNS9NO
M7I>_^#+_S7\]\Q_4?O_IJ^RWWW[WW7>OLW_=_VKL=_TB(_OV]7]_N%FX:[)Q
M7OEAG#BARQG$_K_B[(<WD>LD&9+2<;WH_0W^MU?EK[WB/WKU]MVKK][^_3GV
M]D-DO^,E>S95 E^_SO_Q)<?KQ8M_TR@@=V3Y(IOBOY+=EGS_,O8WVX"///O9
MFI+E]R_3K<N8O7OWYKNOWG!6_P_[P6_TM_,HC*/ ][B(SIR SWBQ)B1Y^8(3
M_G1W79OKI]#GBXG<KAVZ<5R2)K[K!/'UQW,N]]?\D]>]%%__+\P!_W;K4!(F
M:Y(/"7[\30;PT[EF.W-#%@G[\X9Q@IE"D^AK^'738($B"0D/H%DMV&C(.@H\
M-K3+/U,_V=TS$N\B^I7Y+ 0T7V?')+0XSIUX?15$3S# [ZEE@P48ZIRNG-#_
MG!VD3NB=I;$?DCB^(+%+_2W_J?G %6C#;-M%NMDX=!<M%_XJ])=L)&$R<]TH
M#1-VM=XR\%R?#%CZBO3S!00PGX)V?$=<XC\Z#P'Y..0.Z"8'M]ROPT>V^R.Z
M&S3*&A6@$V3F/?(;(XD6Z78;^&P( U!LTP(3^"TE6V?'CU*FV#%&A"9^S->6
M^7#[24(='74.+CM,8W_8@=%+$>B86$<TN2=TPY=:G' ^0PZ%+FIPV$9;)K'=
M+=-XF.+K\:MJRUD,VF)"JF"+^9K37OGLF)G%,4GB@:="FQC,:J@MMO/K6P;.
M[\0=A&XW09Q3XI89>&MFLT1+IQ0KT-"[*(-I=,6>.7/"/VXB9L@"[+\#+3"D
M[TC M2VFUC+]D-O;CLO/H0&C[:4(LYCOG><A"D[^.=3AQ116ERTEZ@S$K$$'
MZA)H&@"0Q@3<$CR/-AL_OU782<V@X'<W"8<ILB*B4%N<K#C].[)EVW.0!M.B
M!*>Q+M*'F/R9,NJ7CP.U@"8E4"O2(V%,O"N?F4^N[P37(??[9=LA6C)S.S>[
MN6/0"0<L8UU&4,IYRX(ZVV5_&C 5 4TXP<CMVGMN9 U85<H<H(YL-0MWZ+2T
MN, <]YVV[]!YB(@";8ZJ-3QTN!VTX%P5+:MX,+A]%/&,P,'KNI\FW*DC,MZ&
M3D"!-@SZ'>;<\-7=1Q+%T7$P[(:#+B(+O-KW1A+86F]2A!EPGYTT=-@2NE!+
M)3.DAHZU2@10YVVHTX,70C<]N(B6CDXZ=#)F[,!N41[E]M* 1,N8V1.^YSN4
M*4(97[?"<8"P%!D G3I[;MOB8MD6%PLI+Q9V3?H;OB/3F"S3(&!3B,'F:, 5
M3)'>#\+?WTM.=B^ASEB=&>"!LN?NII1M#G='GMTU&T:6LP(VM7[B\#)S"L6>
M[A5[E]T1?IS 24K& D,^AUT>M]FS_1'OG1AN%+ ![0U,B F;,X?R2!VP#X+H
MB1L7[&CWHO0A85NC'!.<@*5,$*X-OS3Q $^4&D7HB\')K;PXB>+2S L+Q1U$
M" +RX,LJYBIQPE1BOV'^@=S7O<3AC[_>>Y-A!WX0JC/#.!*;%^:!*=J=W&2!
M,:W]O;],DY029\-U\]R/2)ZW7,-EIU)S8& S'L =X4S,!\'VC;])-ZZS]1,G
MR(;A^?P?X*:MQ@COV'E@EGBPM\1!#YT&:00IA0['*%I2;J!SBWSM;^,G/UG3
MW&+?,HO=!Q26%C_H6\]+R9)&&Z2I":ACG#6,'=,/T*;231M:(EPU9:<3NU0S
M3=7/$EL3YYG=3H\^S]-_("%9^G"W@AY#^#L^X70I-SI</V '-M/.UW[HQ G;
M%US=X^854YLJ6CM9+KE6_LA'"6K900T%97&3)6%VI\<8 5^2/93!KX>$>Q&W
MSHY3!Q19DRCXN"EAAD=*'G9L1WBIF^1/6<!F("(/+X.(J0(%QWC/TF4K=Q51
MR/-2C1'X_+:94[38G0_Y\XR8/\\ -!,D+# VOX0GV),*8X[HDX[+IQTQMV/X
M%<4L-/YOE*R9'L^FEO\41\QZW!&4TM[1N$Z\7@;1$]+Z%K""47SDB247[&[U
MARQJ=1:0^5PJB26#IZ;'!DIWZ\PV&3P7(57\APV#QR^E#'39];U) )Y FS#@
M[NA(3QF^%P1$P:#OSTH!@%].'&H'=Z2H#!Z_@"9DSE%GB@KLVF_314G<Z7C6
M #L/ 0.L9!ZX7=PB"26#OL2;P4.7$8;;!5D^SN#QUJC 9<E47D@,'F(W.<B+
MJ/E> F !]Y&$>\W2^V8" ' I;:"CHY&L-1SW'H)PQECC806 \MY-$/#%CE8.
M&<1N->$W=$%=1&[*13]C.A-;K\FNPM5\,D*J^ZWL4%=UW#T57\J"+;S4R]?9
M?#Q_PWT*4?C*(TLG#9*7+PHVU7GL:?AA\II]\KKXG=?MSPN D<<:;1P_-!YJ
M_O5AZ6,,=LU(4#=](*_VC/7&VT6@<AFA )P!\VI#-@^$:J);^Q1UR3I!H#<V
M_L%^1&R=^F%F:MXPWK51D>>$L$/%*\?%/X8K.93M"S: (')K7 ->R"FB)=/
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MNW1HR.Z:F*EPZ2;-5.X+!HGK0]\#"@PM&HXJBUP%,B3KL<(J4[C/J_5^\HC
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MUKB<5(KX]WJ@H"^63-)Y]8^+E/) -Z%^E-?9^4B>LG^!M]I5>$Y 2FK8(25
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M#A9A+*V7";9A&3VOWJ:V7O2Z\F_'V,\ZP_F"3G)=06!5[E1/:+"6FF.[S,0
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MZWZ>M>U#M\IK4I^N,!HH*:5,V:O8.*<K)RQ**#FA5R8@7)#8I7X6$WUIW#6
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M7?ZD)?9-7$@U-.JD;II=5Y261Q^-82NW3O6^72Q$:U3WE8HN&.O5"0+1*I7
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M]3')$3=Q]1+2D@Q6\73!( Y#^.AL<"(ONMSQU'VE((S!7E(4>#?6*($9S5&
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MKRK&0X!>/GCB0CX\%2!$B>Q5N'QT-NR/V1,]Q\W&BO$T0(&AG8-3>1'7Q*4
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M;BNIG4ELC^>5['Y7LBS/*/%87DF3[.S65HHF(9L9BE3X\-CYZP\ '^(#;Y*
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M64G]!8P-Y<#A%:UM9F>CRGV.=NXO>U)<1/'$_2WS\ZPBJJQ0N\J(()B[0I#
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M41$DJ-94R 'I"(E45<&.]?-55W=1G*YAO#USPL^7D1-BK7,5I3"Y=AYQ(MS
M4B1>STH.D@@K5CU?/.\Y K\%-V@F"/!4RQ?$TAQMY"U)$4#[FK',KRR C9M-
MVUK$8"R=BX@H?W:7C[:;V\9G%"UEEK))S;#X>0;7D:%$6=9"QJ-83%0X";)I
MQ$Z/M90?*V!<*SN6MV7]HRQ/;''=.(->][P<XW*%O9@%!YF/$5O[X/&\K*=@
M#\OZ%8R0NYV+&#Y!='(O.R;\"QWOZ85E[^G%$_">7C2XRMY%#^\)%Z+WR:T,
M-GAP[QH_O(6A.WR./6\E\R8*!QN6"[7X\&&^_H"\J#SZ,EU<K>=7[V97T[HS
M9>,MF)B%C2=B@IUK9(9TQ/)41R.<6M8(IT] (YP*-<)I7XU@+-C.#Z^;=7]5
MH^DRH5<;KJ]2I%4B0JY_J!3=37YR@FSH$$H'O&EQ:2/ $))%[/DA;B61D!8O
MS\#_/OH&+7)\\A*[+> >3WT&CH^.GAWE_RL& B=+[Z+8_QUZS\#)\;/7+QM_
M]7&O#R\W5/==8X"3X#S'%9(0B(L[@!=':#(B'1F(?CBV')9A"47[;.H0=GA7
M0N*NAH8)[4[F('A\7/+XR*KVT>7P45\#M@"(G.E%C-M90(_ OH8Q::XTGOIA
MKFC!_95 2U9/59(+OO)#<!X%@1,G8(<$CHSX^G TB8CE#-'C$LC"S; D:A(*
M2)YW?SC&Z5P&=U?(V[%-*NT\GO+HK&3'"V9@(ZLK.L?9@0@8BX\,P:)N?V"[
M4DT1T#"240!_1$X<J0<J68!)I[S1O^IB%1M7N0Q<%+_GW "U7.2(SSNN_-0V
M/;A:U?F.]_C(?,-_'.H?#1-&4.F1.\@';*M?K@Q"BI]R1.V4>P@2Q6B3*TT#
M_70,SR-5)IS@VO&]>3AU=G[J! ,+%6L5*X7-Z+@P:PZ5HP&I"8$\"3>?8-GU
M$S"ND9_!V;&-(X&##^U(:+'@.8T%3Y8!6J?"SOV%]"I%?WI<P@3&]ZW(#O6:
MJ3/%[-/B]O*L^X1R&(CS<18OG5A$+J^<J%O23'E:PM3Q0^C-G#A$6CV9N&ZV
MS4AJS#G<^*X_]*63Q(+&7P>+<6)(33D1P&*F38]/GI5U)2&Y]W[E3$N()"$&
M]XZ*X1T,$_\>YD\)+Z,$OR)<;-;.P] V@.+J5I(U53!DYU&54,KTJ3H<\%6
M8'R-# D,SW9I5!UY:*5^*I/,?"Q) TNJ(2+@;)NE___P5",J1<O8>*F3+//2
M<K+,RR>0+/.R;;DP=M'C<%G">QAF@^?*56!MN(KEXDRC@_S9]O.A-N6;1D5M
M!S9\O3H"-)VZCI CA$S]#B4/F)"Z/EOGHWNEH^]>6=9WKYZ OGLEU'>O^NJ[
MQ0[&#DX8+<IICM4!AKV.C8<%+&18@=AR?/6JP*YU)&1:X]$ =[.#&#RO=13
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ME"HA.(3T@KW1E2]BV=+2D@X=86Y:9@,*<G%TC_V<6G5U\Y>QBA@.(LT4P^^
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M%*-QI]M0NKD_76' -<\6FR6\AV$V=(YA$_:0/MO;7!)">(LL.(\G"PT<6)*
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M*8*<C.I*]T+%ACCVP%="H]:>%OSESV].CE]_GU"U++X"PL\2X&\9O@-RHR"
M;C.'UX:0#R!7C4^@+[%U<B2ZW]T9W" GGGQ]/SE!)N,R20 Q[#R),6(5S'$"
MS )K'I0\/TI?2G*K6HV7JV]N6GUR$N) G6;R;0 - 98Z.ARU(B!X]>Z?M3F]
MH-D^ SU_[:3!;R$(H_ZM!$*L-/-J6OD.CB,9QA,-)/E4Y13(T$#;0668:V;L
M<ROQ$@8NLL?(0=GA"@:X?FK4*@L[0I>0QM@$L*BK+>-D485IV.Y01E#K6#)^
M*FER<G]DZ5!%QV+A 55Z^B8)R.BUD!Q.@QQNID5,C6^E7"D01+<"%D5RZW[:
M>93=I)LL*-?7U&%<D&9K9BEBIV=6FQ<P74;R5)B0+II"QX.KJ<Z401H5.E7L
MGJ2*T^5JY>?K$&G02/P5'#\ C]>P4+FKBX6T87\09GV--7RCOMR97K" J@7%
M<B)_#K+DP?8)J" AHJ/O$ X^H?PHTT&C?R85F-JI)H!@5G $V QQ:%D/1E,Y
MQ(Y$=PF@7VZR!9I^6S+N[9T>$N;+(6OA*9,!48+)&ZD41DAU96>[.F4/">$?
MFM+D&^,Y5EG=>?!.4>(%C4NN&"=!-6_+#UKDF2CU$*NYZQ["M89;7$0J?L2@
M27=AG*4]+9+5U[$3)D%>5=+[-1NG0:86"N;?M>B@R9#)8N[^34"ZGPV<_72K
M:K./9-1E6)MNF@8!;MX8XNKGX^?T<I>R<17%0X@AB_.KGV97Z\7RD_V\7!G.
M-5]="78[0)9MM4:1;V;L52IW6:M%9_FX23U!+0#8?!JMRF+6LU(A+723$RO0
M2^?+!P?QQW>"H8]>^AJFHVQ4+%B=%IPO8%N.L9S+RN4055%U-MCGH7$!\\(/
M_03)(W[./)I\-!>Q\:B8A@C+O"K&@%L\R*:2X3.)*B+=#>H$T+Q[[)0FZVB5
M[7:!C\BK4F.&.]WL_0\'$Y;#=_[3Y&HZ ^L%6'V\OKZ<SY8KFY<[$JRHPF2B
MW>K>5>]?;717D(S)BT"8SN03(203M"HF@C0"23D5A#"U>ATMR:LJ&"]#!VU#
MF'IR34*O6,&(/5)?SN+)PT")&7:BR18.CE;6+XBIMLRA&#(4+@MMFC9==&/Z
MG OMZQAN_6R;4!Y;#AW4U\3"\FL<!509LGL)D^2[PP[I]Q,0UML:5=+ING9E
M&_::IL;!W>TNB![AX'(L6LVTNR? 1T6A/FN>UC;B^G*L; 3U)?:O^6*CZIN.
MA!D1#,:IG^"ZEFH%)H5 C+<#$&'$ND%?SJXGGS[,KM;@8K$$R#.8+=?S%:Y@
M:NWF7)Y'^QJ04MO7ZQ!1!^W^EOE%X1UM>:'!,%Q\5(".I*Q,__%QOIHW.\F9
M]P:D&407%M;V-?W(]S#PUA&R]K*8]!ZZA_E]C?"FA2HX*M",BI "8BPO\_UB
MN7Z^GBT_ 'R_LEICN5K9>J6AP;92G%1)T>,FNKG4"KKXOR,6[Q:O9^,&3XB5
M3)^^NRA.G^.*A,39/(3+9&GFU@TE.5IH/4&;>-XUXMV=D\"?H1.D=Q^<T+DE
M=>CV5>CBR,M<J9<;2N!,/WA7P(V=0_,=V!5 P!<"!6PK,&!3PL$EN@D@FV>F
M#F_W$5A%8NG?[KDQ1*N<P_R_<YQ!&V?0V^O8O/<QZQ7D +$V=0S,WPPJX\BN
MA(/GU10B^A'/!%_A]ME?VZXYJRT-S9B<'KGT;R'+&LKLK)YWCA]>#O\ 7&%A
M\S%C>>2><H*8.N_KLJI((\U(,C.!<OSD,*6E#R>?5M[)N5XNKF?+]:=GX/J2
MM(>Y.@<SY#5?8V>GE4UV4"FWDNEERB0:(\?;N'0>HDP.UB2&Q(L/I32C/,^E
MI')\61RCD(M@L4-J^L*KZK+*;E)<<N! -1ZSMHO$9O4]G&;'#1/IV.(5+0B4
M!%K,W.SUY.K=_.QR!B:KU6R].H0<;6FNMAID2-&@?T<AG#^'FW#<8Z^GN:BI
M7AC2&%AL>2&+HTY'H<8I>RA]A)3E@M'&0HEP^HXU>YW1>@E)+6E:9&604NDH
M9$$&55A9%SKIK8\A9<D8QIYP.?.A&A%*#-E:-XV]@Y*JA&GM26U6,]+"@3UQ
MW6R;!;C%W&0;Q:G_N].M'SJF<+$0L& ,JF/)3]+;SP%.;9+M\I+ZTB IKSQB
M#>6Q7,%T]N &F>>'MV6X<F27A;JD^5L7,5(LCX5J"]J^7)%G*\]G89)!__PM
M[<J(9U=>9"GRD^I2/GO8P3#A]HX>S)\9!#5;CLX0R$MX0/L.JAL"LZ&* <RA
M%LG_K>_#J@TQAOC1W*;!V#"*I4M9^@JMNHR" "=9?H'!/?P0A>F=07-8 2?C
M8?I!T&9\58A&+^R>%H,*BJPQHT:V'K%]-20*!'#WQ?67R*KTMU Y,,M=A"];
MVD\M7T(-(1#Z4DZADJ[QKK\PDF=SH30I9 XJ#"*!,%N\7]I\UCB,2 PCW169
M1@BO<%>^0,)R*-)-<#F<"+($MFS)?G7((19IB1A$N"M"F3+/ZVNC*0<CWAB7
MIR/>: I;O%\_7?&N2<0PXET2RK!X3S:(^8<DXTV$GH2@-U!FW>7<P1@Z>."3
M,U:H(M);Z+M$&^ Y\C0*DS3.2-GJ>7@=1[=(2I2J$BF!L_E$68";W /4Z?P:
M7"\7/\RF:UOO!G7X1WV'*D.0 3)_2"#Q Y+X;;:]Q.\?RI?V& 5GYZ=.0'YM
M+!%(%R&+>4&:*$L$R8O0^#:'#=P<6!X=]WS\-\LEFH>3)$;J4!_:FK(]#B'6
MUPSR';*5(0SOO3C4'!$QZ_7-B'8XSY386@_DM2)X!R^Y_-C=TPI-#QBWZP3L
M^EF^Y8/BQ692IMMKF[U<6&:;VDCC)6?O7G]<3M]/5C.PN  34+XMLUBX4YF'
M5--72!C->/ YO#'PAI&UBHV3F8&+N ++V>3J1W"YF%Q9*P,KQ[.ZPN)M=H"J
M]BM<(60-XRU>9WQ'B+&<^6LN$4IJQ55NG/ S""(GM%?N0I&S=,>$0PN-VM,5
MM#-$GDM,G<D-\OX=5ZK,,'NRX5Y_3$18,D*3B^\LGE]B/E0EA/E[U9 ! @1Y
MM\2/C7[P$:$>_,L,!Q>76>P$TVB[A3$NID*6C%W\'P4QZ0??K"3UPI65_(UA
M@ET.%%?$+,""'"X@@,$>,L PP5=_^?,;1,CO+Y=3\@ORS^/OO_[.5H!Q$#$I
MI;@_G35-L?WG$\5Q] 6M-W2B(&T%XVE_%"1XCV,$!Z6-0Y+-I\:YR-BG9LU$
M+&6+#1:^+/1=XF8FT^@R]134G1B&T?J(0G28'9*1&" 3JCD3_?.;9P#-MEDS
M3)I+I;:1HT&/3,TE)(];KAWL,>*B. ZY/C'PC%YE91N.H )^K"9"L\O)>G8.
MKB?+]2>P7B+7<#+%I5YM>X@:3*^K+E7*#.!)LI8T=,4FN;P-,55%4L+W#!UR
MA89^BF%>(RNY\W<)^.*G=_FOH(>LPA@7R;0LR;H20O=0%2BH+=.,-; E@.NS
M?W#"$,;(689I&I""D&;4+F=]XR:@,HHL_5N3WEQXTSL(;N,HV]DT$+4E0$('
M"VC4N['3>08OT&9JJ_O\/ =!ER<9>,;2%%0QDU"E7@8!YCY;;5KK^Z3 RFX3
M*%GJZ&5T73E;J."W-(:;;A!67YPA$'B(-8;3:%GRLX.[]JE6R$/1OJ8N%$7'
MTJ%OC(3K6;D[$F'%C62(=865VR19SC;NE:0(H552O:&#UM&0)Y$ FM'@AP)B
MDL=0&AV(8.DQD7H&21!&T^2IJ\8CQ3/HR*RH-):6.H)LGD%'O$/HJ&\XBR(3
M5PBWL<X@SEK&O28N.L*#AZ<=[)PZ8CZV3AS![GM(55[-?NT\F"@NREG*ADW#
M0X@E59-_SE:VB_&(.=9J:<#?Y0 QS'R-,[B)8KA?#_TG27T7^>Q%B7I#(4T]
M;.Q&.+5PEC"/$*1=%.(4>?PO'"0JFG:DS@.N]'WO)[C"SE<W,(0;/[7<Q6,@
MB:*'0/5)K&7-%^X 6N.Z)+."X\^;;3H.P,&%(8'%C*:0?6?S>E*"&Z75)MJN
MMKXL %>R5R1+G^6?WL#J4+"8A?1Z/D8JDF0SQ"W'Q+H&DMBW3H;\.=Q !-BK
MRVD!4T'/R$ Q&:66P(<A*>5,ULEF,Y-0@5>E%I(E1/_2B8O-;+.!;NK?[X_%
M)7(VEA#OR@]\<M-DR';30,6"*NN#KX31EI*DQ+@ @CMV([O-O?-#!R2IDV:(
MIX\@1NN07M[DC\C,<\)'G(]X_/K[!, 2+?(UX*%6\\8&D#2Z3:=)?MVGTC++
M3=(+Z,'8"58EJQJ#!_YRAL#(_"N" ;!F?4;5]W&]G-9]'=O?P("B4_\4AJ*D
M9N:NS/+G?K*+\A[:B\U9EO@A'+PNOCX>ARG\5%Q9SP!AO'6PBP\\'X'&30#M
MMFOH+12J LZFUHAB780+&B/."P:DOC-TG?-!4+(1XQH"<=;53Q0^QVH>#\)A
M<1!&*4BRFU_1@M@R:AX!EO/YAI0IU0]$BK[:<0T9#*9WB'%HP"Q$C@OQ:BP9
M0PQ$#O7+H*/+ZAV G  D^<CK/5]/RKLOET! WP%P=KO =XEOP3*,#OC;X$N0
MZA?!H:N1[Z#FWN=5%'YR@BRWUH(@^N*$KLV/0P8[X[?  V^ %7"L/I?[<@IP
MRCEV;T=&DB_=3T>6QCUNI^GH3"-T:(69']XN=LBM(7G01CX6ZL*'XD#0D&/(
M> 7@P \ 'J/%4LLDB.XKU7UZ5EOR)Z%WZ3LWZ L1I>H-&"I5P\)JE%0)59FD
MOWJLO]4&QFI\4TLRZ*%-=9KUO$4J5M&Z.VK-M71CU,1"YIXHEQUKS_>%U*?<
M!E$VJ7\'U(%;J,KP]C)*DJD3QX^;*/[BQ-[0)ZS*RG:*)4GCQXI.0.2*E9-
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M[/I30X2C]"UKMFF5O+'% $I,S=X[_PT5"<1@5^P ;4A1-B3/GC-!L@*UE+-
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M5Y_V8=)]F=^#$*[!OAX9L^AC1&I\-G_@Y"&OPR\E&Q%[2G)<F!)J17A>$YR
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MO6SC#+=R@$33 %#J+UGRF.4<LM.#H"=\R@J56Z-;#"BWFR_3'@B11,0"2!,
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MDF#]>5)_B"O8/X<+]L]+$NR?O8+]<US!3JCZ_*<E"=9?]OE/,6S@U2[)V5W
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M?5#KP5Q>L$>]ZMFBWE?QZU],XM(THU/D@UQL,ZFW; G!'Q @\)KDL.P"X_6
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M66^,U5BU7\;-H7,<=H6,982- +3)FB^R,M>Q88+ &#2P#[%_YCM>?^(6%B1
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M%Z3KPZ"$1,!R"^%R%-<R23K(>T%N3<:YVZ_?'E)MR]C'TG#D=K?HD#ML6-0
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MO:-#\D<LW&%%!8T=X&<\;Y?GN,*;P'K0&>($B* EHLX#IXYX"_E9&]Y)H<)
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M_(CW20R?A$R@?8 ),6!]YE 9J0/V84@>>7#!EO: I/<)FQJE3' *'F1B8=O
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MN99:OEL2\B1"GEXSL:4=L)?6@2*HW]X<)X8Z<76+@=%OLY#[Y1>16:5[*U2
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M#0G'NXA8T9?&@0;DU94%VO G<.B.3XYDQQ!!>!65-QP7U(OB,-=.\'N:EP1
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M9C(P,C)?=6YI=F5R<V4N:'1M4$L! A0#%     @ &X=*5NI-'8<'!P  S1P
M !L              ( != @$ &8R,&8R,#(R97@Q,BTQ7W5N:79E<G-E+FAT
M;5!+ 0(4 Q0    ( !N'2E8M'PH/WP8  )D<   ;              "  ;0/
M! !F,C!F,C R,F5X,3(M,E]U;FEV97)S92YH=&U02P$"% ,4    "  ;ATI6
MX632G[0#   8#0  &P              @ ',%@0 9C(P9C(P,C)E>#$S+3%?
M=6YI=F5R<V4N:'1M4$L! A0#%     @ &X=*5APCF-ZP P  %@T  !L
M         ( !N1H$ &8R,&8R,#(R97@Q,RTR7W5N:79E<G-E+FAT;5!+ 0(4
M Q0    ( !N'2E9+MLPQ'P0  )D3   ;              "  :(>! !F,C!F
M,C R,F5X,34M,5]U;FEV97)S92YH=&U02P$"% ,4    "  ;ATI6AGFA!H,"
M   @"@  &P              @ 'Z(@0 9C(P9C(P,C)E>#$U+3)?=6YI=F5R
M<V4N:'1M4$L! A0#%     @ &X=*5OD$,[*3 @  "@@  !L
M ( !MB4$ &8R,&8R,#(R97@Q-2TS7W5N:79E<G-E+FAT;5!+ 0(4 Q0    (
M !N'2E9['.*:%3P  -1S 0 :              "  8(H! !F,C!F,C R,F5X
M,BTS7W5N:79E<G-E+FAT;5!+ 0(4 Q0    ( !N'2E91I060;D,  &K1 0 ;
M              "  <]D! !F,C!F,C R,F5X-"TQ,5]U;FEV97)S92YH=&U0
M2P$"% ,4    "  ;ATI6/=3 J<]'  #Y30( &P              @ %VJ 0
M9C(P9C(P,C)E>#0M,3)?=6YI=F5R<V4N:'1M4$L! A0#%     @ &X=*5F0L
MY>(\6   =.0" !L              ( !?O $ &8R,&8R,#(R97@T+3$S7W5N
M:79E<G-E+FAT;5!+ 0(4 Q0    ( !N'2E;[Y>=\/A,  'Z&   ;
M      "  ?-(!0!F,C!F,C R,F5X-"TQ-%]U;FEV97)S92YH=&U02P$"% ,4
M    "  ;ATI6MM@JU$KV  !;&@$ "P              @ %J7 4 :6UG7S P
M,2YJ<&=02P$"% ,4    "  ;ATI6H FC>^L+ 0 K& $ "P
M@ '=4@8 :6UG7S P,BYJ<&=02P$"% ,4    "  ;ATI6PIY-)@ <  #_'
M"P              @ 'Q7@< :6UG7S P,RYJ<&=02P$"% ,4    "  ;ATI6
M3L/<'VT7  !"&   "P              @ $:>P< :6UG7S P-"YJ<&=02P$"
M% ,4    "  ;ATI6@J<V^@0@   UI $ $               @ &PD@< =7!C
M+3(P,C(P.3,P+GAS9%!+ 0(4 Q0    ( !N'2E9W@,5;0P\  /"S   4
M          "  >*R!P!U<&,M,C R,C Y,S!?8V%L+GAM;%!+ 0(4 Q0    (
M !N'2E;UE8*%$EH  *J+!0 4              "  5?"!P!U<&,M,C R,C Y
M,S!?9&5F+GAM;%!+ 0(4 Q0    ( !N'2E;Q_KJ->M@   ]V"@ 4
M      "  9L<" !U<&,M,C R,C Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( !N'
M2E:,3/96-UP  $_(!0 4              "  4?U" !U<&,M,C R,C Y,S!?
=<')E+GAM;%!+!08     %@ 6 -@%  "P40D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
